PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lima, WF; Crooke, ST				Lima, WF; Crooke, ST			Cleavage of single strand RNA adjacent to RNA-DNA duplex regions by Escherichia coli RNase H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-H; HYDROLYSIS; ENZYME; GENE	RNase H1 from Escherichia coli cleaves single strand RNA extending 3' from an RNA-DNA duplex. Substrates consisting of a 25-mer RNA annealed to complementary DNA ranging in length from 9-17 nucleotides were designed to create overhanging single strand RNA regions extending 5' and 3' from the RNA-DNA duplex. Digestion of single strand RNA was observed exclusively within the 3' overhang region and not the 5' overhang region. RNase H digestion of the 3' overhang region resulted in digestion products with 5'-phosphate and 3'-hydroxyl termini. The number of single strand RNA residues cleaved by RNase H is influenced by the sequence of the single strand RNA immediately adjacent to the RNA-DNA duplex and appears to be a function of the stacking properties of the RNA residues adjacent to the RNA-DNA duplex. RNase H digestion of the 3' overhang region was not observed for a substrate that contained a 2'-methoxy antisense strand. The introduction of 3 de oxynucleotides at the 5' terminus of the 2'-methoxy antisense oligonucleotide resulted in cleavage. These results offer additional insights into the binding directionality of RNase H with respect to the heteroduplex substrate.			Lima, WF (corresponding author), ISIS PHARMACEUT,2280 FARADAY AVE,CARLSBAD,CA 92008, USA.							BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; BUSEN W, 1980, J BIOL CHEM, V255, P9434; CECH TR, 1993, RNA WORLD, P239; CERRITELLI SM, 1995, RNA, V1, P246; CROOKE ST, 1995, BIOCHEM J, V312, P599, DOI 10.1042/bj3120599; Crouch R. J., 1982, NUCLEASES, P211; Daniher AT, 1997, BIOORGAN MED CHEM, V5, P1037, DOI 10.1016/S0968-0896(97)00040-0; HAUSEN P, 1970, EUR J BIOCHEM, V14, P279; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HUANG L, 1994, J BIOL CHEM, V269, P25922; IKEHARA M, 1986, P NATL ACAD SCI USA, V83, P4695, DOI 10.1073/pnas.83.13.4695; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; ITAYA M, 1991, NUCLEIC ACIDS RES, V19, P4443, DOI 10.1093/nar/19.16.4443; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KELLER W, 1972, P NATL ACAD SCI USA, V81, P3993; Lima WF, 1997, J BIOL CHEM, V272, P18191, DOI 10.1074/jbc.272.29.18191; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; MONIA BP, 1993, J BIOL CHEM, V268, P14514; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; ODA Y, 1993, J BIOL CHEM, V268, P88; POSRSCHE D, 1973, EUR J BIOCHEM, V39, P117; REICH C, 1980, BIOPOLYMERS, V19, P833, DOI 10.1002/bip.1980.360190409; ROBERTS GCK, 1969, P NATL ACAD SCI USA, V62, P1151, DOI 10.1073/pnas.62.4.1151; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; UCHIYAMA Y, 1994, J BIOCHEM-TOKYO, V116, P1322, DOI 10.1093/oxfordjournals.jbchem.a124682	26	60	70	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27513	27516		10.1074/jbc.272.44.27513	http://dx.doi.org/10.1074/jbc.272.44.27513			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346880	hybrid			2022-12-25	WOS:A1997YD47300006
J	Murray, NR; Fields, AP				Murray, NR; Fields, AP			Atypical protein kinase C iota protects human leukemia cells against drug-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K562 CELLS; PHOSPHATASE INHIBITOR; OKADAIC ACID; PKC-LAMBDA; IN-VITRO; DIFFERENTIATION; ACTIVATION; ISOZYMES; PROLIFERATION; ISOENZYMES	Protein kinase C (PHC) isozymes play distinct roles in cellular function. In human K562 leukemia cells, PKC alpha is important for cellular differentiation and PKC beta(II) is required for proliferation. In this report, we assess the role of the atypical PKC isoform PKC iota in H562 leukemia cell physiology. K562 cells were stably transfected with expression plasmids containing the cDNA for human PKC iota in sense or antisense orientation to increase or decrease cellular PKC iota levels, respectively. Overexpression or inhibition of expression of PKC iota had no significant effect on the proliferative capacity of K562 cells nor their sensitivity to phorbol myristate acetate-induced cytostasis and megakaryocytic differentiation, suggesting that PKC iota does not play a critical role in these processes, Rather, PKC iota serves to protect K562 cells against drug-induced apoptosis, K562 cells, which are resistant to most apoptotic agents, undergo apoptosis when treated with the protein phosphatase inhibitor okadaic acid (OA). Overexpression of PKC iota leads to increased resistance to OA induced apoptosis whereas inhibition of PKC iota expression sensitizes cells to OA-induced apoptosis, Overexpression of the related atypical PKC zeta has no protective effect, demonstrating that the effect is isotype-specific, PKC iota also protects K562 cells against taxol-induced apoptosis, indicating that it plays a general protective role against apoptotic stimuli. These data support a role for PKC iota in leukemia cell survival.	UNIV TEXAS,MED BRANCH,SEALY CTR ONCOL & HEMATOL,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,DEPT PHARMACOL,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston								AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; CLEMENS MJ, 1992, J CELL SCI, V103, P881; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; HOCEVAR BA, 1992, J CELL SCI, V101, P671; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MELLONI E, 1987, P NATL ACAD SCI USA, V84, P5282, DOI 10.1073/pnas.84.15.5282; Mueller Gertraud, 1995, EMBO (European Molecular Biology Organization) Journal, V14, P1961; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; MURRAY NR, 1997, PROTEIN KINASE C, P97; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; RAY S, 1994, CANCER CHEMOTH PHARM, V34, P365, DOI 10.1007/s002800050156; Ray S, 1996, CELL GROWTH DIFFER, V7, P1617; RITKE MK, 1994, MOL PHARMACOL, V46, P605; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868; ZHENG B, 1991, J BIOL CHEM, V266, P10031; ZHENG B, 1994, J BIOL CHEM, V269, P12332	33	155	163	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27521	27524		10.1074/jbc.272.44.27521	http://dx.doi.org/10.1074/jbc.272.44.27521			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346882	hybrid			2022-12-25	WOS:A1997YD47300008
J	Swietnicki, W; Petersen, R; Gambetti, P; Surewicz, WK				Swietnicki, W; Petersen, R; Gambetti, P; Surewicz, WK			pH-dependent stability and conformation of the recombinant human prion protein PrP(90-231)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; MOLECULAR-BIOLOGY; PRP 27-30; SCRAPIE; CONVERSION; INFECTIVITY; MECHANISM; DISEASES	A recombinant protein corresponding to the human prion protein domain encompassing residues 90-231 (huPrP(90-231)) was expressed in Escherichia coli in a soluble form and purified to homogeneity. Spectroscopic data indicate that the conformational properties and the folding pathway of huPrP(90-231) are strongly pH-dependent, Acidic pH induces a dramatic increase in the exposure of hydrophobic patches on the surface of the protein. At pH between 7 and 5, the unfolding of hPrP(90-231) in guanidine hydrochloride occurs as a two-state transition, This contrasts with the unfolding curves at lower pH values, which indicate a three-state transition, with the presence of a stable protein folding intermediate, While the secondary structure of the native huPrP(90-231) is largely alpha-helical, the stable intermediate is rich in beta-sheet structure, These findings have important implications for understanding the initial events on the pathway toward the conversion of the normal into the pathological forms of prion protein.	CASE WESTERN RESERVE UNIV,DEPT PATHOL,CLEVELAND,OH 44106	Case Western Reserve University			Swietnicki, Wieslaw/GOP-2576-2022; Swietnicki, Wieslaw/AAL-2452-2021; Petersen, Robert/B-5075-2011; Swietnicki, Wieslaw/AAU-1536-2020	Petersen, Robert/0000-0002-3154-0072; Swietnicki, Wieslaw/0000-0002-9354-8184				Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; GAJDUSEK DC, 1988, J NEUROIMMUNOL, V20, P95; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HORNEMANN S, 1996, J MOL BIOL, V262, P614; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1536; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1996, SEMIN VIROL, V7, P181, DOI 10.1006/smvy.1996.0023; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; Safar J, 1996, SEMIN VIROL, V7, P207, DOI 10.1006/smvy.1996.0026; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yehiely F, 1997, NEUROBIOL DIS, V3, P339, DOI 10.1006/nbdi.1997.0130; Zhang H, 1997, BIOCHEMISTRY-US, V36, P3543, DOI 10.1021/bi961965r	37	239	247	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27517	27520		10.1074/jbc.272.44.27517	http://dx.doi.org/10.1074/jbc.272.44.27517			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346881	hybrid			2022-12-25	WOS:A1997YD47300007
J	Cooksey, CJ; Garratt, PJ; Land, EJ; Pavel, S; Ramsden, CA; Riley, PA; Smit, NPM				Cooksey, CJ; Garratt, PJ; Land, EJ; Pavel, S; Ramsden, CA; Riley, PA; Smit, NPM			Evidence of the indirect formation of the catecholic intermediate substrate responsible for the autoactivation kinetics of tyrosinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3,4-DIHYDROXYPHENYLALANINE DOPA; MELANIN BIOSYNTHESIS; PULSE-RADIOLYSIS; OXIDATION; PRECURSORS; PATHWAY; MODEL	Tyrosinase (EC 1.14.18.1) exhibits unusual kinetic properties in the oxidation of monohydric phenol substrates consisting of a lag period that increases with increasing substrate concentration, The cause of this is an autocatalytic process dependent on the generation of a dihydric phenol substrate, which acts as an activator of the enzyme, Experiments with N-substituted dihydric phenol substrate (N-methyldopamine, N-acetyldopamine) demonstrate that oxygen consumption is retarded in the N-acetyl substituted material due to a diminished rate of cyclization, The oxygen uptake exhibited a similar pattern when N-acetyltyramine was oxidized, and this was reflected by a prolongation of the lag period, N,N-Dipropyldopamine was oxidized with. normal kinetics but with an oxygen stoichiometry of 0.5 mol of oxygen/mol of substrate, We show that this is the result of the formation of a stable indoliumolate product with oxidation-reduction properties that prevent the formation of dopaminochrome, thus blocking further stages in the tyrosinase-catalyzed oxidation, Evidence that the indoliumolate product is formed by cyclization of the ortho-quinone is presented by pulse radiolysis studies, which demonstrate the formation of the ortho-quinone (by disproportionation of the corresponding semiquinones), which cyclizes to give the indoliumolate, The rate constant for cyclization was shown to be 48 s(-1) (at pH 6.0), Tyrosinase-catalyzed oxidation of the monohydric phenol analogue, N,N-dimethyltyramine, was shown to require the addition of a dihydric phenol, Oxygen utilization then exhibited a stoichiometry of 1.0, indicating that the reactions proceed only as far as the cyclization. The analogous stable cyclic indoliumolate product was shown to be formed, with UV absorption and NMR spectra closely similar to the indoliumolate derived from N,N-dipropyldopamine. This material was methylated by catechol O-methyltransferase but was unreactive to redox reagents, The formation of the cyclic product accounts for the indefinite lag when N,N-dimethyltyramine is used as the substrate for tyrosinase in the absence of a dihydric phenol cofactor.	UNIV COLL & MIDDLESEX SCH MED, WINDEYER INST, LONDON W1P 6DB, ENGLAND; UNIV LONDON UNIV COLL, CHRISTOPHER INGOLD LABS, DEPT CHEM, LONDON WC1H 0AJ, ENGLAND; CHRISTIE HOSP NHS TRUST, PATERSON INST CANC RES, DEPT BIOPHYS CHEM, CRC, MANCHESTER M20 9BX, LANCS, ENGLAND; LEIDEN UNIV HOSP, DEPT DERMATOL, NL-2333 ZA LEIDEN, NETHERLANDS; UNIV KEELE, DEPT CHEM, KEELE ST5 5BG, STAFFS, ENGLAND	University of London; University College London; University of London; University College London; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Leiden University; Leiden University Medical Center (LUMC); Keele University				Cooksey, Christopher/0000-0002-4151-082X				ADAMS GE, 1965, PULSE RADIOLYSIS, P117; BELL VL, 1986, J CHEM SOC PERK T 1, P1515, DOI 10.1039/p19860001515; BHATNAGAR V, 1993, ARCH BIOCHEM BIOPHYS, V307, P183, DOI 10.1006/abbi.1993.1577; BUTLER J, 1989, RADIAT PHYS CHEM, V34, P633; BUTLER J, 1984, RADIAT PHYS CHEM, V23, P265, DOI 10.1016/0146-5724(84)90118-3; CABANES J, 1987, BIOCHIM BIOPHYS ACTA, V923, P187, DOI 10.1016/0304-4165(87)90003-1; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; CHEDEKEL MR, 1984, J CHEM SOC CHEM COMM, P1170, DOI 10.1039/c39840001170; Cooksey CJ, 1996, QUANT STRUCT-ACT REL, V15, P498, DOI 10.1002/qsar.19960150606; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; Evans WC, 1937, BIOCHEM J, V31, P2162, DOI 10.1042/bj0312162; HEARING VJ, 1981, INT J BIOCHEM, V13, P99, DOI 10.1016/0020-711X(81)90141-5; KEENE JP, 1964, J SCI INSTRUM, V41, P493, DOI 10.1088/0950-7671/41/8/302; LAMBERT C, 1991, J CHEM SOC FARADAY T, V87, P2939, DOI 10.1039/ft9918702939; LAND EJ, 1993, J CHEM SOC FARADAY T, V89, P803, DOI 10.1039/ft9938900803; LERCH K, 1981, MET IONS BIOL SYST, V13, P143; LERNER AB, 1949, J BIOL CHEM, V178, P185; Naish-Byfield S, 1991, Melanoma Res, V1, P273; NAISHBYFIELD S, 1992, BIOCHEM J, V288, P63, DOI 10.1042/bj2880063; RODRIGUEZLOPEZ JN, 1992, J BIOL CHEM, V267, P3801; SMIT NPM, 1990, ANAL BIOCHEM, V190, P286, DOI 10.1016/0003-2697(90)90195-F; SOLOMON EI, 1993, SCIENCE, V259, P1575, DOI 10.1126/science.8384374; SUGUMARAN M, 1992, J BIOL CHEM, V267, P10355; THOMPSON A, 1985, BIOCHIM BIOPHYS ACTA, V843, P49, DOI 10.1016/0304-4165(85)90048-0; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x	25	293	305	3	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26226	26235		10.1074/jbc.272.42.26226	http://dx.doi.org/10.1074/jbc.272.42.26226			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334191	hybrid			2022-12-25	WOS:A1997YB13900025
J	Wang, HY; Singh, D; Fliegel, L				Wang, HY; Singh, D; Fliegel, L			The Na+/H+ antiporter potentiates growth and retinoic acid-induced differentiation of P19 embryonal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH REGULATION; GENE-EXPRESSION; HL-60 CELLS; MONOCYTIC DIFFERENTIATION; PROXIMAL TUBULES; LEUKEMIC-CELLS; EXCHANGER GENE; SMOOTH-MUSCLE; ACTIVATION; PROLIFERATION	The Na+/H+ exchanger is a ubiquitous plasma membrane protein that is responsible for pH regulation and is activated by growth factors. We examined the role of the Na+/H+ exchanger in cell growth and differentiation. Treatment of P19 cells with the Na+/H+ exchanger inhibitor Hoe 694 eliminated retinoic acid-induced differentiation in this cell line. We developed a P19 embryonal carcinoma cell line that was deficient in the Na+/H+ antiporter. Na+/H+ exchanger-deficient cells were reduced in the rate of cell growth and this effect was enhanced by the removal of added HCO(3)(-)1 and by reducing extracellular pH. The antiporter-deficient cells were also markedly deficient in their ability to differentiate to neuronal-like cells and recovered this ability when the Na+/H+ antiporter was reintroduced. The results show that the absence of Na+/H+ antiport as a pH regulatory mechanism can result in deficiencies in both cell growth and differentiation in embryonal carcinoma cells.	UNIV ALBERTA,FAC MED,DEPT PEDIAT,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,FAC MED,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,FAC MED,DEPT ANAT & CELL BIOL,MRC,GRP MOL BIOL MEMBRANES,EDMONTON,AB T6G 2H7,CANADA	University of Alberta; University of Alberta; University of Alberta								ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; ALVAREZ J, 1989, EUR J BIOCHEM, V183, P709, DOI 10.1111/j.1432-1033.1989.tb21102.x; BORON WF, 1983, J GEN PHYSIOL, V81, P29, DOI 10.1085/jgp.81.1.29; BURNS CP, 1983, BIOCHEM BIOPH RES CO, V116, P931; CASSEL D, 1988, J BIOL CHEM, V263, P6122; CHAILLET JR, 1985, J GEN PHYSIOL, V86, P765, DOI 10.1085/jgp.86.6.765; CHURCH JG, 1989, BIOCHEM J, V257, P151, DOI 10.1042/bj2570151; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DYCK JRB, 1995, J BIOL CHEM, V270, P10420, DOI 10.1074/jbc.270.18.10420; DYCK JRB, 1995, CARDIOVASC RES, V29, P203, DOI 10.1016/S0008-6363(96)88571-3; DYCK JRB, 1995, J BIOL CHEM, V270, P1375, DOI 10.1074/jbc.270.3.1375; FLIEGEL L, 1993, MOL CELL BIOCHEM, V125, P137, DOI 10.1007/BF00936442; FLIEGEL L, 1993, BIOCHEM J, V289, P101, DOI 10.1042/bj2890101; GLEESON D, 1989, J CLIN INVEST, V84, P312, DOI 10.1172/JCI114156; GRINSTEIN S, 1983, J GEN PHYSIOL, V82, P619, DOI 10.1085/jgp.82.5.619; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAZAV P, 1989, CANCER RES, V49, P72; HENSLEY CB, 1989, AM J PHYSIOL, V257, pC637, DOI 10.1152/ajpcell.1989.257.4.C637; HORIE S, 1992, J CLIN INVEST, V89, P365, DOI 10.1172/JCI115594; KRAPF R, 1991, J CLIN INVEST, V87, P747, DOI 10.1172/JCI115057; LADOUX A, 1988, EUR J BIOCHEM, V175, P455, DOI 10.1111/j.1432-1033.1988.tb14216.x; LAGARDE AE, 1986, CANCER BIOCHEM BIOPH, V9, P1; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; NEYLON CB, 1990, CIRC RES, V67, P814, DOI 10.1161/01.RES.67.4.814; POUYSSEGUR J, 1985, TRENDS BIOCHEM SCI, V10, P453, DOI 10.1016/0968-0004(85)90030-1; POUYSSEGUR J, 1980, P NATL ACAD SCI-BIOL, V77, P2698, DOI 10.1073/pnas.77.5.2698; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RAO GN, 1990, J BIOL CHEM, V265, P19393; RAO GN, 1992, J CELL PHYSIOL, V151, P361, DOI 10.1002/jcp.1041510217; RAO GN, 1991, J BIOL CHEM, V266, P13485; SINGH G, 1995, BBA-BIOMEMBRANES, V1239, P74, DOI 10.1016/0005-2736(95)00148-V; VAIRO G, 1993, CELL GROWTH DIFFER, V4, P461; VAIRO G, 1992, J BIOL CHEM, V267, P19043; YAMAGATA Y, 1996, NA PLUS H PLUS EXCHA, P269; Yang WD, 1996, BBA-GENE STRUCT EXPR, V1306, P107, DOI 10.1016/0167-4781(95)00236-7	36	61	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26545	26549		10.1074/jbc.272.42.26545	http://dx.doi.org/10.1074/jbc.272.42.26545			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334233	hybrid			2022-12-25	WOS:A1997YB13900067
J	Apte, SS; Fukai, N; Beier, DR; Olsen, BR				Apte, SS; Fukai, N; Beier, DR; Olsen, BR			The matrix metalloproteinase-14 (MMP-14) gene is structurally distinct from other MMP genes and is co-expressed with the TIMP-2 gene during mouse embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE; MOLECULAR-CLONING; PROGELATINASE-A; ACTIVATION; SURFACE; 72-KDA; CELLS; FIBROBLASTS; LOCATION; DOMAIN	The matrix metalloproteinases (MMPs) are a family of zinc-containing matrix degrading endopeptidases. A subfamily of membrane type (MT) -MMPs has been described recently. We have determined the structure of the gene (Mmp14) encoding the first MT-MMP to be described, MT1-MMP (MMP-14), and mapped it to mouse chromosome 14. The mouse MMP-14 protein is encoded by ten exons. The novel C-terminal peptide domains of MMP-14 are encoded by a single large exon that also encodes the 3'-untranslated region, The structure of the exons encoding the catalytic domain and pro domain of MMP-14 is distinct from previously described MMP genes, whereas the exons encoding the hemopexin-like domains are similar to those of most other MMP genes. Mmp14 and the gene for tissue inhibitor of metalloproteinases-2 (Timp2) show a temporally and spatially coregulated expression during mouse development. They are co-expressed during vascular and urogenital development and during the development of osteocartilaginous and musculotendinous structures. The stringent co-expression of these two genes suggests common regulatory pathways that may have important functional implications for the activation of pro-gelatinase A in health and disease.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Apte, SS (corresponding author), CLEVELAND CLIN FDN,DEPT BIOMED ENGN,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.			Apte, Suneel/0000-0001-8441-1226	NIAMS NIH HHS [AR 44436, AR36819, AR36820] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036819, R01AR036820, R01AR044436, R29AR044436, R37AR036820, R01AR036819, R56AR036819] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANGLARD P, 1995, J BIOL CHEM, V270, P20337, DOI 10.1074/jbc.270.35.20337; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BLAVIER L, 1997, IN PRESS MOL BIOL CE, V8; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; FUKAI N, 1994, METHOD ENZYMOL, V245, P3; GAIRE M, 1994, J BIOL CHEM, V269, P6600; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Imai K, 1996, CANCER RES, V56, P2707; KIDWELL JF, 1961, J HERED, V52, P145, DOI 10.1093/oxfordjournals.jhered.a107050; KONOH H, 1996, J CELL SCI, V109, P953; LECO KJ, 1992, GENE, V117, P209, DOI 10.1016/0378-1119(92)90731-4; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mattei MG, 1997, GENOMICS, V40, P168, DOI 10.1006/geno.1996.4559; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PENDAS AM, 1995, GENOMICS, V26, P615, DOI 10.1016/0888-7543(95)80186-P; PENDAS KAM, 1997, GENOMICS, V40, P222; Puente XS, 1996, CANCER RES, V56, P944; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; REPONEN P, 1992, J BIOL CHEM, V267, P7856; Sang QXA, 1996, J PROTEIN CHEM, V15, P137, DOI 10.1007/BF01887395; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1997, GENOMICS, V39, P412, DOI 10.1006/geno.1996.4496; Sato T, 1997, J CELL SCI, V110, P589; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Taylor B.A, 1978, ORIGINS INBRED MICE; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Yang MZ, 1996, J BIOL CHEM, V271, P25548, DOI 10.1074/jbc.271.41.25548	41	115	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25511	25517		10.1074/jbc.272.41.25511	http://dx.doi.org/10.1074/jbc.272.41.25511			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325265	hybrid			2022-12-25	WOS:A1997YA35800020
J	Blain, SW; Montalvo, E; Massague, J				Blain, SW; Montalvo, E; Massague, J			Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) with cyclin A-Cdk2 and cyclin D2-Cdk4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN-PHOSPHORYLATION; FIBROBLAST CELL-CYCLE; GROWTH-FACTOR-BETA; G1 PHASE; TGF-BETA; POTENTIAL MEDIATOR; ACTIVATING KINASE; MAMMALIAN-CELLS; MICE LACKING; P21	Although p27(Kip1) has been considered a general inhibitor of G(1) and S phase cyclin-dependent kinases, we report that the interaction of p27 with two such kinases, cyclin A-Cdk2 and cyclin D-Cdk4, is different. In Mv1Lu cells containing a p27 inducible system, a 6-fold increase over the basal p27 level completely inhibited Cdk2 and cell cycle progression. In contrast, the same or a larger increase in p27 levels did not inhibit Cdk4 or its homologue Cdk6, despite extensive binding to these kinases. A p27-cyclin A-Cdk2 complex formed in vitro was essentially inactive, whereas a p27-cyclin D2-Cdk4 complex was active as a retinoblastoma kinase and served as a substrate for the Cdk-activating kinase Cak. High concentrations of p27 inhibited cyclin D2 Cdk4, apparently by conversion of active complexes into inactive ones by the binding of additional p27 molecules. In contrast to their differential interaction, cyclin A-Cdk2 and cyclin D2-Cdk4 were similarly inhibited by bound p21(Cip1/Waf1). Roles of cyclin A-Cdk2 as a p27 target and cyclin D2-Cdk4 as a p27 reservoir may result from the differential ability of bound p27 to inhibit the kinase subunit in these complexes.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELL BIOL PROGRAM,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center				Massague, Joan/0000-0001-9324-8408				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	73	241	268	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25863	25872		10.1074/jbc.272.41.25863	http://dx.doi.org/10.1074/jbc.272.41.25863			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325318	hybrid			2022-12-25	WOS:A1997YA35800073
J	GarciaCardena, G; Martasek, P; Masters, BSS; Skidd, PM; Couet, J; Li, SW; Lisanti, MP; Sessa, WC				GarciaCardena, G; Martasek, P; Masters, BSS; Skidd, PM; Couet, J; Li, SW; Lisanti, MP; Sessa, WC			Dissecting the interaction between nitric oxide synthase (NOS) and caveolin - Functional significance of the NOS caveolin binding domain in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCULAR-DYSTROPHY; ESCHERICHIA-COLI; PROTEIN; CELLS; PALMITOYLATION; PURIFICATION; ASSOCIATION; EXPRESSION; SARCOLEMMA; MEMBRANES	Endothelial nitric oxide synthase (eNOS) is a dually acylated peripheral membrane protein that targets to the Golgi region and caveolae of endothelial cells. Recent evidence has shown that eNOS can co-precipitate with caveolin-1, the resident coat protein of caveolae, suggesting a direct interaction between these two proteins, To test this idea, we examined the interactions of eNOS with caveolin-1 in vitro and in vivo. Incubation of endothelial cell lysates or purified eNOS with glutathione S-transferase (GST)-caveolin-1 resulted in the direct interaction of the two proteins. Utilizing a series of GST-caveolin-1 deletion mutants, we identified two cytoplasmic domains of caveolin-1 that interact with eNOS, the scaffolding domain (amino acids 61-101) and to a lesser extent the C-terminal tail (amino acids 135-178). Incubation of pure eNOS with peptides derived from the scaffolding domains of caveolin-1 and -3, but not the analogous regions from caveolin-2, resulted in inhibition of eNOS, inducible NOS (iNOS), and neuronal NOS (nNOS) activities. These results suggest a common mechanism and site of inhibition. Utilizing GST-eNOS fusions, the site of caveolin binding was localized between amino acids 310 and 570. Site-directed mutagenesis of the predicted caveolin binding motif within eNOS blocked the ability of caveolin-1 to suppress NO release in co-transfection experiments. Thus, our data demonstrate a novel functional role for caveolin-1 in mammalian cells as a potential molecular chaperone that directly inactivates NOS. This suggests that the direct binding of eNOS to caveolin-1, per se, and the functional consequences of eNOS targeting to caveolae are likely temporally and spatially distinct events that regulate NO production in endothelial cells. Additionally, the inactivation of eNOS and nNOS by the scaffolding domain of caveolin-3 suggests that eNOS in cardiac myocytes and nNOS in skeletal muscle are likely subject to negative regulation by this muscle-specific caveolin isoform.	YALE UNIV, SCH MED, BOYER CTR MOL MED, DEPT PHARMACOL, NEW HAVEN, CT 06536 USA; UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA	Yale University; University of Texas System; University of Texas Health San Antonio; Yeshiva University; Albert Einstein College of Medicine			Garcia-Cardena, Guillermo/Q-6649-2019; Sessa, William C/B-6844-2011; Lisanti, Michael/B-6131-2018; Li, Shengwen Calvin/H-1725-2012; Lisanti, Michael P/C-6866-2013; Martasek, Pavel/G-6622-2017	Sessa, William C/0000-0001-5759-1938; Lisanti, Michael/0000-0003-2034-1382; Li, Shengwen Calvin/0000-0002-9699-9204; Couet, Jacques/0000-0001-5409-8689; Martasek, Pavel/0000-0001-6165-4444	NCI NIH HHS [F32 CA071326] Funding Source: Medline; NHLBI NIH HHS [HL57665, HL51948] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057665, R29HL051948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Chang WJ, 1996, P NATL ACAD SCI USA, V93, P9142, DOI 10.1073/pnas.93.17.9142; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FREY C, 1994, J BIOL CHEM, V269, P26083; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, CELL MOL BIOL, V43, P293; Stuehr DJ, 1996, METHOD ENZYMOL, V268, P324; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554	27	667	687	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25437	25440		10.1074/jbc.272.41.25437	http://dx.doi.org/10.1074/jbc.272.41.25437			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325253	hybrid			2022-12-25	WOS:A1997YA35800008
J	Heimburg, T; Esmann, M; Marsh, D				Heimburg, T; Esmann, M; Marsh, D			Characterization of the secondary structure and assembly of the transmembrane domains of trypsinized Na,K-ATPase by Fourier transform infrared spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; SARCOPLASMIC-RETICULUM; SQUALUS-ACANTHIAS; RECTAL GLANDS; ATPASE; NA+,K+-ATPASE; PROTEINS; SEQUENCE; SODIUM; (NA++K+)-ATPASE	Fourier transform infrared spectroscopy has been used to compare native Na,K-ATPase-containing membranes with those trypsinized in the presence of either Rb+ or Na+ ions to remove the extramembranous parts of the protein, The protein secondary structure content deduced from the amide I band is approximately 30-35% alpha-helix, 37-40% beta-structure, and 13-15% random coli for native membranes from shark rectal gland and from pig kidney, in both the Na- and K-forms. Trypsinization in either Rb+ (a K+ congener) or Na+ removes approximately 35% of the amide I band intensity of native membranes from shark rectal gland. The protein secondary structural content of the trypsinized membranes lies in the range of approximately 23-32% alpha-helix, 37-46% beta-structure, and 12-18% random coil for the shark and kidney enzymes. The distribution of intensity between the bands corresponding to protonated and deuterium-exchanged alpha-helices, and between the component bands attributed to beta-structure, changes considerably on trypsinization, in the direction of a greater proportion of protonated alpha-helix and a broader range of frequencies for beta-structure. The kinetics of deuteration of the slowly exchanging population of protein amide groups is also changed on trypsinization, The mean rate constant for deuteration of trypsinized membranes is approximately half that for native membranes, whereas the proportion of amides contributing to this population increases on trypsinization. The temperature dependence of the amide I band in the Fourier transform infrared spectra indicates that the onset of thermal denaturation occurs at 58 degrees C for native membranes (in either Na+ or K+) and for membranes trypsinized in Rb+, but the major denaturation event for membranes trypsinized in Na+ occurs at approximately 84 degrees C. These results correlate with the functional properties of the intramembranous section of the enzyme.	MAX PLANCK INST BIOPHYS CHEM,ABT SPECKTROSKOPIE,D-37077 GOTTINGEN,GERMANY; AARHUS UNIV,DEPT BIOPHYS,DK-8000 AARHUS C,DENMARK	Max Planck Society; Aarhus University			Heimburg, Thomas/AAA-7726-2022; Heimburg, Thomas R/I-5064-2014	Heimburg, Thomas R/0000-0003-4599-4582				ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHETVERIN AB, 1985, J BIOL CHEM, V260, P7817; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; CORBALANGARCIA S, 1994, BIOCHEMISTRY-US, V33, P8247, DOI 10.1021/bi00193a011; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; ESMANN M, 1988, BIOCHIM BIOPHYS ACTA, V940, P71, DOI 10.1016/0005-2736(88)90009-0; ESMANN M, 1987, BIOCHEMISTRY-US, V26, P8675, DOI 10.1021/bi00400a028; ESMANN M, 1994, BIOCHEMISTRY-US, V33, P3693, DOI 10.1021/bi00178a028; ESMANN M, 1994, BIOCHEMISTRY-US, V33, P8044, DOI 10.1021/bi00192a008; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; GORNETSCHELNOKOW U, 1994, EMBO J, V13, P338, DOI 10.1002/j.1460-2075.1994.tb06266.x; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; HEIMBURG T, 1993, BIOPHYS J, V65, P2408, DOI 10.1016/S0006-3495(93)81299-2; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAUNSBACH AB, 1989, PROG CLIN BIOL RES, V268, P39; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; MUGA A, 1990, BIOCHEMISTRY-US, V29, P2925, DOI 10.1021/bi00464a006; SKOU JC, 1979, BIOCHIM BIOPHYS ACTA, V567, P436, DOI 10.1016/0005-2744(79)90129-3; SKRIVER E, 1992, J STRUCT BIOL, V108, P176, DOI 10.1016/1047-8477(92)90017-5; SUREWICZ WK, 1990, BIOCHEMISTRY-US, V29, P8106, DOI 10.1021/bi00487a017; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VIGNERON L, 1995, J BIOL CHEM, V270, P17685, DOI 10.1074/jbc.270.30.17685	32	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25685	25692		10.1074/jbc.272.41.25685	http://dx.doi.org/10.1074/jbc.272.41.25685			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325292	hybrid, Green Submitted			2022-12-25	WOS:A1997YA35800047
J	Shimkets, RA; Lifton, RP; Canessa, CM				Shimkets, RA; Lifton, RP; Canessa, CM			The activity of the epithelial sodium channel is regulated by clathrin-mediated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIDDLES SYNDROME; BETA-SUBUNIT; NA+ CHANNEL; BREFELDIN-A; MISSENSE MUTATION; HYPERTENSION; ACTIVATION; SEQUENCE	Activity of the epithelial sodium channel (ENaC) is a key determinant of sodium homeostasis and blood pressure, Liddle's syndrome, an inherited form of hypertension, is caused by mutations that delete or alter PY domains in the carboxyl termini of beta or gamma ENaC subunits, leading to increased channel activity. In this study we investigated the mechanism of this effect by analysis of wild-type and mutant ENaC activity in Xenopus oocytes, By inhibiting insertion of new channels into the plasma membrane with brefeldin A, we demonstrate that the half-life of the activity of channels containing Liddle's mutations is markedly prolonged compared with wild type channels (t(1/2) of 30 h in mutant versus 3.6 in wild type, p < 0.001), We investigated the involvement of clathrin-coated pit-mediated endocytosis by co-expressing a dominant-negative dynamin mutant with wildtype ENaC in oocytes. Expression of this specific inhibitor of endocytosis leads to a large increase in the activity of wild-type channels, demonstrating that normal turnover of this channel is through the clathrin-coated pit pathway, In contrast, co-expression of Liddle's mutations and dynamin mutants leads to no further increase in channel activity, consistent with one of the effects of Liddle's mutations being the loss of endocytosis of these channels, These findings demonstrate the normal mechanism of turnover of ENaC from the cell surface and demonstrate a mechanism that can account for the increased number of channels in the plasma membrane seen in Liddle's syndrome.	YALE UNIV,DEPT CELLULAR & MOL PHYSIOL,SCH MED,NEW HAVEN,CT 06520; YALE UNIV,DEPT GENET,SCH MED,NEW HAVEN,CT 06520	Yale University; Yale University								CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; EATON DC, 1995, KIDNEY INT, V48, P941, DOI 10.1038/ki.1995.375; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Ismailov II, 1996, AM J PHYSIOL-CELL PH, V270, pC214, DOI 10.1152/ajpcell.1996.270.1.C214; JUNPING L, 1995, ENDOCR REV, V16, P590; MULNERLORILLON O, 1995, DEV BIOL, V170, P223, DOI 10.1006/dbio.1995.1209; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P56699; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	24	237	239	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25537	25541		10.1074/jbc.272.41.25537	http://dx.doi.org/10.1074/jbc.272.41.25537			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325269	hybrid			2022-12-25	WOS:A1997YA35800024
J	Simmons, T; Newhouse, YM; Arnold, KS; Innerarity, TL; Weisgraber, KH				Simmons, T; Newhouse, YM; Arnold, KS; Innerarity, TL; Weisgraber, KH			Human low density lipoprotein receptor fragment - Successful refolding of a functionally active ligand-binding domain produced in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN-E; CYSTEINE-RICH REPEAT; HUMAN-PLASMA-LIPOPROTEINS; AMINO-ACID-SEQUENCE; HUMAN-E APOPROTEIN; LDL-RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; 3-DIMENSIONAL STRUCTURE; MULTIFUNCTIONAL RECEPTOR; MONOCLONAL-ANTIBODIES	The low density lipoprotein (LDL) receptor plays a key role in cholesterol homeostasis, mediating cellular uptake of Lipoprotein particles by high affinity binding to its ligands, apolipoprotein (ape) B-100 and apoE. The ligand-binding domain of the LDL receptor contains 7 cysteine-rich repeats of approximately 40 amino acids; each repeat contains 6 cysteines, which form 3 intra-repeat disulfide bonds, As a first step toward determining the structure of the LDL receptor, both free and bound to its ligands, we produced in Escherichia coli a soluble fragment containing the Ligand-binding domain (residues 1-292) as a thrombin-cleavable, heat-stable thioredoxin fusion, Modest amounts (5 mg/liter) of partially purified but inactive fragment were obtained after cell lysis, heat treatment, thrombin cleavage, and gel filtration under denaturing conditions, We were able to refold the receptor fragment to an active conformation with approximately 10% efficiency, The active fragment was isolated and purified with an LDL affinity column, The refolded receptor fragment was homogeneous, as determined by sodium dodecyl sulfate or non-denaturing polyacrylamide gel electrophoresis and isoelectric focusing, The purified fragment did not react with fluorescein-5-maleimide, indicating that all 42 cysteines were disulfide linked, In addition, the refolded fragment exhibited properties identical to those of the intact native receptor: Ca2+-dependent binding and isoform-dependent apoE binding (apoE2 binding <5% of apoE3). Furthermore, antibodies to the fragment recognized native receptors and inhibited the binding of I-125-LDL to fibroblast LDL receptors, We conclude that we have produced a properly folded and fully active receptor fragment that can be used for further structural studies.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,DEPT PATHOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes					NCRR NIH HHS [RR00083] Funding Source: Medline; NHLBI NIH HHS [HL41633] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOLD KS, 1992, LIPOPROTEIN ANAL PRA, P145; AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V2; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1984, SCI AM, V251, P58, DOI 10.1038/scientificamerican1184-58; Creighton TE, 1997, TRENDS BIOCHEM SCI, V22, P6, DOI 10.1016/S0968-0004(96)20030-1; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; INNERARITY TL, 1978, J BIOL CHEM, V253, P6289; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; McLachlin DT, 1996, PROTEIN EXPRES PURIF, V7, P275, DOI 10.1006/prep.1996.0039; RALL SC, 1986, METHOD ENZYMOL, V128, P273; RALL SC, 1982, J BIOL CHEM, V257, P4171; RALL SC, 1984, LATENT DYSLIPOPROTEI, P157; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER WJ, 1985, METHOD ENZYMOL, V109, P405; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	40	37	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25531	25536		10.1074/jbc.272.41.25531	http://dx.doi.org/10.1074/jbc.272.41.25531			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325268	hybrid			2022-12-25	WOS:A1997YA35800023
J	Vilei, EM; Calderara, S; Anagli, J; Berardi, S; Hitomi, K; Maki, M; Carafoli, E				Vilei, EM; Calderara, S; Anagli, J; Berardi, S; Hitomi, K; Maki, M; Carafoli, E			Functional properties of recombinant calpain I and of mutants lacking domains III and IV of the catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; CALCIUM-DEPENDENT PROTEASE; CYSTEINE PROTEINASES; MOLECULAR DIVERSITY; MU-CALPAIN; INVOLVEMENT; CALPASTATIN; EXPRESSION; BINDING; RECONSTITUTION	The catalytic subunit (L-mu CANP) of human calpain I (mu CANP, the high Ca2+ affinity form) and two of its mutants were expressed in Escherichia coli or using the baculovirus Sf9 system. The mutants lacked domain III (L-mu CANP Delta 3) and the calmodulin-like domain IV (L-mu CANP Delta 4), respectively. The bacterially expressed proteins were solubilized from the inclusion bodies and refolded with polyethylene glycol. In Sf9 cells, co-expression of the inhibitor calpastatin was necessary to prevent autolysis of L-mu CANP, whereas co-expression of the regulatory subunit enhanced it. Only very low levels of mRNA of the truncated form L-mu CANP Delta 4 were found in bacmid-transfected Sf9 cells, and it proved impossible to isolate this mutant using the baculovirus expression system. While the apparent K-m(Ca2+) of freshly isolated human erythrocyte mu CANP was about 60 mu M, the recombinant monomeric forms L-mu CANP and L-mu CANP Delta 3 required 65-215 and 400-530 mu M Ca2+, respectively. Bacterially expressed L-mu CANP Delta 4 was Ca2+-independent; the presence of inhibitors during its renaturation was necessary to prevent its autolysis. A chimeric form (L-mu mCANP) composed by domains I-III of mu CANP and domain IV of calpain II (mcANP, the low Ca2+ affinity form) was also expressed in Sf9 cells. This mutant required less Ca2+ (about 50 mu M) than native erythrocyte calpain for half-maximal activity and had the highest specific activity of all calpains tested. Domain III proved unnecessary for the activity of the recombinant catalytic subunit, but its absence raised the K-m(Ca2+) and removed its inactivation at high Ca2+ concentrations. All recombinant proteins were active as monomers in polyethylene glycol-containing buffers; the in vitro association with the regulatory subunit enhanced only slightly the V-max and the Ca2+ dependence of the expressed proteins. Activation by Ca2+ promoted the separation of the two subunits of the expressed recombinant proteins.	ETH ZURICH, INST BIOCHEM, CH-8092 ZURICH, SWITZERLAND; HENRY FORD HOSP, DEPT PATHOL, DIV BIOCHEM RES, DETROIT, MI 48202 USA; UNIV ZURICH HOSP, DEPT INTERNAL MED, DIV CLIN PHARMACOL & TOXICOL, CH-8091 ZURICH, SWITZERLAND; NAGOYA UNIV, SCH AGR SCI, DEPT APPL BIOL SCI, NAGOYA, AICHI 46401, JAPAN	Swiss Federal Institutes of Technology Domain; ETH Zurich; Henry Ford Health System; Henry Ford Hospital; University of Zurich; University Zurich Hospital; Nagoya University			Carafoli, Ernesto/K-5192-2016; Vilei, Edy/A-6138-2009; Maki, Masatoshi/AAM-6839-2021	Carafoli, Ernesto/0000-0002-7826-0094; Maki, Masatoshi/0000-0001-9144-5491				Anagli J, 1996, EUR J BIOCHEM, V241, P948, DOI 10.1111/j.1432-1033.1996.00948.x; Asada K, 1989, J Enzyme Inhib, V3, P49, DOI 10.3109/14756368909030363; COTTIN P, 1991, BIOCHIM BIOPHYS ACTA, V1079, P139, DOI 10.1016/0167-4838(91)90118-J; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; CROALL DE, 1984, BIOCHIM BIOPHYS ACTA, V788, P348, DOI 10.1016/0167-4838(84)90048-7; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DELUCA CI, 1993, BIOCHIM BIOPHYS ACTA, V1216, P81, DOI 10.1016/0167-4781(93)90040-K; GRAHAMSIEGENTHALER K, 1994, J BIOL CHEM, V269, P30457; HATHAWAY DR, 1982, J BIOL CHEM, V257, P9072; Higuchi R., 1989, PCR TECHNOLOGY, P61; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; JOHNSON P, 1990, INT J BIOCHEM, V22, P811, DOI 10.1016/0020-711X(90)90284-A; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KIKUCHI T, 1984, ARCH BIOCHEM BIOPHYS, V234, P639, DOI 10.1016/0003-9861(84)90314-X; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WJ, 1992, J BIOL CHEM, V267, P8437; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MA H, 1993, J BIOCHEM, V113, P591, DOI 10.1093/oxfordjournals.jbchem.a124088; Meyer SL, 1996, BIOCHEM J, V314, P511, DOI 10.1042/bj3140511; MINAMI Y, 1988, J BIOCHEM-TOKYO, V104, P927, DOI 10.1093/oxfordjournals.jbchem.a122585; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; RUSSELLHARDE D, 1995, J INTERF CYTOK RES, V15, P31, DOI 10.1089/jir.1995.15.31; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAIDO TC, 1993, INNOVATION PROTEASES, P197; SAKIHAMA T, 1985, P NATL ACAD SCI USA, V82, P6075, DOI 10.1073/pnas.82.18.6075; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; YANG HQ, 1994, J BIOL CHEM, V269, P18977; YOSHIZAWA T, 1995, BIOCHEM BIOPH RES CO, V208, P376, DOI 10.1006/bbrc.1995.1348; YOSHIZAWA T, 1995, FEBS LETT, V358, P101, DOI 10.1016/0014-5793(94)01401-L; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007; Zhang WL, 1996, BIOCHEM BIOPH RES CO, V227, P890, DOI 10.1006/bbrc.1996.1601; ZIMMERMAN UJP, 1984, PROG NEUROBIOL, V23, P63, DOI 10.1016/0301-0082(84)90012-1	42	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25802	25808		10.1074/jbc.272.41.25802	http://dx.doi.org/10.1074/jbc.272.41.25802			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325309	hybrid			2022-12-25	WOS:A1997YA35800064
J	Werner, I; Bacher, A; Eisenreich, W				Werner, I; Bacher, A; Eisenreich, W			Retrobiosynthetic NMR studies with C-13-labeled glucose - Formation of gallic acid in plants and fungi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOBACTERIUM-THERMOAUTOTROPHICUM; BIOSYNTHESIS	The biosynthesis of gallic acid was studied in cultures of the fungus Phycomyces blakesleeanus and in leaves of the tree Rhus typhina. Fungal cultures were grown with [1-C-13]gluose or with a mixture of unlabeled glucose and [U-C-13(6)]glucose. Young leaves of R. typhina were kept in an incubation chamber and were supplied with a solution containing a mixture of unlabeled glucose and [U-C-13(6)]glucose via the leaf stem. Isotope distributions in isolated gallic acid and aromatic amino acids were analyzed by one-dimensional H-1 and C-13 NMR spectroscopy. A quantitative analysis of the complex isotopomer composition of metabolites was obtained by deconvolution of the (CC)-C-13-C-13 coupling multiplets using numerical simulation methods. This approach required the accurate analysis of heavy isotope chemical shift effects in a variety of different isotopomers and the analysis of long range (CC)-C-13-C-13 coupling constants. The resulting isotopomer patterns were interpreted using a retrobiosynthetic approach based on a comparison between the isotopomer patterns of gallic acid and tyrosine. The data show that both in the fungus and in the plant all carbon atoms of gallic acid are biosynthetically equivalent to carbon atoms of shikimate. Notably, the carboxylic group of gallic acid is derived from the carboxylic group of an early intermediate of the shikimate pathway and not from the side chain of phenylalanine or tyrosine. It follows that the committed precursor of gallic acid is an intermediate of the shikimate pathway prior to prephenate or arogenate, most probably 5-dehydroshikimate. A formation of gallic acid via phenylalanine, the lignin precursor, caffeic acid, or 3,4,5-trihydroxycinnamic acid can be ruled out as major pathways in the fungus and in young leaves of R. typhina. The incorporation of uniformly C-13-labeled glucose followed by quantitative NMR analysis of isotopomer patterns is suggested as a general method for biosynthetic studies. As shown by the plant experiment, this approach is also applicable to systems with low incorporation rates.	TECH UNIV MUNICH,DEPT ORGAN CHEM & BIOCHEM,D-85747 GARCHING,GERMANY	Technical University of Munich			Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				BRUCKER W., 1962, BER DEUTSCH BOT GES, V75, P3; BRUCKER W, 1957, PLANTA, V48, P627, DOI 10.1007/BF01945032; BRUCKER W, 1958, ARCH MIKROBIOL, V30, P396, DOI 10.1007/BF00411234; CONN EE, 1961, CHEM IND-LONDON, P592; CORNTHWAITE D, 1965, J CHEM SOC, P3008, DOI 10.1039/jr9650003008; DEWICK PM, 1968, CHEM COMMUN, P673, DOI 10.1039/c19680000673; DEWICK PM, 1969, BIOCHEM J, V113, P537, DOI 10.1042/bj1130537; Dixon RA, 1996, GENE, V179, P61, DOI 10.1016/S0378-1119(96)00327-7; Eisenreich W, 1997, J BIOL CHEM, V272, P867, DOI 10.1074/jbc.272.2.867; EISENREICH W, 1991, J BIOL CHEM, V266, P23840; Eisenreich W, 1996, P NATL ACAD SCI USA, V93, P6431, DOI 10.1073/pnas.93.13.6431; EISENREICH W, 1991, J BIOL CHEM, V266, P9622; Gilchrist D. G., 1980, The biochemistry of plants. A comprehensive treatise. Volume 5. Amino acids and derivatives., P507; GROSS GG, 1992, BASIC LIFE SCI, V59, P43; HASLAM E, 1961, J CHEM SOC, P1854, DOI 10.1039/jr9610001854; HASLAM E, 1992, BASIC LIFE SCI, V59, P169; ISHIKURA N, 1975, EXPERIENTIA, V31, P1407, DOI 10.1007/BF01923213; ISHIKURA N, 1984, BOT MAG TOKYO, V97, P355, DOI 10.1007/BF02488668; KATO N, 1968, BOT MAG TOKYO, V81, P506; MARIGO G, 1969, CR ACAD SCI D NAT, V269, P1852; NEISH AC, 1964, PHYTOCHEMISTRY, V3, P485; SAIJO R, 1983, AGR BIOL CHEM TOKYO, V47, P455, DOI 10.1080/00021369.1983.10865673; STRAUSS G, 1992, EUR J BIOCHEM, V205, P853, DOI 10.1111/j.1432-1033.1992.tb16850.x; TATEOKA TN, 1968, BOT MAG TOKYO, V81, P103; ZAPROMETOV M N, 1968, Biokhimiya, V33, P383; ZENK MH, 1964, Z NATURFORSCH PT B, VB 19, P83	26	77	84	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25474	25482		10.1074/jbc.272.41.25474	http://dx.doi.org/10.1074/jbc.272.41.25474			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325260	hybrid			2022-12-25	WOS:A1997YA35800015
J	Samson, M; LaRosa, G; Libert, F; Paindavoine, P; Detheux, M; Vassart, G; Parmentier, M				Samson, M; LaRosa, G; Libert, F; Paindavoine, P; Detheux, M; Vassart, G; Parmentier, M			The second extracellular loop of CCR5 is the major determinant of ligand specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR GENE; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; HIV-1 INFECTION; INTERLEUKIN-8 RECEPTOR; CELLS; ENTRY; MIP-1-ALPHA; MIP-1-BETA; RANTES	The chemokine receptor CCR5 binds macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta, and regulated on activation, normal T-cell expressed and secreted (RANTES), and constitutes the major co-receptor allowing infection of CD4(+) T lymphocytes, macrophages, and microglial cells by macrophage-tropic strains of human and simian immunodeficiency virus, CCR5 is most closely related to CCR2b, another chemokine receptor that responds to monocyte chemoattractant protein (MCP)-1, MCP-2, MCP-3, and MCP-4, We have investigated by mutagenesis the regions of CCR5 and CCR2b involved in the specificity of binding and functional response to their respective ligands, We demonstrate that the key region of CCR5 involved in its specific interaction with MIP-1 alpha, MIP-1 beta, and RANTES, and its subsequent activation, lies within the second extracellular loop (and possibly the adjacent transmembrane segments), Conversely, the NH2-terminal domain of CCR2b is responsible for the high affinity binding of MCP-1, but is not sufficient to confer activation of the intracellular cascades. Extracellular loops of the receptor, among which the second loop plays a prominent role, are necessary to achieve efficient signaling of the receptor, These data complement our previous mapping of CCR5 domains functionally involved in the fusion process with the human immunodeficiency virus envelope, and will help in the development of agents able to interfere with the early steps of viral infection.	ULB,IRIBHN,SERV GENET MED,B-1070 BRUSSELS,BELGIUM; EUROSCREEN SA,INST INTERDISCIPLINARY RES,BRUSSELS,BELGIUM; LEUKOSITE INC,CAMBRIDGE,MA 02142	Universite Libre de Bruxelles			Samson, Michel/F-8356-2013	Parmentier, Marc/0000-0001-8081-4685				Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P4005, DOI 10.1073/pnas.94.8.4005; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FRANCI C, 1995, J IMMUNOL, V154, P651; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; OWICKI JC, 1992, BIOSENS BIOELECTRON, V7, P255, DOI 10.1016/0956-5663(92)87004-9; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PERRET J, 1990, BIOCHEM BIOPH RES CO, V171, P1044, DOI 10.1016/0006-291X(90)90789-P; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zhao-Hai Lu, 1995, Journal of Biological Chemistry, V270, P26239	37	165	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24934	24941		10.1074/jbc.272.40.24934	http://dx.doi.org/10.1074/jbc.272.40.24934			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312096	hybrid			2022-12-25	WOS:A1997XY97000035
J	Vandana, S; Raje, M; Krishnasastry, MV				Vandana, S; Raje, M; Krishnasastry, MV			The role of the amino terminus in the kinetics and assembly of alpha-hemolysin of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-FORMING PROTEIN; ESCHERICHIA-COLI; TRANSMEMBRANE PORE; KEY RESIDUES; MEMBRANE; TOXIN; MUTAGENESIS; EXPRESSION; BACTERIA; SEQUENCE	The nature of the involvement of an intact NH2 terminus in the assembly of alpha-hemolysin of Staphylococcus aureus was reinvestigated, For the first time, a deletion of the first four amino acids at the NH2 terminus of alpha-hemolysin yielded a novel mutant that undergoes all of the conformational changes to form a lytic pore, The experimental evidence shows unequivocally that the mutant toxin forms heat and sodium dodecyl sulfate-stable heptameric oligomers. The concentration required to achieve 50% lysis of red blood cells is around 58-116 ng/ml, and the time taken to achieve lysis to the same extent as that of intact toxin is considerably longer. Transmission electron microscopic studies also suggest that the pores formed by this deletion mutant are similar to those by the full-length toxin, This is in contrast to the previously reported 2- and 11 amino acid deletions that failed to proceed further from a presumed prefinal nonlytic pore to a lytic pore, Studies on the kinetics of assembly indicate that this mutant can form heat-and sodium dodecyl sulfate-stable oligomers as fast as full-length alpha-hemolysin but that pore opening is slowed down. The data strongly suggest that these amino acids (Ala-Asp-Ser-Asp) are involved in the final stages of assembly of alpha-hemolysin in target membranes.	INST MICROBIAL TECHNOL, CHANDIGARH 160036, INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)								Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; ARBUTHNOTT JP, 1967, J BACTERIOL, V94, P1170, DOI 10.1128/JB.94.4.1170-1177.1967; CHAZIN WJ, 1995, NAT STRUCT BIOL, V2, P707, DOI 10.1038/nsb0995-707; Engelman DM, 1996, SCIENCE, V274, P1850, DOI 10.1126/science.274.5294.1850; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; IKIGAI H, 1984, FEMS MICROBIOL LETT, V24, P319, DOI 10.1111/j.1574-6968.1984.tb01327.x; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LATHROP BK, 1992, PROTEIN EXPRES PURIF, V3, P512, DOI 10.1016/1046-5928(92)90069-9; LEMA MW, 1994, J MICROBIOL METH, V19, P167, DOI 10.1016/0167-7012(94)90066-3; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; OLOFSSON A, 1990, J MOL BIOL, V214, P299, DOI 10.1016/0022-2836(90)90162-F; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; WALKER B, 1993, J BIOL CHEM, V268, P5285; WALKER B, 1992, J BIOL CHEM, V267, P10902; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; WALKER B, 1994, PROTEIN ENG, V7, P655, DOI 10.1093/protein/7.5.655	26	29	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24858	24863		10.1074/jbc.272.40.24858	http://dx.doi.org/10.1074/jbc.272.40.24858			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312085	hybrid			2022-12-25	WOS:A1997XY97000024
J	Bevan, AP; Krook, A; Tikerpae, J; Seabright, PJ; Siddle, K; Smith, GD				Bevan, AP; Krook, A; Tikerpae, J; Seabright, PJ; Siddle, K; Smith, GD			Chloroquine extends the lifetime of the activated insulin receptor complex in endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; DEPENDENT DIABETES-MELLITUS; LOW-DENSITY VESICLES; RAT HEPATOMA-CELLS; KINASE; LIVER; DEGRADATION; INTERNALIZATION; BINDING; INVIVO	Insulin signal transduction, initiated by binding of insulin to its receptor at the plasma membrane, activates the intrinsic receptor tyrosine kinase and leads to internalization of the activated ligand-receptor complex into endosomes, This study addresses the role played by the activated insulin receptor within hepatic endosomes and provides evidence for its central role in insulin-stimulated events in vivo. Rats were treated with chloroquine, an acidotrophic agent that has been shown previously to inhibit endosomal insulin degradation, and then with insulin. Livers were removed and fractionated by density gradient centrifugation to obtain endosomal and plasma membrane preparations, Chloroquine treatment increased the amount of receptor bound insulin in endosomes at 2 min after insulin injection by 93% as determined by exclusion from G-50 columns and by 90% as determined by polyethylene glycol precipitation (p < 0.02), Chloroquine treatment also increased the insulin receptor content of endosomes after insulin injection (integrated over 0-45 min) by 31% when compared with controls (p < 0.05), Similarly, chloroquine increased both insulin receptor phosphotyrosine content and its exogenous tyrosine kinase activity after insulin injection (64%; p < 0.01 and 96% and p < 0.001, respectively), In vivo chloroquine treatment was without any observable effect on insulin binding to plasma membrane insulin receptors, nor did it augment insulin-stimulated receptor autophosphorylation or kinase activity in the plasma membrane. Concomitant with its effects on endosomal insulin receptors, chloroquine treatment augmented insulin-stimulated incorporation of glucose into glycogen in diaphragm (p < 0.001), These observations are consistent with the hypothesis that chloroquine-dependent inhibition of endosomal insulin receptor dissociation and subsequent degradation prolongs the half-life of the active endosomal receptor and potentiates insulin signaling from this compartment.			Bevan, AP (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,HILLS RD,CAMBRIDGE CB2 2QR,ENGLAND.		Krook, Anna/K-1192-2015	Krook, Anna/0000-0002-0891-0258; Bevan, Paul/0000-0002-0656-9164	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Armitage P., 1987, STAT METHODS MED RES; AUTHIER F, 1994, J BIOL CHEM, V269, P3010; Bevan AP, 1996, TRENDS ENDOCRIN MET, V7, P13, DOI 10.1016/1043-2760(95)00179-4; BEVAN AP, 1995, BIOCHEM J, V311, P787, DOI 10.1042/bj3110787; BEVAN AP, 1995, AM J PHYSIOL-ENDOC M, V268, pE60, DOI 10.1152/ajpendo.1995.268.1.E60; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; BEVAN AP, 1997, KEYS S TEMP SPAT DET, P58; BLAZAR BR, 1984, DIABETES, V33, P1133, DOI 10.2337/diabetes.33.12.1133; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHRISTENSEN JR, 1985, CELL BIOCHEM FUNCT, V3, P13, DOI 10.1002/cbf.290030105; CHRISTENSEN JR, 1987, BIOCHEM SOC T, V16, P574; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; DENNIS PA, 1981, ARCH BIOCHEM BIOPHYS, V212, P170, DOI 10.1016/0003-9861(81)90356-8; DESBUQUOIS B, 1992, DIABETES METAB, V18, P104; DEVRIES CP, 1990, DIABETES METAB, V16, P70; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; Drake PG, 1996, ENDOCRINOLOGY, V137, P4960, DOI 10.1210/en.137.11.4960; ECKEL J, 1988, BIOCHEM J, V249, P111, DOI 10.1042/bj2490111; FAURE R, 1992, J BIOL CHEM, V267, P11215; Hansen BF, 1996, BIOCHEM J, V315, P271; IWAMOTO Y, 1982, BIOCHEM BIOPH RES CO, V103, P863; JORGENSEN KH, 1980, DIABETOLOGIA, V19, P546; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; KASUYA J, 1994, BIOCHEM BIOPH RES CO, V200, P777, DOI 10.1006/bbrc.1994.1518; KAY DG, 1986, J BIOL CHEM, V261, P8473; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KLEIN HH, 1987, J BIOL CHEM, V262, P10557; KNUTSON VP, 1991, FASEB J, V5, P2130, DOI 10.1096/fasebj.5.8.2022311; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; MORGAN DO, 1985, ENDOCRINOLOGY, V116, P1224, DOI 10.1210/endo-116-3-1224; MURPHY RF, 1984, J CELL BIOL, V98, P1757, DOI 10.1083/jcb.98.5.1757; PEASE RJ, 1985, BIOCHEM J, V228, P137, DOI 10.1042/bj2280137; PEASE RJ, 1987, EUR J BIOCHEM, V164, P251, DOI 10.1111/j.1432-1033.1987.tb11018.x; POSNER BI, 1980, J BIOL CHEM, V255, P735; POSNER BI, 1982, J BIOL CHEM, V257, P5789; POWRIE JK, 1991, AM J PHYSIOL, V260, pE897, DOI 10.1152/ajpendo.1991.260.6.E897; RAFAELSE.OJ, 1965, DIABETES, V14, P19, DOI 10.2337/diab.14.1.19; RIDEOUT JM, 1985, BIOCHEM SOC T, V13, P1225; Seabright PJ, 1996, BIOCHEM J, V320, P947, DOI 10.1042/bj3200947; SMITH GD, 1982, BIOCHIM BIOPHYS ACTA, V716, P24, DOI 10.1016/0304-4165(82)90198-2; SMITH GD, 1989, EUR J BIOCHEM, V181, P287, DOI 10.1111/j.1432-1033.1989.tb14723.x; SMITH GD, 1987, BRIT MED J, V294, P465, DOI 10.1136/bmj.294.6570.465; SOOS MA, 1992, J BIOL CHEM, V267, P12955; SORIMACHI K, 1987, ENDOCR RES, V13, P49, DOI 10.1080/07435808709023662; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430; YOUN JH, 1990, AM J PHYSIOL, V258, pE899, DOI 10.1152/ajpendo.1990.258.6.E899; ZHANG B, 1991, J BIOL CHEM, V266, P990	55	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26833	26840		10.1074/jbc.272.43.26833	http://dx.doi.org/10.1074/jbc.272.43.26833			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341114	hybrid			2022-12-25	WOS:A1997YC65900010
J	Krueger, KA; Bhatt, H; Landt, M; Easom, RA				Krueger, KA; Bhatt, H; Landt, M; Easom, RA			Calcium-stimulated phosphorylation of MAP-2 in pancreatic beta TC3-cells is mediated by Ca2+/calmodulin-dependent kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; INSULIN-SECRETION; CYCLIC-AMP; BETA-CELL; ASSEMBLY INVITRO; RAT ISLETS; TAU-FACTOR; B-CELL; CALMODULIN; INHIBITOR	An understanding of the role of CaM kinase II in the pancreatic beta-cell is dependent on the identification of its cellular targets, One of the best substrates of CaM kinase II in vitro that could function in secretory events is the microtubule-associated protein, MAP-2. By immuno-blot analysis, a high molecular weight protein with electrophoretic properties characteristic of MAP-2, was identified in rat insulinoma beta TC3 cells and isolated rat islets. In immunoprecipitation experiments employing alpha-toxin-permeabilized beta TC3 cells, elevation of intracellular Ca2+ or addition of forskolin, an adenylate cyclase activator, induced significant phosphorylation of MAP-2 in situ. The effect of Ca2+ was rapid, concentration-dependent and closely correlated with activation of CaM kinase II under similar experimental conditions, H-89, a specific and potent inhibitor of cAMP-dependent protein kinase (PKA),prevented forskolin-induced MAP-2 phosphorylation but had little effect on MAP-2 phosphorylation stimulated by elevated Ca2+. Phosphopeptide mapping revealed that the phosphorylation pattern observed in situ upon incubation of the beta TC3 cells with increased free Ca2+, was strikingly similar to that generated in vitro by CaM kinase Il, most notably with regard to the increased phosphate incorporated into one prominent site, These data provide evidence that MAP-2 is phosphorylated by CaM kinase II in the pancreatic beta-cell in situ, and that this event may provide an important Link in the mediation of Ca2+-dependent insulin secretion.	UNIV N TEXAS,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,FT WORTH,TX 76107; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110	University of North Texas System; University of North Texas Health Science Center; Washington University (WUSTL)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047925] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47925] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1994, CELL BIOL LAB HDB, V3, P77; AINSZTEIN AM, 1994, J BIOL CHEM, V269, P28465; Babb EL, 1996, BIOCHEM J, V317, P167, DOI 10.1042/bj3170167; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; CACERES A, 1983, P NATL ACAD SCI-BIOL, V80, P1738, DOI 10.1073/pnas.80.6.1738; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CLYNE CD, 1995, ENDOCR RES, V21, P259, DOI 10.3109/07435809509030441; DECAMILLI P, 1984, NEUROSCIENCE, V11, P761, DOI 10.1016/0306-4522(84)90193-3; DIAZNIDO J, 1993, EUR J NEUROSCI, V5, P818, DOI 10.1111/j.1460-9568.1993.tb00933.x; Easom RA, 1997, ENDOCRINOLOGY, V138, P2359, DOI 10.1210/en.138.6.2359; EASOM RA, 1990, J BIOL CHEM, V265, P14938; FARSHORI PQ, 1997, J SUBMICR CYTOL PATH, V26, P137; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; FERREIRA A, 1993, MOL BIOL CELL, V4, P1225, DOI 10.1091/mbc.4.12.1225; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GILON P, 1995, BIOCHEM J, V311, P259, DOI 10.1042/bj3110259; GOLDENRING JR, 1985, J NEUROCHEM, V45, P900, DOI 10.1111/j.1471-4159.1985.tb04078.x; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HARRISON DE, 1982, BIOCHIM BIOPHYS ACTA, V714, P313, DOI 10.1016/0304-4165(82)90339-7; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; Hisatomi M, 1996, ENDOCRINOLOGY, V137, P4644, DOI 10.1210/en.137.11.4644; HUGHES SJ, 1987, MOL CELL ENDOCRINOL, V50, P231, DOI 10.1016/0303-7207(87)90021-9; JEFFERSON AB, 1991, J BIOL CHEM, V266, P346; KOSIK KS, 1988, J NEUROCHEM, V51, P587, DOI 10.1111/j.1471-4159.1988.tb01079.x; KOSZKA C, 1985, EUR J CELL BIOL, V38, P149; LACY PE, 1972, DIABETES, V21, P987, DOI 10.2337/diab.21.10.987; LACY PE, 1975, LAB INVEST, V33, P570; LI GD, 1992, MOL PHARMACOL, V42, P489; LICHTENBERG B, 1988, NATURE, V334, P359, DOI 10.1038/334359a0; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; Mohlig M, 1997, ENDOCRINOLOGY, V138, P2577, DOI 10.1210/en.138.6.2577; NIKI I, 1993, BIOCHEM BIOPH RES CO, V191, P255, DOI 10.1006/bbrc.1993.1210; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; PIPELEERS DG, 1976, SCIENCE, V191, P88, DOI 10.1126/science.1108194; RAFFAELLI N, 1992, FEBS LETT, V296, P21, DOI 10.1016/0014-5793(92)80394-V; SATTILARO RF, 1986, BIOCHEMISTRY-US, V25, P2003, DOI 10.1021/bi00356a025; SCHUIT FC, 1985, ENDOCRINOLOGY, V117, P834, DOI 10.1210/endo-117-3-834; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; SHARP GWG, 1979, DIABETOLOGIA, V16, P287, DOI 10.1007/BF01223617; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; SOMERS G, 1979, ENDOCRINOLOGY, V104, P255, DOI 10.1210/endo-104-1-255; SUPRENANT KA, 1982, J CELL BIOL, V93, P164, DOI 10.1083/jcb.93.1.164; THEURKAUF WE, 1983, J BIOL CHEM, V258, P7883; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; TSUYAMA S, 1987, J BIOL CHEM, V262, P10886; TSUYAMA S, 1986, J BIOL CHEM, V261, P4110; VALDIVIA MM, 1982, BIOCHEM BIOPH RES CO, V105, P1241, DOI 10.1016/0006-291X(82)90920-2; VANDERGEER P, 1994, CELL BIOL LAB HDB, V3, P422; WANG JL, 1990, BIOCHEM BIOPH RES CO, V171, P424, DOI 10.1016/0006-291X(90)91410-T; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; WENHAM RM, 1992, BIOCHEM BIOPH RES CO, V189, P128, DOI 10.1016/0006-291X(92)91534-W; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x	56	40	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27464	27469		10.1074/jbc.272.43.27464	http://dx.doi.org/10.1074/jbc.272.43.27464			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341200	hybrid			2022-12-25	WOS:A1997YC65900096
J	Mitamura, T; Umata, T; Nakano, F; Shishido, Y; Toyoda, T; Itai, A; Kimura, H; Mekada, E				Mitamura, T; Umata, T; Nakano, F; Shishido, Y; Toyoda, T; Itai, A; Kimura, H; Mekada, E			Structure-function analysis of the diphtheria toxin receptor toxin binding site by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; VERO CELLS; MEMBRANE-PROTEIN; MUTANT PROTEINS; CD9 ANTIGEN; EGF; DOMAIN; EXPRESSION; IDENTIFICATION; TRANSLOCATION	Diphtheria toxin (DT) binds to the epidermal growth factor (EGF)-like domain of human membrane-anchored heparin-binding EGF-like growth factor (proHB-EGF), the human DT receptor (DTR). DT does not bind to mouse proHB-EGF because of amino acid substitutions within the EGF-like domain. We made 10 independent mutants, replacing a single amino acid within the EGF-like domain of human DTR/proHB-EGF with the corresponding amino acid residue in mouse proHB-EGF. The mutant proteins were transiently expressed in mouse L cells either expressing or not expressing DRAP27/CD9, and DT binding was measured. DT binding activity of GST fusion proteins containing the mutated EGF-like domain was also determined by a cell-free binding assay. The largest effect was seen with E141H, and second largest effects were seen with F115Y and L127F in all of the assay systems. We conclude that Phe(115), Leu(127), and Glu(141) are critical amino acid residues for DT binding. A computer model of the tertiary structure of the EGF-like domain of human DTR/proHB-EGF was made. The model predicts that three amino acid residues critical for DT binding activity, Phe(115), Leu(127), and Glu(141) are all located on the same face of the EGF-like domain, suggesting that this face of DTR/proHB-EGF interacts with the receptor-binding domain of DT.	KURUME UNIV,INST LIFE SCI,DIV CELL BIOL,KURUME,FUKUOKA 830,JAPAN; KURUME UNIV,SCH MED,DEPT LEGAL MED,KURUME,FUKUOKA 839,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,TOKYO 113,JAPAN	Kurume University; Kurume University; University of Tokyo			Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Mekada, Eisuke/0000-0001-8858-4781				ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; BENEDETTI E, 1983, INT J PEPT PROT RES, V22, P1; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BOQUET P, 1976, P NATL ACAD SCI USA, V73, P4449, DOI 10.1073/pnas.73.12.4449; BROWN JG, 1993, P NATL ACAD SCI USA, V90, P8184, DOI 10.1073/pnas.90.17.8184; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; GABLIKS J, 1962, J IMMUNOL, V88, P505; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HARVEY TS, 1991, EUR J BIOCHEM, V198, P555, DOI 10.1111/j.1432-1033.1991.tb16050.x; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hooper KP, 1996, BIOCHEM BIOPH RES CO, V220, P675, DOI 10.1006/bbrc.1996.0463; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; JORGENSEN WL, 1981, J AM CHEM SOC, V103, P335, DOI 10.1021/ja00392a016; LENNOX ES, 1957, P SOC EXP BIOL MED, V95, P700, DOI 10.3181/00379727-95-23335; MEKADA E, 1991, J BIOL CHEM, V266, P20457; MEKADA E, 1988, J CELL BIOL, V107, P511, DOI 10.1083/jcb.107.2.511; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MONTELIONE GT, 1986, P NATL ACAD SCI USA, V83, P8594, DOI 10.1073/pnas.83.22.8594; MORRIS RE, 1985, INFECT IMMUN, V50, P721, DOI 10.1128/IAI.50.3.721-727.1985; MOSKAUG JO, 1989, J BIOL CHEM, V264, P15709; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OKEEFE DO, 1992, P NATL ACAD SCI USA, V89, P6202, DOI 10.1073/pnas.89.13.6202; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PEARLMAN DA, 1995, AMBER VERSION 4 1; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SHEN WH, 1994, J BIOL CHEM, V269, P29077; SHISHIDO Y, 1995, J BIOL CHEM, V270, P29578, DOI 10.1074/jbc.270.49.29578; SILVERMAN JA, 1994, J BIOL CHEM, V269, P22524; UCHIDA T, 1977, NATURE, V266, P839, DOI 10.1038/266839a0; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; VANDERSPEK J, 1994, J BIOL CHEM, V269, P21455	42	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27084	27090		10.1074/jbc.272.43.27084	http://dx.doi.org/10.1074/jbc.272.43.27084			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341148	hybrid			2022-12-25	WOS:A1997YC65900044
J	Osipovich, O; Durum, SK; Muegge, K				Osipovich, O; Durum, SK; Muegge, K			Defining the minimal domain of Ku80 for interaction with Ku70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRAND-BREAK-REPAIR; X-RAY RESISTANCE; V(D)J RECOMBINATION; AUTOANTIGEN-KU; DNA-BINDING; ANTIGEN; SUBUNIT; CELLS; CDNA	The Ku protein has a critical function in the repair of double-strand DNA breaks induced for example by ionizing radiation or during VDJ recombination. Ku serves as the DNA-binding subunit of the DNA-dependent kinase and is a heterodimeric protein composed of 80- and 70-kDa subunits. We used the two hybrid system to analyze the interaction domains of the Ku subunits and to identify possible additional partners for Ku. Screening a human cDNA library with the Ku heterodimer did not reveal any novel partners. Screening with the individual subunits, we detected only Ku70 clones interacting with Ku80 and only Ku80 clones interacting with Ku70, indicating that these are the primary partners for one another. Ku80 and Ku70 formed only heterodimers and did not homodimerize. Ku80 was restricted to interacting with just one Ku70 molecule at a time. The minimal functional interaction domain of Ku80 that interacted with Ku70 was defined. It consisted of a 28-amino acid region extending from amino acid 449 to 477. This region was crucial for interaction with Ku70, since mutation within this critical site at amino acids 453 and 454 abrogated the ability to interact with Ku70. We furthermore verified that the same region is crucial for interaction with Ku70 using in vitro co-translation of both subunits followed by an immunoprecipitation with anti Ku70 antibodies. This interaction domain of Ku80 does not contain any motif previously recognized in protein-protein interactions.	NCI,FREDERICK CANC RES & DEV CTR,MOL IMMUNOREGULAT LAB,SAIC,INTRAMURAL RES SUPPORT PROGRAM,NIH,FREDERICK,MD 21702; NCI,MOL IMMUNOREGULAT LAB,NIH,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				durum, scott/0000-0003-1307-9582				ABUELHEIGA L, 1992, CLIN IMMUNOL IMMUNOP, V64, P145, DOI 10.1016/0090-1229(92)90192-Q; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Errami A, 1996, MOL CELL BIOL, V16, P1519; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRIFFITH AJ, 1992, MOL BIOL REP, V16, P91, DOI 10.1007/BF00419754; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HARPER JW, 1993, CELL, V75, P805; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; KAISER P, 1993, BIOTECHNIQUES, V14, P552; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; MAY G, 1991, J BIOL CHEM, V266, P3052; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; REEVES WH, 1989, J BIOL CHEM, V264, P5047; ROSE MD, 1990, METHODS GENETICS LAB; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHLIESTL RH, 1989, CURR GENET, V16, P339; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SNGLETON BK, 1997, MOL CELL BIOL, V17, P1264; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WANG JS, 1994, J CELL SCI, V107, P3223; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; Wu XT, 1996, MOL CELL BIOL, V16, P5186; YANEVA M, 1989, J BIOL CHEM, V264, P13407	40	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27259	27265		10.1074/jbc.272.43.27259	http://dx.doi.org/10.1074/jbc.272.43.27259			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341172	hybrid			2022-12-25	WOS:A1997YC65900068
J	Rauch, U; Clement, A; Retzler, C; Frohlich, L; Fassler, R; Gohring, W; Faissner, A				Rauch, U; Clement, A; Retzler, C; Frohlich, L; Fassler, R; Gohring, W; Faissner, A			Mapping of a defined neurocan binding site to distinct domains of tenascin-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX PROTEIN; CELL-ADHESION MOLECULES; NEURITE OUTGROWTH; NERVOUS-TISSUE; EGF-LIKE; N-CAM; FIBRONECTIN; BRAIN; PHOSPHACAN	Neurocan is a member of the aggrecan family of proteoglycans which are characterized by NH2-terminal domains binding hyaluronan, and COOH-terminal domains containing C type lectin like modules, To detect and enhance the affinity for complementary ligands of neurocan, the COOH terminal neurocan domain was fused with the NH2-terminal region of tenascin-C, which contains the hexamerization domain of this extracellular matrix glycoprotein, The fusion protein was designed to contain the last downstream glycosaminoglycan attachment site and was expressed as a proteoglycan, In ligand overlay blots carried out with brain extracts, it recognized tenascin-C. The interaction was abolished by the addition of EDTA, or TNfn4,5, a bacterially expressed tenascin-C fragment comprising the fourth and fifth fibronectin type III module, The fusion protein directly reacted with this fragment in ligand blot and enzyme linked immunosorbent assay procedures, Both tenascin-C and TNfn4,5 were retained on Sepharose 4B-linked carboxyl-terminal neurocan domains, which in BIAcore binding studies yielded a K-D value of 17 nM for purified tenascin-C, We conclude that a divalent cation-dependent interaction between the COOH-terminal domain of neurocan and those fibronectin type III repeats is substantially involved in the binding of neurocan to tenascin-C.	UNIV HEIDELBERG,DEPT NEUROBIOL,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	Rauch, U (corresponding author), MAX PLANCK INST BIOCHEM,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Faissner, Andreas/A-5314-2008	Faissner, Andreas/0000-0002-2211-8259				ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; CHIQUETEHRISMANN R, 1991, CELL REGUL, V2, P927, DOI 10.1091/mbc.2.11.927; CHUNG CY, 1995, J BIOL CHEM, V270, P29012, DOI 10.1074/jbc.270.48.29012; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FAISSNER A, 1995, GLIA, V13, P233, DOI 10.1002/glia.440130402; Faissner A, 1996, SEMIN NEUROSCI, V8, P347, DOI 10.1006/smns.1996.0043; Faissner Andreas, 1995, Seminars in Developmental Biology, V6, P139, DOI 10.1016/S1044-5781(06)80023-X; Forsberg E, 1996, P NATL ACAD SCI USA, V93, P6594, DOI 10.1073/pnas.93.13.6594; FRIEDLANDER DR, 1988, J CELL BIOL, V107, P2329, DOI 10.1083/jcb.107.6.2329; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; Gotz B, 1996, J CELL BIOL, V132, P681, DOI 10.1083/jcb.132.4.681; Gotz M, 1997, EUR J NEUROSCI, V9, P496, DOI 10.1111/j.1460-9568.1997.tb01627.x; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HOFFMAN S, 1988, J CELL BIOL, V106, P519, DOI 10.1083/jcb.106.2.519; HUSMANN K, 1992, J CELL BIOL, V116, P1475, DOI 10.1083/jcb.116.6.1475; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; IWATA M, 1993, J NEUROSCI, V13, P195; IWATA M, 1993, J BIOL CHEM, V268, P15061; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kappler J, 1997, EUR J NEUROSCI, V9, P306, DOI 10.1111/j.1460-9568.1997.tb01401.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOCHTER A, 1991, J CELL BIOL, V113, P1159, DOI 10.1083/jcb.113.5.1159; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; Milev P, 1997, J BIOL CHEM, V272, P15501, DOI 10.1074/jbc.272.24.15501; MILEV P, 1995, J BIOL CHEM, V270, P24650, DOI 10.1074/jbc.270.42.24650; MORGELIN M, 1994, BIOPHYS CHEM, V50, P113, DOI 10.1016/0301-4622(94)85024-0; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; RATHJEN FG, 1991, DEVELOPMENT, V113, P151; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Retzler C, 1996, J BIOL CHEM, V271, P27304, DOI 10.1074/jbc.271.44.27304; Retzler C, 1996, J BIOL CHEM, V271, P17107, DOI 10.1074/jbc.271.29.17107; Scholze A, 1996, INT J DEV NEUROSCI, V14, P315, DOI 10.1016/0736-5748(96)00016-0; Schumacher S, 1997, J CELL BIOL, V136, P895, DOI 10.1083/jcb.136.4.895; SEIDENBECHER CI, 1995, J BIOL CHEM, V270, P27206, DOI 10.1074/jbc.270.45.27206; TAYLOR HC, 1989, J CELL BIOCHEM, V41, P71, DOI 10.1002/jcb.240410204; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; Weber P, 1996, FEBS LETT, V389, P304, DOI 10.1016/0014-5793(96)00609-6; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	54	73	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26905	26912		10.1074/jbc.272.43.26905	http://dx.doi.org/10.1074/jbc.272.43.26905			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341124	hybrid			2022-12-25	WOS:A1997YC65900020
J	Vogt, A; Sun, JZ; Qian, YM; Hamilton, AD; Sebti, SM				Vogt, A; Sun, JZ; Qian, YM; Hamilton, AD; Sebti, SM			The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G(0)/G(1) and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; PROTEIN GERANYLGERANYLATION; RAS TRANSFORMATION; P21; G1; FARNESYLTRANSFERASE; G(1); FARNESYLATION; PRENYLATION; FIBROBLASTS	Recently we have shown that in fibroblasts (NIH 3T3 and Rat-1 cells) inhibition of protein geranylgeranylation leads to a G(0)/G(1) arrest, whereas inhibition of protein farnesylation does not affect cell cycle distribution, Here we demonstrate that in human tumor cells the geranylgeranyltransferase-I (GGTase-I) inhibitor GGTI-298 blocked cells in G(0)/G(1), whereas the farnesyltransferase (FTase) inhibitor FTI-277 showed a differential effect depending on the cell line, FTI-277 accumulated Calu-1 and A-549 lung carcinoma and Cola 357 pancreatic carcinoma cells in G(2)/M, T-24 bladder carcinoma, and HT-1080 fibrosarcoma cells in G(0)/G(1), but had no effect on cell cycle distribution of pancreatic (Panc-1), breast (SKBr 3 and MDAMB-231), and head and neck (A-253) carcinoma cells, Furthermore, treatment of Calu-1, Panc-1, Cole 357, T-24, A-253, SKBr 3, and MDAMB-231 cells with GGTI-298, but not FTI-277, induced the protein expression levels of the cyclin-dependent kinase inhibitor p21(WAF). HT-1080 and A-549 cells had a high basal level of p21(WAF), and GGTI-298 did not further increase these levels, Furthermore, GGTI-298 also induces the accumulation of large amounts of p21(WAF) mRNA in Calu-1 cells, a cell line that lacks the tumor suppressor gene p53. There was little effect of GGTI-298 on the cellular levels of another cyclin-dependent kinase inhibitor p27(KIP) as well as cyclin E and cyclin D1. These results demonstrate that GGTase-I inhibitors arrest cells in G(0)/G(1) and induce accumulation of p21(WAF) in a p53-independent manner and that FTase inhibitors can interfere with cell cycle events by a mechanism that involves neither p21(WAF) nor p27(KIP). The results also point to the potential of GGTase-I inhibitors as agents capable of restoring growth arrest in cells lacking functional p53.	UNIV S FLORIDA,DEPT BIOCHEM & MOL BIOL,H LEE MOFFIT CANC CTR & RES INST,TAMPA,FL 33612; UNIV PITTSBURGH,DEPT CHEM,SCH ARTS & SCI,PITTSBURGH,PA 15261; UNIV PITTSBURGH,DEPT PHARMACOL,SCH MED,PITTSBURGH,PA 15261	State University System of Florida; University of South Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [U19-CA-67771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALPAN RS, 1996, CELL GROWTH DIFFER; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CASEY PJ, 1992, J LIPID RES, V33, P1731; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crick D C, 1996, SAAS Bull Biochem Biotechnol, V9, P37; CRICK DC, 1994, BIOCHEM BIOPH RES CO, V205, P955, DOI 10.1006/bbrc.1994.2758; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINDER JD, 1997, J BIOL CHEM, V272, P1384; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Macchia M, 1996, J MED CHEM, V39, P1352, DOI 10.1021/jm960127s; McGuire TF, 1997, ONCOGENE, V14, P305, DOI 10.1038/sj.onc.1200819; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; Miguel K., 1997, CANCER RES, V57, P1846; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SUN JZ, 1995, CANCER RES, V55, P4243; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zeng YX, 1996, ONCOGENE, V12, P1557	46	169	178	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27224	27229		10.1074/jbc.272.43.27224	http://dx.doi.org/10.1074/jbc.272.43.27224			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341167	hybrid			2022-12-25	WOS:A1997YC65900063
J	Zhang, J; Barak, LS; Winkler, KE; Caron, MG; Ferguson, SSG				Zhang, J; Barak, LS; Winkler, KE; Caron, MG; Ferguson, SSG			A central role for beta-arrestins and clathrin-coated vesicle-mediated endocytosis in beta(2)-adrenergic receptor resensitization - Differential regulation of receptor resensitization in two distinct cell types	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HIGH-AFFINITY BINDING; FAILING HUMAN HEART; BETA-2-ADRENERGIC RECEPTOR; SEQUESTRATION; DYNAMIN; KINASE; MUTANT; INTERNALIZATION; EXPRESSION	G protein-coupled receptor (GPCR) sequestration to endosomes is proposed to be the mechanism by which G protein-coupled receptor kinase (GRK)-phosphorylated receptors are dephosphorylated and resensitized. The identification of beta-arrestins as GPCR trafficking molecules suggested that beta-arrestins might represent critical determinants for GPCR resensitization. Therefore, we tested whether beta(2)-adrenergic receptor (beta(2)AR) resensitization was dependent upon beta-arrestins and an intact clathrin coated vesicle endocytic pathway. The overexpression of either the beta-arrestin 1-V53D dominant negative inhibitor of beta(2)AR sequestration or dynamin I-K44A to block, clathrin-coated vesicle-mediated endocytosis impaired both beta(2)AR dephosphorylation and resensitization. In contrast, resensitization of a sequestration impaired beta(2)AR mutant (Y326A) was reestablished following the overexpression of either GRK2 or beta-arrestin 1. Moreover, beta(2)ARs did not resensitize in COS-7 cells as the consequence of impaired sequestration and dephosphorylation. However, beta(2)AR resensitization was restored in these cells following the overexpression of beta-arrestin 2. These findings demonstrate, using both loss and gain of function paradigms, that beta(2)AR dephosphorylation and resensitization are dependent upon an intact sequestration pathway. These studies also indicate that beta-arrestins play an integral role in regulating not only the desensitization and intracellular trafficking of GPCRs but their ability to resensitize. beta-Arrestin expression levels appear to underlie cell type specific differences in the regulation of GPCR resensitization.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 03422] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Ferguson SSG, 1996, BIOCHEM SOC T, V24, P953, DOI 10.1042/bst0240953; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Garland AM, 1996, MOL PHARMACOL, V49, P438; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; ITCKAWA M, 1996, MOL PHARMACOL, V49, P560; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MOORE RH, 1995, J CELL SCI, V108, P2983; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SCHLADOR ML, 1996, 26 ANN M NOV 16 21 1, P1257; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TERWILLIGER RZ, 1994, J NEUROCHEM, V63, P1983; TSUGA H, 1994, J BIOL CHEM, V269, P32522; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; ZHANG J, 1997, IN RPESS RECEPTORS C	49	213	216	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27005	27014		10.1074/jbc.272.43.27005	http://dx.doi.org/10.1074/jbc.272.43.27005			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341139	hybrid, Green Submitted			2022-12-25	WOS:A1997YC65900035
J	Bratton, DL; Fadok, VA; Richter, DA; Kailey, JM; Guthrie, LA; Henson, PM				Bratton, DL; Fadok, VA; Richter, DA; Kailey, JM; Guthrie, LA; Henson, PM			Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; PLASMA-MEMBRANE; TRANSBILAYER MOVEMENT; ERYTHROCYTE-MEMBRANE; TISSUE TRANSGLUTAMINASE; EXTRACELLULAR RELEASE; LEUKEMIA-CELLS; T-LYMPHOCYTES; ICE-LIKE; PHOSPHOLIPIDS	Phosphatidylserine (PS), ordinarily sequestered in the plasma membrane inner leaflet, appears in the outer leaflet during apoptosis, where it triggers non-inflammatory phagocytic recognition of the apoptotic cell, The mechanism of PS appearance during apoptosis is not well understood but has been associated with loss of aminophospholipid translocase activity and nonspecific flip flop of phospholipids of various classes, The human leukemic cell line HL-60, the T cell line Jurkat, and peripheral blood neutrophils, undergoing apoptosis induced either with UV irradiation or anti-Fas antibody, were probed in the cytofluorograph for (i) surface PS using fluorescein isothiocyanate-labeled annexin V, (ii) PS uptake by the aminophospholipid translocase using [6-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino] caproyl] (NBD)-labeled PS, (iii) nonspecific uptake of phospholipids (as a measure of transbilayer flip flop) using NBD-labeled phosphatidylcholine, and (iv) the appearance of hypodiploid DNA, In all three types of cells undergoing apoptosis, the appearance of PS followed loss of aminophospholipid translocase and was accompanied by nonspecific phospholipid flip-flop, Importantly, however, in the absence of extracellular calcium, the appearance of PS was completely inhibited despite DNA fragmentation and loss of aminophospholipid translocase activity, the latter demonstrating that loss of the translocase is insufficient for PS appearance during apoptosis, Furthermore, while both the appearance of PS and nonspecific phospholipid uptake demonstrated identical extracellular calcium requirements with an ED50 of nearly 100 mu m, the magnitude of PS appearance depended on the level of aminophospholipid translocase activity, Taken together, the data strongly suggest that while nonspecific flip-flop is the driving event for PS appearance in the plasma membrane outer leaflet, aminophospholipid translocase activity ultimately modulates its appearance.			Bratton, DL (corresponding author), NATL JEWISH MED & RES CTR, DEPT PEDIAT, 1400 JACKSON ST, DENVER, CO 80206 USA.				NHLBI NIH HHS [HL34303] Funding Source: Medline; NIGMS NIH HHS [GM48211] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048211] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amendola A, 1996, P NATL ACAD SCI USA, V93, P11057, DOI 10.1073/pnas.93.20.11057; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; BEVERS EM, 1989, BIOCHEMISTRY-US, V28, P2382, DOI 10.1021/bi00432a007; BRATTON DL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P24, DOI 10.1016/0005-2736(91)90330-B; BRATTON DL, 1994, J BIOL CHEM, V269, P22517; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; BRATTON DL, 1994, J LIPID MEDIAT CELL, V10, P43; BRATTON DL, 1993, J BIOL CHEM, V268, P3364; BRATTON DL, 1992, J IMMUNOL, V148, P514; CHANG CP, 1993, J BIOL CHEM, V268, P7171; COTTER TG, 1992, CANCER RES, V52, P997; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FADOK VA, 1992, J IMMUNOL, V148, P2207; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HASLETT C, 1985, AM J PATHOL, V119, P101; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; KOK JW, 1995, BIOCHEM J, V309, P905, DOI 10.1042/bj3090905; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LENNON SV, 1992, CLIN EXP IMMUNOL, V87, P465; LESLIE CC, 1990, METHOD ENZYMOL, V187, P216; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; Nagy L, 1996, LEUKEMIA RES, V20, P499, DOI 10.1016/0145-2126(95)00118-2; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; Park HJ, 1996, EUR J CANCER, V32A, P540, DOI 10.1016/0959-8049(95)00606-0; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; Squier MKT, 1997, J IMMUNOL, V158, P3690; SUNE A, 1987, BIOCHEMISTRY-US, V26, P2972, DOI 10.1021/bi00385a003; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TILLY RHJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P188, DOI 10.1016/0005-2736(90)90453-U; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; WHYTE MKB, 1993, J CLIN INVEST, V92, P446, DOI 10.1172/JCI116587; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; ZACHOWSKI A, 1986, BIOCHEMISTRY-US, V25, P2585, DOI 10.1021/bi00357a046; Zhu WH, 1996, BIOCHEM PHARMACOL, V51, P1229	39	376	392	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26159	26165		10.1074/jbc.272.42.26159	http://dx.doi.org/10.1074/jbc.272.42.26159			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334182	hybrid			2022-12-25	WOS:A1997YB13900016
J	Elenius, K; Corfas, G; Paul, S; Choi, CJ; Rio, C; Plowman, GD; Klagsbrun, M				Elenius, K; Corfas, G; Paul, S; Choi, CJ; Rio, C; Plowman, GD; Klagsbrun, M			A novel juxtamembrane domain isoform of HER4/ErbB4 - Isoform-specific tissue distribution and differential processing in response to phorbol ester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; GENE ENCODES; PROTEOLYTIC CLEAVAGE; EXTRACELLULAR DOMAIN; TYROSINE KINASE; CARCINOMA-CELLS; ERBB RECEPTORS; TRUNCATED FORM; MESSENGER-RNA; LIGAND	Human epidermal growth factor receptor 4 (HER4) is a member of the epidermal growth factor (EGF) receptor subfamily of receptor tyrosine kinases that is activated by neuregulins (NRG), betacellulin (ETC), and heparin-binding EGF-like growth factor, Sequencing of full-length human HER4 cDNAs revealed the existence of two HER4 isoforms that differed by insertion of either 23 or 13 alternative amino acids in the extracellular juxtamembrane (JM) region, The 23-amino acid form (HERC JM-a) and the 13-amino acid form (HER4 JM-b) were expressed in a tissue-specific manner, as demonstrated by reverse transcriptase-polymerase chain reaction analysis of mouse and human tissues. Both isoforms were expressed in neural tissues such as cerebellum, whereas kidney expressed HER4 JM-a only and heart HER4 JM-b only, In situ hybridization using specific oligonucleotides demonstrated transcription of both JM-a and JM-b isoforms in the mouse cerebellum, Tyro sine phosphorylation analysis indicated that both receptor isoforms were activated to the same extent by NRG-beta 1 and ETC, and to a lesser extent by NRG-alpha 1 and heparin-binding EGF-like growth factor. A functional difference was found, however, in response 60 phorbol ester treatment, Stimulation of cells with phorbol ester resulted in a loss of I-125-NRG-beta 1 binding and in a reduction of total cell-associated HER4 protein in HER4 JM-a transfectants but not in HER4 JM-b transfectants. It was concluded that novel alternatively spliced isoforms of HER4 exist, that they are distributed differentially in vivo in mouse and human tissues, that they are both activated by HER4 ligands, and that they may represent cleavable and noncleavable forms of HER4.	CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115; CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02115; CHILDRENS HOSP,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; SUGEN INC,REDWOOD CITY,CA 94063	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			PLOWMAN, Greg D/E-2012-2011; Río, Carlos/GQA-4045-2022; Corfas, Gabriel/AAH-2378-2020; Elenius, Klaus/AAI-7594-2021	Río, Carlos/0000-0003-2666-7746; Corfas, Gabriel/0000-0001-5412-9473; Elenius, Klaus/0000-0001-5700-0827	NCI NIH HHS [CA 37392] Funding Source: Medline; NICHD NIH HHS [P30-HD 18655] Funding Source: Medline; NIGMS NIH HHS [GM 47397] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA037392, R37CA037392, R56CA037392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baulida J, 1996, J BIOL CHEM, V271, P5251; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARPENTER G, 1991, PEPTIDE GROWTH FACTO, P69; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KATOH M, 1993, BIOCHEM BIOPH RES CO, V192, P1189, DOI 10.1006/bbrc.1993.1542; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEVI E, 1996, P NATL ACAD SCI USA, V93, P7096; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; PUPA SM, 1993, ONCOGENE, V8, P2917; Reiter JL, 1996, NUCLEIC ACIDS RES, V24, P4050, DOI 10.1093/nar/24.20.4050; REITER JL, 1996, MOL CELL BIOL, V24, P4050; Riese DJ, 1996, ONCOGENE, V12, P345; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Strohmaier C, 1996, EMBO J, V15, P3332, DOI 10.1002/j.1460-2075.1996.tb00698.x; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; WARRINGTON AE, 1992, J NEUROSCI RES, V33, P338, DOI 10.1002/jnr.490330218; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YEE NS, 1993, J BIOL CHEM, V268, P14189; Zhang K, 1996, J BIOL CHEM, V271, P3884; ZIMONJIC DB, 1995, ONCOGENE, V10, P1235	57	177	187	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26761	26768		10.1074/jbc.272.42.26761	http://dx.doi.org/10.1074/jbc.272.42.26761			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334263	hybrid			2022-12-25	WOS:A1997YB13900097
J	Kast, C; Gros, P				Kast, C; Gros, P			Topology mapping of the amino-terminal half of multidrug resistance-associated protein by epitope insertion and immunofluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; CONJUGATE EXPORT PUMP; HUMAN TUMOR-CELLS; P-GLYCOPROTEIN; TRANSMEMBRANE ORGANIZATION; MEMBRANE TOPOLOGY; MRP GENE; MONOCLONAL-ANTIBODIES; CANALICULAR ISOFORM; CLINICAL RELEVANCE	The multidrug resistance-associated protein (MRP) is an integral membrane protein that causes multidrug resistance when overexpressed in mammalian cells, Within the ATP-binding cassette superfamily, MRP belongs to a subgroup of structurally and functionally related proteins that includes the yeast cadmium factor 1 and yeast oligomycin resistance I proteins, and the mammalian sulfonylurea receptors SUR1 and SURE, Hydropathy analysis of these proteins predicts a unique membrane-associated region at the amino terminus followed by a structural unit composed of 12 transmembrane (TM) domains and two nucleotide-binding domains that is characteristic of eukaryotic ATP-binding cassette transporters, The topology of the membrane-associated regions of MRP remains largely unknown and was investigated, Small hemagglutinin epitopes (YPYDVPDYAS) were inserted in predicted hydrophilic segments of the membrane-associated regions from the amino-terminal half of MRP and these proteins were expressed in HeLa cells, and tested for their capacity to confer etoposide resistance, The polarity of the inserted tags with respect to plasma membrane was then deduced by immunofluorescence in intact and permeabilized cells, Insertion of epitopes at positions 4, 163, 271, 574, and 653 produced functional proteins while insertions at positions 127, 417, 461, and 529 abrogated the capacity of MRP to confer drug resistance, Epitopes inserted at positions 4, 163, and 574 were localized extracellularly, whereas those inserted at positions 271 and 653 revealed an intracellular location, Although a single epitope inserted at position 461 was compatible with MRP function, it was inaccessible to the anti-epitope antibody and two copies of the tag at that site abrogated MRP function, These results indicate that the amino terminus of MRP is extracellular, while the linker segment joining the first and second membrane-associated regions is intracellular as is the first nucleotide binding domain, Our findings are therefore consistent with a topological model of MRP that contains 5 TM segments in the first membrane-associated region and 6 TM segments in the second membrane region.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA	McGill University								AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ALMQUIST KC, 1995, CANCER RES, V55, P102; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Buchler M, 1996, J BIOL CHEM, V271, P15091; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CHANG XB, 1994, J BIOL CHEM, V269, P18572; COLE SPC, 1993, SCIENCE, V260, P879, DOI 10.1126/science.8098549; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; FLENS MJ, 1994, CANCER RES, V54, P4557; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V208, P345, DOI 10.1006/bbrc.1995.1344; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, 1994, CANCER RES, V54, P357; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; LEE M, 1996, HDB BIOL PHYSICS, P189; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NOOTER K, 1994, LEUKEMIA RES, V18, P233, DOI 10.1016/0145-2126(94)90025-6; OTA E, 1995, BRIT J CANCER, V72, P550, DOI 10.1038/bjc.1995.372; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHUSTIK C, 1995, MOL ASPECTS MED, V16, P1, DOI 10.1016/0098-2997(94)00040-A; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; Stride BD, 1996, MOL PHARMACOL, V49, P962; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TANGWAI DF, 1993, BIOCHEMISTRY-US, V32, P6470, DOI 10.1021/bi00076a022; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	55	104	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26479	26487		10.1074/jbc.272.42.26479	http://dx.doi.org/10.1074/jbc.272.42.26479			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334225	hybrid			2022-12-25	WOS:A1997YB13900059
J	Matveeva, EA; He, P; Whiteheart, SW				Matveeva, EA; He, P; Whiteheart, SW			N-ethylmaleimide-sensitive fusion protein contains high and low affinity ATP-binding sites that are functionally distinct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SNAP; VESICULAR TRANSPORT; REGULATED EXOCYTOSIS; SECRETORY PATHWAY; VESICLE FORMATION; GOLGI TRANSPORT; MEMBRANE-FUSION; MDCK CELLS; IN-VITRO; NSF	N-Ethylmaleimide-sensitive factor (NSF) has been shown to be involved in numerous intracellular membrane fusion events of both the regulated and constitutive secretory pathways. Sequence analysis indicates that the NSF subunit contains two nucleotide-binding sites, both with the classical Walker A and B motifs. In this report, we examine the nucleotide binding properties of NSF. The homotrimer contains three high affinity ATP-binding sites with K-d = 30-40 nM for ATP and K-d = 2 mu M for ADP. This class of binding sites did not bind AMP, adenine, or GTP. A second class of lower affinity nucleotide binding sites with a K-d = 15-20 mu M was also detected. Using various mutant forms of NSF, the high affinity nucleotide-binding sites were localized to the D2 domains and the low affinity sites were localized to the D1 domains, Functionally it is these lower affinity sites in D1 that are crucial for NSF activity. Nucleotide concentration greatly affected the ability of NSF to interact with alpha-SNAP SNARE (soluble NSF attachment protein-SNAP receptor) complex, suggesting that only when the D1 domain ATP-binding sites are occupied does NSF bind to the alpha-SNAP SNARE complex.	UNIV KENTUCKY,COLL MED,CHANDLER MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky				Whiteheart, Sidney/0000-0001-5577-0473	NHLBI NIH HHS [HL56652] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056652] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ANTONOFF RS, 1976, PHOTOCHEM PHOTOBIOL, V23, P327, DOI 10.1111/j.1751-1097.1976.tb07256.x; Apodaca G, 1996, EMBO J, V15, P1471, DOI 10.1002/j.1460-2075.1996.tb00491.x; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hicke L, 1997, MOL BIOL CELL, V8, P13, DOI 10.1091/mbc.8.1.13; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PALLANCK L, 1995, J BIOL CHEM, V270, P18742, DOI 10.1074/jbc.270.32.18742; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steel GJ, 1996, EMBO J, V15, P745, DOI 10.1002/j.1460-2075.1996.tb00410.x; SUMIDA M, 1994, J BIOL CHEM, V269, P20636; SZTUL E, 1993, J BIOL CHEM, V268, P1876; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	47	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26413	26418		10.1074/jbc.272.42.26413	http://dx.doi.org/10.1074/jbc.272.42.26413			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334216	hybrid			2022-12-25	WOS:A1997YB13900050
J	Morrione, A; Valentinis, B; Resnicoff, M; Xu, SQ; Baserga, R				Morrione, A; Valentinis, B; Resnicoff, M; Xu, SQ; Baserga, R			The role of mGrb10 alpha in insulin-like growth factor I-mediated growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2 DOMAIN PROTEINS; RECEPTOR-BINDING-SITES; TUMOR-CELLS; GRB-IR; IGF-I; SUBSTRATE-1; APOPTOSIS; TRANSFORMATION; FIBROBLASTS; EXPRESSION	Several isoforms of Grb10 are known to interact with either the insulin receptor or the insulin-like growth factor I (IGF-I) receptor, or both. Inasmuch as the data in the literature on the function of Grb10 are not-always concordant, we have investigated the role of one of these isoforms, mGrb10 alpha, in cell proliferation. For this pul-pose, a plasmid expressing mGrb10 alpha was stably transfected into p6 cells and other mouse embryo fibroblast cell lines, An overexpressed mGrb10 alpha inhibits IGF-l-mediated growth, causes a delay in the S and G(2) phases of the cell cycle, and partially reverses the transformed phenotype. In contrast, it has no effect on insulin stimulation of cell proliferation These studies indicate that this isoform of Grb10 has an inhibitory effect on IGF-I signaling of cell proliferation.	THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,PHILADELPHIA,PA 19107	Jefferson University					NCI NIH HHS [CA 53424] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Baserga R, 1997, VITAM HORM, V53, P65, DOI 10.1016/S0083-6729(08)60704-9; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DAmbrosio C, 1996, CANCER RES, V56, P4013; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; Hongo A, 1996, ONCOGENE, V12, P1231; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; Morrione A, 1996, CANCER RES, V56, P3165; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; SURMACZ E, 1992, EXP CELL RES, V199, P275, DOI 10.1016/0014-4827(92)90435-B; ULLRICH A, 1986, EMBO J, V5, P503; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1	42	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26382	26387		10.1074/jbc.272.42.26382	http://dx.doi.org/10.1074/jbc.272.42.26382			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334212	Green Published, hybrid			2022-12-25	WOS:A1997YB13900046
J	Seok, YJ; Sondej, M; Badawi, P; Lewis, MS; Briggs, MC; Jaffe, H; Peterkofsky, A				Seok, YJ; Sondej, M; Badawi, P; Lewis, MS; Briggs, MC; Jaffe, H; Peterkofsky, A			High affinity binding and allosteric regulation of Escherichia coli glycogen phosphorylase by the histidine phosphorylase protein, HPr	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING PHOSPHOCARRIER PROTEIN; SUGAR PHOSPHOTRANSFERASE SYSTEM; GRAM-POSITIVE BACTERIA; SALMONELLA-TYPHIMURIUM; RESOLUTION STRUCTURE; GENE; PHOSPHOENOLPYRUVATE; PURIFICATION; SEQUENCE; OPERON	The histidine phosphocarrier protein (HPr) is an essential element in sugar transport by the bacterial phosphoenolpyruvate:sugar phosphotransferase system, Ligand fishing, using surface plasmon resonance, was used to show the binding of HPr to a nonphosphotransferase protein in extracts of Escherichia coli; the protein was subsequently identified as glycogen phosphorylase (GP), The high affinity (association constant similar to 10s M-1), species-specific interaction was also demonstrated in electrophoretic mobility shift experiments by polyacrylamide gel electrophoresis, Equilibrium ultracentrifugation analysis indicates that HPr allosterically regulates the oligomeric state of glycogen phosphorylase. HPr binding increases GP activity to 250% of the level in control assays, Kinetic analysis of coupled enzyme as says shows that the binding of HPr to GP causes a decrease in the K-m for glycogen and an increase in the V-max for phosphate, indicating a mixed type activation, The stimulatory effect of E, coli HPr on E, coli GP activity is species-specific, and the unphosphorylated form of HPr activates GP more than does the phosphorylated form, Replacement of specific amino acids in]HPr results in reduced GP activation; HPr residues Arg-17, Lys-24, Lys-27, Lys-40, Ser-46, Gln-51, and Lys-72 were established to be important, This novel mechanism for the regulation of GP provides the first evidence directly linking E, coli HPr to the regulation of carbohydrate metabolism.	NHLBI,NIH,BETHESDA,MD 20892; NIH,NATL CTR RES RESOURCES,BETHESDA,MD 20892; NINCDS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Seok, Yeong-Jae/0000-0003-0379-3619				ANDERSON B, 1971, J BIOL CHEM, V246, P7023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUVIN F, 1996, P NATL ACAD SCI USA, V93, P7038; CHEN GS, 1968, ARCH BIOCHEM BIOPHYS, V127, P164, DOI 10.1016/0003-9861(68)90213-0; CHEN GS, 1968, ARCH BIOCHEM BIOPHYS, V127, P175, DOI 10.1016/0003-9861(68)90214-2; DEREUSE H, 1985, GENE, V35, P199; DEUTSCHER J, 1995, MOL MICROBIOL, V15, P1049, DOI 10.1111/j.1365-2958.1995.tb02280.x; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; Fisher Robert J., 1994, Current Opinion in Biotechnology, V5, P389, DOI 10.1016/0958-1669(94)90047-7; GARRETT D, 1997, BIOCHEMISTRY-US, V36, P4398; GEERSE RH, 1989, MOL GEN GENET, V216, P517, DOI 10.1007/BF00334399; HAMMEN PK, 1991, BIOCHEMISTRY-US, V30, P11842, DOI 10.1021/bi00115a014; HELMREICH E, 1964, P NATL ACAD SCI USA, V51, P131, DOI 10.1073/pnas.51.1.131; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HERZBERG O, 1994, CURR OPIN STRUC BIOL, V4, P812; HUDSON JW, 1993, J MOL BIOL, V234, P700, DOI 10.1006/jmbi.1993.1621; JIA ZC, 1993, J BIOL CHEM, V268, P22490; JOHNSON LN, 1992, FARADAY DISCUSS, V93, P131, DOI 10.1039/fd9929300131; JONES DHA, 1994, MICROBIOL-SGM, V140, P1035, DOI 10.1099/13500872-140-5-1035; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEWIS MS, 1996, EXPLORATION NEWSLETT, V3, P11; LIN K, 1995, J BIOL CHEM, V270, P26833, DOI 10.1074/jbc.270.45.26833; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; LIN K, 1996, J BIOL CHEM, V273, P1539; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; PETERKOFSKY A, 1995, BIOCHEMISTRY-US, V34, P8950, DOI 10.1021/bi00028a003; PIEPER U, 1995, STRUCTURE, V3, P781, DOI 10.1016/S0969-2126(01)00213-1; PLANUTIS KS, 1982, BIOCHEM BIOPH RES CO, V109, P583, DOI 10.1016/0006-291X(82)91761-2; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; PREISS J, 1994, PROG NUCLEIC ACID RE, V47, P299, DOI 10.1016/S0079-6603(08)60255-X; PRIES A, 1991, J BACTERIOL, V173, P5843, DOI 10.1128/jb.173.18.5843-5853.1991; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; REIZER J, 1993, J CELL BIOCHEM, V51, P19, DOI 10.1002/jcb.240510105; REIZER J, 1994, FEMS MICROBIOL LETT, V118, P159, DOI 10.1111/j.1574-6968.1994.tb06819.x; Reizer J, 1996, RES MICROBIOL, V147, P458, DOI 10.1016/0923-2508(96)84000-9; ROMEO T, 1988, GENE, V70, P363, DOI 10.1016/0378-1119(88)90208-9; Seok YJ, 1996, P NATL ACAD SCI USA, V93, P347, DOI 10.1073/pnas.93.1.347; Stone K. L., 1993, PRACTICAL GUIDE PROT, P43; VADEBONCOEUR C, 1995, RES MICROBIOL, V146, P525, DOI 10.1016/0923-2508(96)80558-4; VANNULAND NAJ, 1994, J MOL BIOL, V237, P544, DOI 10.1006/jmbi.1994.1254; WEIGEL N, 1982, J BIOL CHEM, V257, P4499; YU F, 1988, J BIOL CHEM, V263, P13706; ZHU PP, 1993, J BIOL CHEM, V268, P26531	49	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26511	26521		10.1074/jbc.272.42.26511	http://dx.doi.org/10.1074/jbc.272.42.26511			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334229	hybrid			2022-12-25	WOS:A1997YB13900063
J	Davis, DA; Newcomb, FM; Starke, DW; Ott, DE; Mieyal, JJ; Yarchoan, R				Davis, DA; Newcomb, FM; Starke, DW; Ott, DE; Mieyal, JJ; Yarchoan, R			Thioltransferase (glutaredoxin) is detected-within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; OXIDATIVE STRESS; S-THIOLATION; ESCHERICHIA-COLI; VIRAL INFECTIVITY; CYSTEINE RESIDUES; RESPIRATORY BURST; VACCINIA VIRUS; TYPE-1; PROTEINS	Previous studies have suggested that the two conserved cysteines of the HIV-1 protease may be involved in regulating protease activity, Here, we examined diglutathionylated wild type protease (Cys-67-SSG, Cys-95-SSG) and the monoglutathionylated protease mutants (C67A, Cys-95-SSG and C95A, Cys-67-SSG) as potential substrates for thioltransferase (glutaredoxin). Time-dependent changes in the extent of deglutathionylation of each protein were assayed by reverse phase-high performance liquid chromatography. Glutathione alone was not an effective reductant, whereas thioltransferase displayed differential catalysis toward the Cys-95-SSG and Cys-67-SSG sites. At low thioltransferase concentrations (5 nM), deglutathionylation occurred almost exclusively at Cys-95-SSG. With substantially more thioltransferase (100 nM) Cys-67-SSG was partially deglutathionylated but only at 20% of the rate of Cys-95-SSG reduction, Treatment of the diglutathionylated protease with thioltransferase not only restored protease activity but generated an enzyme preparation that had a 3- to 5-fold greater specific activity relative to the fully reduced form, Immunoblot analysis of HIV-1(MN) virus with an antibody to thioltransferase detected a band co-migrating with recombinant thioltransferase that persisted following subtilisin treatment, indicating the presence of thioltransferase within HIV-1. Our results implicate thioltransferase in the regulation and/or maintenance of protease activity in HIV-1 infected cells.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106; SCI APPLICAT INT CORP,AIDS VACCINE PROGRAM,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Davis, DA (corresponding author), NCI,HIV & AIDS MALIGNANCY BRANCH,NIH,BETHESDA,MD 20892, USA.							AHN BY, 1992, P NATL ACAD SCI USA, V89, P7060, DOI 10.1073/pnas.89.15.7060; ARAD G, 1995, J GEN VIROL, V76, P1917, DOI 10.1099/0022-1317-76-8-1917; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; AUKRUST P, 1995, BLOOD, V86, P258, DOI 10.1182/blood.V86.1.258.bloodjournal861258; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BUHL R, 1989, LANCET, V2, P1294; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; CHRESTENSEN CA, 1995, FEBS LETT, V374, P25, DOI 10.1016/0014-5793(95)01066-N; Ciriolo MR, 1997, J BIOL CHEM, V272, P2700, DOI 10.1074/jbc.272.5.2700; DARKE PL, 1994, BIOCHEMISTRY-US, V33, P98, DOI 10.1021/bi00167a013; Davis DA, 1996, BIOCHEMISTRY-US, V35, P2482, DOI 10.1021/bi951525k; DETTORRE C, 1994, ARCH BIOCHEM BIOPHYS, V313, P71, DOI 10.1006/abbi.1994.1360; DONALD LJ, 1991, J BIOL CHEM, V266, P20709; Gluschankof P, 1997, VIROLOGY, V230, P125, DOI 10.1006/viro.1997.8453; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; GRASSER FA, 1992, ONCOGENE, V7, P1005; Gravina Mieyal S.A, 1995, BIOTHIOLS HLTH DIS, P305; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GRIERSON AW, 1994, J GEN VIROL, V75, P2761, DOI 10.1099/0022-1317-75-10-2761; Gvakharia BO, 1996, VIROLOGY, V226, P408, DOI 10.1006/viro.1996.0669; Gvakharia BO, 1996, J BIOL CHEM, V271, P15307, DOI 10.1074/jbc.271.26.15307; HAN JC, 1994, ANAL BIOCHEM, V220, P5, DOI 10.1006/abio.1994.1290; Humphrey RW, 1997, ANTIMICROB AGENTS CH, V41, P1017, DOI 10.1128/AAC.41.5.1017; KAPLAN AH, 1993, J VIROL, V67, P4050, DOI 10.1128/JVI.67.7.4050-4055.1993; KARLSTROM AR, 1993, ARCH BIOCHEM BIOPHYS, V304, P163, DOI 10.1006/abbi.1993.1334; KARLSTROM AR, 1991, P NATL ACAD SCI USA, V88, P5552, DOI 10.1073/pnas.88.13.5552; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; KRAUSSLICH HG, 1992, J VIROL, V66, P150; Kurata SI, 1996, J BIOL CHEM, V271, P21798, DOI 10.1074/jbc.271.36.21798; LUNDSTROMLJUNG J, 1995, J BIOL CHEM, V270, P7822, DOI 10.1074/jbc.270.14.7822; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MERGENER K, 1992, VIROLOGY, V186, P25, DOI 10.1016/0042-6822(92)90058-W; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; MYERS G, 1995, HUMAN RETROVIRUSES A; OTT DE, 1995, AIDS RES HUM RETROV, V11, P1003, DOI 10.1089/aid.1995.11.1003; Ott DE, 1996, J VIROL, V70, P7734, DOI 10.1128/JVI.70.11.7734-7743.1996; PACE GW, 1995, FREE RADICAL BIO MED, V19, P523, DOI 10.1016/0891-5849(95)00047-2; PIETTE J, 1994, CHEM-BIOL INTERACT, V91, P79, DOI 10.1016/0009-2797(94)90028-0; RAJAGOPAL I, 1995, J BIOL CHEM, V270, P27415, DOI 10.1074/jbc.270.46.27415; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; ROKUTAN K, 1991, J IMMUNOL, V147, P260; ROSE JR, 1995, J VIROL, V69, P2751; ROZELL B, 1993, EUR J CELL BIOL, V62, P314; SALTO R, 1994, J BIOL CHEM, V269, P10691; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; STAAL FJT, 1992, LANCET, V339, P909, DOI 10.1016/0140-6736(92)90939-Z; Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571; TERADA T, 1992, J BIOCHEM-TOKYO, V111, P688, DOI 10.1093/oxfordjournals.jbchem.a123819; WEBSTER A, 1994, J VIROL, V68, P7292, DOI 10.1128/JVI.68.11.7292-7300.1994; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; YOSHITAKE S, 1994, J BIOCHEM-TOKYO, V116, P42, DOI 10.1093/oxfordjournals.jbchem.a124500	55	129	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25935	25940		10.1074/jbc.272.41.25935	http://dx.doi.org/10.1074/jbc.272.41.25935			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325327	hybrid			2022-12-25	WOS:A1997YA35800082
J	Gerton, JL; Brown, PO				Gerton, JL; Brown, PO			The core domain of HIV-1 integrase recognizes key features of its DNA substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE LEUKEMIA-VIRUS; SITE-DIRECTED MUTAGENESIS; CARBOXYL-TERMINAL DOMAINS; TYPE-1 INTEGRASE; CATALYTIC DOMAIN; RETROVIRAL DNA; ESCHERICHIA-COLI; PROTEIN INVITRO; IN-VITRO	We investigated which features of the substrate specificity of human immunodeficiency virus type 1 (HIV-1) integrase could be assigned to the central domain of the 288-residue HIV-1 integrase protein, composed of amino acids 50-212. This domain contains the active site and shares structural homology with a large family of polynucleotidyl transferases. Using model substrates with defined alterations in critical features we found that this domain alone is sufficient for recognition of: 1) the phylogenetically conserved CA/TG base pairs near the viral DNA end; 2) the 5'-terminal dinucleotide that is left unpaired after end processing; and 3) target DNA flanking the site of joining. Future efforts aimed at identifying specific amino acids involved in recognition of these key substrate features can now be targeted at this domain.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University								BOR YC, 1995, P NATL ACAD SCI USA, V92, P10334, DOI 10.1073/pnas.92.22.10334; Brown P.O., 1997, RETROVIRUSES; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHOW SA, 1994, J VIROL, V68, P3896, DOI 10.1128/JVI.68.6.3896-3907.1994; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CHOW SA, 1994, J VIROL, V68, P7869, DOI 10.1128/JVI.68.12.7869-7878.1994; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGLEMAN A, 1992, J VIROL, V66, P6361; HAGINOYAMAGISHI K, 1987, J VIROL, V61, P1964, DOI 10.1128/JVI.61.6.1964-1971.1987; JENKINS TM, 1995, P NATL ACAD SCI USA, V92, P6057, DOI 10.1073/pnas.92.13.6057; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; KATZMAN M, 1995, J VIROL, V69, P5687, DOI 10.1128/JVI.69.9.5687-5696.1995; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; MULLER HP, 1994, EMBO J, V13, P4707; PAHL A, 1995, J BIOL CHEM, V270, P2957, DOI 10.1074/jbc.270.7.2957; PRUSS D, 1994, J BIOL CHEM, V269, P25031; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; PURASLUTZKE RA, 1994, NUCLEIC ACIDS RES, V22, P4125; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; Scottoline BP, 1997, GENE DEV, V11, P371, DOI 10.1101/gad.11.3.371; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; Shibagaki Y, 1997, J BIOL CHEM, V272, P8361, DOI 10.1074/jbc.272.13.8361; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419	45	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25809	25815		10.1074/jbc.272.41.25809	http://dx.doi.org/10.1074/jbc.272.41.25809			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325310	hybrid			2022-12-25	WOS:A1997YA35800065
J	Michel, JB; Feron, O; Sase, K; Prabhakar, P; Michel, T				Michel, JB; Feron, O; Sase, K; Prabhakar, P; Michel, T			Caveolin versus calmodulin - Counterbalancing allosteric modulators of endothelial nitric oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; BINDING; MUTAGENESIS; RECOGNITION; EXPRESSION; ACYLATION; TARGETS	Nitric oxide is synthesized in diverse mammalian tissues by a family of calmodulin-dependent nitric oxide synthases, The endothelial isoform of nitric oxide synthase (eNOS) is targeted to the specialized signal-transducing membrane domains termed plasmalemmal caveolae, Caveolin, the principal structural protein in caveolae, interacts with eNOS and leads to enzyme inhibition in a reversible process modulated by Ca2+-calmodulin (Michel, J. B., Feron, O., Sacks, D., and Michel, T. (1997) J. Biol. Chem. 272, 15583-15586). Caveolin also interacts with other structurally distinct signaling proteins via a specific region identified within the caveolin sequence (amino acids 82-101) that appears to subserve the role of a ''scaffolding domain.'' We now report that the co-immunoprecipitation of eNOS with caveolin is completely and specifically blocked by an oligopeptide corresponding to the caveolin scaffolding domain, Peptides corresponding to this domain markedly inhibit nitric oxide synthase activity in endothelial membranes and interact directly with the enzyme to inhibit activity of purified recombinant eNOS expressed in Escherichia coli, The inhibition of purified eNOS by the caveolin scaffolding domain peptide is competitive and completely reversed by Ca2+-calmodulin. These studies establish that caveolin, via its scaffolding domain, directly forms an inhibitory complex with eNOS and suggest that caveolin inhibits eNOS by abrogating the enzyme's activation by calmodulin.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, CARDIOVASC DIV, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School			FERON, Olivier/AAM-6395-2020	FERON, Olivier/0000-0001-5360-0286				ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCONI L, 1995, MOL PHARMACOL, V47, P655; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; HANSON PI, 1992, J BIOL CHEM, V267, P17216; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Michel JB, 1997, FEBS LETT, V405, P356, DOI 10.1016/S0014-5793(97)00222-6; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; NATHAN C, 1994, J BIOL CHEM, V269, P13725; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Sase K, 1997, TRENDS CARDIOVAS MED, V7, P28, DOI 10.1016/S1050-1738(96)00121-1; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435	24	268	273	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25907	25912		10.1074/jbc.272.41.25907	http://dx.doi.org/10.1074/jbc.272.41.25907			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325323	hybrid			2022-12-25	WOS:A1997YA35800078
J	TorresRamos, CA; Prakash, S; Prakash, L				TorresRamos, CA; Prakash, S; Prakash, L			Requirement of yeast DNA polymerase delta in post-replicational repair of UV-damaged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; INDUCED MUTAGENESIS; ESCHERICHIA-COLI; RAD18; PROTEINS; MUTATIONS; MUTANTS; EPSILON; BYPASS; GENOME	DNA lesions in the template strand pose a block to the replication machinery, Replication across such lesions may occur by a mutagenic bypass process in which a wrong base is inserted opposite the lesion or may involve processes that are relatively error-free. Genetic studies in the yeast Saccharomyces cerevisiae have indicated the requirement of REV3-encoded DNA polymerase in mutagenic bypass, The DNA polymerase responsible for error-free bypass, however, has not been identified, but genetic studies implicating proliferating cell nuclear antigen in this process have suggested that either DNA polymerase delta or DNA polymerase epsilon may be involved, Here, we use temperature sensitive (ts) conditional lethal mutations of the S. cerevisiae POL2 and POL3 genes, which encode DNA polymerase epsilon and delta, respectively, and show that post-replicational bypass of UV-damaged DNA is severely inhibited in the pol3-3 mutant at the restrictive temperature, By contrast, the pol2-18 mutation has no adverse effect on this process at the restrictive temperature, From these observations, we infer a requirement of DNA polymerase delta in post-replicative bypass of UV-damaged DNA.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NIGMS NIH HHS [GM19261] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARMSTRONG JD, 1994, MUTAT RES-DNA REPAIR, V315, P281, DOI 10.1016/0921-8777(94)90039-6; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; CASSIERCHAUVAT C, 1991, MUTAT RES, V254, P247, DOI 10.1016/0921-8777(91)90063-U; CONRAD MN, 1983, MOL CELL BIOL, V3, P1000, DOI 10.1128/MCB.3.6.1000; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FRIEDBERG EC, 1995, DNA REPAIR; GIBBS PEM, 1995, NUCLEIC ACIDS RES, V23, P1919, DOI 10.1093/nar/23.11.1919; GIBBS PEM, 1993, J BACTERIOL, V175, P2607, DOI 10.1128/JB.175.9.2607-2612.1993; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; LAWRENCE CW, 1982, ADV GENET, V21, P173, DOI 10.1016/S0065-2660(08)60299-0; LAWRENCE CW, 1985, MOL GEN GENET, V200, P86, DOI 10.1007/BF00383317; LEMONTT JF, 1970, GENETICS, V68, P21; Longley MJ, 1997, J BIOL CHEM, V272, P10917; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TorresRamos CA, 1996, P NATL ACAD SCI USA, V93, P9676, DOI 10.1073/pnas.93.18.9676; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	27	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25445	25448		10.1074/jbc.272.41.25445	http://dx.doi.org/10.1074/jbc.272.41.25445			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325255	hybrid			2022-12-25	WOS:A1997YA35800010
J	Zhou, YT; Shimabukuro, M; Lee, Y; Koyama, K; Trieu, F; Unger, RH				Zhou, YT; Shimabukuro, M; Lee, Y; Koyama, K; Trieu, F; Unger, RH			Leptin normalizes the impaired response of proinsulin mRNA to long chain fatty acids in heterozygous Zucker diabetic fatty rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLETS; RECEPTOR; OBESITY; MUTATION; WEIGHT; LIPOTOXICITY; PATHOGENESIS; GLUCOSE; GENE	To determine if underleptinization of islets of Zucker diabetic fatty (ZDF) rats is the proximal cause of their inability to compensate for obesity, we compared the proinsulin/beta-actin mRNA ratio in heterozygous (fa/+) ZDF rats with that of wild-type (+/+) and homozygous (fa/fa) ZDF rats. In +/+ islets cultured with 2 mM free fatty acids (FFA) the proinsulin mRNA ratio rose 2.4-fold at 12 h. In fa/+ islets, the ratio rose only 65% above normal. There was no change in fa/fa islets. The presence of leptin (20 ng/ml) in the culture medium increased the FFA-induced response of proinsulin mRNA of fa/+ islets to that of +/+ islets while reducing FFA incorporation into triglycerides. The leptin-induced improvement in the proinsulin mRNA response was independent of any changes in glucose usage. These findings support a causal relationship between diminished leptin action on islets and the impaired beta-cell response to FFA in ZDF rats.	UNIV TEXAS,SW MED CTR,CTR DIABET RES,DEPT INTERNAL MED,GIFFORD LABS,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,CTR DIABET RES,DEPT BIOCHEM,GIFFORD LABS,DALLAS,TX 75235; DEPT VET AFFAIRS MED CTR,DALLAS,TX 75216	Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Shimabukuro, Michio/0000-0001-7835-7665	NIDDK NIH HHS [DK02700-37] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK002700, R01DK002700] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Hirose H, 1996, J BIOL CHEM, V271, P5633, DOI 10.1074/jbc.271.10.5633; Iida M, 1996, BIOCHEM BIOPH RES CO, V224, P597, DOI 10.1006/bbrc.1996.1070; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MATCHINSKY FM, 1980, DIABETES 1979, P154; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NABER SP, 1980, DIABETOLOGIA, V19, P439, DOI 10.1007/BF00281823; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Shimabukuro M, 1997, J CLIN INVEST, V100, P290, DOI 10.1172/JCI119534; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; ZAWALICH WS, 1977, ENDOCRINOLOGY, V100, P1276, DOI 10.1210/endo-100-5-1276; ZAWALICH WS, 1977, ENDOCRINOLOGY, V100, P1	20	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25648	25651		10.1074/jbc.272.41.25648	http://dx.doi.org/10.1074/jbc.272.41.25648			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325287	hybrid			2022-12-25	WOS:A1997YA35800042
J	McPhie, DL; Lee, RKK; Eckman, CB; Olstein, DH; Durham, SP; Yager, D; Younkin, SG; Wurtman, RJ; Neve, RL				McPhie, DL; Lee, RKK; Eckman, CB; Olstein, DH; Durham, SP; Yager, D; Younkin, SG; Wurtman, RJ; Neve, RL			Neuronal expression of beta-amyloid precursor protein Alzheimer mutations causes intracellular accumulation of a C-terminal fragment containing both the amyloid beta and cytoplasmic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE; CELLS; IDENTIFICATION; BRAIN; NEUROTOXICITY	Five different Alzheimer mutations of the beta-amyloid precursor protein (APP) were expressed in neurons via recombinant herpes simplex virus (HSV) vectors, and the levels of APP metabolites were quantified, The predominant intracellular accumulation product was a C-terminal fragment of APP that co-migrated with the protein product of an HSV recombinant expressing the C-terminal 100 amino acids (C100) of APP, which is known to cause neurodegeneration. Fractionation studies revealed that the C-terminal fragment generated by expression of the Alzheimer mutations, Like C100, partitioned into membrane fractions and was particularly enriched in synaptosomes. The processing abnormality caused by expression of the Alzheimer mutations occurs predominantly in neurons. Expression of these mutations or of C100 alone in neurons caused increased secretion of A beta relative to that of neurons infected with wild type APP recombinant vectors, These data show that expression of APP mutations that cause familial Alzheimer's disease increases the intracellular accumulation of potentially amyloidogenic and neurotoxic C-terminal fragments of APP in neurons.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; MAYO CLIN JACKSONVILLE,JACKSONVILLE,FL 32224	Massachusetts Institute of Technology (MIT); Mayo Clinic	McPhie, DL (corresponding author), HARVARD UNIV,MCLEAN HOSP,SCH MED,DEPT GENET,BELMONT,MA 02178, USA.				NATIONAL INSTITUTE ON AGING [R01AG012954] Funding Source: NIH RePORTER; NIA NIH HHS [AG12954] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CITRON M, 1996, NEURON, V17, P1471; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DYRKS T, 1992, J BIOL CHEM, V267, P18210; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FELSENSTEIN KM, 1993, NEUROSCI LETT, V152, P185, DOI 10.1016/0304-3940(93)90514-L; Fraser SP, 1997, TRENDS NEUROSCI, V20, P67, DOI 10.1016/S0166-2236(96)10079-5; FUKUCHI K, 1993, NEUROSCI LETT, V154, P145, DOI 10.1016/0304-3940(93)90192-N; FUKUCHI KI, 1994, EXP NEUROL, V127, P253, DOI 10.1006/exnr.1994.1101; GARDELLA JE, 1993, BIOCHEM J, V294, P667, DOI 10.1042/bj2940667; GRAY EG, 1962, J ANAT, V96, P79; HAASS C, 1991, J NEUROSCI, V11, P3783; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; LEVISON SW, 1991, CULTURING NERVE CELL, P310; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; NEVE RL, 1992, P NATL ACAD SCI USA, V89, P3448, DOI 10.1073/pnas.89.8.3448; Neve RL, 1997, NEUROSCIENCE, V79, P435, DOI 10.1016/S0306-4522(96)00645-8; NEVE RL, 1995, METH NEUROSCI, V25, P163; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SOPHER BL, 1994, MOL BRAIN RES, V26, P207, DOI 10.1016/0169-328X(94)90092-2; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TATE B, 1992, P NATL ACAD SCI USA, V89, P7090, DOI 10.1073/pnas.89.15.7090; Tjernberg LO, 1997, J BIOL CHEM, V272, P1870, DOI 10.1074/jbc.272.3.1870; VANBROECKHOVEN CL, 1995, EUR NEUROL, V35, P8, DOI 10.1159/000117083; WOLF D, 1990, EMBO J, V9, P2079, DOI 10.1002/j.1460-2075.1990.tb07375.x; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201	33	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24743	24746		10.1074/jbc.272.40.24743	http://dx.doi.org/10.1074/jbc.272.40.24743			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312066	hybrid			2022-12-25	WOS:A1997XY97000005
J	Motevalli, M; GoldschmidtClermont, PJ; Virgil, D; Kwiterovich, PO				Motevalli, M; GoldschmidtClermont, PJ; Virgil, D; Kwiterovich, PO			Abnormal protein tyrosine phosphorylation in fibroblasts from hyperapobetalipoproteinemia subjects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLATION STIMULATING PROTEIN; CORONARY-ARTERY DISEASE; SERUM BASIC-PROTEIN; ORAL FAT LOAD; HYPERAPOB FIBROBLASTS; KINASE; LIPOPROTEIN; INSULIN; PURIFICATION; PHOSPHATASES	The stimulatory effects of three normal human serum basic proteins (EP), BP I (M-r 14,000, pI 9.10), BP II (M-r 27, 500, pI 8.48), and BP III (M-r 55,000, pI 8.73) on cellular triglyceride and cholesterol formation require intact protein-tyrosine kinase phosphorylation (TKP). Here we examined whether there is an abnormality in TKP in cultured fibroblasts from 11 patients with hyperapobetalipoproteinemia (hyperapoB) that manifest two acylation-stimulatory defects, decreased stimulation of triglyceride synthesis by BP I but enhanced formation of cholesterol by BP II. Soluble and insoluble proteins in Triton X-100 extracts were isolated by immunoprecipitation with a monoclonal anti-phosphotyrosine antibody (MAPA) bound to agarose beads and by ultracentrifugation, respectively, from confluent fibroblasts after incubation for 24 h in supplemented serum-free and lipid-free medium (DMEM/F12). Western blots of insoluble proteins showed that group (Gp) II (M-r 36,000-55,000) and Gp III (M-r 14,000-35,000) from hyperapoB cells, grown in DMEM/F12 medium without BP, had significantly decreased reactivity to MAPA. No significant differences in reactivity to MAPA were detected between normal and hyperapoB cells for Gp I (M-r 97-120,000). BP II, but not BP I or BP III, reversed the decreased reactivity of Gp II and Gp III to MAPA in hyperapoB cells. Sodium vanadate, an inhibitor of phosphotyrosine phosphatases, did not reverse the deficiency in TKP or the 50% deficiency in the stimulation of mass triglyceride by BP I in hyperapoB cells. Tyrosine-phosphorylated Erk-2, a mitogen-activated protein kinase, identified as one of the proteins in Gp II, was significantly decreased in hyperapoB cells. These results provide further evidence for abnormal protein TKP in hyperapoB cells and suggest a possible link between atherosclerotic changes in hyperapoB patients and growth factors upstream from mitogen-activated protein kinase.	JOHNS HOPKINS UNIV HOSP,LIPID RES ATHEROSCLEROSIS UNIT,DEPT PEDIAT,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV HOSP,LIPID RES ATHEROSCLEROSIS UNIT,DEPT MED,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV HOSP,DIV CARDIOL,DEPT MED,BERNARD LAB,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV HOSP,DIV CARDIOL,DEPT PEDIAT,BERNARD LAB,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032193] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047212, P50HL052315] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 52315-03, 1P50HL-47212-05] Funding Source: Medline; NICHD NIH HHS [R01HD-32193-03] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABLER A, 1992, J BIOL CHEM, V267, P3946; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AMOROSA LF, 1984, BIOCHIM BIOPHYS ACTA, V792, P192, DOI 10.1016/0005-2760(84)90222-4; BACHORIK PS, 1996, CIRCULATION S1, V94, P347; BALDO A, 1993, J CLIN INVEST, V92, P1543, DOI 10.1172/JCI116733; BOLEN JB, 1993, ONCOGENE, V8, P2025; CIANFLONE K, 1989, J LIPID RES, V30, P1727; CIANFLONE K, 1994, BIOCHEMISTRY-US, V33, P9489, DOI 10.1021/bi00198a014; CIANFLONE KM, 1989, J BIOL CHEM, V264, P426; CORESH J, 1993, J LIPID RES, V34, P1687; DISE KR, 1993, ECL HIGHLIGHTS, V1, P4; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GENEST J, 1986, ARTERIOSCLEROSIS, V6, P297, DOI 10.1161/01.ATV.6.3.297; GERMINARIO R, 1993, METABOLISM, V40, P574; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HRESKO RC, 1990, J BIOL CHEM, V265, P21075; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KWITEROVICH P, 1990, P NATL ACAD SCI USA, V87, P8980, DOI 10.1073/pnas.87.22.8980; Kwiterovich Peter O. Jr., 1993, Current Opinion in Lipidology, V4, P133, DOI 10.1097/00041433-199304000-00009; KWITEROVICH PO, 1993, AM J CARDIOL, V71, P631, DOI 10.1016/0002-9149(93)91002-Y; KWITEROVICH PO, 1994, ARTERIOSCLER THROMB, V14, P1, DOI 10.1161/01.ATV.14.1.1; KWITEROVICH PO, 1995, ARTERIOSCL THROM VAS, V15, P1195, DOI 10.1161/01.ATV.15.8.1195; KWITEROVICH PO, 1991, CLIN CHEM, V37, P317; KWITEROVICH PO, 1995, CIRCULATION, V92, P426; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONTESANO R, 1988, J CELL PHYSIOL, V134, P460, DOI 10.1002/jcp.1041340318; NELSON RL, 1984, MOL CELL BIOL, V4, P1003, DOI 10.1128/MCB.4.6.1003; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; SNIDERMAN A, 1987, NIH872646 US DEP HLT, P293; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; TENG B, 1988, CAN J PHYSIOL PHARM, V66, P239, DOI 10.1139/y88-040; TOMASKA L, 1993, BIOCHEM J, V293, P215, DOI 10.1042/bj2930215; YASRUEL Z, 1991, LIPIDS, V26, P495, DOI 10.1007/BF02536592	34	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24703	24709		10.1074/jbc.272.39.24703	http://dx.doi.org/10.1074/jbc.272.39.24703			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305942	hybrid			2022-12-25	WOS:A1997XY51500093
J	Rosendahl, MS; Ko, SC; Long, DL; Brewer, MT; Rosenzweig, B; Hedl, E; Anderson, L; Pyle, SM; Moreland, J; Meyers, MA; Kohno, T; Lyons, D; Lichenstein, HS				Rosendahl, MS; Ko, SC; Long, DL; Brewer, MT; Rosenzweig, B; Hedl, E; Anderson, L; Pyle, SM; Moreland, J; Meyers, MA; Kohno, T; Lyons, D; Lichenstein, HS			Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHIMERIC MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; TNF RECEPTOR; CELL; INHIBITOR; MEMBRANE; DISINTEGRIN; CLEAVAGE; CA2	Tumor necrosis factor-alpha (TNF) is initially expressed as a 26-kDa membrane-bound precusor protein (pro-TNF) that is shed proteolytically from the cell surface, releasing soluble 17-kDa TNF. We have identified human ADAM 10 (HuAD10) from THP-1 membrane extracts as a metalloprotease that specifically clips a peptide substrate spanning the authentic cleavage site between Ala(76) and Val(77) in pro-TNF. To confirm that HuAD10 has TNF processing activity, we cloned, expressed, and purified an active, truncated form of HuAD10. Characterization of recombinant HuAD10 (rHuAD10) suggests that this enzyme has many of the properties (i.e. , substrate specificity, metalloprotease activity, cellular location) expected for a physiologically relevant TNF-processing enzyme.			Rosendahl, MS (corresponding author), AMGEN INC,8200 WALNUT ST,BOULDER,CO 80301, USA.		Hedl, Erik/F-3479-2011	Hedl, Erik/0000-0002-9419-4648				Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; MAEDA T, 1983, BIOCHIM BIOPHYS ACTA, V731, P115, DOI 10.1016/0005-2736(83)90404-2; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MouradaSilva AM, 1996, EUR J IMMUNOL, V26, P2000, DOI 10.1002/eji.1830260905; MULLBERG J, 1995, J IMMUNOL, V155, P5198; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; ROBACHEGALLEA S, 1995, J BIOL CHEM, V270, P23688, DOI 10.1074/jbc.270.40.23688; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585	22	172	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24588	24593		10.1074/jbc.272.39.24588	http://dx.doi.org/10.1074/jbc.272.39.24588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305925	hybrid			2022-12-25	WOS:A1997XY51500076
J	Hahn, SL; Criqui, P; Wasylyk, B				Hahn, SL; Criqui, P; Wasylyk, B			Modulation of ETS-1 transcriptional activity by huUBC9, a ubiquitin-conjugating enzyme	ONCOGENE			English	Article						transcription activation; ubiquitination; physical interactions; UBC9; Hus5; pointed domain	DNA-BINDING; GENE FAMILY; SECONDARY STRUCTURE; T-CELLS; KAPPA-B; C-JUN; V-ETS; PROTEIN; DOMAIN; PROMOTER	Ets transcription factors have Ets DNA binding domains, that have a winged helix-turn-helix structure. ETS-1, the founding member of the family, is regulated by the Ras and Ca2+ signaling pathways and is implicated in various physiological processes leading to cell growth, differentiation and apoptosis. We have identified ETS-1 interacting factors with a yeast two-hybrid screen. The majority of the positive clones turned out to encode the human homologue of the yeast ubiquitin-conjugating enzymes UBC9 and Hus5. In two different yeast assays, ETS-1 interacted with HuUBC9. In an in vitro GST 'pull-down' assay, ETS-1 and several other Ets family members complexed with huUBC9. Interestingly, in mammalian cells, coexpression of huUBC9 resulted in a substantial increase in the transcriptional activity of ETS-1. Coexpressed huUBC9 did not affect the ETS-1 protein level, and moreover, a point mutation at Cys93, an amino acid known to be essential for ubiquitination, did not abolish the stimulation of the ETS-1 transcriptional activity. Our results indicate that the modulation of ETS-1 activity by huUBC9 results from processes other than ubiquitination and ETS-1 stabilization.	ULP,INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				ALKHODAIRY F, 1995, J CELL SCI, V108, P475; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BELLACOSA A, 1994, J VIROL, V68, P2320, DOI 10.1128/JVI.68.4.2320-2330.1994; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COFFER P, 1994, ONCOGENE, V9, P911; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FISHER RJ, 1994, PROTEIN SCI, V3, P257; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAHN SL, 1994, ONCOGENE, V9, P2499; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; LEPRINCE D, 1983, NATURE, V306, P295; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rose MD., 1990, METHODS YEAST GENETI; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1997, IN PRESS RG LANDES C; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	48	40	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1489	1495		10.1038/sj.onc.1201301	http://dx.doi.org/10.1038/sj.onc.1201301			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333025				2022-12-25	WOS:A1997XW41100013
J	Huang, SS; Liu, QJ; Johnson, FE; Konish, Y; Huang, JS				Huang, SS; Liu, QJ; Johnson, FE; Konish, Y; Huang, JS			Transforming growth factor beta peptide antagonists and their conversion to partial agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; V RECEPTOR; CELLS; GROWTH-FACTOR-BETA-1; EXPRESSION; IDENTIFICATION; ANTIBODIES; DISEASE; BINDING	Transforming growth factor beta (TGF-beta) has been implicated in the pathogenesis of various human diseases. Synthetic TGF-beta antagonists therefore could have therapeutic utility. Here we show the development of such compounds. Three synthetic pentacosapeptides designated beta(1)(25)-(41-65), beta(2)(25)-(41-65), and beta(3)(25)-(41-65), whose amino acid sequences correspond to the 41st to 65th amino acid residues of TGF-beta(1), TGF-beta(2), and TGF-beta(3), respectively, inhibit the binding of I-125-labeled TGF-beta isoforms to TGF-beta receptors in mink lung epithelial cells with IC50 of similar to 0.06-2 mu M. beta(1)(25)-(41-65) blocks TGF-beta(1)-induced growth inhibition and TGF-beta(1)-induced plasminogen activator inhibitor-1 expression in these cells. The variants designated beta(1)(25)-(41-65)W52A/D55A and beta(3)(25)-(41-65)R52A/D55A, in which both Trp(52)/Arg(52) and Asp(55) are replaced by alanine residues, do not have TGF-beta antagonist activity. Multiple conjugation of beta(1)(25)-(41-65) to carrier proteins enhances its antagonist activity but also confers partial agonist activity as measured by DNA synthesis inhibition. These results suggest that the (W/R)XXD motif is important for the activities of these TGF-beta peptide antagonists and that this motif may be the active site sequence of TGF-beta.	ST LOUIS UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63104	Saint Louis University; Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NCI NIH HHS [CA-38808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATAYAKULCHANTLER S, 1994, J BIOL CHEM, V269, P27687; BORDER WA, 1995, J CLIN INVEST, V96, P655, DOI 10.1172/JCI118107; BORDER WA, 1995, NAT MED, V1, P1000, DOI 10.1038/nm1095-1000; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; ENGSTROM U, 1992, J BIOL CHEM, V267, P16581; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; LIU QJ, 1994, J BIOL CHEM, V269, P9221; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; MADISON L, 1988, DNA CELL BIOL, V7, P18; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; OGRADY P, 1992, J BIOL CHEM, V267, P21033; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; Qian SW, 1996, J BIOL CHEM, V271, P30656, DOI 10.1074/jbc.271.48.30656; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SHAH M, 1995, J CELL SCI, V108, P985; SHENKAR R, 1994, AM J RESP CELL MOL, V11, P351, DOI 10.1165/ajrcmb.11.3.8086171; WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473	27	35	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27155	27159		10.1074/jbc.272.43.27155	http://dx.doi.org/10.1074/jbc.272.43.27155			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341157	hybrid			2022-12-25	WOS:A1997YC65900053
J	Kitajima, I; Hanyu, N; Soejima, Y; Hirano, R; Arahira, S; Yamaoka, S; Yamada, R; Maruyama, I; Kaneda, Y				Kitajima, I; Hanyu, N; Soejima, Y; Hirano, R; Arahira, S; Yamaoka, S; Yamada, R; Maruyama, I; Kaneda, Y			Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of Japan (HVJ)-cationic liposomes - Application for ribozymes that target human T-cell leukemia virus type I tax/rex mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HVJ SENDAI VIRUS; ADULT-RAT LIVER; NF-KAPPA-B; ANTISENSE OLIGONUCLEOTIDES; THERAPEUTIC AGENTS; NUCLEAR-PROTEIN; SELF-CLEAVAGE; CATALYTIC RNA; C-MYB; SEQUENCE	We investigated the usefulness of ribozymes in inhibiting the expression of human T cell leukemia virus type I (HTLV-I) gene, Two hammerhead ribozymes that were against HTLV-I rex (RR) and tax (TR) mRNA were synthesized. Both ribozymes were sequence-specific in the in vitro cleavage analysis of run-off transcripts from tax/rex cDNA. Intracellular activities of the ribozymes were studied in HTLV-I tax cDNA-transfected rat embryonic fibroblasts (Rat/Tax cells), which expressed the Tax but not Rex. Ribozymes were delivered into cells using anionic or cationic liposomes fused with hemagglutinating virus of Japan (HVJ). Cellular uptake of ribozymes complexed with HVJ-cationic liposomes was 15-20 times higher cellular uptake than naked ribozymes, and 4-5 times higher than that of ribozymes complexed with HVJ anionic liposomes. HVJ-cationic liposomes promoted accumulation of ribozymes in cytoplasm and accelerated transport to the nucleus. Tax protein levels were decreased about 95% and were five times lower when the same amount of TR was introduced into the cells using HVJ-cationic, rather than HVJ-anionic liposomes. Inactive ribozyme and tax antisense oligodeoxynucleotides reduced Tax expression by about 20%, whereas RR and tar sense oligodeoxynucleotides had no effect. These results suggest that the ribozymes' effect against tax mRNA was sequence-specific, and HVJ-cationic liposomes can be useful for intracellular introduction of ribozymes.	KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 60601,JAPAN; HITACHI CHEM CO,TSUKUBA RES & DEV DIV,TSUKUBA,IBARAKI 30042,JAPAN; OSAKA UNIV,INST MOL & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Kyoto University; Hitachi Limited; Osaka University	Kitajima, I (corresponding author), KAGOSHIMA UNIV,DEPT LAB & MOL MED,8-35-1 SAKURAGAOKA,KAGOSHIMA 890,JAPAN.							ASANO K, 1988, BIOCHEMISTRY-US, V27, P1321, DOI 10.1021/bi00404a035; BEIGELMAN L, 1995, J BIOL CHEM, V270, P25702, DOI 10.1074/jbc.270.43.25702; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9137; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISEY L, 1991, ANTISENSE RES DEV, V1, P57, DOI 10.1089/ard.1991.1.57; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; HEIDENREICH O, 1995, NUCLEIC ACIDS RES, V23, P2223, DOI 10.1093/nar/23.12.2223; Jarvis TC, 1996, J BIOL CHEM, V271, P29107, DOI 10.1074/jbc.271.46.29107; Jarvis TC, 1996, RNA, V2, P419; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KANEDA Y, 1987, EXP CELL RES, V173, P56, DOI 10.1016/0014-4827(87)90331-4; KATO K, 1991, J BIOL CHEM, V266, P3361; Kijima H, 1995, PHARMACOL THERAPEUT, V68, P247, DOI 10.1016/0163-7258(95)02008-X; Kitajima I, 1996, J CELL SCI, V109, P609; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KITAJIMA I, 1991, J CLIN INVEST, V88, P1315, DOI 10.1172/JCI115436; KITAJIMA I, 1992, J BIOL CHEM, V267, P25881; KITAJIMA I, 1997, IN RPESS ARTHRITIS R; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; SAEKI Y, 1997, IN PRESS HUM GENE TH; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; Sarver N, 1991, Antisense Res Dev, V1, P373; Scherr M, 1997, J BIOL CHEM, V272, P14304, DOI 10.1074/jbc.272.22.14304; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHARMA HW, 1995, BIOESSAYS, V17, P1055, DOI 10.1002/bies.950171210; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; Wattiaux R, 1996, BIOCHEM BIOPH RES CO, V227, P448, DOI 10.1006/bbrc.1996.1527; WongStaal F, 1995, ADV DRUG DELIVER REV, V17, P363, DOI 10.1016/0169-409X(95)00072-F; XING Z, 1992, J VIROL, V66, P1361, DOI 10.1128/JVI.66.3.1361-1369.1992; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1989, HTLV I NERVOUS SYSTE, P19	41	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27099	27106		10.1074/jbc.272.43.27099	http://dx.doi.org/10.1074/jbc.272.43.27099			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341150	hybrid			2022-12-25	WOS:A1997YC65900046
J	Ohya, K; Kajigaya, S; Yamashita, Y; Miyazato, A; Hatake, K; Miura, Y; Ikeda, U; Shimada, K; Ozawa, K; Mano, H				Ohya, K; Kajigaya, S; Yamashita, Y; Miyazato, A; Hatake, K; Miura, Y; Ikeda, U; Shimada, K; Ozawa, K; Mano, H			SOCS-1/JAB/SSI-1 can bind to and suppress Tec protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; COLONY-STIMULATING FACTOR; CELL LINE; FAMILY; GENE; INTERLEUKIN-3; EXPRESSION; PHOSPHORYLATION; ERYTHROPOIETIN; ASSOCIATION	Tec is the prototype of a recently emerging subfamily among nonreceptor type protein-tyrosine kinases and is known to become tyrosine-phosphorylated and activated by a wide range of cytokine stimulations in hematopoietic cells. Although Tec was recently shown to be involved in the cytokine-driven activation mechanism of c-fos transcription, it is yet obscure how Tec relays the signals from cell surface receptors to the nucleus. To identify signaling molecules: acting downstream of Tec, we have looked for Tec-interacting proteins (TIPs) by using the yeast two-hybrid system. Here we report the identification and characterization of a novel protein, TIP3, which has been simultaneously identified by other groups as SOCS-1, JAB, or SSI-l. TIP3 carries one Src homology 2 domain with a sequence similarity to that of CIS. In 293 cells, TIPB associates with Tec and suppresses its kinase activity. Interestingly, TIPB can also down-regulate the activity of Jak2 but not that of Lyn. We propose that SOCS-1/JAB/SSI-1/TIP3 is a novel type of negative regulator to a subset of protein-tyrosine kinases.	JICHI MED SCH, DEPT MOL BIOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; JICHI MED SCH, DIV CARDIOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; JICHI MED SCH, DIV HEMATOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; NHLBI, HEMATOL BRANCH, NIH, BETHESDA, MD 20892 USA	Jichi Medical University; Jichi Medical University; Jichi Medical University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BAIER G, 1994, BIOTECHNIQUES, V17, P94; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; KIKUCHI Y, 1995, P NATL ACAD SCI USA, V92, P11814, DOI 10.1073/pnas.92.25.11814; KOMATSU N, 1991, CANCER RES, V51, P341; MACHIDE M, 1995, ONCOGENE, V11, P619; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1995, BLOOD, V85, P343; Mano H, 1996, FASEB J, V10, P637, DOI 10.1096/fasebj.10.5.8621063; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Miyazato A, 1996, CELL GROWTH DIFFER, V7, P1135; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; Yamashita Y, 1997, EXP HEMATOL, V25, P211; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	27	99	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27178	27182		10.1074/jbc.272.43.27178	http://dx.doi.org/10.1074/jbc.272.43.27178			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341160	hybrid			2022-12-25	WOS:A1997YC65900056
J	vandeLoo, JWHP; Creemers, JWM; Bright, NA; Young, BD; Roebroek, AJM; VandeVen, WJM				vandeLoo, JWHP; Creemers, JWM; Bright, NA; Young, BD; Roebroek, AJM; VandeVen, WJM			Biosynthesis, distinct post-translational modifications, and functional characterization of lymphoma proprotein convertase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PROCESSING ENZYME FURIN; CYTOPLASMIC DOMAIN; KEX2 PROTEASE; CELL-SURFACE; INTRACELLULAR TRAFFICKING; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; YEAST KEX2	Proprotein convertases are responsible for the endoproteolytic processing of prohormones, neuropeptide precursors, and other proproteins within the constitutive and regulated secretory pathways. Cleavage occurs carboxyl-terminally of basic amino acid motifs, such as RX(K/R)R, RXXR, and (R/K)R. As already available for the other known mammalian members of this enzyme family, we here define structural and functional features of human lymphoma proprotein convertase (LPC). Analysis of expression of recombinant LPC in stably transfected Chinese hamster ovary cells reveals biosynthesis of a 92-kDa nonglycosylated precursor (proLPC) and a 102-kDa endoglycosidase H-sensitive glycosylated form of proLPC. Only the latter is further processed and after propeptide removal converted into a complexly N-glycosylated mature form of LPC of about 92 kDa. Co-expression experiments of truncated LPC with an active site mutant of LPC (LPCS265A) indicate that prodomain removal of LPC occurs via an autoproteolytic, intramolecular mechanism, as was demonstrated before for some of the other members of this enzyme family. Prodomain removal is shown to be required for LPC to exit the endoplasmic reticulum. As far as subcellular localization is concerned, immunocytochemical, ultrastructural, and biochemical analyses show that LPC is concentrated in the trans-Golgi network, associated with membranes, and not secreted. Carboxyl-terminal domains are critically involved in this cellular retention, because removal of both the hydrophobic region and the cytoplasmic tail of LPC results in secretion. Of interest are the observations that LPC is not phosphorylated like furin but is palmitoylated in its cytoplasmic tail. Finally, substrate specificity of LPC is similar to that of furin but not identical. Whereas for furin a basic substrate residue at position P-2 is dispensable, it is essential for LPC. For optimal LPC substrate processing activity, an arginine at position P-6 is preferred over an arginine at P-4.	KATHOLIEKE UNIV LEUVEN,CTR HUMAN GENET,MOL ONCOL LAB,B-3000 LOUVAIN,BELGIUM; FLANDERS INTERUNIV INST BIOTECHNOL,B-3000 LOUVAIN,BELGIUM; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT MED ONCOL,IMPERIAL CANC RES FUND,LONDON EC1 M6BQ,ENGLAND	KU Leuven; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge								AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; Ayoubi TAY, 1996, MOL BIOL REP, V23, P87, DOI 10.1007/BF00424434; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; Griffiths G., 1993, FINE STRUCTURE IMMUN, P1; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; Inocencio NM, 1997, J BIOL CHEM, V272, P1344, DOI 10.1074/jbc.272.2.1344; JANSEN E, 1995, J BIOL CHEM, V270, P15391, DOI 10.1074/jbc.270.25.15391; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOCKER JK, 1995, J BIOL CHEM, V270, P8815, DOI 10.1074/jbc.270.15.8815; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Meerabux J, 1996, CANCER RES, V56, P448; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Nilsson T, 1996, J CELL SCI, V109, P1975; OHAGI S, 1992, P NATL ACAD SCI USA, V89, P4977, DOI 10.1073/pnas.89.11.4977; OHNISHI Y, 1994, J VIROL, V68, P4075, DOI 10.1128/JVI.68.6.4075-4079.1994; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; REHEMTULLA A, 1993, BIOCHEMISTRY-US, V32, P11586, DOI 10.1021/bi00094a015; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; TAKAHASHI S, 1994, J BIOCHEM-TOKYO, V116, P47, DOI 10.1093/oxfordjournals.jbchem.a124501; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VANDUIJNHOVEN HLP, 1992, HYBRIDOMA, V11, P71, DOI 10.1089/hyb.1992.11.71; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; WONG SH, 1993, J BIOL CHEM, V268, P22853; [No title captured]	52	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27116	27123		10.1074/jbc.272.43.27116	http://dx.doi.org/10.1074/jbc.272.43.27116			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341152	hybrid			2022-12-25	WOS:A1997YC65900048
J	Alenius, M; Bohm, S				Alenius, M; Bohm, S			Identification of a novel neural cell adhesion molecule-related gene with a potential role in selective axonal projection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY OLFACTORY PROJECTION; GROWTH CONE GUIDANCE; FASCICLIN-II; N-CAM; EXPRESSION; SYSTEM; ORGANIZATION; EPITHELIUM; PROTEINS; MOUSE	We describe here the cloning of mouse complementary DNAs encoding a novel protein, Rb-8 neural cell adhesion molecule (RNCAM), with a predicted extracellular region of five immunoglobulin Ca-type domains followed by two fibronectin type III domains, Alternative splicing is likely to generate two RNCAM isoforms, which are differently attached to the cell membrane, These structural features and overall sequence identity identify this protein as a novel member of a cell adhesion molecule subgroup together with vertebrate neural cell adhesion molecule, Aplysia cell adhesion molecule, and Drosophila fasciclin II, In insects, fasciclin II is present on a restricted subset of embryonic central nervous system axons where it controls selective axon fasciculation. Intriguingly, RNCAM likewise is expressed in subsets of olfactory and vomeronasal neurons with topographically defined axonal projections, The spatial expression RNCAM corresponds precisely to that of certain odorant receptor expression zones of the olfactory epithelium. These expression patterns thus render RNCAM the first described cell adhesion molecule with a potential regulatory role in formation of selective axonal projections important for olfactory sensory information coding.	UMEA UNIV,DEPT CELL & MOL BIOL,S-90187 UMEA,SWEDEN	Umea University								BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; Berghard A, 1996, J NEUROSCI, V16, P909; CALOF AL, 1989, NEURON, V3, P115, DOI 10.1016/0896-6273(89)90120-7; Chen H, 1996, GENOME RES, V6, P747, DOI 10.1101/gr.6.8.747; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Goridis C, 1992, Semin Cell Biol, V3, P189; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; MORI K, 1995, PROG NEUROBIOL, V45, P585, DOI 10.1016/0301-0082(94)00058-P; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWOB JE, 1988, J NEUROSCI, V8, P3470; SCHWOB JE, 1986, J NEUROSCI, V6, P3393; SHINOHARA H, 1992, J NEUROSCI, V12, P1275; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; TESSIERLAVIGNE M, 1996, SCIENCE, V274, P1128; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; VarelaEchavarria A, 1997, GENE DEV, V11, P545, DOI 10.1101/gad.11.5.545; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M	26	82	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26083	26086		10.1074/jbc.272.42.26083	http://dx.doi.org/10.1074/jbc.272.42.26083			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334170	hybrid			2022-12-25	WOS:A1997YB13900004
J	Benjannet, S; Savaria, D; Laslop, A; Munzer, JS; Chretien, M; Marcinkiewicz, M; Seidah, NG				Benjannet, S; Savaria, D; Laslop, A; Munzer, JS; Chretien, M; Marcinkiewicz, M; Seidah, NG			alpha 1-antitrypsin portland inhibits processing of precursors mediated by proprotein convertases primarily within the constitutive secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASES; KEX2-LIKE ENDOPROTEASE; SUBTILISIN FAMILY; POLYPEPTIDE 7B2; HUMAN FURIN; PROTEIN; PC2; CELLS; CLEAVAGE; SEQUENCE	We studied the extent of cellular inhibitory activity of alpha 1-antitrypsin Portland (alpha 1-PDX), a patent inhibitor of proprotein convertases of the subtilisin/kexin type. We compared the inhibitory effects of alpha 1-PDX on the intracellular processing of two model precursors (pro ?Ba and POMC) mediated by six of the seven known mammalian convertases, namely furin, PC1, PC2, PACE4, PCB-A, PC5-B, and PC7, The substrates selected were pro7B2, a precursor cleaved within the trans-Golgi network (TGN), and pro-opiomelanocortin, which is processed in the TGN and secretory granules. Biosynthetic analyses were performed using either vaccinia virus expression in BSC40, GH4C1, and AtT20 cells, or stable transfectants of alpha 1-PDX in AtT20 cells. Results revealed that alpha 1-PDX inhibits processing of these precursors primarily within the constitutive secretory pathway and that alpha 1-PDX is cleaved into a shorter form by some convertases. Evidence is presented demonstrating that in contrast to the full-length alpha 1-PDX (64 kDa), the cleaved (56 kDa) secreted product; does not significantly inhibit furin activity in vitro, Cellular expression of alpha 1-PDX results in modified contents of mature secretory granules with increased levels of partially processed products. Biosynthetic and immunocytochemical analyses of AtT20/alpha 1-PDX cells demonstrated that alpha 1-PDX is primarily localized within the TGN, and that a small proportion enters secretory granules where it is mostly stored as the cleaved product.	CLIN RES INST MONTREAL,JA DESEVE LABS BIOCHEM,MONTREAL,PQ H2W 1R7,CANADA; CLIN RES INST MONTREAL,JA DESEVE LABS MOL NEUROENDOCRINOL,MONTREAL,PQ H2W 1R7,CANADA; PROT ENGN NETWORK CTR EXCELLENCE,MONTREAL,PQ H2W 1R7,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; CHRETIEN, Michel/0000-0002-8588-4460				ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRESNAHAN PA, 1993, MECHANISMS INTRACELL, P225; CHRETIEN M, 1995, P ASSOC AM PHYSICIAN, V107, P47; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; DECROLY E, 1994, J BIOL CHEM, V269, P12240; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HUTTON JC, 1994, DIABETOLOGIA, V37, pS48, DOI 10.1007/BF00400826; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Komiyama T, 1996, PROTEIN SCI, V5, P874; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; KURACHI K, 1981, P NATL ACAD SCI-BIOL, V78, P6826, DOI 10.1073/pnas.78.11.6826; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LU WY, 1993, J BIOL CHEM, V268, P14583; Mains RE, 1997, BIOCHEM J, V321, P587, DOI 10.1042/bj3210587; MARTENS GJM, 1988, FEBS LETT, V234, P160, DOI 10.1016/0014-5793(88)81324-3; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MATSUUCHI L, 1988, J CELL BIOL, V106, P239, DOI 10.1083/jcb.106.2.239; MBIKAY M, 1989, INT J PEPT PROT RES, V33, P39; MILGRAM SL, 1994, J CELL SCI, V107, P735; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PAQUET L, 1994, J BIOL CHEM, V269, P19279; PERLMUTTER DH, 1989, AM J PHYSIOL, V257, pL147, DOI 10.1152/ajplung.1989.257.4.L147; REAVES B, 1992, BIOCHEM J, V283, P313, DOI 10.1042/bj2830313; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SEIDAH NG, 1995, INTRAMOLECULAR CHAPE, P181; THOMAS G, 1995, PROPEPTIDE MEDIATED, P157; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; Vollenweider F, 1996, BIOCHEM J, V314, P521, DOI 10.1042/bj3140521; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	50	80	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26210	26218		10.1074/jbc.272.42.26210	http://dx.doi.org/10.1074/jbc.272.42.26210			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334189	hybrid			2022-12-25	WOS:A1997YB13900023
J	Caloca, MJ; Fernandez, N; Lewin, NE; Ching, DX; Modali, R; Blumberg, PM; Kazanietz, MG				Caloca, MJ; Fernandez, N; Lewin, NE; Ching, DX; Modali, R; Blumberg, PM; Kazanietz, MG			beta 2-chimaerin is a high affinity receptor for the phorbol ester tumor promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTPASE-ACTIVATING PROTEIN; CYSTEINE-RICH REGION; MOUSE-BRAIN; N-CHIMAERIN; 12,13-DIBUTYRATE BINDING; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; CALCIUM; ISOZYMES	beta 2-chimaerin, a member of the GTPase-activating proteins for the small GTP-binding protein p21Rac, possesses a single cysteine-rich domain with high homology to those implicated in phorbol ester and diacylglycerol binding in protein kinase C (PKC) isozymes. We have expressed beta 2-chimaerin in Sf9 insect cells using the baculovirus expression system and determined that, like PKCs, beta 2-chimaerin binds phorbol esters with high affinity in the presence of phosphatidylserine as a cofactor. Scatchard plot analysis using the radioligand [H-3]phopbol 12,13-dibutyrate revealed a dissociation constant of 1.9 +/- 0.2 nM for beta 2-chimaerin. Likewise, beta 2-chimaerin is a high affinity receptor for the bryostatins, a class of atypical PHC activators. A detailed comparison of structure activity relations using several phorbol ester analogs revealed striking differences in binding recognition between beta 2-chimaerin and PKC alpha. Although the diacylglycerol 1-oleoyl-2-acetylglycerol binds with similar potency to both beta 2-chimaerin and PKC alpha; the mezerein analog thymeleatoxin has 56-foId less affinity for binding to beta 2-chimaerin. To establish whether beta 2-chimaerin responds to phorbol esters in cellular sys-- tems, we overexpressed beta 2-chimaerin in COS-7 cells and monitored its subcellular distribution after phorbol ester treatment. Interestingly, as described previously for PI(C isozymes, beta 2-chimaerin translocates from cytosolic to particulate fractions as a consequence of phorbol ester treatment. Our results demonstrate that beta 2-chimaerin is a novel target for the phorbol aster tumor promoters. The expansion of the family of phorbol ester receptors strongly suggests a potential for the ''nonkinase'' receptors as cellular mediators of the phorbol ester responses.	UNIV PENN, SCH MED, CTR EXPT THERAPEUT, STELLAR CHANCE LABS 905, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA; NCI, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, NIH, BETHESDA, MD 20892 USA; BIOSERVE BIOTECHNOL, LAUREL, MD 20707 USA	University of Pennsylvania; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Caloca, María-José/K-9357-2014; Fernández, Nieves/N-5426-2018	Fernández, Nieves/0000-0002-9141-3956; Caloca, Maria-Jose/0000-0002-1003-2685	NCI NIH HHS [IROICA74197-OIAI] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; ARECES LB, 1994, J BIOL CHEM, V269, P19553; ASHENDEL CL, 1983, CANCER RES, V43, P4333; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DUNPHY WG, 1981, CANCER RES, V41, P2640; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HALL C, 1993, MOL CELL BIOL, V13, P4986, DOI 10.1128/MCB.13.8.4986; Hurley JH, 1997, PROTEIN SCI, V6, P477; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P10777, DOI 10.1074/jbc.270.18.10777; KAZANIETZ MG, 1994, MOL PHARMACOL, V46, P374; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KONIG B, 1985, J CELL BIOCHEM, V27, P255, DOI 10.1002/jcb.240270307; Kozma R, 1996, MOL CELL BIOL, V16, P5069; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; Lee J, 1993, Bioorg Med Chem, V1, P119, DOI 10.1016/S0968-0896(00)82109-4; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEUNG T, 1994, J BIOL CHEM, V269, P12888; LEUNG T, 1993, J BIOL CHEM, V268, P3813; LEWIN NE, 1992, BIOCHEM PHARMACOL, V43, P2007, DOI 10.1016/0006-2952(92)90644-X; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; RIDLEY AJ, 1994, J CELL SCI, P127; SANDO JJ, 1983, P NATL ACAD SCI-BIOL, V80, P2642, DOI 10.1073/pnas.80.9.2642; SHARKEY NA, 1985, CANCER RES, V45, P19; Summers MD, 1987, TEXAS AGR EXPT STATI; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; TAKAI Y, 1979, J BIOL CHEM, V254, P3692	42	90	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26488	26496		10.1074/jbc.272.42.26488	http://dx.doi.org/10.1074/jbc.272.42.26488			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334226	hybrid			2022-12-25	WOS:A1997YB13900060
J	Ogino, T; Kobuchi, H; Sen, CK; Roy, S; Packer, L; Maguire, JJ				Ogino, T; Kobuchi, H; Sen, CK; Roy, S; Packer, L; Maguire, JJ			Monochloramine inhibits phorbol ester-inducible neutrophil respiratory burst activation and T cell interleukin-2 receptor expression by inhibiting inducible protein kinase C activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NADPH-OXIDASE; SIGNAL-TRANSDUCTION; POLYMORPHONUCLEAR LEUKOCYTES; SUPEROXIDE PRODUCTION; INTRACELLULAR CA2+; ARACHIDONIC-ACID; BINDING-PROTEINS; ALPHA GENE; PHOSPHORYLATION	Monochloramine derivatives are long lived physiological oxidants produced by neutrophils during the respiratory burst, The effects of chemically prepared monochloramine (NH2Cl) on protein kinase C (PKC) and PKC-mediated cellular responses were studied in elicited rat peritoneal neutrophils and human Jurkat T cells, Neutrophils pretreated with NH2Cl (30-50 mu M) showed a marked decrease in the respiratory burst activity induced by phorbol 12-myristate 13-acetate (PMA), which is a potent PKC activator. These cells, however, were viable and showed a complete respiratory burst upon arachidonic acid stimulation, which induces the respiratory burst by a PKC-independent mechanism, The NH2Cl-treated neutrophils showed a decrease in both PRC activity and PMA-induced phosphorylation of a 47-kDa protein, which corresponds to the cytosolic factor of NADPH oxidase, p47(phox). Jurkat T cells pretreated with NH2Cl (20-70 mu M) showed a decrease in the expression of the interleukin-a receptor a chain following PMA stimulation. This was also accompanied by a decrease in both PKC activity and nuclear transcription factor-kappa B activation, also without loss of cell viability, These results show that NH2Cl inhibits PKC-mediated cellular responses through inhibition of the inducible PKC activity.	UNIV CALIF BERKELEY,ENVIRONM ENERGY TECHNOL DIV,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Ogino, T (corresponding author), UNIV CALIF BERKELEY,DEPT CELLULAR & MOL BIOL,LAWRENCE BERKELEY LAB,251 LSA,BERKELEY,CA 94720, USA.		Sen, Chandan K/A-8762-2013; OGINO, Tetsuya/B-1999-2011; Roy, sashwati/E-3990-2011		NIGMS NIH HHS [GM27345] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM027345] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BADWEY JA, 1981, J BIOL CHEM, V256, P2640; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; Bell R M, 1986, Methods Enzymol, V124, P353; Blobe GC, 1996, CANCER SURV, V27, P213; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOHNLEIN E, 1989, J BIOL CHEM, V264, P8475; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BUTTERWORTH RF, 1987, NEUROCHEM PATHOL, V6, P1, DOI 10.1007/BF02833598; COHEN P, 1989, J BIOL CHEM, V264, P21435; COX JA, 1987, J IMMUNOL, V138, P1884; CUNNINGHAM FM, 1979, J PATHOL, V128, P15, DOI 10.1002/path.1711280104; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DING JB, 1992, J BIOL CHEM, V267, P6442; DING JB, 1992, BIOCHIM BIOPHYS ACTA, V1133, P235, DOI 10.1016/0167-4889(92)90074-L; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; GREENE WC, 1984, J IMMUNOL, V133, P1042; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOWANITZ JH, 1984, CLIN CHEM, V30, P906; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; JAMIESON C, 1991, J IMMUNOL, V147, P416; KAKINUMA K, 1976, J BIOCHEM-TOKYO, V79, P795, DOI 10.1093/oxfordjournals.jbchem.a131132; LEARN DB, 1990, J LEUKOCYTE BIOL, V48, P174, DOI 10.1002/jlb.48.2.174; LEVY R, 1994, BBA-MOL CELL RES, V1220, P253, DOI 10.1016/0167-4889(94)90146-5; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MAJUMDAR S, 1993, BIOCHIM BIOPHYS ACTA, V1176, P276, DOI 10.1016/0167-4889(93)90056-U; MAKINO R, 1986, J BIOL CHEM, V261, P1444; Marcinkiewicz J, 1995, J LEUKOCYTE BIOL, V58, P667, DOI 10.1002/jlb.58.6.667; NAKAMURA TY, 1995, J CELL BIOL, V131, P509, DOI 10.1083/jcb.131.2.509; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Ogino T, 1997, FREE RADICAL BIO MED, V23, P445, DOI 10.1016/S0891-5849(97)00115-9; Pero RW, 1996, CARCINOGENESIS, V17, P13, DOI 10.1093/carcin/17.1.13; PILLOUDDAGHER MC, 1992, BIOCHEM BIOPH RES CO, V186, P731, DOI 10.1016/0006-291X(92)90807-W; ROBINSON JM, 1995, HISTOCHEM CELL BIOL, V103, P163, DOI 10.1007/BF01454021; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SALAMINO F, 1991, EUR J BIOCHEM, V200, P573, DOI 10.1111/j.1432-1033.1991.tb16220.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sen CK, 1996, FEBS LETT, V385, P58, DOI 10.1016/0014-5793(96)00346-8; SHACKELFORD DA, 1984, J BIOL CHEM, V259, P1706; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; SUZUKI YJ, 1992, BIOCHEM BIOPH RES CO, V189, P1709, DOI 10.1016/0006-291X(92)90275-P; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; SZAMEL M, 1995, EUR J BIOCHEM, V228, P1; SZAMEL M, 1993, EUR J IMMUNOL, V23, P3072, DOI 10.1002/eji.1830231205; TAUBER AI, 1987, BLOOD, V69, P711; TEST ST, 1984, J CLIN INVEST, V74, P1341, DOI 10.1172/JCI111544; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1983, J CLIN INVEST, V72, P441, DOI 10.1172/JCI110992; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; ZGLICZYNSKI JM, 1988, RESP BURST ITS PHYSL, P315	63	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26247	26252		10.1074/jbc.272.42.26247	http://dx.doi.org/10.1074/jbc.272.42.26247			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334193	hybrid			2022-12-25	WOS:A1997YB13900027
J	Zhang, CY; Gadue, P; Scott, E; Atchison, M; Poncz, M				Zhang, CY; Gadue, P; Scott, E; Atchison, M; Poncz, M			Activation of the megakaryocyte-specific gene platelet basic protein (PBP) by the Ets family factor PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTOR GATA-1; HUMAN BETA-THROMBOGLOBULIN; ERYTHROLEUKEMIA CELL-LINE; ALPHA-GRANULE PROTEINS; FACTOR-IV; REGULATORY ELEMENTS; GLYCOPROTEIN-IIB; FACTOR-RECEPTOR; MYELOID CELLS	Platelet basic protein (PBP) is a chemokine family member that is only found in platelets and their precursors megakaryocytes. The PBP gene is physically linked to the gene for another platelet-specific chemokine, platelet factor 4. While the. biological basis of platelet factor 4 expression has been pursued by others, the regulatory features controlling the platelet specific expression of PBP have not been investigated, In this article, we examined the molecular basis by which this megakaryocyte-specific gene is regulated, Transient expression studies of truncated reporter constructs containing from 4.5 to 0.1 kilobases of the functional PBP gene 5'-flanking region, demonstrated that the proximal 0.1 kilobases of the promoter was sufficient for high levels of expression in human erythroleukemia and CHRF-288 cells, two megakaryocytic cell lines, He-Never, none of these constructs was expressed above background levels in HeLa and 293 cells, two non-megakaryocytic cell lines, Further truncation of this promoter suggested that there was an important regulatory element(s) within a pyrimidine-rich tract. Mobility shift analysis of the pyrimidine-rich tract defined a region between -85 and -64 which bound to a nuclear factor(s), This region contains sequences matching the consensus Ets-binding site from -78 to -75 base pairs, In particular, we noted that this site matched a PU,I consensus sequence known as a PU box, Mobility shift and supershift studies with nuclear extracts as well as recombinant PU.1 protein and anti-PU.1 antibody further confirmed that PU.1 was the specific Ets family factor that bound to this site, Transient expression assays using reporter constructs which contained point mutations that abrogated PU.1 binding also significantly reduced PBP promoter activity in human erythroleukemia and CHRF cells, In addition, while all reporter gene constructs containing PBP promoters were completely inactive in HeLa cells, transactivation experiments using a PU,I expression construct demonstrated that exogenous expression of PU.1 could increase reporter gene expression up to 8-fold in these cells, Finally, the role of PU.1 in PBP gene expression was compared between wild-type and PU.1-null embryonic stem (ES) cells that were differentiated in vitro into cells that resembled megakaryocytes both morphologically and immunologically. We found that PBP gene expression in the differentiated PU.1(-/-) null ES cells (as determined by semi-quantitative reverse transcriptase-polymerase chain reaction) was more that four times lower than that in the wild-type ES cells, while other platelet-specific genes were expressed equally or similarly in the two ES cell lines. Previous reports have shown the PU.1 is expressed in several hematopoietic lineages, including megakaryocytes. However, the functional role of PU.1 has only been previously demonstrated in the myeloid and lymphoid lineages. Therefore, our studies are the first to show the biological importance of this nuclear factor in the regulated expression of a megakaryocyte-specific gene.	UNIV PENN, GRAD GRP PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, IMMUNOL GRAD GRP, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT MOL & CELLULAR ENGN, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT ANIM BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NATIONAL CANCER INSTITUTE [R01CA072769] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037419] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042415] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72769] Funding Source: Medline; NHLBI NIH HHS [HL 37419] Funding Source: Medline; NIGMS NIH HHS [GM 42415] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKRIGG A, 1985, VIRUS RES, V2, P107, DOI 10.1016/0168-1702(85)90242-4; AVRAHAM H, 1993, STEM CELLS, V11, P499, DOI 10.1002/stem.5530110619; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; BEGG GS, 1978, BIOCHEMISTRY-US, V17, P1739, DOI 10.1021/bi00602a024; BIGGS R, 1976, HUMAN BLOOD COAGULAT; BLOCK KL, 1994, BLOOD, V84, P3385; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EISMAN R, 1990, BLOOD, V76, P336; FONG AM, 1994, J BIOL CHEM, V269, P18441; FUGMAN DA, 1990, BLOOD, V75, P1252; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEWIRTZ AM, 1995, THROMB HAEMOSTASIS, V74, P204; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GRIFFIN CA, 1987, CYTOGENET CELL GENET, V45, P67, DOI 10.1159/000132431; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HOLT JC, 1985, SEMIN HEMATOL, V22, P151; HROMAS R, 1993, BLOOD, V82, P2998; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUTER DJ, 1989, BLOOD, V74, P1952; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LONG MW, 1988, EXP HEMATOL, V16, P62; Ludlow LB, 1996, J BIOL CHEM, V271, P22076, DOI 10.1074/jbc.271.36.22076; MAJERUS PW, 1978, ANNU REV MED, V29, P41, DOI 10.1146/annurev.me.29.020178.000353; MAJUMDAR S, 1991, J BIOL CHEM, V266, P5785; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATTILA P, 1991, NUCLEIC ACIDS RES, V19, P4967, DOI 10.1093/nar/19.18.4967; MAZUR EM, 1987, EXP HEMATOL, V15, P340; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PAPAYANNOPOULOU T, 1983, GLOBIN GENE EXPRESSI, P277; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; RAMACHANDRAN B, 1995, EXP HEMATOL, V23, P49; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; RAY D, 1990, ONCOGENE, V5, P663; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; STOECKLE M Y, 1990, New Biologist, V2, P313; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TJIAN R, 1995, SCI AM, V272, P54, DOI 10.1038/scientificamerican0295-54; TUNNACLIFFE A, 1992, BLOOD, V79, P2896; TWEARDY DJ, 1992, BLOOD, V79, P1148, DOI 10.1182/blood.V79.5.1148.bloodjournal7951148; UZAN G, 1991, J BIOL CHEM, V266, P8932; VISVADER J, 1993, BLOOD, V82, P1493; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WENGER RH, 1989, BLOOD, V73, P1498; WENGER RH, 1991, HUM GENET, V87, P367; WORTHINGTON RE, 1984, CYTOMETRY, V5, P501, DOI 10.1002/cyto.990050511; ZUCKER MB, 1991, P SOC EXP BIOL MED, V198, P693	69	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26236	26246		10.1074/jbc.272.42.26236	http://dx.doi.org/10.1074/jbc.272.42.26236			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334192	hybrid			2022-12-25	WOS:A1997YB13900026
J	Strickland, E; Qu, BH; Millen, L; Thomas, PJ				Strickland, E; Qu, BH; Millen, L; Thomas, PJ			The molecular chaperone Hsc70 assists the in vitro folding of the N-terminal nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; DELTA-F508 MUTATION; PROTEIN; HSP70; COMMON; PROTEASOME; STABILITY; PATHWAY; PEPTIDE; ATPASE	The most common disease-causing mutation in the cystic fibrosis transmembrane conductance regulator is a single amino acid deletion (Delta F508) in the N-terminal cytosolic nucleotide-binding domain (NBD1), This mutation has previously been shown to be a temperature-sensitive folding mutation that alters the folding pathway but not the native state stability of the isolated domain (Qu, B.-H., and Thomas, P. J. (1996) J. Biol. Chem, 271, 7261-7264), Here we provide evidence that the molecular chaperone Hsc70 productively interacts with NBD1 to increase the folding yield of the domain and inhibit off-pathway associations leading to the formation of high molecular weight aggregates, Furthermore, we have sublocalized a region within NBD1 where Hsc70 binds, Notably, inhibition of NBD1 aggregation is not dependent upon the presence of Hsc70 in the early stages of folding, indicating that the chaperone may act on a folding intermediate. In the presence of K+ and Mg2+-ATP, conditions where Hsp70 binds substrate rapidly and can release it, Hsc70 is less effective at inhibiting NBD1 aggregation, Thus, the rate of release of unfolded substrate is an important factor in preventing aggregation and promoting folding of the domain, These results demonstrate that Hsc70 promotes the otherwise inefficient folding of Delta F-NBD1 and provide insight into the mechanisms by which molecular chaperones assist proteins in folding.	UNIV TEXAS,SW MED CTR,GRAD PROGRAM MOL BIOPHYS,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Thomas, Philip J/F-7115-2012		NIDDK NIH HHS [NIDDK49835] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK049835, R01DK049835] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Bercovich B, 1997, J BIOL CHEM, V272, P9002; BLONDELGUINDI S, 1993, CELL, V75, P1; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; GREENE LE, 1990, J BIOL CHEM, V265, P6682; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; JACOB U, 1996, J BIOL CHEM, V271, P10035; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KAMATHLOEB AS, 1995, J BIOL CHEM, V270, P30051; LAM KT, 1992, BIOCHEM BIOPH RES CO, V184, P167, DOI 10.1016/0006-291X(92)91174-O; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Qu BH, 1997, J BIOL CHEM, V272, P15739, DOI 10.1074/jbc.272.25.15739; QU BH, 1997, IN PRESS J BIOENERG; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	32	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25421	25424		10.1074/jbc.272.41.25421	http://dx.doi.org/10.1074/jbc.272.41.25421			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325249	hybrid			2022-12-25	WOS:A1997YA35800004
J	Tiruppathi, C; Song, W; Bergenfeldt, M; Sass, P; Malik, AB				Tiruppathi, C; Song, W; Bergenfeldt, M; Sass, P; Malik, AB			Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONALLY MODIFIED ALBUMINS; SRC SH2 DOMAIN; CAPILLARY-PERMEABILITY; SIGNAL-TRANSDUCTION; BINDING PROTEINS; RECEPTOR; ENDOCYTOSIS; TRANSPORT; CAVEOLAE; SURFACE	We investigated the function of gp60, an endothelial cell membrane 60-kDa albumin-binding protein localized in caveolae, and the mechanism of its activation in regulating endothelial permeability of albumin, Gp60 organization on the bovine pulmonary microvessel endothelial cell (BPMVEC) surface was punctate as shown by immunofluorescence using an anti-gp60 antibody (Ab) conjugated with bisfunctional, N-hydroxysuccinimidyl fluorophore (Cy3), Addition of a secondary Ab to anti-gp60 Ab-treated BPMVEC induced cross-linking of gp60 as evident by increased size of fluorescent particles and cell surface gp60 clustering, Gp60 cross-linking also produced 2-3-fold increases in the endothelial cell uptake and the luminal to abluminal permeability of I-125-albumin as well as the fluid-phase tracer, horseradish peroxidase, The increased transendothelial permeability of macromolecules was the result of transcytosis as it was not associated with an increase in the paracellular pathway, Incubation of anti-gp60 Ab with BPMVEC at 37 degrees C caused internalization of gp60, and thereby reduced the uptake of the macromolecules. Activation of gp60 by either albumin (the gp60 ligand) or gp60 crosslinking induced the phosphorylation of both gp60 and caveolin-1 (the major structural caveolar protein) on tyrosine residues, Gp60 activation also phosphorylated the Src family tyrosine kinases pp60(c-Src) and Fyn. The activated pp60(c-Src) and Fyn co-immunoprecipitated with caveolin-1 in BPMVEC membrane, Protein tyrosine kinase (PTK) inhibitors, herbimycin A and genistein, prevented gp60-activated macromolecule uptake and transcytosis in a concentration-dependent manner, indicating the functional significance of the PTK pathway in activating albumin transcytosis, These findings indicate that activation of gp60 stimulates the Src PTK signaling pathway, and thus regulates the transcytosis of albumin across the endothelial cell monolayer.			Tiruppathi, C (corresponding author), UNIV ILLINOIS, COLL MED, DEPT PHARMACOL MC 868, 835 S WOLCOTT AVE, CHICAGO, IL 60612 USA.			Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [HL27016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027016, R37HL027016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CURRY FE, 1980, MICROVASC RES, V20, P96, DOI 10.1016/0026-2862(80)90024-2; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DELVECCHIO PJ, 1992, IN VITRO CELL DEV-AN, V28A, P711; FORKER EL, 1983, J CLIN INVEST, V72, P1764, DOI 10.1172/JCI111136; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GHINEA N, 1988, J CELL BIOL, V107, P231, DOI 10.1083/jcb.107.1.231; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; GORDEN P, 1982, METABOLISM, V31, P664, DOI 10.1016/0026-0495(82)90196-2; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; KAHN CR, 1978, P NATL ACAD SCI USA, V75, P4209, DOI 10.1073/pnas.75.9.4209; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Li SW, 1996, J BIOL CHEM, V271, P3863; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU XQ, 1993, ONCOGENE, V8, P1119; MAJNO G, 1969, J CELL BIOL, V42, P647, DOI 10.1083/jcb.42.3.647; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; PARDRIDGE WM, 1979, ENDOCRINOLOGY, V105, P605, DOI 10.1210/endo-105-3-605; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PREDESCU D, 1988, J CELL BIOL, V107, P1729, DOI 10.1083/jcb.107.5.1729; PREDESCU D, 1994, P NATL ACAD SCI USA, V91, P3014, DOI 10.1073/pnas.91.8.3014; Putnam E., 1975, 3 SERUM ALBUMIN, VSecond, P133, DOI [10.1016/B978-0-12-568401-9.50010-4, DOI 10.1016/B978-0-12-568401-9.50010-4]; RESINK TJ, 1990, MOL PHARMACOL, V38, P244; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SCHLESSINGER J, 1980, TRENDS BIOCHEM SCI, V5, P210, DOI 10.1016/S0968-0004(80)80010-7; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHNITZER JE, 1988, P NATL ACAD SCI USA, V85, P6773, DOI 10.1073/pnas.85.18.6773; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1992, J BIOL CHEM, V267, P24544; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SCHNITZER JE, 1994, BIOCHEM BIOPH RES CO, V199, P11, DOI 10.1006/bbrc.1994.1185; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; SIFLINGERBIRNBOIM A, 1991, J CELL PHYSIOL, V149, P575, DOI 10.1002/jcp.1041490329; SIFLINGERBIRNBOIM A, 1987, J CELL PHYSIOL, V132, P111, DOI 10.1002/jcp.1041320115; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TIRUPPATHI C, 1992, AM J PHYSIOL, V263, pL595, DOI 10.1152/ajplung.1992.263.5.L595; Tiruppathi C, 1996, P NATL ACAD SCI USA, V93, P250, DOI 10.1073/pnas.93.1.250; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WALZOG B, 1994, J LEUKOCYTE BIOL, V56, P625, DOI 10.1002/jlb.56.5.625; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	278	281	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25968	25975		10.1074/jbc.272.41.25968	http://dx.doi.org/10.1074/jbc.272.41.25968			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325331	hybrid			2022-12-25	WOS:A1997YA35800086
J	Tseng, WC; Haselton, FR; Giorgio, TD				Tseng, WC; Haselton, FR; Giorgio, TD			Transfection by cationic liposomes using simultaneous single cell measurements of plasmid delivery and transgene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; GENE DELIVERY; FLOW-CYTOMETRY; DNA; MECHANISM; THERAPY; HUMANS; SERIES	Cationic liposomes are potentially important gene transfer vehicles, although their application has been limited by relatively low efficiency of transgene expression. Single cell, quantitative methods, such as those used in this study, should permit a more detailed understanding of the relationships between delivered plasmid and transgene expression, Intracellular plasmid delivery and transgene expression were measured simultaneously using photoconjugated ethidium monoazide as an intracellular plasmid delivery marker and green fluorescent protein (GFP(S65T)) as a transgene expression marker, Quantitative flow cytometry was used to estimate plasmid copy number and GFP(S65T) molecules in single cells, The plasmid was delivered to HeLa cells with a cationic liposome vehicle containing 1,2-dioleoyloxy-3-trimethylammonium-propane and dioleoylphosphatidylethanolamine (1:1 mol/mol). Treatment was carried out continuously for 24 h. Flow cytometry measurements on 20,000 cells were performed during treatment and for 48 h post-treatment. On a single cell basis, transgene expression efficiency and average GFP(S65T) expression level increased with intracellular plasmid copy number. After 3-h exposure to the liposomal vector, more than 95% of the cells were positive for plasmid entry, but none had detectable transgene expression, Maximum transgene expression was achieved at 24 h and remained unchanged at the 72-h measurement. At 24 h, the average positive cell contained 1.6 x 10(5) plasmid copies and 2.3 x 10(6) GFP(S65T) molecules, importantly, the measurement strategies revealed that transgene expression varied widely within the entire cell population. Although only 30% of all cells expressed transgene, the subpopulation of cells that rapidly incorporated the vector demonstrated 100% efficiency in transgene expression. This study identifies parameters that modulate highly efficient transgene expression from plasmid delivery by cationic liposomes.	VANDERBILT UNIV, DEPT CHEM, NASHVILLE, TN 37235 USA; VANDERBILT UNIV, DEPT BIOMED ENGN, NASHVILLE, TN 37235 USA	Vanderbilt University; Vanderbilt University								BAGWELL CB, 1993, ANN NY ACAD SCI, V677, P167, DOI 10.1111/j.1749-6632.1993.tb38775.x; Barak Z, 1996, J MOL BIOL, V256, P676, DOI 10.1006/jmbi.1996.0117; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; Friend DS, 1996, BBA-BIOMEMBRANES, V1278, P41, DOI 10.1016/0005-2736(95)00219-7; Fritz JD, 1996, HUM GENE THER, V7, P1395, DOI 10.1089/hum.1996.7.12-1395; Gao X, 1996, BIOCHEMISTRY-US, V35, P1027, DOI 10.1021/bi952436a; GuyCaffey JK, 1995, J BIOL CHEM, V270, P31391, DOI 10.1074/jbc.270.52.31391; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; Lee RJ, 1996, J BIOL CHEM, V271, P8481, DOI 10.1074/jbc.271.14.8481; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; NISWENDER KD, 1995, J MICROSC-OXFORD, V180, P109, DOI 10.1111/j.1365-2818.1995.tb03665.x; ROPP JD, 1995, CYTOMETRY, V21, P309, DOI 10.1002/cyto.990210402; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHREIER H, 1994, J BIOL CHEM, V269, P9090; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; Stephan DJ, 1996, HUM GENE THER, V7, P1803, DOI 10.1089/hum.1996.7.15-1803; Tseng WC, 1996, BIOTECHNOL BIOENG, V50, P548, DOI 10.1002/(SICI)1097-0290(19960605)50:5<548::AID-BIT9>3.0.CO;2-F; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	27	133	141	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25641	25647		10.1074/jbc.272.41.25641	http://dx.doi.org/10.1074/jbc.272.41.25641			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325286	hybrid			2022-12-25	WOS:A1997YA35800041
J	Chihara, K; Amano, M; Nakamura, N; Yano, T; Shibata, M; Tokui, T; Ichikawa, H; Ikebe, R; Ikebe, M; Kaibuchi, K				Chihara, K; Amano, M; Nakamura, N; Yano, T; Shibata, M; Tokui, T; Ichikawa, H; Ikebe, R; Ikebe, M; Kaibuchi, K			Cytoskeletal rearrangements and transcriptional activation of c-fos serum response element by Rho-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; SERINE-THREONINE KINASE; ACTIN STRESS FIBERS; ADP-RIBOSYLATION; SMOOTH-MUSCLE; FOCAL ADHESIONS; MAMMALIAN-CELLS; PUTATIVE TARGET; PHOSPHORYLATION; INVOLVEMENT	The small GTPase Rho is implicated in cytoskeletal rearrangements including stress fiber and focal adhesion formation and in the transcriptional activation of c-fos serum response element. In vitro, Rho-kinase, which is activated by Rho, phosphorylates not only myosin light chain (MLC) (thereby activating myosin ATPase) but also myosin phosphatase, thus inactivating myosin phosphatase. Rho-kinase is involved in the formation of stress fibers and focal adhesions in fibro blasts. Here we show that the expression of constitutively active Rho-kinase increased the level of MLC phosphorylation, The activity of Rho-kinase was necessary for maintaining the vinculin-containing focal adhesions, whereas organized actin stress fibers were not necessary for this, The microinjection of constitutively active Rho-kinase into fibroblasts induced the forma tion of focal adhesions to some extent under the conditions where organized actin stress fibers were disrupted, The expression of constitutively active Rho-kinase also stimulated the transcriptional activity of c-fos serum response element. These results suggest that Rho-kinase has distinct roles in divergent pathways downstream of Rho, which include MLC phosphorylation leading to stress fiber formation, focal adhesion formation, and gene expression.	NARA INST SCI & TECHNOL, DIV SIGNAL TRANSDUCT, IKOMA 63001, JAPAN; UNIV MASSACHUSETTS, MED CTR, DEPT PHYSIOL, WORCESTER, MA 01655 USA; MED & BIOL LABS, INA, SAITAMA 396, JAPAN	Nara Institute of Science & Technology; University of Massachusetts System; University of Massachusetts Worcester			Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047530, P50HL037117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37117, HL47530] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BARSAGI D, 1995, METHOD ENZYMOL, V255, P436; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kolega J., 1993, Bioimaging, V1, P136, DOI 10.1002/1361-6374(199309)1:3<136::AID-BIO2>3.3.CO;2-4; Kosako H, 1997, J BIOL CHEM, V272, P10333; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PALMER RH, 1994, FEBS LETT, V356, P5, DOI 10.1016/0014-5793(94)01202-4; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; ZHANG J, 1993, J BIOL CHEM, V268, P22251	45	161	162	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25121	25127		10.1074/jbc.272.40.25121	http://dx.doi.org/10.1074/jbc.272.40.25121			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312122	hybrid			2022-12-25	WOS:A1997XY97000061
J	Li, DX; Lin, HH; McMahon, M; Ma, HY; Ann, DK				Li, DX; Lin, HH; McMahon, M; Ma, HY; Ann, DK			Oncogenic Raf-1 induces the expression of non-histone chromosomal architectural protein HMGI-C via a p44/p42 mitogen-activated protein kinase-dependent pathway in salivary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MOBILITY-GROUP PROTEIN; SIGNAL-TRANSDUCTION PATHWAY; MAP-KINASE; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; PHOSPHORYLATION SITES; IN-VITRO; RECEPTOR; CASCADE	The enzyme activity of mitogen-activated protein kinase (MAP kinase) increases in response to agents acting on a variety of cell surface receptors, including receptors linked to heterotrimeric G proteins, In this report, we demonstrated that Raf-1 protein kinase activity in the mouse parotid glands was induced by chronic isoproterenol administration in whole animals, To investigate the molecular nature underlying cellular responses to Raf-1 activation, we have stably transfected rat salivary epithelial Pa-4 cells with human Raf-1-estrogen receptor fusion gene (Delta Raf-1:ER) and used mRNA differential display in search of messages induced by Delta Raf-1:ER activation, Through this approach, the gene encoding non-histone chromosomal protein HMGI-C was identified as one of the target genes activated by oncogenic Raf-1 kinase, Activation of Raf-1 kinase resulted in a delayed and sustained increase of HMGI-C expression in the Pa-4 cells, The induction of HMGI-C mRNA level is sensitive to both the protein synthesis inhibitor cycloheximide and transcription inhibitor actinomycin D, The role of the extracellular signal-related kinase (ERK) signaling pathway in the HMGI-C induction was highlighted by the result that the MAP kinase kinase (MEK) inhibitor, PD 98059, blocked Delta Raf-1:ER-and 12-O-tetradecanoylphorbol-13-acetate-stimulated HMGI-C induction, Altogether, these findings support the notion that the Raf/MEK/ERK signaling module, at least in part, regulates transcriptional activation of the chromosomal architectural protein HMGI-C.	UNIV SO CALIF,DEPT MOL PHARMACOL & TOXICOL,LOS ANGELES,CA 90033; DNAX RES INST MOL & CELLULAR BIOL INC,PALO ALTO,CA 94304	University of Southern California; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			McMahon, Martin/L-3303-2013	McMahon, Martin/0000-0003-2812-1042	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01-DE10742] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ann DK, 1997, CRIT REV ORAL BIOL M, V8, P244, DOI 10.1177/10454411970080030101; ASHAR HR, 1995, CELL, V82, P57; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BUSCHER D, 1993, ONCOGENE, V8, P3323; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHAU KY, 1995, NUCLEIC ACIDS RES, V23, P4262, DOI 10.1093/nar/23.21.4262; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; French SW, 1996, MOL CELL BIOL, V16, P5393; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HAMBLETON J, 1995, J EXP MED, V182, P147, DOI 10.1084/jem.182.1.147; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Holt KH, 1996, MOL CELL BIOL, V16, P577; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG TH, 1994, AM J RESP CELL MOL, V10, P192, DOI 10.1165/ajrcmb.10.2.7509163; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LEGER H, 1995, MOL CELL BIOL, V15, P3738; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Lin HH, 1996, J BIOL CHEM, V271, P27637, DOI 10.1074/jbc.271.44.27637; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Manfioletti G, 1995, GENE, V167, P249, DOI 10.1016/0378-1119(95)00666-4; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MUNDSCHAU LJ, 1994, J BIOL CHEM, V269, P16137; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PORRAS A, 1994, J BIOL CHEM, V269, P12741; PURUSHOTHAM KR, 1994, BIOCHEM BIOPH RES CO, V202, P743, DOI 10.1006/bbrc.1994.1993; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0; Zhou XJ, 1996, NUCLEIC ACIDS RES, V24, P4071, DOI 10.1093/nar/24.20.4071	65	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25062	25070		10.1074/jbc.272.40.25062	http://dx.doi.org/10.1074/jbc.272.40.25062			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312114	hybrid			2022-12-25	WOS:A1997XY97000053
J	Wang, DZ; Zamorano, J; Keegan, AD; Boothby, M				Wang, DZ; Zamorano, J; Keegan, AD; Boothby, M			HMG-I(Y) phosphorylation status as a nuclear target regulated through insulin receptor substrate-1 and the I4R motif of the interleukin-4 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAK-3 JANUS KINASE; P70 S6 KINASE; GENE-EXPRESSION; B-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; PROTEIN HMG-I(Y); EPSILON-PROMOTER	Interleukin (IL)-4 is a cytokine that regulates both the growth and differentiation of hematopoietic cells. Its ligand binding specificity and important signal transduction mechanisms are conferred by the IL-4 receptor alpha chain (IL-4R alpha). The I4R is a tyrosine containing motif within IL-4R alpha that is critical for proliferative responses to IL-4. Although the I4R also contributes to gene regulation, nuclear targets directly regulated by this motif have not been described, It is shown here that the tyrosine at position 497 in the I4R is critical for regulation of the phosphorylation status of a set of nuclear proteins that includes HMG-I(Y), small non-histone chromosomal proteins involved in the control of gene expression in hematopoietic cell lines. Moreover, IL-4 is unable to induce HMG-I(Y) phosphorylation in insulin receptor substrate-1-deficient cells, and the inhibitor wortmannin completely blocks IL-4 regulation of HMG-I(Y) phosphorylation status but not activation of an IL-4 Stat protein. Taken together, these data indicate that HMG-I(Y) is a nuclear target whose phosphorylation status is regulated through the I4R motif via insulin receptor substrate proteins, independent of activation of the Stat pathway.	VANDERBILT UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232; AMER RED CROSS,DEPT IMMUNOL,HOLLAND LAB,BETHESDA,MD 20855	Vanderbilt University; American Red Cross			Zamorano, Jose/Q-2514-2017	Zamorano, Jose/0000-0002-4271-3741	NIAID NIH HHS [AI 38985] Funding Source: Medline; NIGMS NIH HHS [GM42550] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038985, R01AI038985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042550, R01GM042550] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOTHBY M, 1988, SCIENCE, V242, P1559, DOI 10.1126/science.3144043; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; Dahl J, 1996, MOL CELL BIOL, V16, P2728; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ikizawa K, 1996, CELL IMMUNOL, V170, P134, DOI 10.1006/cimm.1996.0143; JANSEN JH, 1990, BLUT, V60, P269, DOI 10.1007/BF01736226; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kaplan M. H., 1997, Journal of Allergy and Clinical Immunology, V99, pS484; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KARDALINOU E, 1994, MOL CELL BIOL, V14, P1066, DOI 10.1128/MCB.14.2.1066; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KIM J, 1995, EUR J IMMUNOL, V25, P798, DOI 10.1002/eji.1830250326; KleinHessling S, 1996, P NATL ACAD SCI USA, V93, P15311, DOI 10.1073/pnas.93.26.15311; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; MATIS LA, 1983, P NATL ACAD SCI-BIOL, V80, P6019, DOI 10.1073/pnas.80.19.6019; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; MYERS MG, 1994, J BIOL CHEM, V269, P28783; PAUL WE, 1991, BLOOD, V77, P1589; PERNIS A, 1995, P NATL ACAD SCI USA, V92, P7971, DOI 10.1073/pnas.92.17.7971; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; RICHARDS ML, 1994, J IMMUNOL, V152, P3453; ROTHMAN P, 1990, MOL CELL BIOL, V10, P1672, DOI 10.1128/MCB.10.4.1672; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Snapper CM, 1996, J IMMUNOL, V156, P183; STACK RM, 1994, J IMMUNOL, V152, P5723; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Wang DZ, 1996, INT IMMUNOL, V8, P977, DOI 10.1093/intimm/8.7.977; WANG DZ, 1995, J BIOL CHEM, V270, P22924, DOI 10.1074/jbc.270.39.22924; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG Y, 1995, INSECT MOL BIOL, V4, P113, DOI 10.1111/j.1365-2583.1995.tb00015.x; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zamorano J, 1996, J IMMUNOL, V157, P4926; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	64	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25083	25090		10.1074/jbc.272.40.25083	http://dx.doi.org/10.1074/jbc.272.40.25083			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312117	hybrid			2022-12-25	WOS:A1997XY97000056
J	Jares, P; Fernandez, PL; Nadal, A; Cazorla, M; Hernandez, L; Pinyol, M; Hernandez, S; Traserra, J; Cardesa, A; Campo, E				Jares, P; Fernandez, PL; Nadal, A; Cazorla, M; Hernandez, L; Pinyol, M; Hernandez, S; Traserra, J; Cardesa, A; Campo, E			p16(MTS1/CDK4I) mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx	ONCOGENE			English	Article						p16(MTS1/CDK4I); LOH 9p21-23; larynx; squamous cell carcinoma	KINASE-4 INHIBITOR GENE; CYCLIN D1 FUNCTION; HUMAN CANCERS; SOMATIC MUTATIONS; NONSMALL CELL; GEL-ELECTROPHORESIS; ALTERED EXPRESSION; PRIMARY TUMORS; LUNG CANCERS; CDKN2 GENE	We have examined the presence of p16(MTS1/CDK4I) gene deletions, mutations and methylation status, and 9p21-23 deletions in a series of 46 squamous cell carcinomas of the larynx and paired normal mucosa previously characterized for cyclin D1 gene amplification and overexpression. pRb expression was also examined by immunohistochemistry. p16(MTS1/CDK4I) mutations were found in 10/46 (22%) carcinomas and hypermethylation in 2/31 (7%). Loss of heterozygosity at 9p21-23 was found in 24 out of 42 (57%) carcinomas examined. All p16(MTS1/CDK4I) mutated cases and the two hypermethylated carcinomas showed 9p21-23 loss of heterozygosity. The loss of heterozygosity correlated with advanced local invasion (P = 0.0045), lymph node metastases (P = 0.0326), stage IV of the tumors (P = 0.0058), and existence of cyclin D1 amplification/overexpression (P < 0.03). Only one out of 37 carcinomas was negative for pRb expression. No alterations in p16 gene or 9p21-23 loss of heterozygosity were detected in this case. These findings indicate that p16(MTS1/CDK4I) is frequently inactivated by gene mutation, hypermethylation, and allelic deletions in a significant subset of squamous cell carcinomas of larynx. Since 9p21-233 loss of heterozygosity was more frequently detected than p16(MTS1/CDK4I) mutations, and mutated carcinomas invariably had loss of heterozygosity, allelic losses probably precede the p16(MTS1/CDK4I) mutations. Their association with cyclin D1 deregulation in advanced carcinomas could indicate a possible cooperative effect in the progression of these neoplasms.	UNIV BARCELONA,HOSP CLIN & PROV BARCELONA,DEPT ANAT PATHOL,E-08007 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN & PROV BARCELONA,DEPT OTOLARYNGOL,E-08007 BARCELONA,SPAIN; UNIV LLEIDA,DEPT BASIC MED SCI,LLEIDA,SPAIN; HOSP CASA MATERNITAT,BARCELONA,SPAIN	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; Universitat de Lleida			Hernandez-Llodra, S/H-6863-2014; Hernandez, Luis/D-4684-2018; Jares, Pedro/T-3778-2019; Fernandez, Pedro L/H-2594-2017; Campo, Elias/AAC-5593-2019	Hernandez-Llodra, S/0000-0003-3963-3756; Hernandez, Luis/0000-0002-4854-3069; Campo, Elias/0000-0001-9850-9793; JARES, PEDRO/0000-0002-8401-579X; Fernandez, Pedro Luis/0000-0002-8618-4597				American Joint Committee on Cancer, 1992, MAN STAG CANC; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; DOLCETTI R, 1992, INT J CANCER, V52, P178, DOI 10.1002/ijc.2910520204; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; GERADTS J, 1994, INT J CANCER, V58, P161, DOI 10.1002/ijc.2910580203; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HERMAN JG, 1995, CANCER RES, V55, P4525; Jares P, 1996, AM J PATHOL, V148, P1591; JARES P, 1994, CANCER RES, V54, P4813; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kwiatkowski David J., 1993, Cytogenetics and Cell Genetics, V64, P93, DOI 10.1159/000133566; LO KW, 1995, CANCER RES, V55, P2039; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, CANCER RES, V55, P4818; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MEREDITH SD, 1995, ARCH OTOLARYNGOL, V121, P790; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MICHALIDES R, 1995, CANCER RES, V55, P975; MORI T, 1994, CANCER RES, V54, P3396; NADAL A, 1995, J PATHOL, V175, P181, DOI 10.1002/path.1711750205; NAWROZ H, 1994, CANCER RES, V54, P1152; NEVILLE EM, 1995, ONCOGENE, V11, P581; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; OTO M, 1993, ANAL BIOCHEM, V213, P19, DOI 10.1006/abio.1993.1379; Pinyol M, 1997, BLOOD, V89, P272, DOI 10.1182/blood.V89.1.272.272_272_280; POLLOCK PM, 1995, ONCOGENE, V11, P663; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; PUIG S, 1995, AM J HUM GENET, V57, P395; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHIMIZU T, 1995, INT J CANCER, V63, P616, DOI 10.1002/ijc.2910630503; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAM SW, 1994, ONCOGENE, V9, P2663; TUYNS AJ, 1988, INT J CANCER, V41, P483, DOI 10.1002/ijc.2910410403; Ueki K, 1996, CANCER RES, V56, P150; VANDERRIET P, 1994, CANCER RES, V54, P1156; VANDYKE DL, 1994, GENE CHROMOSOME CANC, V9, P192, DOI 10.1002/gcc.2870090308; Yang R, 1996, BIOCHEM BIOPH RES CO, V218, P254, DOI 10.1006/bbrc.1996.0045; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737	50	47	48	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1445	1453		10.1038/sj.onc.1201309	http://dx.doi.org/10.1038/sj.onc.1201309			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333020				2022-12-25	WOS:A1997XW41100008
J	Kogerman, P; Sy, MS; Culp, LA				Kogerman, P; Sy, MS; Culp, LA			Counter-selection for over-expressed human CD44s in primary tumors versus lung metastases in a mouse fibrosarcoma model	ONCOGENE			English	Article						CD44; metastasis; nude mice; 3T3; sis	SPLICE VARIANTS; 3T3 CELLS; PROGRESSION; DEGRADATION; ONCOGENE; CANCER; GROWTH; HYALURONAN; CARCINOMAS; ISOFORMS	Human CD44 standard isoform cDNA (hCD44s) was transfected into sis-transformed Balb/c 3T3 cells and into ras-revertant IIIA4 cells (both tumorigenic but nonmetastatic). Transfectants were injected subcutaneously into athymic nude mice to elucidate the functional role of hCD44s over-expression in progression and metastasis. The transfectants (but not parental cells) vr ere capable of lung micrometastasis and of binding exogenously-added hyaluronan. hCD44s protein expression was conserved in lung micrometastases suggesting that it may have been necessary for their formation. In contrast, no hCD44s protein was detected in large subcutaneous (s.c.) tumors but normal levels of murine CD44 were detected. A second round of tumor development, using these two tumor cell classes, demonstrated that hCD44s-nonexpressing s.c. tumor cells re-expressed it in lung micrometastases. Conversely, hCD44s-expressing lung micrometastatic cells, when injected into a second group of mice, downregulated hCD44s expression in order to grow sizable s.c. tumors. S.c. tumor cells still contained the hCD44s gene but its expression was inhibited by epigenetic mechanisms, one of which was shown to be methylation of the hCD44s gene. These studies demonstrate (a) opposing selective pressures on CD44s over-expression for s.c. tumor growth and for metastatic spread to the lung and (b) further credence for the significance of CD44 for metastatic spread of fibrosarcomas. Therefore, CD44s may he a critical component of the metastatic phenotype induced by specific oncogenes.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PATHOL,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University			Kogerman, Priit/B-6333-2008		NCI NIH HHS [CA27755, CA60469] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA060469, R01CA027755] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CULTY M, 1994, J CELL PHYSIOL, V160, P275, DOI 10.1002/jcp.1041600209; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; FIDLER IJ, 1994, CANCER METAST REV, V13, P209, DOI 10.1007/BF00689637; FOX SB, 1994, CANCER RES, V54, P4539; GOROWSKI JJ, 1995, J BIOL CHEM, V270, P26940; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUO YJ, 1994, CANCER RES, V54, P1561; GUO YJ, 1993, CELL IMMUNOL, V152, P186, DOI 10.1006/cimm.1993.1278; HEIDER KH, 1993, CANCER RES, V53, P4197; HOUCHENS DP, 1978, P S USE ATHYMIC NUDE, P267; Jackson PA, 1995, J CLIN PATHOL, V48, P1098, DOI 10.1136/jcp.48.12.1098; Kogerman P, 1996, CLIN EXP METASTAS, V14, P73, DOI 10.1007/BF00157688; Kogerman P, 1996, J CELL PHYSIOL, V169, P341, DOI 10.1002/(SICI)1097-4652(199611)169:2<341::AID-JCP13>3.3.CO;2-M; Kogerman P, 1997, INT J ONCOL, V10, P553; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LEWIN DI, 1996, J NIH RES, V8, P24; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; NICOLSON GL, 1993, EXP CELL RES, V204, P171, DOI 10.1006/excr.1993.1022; RADINSKY R, 1992, In Vivo (Attiki), V6, P325; RADINSKY R, 1987, P NATL ACAD SCI USA, V84, P5143, DOI 10.1073/pnas.84.15.5143; RADINSKY R, 1991, INT J CANCER, V48, P148; RUDY W, 1993, CANCER RES, V53, P1262; Sambrook J., 2002, MOL CLONING LAB MANU; Sinn Hans-Peter, 1995, Breast Cancer Research and Treatment, V36, P307, DOI 10.1007/BF00713402; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; Weiss L, 1990, Adv Cancer Res, V54, P159, DOI 10.1016/S0065-230X(08)60811-8; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; WIELENGA VJM, 1993, CANCER RES, V53, P4754	31	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1407	1416		10.1038/sj.onc.1201306	http://dx.doi.org/10.1038/sj.onc.1201306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333016				2022-12-25	WOS:A1997XW41100004
J	Behncken, SN; Rowlinson, SW; Rowland, JE; ConwayCampbell, BL; Monks, TA; Waters, MJ				Behncken, SN; Rowlinson, SW; Rowland, JE; ConwayCampbell, BL; Monks, TA; Waters, MJ			Aspartate 171 is the major primate-specific determinant of human growth hormone - Engineering porcine growth hormone to activate the human receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; EXTRACELLULAR DOMAIN; SCANNING MUTAGENESIS; RATIONAL DESIGN; BINDING; DIMERIZATION; IDENTIFICATION; INVOLVEMENT; AFFINITY; MOLECULE	It has been known for more than 4 decades that only primate growth hormones are effective in primate species, but it is only with the availability of the 2.8 A structure of the human growth hormone (hGH). hGH-binding protein (hGHBP)(2) complex that Souza and co-workers (Souza, S. C., Frick, G. P., Wang, X., Kopchick, J. J., Lobo, R. B., and Goodman, H. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 959-963) were able to provide evidence that Arg-43 on the primate receptor is responsible. Here we have examined systematically the interaction between Arg-43 (primate receptor) or Leu-43 (non-primate receptors) and their complementary hormone residues Asp-171 (primate GH) and His-170 (nonprimate hormones) in a four-way comparison involving exchanges of histidine and aspartate and exchanges of arginine and leucine. BAF/BO3 lines were created and characterized which stably expressed hGH receptor, R43L hGH receptor, rabbit GH receptor, and L43R rabbit GH receptor. These were examined for site 1 affinity, for the ability to bind intact cells, and for proliferative biopotency using hGH, D171H hGH, porcine GH, or H170D porcine GH. We find that the single interaction between Arg-43 and His-170/171 is sufficient to explain virtually all of the primate species specificity, and this is congruent with the crystal structure. Accordingly, for the first time we have been able to engineer a nonprimate hormone to bind to and activate the human GH receptor.	UNIV QUEENSLAND,CTR MOL & CELLULAR BIOL,BRISBANE,QLD 4072,AUSTRALIA	University of Queensland	Behncken, SN (corresponding author), UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,BRISBANE,QLD 4072,AUSTRALIA.		waters, michael j/C-9582-2014	Rowland, Jennifer/0000-0003-2313-6106				ASTON R, 1986, J ENDOCRINOL, V110, P381, DOI 10.1677/joe.0.1100381; BARNARD R, 1989, J THEOR BIOL, V140, P355, DOI 10.1016/S0022-5193(89)80092-X; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOBIUS KS, 1992, J MOL ENDOCRINOL, V9, P213, DOI 10.1677/jme.0.0090213; LAUTERIC TJ, 1988, COMP BIOCHEM PHYS A, V91, P15, DOI 10.1016/0300-9629(88)91585-X; LAYTON MJ, 1994, J BIOL CHEM, V269, P29891; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; ROWLINSON SW, 1995, J BIOL CHEM, V270, P16833, DOI 10.1074/jbc.270.28.16833; ROWLINSON SW, 1994, BIOCHEMISTRY-US, V33, P11724, DOI 10.1021/bi00205a008; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; SHANAFELT AB, 1991, J BIOL CHEM, V266, P13804; SOUZA SC, 1995, P NATL ACAD SCI USA, V92, P959, DOI 10.1073/pnas.92.4.959; STATEN NR, 1993, J BIOL CHEM, V268, P18467; Takahashi Y, 1996, NEW ENGL J MED, V334, P432, DOI 10.1056/NEJM199602153340704; WATERS MJ, 1979, J BIOL CHEM, V254, P6815; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1	24	45	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27077	27083		10.1074/jbc.272.43.27077	http://dx.doi.org/10.1074/jbc.272.43.27077			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341147	hybrid			2022-12-25	WOS:A1997YC65900043
J	Flierl, A; Reichmann, H; Seibel, P				Flierl, A; Reichmann, H; Seibel, P			Pathophysiology of the MELAS 3243 transition mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; SODIUM DODECYL-SULFATE; STROKE-LIKE EPISODES; RIBOSOMAL-RNA GENES; MITOCHONDRIAL MYOPATHY; RESPIRATORY-CHAIN; ESCHERICHIA-COLI; LACTIC-ACIDOSIS; TRANSCRIPTION TERMINATION	Single base substitutions of the mitochondrial genome are associated with a variety of metabolic disorders, The myopathy, encephalopathy, lactic acidosis, stroke-like episodes syndrome, most frequently associated with an A to G transition mutation at position 3243 of the mitochondrial tRNA(Leu(UUR)) gene, is characterized by biochemical and structural alterations of mitochondria, To investigate the pathophysiology of the mutation, we established distinct Epstein-Barr virus-transformed B-cell lines for analyses that harbored 30-70% of the mutated genome, Interestingly, neither an alteration of the processing of primary transcripts nor a general impairment of individual mitochondrial protein subunit synthesis rates could be observed, Nevertheless a marked decrease of cytochrome-c oxidase activity and reduced content of mitochondrial encoded subunits in the assembled respiratory complex TV was recorded on the cell line harboring 70% mutated mtDNA, Quantitative analysis of incorporation rates of the amino acid leucine into newly synthesized mitochondrial proteins, representing the functionality of the tRNA(Leu(UUR)) in protein biosynthesis, revealed a specific decrease of this amino acid in distinct mitochondrial translation products, This observation was supported by a variation in the proteolytic fingerprint pattern, Our results suggest that the malfunctioning mitochondrial tRNA(Leu(UUR)) leads to an alteration of amino acid incorporation into the mitochondrially synthesized subunits of the oxidative phosphorylation system, thus altering it's structure and function.	UNIV WURZBURG,BIOZENTRUM,THEODOR BOVERI INST,WISSENSCH NACHWUCHSGRP,D-97074 WURZBURG,GERMANY; UNIV DRESDEN,NEUROL KLIN,KLINIKUM CARL GUSTAV CARUS,D-01307 DRESDEN,GERMANY	University of Wurzburg; Technische Universitat Dresden			Flierl, Adrian/W-3453-2019	Flierl, Adrian/0000-0003-0933-2493				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BANTLE JA, 1976, CELL, V8, P139, DOI 10.1016/0092-8674(76)90195-1; BINDOFF LA, 1993, J BIOL CHEM, V268, P19559; BOURGERON T, 1993, NEUROMUSCULAR DISORD, V3, P605, DOI 10.1016/0960-8966(93)90124-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FOX TD, 1980, NATURE, V288, P60, DOI 10.1038/288060a0; GABRIDGE MG, 1976, J CLIN MICROBIOL, V3, P560; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527; GRIVELL LA, 1995, CRIT REV BIOCHEM MOL, V30, P121, DOI 10.3109/10409239509085141; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; ICHIBA T, 1995, BBA-GENE STRUCT EXPR, V1262, P83, DOI 10.1016/0167-4781(95)00062-L; IRWIN B, 1995, J BIOL CHEM, V270, P22801, DOI 10.1074/jbc.270.39.22801; JANKE A, 1993, NUCLEIC ACIDS RES, V21, P1523, DOI 10.1093/nar/21.7.1523; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KOBAYASHI M, 1987, J PEDIATR-US, V110, P223, DOI 10.1016/S0022-3476(87)80158-0; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9; MOREADITH RW, 1984, ANAL BIOCHEM, V137, P360, DOI 10.1016/0003-2697(84)90098-8; NAKAMURA M, 1978, J LAB CLIN MED, V91, P568; NYSTROM T, 1994, MOL MICROBIOL, V12, P833, DOI 10.1111/j.1365-2958.1994.tb01069.x; OCONNOR M, 1993, EMBO J, V12, P2559, DOI 10.1002/j.1460-2075.1993.tb05911.x; OFVERSTEDT LG, 1994, CELL, V79, P629, DOI 10.1016/0092-8674(94)90548-7; OLSZEWSKA E, 1988, TRENDS GENET, V4, P92, DOI 10.1016/0168-9525(88)90095-9; PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409; REEDMAN BM, 1972, INT J CANCER, V9, P172; ROJIANI MV, 1990, P NATL ACAD SCI USA, V87, P1511, DOI 10.1073/pnas.87.4.1511; SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/S0005-2728(05)80021-0; SEIBEL P, 1991, J NEUROL SCI, V105, P217, DOI 10.1016/0022-510X(91)90148-Z; TANAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P861, DOI 10.1016/0006-291X(91)91497-Z; TAYLOR RW, 1993, BIOCHIM BIOPHYS ACTA, V1181, P261, DOI 10.1016/0925-4439(93)90030-5; TAYLOR RW, 1993, BIOCHEM SOC T, V21, P804, DOI 10.1042/bst0210804; ULRICH AK, 1991, BIOCHIM BIOPHYS ACTA, V1089, P362, DOI 10.1016/0167-4781(91)90177-N; VOGEL U, 1992, MOL MICROBIOL, V6, P2191, DOI 10.1111/j.1365-2958.1992.tb01393.x; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1995, HUMAN GENE MAPPING 1, P910; WEISS R, 1988, J MOL BIOL, V203, P403, DOI 10.1016/0022-2836(88)90008-3; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WEISS RB, 1990, PROG NUCL ACID RES M, V18, P3529; ZIMMERMANN P, 1992, BIOCHIM BIOPHYS ACTA, V1180, P99, DOI 10.1016/0925-4439(92)90032-I	47	73	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27189	27196		10.1074/jbc.272.43.27189	http://dx.doi.org/10.1074/jbc.272.43.27189			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341162				2022-12-25	WOS:A1997YC65900058
J	Kobayashi, M; Rodriguez, R; Lara, C; Omata, T				Kobayashi, M; Rodriguez, R; Lara, C; Omata, T			Involvement of the C-terminal domain of an ATP-binding subunit in the regulation of the ABC-type nitrate/nitrite transporter of the cyanobacterium Synechococcus sp. strain PCC 7942	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANACYSTIS-NIDULANS; NITRATE TRANSPORT; NITRITE REDUCTASE; ESCHERICHIA-COLI; MALTOSE TRANSPORT; INDUCER EXCLUSION; SP PCC-7942; PROTEIN; GENE; ASSIMILATION	In Synechococcus sp. strain PCC 7942, an ATP-binding cassette transporter encoded by the genes nrtA, nrtB, nrtC, and nrtD mediates active transport of nitrate and nitrite, which is inhibited by ammonium, a preferred source of nitrogen for the cyanobacterium. One of the ATP-binding subunits of the transporter, NrtC, has a distinct C-terminal domain of 380 amino acid residues. A mutant NC2, constructed by removal of this domain using genetic engineering techniques, assimilated low concentrations of nitrate and nitrite and accumulated nitrate intracellularly, showing that the domain is not essential for the transporter activities, Assimilation of low concentrations of nitrite was only partially inhibited by ammonium in NC2 but was completely inhibited in the wild-type cells, Cells of NC2 and its derivative (nitrate reductase-less strain NC4) carrying the truncated NrtC but not the cells with the wild-type NrtC accumulated nitrate intracellularly in the presence of ammonium in medium, These findings indicated that the C-terminal domain of NrtC is involved in the ammonium-promoted inhibition of the nitrate/nitrite transporter, In the presence of ammonium, NC2 could not assimilate nitrate despite its ability to accumulate nitrate intracellularly, which suggested that reduction of intracellular nitrate by nitrate reductase is also subject to inhibition by ammonium.	NAGOYA UNIV, SCH AGR SCI, DEPT APPL BIOL SCI, NAGOYA, AICHI 46401, JAPAN; UNIV SEVILLA, FAC BIOL, DEPT BIOQUIM VEGETAL & BIOL MOL, E-41080 SEVILLE, SPAIN	Nagoya University; University of Sevilla			Lara, Catalina/H-4595-2015	Lara, Catalina/0000-0001-7017-9446				AIBA H, 1981, J BIOL CHEM, V256, P1905; ANDERSON PM, 1986, BIOCHEMISTRY-US, V25, P1621, DOI 10.1021/bi00355a026; ANDRIESSE X, 1990, INORGANIC NITROGEN P, P303; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; CORONIL T, 1991, PLANT PHYSIOL BIOCH, V29, P651; DEAN DA, 1990, J BIOL CHEM, V265, P21005; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; FLORES E, 1987, BIOCHIM BIOPHYS ACTA, V896, P103, DOI 10.1016/0005-2736(87)90361-0; FLORES E, 1980, ARCH MICROBIOL, V128, P137, DOI 10.1007/BF00406150; Guerrero M. G., 1987, The Cyanobacteria., P163; GUERRERO MG, 1981, ANNU REV PLANT PHYS, V32, P169, DOI 10.1146/annurev.pp.32.060181.001125; HERRERO A, 1986, J GEN MICROBIOL, V132, P2463; HERRERO A, 1981, J BACTERIOL, V145, P175, DOI 10.1128/JB.145.1.175-180.1981; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; Kikuchi H, 1996, J BACTERIOL, V178, P5822, DOI 10.1128/jb.178.19.5822-5825.1996; KUHLEMEIER CJ, 1984, J BACTERIOL, V159, P36, DOI 10.1128/JB.159.1.36-41.1984; KUHNAU S, 1991, J BACTERIOL, V173, P2180; LARA C, 1987, J BACTERIOL, V169, P4376, DOI 10.1128/jb.169.9.4376-4378.1987; LARA C, 1993, PHYSIOL PLANTARUM, V89, P582, DOI 10.1111/j.1399-3054.1993.tb05217.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUQUE I, 1993, PLANT MOL BIOL, V21, P1201, DOI 10.1007/BF00023618; LUQUE I, 1994, BBA-BIOENERGETICS, V1184, P296, DOI 10.1016/0005-2728(94)90236-4; MacKinney G, 1941, J BIOL CHEM, V140, P315; Maeda SI, 1997, J BIOL CHEM, V272, P3036, DOI 10.1074/jbc.272.5.3036; OHMORI M, 1977, ARCH MICROBIOL, V114, P225, DOI 10.1007/BF00446866; OMATA T, 1989, P NATL ACAD SCI USA, V86, P6612, DOI 10.1073/pnas.86.17.6612; OMATA T, 1993, MOL GEN GENET, V236, P193, DOI 10.1007/BF00277112; OMATA T, 1991, PLANT CELL PHYSIOL, V32, P151, DOI 10.1093/oxfordjournals.pcp.a078059; RIED JL, 1987, GENE, V57, P239, DOI 10.1016/0378-1119(87)90127-2; RODRIGUEZ R, 1992, BIOCHEM J, V282, P639, DOI 10.1042/bj2820639; RODRIGUEZ R, 1994, FEBS LETT, V350, P19, DOI 10.1016/0014-5793(94)00720-9; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; SUZUKI I, 1993, PLANT CELL PHYSIOL, V34, P1311; Suzuki I, 1996, J BACTERIOL, V178, P2688, DOI 10.1128/jb.178.9.2688-2694.1996; SUZUKI I, 1995, PLANT PHYSIOL, V107, P791, DOI 10.1104/pp.107.3.791; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	38	56	59	1	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27197	27201		10.1074/jbc.272.43.27197	http://dx.doi.org/10.1074/jbc.272.43.27197			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341163	Green Published, hybrid			2022-12-25	WOS:A1997YC65900059
J	Kunapuli, P; Lawson, JA; Rokach, J; FitzGerald, GA				Kunapuli, P; Lawson, JA; Rokach, J; FitzGerald, GA			Functional characterization of the ocular prostaglandin F-2 alpha (PGF(2 alpha)) receptor - Activation by the isoprostane, 12-iso-PGF(2 alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; F2-ISOPROSTANE RECEPTORS; INVITRO CHARACTERIZATION; LIPID HYDROPEROXIDES; UVEOSCLERAL OUTFLOW; HUMAN MYOMETRIUM; CORPUS-LUTEUM; FP-RECEPTOR; EXPRESSION	Prostaglandin F-2 alpha (PGF(2) alpha) is a product of cyclooxygenase-catalyzed metabolism of arachidonic acid. Recently, PGF(2) alpha analogs have been hypothesized to reduce intraocular pressure via relaxation of the ciliary muscle. To investigate the molecular basis of PGF(2) alpha receptor (FP) activation in the eye, we cloned the FP from a human ciliary body (hcb) cDNA library. The open reading frame of the hcb-FP cDNA was identical to the uterine FP cDNA, The hcb-FP appeared to be predominantly membrane-localized, as visualized by an FP-specific peptide antibody, and coupled to inositol phosphate formation when stably expressed in HEK 293 cells. Interestingly, the hcb-FP could also be activated by the F-2 isoprostane, 12-iso-PGF(2) alpha, in addition to its cognate ligand, PGF(2) alpha. 12 iso-PGF(2) alpha was less potent (EC50 = 5 mu M) than PGF(2) alpha (EC50 = 10 nM) in generating inositol phosphates via the hcb-FP in HEK 293 cells. Both ligands also stimulated mitogenesis in NIH 3T3 cells. Although 12-iso-PGF(2) alpha caused a dose-dependent activation of the FP, it failed to activate the recombinant human prostacyclin receptor and caused only minimal activation of the thromboxane receptor isoforms stably expressed in HEK 293 cells. Four additional F-2 isoprostanes, 8-iso-PGF(2) alpha, IPF2 alpha,-I, IPF2 alpha-III, and 9 beta,11 beta-PGF(2), caused trivial, or no, activation of the FP. Consistent with these observations, only PGF(2) alpha and 12-iso-PGF(2) alpha caused rapid homologous desensitization of FP and also exhibited cross-desensitization, with PGF(2) alpha resulting in a maximum of similar to 60% desensitization. The human FP may thus be activated specifically, by the free radical-catalyzed F-2 isoprostane, 12-iso-PGF(2) alpha, in addition to the cyclooxygenase product, PGF(2) alpha. Incidental receptor activation by isoprostanes may complement the actions of PGF(2) alpha in clinical syndromes where oxidant stress and augmented prostaglandin biosynthesis coincide.	UNIV PENN, CTR EXPT THERAPEUT, PHILADELPHIA, PA 19104 USA; FLORIDA INST TECHNOL, CLAUDE PEPPER INST, MELBOURNE, FL 32901 USA; FLORIDA INST TECHNOL, DEPT CHEM, MELBOURNE, FL 32901 USA	University of Pennsylvania; Florida Institute of Technology; Florida Institute of Technology			FitzGerald, Garret A/A-4222-2010	Rokach, Joshu/0000-0003-1814-7505	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044730] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07843, HL54500] Funding Source: Medline; NIDDK NIH HHS [DK44730] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; Adams JW, 1996, J BIOL CHEM, V271, P1179, DOI 10.1074/jbc.271.2.1179; Adiyaman M, 1996, TETRAHEDRON LETT, V37, P4849, DOI 10.1016/0040-4039(96)00973-2; Adiyaman M, 1997, TETRAHEDRON LETT, V38, P3339, DOI 10.1016/S0040-4039(97)00622-9; ALM A, 1993, OPHTHALMOLOGY, V100, P1312; BARNARD JW, 1992, J APPL PHYSIOL, V72, P2469, DOI 10.1152/jappl.1992.72.6.2469; COLEMAN RA, 1981, BRIT J PHARMACOL, V74, pP913; CRAWFORD K, 1987, ARCH OPHTHALMOL-CHIC, V105, P1112, DOI 10.1001/archopht.1987.01060080114039; CSEPLI J, 1975, PROSTAGLANDINS, V10, P689, DOI 10.1016/S0090-6980(75)80017-7; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DONG YJ, 1986, BRIT J PHARMACOL, V87, P97, DOI 10.1111/j.1476-5381.1986.tb10161.x; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; FUKUNAGA M, 1993, BIOCHEM BIOPH RES CO, V195, P507, DOI 10.1006/bbrc.1993.2075; GABELT BT, 1989, EXP EYE RES, V49, P389, DOI 10.1016/0014-4835(89)90049-3; GOTOH M, 1994, NEUROCHEM RES, V19, P679, DOI 10.1007/BF00967706; GRAVES PE, 1995, ENDOCRINOLOGY, V136, P3430, DOI 10.1210/en.136.8.3430; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; HARDY P, 1994, INVEST OPHTH VIS SCI, V35, P580; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; HORTON EW, 1976, PHYSIOL REV, V56, P595, DOI 10.1152/physrev.1976.56.4.595; Hwang SW, 1996, TETRAHEDRON LETT, V37, P779, DOI 10.1016/0040-4039(95)02390-9; HWANG SW, 1994, J AM CHEM SOC, V116, P10829, DOI 10.1021/ja00102a076; JIMENEZDEASUA L, 1975, P NATL ACAD SCI USA, V72, P2724; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LAKE S, 1994, FEBS LETT, V355, P317, DOI 10.1016/0014-5793(94)01198-2; LINDSEY JD, 1994, INVEST OPHTH VIS SCI, V35, P242; MCCRACKEN JA, 1970, J CLIN ENDOCR METAB, V30, P544, DOI 10.1210/jcem-30-4-544; MEAGHER EA, 1997, ENDOTHERLIUM CLIN PR, P413; MINAMI T, 1992, PAIN, V50, P223, DOI 10.1016/0304-3959(92)90166-9; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; Morrow JD, 1996, BIOCHEM PHARMACOL, V51, P1, DOI 10.1016/0006-2952(95)02072-1; NAKAMURA T, 1983, J BIOCHEM-TOKYO, V94, P1029, DOI 10.1093/oxfordjournals.jbchem.a134444; NAKAO A, 1993, J CELL PHYSIOL, V155, P257, DOI 10.1002/jcp.1041550206; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Pierce KL, 1997, J BIOL CHEM, V272, P883, DOI 10.1074/jbc.272.2.883; PORTER NA, 1984, TETRAHEDRON LETT, V25, P807, DOI 10.1016/S0040-4039(01)80032-0; Pratico D, 1996, J BIOL CHEM, V271, P14916, DOI 10.1074/jbc.271.25.14916; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; SENIOR J, 1993, BRIT J PHARMACOL, V108, P501, DOI 10.1111/j.1476-5381.1993.tb12832.x; SENIOR J, 1992, BRIT J PHARMACOL, V107, P215, DOI 10.1111/j.1476-5381.1992.tb14489.x; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; Smyth EM, 1996, J BIOL CHEM, V271, P33698, DOI 10.1074/jbc.271.52.33698; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; TACHADO SD, 1993, INVEST OPHTH VIS SCI, V34, P2023; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; Waugh RJ, 1996, J AM SOC MASS SPECTR, V7, P490, DOI 10.1016/1044-0305(95)00709-1; WOODWARD DF, 1989, INVEST OPHTH VIS SCI, V30, P1838; YURA T, 1995, ADV PROSTAG THROMB L, V23, P237; ZIAI N, 1993, ARCH OPHTHALMOL-CHIC, V111, P1351, DOI 10.1001/archopht.1993.01090100059027	57	92	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27147	27154		10.1074/jbc.272.43.27147	http://dx.doi.org/10.1074/jbc.272.43.27147			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341156	hybrid			2022-12-25	WOS:A1997YC65900052
J	Seoane, J; Trinh, K; ODoherty, RM; GomezFoix, AM; Lange, AJ; Newgard, CB; Guinovart, JJ				Seoane, J; Trinh, K; ODoherty, RM; GomezFoix, AM; Lange, AJ; Newgard, CB; Guinovart, JJ			Metabolic impact of adenovirus-mediated overexpression of the glucose-6-phosphatase catalytic subunit in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE-DISEASE TYPE-1A; RAT-LIVER GLUCOSE-6-PHOSPHATASE; HEPATIC GLYCOGEN-SYNTHESIS; GENE-EXPRESSION; MICROSOMAL GLUCOSE-6-PHOSPHATASE; DIABETIC RATS; HEXOKINASE-I; GLUCOSE; INSULIN; SYNTHASE	Glucose-6-phosphatase (G6Pase) catalyzes the hydrolysis of glucose 6-phosphate (Glu-6-P) to free glucose and, as the last step in gluconeogenesis and glycogenolysis in liver, is thought to play an important role in glucose homeostasis. G6Pase activity appears to be conferred by a set of proteins localized to the endoplasmic reticulum, including a glucose-6-phosphate translocase, a G6Pase phosphohydrolase or catalytic subunit, and glucose and inorganic phosphate transporters in the endoplasmic reticulum membrane. in the current study, we used a recombinant adenovirus containing the cDNA encoding the G6Pase catalytic subunit (AdCMV-G6Pase) to evaluate the metabolic impact of overexpression of the enzyme in primary hepatocytes. We found that AdCMV-G6Pase-treated liver cells contain significantly less glycogen and Glu-6-P, but unchanged UDP-glucose levels, relative to control cans, Further, the glycogen synthase activity state was closely correlated with Glu-6-P levels over a wide range of glucose concentrations in both G6Pase-overexpressing land control cells, The reduction in glycogen synthesis in AdCMV-G6Pase-treated hepatocytes is therefore mot a function of decreased substrate availability but rather occurs because of the regulatory effects of Glu-6-P on glycogen synthase activity, We also found that AdCMV-G6Pase-treated-cells had significantly lower rates of lactate production and [3-H-3]glucose usage, coupled with enhanced rates of gluconeogenesis and Glu-6-P hydrolysis, We conclude that overexpression of the G6Pase catalytic subunit alone is sufficient to activate Bur through the G6Pase system in liver cells, Further, hepatocytes treated with AdCMV-G6Pase exhibit a metabolic profile resembling that of liver cells front patients or animals with non-insulin-dependent diabetes mellitus, suggesting that dysregulation of the catalytic subunit of G6Pase could contribute to the etiology of the disease.	UNIV BARCELONA, FAC QUIM, DEPT BIOQUIM & BIOL MOL, E-08028 BARCELONA, SPAIN; UNIV TEXAS, SW MED CTR, GIFFORD LABS DIABET RES, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, GIFFORD LABS DIABET RES, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV MINNESOTA, SCH MED, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA	University of Barcelona; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Minnesota System; University of Minnesota Twin Cities			Seoane, Joan/AAG-9173-2019	Seoane, Joan/0000-0002-6541-5974	PHS HHS [NIH1P50H2598801] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEGRE M, 1988, ANAL BIOCHEM, V173, P185, DOI 10.1016/0003-2697(88)90176-5; Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; ARION WJ, 1980, J BIOL CHEM, V255, P396; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; BECKER TC, 1994, METHOD CELL BIOL, V43, P162; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCHELL A, 1985, DIABETOLOGIA, V28, P852, DOI 10.1007/BF00291077; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; CHEN YT, 1994, METABOLIC BASIS INHE, P935; CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1; ELREFAI M, 1976, AM J PHYSIOL, V231, P1608, DOI 10.1152/ajplegacy.1976.231.5.1608; FernandezNovell JM, 1996, EUR J BIOCHEM, V238, P570, DOI 10.1111/j.1432-1033.1996.0570z.x; Gutmann I., 1974, METHODS ENZYMATIC AN, P1464; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; KEPPLER D, 1974, METHOD ENZYMAT AN, V3, P1464; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; LANG G, 1974, METHOD ENZYMAT AN, V3, P1238; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LEI KJ, 1995, J CLIN INVEST, V95, P234, DOI 10.1172/JCI117645; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; NOEL RJ, 1996, DIABET ANN, V10, P65; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; Trinh K, 1997, J BIOL CHEM, V272, P24837, DOI 10.1074/jbc.272.40.24837; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; VILLARPALASI C, 1995, BBA-GEN SUBJECTS, V1244, P203, DOI 10.1016/0304-4165(95)00006-W; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173	39	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26972	26977		10.1074/jbc.272.43.26972	http://dx.doi.org/10.1074/jbc.272.43.26972			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341134	hybrid			2022-12-25	WOS:A1997YC65900030
J	Yu, LX; Zhen, L; Dinauer, MC				Yu, LX; Zhen, L; Dinauer, MC			Biosynthesis of the phagocyte NADPH oxidase cytochrome b(558) - Role of heme incorporation and heterodimer formation in maturation and stability of gp91(phox) and p22(phox) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; LEUKEMIA CELL-LINE; SUPEROXIDE PRODUCTION; RESPIRATORY BURST; BINDING-SITE; NEUTROPHIL CYTOCHROME-B558; HL-60 CELLS; MYELOPEROXIDASE; EXPRESSION; PROTEIN	The NADPH oxidase cytochrome b(558) is a membrane heterodimer comprised of a glycosylated 91-kDa subunit, gp91(phox), and a nonglycosylated 22-kDa subunit, p22(phox). The role of heme in cytochrome b(558) biosynthesis was studied using succinyl acetone, an inhibitor of heme synthesis, in PLB-985 myeloid cells undergoing granulocytic differentiation. Succinyl acetone markedly reduced expression of p22(phox) and the mature 91-kDa form of gp91(phox) but not its 65-kDa high mannose precursor, in association with a profound reduction in NADPH oxidase activity, Expression of non-hems-con; taining cytosolic oxidase components was unaffected. The reduction in cytochrome b(558) expression and NADPH oxidase activity was prevented by adding exogenous heme and was reversible upon removal of succinyl acetone. Transgenic expression of gp91(phox) in monkey COS-7 and murine 3T3 cells, both of which lacked endogenous p22(phox) mRNA, demonstrated that p22(phox) was not required for maturation of gp91(phox) carbohydrate to complex oligosaccharides. However, coexpression of transgenic p22(phox) increased the abundance of the mature gp91(phox) glycoprotein. These results suggest that heme incorporation plays an important Pole in cytochrome bass assembly and provide further support fur the concept that stability of p22(phox) and the mature gp91(phox) subunit is increased by heterodimer formation.	INDIANA UNIV,JAMES WHITCOMB RILEY HOSP CHILDREN,SCH MED,DEPT PEDIAT HEMATOL ONCOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL45635] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNLJOTS K, 1987, J BIOL CHEM, V262, P10430; CASTANEDA VL, 1992, EXP HEMATOL, V20, P916; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; CURNUTTE JT, 1994, J BIOL CHEM, V269, P10813; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DINAUER M, 1993, IMMUNODEFICIENCIES, P335; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; DOUSSIERE J, 1993, BIOCHEMISTRY-US, V32, P8880, DOI 10.1021/bi00085a020; DOUSSIERE J, 1995, BIOCHEMISTRY-US, V34, P1760, DOI 10.1021/bi00005a033; EBERT PS, 1979, BIOCHEM BIOPH RES CO, V88, P1382, DOI 10.1016/0006-291X(79)91133-1; Finegold AA, 1996, J BIOL CHEM, V271, P31021, DOI 10.1074/jbc.271.49.31021; GREEN SP, 1994, J LEUKOCYTE BIOL, V55, P530, DOI 10.1002/jlb.55.4.530; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; HURST JK, 1991, J BIOL CHEM, V266, P1627; KOMAR AA, 1993, FEBS LETT, V326, P261, DOI 10.1016/0014-5793(93)81803-8; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; KUME A, 1994, BLOOD, V84, P3311; Leusen JHW, 1996, J LAB CLIN MED, V128, P461, DOI 10.1016/S0022-2143(96)90043-8; LEVY R, 1990, J IMMUNOL, V145, P2595; MALY FE, 1993, J EXP MED, V178, P2047, DOI 10.1084/jem.178.6.2047; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; MERLIE JP, 1984, CELL, V36, P573, DOI 10.1016/0092-8674(84)90335-0; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2689; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; Nauseef WM, 1996, J BIOL CHEM, V271, P9546, DOI 10.1074/jbc.271.16.9546; NAUSEEF WM, 1992, BLOOD, V80, P2622; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PINNIX IB, 1994, ARCH BIOCHEM BIOPHYS, V312, P447, DOI 10.1006/abbi.1994.1331; PORTER CD, 1994, BLOOD, V84, P2767; Porter CD, 1996, BIOCHEM J, V315, P571, DOI 10.1042/bj3150571; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1992, J BIOL CHEM, V267, P7303; Roos D, 1996, BLOOD, V87, P1663; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SMITH RM, 1991, BLOOD, V77, P673; Smith RM, 1996, J CLIN INVEST, V98, P977, DOI 10.1172/JCI118882; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; TUCKER KA, 1987, BLOOD, V70, P372; UENO I, 1991, FEBS LETT, V281, P130, DOI 10.1016/0014-5793(91)80375-D; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; WIENHUES U, 1992, BIOESSAYS, V14, P17, DOI 10.1002/bies.950140105; YU LX, 1993, BIOCHIM BIOPHYS ACTA, V1178, P73, DOI 10.1016/0167-4889(93)90111-2; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	51	126	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27288	27294		10.1074/jbc.272.43.27288	http://dx.doi.org/10.1074/jbc.272.43.27288			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341176	Green Submitted, hybrid			2022-12-25	WOS:A1997YC65900072
J	Folco, E; Mathur, R; Mori, Y; Buckett, P; Koren, G				Folco, E; Mathur, R; Mori, Y; Buckett, P; Koren, G			A cellular model for long QT syndrome - Trapping of heteromultimeric complexes consisting of truncated Kv1.1 potassium channel polypeptides and native Kv1.4 and Kv1.5 channels in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-CHANNEL; CARDIAC-ARRHYTHMIA; PROTEINS; EXPRESSION; GENE	We demonstrated that overexpression of a cRNA encoding a truncated potassium channel polypeptide that contains the NH, terminus and the first transmembrane segment (Kv1.1206Tag) abolished the expression of Kv1.1 and Kv1.5 outward currents in Xenopus oocytes (Babila, T., Moscucci, A., Wang, H., Weaver, F. E. & Koren, G. (1994) Neuron 12, 615-626), Recently, we showed that expression of Kv1.1N206Tag in the heart of transgenic mice resulted in the creation of mice with prolongation of the surface electrocardiogram's QT interval (London, B., Han, X., Folco, E, & Koren, G. (1996) Biophys, J. 70, A2601), To study the dominant negative mechanism of Kv1.1N206Tag, we overexpressed it in GH3 cells, a pituitary cell line expressing Kv1.5 and Kv1.4, RNase protection analysis comparing the steady-state levels of native Kv1.5 and Kv1.1N206Tag transcripts revealed an excess of Kv1.1N206Tag transcript, Immunoprecipitation analysis using 12CA5 monoclonal antibody detected a 25-kDa polypeptide in the transfected cells, The half-life of Kv1.1N206Tag was 2.6 h, Subcellular fractionation of cell lysates labeled with [S-35]methionine revealed that Kv1.1N206Tag polypeptide is detectable in the particulate (membranous) fraction, but not in the soluble (cytosol) fraction, A series of double immunoprecipitations with 12CA5 and polyclonal antibodies against I(v1.5 and Kv1.4 revealed that Kv1.1N206Tag forms het eromultimeric complexes with the native Kv1.4 and Kv1.5 polypeptides. The steady-state levels of Kv1.5 were not affected by the overexpression of Kv1.1N206Tag, Immunofluorescence colocalization and confocal microscopy analyses revealed that Kv1.1N20gTagFlag did not reach the plasma membrane, and its distribution pattern was characteristic to that of a resident endoplasmic reticulum polypeptide. Our observations establish that the negative effect of Kv1.1N20BTag is mediated by the formation of heteromultimeric complexes with the native channels and by the retention of these complexes in the endoplasmic reticulum.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOVASC,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School								Adelman JP, 1995, NEURON, V15, P1449, DOI 10.1016/0896-6273(95)90022-5; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; CHUNG SW, 1995, P NATL ACAD SCI USA, V92, P5955, DOI 10.1073/pnas.92.13.5955; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; HURTLEY SM, 1989, ANN REV CELL BIOL, V5, P227; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; London B., 1996, Biophysical Journal, V70, pA260; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MORI Y, 1995, J BIOL CHEM, V270, P27788, DOI 10.1074/jbc.270.46.27788; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; PeledZehavi H, 1996, BIOCHEMISTRY-US, V35, P6828, DOI 10.1021/bi952988t; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; TAKIMOTO K, 1993, NEURON, V11, P359, DOI 10.1016/0896-6273(93)90191-S; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904	23	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26505	26510		10.1074/jbc.272.42.26505	http://dx.doi.org/10.1074/jbc.272.42.26505			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334228	hybrid			2022-12-25	WOS:A1997YB13900062
J	Ribbe, M; Gadkari, D; Meyer, O				Ribbe, M; Gadkari, D; Meyer, O			N-2 fixation by Streptomyces thermoautotrophicus involves a molybdenum-dinitrogenase and a manganese-superoxide oxidoreductase that couple N-2 reduction to the oxidation of superoxide produced from O-2 by a molybdenum-CO dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; DISMUTASE GENE; NITROGENASE; PROTEIN; PURIFICATION; BACTERIA	N-2 fixation by Streptomyces thermoautofrophicus follows the equation N-2 + 4-12 MgATP + 8H(+) + 8e(-) --> 2NH(3) + H-2 + 4-12 MgADP + 4-12P(i) and exhibits features which are not obvious in the diazotrophic bacteria studied so far, The reaction is coupled to the oxidation of carbon monoxide (CO) by a molybdenum-containing CO dehydrogenase that transfers the electrons derived from CO oxidation to O-2, thereby producing superoxide anion radicals (O-2(radical anion). A manganese-containing superoxide oxidoreductase reoxidizes the )(2)(radical anion) anions to O-2 and transfers the electrons to a MoFeS-dinitrogenase for the reduction of N-2 to ammonium, Among the most striking properties of the S. thermoautotrophicus nitrogenase system are the dependence on O-2 and O-2(radical anion) the complete insensitivity of all components involved toward O-2 and H2O2, the inability to reduce ethine or ethene, and a low MgATP requirement, In addition, the subunit structure of the S. thermoautotrophicus nitrogenase components and the polypeptides involved seem to be dissimilar from the known nitrogenases.	UNIV BAYREUTH, LEHRSTUHL MIKROBIOL, D-95440 BAYREUTH, GERMANY	University of Bayreuth								BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Blanchard CZ, 1996, BIOCHEMISTRY-US, V35, P472, DOI 10.1021/bi951429j; BOWLER C, 1990, J BACTERIOL, V172, P1539, DOI 10.1128/jb.172.3.1539-1546.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; CARDENAS J, 1974, ANAL BIOCHEM, V60, P372, DOI 10.1016/0003-2697(74)90244-9; CHAMBERS SP, 1992, FEMS MICROBIOL LETT, V91, P277; DALTON H, 1972, BACTERIOL REV, V36, P231, DOI 10.1128/MMBR.36.2.231-260.1972; DALTON H, 1971, BIOCHEMISTRY-US, V10, P2066; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; Eady RR, 1996, CHEM REV, V96, P3013, DOI 10.1021/cr950057h; EADY RR, 1972, BIOCHEM J, V128, P655, DOI 10.1042/bj1280655; Evans HJ, 1992, BIOL NITROGEN FIXATI, P1; GADKARI D, 1984, ZBL MIKROBIOL, V139, P623, DOI 10.1016/S0232-4393(84)80056-6; GADKARI D, 1990, APPL ENVIRON MICROB, V56, P3727, DOI 10.1128/AEM.56.12.3727-3734.1990; GADKARI D, 1992, J BACTERIOL, V174, P6840, DOI 10.1128/JB.174.21.6840-6843.1992; GADKARI D, 1994, BIOENGINEERING, V2, P27; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KRAUT M, 1989, ARCH MICROBIOL, V152, P335, DOI 10.1007/BF00425170; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENGFELDER E, 1979, Z NATURFORSCH C, V34, P374; LOW A, 1993, EUR J BIOCHEM, V215, P473, DOI 10.1111/j.1432-1033.1993.tb18056.x; MEYER O, 1983, ANNU REV MICROBIOL, V37, P277, DOI 10.1146/annurev.mi.37.100183.001425; MEYER O, 1982, J BIOL CHEM, V257, P1333; MEYER O, 1990, FEMS MICROBIOL LETT, V87, P253, DOI 10.1016/0378-1097(90)90463-Z; MEYER O, 1993, ACS SYM SER, V535, P50; MEYER O, 1991, 3 S BIOT COAL COAL D, P111; MEYER O, 1997, KOHLEREI FICHTELGEBI, P1; MISRA HP, 1978, ARCH BIOCHEM BIOPHYS, V189, P317, DOI 10.1016/0003-9861(78)90218-7; RIBBE M, 1994, BIOENGINEERING, V2, P80; Santiago B, 1996, FEMS MICROBIOL LETT, V136, P157; SCHADE AL, 1954, P SOC EXP BIOL MED, V87, P443, DOI 10.3181/00379727-87-21407; SCHMIDT K, 1963, ARCH MIKROBIOL, V46, P117, DOI 10.1007/BF00408204; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; YATES MG, 1972, FEBS LETT, V27, P63, DOI 10.1016/0014-5793(72)80410-1	37	116	127	1	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26627	26633		10.1074/jbc.272.42.26627	http://dx.doi.org/10.1074/jbc.272.42.26627			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334244	hybrid			2022-12-25	WOS:A1997YB13900078
J	Antonenkov, VD; VanVeldhoven, PP; Waelkens, E; Mannaerts, GP				Antonenkov, VD; VanVeldhoven, PP; Waelkens, E; Mannaerts, GP			Substrate specificities of 3-oxoacyl-CoA thiolase A and sterol carrier protein 2/3-oxoacyl-CoA thiolase purified from normal rat liver peroxisomes - Sterol carrier protein 2/3-oxoacyl-CoA thiolase is involved in the metabolism of 2-methyl-branched fatty acids and bile acid intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; COENZYME-A THIOLASE; BETA-OXIDATION; 3-KETOACYL-COA THIOLASE; KINETIC MECHANISM; 58-KDA PROTEIN; PURIFICATION; CDNA; SEQUENCE; IDENTIFICATION	The two main thiolase activities present in isolated peroxisomes from normal rat liver were purified to near homogeneity. On sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the first enzyme preparation displayed a single band of 41 kDa that was identified as 3-oxoacyl-CoA thiolase A (thiolase A) by N-terminal amino acid sequencing, The second enzyme preparation consisted of a 58- and a 46-kDa band, The 58-kDa polypeptide reacted with antibodies raised against either sterol carrier protein 2 or the thiolase domain of sterol carrier protein 2/3-oxoacyl-CoA thiolase (SCP-2/thiolase), formerly also called sterol carrier protein X, whereas the 46-kDa polypeptide reacted only with the antibodies raised against the thiolase domain, Internal peptide sequencing confirmed that the 58-kDa polypeptide is SCP-2/thiolase and that the 46-kDa polypeptide is the thiolase domain of SCP-2/thiolase. Thiolase A catalyzed the cleavage of short, medium, and long straight chain 3-oxoacyl-CoAs, medium chain 3-oxoacyl-CoAs being the best substrates, The enzyme was inactive with the 2-methyl-branched 3-oxo-2-methylpalmitoyl-CoA and with the bile acid intermediate 24-oxo-trihydroxycoprostanoyl-CoA. SCP-2/thiolase was active with medium and long straight chain 3-oxoacyl-CoAs but also with the 2-methyl-branched 3-oxoacyl-CoA and the bile acid intermediate. In peroxisomal extracts, more than 90% of the thiolase activity toward straight chain 3-oxoacyl-CoAs was associated with thiolase A. Kinetic parameters (K-m and V-max) were determined for each enzyme with the different substrates. Our results indicate the following: 1) the two (main) thiolases present in peroxisomes from normal rat liver are thiolase A and SCP-2/thiolase; 2) thiolase A is responsible for the thiolytic cleavage of straight chain 3-oxoacyl-CoAs; and 3) SCP-2/thiolase is responsible for the thiolytic cleavage of the 3-oxoacyl-CoA derivatives of 2-methyl-branched fatty acids and the side chain of cholesterol.	UNIV CATHOLIQUE LOUVAIN, DEPT MOL CELLBIOL, AFDELING FARMACOL, B-3000 LOUVAIN LA NEUVE, BELGIUM; UNIV CATHOLIQUE LOUVAIN, DEPT MOL CELLBIOL, AFDELING BIOCHEM, B-3000 LOUVAIN LA NEUVE, BELGIUM	Universite Catholique Louvain; Universite Catholique Louvain			, Van Veldhoven Paul/U-6359-2019	, Van Veldhoven Paul/0000-0002-4478-2564				Baumgart E, 1996, P NATL ACAD SCI USA, V93, P13748, DOI 10.1073/pnas.93.24.13748; BODNAR AG, 1990, GENE, V91, P193, DOI 10.1016/0378-1119(90)90088-9; BOUT A, 1991, BIOCHIM BIOPHYS ACTA, V1090, P43, DOI 10.1016/0167-4781(91)90035-K; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLINKENBEARD KD, 1973, J BIOL CHEM, V248, P2275; DieuaideNoubhani M, 1997, BIOCHEM J, V321, P253, DOI 10.1042/bj3210253; DieuaideNoubhani M, 1996, EUR J BIOCHEM, V240, P660, DOI 10.1111/j.1432-1033.1996.0660h.x; DieuaideNoubhani M, 1997, BIOCHEM J, V325, P367, DOI 10.1042/bj3250367; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; GEHRING U, 1972, ENZYMES, V7, P391; HIJIKATA M, 1987, J BIOL CHEM, V262, P8151; HIJIKATA M, 1990, J BIOL CHEM, V265, P4600; HUTH W, 1973, H-S Z PHYSIOL CHEM, V354, P635, DOI 10.1515/bchm2.1973.354.1.635; HUTH W, 1975, EUR J BIOCHEM, V59, P475, DOI 10.1111/j.1432-1033.1975.tb02476.x; LAZAROW PB, 1978, J BIOL CHEM, V253, P1522; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; Leenders F, 1996, J BIOL CHEM, V271, P5438, DOI 10.1074/jbc.271.10.5438; Mannaerts GP, 1996, ANN NY ACAD SCI, V804, P99, DOI 10.1111/j.1749-6632.1996.tb18611.x; MIDDLETON B, 1983, CLIN CHIM ACTA, V128, P291, DOI 10.1016/0009-8981(83)90329-7; MIDDLETON B, 1973, BIOCHEM J, V132, P717, DOI 10.1042/bj1320717; MIDDLETON B, 1974, BIOCHEM J, V139, P109, DOI 10.1042/bj1390109; MIYAZAWA S, 1980, EUR J BIOCHEM, V103, P589, DOI 10.1111/j.1432-1033.1980.tb05984.x; MIYAZAWA S, 1981, J BIOCHEM, V90, P511, DOI 10.1093/oxfordjournals.jbchem.a133499; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; NOVIKOV DK, 1994, J BIOL CHEM, V269, P27125; OHBA T, 1995, BIOCHEMISTRY-US, V34, P10660, DOI 10.1021/bi00033a042; Ossendorp BC, 1996, ARCH BIOCHEM BIOPHYS, V334, P251, DOI 10.1006/abbi.1996.0453; OSSENDORP BC, 1991, EUR J BIOCHEM, V201, P233, DOI 10.1111/j.1432-1033.1991.tb16279.x; OSUMI T, 1980, J BIOCHEM, V87, P1735, DOI 10.1093/oxfordjournals.jbchem.a132918; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITZ W, 1995, EUR J BIOCHEM, V231, P815, DOI 10.1111/j.1432-1033.1995.0815d.x; SEEDORF U, 1994, J BIOL CHEM, V269, P21277; SEUBERT W, 1968, BIOCHIM BIOPHYS ACTA, V164, P498, DOI 10.1016/0005-2760(68)90180-X; STAACK H, 1978, J BIOL CHEM, V253, P1827; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P931, DOI 10.1016/S0076-6879(57)03481-3; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; Vanhooren JCT, 1997, BIOCHEM J, V325, P593, DOI 10.1042/bj3250593; VANHOVE G, 1991, J BIOL CHEM, V266, P24670; VanVeldhoven PP, 1996, FEBS LETT, V388, P80, DOI 10.1016/0014-5793(96)00508-X; VanVeldhoven PP, 1997, BBA-LIPID LIPID MET, V1347, P62, DOI 10.1016/S0005-2760(97)00053-2; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P24676; VANVELDHOVEN PP, 1992, J BIOL CHEM, V267, P20065; VERHEYDEN K, 1992, BIOCHIM BIOPHYS ACTA, V1109, P48, DOI 10.1016/0005-2736(92)90185-O; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; Xu RF, 1996, BIOCHEM BIOPH RES CO, V221, P271, DOI 10.1006/bbrc.1996.0585	49	126	130	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26023	26031		10.1074/jbc.272.41.26023	http://dx.doi.org/10.1074/jbc.272.41.26023			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325339	hybrid			2022-12-25	WOS:A1997YA35800094
J	Duchateau, PN; Pullinger, CR; Orellana, RE; Kunitake, ST; NayaVigne, J; OConnor, PM; Malloy, MJ; Kane, JP				Duchateau, PN; Pullinger, CR; Orellana, RE; Kunitake, ST; NayaVigne, J; OConnor, PM; Malloy, MJ; Kane, JP			Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas - Identification, cloning, characterization, and plasma distribution of apolipoprotein L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTERYL ESTER TRANSFER; I-CONTAINING LIPOPROTEINS; SEPHAROSE AFFINITY-CHROMATOGRAPHY; CELL-DERIVED CHOLESTEROL; APOPROTEIN-A-I; POLYACRYLAMIDE GELS; HEART-DISEASE; PROTEINS; ACYLTRANSFERASE; IMMUNOSORPTION	In this study, we have identified and characterized a new protein present in human high density lipoprotein that we have designated apolipoprotein L. Using a combination of liquid-phase isoelectrophoresis and high resolution two-dimensional gel electrophoresis, apolipoprotein L was identified and partially sequenced from immunoisolated high density lipoprotein (Lp(A-I)). Expression was only detected in the pancreas, The cDNA sequence encoding the full-length protein was cloned using reverse transcription-polymerase chain reaction, The deduced amino acid sequence contains 383 residues, including a typical signal peptide of 12 amino acids, No significant homology was found with known sequences, The plasma protein is a single chain polypeptide with an apparent molecular mass of 42 kDa, Antibodies raised against this protein detected a truncated form with a molecular mass of 39 kDa, Both forms were predominantly associated with immunoaffinity-isolated apoA-I-containing lipoproteins and detected mainly in the density range 1.123 < d < 1.21 g/ml. Free apoL was not detected in plasma. Anti-apoL immunoaffinity chromatography was used to purify apoL-containing lipoproteins (Lp(L)) directly from plasma. Nondenaturing gel electrophoresis of Lp(L) showed two major molecular species with apparent diameters of 12.2-17 and 10.4-12.2 nm. Moreover, Lp(L) exhibited both pre-beta and alpha electromobility. Apolipoproteins A-I, A-II, A-IV, and C-III were also detected in the apoL-containing lipoprotein particles.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NHLBI NIH HHS [HL-50792, HL-50779, HL-31210] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL031210, R01HL031210, R01HL050779] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALAUPOVIC P, 1980, HDB ELECTROPHORESIS, V1, P27; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; BOJANOVSKI D, 1985, J LIPID RES, V26, P185; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEUNG MC, 1986, J LIPID RES, V27, P1135; CHEUNG MC, 1988, J LIPID RES, V29, P15; EDELSTEIN C, 1983, J BIOL CHEM, V258, P1430; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING PE, 1980, P NATL ACAD SCI-BIOL, V77, P3327, DOI 10.1073/pnas.77.6.3327; FRANCONE OL, 1990, EUR HEART J, V11, P218, DOI 10.1093/eurheartj/11.suppl_E.218; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON T, 1977, JAMA-J AM MED ASSOC, V238, P497, DOI 10.1001/jama.238.6.497; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JAMES RW, 1988, J LIPID RES, V29, P1557; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KUNITAKE S, 1987, NATL I HLTH WORKSH L, V87, P419; KUNITAKE ST, 1985, J LIPID RES, V26, P549; KUNITAKE ST, 1982, J LIPID RES, V23, P936; KUNITAKE ST, 1992, P NATL ACAD SCI USA, V89, P6993, DOI 10.1073/pnas.89.15.6993; KUNITAKE ST, 1994, BIOCHEMISTRY-US, V33, P1988, DOI 10.1021/bi00174a003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCEL YL, 1981, J LIPID RES, V22, P1198; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MCVICAR JP, 1984, P NATL ACAD SCI-BIOL, V81, P1356, DOI 10.1073/pnas.81.5.1356; MILLER GJ, 1975, LANCET, V1, P16; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OHTA T, 1989, FEBS LETT, V257, P435, DOI 10.1016/0014-5793(89)81590-X; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROFATTER JA, 1995, GENOME RES, V5, P214, DOI 10.1101/gr.5.3.214; WEISGRABER KH, 1980, J LIPID RES, V21, P316; WIELAND H, 1982, J LIPID RES, V23, P893; WILSON HM, 1992, BIOCHEM J, V284, P477, DOI 10.1042/bj2840477; ZEHR BD, 1989, ANAL BIOCHEM, V182, P157, DOI 10.1016/0003-2697(89)90734-3	39	165	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25576	25582		10.1074/jbc.272.41.25576	http://dx.doi.org/10.1074/jbc.272.41.25576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325276	hybrid			2022-12-25	WOS:A1997YA35800031
J	Atfi, A; Buisine, M; Mazars, A; Gespach, C				Atfi, A; Buisine, M; Mazars, A; Gespach, C			Induction of apoptosis by DPC4, a transcriptional factor regulated by transforming growth factor-beta through stress-activated protein kinase c-Jun N-terminal kinase (SAPK/JNK) signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; CELL-DEATH; RECEPTORS; FAMILY; JNK; TRANSDUCTION; DOMAIN; ERK	Many of the actions of serine/threonine kinase receptors for the transforming growth factor-beta (TGF beta) are mediated by DPC4, a human MAD-related protein identified as a tumor suppressor gene in pancreatic carcinoma. Overexpression of DPC4 is sufficient to induce the activation of gene expression and cell cycle arrest, characteristic of the TGF beta response. The stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) is also one of the downstream targets required for TGF beta-mediated signaling, Here we report that expression of the dominant-interfering mutant of various components of the SAPK/JNK. cascade specifically blocked both TGF beta and DPC4-induced gene expression, These dominant-interfering mutants also inhibited TGF beta-stimulated DPC4 transcriptional activity. Moreover, we find that overexpression of DPC4 causes transfected cells to undergo the morphological changes typical of apoptosis, These findings define a mechanism whereby TGF beta signals mediated by DPC4 and SAPK/JNK cascade are integrated in the nucleus to activate gene expression and identify a new cellular function for DPC4.	HOP ST ANTOINE,INSERM,U55,F-75571 PARIS 12,FRANCE; HOP ST ANTOINE,CTR HOSP UNIV ST ANTOINE,INST FEDERATIF RECH,IFR 65,F-75571 PARIS 12,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite								Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1995, P NATL ACAD SCI USA, V92, P12110, DOI 10.1073/pnas.92.26.12110; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Frey RS, 1997, CANCER RES, V57, P628; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; RAPP UR, 1994, ONCOGENE, V9, P3493; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	31	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24731	24734		10.1074/jbc.272.40.24731	http://dx.doi.org/10.1074/jbc.272.40.24731			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312063	hybrid			2022-12-25	WOS:A1997XY97000002
J	Molinari, M; Galii, C; Norais, N; Telford, JL; Rappuoli, R; Luzio, JP; Montecucco, C				Molinari, M; Galii, C; Norais, N; Telford, JL; Rappuoli, R; Luzio, JP; Montecucco, C			Vacuoles induced by Helicobacter pylori toxin contain both late endosomal and lysosomal markers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLATING CYTOTOXIN; CAMPYLOBACTER-PYLORI; ENDOCYTIC PATHWAY; VIRULENCE FACTORS; GASTRIC LYMPHOMA; PEPTIC-ULCER; DISEASE; INFECTION; RECEPTORS; STRAINS	Intoxication of mammalian cells with the vacuolating toxin (VacA) released by Helicobacter pylori causes the formation of large acidic vacuoles containing the vacuolar ATPase proton pump and Rab7, a late endosome marker. Here, we describe a novel subcellular fractionation procedure, and we show that nanomolar concentrations of VacA induce a clear redistribution of lysosomal membrane glycoproteins among endocytic compartments. This redistribution is an early event in the process of cellular intoxication by VacA and precedes the formation of macroscopic vacuoles. The absence of the cation independent mannose 6-P receptor and the presence of Rab7 and of lysosomal membrane proteins in the newly formed compartment suggest that the vacuolating toxin induces the accumulation of a post-endosomal hybrid compartment presenting both late endosomal and lysosomal features.	UNIV PADUA,DIPARTIMENTO SCI BIOMED,I-35100 PADUA,ITALY; CTR RIC IRIS,BIOCINE CHIRON,I-53100 SIENA,ITALY; UNIV CAMBRIDGE,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	University of Padua; University of Cambridge	Molinari, M (corresponding author), UNIV PADUA,CTR CNR,VIA G COLOMBO 3,I-35100 PADUA,ITALY.		Molinari, Maurizio/N-2587-2019; Telford, John Laird/ABG-8144-2020	Molinari, Maurizio/0000-0002-7636-5829; 				ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; COVER TL, 1994, J BIOL CHEM, V269, P10566; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; DESJARDINS M, 1995, TRENDS CELL BIOL, V5, P183, DOI 10.1016/S0962-8924(00)88989-8; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; FernandezBorja M, 1996, INT IMMUNOL, V8, P625, DOI 10.1093/intimm/8.5.625; FIOCCA R, 1992, VIRCHOWS ARCH A, V420, P489, DOI 10.1007/BF01600253; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GOODWIN CS, 1988, LANCET, V2, P1467; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P615, DOI 10.1016/S0016-5085(89)80057-5; Griffiths G, 1996, PROTOPLASMA, V195, P37, DOI 10.1007/BF01279185; ISAACSON PG, 1994, NEW ENGL J MED, V330, P1310, DOI 10.1056/NEJM199405053301812; LEUNK RD, 1991, REV INFECT DIS S, V13, P686; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; MANETTI R, 1995, INFECT IMMUN, V63, P4476, DOI 10.1128/IAI.63.11.4476-4480.1995; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MERESSE S, 1995, J CELL SCI, V108, P3349; Moll G, 1995, EUR J BIOCHEM, V234, P947, DOI 10.1111/j.1432-1033.1995.947_a.x; MONTECUCCO C, 1994, FEBS LETT, V346, P92, DOI 10.1016/0014-5793(94)00449-8; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; PAPINI E, 1993, MOL MICROBIOL, V7, P323, DOI 10.1111/j.1365-2958.1993.tb01123.x; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; PAPINI E, 1996, BACTERIAL PROTEIN TO, V28, P181; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Reaves BJ, 1996, J CELL SCI, V109, P749; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; TOMPKINS LS, 1995, SCIENCE, V267, P1621, DOI 10.1126/science.7886448; XIANG ZY, 1995, INFECT IMMUN, V63, P94, DOI 10.1128/IAI.63.1.94-98.1995; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	36	165	177	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25339	25344		10.1074/jbc.272.40.25339	http://dx.doi.org/10.1074/jbc.272.40.25339			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312153	hybrid			2022-12-25	WOS:A1997XY97000092
J	Ueda, H; Siani, MA; Gong, WH; Thompson, DA; Brown, GG; Wang, JM				Ueda, H; Siani, MA; Gong, WH; Thompson, DA; Brown, GG; Wang, JM			Chemically synthesized SDF-1 alpha analogue, N33A, is a potent chemotactic agent for CXCR4/Fusin/LESTR-expressing human leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-3 MCP3 INTERACTS; MOLECULAR-CLONING; CHEMOKINE RECEPTORS; HIV-1 ENTRY; LYMPHOCYTE CHEMOATTRACTANT; CHROMOSOMAL LOCALIZATION; 7-TRANSMEMBRANE; RANTES; SDF-1; GENE	Stromal cell-derived factor (SDF) 1 is a potent chemoattractant for leukocytes through activation of the receptor CXCR4/Fusin/LESTR, which is a fusion co-factor for the entry of T lymphocytotropic human immunodeficiency virus type 1 (HIV-1), This CXCR4-mediated HIV-1 fusion can be inhibited by SDF-1, Because of its importance in the study of immunity and AIDS, large scale production of SDF-1 is desirable, In addition to recombinant technology, chemical synthesis provides means by which biologically active proteins can be produced not only in large quantity but also with a variety of designed modifications, In this study, we investigated the binding and function of an SDF-1 alpha analogue, N33A, synthesized by a newly developed native chemical ligation approach, Radioiodinated N33A showed high affinity binding to human monocytes, T lymphocytes, as well as neutrophils, and competed equally well with native recombinant SDF-1 alpha for binding sites on leukocytes. N33A also showed equally potent chemoattractant activity as native recombinant SDF-1 alpha for human leukocytes. Further study with CXCR4/Fusin/LESTR transfected HEK 293 cells showed that N33A binds and induces directional migration of these cells in vitro. These results demonstrate that the chemically synthesized SDF-1 alpha analogue, N33A, which can be produced rapidly in large quantity, possesses the same capacity as native SDF-1 alpha to activate CXCR4-expressing cells and will provide a valuable agent for research on the host immune response and AIDS.	NCI,FREDERICK CANC RES & DEV CTR,MOL IMMUNOREGULAT LAB,DIV BASIC SCI,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,INTRAMURAL RES SUPPORTPROGRAM,SAIC FREDRICK,FREDERICK,MD 21702; GRYPHON SCI,S SAN FRANCISCO,CA 94080; NEN LIFE SCI PROD,IODINAT GRP,BILLERICA,MA 01862	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Thompson, Darren/0000-0002-3725-7112				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; CANNE LE, 1995, TETRAHEDRON LETT, V36, P1217, DOI 10.1016/0040-4039(95)00037-D; CANNE LE, 1995, J AM CHEM SOC, V117, P2998, DOI 10.1021/ja00116a005; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P; JIANG W, 1994, EXP CELL RES, V215, P284, DOI 10.1006/excr.1994.1344; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Maeda Y, 1996, PROTEIN ENG, V9, P95, DOI 10.1093/protein/9.1.95; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Oppenheim Joost J., 1996, P187; Robson B, 1996, NAT BIOTECHNOL, V14, P892, DOI 10.1038/nbt0796-892; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; XU LL, 1995, EUR J IMMUNOL, V25, P2612, DOI 10.1002/eji.1830250931; XU LL, 1995, J LEUKOCYTE BIOL, V57, P335, DOI 10.1002/jlb.57.2.335	33	61	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24966	24970		10.1074/jbc.272.40.24966	http://dx.doi.org/10.1074/jbc.272.40.24966			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312101	hybrid			2022-12-25	WOS:A1997XY97000040
J	Lauber, AH; Barrett, TJ; Subramaniam, M; Schuchard, M; Spelsberg, TC				Lauber, AH; Barrett, TJ; Subramaniam, M; Schuchard, M; Spelsberg, TC			A DNA-binding element for a steroid receptor-binding factor is flanked by dual nuclear matrix DNA attachment sites in the c-myc gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							OVIDUCT PROGESTERONE-RECEPTOR; ESTROGEN-INDUCED EXPRESSION; CHROMOSOMAL LOOP ANCHORAGE; CHROMATIN ACCEPTOR SITES; BREAST-CANCER-CELLS; AVIAN OVIDUCT; JUN PROTOONCOGENE; FACTOR-I; TRANSCRIPTION FACTORS; HORMONE ACTION	The receptor-binding factor (RBF) for the avian oviduct progesterone (Pg) receptor (PR) has previously been shown to be a unique 10-kDa nuclear matrix protein that generates high affinity PR-binding sites on avian DNA. This paper describes the use of Southwestern blot and DNA gel shift analyses with RBF protein to identify a minimal 54-base pair RBF-binding element in the matrix-associated region (MAR) of the Pg-regulated c-myc gene promoter, This element contains a 5'-GC-rich domain and a 3'-AT-rich domain, the latter of which has a homopurine/homopyrimidine structure. The gel shift assays required the generation of an RBF-maltose fusion protein (RBF-MBP), which specifically binds this element and is supershifted when the anti-RBF polyclonal antibody is added. Computer analysis of the full-length amino acid sequence for RBF predicts a DNA-binding motif involving a beta-sheet structure at the N-terminal domain. Southern blot analyses using nuclear matrix DNA suggests that there are dual MAR sites in the c-myc promoter, which flank an intervening domain containing the RBF element. The co-transfection of this MAR sequence, containing the RBF element and cloned into a luciferase reporter vector, together with an RBF expression vector construct, into steroid treated human MCF-7 cells, results in a decrease of the c-myc promoter activity relative to control transfections containing only the parent vector of the RBF expression construct. These data suggest that a unique chromatin/nuclear matrix structure, composed of the RBF-DNA element complex which is flanked by nuclear matrix attachment sites, serves to bind the PR and repress the c-myc promoter.	MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOL BIOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, MAYO MED VENTURES, ROCHESTER, MN 55905 USA; SIGMA CHEM CO, ELECTROPHORESIS DEPT, ST LOUIS, MO 63118 USA	Mayo Clinic; Mayo Clinic					NCI NIH HHS [CA90441] Funding Source: Medline; NICHD NIH HHS [HD09140, HD07108] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140, T32HD007108] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA090441, R56CA090441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; AGUTTER PS, 1979, EXP CELL RES, V124, P453, DOI 10.1016/0014-4827(79)90224-6; ALEXANDER RB, 1987, ENDOCRINOLOGY, V120, P1851, DOI 10.1210/endo-120-5-1851; ANDERSON JN, 1986, NUCLEIC ACIDS RES, V14, P8513, DOI 10.1093/nar/14.21.8513; BAGCHI MK, 1992, ENDOCR REV, V13, P525, DOI 10.1210/er.13.3.525; BARRACK ER, 1987, J STEROID BIOCHEM, V27, P115, DOI 10.1016/0022-4731(87)90302-5; BARRACK ER, 1980, J BIOL CHEM, V255, P7265; BARRACK ER, 1983, BIOCHEM ACTION HORM, V10, P23; BARRACK ER, 1982, RECENT PROG HORM RES, V38, P133; BARRACK ER, 1987, STEROID HORMONE RECE, P86; Barrack ER, 1987, RECENT ADV STEROID H, P85; Barrett TJ, 1996, BIOCHEMISTRY-US, V35, P9746, DOI 10.1021/bi960058j; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BEREZNEY R, 1984, CHROMOSOMAL NONHISTO, V4, P120; BEREZNEY R, 1995, INT REV CYTOLOGY CEL; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; BIDWELL JP, 1993, P NATL ACAD SCI USA, V90, P3162, DOI 10.1073/pnas.90.8.3162; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Bode J, 1995, INT REV CYTOL, V162A, P389; BOULIKAS T, 1993, J CELL BIOCHEM, V53, P1, DOI 10.1002/jcb.240530102; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; CHUKNYISKA RS, 1984, ENDOCRINOLOGY, V115, P836, DOI 10.1210/endo-115-2-836; CIEJEK EM, 1983, NATURE, V306, P607, DOI 10.1038/306607a0; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLVARD DS, 1984, BIOCHEMISTRY-US, V23, P3479, DOI 10.1021/bi00310a015; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Coutts AS, 1996, J CELL BIOCHEM, V63, P174, DOI 10.1002/(SICI)1097-4644(19961101)63:2<174::AID-JCB5>3.0.CO;2-V; DEBOER W, 1984, J STEROID BIOCHEM, V20, P387, DOI 10.1016/0022-4731(84)90239-5; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DUBIK D, 1987, CANCER RES, V47, P6517; DWORETZKY SI, 1992, P NATL ACAD SCI USA, V89, P4178, DOI 10.1073/pnas.89.9.4178; EDWARDS DP, 1989, MOL ENDOCRINOL, V3, P381, DOI 10.1210/mend-3-2-381; ELLIOTT TS, 1993, BIOCHEM BIOPH RES CO, V190, P167, DOI 10.1006/bbrc.1993.1026; EPPERLY M, 1984, J STEROID BIOCHEM, V20, P691, DOI 10.1016/0022-4731(84)90072-4; FINK KL, 1988, P NATL ACAD SCI USA, V85, P1796, DOI 10.1073/pnas.85.6.1796; FORNACE AJ, 1988, MOL CELL BIOL, V8, P4716, DOI 10.1128/MCB.8.11.4716; FORSTHOEFEL AM, 1987, MOL ENDOCRINOL, V1, P899, DOI 10.1210/mend-1-12-899; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GOLDBERGER A, 1988, BIOCHEMISTRY-US, V27, P2103, DOI 10.1021/bi00406a043; GOLDBERGER A, 1986, ENDOCRINOLOGY, V118, P2235, DOI 10.1210/endo-118-6-2235; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; HAGER GL, 1991, NUCLEAR HORMONE RECE, P217; HIGUTI T, 1992, BIOCHEMISTRY-US, V31, P12451, DOI 10.1021/bi00164a022; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; HORA J, 1986, P NATL ACAD SCI USA, V83, P8839, DOI 10.1073/pnas.83.23.8839; JOST JP, 1984, P NATL ACAD SCI-BIOL, V81, P429, DOI 10.1073/pnas.81.2.429; KLYZSEJKOSTEFANOWICZ L, 1976, P NATL ACAD SCI USA, V73, P1954, DOI 10.1073/pnas.73.6.1954; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; LANDERS J P, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P19; LANDERS JP, 1991, ANN NY ACAD SCI, V637, P26, DOI 10.1111/j.1749-6632.1991.tb27299.x; LANDERS JP, 1994, J CELL BIOCHEM, V55, P241, DOI 10.1002/jcb.240550211; LAU CK, 1990, ENDOCRINOLOGY, V127, P2595, DOI 10.1210/endo-127-5-2595; LAU CK, 1991, P NATL ACAD SCI USA, V88, P829, DOI 10.1073/pnas.88.3.829; Lauber Andrea H., 1995, V162B, P337; METZGER DA, 1990, ENDOCRINOLOGY, V126, P2190, DOI 10.1210/endo-126-4-2190; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1882, DOI 10.1210/endo-120-5-1882; OGLE TF, 1987, ENDOCRINOLOGY, V121, P28, DOI 10.1210/endo-121-1-28; PAVLIK EJ, 1986, ENDOCRINOLOGY, V118, P1924, DOI 10.1210/endo-118-5-1924; PHILLIPS SEV, 1993, NUCLEIC ACIDS MOL BI, V7, P28; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; PIENTA K J, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P355; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; REJMAN J, 1991, J PROTEIN CHEM, V10, P651, DOI 10.1007/BF01025717; RORIES C, 1989, MOL ENDOCRINOL, V3, P991, DOI 10.1210/mend-3-6-991; RORIES C, 1989, ANNU REV PHYSIOL, V51, P653, DOI 10.1146/annurev.physiol.51.1.653; RUH TS, 1983, BIOCHEM J, V210, P905, DOI 10.1042/bj2100905; RUH TS, 1981, BIOCHEM J, V200, P133, DOI 10.1042/bj2000133; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SARKAR G, 1988, NUCLEIC ACIDS RES, V16, P5197, DOI 10.1093/nar/16.11.5197; SCHUCHARD M, 1991, BIOCHEMISTRY-US, V30, P9516, DOI 10.1021/bi00103a019; SCHUCHARD M, 1991, BIOCHEMISTRY-US, V30, P4535, DOI 10.1021/bi00232a024; SCHUCHARD M, 1993, ENDOCR REV, V14, P659, DOI 10.1210/er.14.6.659; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SPELSBERG TC, 1976, J STEROID BIOCHEM, V7, P1091, DOI 10.1016/0022-4731(76)90039-X; Spelsberg TC, 1996, RECENT PROG HORM RES, V51, P63; SPELSBERG TC, 1988, J STEROID BIOCHEM, V31, P579, DOI 10.1016/0022-4731(88)90009-X; SPELSBERG TC, 1983, RECENT PROG HORM RES, V39, P463; SPELSBERG TC, 1971, J BIOL CHEM, V246, P4188; SPELSBERG TC, 1972, J BIOL CHEM, V247, P1368; SPELSBERG TC, 1984, BIOCHEMISTRY-US, V23, P5103, DOI 10.1021/bi00317a004; SPELSBERG TC, 1987, J STEROID BIOCHEM, V27, P133, DOI 10.1016/0022-4731(87)90304-9; SPELSBERG TC, 1987, RECENT ADV STEROID H, P31; STEIN GS, 1994, J CELL BIOCHEM, V55, P4, DOI 10.1002/jcb.240550103; SUBRAMANIAM M, 1993, ENDOCRINOLOGY, V133, P2049, DOI 10.1210/en.133.5.2049; TOYODA H, 1985, P NATL ACAD SCI USA, V82, P4722, DOI 10.1073/pnas.82.14.4722; TRAVERS MT, 1987, FEBS LETT, V211, P27, DOI 10.1016/0014-5793(87)81267-X; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI SY, 1991, NUCLEAR HORMONE RECE, P103; VANSTEENSEL B, 1991, FEBS LETT, V292, P229, DOI 10.1016/0014-5793(91)80873-2; VIG E, 1994, MOL ENDOCRINOL, V8, P1336, DOI 10.1210/me.8.10.1336; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WEBB DK, 1990, BIOCHEM BIOPH RES CO, V168, P721, DOI 10.1016/0006-291X(90)92381-9; ZHUANG YH, 1993, J CELL BIOCHEM, V53, P383, DOI 10.1002/jcb.240530416	102	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24657	24665		10.1074/jbc.272.39.24657	http://dx.doi.org/10.1074/jbc.272.39.24657			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305935	hybrid			2022-12-25	WOS:A1997XY51500086
J	Hoffmann, KMV; Tonks, NK; Barford, D				Hoffmann, KMV; Tonks, NK; Barford, D			The crystal structure of domain 1 of receptor protein-tyrosine phosphatase mu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTP-MU; HOMOPHILIC BINDING; KAPPA	Receptor like protein-tyrosine phosphatases (RPTPs) play important roles in regulating intracellular processes, We have been investigating the regulation and function of RPTP mu, a receptor-like PTP related to the Ig superfamily of cell adhesion molecules, Recently, the crystal structure of a dimer of the membrane proximal domain of RPTP alpha (RPTP alpha D1) was described (Bilwes, A. M., den Hertog, J., Hunter, T., and Noel J. P. (1996) Nature 382, 555-559). Within this crystal structure, the catalytic site of each subunit of the dimer is sterically blocked by the insertion of the N-terminal helix-turn-helix segment of the dyad-related monomer, It was proposed that dimerization would lead to inhibition of catalytic activity and may provide a paradigm for the regulation of the RPTP family, We have determined the crystal structure, to 2.3 Angstrom resolution, of RPTP mu D1, which shares 46% sequence identity with that of RPTP alpha D1, Although the tertiary structures of RPTP alpha D1 and RPTP mu D1 are very similar, with a root mean square deviation between equivalent C alpha atoms of 1.1 Angstrom, the quaternary structures of these two proteins are different, Neither the catalytic site nor the N-terminal helix-turn-helix segment of RPTP mu D1 participates in protein-protein interactions, The catalytic site of RPTP mu D1 is unhindered and adopts an open conformation similar to that of the cytosolic PTP, PTP1B (Barford, D., Flint, A. J., and Tonks, N. K. (1994) Science 263, 1397-1404), We propose that dimerization-induced modulation of RPTP activity may not be a general feature of this family of enzymes.	UNIV OXFORD, MOL BIOPHYS LAB, OXFORD OX1 3QU, ENGLAND; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of Oxford; Cold Spring Harbor Laboratory			Hoffmann, Kurt/P-2539-2014	Hoffmann, Kurt/0000-0002-7991-423X	NIGMS NIH HHS [GM 55989] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055989] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; BRUNGER AT, 1992, XPLOR VERSION 3 1; Cheng J, 1997, J BIOL CHEM, V272, P7264, DOI 10.1074/jbc.272.11.7264; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; SAP J, 1994, MOL CELL BIOL, V14, P1; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0	22	100	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27505	27508		10.1074/jbc.272.44.27505	http://dx.doi.org/10.1074/jbc.272.44.27505			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346878	hybrid			2022-12-25	WOS:A1997YD47300004
J	Pal, S; Claffey, KP; Dvorak, HF; Mukhopadhyay, D				Pal, S; Claffey, KP; Dvorak, HF; Mukhopadhyay, D			The von Hippel-Lindau gene product inhibits vascular permeability factor vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; GERMLINE MUTATIONS; RAS ONCOGENES; ANGIOGENESIS; ACTIVATION; IDENTIFICATION; RECEPTORS; INDUCTION; MITOGEN; PHENOTYPE	Mutation or loss of function of the von Hippel-Lindau (VHL) tumor suppressor gene is regularly found in sporadic renal cell carcinomas (RCC), well vascularized malignant tumors that characteristically overexpress vascular permeability factor/vascular endothelial growth factor (VPF/VEGF). The wild-type VHL (wt VHL) gene product acts to suppress VPF/VEGF expression, which is overexpressed when wt-VHL is inactive. The present study investigated the pathways by which VHL regulates VPF/VEGF expression, We found that inhibition of protein kinase C (PKC) represses VPF/VEGF expression in RCC cells that regularly overexpress VPF/VEGF. The wt-VHL expressed by stably transfected RCC cells forms cytoplasmic complexes with two specific PKC isoforms, xi and delta, and prevents their translocation to the cell membrane where they otherwise would engage in signaling steps that lead to VPF/VEGF overexpression. Other experiments implicated mitogen-activated protein kinase (MAPK) phosphorylation as a downstream step in PKC regulation of VPF/VEGF expression. Taken together, these data demonstrate that wt-VHL, by neutralizing PKC isoforms xi and delta and thereby inhibiting MAPK activation, plays an important role in preventing aberrant VPF/VEGF overexpression and the angiogenesis that results from such overexpression.	BETH ISRAEL DEACONESS MED CTR,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R29CA064436, R01CA064436, R01CA050453] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054465] Funding Source: NIH RePORTER; NCI NIH HHS [CA50453, CA64436] Funding Source: Medline; NHLBI NIH HHS [HL54465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARENZANASEISDED.F, 1989, ONCOGENE, V2, P1359; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BROWN LF, 1993, AM J PATHOL, V143, P1255; CHEN F, 1995, CANCER RES, V55, P4804; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSSEY PA, 1994, HUM GENET, V93, P53; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; FUJITA J, 1988, CANCER RES, V48, P5251; GNARRA JR, 1993, UROL CLIN N AM, V20, P207; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1997, KIDNEY INT, V51, P575, DOI 10.1038/ki.1997.82; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; OKA H, 1995, CANCER RES, V55, P4182; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RAK J, 1995, CANCER RES, V55, P4575; RICHARDS FM, 1995, HUM MOL GENET, V4, P2139, DOI 10.1093/hmg/4.11.2139; RICHARDS FM, 1993, HUM MOL GENET, V2, P879, DOI 10.1093/hmg/2.7.879; RICHARDS FM, 1993, J MED GENET, V30, P104, DOI 10.1136/jmg.30.2.104; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TAKAHASHI A, 1994, CANCER RES, V54, P4233; UCHIDA T, 1994, CANCER RES, V54, P3682; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Watts SW, 1996, J PHARMACOL EXP THER, V279, P1541; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358	38	132	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27509	27512		10.1074/jbc.272.44.27509	http://dx.doi.org/10.1074/jbc.272.44.27509			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346879	hybrid			2022-12-25	WOS:A1997YD47300005
J	Fruen, BR; Mickelson, JR; Louis, CF				Fruen, BR; Mickelson, JR; Louis, CF			Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIGNANT-HYPERTHERMIA; CALCIUM-RELEASE; CHANNEL; SODIUM; CALMODULIN; ACTIVATION; AZUMOLENE; CAFFEINE; IDENTIFICATION; DEPOLARIZATION	The skeletal muscle relaxant dantrolene inhibits the release of Ca2+ from the sarcoplasmic reticulum during excitation contraction coupling and suppresses the un controlled Ca2+ release that underlies the skeletal muscle pharmacogenetic disorder malignant hyperthermia; however, the molecular mechanism by which dantrolene selectively affects skeletal muscle Ca2+ regulation remains to be defined, Here we provide evidence of a high-affinity, monophasic inhibition by dantrolene of ryanodine receptor Ca2+ channel function in isolated sarcoplasmic reticulum vesicles prepared from malignant hyperthermia-susceptible and normal pig skeletal muscle. In media simulating resting myoplasm, dantrolene increased the half-time for Ca-45(2+) release from both malignant hyperthermia and normal vesicles approximately 3.5-fold and inhibited sarcoplasmic reticulum vesicle [H-3]ryanodine binding (K-i similar to 150 nM for both malignant hyperthermia and normal). Inhibition of vesicle [H-3]ryanodine binding by dantrolene was associated with a decrease in the extent of activation by both calmodulin and Ca2+, Dantrolene also inhibited [H-3]ryanodine binding to purified skeletal muscle ryanodine receptor protein reconstituted into liposomes, In contrast, cardiac sarcoplasmic reticulum vesicle Ca-45(2+) release and [H-3]ryanodine binding were unaffected by dantrolene. Together, these results demonstrate selective effects of dantrolene on skeletal muscle ryanodine receptors that are consistent with the actions of dantrolene in vivo and suggest a mechanism of action in which dantrolene may act directly at the skeletal muscle ryanodine receptor complex to limit its activation by calmodulin and Ca2+, The potential implications of these results for understanding how dantrolene and malignant hyperthermia mutations may affect the voltage-dependent activation of Ca2+ release in intact skeletal muscle are discussed.	UNIV MINNESOTA,DEPT VET PATHOBIOL,ST PAUL,MN 55108; UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Mickelson, James/0000-0001-6951-0234	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031382] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31382] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PD, 1992, ANESTHESIOLOGY, V76, P132, DOI 10.1097/00000542-199201000-00019; ANDERSON K, 1995, J GEN PHYSIOL, V105, P363, DOI 10.1085/jgp.105.3.363; BULL R, 1994, AM J PHYSIOL, V266, pC391, DOI 10.1152/ajpcell.1994.266.2.C391; DANKO S, 1985, BIOCHIM BIOPHYS ACTA, V816, P18, DOI 10.1016/0005-2736(85)90388-8; DHILLON DS, 1992, DRUG DEVELOP RES, V25, P161, DOI 10.1002/ddr.430250208; Dietze B., 1997, Biophysical Journal, V72, pA273; ELHAYEK R, 1992, BIOCHEM BIOPH RES CO, V187, P894, DOI 10.1016/0006-291X(92)91281-T; ELHAYEK R, 1995, AM J PHYSIOL-CELL PH, V268, pC1381, DOI 10.1152/ajpcell.1995.268.6.C1381; FILL M, 1990, BIOPHYS J, V50, P471; FLEWELLEN EH, 1983, ANESTHESIOLOGY, V59, P275, DOI 10.1097/00000542-198310000-00002; FRANDSEN A, 1992, P NATL ACAD SCI USA, V89, P2590, DOI 10.1073/pnas.89.7.2590; Fratea S, 1997, ANESTHESIOLOGY, V86, P205, DOI 10.1097/00000542-199701000-00025; Fruen BR, 1996, BIOPHYS J, V71, P2522, DOI 10.1016/S0006-3495(96)79445-6; FRUEN BR, 1994, J BIOL CHEM, V269, P192; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GALLANT EM, 1995, J CELL PHYSIOL, V165, P254, DOI 10.1002/jcp.1041650206; GALLANT EM, 1982, NEUROSCI LETT, V28, P181, DOI 10.1016/0304-3940(82)90149-5; HAINAUT K, 1974, NATURE, V252, P728, DOI 10.1038/252728a0; Jong DS, 1997, J PHYSIOL-LONDON, V499, P787, DOI 10.1113/jphysiol.1997.sp021969; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LOUIS CF, 1992, ANESTHESIOLOGY, V77, P114, DOI 10.1097/00000542-199207000-00017; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Mickelson JR, 1996, PHYSIOL REV, V76, P537, DOI 10.1152/physrev.1996.76.2.537; MODY I, 1995, TRENDS PHARMACOL SCI, V16, P356, DOI 10.1016/S0165-6147(00)89070-7; MORGAN KG, 1977, J PHARMACOL EXP THER, V201, P138; Nelson TE, 1996, ANESTHESIOLOGY, V84, P1368, DOI 10.1097/00000542-199606000-00013; ODriscoll S, 1996, BIOCHEM J, V319, P421, DOI 10.1042/bj3190421; OHTA T, 1989, AM J PHYSIOL, V256, pC358, DOI 10.1152/ajpcell.1989.256.2.C358; OHTA T, 1990, EUR J PHARMACOL, V178, P11; Palnitkar SS, 1997, BIOCHEM J, V326, P847, DOI 10.1042/bj3260847; PARNESS J, 1995, J BIOL CHEM, V270, P18465, DOI 10.1074/jbc.270.31.18465; Pessah IN, 1996, ANESTHESIOLOGY, V84, P1275, DOI 10.1097/00000542-199606000-00001; PUTNEY JW, 1974, J PHARMACOL EXP THER, V189, P202; Richter M, 1997, J BIOL CHEM, V272, P5256, DOI 10.1074/jbc.272.8.5256; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SHOMER NH, 1993, AM J PHYSIOL, V264, pC125, DOI 10.1152/ajpcell.1993.264.1.C125; SNYDER HR, 1967, J MED CHEM, V10, P807, DOI 10.1021/jm00317a011; SUDA N, 1994, P NATL ACAD SCI USA, V91, P5725, DOI 10.1073/pnas.91.12.5725; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TIAN Q, 1991, BIOCHIM BIOPHYS ACTA, V1094, P27; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; VANWINKLE WB, 1976, SCIENCE, V193, P1130, DOI 10.1126/science.959824; WARD A, 1986, DRUGS, V32, P130, DOI 10.2165/00003495-198632020-00003; Zucchi R, 1997, PHARMACOL REV, V49, P1	45	155	157	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26965	26971		10.1074/jbc.272.43.26965	http://dx.doi.org/10.1074/jbc.272.43.26965			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341133	hybrid			2022-12-25	WOS:A1997YC65900029
J	Takagi, Y; Pause, A; Conaway, RC; Conaway, JW				Takagi, Y; Pause, A; Conaway, RC; Conaway, JW			Identification of Elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR-SIII; ELONGATION; ACTIVATION; COMPLEX	Elongin C is a 112-amino acid protein that is found in mammalian cells as a positive regulatory subunit of heterotrimeric RNA polymerase ll elongation factor Elongin (Sill) and as a component of a multiprotein complex containing the von Hippel-Lindau (VHL) tumor suppressor protein, As a subunit of the Elongin complex, Elongin C interacts directly with the transcriptionally active Elongin A subunit and potently induces its elongation activity; in addition, Elongin C interacts with the ubiquitin-like Elongin B subunit, which regulates the interaction of Elongin C with Elongin A, As a component of the VHL complex, Elongin C interacts directly with both Elongin B and the VHL, protein. Binding of the VHL protein to Elongin C was found to prevent Elongin C from interacting with and activating. Elongin A in vitro, leading to the proposal that one function of the VHL protein may be to regulate RNA polymerase II elongation by negatively regulating the Elongin complex. In this report, we identify Elongin C sequences required for its interaction with the VHL protein, We previously demonstrated that the ability of Elongin C to hind and activate Elongin A is sensitive to mutations in the C-terminal half of Elongin C, as well as to mutations in an N-terminal Elongin C region needed for formation of the Elongin BC complex. Here we show that interaction of Elongin C with the VHL tumor suppressor protein depends strongly on sequences in the C terminus of Elongin C but is independent of the N-terminal Elongin C region required for binding to Elongin B and for binding and activation of Elongin A. Taken together, our results are consistent with the proposal that the VHL protein negatively regulates Elongin C activation of the Elongin complex by sterically blocking the interaction of C-terminal Elongin C sequences with Elongin A. In addition, our finding that only a subset of Elongin C sequences required for its interaction with Elongin A are critical for binding to VHL may offer the opportunity to develop reagents that selectively interfere with Elongin and VHL function.	OKLAHOMA MED RES FDN,PROGRAM MOL & CELL BIOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,OKLAHOMA CITY,OK 73190; NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD 20892	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Pause A, 1996, METHOD ENZYMOL, V274, P436; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Takagi Y, 1996, J BIOL CHEM, V271, P25562, DOI 10.1074/jbc.271.41.25562; TAN SY, 1994, BIOTECHNIQUES, V16, P824	17	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27444	27449		10.1074/jbc.272.43.27444	http://dx.doi.org/10.1074/jbc.272.43.27444			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341197	hybrid			2022-12-25	WOS:A1997YC65900093
J	Comte, B; Vincent, G; Bouchard, B; Jette, M; Cordeau, S; DesRosiers, C				Comte, B; Vincent, G; Bouchard, B; Jette, M; Cordeau, S; DesRosiers, C			A C-13 mass isotopomer study of anaplerotic pyruvate carboxylation in perfused rat hearts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ACETYL-COA CARBOXYLASE; SUBSTRATE SELECTION; NMR-SPECTROSCOPY; CYCLE METABOLITES; GLUCOSE-OXIDATION; GLOBAL-ISCHEMIA; MALIC ENZYMES; WORKING HEART; CARBON FLUX	Anaplerotic pyruvate carboxylation was examined in hearts perfused with physiological concentrations of glucose, [U-C-13(3)]lactate, and [U-C-13(3)]pyruvate. Also, a fatty acid, [1-C-13]octanoate, or ketone bodies were added at concentrations providing acetyl-CoA at a rate resulting in either low or substantial pyruvate decarboxylation. Relative contributions of pyruvate and fatty acids to citrate synthesis were determined from the C-13 labeling pattern of effluent citrate by gas chromatography-mass spectrometry (see companion article, Comte, B., Vincent, G., Bouchard, B., and Des Rosiers, C. (1997) J. Biol. Chem, 272, 26117-26124). Precision on flux measurements of anaplerotic pyruvate carboxylation depended on the mix of substrates supplied to the heart. Anaplerotic fluxes were precisely determined under conditions where acetyl-CoA was predominantly supplied by beta-oxidation, as it occurred with 0.2 or 1 mM octanoate, Then, anaplerotic pyruvate carboxylation provided 3-8% of the OAA moiety of citrate and was modulated by concentrations of lactate and pyruvate in the physiological range, Also, the contribution of pyruvate to citrate formation through carboxylation was equal to or greater than through decarboxylation. Furthermore, C-13 labeling data on tissue citric acid cycle intermediates and pyruvate suggest that (i) anaplerosis occurs also at succinate and (ii) cataplerotic malate decarboxylation is low, Rather, the presence of citrate in the effluent perfusate of hearts perfused with physiological concentrations of glucose, lactate, and pyruvate and concentrations of octanoate leading to maximal oxidative rates suggests a cataplerotic citrate efflux from mitochondria to cytosol. Taken altogether, our data raise the possibility of a link between pyruvate carboxylation and mitochondrial citrate efflux. In view of the proposed feedback regulation of glycolysis by cytosolic citrate, such a link would support a role of anaplerosis and cataplerosis in metabolic signal transmission between mitochondria and cytosol in the normoxic heart.	UNIV MONTREAL, DEPT NUTR, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, DEPT BIOCHEM, MONTREAL, PQ H3C 3J7, CANADA	Universite de Montreal; Universite de Montreal			Rosiers, Christine Des/O-6285-2014					ATTWOOD PV, 1995, INT J BIOCHEM CELL B, V27, P231, DOI 10.1016/1357-2725(94)00087-R; BARRON JT, 1994, AM J PHYSIOL, V267, pH764, DOI 10.1152/ajpheart.1994.267.2.H764; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, P1836; BRUNET J, 1995, FREE RADICAL BIO MED, V19, P627, DOI 10.1016/0891-5849(95)00077-B; BUNGER R, 1989, EUR J BIOCHEM, V180, P221, DOI 10.1111/j.1432-1033.1989.tb14637.x; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; CHATHAM JC, 1995, J BIOL CHEM, V270, P7999, DOI 10.1074/jbc.270.14.7999; CLARK AS, 1987, J CLIN INVEST, V79, P588, DOI 10.1172/JCI112851; COHEN DM, 1995, AM J PHYSIOL-ENDOC M, V268, pE397, DOI 10.1152/ajpendo.1995.268.3.E397; Comte B, 1997, J BIOL CHEM, V272, P26117, DOI 10.1074/jbc.272.42.26117; COMTE B, 1995, CIRCULATION, V92, P3703; COMTE B, 1997, FASEB J, V11, P268; DESROSIERS C, 1990, AM J PHYSIOL, V258, pE519, DOI 10.1152/ajpendo.1990.258.3.E519; FINK G, 1988, J BIOL CHEM, V263, P18036; FORSEY RGP, 1987, CAN J PHYSIOL PHARM, V65, P401, DOI 10.1139/y87-067; GAMBLE J, 1994, BBA-MOL BASIS DIS, V1225, P191, DOI 10.1016/0925-4439(94)90078-7; GARLAND PB, 1963, NATURE, V200, P169, DOI 10.1038/200169a0; GAVVA SR, 1994, BIOCHEM J, V303, P847, DOI 10.1042/bj3030847; GOODWIN GW, 1994, AM J PHYSIOL, V267, pH462, DOI 10.1152/ajpheart.1994.267.2.H462; HILTUNEN JK, 1977, INT J BIOCHEM, V8, P505, DOI 10.1016/0020-711X(77)90112-4; ICHIHARA K, 1980, AM J PHYSIOL, V239, pE430, DOI 10.1152/ajpendo.1980.239.6.E430; Jeffrey FMH, 1996, AM J PHYSIOL-ENDOC M, V271, pE788, DOI 10.1152/ajpendo.1996.271.4.E788; JEFFREY FMH, 1995, BASIC RES CARDIOL, V90, P388, DOI 10.1007/BF00788500; JESSEN ME, 1993, J CLIN INVEST, V92, P831, DOI 10.1172/JCI116657; LANCHA AH, 1994, BIOCHEM MOL BIOL INT, V32, P483; LANOUE K, 1970, J BIOL CHEM, V245, P102; Laplante A, 1997, AM J PHYSIOL-ENDOC M, V272, pE74, DOI 10.1152/ajpendo.1997.272.1.E74; LAPLANTE A, 1995, ANAL BIOCHEM, V224, P580, DOI 10.1006/abio.1995.1090; LATIPAA PM, 1983, BIOCHIM BIOPHYS ACTA, V752, P162, DOI 10.1016/0005-2760(83)90244-8; LERCH R, 1993, BASIC RES CARDIOL, V88, P525, DOI 10.1007/BF00788872; LEWANDOWSKI ED, 1995, CIRCULATION, V91, P2071, DOI 10.1161/01.CIR.91.7.2071; LEWANDOWSKI ED, 1992, BIOCHEMISTRY-US, V31, P8916, DOI 10.1021/bi00152a031; LIN RC, 1974, J BIOL CHEM, V249, P3867; LOPASCHUK GD, 1990, CIRC RES, V66, P546, DOI 10.1161/01.RES.66.2.546; LOPASCHUK GD, 1994, CAN J PHYSIOL PHARM, V72, P1101, DOI 10.1139/y94-156; MALLET RT, 1990, EUR J BIOCHEM, V188, P481, DOI 10.1111/j.1432-1033.1990.tb15426.x; MALLOY CR, 1987, FEBS LETT, V212, P58, DOI 10.1016/0014-5793(87)81556-9; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MARKOVITZ LJ, 1985, J SURG RES, V38, P231, DOI 10.1016/0022-4804(85)90031-9; MCVEIGH JJ, 1990, AM J PHYSIOL, V259, pH1079, DOI 10.1152/ajpheart.1990.259.4.H1079; MONTGOMERY JA, 1993, BIOCHEM J, V294, P727, DOI 10.1042/bj2940727; NUUTINEN EM, 1981, BIOCHEM J, V194, P867, DOI 10.1042/bj1940867; PEUHKURINEN KJ, 1984, J MOL CELL CARDIOL, V16, P487, DOI 10.1016/S0022-2828(84)80637-9; PEUHKURINEN KJ, 1982, BIOCHEM J, V202, P67, DOI 10.1042/bj2020067; PEUHKURINEN KJ, 1982, BIOCHEM J, V208, P577, DOI 10.1042/bj2080577; PEUHKURINEN KJ, 1983, AM J PHYSIOL, V244, pH281, DOI 10.1152/ajpheart.1983.244.2.H281; PISARENKO O, 1988, BIOCHIM BIOPHYS ACTA, V934, P55, DOI 10.1016/0005-2728(88)90119-3; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Reed L J, 1981, Curr Top Cell Regul, V18, P95; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; ROSIERS CD, 1988, ANAL BIOCHEM, V173, P96, DOI 10.1016/0003-2697(88)90165-0; RUSSELL RR, 1991, AM J PHYSIOL, V261, pH1756, DOI 10.1152/ajpheart.1991.261.6.H1756; SADDIK M, 1993, J BIOL CHEM, V268, P25836; Saha AK, 1997, AM J PHYSIOL-ENDOC M, V272, pE641, DOI 10.1152/ajpendo.1997.272.4.E641; SCHULZ H, 1994, J NUTR, V124, P165, DOI 10.1093/jn/124.2.165; SLUSE FE, 1971, FEBS LETT, V18, P149, DOI 10.1016/0014-5793(71)80432-5; STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6; SUNDQVIST KE, 1987, BIOCHEM J, V243, P853, DOI 10.1042/bj2430853; SUNDQVIST KE, 1989, BIOCHEM J, V257, P913, DOI 10.1042/bj2570913; SUNDQVIST KE, 1994, EUR HEART J, V15, P561, DOI 10.1093/oxfordjournals.eurheartj.a060543; TAEGTMEYER H, 1978, CIRC RES, V43, P808, DOI 10.1161/01.RES.43.5.808; TAKALA T, 1980, BIOCHEM J, V192, P285, DOI 10.1042/bj1920285; Utter MF, 1969, CURR TOP CELL REGUL, V1, P253, DOI [10.1016/B978-0-12-152801-0.50015-8, DOI 10.1016/B978-0-12-152801-0.50015-8]; VINCENT G, 1997, FASEB J, V11, P269; WEISS RG, 1989, P NATL ACAD SCI USA, V86, P6426, DOI 10.1073/pnas.86.16.6426; WEISS RG, 1993, CIRCULATION, V87, P270, DOI 10.1161/01.CIR.87.1.270; WIESNER RJ, 1988, BIOCHEM MED METAB B, V40, P19, DOI 10.1016/0885-4505(88)90100-4	67	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26125	26131		10.1074/jbc.272.42.26125	http://dx.doi.org/10.1074/jbc.272.42.26125			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334177	hybrid			2022-12-25	WOS:A1997YB13900011
J	ElSayed, NMA; Donelson, JE				ElSayed, NMA; Donelson, JE			African trypanosomes have differentially expressed genes encoding homologues of the Leishmania GP63 surface protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-I; PROTEINASE GP63; HERPETOMONAS-SAMUELPESSOAI; CUTANEOUS LEISHMANIASIS; DONOVANI PROMASTIGOTES; CRITHIDIA-FASCICULATA; CHAGASI PROMASTIGOTES; ANTIGENIC VARIATION; POINT MUTATIONS; CODING GENES	The genomes of various Leishmania parasites contain tandemly arrayed genes encoding an abundant; 63-kDa surface glycoprotein called GP63. Leishmania GP63s are metalloproteases that play an important role in the invasion and survival of the parasites within the macro phage, and their presence on the Leishmania surface has been correlated with resistance to complement;mediated lysis, Here we report the identification of GP63-like genes in African trypanosomes. The predicted trypanosome and Leishmania GP63s share a metalloprotease catalytic site motif of HEXXH as well as 19 cysteines and 10 prolines, implying a conservation of enzymatic activity and secondary/tertiary structure. The trypanosome GP63 genes are. transcribed equally in procyclic and bloodstream trypanosomes, but their mRNAs accumulate to a 50-fold higher steady state level in bloodstream trypanosomes, where the ratio of mRNAs for GP63 and variant surface glycoprotein is about 1:150. Transcription of the GP63 genes is sensitive to alpha-amanitin, indicating that they are transcribed by a different polymerase than the variant, surface glycoprotein genes, These results lead to a reconsideration of the potential functions of GP63, inasmuch as African trypanosomes are not known to interact with macrophages and do not have an intracellular stage during their life cycle.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa			Donelson, John E/F-5795-2010; El-Sayed, Najib M.A./K-7266-2015	El-Sayed, Najib M.A./0000-0001-7970-3312	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032135, R21AI032135] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32135] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOLARIN MO, 1986, T ROY SOC TROP MED H, V80, P618, DOI 10.1016/0035-9203(86)90160-4; ABOLARIN MO, 1982, BRIT MED J, V285, P1380, DOI 10.1136/bmj.285.6352.1380; ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BERBEROF M, 1995, EMBO J, V14, P2925, DOI 10.1002/j.1460-2075.1995.tb07292.x; BORDIER C, 1987, PARASITOL TODAY, V3, P151, DOI 10.1016/0169-4758(87)90199-2; BORST P, 1994, SCIENCE, V264, P1872, DOI 10.1126/science.7516579; BOUVIER J, 1990, BIOCHEMISTRY-US, V29, P10113, DOI 10.1021/bi00495a015; BOUVIER J, 1995, METHOD ENZYMOL, V248, P614; BRITTINGHAM A, 1995, J IMMUNOL, V155, P3102; CARVALHO E. B., 1977, Revista Goiana de Medicina, V23, P41; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; CHAUDHURI G, 1989, J BIOL CHEM, V264, P7483; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON CE, 1992, PROGR NUCLEIC ACID R, P37; CONNELL ND, 1993, P NATL ACAD SCI USA, V90, P11473, DOI 10.1073/pnas.90.24.11473; COQUELET H, 1989, MOL CELL BIOL, V9, P4022, DOI 10.1128/MCB.9.9.4022; COQUELET H, 1991, MOL BIOCHEM PARASIT, V44, P33, DOI 10.1016/0166-6851(91)90218-U; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P93; DEVINE DV, 1986, INFECT IMMUN, V52, P223, DOI 10.1128/IAI.52.1.223-229.1986; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; ElSayed NMA, 1997, MOL BIOCHEM PARASIT, V84, P167, DOI 10.1016/S0166-6851(96)02792-2; EMINI EA, 1983, NATURE, V304, P699, DOI 10.1038/304699a0; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; ETGES R, 1986, EMBO J, V5, P597, DOI 10.1002/j.1460-2075.1986.tb04252.x; ETGES R, 1992, ACTA TROP, V50, P205, DOI 10.1016/0001-706X(92)90077-B; FERNANDES AP, 1993, P NATL ACAD SCI USA, V90, P11608, DOI 10.1073/pnas.90.24.11608; FONG D, 1982, P NATL ACAD SCI-BIOL, V79, P7366, DOI 10.1073/pnas.79.23.7366; GHEORGHIU M, 1995, MICROBIOLOGY, V141, P1585; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; INVERSO JA, 1993, MOL BIOCHEM PARASIT, V57, P47, DOI 10.1016/0166-6851(93)90242-P; LANDWEBER LF, 1994, P NATL ACAD SCI USA, V91, P918, DOI 10.1073/pnas.91.3.918; LEPAY DA, 1983, J EXP MED, V157, P1562, DOI 10.1084/jem.157.5.1562; LIU X, 1992, P NATL ACAD SCI USA, V89, P4991, DOI 10.1073/pnas.89.11.4991; LU Y, 1994, MOL CELL BIOL, V14, P3971, DOI 10.1128/MCB.14.6.3971; LU Y, 1993, CELL, V72, P397, DOI 10.1016/0092-8674(93)90116-8; MCGWIRE B, 1994, MOL BIOCHEM PARASIT, V66, P345, DOI 10.1016/0166-6851(94)90160-0; McGwire BS, 1996, J BIOL CHEM, V271, P7903, DOI 10.1074/jbc.271.14.7903; MEDINAACOSTA E, 1993, INFECT AGENT DIS, V2, P25; Morgan RW, 1996, J BIOL CHEM, V271, P9771, DOI 10.1074/jbc.271.16.9771; MOSSER DM, 1982, EXP PARASITOL, V54, P310, DOI 10.1016/0014-4894(82)90040-6; OLOBO JO, 1995, VET PARASITOL, V60, P199, DOI 10.1016/0304-4017(95)00788-6; ORMEROD WE, 1986, T ROY SOC TROP MED H, V80, P626, DOI 10.1016/0035-9203(86)90161-6; PAYS E, 1990, EMBO J, V9, P3145, DOI 10.1002/j.1460-2075.1990.tb07512.x; PEARSON RD, 1983, REV INFECT DIS, V5, P907; PUENTES SM, 1989, J IMMUNOL, V143, P3743; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; ROBERTS SC, 1993, MOL BIOCHEM PARASIT, V62, P157, DOI 10.1016/0166-6851(93)90106-8; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; RUDENKO G, 1989, EMBO J, V8, P4259, DOI 10.1002/j.1460-2075.1989.tb08611.x; SALLES JM, 1996, MEM I OSWALDO CRUZ S, V91, P269; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER P, 1993, MOL BIOCHEM PARASIT, V58, P277, DOI 10.1016/0166-6851(93)90049-4; SOTERIADOU KP, 1992, J BIOL CHEM, V267, P13980; STEINKRAUS HB, 1993, MOL BIOCHEM PARASIT, V62, P173, DOI 10.1016/0166-6851(93)90107-9; SZARFMAN A, 1981, AM J TROP MED HYG, V30, P43, DOI 10.4269/ajtmh.1981.30.43; TURNER MJ, 1985, BRIT MED BULL, V41, P137, DOI 10.1093/oxfordjournals.bmb.a072040; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VICKERMAN K, 1988, BIOL CELL, V64, P109, DOI 10.1016/0248-4900(88)90070-6; WALLACE FG, 1966, EXP PARASITOL, V18, P124, DOI 10.1016/0014-4894(66)90015-4; WEIDER MK, 1989, PARASITE IMMUNOL, V11, P197; XU D, 1995, IMMUNOLOGY, V85, P1; YANG DM, 1990, J IMMUNOL, V145, P2281; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0	68	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26742	26748		10.1074/jbc.272.42.26742	http://dx.doi.org/10.1074/jbc.272.42.26742			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334260	hybrid			2022-12-25	WOS:A1997YB13900094
J	Huang, XD; Atwood, CS; Moir, RD; Hartshorn, MA; Vonsattel, JP; Tanzi, RE; Bush, AI				Huang, XD; Atwood, CS; Moir, RD; Hartshorn, MA; Vonsattel, JP; Tanzi, RE; Bush, AI			Zinc-induced Alzheimer's A beta 1-40 aggregation is mediated by conformational factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-AMYLOID PEPTIDES; PROTEIN-PRECURSOR; CORTICAL-NEURONS; DISEASE BRAINS; NEUROTOXICITY; DEPOSITION; PATHOGENESIS; FRAGMENTS; PLATELETS; CLEAVAGE	The heterogeneous precipitates of A beta that accumulate in the brain cortex in Alzheimer's disease possess varying degrees of resistance to resolubilization. We previously found that A beta 1-40 is rapidly precipitated in vitro by physiological concentrations of zinc, a neurochemical that is highly abundant in brain compartments where A beta is most likely to precipitate. We now present evidence that the zinc-induced precipitation of A beta is mediated by a peptide dimer and favored by conditions that promote alpha-helical and diminish beta-sheet conformations. The manner in which the synthetic peptide is solubilized was critical to its behavior in vitro. Zinc-induced A beta aggregation was dependent upon the presence of NaCl, was enhanced when the peptide stock solution was stored frozen. The A beta aggregates induced by zinc were reversible by chelation, but could then be reprecipitated by zinc for several cycles, indicating that the peptide's conformation is probably preserved in the zinc-mediated assembly. In contrast, A beta aggregates induced by low pH (5.5) were not resolubilized by returning the pH milieu to 7.4. The zinc-A beta interaction exhibits features resembling the gelation process of zinc-mediated fibrin assembly, suggesting that, in events such as clot formation or injury, reversible A beta assembly could be physiologically purposive. Such a mechanism is contemplated in the early evolution of diffuse plaques in Alzheimer's disease and suggests a possible therapeutic strategy for the resolubilization of some forms of A beta deposit in the disease.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT PSYCHIAT, BOSTON, MA 02114 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL, GENET & AGING UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital			Bush, Ashley/Y-2457-2019; Moir, Robert D./M-7612-2017; , Craig/AAB-3963-2022; Tanzi, Rudolph/AAE-9622-2019; Bush, Ashley I/A-1186-2007	Bush, Ashley/0000-0001-8259-9069; Moir, Robert D./0000-0001-5431-3553; Tanzi, Rudolph/0000-0002-7032-1454; Bush, Ashley I/0000-0001-8259-9069	NIA NIH HHS [1R29AG126801] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1992, NEUROBIOL AGING, V13, P609, DOI 10.1016/0197-4580(92)90065-6; BUSH AI, 1995, SCIENCE, V268, P1921, DOI 10.1126/science.268.5219.1921; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; BUSH AI, 1990, J BIOL CHEM, V265, P15977; BUSH AI, 1994, J BIOL CHEM, V269, P26618; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CHEN M, 1995, BIOCHEM BIOPH RES CO, V213, P96, DOI 10.1006/bbrc.1995.2103; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 1996, J NEUROCHEM, V66, P723; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; Kuo YM, 1996, J BIOL CHEM, V271, P4077; MACKENZIE I, 1993, J NEUROPATH EXP NEUR, V52, P335, DOI 10.1097/00005072-199305000-00300; MARX G, 1987, THROMB HAEMOSTASIS, V57, P73; MARX G, 1993, J CELL PHYSIOL, V156, P437, DOI 10.1002/jcp.1041560302; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; OTVOS L, 1993, EUR J BIOCHEM, V211, P249, DOI 10.1111/j.1432-1033.1993.tb19893.x; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1991, EUR J PHARM-MOLEC PH, V207, P367, DOI 10.1016/0922-4106(91)90014-9; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROHER AE, 1991, BIOCHEM BIOPH RES CO, V174, P572, DOI 10.1016/0006-291X(91)91455-L; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHEN CL, 1994, BIOPHYS J, V67, P1238, DOI 10.1016/S0006-3495(94)80593-4; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SHEN CL, 1993, BIOPHYS J, V65, P2383, DOI 10.1016/S0006-3495(93)81312-2; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; THOLEY G, 1988, NEUROCHEM RES, V13, P45, DOI 10.1007/BF00971853; VANNOSTRAND WE, 1995, THROMB RES, V78, P43, DOI 10.1016/0049-3848(95)00033-X; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	52	302	311	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26464	26470		10.1074/jbc.272.42.26464	http://dx.doi.org/10.1074/jbc.272.42.26464			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334223	hybrid			2022-12-25	WOS:A1997YB13900057
J	Ribeiro, CMP; Reece, J; Putney, JW				Ribeiro, CMP; Reece, J; Putney, JW			Role of the cytoskeleton in calcium signaling in NIH 3T3 cells - An intact cytoskeleton is required for agonist-induced [Ca2+](i) signaling, but not for capacitative calcium entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL CA2+ RELEASE; PAROTID ACINAR-CELLS; ENDOPLASMIC-RETICULUM; INOSITOL 1,4,5-TRISPHOSPHATE; PLASMA-MEMBRANE; ACTIN-FILAMENTS; RECEPTOR; ANKYRIN; INFLUX; REORGANIZATION	Treatment of NIH 3T3 cells with cytochalasin D (10 mu M, 1 h at 37 degrees C) disrupted the actin cytoskeleton and changed the cells from a planar, extended morphology, to a rounded shape, Calcium mobilization by ATP or by platelet-derived growth factor was abolished, while the ability of thapsigargin (2 mu M) to empty calcium stores and activate calcium influx was unaffected, Similar experiments with nocodazole to depolymerize the tubulin network yielded identical results, Platelet-derived growth factor induced an increase in inositol phosphates, and this increase was undiminished in the presence of cytochalasin D, Therefore, the blockade of agonist responses by this drug does not result from decreased phospholipase C, Injection of inositol 1,4,5-trisphosphate (IP3) released calcium to the same extent in control and cytochalasin D-treated cells. Confocal microscopic studies revealed a significant rearrangement of the endoplasmic reticulum after cytochalasin D treatment, Thus, disruption of the cytoskeleton blocks agonist-elicited [Ca2+](i) mobilization, but this effect does not result from a lower calcium storage capacity, impaired function of the IP3 receptor, or diminished phospholipase C activity, We suggest that cytoskeletal disruption alters the spatial relationship between phospholipase C and IP3 receptors, impairing phospholipase C-dependent calcium signaling, Capacitative calcium entry was not altered under these conditions, indicating that the coupling between depletion of intracellular calcium stores and calcium entry does not depend on a precise structural relationship between intracellular stores and plasma membrane calcium channels.			Ribeiro, CMP (corresponding author), NIEHS, LAB SIGNAL TRANSDUCT, NIH, POB 12233, RES TRIANGLE PK, NC 27709 USA.		Putney, James W/F-7247-2019; Ribeiro, Carla Maria P/A-6955-2009	Putney, James W/0000-0002-3379-4789; 				ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BAUMANN O, 1994, CELL TISSUE RES, V278, P419; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; FJOSE A, 1984, CELL BIOCHEM FUNCT, V2, P38, DOI 10.1002/cbf.290020111; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEDBERG KK, 1991, CELL REGUL, V2, P1067, DOI 10.1091/mbc.2.12.1067; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; KACHAR B, 1988, J CELL BIOL, V106, P1545, DOI 10.1083/jcb.106.5.1545; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; Lobaugh LA, 1996, MOL PHARMACOL, V50, P493; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; Pettit EJ, 1996, BIOCHEM BIOPH RES CO, V229, P109, DOI 10.1006/bbrc.1996.1765; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; RIFKIN DB, 1979, CELL, V18, P361, DOI 10.1016/0092-8674(79)90055-2; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SCHLIWA M, 1984, J CELL BIOL, V99, P1045, DOI 10.1083/jcb.99.3.1045; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; SUGIYA H, 1987, BIOCHEM J, V244, P647, DOI 10.1042/bj2440647; TASAKA K, 1991, BIOCHEM PHARMACOL, V41, P1031; TERASAKI M, 1989, METHOD CELL BIOL, V29, P125; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0	36	138	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26555	26561		10.1074/jbc.272.42.26555	http://dx.doi.org/10.1074/jbc.272.42.26555			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334235	hybrid			2022-12-25	WOS:A1997YB13900069
J	Higashita, R; Li, LY; VanPutten, V; Yamamura, Y; Zarinetchi, F; Heasley, L; Nemenoff, RA				Higashita, R; Li, LY; VanPutten, V; Yamamura, Y; Zarinetchi, F; Heasley, L; Nemenoff, RA			G alpha(16) mimics vasoconstrictor action to induce smooth muscle alpha-actin in vascular smooth muscle cells through a Jun-NH2-terminal kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GTPASE-DEFICIENT G-ALPHA(16); SIGNAL-TRANSDUCTION PATHWAYS; MAP KINASE; ANGIOTENSIN-II; GROWTH-FACTOR; C-JUN; ARGININE VASOPRESSIN; PHORBOL ESTERS; DIFFERENTIATION	Prolonged exposure of vascular smooth muscle cells (VSMC) to vasoconstrictors such as vasopressin or angiotensin II induces hypertrophy and increases expression of muscle-specific genes including smooth muscle alpha-actin (SM-alpha-actin). These vasoconstrictors signal through G-proteins, including members of the Gq family. To further investigate the role of Gq family members, VSMC were transfected with a constitutively active mutant of a G(q) family member, G alpha(16) (G alpha(16)Q212L). Stable expression of G alpha(16)Q212L persistently stimulated phospholipase C, resulting in increased basal levels of inositol phosphates. These cells were hypertrophied and expressed elevated levels of SM-alpha-actin compared with wild-type VSMC or cells transfected with a control plasmid (Neo), SM-alpha-actin promoter activity was markedly increased in cells stably or transiently expressing G alpha(16)Q212L. Basal c-Jun-NH2-terminal kinase (JNK) activity was increased 3-9-fold in cells stably expressing G alpha(16)Q212L, while basal activity of the p42/44 mitogen-activated protein kinases (ERKs) was unaffected, Transient expression of a kinase inactive JNK kinase partially inhibited induction of SM-alpha-actin promoter activity in response to vasoconstrictors or expression of G alpha(16)Q212L. These results indicate that expression of constitutively active G alpha(16) in VSMC mimics the effects of vasoconstrictors on hypertrophy and muscle-specific gene expression, and activation of JNK may play a role in these responses.	UNIV COLORADO,HLTH SCI CTR,DIV RENAL DIS & HYPERTENS,DEPT MED,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Higashita, Ryuji/AAN-6273-2020		NHLBI NIH HHS [HL 09039] Funding Source: Medline; NIDDK NIH HHS [DK 39902, DK 19928] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928, R01DK039902] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CARAMELO C, 1988, BIOCHEM J, V254, P625, DOI 10.1042/bj2540625; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GEISTERFER AAT, 1989, HYPERTENSION, V14, P413, DOI 10.1161/01.HYP.14.4.413; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KARIYA K, 1987, ATHEROSCLEROSIS, V63, P251, DOI 10.1016/0021-9150(87)90128-6; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; KRIBBEN A, 1993, AM J PHYSIOL, V265, pC939, DOI 10.1152/ajpcell.1993.265.4.C939; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LI XM, 1994, J BIOL CHEM, V269, P19653; OWENS GK, 1995, PHYSIOL REV, V75, P487; QIAN NX, 1994, J BIOL CHEM, V269, P17417; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; THIBONNIER M, 1992, REGUL PEPTIDES, V38, P1, DOI 10.1016/0167-0115(92)90067-5; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; VANPUTTEN V, 1994, CIRC RES, V75, P1126, DOI 10.1161/01.RES.75.6.1126; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106	36	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25845	25850		10.1074/jbc.272.41.25845	http://dx.doi.org/10.1074/jbc.272.41.25845			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325315	hybrid			2022-12-25	WOS:A1997YA35800070
J	Keranen, LM; Newton, AC				Keranen, LM; Newton, AC			Ca2+ differentially regulates conventional protein kinase Cs' membrane interaction and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT ACTIVATION; C2 DOMAIN; DIACYLGLYCEROL; BINDING; PHOSPHATIDYLSERINE; PHOSPHOLIPIDS; COOPERATIVITY; SPECIFICITY; SUBSTRATE	The regulation of conventional protein kinase Cs by Ca2+ was examined by determining how this cation affects the enzyme's 1) membrane binding and catalytic function and 2) conformation. In the first part, we show that significantly lower concentrations of Ca2+ are required to effect half-maximal membrane binding than to half-maximally activate the enzyme, The disparity between binding and activation kinetics is most striking for protein kinase C beta II, where the concentration of Ca2+ promoting half-maximal membrane binding is approximately 40-fold higher than the apparent K-m for Ca2+ for activation, In addition, the Ca2+ requirement for activation of protein kinase C beta II is an order of magnitude greater than that for the alternatively spliced protein kinase C beta I; these isozymes differ only in 50 amino acids at the carboxyl terminus, revealing that residues in the carboxyl terminus influence the enzyme's Ca2+ regulation, In the second part, we use proteases as conformational probes to show that Ca2+-dependent membrane binding and Ca2+-dependent activation involve two distinct sets of structural changes in protein kinase C beta II. Three separate domains spanning the entire protein participate in these conformational changes, suggesting significant interdomain interactions, A highly localized hinge motion between the regulatory and catalytic halves of the protein accompanies membrane binding; release of the carboxyl terminus accompanies the low affinity membrane binding mediated by concentrations of Ca2+ too low to promote catalysis; and exposure of the amino-terminal pseudosubstrate and mashing of the carboxyl terminus accompany catalysis. In summary, these data reveal that structural determinants unique to each isozyme of protein kinase C dictate the enzyme's Ca2+-dependent affinity for acidic membranes and show that, surprisingly, some of these determinants are in the carboxyl terminus of the enzyme, distal from the Ca2+-binding site in the amino-terminal regulatory domain.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMADEO LS, 1993, RECEPTOR CHANNEL, V1, P1; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; JEAN T, 1986, J BIOL CHEM, V261, P6414; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; LUO JH, 1993, J BIOL CHEM, V268, P23580; MAURER MC, 1992, BIOCHEMISTRY-US, V31, P7714, DOI 10.1021/bi00148a036; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1994, J BIOL CHEM, V269, P13798; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5	32	74	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25959	25967		10.1074/jbc.272.41.25959	http://dx.doi.org/10.1074/jbc.272.41.25959			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325330	hybrid			2022-12-25	WOS:A1997YA35800085
J	Koshiba, M; Kojima, H; Huang, S; Apasov, S; Sitkovsky, MV				Koshiba, M; Kojima, H; Huang, S; Apasov, S; Sitkovsky, MV			Memory of extracellular adenosine A(2A) purinergic receptor-mediated signaling in murine T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DEAMINASE DEFICIENCY; EFFECTOR FUNCTIONS; LYMPHOCYTES-T; DNA CLEAVAGE; ANTIGEN; CYTOTOXICITY; ACTIVATION; INHIBITOR; PHARMACOLOGY	Accumulation of extracellular and intracellular adenosine (Ado) under hypoxic conditions or in the absence of adenosine deaminase results in lymphocyte depletion and in severe combined immunodeficiency, which are currently explained by direct intracellular lymphotoxicity of Ado metabolites. In support of the alternative, ''signaling'' mechanism, we show that extracellular Ado (extAdo) suppresses all tested T cell receptor (TCR)triggered effector functions of T Lymphocytes including the TCR-triggered Fast mRNA up-regulation in cytotoxic T lymphocytes. Strong evidence against the intracellular lymphotoxicity of Ado (and in support of the signaling model) is provided by abrogation of TCR-triggered growth inhibition in Ado exposed T cells. The brief exposure to Ado was sufficient to observe inhibition of TCR-triggered effector functions. The ''memory'' of T cells to exposure to extAdo is best explained by sustained increases in cAMP. Selective agonist (CGS21680) and antagonist (ZM241385) of A(2A) adenosine receptor were used in functional assays and cDNA probes for different sybtypes of adenosine receptors were used in Northern blot studies. A(2A) receptors are identified as the predominantly expressed subtype of G(s)-coupled Ado receptors in T cells, The demonstration of cross-talk between the A(2A) receptors and TCR in both directions support the possible role of A(2A) receptors in mechanisms of extAdo-mediated immunosuppression in vivo under adenosine deaminase deficiency and hypoxic conditions in, e.g., solid tumors.	NIAID,IMMUNOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								APASOV S, 1995, IMMUNOL REV, V146, P5, DOI 10.1111/j.1600-065X.1995.tb00680.x; Apasov SG, 1997, J IMMUNOL, V158, P5095; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BLACKBURN MR, 1996, J BIOL CHEM, V271, P15208; CRONSTEIN BN, 1995, ARTHRITIS RHEUM, V38, P1040, DOI 10.1002/art.1780380804; GIBLETT ER, 1972, LANCET, V2, P1067; HENKART PA, 1992, CYTOTOXIC CELLS RECO, P153; Hershfield MS, 1995, METABOLIC MOL BASES, V2, P1725; HIRSCHHORN R, 1995, CLIN IMMUNOL IMMUNOP, V76, pS219, DOI 10.1016/S0090-1229(95)90288-0; HOSKIN DW, 1994, INT J CANCER, V59, P854, DOI 10.1002/ijc.2910590625; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; HUTCHISON AJ, 1990, J MED CHEM, V33, P1919, DOI 10.1021/jm00169a015; Jacobson KA, 1996, TRENDS PHARMACOL SCI, V17, P108, DOI 10.1016/0165-6147(96)10002-X; JACOBSON KA, 1993, FEBS LETT, V323, P141, DOI 10.1016/0014-5793(93)81466-D; JACOBSON KA, 1992, J MED CHEM, V35, P407, DOI 10.1021/jm00081a001; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; Kataoka T, 1996, J IMMUNOL, V156, P3678; KIZAKI H, 1988, J IMMUNOL, V141, P1652; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; Koshiba M, 1997, P NATL ACAD SCI USA, V94, P831, DOI 10.1073/pnas.94.3.831; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARQUARDT DL, 1994, J IMMUNOL, V152, P4508; MARTZ E, 1993, CYTOTOXIC CELLS RECO, P9; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; Mizumura T, 1996, CIRC RES, V79, P415, DOI 10.1161/01.RES.79.3.415; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; POUCHER SM, 1995, BRIT J PHARMACOL, V115, P1096, DOI 10.1111/j.1476-5381.1995.tb15923.x; RATNER A, 1993, CYTOTOXIC CELLS RECO, P487; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; STAERZ UD, 1985, NATURE, V314, P628, DOI 10.1038/314628a0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUGIYAMA H, 1992, J BIOL CHEM, V267, P25256; TAFFS RE, 1991, J IMMUNOL, V147, P722; TAKAYAMA H, 1988, J BIOL CHEM, V263, P2330; TAKAYAMA H, 1991, INT IMMUNOL, V3, P1149, DOI 10.1093/intimm/3.11.1149; TAKAYAMA H, 1987, J EXP MED, V166, P725, DOI 10.1084/jem.166.3.725; TOES RE, 1996, INT J CANCER, V29, P686; vanderPloeg I, 1996, N-S ARCH PHARMACOL, V353, P250, DOI 10.1007/BF00168626	41	154	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25881	25889		10.1074/jbc.272.41.25881	http://dx.doi.org/10.1074/jbc.272.41.25881			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325320	hybrid			2022-12-25	WOS:A1997YA35800075
J	Lin, HC; Barylko, B; Achiriloaie, M; Albanesi, JP				Lin, HC; Barylko, B; Achiriloaie, M; Albanesi, JP			Phosphatidylinositol (4,5)-bisphosphate-dependent activation of dynamins I and II lacking the proline/arginine-rich domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE ACTIVITY; BINDING-SITE; ACIDIC PHOSPHOLIPIDS; SH3 DOMAINS; MICROTUBULES; BRAIN; PHOSPHOINOSITIDES; ENDOCYTOSIS; PROTEINS	Dynamins comprise a family of GTPases that participate in the early stages of endocytosis. The GTPase activity of neuronal specific dynamin I is stimulated by microtubules, negatively charged phospholipid vesicles, and Src homology 3-containing proteins, including Grb2. These activators were previously shown to bind to a proline/arginine-rich domain (PRD) in the carboxyl-terminal region of the enzyme. Dynamin II, which is ubiquitously expressed, had not been purified or characterized previously. In this study, the enzymatic properties of rat dynamin II and of D746, a dynamin II truncation mutant lacking the PRD, have been characterized. Dynamin II has a higher basal activity than dynamin I, but the two types of dynamin are stimulated similarly by microtubules, Grb2, and phospholipids. D746 is not activated by microtubules or Grb2, highlighting the significance of the PRD for these interactions, but it is activated by phospholipid vesicles containing phosphatidylserine or phosphatidylinositol-4,5-bisphosphate. Moreover, in contrast to previous reports, the PRD appears not to be required for phospholipid-stimulated self-assembly of dynamin, which is a key element in the regulation of its activity. Similar results were obtained with bovine brain dynamin I that had been subjected to limited proteolytic digestion to remove the PRD. Our data highlight the potential involvement of dynamin pleckstrin homology domains in the regulation of GTPase activity by phospholipids.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM38567, 2-T32 GM07062-22, GM 34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062, R37GM034497, R01GM034497, R01GM038567] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], ALLOSTERIC ENZYMES K; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Earnest S, 1996, FEBS LETT, V396, P62, DOI 10.1016/0014-5793(96)01074-5; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; KORN ED, 1982, METHOD ENZYMOL, V85, P357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; McClure SJ, 1996, MOL MEMBR BIOL, V13, P189, DOI 10.3109/09687689609160598; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1993, J BIOL CHEM, V268, P17240; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VALLEE RB, 1995, TRENDS CELL BIOL, V5, P43, DOI 10.1016/S0962-8924(00)88937-0; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	31	71	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25999	26004		10.1074/jbc.272.41.25999	http://dx.doi.org/10.1074/jbc.272.41.25999			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325335	hybrid			2022-12-25	WOS:A1997YA35800090
J	Nastri, HG; Evans, PD; Walker, IH; Riggs, PD				Nastri, HG; Evans, PD; Walker, IH; Riggs, PD			Catalytic and DNA binding properties of P upsilon uII restriction endonuclease mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ECORI ENDONUCLEASE; CRYSTAL-STRUCTURE; AMINO-ACID; MUTATIONAL ANALYSIS; PVUII ENDONUCLEASE; PROTEUS-VULGARIS; ESCHERICHIA-COLI; COGNATE DNA; ACTIVE-SITE	The role of particular residues of the PvuII endonuclease in DNA binding and cleavage was studied by mutational analysis using a number of in vivo and in vitro approaches. While confirming the importance of residues predicted to be involved directly in function by the crystal structure, the analysis led to several striking results. Aspartate 34, which contacts the central base pair of the PvuII site (5'-CAGCTG-3') through the minor groove, plays a critical role in binding specificity. A D34G mutant binds with high affinity to any of the sequences in the set CANNTG, although its low level of cleavage activity acts only on the wild-type site. In addition, a His to Ala mutation at the residue that contacts the central G and is predicted to be blocked by PvuII methylation still requires the PvuII methylase to be maintained in vivo, arguing against this hypothesis as the only mechanism for methylation protection. Finally, four of the five mutations that reduce cleavage activity while still exhibiting binding in the gel shift assay are at residues that form DNA- or subunit-subunit contacts rather than in the catalytic center. This provides further evidence for a strong linkage between specific binding and catalysis.	NEW ENGLAND BIOLABS INC, BEVERLY, MA 01915 USA									AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; ANDERSON JE, 1993, CURR OPIN STRUC BIOL, V3, P24, DOI 10.1016/0959-440X(93)90197-S; ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; BALENDIRAN K, 1994, PROTEINS, V19, P77, DOI 10.1002/prot.340190110; BLUMENTHAL RM, 1985, J BACTERIOL, V164, P501, DOI 10.1128/JB.164.2.501-509.1985; Bozic D, 1996, J MOL BIOL, V255, P176, DOI 10.1006/jmbi.1996.0015; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; DORNER LF, 1994, NUCLEIC ACIDS RES, V22, P1068, DOI 10.1093/nar/22.6.1068; ELLEDGE SJ, 1989, GENE DEV, V3, P185, DOI 10.1101/gad.3.2.185; FLORES H, 1995, GENE, V157, P295, DOI 10.1016/0378-1119(94)00863-N; FOMENKOV A, 1994, NUCLEIC ACIDS RES, V22, P2399, DOI 10.1093/nar/22.12.2399; GINGERAS TR, 1981, NUCLEIC ACIDS RES, V9, P4525, DOI 10.1093/nar/9.18.4525; Grabowski G, 1996, FEBS LETT, V381, P106, DOI 10.1016/0014-5793(96)00075-0; GRABOWSKI G, 1995, GENE, V157, P113, DOI 10.1016/0378-1119(94)00714-4; HEITMAN J, 1991, GENE, V103, P1, DOI 10.1016/0378-1119(91)90383-M; HEITMAN J, 1990, EMBO J, V9, P3369, DOI 10.1002/j.1460-2075.1990.tb07538.x; HOLTZ JK, 1994, J BIOL CHEM, V269, P27286; JELTSCH A, 1992, FEBS LETT, V304, P4, DOI 10.1016/0014-5793(92)80576-3; Jeltsch A, 1996, TRENDS BIOTECHNOL, V14, P235, DOI 10.1016/0167-7799(96)10030-5; JELTSCH A, 1993, J MOL BIOL, V229, P221, DOI 10.1006/jmbi.1993.1019; JenJacobson L, 1996, EMBO J, V15, P2870, DOI 10.1002/j.1460-2075.1996.tb00648.x; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KING K, 1989, J BIOL CHEM, V264, P11807; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; NEEDELS MC, 1989, P NATL ACAD SCI USA, V86, P3579, DOI 10.1073/pnas.86.10.3579; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; OTWINOWSKI Z, 1988, NATURE, V366, P178; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; Stahl F, 1996, P NATL ACAD SCI USA, V93, P6175, DOI 10.1073/pnas.93.12.6175; THIELKING V, 1992, BIOCHEMISTRY-US, V31, P3727, DOI 10.1021/bi00130a001; THIELKING V, 1991, BIOCHEMISTRY-US, V30, P6416, DOI 10.1021/bi00240a011; THOMAS M, 1992, BIOTECHNIQUES, V13, P533; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6089, DOI 10.1021/bi00141a019; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1701, DOI 10.1021/bi952391d; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; Wenz C, 1996, J BIOL CHEM, V271, P5565, DOI 10.1074/jbc.271.10.5565; WENZ C, 1994, BBA-GENE STRUCT EXPR, V1219, P73, DOI 10.1016/0167-4781(94)90248-8; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; XU SY, 1991, J BIOL CHEM, V266, P4425; XU SY, 1991, J BACTERIOL, V173, P5030, DOI 10.1128/jb.173.16.5030-5035.1991; [No title captured]	46	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25761	25767		10.1074/jbc.272.41.25761	http://dx.doi.org/10.1074/jbc.272.41.25761			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325303	hybrid			2022-12-25	WOS:A1997YA35800058
J	Subramaniam, VN; Loh, E; Hong, WJ				Subramaniam, VN; Loh, E; Hong, WJ			N-ethylmaleimide-sensitive factor (NSF) and alpha-soluble NSF attachment proteins (SNAP) mediate dissociation of GS28-syntaxin 5 Golgi SNAP receptors (SNARE) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; VESICULAR TRANSPORT; CIS-GOLGI; FUSION; YEAST; FAMILY; SED5; ER	Golgi soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) GS28 and syntaxin 5 can be reciprocally coimmunoprecipitated from Golgi extracts, suggesting that they exist in a protein complex. When Golgi extract is preincubated with soluble NSF attachment proteins (alpha-SNAP) and N-ethylmaleimide-sensitive factor (NSF) under conditions that allow ATP hydrolysis by NSF, GS28 and syntaxin 5 become dissociated, GS28 and syntaxin 5 remain in a protein complex when Golgi extract is preincubated with similar amounts of alpha-SNAP and NSF under conditions that prevent ATP hydrolysis by NSF, suggesting that ATP hydrolysis by NSF is necessary for dissociating the GS28-syntaxin 5 complex. Since preincubation of Golgi extract with either alpha-SNAP or NSF alone has no effect on the GS28-syntaxin 5 complex, a concerted action of alpha-SNAP and NSF therefore mediates the dissociation of the GS28-syntaxin 5 complex. Furthermore, GS28 but not syntaxin 5 is capable of binding to immobilized alpha-SNAP when the GS28-syntaxin 5 complex is dissociated.	INST MOL & CELL BIOL, MEMBRANE BIOL LAB, SINGAPORE 119076, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)			HONG, Wanjin/E-9927-2010; Subramaniam, V. Nathan/A-1901-2010	Subramaniam, V. Nathan/0000-0002-4583-7790				BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1994, J BIOL CHEM, V269, P29363; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Harlow E., 1988, ANTIBODIES LAB MANUA; Lowe SL, 1996, J CELL SCI, V109, P209; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; SUBRAMANIAM VN, 1995, J CELL SCI, V108, P2405; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5	21	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25441	25444		10.1074/jbc.272.41.25441	http://dx.doi.org/10.1074/jbc.272.41.25441			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325254	Green Published, hybrid			2022-12-25	WOS:A1997YA35800009
J	Vertessy, BG; Orosz, F; Kovacs, J; Ovadi, J				Vertessy, BG; Orosz, F; Kovacs, J; Ovadi, J			Alternative binding of two sequential glycolytic enzymes to microtubules - Molecular studies in the phosphofructokinase/aldolase/microtubule system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE PHOSPHOFRUCTOKINASE; TUBULIN INTERACTIONS; ALDOLASE; CALMODULIN; ASSOCIATION; TERMINALS; PROTEINS	Simultaneous binding of two sequential glycolytic enzymes, phosphofructokinase and aldolase, to a microtubular network was investigated. The binding of the phosphofructokinase to microtubules and its bundling activity has been previously characterized (Lehotzky, A., Telegdi, M., Liliom, K., and Ovadi, J. (1993) J. Biol. Chem. 268, 10888-10894). Aldolase binding to microtubules at near physiological ionic strength is weak (K-d = 20 mu M) as compared with that of the kinase (K-d = 1 mu M). The interactions of both enzymes with microtubules are modulated by their common intermediate, fructose-1,6-bisphosphate. Pelleting and electron microscopic measurements have revealed that the aldolase binding interferes with that of phosphofructokinase, although they have distinct binding domains on microtubules. The underlying molecular mechanism responsible for this finding is that in the solution phase aldolase and phosphofructokinase form a bienzyme complex that does not bind to the microtubule. The bienzyme complex formation does not influence the catalytic activity of aldolase, however, it inhibits the dissociation-induced inactivation of the kinase by stabilizing a catalytically active molecular form, The present data suggest the first experimental evidence that two sequential glycolytic enzymes do not associate simultaneously to microtubules, but their complexation in solution provides kinetic advantage for glycolysis.	HUNGARIAN ACAD SCI, INST ENZYMOL, BIOL RES CTR, H-1518 BUDAPEST, HUNGARY; EOTVOS LORAND UNIV, FAC SCI, DEPT GEN ZOOL, H-1445 BUDAPEST, HUNGARY	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University			Vertessy, Beata G/H-6202-2012	Ovadi, Judit/0000-0002-3420-682X; Vertessy, Beata G./0000-0002-1288-2982				Bershadsky AD., 1988, CYTOSKELETON, V1st; BISZKU E, 1964, ACTA PHYSIOL HUNG, V25, P161; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY ST, 1982, T AM SOC NEUROCHEM, V13, P226; CARR D, 1993, BIOCHEM BIOPH RES CO, V195, P289, DOI 10.1006/bbrc.1993.2043; CLARKE FM, 1985, CELL MOTILITY MECHAN, P235; DURRIEU C, 1987, ARCH BIOCHEM BIOPHYS, V252, P32, DOI 10.1016/0003-9861(87)90005-1; HESTERBERG LK, 1982, BIOCHEMISTRY-US, V21, P216, DOI 10.1021/bi00531a003; HOWARD WD, 1988, J BIOL CHEM, V263, P1342; KNULL HR, 1992, CURR TOP CELL REGUL, V33, P15; KNULL HR, 1990, UCLA SYM BI, V133, P215; LEHOTZKY A, 1994, BIOCHEM BIOPH RES CO, V204, P585, DOI 10.1006/bbrc.1994.2499; LEHOTZKY A, 1993, J BIOL CHEM, V268, P10888; MACRAE TH, 1992, BIOCHIM BIOPHYS ACTA, V1160, P145, DOI 10.1016/0167-4838(92)90001-T; MALAMUD D, 1978, ANAL BIOCHEM, V86, P620, DOI 10.1016/0003-2697(78)90790-X; MASTERS C, 1992, INT J BIOCHEM, V24, P405, DOI 10.1016/0020-711X(92)90031-U; MASTERS CJ, 1981, CRC CR REV BIOCH MOL, V11, P105, DOI 10.3109/10409238109108700; MAYR GW, 1984, EUR J BIOCHEM, V143, P513, DOI 10.1111/j.1432-1033.1984.tb08400.x; Na C.N., 1986, BIOCHEMISTRY-US, V25, P6214; OBLINGER MM, 1988, J NEUROSCI RES, V21, P25, DOI 10.1002/jnr.490210105; OROSZ F, 1986, EUR J BIOCHEM, V160, P615, DOI 10.1111/j.1432-1033.1986.tb10082.x; OROSZ F, 1987, BIOCHEM BIOPH RES CO, V147, P1121, DOI 10.1016/S0006-291X(87)80186-9; Orosz F, 1997, BRIT J PHARMACOL, V121, P947, DOI 10.1038/sj.bjp.0701189; OROSZ F, 1988, BIOCHIM BIOPHYS ACTA, V957, P293, DOI 10.1016/0167-4838(88)90286-5; OVADI J, 1992, CURR TOP CELL REGUL, V33, P105; OVADI J, 1995, CELL ARCHITECTURE ME; ROBERTS SJ, 1987, BIOCHEMISTRY-US, V26, P3437, DOI 10.1021/bi00386a028; SACKETT DL, 1986, J BIOL CHEM, V261, P9070; SERRANO L, 1984, P NATL ACAD SCI-BIOL, V81, P5989, DOI 10.1073/pnas.81.19.5989; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846; Vertessy BG, 1997, BIOCHEMISTRY-US, V36, P2051, DOI 10.1021/bi9623441; Vertessy BG, 1996, FEBS LETT, V379, P191, DOI 10.1016/0014-5793(95)01510-8; Volker KW, 1997, ARCH BIOCHEM BIOPHYS, V338, P237, DOI 10.1006/abbi.1996.9819; VOLKER KW, 1993, J MOL RECOGNIT, V6, P167, DOI 10.1002/jmr.300060405	34	67	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25542	25546		10.1074/jbc.272.41.25542	http://dx.doi.org/10.1074/jbc.272.41.25542			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325270	hybrid			2022-12-25	WOS:A1997YA35800025
J	Bienkowska, J; Cruz, M; Atiemo, A; Handin, R; Liddington, R				Bienkowska, J; Cruz, M; Atiemo, A; Handin, R; Liddington, R			The von Willebrand factor A3 domain does not contain a metal ion-dependent adhesion site motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA-2-BETA-1 VLA-2; I-DOMAIN; VONWILLEBRAND-FACTOR; CRYSTAL-STRUCTURE; BINDING-SITE; FACTOR VWF; CD49B/CD29; COLLAGENS; PROTEIN; PROGRAM	von Willebrand factor (vWF) is a multimeric plasma protein that mediates platelet adhesion to exposed subendothelium at sites of vascular injury, The A3 domain of vWF (vWF-A3) forms the principal binding site for collagens type I and III, We report here the crystal structure of the vWF A3 domain at 2.2-Angstrom resolution, As expected, the structure is similar to the integrin I domain but with several novel features, Sequence alignments had suggested that the domain contained an integrin metal ion-dependent adhesion site (MIDAS) motif, but the crystal structure shows that the motif is modified and that no metal ion is bound, We have introduced mutations into the vestigial MIDAS motif and report that, unlike the I domain of integrin (alpha 2 beta 1, vWF-A3 continues to bind collagen after disruption of the motif. We conclude that collagen recognition by vWF-A3 occurs by a mechanism different from that of the integrin alpha 2 beta 1.	UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND; BRIGHAM & WOMENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; BOSTON UNIV, BIOMED ENGN RES CTR, BOSTON, MA 02115 USA	University of Leicester; Harvard University; Brigham & Women's Hospital; Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054876] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL54876] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P43; BRUNGER AT, 1992, XPLOR MANUAL VERSION; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; CRUZ MA, 1995, J BIOL CHEM, V270, P10822, DOI 10.1074/jbc.270.18.10822; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; EWENSWTEIN BM, 1994, BLEEDING, P1069; FOWLER WE, 1985, J CLIN INVEST, V76, P1491, DOI 10.1172/JCI112129; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nicholls A., 1992, GRASP GRAPHICAL REPR; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P59; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rieu P, 1996, J BIOL CHEM, V271, P15858, DOI 10.1074/jbc.271.27.15858; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SLAYTER H, 1985, J BIOL CHEM, V260, P8559; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TUCKWELL D, 1995, J CELL SCI, V108, P1629; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x	27	104	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25162	25167		10.1074/jbc.272.40.25162	http://dx.doi.org/10.1074/jbc.272.40.25162			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312128	hybrid			2022-12-25	WOS:A1997XY97000067
J	Gregoire, CJ; Gautheret, D; Loret, EP				Gregoire, CJ; Gautheret, D; Loret, EP			No tRNA(3)(Lys) unwinding in a complex with HIV NCp7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TERMINAL ZINC-FINGER; NUCLEOCAPSID PROTEIN NCP7; PRIMER TRANSFER-RNA; IN-VITRO; REVERSE-TRANSCRIPTASE; REPLICATION PRIMER; CIRCULAR-DICHROISM; ANNEALING ACTIVITIES; BINDING-SITE	The nucleocapsid protein NCp7 of the human immunodeficiency virus (HIV) type 1 is important for the annealing of HIV RNA and tRNA(3)(Lys), the tRNA acting as a primer during reverse transcription of HIV RNA, A wild type NCp7 and a Cys(23) mutant having a disrupted zinc finger were analyzed with far UV circular dichroism (CD), CD data analysis revealed that NCp7 has a high content of extended structures in aqueous buffer, decreasing in Cys(23) NCp7 and in NCp7 in the absence of zinc, An increase in beta-turn structures is observed in NCp7 bound to tRNA(3)(Lys). Furthermore, CD data shows that Cys(23) NCp7 binds tRNA(3)(Lys). The CD spectrum of tRNA(3)(Lys) is typical of an A-form helix and retains this structure after binding of NCp7, which demonstrates that NCp7 does not induce tRNA(3)(Lys) unwinding, CD spectra of tRNA(3)(Lys) were measured from 5 to 80 degrees C to observe CD changes resulting from tRNA(3)(Lys) melting. Molecular modeling of the complex identifies two potential tRNA anticodon binding sites in the NCp7 N-terminal region and first zinc finger, In this model, both binding sites can interact with 12 nucleotides in the anticodon domain without requiring a base specificity.	CNRS, LAB INGN SYST MACROMOL, F-13402 MARSEILLE 20, FRANCE; CNRS, INST BIOL STRUCT & MICROBIOL, F-13402 MARSEILLE 20, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS)				Gautheret, Daniel/0000-0002-1508-8469				Bailly C, 1996, NUCLEIC ACIDS RES, V24, P1460, DOI 10.1093/nar/24.8.1460; BARAT C, 1993, J MOL BIOL, V231, P185, DOI 10.1006/jmbi.1993.1273; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; DANNULL J, 1994, EMBO J, V13, P1525, DOI 10.1002/j.1460-2075.1994.tb06414.x; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DEMENE H, 1994, BIOCHEMISTRY-US, V33, P11707, DOI 10.1021/bi00205a006; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2; JULIAN N, 1993, FEBS LETT, V331, P43, DOI 10.1016/0014-5793(93)80294-5; KHAN R, 1992, J BIOL CHEM, V267, P6689; LAM WC, 1994, BIOCHEMISTRY-US, V33, P10693, DOI 10.1021/bi00201a017; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MATHEWS CK, 1990, BIOCHEMISTRY-US, P133; Mely Y, 1996, BIOCHEMISTRY-US, V35, P5175, DOI 10.1021/bi952587d; MELY Y, 1995, J BIOL CHEM, V270, P1650, DOI 10.1074/jbc.270.4.1650; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; PRINZ H, 1974, BIOCHEMISTRY-US, V13, P1322, DOI 10.1021/bi00704a003; SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219; SANGER F, 1963, BIOCHIM BIOPHYS ACTA, V71, P468, DOI 10.1016/0006-3002(63)91108-9; Schmalzbauer E, 1996, J VIROL, V70, P771, DOI 10.1128/JVI.70.2.771-777.1996; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; SOUTH TL, 1993, PROTEIN SCI, V2, P3; TANCHOU V, 1995, J MOL BIOL, V252, P563, DOI 10.1006/jmbi.1995.0520; WAKEFIELD JK, 1995, J VIROL, V69, P6021, DOI 10.1128/JVI.69.10.6021-6029.1995; WESTHOF E, 1988, ACTA CRYSTALLOGR A, V44, P112, DOI 10.1107/S010876738700446X; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15	37	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25143	25148		10.1074/jbc.272.40.25143	http://dx.doi.org/10.1074/jbc.272.40.25143			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312125	hybrid			2022-12-25	WOS:A1997XY97000064
J	Zwick, E; Daub, H; Aoki, N; YamaguchiAoki, Y; Tinhofer, I; Maly, K; Ullrich, A				Zwick, E; Daub, H; Aoki, N; YamaguchiAoki, Y; Tinhofer, I; Maly, K; Ullrich, A			Critical role of calcium-dependent epidermal growth factor receptor transactivation in PC12 cell membrane depolarization and bradykinin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GENE-EXPRESSION; MAP KINASE; TYROSINE KINASE; ACTIVATION; RAS; SRC; NEURONS; INFLUX; STIMULATION	PC12 cells respond to a variety of external stimuli such as growth factors, neurotransmitters, and membrane depolarization by activating the Ras/mitogen-activated protein kinase pathway, Here we demonstrate that both depolarization-induced calcium influx and treatment with bradykinin stimulate tyrosine phosphorylation of the epidermal growth factor receptor (EGFR). Using a tetracycline-controlled expression system in conjunction with a dominant-negative EGFR mutant, we demonstrate that depolarization and bradykinin triggered signals involve EG;FR function upstream of SHC and MAP kinase, Furthermore, bradykinin-stimulated EGFR transactivation is critically dependent on the presence of extracellular calcium, and when triggered by ionophore treatment, calcium influx is already sufficient to induce EGFR tyrosine phosphorylation, Taken together, our results establish calcium-dependent EGFR transactivation as a signaling mechanism mediating activation of the Ras/mitogen-activated protein kinase pathway in neuronal cell types.	UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA; MAX PLANCK INST BIOCHEM, DEPT MOL BIOL, D-82152 MARTINSRIED, GERMANY	University of Innsbruck; Max Planck Society				Tinhofer, Ingeborg/0000-0002-0512-549X				BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haller T, 1996, CELL CALCIUM, V19, P157, DOI 10.1016/S0143-4160(96)90084-6; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; TUCKER MS, 1993, BRAIN RES, V631, P65, DOI 10.1016/0006-8993(93)91187-W; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309	24	184	186	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24767	24770		10.1074/jbc.272.40.24767	http://dx.doi.org/10.1074/jbc.272.40.24767			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312072	hybrid			2022-12-25	WOS:A1997XY97000011
J	Raju, U; Lu, RS; Noel, F; Gumin, GJ; Tofilon, PJ				Raju, U; Lu, RS; Noel, F; Gumin, GJ; Tofilon, PJ			Failure of a second x-ray dose to activate nuclear factor kappa B in normal rat astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION INDUCES EXPRESSION; IONIZING-RADIATION; TRANSCRIPTIONAL ACTIVATION; INDUCTION; ALPHA; GROWTH; IRRADIATION; INJURY; CELLS; IMMUNOSUPPRESSION	Induced gene expression and subsequent cytokine production have been implicated in the normal tissue injury response to radiotherapy. However, studies of radiation-induced gene expression have used single radiation doses rather than the fractionated exposures typical of the clinical situation. To study the effects of multiple radiation doses oil gene expression, we investigated nuclear factor kappa B (NF kappa B) DNA binding activity in primary astrocyte cultures after one and two exposures to x-rays. After a single dose of x-rays (3.8-15 gray (Gy)), NF kappa B binding activity in astrocytes increased in a dose-dependent manner, reaching a maximum by 2-4 h and returning to control levels by 8 h after irradiation, In split-dose experiments, when an interval of 24 h was used between two doses of 7.5 Gy, the second 7.5 Gy exposure failed to induce NF kappa B activation, The period of desensitization induced by the first radiation exposure was dose-dependent, persisting approximately 72 h after 7.5 Gy compared with 24 h after 1.5 Gy. No changes in I kappa B alpha protein levels were detected, However, the presence of a transcription inhibitor prevented the desensitizing effect of the initial irradiation. Irradiation also prevented NF kappa B activation in astrocytes by a subsequent exposure to H2O2, but it had mo effect on the activation induced by tumor necrosis factor-alpha. These data indicate that an initial x-ray exposure can desensitize astrocytes to the NF kappa B-activating effects of a subsequent radiation exposure, Furthermore, they suggest that this desensitization depends on gene transcription and may have some specificity for NF kappa B activation mediated by reactive oxygen species.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT EXPT RADIAT ONCOL 66,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT NEUROSURG,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA-16672, CA-72156] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072156, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BARCELLOSHOFF MH, 1993, CANCER RES, V53, P3880; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BRACH MA, 1993, J BIOL CHEM, V268, P8466; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Desnoyers S, 1996, EXP CELL RES, V227, P146, DOI 10.1006/excr.1996.0259; DIEHL JA, 1995, J BIOL CHEM, V270, P2703, DOI 10.1074/jbc.270.6.2703; FUKS Z, 1992, INT J RADIAT ONCOL, V24, P183, DOI 10.1016/0360-3016(92)91041-K; HALL EJ, 1994, RADIOBIOLOGY RADIOLO, P29; Hallahan D, 1995, BIOCHEM BIOPH RES CO, V217, P784, DOI 10.1006/bbrc.1995.2841; Hensold JO, 1996, J CELL PHYSIOL, V168, P105; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; MCBRIDE WH, 1995, INT J RADIAT ONCOL, V33, P233, DOI 10.1016/0360-3016(95)02019-8; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCMILLIAN MK, 1994, TRENDS NEUROSCI, V17, P138, DOI 10.1016/0166-2236(94)90086-8; MONTGOMERY DL, 1994, VET PATHOL, V31, P145, DOI 10.1177/030098589403100201; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER HW, 1995, PHARMACOL THERAPEUT, V65, P1, DOI 10.1016/0163-7258(94)00047-7; Noel F, 1997, RADIAT RES, V147, P484, DOI 10.2307/3579506; RUBIN P, 1992, INT J RADIAT ONCOL, V24, P93, DOI 10.1016/0360-3016(92)91027-K; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tolentino PJ, 1996, MOL BRAIN RES, V39, P89, DOI 10.1016/0169-328X(96)00004-6; Weill D, 1996, J INTERF CYTOK RES, V16, P395, DOI 10.1089/jir.1996.16.395; WILSON RE, 1993, ONCOGENE, V8, P3229; WITTE L, 1989, CANCER RES, V49, P5066	30	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24624	24630		10.1074/jbc.272.39.24624	http://dx.doi.org/10.1074/jbc.272.39.24624			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305931	hybrid			2022-12-25	WOS:A1997XY51500082
J	Huang, YD; Schwendner, SW; Rall, SC; Sanan, DA; Mahley, RW				Huang, YD; Schwendner, SW; Rall, SC; Sanan, DA; Mahley, RW			Apolipoprotein E2 transgenic rabbits - Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HERITABLE HYPERLIPIDEMIC RABBITS; INCREASED MESSENGER-RNA; FAMILIAL HYPERCHOLESTEROLEMIA; ANIMAL-MODEL; WHHL-RABBIT; LIPOLYTIC CONVERSION; REMNANT CLEARANCE; HEPATIC LIPASE; E DEFICIENCY	Transgenic rabbits were produced that expressed high plasma levels (30-70 mg/dl) of human apolipoprotein (ape) E2(Cys-158), an apoE variant associated with the human genetic disorder type III hyperlipoproteinemia (HLP), Male transgenic rabbits fed normal chow had up to 8-fold (289 +/- 148 mg/dl) and 15-fold (697 +/- 452 mg/dl) increases in plasma total cholesterol and triglycerides, respectively, compared with nontransgenic males, Female transgenic rabbits had only a modest hyperlipidemia (total cholesterol, 140 +/- 46 mg/dl; total triglycerides, 174 +/- 66 mg/dl). Both sexes displayed the hallmarks of type III HLP: beta-migrating very low density lipoproteins (beta-VLDL) (intestinal and hepatic remnant lipoproteins) and significantly increased VLDL and intermediate density lipoproteins. Apolipoprotein E2-containing VLDL particles were cleared from the circulation more slowly and were more resistant to lipoprotein lipase-mediated lipolysis than normal VLDL, Only females had increased high density lipoproteins (HDL) (40%), which were shifted from typical small HDL to larger HDL1. Plasma apoE2 was predominantly associated with beta-VLDL in males and with HDL in females, To ascertain reasons for the phenotypic gender difference, we treated the male transgenic rabbits with 17 alpha-ethinyl estradiol, Estrogen treatment for 10 days dramatically decreased total cholesterol (73%) and triglycerides (89%) and converted beta-VLDL to pre-beta-migrating VLDL. Concomitantly, lipoprotein lipase and hepatic lipase activities increased by 90%, low density lipoprotein receptor activity was stimulated significantly, apoE2 was redistributed to HDL, and HDL were converted to HDL1, Conversely, ovariectomy in female transgenic rabbits significantly increased total cholesterol (75%), triglycerides (117%), and beta-VLDL, while decreasing lipoprotein! lipase and hepatic lipase activities by 35% and redistributing apoE2 to the beta-VLDL, Thus, estrogen status appears to be responsible for much of the gender difference of the lipoprotein phenotype, mainly by modulating both lipase and low density lipoprotein receptor activities, Furthermore, transgenic rabbits fed normal chow for 11 months developed fatty streaks, and some had more advanced atherosclerotic lesions, especially around the aortic arch and proximal abdominal aorta, The lesions were more extensive in males, roughly correlating with the magnitude of the hyperlipidemia Therefore, high plasma levels of human apoE2 in transgenic rabbits result in a type III HLP phenotype, in which males have both more severe hyperlipidemia and more extensive atherosclerosis than females.	UNIV CALIF SAN FRANCISCO, INST CARDIOVASC RES, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94141 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Huang, YD (corresponding author), UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, POB 419100, SAN FRANCISCO, CA 94141 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS CWM, 1982, ATHEROSCLEROSIS, V44, P1, DOI 10.1016/0021-9150(82)90047-8; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BUJA LM, 1983, ARTERIOSCLEROSIS, V3, P87, DOI 10.1161/01.ATV.3.1.87; CHAPMAN MJ, 1986, METHOD ENZYMOL, V128, P70; CHUNG BH, 1983, J LIPID RES, V24, P1148; CLARK G, 1981, STAINING PROCEDURES, P189; CONNELLY PW, 1994, J BIOL CHEM, V269, P20554; CORNHILL JF, 1985, ARTERIOSCLEROSIS, V5, P415, DOI 10.1161/01.ATV.5.5.415; DEKNIJFF P, 1991, J CLIN INVEST, V88, P643, DOI 10.1172/JCI115349; DEMACKER PNM, 1977, CLIN CHEM, V23, P1238; DEMACKER PNM, 1991, ARTERIOSCLER THROMB, V11, P1652, DOI 10.1161/01.ATV.11.6.1652; Duverger N, 1996, CIRCULATION, V94, P713, DOI 10.1161/01.CIR.94.4.713; EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; FAN JL, 1995, ARTERIOSCL THROM VAS, V15, P1889, DOI 10.1161/01.ATV.15.11.1889; FAZIO S, 1992, J BIOL CHEM, V267, P6941; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; GOMORI G, 1950, AM J CLIN PATHOL, V20, P661, DOI 10.1093/ajcp/20.7_ts.661; HAARBO J, 1991, J CLIN INVEST, V87, P1274, DOI 10.1172/JCI115129; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; Hoeg JM, 1996, J BIOL CHEM, V271, P4396; HORIE Y, 1992, J BIOL CHEM, V267, P1962; Huang YD, 1996, J BIOL CHEM, V271, P29146, DOI 10.1074/jbc.271.46.29146; HUETTINGER M, 1984, J CLIN INVEST, V74, P1017, DOI 10.1172/JCI111469; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; HUSSAIN MM, 1995, J BIOL CHEM, V270, P8578, DOI 10.1074/jbc.270.15.8578; IVERIUS PH, 1972, J BIOL CHEM, V247, P6610; Johnson FB, 1992, LAB METHODS HISTOTEC, P177; KITA T, 1981, P NATL ACAD SCI-BIOL, V78, P2268, DOI 10.1073/pnas.78.4.2268; KOVANEN PT, 1979, J BIOL CHEM, V254, P1367; MA PTS, 1986, P NATL ACAD SCI USA, V83, P792, DOI 10.1073/pnas.83.3.792; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; MAHLEY RW, 1985, CIRCULATION, V72, P943, DOI 10.1161/01.CIR.72.5.943; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1985, ANN NY ACAD SCI, V454, P209, DOI 10.1111/j.1749-6632.1985.tb11860.x; MAHLEY RW, 1995, METABOLIC MOL BASES, P1953; MCLEAN JW, 1984, J BIOL CHEM, V259, P6498; MCPHERSON R, 1991, ARTERIOSCLER THROMB, V11, P797, DOI 10.1161/01.ATV.11.4.797; MORGANROTH J, 1975, ANN INTERN MED, V82, P158, DOI 10.7326/0003-4819-82-2-158; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; RALL SC, 1992, J INTERN MED, V231, P653, DOI 10.1111/j.1365-2796.1992.tb01254.x; Sacks Frank M., 1994, Current Opinion in Lipidology, V5, P236, DOI 10.1097/00041433-199405030-00012; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; SHIOMI M, 1995, ARTERIOSCL THROM VAS, V15, P1938, DOI 10.1161/01.ATV.15.11.1938; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TANZAWA K, 1980, FEBS LETT, V118, P81, DOI 10.1016/0014-5793(80)81223-3; TSUKADA T, 1986, ARTERIOSCLEROSIS, V6, P601, DOI 10.1161/01.ATV.6.6.601; VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540; VANVLIJMEN BJM, 1994, J CLIN INVEST, V93, P1403, DOI 10.1172/JCI117117; VANVLIJMEN BJM, 1996, ARTERIOSCL THROM VAS, V271, P30595; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	56	44	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22685	22694		10.1074/jbc.272.36.22685	http://dx.doi.org/10.1074/jbc.272.36.22685			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9312550	hybrid			2022-12-25	WOS:A1997XV49200047
J	Fu, C; Chan, AC				Fu, C; Chan, AC			Identification of two tyrosine phosphoproteins, pp70 and pp68, which interact with phospholipase C gamma, Grb2, and Vav after B cell antigen receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; LYN-DEFICIENT MICE; PROTEIN-KINASE-C; T-CELL; CROSS-LINKING; SIGNAL-TRANSDUCTION; LYMPHOCYTES-B; PROTOONCOGENE PRODUCT; AUTOIMMUNE-DISEASE; MOLECULAR-CLONING	Tyrosine phosphorylation of cellular proteins mediates the assembly and localization of effector proteins through interactions facilitated by modular Src homology 2 (SH2) and phosphotyrosine binding domains. We describe here two tyrosine-phosphorylated proteins with M-r values of 70,000 and 68,000 that interact with Grb2, phospholipase C (PLC gamma 1 and PLC gamma 2), and Vav after B cell receptor cross-linking. The interaction of pp70 and pp68 with PLC and Vav is mediated by the carboxyl-terminal SH2 domain of PLC and the SH2 domain of Vav, In contrast, the interaction of pp70 and pp68 with Grb2 requires cooperative binding of the SH2 and SH3 domains of Grb2. Western blot analysis demonstrated that neither pp70 nor pp68 represented the recently described linker protein SLP-76, which binds Grb2, PLC, and Vav in T cells after T cell receptor activation, However, SLP-76 protein was not detected in a number of B cell lines or in normal mouse B cells. Hence, we propose that pp70 and pp68 likely represent B cell homologs of SLP-76 which facilitate and coordinate B cell activation.	WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,GENET PROGRAM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)								BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DAmbrosio D, 1996, EUR J IMMUNOL, V26, P1960, DOI 10.1002/eji.1830260842; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DeFranco AL, 1995, ANN NY ACAD SCI, V766, P195, DOI 10.1111/j.1749-6632.1995.tb26662.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; Law CL, 1996, MOL CELL BIOL, V16, P1305; LAW CL, 1994, J BIOL CHEM, V269, P12310; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Mizuno K, 1996, J EXP MED, V184, P457, DOI 10.1084/jem.184.2.457; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; ROIFMAN CM, 1992, BIOCHEM BIOPH RES CO, V183, P411, DOI 10.1016/0006-291X(92)90496-8; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SILLMAN AL, 1995, J BIOL CHEM, V270, P11806, DOI 10.1074/jbc.270.20.11806; SMIT L, 1994, J BIOL CHEM, V269, P20209; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	60	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27362	27368		10.1074/jbc.272.43.27362	http://dx.doi.org/10.1074/jbc.272.43.27362			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341187	hybrid			2022-12-25	WOS:A1997YC65900083
J	Gorovits, BM; Ybarra, J; Seale, JW; Horowitz, PM				Gorovits, BM; Ybarra, J; Seale, JW; Horowitz, PM			Conditions for nucleotide-dependent GroES-GroEL interactions - GroEL(14)(GroES(7))(2) is favored by an asymmetric distribution of nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONIN GROEL; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ATP HYDROLYSIS; CENTRAL CAVITY; PROTEIN; BINDING; CYCLE; RELEASE; MECHANISM	A still unresolved question regarding the mechanism of chaperonin-assisted protein folding involves the stoichiometry of the GroEL-GroES complex. This is important, because the activities of the Escherichia coli chaperonin GroEL are modulated by the cochaperonin GroES. In this report, the binding of GroES to highly purified GroEL in the presence of ATP, ADP, and the nonhydrolyzable ATP analogue, 5'-adenylyl beta,gamma-imidodiphosphate (AMP-PNP), was investigated by using the fluorescence anisotropy of succinimidyl-1-pyrenebutyrate-labeled GroES. In the presence of Mg2+-ATP and high [KC1] (10 nM), two GroES(7) rings bind per one GroEL(14). In contrast, in the presence of ADP or AMP-PNP only one molecule of oligomeric GroES can be tightly bound by GroEL. With AMP-PNP, binding of a small amount (<20%) of a second GroES can be detected. In the presence of ADP alone, a second GroES ring can bind to GroEL weakly and with negative cooperativity. Strikingly, addition of AMP-PNP to the solution containing preformed GroEL(14)(GroES(7)) complexes formed in the presence of ADP results in an increase in the fluorescence anisotropy. Analysis of this effect indicates that 2 mol of GroES oligomer can be bound in the presence of mixed nucleotides. A similar conclusion follows from studies in which ADP is added to an GroEL(14) (GroES(7)) complex formed in the presence of AMP-PNP. This is the first demonstration of an asymmetric distribution of nucleotides bound on the 1:2 GroEL(14) (GroES(7))(2) complex. The relation of the observed phenomena to the proposed mechanism of the GroEL function is discussed.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; Azem A, 1995, P NATL ACAD SCI USA, V92, P12021, DOI 10.1073/pnas.92.26.12021; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; Clark AC, 1996, BIOCHEMISTRY-US, V35, P5893, DOI 10.1021/bi953051v; Corrales FJ, 1996, FOLD DES, V1, P265, DOI 10.1016/S1359-0278(96)00040-5; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V28, P439, DOI 10.1101/SQB.1963.028.01.060; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; FERSHT A, 1977, ENZYME STRUCTURE MEC, P217; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gorovits BM, 1997, J BIOL CHEM, V272, P6842, DOI 10.1074/jbc.272.11.6842; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; LORCA O, 1997, J STRUCT BIOL, V118, P31; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Saibil Helen R., 1996, P245, DOI 10.1016/B978-012237455-5/50010-5; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; Torok Z, 1996, J BIOL CHEM, V271, P16180, DOI 10.1074/jbc.271.27.16180; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YBARRA J, 1995, J BIOL CHEM, V270, P22113, DOI 10.1074/jbc.270.38.22113	42	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26999	27004		10.1074/jbc.272.43.26999	http://dx.doi.org/10.1074/jbc.272.43.26999			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341138	hybrid			2022-12-25	WOS:A1997YC65900034
J	Peracchi, A; Beigelman, L; Scott, EC; Uhlenbeck, OC; Herschlag, D				Peracchi, A; Beigelman, L; Scott, EC; Uhlenbeck, OC; Herschlag, D			Involvement of a specific metal ion in the transition of the hammerhead ribozyme to its catalytic conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-CLEAVAGE REACTION; RNA; MECHANISM; PHOSPHOROTHIOATES; STEREOCHEMISTRY; 1,1-DIOXIDE; REAGENT	Previous crystallographic and biochemical studies of the hammerhead ribozyme suggest that a metal ion is ligated by the pro-R-p oxygen of phosphate 9 and by N-7 of G10.1 and has a functional role in the cleavage reaction, We have tested this model by examining the cleavage properties of a hammerhead containing a unique phosphorothioate at position 9. The R-p-, but not S-p-, phosphorothioate reduces the cleavage rate by 10(3)-fold, and the rate can be fully restored by addition of low concentrations of Cd2+, a thiophilic metal ion. These results strongly suggest that this bound metal ion is critical for catalysis, despite its location similar to 20 Angstrom from the cleavage site in the crystal structure. Analysis of the concentration dependence suggests that Cd2+ binds with a K-d of 25 mu M in the ground state and a K-d of 2.5 nm in the transition state, The much stronger transition state binding suggests that the P9 metal ion adopts at least one additional ligand in the transition state and that this metal ion may participate in a large scale conformational change that precedes hammerhead cleavage.	STANFORD UNIV,DEPT BIOCHEM,BECKMAN CTR B400,STANFORD,CA 94305; RIBOZYME PHARMACEUT INC,BOULDER,CO 80301; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Stanford University; University of Colorado System; University of Colorado Boulder			Peracchi, Alessio/G-5167-2012; Peracchi, Alessio/Q-5173-2019	Peracchi, Alessio/0000-0003-3254-4099; Peracchi, Alessio/0000-0003-3254-4099	NIGMS NIH HHS [GM36944, GM49243] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049243, R37GM036944, R01GM036944, R01GM049243] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGERS PMJ, 1978, P NATL ACAD SCI USA, V75, P4798, DOI 10.1073/pnas.75.10.4798; BUZAYAN JM, 1990, NUCLEIC ACIDS RES, V18, P4447, DOI 10.1093/nar/18.15.4447; ClouetDOrval B, 1996, RNA, V2, P483; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; IYER RP, 1990, J ORG CHEM, V55, P4693, DOI 10.1021/jo00302a039; IYER RP, 1990, J AM CHEM SOC, V112, P1253, DOI 10.1021/ja00159a059; JAFFE EK, 1978, J BIOL CHEM, V253, P4823; Knoll R, 1997, RNA, V3, P132; Kragten J., 1978, ATLAS METAL LIGAND E; McKay DB, 1996, RNA, V2, P395; PABONPENA LM, 1991, MOL CELL BIOL, V11, P6109, DOI 10.1128/MCB.11.12.6109; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; Peracchi A, 1996, P NATL ACAD SCI USA, V93, P11522, DOI 10.1073/pnas.93.21.11522; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1989, GENE, V82, P31, DOI 10.1016/0378-1119(89)90027-9; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; Sigel RKO, 1997, J AM CHEM SOC, V119, P744, DOI 10.1021/ja962970l; Sillen L, 1964, STABILITY CONSTANTS; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; TUSCHL T, 1993, P NATL ACAD SCI USA, V90, P6991, DOI 10.1073/pnas.90.15.6991; Warnecke JM, 1996, P NATL ACAD SCI USA, V93, P8924, DOI 10.1073/pnas.93.17.8924; WEINSTEIN LB, 1997, IN PRESS NATURE; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677	31	121	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26822	26826		10.1074/jbc.272.43.26822	http://dx.doi.org/10.1074/jbc.272.43.26822			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341112	hybrid			2022-12-25	WOS:A1997YC65900008
J	Cupane, A; Leone, M; Militello, V; Friedman, FK; Koley, AP; Vasquez, GB; Brinigar, WS; Karavitis, M; Fronticelli, C				Cupane, A; Leone, M; Militello, V; Friedman, FK; Koley, AP; Vasquez, GB; Brinigar, WS; Karavitis, M; Fronticelli, C			Modification of beta-chain or beta-chain heme pocket polarity by Val(E11)->Thr substitution has different effects on the steric, dynamic, and functional properties of human recombinant hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DYNAMICS; OPTICAL SPECTROSCOPY; LIGAND-BINDING; ABSORPTION-SPECTROSCOPY; TEMPERATURE-DEPENDENCE; NEUTRON-SCATTERING; ESCHERICHIA-COLI; FLASH-PHOTOLYSIS; GLOBIN LINKAGE; SORET BAND	The dynamic and functional properties of mutant deoxyhemoglobins in which either the beta-globin Val(67)(E11) or the alpha-globin Val(62)(E11) is replaced by threonine have been investigated through the thermal evolution of the Soret absorption band in the temperature range 300 to 20 K and through the kinetics of CO rebinding after flash photolysis at room temperature. The conformational properties of the modified alpha chain and beta chain distal heme pockets were also studied through x-ray crystallography and molecular modeling. The data obtained with the various techniques consistently indicate that the polar isosteric mutation in the distal side of the alpha chain heme pocket has a larger effect on the investigated properties than the analogous mutation on the beta chain. We attribute the observed differences to the presence of a water molecule in the distal heme pocket of the modified alpha chains, interacting with the hydroxyl of the threonine side chain. This is indicated by molecular modeling which showed that the water molecule present in the cu chain distal heme pocket can bridge by H bonding between Thr(62)(E11) and His(58)(E7) without introducing any unfavorable steric interactions. Consistent with the dynamic and functional data, the presence of a water molecule in the distal heme pocket of the modified beta chains is not observed by x-ray crystallography.	INFM, I-90123 PALERMO, ITALY; NCI, MOL CARCINOGENESIS LAB, NIH, BETHESDA, MD 20892 USA; UNIV MARYLAND, INST BIOTECHNOL, CTR ADV RES BIOTECHNOL, ROCKVILLE, MD 20850 USA; TEMPLE UNIV, DEPT CHEM, PHILADELPHIA, PA 19122 USA; UNIV MARYLAND, SCH MED, DEPT BIOCHEM & MOL BIOL, BALTIMORE, MD 21201 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University System of Maryland; University of Maryland Baltimore	Cupane, A (corresponding author), UNIV PALERMO, IST FIS, VIA ARCHIRAFI 36, I-90123 PALERMO, ITALY.		Friedman, Fred K/D-4208-2016; Friedman, Fred/O-6173-2019; Leone, Maurizio/F-2353-2010; MILITELLO, VALERIA/F-2664-2011	Friedman, Fred/0000-0002-0284-7067; Leone, Maurizio/0000-0002-0292-7657; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048517] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLBI-48517] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANSARI A, 1987, BIOPHYS CHEM, V26, P337, DOI 10.1016/0301-4622(87)80034-0; BANGCHAROENPAURPONG O, 1984, J AM CHEM SOC, V106, P5688, DOI 10.1021/ja00331a045; BENESCH RE, 1990, J BIOL CHEM, V265, P14881; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; CASE DA, 1979, J MOL BIOL, V132, P353; CHAN CK, 1983, J CHEM PHYS, V79, P5234, DOI 10.1063/1.445712; CHU AH, 1981, J BIOL CHEM, V256, P1199; CORDONE L, 1986, BIOPHYS CHEM, V24, P259, DOI 10.1016/0301-4622(86)85031-1; CORDONE L, 1988, J MOL BIOL, V199, P213, DOI 10.1016/0022-2836(88)90390-7; CUPANE A, 1995, EUR BIOPHYS J BIOPHY, V23, P385, DOI 10.1007/BF00196825; CUPANE A, 1993, BIOPHYS J, V65, P2461, DOI 10.1016/S0006-3495(93)81311-0; CUPANE A, 1993, EUR BIOPHYS J BIOPHY, V21, P385, DOI 10.1007/BF00185865; DIPACE A, 1992, BIOPHYS J, V63, P475, DOI 10.1016/S0006-3495(92)81606-5; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; DOYLE ML, 1992, BIOCHEMISTRY-US, V31, P8629, DOI 10.1021/bi00151a033; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; FRONTICELLI C, 1994, J BIOL CHEM, V269, P23965; FRONTICELLI C, 1993, BIOCHEMISTRY-US, V32, P1235, DOI 10.1021/bi00056a006; FRONTICELLI C, 1991, J PROTEIN CHEM, V10, P495, DOI 10.1007/BF01025477; Gattoni M, 1996, J BIOL CHEM, V271, P10130, DOI 10.1074/jbc.271.17.10130; Hargrove MS, 1997, J BIOL CHEM, V272, P17385, DOI 10.1074/jbc.272.28.17385; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOTTALAM J, 1988, J AM CHEM SOC, V110, P7690, DOI 10.1021/ja00231a018; LEONE M, 1994, EUR BIOPHYS J BIOPHY, V23, P349; Leone M, 1996, EUR BIOPHYS J BIOPHY, V24, P117, DOI 10.1007/BF00180268; LONCHARICH RJ, 1990, J MOL BIOL, V215, P439, DOI 10.1016/S0022-2836(05)80363-8; MARKOWITZ A, 1992, ANAL INSTRUM, V20, P213; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; Melchers B, 1996, BIOPHYS J, V70, P2092, DOI 10.1016/S0006-3495(96)79775-8; MILITELLO V, 1995, PROTEINS, V22, P12, DOI 10.1002/prot.340220103; MURRAY LP, 1988, BIOPHYS CHEM, V29, P63, DOI 10.1016/0301-4622(88)87025-X; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; PARAK F, 1982, J MOL BIOL, V161, P177, DOI 10.1016/0022-2836(82)90285-6; Pechik I, 1996, BIOCHEMISTRY-US, V35, P1935, DOI 10.1021/bi9519967; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; Sanna MT, 1997, J BIOL CHEM, V272, P3478, DOI 10.1074/jbc.272.6.3478; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; Spiro T.G., 1983, IRON PORPHYRINS P2, P89; SRAJER V, 1991, BIOCHEMISTRY-US, V30, P7390, DOI 10.1021/bi00244a005; SRAJER V, 1986, PHYS REV LETT, V57, P6656	46	12	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26271	26278		10.1074/jbc.272.42.26271	http://dx.doi.org/10.1074/jbc.272.42.26271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334196	hybrid			2022-12-25	WOS:A1997YB13900030
J	Saba, JD; Nara, F; Bielawska, A; Garrett, S; Hannun, YA				Saba, JD; Nara, F; Bielawska, A; Garrett, S; Hannun, YA			The BST1 gene of Saccharomyces cerevisiae is the sphingosine-1-phosphate lyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND MESSENGER; SPHINGOSINE; INVASIVENESS; CERAMIDE; GROWTH	Sphingolipids elicit a wide variety of eukaryotic cellular responses, most involving regulation of cell growth, differentiation, and apoptosis, Sphingosine 1-phosphate, a sphingolipid catabolite, is mitogenic in fibroblasts and inhibits the chemotactic mobility and invasiveness of human tumor cells, Sphingosine 1-phosphate degradation requires cleavage at the C2-3 carbon bond by sphingosine phosphate lyase, A yeast genetic approach was used to clone the first sphingosine phosphate lyase gene, BST1, BST1 overexpression conferred resistance to sphingosine in yeast, BST1 deletion produced sensitivity to exogenous D-erythro-sphingosine and phytosphingosine and intracellular accumulation of sphingosine 1-phosphate upon exposure to exogenous sphingosine, This study confirms that sphingoid base metabolism is similar in all eukaryotes and suggests that yeast genetics may be useful in the isolation and identification of other genes involved in sphingolipid signaling and metabolism.	DUKE UNIV,MED CTR,DURHAM,NC 27710	Duke University					NATIONAL CANCER INSTITUTE [K11CA059656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NCI NIH HHS [CA59656-06] Funding Source: Medline; NIGMS NIH HHS [GM 43825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Saba JD, 1996, PHILOS T ROY SOC B, V351, P233, DOI 10.1098/rstb.1996.0021; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SIKORSKI RS, 1989, GENETICS, V122, P19; SPEIGEL S, 1996, FASEB J, V10, P1388; SPIEGEL S, 1994, BREAST CANCER RES TR, V31, P337, DOI 10.1007/BF00666166; VELDHOVEN PV, 1991, J BIOL CHEM, V266, P12502; VELDHOVEN PV, 1993, ADV LIPID RES, V26, P69; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WELLS GB, 1983, J BIOL CHEM, V258, P200	14	201	213	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26087	26090		10.1074/jbc.272.42.26087	http://dx.doi.org/10.1074/jbc.272.42.26087			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334171	hybrid			2022-12-25	WOS:A1997YB13900005
J	Shyur, LF; Poland, BW; Honzatko, RB; Fromm, HJ				Shyur, LF; Poland, BW; Honzatko, RB; Fromm, HJ			Major changes in the kinetic mechanism of AMP inhibition and AMP cooperativity attend the mutation of Arg(49) in fructose-1,6-bisphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RABBIT LIVER FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; PORCINE FRUCTOSE-1,6-BISPHOSPHATASE; BISPHOSPHATASE; BINDING; 1,6-BISPHOSPHATASE; 6-PHOSPHATE; TRANSITION; CATIONS	The significance of subunit interface residues Arg(49) and Lys(50) in the function of porcine liver fructose-1,6-bisphosphatase was explored by site-directed mutagenesis, initial rate kinetics, and circular dichroism spectroscopy. The Lys(50) --> Met mutant had kinetic properties similar to the wild-type enzyme but was more thermostable. Mutants Arg(49) --> Leu, Arg(49) --> Asp, Arg(49) --> Cys were less thermostable than the wild-type enzyme yet exhibited wild-type values for k(cat) and K-m. The K-i for the competitive inhibitor fructose 2, 6-bisphosphate increased 3- and 8-fold in Arg(49) --> Leu and Arg(49) --> Asp, respectively, The K-a for Mg2+ increased 4-8-fold for the Arg(49) mutants, with no alteration in the cooperativity of Mg2+ binding, Position 49 mutants had 4-10-fold lower AMP affinity, Most significantly, the mechanism of AMP inhibition with respect to fructose 1,6-bisphosphate changed from noncompetitive (wild-type enzyme) to competitive (Arg(49) --> Leu and Arg(49) --> ASP mutants) and to uncompetitive (Arg(49) --> Cys mutant), In addition, AMP cooperativity was absent in the Arg(49) mutants, The R and T-state circular dichroism spectra of the position 49 mutants were identical and superimposable on only the R-state spectrum of the wild-type enzyme. Changes from noncompetitive to competitive inhibition by AMP can be accommodated within the framework of a steady-state Random Ri Ri mechanism, The appearance of uncompetitive inhibition, however, suggests that a more complex mechanism may be necessary to account for the kinetic properties of the enzyme.	IOWA STATE UNIV,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, XPLOR SYSTEM CRYSTAL; BURTON VA, 1993, BIOCHEM BIOPH RES CO, V192, P511, DOI 10.1006/bbrc.1993.1445; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KE HM, 1991, BIOCHEMISTRY-US, V30, P4412, DOI 10.1021/bi00232a007; KITAJIMA S, 1983, J BIOL CHEM, V258, P7352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3371, DOI 10.1021/bi00794a009; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; Lu GQ, 1997, J BIOL CHEM, V272, P5076, DOI 10.1074/jbc.272.8.5076; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; RUDOLPH FB, 1971, J BIOL CHEM, V246, P6611; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; SHYUR LF, 1995, ARCH BIOCHEM BIOPHYS, V319, P123, DOI 10.1006/abbi.1995.1273; Shyur LF, 1996, J BIOL CHEM, V271, P33301, DOI 10.1074/jbc.271.52.33301; Shyur LF, 1996, J BIOL CHEM, V271, P3005, DOI 10.1074/jbc.271.6.3005; SIANO DB, 1975, ARCH BIOCHEM BIOPHYS, V170, P587, DOI 10.1016/0003-9861(75)90154-X; SOLA MM, 1993, INT J BIOCHEM, V25, P1963, DOI 10.1016/0020-711X(88)90332-1; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TAKETA K, 1965, J BIOL CHEM, V240, P651; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Ulm E H, 1975, Methods Enzymol, V42, P369; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P2861; XUE YF, 1994, P NATL ACAD SCI USA, V91, P12482, DOI 10.1073/pnas.91.26.12482; Zhang RL, 1996, BIOCHEMISTRY-US, V35, P3038, DOI 10.1021/bi952188i; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	35	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26295	26299		10.1074/jbc.272.42.26295	http://dx.doi.org/10.1074/jbc.272.42.26295			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334199	hybrid			2022-12-25	WOS:A1997YB13900033
J	Kahyaoglu, A; Haghjoo, K; Guo, FS; Jordan, F; Kettner, C; Felfoldi, F; Polgar, L				Kahyaoglu, A; Haghjoo, K; Guo, FS; Jordan, F; Kettner, C; Felfoldi, F; Polgar, L			Low barrier hydrogen bond is absent in the catalytic triads in the ground state but is present in a transition-state complex in the prolyl oligopeptidase family of serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; CYTOSOLIC ASPARTATE-AMINOTRANSFERASE; N-15 NMR-SPECTROSCOPY; ENZYME CATALYSIS; ESCHERICHIA-COLI; HISTIDINE-RESIDUES; 10-18-PPM RANGE; H-1 RESONANCES; ACTIVE-SITE; CHYMOTRYPSIN	High frequency proton NMR spectra for two members of the prolyl oligopeptidase class of serine proteases, prolyl oligopeptidase and oligopeptidase B, showed that resonances corresponding to the active center histidine (NH)-H-delta 1 and (NH)-H-epsilon 2 generally observed in this region, are absent in these enzymes, However, for both enzymes, as well as with the H652A and H652Q active center variants of oligopeptidase B, there are two resonances observed in this region that could be assigned to two protonated histidines with a noncatalytic function, The results indicate that these two histidines participate in strong hydrogen bonds, The absence of resonances pertinent to the active center histidine resonances suggests the absence of a low barrier hydrogen bond between the Asp and His in these two enzymes in their ground states, Addition of the peptide boronic acid t-butoxycarbonyl-(D)Val-Leu-(L)boroArg to oligopeptidase B resulted in potent, slow binding inhibition of the enzyme and the appearance of a new resonance at 15.8 ppm, whose chemical shift is appropriate for a tetrahedral boronate complex and a low barrier hydrogen bond. The results demonstrate important dissimilarities between the active centers of the prolyl oligopeptidase class of serine proteases and the pancreatic and subtilisin classes both in the ground state and in the transition-state analog complexes.	RUTGERS STATE UNIV, DEPT CHEM, NEWARK, NJ 07102 USA; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA; HUNGARIAN ACAD SCI, BIOL RES CTR, INST ENZYMOL, H-1113 BUDAPEST, HUNGARY	Rutgers State University Newark; Rutgers State University New Brunswick; DuPont; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences								ADEBODUN F, 1989, J CELL BIOCHEM, V40, P249, DOI 10.1002/jcb.240400213; BACHOVCHIN WW, 1985, P NATL ACAD SCI USA, V82, P7948, DOI 10.1073/pnas.82.23.7948; BACHOVCHIN WW, 1986, BIOCHEMISTRY-US, V25, P7751, DOI 10.1021/bi00371a070; BACHOVCHIN WW, 1988, BIOCHEMISTRY-US, V27, P7689, DOI 10.1021/bi00420a018; CLELAND WW, 1995, SCIENCE, V269, P104, DOI 10.1126/science.269.5220.104; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; FREY PA, 1995, SCIENCE, V269, P104, DOI 10.1126/science.269.5220.104-a; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; HAGHJOO K, 1996, THESIS RUTGERS NEWAR; Halkides CJ, 1996, BIOCHEMISTRY-US, V35, P15941, DOI 10.1021/bi961805f; Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7; HORE PJ, 1983, J MAGN RESON, V55, P283, DOI 10.1016/0022-2364(83)90240-8; JORDAN F, 1981, BIOCHEMISTRY-US, V20, P6366, DOI 10.1021/bi00525a013; Kahyaoglu A, 1997, BIOCHEM J, V322, P839, DOI 10.1042/bj3220839; KANATANI A, 1991, J BIOCHEM-TOKYO, V110, P315, DOI 10.1093/oxfordjournals.jbchem.a123577; KETTNER CA, 1984, J BIOL CHEM, V259, P5106; KINTANAR A, 1991, J BIOL CHEM, V266, P17222; LIANG TC, 1987, BIOCHEMISTRY-US, V26, P7603, DOI 10.1021/bi00398a011; Markley JL, 1996, BIOCHEMISTRY-US, V35, P11092, DOI 10.1021/bi961366k; MARKLEY JL, 1978, BIOCHEMISTRY-US, V17, P4648, DOI 10.1021/bi00615a010; METZLER DE, 1994, J BIOL CHEM, V269, P28027; METZLER DE, 1994, J BIOL CHEM, V269, P28017; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; POLGAR L, 1994, METHOD ENZYMOL, V244, P188; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; ROBILLAR.G, 1974, J MOL BIOL, V86, P519, DOI 10.1016/0022-2836(74)90178-8; ROBILLAR.G, 1974, J MOL BIOL, V86, P541, DOI 10.1016/0022-2836(74)90179-X; ROBILLARD G, 1972, J MOL BIOL, V71, P507, DOI 10.1016/0022-2836(72)90366-X; STRONGIN AY, 1978, J BACTERIOL, V133, P1401, DOI 10.1128/JB.133.3.1401-1411.1978; TOBIN JB, 1995, BIOCHEMISTRY-US, V34, P6919, DOI 10.1021/bi00021a002; TONG HX, 1995, BIOCHEMISTRY-US, V34, P3362, DOI 10.1021/bi00010a027; TSURU D, 1994, METHOD ENZYMOL, V244, P201; WARSHEL A, 1995, SCIENCE, V269, P102, DOI 10.1126/science.7661987; WILK S, 1983, J NEUROCHEM, V41, P69, DOI 10.1111/j.1471-4159.1983.tb11815.x; ZHONG S, 1995, J AM CHEM SOC, V117, P7048, DOI 10.1021/ja00132a002; ZHONG S, 1991, THESI SRUTGERS NEWAR	36	28	28	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25547	25554		10.1074/jbc.272.41.25547	http://dx.doi.org/10.1074/jbc.272.41.25547			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325271	hybrid			2022-12-25	WOS:A1997YA35800026
J	Peppel, K; Boekhoff, I; McDonald, P; Breer, H; Caron, MG; Lefkowitz, RJ				Peppel, K; Boekhoff, I; McDonald, P; Breer, H; Caron, MG; Lefkowitz, RJ			G protein-coupled receptor kinase 3 (GRK3) gene disruption leads to loss of odorant receptor desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAILING HUMAN HEART; BETA-ARRESTIN; FAMILY; EXPRESSION; ACTIVATION; RHODOPSIN; MEMBER	G protein-coupled receptor kinases (GRKs) 2 and 3 (beta-adrenergic receptor kinases 1 and 2 (beta ARK1 and -2)) mediate the agonist dependent phosphorylation and uncoupling of many G protein-coupled receptors, These two members of the GRK family share a high degree of sequence homology and show overlapping patterns of substrate specificity in vitro. To define their physiological roles in vivo we have generated mice that carry targeted disruption of these genes. In contrast to GRK2-deficient mice, which die in utero (Jaber, M., Koch, W. J., Rockman, H., Smith, B., Bond, R. A., Sulik, K. K., Boss, J. JR., Lefkowitz, R. J. Caron, M. G., and Giros, B. (1996) Proc. Natl. Acad, Sci, U. S. A. 93, 12974-12979), GRK3 deletion allows for normal embryonic and postnatal development, GRK3 is expressed to a high degree in the olfactory epithelium, where GRK2 is absent, Here we report that cilia preparations derived from GRK3-deficient mice lack the fast agonist-induced desensitization normally seen after odorant stimulation, Moreover, total second messenger (cAMP) generation in these cilia preparations following odorant stimulation is markedly reduced when compared with preparations from wildtype littermates, This reduction in the ability to generate cAMP is evident even in the presence of nonodorant receptor stimuli (GTP gamma S and forskolin), suggesting a compensatory dampening of the G protein-adenylyl cyclase system in the GRK3 (-/-) mice in the olfactory epithelium, These findings demonstrate the requirement of GRK3 for odorant-induced desensitization of cAMP responses.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,HOWARD HUGHES MED INST,DURHAM,NC 27710; UNIV HOHENHEIM,DEPT PHYSIOL,D-70593 STUTTGART,GERMANY	Duke University; Duke University; Duke University; Howard Hughes Medical Institute; University Hohenheim			Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANHOLT RRH, 1986, J NEUROSCI, V6, P1403; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FUCHS S, 1995, NAT GENET, V10, P360, DOI 10.1038/ng0795-360; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KRIEGER J, 1994, EUR J BIOCHEM, V219, P829, DOI 10.1111/j.1432-1033.1994.tb18564.x; LEFKOWITZ RJ, 1993, HDB EXP PHARM, V46, P33; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; NIH, 1985, NIH PUBL; PERSHADSINGH HA, 1980, J BIOL CHEM, V255, P4087; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Yamamoto S, 1997, NAT GENET, V15, P175, DOI 10.1038/ng0297-175	25	129	131	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25425	25428		10.1074/jbc.272.41.25425	http://dx.doi.org/10.1074/jbc.272.41.25425			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325250	hybrid			2022-12-25	WOS:A1997YA35800005
J	Rivas, S; Bolland, S; Cabezon, E; Goni, FM; delaCruz, F				Rivas, S; Bolland, S; Cabezon, E; Goni, FM; delaCruz, F			TrwD, a protein encoded by the IncW plasmid R388, displays an ATP hydrolase activity essential for bacterial conjugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; PULLULANASE SECRETION; CYTOPLASMIC MEMBRANE; OUTER-MEMBRANE; BINDING SITE; DNA TRANSFER; PURIFICATION; SYSTEM; ORGANIZATION	A 1.7-kilobase pair segment from the conjugative transfer region of plasmid R388 DNA was cloned and sequenced, It contained trwD, a gene essential for plasmid R388 conjugation, for expression of the conjugative W-pilus and for sensitivity to phage PRD1. The deduced amino acid sequence of TrwD showed homology to the PulE/VirB11 superfamily of potential ATPases involved in various types of transport processes, A fusion of trwD with the glutathione S-transferase (GST) was constructed, and the resulting fusion protein was purified from overproducing bacteria. Factor X-a hydrolysis of GST-TrwD and further purification rendered TrwD protein with more than 95% purity, Antibodies raised against TrwD localized it both in the soluble fraction and in the outer membrane of Escherichia coli. TrwD is probably a peripheral outer membrane protein because it could be solubilized by increasing salt concentration to 0.5 M NaCl in the lysis buffer, Both purified GST-TrwD and TrwD could hydrolize ATP, ATPase activity increased 2-fold in the presence of detergent-phospholipid mixed micelles, To study the importance of the nucleotide-binding site, Walker box A (GXXGXGK(T/S)), present in TrwD, the conserved lysine residue was replaced by glutamine, The mutant protein, expressed and purified under the same conditions as the wild type, did not exhibit ATPase activity, TrwD(K203Q) was not able to complement the mutation in trwD of the R388 mutant plasmid, suggesting the essentiality of the ATPase activity of the protein in the conjugative process. Further more, the dominant character of this mutation suggested that GST-TrwD(K432Q) was still able to interact either with itself or with other component(s) of the conjugative machinery.	UNIV CANTABRIA, DEPT BIOL MOL, SANTANDER 39011, SPAIN; UNIV BASQUE COUNTRY, DEPT BIOQUIM,CSIC,GRP BIOMEMBRANES,UNIDAD ASOCIADA, E-48080 BILBAO, SPAIN	Universidad de Cantabria; Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country			Goni, Felix M/M-5425-2015; Cabezon, Elena/K-5874-2014; de la Cruz, Fernando/L-2812-2014	Goni, Felix M/0000-0001-6270-9216; de la Cruz, Fernando/0000-0003-4758-6857; Cabezon, Elena/0000-0002-6177-5016				ATSCHUL SF, 1990, J MOL BIOL, V215, P403; BAKELS RHA, 1994, BIOCHEM BIOPH RES CO, V201, P487, DOI 10.1006/bbrc.1994.1728; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BOLLAND S, 1990, J BACTERIOL, V172, P5795, DOI 10.1128/jb.172.10.5795-5802.1990; BOLLAND S, 1991, THESIS U CANTABRIA S; CAZAUX C, 1994, J BIOL CHEM, V269, P8246; CHRISTIE PJ, 1989, P NATL ACAD SCI USA, V86, P9677, DOI 10.1073/pnas.86.24.9677; DATTA N, 1972, J GEN MICROBIOL, V72, P349, DOI 10.1099/00221287-72-2-349; DEMAAGD RA, 1986, J BACTERIOL, V167, P1083, DOI 10.1128/jb.167.3.1083-1085.1986; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Harlow E., 1988, ANTIBODIES LAB MANUA; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x; INOUYE S, 1991, DIRECTED MUTAGENESIS, P71; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKA E, 1995, ANNU REV BIOCHEM, V64, P141, DOI 10.1146/annurev.bi.64.070195.001041; LLOSA M, 1994, J MOL BIOL, V235, P448, DOI 10.1006/jmbi.1994.1005; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; Maniatis T., 1982, MOL CLONING; MOTALLEBIVESHAREH M, 1992, MOL MICROBIOL, V6, P907, DOI 10.1111/j.1365-2958.1992.tb01541.x; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Pansegrau W, 1996, PROG NUCLEIC ACID RE, V54, P197, DOI 10.1016/S0079-6603(08)60364-5; POSSOT O, 1992, MOL MICROBIOL, V6, P95, DOI 10.1111/j.1365-2958.1992.tb00841.x; POSSOT O, 1994, MOL MICROBIOL, V12, P287, DOI 10.1111/j.1365-2958.1994.tb01017.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; SADLER JR, 1980, GENE, V8, P279, DOI 10.1016/0378-1119(80)90005-0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENS KM, 1995, J BACTERIOL, V177, P27, DOI 10.1002/path.1711770106; TURNER LR, 1993, J BACTERIOL, V175, P4962, DOI 10.1128/JB.175.16.4962-4969.1993; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WEISSBACH A, 1959, J BIOL CHEM, V234, P705; WHITCHURCH CB, 1991, GENE, V101, P33, DOI 10.1016/0378-1119(91)90221-V; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	38	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25583	25590		10.1074/jbc.272.41.25583	http://dx.doi.org/10.1074/jbc.272.41.25583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325277	hybrid			2022-12-25	WOS:A1997YA35800032
J	Ascoli, GA; Luu, KX; Olds, JL; Nelson, TJ; Gusev, PA; Bertucci, C; Bramanti, E; Raffaelli, A; Salvadori, P; Alkon, DL				Ascoli, GA; Luu, KX; Olds, JL; Nelson, TJ; Gusev, PA; Bertucci, C; Bramanti, E; Raffaelli, A; Salvadori, P; Alkon, DL			Secondary structure and Ca2+-induced conformational change of calexcitin, a learning-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CALCIUM-MODULATED PROTEINS; EF-HAND; CIRCULAR-DICHROISM; KINASE-C; MOLECULAR MECHANISMS; STRUCTURE PREDICTION; POTASSIUM CHANNELS; ESCHERICHIA-COLI; MEMORY STORAGE	Calexcitin/cp20 is a low molecular weight GTP- and Ca2+-binding protein, which is phosphorylated by protein kinase C during associative learning, and reproduces many of the cellular effects of learning, such as the reduction of potassium currents in neurons, Here, the secondary structure of cloned squid calexcitin was determined by circular dichroism in aqueous solution and by Fourier transform infrared spectroscopy both in solution and on dried films, The results obtained with the two techniques are in agreement with each other and coincide with the secondary structure computed from the amino acid sequence, In solution, calexcitin is one-third in alpha-helix and one-fifth in beta-sheet. The conformation of the protein in solid state depends on the concentration of the starting solution, suggesting the occurrence of surface aggregation. The secondary structure also depends on the binding of calcium, which causes an increase in alpha-helix and a decrease in beta-sheet, as estimated by circular dichroism, The conformation of calexcitin is independent of ionic strength, and the calcium-induced structural transition is slightly inhibited by Mg2+ and low pH, while favored by high pH. The switch of calexcitin's secondary structure upon calcium binding, which was confirmed by intrinsic fluorescence spectroscopy and nondenaturing gel electrophoresis, is reversible and occurs in a physiologically meaningful range of Ca2+ concentration. The calcium-bound form is more globular than the apoprotein, Unlike other EF-hand proteins, calexcitin's overall lipophilicity is not affected by calcium binding, as assessed by hydrophobic liquid chromatography. Preliminary results from patch-clamp experiments indicated that calcium is necessary for calexcitin to inhibit potassium channels and thus to increase membrane excitability, Therefore the calcium-dependent conformational equilibrium of calexcitin could serve as a molecular switch for the short term modulation of neuronal activity following associative conditioning.	UNIV PISA,DIPARTIMENTO CHIM & CHIM IND,CNR,CTR STUDIO MACROMOL STEREORDINATE & OTTICAMENTE,I-56126 PISA,ITALY; CNR,INST INSTRUMENTAL ANALYT CHEM,I-56126 PISA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Pisa; Consiglio Nazionale delle Ricerche (CNR)	Ascoli, GA (corresponding author), NINCDS,LAS,NIH,BLDG 36,RM 4A24,35 CONVENT DR MSC 4124,BETHESDA,MD 20892, USA.		Olds, James L./P-4917-2019; Olds, James/D-2867-2011; Bramanti, Emilia/E-1114-2011; Bramanti, Emilia/AAQ-9425-2021	Olds, James L./0000-0003-3214-946X; Bramanti, Emilia/0000-0001-8478-7370; Raffaelli, Andrea/0000-0002-6094-835X				ALKON DL, 1989, SCI AM, V261, P42, DOI 10.1038/scientificamerican0789-42; ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; ALKON DL, 1990, FASEB J, V4, P1567, DOI 10.1096/fasebj.4.6.2108074; ALKON DL, 1990, P NATL ACAD SCI USA, V87, P1611, DOI 10.1073/pnas.87.4.1611; ALKON DL, 1995, BEHAV BRAIN RES, V66, P151, DOI 10.1016/0166-4328(94)00142-3; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; AURELL L, 1977, THROMB RES, V11, P595, DOI 10.1016/0049-3848(77)90018-4; BRAMANTI E, 1994, J CHEMOMETR, V8, P409, DOI 10.1002/cem.1180080606; Bramanti E, 1996, BIOPOLYMERS, V38, P639, DOI 10.1002/(SICI)1097-0282(199605)38:5<639::AID-BIP8>3.0.CO;2-T; BRAMANTI E, 1997, IN PRESS BIOPOLYMERS, V41; COSTANTINO HR, 1995, BBA-PROTEIN STRUCT M, V1253, P69, DOI 10.1016/0167-4838(95)00156-O; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DUDAI Y, 1985, FEBS LETT, V191, P165, DOI 10.1016/0014-5793(85)80001-6; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; FU FN, 1994, APPL SPECTROSC, V48, P1432, DOI 10.1366/0003702944028065; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; HADDEN JM, 1995, BBA-PROTEIN STRUCT M, V1248, P115, DOI 10.1016/0167-4838(95)00010-R; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HENNESSEY JP, 1987, BIOPOLYMERS, V26, P561, DOI 10.1002/bip.360260409; IKURA M, 1996, TRENDS BIOCHEM SCI, V21, P6; JENG AY, 1987, BIOCHEM BIOPH RES CO, V145, P782, DOI 10.1016/0006-291X(87)91033-3; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOHNSON WC, 1992, METHOD ENZYMOL, V210, P426; KIM CS, 1995, P NATL ACAD SCI USA, V92, P3060, DOI 10.1073/pnas.92.7.3060; LINSE S, 1987, BIOCHEMISTRY-US, V26, P6723, DOI 10.1021/bi00395a023; LU GH, 1994, PLANT CELL, V6, P501, DOI 10.1105/tpc.6.4.501; MANNING MC, 1989, J PHARMACEUT BIOMED, V7, P1103, DOI 10.1016/0731-7085(89)80049-4; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MOSHIACH S, 1993, BRAIN RES, V605, P298, DOI 10.1016/0006-8993(93)91754-G; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; NEARY JT, 1981, NATURE, V293, P658, DOI 10.1038/293658a0; Nelson TJ, 1996, P NATL ACAD SCI USA, V93, P13808, DOI 10.1073/pnas.93.24.13808; NELSON TJ, 1990, SCIENCE, V247, P1479, DOI 10.1126/science.2108498; NELSON TJ, 1991, MOL NEUROBIOL, V5, P315, DOI 10.1007/BF02935554; NELSON TJ, 1994, P NATL ACAD SCI USA, V91, P9287, DOI 10.1073/pnas.91.20.9287; NELSON TJ, 1995, J NEUROCHEM, V65, P2350; NELSON TJ, 1994, J NEUROCHEM, V57, P2065; OLDS JL, 1989, SCIENCE, V245, P866, DOI 10.1126/science.2772638; PORTZEHL H, 1964, BIOCHIM BIOPHYS ACTA, V79, P581, DOI 10.1016/0926-6577(64)90224-4; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; SAKAKIBARA M, 1986, BIOPHYS J, V50, P319, DOI 10.1016/S0006-3495(86)83465-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARTZ JH, 1987, ANNU REV NEUROSCI, V10, P459; SHETERLINE P, 1995, PROTEIN PROFILE, V2, P305; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TRAVE G, 1995, EUR J BIOCHEM, V227, P35, DOI 10.1111/j.1432-1033.1995.tb20357.x; WEBER C, 1994, J BIOL CHEM, V269, P15795	53	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24771	24779		10.1074/jbc.272.40.24771	http://dx.doi.org/10.1074/jbc.272.40.24771			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312073	hybrid			2022-12-25	WOS:A1997XY97000012
J	Ault, BH; Schmidt, BZ; Fowler, NL; Kashtan, CE; Ahmed, AE; Vogt, BA; Colten, HR				Ault, BH; Schmidt, BZ; Fowler, NL; Kashtan, CE; Ahmed, AE; Vogt, BA; Colten, HR			Human factor H deficiency - Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT FACTOR-H; NASCENT POLYPEPTIDE-CHAINS; HOMOZYGOUS FACTOR-H; REGULATORY PROTEINS; MENINGOCOCCAL DISEASE; HUMAN GENES; B-SUBUNIT; DEGRADATION; COMPONENTS; SEQUENCE	The synthesis and secretion of factor H, a regulatory protein of the complement system, were studied in skin fibroblasts from an H-deficient child who has chronic hypocomplementemic renal disease, In normal fibro blasts, factor H transcripts of 4.3 and 1.8 kilobase pairs (kb) encode a 155-kDa protein containing short consensus repeat (SCR) domains 1-20 and a 45-kDa protein which contains SCRs 1-7, respectively. The patient's fibroblasts expressed normal amounts of the 4.3- and 1.8-kb messages constitutively and after tumor necrosis factor-alpha/interferon-gamma stimulation. Lysates of [S-35]methionine-labeled fibroblasts from the patient contained the 155- and 45-kDa H polypeptides, but secretion of the 155-kDa protein was blocked; the 45-kDa protein was secreted with normal kinetics, The patient's plasma lacked the 155-kDa protein but contained the small form of H. Moreover, in fibroblasts the retained 155-kDa factor H protein was not degraded, even after 12 h, Immunoflourescent staining and confocal microscopic imaging of the patient's fibroblasts indicated that factor H was retained in the endoplasmic reticulum, Sequence analysis of reverse transcription-polymerase chain reaction products (the entire coding region) and genomic DNA revealed a T1679C substitution on one allele and a G2949A substitution on the other (C518R mutation in SCR 9 and C991Y mutation in SCR 16, respectively), Both mutations affect conserved cysteine residues characteristic of SCR modules and therefore predict pro found changes in the higher order structure of the 155-kDa factor H protein, These data provide the first description of a molecular mechanism for factor H deficiency and yield important insights into the normal secretory pathway for this and other plasma proteins with SCR motifs.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; UNIV MINNESOTA,DEPT PEDIAT,MINNEAPOLIS,MN 55455; SPECIALTY LABS INC,SANTA MONICA,CA 90404	Washington University (WUSTL); University of Minnesota System; University of Minnesota Twin Cities				Schmidt, Bela Z/0000-0003-1085-9372				BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAI M, 1988, J CLIN IMMUNOL, V8, P50, DOI 10.1007/BF00915156; BROOIMANS RA, 1989, J IMMUNOL, V142, P2024; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLTEN HR, 1992, ANNU REV IMMUNOL, V10, P809, DOI 10.1146/annurev.iy.10.040192.004113; COLTEN HR, 1995, BLOOD PRINCIPLES PRA, P477; DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588; DECORDOBA SR, 1985, J EXP MED, V161, P1189, DOI 10.1084/jem.161.5.1189; DISCIPIO RG, 1992, J IMMUNOL, V149, P2592; ESTALLER C, 1991, EUR J IMMUNOL, V21, P799, DOI 10.1002/eji.1830210337; FELICIELLO I, 1993, ANAL BIOCHEM, V212, P304; FIJEN CAP, 1989, LANCET, V2, P585; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GARNIER G, 1992, J EXP MED, V175, P471, DOI 10.1084/jem.175.2.471; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; HASHIGUCHI T, 1995, J CLIN INVEST, V95, P1002, DOI 10.1172/JCI117744; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751; JANATOVA J, 1989, BIOCHEMISTRY-US, V28, P4754, DOI 10.1021/bi00437a036; KATZ Y, 1988, J IMMUNOL, V141, P559; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KUHN S, 1995, J IMMUNOL, V155, P5663; KULICS J, 1994, IMMUNOLOGY, V82, P509; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642; LEVY M, 1986, KIDNEY INT, V30, P949, DOI 10.1038/ki.1986.278; LITZ CE, 1988, AM J MED GENET, V30, P821, DOI 10.1002/ajmg.1320300316; LOPEZLARREA C, 1987, BIOCHEM SOC T, V15, P648, DOI 10.1042/bst0150648; MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C; NIELSEN HE, 1989, SCAND J IMMUNOL, V30, P711, DOI 10.1111/j.1365-3083.1989.tb02480.x; NILSSON UR, 1965, J EXP MED, V122, P277, DOI 10.1084/jem.122.2.277; PICHETTE V, 1994, AM J KIDNEY DIS, V24, P936, DOI 10.1016/S0272-6386(12)81065-1; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; REYCAMPOS J, 1990, GENOMICS, V7, P644, DOI 10.1016/0888-7543(90)90213-E; RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593; SCHULZ TF, 1986, EUR J IMMUNOL, V16, P1351, DOI 10.1002/eji.1830161107; SCHWAEBLE W, 1991, EUR J BIOCHEM, V198, P399, DOI 10.1111/j.1432-1033.1991.tb16028.x; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; SIMSEK S, 1994, BRIT J HAEMATOL, V88, P839, DOI 10.1111/j.1365-2141.1994.tb05125.x; SKERKA C, 1995, IMMUNOGENETICS, V42, P268; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; TAYLOR SAM, 1992, THROMB HAEMOSTASIS, V67, P63; THOMPSON RA, 1981, CLIN EXP IMMUNOL, V46, P110; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; VIK DP, 1989, CURR TOP MICROBIOL I, V153, P147; VOGT BA, 1995, PEDIATR NEPHROL, V9, P11, DOI 10.1007/BF00858956; WHALEY K, 1980, J EXP MED, V151, P501, DOI 10.1084/jem.151.3.501; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; Yel L, 1996, NEW ENGL J MED, V335, P1486, DOI 10.1056/NEJM199611143352003; ZIPFEL PF, 1994, IMMUNOL TODAY, V15, P121, DOI 10.1016/0167-5699(94)90155-4	52	121	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25168	25175		10.1074/jbc.272.40.25168	http://dx.doi.org/10.1074/jbc.272.40.25168			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312129	hybrid			2022-12-25	WOS:A1997XY97000068
J	Jackson, DE; Kupcho, KR; Newman, PJ				Jackson, DE; Kupcho, KR; Newman, PJ			Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of platelet endothelial cell adhesion molecule-1 (PECAM-1) that are required for the cellular association and activation of the protein-tyrosine phosphatase, SHP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SH2 DOMAINS; TRANSENDOTHELIAL MIGRATION; PHOSPHOLIPASE-C; BETA-SUBUNIT; SH-PTP2; PHOSPHORYLATION; KINASE; SRC; SYP	Recent studies have shown that the Src homology-2 (SH2) domain containing protein-tyrosine phosphatase, SHP-2, associates with the cytoplasmic domain of PECAM-1 as it becomes tyrosine-phosphorylated during platelet aggregation: a process that can be mimicked in part by small synthetic phosphopeptides corresponding to the cytoplasmic domain of PECAM-1 encompassing tyrosine residues Tyr-663 or Tyr-686. To further examine the molecular requirements for PECAM-1/SHP-2 interactions, we generated human embryonic kidney (HEK)-293 cell lines that stably expressed mutant forms of PECAM-1 harboring tyrosine to phenylalanine (Tyr --> Phe) mutations in the cytoplasmic domain, Y663F and Y686F forms of PECAM-1 were tyrosine-phosphorylated to a somewhat lesser extent than wild-type PECAM-1, and a doubly substituted Y663,686F form of PECAM-1 failed to become tyrosine-phosphorylated, suggesting that the PECAM-1 cytoplasmic domain tyrosine residues 596, 636 and 701 do nob serve as substrates for cellular kinases, Interestingly, SHP-2 binding was lost when either Tyr-663 or Tyr-686 were changed to phenylalanine, indicating that both residues are required for SHP-2/PECAM-1 association, Although PECAM-1 phosphopeptides NSDVQpY(663)TEVQV and DTETVpY(686)SEVRK stimulated the catalytic activity of the phosphatase to a similar extent, surface plasmon resonance studies revealed that the Tyr-663 containing peptide had approximately 10-fold higher affinity for SHP-2 than did the Tyr-686 peptide. Finally, peptido-precipitation analysis showed that the NH2-terminal SH2 domain of SHP-2 reacted preferentially with the Tyr-663 PECAM-1 phosphopeptide, while the Tyr-686 phosphopeptide associated only with the COOH-terminal SH2 domain of the phosphatase, Together, these data provide a molecular model for PECAM-1/SHP-2 interactions that may shed light on the downstream events that follow PECAM-1-mediated interactions of vascular cells.	BLOOD CTR SE WISCONSIN INC, BLOOD RES INST, MILWAUKEE, WI 53233 USA; MED COLL WISCONSIN, DEPT PHARMACOL, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT CELLULAR BIOL, MILWAUKEE, WI 53226 USA	Versiti Blood Center of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044612] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-44612] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BERMAN ME, 1995, J IMMUNOL, V154, P299; Berman ME, 1996, J IMMUNOL, V156, P1515; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASE RD, 1994, J BIOL CHEM, V269, P10467; DECHERT U, 1994, J BIOL CHEM, V269, P5602; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GOLDBERGER A, 1994, J BIOL CHEM, V269, P17183; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HUYER G, 1995, BIOCHEMISTRY-US, V34, P1040, DOI 10.1021/bi00003a039; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEAVESLEY DI, 1994, J IMMUNOL, V153, P4673; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Liao F, 1997, J EXP MED, V185, P1349, DOI 10.1084/jem.185.7.1349; Lu TT, 1997, J BIOL CHEM, V272, P14442, DOI 10.1074/jbc.272.22.14442; Matsumura T, 1997, J IMMUNOL, V158, P3408; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MODDERMAN PW, 1994, BIOCHEM J, V299, P613, DOI 10.1042/bj2990613; MULLER WA, 1992, J EXP MED, V176, P819, DOI 10.1084/jem.176.3.819; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; NEWMAN PJ, 1994, PLATELET DEPENDENT V, P165; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Osawa M, 1997, EUR J CELL BIOL, V72, P229; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENG ZY, 1995, ONCOGENE, V11, P1955; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; ROTIN D, 1992, J BIOL CHEM, V267, P9678; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sagawa K, 1997, J BIOL CHEM, V272, P13412, DOI 10.1074/jbc.272.20.13412; SCHIMMENTI LA, 1992, J CELL PHYSIOL, V153, P417, DOI 10.1002/jcp.1041530222; Sheibani N, 1997, MOL BIOL CELL, V8, P1329, DOI 10.1091/mbc.8.7.1329; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STONE RL, 1994, J BIOL CHEM, V269, P31323; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; Sun J, 1996, J BIOL CHEM, V271, P18561, DOI 10.1074/jbc.271.31.18561; Sun QH, 1996, J BIOL CHEM, V271, P11090, DOI 10.1074/jbc.271.19.11090; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Varon D, 1996, TISSUE ANTIGENS, V48, pPL402; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zocchi MR, 1996, EUR J IMMUNOL, V26, P759, DOI 10.1002/eji.1830260406	62	129	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24868	24875		10.1074/jbc.272.40.24868	http://dx.doi.org/10.1074/jbc.272.40.24868			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312087	hybrid			2022-12-25	WOS:A1997XY97000026
J	Lu, XH; Nemoto, S; Lin, AN				Lu, XH; Nemoto, S; Lin, AN			Identification of c-Jun NH2-terminal protein kinase (JNK)-activating kinase 2 as an activator of JNK but not p38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; MAMMALIAN-CELLS; STRESS; PHOSPHORYLATION; EXPRESSION; MEK; RAF; CASCADE; INVITRO	c-Jun NH2-terminal protein kinase (JNK), a distant member of the mitogen-activated protein (MAP) kinase family, regulates gene expression in response to various extracellular stimuli. JNK is activated by JNK-activating kinase 1 (JNKK1), a dual specificity protein kinase that phosphorylates JNK on threonine 183 and tyrosine 185 residues. Here we show that JNKK2, a novel member of the MAP kinase kinase family, was phosphorylated and activated by MEKK1, a MAP kinase kinase kinase in the JNK signaling cascade. JNKK2 activity was also stimulated by constitutively active forms of Pac and Cdc42Hs, members of the Rho small GTP-binding protein family. Unlike JNKK1 that activates both JNK and p38 MAP kinases, JNKK2 stimulated only JNK. Transient transfection assays demonstrated that JNKK2 potentiated the stimulation of c-Jun transcriptional activity by MEKK1. The existence of multiple JNK-activating kinases may contribute to the specificity of the JNK signaling cascade.	UNIV ALABAMA,DEPT PATHOL,DIV MOL & CELLULAR PATHOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NCI NIH HHS [CA73740] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073740] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1992, J BIOL CHEM, V267, P25628; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	40	105	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24751	24754		10.1074/jbc.272.40.24751	http://dx.doi.org/10.1074/jbc.272.40.24751			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312068	hybrid			2022-12-25	WOS:A1997XY97000007
J	Menice, CB; Hulvershorn, J; Adam, LP; Wang, CLA; Morgan, KG				Menice, CB; Hulvershorn, J; Adam, LP; Wang, CLA; Morgan, KG			Calponin and mitogen-activated protein kinase signaling in differentiated vascular smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHORYLATION; ESTER-INDUCED CONTRACTION; MYOSIN PHOSPHORYLATION; INTRACELLULAR CALCIUM; CALDESMON; FORCE; CELLS; CA2+	Contraction of smooth muscle cells is generally assumed to require Ca2+/calmodulin-dependent phosphorylation of the 20-kDa myosin light chains. However, we report here that in the absence of extracellular calcium, phenylephrine induces a contraction of freshly isolated ferret aorta cells in the absence of increases in intracellular ionized calcium or light chain phosphorylation levels but in the presence of activation of mitogen-activated protein kinase. A protein at 36 kDa co-immunoprecipitated with the mitogen-activated protein kinase and was identified as the actin-binding protein, calponin, by immunoblot. An overlay assay further confirmed an interaction between the kinase and calponin, even though the kinase did not phosphorylate calponin in vitro. Calponin also co-immunoprecipitated from smooth muscle cells with protein kinase C-epsilon. High resolution digital confocal studies indicated that calponin redistributes to the cell membrane during phenylephrine stimulation at a time when mitogen-activated protein kinase and protein kinase C-epsilon are targeted to the plasmalemma. These results suggest a role for calponin as a signaling molecule, possibly an adapter protein, linking the targeting of mitogen-activated protein kinase and protein kinase C-epsilon to the surface membrane.	BOSTON BIOMED RES INST,SIGNAL TRANSDUCT GRP,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02215; BETH ISRAEL DEACONESS MED CTR,BOSTON,MA 02215	Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center				Morgan, Kathleen/0000-0003-3300-3630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056035, R01HL031704, R01HL042293] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42293, HL56035, HL31704] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM LP, 1989, J BIOL CHEM, V264, P7698; ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; CHATTERJEE M, 1986, AM J PHYSIOL, V251, pC356, DOI 10.1152/ajpcell.1986.251.3.C356; COLLINS EM, 1992, AM J PHYSIOL, V262, pH754, DOI 10.1152/ajpheart.1992.262.3.H754; DANTHULURI NR, 1984, BIOCHEM BIOPH RES CO, V125, P1103, DOI 10.1016/0006-291X(84)91397-4; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; Gerthoffer WT, 1996, J PHYSIOL-LONDON, V495, P597, DOI 10.1113/jphysiol.1996.sp021619; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; Horowitz A, 1996, AM J PHYSIOL-HEART C, V270, pH1858, DOI 10.1152/ajpheart.1996.270.5.H1858; Horowitz A, 1996, AM J PHYSIOL-CELL PH, V271, pC589, DOI 10.1152/ajpcell.1996.271.2.C589; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; ITOH T, 1995, J BIOL CHEM, V270, P20400, DOI 10.1074/jbc.270.35.20400; JIANG MJ, 1987, AM J PHYSIOL, V253, pH1365, DOI 10.1152/ajpheart.1987.253.6.H1365; JIANG MJ, 1989, PFLUG ARCH EUR J PHY, V413, P637, DOI 10.1007/BF00581814; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; KHALIL RA, 1993, AM J PHYSIOL, V265, pC406, DOI 10.1152/ajpcell.1993.265.2.C406; KHALIL RA, 1995, CIRC RES, V76, P1101, DOI 10.1161/01.RES.76.6.1101; MABUCHI K, 1996, J MUSCLE RES CELL M, V17, P1; MORGAN JP, 1982, PFLUG ARCH EUR J PHY, V395, P75, DOI 10.1007/BF00584972; PARKER CA, 1994, AM J PHYSIOL-CELL PH, V267, pC1262, DOI 10.1152/ajpcell.1994.267.5.C1262; RASMUSSEN H, 1984, BIOCHEM BIOPH RES CO, V122, P776, DOI 10.1016/S0006-291X(84)80101-1; REMBOLD CM, 1988, AM J PHYSIOL, V255, pC719, DOI 10.1152/ajpcell.1988.255.6.C719; RUZYCKY AL, 1989, BRIT J PHARMACOL, V97, P391, DOI 10.1111/j.1476-5381.1989.tb11966.x; SINGER HA, 1987, J PHARMACOL EXP THER, V243, P814; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	29	110	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25157	25161		10.1074/jbc.272.40.25157	http://dx.doi.org/10.1074/jbc.272.40.25157			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312127	hybrid			2022-12-25	WOS:A1997XY97000066
J	Schaller, MD; Sasaki, T				Schaller, MD; Sasaki, T			Differential signaling by the focal adhesion kinase and cell adhesion kinase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; INTEGRIN-DEPENDENT PHOSPHORYLATION; SWISS 3T3 CELLS; LYSOPHOSPHATIDIC ACID; MONOCLONAL-ANTIBODIES; GROWTH-FACTOR; PAXILLIN; ACTIVATION; PP125(FAK); IDENTIFICATION	pp125(FAK) and CAK beta/Pyk2/CadTK/RAFTK are related protein-tyrosine kinases. It is therefore of interest whether CAK beta shares some of the properties of pp125(FAK). Using recombinant glutathione S-transferase fusion proteins, we show that the C-terminal domains of both proteins bind paxillin in vitro. The C-terminal domain of CAK beta was engineered to be autonomously expressed in chicken embryo cells and, like pp125(FAK) and p41/43(FRNK) (the C-terminal noncatalytic domain of pp125(FAK)) was found to localize to cellular focal adhesions. In contrast, full-length CAK beta was generally found diffusely distributed throughout the cell, although a fraction of the cells exhibited focal adhesion localization. Vanadate treatment of pp125(FAK) and CAK beta-overexpressing CE cells induced a dramatic increase in the phosphotyrosine content of a common set of proteins including tensin, paxillin, and p130(Cas), but some of these substrates, particularly p130(Cas), appeared to be differentially phosphorylated by pp125(FAK) and CAK beta. Levels of tyrosine phosphorylation were higher in CAK beta-overexpressing cells, and additional phosphotyrosine-containing species were specifically immunoprecipitated, In addition, vanadate treatment of CE cells overexpressing CAK beta, but not pp125(FAK) overexpressors, induced a profound morphological change, which could be a consequence of the observed differences in substrate phosphorylation.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; SAPPORO MED INST,CANC RES INST,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	University of North Carolina; University of North Carolina Chapel Hill	Schaller, MD (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,534 TAYLOR HALL,CB 7090,CHAPEL HILL,NC 27599, USA.							ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HUGHES HS, 1987, J VIROL, V62, P3004; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Richardson A, 1997, BIOCHEM J, V324, P141, DOI 10.1042/bj3240141; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	51	105	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25319	25325		10.1074/jbc.272.40.25319	http://dx.doi.org/10.1074/jbc.272.40.25319			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312150	hybrid			2022-12-25	WOS:A1997XY97000089
J	Yamaguchi, T; Yamamoto, A; Furuno, A; Hatsuzawa, K; Tani, K; Himeno, M; Tagaya, M				Yamaguchi, T; Yamamoto, A; Furuno, A; Hatsuzawa, K; Tani, K; Himeno, M; Tagaya, M			Possible involvement of heterotrimeric G proteins in the organization of the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; ETHYLMALEIMIDE-SENSITIVE FACTOR; GTP-BINDING PROTEINS; BETA-GAMMA-SUBUNITS; COATED VESICLES; ALPHA-SUBUNITS; BREFELDIN-A; HELA-CELLS; MITOTIC FRAGMENTATION; EPITHELIAL-CELLS	Nordihydroguaiaretic acid (NDGA) caused disassembly of the Golgi apparatus of NRK cells in a dose-, time-, and energy-dependent manner but not in a microtubule-dependent manner. In contrast to brefeldin A, NDGA did not cause release of beta-COP, a component of Golgi-derived vesicles. However, NDGA-induced disassembly was blocked by AlF4-, an activator of the heterotrimeric but not the small GTP-binding proteins. In digitonin-permeabilized cells, guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) as well as AlF4- blocked the NDGA-promoted disassembly of the Golgi apparatus, and G beta gamma (beta gamma subunits of heterotrimeric G proteins) reversed this effect. Our present results suggest the possible involvement of heterotrimeric G proteins in the organization of the Golgi apparatus.	TOKYO UNIV PHARM & LIFE SCI, SCH LIFE SCI, HACHIOJI, TOKYO 19203, JAPAN; KYUSHU UNIV, FAC PHARMACEUT SCI, DIV PHYSIOL CHEM, HIGASHI KU, FUKUOKA 81282, JAPAN; KANSAI MED UNIV, DEPT PHYSIOL, MORIGUCHI, OSAKA 570, JAPAN	Tokyo University of Pharmacy & Life Sciences; Kyushu University; Kansai Medical University								ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; ADAM SA, 1991, METHOD CELL BIOL, V35, P469; ASANO T, 1993, J BIOL CHEM, V268, P20512; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; DIAZ R, 1989, METHOD CELL BIOL, V31, P25; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; Glick J, 1996, J BIOL CHEM, V271, P2949, DOI 10.1074/jbc.271.6.2949; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MISTELI T, 1995, J CELL BIOL, V130, P1027, DOI 10.1083/jcb.130.5.1027; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; Nurnberg B, 1996, FEBS LETT, V389, P61, DOI 10.1016/0014-5793(96)00584-4; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PUSCHEL AW, 1994, FEBS LETT, V347, P55, DOI 10.1016/0014-5793(94)00505-2; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TAGAYA M, 1993, FEBS LETT, V324, P201, DOI 10.1016/0014-5793(93)81393-E; Tagaya M, 1996, J BIOCHEM, V119, P863; Tagaya M, 1996, J BIOL CHEM, V271, P466, DOI 10.1074/jbc.271.1.466; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; VEIT B, 1993, J CELL BIOL, V122, P1197, DOI 10.1083/jcb.122.6.1197; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	55	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25260	25266		10.1074/jbc.272.40.25260	http://dx.doi.org/10.1074/jbc.272.40.25260			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312142	hybrid			2022-12-25	WOS:A1997XY97000081
J	Fautsch, MP; Perdok, MM; Wieben, ED				Fautsch, MP; Perdok, MM; Wieben, ED			Production of SVP-1/-3/-4 in guinea pig testis - Characterization of novel transcripts containing long 5'-untranslated regions and multiple upstream AUG codons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMINAL-VESICLE; MESSENGER-RNA; SECRETORY PROTEIN; HUMAN-SEMEN; GENE; TRANSLATION; SEQUENCES; IDENTIFICATION; SEMENOGELIN; INITIATION	The GP1G gene of the guinea pig codes for three of the four abundant seminal vesicle secretory proteins produced in this species, This gene is expressed at highest efficiency in the seminal vesicle (SV) from a promoter that contains a canonical TATA box and CCAAT box. However, GP1G gene transcripts and proteins have also been identified in other tissues. To investigate the structure of GP1G transcripts produced in the testis, cDNA clones were isolated by screening a testis library. Three unique cDNAs (TSM1-3) were isolated. Each of these clones contained a 3'-untranslated region (UTR) and coding region identical to that of the seminal vesicle transcript. However, the 5'-UTRs of the testis transcripts were significantly longer than that found on the SV mRNA (416-646 nucleotides compared with only 23 nucleotides for the SV). Each of these alternatively spliced 5'-UTRs incorporated the SV promoter elements into transcribed sequence, and each contained multiple upstream AUG codons predicted to abolish translation of the major open reading frame. Nevertheless, each of the testis transcripts was capable of directing the synthesis of GP1G-related proteins in vitro. Analysis of the translation products suggests that the extended 8'-UTR of the testis transcripts regulate both the choice of translation start site and the efficiency of translation in this system. Western blot analysis of testis proteins revealed that the protein products of GP1G are also synthesized by the testis in vivo.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905	Mayo Clinic								Aumuller G, 1990, Int Rev Cytol, V121, P127, DOI 10.1016/S0074-7696(08)60660-9; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; DODD JG, 1986, MOL CELL ENDOCRINOL, V47, P191, DOI 10.1016/0303-7207(86)90112-7; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; HAGSTROM JE, 1989, MOL ENDOCRINOL, V3, P1797, DOI 10.1210/mend-3-11-1797; Hagstrom JE, 1996, J BIOL CHEM, V271, P21114, DOI 10.1074/jbc.271.35.21114; HARRIS SE, 1990, J BIOL CHEM, V265, P9896; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; JANUSZESKI MM, 1994, ENDOCRINOLOGY, V134, P1859, DOI 10.1210/en.134.4.1859; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1978, J BIOL CHEM, V253, P6568; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lundwall A, 1996, BIOCHEM BIOPH RES CO, V221, P323, DOI 10.1006/bbrc.1996.0594; Lundwall A, 1996, EUR J BIOCHEM, V235, P424, DOI 10.1111/j.1432-1033.1996.00424.x; MEZQUITA J, 1994, GENE, V147, P231, DOI 10.1016/0378-1119(94)90072-8; MOORE JT, 1987, P NATL ACAD SCI USA, V84, P6712, DOI 10.1073/pnas.84.19.6712; NORVITCH ME, 1988, BIOL REPROD, V38, P1155, DOI 10.1095/biolreprod38.5.1155; NOTIDES AC, 1967, P NATL ACAD SCI USA, V58, P1991, DOI 10.1073/pnas.58.5.1991; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PLUCKTHUN A, 1987, J BIOL CHEM, V262, P3951; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; SPENCE AM, 1989, P NATL ACAD SCI USA, V86, P7843, DOI 10.1073/pnas.86.20.7843; ULVSBACK M, 1992, J BIOL CHEM, V267, P18080; VENEZIALE CM, 1976, ANDROLOGIA, V8, P73; WILLIAMS.HG, 1972, P NATL ACAD SCI USA, V69, P2322, DOI 10.1073/pnas.69.8.2322; WILLIAMSASHMAN HG, 1983, CURR TOP CELL REGUL, V22, P201; YOCWARREN H, 1993, J EXP ZOOL, V265, P653; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557	34	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24691	24695		10.1074/jbc.272.39.24691	http://dx.doi.org/10.1074/jbc.272.39.24691			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305940	hybrid			2022-12-25	WOS:A1997XY51500091
J	Schmale, H; Bamberger, C				Schmale, H; Bamberger, C			A novel protein with strong homology to the tumor suppressor p53	ONCOGENE			English	Article						keratinocyte; taste bud; differentiation; gene evolution	CRYSTAL-STRUCTURE; CELLS; EXPRESSION; SEQUENCE; ONCOPROTEIN; ANTIGEN; DOMAIN	The p53 tumor important genes apoptosis. Mice deficient for p53 show a high incidence of cancer but are developmentally normal suggesting that compensatory mechanisms exist in embryogenesis and differentiation. The new KET protein is the first mammalian protein with strong homology to p53 in all evolutionary conserved regions. This conservation makes a functional redundancy of the two proteins in cell-cycle control possible. KET is expressed during embryonic development and in certain adult tissues. Among all of the known p53 proteins of different species KET is most closely related to that found in squid. The relationship between KET and the invertebrate p53 protein sheds light on the evolutionary origin of p53. KET appears to be an ancestral p53-related protein in vertebrates,vith a possible role in development and differentiation while the ubiquitously expressed p53 protein attained its general role as 'guardian of the genome' during evolution.			Schmale, H (corresponding author), UNIV HAMBURG,HOSP EPPENDORF,INST ZELLBIOCHEM & KLIN NEUROBIOL,MARTINISTR 52,D-20246 HAMBURG,GERMANY.		Bamberger, Casimir/E-7356-2011; Bamberger, Tom Casimir/D-1292-2014	Bamberger, Tom Casimir/0000-0002-3830-4486				BEIDLER LM, 1965, J CELL BIOL, V27, P263, DOI 10.1083/jcb.27.2.263; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHMALE H, 1995, EXPT CELL BIOL TASTE, P147; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STONE LM, 1995, P NATL ACAD SCI USA, V92, P1916, DOI 10.1073/pnas.92.6.1916; STRIEM B J, 1991, Cellular Physiology and Biochemistry, V1, P46, DOI 10.1159/000154592; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; VONGAUDECKER B, 1991, ANAT EMBRYOL, V183, P1; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	24	246	266	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1363	1367		10.1038/sj.onc.1201500	http://dx.doi.org/10.1038/sj.onc.1201500			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315105				2022-12-25	WOS:A1997XV84500015
J	Fan, JQ; Lee, YC				Fan, JQ; Lee, YC			Detailed studies on substrate structure requirements of glycoamidases A and F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-GLYCOSIDASE-F; PEPTIDE-N-4-(N-ACETYL-BETA-D-GLUCOSAMINYL)ASPARAGINE AMIDASE-F; ASPARAGINE-LINKED GLYCANS; ANIMAL-CELLS; PEPTIDE; OLIGOSACCHARIDES; GLYCOPEPTIDES; DERIVATIVES; ACETYLGLUCOSAMINIDASE; DEGLYCOSYLATION	Glycoamidases (peptide-N-4-(N-acetyl-beta-glucosaminyl)-asparagine amidase, EC 3.5.1.52; also known as peptide: N-glycanases (PNGases) release N-linked oligosaccharides from glycopeptides and/or glycoproteins by hydrolyzing the glycosylated beta-amide bond of the asparagine side chain. The most widely used glycoamidases are those from Flavobacterium meningosepticum (glycoamidase F or PNGase F) and almond emulsin (glycoamidase A or PNGase A). The study the substrate structure requirement of these enzymes systematically, we synthesized >30 glycopeptides containing cellobiose, lactose, GlcNAc, and di-N,N'-acetylchitobiose (CTB). The length of the peptide was varied from one to five amino acids, and glycosylamines were linked to either Asn or Gln located at different positions in the peptide, including NH2 and COOH termini. Neither enzyme could cleave cellobiose and lactose glycopeptides, indicating that the 2-acetamido group on the Asn-linked GlcNAc is important in the recognition by both glycoamidases A and F. GlcNAc peptides could be cleaved by both enzymes, albeit not as effectively as CTB glycopeptides. Neither enzyme requires the Asn-Xaa-(Ser/Thr) sequence (required for N-glycosylation) for activity. Glycoamidase A could even hydrolyze a Gln-bound CTB glycopeptide, whereas the action of glycoamidase A could act on CTB dipeptides, glycoamidase A could act on CTB dipeptides, glycoamidase F preferred a tripeptide or longer. The K-m and V-max values of glycoamidase A for t-butoxycarbonyl-(CTB)-Asn-Ala-Ser-OMe were 2.1 nM and 0.66 mu mol/min/mg, respectively. A natural glycodipeptide, Man(9)-GlcNAc(2)-Asn-Phe, was also completely hydrolyzed by glycoamidase A.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; TOKYO METROPOLITAN INST MED SCI,DEPT CLIN GENET,TOKYO 113,JAPAN	Johns Hopkins University; Tokyo Metropolitan Institute of Medical Science								ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P84, DOI 10.1007/BF00731873; ANISFELD ST, 1990, J ORG CHEM, V55, P5560, DOI 10.1021/jo00308a009; CHU FK, 1986, J BIOL CHEM, V261, P172; DUNSTAN D, 1972, CARBOHYD RES, V23, P17, DOI 10.1016/S0008-6215(00)81572-4; EBERT RF, 1986, ANAL BIOCHEM, V154, P431, DOI 10.1016/0003-2697(86)90010-2; FAN JQ, 1994, ANAL BIOCHEM, V219, P224, DOI 10.1006/abio.1994.1261; FAN JQ, 1995, J BIOL CHEM, V270, P17723, DOI 10.1074/jbc.270.30.17723; FAYE L, 1989, PHYSIOL PLANTARUM, V75, P309, DOI 10.1111/j.1399-3054.1989.tb06187.x; GARG HG, 1975, CARBOHYD RES, V43, P371, DOI 10.1016/S0008-6215(00)83502-8; GARG HG, 1985, ADV CARBOHYD CHEM BI, V43, P135, DOI 10.1016/S0065-2318(08)60068-2; GARG HG, 1972, CARBOHYD RES, V23, P437, DOI 10.1016/S0008-6215(00)82696-8; HIRANI S, 1987, ANAL BIOCHEM, V162, P485, DOI 10.1016/0003-2697(87)90424-6; ISHIHARA H, 1979, J BIOL CHEM, V254, P715; KALLIN E, 1986, GLYCOCONJUGATE J, V3, P311, DOI 10.1007/BF01049500; KARTHA KPR, 1990, J CARBOHYD CHEM, V9, P777, DOI 10.1080/07328309008543873; KHORLIN AY, 1980, CARBOHYD RES, V85, P201, DOI 10.1016/S0008-6215(00)84671-6; KITAJIMA K, 1995, ARCH BIOCHEM BIOPHYS, V319, P393, DOI 10.1006/abbi.1995.1309; KUHN P, 1994, BIOCHEMISTRY-US, V33, P11699, DOI 10.1021/bi00205a005; KUHN P, 1995, J BIOL CHEM, V270, P29493, DOI 10.1074/jbc.270.49.29493; KUNZ H, 1987, ANGEW CHEM INT EDIT, V26, P294, DOI 10.1002/anie.198702941; LEE KB, 1995, ANAL BIOCHEM, V230, P31, DOI 10.1006/abio.1995.1433; LHERNOULD S, 1992, GLYCOCONJUGATE J, V9, P191, DOI 10.1007/BF00731164; MANGER ID, 1992, BIOCHEMISTRY-US, V31, P10724, DOI 10.1021/bi00159a012; MUSSAR KJ, 1989, J BIOCHEM BIOPH METH, V20, P53, DOI 10.1016/0165-022X(89)90081-X; NISHIMURA SI, 1989, CARBOHYD RES, V194, P223, DOI 10.1016/0008-6215(89)85021-9; PLUMMER TH, 1987, EUR J BIOCHEM, V163, P167, DOI 10.1111/j.1432-1033.1987.tb10751.x; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; PLUMMER TH, 1981, J BIOL CHEM, V256, P243; SEKO A, 1991, J BIOL CHEM, V266, P22110; SPINOLA M, 1970, CARBOHYD RES, V15, P361, DOI 10.1016/S0008-6215(00)80452-8; SPINOLA M, 1970, J BIOL CHEM, V245, P4158; STAUDACHER E, 1992, GLYCOCONJUGATE J, V9, P82, DOI 10.1007/BF00731703; SUGIYAMA K, 1983, BIOCHEM BIOPH RES CO, V112, P155, DOI 10.1016/0006-291X(83)91810-7; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; SUZUKI T, 1993, BIOCHEM BIOPH RES CO, V194, P1124, DOI 10.1006/bbrc.1993.1938; SUZUKI T, 1994, GLYCOCONJUGATE J, V11, P469, DOI 10.1007/BF00731283; SUZUKI T, 1995, J BIOL CHEM, V270, P15181, DOI 10.1074/jbc.270.25.15181; SUZUKI T, 1994, GLYCOBIOLOGY, V4, P777, DOI 10.1093/glycob/4.6.777; TAKAHASHI N, 1977, BIOCHEM BIOPH RES CO, V76, P1194, DOI 10.1016/0006-291X(77)90982-2; TAKAHASHI N, 1978, J BIOCHEM-TOKYO, V84, P1467, DOI 10.1093/oxfordjournals.jbchem.a132270; TAKAHASHI N, 1986, BIOCHEMISTRY-US, V25, P388, DOI 10.1021/bi00350a018; TAKAHASHI N, 1992, HDB ENDOGLYCOSIDASES, P199; TAKAHASHI N, 1992, HDB ENDOGLYCOSIDASES, P183; TAMURA T, 1994, ANAL BIOCHEM, V216, P335, DOI 10.1006/abio.1994.1050; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; Wang LX, 1996, TETRAHEDRON LETT, V37, P1975; WONG SYC, 1993, GLYCOCONJUGATE J, V10, P227, DOI 10.1007/BF00702204	48	55	63	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27058	27064		10.1074/jbc.272.43.27058	http://dx.doi.org/10.1074/jbc.272.43.27058			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341145	hybrid			2022-12-25	WOS:A1997YC65900041
J	Nadeau, OW; Sacks, DB; Carlson, GM				Nadeau, OW; Sacks, DB; Carlson, GM			The structural effects of endogenous and exogenous Ca2+/calmodulin on phosphorylase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT-SKELETAL-MUSCLE; GAMMA-SUBUNIT; CATALYTIC SUBUNIT; MOLECULAR-BASIS; PROTEIN-KINASE; CDNA CLONING; BETA-SUBUNIT; B KINASE; CALMODULIN; ACTIVATION	The activity of phosphorylase b kinase (PbK) is stimulated by Ca2+ ions, which act through its endogenous calmodulin subunit (delta), and further stimulated by the Ca2+-dependent binding of exogenous calmodulin (delta'). In contrast to their highly characterized effects on activity, little is known regarding the structural effects on the (alpha beta gamma delta)(4) PbK. holoenzyme induced by Ca2+ and delta'/Ca2+, We have used mono- and bifunctional chemical modifiers as conformational probes to compare how the two effecters influence the structure of the catalytic gamma subunit and the interactions among all of the subunits. As determined by reductive methylation and carboxymethylation, Ca2+ increased She accessibility of the gamma subunit; it also increased the formation by phenylenedimaleimide of an alpha gamma gamma conjugate that is characteristic of activated conformations of PbK (Nadeau, O.W., Sacks, D.M., and Carlson, G.M. (1997) J. Biol. Chem:. 272, 26196-26201); however; Ca2+ also had structural effects that were clearly distinct fi om other activators, Moreover, similar structural effects of Ca2+ were observed with PbK that had been activated by phosphorylation, consistent with the fact that such activation does not eliminate the catalytic dependence of the enzyme on Ca2+, Our results suggest tiers of conformational transitions in the activation of PbK, with the most fundamental being induced by Ca2+. Analysis of the various cross-linked conjugates formed in the presence of Ca2+ by o-phenylenedimaleimide or m-maleimidobenzoyl-N-hydroxysuccinimide ester showed that the binding of Ca2+ to the delta subunit triggers changes in the interactions among all subunits, including between protomers, indicating an extensive communication network throughout the PbK complex. Most of the structural effects of delta'/Ca2+ were qualitatively similar to, but quantitatively greater than, the effects of Ca2+ alone; but delta'/Ca2+ also had distinct effects, especially involving cross-linking of the delta subunit.	UNIV TENNESSEE, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Sacks, David/0000-0003-3100-0735	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032953, R56DK032953] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32953] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROSTROM CO, 1971, J BIOL CHEM, V246, P1961; CHAN KFJ, 1982, J BIOL CHEM, V257, P5948; CHENG A, 1985, J BIOL CHEM, V260, P2535; COHEN P, 1979, FEBS LETT, V104, P25, DOI 10.1016/0014-5793(79)81078-9; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; COHEN P, 1980, EUR J BIOCHEM, V111, P563, DOI 10.1111/j.1432-1033.1980.tb04972.x; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEPAOLIROACH AA, 1979, FEBS LETT, V105, P321, DOI 10.1016/0014-5793(79)80639-0; FARRAR YJK, 1991, BIOCHEMISTRY-US, V30, P10274, DOI 10.1021/bi00106a027; FARRAR YJK, 1993, J BIOL CHEM, V268, P4120; FITZGERALD TJ, 1984, J BIOL CHEM, V259, P3266; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRAND RJA, 1981, EUR J BIOCHEM, V113, P359, DOI 10.1111/j.1432-1033.1981.tb05074.x; HALLENBECK PC, 1983, J BIOL CHEM, V258, P3493; HEILMEYER LMG, 1991, BIOCHIM BIOPHYS ACTA, V1094, P168, DOI 10.1016/0167-4889(91)90005-I; HEILMEYER LMG, 1993, MOL CELL BIOCHEM, V128, P19, DOI 10.1007/BF01076754; JAMES P, 1991, J BIOL CHEM, V266, P7087; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; KEE SM, 1987, J BIOL CHEM, V262, P9448; KEE SM, 1986, J BIOL CHEM, V261, P4732; KILIMANN MW, 1988, P NATL ACAD SCI USA, V85, P9381, DOI 10.1073/pnas.85.24.9381; KING MM, 1982, J BIOL CHEM, V257, P4058; KING MM, 1982, FEBS LETT, V140, P131, DOI 10.1016/0014-5793(82)80537-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN DM, 1989, J BIOL CHEM, V264, P2373; Nadeau OW, 1997, J BIOL CHEM, V272, P26196, DOI 10.1074/jbc.272.42.26196; NADEAU OW, 1995, FASEB J, V9, pA1304; NADEAU OW, 1994, J BIOL CHEM, V269, P29670; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; PAUDEL HK, 1990, P NATL ACAD SCI USA, V87, P7285, DOI 10.1073/pnas.87.18.7285; Pickett-Gies CA., 1986, ENZYMES, V17, P395; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; REIMANN EM, 1984, BIOCHEMISTRY-US, V23, P4185, DOI 10.1021/bi00313a027; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SANCHEZ VE, 1992, FASEB J, V6, pA339; SHENOLIKAR S, 1979, EUR J BIOCHEM, V100, P329, DOI 10.1111/j.1432-1033.1979.tb04175.x; TREMPE MR, 1987, J BIOL CHEM, V262, P4333; WALSH DA, 1971, J BIOL CHEM, V246, P1968; WALSH KX, 1980, J BIOL CHEM, V255, P5036; Wangsgard WP, 1997, BIOCHEM BIOPH RES CO, V230, P179, DOI 10.1006/bbrc.1996.5927; Wilkinson DA, 1997, J MOL BIOL, V265, P319, DOI 10.1006/jmbi.1996.0739; WILKINSON DA, 1993, THESIS U TENNESSEE M, P107; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5014, DOI 10.1021/bi9528107; YOSHIKAWA K, 1983, EUR J BIOCHEM, V136, P413, DOI 10.1111/j.1432-1033.1983.tb07758.x; ZANDER NF, 1988, P NATL ACAD SCI USA, V85, P2929, DOI 10.1073/pnas.85.9.2929	46	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26202	26209		10.1074/jbc.272.42.26202	http://dx.doi.org/10.1074/jbc.272.42.26202			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334188	hybrid			2022-12-25	WOS:A1997YB13900022
J	Cotten, JF; Welsh, MJ				Cotten, JF; Welsh, MJ			Covalent modification of the regulatory domain irreversibly stimulates cystic fibrosis transmembrane conductance regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; CYSTEINE SCANNING MUTAGENESIS; NUCLEOTIDE-BINDING DOMAINS; R-DOMAIN; ATP HYDROLYSIS; CL CHANNELS; LACTOSE PERMEASE; ESCHERICHIA-COLI; PHOSPHORYLATION; IDENTIFICATION	The cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel is regulated by three cytosolic domains, the regulatory domain (R domain) and two nucleotide binding domains, To learn more about how the cytosolic domains regulate channel activity, we used chemical modification to probe their structure. When we applied the sulfhydryl-modifying reagent N-ethylmaleimide (NEM) and other N-substituted maleimides to the cytosolic domains, we found that they rapidly and irreversibly stimulated channel activity, CFTR contains 14 intracellular cysteine residues that might be targets for NEM modification. We identified one, Cys(832), that was essential for the response, Cys(832) is located in the R domain. Single channel studies showed that NEM stimulated CFTR by increasing the duration of bursts of activity and by shortening the closed interval between bursts. At the single channel level, CFTR in which Cys(832) was mutated to alanine behaved identically to wild-type CFTR, except that it failed to respond to NEM, Additional studies showed that NEM modification increased the potency of ATP-mediated stimulation. Previous work has shown that modification of the R domain by phosphorylation, which introduces negative charge, or replacement of multiple serines by negatively charged aspartates stimulates the channel. Our current data show that covalent modification of the R domain with a neutral, hydrophobic adduct at a site that is not phosphorylated can also stimulate CFTR. This finding suggests that an alteration in the conformation of the R domain may be a key feature that regulates channel activity.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,EMRB 500,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; University of Iowa				Welsh, Michael/0000-0002-1646-6206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042385, R37HL029851, R01HL029851] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29851, HL42385] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKABAS MH, 1994, J BIOL CHEM, V269, P14865; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CARSON MR, 1995, J BIOL CHEM, V270, P20466, DOI 10.1074/jbc.270.35.20466; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Crampton MR., 1974, CHEM THIOL GROUP, P379; DULHANTY AM, 1994, FEBS LETT, V343, P109, DOI 10.1016/0014-5793(94)80300-5; DULHANTY AM, 1994, BIOCHEMISTRY-US, V33, P4072, DOI 10.1021/bi00179a036; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HWANG TC, 1993, J GEN PHYSIOL, V101, P629, DOI 10.1085/jgp.101.5.629; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; WU JH, 1994, PROTEIN SCI, V3, P2294, DOI 10.1002/pro.5560031214	34	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25617	25622		10.1074/jbc.272.41.25617	http://dx.doi.org/10.1074/jbc.272.41.25617			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325282	hybrid			2022-12-25	WOS:A1997YA35800037
J	Yuan, DS; Dancis, A; Klausner, RD				Yuan, DS; Dancis, A; Klausner, RD			Restriction of copper export in Saccharomyces cerevisiae to a late Golgi or post-Golgi compartment in the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON-DISEASE GENE; VACUOLAR H+-ATPASE; CLASS-II MOLECULES; MENKES DISEASE; CANDIDATE GENE; IRON-METABOLISM; TRANSPORTING ATPASE; PLASMA-MEMBRANE; YEAST-CELLS; FET3 GENE	The CCC2 gene in the yeast Saccharomyces cerevisiae encodes a P-type ATPase (Ccc2p) required for the export of cytosolic copper to the extracytosolic domain of a copper dependent oxidase, Fet3p. Ccc2p appears to be both a structural and functional homolog of ATPases impaired in two human disorders of intracellular copper transport, Menkes disease and Wilson disease. In the present work, three approaches were used to determine the locus of Ccc2p-dependent copper export within the secretory pathway. First, like ccc2 mutants, sec mutants blocked in the secretory pathway at steps prior to and including the Golgi complex failed to deliver radioactive copper to Fet3p. Second, also like ccc2 mutants, vps33 and certain other mutants with defects in post-Golgi sorting exhibited phenotypes traceable to deficient copper delivery to Fet3p. These findings were sufficient to explain the respiratory deficiency of these mutants. Third, immunofluorescence microscopy revealed that Ccc2p was distributed among several punctate foci within wild-type cells, consistent with late Golgi or post-Golgi localization. Thus, copper export by Ccc2p appears to be restricted to a late or post-Golgi compartment in the secretary pathway.	NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD 20892; UNIV PENN,DEPT MED,DIV HEMATOL ONCOL,PHILADELPHIA,PA 19104; NCI,OFF DIRECTOR,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								[Anonymous], 1995, METABOLIC BASIS INHE; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; ASLANIDIS C, 1990, NUCLEIC ACIDS RES, V18, P6069, DOI 10.1093/nar/18.20.6069; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Calakos N, 1996, PHYSIOL REV, V76, P1; CEREGHINO JL, 1995, MOL BIOL CELL, V6, P1089, DOI 10.1091/mbc.6.9.1089; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; CONIBEAR E, 1995, CELL, V83, P513, DOI 10.1016/0092-8674(95)90088-8; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; HORAZDOVSKY BF, 1995, CURR OPIN CELL BIOL, V7, P544, DOI 10.1016/0955-0674(95)80012-3; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JONES EW, 1977, GENETICS, V85, P23; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; LIN CM, 1993, J GEN MICROBIOL, V139, P1617, DOI 10.1099/00221287-139-7-1617; LINDER MC, 1991, BIOCH COPPER, P4; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P381; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; RAO K, 1983, FEBS LETT, V160, P213, DOI 10.1016/0014-5793(83)80969-7; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBINSON JS, 1991, MOL CELL BIOL, V11, P5813, DOI 10.1128/MCB.11.12.5813; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROESER HP, 1970, J CLIN INVEST, V49, P2408, DOI 10.1172/JCI106460; ROTHBLATT J, 1994, GUIDEBOOK SECRETORY; SCHOSINSKY KH, 1974, CLIN CHEM, V20, P1556; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SIKORSKI RS, 1989, GENETICS, V122, P19; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TARTOF KD, 1987, FOCUS, V9, P12; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WILSBACH K, 1993, EMBO J, V12, P3049, DOI 10.1002/j.1460-2075.1993.tb05974.x; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YAMASHIRO DJ, 1984, J CELL BIOCHEM, V26, P231, DOI 10.1002/jcb.240260404; YAVER DS, 1993, J BIOL CHEM, V268, P10564; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	60	133	137	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25787	25793		10.1074/jbc.272.41.25787	http://dx.doi.org/10.1074/jbc.272.41.25787			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325307	hybrid			2022-12-25	WOS:A1997YA35800062
J	Pak, Y; ODowd, BF; George, SR				Pak, Y; ODowd, BF; George, SR			Agonist-induced desensitization of the mu opioid receptor is determined by threonine 394 preceded by acidic amino acids in the COOH-terminal tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; 3RD INTRACELLULAR LOOP; RHODOPSIN KINASE; PHOSPHORYLATION SITES; IN-VIVO; IDENTIFICATION; MECHANISMS; INVOLVEMENT; EXPRESSION; SUBTYPES	To identify the structural determinants necessary for mu opioid receptor desensitization, we serially ablated potential phosphorylation sites in the carboxyl tail of the receptor and examined their effects on [D-Ala(2),N-Me-Phe(4),Gly-ol(5)]lenkephalin (DAMGO)-induced desensitization, First, we replaced Thr(394) with alanine (T394A) and stably expressed this mutant receptor in Chinese hamster ovary cells, The T394A receptor did not desensitize after 1 h of treatment with DAMGO, indicating that Thr(394) is required for agonist-induced early desensitization, To test whether Thr(394) was the only residue necessary, we investigated the importance of 7 potential phosphorylation sites between residues 363 and 383, which were all replaced by alanines with the Thr(394) maintained, This mutant (AT) showed partial loss of desensitization (30%), which was attributable to the Ala mutation at Thr(383), since complete desensitization was achieved by restoring Thr(383) (ATT), These results suggest that Thr(394) is the primary recognition site for G protein-coupled receptor kinases, but Thr(383) is also required for complete agonist-induced desensitization. The specificity of Thr(394) as the primary initiation site appears to be dependent on the preceding acidic amino acid stretch, because in a mutant in which glutamic acid residues at 388, 391, and 393 were replaced by glutamines (EQ), agonist-induced desensitization was completely abolished, identical to the T394A mutant.	UNIV TORONTO,DEPT PHARMACOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON M5S 1A8,CANADA; ADDICT RES FDN,TORONTO,ON M5S 2S1,CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada			George, Susan/W-7494-2019; George, Susan R/P-9669-2018					BARTON AC, 1990, MOL PHARMACOL, V38, P531; BARTON AC, 1991, MOL PHARMACOL, V39, P650; BATES MD, 1991, MOL PHARMACOL, V39, P55; BLAXALL HS, 1994, MOL PHARMACOL, V45, P176; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CHEN Y, 1994, J BIOL CHEM, V269, P7839; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; FUKUSHIMA N, 1994, NEUROSCI LETT, V176, P55, DOI 10.1016/0304-3940(94)90870-2; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; KOOB G, 1992, SCIENCE, V242, P715; KOOB GF, 1992, TRENDS NEUROSCI, V15, P186, DOI 10.1016/0166-2236(92)90171-4; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1995, J BIOL CHEM, V270, P15294, DOI 10.1074/jbc.270.25.15294; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PEI G, 1995, MOL PHARMACOL, V48, P173; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PULLEN N, 1994, BIOCHEMISTRY-US, V33, P14536, DOI 10.1021/bi00252a021; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMON EJ, 1991, MED RES REV, V11, P357, DOI 10.1002/med.2610110402; TAKANO T, 1994, J BIOL CHEM, V269, P22453; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P4813, DOI 10.1074/jbc.270.9.4813; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	36	74	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24961	24965		10.1074/jbc.272.40.24961	http://dx.doi.org/10.1074/jbc.272.40.24961			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312100	hybrid			2022-12-25	WOS:A1997XY97000039
J	DelBufalo, D; Biroccio, A; Leonetti, C; Zupi, G				DelBufalo, D; Biroccio, A; Leonetti, C; Zupi, G			Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line	FASEB JOURNAL			English	Article						breast carcinoma; metastases; invasion; migration	CELL-DEATH; C-MYC; ANTICANCER DRUGS; PROSTATE CANCERS; TUMOR INVASION; EXPRESSION; APOPTOSIS; CARCINOMA; PROTEIN; GENE	Bcl-2 protein has been shown to contribute to oncogenesis because it can transform and immortalize cells in cooperation with c-myc, ras, or viral genes, However, in vivo studies have not yet established whether bcl-2 can play a role in metastasis, Here we investigate the potential metastatic role off bcl-2, We introduced the human bcl-2 gene into a low bcl-2 expressing human breast cancer cell line MCF7 ADR, We demonstrate that two bcl-2 overexpressing clones injected intravenously or intramuscularly into nude mice induce a significantly higher number of experimental and spontaneous lung metastases compared to the control transfectant clone, We demonstrate that bcl-2 overexpressing clones are more invasive and migratory in response to chemotactic stimuli than the control transfectant clone, Furthermore, zymographic analysis shows that secretion of 72 and 92 kDa gelatinases increases in the two bcl-2 overexpressing transfectants, Tumors originating from bcl-2 overexpressing clones also show a decrease in the latency period of tumor appearance, In conclusion, our data show that bcl-2 overexpression enhances both tumorigenicity and metastatic potential of MCF7 ADR cells by inducing metastasis-associated properties.	REGINA ELENA INST CANC RES,EXPT CHEMOTHERAPY LAB,ROME,ITALY	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena			Leonetti, Carlo/B-2860-2018; Del Bufalo, Donatella/K-8673-2016; Biroccio, Annamaria/B-2861-2018; Del Bufalo, Donatella/AAC-1594-2021	Leonetti, Carlo/0000-0002-3526-7827; Del Bufalo, Donatella/0000-0002-3148-6096; Biroccio, Annamaria/0000-0003-3198-3532; Del Bufalo, Donatella/0000-0002-3148-6096				ALBINI A, 1987, J CELL BIOL, V105, P1867, DOI 10.1083/jcb.105.4.1867; ALBINI A, 1987, CANCER RES, V47, P3239; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAMPOS L, 1993, BLOOD, V81, P3091; CHAN WK, 1993, J PATHOL S, V169, P138; CHAOYING Y, 1997, NATURE, V385, P637; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DAWSON CW, 1995, ONCOGENE, V10, P69; DelBufalo D, 1996, J CLIN INVEST, V98, P1165, DOI 10.1172/JCI118900; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHER TC, 1993, CANCER RES, V53, P3321; Furuya Y, 1996, CLIN CANCER RES, V2, P389; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Krajewska M, 1996, AM J PATHOL, V148, P1567; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LEEK RD, 1994, BRIT J CANCER, V69, P1135; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; LIOTTA LA, 1986, CANCER RES, V46, P1; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; McConkey DJ, 1996, CANCER RES, V56, P5594; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MENSING H, 1984, INT J CANCER, V33, P43, DOI 10.1002/ijc.2910330109; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; NAKJIMA M, 1989, CANCER RES, V49, P1698; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; OLTAVI ZN, 1993, CELL, V74, P609; PIGNATELLI M, 1991, J PATHOL, V165, P25, DOI 10.1002/path.1711650106; PONTA H, 1994, BBA-REV CANCER, V1198, P1, DOI 10.1016/0304-419X(94)90002-7; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; SATO H, 1992, ONCOGENE, V7, P77; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SIERRA A, 1995, INT J CANCER, V60, P54, DOI 10.1002/ijc.2910600108; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; ZUTTER MM, 1990, AM J PATHOL, V137, P863	44	111	113	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1997	11	12					947	953		10.1096/fasebj.11.12.9337147	http://dx.doi.org/10.1096/fasebj.11.12.9337147			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337147				2022-12-25	WOS:A1997YA72400004
J	Stuhlmeier, KM; Kao, JJ; Bach, FH				Stuhlmeier, KM; Kao, JJ; Bach, FH			Arachidonic acid influences proinflammatory gene induction by stabilizing the inhibitor-kappa B alpha/nuclear factor-kappa B (NF-kappa B) complex, thus suppressing the nuclear translocation of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL ACTIVATION; NECROSIS-FACTOR-ALPHA; INDUCED PHOSPHORYLATION; FATTY-ACIDS; EXPRESSION; TRANSCRIPTION; PROTEIN; PROTEOLYSIS; SIGNAL	Arachidonic acid (AA), through its myriad metabolites, is involved in inflammation in a number of ways. AA is produced and released by several cell types, including endothelial cells (EC), and acts on a variety of cells. EC activation plays a key role in inflammation presumably by modulating the immune response through up-or down-regulation of several genes. We have previously shown that AA and its nonmetabolizable analogue, 5,8,11,14-eicosatetraynoic acid (ETYA), inhibit up-regulation of proinflammatory genes in EC. In the present study we identify a mechanism to explain the inhibitory effects: AA and ETYA both inhibit the translocation of nuclear factor-kappa B (NF-kappa B) to the nucleus by blocking the degradation of the inhibitor of NF-kappa B (I kappa B) and thus stabilizing the I kappa B/NF-kappa B complex. To investigate the mechanism whereby AA inhibits upregulation of genes encoding proinflammatory mediators, we examined the ability of ETYA to inhibit tumor necrosis factor-alpha (TNF-alpha) mediated phosphorylation and degradation of I kappa B alpha. Western blot analysis revealed that preincubation of EC with ETYA for 40 min prior to stimulation with TNF-alpha inhibits the phosphorylation and degradation of I kappa B alpha. These findings establish a mechanism by which AA inhibits nuclear translocation of NF-kappa B and thereby explaining its modulatory role in the induction of proinflammatory genes.			Stuhlmeier, KM (corresponding author), HARVARD UNIV,SCH MED,BETH ISRAEL DEACONESS MED CTR,SANDOZ CTR IMMUNOBIOL,99 BROOKLINE AVE,BOSTON,MA 02215, USA.							BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BUCKLEY BJ, 1995, AM J PHYSIOL-CELL PH, V38, pC1489; Camandola S, 1996, BIOCHEM BIOPH RES CO, V229, P643, DOI 10.1006/bbrc.1996.1857; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DOWING DT, 1972, BIOCHIM BIOPHYS ACTA, V280, P343; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; Glick J, 1996, J BIOL CHEM, V271, P2949, DOI 10.1074/jbc.271.6.2949; GOEBELER M, 1995, J IMMUNOL, V155, P2459; Hennig B, 1996, AM J CLIN NUTR, V63, P322, DOI 10.1093/ajcn/63.3.322; JOHNSON DR, 1995, BIOTECHNIQUES, V19, P192; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LANIADOSCHWARTZMAN M, 1994, J BIOL CHEM, V269, P24321; LAPOSATA M, 1987, PROSTAGLANDINS, V33, P603, DOI 10.1016/0090-6980(87)90284-X; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Long SD, 1996, J BIOL CHEM, V271, P1138, DOI 10.1074/jbc.271.2.1138; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pierce JW, 1996, J IMMUNOL, V156, P3961; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; RIZZO MT, 1995, BLOOD, V86, P2967, DOI 10.1182/blood.V86.8.2967.bloodjournal8682967; SCHERER D, 1995, P NATL ACAD SCI USA, V92, P259; Stuhlmeier KM, 1996, EUR J IMMUNOL, V26, P1417, DOI 10.1002/eji.1830260703; STUHLMEIER KM, 1994, EUR J IMMUNOL, V24, P2186, DOI 10.1002/eji.1830240938; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANDERHOEK JY, 1973, BIOCHIM BIOPHYS ACTA, V296, P374, DOI 10.1016/0005-2760(73)90095-7; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013	31	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24679	24683		10.1074/jbc.272.39.24679	http://dx.doi.org/10.1074/jbc.272.39.24679			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305938	hybrid			2022-12-25	WOS:A1997XY51500089
J	Mirkovic, N; Voehringer, DW; Story, MD; McConkey, DJ; McDonnell, TJ; Meyn, RE				Mirkovic, N; Voehringer, DW; Story, MD; McConkey, DJ; McDonnell, TJ; Meyn, RE			Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols	ONCOGENE			English	Article						apoptosis; lymphoma; Bcl-2; radiation; thiols; antioxidants	DNA FRAGMENTATION; BCL-2 PROTECTION; REDOX REGULATION; LYMPHOMA-CELLS; MURINE TUMORS; DEATH; GLUTATHIONE; OXYGEN; P53; GENE	The mechanism by which Bcl-2 oncogene expression inhibits radiation-induced apoptosis has been investigated in two mouse lymphoma cell lines: line LY-as is radiation sensitive, displays substantial radiaton-induced apoptosis. and expresses low levels of Bcl-2; line LY-ar is radiation-resistant, displays a low apoptosis propensity, and expresses 30-fold higher amount of Bcl-2 protein than does the sensitive line. We observed that upon incubation in cystine/methionine-free (C/M-) medium, radiation-induced apoptosis in the LY-ar cells was restored to levels comparable to that seen in the LY-as cells. Intracellular glutathione (GSH) concentrations in LY-ar cells incubated in C/M- medium plummeted to 50% of control values within 2 h. LY-ar cells treated with diethyl maleate (DEM) or diamide, agents that deplete cellular thiols, had increased susceptibility to radiation-induced apoptosis in a manner similar to C/M- medium. These results are consistent with the general idea that Bcl-2 expression blocks apoptosis through an antioxidant pathway that involves cellular thiols. That Bcl-2-expressing tumor cells can be sensitized by exogeneous agents that modify cellular thiols offers strategies for overcoming such resistance.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT EXPT RADIAT ONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Story, Michael/AAX-2864-2021	Story, Michael/0000-0001-6522-4169	NCI NIH HHS [P01-CA-06294, R01-CA-69003, R01-CA-62597] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062597, P01CA006294, R01CA069003] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFY G, 1993, J BIOL CHEM, V268, P6511; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dynlacht JR, 1996, CYTOMETRY, V24, P348, DOI 10.1002/(SICI)1097-0320(19960801)24:4<348::AID-CYTO6>3.0.CO;2-B; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; FAN SJ, 1994, CANCER RES, V54, P5824; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; Herrmann JL, 1996, BIOCHEM SOC T, V24, P1059, DOI 10.1042/bst0241059; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JONES DP, 1995, IMMUNOL LETT, V45, P205, DOI 10.1016/0165-2478(95)00004-O; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KROMER G, 1997, IMMUNOL TODAY, V18, P44; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; MARIN MC, 1994, ONCOGENE, V9, P3107; Marin MC, 1996, ONCOGENE, V12, P2259; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEISTER A, 1994, CANCER RES, V54, pS1969; MEYN RE, 1995, ANTI-CANCER DRUG, V6, P443, DOI 10.1097/00001813-199506000-00013; MEYN RE, 1993, INT J RADIAT BIOL, V64, P583, DOI 10.1080/09553009314551801; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; MUSCHEL RJ, 1995, CANCER RES, V55, P995; OHMORI T, 1993, BIOCHEM BIOPH RES CO, V192, P30, DOI 10.1006/bbrc.1993.1377; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SATO N, 1995, J IMMUNOL, V154, P3194; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Shimizu S, 1996, ONCOGENE, V13, P21; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; STORY MD, 1993, CANCER CHEMOTH PHARM, V32, P129, DOI 10.1007/BF00685615; STORY MD, 1994, INT J RADIAT BIOL, V66, P659; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUZUKAKE K, 1982, BIOCHEM PHARMACOL, V31, P121; Voehringer DW, 1997, INT J RADIAT BIOL, V71, P237, DOI 10.1080/095530097144102; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WALTON MI, 1993, CANCER RES, V53, P1853; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	55	202	205	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1461	1470		10.1038/sj.onc.1201310	http://dx.doi.org/10.1038/sj.onc.1201310			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333022				2022-12-25	WOS:A1997XW41100010
J	Mizuno, T; Kyoizumi, S; Suzuki, T; Iwamoto, KS; Seyama, T				Mizuno, T; Kyoizumi, S; Suzuki, T; Iwamoto, KS; Seyama, T			Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis	ONCOGENE			English	Article						thyroid; radiation; RET oncogene; H4-RET; scid mice	SEVERE COMBINED IMMUNODEFICIENCY; POTENTIALLY LETHAL DAMAGE; DOUBLE-STRAND BREAKS; CARCINOMA CELL-LINE; RET PROTO-ONCOGENE; SCID MICE; PHILADELPHIA-CHROMOSOME; HUMAN-FIBROBLASTS; IN-VIVO; HUMAN SKIN	Ionizing radiation is a well-known risk factor of cancer development, but the mechanism of radiation induced carcinogenesis is not clear. Chromosomal rearrangements induced by radiation most likely are one of the principal genetic alterations resulting in malignant transformation. The chimeric BCR-ABL associated with chronic myelogenous leukemia (CML) and H4-RET oncogenes associated with thyroid papillary carcinoma are the result of a translocation and inversion, respectively. In vitro studies showed these genes were induced by high-doses of X-irradiation in cell lines. Studies also show that therapeutic external X-ray doses as high as 60 Gy for treatment of various childhood cancers including Hodgkin's disease significantly increase the risk of thyroid cancer. Therefore, we examined the induction and persistence of these chimeric genes in human thyroid tissues transplanted in scid mice after 50 Gy exposure as a function of time for 2 months to elucidate the early events of thyroid carcinogenesis. The H4-RET genes were detected on day 2 and throughout the 2 month period. On the other hand, BCR-ABL genes were detected on day 2 and were undetectable subsequently. These results suggest that ionizing radiation causes various oncogene activations, but cells with only specific gene alteration uniquely associated with thyroid carcinogenesis are selectively retained demonstrating one of the early events in the beginnings of radiation carcinogenesis in human thyroid tissues.	RADIAT EFFECTS RES FDN,DEPT RADIOBIOL,HIROSHIMA 732,JAPAN	Radiation Effects Research Foundation - Japan								AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; BEDFORD JS, 1991, INT J RADIAT ONCOL, V21, P1457, DOI 10.1016/0360-3016(91)90320-4; BROWN JM, 1993, ENVIRON MOL MUTAGEN, V22, P218, DOI 10.1002/em.2850220407; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CORNFORTH MN, 1987, RADIAT RES, V111, P385, DOI 10.2307/3576926; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANCOCK SL, 1995, INT J RADIAT ONCOL, V31, P1165, DOI 10.1016/0360-3016(95)00019-U; HILL LL, 1991, CANCER RES, V51, P4937; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1989, JPN J CANCER RES, V80, P1149, DOI 10.1111/j.1349-7006.1989.tb01645.x; ITO T, 1993, JPN J CANCER RES, V84, P105, DOI 10.1111/j.1349-7006.1993.tb02840.x; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P259; ITO T, 1995, CANCER LETT, V88, P113, DOI 10.1016/0304-3835(94)03622-P; Klugbauer S, 1995, ONCOGENE, V11, P2459; KYOIZUMI S, 1994, RADIAT RES, V137, P76, DOI 10.2307/3578793; Lobrich M, 1995, P NATL ACAD SCI USA, V92, P12050, DOI 10.1073/pnas.92.26.12050; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; METTLER FA, 1995, MED EFFECTS IONIZING, P214; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Preston DL, 1994, RADIAT RES, V137, P68; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Soballe PW, 1996, CANCER RES, V56, P757; TAKIZAWA Y, 1995, ARCH DERMATOL RES, V287, P237, DOI 10.1007/BF01105072; TANAKA J, 1987, VIROLOGY, V161, P62, DOI 10.1016/0042-6822(87)90171-1; TERAOKA S, 1994, INT J ONCOL, V5, P501; THOMPSON DE, 1994, RAD RES S, V137, P17; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WARD JF, 1990, INT J RADIAT BIOL, V57, P1141, DOI 10.1080/09553009014551251; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0	35	67	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1455	1460		10.1038/sj.onc.1201313	http://dx.doi.org/10.1038/sj.onc.1201313			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333021				2022-12-25	WOS:A1997XW41100009
J	Michel, C; vanEchtenDeckert, G; Rother, J; Sandhoff, K; Wang, E; Merrill, AH				Michel, C; vanEchtenDeckert, G; Rother, J; Sandhoff, K; Wang, E; Merrill, AH			Characterization of ceramide synthesis - A dihydroceramide desaturase introduces the 4,5-trans-double bond of sphingosine at the level of dihydroceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOVO SPHINGOLIPID BIOSYNTHESIS; SPHINGANINE N-ACYLTRANSFERASE; RAT-LIVER; GOLGI-APPARATUS; DE-NOVO; MEDIATED BIOLOGY; FATTY-ACIDS; CELL-DEATH; SPHINGOMYELIN; CULTURE	Ceramide (N-acylsphingosine) biosynthesis has been proposed to involve introduction of the 4,5-trans-double bond of sphingosine after synthesis of dihydroceramide (i.e. N-acylsphinganine). For the first time, the in vitro conversion of dihydroceramide to ceramide has been demonstrated using rat liver microsomes and N-[1-C-14]octanoyl-D-erythro-sphinganine (st-H,Cer) and either NADH or NADPH as co-substrate; the apparent K-m values for st-H,Cer and NADH were 340 and 120 mu M, respectively. Molecular oxygen is required for enzymatic activity, and cyanide, divalent copper, as well as antibodies raised against cytochrome b(5) are inhibitory, which suggests that this enzyme should be named dihydroceramide desaturase based on these similarities with the mechanism of Delta(9)-desaturase (stearoyl-CoA desaturase). Factors that influenced the activity of dihydroceramide desaturase include the alkyl chain length of the sphingoid base (in the order C-18 > C-12 > C-8) and fatty acid (C-8 > C-18); the stereochemistry of the sphingoid base (D-erythro- > L-threo-dihydroceramides); the nature of the headgroup, with the highest activity with dihydroceramide, but some (similar to 20%) activity with dihydrosphingomyelin (activity was not detected with dihydroglucosylceramide, however); and the ability to utilize alternative reductants (ascorbic acid could substitute for a reduced pyridine nucleotide, but was inhibitory at higher concentrations). Dihydroceramide desaturase was inhibited by dithiothreitol, which suggests that it might be possible to alter ceramide synthesis by varying the thiol status of hepatocytes, Consistent with this hypothesis, when rat hepatocytes were cultured in varying concentrations of N-acetylcysteine (5 and 10 mM), there was a decrease in the relative incorporation of [C-14]serine into [C-14]ceramide. These studies have conclusively established the pathway of ceramide synthesis via desaturation of dihydroceramide and have uncovered several properties of this reaction that warrant further consideration for their relevance to both sphingolipid metabolism and signaling.	UNIV BONN, KEKULE INST ORGAN CHEM & BIOCHEM, D-53121 BONN, GERMANY; EMORY UNIV, DEPT BIOCHEM, ATLANTA, GA 30322 USA	University of Bonn; Emory University				Merrill, Alfred/0000-0002-6673-968X				BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN PE, 1970, J BIOL CHEM, V245, P335; CHIGORNO V, 1994, EUR J BIOCHEM, V221, P1095, DOI 10.1111/j.1432-1033.1994.tb18829.x; DUVAL DL, 1995, ARCH BIOCHEM BIOPHYS, V316, P699, DOI 10.1006/abbi.1995.1093; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; Jeffcoat R, 1979, Essays Biochem, V15, P1; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; LARRAURI A, 1987, Molecular Toxicology, V1, P301; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MERRILL AH, 1995, J BIOL CHEM, V270, P13834, DOI 10.1074/jbc.270.23.13834; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MESSMER TO, 1989, J NUTR, V119, P534, DOI 10.1093/jn/119.4.534; NAKAGAWA Y, 1994, EUR J PHARM-ENVIRON, V270, P341, DOI 10.1016/0926-6917(94)90010-8; ONG DE, 1973, J BIOL CHEM, V248, P3884; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; PALTAUF F, 1974, J BIOL CHEM, V249, P2661; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P319; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; SREEKRISHNA K, 1980, BIOCHIM BIOPHYS ACTA, V619, P267, DOI 10.1016/0005-2760(80)90075-2; STOFFEL W, 1974, H-S Z PHYSIOL CHEM, V355, P911, DOI 10.1515/bchm2.1974.355.2.911; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WANG E, 1991, J BIOL CHEM, V266, P14486; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; YOKOYAMA K, 1995, FEBS LETT, V368, P477, DOI 10.1016/0014-5793(95)00714-K	35	237	250	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22432	22437		10.1074/jbc.272.36.22432	http://dx.doi.org/10.1074/jbc.272.36.22432			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9312549	hybrid			2022-12-25	WOS:A1997XV49200013
J	Chow, KS; Singh, DP; Roper, JM; Smith, AG				Chow, KS; Singh, DP; Roper, JM; Smith, AG			A single precursor protein for ferrochelatase-I from Arabidopsis is imported in vitro into both chloroplasts and mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-PLANTS; PORPHOBILINOGEN DEAMINASE; GLUTATHIONE-REDUCTASE; SUBCELLULAR LOCATION; PARTIAL-PURIFICATION; MALIC ENZYME; GENE; PEA; POLYPEPTIDES; OXIDASE	Ferrochelatase is the last enzyme of heme biosynthesis and in higher plants is found in both chloroplasts and mitochondria, We have isolated cDNAs for two isoforms of ferrochelatase from Arabidopsis thaliana, both of which are imported into isolated chloroplasts. In this paper we show that ferrochelatase-I is also imported into isolated pea mitochondria with approximately the same efficiency as into chloroplasts. Processing of the precursor was observed with both chloroplast stroma and mitochondrial matrix extracts. This was inhibited by EDTA, indicating it was due to the specific processing proteases, The specificity of import was verified by the fact that the mitochondrial preparation did not import the precursor of the light-harvesting chlorophyll alb protein precursor or the precursor of porphobilinogen deaminase, an earlier enzyme of tetrapyrrole biosynthesis, both of which are exclusively chloroplast-located, Furthermore, import of ferrochelatase-I precursor into mitochondria was inhibited by valinomycin, but this had no effect on its import into chloroplasts. Thus a single precursor molecule is recognized by the import machinery of the two organelles, The implications for the targeting of ferrochelatase in a possible protective role against photooxidative stress are discussed.	UNIV CAMBRIDGE,DEPT PLANT SCI,CAMBRIDGE CB2 3EA,ENGLAND	University of Cambridge			Singh, Davinder P/B-4056-2009	Smith, Alison Gail/0000-0001-6511-5704				APREES T, 1983, ARCH BIOCHEM BIOPHYS, V227, P511, DOI 10.1016/0003-9861(83)90480-0; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; BOUTRY M, 1987, NATURE, V328, P340, DOI 10.1038/328340a0; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; Camp W. van, 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P317; CHAUMONT F, 1990, J BIOL CHEM, V265, P16856; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CREISSEN G, 1995, PLANT J, V8, P167, DOI 10.1046/j.1365-313X.1995.08020167.x; CUMSKY MG, 1987, MOL CELL BIOL, V7, P3511, DOI 10.1128/MCB.7.10.3511; DAY DA, 1979, J EXP BOT, V30, P539, DOI 10.1093/jxb/30.3.539; DUKE SO, 1991, ACS SYM SER, V449, P371; EDWARDS EA, 1990, PLANTA, V180, P278, DOI 10.1007/BF00194008; FANG TK, 1987, CURR TOP PLANT BIOCH, V6, P175; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; GIETL C, 1992, BIOCHIM BIOPHYS ACTA, V1100, P217, DOI 10.1016/0167-4838(92)90476-T; HARBIN BM, 1985, BIOCHEMISTRY-US, V24, P366, DOI 10.1021/bi00323a019; HUANG JT, 1990, PLANT CELL, V2, P1249, DOI 10.1105/tpc.2.12.1249; HURT EC, 1986, EMBO J, V5, P1343, DOI 10.1002/j.1460-2075.1986.tb04365.x; JACOBS JM, 1995, ARCH BIOCHEM BIOPHYS, V32, P274; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM SH, 1994, PLANT MOL BIOL, V26, P863, DOI 10.1007/BF00028854; LITTLE HN, 1976, BIOCHEM J, V156, P309, DOI 10.1042/bj1560309; MARTIN NC, 1994, BIOCHIMIE, V76, P1161, DOI 10.1016/0300-9084(94)90045-0; MATRINGE M, 1989, BIOCHEM J, V260, P231, DOI 10.1042/bj2600231; Mireau H, 1996, PLANT CELL, V8, P1027, DOI 10.1105/tpc.8.6.1027; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; PRASAD ARK, 1995, J BIOL CHEM, V270, P18198, DOI 10.1074/jbc.270.31.18198; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; Roper JM, 1997, EUR J BIOCHEM, V246, P32, DOI 10.1111/j.1432-1033.1997.t01-1-00032.x; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SMITH AG, 1993, BIOCHEM J, V292, P503, DOI 10.1042/bj2920503; SMITH AG, 1994, J BIOL CHEM, V269, P13405; STITT M, 1982, PLANT PHYSIOL, V70, P971, DOI 10.1104/pp.70.4.971; SUZUKI T, 1992, EUR J BIOCHEM, V207, P767, DOI 10.1111/j.1432-1033.1992.tb17107.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; Waegemann K, 1995, METHOD CELL BIOL, V50, P255, DOI 10.1016/S0091-679X(08)61035-3; WHELAN J, 1990, PLANT MOL BIOL, V14, P977, DOI 10.1007/BF00019394; WHELAN J, 1991, PLANT MOL BIOL, V16, P283, DOI 10.1007/BF00020559; WINNING BM, 1994, J BIOL CHEM, V269, P4780; WINNING BM, 1992, PLANT J, V2, P763, DOI 10.1046/j.1365-313X.1992.t01-15-00999.x; WITOWSKI DA, 1988, PLANT PHYSIOL, V87, P632; Witty M, 1996, PLANTA, V199, P557, DOI 10.1007/BF00195187	44	88	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27565	27571		10.1074/jbc.272.44.27565	http://dx.doi.org/10.1074/jbc.272.44.27565			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346891	hybrid			2022-12-25	WOS:A1997YD47300017
J	Adams, CM; Snyder, PM; Welsh, MJ				Adams, CM; Snyder, PM; Welsh, MJ			Interactions between subunits of the human epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; SHAKER POTASSIUM CHANNEL; CAENORHABDITIS-ELEGANS; ACETYLCHOLINE-RECEPTOR; PSEUDOHYPOALDOSTERONISM TYPE-1; MEMBRANE TOPOLOGY; LIDDLES SYNDROME; GAMMA-SUBUNIT; NEURODEGENERATION; MUTATIONS	The human epithelial sodium channel (hENaC) mediates Na+ transport across the apical membrane of epithelia, and mutations in hENaC result in hypertensive and salt-wasting diseases. In heterologous expression systems, maximal hENaC function requires co-expression of three homologous proteins, the alpha, beta, and gamma hENaC subunits, suggesting that hENaC subunits interact to form a multimeric channel complex. Using a co immunoprecipitation assay, we found that hENaC subunits associated tightly to form home-and heteromeric complexes and that the association between subunits occurred early in channel biosynthesis. Deletion analysis of gamma hENaC revealed that the N terminus was sufficient but not necessary for co precipitation of alpha hENaC, and that both the N terminus and the second transmembrane segment (M2) were required for gamma subunit function. The biochemical studies were supported by functional studies. Go-expression of gamma subunits lacking M2 with full-length hENaC subunits revealed an inhibitory effect on hENaC channel function that appeared to be mediated by the cytoplasmic N terminus of gamma, and was consistent with the assembly of nonfunctional subunits into the channel complex. We conclude that the N terminus of gamma hENaC is involved in channel assembly.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa				Welsh, Michael/0000-0002-1646-6206; Adams, Christopher/0000-0002-5795-7212	NHLBI NIH HHS [HL-07344, HL-03575] Funding Source: Medline; NIA NIH HHS [T32 AG 00214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; Bubien JK, 1996, AM J PHYSIOL-CELL PH, V270, pC208, DOI 10.1152/ajpcell.1996.270.1.C208; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHALFIE M, 1989, NATURE, P1027; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LI XJ, 1995, MOL PHARMACOL, V47, P1133; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; Liu JD, 1996, SCIENCE, V273, P361, DOI 10.1126/science.273.5273.361; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Ostedgaard LS, 1997, BIOCHEMISTRY-US, V36, P1287, DOI 10.1021/bi962174s; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; RENARD S, 1994, J BIOL CHEM, V269, P12981; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; Tavernarakis N, 1997, NEURON, V18, P107, DOI 10.1016/S0896-6273(01)80050-7; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; Tucker SJ, 1996, J BIOL CHEM, V271, P5866, DOI 10.1074/jbc.271.10.5866; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	43	66	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27295	27300		10.1074/jbc.272.43.27295	http://dx.doi.org/10.1074/jbc.272.43.27295			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341177	hybrid			2022-12-25	WOS:A1997YC65900073
J	Giuriato, S; Payrastre, B; Drayer, AL; Plantavid, M; Woscholski, R; Parker, P; Erneux, C; Chap, H				Giuriato, S; Payrastre, B; Drayer, AL; Plantavid, M; Woscholski, R; Parker, P; Erneux, C; Chap, H			Tyrosine phosphorylation and relocation of SHIP are integrin-mediated in thrombin-stimulated human blood platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 5-PHOSPHATASE; INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; PHOSPHOINOSITIDE 3-KINASE; PHOSPHOLIPASE-C; SIGNAL-TRANSDUCTION; PROTEIN; ACTIVATION; RECEPTOR; IDENTIFICATION; AGGREGATION	The SH2 domain-containing inositol 5-phosphatase, SHIP, known to dephosphorylate inositol 1,3,4,5-tetrakisphosphate and phosphatidylinositol 3,4,5-trisphosphate has recently been shown to be expressed in a variety of hemopoietic cells. This 145-kDa protein is induced to associate with Shc by multiple cytokines and may play an important role in the negative regulation of immunocompetent cells mediated by Fc gamma RIIB receptor. We report here that SHIP is present in human blood platelets and may be involved in platelet activation evoked by thrombin. Platelet SHIP was identified by Western blotting as a single 145-kDa protein, Both phosphatidylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activities could be demonstrated in anti-SHIP immunoprecipitates of platelet lysate. Thrombin stimulation induced a tyrosine phosphorylation of SHIP, this effect being pre vented if platelets were not shaken or if RGD-containing peptides were present, indicating an aggregation-dependent, integrin-mediated event. Moreover, although the intrinsic phosphatase activity of SHIP did not appear to be significantly increased, tyrosine-phosphorylated SHIP was relocated to the actin cytoskeleton upon activation in an aggregation-and integrin engagement-dependent manner. Finally, the striking correlation observed between phosphatidylinositol 3,4-bisphosphate production and the tyrosine phosphorylation of SHIP, as well as its relocation to the cytoskeleton upon thrombin stimulation, suggest a role for SHIP in the aggregation-dependent and GpIIb-IIIa-mediated accumulation of this important phosphoinositide.	HOP PURPAN,INST FEDERAT RECH 30,INSERM U326,F-31059 TOULOUSE,FRANCE; FREE UNIV BRUSSELS,INTERDISCIPLINARY RES INST,IRIBHN,B-1070 BRUSSELS,BELGIUM; IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LAB,LONDON WC2A 3PX,ENGLAND	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Libre de Bruxelles; Vrije Universiteit Brussel; Cancer Research UK			Parker, Peter j/D-5192-2013; Giuriato, Sylvie/A-9113-2010	Giuriato, Sylvie/0000-0003-3274-3397; parker, peter/0000-0002-6218-2933; , Bernard/0000-0002-8693-0190				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; CAZENAVE JP, 1983, ANN BIOL CLIN-PARIS, V41, P167; Chacko GW, 1996, J IMMUNOL, V157, P2234; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; Drayer AL, 1996, BIOCHEM SOC T, V24, P1001, DOI 10.1042/bst0241001; Drayer AL, 1996, BIOCHEM BIOPH RES CO, V225, P243, DOI 10.1006/bbrc.1996.1161; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; ERNEUX C, 1987, BIOCHEM J, V247, P635, DOI 10.1042/bj2470635; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gachet C, 1997, J BIOL CHEM, V272, P4850, DOI 10.1074/jbc.272.8.4850; GAUDETTE DC, 1993, J BIOL CHEM, V268, P13773; Gironcel D, 1996, FEBS LETT, V389, P253, DOI 10.1016/0014-5793(96)00595-9; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; KING WG, 1989, J BIOL CHEM, V264, P6070; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Matsuo T, 1996, BIOCHEM J, V315, P505, DOI 10.1042/bj3150505; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; PAYRASTRE B, 1994, FEBS LETT, V341, P113, DOI 10.1016/0014-5793(94)80251-3; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; Rittenhouse SE, 1996, BLOOD, V88, P4401, DOI 10.1182/blood.V88.12.4401.bloodjournal88124401; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; Shock DD, 1997, BIOCHEM J, V321, P525, DOI 10.1042/bj3210525; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SULTAN C, 1991, J BIOL CHEM, V266, P23554; Tan Z, 1997, J BIOL CHEM, V272, P2285; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; Woscholski R, 1997, J BIOL CHEM, V272, P9625; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; ZHANG J, 1993, J BIOL CHEM, V268, P22251	57	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26857	26863		10.1074/jbc.272.43.26857	http://dx.doi.org/10.1074/jbc.272.43.26857			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341117	hybrid			2022-12-25	WOS:A1997YC65900013
J	Herrera, JE; Bergel, M; Yang, XJ; Nakatani, Y; Bustin, M				Herrera, JE; Bergel, M; Yang, XJ; Nakatani, Y; Bustin, M			The histone acetyltransferase activity of human GCN5 and PCAF is stabilized by coenzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOMAL DNA; ACETYLATION; TRANSCRIPTION; H4; CHROMOSOME; CHROMATIN; YEAST; H3	Here we report that PCAF and human GCN5, two related type A histone acetyltransferases, are unstable enzymes that under the commonly used assay conditions are rapidly and irreversibly inactivated, Ire addition, we report that free histone H1, although not acetylated in vivo, is a preferred and convenient in vitro substrate for the study of PCAF, human GCN5, and possibly other type A histone acetyltransferases, Using either histone H1 or histone H3 as substrates, we find that preincubation with either acetyl-CoA or CoA stabilizes the acetyltransferase activities of PCAF, human GCN5 and an enzymatically active PCAF deletion mutant containing the C-terminal half of the protein. The stabilization requires the continuous presence of coenzyme, suggesting that the acetyltransferase-coenzyme complexes are stable, while the isolated apoenzymes are not, Human GCN5 and the N-terminal deletion mutant of PCAF are stabilized equally well by preincubation with either CoA or acetyl-CoA, while intact PCAF is better stabilized by acetyl-CoA than by CoA, Intact PCAF, but not the N-terminal truncation mutant or human GCN5, is auto-acetylated. These findings raise the possibility that the intracellular concentrations of the coenzymes affect the stability and therefore the nuclear activity of these acetyltransferases.	NICHHD,LAB MOL GROWTH REGULAT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Herrera, JE (corresponding author), NCI,MOL CARCINOGENESIS LAB,DIV BASIC SCI,NIH,BLDG 37,ROOM 3D-12,BETHESDA,MD 20892, USA.		Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242				ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Belyaev ND, 1996, HUM GENET, V97, P573; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; BUSTIN M, 1973, Nature New Biology, V245, P207; Garrard W T, 1978, Methods Cell Biol, V17, P27, DOI 10.1016/S0091-679X(08)61132-2; HORIUCHI K, 1975, ANAL BIOCHEM, V69, P491, DOI 10.1016/0003-2697(75)90151-7; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LOIDL P, 1994, CHROMOSOMA, V103, P441; MARZLUFF WF, 1972, J BIOL CHEM, V247, P2026; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ROMANI M, 1979, J BIOL CHEM, V254, P2918; ROTH SY, 1966, CELL, V87, P5; Tauton J, 1996, SCIENCE, V272, P408; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; van Holde K.E., 1988, CHROMATIN; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	24	51	52	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27253	27258		10.1074/jbc.272.43.27253	http://dx.doi.org/10.1074/jbc.272.43.27253			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341171	hybrid			2022-12-25	WOS:A1997YC65900067
J	Kral, AM; Diehl, RE; deSolms, SJ; Williams, TM; Kohl, NE; Omer, CA				Kral, AM; Diehl, RE; deSolms, SJ; Williams, TM; Kohl, NE; Omer, CA			Mutational analysis of conserved residues of the beta-subunit of human farnesyl:protein transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYLTRANSFERASE TYPE-I; GLUTATHIONE-S-TRANSFERASE; METAL REQUIREMENTS; ALPHA-SUBUNIT; CDNA CLONING; RAT-BRAIN; FARNESYLTRANSFERASE; EXPRESSION; BINDING; INHIBITION	The roles of 11 conserved amino acids of the beta-subunit of human farnesyl:protein transferase (FTase) were examined by performing kinetic and biochemical analyses of site-directed mutants. This biochemical information along with the x-ray crystal structure of rat FTase indicates that residues His-248, Arg-291, Lys-294, and Trp-303 are involved with binding and utilization of the sub strate farnesyl diphosphate. Our data confirm structural evidence that amino acids Cys-299, Asp-297, and His-362 are ligands for the essential Zn2+ ion and suggest that Asp-359 may also play a role in Zn2+ binding. Additionally, we demonstrate that Arg-202 is important for binding the essential C-terminal carboxylate of the protein substrate.	MERCK RES LABS,DEPT CANC RES,W POINT,PA 19486; MERCK RES LABS,DEPT MED CHEM,W POINT,PA 19486; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	Merck & Company; Merck & Company; University of Pennsylvania								ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BUKHTIYAROV YE, 1995, J BIOL CHEM, V270, P19035, DOI 10.1074/jbc.270.32.19035; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DelVillar K, 1997, J BIOL CHEM, V272, P680; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; Fu HW, 1996, J BIOL CHEM, V271, P28541, DOI 10.1074/jbc.271.45.28541; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOFFMAN R, 1992, ANAL BIOCHEM, V203, P70, DOI 10.1016/0003-2697(92)90044-8; Huang CC, 1997, J BIOL CHEM, V272, P20; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KOBLAN KS, 1995, PROTEIN SCI, V4, P681; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LIU SX, 1992, J BIOL CHEM, V267, P4296; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NAGASU T, 1995, CANCER RES, V55, P5310; NELSON N, 1987, ANAL BIOCHEM, V165, P287, DOI 10.1016/0003-2697(87)90271-5; OHYA Y, 1991, J BIOL CHEM, V266, P12356; OMER CA, 1995, METHOD ENZYMOL, V250, P3; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; PEMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800; POMPLIANO DL, 1993, BIOCHEMISTRY-US, V32, P8341, DOI 10.1021/bi00083a038; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Schmitt D, 1996, PLANT PHYSIOL, V112, P767, DOI 10.1104/pp.112.2.767; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; WILLIAMS TM, 1996, J MED CHEM, V39, P13455; YING WL, 1994, J BIOL CHEM, V269, P470; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	42	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27319	27323		10.1074/jbc.272.43.27319	http://dx.doi.org/10.1074/jbc.272.43.27319			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341181	hybrid			2022-12-25	WOS:A1997YC65900077
J	Schwanbeck, R; Wisniewski, JR				Schwanbeck, R; Wisniewski, JR			Cdc2, and mitogen-activated protein kinases modulate DNA binding properties of the putative transcriptional regulator Chironomus high mobility group protein I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-WAY JUNCTION DNA; HMG-I; SIGNAL-TRANSDUCTION; HISTONE H1; PHOSPHORYLATION; DOMAIN; SPECIFICITY; CHROMOSOMES; CHROMATIN; AFFINITY	Cells of the dipteran insect Chironomus contain a high mobility group protein that is homologous to the mammalian high mobility group proteins I/Y (HMGI/Y). These proteins facilitate the assembly of higher order nucleoprotein complexes, In proliferating cells, >30% of Chironomus HMGI was found to be phosphorylated, The phosphorylation sites were mapped to Ser(3), Ser(22), and Ser(72) and were found to be substrates for the kinases Cdc2 (and mitogen-activated protein (MAP)), MAP, and Ca2+/phospholipid-dependent protein kinase, respectively, In mitotically arrested cells, the extent of phosphorylation at Ser(3) increased, whereas phosphorylation at Ser(22) remained unchanged, In nondividing cells, phosphorylation at Ser(3) and Ser(22) was strongly reduced, The DNA binding affinity of Chironomus HMGI was not influenced by single phosphorylation at Sers or Ser(22). In contrast, phosphorylation at both of these sites resulted in a 10-fold weakening of the binding activity and altered the mode of protein-DNA interaction. Since both human and murine HMGI/Y proteins, similarly to the insect HMGI protein, possess phosphorylation sites for Cdc2 and MAP kinases that intersperse the AT-hook DNA-binding motifs, our results may reflect a general mechanism that regulates the properties and function of this class of putative transcriptional regulators.	UNIV GOTTINGEN, ZOOL INST ENTWICKLUNGSBIOL 3, D-37073 GOTTINGEN, GERMANY	University of Gottingen			Schwanbeck, Ralf/A-2648-2008	Schwanbeck, Ralf/0000-0003-0925-929X				AlamiOuahabi N, 1996, MOL CELL BIOL, V16, P3720; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CLAUS P, 1994, J BIOL CHEM, V269, P33042; COBB M, 1996, PROTEIN KINASE FACTS, P214; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; ELTON TS, 1986, ANAL BIOCHEM, V157, P53, DOI 10.1016/0003-2697(86)90195-8; Fiske CH, 1925, J BIOL CHEM, V66, P375; Ghidelli S, 1997, CHROMOSOMA, V105, P369, DOI 10.1007/BF02529752; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; LUND T, 1985, FEBS LETT, V180, P275, DOI 10.1016/0014-5793(85)81085-1; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAMACHANDRAN C, 1984, J BIOL CHEM, V259, P3495; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; RINGER DP, 1991, METHOD ENZYMOL, V201, P3; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANHOLDE K, 1994, CHROMATIN STRUCTURE, P1; VARGAWEISZ P, 1993, J BIOL CHEM, V268, P20699; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; WISNIEWSKI JR, 1992, J BIOL CHEM, V267, P17170; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Wisniewski JR, 1997, EUR J BIOCHEM, V243, P151, DOI 10.1111/j.1432-1033.1997.0151a.x; Wisniewski JR, 1996, INT J DEV BIOL, V40, P177; WISNIEWSKI JR, 1994, EUR J BIOCHEM, V225, P687, DOI 10.1111/j.1432-1033.1994.00687.x; WYSS C, 1982, EXP CELL RES, V139, P309, DOI 10.1016/0014-4827(82)90255-5; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	38	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27476	27483		10.1074/jbc.272.43.27476	http://dx.doi.org/10.1074/jbc.272.43.27476			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341202	hybrid			2022-12-25	WOS:A1997YC65900098
J	Lin, S; Naim, HY; Roth, MG				Lin, S; Naim, HY; Roth, MG			Tyrosine-dependent basolateral sorting signals are distinct from tyrosine dependent internalization signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; AMINO-ACID CHANGE; MDCK CELLS; CYTOPLASMIC DOMAIN; COATED PITS; GOLGI-COMPLEX; FC-RECEPTORS; ENDOCYTOSIS	Converting cysteine 543 to tyrosine in the influenza virus hemagglutinin (HA) introduces both a basolateral sorting signal and an internalization signal into the HA cytoplasmic domain. Another RA mutant, HA+8, contains eight additional amino acids at the end of the cytoplasmic domain that include a powerful internalization signal, HA+8 was also sorted efficiently to the basolateral surface of Madin-Darby canine kidney cells, The simplest explanation for the observation that multiple sorting phenotypes depend upon the same small amino acid sequence is that certain tyrosine-based internalization signals might also function as basolateral sorting signals. To test this hypothesis, second-site mutations were introduced into HA C543Y or HA+8 to determine if the internalization and basolateral sorting functions can be separated, For HA C543Y, the same sequence positions were important for both basolateral sorting and internalization, but the two functions responded differently to individual amino acid replacements, indicating that they were distinct. For HA+8, the basolateral sorting signal required the same tyrosine as the internalization signal, but did not share any other characteristics. Thus, even when basolateral sorting signals that depend on tyrosine overlap or are co-linear with internalizations signals, the two sorting processes are sensitive to different characteristics of the sequence.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Roth, Michael/0000-0002-9056-332X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BREWER CB, 1995, J CELL SCI, V108, P789; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NAIM HY, 1995, J CELL BIOL, V129, P1241, DOI 10.1083/jcb.129.5.1241; NAIM HY, 1992, J VIROL, V66, P7585, DOI 10.1128/JVI.66.12.7585-7588.1992; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; Reich V, 1996, J CELL SCI, V109, P2133; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Zwart DE, 1996, J BIOL CHEM, V271, P907, DOI 10.1074/jbc.271.2.907	32	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26300	26305		10.1074/jbc.272.42.26300	http://dx.doi.org/10.1074/jbc.272.42.26300			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334200	hybrid			2022-12-25	WOS:A1997YB13900034
J	Baek, SH; Choi, KS; Yoo, YJ; Cho, JM; Baker, RT; Tanaka, K; Chung, CH				Baek, SH; Choi, KS; Yoo, YJ; Cho, JM; Baker, RT; Tanaka, K; Chung, CH			Molecular cloning of a novel ubiquitin-specific protease, UBP41, with isopeptidase activity in chick skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL HYDROLASES; DEUBIQUITINATING ENZYME; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; GENE; DEGRADATION; PROTEINS; PROTEOLYSIS; PRECURSOR; ONCOGENE	A cDNA encoding a new ubiquitin-specific protease, UBP41, in chick skeletal muscle was cloned using an Escherichia coli-based in vivo screening method. Nucleotide sequence analysis of the cDNA containing an open reading frame of 1,071 base pairs revealed that the protease consists of 357 residues with a calculated molecular mass of 40,847 Da, and is related to members of the UBP family containing highly conserved Cys and His domains. Chick UBP41 was expressed in E. coli and purified from the cells to apparent homogeneity, using I-125-labeled ubiquitin-alpha NH-MHISPPEPESEEEEEHYC as a substrate. The purified enzyme behaved as an approximately 43-kDa protein under both denaturing and nondenaturing conditions, suggesting that it consists of a single polypeptide chain. Like other deubiquitinating enzymes, it was sensitive to inhibition by ubiquitin-aldehyde and sulfhydryl blocking agents, such as N-ethylmaleimide. The UBP41 protease cleaved at the C terminus of the ubiquitin moiety in natural and engineered fusions irrespective of their sizes; thus, it is active against ubiquitin-beta-galactosidase as well as ubiquitin C-terminal extension protein of 80 amino acids. UBP41 also released free ubiquitin from poly-His-tagged diubiquitin. Moreover, it converted poly-ubiquitinated lysozyme conjugates to mono-ubiquitinated forms of about 24 kDa, although the latter molecules were not further degraded to free ubiquitin and lysozyme. These results suggest that UBP41 may play an important role in the recycling of ubiquitin by hydrolysis of branched poly-ubiquitin chains generated by the action of 26 S proteasome on poly-ubiquitinated protein substrates, as well as in the production of free ubiquitin from linear poly-ubiquitin chains and of certain ribosomal proteins from ubiquitin fusion proteins.	SEOUL NATL UNIV, COLL NAT SCI, DEPT MOL BIOL, SEOUL 151742, SOUTH KOREA; SEOUL NATL UNIV, COLL NAT SCI, RES CTR CELL DIFFERENTIAT, SEOUL 151742, SOUTH KOREA; LG BIOTECH LTD, TAEJON 305380, SOUTH KOREA; AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, MOL GENET GRP, CANBERRA, ACT 2601, AUSTRALIA; JAPAN SCI & TECHNOL CORP, CREST, METROPOLITAN INST MED SCI, BUNKYO KU, TOKYO 113, JAPAN	Seoul National University (SNU); Seoul National University (SNU); Australian National University; John Curtin School of Medical Research; Japan Science & Technology Agency (JST)			Yoo, Yung Joon/AAH-5002-2020					Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Baek SH, 1997, BIOCHEM J, V325, P325, DOI 10.1042/bj3250325; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BOND U, 1986, MOL CELL BIOL, V6, P4602, DOI 10.1128/MCB.6.12.4602; Chung CH, 1996, ADV EXP MED BIOL, V389, P203; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FALQUET L, 1995, FEBS LETT, V376, P233, DOI 10.1016/0014-5793(95)01287-7; FALQUET L, 1995, FEBS LETT, V359, P73, DOI 10.1016/0014-5793(94)01451-6; FINLEY D, 1989, NATURE, V338, P414; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOUGH R, 1986, J BIOL CHEM, V261, P2391; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LUND PK, 1985, J BIOL CHEM, V260, P7609; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; NAKAMURA T, 1992, ONCOGENE, V7, P733; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STEIN RL, 1995, BIOCHEMISTRY-US, V34, P12616, DOI 10.1021/bi00039a017; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; WILKINSON KD, 1992, BIOCHEM SOC T, V20, P631, DOI 10.1042/bst0200631; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Woo SK, 1997, J BIOCHEM-TOKYO, V121, P684; WOO SK, 1995, J BIOL CHEM, V270, P18766, DOI 10.1074/jbc.270.32.18766; YOO Y, 1989, J BIOL CHEM, V264, P17078; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275	44	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25560	25565		10.1074/jbc.272.41.25560	http://dx.doi.org/10.1074/jbc.272.41.25560			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325273	hybrid			2022-12-25	WOS:A1997YA35800028
J	Bowie, AG; Moynagh, PN; ONeill, LAJ				Bowie, AG; Moynagh, PN; ONeill, LAJ			Lipid peroxidation is involved in the activation of NF-kappa B by tumor necrosis factor but not interleukin-1 in the human endothelial cell line ECV304 - Lack of involvement of H2O2 in NF-kappa B activation by either cytokine in both primary and transformed endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY GENE INDUCTION; HUMAN T-CELL; TRANSCRIPTION FACTOR; ADHESION MOLECULE-1; FACTOR-ALPHA; TISSUE FACTOR; POSTTRANSCRIPTIONAL REGULATION; ATHEROSCLEROTIC LESION; HYDROGEN-PEROXIDE; INTACT-CELLS	It has been proposed that reactive oxygen species, and in particular H2O2, may be involved in the activation of NF-kappa B by diverse stimuli in different cell types, Here we have investigated the effect of a range of putative antioxidants on NF-kappa B activation by interleukin-1 and tumor necrosis factor as well as the ability of H2O2 to activate NF-kappa B in primary human umbilical vein endothelial cells and the transformed human endothelial cell line ECV304. Activation of NF-kappa B and stimulation of I kappa B alpha degradation by H2O2 was only evident in the transformed cells and required much longer contact times than that observed with interleukin-1 or tumor necrosis factor. Furthermore, only H2O2 was sensitive to N-acetyl-L-cysteine, and no increase in H2O2 was detected in response to either cytokine, Pyrrolidine dithiocarbamate has been purported to be a specific antioxidant inhibitor of NF-kappa B that acts independently of activating agent or cell type, However, we found that tumor necrosis factor-but not interleukin-1-driven NF-kappa B activation and I kappa B alpha degradation were sensitive to pyrrolidine dithiocarbamate in transformed cells, while neither pathway was inhibited in primary cells, Phorbol ester-mediated activation was sensitive in both transformed and primary cells, Other antioxidants failed to inhibit either cytokine, while the iron chelators desferrioxamine and 2,2,6,6-tetramethylpiperidine-1-oxyl mimicked the pattern of inhibition seen for the dithiocarbamate, This suggested that pyrrolidine dithiocarbamate was inhibiting NF-kappa B activation in endothelial cells primarily through its iron-chelating properties, Tumor necrosis factor, but not interleukin-1, was found to induce lipid peroxidation in ECV304 cells, This was inhibited by pyrrolidine dithiocarbamate and desferrioxamine, t-Butyl hydroperoxide, which induces lipid peroxidation, activated NF-kappa B, Finally, butylated hydroxyanisole, which inhibits lipid peroxidation but has no iron-chelating properties, inhibited NF-kappa B activation by tumor necrosis factor but not interleukin-1. Taken together, the results argue against a role for H2O2 in NF-kappa B activation by cytokines in endothelial cells, Furthermore, tumor necrosis factor and interleukin-1 activate NF-kappa B through different mechanisms in ECV304 cells, with the tumor necrosis factor pathway involving iron-catalyzed lipid peroxidation.	UNIV DUBLIN TRINITY COLL, DEPT BIOCHEM, DUBLIN 2, IRELAND; NATL UNIV IRELAND UNIV COLL DUBLIN, DEPT PHARMACOL, DUBLIN 4, IRELAND	Trinity College Dublin; University College Dublin				Moynagh, Paul/0000-0002-4139-3061; Bowie, Andrew/0000-0001-5316-4373				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARRADAS MA, 1989, FEBS LETT, V245, P105, DOI 10.1016/0014-5793(89)80201-7; BARTOLI GM, 1983, FEBS LETT, V164, P371, DOI 10.1016/0014-5793(83)80319-6; BIERHAUS A, 1995, J BIOL CHEM, V270, P26419, DOI 10.1074/jbc.270.44.26419; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY JR, 1993, AM J PATHOL, V142, P1598; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Brennan P, 1996, BIOCHEM J, V320, P975, DOI 10.1042/bj3200975; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; BRISSEAU GF, 1995, BLOOD, V85, P1025, DOI 10.1182/blood.V85.4.1025.bloodjournal8541025; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHIAO C, 1995, CANCER RES, V55, P3576; COLLINS T, 1993, LAB INVEST, V68, P499; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Fiers W, 1995, BIOL THERAPY CANC, P295; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARPE JD, 1985, J IMMUNOL METHODS, V78, P323; Hennig B, 1996, AM J CLIN NUTR, V63, P322, DOI 10.1093/ajcn/63.3.322; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ISRAEL N, 1992, J IMMUNOL, V149, P3386; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LIAO F, 1994, J CLIN INVEST, V94, P877, DOI 10.1172/JCI117409; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; MIHM S, 1995, FASEB J, V9, P246, DOI 10.1096/fasebj.9.2.7781927; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; NILSSON UA, 1989, J BIOL CHEM, V264, P11131; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; ORTHNER CL, 1995, BLOOD, V86, P436, DOI 10.1182/blood.V86.2.436.bloodjournal862436; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PERRIN D, 1978, IUPAC STABILITY CO B, P329; ROSEN GM, 1984, METHOD ENZYMOL, V105, P198; ROYALL JA, 1992, ARCH BIOCHEM BIOPHYS, V294, P686, DOI 10.1016/0003-9861(92)90742-F; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; Schoonbroodt S, 1997, BIOCHEM J, V321, P777, DOI 10.1042/bj3210777; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sen CK, 1996, BIOCHEM BIOPH RES CO, V218, P148, DOI 10.1006/bbrc.1996.0026; Sen CK, 1996, FEBS LETT, V385, P58, DOI 10.1016/0014-5793(96)00346-8; SLATER TF, 1984, METHOD ENZYMOL, V105, P283; SUNDERMAN FW, 1991, ANN CLIN LAB SCI, V21, P70; SUZUKI YJ, 1995, BIOCHEM BIOPH RES CO, V210, P537, DOI 10.1006/bbrc.1995.1693; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; Tetsuka T, 1996, J BIOL CHEM, V271, P11689, DOI 10.1074/jbc.271.20.11689; VALENTINE WM, 1992, CHEM RES TOXICOL, V5, P254, DOI 10.1021/tx00026a017; VOEST EE, 1993, FREE RADICAL BIO MED, V15, P589, DOI 10.1016/0891-5849(93)90161-M; WEBER C, 1994, ARTERIOSCLER THROMB, V14, P1665, DOI 10.1161/01.ATV.14.10.1665	64	171	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25941	25950		10.1074/jbc.272.41.25941	http://dx.doi.org/10.1074/jbc.272.41.25941			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325328	hybrid, Green Accepted			2022-12-25	WOS:A1997YA35800083
J	Hardwick, JS; Sefton, BM				Hardwick, JS; Sefton, BM			The activated form of the Lck tyrosine protein kinase in cells exposed to hydrogen peroxide is phosphorylated at both Tyr-394 and Tyr-505	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMOLECULAR AUTOPHOSPHORYLATION; FUNCTIONAL DISSECTION; P56LCK; P56(LCK); GENE; PALMITOYLATION; STIMULATION; PP60(C-SRC); MYRISTATE; PROMOTER	Members of the Src family of non-receptor tyrosine protein kinases are known to be inhibited by the intramolecular association between a phosphorylated carboxyl-terminal tyrosine residue and the SH2 domain. We have previously shown that exposure of cells to H2O2 strongly activates Lck, a lymphocyte-specific Src family kinase, by inducing phosphorylation on Tyr-394, an absolutely conserved residue within the activation loop of the catalytic domain. Here we show that Lck that has been activated by H2O2 is simultaneously phosphorylated at both the carboxyl-terminal tyrosine (Tyr-505) and Tyr-394. Thus, dephosphorylation of Tyr-505 is not a prerequisite for either phosphorylation of Lck at Tyr-394 or catalytic activation of the kinase. These results indicate that activation of Lck by phosphorylation of Tyr-394 is dominant over any inhibition induced by phosphorylation of Tyr-505. We propose that these results may be extended to all Src family members.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92037	University of California System; University of California San Diego	Hardwick, JS (corresponding author), SALK INST BIOL STUDIES,MOL BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92186, USA.				NCI NIH HHS [CA42350, CA14195] Funding Source: Medline; NIGMS NIH HHS [2T32-GM07240] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042350, P30CA014195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Bevan AP, 1995, MOL CELL BIOCHEM, V153, P49, DOI 10.1007/BF01075918; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HURLEY TR, 1989, ONCOGENE, V4, P265; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; KAMPS MP, 1988, ONCOGENE, V2, P305; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KWONG J, 1995, BIOCHEM BIOPH RES CO, V207, P868, DOI 10.1006/bbrc.1995.1266; LUO K, 1990, ONCOGENE, V5, P921; MADHUSUDAN T, 1994, PROTEIN SCI, V3, P176; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SULLIVAN SG, 1994, FREE RADICAL BIO MED, V16, P399, DOI 10.1016/0891-5849(94)90042-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914; Yurchak LK, 1996, J BIOL CHEM, V271, P12549, DOI 10.1074/jbc.271.21.12549	44	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25429	25432		10.1074/jbc.272.41.25429	http://dx.doi.org/10.1074/jbc.272.41.25429			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325251	hybrid			2022-12-25	WOS:A1997YA35800006
J	Liochev, SI; Fridovich, I				Liochev, SI; Fridovich, I			A mechanism for complementation of the sodA sodB defect in Escherichia coli by overproduction of the rbo gene product (Desulfoferrodoxin) from Desulfoarculus baarsii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; OXIDATIVE DAMAGE; OXYGEN-TOXICITY; DNA-DAMAGE; IN-VITRO; PURIFICATION; MUTANTS; CELLS; VIVO; IRON	Overexpression of rbo in Escherichia coli prevents the inactivation of the [4Fe-4S]-containing fumarases that otherwise occurs in the sodA sodB strain, It similarly protects against the increased sensitivity toward H2O2, which is imposed by the lack of SOD A and SOD B. These results would be explained on the basis of scavenging of O-2(radical anion) within the cells by RBO. This interpretation was supported by measurements of intracellular scavenging of O-2(radical anion) by the lucigenin luminescence method. Since SOD activity could not be detected in dilute extracts, of the RBO-overexpressing sodA sodB strain, we propose that RBO catalyzes the reduction of O-2(radical anion) at the expense of cellular reductants such as NAD(P)H. A similar mechanism may apply to other instances of complementation of SOD defects by non SOD genes.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University								ARCHIBALD FS, 1986, INFECT IMMUN, V51, P631, DOI 10.1128/IAI.51.2.631-641.1986; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; FAULKNER K, 1993, FREE RADICAL BIO MED, V15, P447, DOI 10.1016/0891-5849(93)90044-U; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Hill RL, 1969, METHOD ENZYMOL, V8, P91, DOI 10.1016/0076-6879(69)13021-9; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Lehmann Y, 1996, J BACTERIOL, V178, P7152, DOI 10.1128/jb.178.24.7152-7158.1996; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LIOCHEV SI, 1993, ARCH BIOCHEM BIOPHYS, V301, P379, DOI 10.1006/abbi.1993.1159; Liochev SI, 1997, P NATL ACAD SCI USA, V94, P2891, DOI 10.1073/pnas.94.7.2891; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; LIOCHEV SI, 1995, ARCH BIOCHEM BIOPHYS, V321, P271, DOI 10.1006/abbi.1995.1395; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V337, P115, DOI 10.1006/abbi.1997.9766; LIOCHEV SI, 1996, FREE RADICAL RES, V5, P369; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; PIANZZOLA MJ, 1996, J BACTERIOL, V178, P3736; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; WAUD WR, 1975, ARCH BIOCHEM BIOPHYS, V169, P695, DOI 10.1016/0003-9861(75)90214-3	26	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25573	25575		10.1074/jbc.272.41.25573	http://dx.doi.org/10.1074/jbc.272.41.25573			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325275	hybrid			2022-12-25	WOS:A1997YA35800030
J	Liu, SC; Hoke, D; Julian, J; Carson, DD				Liu, SC; Hoke, D; Julian, J; Carson, DD			Heparin/heparan sulfate (HP/HS) interacting protein (HIP) supports cell attachment and selective, high affinity binding of HP/HS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN HEPARAN-SULFATE; TUMOR-METASTASIS; MOUSE EMBRYOS; GROWTH-FACTOR; LINE RL95; EXPRESSION; ADHESION	Heparin/heparan sulfate (HP/HS), HS proteoglycans, and their binding proteins play important roles in a variety of biological processes. Previously, we identified a novel cell surface HP/HS interacting protein (HIP) from human uterine epithelia and a variety of other human epithelial and endothelial cells and cell lines (Liu, S., Smith, S. E., Julian, J., Rohde, L. H., Karin, N. J., and Carson, D. D. (1996) J. Biol. Chem. 271, 11817-11823; Rohde, L. H., Julian, J., Babaknia, A., and Carson, D. D. (1996) J. Biol. Chem. 271, 11824-11830). In the current studies, we have purified and characterized HIP from HEC cells, a human uterine epithelial cell line, as well as recombinant HIP from a bacterial expression system. HIP supports attachment of the human trophoblastic cell line, JAR, in a HS-dependent fashion. Predigestion of JAR cells with a mixture of heparitinases, but not chondroitinase AC, abolished cell attachment to HIP. In addition, JAR cell attachment to HIP is highly sensitive to HP inhibition and much more selective for HP/HS than other glycosaminoglycans. Dermatan sulfate displays partial inhibitory activity as well, consistent with the observation that chondroitinase ABC digestion partially reduces JAR cell attachment to HIP. Solid-phase binding assays indicate HIP binds [H-3]HP with high affinity (apparent K-D = 8 nM). Furthermore, HIP bound cell surface/extracellular matrix-associated HS, expressed by RL95 cells, a human uterine epithelial cell line. Anti-HIP antibody generated against a synthetic peptide derived from a putative HP/HS-binding motif resident within HIP inhibited about half of [H-3]HP binding to HIP, indicating that this domain is a functional HP-binding domain of HIP. Similarly, this same synthetic peptide motif of HIP could block about 50% of [H-3]HP binding to HIP; however, this peptide almost completely inhibited cell attachment to HIP, suggesting a critical role, in this regard. Collectively, these results suggest that HIP can function as a HP/HS-binding cell-cell/cell-matrix adhesion molecule.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD025235, R01HD025235] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25235] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; CARSON DD, 1992, CELL SURFACE CARBOHY, P257; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDEGREN V, 1984, J IMMUNOL METHODS, V67, P377; Liu SC, 1996, J BIOL CHEM, V271, P11817, DOI 10.1074/jbc.271.20.11817; Liu SC, 1997, P NATL ACAD SCI USA, V94, P1739, DOI 10.1073/pnas.94.5.1739; Marchetti D, 1997, J BIOL CHEM, V272, P15891, DOI 10.1074/jbc.272.25.15891; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; PATTILLO RA, 1971, ANN NY ACAD SCI, V172, P288, DOI 10.1111/j.1749-6632.1971.tb34942.x; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RABOUDI N, 1992, J BIOL CHEM, V267, P11930; ROHDE LH, 1993, J CELL PHYSIOL, V155, P185, DOI 10.1002/jcp.1041550124; Rohde LH, 1996, J BIOL CHEM, V271, P11824, DOI 10.1074/jbc.271.20.11824; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SKUBITZ APN, 1988, J BIOL CHEM, V263, P4861; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; VLODAVSKY I, 1988, ISRAEL J MED SCI, V24, P464; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; VLODAVSKY I, 1980, CELL, V19, P607, DOI 10.1016/S0092-8674(80)80037-7; WILSON O, 1990, J CELL PHYSIOL, V143, P60, DOI 10.1002/jcp.1041430108; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YABKOWITZ R, 1989, J BIOL CHEM, V264, P10888	26	29	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25856	25862		10.1074/jbc.272.41.25856	http://dx.doi.org/10.1074/jbc.272.41.25856			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325317	hybrid			2022-12-25	WOS:A1997YA35800072
J	Pace, P; Taylor, J; Suntharalingam, S; Coombes, RC; Ali, S				Pace, P; Taylor, J; Suntharalingam, S; Coombes, RC; Ali, S			Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ACTIVATION; GLUCOCORTICOID RECEPTORS; PROGESTERONE RECEPTORS; IN-VITRO; SUPERFAMILY; DOMAINS; GENE; MOUSE; ANTIESTROGENS; REGIONS	The cloning of a novel estrogen receptor beta (denoted ER beta) has recently been described (Kuiper, G. G. J. M., Enmark, E., Pelto-Huikko, M., Nilsson, S., and Gustafsson, J-A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5925-5930 and Mosselman, S., Polman, J., and Dijkema, R. (1996) FEBS Lett. 392, 49-53). ER beta is highly homologous to the ''classical'' estrogen receptor alpha (here referred to as ER alpha), has been shown to bind estrogens with an affinity similar to that of ER alpha; and activates expression of reporter genes containing estrogen response elements in an estrogen-dependent manner. Here we describe functional studies comparing the DNA binding abilities of human ER alpha and beta in gel shift assays. We show that DNA binding by ER alpha and beta are similarly affected by elevated temperature in the absence of ligand or in the presence of 17 beta-estradiol and the partial estrogen agonist 4-hydroxy-tamoxifen. In the absence of ligand, DNA binding by ER alpha and beta is rapidly lost at 37 degrees C, while in the presence of 17 beta-estradiol and 4-hydroxy-tamoxifen the loss in DNA binding at elevated temperature is much more gradual. We show that the loss in DNA binding is not due to degradation of the receptor proteins. However, while the complete antagonist ICI 182,780 does not ''protect'' human ER alpha (hER alpha) from loss of DNA binding at elevated temperature in vitro, it does appear to protect human ER beta (hER beta), suggestive of differences in the way ICI 182,780 acts on hER alpha and beta. We further report that ER alpha and beta can dimerize with each other, the DNA binding domain of hER alpha being sufficient for dimerization with hER beta. Cell and promoter-specific transcription activation by ER alpha has been shown to be dependent on the differential action of the N- and C-terminal transcription activation functions AF-1 and AF-2, respectively. The existence of a second estrogen receptor gene and the dimerization of ER alpha and beta add greater levels of complexity to transcription activation in response to estrogens.	IMPERIAL COLL MED,DEPT MED ONCOL,LONDON W6 8RF,ENGLAND	Imperial College London			Pace, Paul E/A-3104-2012; Ali, Simak/M-6912-2018	Pace, Paul E/0000-0003-1855-5760; Coombes, Raoul Charles/0000-0002-4811-1100; Ali, Simak/0000-0002-1320-0816				ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V89, P1218; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GIBSON MK, 1991, ENDOCRINOLOGY, V129, P2000, DOI 10.1210/endo-129-4-2000; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREEN S, 1987, NATURE, V325, P754; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; KNIPER GGJ, 1996, P NATL ACAD SCI USA, V93, P5925; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; McInerney EM, 1996, J BIOL CHEM, V271, P24172, DOI 10.1074/jbc.271.39.24172; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x	41	247	257	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25832	25838		10.1074/jbc.272.41.25832	http://dx.doi.org/10.1074/jbc.272.41.25832			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325313	hybrid			2022-12-25	WOS:A1997YA35800068
J	Croniger, C; Trus, M; LysekStupp, K; Cohen, H; Liu, Y; Darlington, GJ; Poli, V; Hanson, RW; Reshef, L				Croniger, C; Trus, M; LysekStupp, K; Cohen, H; Liu, Y; Darlington, GJ; Poli, V; Hanson, RW; Reshef, L			Role of the isoforms of CCAAT/enhancer-binding protein in the initiation of phosphoenolpyruvate carboxykinase (GTP) gene transcription at birth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-ALPHA-GENE; MESSENGER-RNA; RAT-LIVER; REGULATORY ELEMENTS; 3T3-L1 ADIPOCYTES; TRANSGENIC MICE; NUCLEAR FACTORS; ADIPOSE-TISSUE; RESPONSE UNIT; EXPRESSION	The gene for phosphoenolpyruvate carboxykinase (PEPCK), a target of CCAAT/enhancer-binding protein-alpha (C/EBP alpha) and -beta (C/EBP beta), begins to be expressed in the liver at birth. Mice homozygous for a deletion in the gene for CEBP alpha (C/EBP alpha(-)/(-) mice) die shortly after birth of hypoglycemia, with no detectable hepatic PEPCK mRNA and negligible hepatic glycogen stores. Half of the mice homozygous for a deletion in the gene for CEBP beta(C/EBP beta(-)/(-) mice) have normal glucose homeostasis (phenotype A), and the other half die at birth of hypoglycemia due to a failure to express the gene for PEPCK and to mobilize hepatic glycogen (phenotype B). Insulin deficiency induces C/EBP alpha and PEPCK gene transcription in the livers of 19-day fetal rats, whereas dibutyryl cyclic AMP (Bt(2)cAMP) increases the expression of the gene for C/EBP beta and causes a transient burst of PEPCK mRNA. Bt(2)cAMP induces PEPCK mRNA in the livers of control animals; however, there is no induction of PEPCK mRNA if the cyclic nucleotide is injected into C/EBP alpha(-)/(-) mice immediately after delivery. The expression of the gene for C/EBP beta is markedly induced in the livers of C/EBP alpha(-)/(-) mice within 2 h after the administration of Bt(2)cAMP. C/EBP beta(-)/(-) mice injected at 20 days of fetal life with Bt(2)cAMP have a normal pattern of induction of hepatic PEPCK mRNA. In C/EBP beta(-)/(-) mice with phenotype B, the administration of Bt(2)cAMP immediately after delivery induces PEPCK mRNA, causes the mobilization of hepatic glycogen, and maintains normal glucose homeostasis for up to 4 h (duration of the experiment). We conclude that C/EBP alpha is required for the cAMP induction of PEPCK gene expression in the liver and that C/EBP beta can compensate for the loss of C/EBP alpha if its concentration is induced to appropriate levels.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT DEV BIOCHEM,IL-91120 JERUSALEM,ISRAEL; BAYLOR COLL MED,DEPT PATHOL & HUMAN GENET,HOUSTON,TX 77030; IST RIC BIOL MOL P ANGELETTI,I-00040 POMEZIA,ITALY	Case Western Reserve University; Hebrew University of Jerusalem; Baylor College of Medicine; Merck & Company			Poli, Valeria/A-9215-2012	Poli, Valeria/0000-0002-3739-3966	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011089, P01HD011089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025541] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-11089] Funding Source: Medline; NIDDK NIH HHS [DK-25541, DK-07319] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONI R, 1992, MOL CELL BIOL, V12, P2203, DOI 10.1128/MCB.12.5.2203; ANG SL, 1993, DEVELOPMENT, V119, P1301; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALLARD FJ, 1967, BIOCHEM J, V104, P866, DOI 10.1042/bj1040866; BALLARD FJ, 1970, PHYSIOLOGY PERINATAL, V1, P417; BENVENISTY N, 1987, P NATL ACAD SCI USA, V84, P1132, DOI 10.1073/pnas.84.5.1132; BERKENMEIER EH, 1989, GENE DEV, V3, P1146; CASCIO S, 1991, DEVELOPMENT, V113, P217; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRABTREE GR, 1992, TRANSCRIPTIONAL REGU, P1063; De Simone V, 1991, CURR OPIN CELL BIOL, V3, P960, DOI 10.1016/0955-0674(91)90114-E; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIEHL AM, 1994, GASTROENTEROLOGY, V106, P1625, DOI 10.1016/0016-5085(94)90420-0; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; Friedman A. D., 1989, GENE DEV, V3, P767; GARCIARUIZ JP, 1978, P NATL ACAD SCI USA, V75, P4189; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GIRARD JR, 1973, J CLIN INVEST, V52, P3190, DOI 10.1172/JCI107519; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREENGARD O, 1970, BIOCHEMICAL ACTIONS, V1, P53; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUNNING P, 1984, CELL, V36, P709, DOI 10.1016/0092-8674(84)90351-9; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HANSON RW, 1975, FED PROC, V34, P166; HOPGOOD MF, 1973, BIOCHEM J, V134, P445, DOI 10.1042/bj1340445; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KIOUSSIS D, 1979, P NATL ACAD SCI USA, V76, P4370, DOI 10.1073/pnas.76.9.4370; LOOSE DS, 1986, P NATL ACAD SCI USA, V83, P5184, DOI 10.1073/pnas.83.14.5184; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; MENCHER D, 1979, EUR J BIOCHEM, V102, P489, DOI 10.1111/j.1432-1033.1979.tb04264.x; MENCHER D, 1979, EUR J BIOCHEM, V94, P581, DOI 10.1111/j.1432-1033.1979.tb12928.x; MENCHER D, 1984, EUR J BIOCHEM, V141, P199, DOI 10.1111/j.1432-1033.1984.tb08175.x; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PARK K, 1993, J BIOL CHEM, V268, P17811; PATEL YM, 1994, J BIOL CHEM, V269, P5619; PHILIPPIDIS H, 1969, BIOCHEM J, V113, P651, DOI 10.1042/bj1130651; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POWELL DJ, 1984, J MOL BIOL, V179, P21, DOI 10.1016/0022-2836(84)90304-8; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; SHERMAN L, 1983, P NATL ACAD SCI-BIOL, V80, P5465, DOI 10.1073/pnas.80.18.5465; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUS M, 1990, MOL CELL BIOL, V10, P2418, DOI 10.1128/MCB.10.5.2418; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; YANUKAKASHLES O, 1994, MOL CELL BIOL, V14, P7124, DOI 10.1128/MCB.14.11.7124; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656; Zaret Kenneth S., 1993, P135; ZORZOLI A, 1969, BIOCHEM J, V111, P181, DOI 10.1042/bj1110181	61	90	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26306	26312		10.1074/jbc.272.42.26306	http://dx.doi.org/10.1074/jbc.272.42.26306			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334201	hybrid			2022-12-25	WOS:A1997YB13900035
J	deVargas, LM; Sobolewski, J; Siegel, R; Moss, LG				deVargas, LM; Sobolewski, J; Siegel, R; Moss, LG			Individual beta cells within the intact islet differentially respond to glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN-FLUORESCENT PROTEIN; INSULIN GENE-EXPRESSION; HUMAN ADENOVIRUS TYPE-5; PANCREATIC B-CELLS; RECOMBINANT ADENOVIRUS; TRANSCRIPTION; HETEROGENEITY; OSCILLATIONS; SECRETION; LINE	Insulin production by the pancreatic islet is tightly coupled to the concentration of blood glucose. The mechanism by which glucose controls proinsulin biosynthesis in beta cells is poorly understood. Analysis of insulin gene expression in individual cells within whole, living islets using adenovirus gene transfer and direct observation of insulin promoter-directed green fluorescent protein activity indicates that beta cells are functionally heterogeneous. An increase in glucose concentration not only stimulates expression within individual beta cells, but unexpectedly acts to increase the total number of positive cells. The net islet response to a given glucose stimulus reflects an integrated action of beta cells with individually differing behaviors. This additional level of functional complexity may provide new insights into the pathophysiology and treatment of diabetes mellitus.	TUFTS UNIV NEW ENGLAND MED CTR,DEPT MED,BOSTON,MA 02111; TUFTS UNIV NEW ENGLAND MED CTR,DEPT PHYSIOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,BOSTON,MA 02111	Tufts Medical Center; Tufts Medical Center; Tufts University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051111, R01DK034447, P30DK034928, R55DK034447] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34928, DK51111, DK34447] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amsterdam A, 1996, GENE, V173, P99, DOI 10.1016/0378-1119(95)00719-9; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BECKER TC, 1994, J BIOL CHEM, V269, P21234; Bennett BD, 1996, J BIOL CHEM, V271, P3647; BERGSTEN P, 1994, J BIOL CHEM, V269, P8749; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; BOSCO D, 1991, DEVELOPMENT CAMB, V113, P1257; Castano JP, 1996, MOL ENDOCRINOL, V10, P599, DOI 10.1210/me.10.5.599; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CSETE ME, 1994, TRANSPLANT P, V26, P756; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; KIEKENS R, 1992, J CLIN INVEST, V89, P117, DOI 10.1172/JCI115551; LEAHY JL, 1990, DIABETES CARE, V13, P992, DOI 10.2337/diacare.13.9.992; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MEDA P, 1981, P NATL ACAD SCI USA, V78, P293; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; ORCI L, 1985, DIABETOLOGIA, V28, P528, DOI 10.1007/BF00281987; PERMUTT MA, 1972, J BIOL CHEM, V247, P1200; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; REDMON JB, 1994, DIABETES, V43, P546, DOI 10.2337/diabetes.43.4.546; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SORIA B, 1991, DIABETES, V40, P1069, DOI 10.2337/diabetes.40.8.1069; STEFAN Y, 1987, J CLIN INVEST, V80, P175, DOI 10.1172/JCI113045; VALDEOLMILLOS M, 1993, DIABETES, V42, P1210, DOI 10.2337/diabetes.42.8.1210; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0	38	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26573	26577		10.1074/jbc.272.42.26573	http://dx.doi.org/10.1074/jbc.272.42.26573			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334237	hybrid			2022-12-25	WOS:A1997YB13900071
J	Huang, CS; Ma, WY; Hanenberger, D; Cleary, MP; Bowden, GT; Dong, ZG				Huang, CS; Ma, WY; Hanenberger, D; Cleary, MP; Bowden, GT; Dong, ZG			Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GREEN TEA; INDUCED TRANSFORMATION; CELL LINES; JB6 CELLS; BLACK TEA; C-FOS; JUN; UV; CANCER	Aspirin is under consideration as a promising chemopreventative agent for human cancers, To study the use fulness of aspirin as a chemopreventative agent for UV-induced human skin cancer, we investigated the effect of aspirin on UVB induced activator protein-1 (AP-1) activity, In the JB6 cell culture system, aspirin or sodium salicylate (SA) inhibited UVB-induced AP-1 activity in a dose-dependent manner; this inhibitory effect occurred only in cells pretreated with aspirin or SA before UVB irradiation but not cells treated with aspirin or SA after UVB irradiation. Furthermore, these inhibitory effects on UVB-induced AP-1 activity appeared to be mediated through blocking of activation of MAP kinase family members, including extracellular signal-regulated protein kinases, c-Jun N-terminal kinases, and p38, It was not due to absorption of UVB light by aspirin, In the skin of AP-l-luciferase transgenic mice, UVB irradiation induced a rapid increase in AP-1 activity, which reached the peak at 48 h post-UVB irradiation, The topical pretreatment of mouse skin with aspirin markedly blocked the UVB induced AP-1 transactivation in vivo, These data provide the first evidence that aspirin and SA are inhibitors of W-induced signal transduction and thus could be used as a chemopreventative agent for skin cancer.	UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912; UNIV ARIZONA,HLTH SCI CTR,DEPT RADIAT ONCOL,TUCSON,AZ 85724	University of Minnesota System; University of Arizona; University of Arizona Health Sciences				Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R29CA074916, P01CA027502] Funding Source: NIH RePORTER; NCI NIH HHS [CA74916-01, CA27502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; BUSCHER M, 1988, ONCOGENE, V3, P301; BUZZELL RA, 1993, OTOLARYNG CLIN N AM, V26, P1; CRAVEN PA, 1992, CARCINOGENESIS, V13, P541, DOI 10.1093/carcin/13.4.541; DANPURE HJ, 1976, PHOTOCHEM PHOTOBIOL, V23, P171, DOI 10.1111/j.1751-1097.1976.tb07238.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1995, INT J ONCOL, V7, P359; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Flower R. J., 1985, PROSTAGLANDINS LEUKO, P583; FLOWER RJ, 1980, PHARMACOL BASIS THER, P682; Gensler HL, 1996, NUTR CANCER, V26, P325, DOI 10.1080/01635589609514488; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; HIGGS GA, 1976, ADV PROSTAGLANDIN TH, P105; HUANG C, 1997, IN PRESS P NATL ACAD, V94; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; Huang CS, 1996, INT J ONCOL, V8, P389; HUMUS JL, 1981, P NATL ACAD SCI USA, V78, P2053; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Li JJ, 1996, CANCER RES, V56, P483; MATSUI MS, 1995, PHOTOCARCINOGENESIS, P21; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MORHAM SG, 1995, CELL, V83, P437; PEDERSEN AK, 1984, NEW ENGL J MED, V311, P1206, DOI 10.1056/NEJM198411083111902; PELAGE II, 1994, ARCH INTERN MED, V154, P394; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; RONAI ZA, 1988, J VIROL, V62, P1057, DOI 10.1128/JVI.62.3.1057-1060.1988; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; SCOTTO J, 1983, PUBLICATION NIH; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WANG ZY, 1992, CANCER RES, V52, P1943; WANG ZY, 1994, CANCER RES, V54, P3428; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063	56	124	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26325	26331		10.1074/jbc.272.42.26325	http://dx.doi.org/10.1074/jbc.272.42.26325			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334204	hybrid			2022-12-25	WOS:A1997YB13900038
J	Kristie, TM				Kristie, TM			The mouse homologue of the human transcription factor C1 (host cell factor) - Conservation of forms and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; VP16 ACCESSORY PROTEIN; ALPHA-GENES; DNA COMPLEX; POU DOMAIN; CIS SITE; OCT-1; BINDING; INDUCTION; RECOGNITION	The assembly of the herpes simplex virus (HSV) alpha/IE gene enhancer complex is determined by the interactions of the Oct-1 POU domain protein, the viral alpha TIF (alpha-trans-induction factor, VP16, ICP25, VMW65), and the C1 factor (host cell factor, HCF). A unique transcription factor, C1 consists of a family of polypeptides derived from a common precursor by site-specific proteolytic processing. To analyze the role of this factor in the determination of HSV lytic-latent infection, cDNAs and genomic DNAs encoding the mouse homologue have been isolated. This factor is nearly identical to the human protein, contains multiple consensus proteolytic processing sites, and functions efficiently in the assembly of a specific HSV enhancer complex. Interestingly, the differential expression of the C1 factors in both human and mouse tissues may be important for the determination of HSV tissue tropism in these two organisms.			Kristie, TM (corresponding author), NIAID,VIRAL DIS LAB,NIH,BLDG 4,RM 133,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BATTERSON W, 1983, J VIROL, V46, P371, DOI 10.1128/JVI.46.2.371-377.1983; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRATTINI A, 1994, GENOMICS, V23, P30, DOI 10.1006/geno.1994.1455; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; KRISTIE TM, 1988, J VIROL, V62, P1145, DOI 10.1128/JVI.62.4.1145-1157.1988; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MCKNIGHT JLC, 1986, CANCER CELL CONTROL, V4, P163; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OReilly D, 1997, EMBO J, V16, P2420, DOI 10.1093/emboj/16.9.2420; PELLETT PE, 1985, P NATL ACAD SCI USA, V82, P5870, DOI 10.1073/pnas.82.17.5870; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; POST LE, 1981, CELL, V24, P555, DOI 10.1016/0092-8674(81)90346-9; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; Roizman B., 1985, VIROLOGY, P497; Roizman Bernard, 1996, P1043; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; WERSTUCK G, 1989, J VIROL, V63, P5509, DOI 10.1128/JVI.63.12.5509-5513.1989; Whitley RJ, 1996, FIELDS VIROLOGY, P2297; WILSON AC, 1995, GENOMICS, V25, P462, DOI 10.1016/0888-7543(95)80046-O; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974	38	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26749	26755		10.1074/jbc.272.42.26749	http://dx.doi.org/10.1074/jbc.272.42.26749			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334261	hybrid			2022-12-25	WOS:A1997YB13900095
J	Barth, A; Kreutz, W; Mantele, W				Barth, A; Kreutz, W; Mantele, W			Ca2+ release from the phosphorylated and the unphosphorylated sarcoplasmic reticulum Ca2+ ATPase results in parallel structural changes - An infrared spectroscopic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-ATPASE; RECONSTITUTED PROTEOLIPOSOMES; DIFFERENCE SPECTROSCOPY; CATALYTIC CYCLE; BINDING-SITES; CAGED-ATP; CA2+-ATPASE; CA-2+; H+; PROTON	Structural changes of the sarcoplasmic reticulum Ca2+-ATPase occurring in the reaction step involving phosphoenzyme conversion and Ca2+ release (Ca2E1-P --> E-2-P) were followed using time-resolved infrared spectroscopy in H2O and (H2O)-H-2. The difference spectra measured between 1800 and 1500 cm(-1) were almost identical to those of Ca2+ release from the unphosphorylated ATPase (Ca2E1 --> E), implying that parallel structural changes occur in both steps, This suggests that characteristic structural features of the high affinity Ca2+ binding sites of Ca2E1 are still present in the ADP-sensitive phosphoenzyme Ca2E1-P. In both Ca2+ release steps at least two carboxyl groups become protonated, each of them experiencing the same strength of hydrogen bonding irrespective of whether or not the Ca2+ free ATPase is phosphorylated, This suggests that the same amino acid residues are involved and that they are most likely those that participate in high affinity Ca2+ binding and H+ countertransport, We propose that during Ca2+ release from the phosphoenzyme protons from the lumenal side have access to these residues, Our results are consistent with only one pair of Ca2+ binding sites on the ATPase that serves both Ca2+ translocation and H+ countertransport.	UNIV FREIBURG,INST BIOPHYS & STRAHLENBIOL,D-79104 FREIBURG,GERMANY	University of Freiburg			Barth, Andreas/N-8872-2013	Barth, Andreas/0000-0001-5784-7673				ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; BARTH A, 1994, BBA-BIOMEMBRANES, V1194, P75, DOI 10.1016/0005-2736(94)90205-4; Barth A, 1996, J BIOL CHEM, V271, P30637, DOI 10.1074/jbc.271.48.30637; BARTH A, 1991, BIOCHIM BIOPHYS ACTA, V1057, P115, DOI 10.1016/S0005-2728(05)80091-X; BARTH A, 1990, FEBS LETT, V277, P147, DOI 10.1016/0014-5793(90)80830-C; BUCHET R, 1992, BIOCHIM BIOPHYS ACTA, V1104, P207, DOI 10.1016/0005-2736(92)90152-C; BUCHET R, 1991, BIOCHIM BIOPHYS ACTA, V1069, P209, DOI 10.1016/0005-2736(91)90126-S; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; DACOSTA AG, 1994, BBA-BIOMEMBRANES, V1189, P181, DOI 10.1016/0005-2736(94)90064-7; DEACON GB, 1980, COORDIN CHEM REV, V33, P227, DOI 10.1016/S0010-8545(00)80455-5; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4253; FORGE V, 1993, J BIOL CHEM, V268, P10953; FORGE V, 1993, J BIOL CHEM, V268, P10961; GEORG H, 1994, BBA-BIOENERGETICS, V1188, P139, DOI 10.1016/0005-2728(94)90032-9; HENDERSON IMJ, 1994, BIOCHEM J, V297, P615, DOI 10.1042/bj2970615; INESI G, 1983, BIOPHYS J, V44, P271, DOI 10.1016/S0006-3495(83)84299-4; INESI G, 1984, J BIOL CHEM, V259, P996; Inesi G, 1995, BIOSCIENCE REP, V15, P327, DOI 10.1007/BF01788365; JENCKS WP, 1993, BIOCHEMISTRY-US, V32, P7030, DOI 10.1021/bi00078a031; LEVY D, 1990, J BIOL CHEM, V265, P19524; MADEIRA VMC, 1979, ARCH BIOCHEM BIOPHYS, V193, P22, DOI 10.1016/0003-9861(79)90003-1; MARTIN RB, 1992, FEBS LETT, V308, P59, DOI 10.1016/0014-5793(92)81050-V; Martonosi AN, 1996, BBA-BIOENERGETICS, V1275, P111, DOI 10.1016/0005-2728(96)00059-X; Martonosi AN, 1995, BIOSCIENCE REP, V15, P263, DOI 10.1007/BF01788359; Mintz E, 1995, BIOSCIENCE REP, V15, P377, DOI 10.1007/BF01788369; MYUNG J, 1991, FEBS LETT, V278, P35, DOI 10.1016/0014-5793(91)80077-G; MYUNG J, 1994, BIOCHEMISTRY-US, V33, P8775, DOI 10.1021/bi00195a020; NARA M, 1994, FEBS LETT, V349, P84, DOI 10.1016/0014-5793(94)00645-8; PICK U, 1979, BIOCHEMISTRY-US, V18, P108, DOI 10.1021/bi00568a017; POLVANI C, 1989, J BIOL CHEM, V264, P17854; STEINER M, 1988, CLIN CHIM ACTA, V177, P107, DOI 10.1016/0009-8981(88)90313-0; TACKETT JE, 1989, APPL SPECTROSC, V43, P483, DOI 10.1366/0003702894202931; Troullier A, 1996, BIOPHYS J, V71, P2970, DOI 10.1016/S0006-3495(96)79537-1; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; YAMAGUCHI M, 1984, J BIOL CHEM, V259, P9526; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9; YU X, 1994, J BIOL CHEM, V269, P16656	41	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25507	25510		10.1074/jbc.272.41.25507	http://dx.doi.org/10.1074/jbc.272.41.25507			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325264	hybrid			2022-12-25	WOS:A1997YA35800019
J	Gill, ZP; Perks, CM; Newcomb, PV; Holly, JMP				Gill, ZP; Perks, CM; Newcomb, PV; Holly, JMP			Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; CERAMIDE; INHIBITION; RECEPTORS; INDUCTION; P53	Insulin-like growth factor (IGF) -independent growth inhibition of human breast cancer cells, Hs578T, by IGF-binding protein-3 (IGFBP-3) has previously been demonstrated. Cell growth is a balance between proliferation and programmed cell death (apoptosis), We have investigated whether IGFBP-3 can affect apoptosis of Hs578T cells. As no induction of apoptosis was found, we also investigated its effect on the response to ceramide, an intracellular second messenger that mediates the signal for apoptosis. Using the cell permeable ceramide analogue, C2, induction of apoptosis was established by 3-(4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) assay, trypan blue uptake, morphological criteria, and flow cytometry, Incubation of cells with non-glycosylated IGFBP-3 (ngIGFBP-3; 0.5-100 ng/ml) resulted in no growth inhibition or increase in apoptosis; whereas, C2 (1-30 mu M) resulted in a dose-dependent induction of apoptosis. Addition of IGFs to the cells, alone or with C2, elicited no response in terms of proliferation or survival, respectively. When the cells were preincubated with ngIGFBP-3 before addition of C2 (2-5 mu M), apoptosis was accentuated in a dose-dependent manner (at 100 ng/ml IGFBP-3, apoptosis increased from 11 to 88%). In conclusion, we found that IGFBP-3 had no direct inhibitory effect on Hs578T cells but could accentuate apoptosis induced by the physiological trigger ceramide in an IGF-independent manner.	BRISTOL ROYAL INFIRM & GEN HOSP,DEPT HOSP MED,DIV SURG,BRISTOL BS2 8HW,AVON,ENGLAND	Bristol Royal Infirmary								Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P3259, DOI 10.1210/endo-129-6-3259; COULSON VJ, 1991, GROWTH REGULAT, V1, P119; CWYFANHUGHES SC, 1995, J ENDOCRINOL, V147, P517; DELBE J, 1990, J CELL PHYSIOL, V142, P359, DOI 10.1002/jcp.1041420219; DELEON DD, 1990, J CLIN ENDOCR METAB, V71, P530, DOI 10.1210/jcem-71-2-530; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lalou C, 1996, ENDOCRINOLOGY, V137, P3206, DOI 10.1210/en.137.8.3206; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LILLIE RD, 1977, HJ CONNS BIOL STAINS, P605; NEELY EK, 1992, ENDOCRINOLOGY, V130, P985, DOI 10.1210/en.130.2.985; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; OH Y, 1993, J BIOL CHEM, V268, P26045; OH YM, 1993, J BIOL CHEM, V268, P14964; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; RESNICOFF M, 1995, CANCER RES, V55, P2463; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; Witty JP, 1996, ENDOCRINOLOGY, V137, P5269, DOI 10.1210/en.137.12.5269	27	195	205	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25602	25607		10.1074/jbc.272.41.25602	http://dx.doi.org/10.1074/jbc.272.41.25602			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325280	hybrid			2022-12-25	WOS:A1997YA35800035
J	Kaburagi, Y; Satoh, S; Tamemoto, H; YamamotoHonda, R; Tobe, K; Veki, K; Yamauchi, T; KonoSugita, E; Sekihara, H; Aizawa, S; Cushman, SW; Akanuma, Y; Yazaki, Y; Kadowaki, T				Kaburagi, Y; Satoh, S; Tamemoto, H; YamamotoHonda, R; Tobe, K; Veki, K; Yamauchi, T; KonoSugita, E; Sekihara, H; Aizawa, S; Cushman, SW; Akanuma, Y; Yazaki, Y; Kadowaki, T			Role of insulin receptor substrate-1 and pp60 in the regulation of insulin-induced glucose transport and GLUT4 translocation in primary adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; TYROSINE-PHOSPHORYLATED PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; HEPATOMA-CELLS; ACTIVATING PROTEIN; PLASMA-MEMBRANE; 3T3-L1 CELLS; KINASE; IRS-1; MICE	In muscle and fat, glucose transport occurs through the translocation of GLUT4 from an intracellular pool to the cell surface. Phosphatidylinositol (PI) 3-kinase has been shown to be required in this process. Insulin is thought to activate this enzyme by stimulating its association with tyrosine-phosphorylated proteins such as insulin receptor substrate (IRS)-1, IRS-2, Grb2-associated binder-1, and pp60. To study the role of these endogenous substrates in glucose transport, we analyzed adipocytes from IRS-1 null mice that we previously generated (Tamemoto, H., Kadowaki, T., Tobe, K., Yagi, T., Sakura, H., Hayakawa, T., Terauchi, Y., Ueki, K., Kaburagi, Y., Satoh, S., Sekihara, H., Yoshioka, S., Horikoshi, H., Furuta, Y., Ikawa, Y., Kasuga, M., Yazaki Y., and Aizawa S. (1994) Nature 372, 182-186). In adipocytes from these mice, we showed that: 1) insulin-induced PI 3-kinase activity in the antiphosphotyrosine immunoprecipitates was 54% of wild-type; 2) pp60 was the major tyrosine-phosphorylated protein that associated with PI 3-kinase, whereas tyrosine phosphorylaion of IRS-2 as well as its association with this enzyme was almost undetectable; and 3) glucose transport and GLUT4 translocation at maximal insulin stimulation were decreased to 52 and 68% of those from wild-type. These data suggest that both IRS-1 and pp60 play a major role in insulin-induced glucose transport in adipocytes, and that pp60 is predominantly involved in regulating this process in the absence of IRS-1.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; YOKOHAMA CITY UNIV,SCH MED,DEPT INTERNAL MED 3,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; INST DIABET CARE & RES,ASAHI LIFE FDN,CHIYODA KU,TOKYO 100,JAPAN; NIDDK,EXPT DIABET METAB & NUTR SECT,DIABET BRANCH,NIH,BETHESDA,MD 20892; KUMAMOTO UNIV,SCH MED,IMEG,LAB MORPHOGENESIS,KUMAMOTO 860,JAPAN	University of Tokyo; Yokohama City University; Asahi Life Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Kumamoto University								ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; GLIEMANN J, 1984, BIOCHIM BIOPHYS ACTA, V804, P68, DOI 10.1016/0167-4889(84)90100-9; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HOLGATOMADRUGA M, 1995, NATURE, V379, P560; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; KELLY KL, 1993, J BIOL CHEM, V268, P4391; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Lavan BE, 1997, J BIOL CHEM, V272, P11439; MILARSKI KL, 1995, BIOCHEM J, V308, P579, DOI 10.1042/bj3080579; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; NISHIMURA H, 1991, P NATL ACAD SCI USA, V88, P11500, DOI 10.1073/pnas.88.24.11500; OGAWA W, 1995, ENDOCRINOLOGY, V136, P476, DOI 10.1210/en.136.2.476; OKADA T, 1994, J BIOL CHEM, V269, P3568; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; SATOH S, 1993, J BIOL CHEM, V268, P17820; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; SUNG CK, 1994, J BIOL CHEM, V269, P12503; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; WEBER TM, 1988, INSULIN RECEPTOR, V2, P171; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; Yeh TC, 1996, J BIOL CHEM, V271, P2921, DOI 10.1074/jbc.271.6.2921; ZhangSun G, 1996, ENDOCRINOLOGY, V137, P2649, DOI 10.1210/en.137.7.2649	42	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25839	25844		10.1074/jbc.272.41.25839	http://dx.doi.org/10.1074/jbc.272.41.25839			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325314	hybrid			2022-12-25	WOS:A1997YA35800069
J	Kimura, M; Ishiguro, A; Ishihama, A				Kimura, M; Ishiguro, A; Ishihama, A			RNA polymerase II subunits 2, 3, and 11 form a core subassembly with DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL ASSEMBLY DOMAIN; SCHIZOSACCHAROMYCES-POMBE; SEQUENCE DETERMINATION; ALPHA-SUBUNIT; YEAST; DROSOPHILA; SITE; GENE; IDENTIFICATION; TRANSCRIPTION	RNA polymerase II purified from the fission yeast Schizosaccharomyces pombe consists of 10 species of subunit polypeptide. We introduced a histidine cluster tag sequence into the chromosomal rpb1 and rpb3 genes, which encode subunit 1 (Rpb1) and subunit 3 (Rpb3), respectively, and purified the RNA polymerase by Ni2+ affinity chromatography. After stepwise dissociation of the Rpb1- and Rpb3-tagged RNA polymerases fixed on Ni2+-resin by increasing concentrations of urea or guanidium hydrochloride, Rpb2-Rpb3-Rpb11 or Rpb2-Rpb3-Rpb11-Rpb10 complexes were obtained. Since the complex consisting of Rpb2, Rpb3, and Rpb11 cannot be dissociated even after treatment with 6 M urea buffer, we propose that this complex represents a core subassembly of the RNA polymerase II, analogous to the alpha(2) beta complex in the assembly of Escherichia coli RNA polymerase. Both the Rpb2-Rpb3-Rpb11 complex and the free Rpb1 protein showed DNA binding activity, although the affinity was weaker compared with the intact RNA polymerase.	NATL INST GENET,DEPT MOL GENET,MISHIMA,SHIZUOKA 411,JAPAN; GRAD UNIV ADV STUDIES,SCH LIFE SCI,MISHIMA,SHIZUOKA 411,JAPAN	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan				Kimura, Makoto/0000-0003-0868-5334; Ishiguro, Akira/0000-0003-1867-3134				AZUMA Y, 1993, NUCLEIC ACIDS RES, V21, P3749, DOI 10.1093/nar/21.16.3749; AZUMA Y, 1991, NUCLEIC ACIDS RES, V19, P461, DOI 10.1093/nar/19.3.461; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BERGHOFER B, 1988, NUCLEIC ACIDS RES, V16, P8113, DOI 10.1093/nar/16.16.8113; CARROLL SB, 1983, J MOL BIOL, V170, P777, DOI 10.1016/S0022-2836(83)80131-4; CHUANG RY, 1987, BIOCHEM BIOPH RES CO, V145, P73, DOI 10.1016/0006-291X(87)91289-7; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; GRACHEV MA, 1986, FEBS LETT, V200, P287, DOI 10.1016/0014-5793(86)81154-1; GUNDELFINGER ED, 1983, FEBS LETT, V157, P133, DOI 10.1016/0014-5793(83)81131-4; HORIKOSHI M, 1983, J BIOCHEM-TOKYO, V94, P1761, DOI 10.1093/oxfordjournals.jbchem.a134527; Ishihama A, 1981, Adv Biophys, V14, P1; KAWAGISHI M, 1993, NUCLEIC ACIDS RES, V21, P469, DOI 10.1093/nar/21.3.469; KIMURA M, 1995, J MOL BIOL, V248, P756, DOI 10.1006/jmbi.1995.0258; KIMURA M, 1994, J MOL BIOL, V242, P107, DOI 10.1006/jmbi.1994.1562; Kimura M, 1996, GENES CELLS, V1, P517, DOI 10.1046/j.1365-2443.1996.d01-258.x; KIMURA M, 1995, J MOL BIOL, V248, P710; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; KONTERMANN RE, 1993, PROTEIN SCI, V2, P223; KONTERMANN RE, 1994, FEBS LETT, V344, P166, DOI 10.1016/0014-5793(94)00380-7; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; Larkin RM, 1997, J BIOL CHEM, V272, P12824, DOI 10.1074/jbc.272.19.12824; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; MIYAO T, 1996, GENES CELLS, V1, P843; RIVA M, 1990, J BIOL CHEM, V265, P16498; RIVA M, 1987, J BIOL CHEM, V262, P14377; Sakurai H, 1996, GENE, V180, P63, DOI 10.1016/S0378-1119(96)00406-4; SAKURAI H, 1997, IN PRESS GENE AMST; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; SHPAKOVSKI GV, 1992, YEAST, V8, P15; Ulmasov T, 1996, J BIOL CHEM, V271, P5085, DOI 10.1074/jbc.271.9.5085; Woychik Nancy A., 1993, Gene Expression, V3, P77; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	33	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25851	25855		10.1074/jbc.272.41.25851	http://dx.doi.org/10.1074/jbc.272.41.25851			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325316	hybrid			2022-12-25	WOS:A1997YA35800071
J	Boice, JA; Hightower, LE				Boice, JA; Hightower, LE			A mutational study of the peptide-binding domain of Hsc70 guided by secondary structure prediction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE HSC70; SHOCK COGNATE PROTEIN; UNCOATING PROTEIN; UNFOLDED PROTEINS; COATED VESICLES; ATPASE; HSP70; FRAGMENT; CLATHRIN; IDENTIFICATION	The abundant, cytoplasmic molecular chaperones of eukaryotic cells, of which mammalian Hsc70 is a member, have central roles in protein folding pathways in cells, Although substantial information is now available on substrate interactions and ATPase activity, neither the crystal structure of the intact Hsc70 molecule nor its isolated peptide-binding domain is known, Recently, the crystal structure of the isolated peptide-binding domain of an evolutionary relative of mammalian Hsc70, the DnaK protein of Escherichia coli, was solved, We have generated several rat Hsc70 mutants using site directed and cassette mutagenesis guided by secondary structure predictions to test the hypothesis that the peptide-binding domains of mammalian Hsc70 and DnaK have similar molecular structures, Biochemical properties along with the ATPase and peptide binding activities of the resulting recombinant proteins were determined, Biochemical analyses included one-and two-dimensional gel electrophoresis, electrospray mass spectrometry, and N-terminal amino acid sequencing, The results of our study suggest that the DnaH molecular structure is a useful working model for the mammalian Hsc70 peptide-binding domain, Evidence is provided that (i) small additions to the N terminus of Hsc70 alter the function of the peptide-binding domain, (ii) alterations in the C-terminal tetrapeptide EEVD result in dramatic increases in basal ATPase activity, (iii) polyalanine substitution of a helical connector segment compensates for changes at the C terminus to restore near-normal function, (iv) specific side chain interactions involving this connector segment are not required for peptide-stimulated ATPase activity, and (v) disruption of the cap homologue region inhibits peptide binding by Hsc70.	UNIV CONNECTICUT,DEPT MOL & CELL BIOL,STORRS,CT 06269	University of Connecticut								Benaroudj N, 1997, J BIOL CHEM, V272, P8744, DOI 10.1074/jbc.272.13.8744; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; GREENE LE, 1990, J BIOL CHEM, V265, P6682; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hu SM, 1996, ARCH BIOCHEM BIOPHYS, V332, P163, DOI 10.1006/abbi.1996.0328; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SADIS S, 1990, CURRENT RES PROTEIN, P339; TACK BF, 1980, J BIOL CHEM, V255, P8842; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; WANG TF, 1993, J BIOL CHEM, V268, P26049; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; ZHANG XJ, 1992, PROTEIN SCI, V1, P761, DOI 10.1002/pro.5560010608; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	31	18	18	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24825	24831		10.1074/jbc.272.40.24825	http://dx.doi.org/10.1074/jbc.272.40.24825			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312080	hybrid			2022-12-25	WOS:A1997XY97000019
J	Miyazaki, H; Fukumoto, S; Okada, M; Hasegawa, T; Furukawa, K; Furukawa, K				Miyazaki, H; Fukumoto, S; Okada, M; Hasegawa, T; Furukawa, K; Furukawa, K			Expression cloning of rat cDNA encoding UDP-galactose:G(D2) beta 1,3-galactosyltransferase that determines the expression of G(D1b)/G(M1)/G(A1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE (BETA-1-4)GALACTOSYLTRANSFERASE; GANGLIOSIDE-MEDIATED MODULATION; GM1 GANGLIOSIDE; ALPHA-1,3 GALACTOSYLTRANSFERASE; MONOCLONAL-ANTIBODIES; GOLGI VESICLES; SYNTHASE GENE; CELL-GROWTH; MICE; RECEPTOR	Using an anti-G(D1b) monoclonal antibody, expression cloning of a cDNA for the beta 1,3-galactosyltransferase gene (EC 2.4.1.62) was performed, KF4C, mouse melanoma B16 transfected with polyoma T antigen gene, and G(M2)/G(D2) synthase cDNA was used as a recipient cell line for the cDNA library transfection. A cDNA clone of G(D3) synthase, pD3T-31 was co-transfected with a cDNA library prepared from rat brain RNA using the pcDNAI expression vector. The isolated cDNA clone pM1T-9 predicted a type II membrane protein with 4 amino acids of cytoplasmic domain, 21 amino acids of transmembrane region, and a large catalytic domain with 346 amino acids, Introduction of the cDNA clone into a mouse melanoma line B16 previously transfected with a G(M2)/G(D2) synthase gene resulted in the neo synthesis of G(M1). Co-transfection of the cell line with pM1T-9 and a G(D3) synthase cDNA resulted in the expression of G(D1b) as well as G(M1). Moreover, introduction of pM1T-9 into L cell (lacking G(M3) synthase), previously transfected with G(M2)/G(D2) synthase gene, resulted in the definite expression of asialo-G(M1). These results indicated that G(D1b)/G(M1)/G(A1) synthases mere identical, as previously suggested based on enzymological analysis. In Northern blots of the beta 1,3-galactosyltransferase gene with total RNA from various rat tissues, a 1.6-kilobase mRNA was strongly expressed in spleen, thymus, kidney, and testis, However, the expression level of the gene in the adult brain tissue was not especially high, On the other hand, this gene was expressed at high levels in the rat brain of embryonal day 12, and reached a peak at around birth, then fell to low level in the adult brain.	NAGOYA UNIV,SCH MED,DEPT BIOCHEM 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGASAKI UNIV,SCH MED,DEPT ONCOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH DENT,DEPT PEDIAT DENT,NAGASAKI 852,JAPAN; MIE UNIV,SCH MED,DEPT BIOCHEM,TSU,MIE 514,JAPAN	Nagoya University; Nagasaki University; Nagasaki University; Mie University				Fukumoto, Satoshi/0000-0002-5046-6891				BOUVIER JD, 1989, J NEUROCHEM, V52, P460, DOI 10.1111/j.1471-4159.1989.tb09143.x; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; DAVIS LG, 1986, BASIC METHODS MOL BI, P285; DAVIS LG, 1986, BASIC METHODS MOL BI, P290; DEERAUSQUIN GA, 1990, P NATL ACAD SCI USA, V87, P8017, DOI 10.1073/pnas.87.20.8017; FACCI L, 1984, J NEUROCHEM, V42, P299, DOI 10.1111/j.1471-4159.1984.tb02678.x; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FISHMAN PH, 1976, SCIENCE, V194, P906, DOI 10.1126/science.185697; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; HOLMGREN J, 1975, P NATL ACAD SCI USA, V72, P2520, DOI 10.1073/pnas.72.7.2520; IBER H, 1989, FEBS LETT, V248, P18, DOI 10.1016/0014-5793(89)80423-5; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; IKEMATSU S, 1993, GLYCOBIOLOGY, V3, P575, DOI 10.1093/glycob/3.6.575; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; Karpiak S E, 1984, Adv Exp Med Biol, V174, P489; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAKAZAWA K, 1988, J BIOCHEM-TOKYO, V104, P165, DOI 10.1093/oxfordjournals.jbchem.a122434; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; ROISEN FJ, 1981, GANGLIOSIDES NEUROLO, P135; RUAN S, 1992, CANCER RES, V52, P5725; RUAN ST, 1995, ARCH BIOCHEM BIOPHYS, V323, P11, DOI 10.1006/abbi.1995.0003; SABEL BA, 1984, SCIENCE, V225, P340, DOI 10.1126/science.6740316; SCHAAL H, 1985, J NEUROCHEM, V45, P544, DOI 10.1111/j.1471-4159.1985.tb04022.x; SCHNEIDER JS, 1992, SCIENCE, V256, P843, DOI 10.1126/science.1350379; SCHULTE S, 1993, P NATL ACAD SCI USA, V90, P10265, DOI 10.1073/pnas.90.21.10265; Seifert W., 1981, GANGLIOSIDES NEUROLO, P99; STAHL N, 1994, J NEUROSCI RES, V38, P234, DOI 10.1002/jnr.490380214; STRAHAN KM, 1995, IMMUNOGENETICS, V41, P101, DOI 10.1007/BF00182319; SUZUKI K, 1965, J NEUROCHEM, V12, P969, DOI 10.1111/j.1471-4159.1965.tb10256.x; SVENNERHOLM L, 1994, LIFE SCI, V55, P2125, DOI 10.1016/0024-3205(94)00393-9; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; UEJIMA T, 1992, CANCER RES, V52, P6158; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149; YAMASHIRO S, 1993, CANCER RES, V53, P5395	54	84	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24794	24799		10.1074/jbc.272.40.24794	http://dx.doi.org/10.1074/jbc.272.40.24794			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312075	hybrid			2022-12-25	WOS:A1997XY97000014
J	Satin, B; Norais, N; Telford, J; Rappuoli, R; Murgia, M; Montecucco, C; Papini, E				Satin, B; Norais, N; Telford, J; Rappuoli, R; Murgia, M; Montecucco, C; Papini, E			Effect of Helicobacter pylori vacuolating toxin on maturation and extracellular release of procathepsin D and on epidermal growth factor degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; LYSOSOMAL-ENZYMES; DIPHTHERIA-TOXIN; CATHEPSIN-D; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOCYTIC VESICLES; MOLECULAR-WEIGHT; MAMMALIAN-CELLS; HELA-CELLS; CYTOTOXIN	The effect of vacuolating toxin (VacA) from Helicobacter pylori on endosomal and lysosomal functions was studied by following procathepsin D maturation and epidermal growth factor (EGF) degradation in HeLa cells exposed to the toxin, VacA inhibited the conversion of procathepsin D (53 kDa) into both the intermediate (47 kDa) and the mature (31 kDa) form, Nonprocessed cathepsin D was partly retained inside cells and partly secreted in the extracellular medium via the constitutive secretion pathway, Intracellular degradation of EGF was also inhibited by VacA with a similar dose-response curve, VacA did not alter endocytosis, cell surface recycling, and retrograde transport from plasma membrane to trans-Golgi network and endoplasmic reticulum, as estimated by using transferrin, diphtheria toxin, and ricin as tracers, Subcellular fractionation of intoxicated cells showed that procathepsin D and non-degraded EGF accumulate in lysosomes, Measurements of intracellular acidification with fluorescein isothiocyanate-dextran revealed a partial neutralization of the lumen of endosomes and lysosomes, sufficient to account for both mistargeting of procathepsin D outside the cell and the decreased activity of lysosomal proteases.	UNIV PADUA, DIPARTIMENTO SCI BIOMED, I-35121 PADUA, ITALY; UNIV PADUA, CNR, CTR BIOMEMBRANE, I-35121 PADUA, ITALY; IRIS, I-53100 SIENA, ITALY	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Novartis			Papini, Emanuele/AAE-6961-2022; Telford, John Laird/ABG-8144-2020	Papini, Emanuele/0000-0001-6033-4473; 				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; Blaser M J, 1993, Trends Microbiol, V1, P255, DOI 10.1016/0966-842X(93)90047-U; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CARROLL SF, 1988, METHOD ENZYMOL, V165, P68; CATRENICH CE, 1992, J MED MICROBIOL, V37, P389, DOI 10.1099/00222615-37-6-389; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; COVER TL, 1993, INFECT IMMUN, V61, P1427, DOI 10.1128/IAI.61.4.1427-1431.1993; COVER TL, 1992, J BIOL CHEM, V267, P10570; COVER TL, 1994, J BIOL CHEM, V269, P10566; CUTLER DF, 1990, J CELL BIOL, V110, P721, DOI 10.1083/jcb.110.3.721; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; DELBRUCK R, 1994, EUR J CELL BIOL, V64, P7; FORMAN D, 1993, LANCET, V341, P1359; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GHIRA P, 1995, INFECT IMMUN, V63, P4154, DOI 10.1128/IAI.63.10.4154-4160.1995; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN LB, 1993, FEBS LETT, V319, P54, DOI 10.1016/0014-5793(93)80036-T; Lemichez E, 1997, MOL MICROBIOL, V23, P445, DOI 10.1111/j.1365-2958.1997.tb02669.x; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; MANETTI R, 1995, INFECT IMMUN, V63, P4476, DOI 10.1128/IAI.63.11.4476-4480.1995; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; Moll G, 1995, EUR J BIOCHEM, V234, P947, DOI 10.1111/j.1432-1033.1995.947_a.x; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Papini E, 1996, J MED MICROBIOL, V45, P84, DOI 10.1099/00222615-45-2-84; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; PAPINI E, 1993, J BIOL CHEM, V268, P1567; PAPINI E, 1993, FEMS MICROBIOL LETT, V113, P155, DOI 10.1016/0378-1097(93)90262-Z; PAPINI E, 1993, MOL MICROBIOL, V7, P323, DOI 10.1111/j.1365-2958.1993.tb01123.x; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; RAPAK A, 1997, IN PRESS P NATL ACAD; RAPPUOLI R, 1983, J CHROMATOGR, V268, P543, DOI 10.1016/S0021-9673(01)95457-3; RENFREW CA, 1991, J BIOL CHEM, V266, P4348; RICHO G, 1991, ADV EXP MED BIOL, V306, P289; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; SIMPSON JC, 1995, J BIOL CHEM, V270, P20078, DOI 10.1074/jbc.270.34.20078; TELFORD JL, 1994, TRENDS BIOTECHNOL, V12, P420, DOI 10.1016/0167-7799(94)90031-0; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; TOMPKINS LS, 1995, SCIENCE, V267, P1621, DOI 10.1126/science.7886448; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WARREN JR, 1983, LANCET, V1, P1273	63	106	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25022	25028		10.1074/jbc.272.40.25022	http://dx.doi.org/10.1074/jbc.272.40.25022			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312109	hybrid			2022-12-25	WOS:A1997XY97000048
J	Yang, WN; Cerione, RA				Yang, WN; Cerione, RA			Cloning and characterization of a novel Cdc42-associated tyrosine kinase, ACK-2, from bovine brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; WISKOTT-ALDRICH SYNDROME; RHO-FAMILY GTPASES; SACCHAROMYCES-CEREVISIAE; SIGNALING PATHWAY; BINDING PROTEIN; CDC42 GTPASES; RAC1; IDENTIFICATION; EFFECTOR	Cdc42 plays an important role in intracellular signaling pathways that influence cell morphology and motility and stimulate DNA synthesis. In attempts to determine whether nonreceptor tyrosine kinases play a fundamental role in Cdc42 signaling, we have cloned and biochemically characterized a new Cdc42-associated tyrosine kinase (ACK) hom bovine brain. This tyrosine kinase, named ACK-2, has a calculated molecular mass of 83 kDa and shares a number of primary structural domains with the 120-kDa ACK (ACK-1), The main differences between the primary structures of ACK-2 and ACK-1 occur in the amino-and carboxyl-terminal regions, Like ACK-1, ACK-2 binds exclusively to activated (GTP-bound) Cdc42 and does not bind to its closest homologs, e.g. activated Rac. ACK-2 could not be activated by addition of glutathione S-transferase (GST)-Cdc42(Q61L), a GTPase-defective mutant, or by GTP gamma S-loaded GST-Cdc42 in in vitro kinase assays. However, ACK-2 was activated when cotransfected with mild type Cdc42 or Cdc42(Q61L) and stably associated with Cdc42(Q61L) in vivo, indicating that ACK-2 interacts with active Cdc42 in cells, Furthermore, the tyrosine kinase activity of ACK-2 was stimulated both by epidermal growth factor and bradykinin, suggesting that ACK-2 may play a role in the signaling actions of both receptor tyrosine kinases or heterotrimeric G-protein-coupled receptors.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University					NIGMS NIH HHS [GM40654, GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458, R01GM040654] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brill S, 1996, MOL CELL BIOL, V16, P4869; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Hoehn GT, 1996, ONCOGENE, V12, P903; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; SCHLAEPFER DD, 1994, NATURE, V372, P786; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	36	92	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24819	24824		10.1074/jbc.272.40.24819	http://dx.doi.org/10.1074/jbc.272.40.24819			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312079	hybrid			2022-12-25	WOS:A1997XY97000018
J	Wise, A; Milligan, G				Wise, A; Milligan, G			Rescue of functional interactions between the alpha(2A)-adrenoreceptor and acylation-resistant forms of G(i1)alpha by expressing the proteins from chimeric open reading frames	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; ALPHA-SUBUNIT; MEMBRANE ATTACHMENT; LIPID MODIFICATIONS; ADENYLATE-CYCLASE; AMINO-TERMINUS; G-BETA; RECEPTOR; PALMITOYLATION; BINDING	Co-expression of the alpha(2A)-adrenoreceptor with a pertussis toxin-resistant (C351G), but not with an also palmitoylation resistant (C3S/C351G), form of the a subunit of G(il) resulted in agonist-induced, pertussis toxin-independent, GTP hydrolysis. Construction and expression of a chimeric fusion protein between the receptor and G351G G(il)alpha generated a membrane protein in which the G protein element was activated by receptor agonist. An equivalent fusion protein containing C3S/G351G G(il)alpha rescued the ability of receptor agonist to activate this mutant. Fusion proteins of a palmitoylation-resistant (C442A) alpha(2A)-adrenoreceptor and either C351G or C3S/C351G G(il)alpha also responded effectively to agonist. Myristoylation resistant (G2A/G351G) and combined acylation resistant (G2A/C3S/C351G) mutants of G(il)alpha are cytosolic proteins. Expression of these as chimeric alpha(2A)-adrenoreceptor-G protein fusions restored membrane localization and activation of the G protein by receptor agonist. These studies demonstrate the general utility of generating chimeric fusion proteins to examine receptor regulation of G protein function and that the lack of functional activation of acylation-negative G proteins by a co-expressed receptor is related to deficiencies in cellular targeting and location rather than an inherent incapacity to produce appropriate protein-protein interactions and signal transmission.	UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV BIOCHEM & MOL BIOL,MOL PHARMACOL GRP,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Glasgow			Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519				BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/bj3030697; GEORGOUSSI Z, 1995, BIOCHEM J, V306, P71, DOI 10.1042/bj3060071; Gillard NP, 1996, BRIT J PHARMACOL, V117, pP298; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREEN A, 1990, J BIOL CHEM, V265, P5206; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HUNT TW, 1994, J BIOL CHEM, V269, P29565; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KOSKI G, 1981, P NATL ACAD SCI-BIOL, V78, P4185, DOI 10.1073/pnas.78.7.4185; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; RICHARDSON A, 1992, P NATL ACAD SCI USA, V89, P10198, DOI 10.1073/pnas.89.21.10198; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; Taylor JM, 1996, J BIOL CHEM, V271, P3336; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; TIAN WN, 1994, MOL PHARMACOL, V45, P524; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Wise A, 1997, BIOCHEM J, V321, P721, DOI 10.1042/bj3210721; Wise A, 1997, BIOCHEM J, V325, P17, DOI 10.1042/bj3250017; WISE A, 1997, IN PRESS BIOCHEMISTR	36	52	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24673	24678		10.1074/jbc.272.39.24673	http://dx.doi.org/10.1074/jbc.272.39.24673			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305937	hybrid			2022-12-25	WOS:A1997XY51500088
J	Mitchell, PJ; Barker, KT; Shipley, J; Crompton, MR				Mitchell, PJ; Barker, KT; Shipley, J; Crompton, MR			Characterisation and chromosome mapping of the human non receptor tyrosine kinase gene, brk	ONCOGENE			English	Article						brk; genomic structure; alternate splicing; SH3; chromosome 19q; protein tyrosine kinase	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN BREAST-CANCER; C-SRC; PROTEIN-KINASE; LINKED AGAMMAGLOBULINEMIA; TRANSCRIPTION FACTOR; DNA; PP60C-SRC; PHOSPHORYLATION; ACTIVATION	The brk gene encodes a non-receptor protein tyrosine kinase that consists of single SH3, SH2 and catalytic domains. Although BRK shows strongest sequence similarity to members of the SRC family of PTKs, there are several key structural and regulatory differences that place it on its own amongst non-receptor PTKs. In this study we have isolated genomic DNA clones corresponding to the human brk locus and used these to determine the intron-exon structure of the brk gene. The genomic structure of brk consists of 8 exons, whose boundaries are distinct from other non-receptor PTK family members, again indicating a structural and functional divergence. Alternate splicing of the primary brk transcript generates a distinct mRNA which encodes a truncated protein consisting of an SH3 domain and a novel C-terminal proline rich sequence. Using an antiserum raised to the SH3 domain, we have demonstrated that the product of this alternate brk transcript is expressed in the human breast tumour cell line T-47D. We have previously reported that expression of a tumour derived brk cDNA in mouse embryonic fibroblasts and human mammary epithelial cells supports anchorage independent growth, and in the latter potentiates the mitogenic response to epidermal growth factor. The protein encoded by the genomic sequence derived from normal human tissue is identical to that encoded by the tumour derived cDNA, and therefore the altered growth regulation is not associated with mutations within brk. In addition, we have identified a 5' genomic region that has promoter activity. The brk gene has been assigned to chromosome 19q 13.3-13.4 using fluorescence in situ hybridisation (FISH).			Mitchell, PJ (corresponding author), INST CANC RES, HADDOW LABS, SECT CELL BIOL & EXPT PATHOL, 15 COTSWOLD RD, SUTTON SM2 5NG, SURREY, ENGLAND.		Mitchell, Philip J/F-6393-2013	Shipley, Janet/0000-0001-6748-8678	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; BARKER KT, 1997, IN PRESS ONCOGENE; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLLA M, 1993, BREAST CANCER RES TR, V26, P283, DOI 10.1007/BF00665806; BRAUNINGER A, 1993, ONCOGENE, V8, P1365; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOKE M P, 1989, New Biologist, V1, P66; DAVIDSON D, 1994, MOL CELL BIOL, V14, P4554, DOI 10.1128/MCB.14.7.4554; DAVIDSON D, 1994, J BIOL CHEM, V269, P10956; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; HAGEMANN TL, 1994, HUM MOL GENET, V3, P1743, DOI 10.1093/hmg/3.10.1743; HENNIPMAN A, 1989, CANCER RES, V49, P516; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Ohta Y, 1996, ONCOGENE, V12, P937; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; OKADA M, 1991, J BIOL CHEM, V266, P24249; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; RIED T, 1995, CANCER RES, V55, P5415; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIPLEY JM, 1993, CYTOGENET CELL GENET, V64, P233, DOI 10.1159/000133585; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	48	39	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	1997	15	12					1497	1502		10.1038/sj.onc.1201292	http://dx.doi.org/10.1038/sj.onc.1201292			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333026				2022-12-25	WOS:A1997XW41100014
J	Aguilar, RC; Ohno, H; Roche, KW; Bonifacino, JS				Aguilar, RC; Ohno, H; Roche, KW; Bonifacino, JS			Functional domain mapping of the clathrin-associated adaptor medium chains mu 1 and mu 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; COATED VESICLES; BINDING SUBUNIT; PLASMA-MEMBRANE; SORTING SIGNALS; AP-2 COMPLEXES; DELTA-COP; GOLGI; IDENTIFICATION; PREDICTION	The clathrin-associated adaptors AP-1 and AP-2 are heterotetrameric complexes involved in the recognition of sorting signals present within the cytosolic domain of integral membrane proteins. The medium chains of these complexes, mu 1 and mu 2, have been implicated in two types of interaction: assembly with the beta 1 and beta 2 chains of the corresponding complexes and recognition of tyrosine-based sorting signals. In this study, we report the results of a structure-function analysis of the mu 1 and mu 2 chains aimed at identifying regions of the molecules that, ape responsible for each of the two interactions. Analyses using the yeast two-hybrid system and proteolytic digestion experiments suggest that mu 1 and mu 2 have a bipartite structure, with the amino-terminal one-third (residues 1-145 of mu 1 and mu 2) being involved in assembly with the beta chains and the carboxyl-terminal two-thirds (residues 147-423 of mu 1 and 164-435 of mu 2) binding tyrosine-based sorting signals, These observations support a model in which the amino-terminal one-third of mu 2 is embedded within the core of the AP-2 complex, while the carboxyl-terminal two-thirds of the protein are exposed to the medium, placing this region in a position to interact with tyrosine-based sorting signals.	NICHHD,CBMB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Roche, Katherine/W-9893-2019; Ohno, Hiroshi/L-7899-2014	Ohno, Hiroshi/0000-0001-8776-9661; Bonifacino, Juan S./0000-0002-5673-6370; Roche, Katherine/0000-0001-7282-6539				AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Faulstich D, 1996, J CELL BIOL, V135, P53, DOI 10.1083/jcb.135.1.53; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; NAKAYAMA Y, 1991, EUR J BIOCHEM, V202, P569, DOI 10.1111/j.1432-1033.1991.tb16409.x; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Ooi CE, 1997, EMBO J, V16, P4508; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PEVSNER J, 1994, GENE, V146, P279, DOI 10.1016/0378-1119(94)90306-9; PEYRARD M, 1994, HUM MOL GENET, V3, P1393, DOI 10.1093/hmg/3.8.1393; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; RADICE P, 1995, GENOMICS, V26, P101, DOI 10.1016/0888-7543(95)80087-3; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1993, J CELL BIOL, V123, P67, DOI 10.1083/jcb.123.1.67; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Traub LM, 1997, TRENDS CELL BIOL, V7, P43, DOI 10.1016/S0962-8924(96)20042-X; Wang XL, 1997, FEBS LETT, V402, P57, DOI 10.1016/S0014-5793(96)01500-1; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108	43	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27160	27166		10.1074/jbc.272.43.27160	http://dx.doi.org/10.1074/jbc.272.43.27160			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341158	hybrid			2022-12-25	WOS:A1997YC65900054
J	Daniel, R; Caminade, E; Martel, A; LeGoffic, F; Canosa, D; Carrascal, M; Abian, J				Daniel, R; Caminade, E; Martel, A; LeGoffic, F; Canosa, D; Carrascal, M; Abian, J			Mass spectrometric determination of the cleavage sites in Escherichia coli dihydroorotase induced by a cysteine-specific reagent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; MAMMALIAN DIHYDROOROTASE; PYRC GENE; PROTEINS; RESIDUES; ZINC; CATALYSIS; ENZYMES; BINDING	Escherichia coli dihydroorotase contains six cysteines/subunit, which are potential ligands of structural and catalytic zinc metals at protein sites of the enzyme, Specific thiol reagents modify, in nondenaturing conditions only, two of these cysteines; these two residues are thought to be ligands of structural zinc. We report here ore the localization of these two cysteines on the polypeptide chain through their cyanylation by 2-nitro-thiocyanobenzoic acid (NTCB) and the analysis by mass spectrometry of the protein adducts. This is the first study of E. coli dihydroorotase by mass spectrometry, allowing the accurate determination of the subunit molecular weight (38,695). Treatment of dihydroorotase by NTCB induced a cleavage N-terminal to the cyanylated cysteines. The resulting fragments visualized on electrophoresis gel have been N-terminal sequenced, and their masses were determined by electrospray-ionizing mass spectrometry. This allowed the identification of cysteines 221 and 265 as the two residues cyanylated by the reagent NTCB. Results from gel filtration of dihydroorotase cyanylated on the two cysteines indicate that these residues are involved in subunit interactions leading to the active dimer. Consistent with literature data, we assume that cysteine 221 and cysteine 265, along with the neighboring cysteines 263 and 268 arranged in cluster, are potential ligands of structural zinc of E. coli dihydroorotase.	ECOLE NATL SUPER CHIM PARIS, CNRS, LAB BIOORGAN & BIOTECHNOL, F-75231 PARIS 05, FRANCE; CSIC, DEPT MED BIOANAL, ES-08034 BARCELONA, SPAIN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Chimie ParisTech; Consejo Superior de Investigaciones Cientificas (CSIC)			Abian, Joaquin/M-1965-2014; Daniel, Regis/S-7890-2016; Carrascal, Montserrat/M-1913-2014	Abian, Joaquin/0000-0003-2823-5429; Daniel, Regis/0000-0003-0725-5439; Carrascal, Montserrat/0000-0002-0205-2176				BACKSTROM D, 1986, EUR J BIOCHEM, V160, P77, DOI 10.1111/j.1432-1033.1986.tb09942.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DC, 1986, J BIOL CHEM, V261, P5917; BROWN DC, 1991, J BIOL CHEM, V266, P1597; Carrey EA, 1995, BIOCHEM SOC T, V23, P899, DOI 10.1042/bst0230899; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CHRISTIANSON DW, 1989, J AM CHEM SOC, V254, P12506; Daniel R, 1996, ANAL BIOCHEM, V239, P130, DOI 10.1006/abio.1996.0307; DEGANI Y, 1974, BIOCHEMISTRY-US, V13, P1, DOI 10.1021/bi00698a001; GIBBS P, 1981, Biochemical Society Transactions, V9, P232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OGILVIE JW, 1980, BIOCHIM BIOPHYS ACTA, V622, P277, DOI 10.1016/0005-2795(80)90038-0; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; SANDER EG, 1965, J BIOL CHEM, V240, P3628; SIMMER JP, 1990, P NATL ACAD SCI USA, V87, P174, DOI 10.1073/pnas.87.1.174; Stark G R, 1977, Methods Enzymol, V47, P129; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WASHABAUGH MW, 1984, J BIOL CHEM, V259, P3293; WASHABAUGH MW, 1986, J BIOL CHEM, V261, P5920; WILLIAMS NK, 1995, BIOCHEMISTRY-US, V34, P11344, DOI 10.1021/bi00036a007; WILSON HR, 1987, J BACTERIOL, V169, P3051, DOI 10.1128/jb.169.7.3051-3058.1987; Wu J, 1996, ANAL BIOCHEM, V235, P161, DOI 10.1006/abio.1996.0108; ZIMMERMANN BH, 1995, BIOCHEMISTRY-US, V34, P7038, DOI 10.1021/bi00021a015; ZIMMERMANN BH, 1995, ADV EXP MED BIOL, V370, P699	25	11	12	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26934	26939		10.1074/jbc.272.43.26934	http://dx.doi.org/10.1074/jbc.272.43.26934			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341128	hybrid			2022-12-25	WOS:A1997YC65900024
J	Krupenko, NI; Wagner, C				Krupenko, NI; Wagner, C			Transport of rat liver glycine N-methyltransferase into rat liver nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE-BINDING-PROTEIN; PURIFICATION; DNA; COMPONENTS; SUBUNIT; IMPORT	Rat liver cytosolic glycine N-methyltransferase (GNMT) catalyzes the S-adenosylmethionine-dependent methylation of glycine to sarcosine. It is comprised of four identical 292-amino acid residue subunits. Recently, evidence has been provided to show that GNMT is identical to the cytosolic receptor for benzo[a]pyrene, which induces cytochrome P450 1A1 gene expression. In the present study we show that chemical modification of purified rat Liver GNMT with fluorescein isothiocyanate (FITC) resulted in dissociation of the tetrameric enzyme and was accompanied by loss of enzyme activity. Amino acid sequence analysis of the FITC-labeled peptides obtained by hydrolysis of the modified protein with Staphylococcus aureus V8 protease revealed that lysines 45, 89, 92, 96, 122, and 147 were modified. Lys-122 and Lys-147 were derivatized in tetrameric, dimeric, and monomeric forms of the enzyme. Lysines 45, 89, 92, and 96 were derivatized only in monomeric GNMT, suggesting that modification of these residues resulted in GNMT dissociation. The modified monomeric GNMT was quickly transported into isolated rat liver nuclei. This transport was specific for the GNMT monomer, since neither tetramer nor dimer was able to enter the nuclei, Bovine carbonic anhydrase, similar in size to the GNMT monomer, was labeled with FITC to a similar extent but was not transported into the nuclei. Disruption of the nuclei containing fluorescein-labeled GNMT and subsequent extraction of the nuclear lysate with both high and low salt buffers recovered FITC-GNMT only in the chromatin pellet. Our study supports the suggestion of an additional function for GNMT, probably connected with regulation of cytochrome P450 1A1 gene expression.	VET AFFAIRS MED CTR,NASHVILLE,TN 37232	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Krupenko, NI (corresponding author), VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,221 KIRKLAND HALL,614 LH,NASHVILLE,TN 37232, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015289, R01DK046788, R01DK015289] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46788, DK15289] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLFREY V, 1951, J BIOL CHEM, V226, P529; BERNHARDT R, 1983, BIOCHIM BIOPHYS ACTA, V745, P140, DOI 10.1016/0167-4838(83)90042-0; Bhat R, 1996, J BIOL CHEM, V271, P32551, DOI 10.1074/jbc.271.51.32551; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CANTONI GL, 1978, TRANSMETHYLATION, P155; COOK RJ, 1984, P NATL ACAD SCI-BIOL, V81, P3631, DOI 10.1073/pnas.81.12.3631; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; Drapeau G R, 1977, Methods Enzymol, V47, P189; ElSeaidy AZ, 1997, AM J PHYSIOL-GASTR L, V272, pG298, DOI 10.1152/ajpgi.1997.272.2.G298; Fu ZJ, 1996, BIOCHEMISTRY-US, V35, P11985, DOI 10.1021/bi961068n; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P19; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; JINDAL HK, 1990, J BIOL CHEM, V265, P6540; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KERR SJ, 1972, J BIOL CHEM, V247, P4248; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; OGAWA H, 1987, EUR J BIOCHEM, V168, P141, DOI 10.1111/j.1432-1033.1987.tb13398.x; Ogawa H, 1997, BIOCHEM BIOPH RES CO, V233, P300, DOI 10.1006/bbrc.1997.6444; OGAWA H, 1982, J BIOL CHEM, V257, P3447; RAHA A, 1994, J BIOL CHEM, V269, P5750; RAHA A, 1995, ARCH BIOCHEM BIOPHYS, V322, P395, DOI 10.1006/abbi.1995.1480; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RONAI Z, 1993, INT J BIOCHEM, V25, P1073, DOI 10.1016/0020-711X(93)90123-V; SMITH DS, 1981, ANN CLIN BIOCHEM, V18, P253, DOI 10.1177/000456328101800501; SPELSBERG TC, 1971, J BIOL CHEM, V246, P4188; WAGNER C, 1989, J BIOL CHEM, V264, P9638; WAGNER C, 1985, BIOCHEM BIOPH RES CO, V127, P746, DOI 10.1016/S0006-291X(85)80006-1; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010; YEO EJ, 1994, P NATL ACAD SCI USA, V91, P210, DOI 10.1073/pnas.91.1.210; YEO EJ, 1992, J BIOL CHEM, V267, P24669	34	13	13	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27140	27146		10.1074/jbc.272.43.27140	http://dx.doi.org/10.1074/jbc.272.43.27140			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341155	hybrid			2022-12-25	WOS:A1997YC65900051
J	Han, JD; Baker, NE; Rubin, CS				Han, JD; Baker, NE; Rubin, CS			Molecular characterization of a novel A kinase anchor protein from Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; REGULATORY SUBUNIT RII; A-KINASE; II-BETA; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; EXPRESSION; LOCALIZATION; CLONING; CYTOSKELETON	Activation of protein kinase A (PKA) at discrete intracellular sites facilitates oogenesis and development in Drosophila, Thus, PKA-anchor protein complexes may involved in controlling these crucial biological processes, Evaluation of this proposition requires knowledge of PKA binding/targeting proteins in the fly, We now report the discovery and characterization of cDNAs encoding a novel, Drosophila A kinase anchor protein, DAKAP550, DAKAP550 is a large (>2300 amino acids) acidic protein that is maximally expressed in anterior tissues, It binds regulatory subunits (RII) of both mammalian and Drosophila PKAII isoforms. The tethering region of DAKAP550 includes two proximal, but noncontiguous RII-binding sites (B1 and B2), The B1 domain (residues 1406-1425) binds RII similar to 20-fold more avidly than B2 (amino acids 1350-1369). Affinity-purified anti-DAKAP550 IgGs were exploited to demonstrate that the anchor protein is expressed in many cells in nearly all tissues throughout the lifespan of the fly, However, DAKAP550 is highly enriched and asymmetrically positioned in subpopulations of neurons and in apical portions of cells in gut and trachea. The combination of RII (PKAII) binding activity with differential expression polarized localization is consistent with a role for DAKAP550 in creating target loci for the reception of signals carried by cAMP. The DAKAP550 gene was mapped to the 4F1.2 region of the X chromosome; flies that carry a deletion for this portion of the X chromosome lack DAKAP550 protein.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,ATRAN LABS,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,DEPT MOL GENET,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				Han, Jing-Dong J./0000-0002-9270-7139	NIGMS NIH HHS [GM47892, GM22792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792, R01GM047892] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ashburner M, 1989, DROSOPHILA LABORATOR, P44; BEEBE SJ, 1986, ENZYMES, P44; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, J BIOL CHEM, V267, P16816; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FEUCHTER AE, 1992, GENOMICS, V13, P1237, DOI 10.1016/0888-7543(92)90041-P; FOSTER JL, 1984, J BIOL CHEM, V259, P3049; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P1256; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOHEISEL JD, 1991, J MOL BIOL, V220, P903, DOI 10.1016/0022-2836(91)90362-A; LAND M, 1994, J BIOL CHEM, V269, P9234; LANE ME, 1995, MECH DEVELOP, V49, P191, DOI 10.1016/0925-4773(94)00317-G; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LU XY, 1990, J BIOL CHEM, V265, P3293; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SHORT JM, 1992, METHOD ENZYMOL, V216, P495; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	40	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26611	26619		10.1074/jbc.272.42.26611	http://dx.doi.org/10.1074/jbc.272.42.26611			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334242	hybrid			2022-12-25	WOS:A1997YB13900076
J	Kuo, HJ; Maslen, CL; Keene, DR; Glanville, RW				Kuo, HJ; Maslen, CL; Keene, DR; Glanville, RW			Type VI collagen anchors endothelial basement membranes by interacting with type IV collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; BETHLEM MYOPATHY; EXTRACELLULAR-MATRIX; BINDING-PROPERTIES; 2-HYBRID SYSTEM; HUMAN PLACENTA; ALPHA-3 CHAIN; CELL-ADHESION; TRIPLE-HELIX; HYALURONAN	Type VI collagen filaments are found associated with interstitial collagen fibers, around cells, and in contact with endothelial basement membranes, To identify type VI collagen binding proteins, the amino-terminal domains of the alpha 1(VI) and alpha 2(VI) chains and a part of the carboxyl-terminal domain of the alpha 3(VI) chain were used as bait in a yeast two-hybrid system to screen a human placenta library. Eight persistently positive clones were identified, two coding the known matrix proteins fibronectin and basement membrane type IV collagen and the rest coding new proteins. The amino-terminal domain of alpha 1(VI) was shown to interact with the carboxyl-terminal globular domain of type IV collagen. The specificity of this interaction was further studied using the yeast two-hybrid system in a one-on-one format and confirmed by using isolated protein domains in immunoprecipitation, affinity blots, and enzyme-linked immunosorbent assay-based binding studies. Co-distribution of type. VI and type IV collagens in human muscle was demonstrated using double labeling immunofluorescent microscopy and immunoelectron microscopy, The strong interaction of type VI collagen filaments with basement membrane collagen provided a possible molecular pathogenesis for the heritable disorder Bethlem myopathy.	SHRINERS HOSP CRIPPLED CHILDRENS, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT MED, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOL BIOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, CONGENITAL HEART RES CTR, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University					NIAMS NIH HHS [R29AR41846-03] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041846] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, P1; BETHLEM J, 1976, BRAIN, V99, P91, DOI 10.1093/brain/99.1.91; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BRINKER JM, 1985, P NATL ACAD SCI USA, V82, P3649, DOI 10.1073/pnas.82.11.3649; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CARTER WG, 1982, J BIOL CHEM, V257, P13805; CARTER WG, 1984, J CELL BIOL, V99, P105, DOI 10.1083/jcb.99.1.105; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FITCH JM, 1991, DEV BIOL, V144, P379, DOI 10.1016/0012-1606(91)90430-B; HAGIWARA H, 1993, CELL TISSUE RES, V272, P155, DOI 10.1007/BF00323581; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HNATOWICH DJ, 1987, J NUCL MED, V28, P1294; IIDA K, 1994, J ELECTRON MICROSC, V43, P367; Jobsis GJ, 1996, NEUROLOGY, V46, P779, DOI 10.1212/WNL.46.3.779; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; KIELTY CM, 1992, J CELL BIOL, V118, P979, DOI 10.1083/jcb.118.4.979; KIELTY CM, 1991, J CELL SCI, V99, P797; KUO HJ, 1995, EUR J BIOCHEM, V232, P364, DOI 10.1111/j.1432-1033.1995.364zz.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; MCDEVITT CA, 1991, FEBS LETT, V294, P167, DOI 10.1016/0014-5793(91)80660-U; MOHIRE MD, 1988, NEUROLOGY, V38, P573, DOI 10.1212/WNL.38.4.573; Nagase T, 1996, DNA Res, V3, P43, DOI 10.1093/dnares/3.1.43; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OZEBBERGER BA, 1995, MOL ENDOCRINOL, V9, P1321; PERRIS R, 1993, EXP CELL RES, V209, P103, DOI 10.1006/excr.1993.1290; Pessier AP, 1996, LAB INVEST, V75, P87; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; QIAN RG, 1984, BIOCHEM J, V222, P447, DOI 10.1042/bj2220447; RIES A, 1995, J BIOL CHEM, V270, P23790, DOI 10.1074/jbc.270.40.23790; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; SENGA K, 1995, ANAT REC, V243, P294, DOI 10.1002/ar.1092430303; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; Speer MC, 1996, HUM MOL GENET, V5, P1043, DOI 10.1093/hmg/5.7.1043; SPISSINGER T, 1995, MATRIX BIOL, V14, P499, DOI 10.1016/0945-053X(95)90007-1; STALLCUP WB, 1990, J CELL BIOL, V111, P3177, DOI 10.1083/jcb.111.6.3177; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; WEBER S, 1984, EUR J BIOCHEM, V139, P401, DOI 10.1111/j.1432-1033.1984.tb08019.x; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; ZHU D, 1994, J HISTOCHEM CYTOCHEM, V42, P577, DOI 10.1177/42.5.8157929	49	226	234	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26522	26529		10.1074/jbc.272.42.26522	http://dx.doi.org/10.1074/jbc.272.42.26522			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334230	hybrid			2022-12-25	WOS:A1997YB13900064
J	Nemoto, T; Sato, N; Iwanari, H; Yamashita, H; Takagi, T				Nemoto, T; Sato, N; Iwanari, H; Yamashita, H; Takagi, T			Domain structures and immunogenic regions of the 90-kDa heat-shock protein (HSP90) - Probing with a library of anti-HSP90 monoclonal antibodies and limited proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONHORMONE-BINDING-COMPONENT; STEROID-RECEPTORS; GLUCOCORTICOID RECEPTOR; HORMONE-BINDING; CASEIN KINASE; RAT-LIVER; SEQUENCE; GROWTH	Domain structures of the 90-kDa heat shock protein (HSP90) have been investigated with a library of anti-HSP90 monoclonal antibodies (mAbs) and by limited proteolysis with trypsin and chymotrypsin. Thirty-three mAbs were obtained by immunization with bacterially expressed human HSP90 alpha and HSP90 beta isoforms, Among them, ten and three mAbs reacted specifically with HSP90 alpha and HSP90 beta, respectively. Immunoblotting and enzyme-linked immunosorbent analyses revealed that major immunogenic domains were located at two restricted regions of HSP90 alpha, i.e. amino acids 227-310 (designated Region I) and 702-716 (Region II), corresponding to a highly charged region and a region near the C terminus, respectively, Taken together with the characteristics of the amino acid sequences, these two immunogenic regions appeared to be exposed at the outer surface of HSP90. We further investigated the domain structures of HSP90 by limited proteolysis in combination with N-terminal sequencing and immunoblotting analyses, Tryptic cleavages of HSP90 alpha at low concentrations revealed the existence of major susceptible sites at Arg(400)-Glu(401), Lys(615)-Ala(616), and Arg(620)-Asp(621). Proteolysis at higher trypsin concentrations caused successive cleavages only toward the N-terminal direction from these sites, and Region I was included in the region selectively deleted during this process, thereby further suggesting its surface location, From these results, we propose three domain structures of HSP90 consisting of amino acids 1-400, 401-615, and 621-732. Differences in the protease sensitivity and immunogenicity further suggest that every domain is composed of two subdomains, This is the first study describing the domain structures and the immunogenic regions of HSP90.	INST IMMUNOL CO,ISHIBASHI,TOCHIGI 32905,JAPAN; TOHOKU UNIV,FAC SCI,INST BIOL,SENDAI,MIYAGI 98077,JAPAN	Tohoku University	Nemoto, T (corresponding author), IWATE UNIV,SCH DENT,DEPT BIOCHEM,19-1 UCHIMARU,MORIOKA,IWATE 020,JAPAN.			Nemoto, Takayuki K./0000-0002-5007-6260				BARDWELL JCA, 1987, P NATL ACAD SCI USA, V84, P5177, DOI 10.1073/pnas.84.15.5177; BINART N, 1989, J STEROID BIOCHEM, V34, P369, DOI 10.1016/0022-4731(89)90110-6; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; CADEPOND F, 1994, J STEROID BIOCHEM, V48, P361, DOI 10.1016/0960-0760(94)90076-0; DOUGHERTY JJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P74, DOI 10.1016/0167-4889(87)90067-X; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KYAKUMOTO S, 1994, ARCH ORAL BIOL, V39, P569, DOI 10.1016/0003-9969(94)90132-5; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; NEMOTO T, 1987, J BIOCHEM-TOKYO, V102, P513, DOI 10.1093/oxfordjournals.jbchem.a122083; Nemoto T, 1996, J BIOCHEM-TOKYO, V120, P249; NEMOTO T, 1995, STEROID BIOCH LIFE S, V14, P59; OLI VT, 1984, SELECTED METHODS CEL, P351; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641	24	58	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26179	26187		10.1074/jbc.272.42.26179	http://dx.doi.org/10.1074/jbc.272.42.26179			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334185	hybrid			2022-12-25	WOS:A1997YB13900019
J	Springer, C; Valerius, O; Strittmatter, A; Braus, GH				Springer, C; Valerius, O; Strittmatter, A; Braus, GH			The adjacent yeast genes ARO4 and HIS7 carry no intergenic region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COMPLEMENT GENES; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION TERMINATION; POLYADENYLATION SITES; TRANSFORMATION; SEQUENCES; END	The region between the open reading frames of the adjacent yeast genes ARO4 and HIS7 consists of 417 base pairs (bp), Termination of ARO4 transcription and initiation of HIS7 transcription has to take place within this interval, because both genes are transcribed into the same direction, We show that, the ARO4 terminator acid the HIS7 promoter are spatially separated, nonoverlapping units. The ARO4 terminator includes 84 bp of the ARO4 3'-untranslated region with several redundant ARO4 3' end processing signals. Deletion of the ARO4 terminator does reduce but not completely shut down its expression, The adjacent region of 40 bp is neither required for correct: ARO4 3' end formation nor for HIS7 initiation but contains the nucleotides corresponding to the wild type mRNA 3' ends, The following 280 bp are required for the HIS7 promoter, Replacement of the housekeeping ARO4 promoter by the stronger ACT1 promoter leads to: reduced HIS7 expression due to transcriptional interference, This underlines the compactness of the yeast genome carrying virtually no intergenic regions between adjacent genes.	UNIV GOTTINGEN,INST MICROBIOL & GENET,D-37077 GOTTINGEN,GERMANY	University of Gottingen			Braus, Gerhard/ABC-6293-2021; Braus, Gerhard H/G-3999-2012	Braus, Gerhard/0000-0002-3117-5626; Braus, Gerhard H/0000-0002-3117-5626				ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; ASHFIELD R, 1991, EMBO J, V10, P4197, DOI 10.1002/j.1460-2075.1991.tb04998.x; BRAUS G, 1985, ARCH MICROBIOL, V142, P383, DOI 10.1007/BF00491908; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; EGLI CM, 1995, MOL CELL BIOL, V15, P2466; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GIEBEL LB, 1990, NUCLEIC ACIDS RES, V18, P4947, DOI 10.1093/nar/18.16.4947; GUO ZJ, 1995, MOL CELL BIOL, V15, P5983; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEIDMANN S, 1994, MOL CELL BIOL, V14, P4633, DOI 10.1128/MCB.14.7.4633; HENIKOFF S, 1984, MOL CELL BIOL, V4, P1515, DOI 10.1128/MCB.4.8.1515; HYMAN LE, 1993, MOL CELL BIOL, V13, P5159, DOI 10.1128/MCB.13.9.5159; IRNIGER S, 1992, MOL CELL BIOL, V12, P2322, DOI 10.1128/MCB.12.5.2322; IRNIGER S, 1991, MOL CELL BIOL, V11, P3060, DOI 10.1128/MCB.11.6.3060; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KUNZLER M, 1992, GENE, V113, P67, DOI 10.1016/0378-1119(92)90670-K; KUNZLER M, 1993, J BACTERIOL, V175, P5548; MIOZZARI G, 1978, J BACTERIOL, V153, P163; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPRINGER C, 1996, J BIOL CHEM, V270, P29637; TAKAHASHI M, 1971, CAN J BIOCHEM CELL B, V49, P1015, DOI 10.1139/o71-149; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	28	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26318	26324		10.1074/jbc.272.42.26318	http://dx.doi.org/10.1074/jbc.272.42.26318			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334203	hybrid			2022-12-25	WOS:A1997YB13900037
J	ToyamaSorimachi, N; Kitamura, F; Habuchi, H; Tobita, Y; Kimata, K; Miyasaka, M				ToyamaSorimachi, N; Kitamura, F; Habuchi, H; Tobita, Y; Kimata, K; Miyasaka, M			Widespread expression of chondroitin sulfate-type serglycins with CD44 binding ability in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTES-T; BONE-MARROW; MAST-CELLS; PROTEOGLYCANS; ACTIVATION; RECEPTOR; SURFACE; HYALURONATE; ANTIBODIES; ADHERENCE	Serglycin is a family of small proteoglycans with Ser-Gly dipeptide repeats and is modified with various types of glycosaminoglycan side chains, We previously demonstrated that chondroitin sulfate-modified serglycin is a navel ligand for CD44 involved in the adherence and activation of lymphoid cells, In this study, we investigated the production and distribution of CD44 binding serglycins in various hematopoietic cells and characterized their carbohydrate side chains. Immunoprecipitation analysis using CD44-IgG; and polyclonal antibody against the serglycin core peptide demonstrated that, various serglycin species capable of binding CD44 are produced by a variety of hematopoietic cells including lymphoid cells, myeloid cells, and a few tumor cell lines, Glycosaminoglycans on these serglycins, which are essential for CD44 binding, are composed of chondroitin 4-sulfate or a mixture of chondroitin 4-sulfate and chondroitin B-sulfate, but no heparin or heparan sulfate side chain was detected. The serglycins are also secreted by normal splenocytes, lymph node lymphocytes, and bone marrow cells, whereas they are secreted in very small amounts by normal thymocytes, Secretion of serglycins is greatly enhanced by mitogenic stimulation with concanavalin A or lipopolysaccharide. Our results showed that serglycin, unlike hyaluronate, is produced and secreted in a functional (CD44 binding) form by many members of the hematopoietic system including various lymphocyte subsets, Our data suggest that serglycin may serve as a major Ligand for CD44 in various events in the lymphohematopoietic system.	AICHI MED UNIV,INST MOL SCI MED,AICHI 48011,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT BIOREGULAT,OSAKA 565,JAPAN	Aichi Medical University; Osaka University	ToyamaSorimachi, N (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT IMMUNOL,BUNKYO KU,3-18-22 HON KOMAGOME,TOKYO 113,JAPAN.		Miyasaka, Masayuki/AAM-6343-2020					ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DELFINO DV, 1994, J IMMUNOL, V152, P5171; FYMAN R, 1991, IMMUNOGENETICS, V33, P392; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; Kolset SO, 1996, J LEUKOCYTE BIOL, V59, P545, DOI 10.1002/jlb.59.4.545; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; KOOPMAN G, 1990, J IMMUNOL, V145, P3589; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LEVITT D, 1989, CELL IMMUNOL, V98, P78; MASSON D, 1990, BIOCHEMISTRY-US, V29, P11229, DOI 10.1021/bi00503a011; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; STELLRECHT CM, 1991, DIFFERENTIATION, V48, P127, DOI 10.1111/j.1432-0436.1991.tb00251.x; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; STEVENS RL, 1988, CURR TOP MICROBIOL I, V140, P93; STEWARD WP, 1990, BIOCHIM BIOPHYS ACTA, V1052, P416, DOI 10.1016/0167-4889(90)90151-3; Tanaka Y, 1993, Curr Top Microbiol Immunol, V184, P99; TOYAMASORIMACHI N, 1993, EUR J IMMUNOL, V23, P439, DOI 10.1002/eji.1830230221; TOYAMASORIMACHI N, 1994, INT IMMUNOL, V6, P655, DOI 10.1093/intimm/6.4.655; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	32	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26714	26719		10.1074/jbc.272.42.26714	http://dx.doi.org/10.1074/jbc.272.42.26714			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334256	hybrid			2022-12-25	WOS:A1997YB13900090
J	Liao, JF; Hodge, C; Meyer, D; Ho, PS; Rosenspire, K; Schwartz, J				Liao, JF; Hodge, C; Meyer, D; Ho, PS; Rosenspire, K; Schwartz, J			Growth hormone regulates ternary complex factors and serum response factor associated with the c-fos serum response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; JAK2 TYROSINE KINASE; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; TERMINAL PHOSPHORYLATION; 3T3-F442A PREADIPOCYTES; GENE-EXPRESSION; INDUCE BINDING; FACTOR P62TCF; RECEPTOR	For insight into the mechanisms of gene regulation by growth hormone (GH), the regulation of transcription factors associated with the serum response element (SRE) located upstream of c-fos was examined, The SRE can mediate induction of reporter expression in response to GH. For insight into the mechanism by which GH regulates transcription factors, regulation of SRE-associated proteins by GH was examined, In nuclear extracts from 3T3-F442A fibroblasts, several SRE-binding complexes were identified by electrophoretic mobility shift assay, GH treatment for 2-10 min transiently increased binding of two complexes; binding returned to control values within 30 min, The two GH-stimulated complexes were supershifted by antibodies against the serum response factor (SRF), indicating that they contained SRF or an antigenically related protein, One of the GH-stimulated complexes was supershifted by antibody against Elk-1, suggesting that it contains a ternary complex factor (TCF) such as Elk-1 in addition to SRF, Induction of binding by GH was lost when the SRF binding site in the SRE was mutated, and mutation of either the SRF or TCF binding site altered the pattern of protein binding to the SRE, Mutation of the SRF or TCF binding site in SRE-luciferase plasmids inhibited the ability of GH to stimulate reporter expression, supporting a role for both SRF and TCF in GH-induced transcription of c-fos via the SRE, The TCF family member Elk-1 is capable of mediating GH-stimulated transcription, since GH-stimulated reporter expression was mediated by the transcriptional activation domain of Elk-1, Consistent with this stimulation, GH rapidly and transiently stimulated the serine phosphorylation of Elk-1. The increase was evident within 10 min and subsided after 30 min, Taken together, these data indicate that SRF and TCF contribute to GH-promoted transcription of c-fos via the SRE and are consistent with GH-promoted phosphorylation of Elk-1 contributing to GH-promoted transcriptional activation via the SRE.	UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,MOL & CELLULAR BIOL PROGRAM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046072, F32DK009293] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46072, DK 09293] Funding Source: Medline; NIGMS NIH HHS [GM 07315] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NG, 1993, BIOCHEM BIOPH RES CO, V193, P284, DOI 10.1006/bbrc.1993.1621; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BENSON BA, 1994, J IMMUNOL, V153, P3862; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4505, DOI 10.1210/en.136.10.4505; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; COX AD, 1994, J BIOL CHEM, V269, P19203; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JANKNECHT R, 1993, EUR J BIOCHEM, V216, P469, DOI 10.1111/j.1432-1033.1993.tb18165.x; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Legraverend C, 1996, MOL ENDOCRINOL, V10, P1507, DOI 10.1210/me.10.12.1507; LIU SH, 1993, J BIOL CHEM, V268, P21147; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; SLIVA D, 1994, J BIOL CHEM, V269, P26208; SLOOTWEG MC, 1991, J MOL ENDOCRINOL, V6, P179, DOI 10.1677/jme.0.0060179; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; SUBRAMANIAN A, 1995, MOL CELL BIOL, V15, P4672; SUMANTRAN VN, 1992, ENDOCRINOLOGY, V130, P2016, DOI 10.1210/en.130.4.2016; THOMPSON MJ, 1994, J BIOL CHEM, V269, P21127; TOLLET P, 1991, MOL ENDOCRINOL, V5, P1351; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; Waxman DJ, 1996, J BIOL CHEM, V271, P29978, DOI 10.1074/jbc.271.47.29978; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	60	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25951	25958		10.1074/jbc.272.41.25951	http://dx.doi.org/10.1074/jbc.272.41.25951			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325329	hybrid			2022-12-25	WOS:A1997YA35800084
J	Rehemtulla, A; Hamilton, CA; Chinnaiyan, AM; Dixit, VM				Rehemtulla, A; Hamilton, CA; Chinnaiyan, AM; Dixit, VM			Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; DEATH DOMAIN; FAS; RECEPTORS; SIGNAL; LIGHT; GENE	Exposure to ultraviolet light (UV) can induce apoptosis in mammalian cells. The mechanism by which UV radiation engages the suicide apparatus is unclear. Here we demonstrate that UV radiation can activate the Fas pathway via receptor aggregation and subsequent recruitment of the death adaptor molecule FADD/MORT1. UV radiation-induced apoptosis was inhibited by both a dominant negative version of FADD (FADD-DN) and the caspase inhibitor CrmA. Thus, activation of the Fas pathway represents a physiologic mechanism by which UV-damaged cells are eliminated.	UNIV MICHIGAN,SCH MED,MED CTR,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT RADIAT ONCOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NIGMS NIH HHS [NIGMS T32] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HUANG RP, 1995, ONCOGENE, V10, P467; JAATTELA M, 1995, ONCOGENE, V10, P2297; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255	13	264	271	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25783	25786		10.1074/jbc.272.41.25783	http://dx.doi.org/10.1074/jbc.272.41.25783			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325306				2022-12-25	WOS:A1997YA35800061
J	Sievert, MK; Ruoho, AE				Sievert, MK; Ruoho, AE			Peptide mapping of the [I-125]iodoazidoketanserin and [I-125]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesicle monoamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR AMINE TRANSPORTER; CHROMAFFIN GRANULE MEMBRANES; CATECHOLAMINE TRANSPORTER; RESERPINE BINDING; STORAGE-VESICLES; ESCHERICHIA-COLI; LAC PERMEASE; HUMAN-BRAIN; SENSITIVITY; SUBSTRATE	The full-length cDNA for the rat recombinant synaptic vesicle monoamine transporter (rVMAT2) containing a COOH-terminal polyhistidine epitope was engineered into baculovirus DNA for expression in Spodoptera frugiperda (Sf9) cells. Using this recombinant baculovirus and cultured Sf9 cells, rVMAT2 has been expressed to high levels and purified to >95% homogeneity using immobilized Ni2+-affinity chromatography followed by lectin (concanavalin A) chromatography. Purified transporter was photolabeled using [I-125]-7-azido-8-iodoketanserin ([I-125]AZIK) and [I-125]2-N-[(3'-iodo-4'-azido-phenyl)propionyl]tetrabenazine ([I-125]TBZ-AIPP). Both [I-125]AZIK [I-125]TBZ-AIPP photoaffinity labeling of purified rVMAT2 were protectable by 10 mu M tetrabenazine (TBZ), 10 mu M 7-aminoketanserin, and 1 mM concentrations of the transporter substrates dopamine, norepinephrine, and serotonin. Radiolabeled peptides were generated using enzymatic and chemical methods, purified using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and NH2-terminal microsequenced. Radiosequencing of [I-125]AZIK-labeled rVMAT2 indicated derivatization of Lys-20 in the NH2 terminus, just prior to putative transmembrane domain 1 (TMD1). [I-125]TBZ-AIPP derivatized a segment of rVMAT2 between Gly-408 and Cys-431 in TMD10 and 11. These data implicate juxtaposition of TMD1 and 10/11.	UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NINDS NIH HHS [NS33650-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033650] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APPS DK, 1980, FEBS LETT, V111, P386, DOI 10.1016/0014-5793(80)80833-7; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CESURA AM, 1990, EUR J PHARMACOL, V186, P95, DOI 10.1016/0014-2999(90)94064-5; DANIELS AJ, 1988, J BIOL CHEM, V263, P5034; DARCHEN F, 1988, MOL PHARMACOL, V33, P672; Edwards R H, 1992, Curr Opin Neurobiol, V2, P586, DOI 10.1016/0959-4388(92)90023-E; ERICKSON JD, 1993, J NEUROCHEM, V61, P2314, DOI 10.1111/j.1471-4159.1993.tb07476.x; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; GASNIER B, 1986, MOL PHARMACOL, V29, P275; Gros E., 1967, METHOD ENZYMOL, V11, P238; HENRY JP, 1989, BIOCHEM PHARMACOL, V38, P2395, DOI 10.1016/0006-2952(89)90082-8; Hockerman GH, 1996, MOL PHARMACOL, V49, P1021; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; ISAMBERT MF, 1989, BIOCHEMISTRY-US, V28, P2265, DOI 10.1021/bi00431a044; JOHNSON RG, 1979, J BIOL CHEM, V254, P3750; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KABACK HR, 1990, TRENDS BIOCHEM SCI, V15, P309; KNOTH J, 1981, BIOCHEMISTRY-US, V20, P6625, DOI 10.1021/bi00526a016; KREJCI E, 1993, FEBS LETT, V335, P27, DOI 10.1016/0014-5793(93)80432-T; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Merickel A, 1997, J BIOL CHEM, V272, P5403, DOI 10.1074/jbc.272.9.5403; NEAR JA, 1983, FEBS LETT, V158, P31, DOI 10.1016/0014-5793(83)80670-X; NEAR JA, 1986, MOL PHARMACOL, V30, P252; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; Peter D, 1996, J BIOL CHEM, V271, P2979, DOI 10.1074/jbc.271.6.2979; PETER D, 1993, GENOMICS, V18, P720, DOI 10.1016/S0888-7543(05)80383-0; PETER D, 1994, J BIOL CHEM, V269, P7231; RUOHO AE, 1984, RECEPTOR BIOCH METHO, V1, P119; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHERMAN D, 1988, EUR J PHARMACOL, V146, P359, DOI 10.1016/0014-2999(88)90317-2; SCHERMAN D, 1988, J NEUROCHEM, V50, P1131, DOI 10.1111/j.1471-4159.1988.tb10583.x; SCHERMAN D, 1980, BIOCHIM BIOPHYS ACTA, V601, P664, DOI 10.1016/0005-2736(80)90567-2; SCHERMAN D, 1988, MOL PHARMACOL, V33, P72; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SCHERMAN D, 1983, P NATL ACAD SCI-BIOL, V80, P584, DOI 10.1073/pnas.80.2.584; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SCHULDINER S, 1993, J BIOL CHEM, V268, P29; SURRATT CK, 1993, FEBS LETT, V318, P325, DOI 10.1016/0014-5793(93)80539-7; VAILLANCOURT RR, 1995, BIOCHEM J, V311, P987, DOI 10.1042/bj3110987	44	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26049	26055		10.1074/jbc.272.41.26049	http://dx.doi.org/10.1074/jbc.272.41.26049			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325342	hybrid			2022-12-25	WOS:A1997YA35800097
J	deAos, I; Metzger, MH; Exley, M; Dahl, CE; Misra, S; Zheng, DX; Varticovski, L; Terhorst, C; Sancho, J				deAos, I; Metzger, MH; Exley, M; Dahl, CE; Misra, S; Zheng, DX; Varticovski, L; Terhorst, C; Sancho, J			Tyrosine phosphorylation of the CD3-epsilon subunit of the T cell antigen receptor mediates enhanced association with phosphatidylinositol 3-kinase in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM SH2 DOMAINS; SIGNAL-TRANSDUCTION; ACTIVATION MOTIFS; PDGF RECEPTOR; ZETA-CHAIN; BINDING-SPECIFICITY; REGULATORY SUBUNIT; KINASE P56LCK; CD3 COMPLEX; ZAP-70 BIND	T cell receptor signaling results both in T cell. proliferation and apoptosis. A key enzyme at the intersection of these downstream pathways is phosphatidylinositol 3'-kinase (PIS-kinase). In a previous report, we showed that the p85 alpha subunit of the PI 3-kinase preferentially associated with the CD3-zeta membrane-proximal immuno-receptor tyrosine-based activation motif of the zeta chain (zeta A-ITAM) (Exley, M., Varticovski, L., Peter, M., Sancho, J., and Terhorst, C. (1994) J. Biol. Chem. 269, 15140-15146). Here, we demonstrate that tyrosine phosphoryl ation of CD3-epsilon can recruit the PI 3-kinase enzyme in a T cell activation-dependent manner. In vivo studies with Jurkat cells stably transfected with a CD8-CD3-epsilon chimera (termed CD8-epsilon) shows that ligation of endogenous CD3-epsilon or CD8-epsilon by specific antibodies induces tyrosine phosphorylation of CD3-epsilon or CD8-epsilon, respectively. Increased tyrosine phosphorylation correlates with increased binding of p85 alpha PI S-kinase and recruitment of PI S-kinase enzymatic activity to CD3-epsilon or CD8-epsilon proteins. Mutagenesis studies in COS-7 cells, transiently transfected with CD8-epsilon, p85 alpha, and Fyn cDNAs in various combinations, show that both Tyr(170) and Tyr(181) within the CD3-epsilon-ITAM are required for efficient binding of p85 alpha PI 3-kinase. Thus, replacement of Tyr(170) by Phe (Y170F), or Tyr(181) by Phe (Y181F) significantly reduces binding of p85 alpha PI 3-kinase, whereas it does not affect binding of Fyn. Further in vitro experiments suggest that a direct binding of the tandem SH2 domains of p85 alpha PI 3-kinase to the two phosphorylated tyrosines in a single CD3-epsilon-ITAM may occur, The data also support a model in which a single CD3 subunit can recruit distinct effector molecules by means of TCR-mediated differential ITAM phosphorylation.	CSIC, INST PARASITOL & BIOMED, GRANADA 18001, SPAIN; HARVARD UNIV, SCH MED, BETH ISRAEL DEACONESS MED CTR, DIV IMMUNOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02215 USA; CHINESE ACAD MED SCI, INST BASIC MED SCI, DEPT BIOCHEM & MOL BIOL, BEIJING 10005, PEOPLES R CHINA; TUFTS UNIV, ST ELIZABETHS HOSP, SCH MED, DEPT BIOMED RES, BOSTON, MA 02135 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Chinese Academy of Medical Sciences - Peking Union Medical College; Tufts University			Sancho, Jaime/O-3228-2013; Sancho, Jaime/K-5989-2019	Sancho, Jaime/0000-0003-3852-7951; Sancho, Jaime/0000-0003-3852-7951; Varticovski, Lyuba/0000-0002-5105-9008; Exley, Mark/0000-0002-5088-1032	NCI NIH HHS [CA 53094] Funding Source: Medline; NIAID NIH HHS [AI-15066] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053094, R01CA053094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI015066, R01AI015066] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATHERTON E, 1975, J AM CHEM SOC, V97, P6584, DOI 10.1021/ja00855a053; AUSUBEL FM, 1995, CURRENT PROTOCOLS S, V17, P16131; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CAMBIER JC, 1995, IMMUNOL LETT, V44, P77, DOI 10.1016/0165-2478(94)00196-X; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; EXLEY M, 1994, J BIOL CHEM, V269, P15140; Exley M, 1991, Semin Immunol, V3, P283; FRY MJ, 1992, BIOCHEM J, V288, P383, DOI 10.1042/bj2880383; GOLD DP, 1987, P NATL ACAD SCI USA, V84, P7649, DOI 10.1073/pnas.84.21.7649; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HOWARD FD, 1992, J EXP MED, V176, P139, DOI 10.1084/jem.176.1.139; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; Osman N, 1996, EUR J IMMUNOL, V26, P1063, DOI 10.1002/eji.1830260516; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANCHO J, 1993, EUR J IMMUNOL, V23, P1636, DOI 10.1002/eji.1830230736; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; SUSA M, 1992, J BIOL CHEM, V267, P22951; TIMSONGAUEN LK, 1994, MOL CELL BIOL, V14, P3729; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YOAKIM M, 1994, MOL CELL BIOL, V14, P5929, DOI 10.1128/MCB.14.9.5929; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25310	25318		10.1074/jbc.272.40.25310	http://dx.doi.org/10.1074/jbc.272.40.25310			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312149	hybrid			2022-12-25	WOS:A1997XY97000088
J	Kato, Y; Matsui, T; Tanaka, N; Muneyuki, E; Hisabori, T; Yoshida, M				Kato, Y; Matsui, T; Tanaka, N; Muneyuki, E; Hisabori, T; Yoshida, M			Thermophilic F-1-ATPase is activated without dissociation of an endogenous inhibitor, epsilon subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; APPARENT NEGATIVE COOPERATIVITY; COUPLING FACTOR-I; ADENOSINE-TRIPHOSPHATASE; ATP SYNTHASE; CATALYTIC SITE; GAMMA-SUBUNIT; DELTA-SUBUNIT; BACTERIUM PS3; BETA-SUBUNIT	Subunit complexes (alpha(3) beta(3) gamma, alpha(3) beta(3) gamma delta, alpha(3) beta(3) gamma epsilon, and alpha(3) beta(3) gamma delta epsilon) of thermophilic F-1-ATPase were prepared, and their catalytic properties were compared to know the role of delta and epsilon subunits in catalysis. The presence of delta subunit in the complexes had slight inhibitory effect on the ATPase activity, The effect of epsilon subunit was more profound, The (-epsilon) complexes, alpha(3) beta(3) gamma and alpha(3) beta(3) gamma delta, initiated ATP hydrolysis without a lag. In contrast, the (+epsilon) complexes, alpha(3) beta(3) gamma epsilon and alpha(3) beta(3) gamma delta epsilon, started hydrolysis of ATP (<700 mu M) with a lag phase that was gradually activated during catalytic turnover. As ATP concentration increased, the lag phase of the (+epsilon) complexes became shorter, and it was not observed above 1 mM ATP, Analysis of binding and hydrolysis of the ATP analog, 2',3'-O-(2,4,6-trinitrophenyl) ATP, suggested that the (+epsilon) complexes bound substrate only slowly. Differing from Escherichia coli F-1-ATPase, the activation of the (+epsilon) complexes from the lag phase was not due to dissociation of epsilon subunit since the re-isolated activated complex retained epsilon subunit. This indicates that there are two alternative forms of the (+epsilon) complex, inhibited form and activated form, and the inhibited one is converted to the activated one during catalytic turnover.	TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, YOKOHAMA, KANAGAWA 226, JAPAN	Tokyo Institute of Technology			Hisabori, Toru/E-5205-2014	Hisabori, Toru/0000-0003-2046-0277				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; DATE T, 1990, GENE, V90, P141, DOI 10.1016/0378-1119(90)90450-6; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1980, J BIOL CHEM, V255, P6891; DUNN SD, 1990, BIOCHEMISTRY-US, V29, P4335, DOI 10.1021/bi00470a011; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HASHIMOTO T, 1996, SEIKAGAKU, V68, pP775; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HISABORI T, 1992, J BIOL CHEM, V267, P4551; Hisabori T, 1997, EUR J BIOCHEM, V247, P1158, DOI 10.1111/j.1432-1033.1997.01158.x; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; JAULT JM, 1993, J BIOL CHEM, V268, P1558; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; NALIN CM, 1984, J BIOL CHEM, V259, P7275; NELSON N, 1972, J BIOL CHEM, V247, P7657; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P126, DOI 10.1021/bi00167a016; RICHTER ML, 1984, J BIOL CHEM, V259, P7371; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SAIKA K, 1995, FEBS LETT, V368, P207, DOI 10.1016/0014-5793(95)00644-O; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; SOTEROPOULOS P, 1994, J BIOL CHEM, V269, P19810; SRERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526; Stiggall D L, 1979, Methods Enzymol, V55, P308; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; TOZAWA K, 1992, J BIOL CHEM, V267, P16484; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; XIAO R, 1994, J BIOL CHEM, V269, P19232; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOHDA M, 1987, J BIOCHEM-TOKYO, V102, P875, DOI 10.1093/oxfordjournals.jbchem.a122128; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1977, P NATL ACAD SCI USA, V74, P936, DOI 10.1073/pnas.74.3.936; YOSHIDA M, 1979, J BIOL CHEM, V254, P9525; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	65	58	59	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24906	24912		10.1074/jbc.272.40.24906	http://dx.doi.org/10.1074/jbc.272.40.24906			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312092	hybrid			2022-12-25	WOS:A1997XY97000031
J	Little, SP; Dixon, EP; Norris, F; Buckley, W; Becker, GW; Johnson, M; Dobbins, JR; Wyrick, T; Miller, JR; MacKellar, W; Hepburn, D; Corvalan, J; McClure, D; Liu, XD; Stephenson, D; Clemens, J; Johnstone, EM				Little, SP; Dixon, EP; Norris, F; Buckley, W; Becker, GW; Johnson, M; Dobbins, JR; Wyrick, T; Miller, JR; MacKellar, W; Hepburn, D; Corvalan, J; McClure, D; Liu, XD; Stephenson, D; Clemens, J; Johnstone, EM			Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE SPECIFIC ANTIGEN; BETA-PROTEIN; PRECURSOR PROTEIN; KALLIKREIN GENES; N-TERMINUS; RAT-BRAIN; PEPTIDE; IDENTIFICATION; DNA; GENERATION	The deposition of the beta amyloid peptide in neuritic plaques and cerebral blood vessels is a hallmark of Alzheimer's disease (AD) pathology, The major component of the amyloid deposit is a 4.2-kDa polypeptide termed amyloid beta-protein of 39-43 residues, which is derived from processing of a larger amyloid precursor protein (APP). It is hypothesized that a chymotrypsin-like enzyme is involved in the processing of APP. We have discovered a new serine protease from the AD brain by polymerase chain reaction amplification of DNA sequences representing active site homologous regions of chymotrypsin-like enzymes, A cDNA clone was identified as one out of one million that encodes Zyme, a serine protease, Messenger RNA encoding Zyme can be detected in some mammalian species but not in mice, rats, or hamster, Zyme is expressed predominantly in brain, kidney, and salivary gland, Zyme mRNA cannot be detected in fetal brain but is seen in adult brain, The Zyme gene maps to chromosome 19q13.3, a region which shows genetic linkage with late onset familial Alzheimer's disease. When Zyme cDNA is co expressed with the APP cDNA in 293 (human embryonic kidney) cells, amyloidogenic fragments are detected using C-terminal antibody to APP, These co-transfected cells release an abundance of truncated amyloid beta-protein peptide and shows a reduction of residues 17-42 of A beta (P3) peptide, Zyme is immunolocalized to perivascular cells in monkey cortex and the AD brain, In addition, Zyme is localized to microglial cells in our AD brain sample, The amyloidogenic potential and localization in brain may indicate a role for this protease in amyloid precursor processing and AD.	LILLY RES LABS,TECHNOL CORE RES,INDIANAPOLIS,IN 46285; LILLY RES LABS,CANC RES,INDIANAPOLIS,IN 46285; LILLY RES LABS,ENDOCRINE RES,INDIANAPOLIS,IN 46285	Eli Lilly; Eli Lilly; Eli Lilly	Little, SP (corresponding author), LILLY RES LABS,CENT NERVOUS SYST RES,INDIANAPOLIS,IN 46285, USA.							ABRAHAM CR, 1991, BIOCHEM BIOPH RES CO, V174, P790, DOI 10.1016/0006-291X(91)91487-W; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P561; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; EAKIN AE, 1990, MOL BIOCHEM PARASIT, V39, P1, DOI 10.1016/0166-6851(90)90002-4; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Genetic Computer Group, 1994, PROGR MAN WISC PACK; Gerard G.F., 1989, FOCUS, V11, P66; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOWING E, 1994, J BIOL CHEM, V269, P10987; HENTTU P, 1989, BIOCHEM BIOPH RES CO, V160, P903, DOI 10.1016/0006-291X(89)92520-5; Higgins LS, 1996, AM J PATHOL, V149, P585; JOHNSTONE EM, 1994, NEUROSCI LETT, V180, P151, DOI 10.1016/0304-3940(94)90509-6; KANG J, 1992, GENE, V110, P181, DOI 10.1016/0378-1119(92)90646-7; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LITTLE SP, 1995, J CELL BIOCH B S, V21, P105; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; NELSON RB, 1990, J BIOL CHEM, V265, P3836; NELSON RB, 1993, J NEUROCHEM, V61, P567; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; RICHARDS RI, 1991, GENOMICS, V11, P77, DOI 10.1016/0888-7543(91)90103-L; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SAHASRABUDHE SR, 1993, J BIOL CHEM, V268, P16699; Sambrook J., 2002, MOL CLONING LAB MANU; SCHENK DB, 1995, J MED CHEM, V38, P4141, DOI 10.1021/jm00021a001; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K; WISNIEWSKI HM, 1993, ACTA NEUROPATHOL, V85, P586, DOI 10.1007/BF00334667; YU CE, 1994, AM J HUM GENET, V54, P631	36	146	157	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25135	25142		10.1074/jbc.272.40.25135	http://dx.doi.org/10.1074/jbc.272.40.25135			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312124	hybrid			2022-12-25	WOS:A1997XY97000063
J	Shimozaki, K; Nakajima, K; Hirano, T; Nagata, S				Shimozaki, K; Nakajima, K; Hirano, T; Nagata, S			Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-RECEPTOR; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; NUCLEOTIDE-SEQUENCE; CYTOPLASMIC REGION; GROWTH-FACTORS; ACTIVATION; PROLIFERATION; SUPPRESSION; APOPTOSIS	Granulocyte colony-stimulating factor (G-CSF) stimulates proliferation and differentiation of the progenitor cells of neutrophilic granulocytes. The binding of G-CSF to its receptor specifically activates JAK1 and JAK2 kinases as well as STAT3, a signal transducer and activator of transcription (STAT), To examine the role of STAT3 in G-CSF receptor-mediated signal transduction, two different forms of the dominant negative STAT3 were introduced into a mouse myeloid cell line that exogenously expresses the mouse G-CSF receptor, In response to G-CSF, the parental myeloid cells grew for about 4 days, and then they stopped dividing and differentiated into cells with lobulated nuclei, During this period, the expression of the myeloperoxidase (MPO) gene was induced, while c-myc gene expression was down-regulated. In contrast, in the cells expressing the dominant negative STAT3, G-CSF could induce neither growth arrest nor morphological change, However, the induction of the MPO gene by G-CSF was not affected by the dominant negative STAT3, These results indicate that STAT3 activation is responsible for part of the G-CSF-induced differentiation of neutrophils but that another pathway, involving the expression of the MPO gene, that does not utilize the activated STAT3, is also required to fully differentiate the cells.	OSAKA UNIV,SCH MED,DEPT GENET,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,DIV MOL ONCOL,SUITA,OSAKA 565,JAPAN; OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Hirano, Toshio/C-8194-2009; Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRY JL, 1987, SCIENCE, V236, P1229; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; deKoning JP, 1996, BLOOD, V87, P132; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DEMETRI GD, 1991, BLOOD, V78, P2791; DONG F, 1995, BLOOD, V85, P902, DOI 10.1182/blood.V85.4.902.bloodjournal854902; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FEGAN CD, 1995, BRIT J HAEMATOL, V90, P486, DOI 10.1111/j.1365-2141.1995.tb05183.x; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KORN A P, 1973, Experimental Hematology (Charlottesville), V1, P362; LIESCHKE GJ, 1994, BLOOD, V84, P1737; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NAGATA S, 1994, CYTOKINE HDB, P371; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Rodel JE, 1996, BLOOD, V87, P858, DOI 10.1182/blood.V87.3.858.bloodjournal873858; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TIAN SS, 1994, BLOOD, V84, P1760; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VENTURELLI D, 1989, NUCLEIC ACIDS RES, V17, P5852, DOI 10.1093/nar/17.14.5852; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	47	150	155	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25184	25189		10.1074/jbc.272.40.25184	http://dx.doi.org/10.1074/jbc.272.40.25184			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312131	hybrid			2022-12-25	WOS:A1997XY97000070
J	Visser, M; Sijmons, C; Bras, J; Arceci, RJ; Godfried, M; Valentijn, LJ; Voute, PA; Baas, F				Visser, M; Sijmons, C; Bras, J; Arceci, RJ; Godfried, M; Valentijn, LJ; Voute, PA; Baas, F			Allelotype of pediatric rhabdomyosarcoma	ONCOGENE			English	Article						RMS; Rhabdomyosarcoma; alleotype; TSG, Tumor Suppressor Gene; LOH, loss of heterozygosity; SRD	TUMOR ALVEOLAR RHABDOMYOSARCOMA; BECKWITH-WIEDEMANN SYNDROME; DEPENDENT KINASE INHIBITOR; HUMAN P57(KIP2) GENE; GROWTH-FACTOR-II; WILMS-TUMORS; HEPATOCELLULAR-CARCINOMA; SUPPRESSOR GENE; ALLELIC LOSS; HETEROZYGOSITY	An allelotype covering all autosomes was constructed for the embryonal form of childhood rhabdomyosarcoma (ERMS) in order to identify regions encompassing tumorsuppressor genes (TSG) involved in ERMS. Thusfar most studies were focussed on chromosome 11p15.5,which frequently shows loss of heterozygozity (LOH) in embryonal tumors like RMS and Wilms' tumor (WT). In this study we show that, besides LOH of chromosome 11p15.5 (72%), LOH of chromosome 16q was present in 54% of the tumors analysed. Delineation of these two regions shows that the smallest region of overlap (SRO) for chromosome 11 was between D11S988 and D11S922. This region, estimated to be 7 cM and 3-5 Mb, is also the location of the putative Wilms' tumor WT2 TSG. It contains several genes including IGF2 and potential tumorsuppressor genes like H19 and p57(kip2), which might contribute to the carcinogenesis of RMS. Analysis of chromosome 16q LOH defined the SRO between D16S752 and D16S413. LOH of chromosome 16 is also found in other tumors, including WT. Our data suggest that genes involved in the development of RMS and WT may not only be similar for chromosome 11 but also for chromosome 16.	ACAD MED CTR,DEPT PEDIAT ONCOL,NL-1100 DE AMSTERDAM,NETHERLANDS; ACAD MED CTR,NEUROZINTUIGEN LAB,NL-1100 DE AMSTERDAM,NETHERLANDS; ACAD MED CTR,DEPT PATHOL,NL-1100 DE AMSTERDAM,NETHERLANDS; CHILDRENS HOSP,MED CTR,DEPT PEDIAT,DIV HEMATOL & ONCOL,CINCINNATI,OH 45229; CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation			Baas, Frank/F-9574-2010	Baas, Frank/0000-0003-3912-5428				AGAMANOLIS DP, 1986, HUM PATHOL, V17, P778, DOI 10.1016/S0046-8177(86)80198-8; AUSTRUY E, 1995, GENE CHROMOSOME CANC, V14, P285, DOI 10.1002/gcc.2870140407; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAVIS RJ, 1994, CANCER RES, V54, P2869; FUJIMORI M, 1991, CANCER RES, V51, P89; GAIGER AM, 1981, NATL CANCER I MONOGR, V56, P19; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GRUNDY PE, 1994, CANCER RES, V54, P2331; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; Hoovers JMN, 1995, P NATL ACAD SCI USA, V92, P12456, DOI 10.1073/pnas.92.26.12456; KNOWLES MA, 1994, CANCER RES, V54, P531; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MAW MA, 1992, CANCER RES, V52, P3094; NEWSHAM I, 1994, GENOMICS, V19, P433, DOI 10.1006/geno.1994.1091; NEWSHAM I, 1995, GENE CHROMOSOME CANC, V12, P1, DOI 10.1002/gcc.2870120102; Orlow I, 1996, CANCER RES, V56, P1219; PAPPO AS, 1995, J CLIN ONCOL, V13, P2123, DOI 10.1200/JCO.1995.13.8.2123; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Reid LH, 1996, HUM MOL GENET, V5, P239, DOI 10.1093/hmg/5.2.239; Reid LH, 1996, CANCER RES, V56, P1214; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; TSUDA H, 1994, CANCER RES, V54, P513; Visser M, 1996, P NATL ACAD SCI USA, V93, P9172, DOI 10.1073/pnas.93.17.9172; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WeberHall SR, 1996, CANCER RES, V56, P3220; WINQVIST R, 1993, CANCER RES, V53, P4486; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	41	82	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1309	1314		10.1038/sj.onc.1201302	http://dx.doi.org/10.1038/sj.onc.1201302			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315099				2022-12-25	WOS:A1997XV84500009
J	Kawaguchi, T; Qin, L; Shimomura, T; Kondo, J; Matsumoto, K; Denda, K; Kitamura, N				Kawaguchi, T; Qin, L; Shimomura, T; Kondo, J; Matsumoto, K; Denda, K; Kitamura, N			Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MESSENGER-RNA; MOLECULAR-CLONING; CDNA; GLYCOSYLATION; SIMILARITY; MITOGEN; DOMAINS; CELLS	Hepatocyte growth factor (HGF) activator is a serine protease responsible for proteolytic activation of HGF in response to tissue injury and thus plays an important role in the regulation of biological functions of HGF in regenerating tissue, We previously purified an inhibitor of HGF activator (HGF activator inhibitor type 1, HAI-1) from the conditioned medium of a human stomach carcinoma cell line MKN45 and cloned its cDNA, HAI-1 is a novel member of the Kunitz family of serine protease inhibitors, In the present study, we purified a second type of HGF activator inhibitor (HAI-2) from the conditioned medium of MKN45 cells and molecularly cloned its cDNk The cDNA sequence revealed that HAI-2 is derived from a precursor protein of 252 amino acids and contains two Kunitz domains, indicating that HAI-2 is also a member of the Kunitz family of serine protease inhibitors, The primary translation product of HAI-S has a hydrophobic sequence in the COOH-terminal region, suggesting that, like HAI-1, HAI-2 is produced in a membrane-associated form and secreted in a proteolytically truncated form, Because HAI-2 and HAI-1 are potent inhibitors specific for HGF activator, they may be involved in regulation of proteolytic activation of HGF in injured tissues.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; MITSUBISHI CHEM CORP,YOKOHAMA RES CTR,YOKOHAMA,KANAGAWA 227,JAPAN	Tokyo Institute of Technology; Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical								BIELINSKA M, 1989, J BIOL CHEM, V264, P17113; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; DUBE S, 1988, J BIOL CHEM, V263, P17516; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; KATAOKA H, 1989, VIRCHOWS ARCH B, V57, P157, DOI 10.1007/BF02899077; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MURAYAMA T, 1991, VIRCHOWS ARCH B, V60, P263, DOI 10.1007/BF02899556; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; Okajima A, 1997, HEPATOLOGY, V25, P97, DOI 10.1002/hep.510250118; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAILER JP, 1990, TRENDS BIOCHEM SCI, V15, P435; SAITO F, 1995, BIOCHEM BIOPH RES CO, V210, P703, DOI 10.1006/bbrc.1995.1716; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; SINHA S, 1990, J BIOL CHEM, V265, P8983; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; WEST CM, 1986, MOL CELL BIOCHEM, V72, P3; WUN TC, 1988, J BIOL CHEM, V263, P6001	28	166	182	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27558	27564		10.1074/jbc.272.44.27558	http://dx.doi.org/10.1074/jbc.272.44.27558			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346890	hybrid			2022-12-25	WOS:A1997YD47300016
J	Sanchez, X; CousinsHodges, B; Aguilar, T; Gosselink, P; Lu, ZJ; Navarro, J				Sanchez, X; CousinsHodges, B; Aguilar, T; Gosselink, P; Lu, ZJ; Navarro, J			Activation of HIV-1 coreceptor (CXCR4) mediates myelosuppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; LYMPHOCYTE CHEMOATTRACTANT; CLONING; CHEMOKINES; RECEPTOR; SDF-1; 7-TRANSMEMBRANE; INTERLEUKIN-8; PROLIFERATION; LESTR/FUSIN	Chemokines are cytokines that activate and induce the migration of leukocytes. Stroma-derived factor-1 (SDF-1) is a novel chemokine that blocks the entry of T-tropic HIV-1 mediated by fusin/CXCR4/LESTR (leukocyte-derived seven-transmembrane domain receptor). In this work we demonstrate that SDF-1 triggers increases in intracellular calcium and inhibits the proliferation of myeloid progenitor cell line 32D. By contrast, SDF-1 neither triggers a calcium response nor affects the proliferation of the myeloid progenitor cell line 32D GR that is deficient in CXCR4. Responsiveness to SDF-1 was rescued by transfection of 32D-GR cells with a cDNA encoding the human CXCR4. The data indicate that SDF-1 induces myelosuppression by activation of CXCR4. The constitutive production of SDF-1 by bone marrow stromal cells argues for a major role of SDF-1 on the regulation of myelopoiesis.	UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,SEALY CTR MOL SCI,GALVESTON,TX 77555; GENET INST INC,CAMBRIDGE,MA 02140	University of Texas System; University of Texas Medical Branch Galveston				Navarro, Javier/0000-0001-7098-4373	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034031] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 34031] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; BROXMEYER HE, 1995, ANN HEMATOL, V71, P235, DOI 10.1007/s002770050112; BROXMEYER HE, 1993, J IMMUNOL, V150, P3448; DALY TJ, 1995, J BIOL CHEM, V270, P23282, DOI 10.1074/jbc.270.40.23282; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Lu ZJ, 1996, J BIOL CHEM, V271, P5059; METCALF D, 1985, BLOOD, V65, P357; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OTHA M, 1989, PATHOL IMMUNOPATH R, V8, P1; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535	22	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27529	27531		10.1074/jbc.272.44.27529	http://dx.doi.org/10.1074/jbc.272.44.27529			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346884	hybrid			2022-12-25	WOS:A1997YD47300010
J	Komissarov, AA; Marchbank, MT; Calcutt, MJ; Quinn, TP; Deutscher, SL				Komissarov, AA; Marchbank, MT; Calcutt, MJ; Quinn, TP; Deutscher, SL			Site-specific mutagenesis of a recombinant anti-single-stranded DNA Fab - Role of heavy chain complementarity-determining region 3 residues in antigen interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE DISPLAY LIBRARIES; 3-DIMENSIONAL STRUCTURE; NUCLEIC-ACIDS; ACTIVE-SITE; BINDING; ANTIBODIES; AUTOANTIBODY; AFFINITY; PROTEIN; CONSTRUCTION	The heavy chain complementarity-determining region 3 (HCDR3) of the anti-oligo(dT) recombinant antibody fragment, DNA-1, contributes significantly to antigen binding (Komissarov, A. A., Calcutt, M. J., Marchbank, M. T., Peletskaya, E. N., and Deutscher, S. L. (1996) J. Biol, Chem, 271, 12241-12246), in the present study, the role of separate HCDR3 residues of DNA-1 in interaction with oligo(dT) was elucidated. Based on a molecular model of the combining site, residues at the base (Arg(98) and Asp(108)) and in the middle (Tyr(101)-Arg-Pro-Tyr-Tyr(105)) Of HCDR3 were predicted to support the loop conformation and directly contact the ligand, respectively. Twenty-five site-specific mutants were produced as hexahistidine-tagged proteins, purified, and examined for binding to (dT)(15) using two independent methods, All mutations in the middle of HCDR3 led to either abolished or diminished affinity, Tyr(101) likely participates in hydrogen bonding, while Tyr(104) and Tyr(105) may be involved in aromatic-aromatic interactions with the ligand. The residues Arg(102) and Pro(103) were not as critical as the tyrosines. It is speculated that HCDR3 interacts with the thymines, rather than the phosphates, of the ligand. A 3-fold increase in affinity was observed by mutation of Asp(108) to alanine. The highly conserved Arg(98) and Asp(108) do not appear to form a salt bridge.	UNIV MISSOURI,SCH MED,DEPT BIOCHEM,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047979] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-47979] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; BARBAS SM, 1995, P NATL ACAD SCI USA, V92, P2529, DOI 10.1073/pnas.92.7.2529; BRUMMELL DA, 1993, BIOCHEMISTRY-US, V32, P1180, DOI 10.1021/bi00055a024; CALCUTT MJ, 1993, GENE, V137, P77, DOI 10.1016/0378-1119(93)90254-Z; Calcutt MJ, 1996, GENE, V168, P9, DOI 10.1016/0378-1119(95)00717-2; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CHIEN NC, 1989, P NATL ACAD SCI USA, V86, P5532, DOI 10.1073/pnas.86.14.5532; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; COLLET TA, 1992, P NATL ACAD SCI USA, V89, P10026, DOI 10.1073/pnas.89.21.10026; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; Deutscher SL, 1996, ARCH BIOCHEM BIOPHYS, V333, P207, DOI 10.1006/abbi.1996.0382; EIGENBROT C, 1993, J MOL BIOL, V229, P969, DOI 10.1006/jmbi.1993.1099; EILAT D, 1994, MOL IMMUNOL, V31, P1377, DOI 10.1016/0161-5890(94)90154-6; GULLIVER GA, 1994, J BIOL CHEM, V269, P7934; GULLIVER GA, 1995, BIOCHEMISTRY-US, V34, P5158, DOI 10.1021/bi00015a029; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; Higuchi R., 1990, PCR PROTOCOLS GUIDE; Hoffman RW, 1995, ARTHRITIS RHEUM-US, V38, P1837, DOI 10.1002/art.1780381218; HOROVITZ A, 1987, J MOL BIOL, V196, P733, DOI 10.1016/0022-2836(87)90045-3; JACKSON JR, 1995, J IMMUNOL, V154, P3310; KABAT EA, 1989, P NATL ACAD SCI USA, V85, P6885; Komissarov AA, 1997, ANAL BIOCHEM, V247, P123, DOI 10.1006/abio.1997.2051; Komissarov AA, 1996, J BIOL CHEM, V271, P12241, DOI 10.1074/jbc.271.21.12241; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; MARION TN, 1992, IMMUNOL REV, V128, P123, DOI 10.1111/j.1600-065X.1992.tb00835.x; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; NOVOTNY J, 1990, PROTEINS, V7, P93, DOI 10.1002/prot.340070109; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PANKA DJ, 1988, P NATL ACAD SCI USA, V85, P3080, DOI 10.1073/pnas.85.9.3080; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PEWZNERJUNG Y, 1996, J IMMUNOL, V154, P2198; PISETSKY DS, 1990, ARTHRITIS RHEUM, V33, P153, DOI 10.1002/art.1780330202; POLYMENIS M, 1995, J IMMUNOL, V156, P3065; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; RUMBLEY CA, 1993, J BIOL CHEM, V268, P13667; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; STENZELJOHNSON PR, 1994, BIOCHEMISTRY-US, V33, P14400, DOI 10.1021/bi00252a005; STOLLAR BD, 1994, FASEB J, V8, P337, DOI 10.1096/fasebj.8.3.7511550; STOLLAR BD, 1986, CRC CRIT REV BIOCH, V21, P1; TAN EM, 1989, ADV IMMUNOL, V44, P93; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551	46	13	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26864	26870		10.1074/jbc.272.43.26864	http://dx.doi.org/10.1074/jbc.272.43.26864			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341118	hybrid			2022-12-25	WOS:A1997YC65900014
J	Loudon, RP; Benovic, JL				Loudon, RP; Benovic, JL			Altered activity of palmitoylation-deficient and isoprenylated forms of the G protein-coupled receptor kinase GRK6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; LIGHT-DEPENDENT PHOSPHORYLATION; HETEROTRIMERIC G-PROTEINS; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; RHODOPSIN KINASE; ACTIVATION; FAMILY; IDENTIFICATION; DESENSITIZATION	G protein-coupled receptor kinases (GRKs) utilize diverse mechanisms to associate with the plasma membrane and mediate phosphorylation of agonist-occupied receptors, For example, two members of this family, GRK4 and CRK6, contain C-terminal cysteine residues that are palmitoylated, To address whether the activity and membrane association of GRK6 is regulated by palmitoylation, we overexpressed and characterized wild-type GRK6 and two GRK6 mutants, one with the palmitoylation sites mutated to serines (GRK6-pal(-)) and one containing a C-terminal CAAX motif to promote geranylgeranylation (GRK6-GG). Compared with wildtype GRK6, GRK6-pal(-) had a similar to 5-fold higher K-m and similar to 2-fold lower V-max for phosphorylating rhodopsin, whereas GRRG-GG exhibited a similar to 2-fold lower K, and similar to 14-fold higher V-max for rhodopsin, In contrast, wildtype GRR6 and GRK6-pal(-) displayed similar activity toward the nonreceptor substrate phosvitin, indicating that nonpalmitoylated GRK6 is catalytically active, Wild-type GRK6 and GRK6-GG, but not GRK6-pal(-), also bound significantly to phosphatidylcholine vesicles (36 +/- 3, 79 +/- 4, and 4 +/- 2%, respectively) suggesting that GRK6 activity is dependent upon its ability to interact with the plasma membrane, When assayed in COS-1 cells GRK6-pal(-) promoted minimal agonist-dependent sequestration of the beta(2)-adrenergic receptor, while sequestration was significantly increased in cells expressing either wild-type GRKG or GRK6-GG. These data demonstrate an important functional Link between the ability of GRK6 to bind to the plasma membrane, a process that appears to be regulated by palmitoylation, and its activity toward receptor substrates.	THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; GOMEZ J, 1992, MOL BIOL RECEPTORS T, P1; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAGA K, 1992, J BIOL CHEM, V267, P2222; HARGRAVE PA, 1992, MOL BIOL RECEPTORS T, P49; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KIM CM, 1993, J BIOL CHEM, V268, P15412; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUHN H, 1973, BIOCHEMISTRY-US, V12, P2495; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; Loudon RP, 1996, BLOOD, V88, P4547, DOI 10.1182/blood.V88.12.4547.bloodjournal88124547; LUODON RP, 1994, J BIOL CHEM, V269, P22691; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	37	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27422	27427		10.1074/jbc.272.43.27422	http://dx.doi.org/10.1074/jbc.272.43.27422			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341194	hybrid			2022-12-25	WOS:A1997YC65900090
J	Martincic, I; Peralta, ME; Ngsee, JK				Martincic, I; Peralta, ME; Ngsee, JK			Isolation and characterization of a dual prenylated Rab and VAMP2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SYNAPTIC VESICLES; 2-HYBRID SYSTEM; GERANYLGERANYL TRANSFERASE; CA2+-DEPENDENT EXOCYTOSIS; FUNCTIONAL INTERACTION; ENDOPLASMIC-RETICULUM; TARGETING SIGNAL; N-TYPE; YEAST	Rab GTPases have been implicated in intracellular vesicle trafficking. Using the yeast two-hybrid screen, we have isolated a rat clone that interacts with Rab3A as well as with Rab1. The gene encodes a 20.6-kDa protein with two extensive hydrophobic domains and is broadly expressed in all tissues. This protein binds to prenylated Rab GTPases but not to other small Ras like GTPases such as the Rho/Rac family. This prenylated Rab acceptor (PRA1) also binds specifically to the synaptic vesicle protein VAMPS (or synaptobrevin II) but shows no affinity for VAMP1 or cellubrevin in both the yeast two-hybrid system and in vitro binding assays. This specificity resides, in part, in the proline-rich domain of VAMPS as a chimera containing this domain of VAMPS fused to VAMP1 is able to bind to PRA1. The transmembrane domain of VAMPS is also essential as its deletion abolished binding to PRA1. Replacement of the deleted VAMPS transmembrane domain by a CAAX prenylation signal can not restore binding to PRA1. This interaction is therefore distinct from that required for VAMPS binding to either syntaxin or both syntaxin and SNAP-25, Deletion analysis on PRA1 indicates that the critical Rab-and VAMP2-interacting residues reside in two regions: the amino-terminal residues 30-54 and the extreme carboxyl-terminal domain. This dual Rab and VAMPS binding characteristic suggests that PRA1 may serve to link these two protein families in the control of vesicle docking and fusion.	UNIV OTTAWA,LOEB RES INST,DEPT MED & BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; Ottawa Hospital Research Institute								ANDRES DA, 1993, J BIOL CHEM, V268, P1383; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Grote E, 1996, J CELL BIOL, V132, P537, DOI 10.1083/jcb.132.4.537; Hao JC, 1997, J NEUROSCI, V17, P1596; HARPER JW, 1993, CELL, V75, P805; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MIYAZAKI A, 1994, FEBS LETT, V350, P333, DOI 10.1016/0014-5793(94)00804-3; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; OMER CA, 1994, MOL MICROBIOL, V11, P219, DOI 10.1111/j.1365-2958.1994.tb00302.x; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Rose M, 1990, LAB COURSE MANUAL ME; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLDATI T, 1995, J BIOL CHEM, V270, P25541, DOI 10.1074/jbc.270.43.25541; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STETTLER O, 1995, EUR J NEUROSCI, V7, P702, DOI 10.1111/j.1460-9568.1995.tb00674.x; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Weber E, 1996, J BIOL CHEM, V271, P6963, DOI 10.1074/jbc.271.12.6963; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; ZHANG FL, 1994, J BIOL CHEM, V269, P3175	51	102	109	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26991	26998		10.1074/jbc.272.43.26991	http://dx.doi.org/10.1074/jbc.272.43.26991			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341137	hybrid			2022-12-25	WOS:A1997YC65900033
J	McCullough, AK; Dodson, ML; Scharer, OD; Lloyd, RS				McCullough, AK; Dodson, ML; Scharer, OD; Lloyd, RS			The role of base flipping in damage recognition and catalysis by T4 endonuclease V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URACIL-DNA GLYCOSYLASE; EXCISION-REPAIR ENZYME; NUCLEOTIDE ANALOG 2-AMINOPURINE; CRYSTAL-STRUCTURE; PYRIMIDINE DIMER; MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; KLENOW FRAGMENT; ACTIVE-SITE; MECHANISM	The process of moving a DNA base extrahelical (base flipping) has been shown in the co-crystal structure of a W-induced pyrimidine dimer-specific glycosylase, T4 endonuclease V, with its substrate DNA. Compared with other enzymes known to use base flipping, endonuclease V is unique in that it moves the base opposite the target site extrahelical, rather than moving the target base itself. Utilizing substrate analogs and catalytically inactive mutants of T4 endonuclease V, this study investigates the discrete steps involved in damage recognition by this DNA repair enzyme. Specifically, fluorescence spectroscopy analysis shows that fluorescence changes attributable to base flipping are specific for only the base directly opposite either abasic site analogs or the 5'-thymine of a pyrimidine dimer, and no changes are detected if the S-aminopurine is moved opposite the 3'-thymine of the pyrimidine dimer. Interestingly, base flipping is not detectable with every specific binding event suggesting that damage recognition can be achieved without base flipping. Thus, base flipping does not add to the stability of the specific enzyme-DNA complex but rather induces a conformational change to facilitate catalysis at the appropriate target site, When used in conjunction with structural information, these types of analyses can yield detailed mechanistic models and critical amino acid residues for extrahelical base movement as a mode of damage recognition.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	University of Texas System; University of Texas Medical Branch Galveston; Harvard University			Schärer, Orlando D./AAF-8613-2021; Scharer, Orlando/B-8908-2008	Scharer, Orlando/0000-0003-2425-2715; Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [F32 ES05780-01, R01 ES04091, P30 ES06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004091, F32ES005780, P30ES006676] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BLOOM LB, 1993, BIOCHEMISTRY-US, V32, P11247, DOI 10.1021/bi00092a039; Cheng XD, 1996, STRUCTURE, V4, P639, DOI 10.1016/S0969-2126(96)00068-8; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOI T, 1992, P NATL ACAD SCI USA, V89, P9420, DOI 10.1073/pnas.89.20.9420; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HOCHSTRASSER RA, 1994, BIOCHEMISTRY-US, V33, P11971, DOI 10.1021/bi00205a036; INAOKA T, 1989, J BIOL CHEM, V264, P2609; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P258; LATHAM KA, 1994, DNA DAMAGE, P181; Law SM, 1996, BIOCHEMISTRY-US, V35, P12329, DOI 10.1021/bi9614545; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; Marquez LA, 1996, J BIOL CHEM, V271, P28903, DOI 10.1074/jbc.271.46.28903; McCullough AK, 1996, J BIOL CHEM, V271, P32147, DOI 10.1074/jbc.271.50.32147; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MORIKAWA K, 1995, J MOL BIOL, V249, P360, DOI 10.1006/jmbi.1995.0302; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PRINCE MA, 1991, J BIOL CHEM, V266, P10686; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; Sastry SS, 1996, BIOCHEMISTRY-US, V35, P15715, DOI 10.1021/bi960729d; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SCHARER OD, 1995, J AM CHEM SOC, V117, P6623, DOI 10.1021/ja00129a039; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; Vassylyev DG, 1997, CURR OPIN STRUC BIOL, V7, P103, DOI 10.1016/S0959-440X(97)80013-9; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; WARD DC, 1969, J BIOL CHEM, V244, P1228	38	61	61	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27210	27217		10.1074/jbc.272.43.27210	http://dx.doi.org/10.1074/jbc.272.43.27210			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341165	hybrid, Green Published			2022-12-25	WOS:A1997YC65900061
J	Schwarz, G; Boxer, DH; Mendel, RR				Schwarz, G; Boxer, DH; Mendel, RR			Molybdenum cofactor biosynthesis - The plant protein Cnx1 binds molybdopterin with high affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVOLVEMENT; REDUCTASE; CINNAMON; GEPHYRIN; LOCI	The molybdenum cofactor is an essential part of all eukaryotic molybdoenzymes. It is a molybdopterin (RIFT) revealing the same core structure in all organisms, The plant protein Cnx1 from Arabidopsis thaliana is involved in the multi step biosynthesis of molybdenum cofactor, Previous studies (Stallmeyer, B., Nerlich, A., Schiemann, J., Brinkmann, H., and Mendel, R, R, (1995) Plant J, 8, 751-762) suggested a function of Cnx1 in a late step of cofactor biosynthesis distal to the formation of MPT, i.e, conversion of MPT into molybdenum cofactor, Here we present the first biochemical evidences confirming this assumption, The protein Cnx1 consists of two domains (E and G) homologous to two distinct Escherichia coli proteins involved in cofactor synthesis. Binding studies with recombinantly expressed and purified Cnx1 and with its single domains revealed a high affinity of the G domain to MPT (kD = 0.1 mu M) with equimolar binding, In contrast, the E domain of Cnx1 binds MPT with lower affinity (kD = 1.6 mu M) and in a cooperative manner (n(H) = 1.5), The entire Cnx1 showed a tight and cooperative MPT binding. Based on these data providing a common link between both domains that matches the previous characterization of plant and bacterial Cnx1 homologous mutants, we present a model for the function of Cnx1.	TECH UNIV CAROLO WILHELMINA BRAUNSCHWEIG,INST BOT,D-38023 BRAUNSCHWEIG,GERMANY; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD 4HN,SCOTLAND	Braunschweig University of Technology; University of Dundee			Schwarz, Guenter/ABE-9643-2021	Schwarz, Guenter/0000-0002-2118-9338				BRAAKSMA FJ, 1973, MUTAT RES, V19, P175; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; Joshi MS, 1996, J BACTERIOL, V178, P4310, DOI 10.1128/jb.178.14.4310-4312.1996; KAMDAR KP, 1994, GENETICS, V137, P791; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; MENDEL RR, 1997, IN PRESS PLANTA; MENDEL RR, 1981, MOL GEN GENET, V18, P395; Muller A. J., 1989, Molecular and genetic aspects of nitrate assimilation., P166; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; STALLMEYER B, 1995, PLANT J, V8, P751, DOI 10.1046/j.1365-313X.1995.08050751.x; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982	15	89	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26811	26814		10.1074/jbc.272.43.26811	http://dx.doi.org/10.1074/jbc.272.43.26811			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341109	hybrid			2022-12-25	WOS:A1997YC65900005
J	Soyombo, AA; Hofmann, SL				Soyombo, AA; Hofmann, SL			Molecular cloning and expression of palmitoyl-protein thioesterase 2 (PPT2), a homolog of lysosomal palmitoyl-protein thioesterase with a distinct substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; INFANTILE TYPE; ENZYME; PURIFICATION; CDNA; SITES	Palmitoyl-protein thioesterase is a lysosomal hydrolase that, removes long chain fatty acyl groups from modified cysteine residues in proteins, Mutations in this enzyme were recently shown to underlie the hereditary neurodegenerative disorder, infantile neuronal ceroid lipofuscinosis, and lipid thioesters derived from acylated proteins were found to accumulate in lymphoblasts from individuals with the disorder. In the current study, we describe the cloning and expression of a second lysosomal thioesterase, palmitoyl-protein thioesterase 2 (PPT2), that shares an 18% identity with palmitoyl-protein thioesterase, Transient expression of a PPT2 cDNA led to the production of a glycosylated lysosomal protein with palmitoyl-CoA hydrolase activity comparable with palmitoyl-protein thioesterase, However, PPT2 did not remove palmitate groups from palmitoylated proteins that are substrates for palmitoyl-protein thioesterase, In cross-correction experiments, PPT2 did not abolish the accumulation of protein-derived lipid thioesters in palmitoyl-protein thioesterase-deficient cell lines, These results indicate that PPT2 is a lysosomal thioesterase that possesses a substrate specificity that is distinct from that of palmitoyl-protein thioesterase.	UNIV TEXAS, SW MED CTR, HAMON CTR THERAPEUT ONCOL RES, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Soyombo, Abigail/0000-0003-0850-2593	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035323] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35323] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BUTOR C, 1995, J CELL SCI, V108, P2213; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; DUNCAN JR, 1993, J NUCL MED, V34, P1728; HALTIA M, 1973, ACTA NEUROPATHOL, V26, P157, DOI 10.1007/BF00697751; HALTIA M, 1973, J NEUROL SCI, V18, P269, DOI 10.1016/0022-510X(73)90076-2; HARLOW E, 1988, ANTIBODIES LABORATOR, P61; Hellsten E, 1996, EMBO J, V15, P5240, DOI 10.1002/j.1460-2075.1996.tb00909.x; HIGA HH, 1989, J BIOL CHEM, V264, P19435; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAWSON DM, 1994, BIOCHEMISTRY-US, V33, P9382, DOI 10.1021/bi00198a003; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MORREAU H, 1989, J BIOL CHEM, V264, P20655; NAGGERT J, 1988, J BIOL CHEM, V263, P1146; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; SAMBROOK J, 1989, MOL CLONING LAB MENA; SAVUKOSKI M, 1994, AM J HUM GENET, V55, P965; SCHLESINGER MJ, 1992, LIPID MODIFICATIONS, P1; Schriner JE, 1996, GENOMICS, V34, P317, DOI 10.1006/geno.1996.0292; Sharp JD, 1997, HUM MOL GENET, V6, P591, DOI 10.1093/hmg/6.4.591; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TOLLERSRUD OK, 1989, BIOCHEM J, V260, P101, DOI 10.1042/bj2600101; Verkruyse LA, 1996, J BIOL CHEM, V271, P15831, DOI 10.1074/jbc.271.26.15831; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	33	76	79	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27456	27463		10.1074/jbc.272.43.27456	http://dx.doi.org/10.1074/jbc.272.43.27456			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341199	hybrid			2022-12-25	WOS:A1997YC65900095
J	Tagliavacca, L; Moon, N; Dunham, WR; Kaufman, RJ				Tagliavacca, L; Moon, N; Dunham, WR; Kaufman, RJ			Identification and functional requirement of Cu(I) and its ligands within coagulation factor VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER-TRANSPORTING ATPASE; PORCINE FACTOR-VIII; FACTOR-V; MAMMALIAN-CELLS; MENKES DISEASE; ISOLATED SUBUNITS; CANDIDATE GENE; PROCOAGULANT ACTIVITY; BLUE OXIDASES; CERULOPLASMIN	Coagulation factor VIII (FVIII) is a heterodimer consisting of a light chain of 80 kDa (domains A3-C1-C2) in a metal ion-dependent association with a 220-kDa heavy chain (domains A1-A2-B). The nature of the metal ion-dependent association be between the heavy and light chains was investigated using atomic absorption spectroscopy, electron paramagnetic resonance spectroscopy (EPR), and site-directed mutagenesis and expression of the FVIII cDNA, Whereas copper ion was not detected in intact recombinant FVIII, EDTA dissociation of the chains yielded an EPR signal consistent with 1 mol of Cu(I)/mol of active protein, supporting the hypothesis that a single molecule of reduced copper ion is hurled within intact FVIII and is released and oxidized upon treatment with EDTA. Cu(I), and not Cu(II), was able to reconstitute FVIII activity from dissociated chains, demonstrating a requirement for Cu(I) in FVIII function, Three potential copper ion binding sites exist within FVIII: one type-2 site and two type-1 sites. The importance of these potential copper ion ligands was tested by studying the effect of site-directed mutants. Of the two histidines that compose the type-a binding site, the His-1957 --> Ala mutant displayed secretion, light and heavy chain assembly, and activity similar to wild-type FVIII, while mutant His-99 --> Ala was partially defective for secretion and had low levels of heavy and light chain association and activity, In contrast, FVIII: having the mutation Cys-310 --> Ser within the type-1 copper binding site in the Al domain was inactive and partially defective for secretion from the cell, and the heavy and light chains of the secreted protein were not associated, Mutant Cys-2000 --> Ser within the A3 domain displayed secretion, assembly, and activity similar to that for wildtype FVIII. These results support the hypothesis that Cu(I) is buried within the type-1 copper binding site within the A1 domain and is required for FVIII chain association and activity.	UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NHLBI NIH HHS [HL52173] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; BIHOREAU N, 1994, EUR J BIOCHEM, V222, P41, DOI 10.1111/j.1432-1033.1994.tb18839.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUWER M, 1992, BIOCHEMISTRY-US, V31, P4096, DOI 10.1021/bi00131a028; CANTERS GW, 1993, FEBS LETT, V325, P39, DOI 10.1016/0014-5793(93)81410-2; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CIRIOLO MR, 1990, J BIOL CHEM, V265, P11030; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; Erlich H.A., 1989, PCR TECHNOLOGY PRINC; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FREEDMAN JH, 1989, J BIOL CHEM, V264, P5598; HUNZIKER PE, 1985, TOPICS MOL STRUCTURA, V7, P149; JENNY RJ, 1987, P NATL ACAD SCI USA, V81, P390; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MALKIN R, 1970, ADV ENZYMOL REL S BI, V33, P177; MALMSTROM BG, 1982, ANNU REV BIOCHEM, V51, P21, DOI 10.1146/annurev.bi.51.070182.000321; MANN KG, 1984, J BIOL CHEM, V259, P2949; MARQUETTE KA, 1995, J BIOL CHEM, V270, P10297, DOI 10.1074/jbc.270.17.10297; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; Musci G, 1996, J BIOL CHEM, V271, P1972, DOI 10.1074/jbc.271.4.1972; NORDFANG O, 1989, EUR J HAEMATOL, V43, P1; NORDFANG O, 1988, J BIOL CHEM, V263, P1115; PAN Y, 1995, NAT STRUCT BIOL, V2, P740, DOI 10.1038/nsb0995-740; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; Pipe SW, 1996, J BIOL CHEM, V271, P25671, DOI 10.1074/jbc.271.41.25671; PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214; PITTMAN DD, 1992, BLOOD, V79, P389; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; RYDEN L, 1982, P NATL ACAD SCI-BIOL, V79, P6767, DOI 10.1073/pnas.79.22.6767; RYDEN LG, 1993, J MOL EVOL, V36, P41, DOI 10.1007/BF02407305; SCHEINBERG IH, 1984, MAJOR PROBLEMS INT A, V22; Sudhakar K, 1996, J BIOL CHEM, V271, P23015, DOI 10.1074/jbc.271.38.23015; Swaroop M, 1997, J BIOL CHEM, V272, P24121, DOI 10.1074/jbc.272.39.24121; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P390, DOI 10.1073/pnas.81.2.390; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WISE RJ, 1991, J BIOL CHEM, V266, P21948; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018; ZATLOUKAL K, 1994, P NATL ACAD SCI USA, V91, P5148, DOI 10.1073/pnas.91.11.5148	52	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27428	27434		10.1074/jbc.272.43.27428	http://dx.doi.org/10.1074/jbc.272.43.27428			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341195	hybrid			2022-12-25	WOS:A1997YC65900091
J	Wang, D; Sul, HS				Wang, D; Sul, HS			Upstream stimulatory factor binding to the E-box at -65 is required for insulin regulation of the fatty acid synthase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; GLUCOSE RESPONSE COMPLEX; MAJOR LATE PROMOTER; PHOSPHOENOLPYRUVATE CARBOXYKINASE; GENE-EXPRESSION; HORMONAL-REGULATION; PROTEIN-KINASE; DNA; IDENTIFICATION; FAMILY	Fatty acid synthase (FAS) plays a central role in de novo lipogenesis in mammals. We have shown that FAS transcription rate is induced dramatically when fasted animals are refed with a high carbohydrate diet or when streptozotocin-diabetic mice are given insulin, We also reported that FAS gene transcription was up regulated by insulin through the proximal promoter region from -71 to -50 and that upstream stimulatory factors (USFs), including USF1 and USF2, interact with this region in vitro, In the present study, by using site-directed mutagenesis of the -71/-50 region and correlating functional assays of the mutated promoter with USF binding activities, we demonstrate that the -65/-60 E-box motif (5'-CATGTG-3') is functionally required for insulin regulation and that USFs are in vivo components of the insulin response complex, Mutation of the -65/-60 E-box sequence abolished insulin response in both transiently and stably transfected 3T3-L1 adipocytes in the -2.1 kb promoter context, which contains all the necessary regulatory elements of the promoter based on our previous transgenic mice studies, and in the minimal -67 promoter context, Gel mobility shift assays demonstrated that USFs can no longer bind to the -71/-50 promoter region when the E-box is mutated. Cotransfection of USF1 and USF2 expression vectors with the FAS promoter-luciferase reporter constructs increased insulin-stimulated FAS promoter activity, Moreover, cotransfection of dominant negative USF1 and USF2 mutants lacking the DNA binding domain inhibited the insulin stimulation of the FAS promoter activity, On the other hand, site-directed mutagenesis of the -65/-60 E-box surrounding sequences within the overlapped tandem copies of sterol regulatory element-binding protein (SREBP) binding sites prevented SREBP from binding to -71/-50 promoter region in vitro but had no effect on insulin regulation of the FAS promoter in vivo, When rat liver nuclear extracts were used in gel mobility shift assays, only USF-containing protein-DNA complexes that can be supershifted by specific USF antibodies were observed, These results demonstrate that upstream stimulatory factor binding to the E-box at -65 is required for insulin regulation of the fatty acid synthase promoter.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Han, Zaiqi/AAI-2233-2019		NIDDK NIH HHS [DK-36264] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036264] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; DATTA PK, 1995, J BIOL CHEM, V270, P8637, DOI 10.1074/jbc.270.15.8637; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Ghosh AK, 1997, ONCOGENE, V14, P589, DOI 10.1038/sj.onc.1200866; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; KOZLOWSKI MT, 1991, DEV BIOL, V148, P625, DOI 10.1016/0012-1606(91)90280-G; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LIU ZR, 1993, J BIOL CHEM, V268, P12787; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; Mezey E, 1993, Alcohol Alcohol Suppl, V2, P57; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Soncini M, 1995, J BIOL CHEM, V270, P30339, DOI 10.1074/jbc.270.51.30339; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; Wang D, 1997, BIOTECHNIQUES, V22, P70, DOI 10.2144/97221bm14; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8	39	126	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26367	26374		10.1074/jbc.272.42.26367	http://dx.doi.org/10.1074/jbc.272.42.26367			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334210	hybrid			2022-12-25	WOS:A1997YB13900044
J	Paterno, GD; Li, Y; Luchman, HA; Ryan, PJ; Gillespie, LL				Paterno, GD; Li, Y; Luchman, HA; Ryan, PJ; Gillespie, LL			cDNA cloning of a novel, developmentally regulated immediate early gene activated by fibroblast growth factor and encoding a nuclear protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY XENOPUS-EMBRYOS; MESODERM INDUCTION; EXPRESSION; CELLS; ADENOCARCINOMA; TRANSCRIPTION; RECEPTORS; SEQUENCE; DOMAINS; LAEVIS	We have utilized the polymerase chain reaction (PCR)-based differential display methodology (Liang, P., and Pardee, A. B. (1992) Science 257, 967-969) to identify a novel transcript whose expression levels increased in Xenopus embryo explants during mesoderm induction by fibroblast growth factor, The PCR product was used to clone a 2.3-kilobase pair cDNA representing this transcript, which we have named er1 (early response 1), The er1 cDNA contained a single open reading frame predicted to encode a protein of 493 amino acid residues, A data base homology search revealed that the predicted ER1 amino acid sequence contains three regions of similarity to the rat and human proteins encoded by the metastasis-associated gene, mta1, and two regions of similarity to the Caenorhabditis elegans sequence that is similar to mta1. The fibroblast growth factor-induced increase in er1 steady-state levels was not dependent on de novo protein synthesis, demonstrating that er1 is an immediate early gene, Northern blot analysis revealed a single 2.8-kilobase pair mRNA that was observed predominantly during the initial cleavage and blastula stages of Xenopus development, with little or no detectable mRNA during subsequent development, Quantitative PCR analysis of early developmental stages showed that er1 peaked during late blastula, Computer-assisted analysis of the predicted ER1 amino acid sequence revealed two putative nuclear localization signals, four highly acidic regions clustered at the N terminus and a proline rich region located near the C terminus, Subcellular localization by immunocytochemistry revealed that the ER1 protein was targeted exclusively to the nucleus, Transactivation assays using various regions of ER1 fused to the DNA binding domain of GAL4 demonstrated that the N-terminal acidic region is a potent transactivator. These data suggest that ER1 may function as a transcription factor.	MEM UNIV NEWFOUNDLAND, FAC MED, DIV BASIC MED SCI, TERRY FOX CANC RES LABS, St John, NF A1B 3V6, CANADA	Memorial University Newfoundland			Ryan, Patrick/HDO-1133-2022					BAIRD A, 1991, FIBROBLAST GROWTH FA; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; Clemens M, 1984, TRANSCRIPTION TRANSL, P231; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; GILLESPIE LL, 1992, MECH DEVELOP, V38, P99, DOI 10.1016/0925-4773(92)90002-2; GILLESPIE LL, 1995, J BIOL CHEM, V270, P22758, DOI 10.1074/jbc.270.39.22758; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; HARTLEY RS, 1994, DEV BIOL, V163, P521, DOI 10.1006/dbio.1994.1168; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PATHAK S, 1979, J NATL CANCER I, V62, P263; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Reynolds JN, 1996, MOL BRAIN RES, V35, P11, DOI 10.1016/0169-328X(95)00172-O; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RYAN PJ, 1994, DEV BIOL, V166, P101, DOI 10.1006/dbio.1994.1299; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; TOH Y, 1994, J BIOL CHEM, V269, P22958; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355	29	35	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25591	25595		10.1074/jbc.272.41.25591	http://dx.doi.org/10.1074/jbc.272.41.25591			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325278	hybrid			2022-12-25	WOS:A1997YA35800033
J	Zhu, YJ; Qi, C; Jain, S; Rao, MS; Reddy, JK				Zhu, YJ; Qi, C; Jain, S; Rao, MS; Reddy, JK			Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; PPAR-GAMMA; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL EXPRESSION; NUCLEAR RECEPTORS; CO-REPRESSOR; FATTY-ACIDS; RAT; SUPERFAMILY; FAMILY	In an attempt to identify cofactors that could possibly influence the transcriptional activity of peroxisome proliferator-activated receptors (PPARs), we used a yeast two-hybrid system with Gal4-PPAR gamma as bait to screen a mouse liver cDNA library and have identified steroid receptor coactivator-l (SRC-1) as a PPAR transcriptional coactivator. We now report the isolation of a cDNA encoding a 165-kDa PPAR gamma-binding protein, designated PBP which also serves as a coactivator. PBP also binds to PPAR alpha, RAR alpha RXR, and TR beta 1, and this binding is increased in the presence of specific ligands. Deletion of the last 12 amino acids from the carboxyl terminus of PPAR gamma results in the abolition of interaction between PBP and PPAR gamma. PBP modestly increased the transcriptional activity of PPAR gamma, and a truncated form of PBP (amino acids 487-735) acted as a dominant-negative repressor, suggesting that PBP is a genuine coactivator for PPAR. In addition, PBP contains two LXXLL signature motifs considered necessary and sufficient for the binding of several coactivators to nuclear receptors. In situ hybridization and Northern analysis showed that PBP is expressed in many tissues of adult mice, including the germinal epithelium of testis, where it appeared most abundant, and during ontogeny, suggesting a possible role for this cofactor in cellular proliferation and differentiation.	NORTHWESTERN UNIV, SCH MED, DEPT PATHOL, CHICAGO, IL 60611 USA	Northwestern University				jain, sanjay/0000-0003-2804-127X	NIGMS NIH HHS [R37 GM23750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvares K, 1996, CARCINOGENESIS, V17, P311, DOI 10.1093/carcin/17.2.311; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHU RY, 1995, J BIOL CHEM, V270, P29636; Chu RY, 1996, J BIOL CHEM, V271, P27670, DOI 10.1074/jbc.271.44.27670; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HUANG Q, 1995, INT J ONCOL, V6, P307; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JOW L, 1995, J BIOL CHEM, V270, P3836, DOI 10.1074/jbc.270.8.3836; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; ONATE SA, 1995, SCIENCE, V270, P1354; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZHU YJ, 1993, J BIOL CHEM, V268, P26817; Zhu YJ, 1996, GENE EXPRESSION, V6, P185	52	288	311	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25500	25506		10.1074/jbc.272.41.25500	http://dx.doi.org/10.1074/jbc.272.41.25500			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325263	hybrid			2022-12-25	WOS:A1997YA35800018
J	Rutberg, SE; Saez, E; Lo, S; Jang, SI; Markova, N; Spiegelman, BM; Yuspa, SH				Rutberg, SE; Saez, E; Lo, S; Jang, SI; Markova, N; Spiegelman, BM; Yuspa, SH			Opposing activities of c-Fos and Fra-2 on AP-1 regulated transcriptional activity in mouse keratinocytes induced to differentiate by calcium and phorbol esters	ONCOGENE			English	Article						c-Fos; Fra-2; mouse keratinocytes; differentiation; calcium; phorbol ester	PROTEIN-KINASE-C; HUMAN INVOLUCRIN GENE; HUMAN EPIDERMAL-KERATINOCYTES; CROSS-LINKED ENVELOPE; HUMAN KERATIN-1 GENE; SKIN CARCINOGENESIS; PROXIMAL PROMOTER; RETINOIC ACID; CELL-ENVELOPE; EXPRESSION	The major differentiation products of maturing keratinocytes contain AP-I regulatory motifs, and AP-1 DNA binding activity increases in cultured keratinocytes induced to differentiate by calcium. Here, we have analysed AP-I transcriptional activity in mouse keratinocytes treated with calcium and 12-O-tetradecanoyl phorbol-13-acetate (TPA), two agents that induce terminal differentiation of keratinocytes with different phenotypic consequences. Reporter constructs representing multimers of AP-I sequences found in keratinocyte marker genes demonstrated that the calcium-induced AP-I DNA binding activity does not correlate with transcriptional activation. Moreover, expression from active subunits of the profilaggrin and spr 1 promoters increased in calcium-treated keratinocytes when the AP-1 sites were disrupted, indicating that AP-I may negatively regulate certain promoters in these cells. In contrast, AP-1 reporter activity was increased in keratinocytes treated with TPA. This induction was dependent upon the expression of c-Fos since AP-I transcriptional activity was not increased in TPA-treated keratinocytes derived from c-fos null mice. Analysis of AP-1 protein expression in calcium-and TPA-treated keratinocytes demonstrated that only TPA increased the expression of c-Jun, while Jun B and Jun D were induced by both of these agents. c-Fos was expressed only in TPA treated keratinocytes, Fra-2 was expressed only in calcium-treated cells, and Fra-1 was expressed in both. Exogenous expression of Fra-2 repressed AP-1 transcriptional activity in TPA-treated keratinocytes, while c-Fos expression activated the AP-I sequence in calcium-treated keratinocytes. These data indicate that Fra-2 and c-Fos play opposing roles in regulating AP-1 activity in keratinocytes and that multiple inducer-dependent regulatory pathways may exist for the expression of keratinocyte differentiation markers.	NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; NIAMSD,SKIN BIOL LAB,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AU YPT, 1994, CIRC RES, V75, P15, DOI 10.1161/01.RES.75.1.15; Bernerd Francoise, 1993, Gene Expression, V3, P187; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P1619; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRUDA MC, 1994, ONCOGENE, V9, P2537; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUFF CA, 1993, J BIOL CHEM, V268, P377; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; JETTEN AM, 1989, J INVEST DERMATOL, V93, P108, DOI 10.1111/1523-1747.ep12277374; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARTASOVA T, 1987, NUCLEIC ACIDS RES, V15, P5945, DOI 10.1093/nar/15.15.5945; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LICHTI U, 1988, CANCER RES, V48, P74; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LU B, 1994, J BIOL CHEM, V269, P7443; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PARKINSON EK, 1984, CARCINOGENESIS, V5, P1071, DOI 10.1093/carcin/5.8.1071; Polakowska R. R., 1991, PHYSL BIOCH MOL BIOL, P168; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; ReifelMiller AE, 1996, J BIOL CHEM, V271, P21666, DOI 10.1074/jbc.271.35.21666; REZZONICO R, 1995, ONCOGENE, V11, P1069; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROOP DR, 1988, CANCER RES, V48, P3245; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; Rutberg SE, 1996, ONCOGENE, V13, P167; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SONOBE MH, 1995, ONCOGENE, V10, P689; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TOFTGARD R, 1985, CANCER RES, V45, P5845; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WIRTH PJ, 1987, CANCER RES, V47, P2831; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; YUSPA SH, 1982, CANCER RES, V42, P2344; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	64	61	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1337	1346		10.1038/sj.onc.1201293	http://dx.doi.org/10.1038/sj.onc.1201293			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315102				2022-12-25	WOS:A1997XV84500012
J	Croteau, DL; apRhys, CMJ; Hudson, EK; Dianov, GL; Hansford, RG; Bohr, VA				Croteau, DL; apRhys, CMJ; Hudson, EK; Dianov, GL; Hansford, RG; Bohr, VA			An oxidative damage-specific endonuclease from rat liver mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMAMIDOPYRIMIDINE DNA GLYCOSYLASE; HAMSTER OVARY CELLS; ESCHERICHIA-COLI; CATALYTIC MECHANISM; FPG PROTEIN; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; IONIZING-RADIATION; BETA-ELIMINATION; REPAIR	Reactive oxygen species have been shown to generate mutagenic lesions in DNA, One of the most abundant lesions in both nuclear and mitochondrial DNA is 7,8-dihydro-8-oxoguanine (8-oxoG). We report here the partial purification and characterization of a mitochondrial oxidative damage endonuclease (mtODE) from rat liver that recognizes and incises at 8-oxoG and abasic sites in duplex DNA. Rat liver mitochondria were purified by differential and Percoll gradient centrifugation, and mtODE was extracted from Triton X-100-solubilized mitochondria. Incision activity was measured using a radiolabeled double-stranded DNA oligonucleotide containing a unique 8-oxoG, and, reaction products were separated by polyacrylamide gel electrophoresis. Gel filtration chromatography predicts mtODE's molecular mass to be between 25 and 30 kDa. mtODE has a monovalent cation optimum between 50 and 100 mM KCl and a pH optimum between 7.5 and 8. mtODE does not require any co-factors and is active in the presence of 5 mM EDTA. It is specific for 8-oxoG and preferentially incises at S-oxoG:C base pairs. mtODE is a putative S-oxoG glycosylase/lyase enzyme, because it can be covalently linked to the 8-oxoG oligonucleotide by sodium borohydride reduction, Comparison of mtODE's activity with other known 8-oxoG glycosglases/lyases and mitochondrial enzymes reveals that this may be a novel protein.	NIA,MOL GENET LAB,NIH,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University			Bohr, Vilhelm/AAP-5931-2020; Croteau, Deb/AAP-5933-2020	Croteau, Deborah/0000-0002-6094-4084				Aburatani H, 1997, CANCER RES, V57, P2151; AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; ANDERSON CTM, 1980, NUCLEIC ACIDS RES, V8, P875; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BESSHO T, 1993, J BIOL CHEM, V268, P19416; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; CLAYTON DA, 1974, P NATL ACAD SCI USA, V89, P7370; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; DEOLIVEIRA R, 1994, NUCLEIC ACIDS RES, V22, P3760, DOI 10.1093/nar/22.18.3760; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; GASNIER F, 1993, ANAL BIOCHEM, V212, P173, DOI 10.1006/abio.1993.1309; GERSCHENSON M, 1995, NUCLEIC ACIDS RES, V23, P88, DOI 10.1093/nar/23.1.88; GERSCHENSON M, 1994, J MOL CELL CARDIOL, V26, P31, DOI 10.1006/jmcc.1994.1005; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KIM J, 1995, J BIOL CHEM, V270, P13620, DOI 10.1074/jbc.270.23.13620; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; LEDOUX SP, 1993, CARCINOGENESIS, V14, P913, DOI 10.1093/carcin/14.5.913; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; MYERS KA, 1988, CARCINOGENESIS, V9, P285, DOI 10.1093/carcin/9.2.285; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; PIRSEL M, 1993, CARCINOGENESIS, V14, P2105, DOI 10.1093/carcin/14.10.2105; RAGAN CI, 1987, PRACTICAL APPROACH S, P80; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SATOH MS, 1988, J BIOL CHEM, V263, P6854; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Thyagarajan B, 1996, J BIOL CHEM, V271, P27536, DOI 10.1074/jbc.271.44.27536; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; TOMKINSON AE, 1990, NUCLEIC ACIDS RES, V18, P929, DOI 10.1093/nar/18.4.929; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210; Yacoub A, 1996, EMBO J, V15, P2306, DOI 10.1002/j.1460-2075.1996.tb00584.x; YAMAMOTO F, 1992, JPN J CANCER RES, V83, P351, DOI 10.1111/j.1349-7006.1992.tb00114.x	49	130	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27338	27344		10.1074/jbc.272.43.27338	http://dx.doi.org/10.1074/jbc.272.43.27338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341184	hybrid			2022-12-25	WOS:A1997YC65900080
J	Kim, JY; Soede, RDM; Schaap, P; Valkema, R; Borleis, JA; VanHaastert, PJM; Devreotes, PN; Hereld, D				Kim, JY; Soede, RDM; Schaap, P; Valkema, R; Borleis, JA; VanHaastert, PJM; Devreotes, PN; Hereld, D			Phosphorylation of chemoattractant receptors is not essential for chemotaxis or termination of G-protein-mediated responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED PHOSPHORYLATION; DICTYOSTELIUM CAMP RECEPTOR; ADENYLYL-CYCLASE; SIGNALING PATHWAYS; GUANINE-NUCLEOTIDES; MOLECULAR-BIOLOGY; CAR1; DISCOIDEUM; CELLS; IDENTIFICATION	In several G-protein-coupled signaling systems, ligand-induced receptor phosphorylation by specific kinases is suggested to lead to desensitization via mechanisms including receptor/G-protein uncoupling, receptor internalization, and receptor down-regulation. We report here that elimination of phosphorylation of a chemoattractant receptor of Dictyostelium, either by site-directed substitution of the serines or by truncation of the C-terminal cytoplasmic domain, completely prevented agonist-induced loss of ligand binding but did not impair the adaptation of several receptor-mediated responses including the activation of adenylyl and guanylyl cyclases and actin polymerization, In addition, the phosphorylation deficient receptors were capable of mediating chemotaxis, aggregation, and differentiation. We propose that for chemoattractant receptors agonist-induced phosphorylation regulates surface binding activity but other phosphorylation-independent mechanisms mediate response adaptation.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; LEIDEN UNIV, INST MOL PLANT SCI, LEIDEN, NETHERLANDS; UNIV GRONINGEN, DEPT BIOCHEM, GRONINGEN, NETHERLANDS	Johns Hopkins University; Leiden University; Leiden University - Excl LUMC; University of Groningen			Schaap, Pauline/M-5355-2019; Schaap, Pauline/A-3682-2009	Schaap, Pauline/0000-0003-4500-2555; Schaap, Pauline/0000-0003-4500-2555	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034933] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34933] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CATERINA MJ, 1994, J BIOL CHEM, V269, P1523; CATERINA MJ, 1991, FASEB J, V5, P3078, DOI 10.1096/fasebj.5.15.1743439; CATERINA MJ, 1995, J BIOL CHEM, V270, P4418, DOI 10.1074/jbc.270.9.4418; CATERINA MJ, 1995, J BIOL CHEM, V270, P8667, DOI 10.1074/jbc.270.15.8667; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CHEN MY, 1994, J BIOL CHEM, V269, P20925; Chen QJ, 1996, MOL CELL BIOL, V16, P247; CONDEELIS J, 1991, METHOD ENZYMOL, V196, P486; DEVREOTES PN, 1979, J CELL BIOL, V80, P291, DOI 10.1083/jcb.80.2.291; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; GUNDERSEN RE, 1990, SCIENCE, V248, P591, DOI 10.1126/science.2110382; HERELD D, 1994, J BIOL CHEM, V269, P7036; INGLESE J, 1993, J BIOL CHEM, V268, P23735; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; KLEIN P, 1987, J BIOL CHEM, V262, P358; KONIJN TM, 1970, EXPERIENTIA, V26, P367, DOI 10.1007/BF01896891; LILLY PJ, 1995, J CELL BIOL, V129, P1659, DOI 10.1083/jcb.129.6.1659; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PUPILLO M, 1992, MOL BIOL CELL, V3, P1229, DOI 10.1091/mbc.3.11.1229; SOEDE RDM, 1994, DEVELOPMENT, V120, P1997; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; VANHAASTERT PJM, 1983, J CELL BIOL, V96, P1559, DOI 10.1083/jcb.96.6.1559; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; VANHAASTERT PJM, 1987, J CELL BIOL, V105, P2301, DOI 10.1083/jcb.105.5.2301; VAUGHAN RA, 1988, J BIOL CHEM, V263, P14538; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171	35	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27313	27318		10.1074/jbc.272.43.27313	http://dx.doi.org/10.1074/jbc.272.43.27313			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341180	Green Published, hybrid			2022-12-25	WOS:A1997YC65900076
J	Akita, K; Ohtsuki, T; Nukada, Y; Tanimoto, T; Namba, M; Okura, T; TakakuraYamamoto, R; Torigoe, K; Gu, Y; Su, MSS; Fujii, M; SatohItoh, M; Yamamoto, K; Kohno, K; Ikeda, M; Kurimoto, M				Akita, K; Ohtsuki, T; Nukada, Y; Tanimoto, T; Namba, M; Okura, T; TakakuraYamamoto, R; Torigoe, K; Gu, Y; Su, MSS; Fujii, M; SatohItoh, M; Yamamoto, K; Kohno, K; Ikeda, M; Kurimoto, M			Involvement of caspase-1 and caspase-3 in the production and processing of mature human interleukin 18 in monocytic THP.1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASE; CONVERTING-ENZYME; INTERLEUKIN-1-BETA-CONVERTING ENZYME; ICE/CED-3 PROTEASE; GAMMA PRODUCTION; T-CELLS; IDENTIFICATION; ACTIVATION; APOPTOSIS; CYTOKINE	Recently, human interleukin 18 (hIL-18) cDNA was cloned, and the recombinant protein with a tentatively assigned NH2-terminal amino acid sequence was generated. However, natural hIL-18 has not yet been isolated, and its cellular processing is therefore still unclear. To clarify this, we purified natural hIL-18 from the cytosolic extract of monocytic THP.1 cells. Natural hIL-18 exhibited a molecular mass of 18.2 kDa, and the NH2-terminal amino acid was Tyr(37). Biological activities of the purified protein were identical to those of recombinant hIL-18 with respect to the enhancement of natural killer cell cytotoxicity and interferon-gamma production by human peripheral blood mononuclear cells. We also found two precursor hIL-18 (prohIL-18)-processing activities in the cytosol of THP.1 cells, These activities were blocked separately by the caspase inhibitors Ac-YVAD-CHO and Ac-DEVD-CHO. Further analyses of the partially purified enzymes revealed that one is caspase-1, which cleaves prohIL-18 at the Asp(36)-Tyr(37) Site to generate the mature hIL-18, and the other is caspase-3, which cleaves both precursor and mature hIL-18 at Asp(71)-Ser(72) and Asp(76)-Asn(77) to generate biologically inactive products, These results suggest that the production and processing of natural hIL-18 are regulated by two processing enzymes, caspase-1 and caspase-3, in THP.1 cells.	VERTEX PHARMACEUT INC,CAMBRIDGE,MA 02139	Vertex Pharmaceuticals	Akita, K (corresponding author), HAYASHIBARA BIOCHEM LABS INC,FUJISAKI INST,675-1 FUJISAKI,OKAYAMA 702,JAPAN.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ANDO S, 1988, JPN J CANCER RES, V79, P757, DOI 10.1111/j.1349-7006.1988.tb02233.x; Bazan JF, 1996, NATURE, V379, P591, DOI 10.1038/379591a0; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FUKUDA S, 1988, LYMPHOKINE RES, V7, P175; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; Kohno K, 1997, J IMMUNOL, V158, P1541; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KURTJONES EA, 1985, P NATL ACAD SCI USA, V82, P1204, DOI 10.1073/pnas.82.4.1204; LICHTMAN AH, 1988, P NATL ACAD SCI USA, V85, P9699, DOI 10.1073/pnas.85.24.9699; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; OKAMURA H, 1995, INFECT IMMUN, V63, P3966, DOI 10.1128/IAI.63.10.3966-3972.1995; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SIDERS WM, 1995, J BIOL CHEM, V270, P16258, DOI 10.1074/jbc.270.27.16258; Takeuchi M, 1997, CELL TISSUE RES, V289, P499, DOI 10.1007/s004410050895; TANIGUCHI M, 1997, IN PRESS J IMMUNOL M; TASTUTA T, 1996, J IMMUNOL, V157, P3949; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1995, PROTEIN SCI, V4, P3; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; Thornberry Nancy A., 1995, Perspectives in Drug Discovery and Design, V2, P389, DOI 10.1007/BF02172032; Ushio S, 1996, J IMMUNOL, V156, P4274; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	36	179	190	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26595	26603		10.1074/jbc.272.42.26595	http://dx.doi.org/10.1074/jbc.272.42.26595			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334240	hybrid			2022-12-25	WOS:A1997YB13900074
J	McCormack, T; Baumeister, W; Grenier, L; Moomaw, C; Plamondon, L; Pramanik, B; Slaughter, C; Soucy, F; Stein, R; Zuhl, F; Dick, L				McCormack, T; Baumeister, W; Grenier, L; Moomaw, C; Plamondon, L; Pramanik, B; Slaughter, C; Soucy, F; Stein, R; Zuhl, F; Dick, L			Active site-directed inhibitors of Rhodococcus 20 S proteasome - Kinetics and mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING ENZYME-INHIBITORS; THERMOPLASMA-ACIDOPHILUM; COMPLEX; LACTACYSTIN	We have studied the mechanism of inhibition of the recombinant Rhodococcus proteasome by four different chemical classes of active site-directed small molecule inhibitors, Clasto-lactacystin beta-lactone is a time-dependent inhibitor of the Rhodococcus proteasome's ability to hydrolyze Suc-Leu-Leu-Val-Tyr-AMC, a substrate for this proteasome's single type of active site, and proceeds with a k(inact)[I] of 1,700 m(-1) s(-1). Using peptide mapping of tryptic digests, LC/MS, and amino acid sequence analysis, we have established that the O gamma of the hydroxyl group on the N terminal threonine of the beta-subunit is the sole modification made by the beta-lactone. Active site titrations of the Rhodococcus proteasome with reversible peptide aldehydes show the expected stoichiometry of one inhibitor molecule per beta-subunit. Prior modification with beta-lactone completely abrogates the binding of peptidyl boronic acid inhibitors, suggesting that these inhibitors also inactivate the enzyme by reacting with the O gamma moiety on Thr(1), High performance liquid chromatography analysis of peptidyl vinyl sulfone-modified intact Rhodococcus proteasome beta-subunit and its tryptic peptides suggests that the peptidyl vinyl sulfone modifies a residue in the N-terminal 20 amino acids, This modification is also blocked by prior treatment with beta-lactone.	PROSCRIPT INC,CAMBRIDGE,MA 02139; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society			Dick, Lawrence/ABA-8831-2021	Dick, Larry/0000-0002-6880-0405				Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Cantor C.R., 1980, BIOPHYSICAL CHEM 2; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DITZEL L, 1997, J BIOL CHEM, V378, P239; FENG R, 1991, J AM SOC MASS SPECTR, V2, P387, DOI 10.1016/1044-0305(91)85005-Q; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GRECO WR, 1979, J BIOL CHEM, V254, P2104; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GUTFREUND H, 1975, ENZYMES PHYSICAL PRI; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SHENVI AB, 1986, BIOCHEMISTRY-US, V25, P1286, DOI 10.1021/bi00354a014; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; UNO H, 1994, J AM CHEM SOC, V116, P2139, DOI 10.1021/ja00084a062; WEBER PC, 1995, BIOCHEMISTRY-US, V34, P3750, DOI 10.1021/bi00011a033; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; Zuhl F, 1997, FEBS LETT, V400, P83, DOI 10.1016/S0014-5793(96)01403-2	25	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26103	26109		10.1074/jbc.272.42.26103	http://dx.doi.org/10.1074/jbc.272.42.26103			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334174	hybrid			2022-12-25	WOS:A1997YB13900008
J	Tomashek, JJ; Graham, LA; Hutchins, MU; Stevens, TH; Klionsky, DJ				Tomashek, JJ; Graham, LA; Hutchins, MU; Stevens, TH; Klionsky, DJ			V-1-situated stalk subunits of the yeast vacuolar proton-translocating ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; GENE DISRUPTION; 13-KDA SUBUNIT; ENZYME COMPLEX; ENCODES; PUMP; EVOLUTION; CONTAINS	The proton-translocating ATPase of the yeast vacuole is an enzyme complex consisting of a large peripheral membrane sector (V-1) and an integral membrane sector (V-0), each composed of multiple subunits. The V-1 sector contains subunits that hydrolyze ATP, whereas the V-0 sector contains subunits that translocate protons across the membrane. Additional subunits in both sectors couple these activities. Here we have continued our examination of intermediate subunits primarily associated with the V-1 but also implicated in interactions with the V-0. Interactions between Vma7p (F) and Vma8p (D) and between Vma4p (E) and Vma10p (G) are described. Although Vma7p and Vma10p have been observed to interact with the V-0 sector, our results indicate that these subunits behave primarily as canonical V-1 sector subunits. We categorize these four subunits as ''stalk'' subunits to distinguish them from the known catalytic (A and B) and proton-translocating (c, c', and Vma16p) subunits and to highlight their intermediate nature. Furthermore, we show that the in vivo stability of Vma4p is dependent upon interaction with Vma10p. This may be important in the regulation of assembly, since these two subunits add to the V-1 during later stages of V-1 assembly. This is the first demonstration of interdependence between ATPase subunits for structural stability.	UNIV CALIF DAVIS, MICROBIOL SECT, DAVIS, CA 95616 USA; UNIV OREGON, INST MOL BIOL, EUGENE, OR 97403 USA	University of California System; University of California Davis; University of Oregon				Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006, R01GM053396] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53396, GM38006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ARAI H, 1988, J BIOL CHEM, V263, P8796; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BOWMAN BJ, 1992, J EXP BIOL, V172, P57; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1995, BBA-BIOMEMBRANES, V1237, P95, DOI 10.1016/0005-2736(95)00108-F; Crider BP, 1997, J BIOL CHEM, V272, P10721; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P18286; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KASHO VN, 1989, P NATL ACAD SCI USA, V86, P8708, DOI 10.1073/pnas.86.22.8708; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Lepier A, 1996, J BIOL CHEM, V271, P8502, DOI 10.1074/jbc.271.14.8502; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SIKORSKI RS, 1989, GENETICS, V122, P19; Supekova L, 1996, J EXP BIOL, V199, P1147; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Tomashek JJ, 1997, J BIOL CHEM, V272, P16618, DOI 10.1074/jbc.272.26.16618	33	93	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26787	26793		10.1074/jbc.272.42.26787	http://dx.doi.org/10.1074/jbc.272.42.26787			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334266	hybrid			2022-12-25	WOS:A1997YB13900100
J	Tong, JF; Oyamada, H; Demaurex, N; Grinstein, S; McCarthy, TV; MacLennan, DH				Tong, JF; Oyamada, H; Demaurex, N; Grinstein, S; McCarthy, TV; MacLennan, DH			Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; TWITCH SKELETAL-MUSCLE; CONTRACTURE-TEST; RYR1 GENE; CA-2+ RELEASE; CELLS; SUBSTITUTION; IDENTIFICATION; DISCORDANCE; CYSTEINE	Malignant hyperthermia (MH) and central core disease (CCD) are autosomal dominant disorders of skeletal muscle in which a potentially fatal hypermetabolic crisis can be triggered by commonly used anesthetic agents, To date, 17 mutations in the human RYR1 gene encoding the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum (the ryanodine receptor) have been associated with MH and/or CCD, Although many of these mutations have been linked to MH and/or CCD, with high Iod (log of the odds favoring linkage versus nonlinkage) scopes, others have been found in single, small families, Independent biochemical evidence for a causal role for these mutations in MH is available for only two mutants, Mutations corresponding to the human MH mutations were made in a full-length rabbit RYR1 cDNA, and wild type. and mutant cDNAs were transected into HEK-293 cells, After about 48 h, intact cells were loaded with the fluorescent Ca2+ indicator, fura-2, and intracellular Ca2+ release, induced by caffeine or halothane, was measured by photometry. Ca2+ release in cells expressing MH or CCD mutant ryanodine receptors was invariably significantly more sensitive to low concentrations of caffeine and halothane than Ca2+ release in cells expressing wild type receptors or receptors mutated in other regions of the molecule, Linear regression analysis showed that there is a strong correlation (r = 0.95, p < 0.001) between caffeine sensitivity of different RYR1 mutants measured by the cellular Ca2+ photometry assay and by the clinical in vitro caffeine halothane contracture test (IVCT). The correlation was weaker, however for halothane (r = 0.49, p > 0.05), Abnormal sensitivity in the Ca2+ photometry assay provides supporting evidence for a causal role in MH for each of 15 single amino acid mutations in the ryanodine receptor, The study demonstrates the usefulness of the cellular Ca2+ photometpy assay in the assessment of the sensitivity to caffeine and halothane of specific ryanodine receptor mutants.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M6S 1A1, CANADA; HOSP SICK CHILDREN, RES INST, DIV CELL BIOL, TORONTO, ON M5G 1X8, CANADA; NATL UNIV IRELAND UNIV COLL CORK, DEPT BIOCHEM, CORK, IRELAND	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University College Cork				Demaurex, Nicolas/0000-0002-9933-6772; McCarthy, Tommie/0000-0003-4884-6972				AIREY JA, 1990, J BIOL CHEM, V265, P14187; BRITT BA, 1991, THERMOREGULATION PAT, P179; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; Chen SRW, 1997, BIOPHYS J, V73, P1904, DOI 10.1016/S0006-3495(97)78221-3; DENBOROUGH MA, 1973, BMJ-BRIT MED J, V1, P272, DOI 10.1136/bmj.1.5848.272; DEUFEL T, 1995, AM J HUM GENET, V56, P1334; DUBOWITZ V, 1960, LANCET, P23; ELLIS FR, 1984, BRIT J ANAESTH, V56, P1267; FILL M, 1990, BIOPHYS J, V57, P471, DOI 10.1016/S0006-3495(90)82563-7; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GILLARD EF, 1991, GENOMICS, V11, P751, DOI 10.1016/0888-7543(91)90084-R; GILLARD EF, 1992, GENOMICS, V13, P1247, DOI 10.1016/0888-7543(92)90042-Q; GROMADA J, 1995, FEBS LETT, V373, P182, DOI 10.1016/0014-5793(95)01070-U; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOGAN K, 1992, ANESTH ANALG, V75, P441; KEATING KE, 1994, HUM MOL GENET, V3, P1855, DOI 10.1093/hmg/3.10.1855; Keating KE, 1997, J MED GENET, V34, P291, DOI 10.1136/jmg.34.4.291; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARACH MG, 1989, ANESTH ANALG, V69, P511; Lynch PJ, 1997, ANESTHESIOLOGY, V86, P620, DOI 10.1097/00000542-199703000-00014; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; MACLENNAN DH, 1995, SOC GEN PHY, V50, P89; MACLENNAN DH, 1995, CURR OPIN NEUROL, V8, P397, DOI 10.1097/00019052-199510000-00013; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MICKELSON JR, 1987, BIOCHIM BIOPHYS ACTA, V897, P364, DOI 10.1016/0005-2736(87)90434-2; MICKELSON JR, 1994, AM J PHYSIOL, V267, pC282, DOI 10.1152/ajpcell.1994.267.1.C282; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; OHNISHI ST, 1983, FEBS LETT, V161, P103; Ording H, 1997, ACTA ANAESTH SCAND, V41, P955, DOI 10.1111/j.1399-6576.1997.tb04820.x; OTSU K, 1994, J BIOL CHEM, V269, P9413; OTSU K, 1991, GENOMICS, V11, P744, DOI 10.1016/0888-7543(91)90083-Q; PHILLIPS MS, 1994, HUM MOL GENET, V3, P2181, DOI 10.1093/hmg/3.12.2181; QUANE KA, 1994, GENOMICS, V23, P236, DOI 10.1006/geno.1994.1483; QUANE KA, 1993, NAT GENET, V5, P51, DOI 10.1038/ng0993-51; QUANE KA, 1994, HUM MOL GENET, V3, P471, DOI 10.1093/hmg/3.3.471; Quane KA, 1997, BRIT J ANAESTH, V79, P332, DOI 10.1093/bja/79.3.332; Richter M, 1997, J BIOL CHEM, V272, P5256, DOI 10.1074/jbc.272.8.5256; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Serfas KD, 1996, ANESTHESIOLOGY, V84, P322, DOI 10.1097/00000542-199602000-00009; SHOMER NH, 1993, AM J PHYSIOL, V264, pC125, DOI 10.1152/ajpcell.1993.264.1.C125; SHY GM, 1956, BRAIN, V79, P610, DOI 10.1093/brain/79.4.610; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREVES S, 1994, BIOCHEM J, V301, P661, DOI 10.1042/bj3010661; ZHANG YL, 1993, NAT GENET, V5, P46, DOI 10.1038/ng0993-46; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	48	194	196	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26332	26339		10.1074/jbc.272.42.26332	http://dx.doi.org/10.1074/jbc.272.42.26332			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334205	hybrid			2022-12-25	WOS:A1997YB13900039
J	Aguado, F; Gombau, L; Majo, G; Marsal, J; Blanco, J; Blasi, J				Aguado, F; Gombau, L; Majo, G; Marsal, J; Blanco, J; Blasi, J			Regulated secretion is impaired in AtT-20 endocrine cells stably transfected with botulinum neurotoxin type A light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; ALPHA-LATROTOXIN; CLOSTRIDIAL NEUROTOXINS; BINDING; PROTEIN; RELEASE; FUSION; EXOCYTOSIS; SNAP-25; TOXIN	Botulinum neurotoxin type A (BoNT/A) inhibits neurotransmitter release by specific cleavage of SNAP-25, a synaptosome-associated protein also expressed in the ACTH secretory cell line AtT-20. Expression of light chain BoNT/A (L-BoNT/A) gene transfected into AtT-20 cells resulted in a cleaved form of SNAP-25 indistinguishable from that generated by bona fide BoNT/A. LBoNT/A-transfected cells showed no difference in replication rate, viability, or phenotype, compared with control AtT-20 cells. In contrast, L-BoNT/A-transfected cells could not be induced to secrete ACTH upon stimulation by 8-bromo-cAMP or KCl. In addition, alpha-latrotoxin induced ACTH release from control cells, but not from L-BoNT/A-transfected cells. These experiments suggest an important role for SNAP-25 in regulated secretion from AtT-20 cells and underline the usefulness of this cell system as a tool for the study of the molecular mechanism of peptide hormone secretion.	UNIV BARCELONA,DEPT BIOL CELLULAR & ANAT PATOL,LHOSPITALET LLOBR 08907,SPAIN; INST RECERCA ONCOL,DEPT CELLULAR BIOL,BARCELONA,SPAIN; CSIC,BARCELONA,SPAIN	University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC)			Blasi, Juan/K-7943-2014; Blanco, Jeronimo/H-2764-2015	Blasi, Juan/0000-0002-0482-9444; Blanco, Jeronimo/0000-0003-3765-0640				Aguado F, 1996, EUR J CELL BIOL, V69, P351; AHNERTHILGER G, 1993, NEUROSCIENCE, V53, P547, DOI 10.1016/0306-4522(93)90219-6; Augustine GJ, 1996, ANNU REV PHARMACOL, V36, P659, DOI 10.1146/annurev.pa.36.040196.003303; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BIGALKE H, 1978, N-S ARCH PHARMACOL, V303, P133, DOI 10.1007/BF00508058; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BOYD RS, 1995, J BIOL CHEM, V270, P18216, DOI 10.1074/jbc.270.31.18216; CULLCANDY SG, 1976, J PHYSIOL-LONDON, V260, P177, DOI 10.1113/jphysiol.1976.sp011510; DASGUPTA BR, 1984, TOXICON, V22, P415, DOI 10.1016/0041-0101(84)90085-0; DAYANITHI G, 1990, NEUROSCIENCE, V39, P711, DOI 10.1016/0306-4522(90)90254-2; Duchen L.W., 1992, GREENFIELDS NEUROPAT, P1; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; KUROKAWA Y, 1987, J GEN MICROBIOL, V133, P2647; LUINI A, 1985, P NATL ACAD SCI USA, V82, P8034, DOI 10.1073/pnas.82.23.8034; MATSUUCHI L, 1988, J CELL BIOL, V106, P239, DOI 10.1083/jcb.106.2.239; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MOCHIDA S, 1990, P NATL ACAD SCI USA, V87, P7844, DOI 10.1073/pnas.87.20.7844; NGSEE JK, 1993, MOL BIOL CELL, V4, P747, DOI 10.1091/mbc.4.7.747; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OsenSand A, 1996, J COMP NEUROL, V367, P222, DOI 10.1002/(SICI)1096-9861(19960401)367:2<222::AID-CNE5>3.0.CO;2-7; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; RAFF H, 1989, CLIN CHEM, V35, P596; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; ROTH D, 1994, FEBS LETT, V351, P207, DOI 10.1016/0014-5793(94)00833-7; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; SIMPSON LL, 1989, BOTULINUM TOXIN TETA; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TOOZE J, 1989, EUR J CELL BIOL, V49, P259; WATERMAN SA, 1995, NEUROSCIENCE, V69, P977, DOI 10.1016/0306-4522(95)00317-C; WILLIAMS RS, 1983, EUR J BIOCHEM, V131, P437, DOI 10.1111/j.1432-1033.1983.tb07282.x	37	15	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26005	26008		10.1074/jbc.272.41.26005	http://dx.doi.org/10.1074/jbc.272.41.26005			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325336	hybrid, Green Published			2022-12-25	WOS:A1997YA35800091
J	CorthesyTheulaz, IE; Bergonzelli, GE; Henry, H; Bachmann, D; Schorderet, DF; Blum, AL; Ornston, LN				CorthesyTheulaz, IE; Bergonzelli, GE; Henry, H; Bachmann, D; Schorderet, DF; Blum, AL; Ornston, LN			Cloning and characterization of Helicobacter pylori succinyl CoA:acetoacetate CoA-transferase, a novel prokaryotic member of the CoA-transferase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A-TRANSFERASE; CLOSTRIDIUM-ACETOBUTYLICUM ATCC-824; ESCHERICHIA-COLI; ACINETOBACTER-CALCOACETICUS; PSEUDOMONAS-PUTIDA; BETA-KETOADIPATE; GASTRIC-CANCER; PURIFICATION; GENES; EXPRESSION	Sequencing of a fragment of Helicobacter pylori genome led to the identification of two open reading frames showing striking homology with Coenzyme A (CoA) transferases, enzymes catalyzing the reversible transfer of CoA from one carboxylic acid to another. The genes were present in all H. pylori strains tested by polymerase chain reaction or slot blotting but not in Campylobacter jejuni. Genes for the putative A and B subunits of H. pylori CoA-transferase were introduced into the bacterial expression vector pKK223-3 and expressed in Escherichia coli JM105 cells. Amino acid sequence comparisons, combined with measurements of enzyme activities using different CoA donors and accepters, identified the H. pylori CoA-transferase as a succinyl CoA:acetoacetate CoA-transferase. This activity was consistently observed in different H. pylori strains, Antibodies raised against either recombinant A or B subunits recognized two distinct subunits of M-r similar to 26,000 and 24,000 that are both necessary for H. pylori CoA transferase function. The lack of alpha-ketoglutarate dehydrogenase and of succinyl CoA synthetase activities indicates that the generation of succinyl CoA is not mediated by the tricarboxylic acid cycle in H. pylori. We postulate the existence of an alternative pathway where the CoA-transferase is essential for energy metabolism.	UNIV LAUSANNE,INST PHARMACOL & TOXICOL,CH-1011 LAUSANNE,SWITZERLAND; CHU VAUDOIS,CENT LAB CLIN CHEM,CH-1011 LAUSANNE,SWITZERLAND; CHU VAUDOIS,DIV MED GENET,CH-1011 LAUSANNE,SWITZERLAND; CHU VAUDOIS,MOL GENET UNIT,CH-1011 LAUSANNE,SWITZERLAND; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Yale University	CorthesyTheulaz, IE (corresponding author), CHU VAUDOIS,DIV GASTROENTEROL,BH-19N-624,CH-1011 LAUSANNE,SWITZERLAND.							BARKER HA, 1978, J BIOL CHEM, V253, P1219; BLAIR JB, 1969, J BIOL CHEM, V244, P951; BRIDGER WA, 1969, METHOD ENZYMOL, V13, P70; BUCKEL W, 1981, EUR J BIOCHEM, V118, P315, DOI 10.1111/j.1432-1033.1981.tb06404.x; CARRINGTON J M, 1981, Biochemical Society Transactions, V9, P55; CARY JW, 1990, APPL ENVIRON MICROB, V56, P1576, DOI 10.1128/AEM.56.6.1576-1583.1990; CHALK PA, 1994, MICROBIOL-UK, V140, P2085, DOI 10.1099/13500872-140-8-2085; Clayton C. L., 1995, Gut, V37, pA67; De Koster E, 1994, Eur J Cancer Prev, V3, P247; DOTEN RC, 1987, J BACTERIOL, V169, P3168, DOI 10.1128/jb.169.7.3168-3174.1987; FENSELAU A, 1974, LIFE SCI, V15, P811, DOI 10.1016/0024-3205(74)90519-0; FENSELAU A, 1974, BIOCHEMISTRY-US, V13, P3884, DOI 10.1021/bi00716a010; FORMAN D, 1994, LANCET, V343, P243, DOI 10.1016/S0140-6736(94)91034-0; GIBSON GE, 1988, ARCH NEUROL-CHICAGO, V45, P836, DOI 10.1001/archneur.1988.00520320022009; HANSON PJ, 1981, BIOCHEM J, V200, P349, DOI 10.1042/bj2000349; HERSH LB, 1967, J BIOL CHEM, V242, P339; HOWARD JB, 1986, J BIOL CHEM, V261, P60; Hua J, 1996, HELICOBACTER PYLORI, P121; HUGHES EJ, 1988, J GEN MICROBIOL, V134, P2877; JENKINS LS, 1987, J BACTERIOL, V169, P42, DOI 10.1128/jb.169.1.42-52.1987; KassovskaBratinova S, 1996, AM J HUM GENET, V59, P519; KOWALCHUK GA, 1994, GENE, V146, P23, DOI 10.1016/0378-1119(94)90829-X; LABIGNE A, 1991, J BACTERIOL, V173, P1920, DOI 10.1128/jb.173.6.1920-1931.1991; LIN TW, 1992, J BIOL CHEM, V267, P975; LOGAN RPH, 1994, LANCET, V344, P1078, DOI 10.1016/S0140-6736(94)91729-9; MARSHALL BJ, 1995, JAMA-J AM MED ASSOC, V274, P1064, DOI 10.1001/jama.274.13.1064; MENDZ GL, 1995, BBA-GEN SUBJECTS, V1244, P269, DOI 10.1016/0304-4165(95)00018-7; MENDZ GL, 1995, ARCH BIOCHEM BIOPHYS, V321, P153, DOI 10.1006/abbi.1995.1380; PARALES RE, 1992, J BACTERIOL, V174, P4657, DOI 10.1128/JB.174.14.4657-4666.1992; REEVES HC, 1971, METHODS MICROBIOLO A, V6, P446; ROCHET JC, 1994, PROTEIN SCI, V3, P975; RUSSELL JJ, 1982, J NEUROCHEM, V38, P1446, DOI 10.1111/j.1471-4159.1982.tb07924.x; SAUDUBRAY JM, 1987, ENZYME, V38, P80, DOI 10.1159/000469194; SCHERF U, 1991, APPL ENVIRON MICROB, V57, P2699, DOI 10.1128/AEM.57.9.2699-2702.1991; SHARP JA, 1978, BIOCHEM J, V173, P759, DOI 10.1042/bj1730759; SRAMEK SJ, 1975, ARCH BIOCHEM BIOPHYS, V171, P14, DOI 10.1016/0003-9861(75)90002-8; STEWART PR, 1966, J BIOL CHEM, V241, P1222; TUNG KK, 1975, J BACTERIOL, V124, P1462, DOI 10.1128/JB.124.3.1462-1474.1975; WHITE H, 1976, J BIOL CHEM, V251, P1688; WHITE H, 1976, J BIOL CHEM, V251, P1708; WIESENBORN DP, 1989, APPL ENVIRON MICROB, V55, P323, DOI 10.1128/AEM.55.2.323-329.1989; YEH WK, 1981, J BIOL CHEM, V256, P1565; ZHU KY, 1995, BIOTECHNIQUES, V18, P222	43	44	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25659	25667		10.1074/jbc.272.41.25659	http://dx.doi.org/10.1074/jbc.272.41.25659			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325289	hybrid			2022-12-25	WOS:A1997YA35800044
J	Realini, C; Jensen, CC; Zhang, ZG; Johnston, SC; Knowlton, JR; Hill, CP; Rechsteiner, M				Realini, C; Jensen, CC; Zhang, ZG; Johnston, SC; Knowlton, JR; Hill, CP; Rechsteiner, M			Characterization of recombinant REG alpha, REG beta, and REG gamma proteasome activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; PEPTIDE-HYDROLYZING ACTIVITY; ATP-DEPENDENT PROTEASE; INTERFERON-GAMMA; 20S PROTEASOME; IN-VIVO; MOLECULAR-CLONING; YEAST PROTEASOME; THERMOPLASMA-ACIDOPHILUM; PROTEOLYTIC ACTIVITIES	Full-length cDNAs for three human proteasome activator subunits, called REG alpha, REG beta, and REG gamma, have been expressed in Escherichia coli, and the purified recombinant proteins have been characterized. Recombinant alpha or gamma subunits form heptameric species; recombinant beta subunits are found largely as monomers or small multimers. Each recombinant REG stimulates cleavage of fluorogenic peptides by human red cell proteasomes. The pattern of activated peptide hydrolysis is virtually identical for REG alpha and REG beta. These two subunits, alone or in combination, stimulate cleavage after basic, acidic, and most hydrophobic residues in many peptides. Recombinant alpha and beta subunits bind each other with high affinity, and the REG alpha/beta heteromeric complex activates hydrolysis of LLVY-methylcoumaryl-7-amide (LLVY-MCA) and LLE-beta-nitroanilide (LLE-beta NA) more than REG alpha or REG beta alone. Using filter binding and gel filtration assays, recombinant REG gamma subunits were shown to bind themselves but not alpha or beta subunits. REG gamma differs from REG alpha and REG beta in that it markedly stimulates hydrolysis of peptides with basic residues in the P1 position but only modestly activates cleavage of LLVY-MCA or LLE-beta NA by the proteasome. REG gamma binds the proteasome with higher affinity than REG alpha or REG beta yet with lower affinity than complexes containing both REG alpha and REG beta. In summary, each of the three REG homologs is a proteasome activator with unique biochemical properties.			Realini, C (corresponding author), UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132, USA.				NIGMS NIH HHS [GM 37009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DEVERAUX Q, 1995, J BIOL CHEM, V270, P23726, DOI 10.1074/jbc.270.40.23726; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HEGERL R, 1991, FEBS LETT, V283, P117, DOI 10.1016/0014-5793(91)80567-M; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HILT W, 1993, J BIOL CHEM, V268, P3479; Hisamatsu H, 1996, J EXP MED, V183, P1807, DOI 10.1084/jem.183.4.1807; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; Hoffman L, 1996, CURR TOP CELL REGUL, V34, P1, DOI 10.1016/S0070-2137(96)80001-X; HONORE B, 1993, EUR J BIOCHEM, V218, P421, DOI 10.1111/j.1432-1033.1993.tb18392.x; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1986, J BIOL CHEM, V261, P2391; KOPP F, 1995, J MOL BIOL, V248, P264; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; Kuehn L, 1996, ARCH BIOCHEM BIOPHYS, V329, P87, DOI 10.1006/abbi.1996.0195; Kuehn L, 1996, FEBS LETT, V394, P183, DOI 10.1016/0014-5793(96)00946-5; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1992, J BIOL CHEM, V267, P10515; MAHAFFEY D, 1993, J BIOL CHEM, V268, P21205; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; NIKAIDO T, 1990, CLIN EXP IMMUNOL, V79, P209; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PETERS JM, 1994, J BIOL CHEM, V269, P7709; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; REALINI C, 1994, J BIOL CHEM, V269, P20727; REALINI C, 1995, J BIOL CHEM, V270, P29664; Realini CA, 1996, ADV EXP MED BIOL, V389, P51; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; SEN GC, 1992, J BIOL CHEM, V267, P5017; Song XL, 1996, J BIOL CHEM, V271, P26410, DOI 10.1074/jbc.271.42.26410; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Stohwasser R, 1996, FEBS LETT, V383, P109, DOI 10.1016/0014-5793(96)00110-X; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; USTRELL V, 1995, FEBS LETT, V376, P155, DOI 10.1016/0014-5793(95)01257-9; USTRELL V, 1995, P NATL ACAD SCI USA, V92, P584, DOI 10.1073/pnas.92.2.584; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; YOO Y, 1989, J BIOL CHEM, V264, P17078	64	142	153	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25483	25492		10.1074/jbc.272.41.25483	http://dx.doi.org/10.1074/jbc.272.41.25483			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325261	hybrid			2022-12-25	WOS:A1997YA35800016
J	Shaywitz, DA; Espenshade, PJ; Gimeno, RE; Kaiser, CA				Shaywitz, DA; Espenshade, PJ; Gimeno, RE; Kaiser, CA			COPII subunit interactions in the assembly of the vesicle coat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; SHUTTLE VECTORS; TRANSPORT; SEC23P; SYSTEM; COMPLEX; ENCODES; BINDING	In vitro analysis of COPII vesicle formation in the yeast Saccharomyces cerevisiae has demonstrated the requirement for three cytosolic factors: Sec31p-Sec13p, Sec23p-Sec24p, and Sar1p. Convergent evidence suggests that the peripheral endoplasmic reticulum (ER) membrane protein Sec16p also represents an important component of the vesicle assembly apparatus: SEC16 interacts genetically with all five COPII genes; Sec16p binds to Sec23p and Sec24p, is found on ER-derived transport vesicles, and is required in vitro for the efficient release of ER-derived vesicle cargo, In this report, we demonstrate an important functional interaction between Sec16p and Sec31p. First, we map onto Sec31p binding regions for Sec16p, Sec23p, Sec24p, and Sec13p. Second, we show that a truncation mutant of Sec31p specifically defective for Sec16p binding is unable to complement a sec31 Delta mutant and cannot rescue the secretion defect of a temperature-sensitive sec31 mutant at nonpermissive temperatures, We propose that Sec16p organizes the assembly of a coat that is stabilized both by the interaction of Sec31p with Sec23p and Sec24p and by the interaction of these three components with Sec16p.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)								BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIMENO RE, 1995, J CELL BIOL, V131, P325, DOI 10.1083/jcb.131.2.325; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; Kaiser C., 1994, METHODS YEAST GENETI; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; Miller JH., 1972, EXPT MOL GENETICS; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Paccaud JP, 1996, MOL BIOL CELL, V7, P1535, DOI 10.1091/mbc.7.10.1535; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PRYER NK, 1993, J CELL BIOL, V120, P867; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Salama NR, 1997, MOL BIOL CELL, V8, P205, DOI 10.1091/mbc.8.2.205; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Saxena K, 1996, BIOCHEMISTRY-US, V35, P15215, DOI 10.1021/bi961616x; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SHAYWITZ DA, 1995, J CELL BIOL, V128, P679; SIKORSKI RS, 1989, GENETICS, V122, P19; SWAROOP A, 1994, HUM MOL GENET, V3, P1281, DOI 10.1093/hmg/3.8.1281; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	34	120	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25413	25416		10.1074/jbc.272.41.25413	http://dx.doi.org/10.1074/jbc.272.41.25413			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325247	hybrid			2022-12-25	WOS:A1997YA35800002
J	Watkins, LM; Mahoney, HJ; McCulloch, JK; Raushel, FM				Watkins, LM; Mahoney, HJ; McCulloch, JK; Raushel, FM			Augmented hydrolysis of diisopropyl fluorophosphate in engineered mutants of phosphotriesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BINUCLEAR METAL CENTER; CARBONIC-ANHYDRASE-II; ZINC-BINDING-SITE; PSEUDOMONAS-DIMINUTA; BACTERIAL PHOSPHOTRIESTERASE; 3-DIMENSIONAL STRUCTURE; HALOALKANE DEHALOGENASE; CATALYTIC ACTIVITY; HYDROGEN-BOND	The phosphotriesterase from Pseudomonas diminuta hydrolyzes a wide variety of organophosphate insecticides and acetylcholinesterase inhibitors. The rate of hydrolysis depends on the substrate and can range from 6000 s(-1) for paraoxon to 0.03 s(-1) for the slower substrates such as diethylphenylphosphate. Increases in the reactivity of phosphotriesterase toward the slower substrates were attempted by the placement of a potential proton donor group at the active site. Distances from active site residues in the wild type protein to a bound substrate analog were measured, and Trp(131), Phe(132), and Phe(306) were found to be located within 5.0 Angstrom of the oxygen atom of the leaving group, Eleven mutants were created using site-directed mutagenesis and purified to homogeneity. Phe(132) and Phe(306) were replaced by tyrosine and/or histidine to generate all combinations of single and double mutants at these two sites. The single mutants W131K, F306K, and F306E were also constructed. Kinetic constants were measured for all of the mutants with the substrates paraoxon, diethylphenylphosphate, acephate, and diisopropylfluorophosphate. V-max values for the mutant enzymes with the substrate paraoxon varied from near wild type values to a 4-order of magnitude decrease for the W131K mutant, There were significant increases in the K-m for paraoxon for all mutants except F132H. V-max values measured using diethylphenylphosphate decreased for all mutants except for F132H and F132Y, whereas K-m values ranged from near wild type levels to increases of 25-fold, V-max values for acephate hydrolysis ranged from near wild type values to a 10(3)-fold decrease for W131R, K-m values for acephate ranged from near wild type to a 5-fold increase. V-max values for the mutants tested with the substrate diisopropylfluorophosphate showed an increase in all cases except for the W131K, F306K, and F306E mutants. The V-max value for the F132H/F306H mutant was increased to 3100 s(-1). These studies demonstrated for the first time that it is possible to significantly enhance the ability of the native phosphotriesterase to hydrolyze phosphorus-fluorine bonds at rates that rival the hydrolysis of paraoxon.	TEXAS A&M UNIV,DEPT CHEM,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station			Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NIGMS NIH HHS [T32 GM 08523, GM 33894] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033894, T32GM008523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNING MM, 1995, BIOCHEMISTRY-US, V34, P7973, DOI 10.1021/bi00025a002; BENNING MM, 1994, BIOCHEMISTRY-US, V33, P15001, DOI 10.1021/bi00254a008; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7438, DOI 10.1021/bi00244a010; CHAE MY, 1994, BIOORG MED CHEM LETT, V4, P1473, DOI 10.1016/S0960-894X(01)80516-3; DONARSKI WJ, 1989, BIOCHEMISTRY-US, V28, P4650, DOI 10.1021/bi00437a021; Dufour E, 1995, BIOCHEMISTRY-US, V34, P16382, DOI 10.1021/bi00050a019; DUMAS DP, 1989, BIOTECHNOL APPL BIOC, V11, P235; DUMAS DP, 1989, J BIOL CHEM, V264, P19659; DUMAS DP, 1990, ARCH BIOCHEM BIOPHYS, V277, P155, DOI 10.1016/0003-9861(90)90564-F; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; HEDSTROM L, 1994, CURR OPIN STRUC BIOL, V4, P608, DOI 10.1016/S0959-440X(94)90225-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hong SB, 1996, BIOCHEMISTRY-US, V35, P10904, DOI 10.1021/bi960663m; Huang CC, 1996, BIOCHEMISTRY-US, V35, P3439, DOI 10.1021/bi9526692; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; JONSSON BM, 1993, FEBS LETT, V322, P186, DOI 10.1016/0014-5793(93)81565-H; KENNES C, 1995, EUR J BIOCHEM, V228, P403; Kuo JM, 1997, BIOCHEMISTRY-US, V36, P1982, DOI 10.1021/bi962099l; KUO JM, 1994, BIOCHEMISTRY-US, V33, P4265, DOI 10.1021/bi00180a022; LESBURG CA, 1995, J AM CHEM SOC, V117, P6838, DOI 10.1021/ja00131a005; LEWIS VE, 1988, BIOCHEMISTRY-US, V27, P1591, DOI 10.1021/bi00405a030; Maniatis T., 1982, MOL CLONING; OMBURO GA, 1992, J BIOL CHEM, V267, P13278; Park IS, 1996, BIOCHEMISTRY-US, V35, P10464, DOI 10.1021/bi9603128; RHEINNECKER M, 1994, BIOCHEMISTRY-US, V33, P221, DOI 10.1021/bi00167a029; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vanhooke JL, 1996, BIOCHEMISTRY-US, V35, P6020, DOI 10.1021/bi960325l; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WANG ZY, 1993, BIOCHEMISTRY-US, V32, P2125, DOI 10.1021/bi00060a001; WATKINS LM, 1997, IN PRESS PROTEINS ST	31	57	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25596	25601		10.1074/jbc.272.41.25596	http://dx.doi.org/10.1074/jbc.272.41.25596			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325279	hybrid			2022-12-25	WOS:A1997YA35800034
J	Chang, MS; McNinch, J; Elias, C; Manthey, CL; Grosshans, D; Meng, T; Boone, T; Andrew, DP				Chang, MS; McNinch, J; Elias, C; Manthey, CL; Grosshans, D; Meng, T; Boone, T; Andrew, DP			Molecular cloning and functional characterization of a novel CC chemokine, stimulated T cell chemotactic protein (STCP-1) that specifically acts on activated T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; MONOCYTE CHEMOATTRACTANT PROTEIN-1; MONOCLONAL-ANTIBODY; LUNG INJURY; IN-VITRO; INTERLEUKIN-8; RECEPTOR; RECRUITMENT; MIP-1-ALPHA; EXPRESSION	A novel human chemokine STCP-1 (stimulated T cell chemotactic protein) was isolated from an activated macrophage cDNA Library. The chemokine has four cysteines positioned in a manner that identifies STCP-1 as a member of the CC chemokine family. The amino acid sequence shows 34% identity with RANTES. The gene consists of 3 exons and 2 introns with the position of intron/exon boundaries similar to that of RANTES. The gene is expressed as a 3.4-kilobase transcript on lymph node, thymus, and appendix. STCP-1 induces Ca2+ mobilization in a small percentage of primary activated T lymphocytes, but on repeated stimulation the percentage of T lymphocytes that respond to STCP-1 increases, The chemokine STCP-1 does not induce Ca2+ mobilization in monocytes, dendritic cells, neutrophils, eosinophils, lipopolysaccharide-activated B lymphocytes, and freshly isolated resting T lymphocytes, Similarly, STCP-1, while acting as a mild chemoattractant for primary activated T lymphocytes, is a potent chemoattractant for chronically activated T lymphocytes but has no chemoattractant activity for monocytes, neutrophils, eosinophils, and resting T lymphocytes. As STCP-1 acts specifically on activated T lymphocytes, it may play a role in the trafficking of activated/effector T lympho- cytes to inflammatory sites and other aspects of activated T lymphocyte physiology.			Chang, MS (corresponding author), AMGEN INC, DEPT COMPUTAT BIOL, M-S 14-1-D, 1840 DEHAVILLAND DR, THOUSAND OAKS, CA 91320 USA.							ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; Bradley LM, 1996, CURR OPIN IMMUNOL, V8, P312, DOI 10.1016/S0952-7915(96)80118-X; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; DAMLE NK, 1993, J IMMUNOL, V151, P2368; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FOLKESSON HG, 1995, J CLIN INVEST, V96, P107, DOI 10.1172/JCI118009; FUENTES ME, 1995, J IMMUNOL, V155, P5769; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; KARPUS WJ, 1995, J IMMUNOL, V155, P5003; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; LARSEN CG, 1995, J IMMUNOL, V155, P2151; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; LUKACS NW, 1995, EUR J IMMUNOL, V25, P245, DOI 10.1002/eji.1830250140; Mackay CR, 1996, J EXP MED, V184, P799, DOI 10.1084/jem.184.3.799; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; Napolitano M, 1996, J IMMUNOL, V157, P2759; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Qin SX, 1996, EUR J IMMUNOL, V26, P640, DOI 10.1002/eji.1830260320; Rossi DL, 1997, J IMMUNOL, V158, P1033; Roth SJ, 1995, EUR J IMMUNOL, V25, P3482, DOI 10.1002/eji.1830251241; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SHANLEY TP, 1995, J IMMUNOL, V154, P4793; SMITH DE, 1994, J EXP MED, V179, P1400; STANDIFORD TJ, 1995, J IMMUNOL, V155, P1515; SUNDERPLASSMANN R, 1996, BLOOD, V12, P5179; Taub D D, 1994, Ther Immunol, V1, P229; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; Taub DD, 1996, J IMMUNOL, V156, P2095; TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788; Taub DD, 1996, J CLIN INVEST, V97, P1931, DOI 10.1172/JCI118625; ZHOU Z, 1993, J IMMUNOL, V151, P4333	40	86	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25229	25237		10.1074/jbc.272.40.25229	http://dx.doi.org/10.1074/jbc.272.40.25229			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312138	hybrid			2022-12-25	WOS:A1997XY97000077
J	Ikezu, T; Okamoto, T; Yonezawa, K; Tompkins, RG; Martyn, JAJ				Ikezu, T; Okamoto, T; Yonezawa, K; Tompkins, RG; Martyn, JAJ			Analysis of thermal injury-induced insulin resistance in rodents - Implication of postreceptor mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE; SKELETAL-MUSCLE; RECEPTOR SUBSTRATE-1; BURN INJURY; TNF-ALPHA; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; PROTEIN-SYNTHESIS	Burn injury is associated with insulin resistance. The molecular basis of this resistance was investigated by examining insulin receptor signaling in rats after thermal injury. The impaired insulin-stimulated transport of [H-3]2-deoxyglucose into soleus muscle strips confirmed the insulin resistance following burns. In vivo insulin-stimulated phosphoinositide 3-kinase activity, pivotal, in translocation of GLUT4, was decreased in burns when assessed by its insulin receptor substrate-1 (IRS-1)-associated activity. Insulin-induced tyrosine kinase activity of insulin receptor (IR) and tyrosine phosphorylation of IRS-I were also attenuated, Immunoprecipitated IR, however, appeared to have normal insulin-responsive kinase activity. Finally, immunoprecipitated IRS-I was tested for its effect on partially purified recombinant IR and was found to inhibit its kinase activity. This inhibitory effect of IRS-1 was abolished by prior treatment of IRS-1 with alkaline phosphatase, indicating that burn injury-related hyperphosphorylation of IRS-1 is similar to that observed in TNF alpha-induced inhibition of LR signaling All of these changes were observed in the absence of quantitative changes in IR, IRS-1, and phosphoinositide 3-kinase. Alterations in postreceptor insulin signaling, therefore, may be responsible for the insulin resistance after thermal injury.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,SHRINERS BURNS INST,DEPT ANESTHESIOL,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,SHRINERS BURNS INST,DEPT MED,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,SHRINERS BURNS INST,DEPT SURG,BOSTON,MA 02114; KOBE UNIV,BIOSIGNAL RES CTR,KOBE,HYOGO 657,JAPAN	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Kobe University				Ikezu, Tsuneya/0000-0002-3979-8596	NIGMS NIH HHS [GM 55032-01, GM 31569-15] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031569, R23GM031569] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; BURKE JF, 1979, ANN SURG, V190, P274, DOI 10.1097/00000658-197909000-00002; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLARK AS, 1984, J CLIN INVEST, V74, P888, DOI 10.1172/JCI111506; CLAUSEN JO, 1995, LANCET, V346, P397, DOI 10.1016/S0140-6736(95)92779-4; COSTELLI P, 1995, J CLIN INVEST, V95, P2367, DOI 10.1172/JCI117929; DEITCH EA, 1990, NEW ENGL J MED, V323, P1249; DEMLING RH, 1985, NEW ENGL J MED, V313, P1389, DOI 10.1056/NEJM198511283132205; ENDO S, 1993, BURNS, V19, P124, DOI 10.1016/0305-4179(93)90033-5; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HERNDON DN, 1988, ANN SURG, V208, P484, DOI 10.1097/00000658-198810000-00010; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HONEYCUTT D, 1992, Journal of Burn Care and Rehabilitation, V13, P181, DOI 10.1097/00004630-199203000-00001; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; JAHOOR F, 1989, AM J PHYSIOL, V257, pE323, DOI 10.1152/ajpendo.1989.257.3.E323; JURASINSKI C, 1995, METABOLISM, V44, P1130, DOI 10.1016/0026-0495(95)90005-5; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LEMARCHANDBRUSTEL Y, 1978, AM J PHYSIOL, V234, pE348, DOI 10.1152/ajpendo.1978.234.4.E348; Long SD, 1996, BIOCHEM BIOPH RES CO, V220, P949, DOI 10.1006/bbrc.1996.0512; MARANO MA, 1990, SURG GYNECOL OBSTET, V170, P32; MOLLOY RG, 1993, J IMMUNOL, V151, P2142; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; MULLER MJ, 1994, LANCET, V343, P216, DOI 10.1016/S0140-6736(94)90995-4; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; NELSON KM, 1982, JPEN-PARENTER ENTER, V6, P3, DOI 10.1177/014860718200600103; OKADA T, 1994, J BIOL CHEM, V269, P3568; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SPIEGELMAN BM, 1993, CELL, V73, P625, DOI 10.1016/0092-8674(93)90243-J; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; THOMAS R, 1979, SURGERY, V86, P742; VARY TC, 1995, SHOCK, V3, P403; VEGA G L, 1991, Journal of Burn Care and Rehabilitation, V12, P463, DOI 10.1097/00004630-199109000-00013; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1990, PEPTIDE HORMONE ACTI; WILLMORE DW, 1991, NEW ENGL J MED, V325, P695; WOLFE RR, 1987, NEW ENGL J MED, V317, P403, DOI 10.1056/NEJM198708133170702; WOLFE RR, 1993, SEMIN NEPHROL, V13, P382; YANG YT, 1989, BIOCHEM J, V261, P1; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; YU CC, 1989, BURNS, V15, P145; ZELLER WP, 1991, BIOCHEM BIOPH RES CO, V176, P535, DOI 10.1016/0006-291X(91)90958-A	50	77	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25289	25295		10.1074/jbc.272.40.25289	http://dx.doi.org/10.1074/jbc.272.40.25289			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312146	hybrid			2022-12-25	WOS:A1997XY97000085
J	Trinh, K; Minassian, C; Lange, AJ; ODoherty, RM; Newgard, CB				Trinh, K; Minassian, C; Lange, AJ; ODoherty, RM; Newgard, CB			Adenovirus-mediated expression of the catalytic subunit of glucose-6-phosphatase in INS-1 cells - Effects on glucose cycling, glucose usage, and insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE-DISEASE TYPE-1A; PANCREATIC-ISLETS; MICROSOMAL GLUCOSE-6-PHOSPHATASE; RECOMBINANT ADENOVIRUS; ENZYME-DEFICIENT; GENE-EXPRESSION; HEXOKINASE-I; METABOLISM; LIVER; RAT	Glucose-6-phosphatase (Glu-6-Pase) catalyzes the terminal step of gluconeogenesis, the conversion of glucose 6-phosphate (Glu-6-P) to free glucose, This enzyme activity is thought to be conferred by a complex of proteins residing in the endoplasmic reticulum (ER), including a Glu-6-P translocase that transports Glu-6-P into the lumen of the ER, a phosphohydrolase catalytic subunit residing in the lumen, and putative glucose and inorganic phosphate transporters that allow exit of the products of the reaction, In this study, we have investigated the effect of adenovirus-mediated overexpression of the Glu-6-Pase catalytic subunit on glucose metabolism and insulin secretion, using a well differentiated insulinoma cell line, INS-1, We found that the overexpressed Glu-6-Pase catalytic subunit was normally glycosylated, correctly sorted to the ER, and caused a 10-fold increase in Glu-6-Pase enzymatic activity in in vitro assays, Consistent with these findings, a 4.2-fold increase in (H2O)-H-3 incorporation into glucose was observed in INS-1 cells treated with the recombinant adenovirus containing the Glu-6-Pase catalytic subunit cDNA (AdCMV-Glu-6-Pase). 3-[H-3]Glucose usage was decreased by 32% in AdCMV-Glu-6-Pase-treated cells relative to controls, resulting in a proportional 30% decrease in glucose-stimulated insulin secretion, Our findings indicate that overexpression of the Glu-6-Pase catalytic subunit significantly impacts glucose metabolism and insulin secretion in islet beta-cells. However, INS-1 cells treated with AdCMV-Glu-6-Pase do not exhibit the severe alterations of beta-cell function and metabolism associated with islets from rodent models of obesity and non-insulin-dependent diabetes mellitus, suggesting the involvement of genes in addition to the catalytic subunit of Glu-6-Pase in the etiology of such beta-cell dysfunction.	UNIV TEXAS,SW MED CTR,GIFFORD LABS DIABET RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046492] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK46492] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARION WJ, 1980, J BIOL CHEM, V255, P396; ASAFARI M, 1992, ENDOCRINOLOGY, V130, P167; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BECKER TC, 1994, J BIOL CHEM, V269, P21234; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUGHES SD, 1991, J BIOL CHEM, V266, P4521; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; IVANOVA V, 1994, PREP BIOCHEM, V24, P83, DOI 10.1080/10826069408010084; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; KHAN A, 1990, ENDOCRINOLOGY, V126, P2413, DOI 10.1210/endo-126-5-2413; KHAN A, 1989, J BIOL CHEM, V264, P9732; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LEI KJ, 1994, J CLIN INVEST, V93, P1994, DOI 10.1172/JCI117192; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; MARIE S, 1993, J BIOL CHEM, V268, P23881; MASSAGUE J, 1978, BIOCHIM BIOPHYS ACTA, V543, P269, DOI 10.1016/0304-4165(78)90073-9; McCrory W.J., 1988, VIROLOGY, V163, P614; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Newgard CB, 1996, DIABETES REV, V4, P191; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; PERALES MA, 1991, MOL CELL BIOCHEM, V101, P67; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; TALJEDAL IB, 1969, BIOCHEM J, V114, P387; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; WADDELL ID, 1988, BIOCHEM J, V255, P471, DOI 10.1042/bj2550471; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173	32	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24837	24842		10.1074/jbc.272.40.24837	http://dx.doi.org/10.1074/jbc.272.40.24837			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312082	hybrid			2022-12-25	WOS:A1997XY97000021
J	Bruneau, N; Nganga, A; Fisher, EA; Lombardo, D				Bruneau, N; Nganga, A; Fisher, EA; Lombardo, D			O-glycosylation of C-terminal tandem-repeated sequences regulates the secretion of rat pancreatic bile salt-dependent lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL ESTERASE GENE; LINKED GLYCOSYLATION; STIMULATED LIPASE; PEST SEQUENCES; CDNA CLONING; PROTEIN; EXPRESSION; HYDROLASE; CELLS; PURIFICATION	Amino acid sequences rich in Pro, Glu, Ser, and Thr (PEST) are common to rapidly degraded proteins (Rogers, S., Wells, R. & Rechsteiner, M. (1986) Science 234, 364-368), On pancreatic bile salt-dependent lipase (BSDL), PEST sequences are present in the C-terminal region of the enzyme to which is associated the O-glycosylation, We have postulated that the O-glycosylation of BSDL may contribute to mask PEST sequences and to trigger the secretion of this enzyme instead of its delivery into a degradative pathway (Bruneau, N., and Lombardo, D. (1995) J. Biol. Chem. 270, 13524-13525). To further examine the role of the O-linked glycosylation on BSDL metabolism, rat pancreatic BSDL cDNA was stably transfected into two Chinese hamster ovary (CHO) cell lines, the CHO K1 wild-type line and the O-glycosylation defective CHO IdlD line. In these latter cells, O-glycosylation can be reversibly modulated by culture conditions. Results indicate that the rate of BSDL synthesis by transfected CHO K1 or CHO IdlD cells reflects, independently of culture conditions, the amount of mRNA specific for BSDL present in these transfected cells. Nevertheless, the rate of secretion of the enzyme depends upon cell culture conditions and increases with the cell capability to O-glycosylate C-terminal tandem-repeated sequences, Immunoprecipitation experiments performed on cell lysates suggested that a rapid degradation of BSDL occurred particularly when transfected CHO IdlD cells were cultured under non-permissive conditions. We further showed that BSDL secreted by CHO IdlD cells grown under nonpermissive conditions that normally prevent O-glycosylation incorporated galactose and was reactive with peanut agglutinin, which recognizes the core structure of O-linked glycans, We concluded that the BSDL expressed by CHO IdlD cells grown under non-permissive conditions was rapidly degraded but a fraction of the enzyme was allowed to O-glycosylate and consequently was secreted.	INSERM, U260, UNITE RECH PHYSIOPATHOL REGULAT HORMONONUTR, F-13385 MARSEILLE, FRANCE; MT SINAI SCH MED, CARDIOVASC INST, NEW YORK, NY 10021 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Icahn School of Medicine at Mount Sinai			Bruneau, Nadine/O-2100-2016	Bruneau, Nadine/0000-0002-1523-3128; Fisher, Edward/0000-0001-9802-143X				ABOUAKIL N, 1993, J BIOL CHEM, V268, P25755; ABOUAKIL N, 1988, BIOCHIM BIOPHYS ACTA, V961, P299, DOI 10.1016/0005-2760(88)90077-X; BARNES JA, 1995, MOL CELL BIOCHEM, V149, P17, DOI 10.1007/BF01076559; BRUNEAU N, 1995, EUR J BIOCHEM, V233, P209, DOI 10.1111/j.1432-1033.1995.209_1.x; BRUNEAU N, 1995, J BIOL CHEM, V270, P13524, DOI 10.1074/jbc.270.22.13524; CALAME KB, 1975, ARCH BIOCHEM BIOPHYS, V168, P57, DOI 10.1016/0003-9861(75)90227-1; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; DIPERSIO LP, 1994, BIOCHEMISTRY-US, V33, P3442, DOI 10.1021/bi00177a038; DOOLITTLE MH, 1991, ANAL BIOCHEM, V195, P364, DOI 10.1016/0003-2697(91)90342-Q; FONTAINE RN, 1991, BIOCHEMISTRY-US, V30, P7008, DOI 10.1021/bi00242a028; GJELLESVIK DR, 1992, BIOCHIM BIOPHYS ACTA, V1124, P123, DOI 10.1016/0005-2760(92)90088-D; GJELLESVIK DR, 1994, EUR J BIOCHEM, V226, P603, DOI 10.1111/j.1432-1033.1994.tb20086.x; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HANSSON L, 1993, J BIOL CHEM, V268, P26692; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HOLTSBERG FW, 1995, BIOCHEM J, V309, P141, DOI 10.1042/bj3090141; HUANG Y, 1991, J BIOL CHEM, V266, P6720; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KRIEGER M, 1989, METHOD CELL BIOL, V32, P57; KUMAR BV, 1992, BIOCHEMISTRY-US, V31, P6077, DOI 10.1021/bi00141a017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1984, J BIOL CHEM, V259, P4616; LOMBARDO D, 1978, BIOCHIM BIOPHYS ACTA, V527, P142, DOI 10.1016/0005-2744(78)90263-2; LOMBARDO D, 1980, BIOCHIM BIOPHYS ACTA, V611, P147, DOI 10.1016/0005-2744(80)90050-9; LOOMES KM, 1995, EUR J BIOCHEM, V230, P607; MAS E, 1993, BIOCHEM J, V289, P609, DOI 10.1042/bj2890609; Mas E, 1997, GLYCOBIOLOGY, V7, P745, DOI 10.1093/glycob/7.6.745; MORLOCKFITZPATRICK KR, 1995, P SOC EXP BIOL MED, V208, P186; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REUE K, 1991, J LIPID RES, V32, P267; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROUDANI S, 1994, EUR J CELL BIOL, V65, P132; ROUDANI S, 1995, BBA-GENE STRUCT EXPR, V1264, P141, DOI 10.1016/0167-4781(95)00141-3; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WANG CS, 1995, BIOCHEMISTRY-US, V34, P10639, DOI 10.1021/bi00033a039; WINKLER KE, 1992, BIOCHIM BIOPHYS ACTA, V1126, P151; YE SQ, 1993, J BIOL CHEM, V268, P8497; ZOLFAGHARI R, 1993, J BIOL CHEM, V268, P13532	40	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27353	27361		10.1074/jbc.272.43.27353	http://dx.doi.org/10.1074/jbc.272.43.27353			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341186	hybrid			2022-12-25	WOS:A1997YC65900082
J	Cvejic, S; Devi, LA				Cvejic, S; Devi, LA			Dimerization of the delta opioid receptor: Implication for a role in receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NG108-15 HYBRID-CELLS; OPIATE ENKEPHALIN RECEPTORS; NEURO-BLASTOMA CELLS; DOWN-REGULATION; BINDING-SITES; CROSS-TALK; IN-VIVO; PHOSPHORYLATION; MORPHINE; COEXPRESSION	Dimerization of G protein-coupled receptors has been increasingly noted in the regulation of their biological activity, However, its involvement in agonist-induced receptor internalization is not well understood. In this study, we examined the ability of mouse delta-opioid receptors to dimerize and the role of receptor dimerization in agonist induced internalization. Using differentially (Flag and c-Myc) epitope-tagged receptors we show that delta-opioid receptors exist as dimers, The level of dimerization is agonist dependent, Increasing concentrations of agonists reduce the levels of dimer with a corresponding increase in the levels of monomer, Interestingly, morphine does not affect the levels of either form, It has been shown that morphine, unlike other opioid agonists, does not induce receptor internalization. This suggests a relationship between the ability of agonists to reduce the levels of dimer and to induce receptor internalization, The time course of the agonist-induced decrease of delta-opioid receptor dimers is shorter than the time course of internalization, suggesting that monomerization precedes the agonist-induced internalization of the receptor, Furthermore, we found that a mutant delta-opioid receptor, with a 15-residue C-terminal deletion, does not exhibit dimerization. This mutant receptor has been shown to lack the ability to undergo agonist-induced internalization. These results suggest that the interconversion between the dimeric and monomeric forms plays a role in opioid receptor internalization.	NYU,SCH MED,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NIDA NIH HHS [DA08863] Funding Source: Medline; NINDS NIH HHS [NS1788] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R56DA008863, R37DA008863, R01DA008863] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ALI H, 1994, J BIOL CHEM, V269, P24557; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BOWEN WD, 1981, P NATL ACAD SCI-BIOL, V78, P4818, DOI 10.1073/pnas.78.8.4818; Cvejic S, 1996, J BIOL CHEM, V271, P4073; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; HAZUM E, 1979, SCIENCE, V206, P1077, DOI 10.1126/science.227058; HAZUM E, 1982, BIOCHEM BIOPH RES CO, V104, P347, DOI 10.1016/0006-291X(82)91981-7; HAZUM E, 1979, NATURE, V282, P626, DOI 10.1038/282626a0; HAZUM E, 1980, P NATL ACAD SCI-BIOL, V77, P3038, DOI 10.1073/pnas.77.5.3038; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; JIANG Q, 1990, EUR J PHARMACOL, V186, P137; JIANG Q, 1990, Journal of Pharmacology and Experimental Therapeutics, V254, P683; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAW PY, 1994, J PHARMACOL EXP THER, V271, P1686; LAW PY, 1982, MOL PHARMACOL, V22, P1; LAW PY, 1984, J BIOL CHEM, V259, P4096; LAW PY, 1995, J PHARMACOL EXP THER, V272, P322; LAW PY, 1983, MOL PHARMACOL, V24, P413; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; ROTHMAN RB, 1986, EUR J PHARMACOL, V124, P113, DOI 10.1016/0014-2999(86)90130-5; ROTHMAN RB, 1987, PEPTIDES, V8, P1015, DOI 10.1016/0196-9781(87)90130-6; ROTHMAN RB, 1989, EUR J PHARMACOL, V160, P71, DOI 10.1016/0014-2999(89)90655-9; ROTHMAN RB, 1988, J PHARMACOL EXP THER, V247, P405; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U	36	404	414	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26959	26964		10.1074/jbc.272.43.26959	http://dx.doi.org/10.1074/jbc.272.43.26959			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341132	hybrid			2022-12-25	WOS:A1997YC65900028
J	Jbilo, O; Vidal, H; Paul, R; DeNys, N; Bensaid, M; Silve, S; Carayon, P; Davi, D; Galiegue, S; Bourrie, B; Guillemot, JC; Ferrara, P; Loison, G; Maffrand, JP; LeFur, G; Casellas, P				Jbilo, O; Vidal, H; Paul, R; DeNys, N; Bensaid, M; Silve, S; Carayon, P; Davi, D; Galiegue, S; Bourrie, B; Guillemot, JC; Ferrara, P; Loison, G; Maffrand, JP; LeFur, G; Casellas, P			Purification and characterization of the human SR 31747A-binding protein - A nuclear membrane protein related to yeast sterol isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG BRAIN; ETORPHINE-INACCESSIBLE SITES; SIGMA-BINDING SITES; AUTORADIOGRAPHIC LOCALIZATION; <H-3>-LABELED SKF-10047; RAT-LIVER; IN-VIVO; RECEPTOR; SR-31747; LIGAND	SR 31747A, defined as a sigma ligand, is a novel immunosuppressive agent that blocks proliferation of human and mouse lymphocytes. Using a radiolabeled chemical probe, we here purified a target of SR 31747A and called it SR 31747A-binding protein (SR-BP). Purified SR-BP retained its binding properties and migrated on SDS-polyacrylamide gel as a M-r 28,000 protein. Cloning of the cDNA encoding human SR-BP shows an open reading frame for a 223-amino acid protein, which is homologous to the recently cloned sigma 1 receptor. Interestingly, the deduced amino acid sequence was found to be related to fungal C8-C7 sterol isomerase, encoded by the ERG2 gene. The ERG2 gene product has been identified recently as the molecular target of SR 31747A that mediates antiproliferative effects of the drug in yeast. Northern blot analysis of SR-BP gene expression revealed a single transcript of 2 kilobases which was widely expressed among organs, with the highest abundance in liver and the lowest abundance in brain. Subcellular localization analysis in various cells, using a specific monoclonal antibody raised against SR-BP, demonstrated that this protein was associated with the nuclear envelope. When studying the binding of SR 31747A on membranes from yeast expressing SR-BP, we found a pharmacological profile of sigma 1 receptors; binding was displaced by (+)-pentazocine, haloperidol, and (+)-SKF 10,047, with (+)-SKF 10,047 being a more potent competitor than (-)-SKF 10,047. Scatchard plot analysis revealed K-d values of 7.1 nM and 0.15 nM for (+)-pentazocine and SR 31747A, respectively, indicating an affinity of SR-BP 50-fold higher for SR 31747A than for pentazocine. Additionally, we showed that pentazocine, a competitive inhibitor of SR 31747A binding, also prevents the immunosuppressive effect of SR 31747A. Taken together, these findings strongly suggest that SR-BP represents the molecular target for SR 31747A in mammalian tissues, which could be critical for T cell proliferation.	SANOFI RECH, F-34184 MONTPELLIER 04, FRANCE; SANOFI RECH, F-31676 LABEGE, FRANCE; SANOFI RECH, F-31036 TOULOUSE, FRANCE; SANOFI RECH, F-75374 PARIS 08, FRANCE	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; [Anonymous], 1991, Methods Enzymol, V194, P1; ASHMAN WH, 1991, LIPIDS, V26, P628, DOI 10.1007/BF02536427; BOURRIE B, 1995, EUR J IMMUNOL, V25, P2882, DOI 10.1002/eji.1830251026; BOWEN WD, 1989, EUR J PHARMACOL, V163, P309, DOI 10.1016/0014-2999(89)90200-8; CASELLAS P, 1994, J NEUROIMMUNOL, V52, P193, DOI 10.1016/0165-5728(94)90113-9; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DEROCQ JM, 1995, J PHARMACOL EXP THER, V272, P224; Dussossoy D, 1996, CYTOMETRY, V24, P39; GUNDLACK AL, 1996, J NEUROSCI, V6, P1757; Hanner M, 1996, P NATL ACAD SCI USA, V93, P8072, DOI 10.1073/pnas.93.15.8072; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HELLEWELL SB, 1990, BRAIN RES, V527, P244, DOI 10.1016/0006-8993(90)91143-5; HELLEWELL SB, 1994, EUR J PHARM-MOLEC PH, V268, P9, DOI 10.1016/0922-4106(94)90115-5; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KARBON EW, 1991, EUR J PHARMACOL, V193, P21; Kekuda R, 1996, BIOCHEM BIOPH RES CO, V229, P553, DOI 10.1006/bbrc.1996.1842; KEON JPR, 1994, CURR GENET, V25, P531, DOI 10.1007/BF00351674; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YH, 1995, J NEUROIMMUNOL, V59, P143, DOI 10.1016/0165-5728(95)00032-W; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Moebius FF, 1997, TRENDS PHARMACOL SCI, V18, P67, DOI 10.1016/S0165-6147(96)01037-1; MYERS AM, 1994, J MED CHEM, V37, P4109, DOI 10.1021/jm00050a008; PAUL R, 1994, J NEUROIMMUNOL, V52, P183, DOI 10.1016/0165-5728(94)90112-0; ROBINSON GW, 1993, MOL CELL BIOL, V13, P2706, DOI 10.1128/MCB.13.5.2706; ROMAN F, 1989, GASTROENTEROLOGY, V97, P76, DOI 10.1016/0016-5085(89)91418-2; ROTHMAN RB, 1991, MOL PHARMACOL, V39, P222; SAMOVILOVA NN, 1988, EUR J PHARMACOL, V147, P259, DOI 10.1016/0014-2999(88)90784-4; Silve S, 1996, MOL CELL BIOL, V16, P2719; Silve S, 1996, J BIOL CHEM, V271, P22434, DOI 10.1074/jbc.271.37.22434; SU TP, 1981, EUR J PHARMACOL, V75, P81, DOI 10.1016/0014-2999(81)90352-6; SU TP, 1982, J PHARMACOL EXP THER, V223, P284; Whitlock BB, 1996, J NEUROIMMUNOL, V67, P83; Wolfe SA, 1997, J NEUROIMMUNOL, V72, P45, DOI 10.1016/S0165-5728(96)00140-3; WOLFE SA, 1989, ENDOCRINOLOGY, V124, P1160, DOI 10.1210/endo-124-3-1160; WOLFE SA, 1988, J PHARMACOL EXP THER, V247, P1114; WOLFE SA, 1994, SIGMA RECEPTORS, P287; WOLFE SA, 1992, MULTIPLE SIGMA PCP R, P927; WU XZ, 1991, J PHARMACOL EXP THER, V257, P351; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	41	62	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27107	27115		10.1074/jbc.272.43.27107	http://dx.doi.org/10.1074/jbc.272.43.27107			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341151	hybrid			2022-12-25	WOS:A1997YC65900047
J	Liu, WM; Wang, D; Chen, P; Halpern, M				Liu, WM; Wang, D; Chen, P; Halpern, M			Cloning and expression of a gene encoding a protein obtained from earthworm secretion that is a chemoattractant for garter snakes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOMERONASAL SYSTEM; CHEMICAL SENSES	The protein ES20, derived from earthworm shock secretion, is a vomeronasally mediated chemoattractant for garter snakes (Jiang, X. C., Lnouchi, J., Wang, D., and Halpern, M. (1990) J. Biol. Chem. 265, 8736-8744). Based on its 15-residue N-terminal amino acid sequence, degenerative oligodeoxynucleotide probes were synthesized and used to screen a cDNA library that was constructed in sense orientation using a Uni-ZAP(TM) XR vector and XL1-Blue MRF' host, A gene was cloned from a polymerase chain reaction as well as from the cDNA library. A combination of the forward degenerative primer and T7 primer was used to obtain gene-specific DNA fragments, from which probes were synthesized and successfully used in screening the cDNA Library, The ES20 gene is about 700 base pairs long and encodes 208 amino residues, The ES20, gene was excised from a recombinant plasmid pSK-ES20, ligated to pQE30 expression vector, and transformed into Escherichia coli strain JM109. The selected recombinant plasmids were transformed into expression host cell, E. coli M15[pREP4]. Three transformants were selected, induced with isopropyl-1-thio-beta-D-galactopyranoside for fusion gene expression and an expressed 20-kDa fusion protein purified under denaturing conditions, This protein was refolded and gave a positive reaction against ES20-specific polyclonal antibodies. The fusion protein that had not been denatured remained as an aggregate and was an active chemoattractant for garter snakes.	SUNY HLTH SCI CTR,DEPT BIOCHEM,BROOKLYN,NY 11203; SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NIDCD NIH HHS [DC 00104] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Burghardt G. M., 1966, PSYCHON SCI, V4, P37; BURGHARDT GM, 1975, PHYSIOL BEHAV, V14, P185, DOI 10.1016/0031-9384(75)90164-X; GABE M, 1976, Memoires du Museum National d'Histoire Naturelle Serie A Zoologie, V98, P1; HALPERN M, 1979, PHYSIOL BEHAV, V22, P1183, DOI 10.1016/0031-9384(79)90274-9; INOUCHI J, 1993, BRAIN BEHAV EVOLUT, V41, P171, DOI 10.1159/000113835; JIANG XC, 1990, J BIOL CHEM, V265, P8736; KUBIE JL, 1979, J COMP PHYSIOL PSYCH, V93, P648, DOI 10.1037/h0077606; KUBIE JL, 1978, J COMP PHYSIOL PSYCH, V92, P362, DOI 10.1037/h0077456; LI CS, 1993, SOC NEUROSCI, V23, P122; LUO YQ, 1994, J BIOL CHEM, V269, P16867; PARSONS TS, 1970, BIOLOGY REPTILIA, V2, P99; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WANG D, 1993, BRAIN BEHAV EVOLUT, V41, P246, DOI 10.1159/000113846; WANG D, 1988, ARCH BIOCHEM BIOPHYS, V267, P459, DOI 10.1016/0003-9861(88)90051-3; WANG D, 1992, COMP BIOCH PHYSL B, V102, P601; WANG D, 1992, CHEM SIGNALS VERTEBR, V6, P107; WANG D, 1997, IN PRESS ARCH BIOCH; Wilde W, 1938, J EXP ZOOL, V77, P445, DOI 10.1002/jez.1400770307	19	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27378	27381		10.1074/jbc.272.43.27378	http://dx.doi.org/10.1074/jbc.272.43.27378			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341189	hybrid			2022-12-25	WOS:A1997YC65900085
J	Luo, GY; YuLee, LY				Luo, GY; YuLee, LY			Transcriptional inhibition by Stat5 - Differential activities at growth-related versus differentiation-specific promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY FACTOR-I; MAMMARY-GLAND FACTOR; SINGLE PHOSPHOTYROSINE RESIDUE; COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASES; DNA-BINDING ACTIVITY; NB2 T-CELLS; PROLACTIN RECEPTOR; GENE-EXPRESSION; SIGNAL-TRANSDUCTION	Prolactin (PRL) induces transcriptional activation of not only growth-related genes such as interferon regulatory factor-1 (LRF-1) but also differentiation-specific genes such as beta-casein through a signaling cascade consisting of Janus kinases and Stat (signal transducer and activator of transcription) factors. To understand better the role of Stats in PRL signaling, we cloned rat Stat5b from a PRL-responsive T cell line Nb2. A Stat5b-specific peptide antibody was generated. In PRL receptor reconstituted COS cells cotransfected with Stat5b or Stat5a, both Stat5 proteins become tyrosine phosphorylated and bind to the IRF-1 GAS (interferon-gamma activation sequence) element in a PRL-inducible manner. Unexpectedly, both Stat5b and Stat5a inhibit PRL induction of the IRF-1 promoter, but they mediate PRL stimulation of the beta-casein promoter. Stat5-mediated inhibition was observed only at the native IRF-1 promoter and not at the isolated IRF-1 GAS element linked to a heterologous thymidine kinase promoter. Mutational analyses showed that the DNA binding activity of Stat5b is not required, but the carboxyl terminal transactivation domain is essential for Stat5b to inhibit PRL induction of the IRF-1 promoter. These results suggest that Stat5b mediates inhibition via protein protein interactions. In contrast, both DNA binding and transactivation domains of Stat5b are required to mediate PRL induction of the beta-casein promoter. Furthermore, at carboxyl-terminal truncated dominant negative Stat5b can reverse Stat5b inhibition at the IRF-1 promoter, These studies suggest that Stat proteins can act as not only positive but also negative regulators of gene transcription. Further, Stat5 can modulate gene expression without binding to DNA but via protein-protein interactions.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT IMMUNOL & MICROBIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NIDDK NIH HHS [DK-44625] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044625] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXTELL SM, 1995, MOL ENDOCRINOL, V9, P312, DOI 10.1210/me.9.3.312; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CHUAI K, 1996, MOL CELL BIOL, V16, P4932; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; Dajee M, 1996, MOL ENDOCRINOL, V10, P171, DOI 10.1210/me.10.2.171; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DEMMER J, 1995, MOL CELL ENDOCRINOL, V107, P113, DOI 10.1016/0303-7207(94)03432-S; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; EDERY M, 1994, MOL CELL ENDOCRINOL, V102, P39, DOI 10.1016/0303-7207(94)90095-7; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; GILMOUR KC, 1995, P NATL ACAD SCI USA, V92, P10772, DOI 10.1073/pnas.92.23.10772; GILMOUR KC, 1994, P NATL ACAD SCI USA, V91, P6850, DOI 10.1073/pnas.91.15.6850; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GOUT PW, 1980, CANCER RES, V40, P2433; HOOGHE R, 1993, IMMUNOL TODAY, V14, P212, DOI 10.1016/0167-5699(93)90165-H; HORSEMAN ND, 1994, ENDOCR REV, V15, P627, DOI 10.1210/er.15.5.627; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hou XS, 1997, TRENDS GENET, V13, P105, DOI 10.1016/S0168-9525(97)01006-8; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LEE KF, 1994, MOL ENDOCRINOL, V3, P447; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURPHY WJ, 1995, LIFE SCI, V57, P1, DOI 10.1016/0024-3205(95)00237-Z; ONEAL KD, 1994, J BIOL CHEM, V269, P26076; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SAVINO W, 1995, IMMUNOL TODAY, V16, P318, DOI 10.1016/0167-5699(95)80144-8; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHWARZ LA, 1992, MOL CELL ENDOCRINOL, V86, P103, DOI 10.1016/0303-7207(92)90180-E; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; STEVENS AM, 1995, MOL ENDOCRINOL, V9, P513, DOI 10.1210/me.9.4.513; STEVENS AM, 1994, MOL ENDOCRINOL, V8, P345, DOI 10.1210/me.8.3.345; STEVENS AM, 1992, MOL ENDOCRINOL, V6, P2236, DOI 10.1210/me.6.12.2236; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; STRUELI HC, 1995, J BIOL CHEM, V270, P21639; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wang YF, 1997, MOL ENDOCRINOL, V11, P1353, DOI 10.1210/me.11.9.1353; Wang YF, 1996, MOL CELL ENDOCRINOL, V121, P19, DOI 10.1016/0303-7207(96)03840-3; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; YuLee LY, 1997, P SOC EXP BIOL MED, V215, P35, DOI 10.3181/00379727-215-44111; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	76	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26841	26849		10.1074/jbc.272.43.26841	http://dx.doi.org/10.1074/jbc.272.43.26841			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341115	hybrid			2022-12-25	WOS:A1997YC65900011
J	Scheirer, KE; Higgins, NP				Scheirer, KE; Higgins, NP			The DNA cleavage reaction of DNA gyrase - Comparison of stable ternary complexes formed with enoxacin and CcdB protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TOPOISOMERASE-IV; BINDING-SITE; QUINOLONE ANTIBACTERIALS; NALIDIXIC-ACID; LETD CCDB; MECHANISM; INHIBITION; ENZYME; REPLICATION	The potent synthetic fluoroquinolones and the natural CcdB protein encoded by the F plasmid both inhibit bacterial growth by attacking DNA gyrase and by stimulating enzyme-induced breaks in bacterial DNA. The cleavage mechanisms of these structurally diverse compounds were analyzed by purifying and characterizing stable ternary complexes of enoxacin and CcdB protein with gyrase bound to a strong gyrase binding site from bacteriophage Mu. Three differences between enoxacin-and CcdB-derived complexes were discovered. 1) Enoxacin binds to the DNA active site and alters the breakage/reunion activity of the enzyme. CcdB binds gyrase-DNA complexes but does not influence enzymatic activity directly. 2) Complexes that produce DNA cleavage with enoxacin are reversible, whereas similar complexes made with CcdB protein are not. 3) Enoxacin stimulates cleavage of both relaxed and supercoiled forms of DNA in the absence of ATP, whereas CcdB induces cleavage only after many cycles of ATP-dependent breakage and reunion. These differences in mechanisms can be explained by a model in which enoxacin induces formation of a novel ''cleavable'' complex, whereas CcdB protein traps a very rare ''cleaved'' conformation of the enzyme.	UNIV ALABAMA,DEPT BIOCHEM & MOL GENET,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NIAID NIH HHS [AI07150, AI35170] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007150] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; BERNARD P, 1993, J MOL BIOL, V234, P534, DOI 10.1006/jmbi.1993.1609; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Chen CR, 1996, J MOL BIOL, V258, P627, DOI 10.1006/jmbi.1996.0274; Critchlow SE, 1996, BIOCHEMISTRY-US, V35, P7387, DOI 10.1021/bi9603175; DOMAGALA JM, 1986, J MED CHEM, V29, P394, DOI 10.1021/jm00153a015; Drlica K, 1994, Adv Pharmacol, V29A, P263; ELLEDGE SJ, 1997, SCIENCE, V274, P1663; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Gari E, 1996, MOL MICROBIOL, V21, P111, DOI 10.1046/j.1365-2958.1996.6221338.x; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Hiasa H, 1996, J BIOL CHEM, V271, P26424, DOI 10.1074/jbc.271.42.26424; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; LOCKSHON D, 1985, J MOL BIOL, V181, P63, DOI 10.1016/0022-2836(85)90324-9; Maki S, 1996, J MOL BIOL, V256, P473, DOI 10.1006/jmbi.1996.0102; Marians KJ, 1997, J BIOL CHEM, V272, P9401; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; MORRISON A, 1980, J BIOL CHEM, V255, P2211; MORRISON A, 1979, CELL, V17, P175, DOI 10.1016/0092-8674(79)90305-2; MORRISON A, 1981, P NATL ACAD SCI-BIOL, V78, P1416, DOI 10.1073/pnas.78.3.1416; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PATO ML, 1990, P NATL ACAD SCI USA, V87, P8716, DOI 10.1073/pnas.87.22.8716; PATO ML, 1995, J BACTERIOL, V177, P5937, DOI 10.1128/jb.177.20.5937-5942.1995; Shen L L, 1994, Adv Pharmacol, V29A, P285; SHEN LL, 1989, J BIOL CHEM, V264, P2973; SHEN LL, 1985, P NATL ACAD SCI USA, V82, P307, DOI 10.1073/pnas.82.2.307; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3886, DOI 10.1021/bi00435a039; STAUDENBAUER WL, 1981, NUCLEIC ACIDS RES, V9, P3589, DOI 10.1093/nar/9.15.3589; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; VANMELDEREN L, 1994, MOL MICROBIOL, V11, P1151; WILLMOTT CJR, 1994, J MOL BIOL, V242, P351, DOI 10.1006/jmbi.1994.1586; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534; YORGEY P, 1994, P NATL ACAD SCI USA, V91, P4519, DOI 10.1073/pnas.91.10.4519; YOSHIDA H, 1991, ANTIMICROB AGENTS CH, V35, P1647, DOI 10.1128/AAC.35.8.1647; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859	44	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27202	27209		10.1074/jbc.272.43.27202	http://dx.doi.org/10.1074/jbc.272.43.27202			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341164	hybrid			2022-12-25	WOS:A1997YC65900060
J	Yiu, GK; Hecht, NB				Yiu, GK; Hecht, NB			Novel testis-specific protein-DNA interactions activate transcription of the mouse protamine 2 gene during spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERM-CELL DEVELOPMENT; RNA-BINDING PROTEINS; Y-BOX PROTEINS; MESSENGER-RNA; TRANSGENIC MICE; INVITRO TRANSCRIPTION; RECEPTOR SUPERFAMILY; ESTROGEN-RECEPTOR; MOLECULAR-CLONING; THYROID-HORMONE	The mouse protamines ape expressed exclusively in postmeiotic male germ cells and are crucial for the compaction of chromatin during the late stages of spermatogenesis, The temporal expression of the two mouse protamines is transcriptionally regulated in the testis. Recent studies have demonstrated that ubiquitous and testis-specific proteins bind to the promoter of the mouse protamine 2 (mP2) gene, We have performed in vitro transcription and mobility shift assays to characterize the functional significance of the protein-DNA interactions within 180 base pairs upstream of the mP2 transcription start site. Deletion and mutational analyses reveal two positive regulatory sequences for mP2 transcription at positions -59/-47 and -83/-72 of the mP2 promoter, The proximal element at -59/-47 binds to a novel testis-specific protein we name protamine-activating factor 1 (PAF-1). PAF-1 reaches high levels in round spermatids at the time of mP2 transcription. Deletion of the -59/-47 sequence results in about a 3-fold reduction of mP2 transcription in vitro, Although the PAF-1 binding site (PAF-responsive element, PAF-RE), contains the sequence GTCA present in the cAMP-responsive element and is very similar to the estrogen-responsive element, mobility shift assays revealed that neither the cAMP-responsive element modulator nor the estrogen receptor is the protein(s) binding to PAF-RE, Competition mobility shift assays reveal that the second positive regulatory element at -88/-72 binds a Y-box-binding protein, Using in vitro transcription assays, a 5-fold decrease in mP2 transcription is seen when both the PAF-RE and this Y-box are deleted, These data suggest that the testis-specific PAF-1 and a Y-box-binding protein are needed to activate mP2 transcription in postmeiotic male germ cells.	TUFTS UNIV, DEPT BIOL, MEDFORD, MA 02155 USA	Tufts University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011878] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 11878] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Balhorn R., 1989, P366; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Borgmeyer U, 1997, EUR J BIOCHEM, V244, P120, DOI 10.1111/j.1432-1033.1997.00120.x; BUNICK D, 1990, P NATL ACAD SCI USA, V87, P891, DOI 10.1073/pnas.87.3.891; CHEN F, 1994, MOL ENDOCRINOL, V8, P1434, DOI 10.1210/me.8.10.1434; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Eddy EM, 1993, MOL BIOL MALE REPROD, P181; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GOLDBERG E, 1977, ISOENZYMES CURRENT T, V1, P79; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Ha H, 1997, J CELL BIOCHEM, V64, P94, DOI 10.1002/(SICI)1097-4644(199701)64:1<94::AID-JCB12>3.3.CO;2-H; HAKE LE, 1990, DEVELOPMENT, V110, P249; HECHT NB, 1995, DEV GENET, V16, P95, DOI 10.1002/dvg.1020160202; Hecht NB, 1989, HISTONES OTHER BASIC, P347; Hecht NB., 1986, EXPT APPROACHES MAMM, P151; HESS RA, 1995, ENVIRON HEALTH PERSP, V103, P59, DOI 10.2307/3432509; HIROSE T, 1995, GENE, V152, P247, DOI 10.1016/0378-1119(94)00656-D; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; JOHNSON PA, 1991, BIOL REPROD, V44, P127, DOI 10.1095/biolreprod44.1.127; KLEENE KC, 1983, DEV BIOL, V98, P455, DOI 10.1016/0012-1606(83)90375-5; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KWON YK, 1993, DEV BIOL, V158, P90, DOI 10.1006/dbio.1993.1170; Lee CH, 1996, MOL REPROD DEV, V44, P305, DOI 10.1002/(SICI)1098-2795(199607)44:3&lt;305::AID-MRD4&gt;3.0.CO;2-Q; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NIKOLAJCZYK BS, 1995, BIOL REPROD, V52, P524, DOI 10.1095/biolreprod52.3.524; Oko R, 1996, MOL REPROD DEV, V44, P1, DOI 10.1002/(SICI)1098-2795(199605)44:1&lt;1::AID-MRD1&gt;3.0.CO;2-S; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; Sommerville J, 1996, CHROMOSOMA, V104, P469, DOI 10.1007/s004120050139; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TAMURA TA, 1992, J BIOL CHEM, V267, P4327; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WOLFFE AP, 1992, NEW BIOL, V4, P290; Yan ZH, 1997, J BIOL CHEM, V272, P10565; Yiu GK, 1997, BIOL REPROD, V56, P1439, DOI 10.1095/biolreprod56.6.1439; ZAMBROWICZ BP, 1994, BIOL REPROD, V50, P65, DOI 10.1095/biolreprod50.1.65; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071; Zhou YD, 1996, P NATL ACAD SCI USA, V93, P12262, DOI 10.1073/pnas.93.22.12262	50	41	43	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26926	26933		10.1074/jbc.272.43.26926	http://dx.doi.org/10.1074/jbc.272.43.26926			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341127	hybrid			2022-12-25	WOS:A1997YC65900023
J	Dusing, MR; Brickner, AC; Thomas, MB; Wiginton, DA				Dusing, MR; Brickner, AC; Thomas, MB; Wiginton, DA			Regulation of duodenal specific expression of the human adenosine deaminase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; ACID-BINDING-PROTEIN; HORMONE FUSION GENES; TRANSGENIC MICE; DEVELOPMENTAL EXPRESSION; REPORTER GENE; ENHANCER; DNA; DIFFERENTIATION; TISSUES	Formation of the mammalian gastrointestinal tract is an ordered process of development and differentiation. Yet, the adult small intestine also retains the plasticity to respond to cues both internal and environmental to modulate intestinal function. The components that regulate this development, differentiation, and modulation at the molecular level are only now being elucidated. We have used the human adenosine deaminase (ADA) gene as a model to identify potential cis-regulatory components involved in these processes within the small intestine. In mammals, high levels of ADA in the small intestine are limited, specifically 60 the differentiated enterocytes within the duodenal region. These studies describe the identification of a region of the human ADA. gene, completely distinct from the previously identified T-cell enhancer, which is capable of directing the human intestinal expression pattern in the intestine of transgenic mice. The reporter gene expression pattern observed in these transgenic mice is identical to the endogenous gene along both the cephalocaudal and crypt/villus axis of development. Timing of this transgene activation, however, varies from that of the endogenous mouse gene in that the transgene is activated approximately 2 weeks earlier in development. Even so, this precocious activation is also limited to the epithelium of the developing villi strictly within the duodenal region of the small intestine.	UNIV CINCINNATI, COLL MED, DEPT PEDIAT, DIV DEV BIOL, CINCINNATI, OH 45229 USA; CHILDRENS HOSP RES FDN, CINCINNATI, OH 45229 USA	University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation								ADAMS A, 1976, CLIN EXP IMMUNOL, V26, P647; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; ARONOW BJ, 1995, MOL CELL BIOL, V15, P123; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRADY TG, 1965, COMP BIOCHEM PHYSIOL, V14, P101, DOI 10.1016/0010-406X(65)90011-3; Brickner AG, 1995, GENE, V167, P261, DOI 10.1016/0378-1119(95)00673-7; BUSTAMANTE S, 1981, TXB GASTROENTEROLOGY, P49; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; CIRILLO LA, 1995, DEV BIOL, V168, P395, DOI 10.1006/dbio.1995.1089; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; DUSING MR, 1994, NUCLEIC ACIDS RES, V22, P669, DOI 10.1093/nar/22.4.669; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; ESS KC, 1995, MOL CELL BIOL, V15, P5707; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HAYASHI S, 1978, J HISTOCHEM CYTOCHEM, V26, P677, DOI 10.1177/26.8.99471; Haynes TL, 1996, NUCLEIC ACIDS RES, V24, P5034, DOI 10.1093/nar/24.24.5034; HE YP, 1993, J NUTR, V123, P1017; HENNING SJ, 1987, PHYSL GASTROINTESTIN, V1, P285; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; KIZAKI H, 1988, J IMMUNOL, V141, P1652; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KNUDSEN TB, 1989, TERATOLOGY, V40, P615, DOI 10.1002/tera.1420400609; KNUDSEN TB, 1988, BIOL REPROD, V39, P937, DOI 10.1095/biolreprod39.4.937; KREDICH NM, 1989, METABOLIC BASIS INHE, V1, P1045; LEE PC, 1973, DEV BIOL, V31, P227, DOI 10.1016/0012-1606(73)90259-5; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; MOHAMEDALI KA, 1993, J BIOL CHEM, V268, P23728; MOOG F, 1981, TXB GASTROENTEROLOGY, P139; OLSEN J, 1991, J BIOL CHEM, V266, P18089; POTTEN CS, 1979, BIOCHIM BIOPHYS ACTA, V560, P281, DOI 10.1016/0304-419X(79)90022-2; ROSE SD, 1994, MOL CELL BIOL, V14, P2048, DOI 10.1128/MCB.14.3.2048; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; TRABER PG, 1994, J LAB CLIN MED, V123, P467; VANDERWEYDEN MB, 1976, J BIOL CHEM, V251, P5448; WAKADE AR, 1995, J BIOL CHEM, V270, P17986, DOI 10.1074/jbc.270.30.17986; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; WALSH A, 1993, J LIPID RES, V34, P617; WIGINTON D, 1991, ADV EXP MED BIOL, V309, P57; WIGINTON DA, 1986, BIOCHEMISTRY-US, V25, P8234, DOI 10.1021/bi00373a017; WINSTON JH, 1992, J BIOL CHEM, V267, P13472; WINSTON JH, 1995, ADV EXP MED BIOL, V370, P579; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	56	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26634	26642		10.1074/jbc.272.42.26634	http://dx.doi.org/10.1074/jbc.272.42.26634			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334245	hybrid			2022-12-25	WOS:A1997YB13900079
J	Nadeau, OW; Sacks, DB; Carlson, GM				Nadeau, OW; Sacks, DB; Carlson, GM			Differential affinity cross-linking of phosphorylase kinase conformers by the geometric isomers of phenylenedimaleimide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT-SKELETAL-MUSCLE; ALPHA-SUBUNIT; BETA-SUBUNIT; MOLECULAR-BASIS; CALMODULIN; BINDING; ACTIVATION; SPECIFICITY; MELITTIN; PROTEINS	Phosphorylase b kinase (PbK) from skeletal muscle is a highly regulated oligomer consisting of four copies of four distinct subunits (alpha beta gamma)delta(4). The gamma subunit is catalytic, and the remaining subunits are regulatory, To characterize effector-induced changes in the quaternary structure of the enzyme, we utilized the ortho-, meta, and para-isomers of phenylenedimaleimide (PDM), which in addition to having different geometries, also vary 2.5-fold in their cross-linking spans, Even at concentrations equivalent to the alpha beta gamma delta protomers of PbK, all three isomers caused specific, rapid, and extensive cross-linking of the holoenzyme to farm primarily alpha beta dimers, plus smaller amounts of beta gamma gamma and alpha gamma gamma trimers, The formation of these three conjugates was nearly totally inhibited by a 10-fold molar excess over PDM of N-(o- and p-tolyl)succinimide, which are chemically inert structural analogs of PDM. This inhibition suggests that PbK has binding sites for PDM and that PDM acts as an affinity cross linker in binding to these sites prior to forming crosslinked conjugates. The largest effect on cross-linking in progressing from o- to p-PDM was on the alpha gamma gamma trimer, which is preferentially formed by the p-isomer. Activation tion of the enzyme by either phosphorylation or the allosteric activators ADP and GDP resulted in large increases in the amount of alpha gamma gamma formed, small increases in beta gamma gamma, and little change in alpha beta. When cross-linked in the presence of the reversibly activating nucleoside diphosphates, PbK remained activated after their removal, indicating-that cross-linking had locked it in the active conformation. Our results provide direct evidence for perturbations in the interactions of the catalytic gamma subunit with the regulatory alpha and beta subunits upon activation of PbK.	UNIV TENNESSEE, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Sacks, David/0000-0003-3100-0735	NIDDK NIH HHS [DK32953] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032953, R56DK032953] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENESCH RE, 1991, J PROTEIN CHEM, V10, P503, DOI 10.1007/BF01025478; CARLSON GM, 1984, BIOCHIM BIOPHYS ACTA, V789, P347, DOI 10.1016/0167-4838(84)90191-2; CHANG FN, 1972, J MOL BIOL, V68, P177, DOI 10.1016/0022-2836(72)90272-0; CHENG A, 1988, J BIOL CHEM, V263, P5534; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; FISCHER EH, 1978, VERSATILITY PROTEINS, P133; FITZGERALD TJ, 1984, J BIOL CHEM, V259, P3266; HEILMEYER LMG, 1991, BIOCHIM BIOPHYS ACTA, V1094, P168, DOI 10.1016/0167-4889(91)90005-I; HESSOVA Z, 1985, EUR J BIOCHEM, V146, P107, DOI 10.1111/j.1432-1033.1985.tb08626.x; ISHII Y, 1986, BIOPHYS J, V50, P75, DOI 10.1016/S0006-3495(86)83440-3; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KILIMANN MW, 1988, P NATL ACAD SCI USA, V85, P9381, DOI 10.1073/pnas.85.24.9381; KING MM, 1983, J BIOL CHEM, V258, P9925; KING MM, 1981, J BIOL CHEM, V256, P1058; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOOY PK, 1982, ARCH BIOCHEM BIOPHYS, V213, P551, DOI 10.1016/0003-9861(82)90583-5; LEE JH, 1992, BIOCHEMISTRY-US, V31, P10616, DOI 10.1021/bi00158a026; MAULET Y, 1983, BIOCHEMISTRY-US, V22, P5680, DOI 10.1021/bi00293a035; MILLER S, 1989, PROTEIN ENG, V3, P77, DOI 10.1093/protein/3.2.77; MORTON A, 1995, BIOCHEMISTRY-US, V34, P8576, DOI 10.1021/bi00027a007; Nadeau OW, 1997, J BIOL CHEM, V272, P26202, DOI 10.1074/jbc.272.42.26202; NADEAU OW, 1994, J BIOL CHEM, V269, P29670; PAUDEL HK, 1988, ARCH BIOCHEM BIOPHYS, V264, P641, DOI 10.1016/0003-9861(88)90330-X; PAUDEL HK, 1993, BIOCHEMISTRY-US, V32, P11865, DOI 10.1021/bi00095a015; PAUDEL HK, 1987, J BIOL CHEM, V262, P11912; Pickett-Gies CA., 1986, ENZYMES, V17, P395; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SANCHEZ V, 1993, THESIS U TENNESSEE M, P79; SANCHEZ VE, 1993, J BIOL CHEM, V268, P17889; SMYTH DG, 1964, BIOCHEM J, V91, P589, DOI 10.1042/bj0910589; TREMPE MR, 1987, J BIOL CHEM, V262, P4333; Wilkinson DA, 1997, J MOL BIOL, V265, P319, DOI 10.1006/jmbi.1996.0739; WILKINSON DA, 1994, J MOL BIOL, V235, P974, DOI 10.1006/jmbi.1994.1051; Wold F, 1972, Methods Enzymol, V25, P623, DOI 10.1016/S0076-6879(72)25061-3; YANG T, 1991, BIOCHEM BIOPH RES CO, V174, P518, DOI 10.1016/0006-291X(91)91447-K	41	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26196	26201		10.1074/jbc.272.42.26196	http://dx.doi.org/10.1074/jbc.272.42.26196			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334187	hybrid			2022-12-25	WOS:A1997YB13900021
J	Saito, F; Yamada, H; Sunada, Y; Hori, H; Shimizu, T; Matsumura, K				Saito, F; Yamada, H; Sunada, Y; Hori, H; Shimizu, T; Matsumura, K			Characterization of a 30-kDa peripheral nerve glycoprotein that binds laminin and heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; TERMINAL GLOBULAR DOMAIN; SCHWANN-CELL MIGRATION; BASAL LAMINA; BASEMENT-MEMBRANES; MEROSIN DEFICIENCY; SYNTHETIC PEPTIDES; NEURITE GROWTH; CHAIN GENE; EXPRESSION	We have shown previously that a bovine peripheral nerve protein with a molecular mass of about 30 kDa binds laminin in blot overlay assay, In this paper, we have characterized this 30-kDa laminin-binding protein (LBP30), LBP30 was extracted from the crude bovine peripheral nerve membranes at pH 12 or by 0.5 M NaCl but not; by 2% Triton X-100. LBP30 bound to heparin-Sepharose in the presence of 0.5 M NaCl. The results of lectin staining indicated that LBP30 contained both terminally sialylated and nonsialylated Ser/Thr-linked oligosaccharides. LBP30 bound laminin-a as well as laminin-1 but not fibronectin or collagen type IV, When immoobilized LBP30 was incubated with the crude peripheral nerve membrane extracts, all of the endogenous peripheral nerve laminin chain isoforms, the alpha 1, alpha 2, beta 1, beta 2, and gamma 1 chains, were detected bound to LBP30. The binding of LBP30 to laminin was inhibited by heparin, heparan sulfate, dextran sulfate, or NaCl but was not affected significantly by chondroitin sulfate, dextran, or EDTA. Although LBP30 bound to laminin-1 denatured with SDS in a nonreducing condition, the binding was reduced drastically when laminin-1 was denatured with SDS in a reducing condition, suggesting that the binding of LBP30 is somewhat dependent on the high order structure of laminin-1, Immunohistochemical analysis demonstrated the broad distribution of LBP30 in the perineurium and endoneurium of bovine peripheral nerve, These results indicate that LBP30 is a laminin-and heparin-binding glycoprotein localized in the perineurium and endoneurium of bovine peripheral nerve.	TEIKYO UNIV,SCH MED,DEPT NEUROL & NEUROSCI,TOKYO 173,JAPAN; TOKYO MED & DENT UNIV,MED RES INST,DEPT TISSUE PHYSIOL,TOKYO 101,JAPAN	Teikyo University; Tokyo Medical & Dental University (TMDU)								ANTON ES, 1994, DEV BIOL, V164, P133, DOI 10.1006/dbio.1994.1186; ARAHATA K, 1993, P JPN ACAD B-PHYS, V69, P259, DOI 10.2183/pjab.69.259; BAILEY SB, 1993, J NEUROCYTOL, V22, P176, DOI 10.1007/BF01246356; BRADLEY WG, 1973, J NEUROL SCI, V18, P227, DOI 10.1016/0022-510X(73)90009-9; Bunge R P, 1993, Curr Opin Neurobiol, V3, P805, DOI 10.1016/0959-4388(93)90157-T; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; ELDRIDGE CF, 1989, J NEUROSCI, V9, P625; FELTRI ML, 1994, DEVELOPMENT, V120, P1287; FERNANDEZVALLE C, 1994, J NEUROBIOL, V25, P1207, DOI 10.1002/neu.480251004; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HORI H, 1994, J BIOCHEM-TOKYO, V116, P1212, DOI 10.1093/oxfordjournals.jbchem.a124666; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JAAKKOLA S, 1993, J NEUROCYTOL, V22, P215, DOI 10.1007/BF01246360; LEIVO L, 1988, P NATL ACAD SCI USA, V85, P1554; MADRID RE, 1975, NATURE, V257, P319, DOI 10.1038/257319a0; Matsumura K, 1997, NEUROMUSCULAR DISORD, V7, P7, DOI 10.1016/S0960-8966(96)00402-6; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; Mercurio AM, 1990, CURR OPIN CELL BIOL, V2, P845, DOI 10.1016/0955-0674(90)90082-P; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; Mora M, 1996, NEUROMUSCULAR DISORD, V6, P377, DOI 10.1016/0960-8966(96)00359-8; NIESSEN CM, 1994, J CELL SCI, V107, P543; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; OBREMSKI VJ, 1995, DEV BIOL, V168, P124, DOI 10.1006/dbio.1995.1066; Pall EA, 1996, J BIOL CHEM, V271, P3817; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; Ryan MC, 1996, MATRIX BIOL, V15, P369, DOI 10.1016/S0945-053X(96)90157-2; SANDROCK AW, 1987, P NATL ACAD SCI USA, V84, P6934, DOI 10.1073/pnas.84.19.6934; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SHARP AH, 1989, J BIOL CHEM, V264, P2816; SHORER Z, 1995, J CHILD NEUROL, V10, P472, DOI 10.1177/088307389501000610; SKUBITZ APN, 1991, J CELL BIOL, V115, P1137, DOI 10.1083/jcb.115.4.1137; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; WANG GY, 1992, BRAIN RES, V570, P116, DOI 10.1016/0006-8993(92)90571-P; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; Yamada H, 1996, J NEUROCHEM, V66, P1518; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981	46	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26708	26713		10.1074/jbc.272.42.26708	http://dx.doi.org/10.1074/jbc.272.42.26708			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334255	hybrid			2022-12-25	WOS:A1997YB13900089
J	AttmaneElakeb, A; Boulanger, H; Vernimmen, C; Bichara, M				AttmaneElakeb, A; Boulanger, H; Vernimmen, C; Bichara, M			Apical location and inhibition by arginine vasopressin of K+/H+ antiport of the medullary thick ascending limb of rat kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	29th Annual Meeting of the American-Society-of-Nephrology	NOV 03-06, 1996	NEW ORLEANS, LA	Amer Soc Nephrol			PLASMA-MEMBRANE VESICLES; BRUSH-BORDER MEMBRANES; FUNCTIONAL-PROPERTIES; BASOLATERAL MEMBRANE; TRANSPORT PATHWAYS; INTRACELLULAR PH; EXCHANGER NHE-2; NH4+ TRANSPORT; NA/H EXCHANGER; RABBIT KIDNEY	To characterize and localize a K+/H+ antiport mechanism in the renal medullary thick ascending limb (MTAL), membrane vesicles were isolated from a rat MTAL homogenate. K+/H+ antiport (in > out H+ gradient-stimulated Rb-86(+) uptake) was abolished by barium and verapamil (apparent K-i of 55 mu M) but unaffected by other K+ channel blockers such as quinidine and high amiloride concentrations, SCH 28080, a H+/K+-ATPase blocker, did not affect K+/H+ antiport. K+/H+ antiport activity was correlated positively with the enrichment factor of the membranes in the apical marker enzyme alkaline phosphatase (r = 0.875, p < 0.01) and negatively correlated with the enrichment factor in basolateral Na+/H+-ATPase (r = -0.665, p < 0.05). Moreover, a functional interaction occurred with Na+/H+ exchange (NBE) consistent with colocation of K+/H+ antiport and apical NHE-3, not basolateral NHE-1. K+/H+ antiport was shown by intracellular pH measurements to be inhibited by arginine vasopressin and 8-bromo-cAMP through cAMP-dependent protein kinase (protein kinase A) activation, These results demonstrate the presence of a K+/H+ antiport mechanism, which is inhibited by arginine vasopressin via protein kinase A, in the apical membrane of the MTAL.	UNIV PARIS 06,INSERM,U356,F-75270 PARIS 06,FRANCE; HOP BROUSSAIS,F-75270 PARIS 06,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite								AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; Amlal H, 1996, AM J PHYSIOL-CELL PH, V271, pC455, DOI 10.1152/ajpcell.1996.271.2.C455; AMLAL H, 1994, J BIOL CHEM, V269, P21962; AMLAL H, 1994, AM J PHYSIOL-CELL PH, V267, pC1607, DOI 10.1152/ajpcell.1994.267.6.C1607; Attmane-Elakeb A., 1996, Journal of the American Society of Nephrology, V7, P1251; AttmaneElakeb A, 1996, KIDNEY INT, V50, P1051, DOI 10.1038/ki.1996.408; BIBER J, 1981, BIOCHIM BIOPHYS ACTA, V647, P169, DOI 10.1016/0005-2736(81)90243-1; BICHARA M, 1995, J AM SOC NEPHROL, V6, P332; BLEICH M, 1990, PFLUG ARCH EUR J PHY, V415, P449, DOI 10.1007/BF00373623; BORENSZTEIN P, 1995, AM J PHYSIOL-RENAL, V268, pF1224, DOI 10.1152/ajprenal.1995.268.6.F1224; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DESIR GV, 1991, BIOCHIM BIOPHYS ACTA, V1067, P38, DOI 10.1016/0005-2736(91)90023-2; DISCALA F, 1992, BRIT J PHARMACOL, V107, P532, DOI 10.1111/j.1476-5381.1992.tb12779.x; FORBUSH B, 1983, ANAL BIOCHEM, V128, P159, DOI 10.1016/0003-2697(83)90356-1; FORBUSH B, 1983, J BIOL CHEM, V258, P1787; FROISSART M, 1992, AM J PHYSIOL, V262, pC963, DOI 10.1152/ajpcell.1992.262.4.C963; GARVIN J L, 1988, American Journal of Physiology, V255, pF57; GOOD DW, 1985, AM J PHYSIOL, V248, pF459, DOI 10.1152/ajprenal.1985.248.4.F459; GOOD DW, 1990, J CLIN INVEST, V85, P1006, DOI 10.1172/JCI114530; Good DW, 1995, P NATL ACAD SCI USA, V92, P12525, DOI 10.1073/pnas.92.26.12525; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; HONDA T, 1993, BIOCHIM BIOPHYS ACTA, V1150, P199, DOI 10.1016/0005-2736(93)90090-M; KIKERI D, 1992, J GEN PHYSIOL, V99, P435, DOI 10.1085/jgp.99.3.435; KIKERI D, 1989, NATURE, V339, P478, DOI 10.1038/339478a0; KINNE R, 1986, J MEMBRANE BIOL, V94, P279, DOI 10.1007/BF01869723; KINNE R, 1992, HDB PHYSL RENAL PHYS, V2, P2083; LEVIEL F, 1992, J CLIN INVEST, V90, P869, DOI 10.1172/JCI115962; MAHNENSMITH RL, 1985, J BIOL CHEM, V260, P2586; MURER H, 1986, KIDNEY INT, V30, P171, DOI 10.1038/ki.1986.169; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; PFALLER W, 1980, INT J BIOCHEM, V12, P17, DOI 10.1016/0020-711X(80)90035-X; REEVES WB, 1988, AM J PHYSIOL, V255, pF1138, DOI 10.1152/ajprenal.1988.255.6.F1138; SABOLIC I, 1984, BIOCHIM BIOPHYS ACTA, V772, P140, DOI 10.1016/0005-2736(84)90037-3; Sun A. M., 1996, Journal of the American Society of Nephrology, V7, P1261; TSURUOKA S, 1993, J CLIN INVEST, V92, P1881, DOI 10.1172/JCI116780; WATTS BA, 1994, J GEN PHYSIOL, V103, P917, DOI 10.1085/jgp.103.5.917; YOUNESIBRAHIM M, 1995, AM J PHYSIOL-RENAL, V268, pF1141, DOI 10.1152/ajprenal.1995.268.6.F1141; YU FH, 1993, J BIOL CHEM, V268, P25536	39	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25668	25677		10.1074/jbc.272.41.25668	http://dx.doi.org/10.1074/jbc.272.41.25668			10	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325290	hybrid			2022-12-25	WOS:A1997YA35800045
J	Bigger, CB; Melnikova, IN; Gardner, PD				Bigger, CB; Melnikova, IN; Gardner, PD			Sp1 and Sp3 regulate expression of the neuronal nicotinic acetylcholine receptor beta 4 subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; BOX-BINDING-PROTEINS; TATA-LESS PROMOTER; TRANSCRIPTION FACTOR; ACTIVATION DOMAINS; ALPHA-3 GENE; POU DOMAIN; FAMILY; BRAIN; MEMBERS	Neuronal nicotinic acetylcholine receptors play important roles in signal transduction within the nervous system. The receptors exist in a variety of functionally distinct subtypes that are determined by their subunit structures. The subunits are encoded by 11 genes, alpha 2-alpha 9 and beta 2-beta 4. Three of the genes, alpha 3, alpha 5, and beta 4, are tightly clustered, and their encoded proteins make up the predominant receptor subtype in the peripheral nervous system. The tight linkage of the genes suggests there may be a common regulatory mechanism underlying their expression. However, although their expression patterns significantly overlap, they are not identical, indicating that independent regulatory mechanisms must also exist. Our studies have focused upon the gene encoding the beta 4 subunit for which we have identified several transcriptional regulatory elements. One of these elements, E2, specifically interacts with the general transcription factor Sp1. Here we show that another member of the Sp family of factors, Sp3, can specifically interact with E2 whereas two other members, Sp2 and Sp4, cannot. Co-transfection experiments indicate that Sp3 can transactivate a beta 4 promoter/reporter gene construct and, furthermore, that Sp1 and Sp3 can transactivate the beta 4 reporter construct synergistically. The transactivation is dependent upon an intact E2 and may involve direct interactions between Sp1 and Sp3.	UNIV TEXAS, HLTH SCI CTR, INST BIOTECHNOL, DEPT MOL MED, SAN ANTONIO, TX 78245 USA	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030243] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS030243, NS30243] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMADOR M, 1995, J NEUROSCI, V15, P4525; BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; Bigger CB, 1996, J BIOL CHEM, V271, P32842, DOI 10.1074/jbc.271.51.32842; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BOULTER J, 1990, J BIOL CHEM, V265, P4472; Boyd RT, 1996, NEUROSCI LETT, V208, P73, DOI 10.1016/0304-3940(96)12561-1; BOYD RT, 1994, J NEUROBIOL, V25, P960, DOI 10.1002/neu.480250806; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAUBAS P, 1993, P NATL ACAD SCI USA, V90, P2237, DOI 10.1073/pnas.90.6.2237; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DINELEYMILLER K, 1992, MOL BRAIN RES, V16, P339, DOI 10.1016/0169-328X(92)90244-6; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; Fyodorov D, 1996, MOL CELL BIOL, V16, P5004; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAMMOND DN, 1990, BRAIN RES, V512, P190, DOI 10.1016/0006-8993(90)90626-M; HEINEMANN S, 1990, PROG BRAIN RES, V86, P195; HERNANDEZ MC, 1995, J BIOL CHEM, V270, P3224, DOI 10.1074/jbc.270.7.3224; HESS N, 1994, FEBS LETT, V346, P135, DOI 10.1016/0014-5793(94)00443-9; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HU MJ, 1995, J BIOL CHEM, V270, P4497, DOI 10.1074/jbc.270.19.11619; HU MJ, 1994, J NEUROCHEM, V62, P392; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MATTER JM, 1995, J NEUROSCI, V15, P5919; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; McDonough J, 1997, J NEUROSCI, V17, P2273; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MILTON NGN, 1995, J BIOL CHEM, V270, P15143, DOI 10.1074/jbc.270.25.15143; Milton NGN, 1996, BIOCHEM J, V317, P419, DOI 10.1042/bj3170419; Miyamoto A, 1996, MOL CELL BIOL, V16, P2394; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; Parks CL, 1996, J BIOL CHEM, V271, P4417; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PATRICK J, 1993, PROG BRAIN RES, V98, P113; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; WADA E, 1990, BRAIN RES, V526, P45, DOI 10.1016/0006-8993(90)90248-A; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; YANG XD, 1994, J BIOL CHEM, V269, P10252; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514; Yang XD, 1997, J NEUROBIOL, V32, P311, DOI 10.1002/(SICI)1097-4695(199703)32:3<311::AID-NEU5>3.0.CO;2-A; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869; ZOLI M, 1995, J NEUROSCI, V15, P1912, DOI 10.1523/JNEUROSCI.15-03-01912.1995	56	78	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25976	25982		10.1074/jbc.272.41.25976	http://dx.doi.org/10.1074/jbc.272.41.25976			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325332	hybrid			2022-12-25	WOS:A1997YA35800087
J	Dragani, B; Stenberg, G; Melino, S; Petruzzelli, R; Mannervik, B; Aceto, A				Dragani, B; Stenberg, G; Melino, S; Petruzzelli, R; Mannervik, B; Aceto, A			The conserved N-capping box in the hydrophobic core of glutathione S-transferase P1-1 is essential for refolding - Identification of a buried and conserved hydrogen bond important for protein stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 3-DIMENSIONAL STRUCTURE; ISOENZYMES; RESOLUTION; RESIDUES; COMPLEX; SIGNALS; MOTIF; ROLES; DNA	The second domain of cytosolic glutathione S-transferases (GSTs) contains a strictly conserved N-capping box motif (Ser/Thr-Xaa-Xaa-Asp) at the beginning of alpha(6)-helix in the hydrophobic core of the molecule. Considering the specific function attributed to capping box residues in the helix nucleation, we decided to investigate, by site-directed mutagenesis, the role that this moth could have in the folding and stability of human GSTP1-1. Both capping box mutants, S150A and D153A, were significantly more thermolabile than wild-type GSTP1-1, indicating that the local destabilization of the alpha(6)-helix determined by a single capping residue mutation affects the overall stability of the protein. The results also show that, in addition to capping interactions, an important role in the stability of the final structure of the protein is played by a buried and conserved hydrogen bond formed between the side chain of Asp-153 and the amide NH of Ile-144 located in the long loop preceding alpha(6)-helix. Reactivation experiments in vitro indicate that the N-capping box is essential for refolding of the denatured protein at a physiological temperature. The results suggest that during folding this buried and conserved moth, making a definite set of native-like contacts, determines the formation of a specific folding nucleus that probably represents a transition state of the folding process.	UNIV G DANNUNZIO,DIPARTIMENTO SCI BIOMED,I-66100 CHIETI,ITALY; UNIV UPPSALA,CTR BIOMED,DEPT BIOCHEM,S-75123 UPPSALA,SWEDEN	G d'Annunzio University of Chieti-Pescara; Uppsala University				MELINO, SONIA/0000-0001-7694-5279				ACETO A, 1990, CARCINOGENESIS, V11, P2267, DOI 10.1093/carcin/11.12.2267; Aceto A, 1997, BIOCHEM J, V322, P229, DOI 10.1042/bj3220229; ACETO A, 1992, BIOCHEM J, V285, P241, DOI 10.1042/bj2850241; AWASTHI YC, 1985, COMP BIOCH PHYSL, V828, P17; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; DASGUPTA S, 1993, INT J PEPT PROT RES, V41, P499; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HAYES JD, 1988, GLUTATHIONE CONJUGAT, P316; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Ketterer B., 1988, P73; KOLM RH, 1995, PROTEIN EXPRES PURIF, V6, P265, DOI 10.1006/prep.1995.1034; KONG KH, 1993, PROTEIN ENG, V6, P93, DOI 10.1093/protein/6.1.93; KOONIN EV, 1994, PROTEIN SCI, V3, P2045, DOI 10.1002/pro.5560031117; LAMOUREUX GL, 1989, GLUTATHIONE CHEM B B, P153; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MUNOZ V, 1995, STRUCT BOL, V5, P380; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; Ptitsyn OB, 1996, FASEB J, V10, P3, DOI 10.1096/fasebj.10.1.8566544; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEALE JW, 1994, PROTEIN SCI, V3, P1741, DOI 10.1002/pro.5560031014; Shakhnovich E, 1996, NATURE, V379, P96, DOI 10.1038/379096a0; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; WANG RW, 1992, J BIOL CHEM, V267, P19866; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x	30	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25518	25523		10.1074/jbc.272.41.25518	http://dx.doi.org/10.1074/jbc.272.41.25518			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325266	hybrid			2022-12-25	WOS:A1997YA35800021
J	Kominato, Y; Tsuchiya, T; Hata, N; Takizawa, H; Yamamoto, F				Kominato, Y; Tsuchiya, T; Hata, N; Takizawa, H; Yamamoto, F			Transcription of human ABO histo-blood group genes is dependent upon binding of transcription factor CBF/NF-Y to minisatellite sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETES SUSCEPTIBILITY LOCUS; HRAS1 MINISATELLITE; DNA-REPLICATION; INSULIN GENE; EXPRESSION; ACTIVATION; ANTIGENS; PROMOTER; PROTEINS; LUNG	We have studied the transcriptional regulatory mechanism of the human histo-blood group ABO genes, and identified DNA cis-elements and trans-activating protein that control the expression of these genes which are important in blood transfusion and organ transplantation. We introduced the 5'-upstream sequence of ABO genes into the promoterless reporter vector and characterized the promoter activity of deletion constructs using transient transfection assays with gastric cancer cell line KATO III cells. The sequence just upstream of the transcription start site (cap site), and an enhancer element, which is located further upstream (between -3899 and -3618 base pairs (bp) from the transcription initiation site) and contains 4 tandem copies of a 43-bp repeat unit, were shown in gastric cancer cells to be responsible for the transcriptional activity of the ABO genes. DNA binding studies have demonstrated that a transcription factor, CBF/NF-Y, bound to the 43-bp repeat unit in the minisatellite. Functional importance of these CBF/NF-Y-binding sites in enhancer activity was confirmed by transfection experiments using reporter plasmids with mutated binding sites. Thus, transcriptional regulation of the human ABO genes is dependent upon binding of CBF/NF-Y to the minisatellite.	TOKYO MED & DENT UNIV, MED RES INST, TOKYO 113, JAPAN; BURNHAM INST, LA JOLLA, CA 92037 USA	Tokyo Medical & Dental University (TMDU); Sanford Burnham Prebys Medical Discovery Institute	Kominato, Y (corresponding author), TOYAMA MED & PHARMACEUT UNIV, FAC MED, DEPT LEGAL MED, 2630 SUGITANI, TOYAMA 93001, JAPAN.		Yamamoto, Fumiichiro/F-1478-2016	Yamamoto, Fumiichiro/0000-0001-9690-7034				BEVILACQUA MA, 1995, BIOCHEM J, V311, P769, DOI 10.1042/bj3110769; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COHEN JB, 1987, J CELL PHYSIOL, P75; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DABELSTEEN E, 1982, J INVEST DERMATOL, V79, P3, DOI 10.1111/1523-1747.ep12510411; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GINSBURG V, 1972, ADV ENZYMOL RAMB, V36, P131; GREEN M, 1993, GENOMICS, V17, P429, DOI 10.1006/geno.1993.1343; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KABAT EA, 1973, ADV CHEM SER, P334; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; Landsteiner K., 1900, ZBL BAKT, V27, P357; LEE JS, 1991, NEW ENGL J MED, V324, P1084, DOI 10.1056/NEJM199104183241603; MADDOX J, 1994, NATURE, V368, P685, DOI 10.1038/368685a0; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Mandel JL, 1997, NATURE, V386, P767, DOI 10.1038/386767a0; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MATSUMOTO H, 1993, CANCER-AM CANCER SOC, V72, P75, DOI 10.1002/1097-0142(19930701)72:1<75::AID-CNCR2820720116>3.0.CO;2-Z; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MIYAKE M, 1992, NEW ENGL J MED, V327, P14, DOI 10.1056/NEJM199207023270103; MORGAN WTJ, 1969, BRIT MED BULL, V25, P30, DOI 10.1093/oxfordjournals.bmb.a070666; Orntoft TF, 1996, CANCER RES, V56, P1031; OWERBACH D, 1993, DIABETES, V42, P1708, DOI 10.2337/diabetes.42.12.1708; ROY B, 1995, MOL CELL BIOL, V15, P2263; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SPANDIDOS DA, 1987, FEBS LETT, V218, P41, DOI 10.1016/0014-5793(87)81014-1; TEUMER J, 1994, KERATINOCYTE HDB, P235; TREPICCHIO WL, 1992, NUCLEIC ACIDS RES, V20, P2427, DOI 10.1093/nar/20.10.2427; TREPICCHIO WL, 1993, NUCLEIC ACIDS RES, V21, P977, DOI 10.1093/nar/21.4.977; WAHLS WP, 1990, CELL, V60, P95, DOI 10.1016/0092-8674(90)90719-U; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Watkins W M, 1980, Adv Hum Genet, V10, P1; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1995, GLYCOBIOLOGY, V5, P51, DOI 10.1093/glycob/5.1.51	41	64	70	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25890	25898		10.1074/jbc.272.41.25890	http://dx.doi.org/10.1074/jbc.272.41.25890			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325321	hybrid			2022-12-25	WOS:A1997YA35800076
J	Wilkinson, CRM; Wallace, M; Seeger, M; Dubiel, W; Gordon, C				Wilkinson, CRM; Wallace, M; Seeger, M; Dubiel, W; Gordon, C			Mts4, a non-ATPase subunit of the 26 S protease in fission yeast is essential for mitosis and interacts directly with the ATPase subunit Mts2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SISTER-CHROMATID SEPARATION; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; REGULATORY SUBUNIT; BINDING-PROTEIN; CDNA CLONING; THERMOPLASMA-ACIDOPHILUM; ANAPHASE TRANSITION; FUNCTIONAL-ANALYSIS	We have isolated a fission yeast gene, mts4(+), by complementation of a temperature-sensitive mutation and show that it encodes subunit 2 (S2) of the 19 S regulatory complex of the 26 S protease. mts4(+) is an essential gene, and we show that loss of this subunit causes cells to arrest in metaphase, illustrating the importance of S2 for mitosis. The Mts4 protein is 48% identical to S2 of the human 26 S protease, and the lethal phenotype of the null mts4 allele can be rescued by the human cDNA encoding S2. We provide genetic and physical evidence to suggest that the Mts4 protein interacts with the product of the mts2(+) gene, an ATPase which has previously been shown to be subunit 4 of the 26 S protease.	HUMBOLDT UNIV BERLIN, FAC MED, INST BIOCHEM, D-10117 BERLIN, GERMANY	Humboldt University of Berlin	Wilkinson, CRM (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.			Dubiel, Wolfgang/0000-0002-3393-0701				BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARINI DJ, 1995, MOL CELL BIOL, V15, P6311; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; Fujiwara T, 1996, FEBS LETT, V387, P184, DOI 10.1016/0014-5793(96)00489-9; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Gordon C, 1996, J BIOL CHEM, V271, P5704, DOI 10.1074/jbc.271.10.5704; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAGAN IM, 1988, J CELL SCI, V89, P343; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILT W, 1995, MOL BIOL REP, V21, P3, DOI 10.1007/BF00990964; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V14, P2620; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KOMINAMI K, 1995, EMBO J, V14, P3105, DOI 10.1002/j.1460-2075.1995.tb07313.x; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; OLD LJ, 1988, SCI AM, V258, P59, DOI 10.1038/scientificamerican0588-59; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; SAZER S, 1990, J CELL SCI, V97, P509; Seeger M, 1996, J MOL BIOL, V263, P423, DOI 10.1006/jmbi.1996.0586; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TANAHASHI N, 1993, ENZYME PROTEIN, V47, P241, DOI 10.1159/000468683; TANAKA K, 1995, MOL BIOL REP, V21, P21, DOI 10.1007/BF00990966; TODA T, 1981, J CELL SCI, V52, P271; Tsurumi C, 1996, EUR J BIOCHEM, V239, P912, DOI 10.1111/j.1432-1033.1996.0912u.x; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WOODS A, 1989, J CELL SCI, V93, P491; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; Yokota K, 1996, MOL BIOL CELL, V7, P853, DOI 10.1091/mbc.7.6.853; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791	59	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25768	25777		10.1074/jbc.272.41.25768	http://dx.doi.org/10.1074/jbc.272.41.25768			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325304	hybrid			2022-12-25	WOS:A1997YA35800059
J	Feyzi, E; Trybala, E; Bergstrom, T; Lindahl, U; Spillmann, D				Feyzi, E; Trybala, E; Bergstrom, T; Lindahl, U; Spillmann, D			Structural requirement of heparan sulfate for interaction with herpes simplex virus type 1 virions and isolated glycoprotein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; BINDING; CELLS; OLIGOSACCHARIDES; DEPOLYMERIZATION; PROTEOGLYCANS; INFECTIONS; ADSORPTION; SEQUENCE	Cell surface heparan sulfates mediate primary attach ment of herpes simplex virus type 1, the first step in virus invasion of the cells, Removal of the host cell hepa ran sulfate results in a significantly diminished susceptibility of the cell to virus infection. On the virus envelope, glycoprotein C has been identified as the major binding site for heparan sulfate in the primary attachment of the virus to host cells, Using selectively desulfated heparins and metabolically labeled host cell heparan sulfate, we have analyzed the structural requirements of heparan sulfate to provide binding sites for glycoprotein C and the whole virus, Employing glycoprotein C affinity chromatography and a virus binding assay, we subfractionated oligosaccharides derived from heparan sulfate and partially desulfated heparin into selectively bound and unbound pools, These were chemically depolymerized and analyzed at the disaccharide level, The shortest glycoprotein C-binding fragment consisted of 10-12 monosaccharide units containing at least one 2-O- and one 6-O-sulfate group that have to be localized in a sequence-specific way, based on the finding that bound and unbound HS fragments do not differ in charge or composition, The binding sequence is found within N-sulfated blocks of heparan sulfate, although several N-acetyl groups can be tolerated within the minimal binding sequence. These minimal requirements for herpes simplex virus type 1 binding to heparan sulfate are clearly distinct from other identified protein binding sites.	UNIV UPPSALA, CTR BIOMED, DEPT MED & PHYSIOL CHEM, S-75123 UPPSALA, SWEDEN; GOTHENBURG UNIV, DEPT CLIN VIROL, S-41346 GOTHENBURG, SWEDEN	Uppsala University; University of Gothenburg				Trybala, Edward/0000-0003-2384-2123; Bergstrom, Tomas/0000-0002-9257-6757				BERGSTROM T, 1992, MOL CELL PROBE, V6, P41, DOI 10.1016/0890-8508(92)90070-E; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; DANISHEF.V, 1965, BIOCHIM BIOPHYS ACTA, V101, P37; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HEROLD BC, 1994, J GEN VIROL, V75, P1211, DOI 10.1099/0022-1317-75-6-1211; HEROLD BC, 1995, VIROLOGY, V206, P1108, DOI 10.1006/viro.1995.1034; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; HOLLAND TC, 1983, J VIROL, V45, P672, DOI 10.1128/JVI.45.2.672-682.1983; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; LYCKE E, 1991, J GEN VIROL, V72, P1131, DOI 10.1099/0022-1317-72-5-1131; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; OLOFSSON S, 1983, J GEN VIROL, V64, P2735, DOI 10.1099/0022-1317-64-12-2735; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; PEJLER G, 1987, J BIOL CHEM, V262, P11413; Rostand KS, 1997, INFECT IMMUN, V65, P1; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SPEAR PG, 1993, SEMIN VIROL, V4, P167, DOI 10.1006/smvy.1993.1012; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; TRYBALA E, 1994, J GEN VIROL, V75, P743, DOI 10.1099/0022-1317-75-4-743; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989	35	109	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24850	24857		10.1074/jbc.272.40.24850	http://dx.doi.org/10.1074/jbc.272.40.24850			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312084	hybrid			2022-12-25	WOS:A1997XY97000023
J	Qin, WN; Khuchua, Z; Klein, SC; Strauss, AW				Qin, WN; Khuchua, Z; Klein, SC; Strauss, AW			Elements regulating cardiomyocyte expression of the human sarcomeric mitochondrial creatine kinase gene in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC EXPRESSION; BOX TRANSCRIPTION FACTORS; ENHANCER-BINDING-FACTOR; RAT MYOCARDIAL-CELLS; LOOP-HELIX PROTEINS; CARDIAC ACTIN GENE; SKELETAL-MUSCLE; DEVELOPING HEART; DROSOPHILA; PROMOTER	Sarcomeric mitochondrial creatine kinase (sMtCK) is one component of a multiprotein, high energy channeling complex consisting of porin, mitochondrial creatine kinase, and adenine nucleotide translocase. To study the transcriptional mechanisms specifying sMtCK gene expression to the heart, transgenic mice were created carrying the 5'-flanking sequences of the human sMtCK gene ligated upstream of the human growth hormone (hGH) reporter gene, RNA blot hybridization demonstrated that the human sMtCK sequence, -485 to +6 base pair (bp), did not activate reporter gene expression to a detectable level, However, the human sMtCK se quence, -921 to +6 bp, expressed the hGH reporter gene at a high level in heart and skeletal muscle and at a very low level in esophagus and kidney, and it did not express the hGH gene in other organs tested (brain, lung, liver, spleen, bladder, uterus, and stomach). In situ hybridization revealed that reporter gene transcription was specified to cardiac and skeletal myocytes, recapitulating precisely the expression pattern of the endogenous gene, Sequence analysis identified several consensus binding sites between -921 and -757 bp, including four GATT motifs, one E box, and one MEF2 site, Further analysis of a third transgenic mouse strain demonstrated that the human sMtCK sequence, -757 to +6 bp, did not direct detectable expression of the hGH reporter gene, We conclude that this 160-bp genomic sequence, from -921 to -757 bp, is necessary in specifying expression of the human sMtCK gene to the oxidative and highly metabolically active heart tissue.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Khuchua, Zaza/J-6536-2016	Khuchua, Zaza/0000-0003-3582-5670	NHLBI NIH HHS [HL52350] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052350] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BODMER R, 1993, DEVELOPMENT, V118, P719; BRAHIC M, 1992, IN SITU HYBRIDIZATIO; CHIEN KR, 1985, J CLIN INVEST, V75, P1770, DOI 10.1172/JCI111889; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; DEVLIN BH, 1989, J BIOL CHEM, V264, P13896; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P1; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; KELLEY C, 1993, DEVELOPMENT, V118, P817; KLEIN SC, 1991, J BIOL CHEM, V266, P18058; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LYONS GE, 1991, DEVELOPMENT, V113, P1017; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Ranganayakulu G, 1996, DEV BIOL, V176, P143, DOI 10.1006/dbio.1996.9987; RINDT H, 1995, P NATL ACAD SCI USA, V92, P1540, DOI 10.1073/pnas.92.5.1540; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; TAMURA S, 1993, P NATL ACAD SCI USA, V90, P10876, DOI 10.1073/pnas.90.22.10876; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WELLER PA, 1986, MOL CELL BIOL, V6, P4539, DOI 10.1128/MCB.6.12.4539; WU XS, 1995, DEV BIOL, V169, P619, DOI 10.1006/dbio.1995.1174; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	50	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25210	25216		10.1074/jbc.272.40.25210	http://dx.doi.org/10.1074/jbc.272.40.25210			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312135	hybrid			2022-12-25	WOS:A1997XY97000074
J	Small, FJ; Ensign, SA				Small, FJ; Ensign, SA			Alkene monooxygenase from Xanthobacter strain Py2 - Purification and characterization of a four-component system central to the bacterial metabolism of aliphatic alkenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOCOCCUS-CAPSULATUS BATH; SOLUBLE METHANE MONOOXYGENASE; IRON-SULFUR PROTEIN; MONO-OXYGENASE; NAPHTHALENE DIOXYGENASE; PSEUDOMONAS-OLEOVORANS; PROPENE MONOOXYGENASE; HYDROXYLASE COMPONENT; CHLORINATED ALKENES; REDUCTASE COMPONENT	Alkene monooxygenase from Xanthobacter strain Py2 is an inducible enzyme that catalyzes the O-2- and NADH-dependent epoxidation of short chain (C-2 to C-6) alkenes to their corresponding epoxides as the initial step in the utilization of aliphatic alkenes as carbon and energy sources, In the present study, alkene monooxygenase has been resolved from the soluble fraction of cell-free extracts into four components, each of which has been purified to homogeneity, that are obligately required for alkene epoxidation activity. The four required components are 1) a monomeric 35.5-kDa protein containing 1 mol of FAD and a probable 2Fe-2S center; 2) a 13.3-kDa ferredoxin containing a Rieske-type 2Fe-2S cluster; 3) an 11-kDa monomeric protein that contains no detectable cofactors; and 4) a 212-kDa alpha(2) beta(2) gamma(2) multimeric protein containing four atoms of nonheme iron, The 35.5-kDa protein has been characterized as an NADH reductase, The physiological electron acceptor for the reductase was the Rieske-type ferredoxin, which is proposed to be an intermediate electron carrier between the reductase and terminal catalytic component of the system, The 212-kDa protein was specifically inactivated in cell-free extracts by the mechanism-based inactivator propyne, suggesting that it is the catalytic component and contains the active site(s) for O-2 activation and alkene epoxidation. The subunit structure and metal analysis of this component suggest that it contains two diiron centers, one for each alpha beta gamma protomeric unit, No specific enzymatic activities could be assigned for the 11-kDa protein, but this component was obligately required for steady state alkene epoxidation, The alkene monooxygenase components were expressed during growth of Xanthobacter Py2 on aliphatic alkenes or epoxides and repressed during growth on other carbon sources, The electron transfer components of alkene monooxygenase were highly specific: other reductase activities present in Xanthobacter were incapable of transferring electrons to the Rieske-type ferredoxin or substituting for the reductase in the alkene monooxygenase complex, Likewise, other bacterial and plant ferredoxins were unable to substitute for the Rieske-type ferredoxin in mediating electron transfer to the oxygenase, The biochemical properties of alkene monooxygenase described in this study suggest that this enzyme combines elements of both the well-characterized aromatic dioxygenase (two-component electron transfer scheme) and methane monooxygenase (small regulatory protein and diiron oxygenase) multicomponent enzyme systems.	UTAH STATE UNIV,DEPT CHEM & BIOCHEM,LOGAN,UT 84322	Utah System of Higher Education; Utah State University					NIGMS NIH HHS [GM51805] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051805, R01GM051805] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen JR, 1996, J BACTERIOL, V178, P1469, DOI 10.1128/jb.178.5.1469-1472.1996; BATIE CJ, 1987, J BIOL CHEM, V262, P1510; CHROMY V, 1974, CLIN CHEM, V20, P1362; COLBY J, 1979, BIOCHEM J, V177, P903, DOI 10.1042/bj1770903; COLBY J, 1977, BIOCHEM J, V165, P395, DOI 10.1042/bj1650395; DESMET MJ, 1983, ENZYME MICROB TECHNO, V5, P352; ENSIGN SA, 1992, APPL ENVIRON MICROB, V58, P3038, DOI 10.1128/AEM.58.9.3038-3046.1992; Ensign SA, 1996, APPL ENVIRON MICROB, V62, P61, DOI 10.1128/AEM.62.1.61-66.1996; FEE JA, 1984, J BIOL CHEM, V259, P124; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1989, J BIOL CHEM, V264, P10023; FROLAND WA, 1992, J BIOL CHEM, V267, P17588; GEARY PJ, 1984, BIOCHEM J, V217, P667, DOI 10.1042/bj2170667; GREEN J, 1985, J BIOL CHEM, V260, P5795; HADDOCK JD, 1995, J BACTERIOL, V177, P5834, DOI 10.1128/jb.177.20.5834-5839.1995; HAIGLER BE, 1990, J BACTERIOL, V172, P457, DOI 10.1128/JB.172.1.457-464.1990; HAIGLER BE, 1990, J BACTERIOL, V172, P465, DOI 10.1128/JB.172.1.465-468.1990; HARTMANS S, 1991, J GEN MICROBIOL, V137, P2555, DOI 10.1099/00221287-137-11-2555; HARTMANS S, 1989, FEMS MICROBIOL LETT, V63, P235, DOI 10.1016/0168-6445(89)90034-X; HYMAN MR, 1985, BIOCHEM J, V227, P719, DOI 10.1042/bj2270719; IWASAKI T, 1995, J BACTERIOL, V177, P2576, DOI 10.1128/jb.177.9.2576-2582.1995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Latimer MT, 1996, J BIOL CHEM, V271, P24023, DOI 10.1074/jbc.271.39.24023; Link TA, 1996, BIOCHEMISTRY-US, V35, P7546, DOI 10.1021/bi960004+; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P358; LIPSCOMB JD, 1994, ANNU REV MICROBIOL, V48, P371, DOI 10.1146/annurev.mi.48.100194.002103; MAY SW, 1973, J BIOL CHEM, V248, P1725; MCKENNA EJ, 1970, J BIOL CHEM, V245, P3882; MIURA A, 1995, BIOSCI BIOTECH BIOCH, V59, P853, DOI 10.1271/bbb.59.853; MURRELL JC, 1990, METHOD ENZYMOL, V188, P27; NEWMAN LM, 1995, BIOCHEMISTRY-US, V34, P14066, DOI 10.1021/bi00043a012; Pikus JD, 1996, BIOCHEMISTRY-US, V35, P9106, DOI 10.1021/bi960456m; PRIOR SD, 1985, FEMS MICROBIOL LETT, V29, P105; ROMANOV V, 1994, J BACTERIOL, V176, P3368, DOI 10.1128/jb.176.11.3368-3374.1994; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P9424, DOI 10.1021/bi9608572; SMALL FJ, 1995, J BACTERIOL, V177, P6170, DOI 10.1128/jb.177.21.6170-6175.1995; SMALL FJ, 1995, APPL ENVIRON MICROB, V61, P1507, DOI 10.1128/AEM.61.4.1507-1513.1995; SUBRAMANIAN V, 1985, J BIOL CHEM, V260, P2355; VANGINKEL CG, 1987, APPL ENVIRON MICROB, V53, P2903, DOI 10.1128/AEM.53.12.2903-2907.1987; VANGINKEL CG, 1986, ARCH MICROBIOL, V145, P403, DOI 10.1007/BF00470879; VESTAL JR, 1969, J BACTERIOL, V99, P216, DOI 10.1128/JB.99.1.216-221.1969; WEBER FJ, 1992, J BACTERIOL, V174, P3275, DOI 10.1128/jb.174.10.3275-3281.1992; WEIJERS CAGM, 1988, ENZYME MICROB TECH, V10, P214, DOI 10.1016/0141-0229(88)90069-5; WOODLAND MP, 1995, ARCH MICROBIOL, V163, P231; WOODS NR, 1989, J GEN MICROBIOL, V135, P2335; Zhou NY, 1996, APPL MICROBIOL BIOT, V44, P582, DOI 10.1007/BF00172489	46	100	110	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24913	24920		10.1074/jbc.272.40.24913	http://dx.doi.org/10.1074/jbc.272.40.24913			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312093	hybrid			2022-12-25	WOS:A1997XY97000032
J	Yegneswaran, S; Wood, GM; Esmon, CT; Johnson, AE				Yegneswaran, S; Wood, GM; Esmon, CT; Johnson, AE			Protein S alters the active site location of activated protein C above the membrane surface - A fluorescence resonance energy transfer study of topography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VA INACTIVATION; COAGULATION FACTOR VIIA; PEPTIDE-BOND CLEAVAGES; BOUND IMMUNOGLOBULIN-E; BLOOD-COAGULATION; FACTOR-XA; PROTHROMBINASE COMPLEX; PHOSPHOLIPID SURFACE; TISSUE-FACTOR; FACTOR-IXA	The location of the active site of membrane-bound activated protein C (APC) relative to the phospholipid surface was determined both in the presence and absence of its cofactor, protein S, using fluorescence resonance energy transfer (FRET). APC was chemically modified to create the FRET donor species, Fl-FPR-APC, with a fluorescein dye (Fl) covalently attached to the active site via a D-Phe-Pro-Arg (FPR) tether and located in the active site near S-4. FRET was observed when Fl-FPR-APC was titrated in the presence of Ca2+ ions with phosphatidylcholine/phosphatidylserine (4:1) vesicles containing the FRET acceptor, octadecylrhodamine (OR). Assuming a random orientation of transition dipoles (kappa(2) = 2/3), the average distance of closest approach between the fluorescein in the active site of the membrane-bound APC and the OR at the membrane surface is 94 Angstrom. The same calcium-dependent distance was obtained for both small and large unilamellar vesicles and for vesicles that contained phosphatidylethanolamine. The active site of membrane-bound APC is therefore located far above the phospholipid surface. Upon addition of protein S, the efficiency of Fl-FPR-APC to OR energy transfer increased due to a protein S-dependent rotational and/or translational movement of the APC protease domain relative to the surface. If this movement were solely translational, then the average height of the fluorescein in the membrane-bound APC protein S complex would be 84 Angstrom above the surface. The extent of Fl-FPR-APC to OR energy transfer was unaltered by the addition of thrombin-inactivated protein S, The protein S effect was also specific for APC, since the addition of protein S to similarly-labeled derivatives of factor Xa, factor Ma, or factor VIIa did not alter the locations of their active sites, This direct measurement demonstrates that the binding of the protein S cofactor to its cognate enzyme elicits a relocation of the active site of APC relative to the membrane surface and thereby provides a structural explanation for the recently observed protein S-dependent change in the site of factor Va cleavage by APC.	TEXAS A&M UNIV, COLL MED, HLTH SCI CTR, DEPT MED BIOCHEM & GENET, COLLEGE STN, TX 77843 USA; UNIV WISCONSIN PARKSIDE, DEPT CHEM, KENOSHA, WI 53141 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT PATHOL, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, OKLAHOMA CITY, OK 73190 USA; HOWARD HUGHES MED INST, OKLAHOMA CITY, OK 73104 USA; TEXAS A&M UNIV, DEPT CHEM, COLLEGE STN, TX 77843 USA; TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Wisconsin System; University of Wisconsin Parkside; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station			Johnson, Arthur E/G-3457-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029807, R37HL030340, R01HL032934] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 29807, R01 HL 32934, R37 HL 30340] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BAIRD B, 1985, BIOCHEMISTRY-US, V24, P6252, DOI 10.1021/bi00343a032; BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; CERIONE RA, 1983, BIOCHEMISTRY-US, V22, P769, DOI 10.1021/bi00273a010; Chen Q, 1997, BIOCHEMISTRY-US, V36, P4701, DOI 10.1021/bi961441r; CHRISTIANSEN WT, 1995, BIOCHEMISTRY-US, V34, P10376, DOI 10.1021/bi00033a008; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; DEWEY TG, 1980, BIOPHYS J, V32, P1023, DOI 10.1016/S0006-3495(80)85033-8; DHARMAWARDANA K, 1994, THESIS U OKLAHOMA NO; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1977, CHEM BIOL THROMBIN, P403; ESMON CT, 1995, HEMATOLOGY BASIC PRI, V2, P1597; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; GUINTO ER, 1982, J BIOL CHEM, V257, P38; HACKENG TM, 1994, J BIOL CHEM, V269, P21051; HEEB MJ, 1994, P NATL ACAD SCI USA, V91, P2728, DOI 10.1073/pnas.91.7.2728; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3466, DOI 10.1021/bi00283a025; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4893, DOI 10.1021/bi00667a022; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KURACHI K, 1976, BIOCHEMISTRY-US, V15, P368, DOI 10.1021/bi00647a020; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; LU RL, 1989, J BIOL CHEM, V264, P12956; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; McCallum CD, 1996, J BIOL CHEM, V271, P28168, DOI 10.1074/jbc.271.45.28168; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; OWEN WG, 1974, J BIOL CHEM, V249, P594; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; ROSING J, 1980, J BIOL CHEM, V255, P274; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SUGO T, 1986, J BIOL CHEM, V261, P5116; TANS G, 1991, BLOOD, V77, P2641; THOMPSON AR, 1977, ARCH BIOCHEM BIOPHYS, V178, P356, DOI 10.1016/0003-9861(77)90204-1; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1984, J BIOL CHEM, V259, P335; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1992, P SOC EXP BIOL MED, V200, P285; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WU PG, 1992, BIOCHEMISTRY-US, V31, P7939, DOI 10.1021/bi00149a027; YE J, 1991, J BIOL CHEM, V266, P23016	70	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25013	25021		10.1074/jbc.272.40.25013	http://dx.doi.org/10.1074/jbc.272.40.25013			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312108	hybrid			2022-12-25	WOS:A1997XY97000047
J	Kimura, Y; Furuhata, T; Shiratsuchi, T; Nishimori, H; Hirata, K; Nakamura, Y; Tokino, T				Kimura, Y; Furuhata, T; Shiratsuchi, T; Nishimori, H; Hirata, K; Nakamura, Y; Tokino, T			GML sensitizes cancer cells to Taxol by induction of apoptosis	ONCOGENE			English	Article						p53; gml; apoptosis; chemosensitivity	ANTICANCER AGENTS; THYMOCYTE APOPTOSIS; OVARIAN-CANCER; P53; CYTOTOXICITY; EXPRESSION; RADIATION; INCREASE; DRUG	Recently we identified a novel gene, gml, whose expression is regulated in a p53-dependent manner and found that gml expression was correlated with the sensitivity of esophageal cancer cells to anticancer drugs. To further investigate the biological mechanism of gml in determining the chemosensitivity of cancer cells to clinically useful agents, we introduced gml cDNA into TE10, an esophageal cancer cell line that lacks endogenous gml expression. In two resulting stable cell lines which expressed gml cDNA in the absence of wild-type p53, cell death occurred within 6 h after treatment with Taxol. TE10 parent cells or TE10 cells transfected with vector alone displayed relative resistance for 36 h. Induction of gml did not by itself affect viability. Morphological analysis confirmed that the increased chemosensitivity to Taxol conferred by gml was due to apoptosis. These data suggest that reduced expression of gml is likely to be associated with poor response rates to chemotherapy, and that an assay for gml expression might serve a clinical purpose as a predictor of chemotherapeutic sensitivity.	SAPPORO MED UNIV,DEPT SURG 1,SAPPORO,HOKKAIDO,JAPAN	Sapporo Medical University	Kimura, Y (corresponding author), UNIV TOKYO,INST MED SCI,MOL MED LAB,4-6-1 SHIROKANEDAI,TOKYO,JAPAN.		Tokino, Takashi/AAI-9887-2021	Kimura, Yasutoshi/0000-0002-7790-9250				CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Delia D, 1996, NAT MED, V2, P724, DOI 10.1038/nm0796-724; DONALDSON KL, 1994, INT J CANCER, V57, P847, DOI 10.1002/ijc.2910570614; Furuhata T, 1996, ONCOGENE, V13, P1965; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREGORY RE, 1993, CLIN PHARMACY, V12, P401; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SIRE EAG, 1995, ANN ONCOL, V6, P589, DOI 10.1093/oxfordjournals.annonc.a059249; SLICHENMYER WJ, 1991, ANTI-CANCER DRUG, V2, P519, DOI 10.1097/00001813-199112000-00002; TISHLER RB, 1995, CANCER RES, V55, P6021; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	18	16	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1369	1374		10.1038/sj.onc.1201255	http://dx.doi.org/10.1038/sj.onc.1201255			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315106				2022-12-25	WOS:A1997XV84500016
J	Su, YA; Lee, MM; Hutter, CM; Meltzer, PS				Su, YA; Lee, MM; Hutter, CM; Meltzer, PS			Characterization of a highly conserved gene (OS4) amplified with CDK4 in human sarcomas	ONCOGENE			English	Article						neoplasm; genetics; chromosome 12q; homogeneously staining region	HUMAN-MALIGNANT GLIOMAS; SOFT-TISSUE SARCOMAS; HUMAN CANCERS; AMPLIFICATION; MDM2; REGION; DNA; SAS; MICRODISSECTION; AMPLICONS	Amplification and overexpression of genes involved in growth control occur frequently in human Here, we report characterization of the fun length OS4 cDNA derived from 12q13-q15 (Su et al., Proc. Natl. Acad. Sci. USA, 91: 9121-9125, 1994), a region frequently amplified in sarcomas and brain tumors. This cDNA consists of 4833 base pairs (bp) encoding an open reading frame (ORF) of 283 amino acids, The ORF predicts a water-soluble acidic (pi 5.50) polypeptide with a molecular weight of 31 759. Database searches revealed highly significant similarity between OS4 and eight proteins predicted from genomic sequences of Caenorhabditis elegans, Schizosaccaharomyces pombe, and Saccharomyces cerevisiae. Thus, OS4 defines a novel evolutionarily conserved gene superfamily. Northern and database analyses revealed OS4 transcripts in numerous human tissues demonstrating its ubiquitous expression. We also observed overexpression of OS4 in three cancer cell lines with amplification of this gene. Furthermore, we detected OS4 amplification in 5/5 primary sarcomas with known amplification of the closely linked marker CDK4. These results demonstrate that the highly conserved OS4 gene is frequently included in the 22q13-q15 amplicon and may contribute to the development of a subset of sarcomas.	NATL HUMAN GENOME RES INST, NIH, CANC GENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; BROWN T, 1993, CURRENT PROTOCOLS MO; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; ELKAHLOUN AG, 1997, IN PRESS GENOMICS; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Gracia E, 1996, HUM MOL GENET, V5, P595, DOI 10.1093/hmg/5.5.595; JANKOWSKI SA, 1994, ONCOGENE, V9, P1205; KHATIB ZA, 1993, CANCER RES, V53, P5535; LEACH FS, 1993, CANCER RES, V53, P2231; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RHIM JS, 1975, INT J CANCER, V15, P23, DOI 10.1002/ijc.2910150104; ROBERTS WM, 1989, CANCER RES, V49, P5407; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SMITH SH, 1992, CANCER RES, V52, P3746; Su YA, 1996, MOL CARCINOGEN, V15, P270, DOI 10.1002/(SICI)1098-2744(199604)15:4<270::AID-MC4>3.0.CO;2-K; SU YA, 1994, P NATL ACAD SCI USA, V91, P9121, DOI 10.1073/pnas.91.19.9121	23	38	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1289	1294		10.1038/sj.onc.1201294	http://dx.doi.org/10.1038/sj.onc.1201294			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315096				2022-12-25	WOS:A1997XV84500006
J	Bennett, KL; Bradshaw, J; Youngman, T; Rodgers, J; Greenfield, B; Aruffo, A; Linsley, PS				Bennett, KL; Bradshaw, J; Youngman, T; Rodgers, J; Greenfield, B; Aruffo, A; Linsley, PS			Deleted in colorectal carcinoma (DCC) binds heparin via its fifth fibronectin type III domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; RECEPTOR; CELLS; ADHESION; MOLECULE; HOMOLOG; ENCODES; CANCER	DCC (deleted in colorectal carcinoma) is a broadly expressed cell-surface receptor. Netrin-1 was recently identified as a DCC ligand in brain, but the possibility of other DCC ligands was suggested by the finding that an anti-DCC antibody (clone AF5) neutralized netrin-1-dependent commissural axon outgrowth without blocking DCC/netrin-1 interactions. Here we have searched for alternative cell-surface DCC ligands. A DCC-Ig fusion protein bound to neural and epithelial derived cell lines, indicating that these lines express ligand(s) for DCC. The cell-surface binding activity was mediated by the loop between beta-strands F and G of the fifth fibronectin type III repeat FNIII-D5. The loop included the sequence KNRR, which resembles heparin-binding motifs in other proteins. Heparinase and heparitinase treatment of cells reduced binding of DCC-Ig, suggesting that heparan sulfate proteoglycans are cell-surface DCC ligand(s). This was further supported by heparin blocking experiments and by binding of DCC-Ig to immobilized heparan sulfate. The interaction between DCC-Ig and heparan sulfate/heparin, both on the surface of cells and immobilized on plastic, was blocked by the same anti-DCC antibody that blocks netrin-1-dependent commissural axon outgrowth. Taken together, these findings suggest that the DCC-Ig/heparin interaction may contribute to the biological activity to DCC.			Bennett, KL (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,POB 4000,OFF K4430B,PRINCETON,NJ 08543, USA.							ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; DRAKE SL, 1993, J BIOL CHEM, V268, P15859; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1996, BIOCHIM BIOPHYS ACTA, V1288, P17; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; WEBER P, 1995, J BIOL CHEM, V270, P4619, DOI 10.1074/jbc.270.9.4619	20	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26940	26946		10.1074/jbc.272.43.26940	http://dx.doi.org/10.1074/jbc.272.43.26940			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341129	hybrid			2022-12-25	WOS:A1997YC65900025
J	Falcon, CM; SwintKruse, L; Matthews, KS				Falcon, CM; SwintKruse, L; Matthews, KS			Designed disulfide between N-terminal domains of lactose repressor disrupts allosteric linkage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPSIN-RESISTANT CORE; LAC REPRESSOR; CRYSTAL-STRUCTURE; DNA-BINDING; OPERATOR; PROTEIN; TETRAMER; HEADPIECE; SEQUENCE; INDUCER	Substitution of Cys for Val at position 52 of the lac repressor was designed to permit disulfide bond formation between the two N-terminal DNA binding domains that comprise an operator DNA binding site. This position marks the closest approach of these domains based on the x-ray crystallographic structures of the homologous purine holorepressor-operator complex and lac repressor-operator complex (Schumacher, M. A., Choi, R. Y,, Zalkin, H., and Brennan, R, G, (1994) Science 266, 763-710; Lewis, M., Chang, G., Horton, N.C., Kercher, M. A., Pace, H. C., Schumacher, M. A., Brennan, R. G., and Lu, P. (1996) Science 271, 1247-1254), The V52C mutation was generated by site-specific methods, and the mutant protein was purified and characterized. In the reduced form, V52C bound operator DNA with slightly increased affinity, Exposure to oxidizing conditions resulted in disulfide bond formation, and the oxidized protein bound operator DNA with similar to 6-fold higher affinity than wild-type protein, Inducer binding for both oxidized and reduced forms of V52C was comparable to wild-type bac repressor, In the presence of inducer, the reduced protein exhibited wild-type, diminished DNA binding. In contrast, DNA binding for the oxidized form was unaffected by inducer, even at 1 mM. Thus, the formation of the designed disulfide between Cys(52) Side chains within each dimer renders the protein-operator complex unresponsive to sugar binding, presumably by disrupting the allosteric linkage between operator and inducer binding.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77005	Rice University				Swint-Kruse, Liskin/0000-0002-5925-9741	NIGMS NIH HHS [GM 22441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER K, 1972, NATURE, V237, P322, DOI 10.1038/237322a0; ALBERTI S, 1991, NEW BIOL, V3, P57; BETZ JL, 1986, GENE, V42, P283, DOI 10.1016/0378-1119(86)90232-5; BEYREUTHER K, 1975, BIOCHEM SOC T, V3, P1125, DOI 10.1042/bst0031125; BOURGEOIS S, 1971, METHODS ENZYMOLOGY D, V21, P491; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHEN J, 1992, J BIOL CHEM, V267, P13843; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5468, DOI 10.1021/bi00367a018; FILES JG, 1976, J BIOL CHEM, V251, P3386; Frank DE, 1997, J MOL BIOL, V267, P1186, DOI 10.1006/jmbi.1997.0920; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GEISLER N, 1977, BIOCHEMISTRY-US, V16, P938, DOI 10.1021/bi00624a020; GILBERT W, 1973, P NATL ACAD SCI USA, V70, P3581, DOI 10.1073/pnas.70.12.3581; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KANIA J, 1977, EUR J BIOCHEM, V79, P381, DOI 10.1111/j.1432-1033.1977.tb11819.x; KANIA J, 1976, P NATL ACAD SCI USA, V73, P3529, DOI 10.1073/pnas.73.10.3529; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LAMERICHS RMJN, 1989, BIOCHEMISTRY-US, V28, P2985, DOI 10.1021/bi00433a037; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; MATTHEWS KS, 1997, IN PRESS PROG NUCL A, V58; Miller J. H., 1980, OPERON; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; MULLERHILL B, 1977, NUCLEIC ACID PROTEIN, P219; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; PFAHL M, 1974, GENETICS, V76, P669; RIGGS AD, 1968, J MOL BIOL, V34, P361, DOI 10.1016/0022-2836(68)90260-X; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Spronk CAEM, 1996, NAT STRUCT BIOL, V3, P916, DOI 10.1038/nsb1196-916; Suckow J, 1996, J MOL BIOL, V261, P509, DOI 10.1006/jmbi.1996.0479; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428	37	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26818	26821		10.1074/jbc.272.43.26818	http://dx.doi.org/10.1074/jbc.272.43.26818			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341111	hybrid			2022-12-25	WOS:A1997YC65900007
J	Li, XM; LopezGuisa, JM; Ninan, N; Weiner, EJ; Rauscher, FJ; Marmorstein, R				Li, XM; LopezGuisa, JM; Ninan, N; Weiner, EJ; Rauscher, FJ; Marmorstein, R			Overexpression, purification, characterization, and crystallization of the BTB/POZ domain from the PLZF oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; PROTEIN INTERACTION MOTIF; ZINC-FINGER PROTEINS; TRANSCRIPTION FACTOR; CONSERVED DOMAIN; DNA-BINDING; ALPHA LOCUS; BTB DOMAIN; POZ-DOMAIN; DROSOPHILA	The BTB/POZ domain defines a conserved region of about 120 residues and has been found in over 40 proteins to date. It is located predominantly at the N terminus of Zn-finger DNA-binding proteins, where it may function as a repression domain, and less frequently in actin-binding and poxvirus-encoded proteins, where it may function as a protein-protein interaction interface, A prototypic human BTB/POZ protein, PLZF (promyelocytic Leukemia zinc finger) is fused to RAR alpha (retinoic acid receptor alpha) in a subset of acute promyeloeytic leukemias (APLs), where it acts as a potent oncogene, The exact role of the BTB/POZ domain in protein-protein interactions and/or transcriptional regulation is unknown. We have overexpressed, purified, characterized, and crystallized the BTB/POZ domain from PLZF (PLZF-BTB/POZ). Gel filtration, dynamic light scattering, and equilibrium sedimentation experiments show that PLZF-BTB/POZ forms a homodimer with a K-d below 200 nM. Differential scanning calorimetry and equilibrium denaturation experiments are consistent with the PLZF-BTB/POZ dimer undergoing a two-state unfolding-transition with a T-m of 70.4 degrees C, and a Delta G of 12.8 +/- 0.4 kcal/mel. Circular dichroism shows that the PLZF-BTB/POZ dimer has significant secondary structure including about 45% helix and 20% beta-sheet, The have prepared crystals of the PLZF-BTB/POZ that are suitable for a high resolution structure determination using x-ray crystallography, The crystals form in the space group I222 or I2(1)2(1)2(1) with a = 38.8, b = 77.7, and c = 85.3 Angstrom and contain 1 protein subunit per asymmetric unit, with approximately 40% solvent. Our data support the hypothesis that the ETB/POZ domain mediates a functionally relevant dimerization function in vivo. The crystal structure of the PLZF-BTB/POZ domain will provide a paradigm for understanding the structural basis underlying BTB/POZ domain function.	UNIV PENN,WISTAR INST,PHILADELPHIA,PA 19104; UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			li, xinmin/C-6173-2011					ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BAVISOTTO L, 1991, J EXP MED, V174, P1097, DOI 10.1084/jem.174.5.1097; BROOKS I, 1994, METHOD ENZYMOL, V240, P459; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CUDNEY R, 1994, ACTA CRYSTALLOGR D, V50, P414; DIBELLO PR, 1991, GENETICS, V129, P385; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; FREEMONT PS, 1993, ZINC FINGER PROTEINS; GEWIRTH D, 1993, HKL VERSION 1 0 MANU; GODT D, 1993, DEVELOPMENT, V119, P799; GUIDEZ F, 1994, LEUKEMIA, V8, P312; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEMONS RS, 1995, J PEDIAT HEMATOL ONC, V17, P198, DOI 10.1097/00043426-199508000-00002; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; McPherson A, 1982, PREPARATION ANAL PRO; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; ROWLEY JD, 1977, LANCET, V1, P549; SCOTT WG, 1995, J MOL BIOL, V250, P327, DOI 10.1006/jmbi.1995.0380; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; ZELENT A, 1994, BRIT J HAEMATOL, V86, P451, DOI 10.1111/j.1365-2141.1994.tb04773.x; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	37	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27324	27329		10.1074/jbc.272.43.27324	http://dx.doi.org/10.1074/jbc.272.43.27324			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341182	hybrid			2022-12-25	WOS:A1997YC65900078
J	Scaffidi, C; Medema, JP; Krammer, PH; Peter, ME				Scaffidi, C; Medema, JP; Krammer, PH; Peter, ME			FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; CELL-DEATH; CYSTEINE PROTEASE; MOLECULAR-CLONING; APOPTOSIS; IDENTIFICATION; FAMILY; GENE; INTERACTS; INDUCTION	Induction of apoptosis by the cell surface receptor CD95 (APO-1/Fas) has been shown to involve activation of a family of cysteine proteases (caspases). Recently, a new member of this family has been identified, designated FLICE (caspase-8/MACH/Mch5). FLICE is part of the CD95 death-inducing signaling complex and is therefore the most upstream caspase in the CD95 apo ptotic pathway. A total of eight different isoforms of FLICE (caspase-8/a-h) have been described. To determine which isoforms are expressed in different cells we have generated a panel of monoclonal antibodies directed against all functional domains of FLICE. Using these antibodies we could show that only two of the FLICE isoforms (caspase-8/a and caspase-8/b) were predominantly expressed in cells of different origin. Both isoforms were recruited to the CD95 death-inducing signaling complex and were activated upon CD95 stimulation with similar kinetics. Taken together, only two of the eight published caspase-8 isoforms could be detected in significant amounts at the protein level.	GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Watzl, Carsten/B-4911-2013	Watzl, Carsten/0000-0001-5195-0995; Medema, Jan Paul/0000-0003-3045-2924; Peter, Marcus Ernst/0000-0003-3216-036X				ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Faucheu C, 1996, EUR J BIOCHEM, V236, P207, DOI 10.1111/j.1432-1033.1996.t01-1-00207.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; MUZIO M, 1996, CELL, V85, P807; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; PETER ME, 1997, APOPTOSIS PROBLEMS D; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580	35	362	373	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26953	26958		10.1074/jbc.272.43.26953	http://dx.doi.org/10.1074/jbc.272.43.26953			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341131	hybrid			2022-12-25	WOS:A1997YC65900027
J	Beyer, K; Dandekar, T; Keller, W				Beyer, K; Dandekar, T; Keller, W			RNA ligands selected by cleavage stimulation factor contain distinct sequence motifs that function as downstream elements in 3'-end processing of pre-mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 DNA-POLYMERASE; GROWTH-HORMONE GENE; 3' END FORMATION; MESSENGER-RNA; POLYADENYLATION FACTOR; POLY(A) SITE; BINDING; AAUAAA; REGION; EFFICIENCY	Critical events in 3'-end processing of pre-mRNA are the recognition of the AAUAAA polyadenylation signal by cleavage and polyadenylation specificity factor (CPSF) and the binding of cleavage stimulation factor (CstF) via its 64-kDa subunit to the downstream element. The stability of this CPSF CstF.RNA complex is thought to determine the efficiency of 3'-end processing. Since downstream elements reveal high sequence variability, in vitro selection experiments with highly purified CstF were performed to investigate the sequence requirements for CstF RNA interaction. CstF was purified from calf thymus and from HeLa cells. Surprisingly, calf thymus CstF contained an additional, novel form of the 64-kDa subunit with a molecular mass of 70 kDa. RNA ligands selected by HeLa and calf thymus CstF contained three highly conserved sequence elements as follows: element 1 (AUGCGUUCCUCGUCC) and two closely related elements, element 2a (YGUGUYN(0-4)UUYAYUGYGU) and element 2b (UUGYUN(0-4)AUUUACU(U/G)N0-2YCU). All selected sequences tested functioned as downstream elements in 3'-end processing in vitro. A computer survey of the EMBL data library revealed significant homologies to all selected elements in naturally occurring 3'-untranslated regions. The majority of element 2a homologies was found downstream of coding sequences. Therefore, we postulate that this element represents a novel consensus sequence for downstream elements in 3'-end processing of pre-mRNA.	UNIV BASEL, BIOZENTRUM, DEPT CELL BIOL, CH-4056 BASEL, SWITZERLAND; EUROPEAN MOL BIOL LAB, D-69117 HEIDELBERG, GERMANY	University of Basel; European Molecular Biology Laboratory (EMBL)			Dandekar, Thomas/A-4431-2017	Dandekar, Thomas/0000-0003-1886-7625				BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHEN JS, 1992, NUCLEIC ACIDS RES, V20, P2565, DOI 10.1093/nar/20.10.2565; CHOU ZF, 1994, NUCLEIC ACIDS RES, V22, P2525, DOI 10.1093/nar/22.13.2525; CONWAY L, 1987, EMBO J, V6, P4177, DOI 10.1002/j.1460-2075.1987.tb02764.x; DANDEKAR T, 1995, TRENDS GENET, V11, P45, DOI 10.1016/S0168-9525(00)88996-9; DAY INM, 1992, GENE, V110, P245, DOI 10.1016/0378-1119(92)90656-A; EDWALDSGILBERT G, 1995, MOL CELL BIOL, V15, P6420; GIL A, 1987, CELL, V49, P399, DOI 10.1016/0092-8674(87)90292-3; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GIMMI ER, 1988, NUCLEIC ACIDS RES, V16, P8977, DOI 10.1093/nar/16.18.8977; GOODWIN EC, 1992, J BIOL CHEM, V267, P16330; KAHN P, 1990, METHOD ENZYMOL, V183, P23; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; Keller W, 1997, CURR OPIN CELL BIOL, V9, P329, DOI 10.1016/S0955-0674(97)80004-X; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; Manley JL, 1996, SCIENCE, V274, P1481, DOI 10.1126/science.274.5292.1481; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MANN KP, 1993, MOL CELL BIOL, V13, P2411, DOI 10.1128/MCB.13.4.2411; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; MASON PJ, 1986, CELL, V46, P263, DOI 10.1016/0092-8674(86)90743-9; MCDEVITT MA, 1986, EMBO J, V5, P2907, DOI 10.1002/j.1460-2075.1986.tb04586.x; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; RYNER LC, 1989, MOL CELL BIOL, V9, P1759, DOI 10.1128/MCB.9.4.1759; SADOFSKY M, 1985, MOL CELL BIOL, V5, P2713, DOI 10.1128/MCB.5.10.2713; SITTLER A, 1994, NUCLEIC ACIDS RES, V22, P222, DOI 10.1093/nar/22.2.222; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; TAYA Y, 1982, EMBO J, V1, P953, DOI 10.1002/j.1460-2075.1982.tb01277.x; TUERK C, 1990, J MOL BIOL, V213, P749, DOI 10.1016/S0022-2836(05)80261-X; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WAHLE E, 1994, RNA PROCESSING PRACT, P1; WEISS EA, 1991, EMBO J, V10, P215, DOI 10.1002/j.1460-2075.1991.tb07938.x; WOYCHIK RP, 1984, P NATL ACAD SCI-BIOL, V81, P3944, DOI 10.1073/pnas.81.13.3944; Yoshio TD, 1997, MOL CELL BIOL, V17, P3907, DOI 10.1128/MCB.17.7.3907; ZARKOWER D, 1988, J BIOL CHEM, V263, P5780; ZHANG F, 1986, MOL CELL BIOL, V6, P4611, DOI 10.1128/MCB.6.12.4611	48	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26769	26779		10.1074/jbc.272.42.26769	http://dx.doi.org/10.1074/jbc.272.42.26769			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334264	Green Accepted, hybrid			2022-12-25	WOS:A1997YB13900098
J	Verdier, F; Chretien, S; Billat, C; Gisselbrecht, S; Lacombe, C; Mayeux, P				Verdier, F; Chretien, S; Billat, C; Gisselbrecht, S; Lacombe, C; Mayeux, P			Erythropoietin induces the tyrosine phosphorylation of insulin receptor substrate-2 - An alternate pathway for erythropoietin-induced phosphatidylinositol 3-kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; LEUKEMIC-CELL-LINE; SERUM-FREE MEDIUM; GROWTH FACTOR-I; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; INTERFERON-GAMMA; PROTEIN; IRS-1; DIFFERENTIATION	In this report, we demonstrate that insulin receptor substrate-a (IRS-P) is phosphorylated on tyrosine following treatment of UT-7 cells with erythropoietin. We have investigated the expression of IRS-1 and IRS-S in several cell lines with erythroid and/or megakaryocytic features, and we observed that IRS-P was expressed in all cell lines tested. In contrast, we did not detect the expression of IRS-1 in these cells. In response to erythropoietin, IRS-2 was immediately phosphorylated on tyrosine, with maximal phosphorylation between 1 and 5 min. Tyrosine-phosphorylated IRS-P was associated with phosphatidylinositol 3-kinase and with a 140-kDa protein that comigrated with the phosphatidylinositol-3,4,5-trisphosphate B-phosphatase, SHIP. Moreover, IRS-2 was constitutively associated with the erythropoietin receptor. We did not observe the association of IRS-2 with JAK2, Grb2, or PTP1D. Using BaF3 cells transfected with mutated erythropoietin receptors, we demonstrate that neither the tyrosine residues of the intracellular domain nor the last 109 amino acids of the erythropoietin receptor are required for erythropoietin-induced IRS-P tyrosine phosphorylation. Altogether, our results indicate that erythropoietin-induced IRS-S tyrosine phosphorylation could account for the previously reported activation of phosphatidylinositol 3-kinase mediated by erythropoietin receptors mutated in the phosphatidylinositol 3-kinase-binding site.	UNIV PARIS 05, INSERM U363, INST COCHIN GENET MOL, F-75014 PARIS, FRANCE; INST NATL TRANSFUS SANGUINE, F-75015 PARIS, FRANCE; UNIV REIMS, UFR SCI EXACTES & NAT, CNRS UPRES A6021, BIOCHIM LAB, F-51687 REIMS 2, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Reims Champagne-Ardenne			Chretien, Stany/M-5166-2018					ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Berlanga JJ, 1997, J BIOL CHEM, V272, P2050; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; CORREA PN, 1991, BLOOD, V78, P2823; CORREA PN, 1994, BLOOD, V83, P99; DAMEN J, 1992, BLOOD, V80, P1923; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HE TC, 1993, BLOOD, V82, P3530; HE TC, 1994, J BIOL CHEM, V269, P18291; HERMINE O, 1992, BLOOD, V80, P3060; Hilton CJ, 1995, GROWTH FACTORS, V12, P263, DOI 10.3109/08977199509028965; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IKAWA Y, 1976, GANN, V67, P767; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KITAMURA T, 1989, BLOOD, V73, P375; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KOMATSU N, 1991, CANCER RES, V51, P341; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA Y, 1994, J BIOL CHEM, V269, P29962; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Porteu F, 1996, MOL CELL BIOL, V16, P2473; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Welham MJ, 1997, J BIOL CHEM, V272, P1377, DOI 10.1074/jbc.272.2.1377; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	61	76	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26173	26178		10.1074/jbc.272.42.26173	http://dx.doi.org/10.1074/jbc.272.42.26173			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334184	hybrid			2022-12-25	WOS:A1997YB13900018
J	Xie, M; Shao, G; Buyse, IM; Huang, S				Xie, M; Shao, G; Buyse, IM; Huang, S			Transcriptional repression mediated by the PR domain zinc finger gene RIZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-TRANSFORMING GENE; ADENOVIRUS E1A PROTEIN; MAMMALIAN-CELLS; IDENTIFICATION; ACTIVATION; EXPRESSION; PROMOTER; BINDING; TRANSLOCATIONS; MATURATION	The RIZ (G3B or MTB-Zf) zinc finger gene is structurally related to the myeloid leukemia gene, MDS1-EVI1, and the transcription repressor/differentiation factor, PRDI-BF1/BLIMP1, through a conserved amino-terminal motif, the TR domain, Similar-to MDS1-EVI1, RIZ gene normally produces two protein product: that differ by the PR domain, The smaller protein RIZ2 lacks the PR domain of RIZ1 but is otherwise identical to RIZ1. Here we show that RIZ proteins bind to GC-rich or Sp-1-binding elements and repress transcription, Both RIZ1 and RIZ2 repressed the herpes simplex virus thymidine kinase (HSV-TK) promoter, one of the best characterized eukaryotic promoters. Recombinant RIZ1 proteins were able to bind tit HSV-TK promoter. This binding was mediated by the GC-rich Sp-l elements of the promoter and the first three zinc finger motifs of RIZ1. RIZ also encodes a repressor domain that was mapped to the central region of the protein, Fusion of this region to the GAL4 DNA-binding domain generated GAL4 site-dependent transcriptional repressors. We also show that RIZ1 protein can efficiently repress the simian virus 40 (SV40) early promoter, which primarily consists of Sp-l sites; RIZ2, however only weakly repressed this promoter, suggesting a role for PR in modulating RIZ protein function. The data have implications for a role of RIZ proteins in the regulation of cellular gene promoters, many of which are characterized by GC-rich elements.	BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA057496] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA57496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Buyse IM, 1996, GENOMICS, V34, P119, DOI 10.1006/geno.1996.0249; Buyse IM, 1997, J VIROL, V71, P6200, DOI 10.1128/JVI.71.8.6200-6203.1997; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; Mock BA, 1996, GENOMICS, V37, P24, DOI 10.1006/geno.1996.0516; MORISHITA K, 1995, ONCOGENE, V10, P1961; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Muraosa Y, 1996, EUR J BIOCHEM, V235, P471, DOI 10.1111/j.1432-1033.1996.00471.x; MURAOSA Y, 1993, MOL CELL BIOL, V13, P7881, DOI 10.1128/MCB.13.12.7881; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHAPIRO VS, 1995, GENE, V163, P329, DOI 10.1016/0378-1119(95)00420-B; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Shin EK, 1996, J BIOL CHEM, V271, P12261, DOI 10.1074/jbc.271.21.12261; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2	37	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26360	26366		10.1074/jbc.272.42.26360	http://dx.doi.org/10.1074/jbc.272.42.26360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334209	hybrid			2022-12-25	WOS:A1997YB13900043
J	Accili, EA; Kiehn, J; Yang, Q; Wang, ZG; Brown, AM; Wible, BA				Accili, EA; Kiehn, J; Yang, Q; Wang, ZG; Brown, AM; Wible, BA			Separable Kv beta subunit domains alter expression and gating of potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; ALPHA-SUBUNITS; INACTIVATION; BINDING; BRAIN; BLOCK	Kv beta subunits have been shown to affect kinetic properties of voltage-gated K+ channel Kv1 alpha subunits and increase the number of cell surface dendrotoxin-binding sites when coexpressed with Kv1.2. Here, we show that Kv beta 1.2 alters both current expression and gating of Kv alpha 1 channels and that each effect is mediated by a distinct Kv beta 1.2 domain. The Kv beta 1.2 N terminus or Kv alpha 1-blocking domain introduced steady state current block, an apparent negative shift in steady state activation, and a slowing of deactivation along with a dramatic reduction in single channel open probability, N-terminal deletions of Kv beta 1.2 no longer altered channel kinetics but promoted dramatic increases in Kv1.2 current. The conserved Kv beta 1 C terminus or Kv alpha 1 expression domain alone was sufficient to increase the number of functional channels. The same effect was observed with the normally noninactivating subunit, Kv beta 2. By contrast, Kv1.5 currents were reduced when coexpressed with either the Kv beta 1 C terminus or Kv beta 2, indicating that the Kv alpha 1 expression domain has Kv alpha 1 isoform-specific effects. Our results demonstrate that Kv beta subunits consist of two domains that are separable on the basis of both primary structure and functional modulation of voltage-gated K+ channels.	CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOCHEM,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,RAMMELKAMP CTR RES,CLEVELAND,OH 44109	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; MetroHealth System			Wang, Zhiguo/GRS-4339-2022	Wang, Zhiguo/0000-0002-0811-2045	NHLBI NIH HHS [HL-36930, HL55404] Funding Source: Medline; NINDS NIH HHS [NS-23877] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930, R01HL055404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHOUINARD SW, 1995, P NATL ACAD SCI USA, V92, P6763, DOI 10.1073/pnas.92.15.6763; DeBiasi M, 1997, AM J PHYSIOL-HEART C, V272, pH2932, DOI 10.1152/ajpheart.1997.272.6.H2932; ENGLAND SK, 1995, J BIOL CHEM, V270, P28531, DOI 10.1074/jbc.270.48.28531; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; Kiehn J, 1996, CIRCULATION, V94, P2572, DOI 10.1161/01.CIR.94.10.2572; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SCHULTEIS CT, 1995, BIOCHEMISTRY-US, V34, P1725, DOI 10.1021/bi00005a029; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; VanDongen AMJ, 1996, BIOPHYS J, V70, P1303, DOI 10.1016/S0006-3495(96)79687-X; Wang ZG, 1996, J BIOL CHEM, V271, P28311, DOI 10.1074/jbc.271.45.28311; Xu J, 1997, J BIOL CHEM, V272, P11728, DOI 10.1074/jbc.272.18.11728; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	21	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25824	25831		10.1074/jbc.272.41.25824	http://dx.doi.org/10.1074/jbc.272.41.25824			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325312	hybrid			2022-12-25	WOS:A1997YA35800067
J	Magalon, A; LemesleMeunier, D; Rothery, RA; Frixon, C; Weiner, JH; Blasco, F				Magalon, A; LemesleMeunier, D; Rothery, RA; Frixon, C; Weiner, JH; Blasco, F			Heme axial ligation by the highly conserved His residues in helix II of cytochrome b (NarI) of Escherichia coli nitrate reductase A (NarGHI)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; BACILLUS-SUBTILIS SUCCINATE; SITE-DIRECTED MUTAGENESIS; TERMINAL OXIDASE COMPLEX; BETA-SUBUNIT; UBIQUINONE OXIDOREDUCTASE; PARACOCCUS-DENITRIFICANS; EPR CHARACTERIZATION; ALPHA-SUBUNIT; SEQUENCE	Optical spectroscopy and EPR studies confirm the existence of two b-type hemes in the NarI subunit (cytochrome b(nr)) of the membrane-bound nitrate reductase (NarGHI) of Escherichia coli. Replacement of His-56 by Arg and His-66 by Tyr results in the loss of the high-potential heme and of the low-potential heme, respectively. These data support the assignment of the axial ligands to the low-potential heme (His-66 and His-187) and to the high-potential heme (His-56 and His-205). This pairing is consistent with the model proposed for NarI of the nitrate reductase of Thiosphaera pantotropha (Berks, B. C., Page, M. D., Richardson, D. J., Reilly, A., Cavill, A., Outen, F., and Ferguson, S. J. (1995) Mol. Microbiol. 15, 319-331) in which the two bis-histidine ligated hemes are coordinated by conserved His residues of helix II and V. EPR and optical studies suggest that the low-potential heme (E-m,E-7 = +17 mV) and the high-potential heme (E-m,E-7 = +122 mV) are located near the periplasmic side and the cytoplasmic side of the membrane, respectively. Moreover, correct insertion of both hemes into NarI requires anchoring to NarGH.	CNRS,IBSM,CHIM BACTERIENNE LAB,F-13402 MARSEILLE 8,FRANCE; CNRS,IBSM,LAB BIOENERGET & INGN PROT,F-13402 MARSEILLE,FRANCE; UNIV ALBERTA,DEPT BIOCHEM,MRC,GRP MOL BIOL MEMBRANES,EDMONTON,AB T6G 2H7,CANADA	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Alberta				Magalon, Axel/0000-0002-3375-738X; Rothery, Richard/0000-0003-3265-1783				AUGIER V, 1993, BIOCHEMISTRY-US, V32, P2013, DOI 10.1021/bi00059a018; BALLARD AL, 1988, EUR J BIOCHEM, V174, P207, DOI 10.1111/j.1432-1033.1988.tb14083.x; Banci L, 1996, J BIOL INORG CHEM, V1, P364, DOI 10.1007/s007750050066; BERKS BC, 1995, MOL MICROBIOL, V15, P319, DOI 10.1111/j.1365-2958.1995.tb02246.x; BLASCO F, 1992, MOL MICROBIOL, V6, P209, DOI 10.1111/j.1365-2958.1992.tb02002.x; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BLASCO F, 1990, MOL GEN GENET, V222, P104, DOI 10.1007/BF00283030; Buc J, 1995, EUR J BIOCHEM, V234, P766, DOI 10.1111/j.1432-1033.1995.766_a.x; CAMMACK R, 1990, BIOCHEMISTRY-US, V29, P8410, DOI 10.1021/bi00488a030; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CRASKE A, 1986, EUR J BIOCHEM, V158, P429, DOI 10.1111/j.1432-1033.1986.tb09771.x; CROUSE BR, 1995, FEBS LETT, V367, P1, DOI 10.1016/0014-5793(95)00522-B; DEGLIESPOSTI M, 1989, BIOCHIM BIOPHYS ACTA, V977, P249; DERVARTANIAN DV, 1975, BIOCHIM BIOPHYS ACTA, V379, P74, DOI 10.1016/0005-2795(75)90009-4; FRIDEN H, 1990, BIOCHIM BIOPHYS ACTA, V1041, P207, DOI 10.1016/0167-4838(90)90067-P; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GUIGLIARELLI B, 1992, EUR J BIOCHEM, V207, P61, DOI 10.1111/j.1432-1033.1992.tb17020.x; Guigliarelli B, 1996, BIOCHEMISTRY-US, V35, P4828, DOI 10.1021/bi952459p; HACKETT NR, 1982, FEMS MICROBIOL LETT, V13, P213; HAGERHALL C, 1992, BIOCHEMISTRY-US, V31, P7411, DOI 10.1021/bi00147a028; HEDERSTEDT L, 1986, J BACTERIOL, V167, P735, DOI 10.1128/jb.167.2.735-739.1986; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JONES RW, 1980, BIOCHEM J, V190, P79, DOI 10.1042/bj1900079; JONES RW, 1977, BIOCHEM J, V164, P199, DOI 10.1042/bj1640199; Magalon A, 1997, J BACTERIOL, V179, P5037, DOI 10.1128/jb.179.16.5037-5045.1997; MILLER MJ, 1983, J BIOL CHEM, V258, P9159; MORPETH FF, 1985, BIOCHEMISTRY-US, V24, P40, DOI 10.1021/bi00322a007; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; NEWTON G, 1991, BIOCHIM BIOPHYS ACTA, V1089, P8, DOI 10.1016/0167-4781(91)90077-Y; PALMER G, 1985, BIOCHEM SOC T, V13, P548, DOI 10.1042/bst0130548; PASCAL MC, 1982, MOL GEN GENET, V188, P103, DOI 10.1007/BF00333001; PETERSON J, 1994, FEBS LETT, V355, P155, DOI 10.1016/0014-5793(94)01189-3; SALERNO JC, 1983, FEBS LETT, V162, P257, DOI 10.1016/0014-5793(83)80767-4; SALERNO JC, 1984, J AM CHEM SOC, V106, P2156, DOI 10.1021/ja00319a041; SASARMAN A, 1968, J BACTERIOL, V96, P1882; vanderOost J, 1996, MOL MICROBIOL, V22, P193; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8	39	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25652	25658		10.1074/jbc.272.41.25652	http://dx.doi.org/10.1074/jbc.272.41.25652			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325288	hybrid			2022-12-25	WOS:A1997YA35800043
J	Chilov, D; Kukk, E; Taira, S; Jeltsch, M; Kaukonen, J; Palotie, A; Joukov, V; Alitalo, K				Chilov, D; Kukk, E; Taira, S; Jeltsch, M; Kaukonen, J; Palotie, A; Joukov, V; Alitalo, K			Genomic organization of human and mouse genes for vascular endothelial growth factor C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERCHAIN DISULFIDE BONDS; RECEPTOR TYROSINE KINASES; TRANSCRIPTIONAL UNIT; MESSENGER-RNAS; VEGF-C; CELLS; ANGIOGENESIS; HYPOXIA; PROTEIN	We report here the cloning and characterization of human and mouse genes for vascular endothelial growth factor C (VEGF-C), a newly isolated member of the vascular endothelial growth factor/platelet-derived growth factor (VEGF/PDGF) family, Both VEGF-C genes comprise over 40 kilobase pairs of genomic DNA and consist of seven exons, all containing coding sequences, The VEGF homology domain of VEGF-C is encoded by exons 3 and 4, Exons 5 and 7 encode cysteine-rich motifs of the type C6C10CRC, and exon 6 encodes additional C10CXCXC motifs typical of a silk protein, A putative alternatively spliced rare RNA form lacking exon 4 was identified in human fibrosarcoma cells, and a major transcription start site was located in the human VEGF-C gene 523 base pairs upstream of the translation initiation codon, The upstream promoter sequences contain conserved putative binding sites for Sp-1, AP-2, and NF-kappa B transcription factors but no TATA box, and they show promoter activity when transfected into cells, The VEGF-C gene structure is thus assembled from exons encoding propeptides and distinct cysteine-rich domains in addition to the VEGF homology domain, and it shows both similarities and distinct differences in comparison with other members of the VEGF/PDGF gene family.	UNIV HELSINKI,HAARTMAN INST,MOL CANC BIOL LAB,FIN-00014 HELSINKI,FINLAND	University of Helsinki			Jeltsch, Michael/I-5340-2012; Alitalo, Kari K/J-5013-2014; Joukov, Vladimir/K-3525-2019	Jeltsch, Michael/0000-0003-2890-7790; Alitalo, Kari K/0000-0002-7331-0902; Palotie, Aarno/0000-0002-2527-5874; chilov, dmitri/0000-0002-2279-0854				ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BONTHRON D, 1988, EUR J BIOCHEM, V171, P51, DOI 10.1111/j.1432-1033.1988.tb13757.x; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; Hu JS, 1997, FASEB J, V11, P498, DOI 10.1096/fasebj.11.6.9194531; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Kukk E, 1996, DEVELOPMENT, V122, P3829; Lagercrantz J, 1996, BIOCHEM BIOPH RES CO, V220, P147, DOI 10.1006/bbrc.1996.0372; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; MAGLIONE D, 1993, ONCOGENE, V8, P925; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Olofsson B, 1996, J BIOL CHEM, V271, P19310, DOI 10.1074/jbc.271.32.19310; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Paavonen K, 1996, CIRCULATION, V93, P1079, DOI 10.1161/01.CIR.93.6.1079; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; RISAU W, 1988, DEVELOPMENT, V102, P471; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774	53	153	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25176	25183		10.1074/jbc.272.40.25176	http://dx.doi.org/10.1074/jbc.272.40.25176			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312130	hybrid			2022-12-25	WOS:A1997XY97000069
J	Moyano, JV; Carnemolla, B; DominguezJimenez, C; GarciaGila, M; Albar, JP; SanchezAparicio, P; Leprini, A; Querze, G; Zardi, L; GarciaPardo, A				Moyano, JV; Carnemolla, B; DominguezJimenez, C; GarciaGila, M; Albar, JP; SanchezAparicio, P; Leprini, A; Querze, G; Zardi, L; GarciaPardo, A			Fibronectin type III5 repeat contains a novel cell adhesion sequence, KLDAPT, which binds activated alpha 4 beta 1 and alpha 4 beta 7 integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; HEPARIN-BINDING; DNA-BINDING; MONOCLONAL-ANTIBODIES; CONNECTING SEGMENT; SYNTHETIC PEPTIDE; DOMAIN; SITE; REGION; IDENTIFICATION	The region of fibronectin encompassing type III repeats 4-6 contains a low affinity heparin binding domain, but its physiological significance is not clear, We have studied whether this domain is able to interact with cells as already shown for other heparin binding domains of fibronectin, A computer search based on homologies with known active sites in fibronectin revealed the sequence KLDAPT located in FN-III5, A synthetic peptide containing this sequence induced lymphoid cell adhesion upon treatment with the activating anti-beta 1 monoclonal antibody (mAb) TS2/16 or with Mn2+ indicating that KLDAPT was binding to an integrin, A recombinant fragment containing repeat III5 (FN-III5) also mediated adhesion of TS2/16/Mn2+-treated cells while the FN-III6 fragment did not, Soluble KLDAPT peptide inhibited cell adhesion to FN-III5 as well as to a 38-kDa fibronectin fragment and VCAM-1, two previously known ligands for alpha 4 beta 1 integrin, KLDAPT also competed with the binding of soluble alkaline phosphatase-coupled VCAM-Ig to Mn2+-treated alpha 4 beta 1. Furthermore, mAbs anti-alpha 4 and anti-alpha 4 beta 7, but not mAbs to other integrins, inhibited cell adhesion to FN-III5 and KLDAPT, These results therefore establish a cell adhesive function for the FN-III5 repeat and show that KLDAPT is a novel fibronectin ligand for activated alpha 4 integrins.	CSIC,CTR INVEST BIOL,DEPT INMUNOL,E-28006 MADRID,SPAIN; IST NAZL RIC CANC,CELL BIOL LAB,I-16132 GENOA,ITALY; CSIC,CTR NACL BIOTECNOL,DEPT INMUNOL & ONCOL,E-28049 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Genoa; IRCCS AOU San Martino IST; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)			Garcia Pardo, Angeles/G-5987-2015	Garcia Pardo, Angeles/0000-0001-5577-2954				BORSI L, 1987, J CELL BIOL, V104, P595, DOI 10.1083/jcb.104.3.595; CALAYCAY J, 1985, J BIOL CHEM, V260, P2136; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; DominguezJimenez C, 1996, CELL ADHES COMMUN, V4, P251, DOI 10.3109/15419069609010770; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ERLE DJ, 1994, J IMMUNOL, V153, P517; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; GARCIAPARDO A, 1987, BIOCHEM J, V241, P923, DOI 10.1042/bj2410923; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; Hynes RO, 1990, FIBRONECTINS; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; Jongewaard IN, 1996, CELL ADHES COMMUN, V3, P487, DOI 10.3109/15419069609081025; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; Lobb RR, 1995, CELL ADHES COMMUN, V3, P385, DOI 10.3109/15419069509081293; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MOORADIAN DL, 1993, INVEST OPHTH VIS SCI, V34, P153; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; PANDE H, 1985, J BIOL CHEM, V260, P2301; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; POSTIGO AA, 1993, J IMMUNOL, V151, P2471; SANCHEZAPARICIO P, 1994, J CELL BIOL, V126, P271, DOI 10.1083/jcb.126.1.271; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V154, P15, DOI 10.1111/j.1432-1033.1986.tb09353.x; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; Zhang QH, 1996, J BIOL CHEM, V271, P33284, DOI 10.1074/jbc.271.52.33284	30	57	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24832	24836		10.1074/jbc.272.40.24832	http://dx.doi.org/10.1074/jbc.272.40.24832			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312081	hybrid, Green Published			2022-12-25	WOS:A1997XY97000020
J	Guerin, S; Mari, B; Fernandez, E; Belhacene, N; Toribio, ML; Auberger, P				Guerin, S; Mari, B; Fernandez, E; Belhacene, N; Toribio, ML; Auberger, P			CD10 is expressed on human thymic epithelial cell lines and modulates thymopentin-induced cell proliferation	FASEB JOURNAL			English	Article						thymic epithelial cell; peptidase; TP; proliferation	ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN-BONE MARROW; NEUTRAL ENDOPEPTIDASE; DIFFERENTIATION; THYMOPOIETIN; INDUCTION; INVITRO; HORMONE; ANTIGEN; MICE	Thymic hormones such as thymopoietin (TP) have been shown to regulate thymocyte differentiation and lymphocyte activation, However, it is not known whether thymopoietin affects thymic epithelial cell (TEC) functions, In this study we have examined the effect of a five amino acid active peptide (TP5), corresponding to amino acids 32-36 of TP, on the proliferation of nontransformed clones of human TEC, Our results indicate that TP5 induced reinitiation of DNA synthesis and potentiated fetal calf serum (FCS)-induced cell growth in postnatal and fetal-derived human TEC, We also found that TEC lines express high levels of endopeptidase 24.11, a cell-surface metallopeptidase also known as the CD10 antigen, We show that TP5 is cleaved by CD10 at the surface of TEC lines, indicating that this endopeptidase may regulate TP5-induced TEC proliferation, Phosphoramidon, a specific endopeptidase 24.11 inhibitor, consistently acts in synergy with TP5 to enhance FCS-induced TEC growth, Hence, we conclude that 1) TP5 alone or in combination with FCS supports the growth of TEC lines, and 2) TEC lines express high levels of CD10, which regulates TP5-induced TEC proliferation by acting as a thymic peptide degrading enzyme.	FAC MED, INSERM, CJF 9605, F-06107 NICE 2, FRANCE; UNIV AUTONOMA MADRID, CTR BIOL MOL, E-28049 MADRID, SPAIN	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Autonomous University of Madrid			Mari, Bernard/Q-5832-2019; AUBERGER, Patrick/G-1491-2013; Mari, Bernard P/GVS-3100-2022; Mari, Bernard P/D-7445-2015; Mari, Bernard P/F-8960-2013; Toribio, Maria L/C-2039-2017	Mari, Bernard/0000-0002-0422-9182; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Toribio, Maria L/0000-0002-8637-0373				BASCH RS, 1974, P NATL ACAD SCI USA, V71, P1474, DOI 10.1073/pnas.71.4.1474; BELHACENE N, 1993, EUR J IMMUNOL, V23, P1948, DOI 10.1002/eji.1830230833; BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J; BROWN SB, 1994, J CELL BIOCHEM, V54, P320, DOI 10.1002/jcb.240540308; CHECLER F, 1992, BIOCHEM J, V286, P217, DOI 10.1042/bj2860217; CONANT MA, 1992, AIDS, V6, P1335, DOI 10.1097/00002030-199211000-00016; FALK W, 1989, J IMMUNOL, V143, P513; FERNANDEZ E, 1994, BLOOD, V83, P3245; GANJU RK, 1994, J CLIN INVEST, V94, P1784, DOI 10.1172/JCI117526; GOLDSTEIN G, 1979, SCIENCE, V204, P1309, DOI 10.1126/science.451537; GOLSTEIN G, 1974, NATURE, V247, P11; Guerin S, 1997, CELL IMMUNOL, V175, P85, DOI 10.1006/cimm.1996.1045; Guerin S, 1997, FASEB J, V11, P376, DOI 10.1096/fasebj.11.5.9141505; HADDEN EM, 1992, CELL IMMUNOL, V144, P228, DOI 10.1016/0008-8749(92)90239-L; HARRIS CA, 1995, GENOMICS, V28, P198, DOI 10.1006/geno.1995.1131; HARRIS CA, 1994, P NATL ACAD SCI USA, V91, P6283, DOI 10.1073/pnas.91.14.6283; Haynes B F, 1990, Semin Immunol, V2, P67; HIRAMINE C, 1990, LAB INVEST, V18, P821; HOKLAND P, 1984, BLOOD, V64, P662; ITOH T, 1988, EUR J IMMUNOL, V18, P821, DOI 10.1002/eji.1830180525; JANOSSY G, 1979, J IMMUNOL, V123, P1525; JENKINSON EJ, 1992, J EXP MED, V176, P845, DOI 10.1084/jem.176.3.845; KALLED SL, 1995, EUR J IMMUNOL, V25, P677, DOI 10.1002/eji.1830250308; MARGUET D, 1992, J BIOL CHEM, V267, P2200; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; MARI B, 1994, IMMUNOLOGY, V82, P433; RANGES GE, 1982, J EXP MED, V156, P1057, DOI 10.1084/jem.156.4.1057; RITZ J, 1980, NATURE, V283, P583, DOI 10.1038/283583a0; ROQUES BP, 1993, PHARMACOL REV, V45, P87; SALLES G, 1993, P NATL ACAD SCI USA, V90, P7618, DOI 10.1073/pnas.90.16.7618; SALLES G, 1992, BLOOD, V80, P2021; SCHEID MP, 1978, J EXP MED, V147, P1727, DOI 10.1084/jem.147.6.1727; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; Small M, 1996, EUR J IMMUNOL, V26, P961, DOI 10.1002/eji.1830260438; SUNDAL E, 1994, ARZNEIMITTEL-FORSCH, V44-2, P1145; SUNSHINE GH, 1978, J IMMUNOL, V120, P1594; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993	38	13	15	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1997	11	12					1003	1011		10.1096/fasebj.11.12.9337153	http://dx.doi.org/10.1096/fasebj.11.12.9337153			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337153				2022-12-25	WOS:A1997YA72400010
J	Ihn, H; LeRoy, EC; Trojanowska, M				Ihn, H; LeRoy, EC; Trojanowska, M			Oncostatin M stimulates transcription of the human alpha 2(I) collagen gene via the Sp1/Sp3-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; LEUKEMIA-INHIBITORY FACTOR; NECROSIS-FACTOR-ALPHA; I COLLAGEN; DERMAL FIBROBLASTS; INTERFERON-GAMMA; EXPRESSION; ACTIVATION; CELLS; INTERLEUKIN-6	Oncostatin M (OSM), a member of the hematopoietic cytokine family, has been implicated in excessive bone growth and in the process of fibrosis, As part of an ongoing study of the molecular mechanisms of fibrosis, we have investigated the transcriptional regulation of the alpha 2(I) collagen gene by OSM in human fibroblasts, An OSM response element was mapped by deletional analysis between base pairs (bp) -148 and -108 in the alpha(I) collagen promoter, Further functional analysis of the alpha 2(I) collagen promoter containing various substitution mutations revealed that both the basal activity and OSM stimulation of this promoter are mediated by a TCCTCC motif located between bp -128 and -123. Futhermore, three copies of the 12-bp synthetic alpha 2(I) collagen promoter fragment containing the ''TCC'' motif conferred OSM inducibility to the otherwise unresponsive thymidine kinase promoter, Electrophoretic mobility shift assays demonstrated that the TCCTCC motif constitutes a novel binding site far the transcription factors Spl and Sp3. No differences have been observed in in vitro gel shift binding assays between unstimulated and OSM-stimulated fibroblasts, However, subtle conformational changes were detected in the region of the promoter surrounding TCC repeats after OSM stimulation using in vivo footprint analysis. In conclusion, this study characterized a dual-function response element that mediates the basal activity and OSM stimulation of the human alpha 2(I) collagen promoter.	MED UNIV S CAROLINA,DEPT MED,DIV RHEUMATOL & IMMUNOL,CHARLESTON,SC 29425	Medical University of South Carolina				Trojanowska, Maria/0000-0001-9550-7178	NIAMS NIH HHS [AR42334] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042334] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ALEVIZOPOULOS A, 1996, J BIOL CHEM, V271, P29872; AMARAL MC, 1993, J CLIN INVEST, V92, P848, DOI 10.1172/JCI116659; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BROWN TJ, 1987, J IMMUNOL, V139, P2977; Bruce A. Gregory, 1992, Progress in Growth Factor Research, V4, P157, DOI 10.1016/0955-2235(92)90029-H; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DUNCAN MR, 1995, J INVEST DERMATOL, V104, P128, DOI 10.1111/1523-1747.ep12613623; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; HAMILTON JA, 1991, BIOCHEM BIOPH RES CO, V180, P652, DOI 10.1016/S0006-291X(05)81115-5; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; Ichiki Y, 1997, J RHEUMATOL, V24, P90; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; ISHIKAWA O, 1990, BIOCHEM BIOPH RES CO, V169, P232, DOI 10.1016/0006-291X(90)91458-5; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KIKUCHI K, 1992, BIOCHEM BIOPH RES CO, V187, P45, DOI 10.1016/S0006-291X(05)81456-1; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; MALIK N, 1995, MOL CELL BIOL, V15, P2349; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; REITAMO S, 1994, J CLIN INVEST, V94, P2489, DOI 10.1172/JCI117618; RICHARDS CD, 1993, J IMMUNOL, V150, P5596; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SCHINDLER R, 1995, ANN REV BIOCH, V64, P621; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; TJIAN R, 1991, GENE DEV, V5, P1646; TRUTER S, 1992, J BIOL CHEM, V267, P25389; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; YAMAKAGE A, 1992, J EXP MED, V175, P1227, DOI 10.1084/jem.175.5.1227; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	41	131	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24666	24672		10.1074/jbc.272.39.24666	http://dx.doi.org/10.1074/jbc.272.39.24666			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305936	hybrid			2022-12-25	WOS:A1997XY51500087
J	OgierDenis, E; Petiot, A; Bauvy, C; Codogno, P				OgierDenis, E; Petiot, A; Bauvy, C; Codogno, P			Control of the expression and activity of the G(alpha)-interacting protein (GAIP) in human intestinal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLS AUTOPHAGIC SEQUESTRATION; GTPASE-ACTIVATING PROTEINS; ISOLATED RAT HEPATOCYTES; N-LINKED GLYCOPROTEINS; COLON CANCER-CELLS; LINE HT-29; ENTEROCYTIC DIFFERENTIATION; ADENYLYL-CYCLASE; ADP-RIBOSYLATION; ALPHA-SUBUNITS	The G(alpha)-interacting protein (GAIP) is known to interact with the G(alpha i3) protein, It has been suggested that, depending on its expression, GAIP can be a regulator of trimeric G(i) protein signaling pathways, In the present study we show that the GAIP mRNA content declines during the enterocytic differentiation of two cell lines derived from human colon adenocarcinomas: HT-29 and Caco-2. In undifferentiated HT-29 cells, when the GDP/GTP cycle on the trimeric G(i3) protein is interrupted by either pertussis toxin treatment or by the transfection of a mutant of the G(alpha i3) protein with no GTPase activity (Q204L), we observed a decrease in the GAIP mRNA content, As these conditions are known to impair the G(i3)-dependent lysosomal-autophagic pathway existing in undifferentiated HT-29 cells, we have investigated the role of G;AIP in controling the lysosomal-autophagic pathway, Overexpression of GAIP stimulated protein degradation along the macroautophagic pathway, In contrast, overexpression of GAIP did not modify the low rate of macroautophagy in cells expressing the Q204L mutant of the G(alpha i3) protein, These results show that GAIP regulates a major catabolic pathway and that the expression of GAIP is dependent upon the activity of the G(alpha i3) protein and the state of enterocytic differentiation of cells.	UNIV PARIS 07,INSERM,U410,F-75018 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Codogno, Patrice/G-1384-2013; Ogier-Denis, Eric/E-5030-2016	Codogno, Patrice/0000-0002-5492-3180; Ogier-Denis, Eric/0000-0002-0057-7593				Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Codogno P, 1997, CELL SIGNAL, V9, P125, DOI 10.1016/S0898-6568(96)00130-1; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HOLEN I, 1992, BIOCHEM J, V284, P633, DOI 10.1042/bj2840633; HOLEN I, 1993, EUR J BIOCHEM, V215, P113, DOI 10.1111/j.1432-1033.1993.tb18013.x; HOURI JJ, 1993, BIOCHEM BIOPH RES CO, V197, P805, DOI 10.1006/bbrc.1993.2550; HOURI JJ, 1995, BIOCHEM J, V309, P521, DOI 10.1042/bj3090521; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; HUNT TW, 1994, J BIOL CHEM, V269, P29565; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LEFKOWITZ RJ, 1993, GTPASES BIOL, V2, P33; LESUFFLEUR T, 1991, INT J CANCER, V49, P721, DOI 10.1002/ijc.2910490516; MIOTTO G, 1994, J BIOL CHEM, V269, P25348; Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; OGIERDENIS E, 1994, J BIOL CHEM, V269, P4285; PINTO M, 1983, BIOL CELL, V47, P323; PINTO M, 1982, BIOL CELL, V44, P193; Roush W, 1996, SCIENCE, V271, P1056, DOI 10.1126/science.271.5252.1056; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WICE BM, 1985, J BIOL CHEM, V260, P139; WICE BM, 1992, J CELL BIOL, V116, P405, DOI 10.1083/jcb.116.2.405; ZWEIBAUM A, 1985, J CELL PHYSIOL, V122, P21, DOI 10.1002/jcp.1041220105	36	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24599	24603		10.1074/jbc.272.39.24599	http://dx.doi.org/10.1074/jbc.272.39.24599			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305927	hybrid			2022-12-25	WOS:A1997XY51500078
J	Mochizuki, T; Kitanaka, C; Noguchi, K; Sugiyama, A; Kagaya, S; Chi, SJ; Asai, A; Kuchino, Y				Mochizuki, T; Kitanaka, C; Noguchi, K; Sugiyama, A; Kagaya, S; Chi, SJ; Asai, A; Kuchino, Y			Pim-1 kinase stimulates c-Myc-mediated death signaling upstream of caspase-3 (CPP32)-like protease activation	ONCOGENE			English	Article						Pim-1; c-Myc; caspase; apoptosis; serine/threonine kinase; transformation	PROGRAMMED CELL-DEATH; BCL-2 HOMOLOG BAK; E-MU-MYC; TRANSGENIC MICE; INTERLEUKIN-1-BETA-CONVERTING ENZYME; INDUCED APOPTOSIS; GLIOMA-CELLS; CYCLE ARREST; GENE-PRODUCT; IN-VIVO	Pim-1 oncoprotein is a serine/threonine kinase that can closely cooperate with c-Myc in lymphomagenesis, as does Bcl-2. Although the molecular mechanism of this cooperative transformation remains unknown, it is speculated that, similar to Bcl-2, Pim-1 contributes to transformation by inhibiting apoptosis. In this study, therefore, we examined the effect of Pim-1 expression on c-Myc-mediated apoptosis of Rat-1 fibroblasts triggered by serum deprivation. Our results showed that, rather than inhibiting apoptosis, Pim-1 expression stimulated c-Myc-mediated apoptosis in Rat-1 fibroblasts. Pim-1 stimulated c-Myc-mediated apoptosis through an enhancement of the c-Myc-mediated activation of caspase-3 (CPP32)-like proteases, since the suppression of this activity by a specific caspase inhibitor abolished the apoptosis stimulation by Pim-1. A kinase-defective Pim-1 mutant failed to stimulate c-Myc-mediated apoptosis, and Pim-1 expression alone in the absence of c-Myc overexpression did not induce apoptosis of serum-deprived Rat-1 cells, indicating that the kinase activity of Pim-1 and the activated c-Myc signaling pathway mere required for apoptosis stimulation by Pim-1. Together, these results suggest that Pim-1 oncoprotein stimulates as a serine/threonine kinase the death signaling elicited by c-Myc at a step upstream of caspase-3-like protease activation in Rat-1 fibroblasts. Our results also suggest that Pim-1 kinase might function cooperatively with c-Myc through the phosphorylation of a factor(s) which regulates the common signaling pathway involved in c-Myc-mediated apoptosis and transformation.	NATL CANC CTR,RES INST,DIV BIOPHYS,CHUO KU,TOKYO 104,JAPAN; UNIV TOKYO,SCH MED,DEPT NEUROSURG,BUNKYO KU,TOKYO 113,JAPAN	National Cancer Center - Japan; University of Tokyo								Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASAI A, 1994, CELL GROWTH DIFFER, V5, P1153; ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CROIX BS, 1996, NAT MED, V2, P1204; CUYPERS HT, 1984, CELL, V37, P141; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOOVER D, 1991, J BIOL CHEM, V266, P14018; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KITANAKA C, 1995, CELL DEATH DIFFER, V2, P123; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PADMA R, 1991, CANCER RES, V51, P2486; Poluha W, 1996, MOL CELL BIOL, V16, P1335; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TELERMAN A, 1988, MOL CELL BIOL, V8, P1498, DOI 10.1128/MCB.8.4.1498; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WINGETT D, 1992, NUCLEIC ACIDS RES, V20, P3183, DOI 10.1093/nar/20.12.3183; Zornig M, 1996, ONCOGENE, V12, P1789	51	33	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1471	1480		10.1038/sj.onc.1201326	http://dx.doi.org/10.1038/sj.onc.1201326			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333023				2022-12-25	WOS:A1997XW41100011
J	Resnick, RJ; Taylor, SJ; Lin, Q; Shalloway, D				Resnick, RJ; Taylor, SJ; Lin, Q; Shalloway, D			Phosphorylation of the Src substrate Sam68 by Cdc2 during mitosis	ONCOGENE			English	Article						Sam68; mitosis; Cdc2; Src	RNA-BINDING PROTEIN; C-SRC; KINASE; CELLS; GENE; ASSOCIATION; P62; PP60(C-SRC); ACTIVATION; POLYMERASE	Sam68 (Src-associated in mitosis) is an SH3 (Srchomology 3), SH2 (Src-homology 2), and RNA binding protein which associates with and is tyrosine phosphorylated by mild-type and activated forms of c-Src in a mitosis-specific manner. We now show that Sam68 immunoprecipitated from either HeLa S3 or NIH3T3 cells is phosphorylated on threonine residues exclusively during mitosis as well as on serine residues during both interphase and mitosis. Recombinant Sam68, expressed as a glutathione S-transferase (GST) fusion protein, was phosphorylated on threonine and serine residues after incubation with mitotic lysates several-fold more extensively than after incubation with unsynchronized lysates. Cdc2 was identified as the kinase responsible for the mitotic threonine phosphorylation by (1) immunodepletion of the mitotic Sam68 kinase from cell lysates with anti-Cdc2 antibodies, (2) inhibition of Sam68 phosphorylation in vitro and in vivo by the cyclin-dependent kinase inhibitor olomoucine and (3) phosphorylation of Sam68 by purified Cdc2. These data demonstrate that Sam68 is a direct target of Cdc2 and may therefore mediate some of its biological effects during mitosis.	CORNELL UNIV, BIOCHEM MOL & CELL BIOL SECT, ITHACA, NY 14853 USA	Cornell University					NCI NIH HHS [CA 32317] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032317] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; Ebersole TA, 1996, NAT GENET, V12, P260, DOI 10.1038/ng0396-260; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; LEE KS, 1995, MOL CELL BIOL, V15, P7143; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; MEIJER L, 1991, EUR J BIOCHEM, V196, P557, DOI 10.1111/j.1432-1033.1991.tb15850.x; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; PINOLROMA S, 1993, MOL CELL BIOL, V13, P5762, DOI 10.1128/MCB.13.9.5762; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; STOVER DR, 1994, J BIOL CHEM, V269, P26885; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0	41	44	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1247	1253		10.1038/sj.onc.1201289	http://dx.doi.org/10.1038/sj.onc.1201289			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315091				2022-12-25	WOS:A1997XV84500001
J	Lindesmith, L; McIlvain, JM; Argon, Y; Sheetz, MP				Lindesmith, L; McIlvain, JM; Argon, Y; Sheetz, MP			Phosphotransferases associated with the regulation of kinesin motor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE TRANSPORT; OKADAIC ACID; HEAVY-CHAIN; PHOSPHORYLATION; BINDING; PROTEIN; MOTILITY; FORMS; CELLS	Kinesin, a plus-end-directed microtubule motor protein, functions in concert with accessory factors that have been shown to regulate enzyme activity and may also provide cargo specificity. This report identifies the 79-kDa kinesin-associated phosphoprotein as a phosphoisoform of kinesin light chain. Increased phosphorylation of this light chain isoform is sufficient to account for the increase in kinesin-mediated microtubule-gliding activity. Additionally, it was found that the degree of phosphorylation of this isoform is regulated by a 100-kDa kinase and 150-kDa type 1 phosphatase. Both the kinesin light chain kinase and phosphatase co-purify with the kinesin heavy chain, suggesting that kinesin exists in a large complex capable of self-regulation.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637	Duke University; University of Chicago								ALLAN V, 1995, J CELL BIOL, V128, P879, DOI 10.1083/jcb.128.5.879; BRAUTIGAN DL, 1989, ARCH BIOCHEM BIOPHYS, V275, P44, DOI 10.1016/0003-9861(89)90348-2; BURKHARDT JK, 1993, J CELL SCI, V104, P151; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Thaler C D, 1996, Int Rev Cytol, V164, P269; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YU H, 1992, J BIOL CHEM, V267, P20457	22	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22929	22933		10.1074/jbc.272.36.22929	http://dx.doi.org/10.1074/jbc.272.36.22929			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9312551	hybrid			2022-12-25	WOS:A1997XV49200078
J	Barak, LS; Ferguson, SSG; Zhang, J; Caron, MG				Barak, LS; Ferguson, SSG; Zhang, J; Caron, MG			A beta-arrestin green fluorescent protein biosensor for detecting G protein-coupled receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSED SEQUENCE TAGS; BETA(2)-ADRENERGIC RECEPTOR; SEQUESTRATION; BINDING; PHOSPHORYLATION; SUPERFAMILY; RHODOPSIN	G protein-coupled receptors (GPCR) represent the single most important drug targets for medical therapy, and information from genome sequencing and genomic data bases has substantially accelerated their discovery. The lack of a systematic approach either to identify the function of a new GPCR or to associate it with a cognate ligand has added to the growing number of orphan receptors. In this work we provide a novel approach to this problem using a beta-arrestin2/green fluorescent protein conjugate (beta arr2-GFP). It provides a real-time and single cell based assay to monitor GPCR activation and GPCR-Gr protein-coupled receptor kinase or GPCR-arrestin interactions, Confocal microscopy demonstrates the translocation of beta arr2-GFP to more than 15 different ligand-activated GPCRs, These data clearly support the common hypothesis that the beta-arrestin binding of an activated receptor is a convergent step of GPCR signaling, increase by 5-fold the number of GPCRs known to interact with beta-arrestins, demonstrate that the cytosol is the predominant reservoir of biologically active beta-arrestins, and provide the first direct demonstration of the critical importance of G protein-coupled receptor kinase phosphorylation to the biological regulation of beta-arrestin activity and GPCR signal transduction in living cells, The use of beta arr2-GFP as a biosensor to recog- nize the activation of pharmacologically distinct GPCRs should accelerate the identification of orphan receptors and permit the optical study of their signal transduction biology intractable to ordinary biochemical methods.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 03422] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; KAETHER C, 1995, FEBS LETT, V369, P267, DOI 10.1016/0014-5793(95)00765-2; LopezNieto CE, 1996, NAT BIOTECHNOL, V14, P857, DOI 10.1038/nbt0796-857; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Oliver SG, 1996, NATURE, V379, P597, DOI 10.1038/379597a0; OLSON KR, 1995, J CELL BIOL, V130, P639, DOI 10.1083/jcb.130.3.639; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAYMOND JR, 1990, HYPERTENSION, V15, P119, DOI 10.1161/01.HYP.15.2.119; ROSS E M, 1990, P33; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; TSUGA H, 1994, J BIOL CHEM, V269, P522; VALETTE F, 1989, NUCLEIC ACIDS RES, V17, P723; Wells TNC, 1997, J LEUKOCYTE BIOL, V61, P545, DOI 10.1002/jlb.61.5.545	26	369	448	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27497	27500		10.1074/jbc.272.44.27497	http://dx.doi.org/10.1074/jbc.272.44.27497			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346876	hybrid			2022-12-25	WOS:A1997YD47300002
J	Chen, D; Elmendorf, JS; Olson, AL; Li, X; Earp, S; Pessin, JE				Chen, D; Elmendorf, JS; Olson, AL; Li, X; Earp, S; Pessin, JE			Osmotic shock stimulates GLUT4 translocation in 3T3L1 adipocytes by a novel tyrosine kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; INSULIN-RECEPTOR SUBSTRATE-1; RAT ADIPOSE-CELLS; ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT ACTIVITY; 3T3-L1 ADIPOCYTES; PROTEIN-KINASE; SKELETAL-MUSCLE; OKADAIC ACID; GLUCOSE-TRANSPORTER-4 TRANSLOCATION	Similar to insulin, osmotic shock of 3T3L1 adipocytes stimulated an increase in glucose transport activity and translocation of GLUT4 protein from intracellularly localized vesicles to the plasma membrane, The docking/ fusion of GLUT4 vesicles with the plasma membrane appeared to utilize a similar mechanism, since expression of a dominant interfering mutant of syntaxin-4 prevented both insulin-and osmotic shock-induced GLUT4 translocation, However, although the insulin stimulation of GLUT4 translocation and glucose transport activity was completely inhibited by wortmannin, activation by osmotic shock was wortmannin-insensitive, Furthermore, insulin stimulated the phosphorylation and activation of the Akt kinase, whereas osmotic shock was completely without effect, Surprisingly, treatment of cells with the tyrosine kinase inhibitor, genistein, or microinjection of phosphotyrosine antibody prevented both the insulin-and osmotic shock stimulated translocation of GLUT4, In addition, osmotic shock induced the tyrosine phosphorylation of several discrete proteins including Cbl, p130(cas), and the recently identified soluble tyrosine kinase, calcium-dependent tyrosine kinase (CADTK), In contrast, insulin had no effect on CADTK but stimulated the tyrosine phosphorylation of Cbl and the tyrosine dephosphorylation of pp125(FAK) and p130(cas), These data demonstrate that the osmotic shock stimulation of GLUT4 translocation in adipocytes occurs through a novel tyrosine kinase pathway that is independent of both the phosphatidylinositol S-kinase and the Akt kinase.	UNIV IOWA,PROGRAM MOL BIOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT PHYSIOL,IOWA CITY,IA 52242; UNIV N CAROLINA,CTR COMPREHENS CANC,CHAPEL HILL,NC 27599	University of Iowa; University of Iowa; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033823, R37DK033823, R01DK049012] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25925, DK49012, DK33823] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BIRNBAUM MJ, 1995, CURR OPIN ENDOCRINOL, V2, P383; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; CLAUSEN T, 1975, BIOCHIM BIOPHYS ACTA, V375, P292, DOI 10.1016/0005-2736(75)90197-2; CLAUSEN T, 1968, BIOCHIM BIOPHYS ACTA, V150, P56, DOI 10.1016/0005-2736(68)90008-4; CLAUSEN T, 1970, BIOCHIM BIOPHYS ACTA, V211, P233, DOI 10.1016/0005-2736(70)90096-9; CORVERA S, 1991, J BIOL CHEM, V266, P9271; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Kishi K, 1996, J BIOL CHEM, V271, P26561, DOI 10.1074/jbc.271.43.26561; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KUZUYA T, 1965, J BIOL CHEM, V240, P2277; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; LEMARCHANDBRUSTEL Y, 1995, ENDOCRINOLOGY, V136, P3564, DOI 10.1210/en.136.8.3564; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLEFSKY JM, 1976, BIOCHEM BIOPH RES CO, V71, P106, DOI 10.1016/0006-291X(76)90255-2; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Rondinone CM, 1996, J BIOL CHEM, V271, P18148, DOI 10.1074/jbc.271.30.18148; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TSAKIRIDIS T, 1995, BIOCHEM J, V309, P1; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WHEELER TJ, 1994, BBA-BIOMEMBRANES, V1196, P191, DOI 10.1016/0005-2736(94)00211-8; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; YANG J, 1993, J BIOL CHEM, V268, P4600; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	90	136	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27401	27410		10.1074/jbc.272.43.27401	http://dx.doi.org/10.1074/jbc.272.43.27401			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341192	hybrid			2022-12-25	WOS:A1997YC65900088
J	Johnson, ES; Blobel, G				Johnson, ES; Blobel, G			Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING ENZYME; YEAST; DEGRADATION; GENE; PURIFICATION; CYCLINS; SACCHAROMYCES; INTERACTS; HOMOLOG; ENCODES	At least one essential function of Smt3p, a Saccharomyces cerevisiae ubiquitin-like protein similar to the mammalian protein SUMO-1, involves its posttranslational covalent attachment to other proteins, Using Smt3p affinity chromatography, we have isolated the second enzyme of the Smt3p conjugation pathway and have found that it is identical to Ubc9p, a previously identified protein that has extensive sequence similarity to the ubiquitin-conjugating enzymes (E2s) and that is required for yeast to progress through mitosis, A hallmark of E2s is the ability to form a thioester bond-containing covalent intermediate with ubiquitin (Ub). While we were unable to detect formation of a Ub similar to Ubc9p thioester, Ubc9p was found to form a thioester with Smt3p, indicating that Ubc9p is the functional analog of E2s in the Smt3p pathway and that this step is distinct from the ubiquitin pathway. Ubc9p is required for attachment of Smt3p to other proteins in vitro, suggesting that it is the only such enzyme in S. cerevisiae. These results suggest that, like ubiquitination, Smt3p conjugation may be a critical modification in cell cycle regulation.			Johnson, ES (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,BOX 168,1230 YORK AVE,NEW YORK,NY 10021, USA.							Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Betting J, 1996, J BIOL CHEM, V271, P25790, DOI 10.1074/jbc.271.42.25790; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; Boddy MN, 1996, ONCOGENE, V13, P971; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Gharahdaghi F, 1996, ANAL BIOCHEM, V233, P94, DOI 10.1006/abio.1996.0012; Gonen H, 1996, ADV EXP MED BIOL, V389, P209; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jiang WD, 1996, MOL GEN GENET, V251, P153; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Okura T, 1996, J IMMUNOL, V157, P4277; PICKART CM, 1994, J BIOL CHEM, V269, P7115; PICKART CM, 1988, UBIQUITIN, P77; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; STRAMBIODECASTILLIA C, 1995, J CELL BIOL, V131, P19, DOI 10.1083/jcb.131.1.19; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4	34	320	332	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26799	26802		10.1074/jbc.272.43.26799	http://dx.doi.org/10.1074/jbc.272.43.26799			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341106	hybrid			2022-12-25	WOS:A1997YC65900002
J	Yurieva, O; Skangalis, M; Kuriyan, J; ODonnell, M				Yurieva, O; Skangalis, M; Kuriyan, J; ODonnell, M			Thermus thermophilis dnaX homolog encoding gamma- and tau-like proteins of the chromosomal replicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI; ACCESSORY PROTEINS; SLIDING CLAMPS; SUBUNIT; SEQUENCE; GENE; IDENTIFICATION; STRAND; REGION	This report identifies the dnaX homolog from Thermus thermophilis. Replicases from bacteria to humans contain subunits that are homologous to one another. These homologs are subunits of a clamp loading apparatus that loads sliding clamps onto DNA, which in turn act as mobile tethers for the replication machinery. In Escherichia coli, two of these subunits (gamma and tau) are encoded by one gene (dnaX) in nearly equal amounts by way of an efficient translational frameshift. The gamma and tau subunits form the central touchpoint that holds together two DNA polymerases with one clamp loading apparatus to form the E. coli chromosomal replicase, DNA polymerase III holoenzyme. The E. coli holoenzyme is an efficient replication machine that simultaneously replicates both strands of duplex DNA. The T. thermophilis dnaX homolog also contains a frameshift signature and produces both tau- and gamma-like proteins. Recombinant T. thermophilis tau- and gamma-like proteins, expressed in E. coli, have an oligomeric state similar to that of their E. coli counterparts and display ATPase activity that is stimulated by DNA. These results imply that T. thermophilis utilizes a DNA polymerase III holoenzyme replication machinery similar to that of E. coli.	ROCKEFELLER UNIV,LAB DNA REPLICAT,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOL BIOPHYS LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University				O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM38839, GM 45547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO JC, 1990, NUCLEIC ACIDS RES, V18, P6771, DOI 10.1093/nar/18.23.6771; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; CHEN M, 1992, P NATL ACAD SCI USA, V89, P5211, DOI 10.1073/pnas.89.12.5211; CULLMAN G, 1995, MOL CELL BIOL, V150, P4661; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gesteland RF, 1996, ANNU REV BIOCHEM, V65, P741, DOI 10.1146/annurev.bi.65.070196.003521; GUENTHER BD, 1996, THESIS ROCKEFELLER U; GUIBUS JM, 1996, CELL, V87, P297; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LARSEN B, 1994, J BACTERIOL, V176, P6842, DOI 10.1128/JB.176.22.6842-6851.1994; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; MAKI H, 1988, J BIOL CHEM, V263, P6570; Maniatis T., 1982, MOL CLONING LABORATO, P76; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; TSUCHIHASHI Z, 1992, GENE DEV, V6, P511, DOI 10.1101/gad.6.3.511; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WU CA, 1992, J BIOL CHEM, V267, P4064; YIN KC, 1986, NUCLEIC ACIDS RES, V14, P6541, DOI 10.1093/nar/14.16.6541; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	36	15	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27131	27139		10.1074/jbc.272.43.27131	http://dx.doi.org/10.1074/jbc.272.43.27131			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341154	hybrid			2022-12-25	WOS:A1997YC65900050
J	CoskunAri, FF; Hill, TM				CoskunAri, FF; Hill, TM			Sequence-specific interactions in the Tus-Ter complex and the effect of base pair substitutions on arrest of DNA replication in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATOR PROTEIN; BACILLUS-SUBTILIS; LAC REPRESSOR; OPERATOR DNA; IDENTIFICATION; TRANSLOCATION; EQUILIBRIUM; COMPETITION; HELICASES; PLASMID	Arrest of DNA replication in Escherichia coli is mediated by specific interactions between the Tus protein and terminator (Ter) sequences, Binding of Tus to a Ter site forms a asymmetric protein-DNA complex that arrests DNA replication in an orientation-dependent fashion, In this study, mutant Ter sites carrying single base pair substitutions at 16 different positions were examined for their ability to bind purified Tus protein and arrest DNA replication, In vitro competition assays demonstrated that base pair substitutions at positions 8-19 had significant effects on the free energy of Tus binding (Delta Delta G(0) Of 1.5 to >4.0 kcal/mol). Concomitant with loss of binding affinity, mutations at these positions also showed significantly lower or undetectable replication arrest activities in vivo, Substitutions at positions 6, 20, and 21 had moderate effects on Tus-Ter interactions, suggesting that these base pairs contribute to, but are. not absolutely critical for, Tus binding. Even though the effects on binding were minimal, these Ter mutants were not as efficient as wild type Tus-TerB complexes at arresting replication forks. Three new potential Ter sites, referred to as TerH, TerI, and TerJ, were identified by searching the E. coli genome for sequence similarity to a consensus Ter site sequence.	UNIV N DAKOTA,SCH MED & HLTH SCI,DEPT MICROBIOL & IMMUNOL,GRAND FORKS,ND 58202; DREXEL UNIV,DEPT BIOSCI & BIOTECHNOL,PHILADELPHIA,PA 19104	University of North Dakota Grand Forks; Drexel University					NIGMS NIH HHS [GM43193] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043193, R01GM043193] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIERNE H, 1995, PLASMID, V33, P101, DOI 10.1006/plas.1995.1012; BIERNE H, 1994, J BACTERIOL, V176, P4165, DOI 10.1128/JB.176.13.4165-4167.1994; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COSKUNARI FF, 1994, J BIOL CHEM, V269, P4027; Duggan LJ, 1996, BIOCHEMISTRY-US, V35, P15391, DOI 10.1021/bi962208w; DUGGAN LJ, 1995, J BIOL CHEM, V270, P28049; FRANKS AH, 1995, MOL MICROBIOL, V17, P13, DOI 10.1111/j.1365-2958.1995.mmi_17010013.x; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HILL TM, 1996, ESCHERICHIA COLI SAL, V2, P1602; JENJACOBSON L, 1991, NUCL ACIDS MOL BIOL, V5, P142; Kamada K, 1996, NATURE, V383, P598, DOI 10.1038/383598a0; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; Messing J, 1979, RECOMBINANT DNA TECH, V2, P43; SAHOO T, 1995, J BIOL CHEM, V270, P29138, DOI 10.1074/jbc.270.49.29138; SHARMA B, 1992, J BACTERIOL, V174, P7854, DOI 10.1128/JB.174.23.7854-7858.1992; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SKOKOTAS A, 1994, J BIOL CHEM, V269, P20446; Skokotas A, 1995, J BIOL CHEM, V270, P30941, DOI 10.1074/jbc.270.52.30941; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439	27	51	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26448	26456		10.1074/jbc.272.42.26448	http://dx.doi.org/10.1074/jbc.272.42.26448			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334221	hybrid			2022-12-25	WOS:A1997YB13900055
J	Domanski, P; Fish, E; Nadeau, OW; Witte, M; Platanias, LC; Yan, H; Krolewski, J; Pitha, P; Colamonici, OR				Domanski, P; Fish, E; Nadeau, OW; Witte, M; Platanias, LC; Yan, H; Krolewski, J; Pitha, P; Colamonici, OR			A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; ERYTHROPOIETIN RECEPTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; CYTOKINE RECEPTORS; ASSOCIATION; BINDING; CELLS; EXPRESSION; PROTEINS	Coexpression of the alpha and beta(L) subunits of the human interferon alpha (IFN alpha) receptor is required for the induction of an antiviral state by human IFN alpha. To explore the role of the different domains of the beta(L) subunit in IFN alpha signaling, we coexpressed wild-type alpha subunit and truncated forms of the beta(L) chain in L-929 cells. Our results demonstrated that the first 82 amino acids (AAs) (AAs 265-346) of the cytoplasmic domain of the beta(L) chain are sufficient to activate the Jak-Stat pathway and trigger an antiviral state after IFN alpha 2 binding to the receptor. This region of the beta(L) chain, required for Jak1 binding and activation, contains the Bos 1 motif that is important; for the interaction of some cytokine receptors with Jak kinases, However, using glutathione S-transferase fusion proteins containing amino-and carboxyl-terminal deletions of the beta(L) cytoplasmic domain, we demonstrate that the main Jak1-binding region (corresponding to AAs 300-346 on the beta subunit) is distinct from the Box 1 domain (AAs 287-295).	UNIV TENNESSEE,DEPT PATHOL,MEMPHIS,TN 38163; UNIV TORONTO,DEPT MED GENET & MICROBIOL,TORONTO,ON M5S 1A8,CANADA; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231; UNIV ILLINOIS,HEMATOL ONCOL SECT,CHICAGO,IL; VET ADM W SIDE MED CTR,CHICAGO,IL 60607; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032	University of Tennessee System; University of Tennessee Health Science Center; University of Toronto; Johns Hopkins University; Johns Hopkins Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Columbia University; Columbia University			, Otto/P-4127-2018	, Otto/0000-0003-2101-4105	NATIONAL CANCER INSTITUTE [R01CA055079, R29CA073381] Funding Source: NIH RePORTER; NCI NIH HHS [CA73381, CA55079] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEUNG SC, 1991, J IMMUNOL, V146, P121; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1995, J BIOL CHEM, V270, P15974, DOI 10.1074/jbc.270.27.15974; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLOSI P, 1993, J BIOL CHEM, V268, P12617; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; HE TC, 1994, J BIOL CHEM, V269, P18291; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jiang N, 1996, J BIOL CHEM, V271, P16472, DOI 10.1074/jbc.271.28.16472; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Platanias LC, 1996, J BIOL CHEM, V271, P23630, DOI 10.1074/jbc.271.39.23630; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SCHINDLER S, 1995, ANNU REV BIOCHEM, V64, P621; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WANG XZ, 1995, J BIOL CHEM, V270, P6261, DOI 10.1074/jbc.270.11.6261; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yan H, 1996, MOL CELL BIOL, V16, P2074	36	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26388	26393		10.1074/jbc.272.42.26388	http://dx.doi.org/10.1074/jbc.272.42.26388			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334213	hybrid			2022-12-25	WOS:A1997YB13900047
J	Lindahl, B; Lindahl, U				Lindahl, B; Lindahl, U			Amyloid-specific heparan sulfate from human liver and spleen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; MONOCLONAL-ANTIBODY; AA-AMYLOIDOSIS; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; CELLS; DEPOLYMERIZATION; ANTITHROMBIN; DEPOSITION; AFFINITY	Heparan sulfate proteoglycans are consistently accumulated in tissues afflicted by amyloidosis and have been implicated in the mechanism of amyloid deposition. To study this relationship, heparan sulfate was isolated from liver and spleen of patients with AA amyloidosis and from normal organs and subjected to struc tural analysis, The polysaccharides were deaminated with nitrous acid, and the products were reduced with (NaBH4)-H-3 to yield labeled oligosaccharides. Disaccharides obtained by selective deamination of intact or N-deacetylated polysaccharides were separated and quantified by anion-exchange high performance liquid chromatography and thus defined the composition of N-sulfated block regions or the entire heparan sulfate chains, respectively, The heparan sulfate samples derived from liver or spleen with AA-type amyloidosis were all similar in composition, regardless of tissue source, but differed from either control material, These findings suggest that secondary amyloidosis is associated with the deposition in the affected tissues of a heparan sulfate with a specifically modified structure.	UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN	Uppsala University								AILLES L, 1993, LAB INVEST, V69, P443; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BITTER T, 1966, J CLIN INVEST, V45, P963, DOI 10.1172/JCI105412; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; KISILEVSKY R, 1992, J INTERN MED, V232, P515, DOI 10.1111/j.1365-2796.1992.tb00628.x; KJELLEN L, 1983, DIABETES, V32, P337, DOI 10.2337/diabetes.32.4.337; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINKER A, 1987, LAB INVEST, V57, P297; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MAGNUS JH, 1997, IN PRESS AMYLOID INT, V4; NAKANISHI H, 1992, BIOCHEM J, V288, P215, DOI 10.1042/bj2880215; NELSON SR, 1991, BIOCHEM J, V275, P67, DOI 10.1042/bj2750067; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PEJLER G, 1987, J BIOL CHEM, V262, P5036; RIESENFELD J, 1982, J BIOL CHEM, V257, P421; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; SKINNER M, 1992, J INTERN MED, V232, P513, DOI 10.1111/j.1365-2796.1992.tb00627.x; SNOW AD, 1987, LAB INVEST, V56, P665; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; SNOW AD, 1985, LAB INVEST, V53, P37; STENSTAD T, 1994, BIOCHEM J, V303, P663, DOI 10.1042/bj3030663; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; vandenBorn J, 1996, J BIOL CHEM, V271, P22802, DOI 10.1074/jbc.271.37.22802; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310	30	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26091	26094		10.1074/jbc.272.42.26091	http://dx.doi.org/10.1074/jbc.272.42.26091			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334172	hybrid			2022-12-25	WOS:A1997YB13900006
J	Nass, R; Cunningham, KW; Rao, R				Nass, R; Cunningham, KW; Rao, R			Intracellular sequestration of sodium by a novel Na+/H+ exchanger in yeast is enhanced by mutations in the plasma membrane H+-ATPase - Insights into mechanisms of sodium tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT PMA1 MUTANTS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; POTASSIUM-TRANSPORT; SALT TOLERANCE; GENE; STRESS; CALCINEURIN; ANTIPORTER; VESICLES	Sodium tolerance in yeast is disrupted by mutations in calcineurin, a Ca2+/calmodulin dependent protein phosphatase, which is required for modulation of Na+ uptake and efflux mechanisms, Five Na+-tolerant mutants were isolated by selecting for suppressors of calcineurin mutations, and mapped to the PMA1 gene, encoding the plasma membrane H+-ATPase, One mutant, pma1-alpha 4, which has the single amino acid change Glu(367) --> Lys at a highly conserved site within the catalytic domain of the ATPase, was analyzed in detail to determine the mechanism of Na+ tolerance. After exposure to Na+ in the culture medium, Na-22 influx in the pma1 mutant was reduced 2-fold relative to control, consistent with a similar decrease in ATPase activity, Efflux of Na-22 from intact cells was relatively unchanged in the pma1 mutant, However, selective permeabilization of the plasma membrane revealed that mutant cells retained up to 80% of intracellular Na+ within a slowly exchanging pool, We show that NHX1, a novel gene homologous to the mammalian NHE family of Na+/H+ exchangers, is required for Na+ sequestration in yeast and contributes to the Na+-tolerant phenotype of pma1-alpha 4.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053082, R01GM052414] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53082, GM 52414] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; Barkla B J, 1994, Symp Soc Exp Biol, V48, P141; BASSILANA M, 1984, BIOCHEMISTRY-US, V23, P5288, DOI 10.1021/bi00317a029; BLUMWALD E, 1987, PLANT PHYSIOL, V83, P884, DOI 10.1104/pp.83.4.884; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GARBARINO J, 1988, PLANT PHYSIOL, V86, P231, DOI 10.1104/pp.86.1.231; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HAJIBAGHERI MA, 1993, MICROSC RES TECHNIQ, V24, P395, DOI 10.1002/jemt.1070240505; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HARO R, 1993, PHYSIOL PLANTARUM, V89, P868, DOI 10.1111/j.1399-3054.1993.tb05298.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KO CH, 1990, GENETICS, V125, P305; LATTERICH M, 1993, BIOCHEM BIOPH RES CO, V191, P1111, DOI 10.1006/bbrc.1993.1331; MARTINUSSEN J, 1994, J BACTERIOL, V176, P6457, DOI 10.1128/JB.176.21.6457-6463.1994; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; Mendoza I, 1996, J BIOL CHEM, V271, P23061, DOI 10.1074/jbc.271.38.23061; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; MISOGA T, 1994, YEAST, V10, P965; MUNRO AW, 1991, MOL MICROBIOL, V5, P607, DOI 10.1111/j.1365-2958.1991.tb00731.x; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676-2682.1988; ORTEGA M D, 1988, Microbiologia (Madrid), V4, P61; PANARETOU B, 1990, J GEN MICROBIOL, V136, P1763, DOI 10.1099/00221287-136-9-1763; PERKINS J, 1993, FEMS MICROBIOL LETT, V107, P255; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; RAMOS J, 1994, J BACTERIOL, V176, P249, DOI 10.1128/JB.176.1.249-252.1994; RAO R, 1996, MYCOTA, V3, P29; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SERRANO R, 1994, CRIT REV PLANT SCI, V13, P121, DOI 10.1080/713608057; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; TSE CM, 1994, CELL PHYSIOL BIOCHEM, V4, P282, DOI 10.1159/000154731; ULASZEWSKI S, 1983, EUR J BIOCHEM, V130, P235, DOI 10.1111/j.1432-1033.1983.tb07141.x; VALLEJO CG, 1989, YEAST, V5, P307, DOI 10.1002/yea.320050411; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WASER M, 1992, J BIOL CHEM, V267, P5396; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x	49	205	224	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26145	26152		10.1074/jbc.272.42.26145	http://dx.doi.org/10.1074/jbc.272.42.26145			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334180	hybrid			2022-12-25	WOS:A1997YB13900014
J	Ramalingam, R; Ennis, HL				Ramalingam, R; Ennis, HL			Characterization of the Dictyostelium discoideum cellulose-binding protein CelB and regulation of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORE GERMINATION; FAMILY; DOMAINS; RNA	Similar to other stages of Dictyostelium development, spore germination is a particularly suitable model for studying regulation of gene expression. The transition from spore to amoeba is accompanied by developmentally regulated changes in both protein and mRNA synthesis. A number of spore germination-specific cDNAs have been isolated previously. Among these are two members of the 270 gene family, a group of four genes defined by the presence of a common tetrapeptide repeat of Thr-Glu-Thr-Pro, celA (formerly called 270-6) and celB (formerly 270-11) are expressed solely and coordinately during spore germination, the levels of the respective mRNAs being low in dormant spores, rising during gemination to a maximum level at about 2 h, and then rapidly declining as amoebae are released from spores. The mRNAs are not found in growing cells or during multicellular development. The rapidity with which these transcripts accumulate and then disappear during germination implies that the respective products may be important for the process. We reported previously that the CelA protein is a cellulase (endo-1,4-beta-glucanase (EC 3.2.1.4)). In the present investigation, properties of the CelB protein, a glycosylated protein of 532 amino acids, 36% of which are serine or threonine, were examined, and the upstream sequences involved in the developmental regulation of the expression of the gene have been determined. The CelB protein does not demonstrate cellulase activity, but it has a cellulose-binding domain. Its role, if any, in degradation of the cellulose-containing spore wall is unknown. To identify cis-acting elements in the celB promoter, unidirectional 5' deletions of the celB upstream noncoding region were constructed and used to transform amoebae. Analysis of promoter activity during different stages of development shows that a short, very APT-rich sequence of approximately 81 base pairs is sufficient for spore-specific celB transcription. Contained in this sequence is the Myb oncogene protein binding site, TAACTG, which was shown previously to be a negative regulator of celA transcription. Dictyostelium and mouse Myb proteins bind to this region of the promoter, suggesting that Myb might regulate celB gene expression negatively as it does in celA.	ROCHE INST MOL BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA	Roche Holding								ALEXANDER A, 1982, METHOD ENZYMOL, V179, P505; ALEXANDER S, 1988, DIFFERENTIATION, V38, P82, DOI 10.1111/j.1432-0436.1988.tb00201.x; BLUME JE, 1991, J BIOL CHEM, V266, P15432; COTTER DA, 1966, P NATL ACAD SCI USA, V69, P1402; DASILVA AM, 1990, DEV BIOL, V140, P139, DOI 10.1016/0012-1606(90)90061-M; DIN N, 1994, P NATL ACAD SCI USA, V91, P11383, DOI 10.1073/pnas.91.24.11383; DIN N, 1991, BIO-TECHNOL, V9, P1096, DOI 10.1038/nbt1191-1096; DOWBENKO DJ, 1980, P NATL ACAD SCI-BIOL, V77, P1791, DOI 10.1073/pnas.77.4.1791; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; GIORDA R, 1990, BIOCHEMISTRY-US, V29, P7264, DOI 10.1021/bi00483a015; GIORDA R, 1987, MOL CELL BIOL, V6, P2097; GIRI JG, 1978, DEV BIOL, V67, P189, DOI 10.1016/0012-1606(78)90308-1; GIRI JG, 1977, BIOCHEM BIOPH RES CO, V77, P282, DOI 10.1016/S0006-291X(77)80194-0; KELLY LJ, 1983, MOL CELL BIOL, V3, P1943, DOI 10.1128/MCB.3.11.1943; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI, P3; MAY T, 1989, MOL CELL BIOL, V9, P4653, DOI 10.1128/MCB.9.11.4653; MEINKE A, 1991, Protein Sequences and Data Analysis, V4, P349; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; RAMALINGAM R, 1992, J BACTERIOL, V174, P7834, DOI 10.1128/JB.174.23.7834-7837.1992; RAMALINGAM R, 1995, NUCLEIC ACIDS RES, V23, P3018, DOI 10.1093/nar/23.15.3018; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; SHOSEYOV O, 1990, P NATL ACAD SCI USA, V87, P2192, DOI 10.1073/pnas.87.6.2192; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; WONG WKR, 1986, GENE, V44, P315	24	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26166	26172		10.1074/jbc.272.42.26166	http://dx.doi.org/10.1074/jbc.272.42.26166			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334183	hybrid			2022-12-25	WOS:A1997YB13900017
J	Satlin, LM; Amin, V; Wolkoff, AW				Satlin, LM; Amin, V; Wolkoff, AW			Organic anion transporting polypeptide mediates organic anion/HCO3- exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; ACID COTRANSPORT SYSTEM; PERFUSED-RAT-LIVER; INTRACELLULAR PH; EXPRESSION CLONING; HELA-CELLS; HEPATOCYTES; CHLORIDE; BINDING; CHOLATE	Organic anion transporting polypeptide (oatp) is an integral membrane protein cloned from rat liver that mediates Na+-independent transport of organic anions such as sulfobromophthalein and taurocholic acid, Previous studies in rat hepatocytes suggested that organic anion uptake is associated with base exchange, To better characterize the mechanism of oatp-mediated organic anion uptake, we examined transport of taurocholate in a HeLa cell line stably transfected with oatp under the regulation of a zinc-inducible promoter (Shi, X., Bai, S., Forci, A. C., Burk, R. D., Jacquemin, E., Hagenbuch, B., Meier, P. J., and Wolkoff, A. W. (1995) J. Biol. Chem. 270, 25591-25595). Whereas noninduced transfected cells showed virtually no uptake of [H-3]taurocholate, taurocholate uptake by induced cells was Na+-independent and saturable (K-m = 19.4 +/- 3.3 mu M; V-max = 62.2 +/- 1.4 pmol/min/mg protein; n = 3). To test whether organic anion transport is coupled to HCO3- extrusion, we compared the rates of taurocholate-dependent HCO3- efflux from alkali-loaded noninduced and induced cells. Monolayers grown on glass coverslips were loaded with the pH-sensitive dye 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein; intracellular pH (pH(I)) was measured by excitation ratio fluorometry, Noninduced and induced cells were alkalinized to an equivalent pH(i) (similar to 7.7) by transient exposure to a 50 mM HCO3- Cl--free solution. In the absence of extracellular Cl- and taurocholate , isohydric reduction of superfusate HCO3- concentration from 50 to 25 mM resulted in an insignificant change in pH(i) over time (dpH(i)/dt) in both groups. Addition of 25 mu M taurocholate to the superfusate led to a rapid fall in pH(i) in induced (-0.037 +/- 0.011 pH units/min to pH(i) of 7.41 +/- 0.14) but not in noninduced (0.003 +/- 0.006 pH units/min to pH(i) of 7.61 +/- 0.08) cells (p < 0.03). These data indicate that oatp-mediated taurocholate transport is Na+-independent, saturable, and accompanied by HCO, exchange, We conclude that organic anion/base exchange is an important, potentially regulatable component of oatp function.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	Satlin, LM (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,RM 721 RFK,1410 PELHAM PKWY S,BRONX,NY 10461, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK023026] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK23026, DK41296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENEDETTI A, 1991, AM J PHYSIOL, V261, pG512, DOI 10.1152/ajpgi.1991.261.3.G512; Bergwerk AJ, 1996, AM J PHYSIOL-GASTR L, V271, pG231, DOI 10.1152/ajpgi.1996.271.2.G231; BLITZER BL, 1986, J BIOL CHEM, V261, P2042; BOYER JL, 1994, AM J PHYSIOL, V266, pG382, DOI 10.1152/ajpgi.1994.266.3.G382; FITZ JG, 1991, J MEMBRANE BIOL, V122, P1, DOI 10.1007/BF01872734; FITZ JG, 1987, AM J PHYSIOL, V252, pG56, DOI 10.1152/ajpgi.1987.252.1.G56; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GLEESON D, 1989, J CLIN INVEST, V84, P312, DOI 10.1172/JCI114156; GRAF J, 1987, J MEMBRANE BIOL, V95, P241, DOI 10.1007/BF01869486; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HOLSEY C, 1990, J CELL PHYSIOL, V142, P586, DOI 10.1002/jcp.1041420319; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; JACQUEMIN E, 1991, J CLIN INVEST, V88, P2146, DOI 10.1172/JCI115546; Kanai N, 1996, AM J PHYSIOL-RENAL, V270, pF319, DOI 10.1152/ajprenal.1996.270.2.F319; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUKACS GL, 1993, AM J PHYSIOL, V265, pC3, DOI 10.1152/ajpcell.1993.265.1.C3; Meier PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG801, DOI 10.1152/ajpgi.1995.269.6.G801; MIN AD, 1991, J CLIN INVEST, V87, P1496, DOI 10.1172/JCI115159; MOSELEY RH, 1986, AM J PHYSIOL, V250, pG35, DOI 10.1152/ajpgi.1986.250.1.G35; RENNER EL, 1989, J CLIN INVEST, V83, P1225, DOI 10.1172/JCI114005; SATLIN LM, 1992, AM J PHYSIOL, V262, pF199, DOI 10.1152/ajprenal.1992.262.2.F199; SCHARSCHMIDT BF, 1975, J CLIN INVEST, V56, P1280, DOI 10.1172/JCI108204; SHI XY, 1995, J BIOL CHEM, V270, P25591, DOI 10.1074/jbc.270.43.25591; Silver RB, 1996, AM J PHYSIOL-RENAL, V270, pF539, DOI 10.1152/ajprenal.1996.270.3.F539; STOLLMAN YR, 1983, J CLIN INVEST, V72, P718, DOI 10.1172/JCI111021; VEITH CM, 1992, BIOCHIM BIOPHYS ACTA, V1103, P51, DOI 10.1016/0005-2736(92)90056-R; Wolkoff Allan W., 1994, P179; WOLKOFF AW, 1987, J CLIN INVEST, V79, P1259, DOI 10.1172/JCI112946	28	125	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26340	26345		10.1074/jbc.272.42.26340	http://dx.doi.org/10.1074/jbc.272.42.26340			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334206	hybrid			2022-12-25	WOS:A1997YB13900040
J	DiSepio, D; Malhotra, M; Chandraratna, RAS; Nagpal, S				DiSepio, D; Malhotra, M; Chandraratna, RAS; Nagpal, S			Retinoic acid receptor-nuclear factor-interleukin 6 antagonism - A novel mechanism of retinoid-dependent inhibition of a keratinocyte hyperproliferative differentiation marker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; RESPONSE ELEMENT; PSORIATIC SKIN; TRANSACTIVATION; IDENTIFICATION; EXPRESSION; DOMAIN; CELLS; PROLIFERATION; TRANSCRIPTION	Retinoids inhibit the expression of migration inhibitory factor-related protein-8 (MRP-8), a marker of hyperproliferative or abnormal keratinocyte differentiation, in a retinoic acid receptor (RAR)-dependent manner in various cell culture systems. MRP-8 expression is also down-regulated in vivo in psoriatic lesions after topical application of an anti-psoriatic RAR beta/gamma-selective synthetic retinoid, tazarotene. We demonstrate that an MRP-8 promoter linked to a chloramphenicol acetyltransferase reporter (MRP8CAT) faithfully replicates the differentiation-specific regulation of the endogenous keratinocyte MRP-8 gene. Further, interferon gamma and serum-induced expression of MRP8CAT is inhibited by retinoid receptors in a ligand-dependent manner, We also show that NF-IL6 acts as a transcriptional enhancer of MRP-8, and that RARs inhibit MRP8CAT by inhibiting the enhancer action of nuclear factor-interleukin-6 (NF-IL6), The NF-IL6 antagonism function of RAR is a complex of the core of the DNA binding domain and the hydrophobic zipper region. This manuscript identifies NF-IL6 as another transcription factor, in addition to API, whose activity is inhibited by RAR in a ligand-dependent manner, The interdiction of NF-IL6-dependent signal transduction pathway by RARs may explain some of the therapeutic effects of retinoids in inflammatory and proliferative diseases.	ALLERGAN PHARMACEUT INC, RETINOID RES, DEPT BIOL, IRVINE, CA 92612 USA; ALLERGAN PHARMACEUT INC, RETINOID RES, DEPT CHEM, IRVINE, CA 92612 USA	AbbVie; Allergan; AbbVie; Allergan								ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ANDREATTAVANLEYEN S, 1994, J CELL PHYSIOL, V160, P265, DOI 10.1002/jcp.1041600208; BARTHE C, 1991, BIOCHIM BIOPHYS ACTA, V1096, P175, DOI 10.1016/0925-4439(91)90057-G; Boehm MF., 1995, EXPERT OPIN INV DRUG, V4, P593, DOI DOI 10.1517/13543784.4.7.593; BRASIER AR, 1994, J BIOL CHEM, V269, P10341; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; KRUEGER GG, 1994, J INVEST DERMATOL, V102, pS14, DOI 10.1111/1523-1747.ep12386079; LACKMANN M, 1993, J IMMUNOL, V150, P2981; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; Nagpal S, 1996, CELL GROWTH DIFFER, V7, P1783; Nagpal S, 1996, J INVEST DERMATOL, V106, P269, DOI 10.1111/1523-1747.ep12340668; Nagpal S, 1997, MOL CELL BIOL, V17, P4159, DOI 10.1128/MCB.17.7.4159; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nagpal S, 1996, CURR PHARM DESIGN, V2, P295; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; WILKINSON MM, 1988, J CELL SCI, V91, P221	26	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25555	25559		10.1074/jbc.272.41.25555	http://dx.doi.org/10.1074/jbc.272.41.25555			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325272	hybrid			2022-12-25	WOS:A1997YA35800027
J	Piotrowicz, RS; Levin, EG				Piotrowicz, RS; Levin, EG			Basolateral membrane-associated 27-kDa heat shock protein and microfilament polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUID-PHASE PINOCYTOSIS; ACTIN POLYMERIZATION; POLYMORPHONUCLEAR LEUKOCYTES; CELLULAR THERMORESISTANCE; ENDOTHELIAL-CELLS; MAPKAP KINASE-2; ALPHA-ACTININ; F-ACTIN; PHOSPHORYLATION; ORGANIZATION	The in vivo activity of the 27-kDa heat shock protein, a barbed-end microfilament capping protein, may be localized to the plasma membrane. To investigate this putative association, bovine endothelial cells expressing the human wild type or a mutant nonphosphorylatable 27-kDa heat shock protein were subjected to subcellular fractionation and immunoblot analysis. The 25-kDa endogenous bovine homolog and both exogenous gene products partitioned with cytosolic or plasma membrane components, indicating that phosphorylation is not required for membrane association. Phorbol ester treatment resulted in phosphorylation of only membrane-associated 25-kDa and wild type 27-kDa heat shock protein and did not induce redistribution. In a second fractionation protocol, streptavidin-agarose precipitation of extracts prepared from cells biotinylated at either the apical or basal surface localized membrane 25- and 27-kDa heat shock protein exclusively to the basolateral surface. Stimulation of transfectants expressing the wild type 27-kDa heat shock protein resulted in its phosphorylation and a doubling in the amount of membrane-associated F-actin precipitated, whereas the mutant protein decreased the amount of F-actin precipitated. These data suggest that membrane-associated 25- and 27-kDa heat shock proteins inhibit the generation of basolateral microfilaments and that phosphorylation releases this inhibition.	Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040435] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40435] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLERS A, 1994, MOL PHARMACOL, V46, P1077; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; ELLIS JA, 1992, BIOCHEM J, V283, P553, DOI 10.1042/bj2830553; ENGEL K, 1995, J CELL BIOCHEM, V57, P321, DOI 10.1002/jcb.240570216; GAZITT Y, 1981, CANCER RES, V41, P1064; GLOCK GE, 1953, BIOCHEM J, V55, P400, DOI 10.1042/bj0550400; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; GOTLIEB AI, 1990, TOXICOL PATHOL, V18, P603; GUESDON F, 1993, J BIOL CHEM, V268, P4236; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HOGEBOOM GH, 1950, J BIOL CHEM, V186, P417; HUOT J, 1995, EUR J BIOCHEM, V227, P418; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEVIN EG, 1991, J BIOL CHEM, V266, P174; LEVIN EG, 1991, J IMMUNOL, V146, P3772; Li S, 1996, AM J PHYSIOL-CELL PH, V271, pC994, DOI 10.1152/ajpcell.1996.271.3.C994; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; PIOTROWICZ RS, 1995, FASEB J, V9, P1079, DOI 10.1096/fasebj.9.11.7649407; PODLUBNAYA ZA, 1975, J MOL BIOL, V92, P357, DOI 10.1016/0022-2836(75)90234-X; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; THERIOT JA, 1994, ADV EXP MED BIOL, V358, P133; WATTS RG, 1992, CELL MOTIL CYTOSKEL, V21, P25, DOI 10.1002/cm.970210104; WATTS RG, 1994, CELL MOTIL CYTOSKEL, V28, P155, DOI 10.1002/cm.970280207	33	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25920	25927		10.1074/jbc.272.41.25920	http://dx.doi.org/10.1074/jbc.272.41.25920			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325325	Green Published, hybrid			2022-12-25	WOS:A1997YA35800080
J	Jin, SF; Kharbanda, S; Mayer, B; Kufe, D; Weaver, DT				Jin, SF; Kharbanda, S; Mayer, B; Kufe, D; Weaver, DT			Binding of Ku and c-Abl at the kinase homology region of DNA-dependent protein kinase catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK REPAIR; V(D)J RECOMBINATION; TYROSINE KINASE; END; PHOSPHORYLATION; AUTOANTIGEN; DEFECTS; DOMAINS; COMPLEX; CELLS	The DNA-dependent protein kinase (DNA-PK) con trols the repair of double-stranded DNA breaks in mammalian cells. The protein kinase subunit of DNA-PK (DNA-PKcs) is targeted to DNA breaks by association with the Hu DNA-binding heterodimer. Here we show that a Ku association site is present at the carboxyl terminus of DNA-PKcs (amino acids 3002-3850) near the protein kinase domain. Correspondingly, the nuclear c-Abl tyrosine kinase that associates with DNA-PK also binds to the kinase homology domain. The c-Abl SH3 domain binds to amino acids 3414-3850 of DNA-PKcs. c-Abl phosphorylates C-terminal fragments of DNA-PKcs, particularly amino acids 3414-3850. c-Abl phosphorylation of DNA-PKcs disassociates the DNA-PKcs.Ku complex. Thus, Ku and c-Abl provide opposing functions with regard to DNA-PK activity.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; CTR BLOOD RES,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)					NATIONAL CANCER INSTITUTE [R01CA054326] Funding Source: NIH RePORTER; NCI NIH HHS [CA54326] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Jackson SP, 1996, CURR OPIN GENET DEV, V6, P19, DOI 10.1016/S0959-437X(96)90005-2; Jin SF, 1997, CANCER SURV, V29, P221; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0	28	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24763	24766		10.1074/jbc.272.40.24763	http://dx.doi.org/10.1074/jbc.272.40.24763			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312071	hybrid			2022-12-25	WOS:A1997XY97000010
J	Mitchell, C; Blaho, JA; McCormick, AL; Roizmann, B				Mitchell, C; Blaho, JA; McCormick, AL; Roizmann, B			The nucleotidylylation of herpes simplex virus 1 regulatory protein alpha 22 by human casein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GENE-EXPRESSION; WILD-TYPE; MACROMOLECULAR-SYNTHESIS; VIRAL POLYPEPTIDES; DELETION MUTANTS; TRANSCRIPTION; SUBUNIT; CELLS; DNA	The products of the alpha genes of herpes simplex virus 1, the infected cells proteins (ICP) 0, 4, 22, and 27 perform regulatory functions, are nucleotidylylated, and share the signaling or recognition sequence (RR(A/T)(P/S)R) that correctly predicted the nucleotidylylation of viral proteins encoded by U(L)21, U(L)31, U(L)49, and U(L)47 genes expressed later in infection. Extracts from uninfected HeLa cells or casein kinase II purified from sea star nucleotidylylated the ICP22 moiety of a glutathione S-transferase-ICP22 (GST22P) fusion protein with [(alpha-P-32]ATP or [2-H-3]ATP, We report that: (i) Purified HeLa cell casein kinase II specifically labeled a glutathione S-transferase fusion protein containing the aminoterminal 151 amino acids of ICP22 with [2-H-3]ATP, (ii) Nucleotidylylation of GST-ICP22 by purified enzyme exhibited positive cooperativity (Hill coefficient of 2 and a K' of 3.7 mu M) and a K-m = 37.7 mu m for ATP, (iii) Nucleotidylylation was inhibited by heparin, casein, or ATP alpha S but not by ATP gamma S, (iv) Mutation of the signaling sequence from RRAPRR to LKAPEK abolished nucleotidylylation, We conclude that nucleotidylylation of proteins by casein kinase II requires the presence of the signaling or recognition sequence, involves the cleavage of the phosphodiester bond between the alpha and beta phosphate, and need not be preceded by phosphorylation.	UNIV CHICAGO, MARJORIE B KOVLER VIRAL ONCOL LABS, CHICAGO, IL 60637 USA	University of Chicago					NCI NIH HHS [CA47451] Funding Source: Medline; NIAID NIH HHS [AI124009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047451] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI124009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLAHO JA, 1993, J VIROL, V67, P3891, DOI 10.1128/JVI.67.7.3891-3900.1993; BLAHO JA, 1994, J BIOL CHEM, V269, P17401; BLAHO JA, 1991, J VIROL, V65, P3759, DOI 10.1128/JVI.65.7.3759-3769.1991; BLAHO JA, 1992, J VIROL, V66, P6393; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; DELUCA NA, 1985, MOL CELL BIOL, V5, P1997, DOI 10.1128/MCB.5.8.1997; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P19; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EJERCITO PM, 1968, J GEN VIROL, V2, P357, DOI 10.1099/0022-1317-2-3-357; EVERETT RD, 1984, EMBO J, V3, P3135, DOI 10.1002/j.1460-2075.1984.tb02270.x; HIBBARD MK, 1995, J VIROL, V69, P4656, DOI 10.1128/JVI.69.8.4656-4667.1995; HONESS RW, 1975, P NATL ACAD SCI USA, V72, P1276, DOI 10.1073/pnas.72.4.1276; HONESS RW, 1974, J VIROL, V14, P8, DOI 10.1128/JVI.14.1.8-19.1974; HU E, 1990, J BIOL CHEM, V265, P20609; KRECK W, 1992, J CELL BIOL, V116, P43; KRISTIE TM, 1984, P NATL ACAD SCI-BIOL, V81, P4065, DOI 10.1073/pnas.81.13.4065; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; MITCHELL C, 1994, P NATL ACAD SCI USA, V91, P11864, DOI 10.1073/pnas.91.25.11864; PANAGIOTIDIS CA, 1995, GENE, V164, P45, DOI 10.1016/0378-1119(95)00417-5; PRESTON CM, 1979, J VIROL, V29, P275, DOI 10.1128/JVI.29.1.275-284.1979; PRESTON CM, 1983, VIROLOGY, V131, P492, DOI 10.1016/0042-6822(83)90515-9; PURVES FC, 1992, P NATL ACAD SCI USA, V89, P7310, DOI 10.1073/pnas.89.16.7310; PURVES FC, 1993, P NATL ACAD SCI USA, V90, P6701, DOI 10.1073/pnas.90.14.6701; RICE SA, 1988, J VIROL, V62, P3814, DOI 10.1128/JVI.62.10.3814-3823.1988; Roizman B, 1996, FIELDS VIROLOGY, P2231; SACKS WR, 1987, J VIROL, V61, P829, DOI 10.1128/JVI.61.3.829-839.1987; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; SEARS AE, 1985, J VIROL, V55, P338, DOI 10.1128/JVI.55.2.338-346.1985; SMITH IL, 1992, VIROLOGY, V186, P74, DOI 10.1016/0042-6822(92)90062-T; STEVELY WS, 1985, J GEN VIROL, V66, P661, DOI 10.1099/0022-1317-66-4-661; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TRAUGH JA, 1990, ADV SEC MESS PHOSPH, V24, P224; Wada T, 1996, NUCLEIC ACIDS RES, V24, P876, DOI 10.1093/nar/24.5.876; WILCOX KW, 1980, J VIROL, V33, P167, DOI 10.1128/JVI.33.1.167-182.1980	36	23	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25394	25400		10.1074/jbc.272.40.25394	http://dx.doi.org/10.1074/jbc.272.40.25394			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312161	hybrid			2022-12-25	WOS:A1997XY97000100
J	BenMamoun, C; Beckerich, JM; Gaillardin, C				BenMamoun, C; Beckerich, JM; Gaillardin, C			Yarrowia lipolytica TSR1 gene product - A novel endoplasmic reticulum membrane component involved in the signal recognition particle-dependent translocation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; YEAST; COMPLEX; TRANSPORT; RNA	The tsr1-1 mutation has been initially identified as an extragenic suppressor of the scr2.II-13 mutation that alters the 7SL RNA component of the signal recognition particle (SRP) and results in severe defects in protein translocation and SRP stability. We showed previously that the TSR1 gene was essential and that the tsr1-1 mutation allowed complete recovery of scr2.II-13-associated secretory defects. We show here that the tsr1-1 mutation also restores SRP stability in an scr2.II-13 context. The TSR1 gene product (Tsr1p) is stably associated with rapidly sedimenting material and cofractionates with the lumenal protein Kar2p of the endoplasmic reticulum; it behaves in protease protection assays as a transmembrane component. Coimmunoprecipitation experiments revealed a physical interaction with Kar2p and with ribosomal components associated to the 5.8S rRNA as well as with SRP components like Sec65p and 7SL RNA. We propose that Tsr1p is an important component of the endoplasmic reticulum membrane, interacting both with the SRP-ribosome complex in the cytosol and with Kar2p in the lumen of the endoplasmic reticulum.	WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MED, ST LOUIS, MO 63110 USA; INRA, INST NATL AGRON PARIS GRIGNON, LAB GENET MOL & CELLULAIRE,CTR BIOTECHNOL AGROIND, CNRS, F-78850 THIVERVAL GRIGNON, FRANCE	Howard Hughes Medical Institute; Washington University (WUSTL); AgroParisTech; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay	BenMamoun, C (corresponding author), WASHINGTON UNIV, SCH MED,HOWARD HUGHES MED INST,DEPT MOL MICROBIOL, 660 S EUCLID AVE, BOX 8230, ST LOUIS, MO 63110 USA.							AGAPHONOV MO, 1994, YEAST, V10, P509, DOI 10.1002/yea.320100410; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BENMAMOUN C, 1996, J BIOL CHEM, V27, P23895; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CONNOLLY T, 1993, J CELL BIOL, V123, P799, DOI 10.1083/jcb.123.4.799; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; HE F, 1992, J BIOL CHEM, V267, P1932; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; Maniatis T., 1982, MOL CLONING; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; RUOHOLA H, 1987, P NATL ACAD SCI USA, V84, P8468, DOI 10.1073/pnas.84.23.8468; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; VANHEERIKHUIZEN H, 1985, GENE, V39, P213, DOI 10.1016/0378-1119(85)90315-4; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335; XUAN JW, 1988, CURR GENET, V14, P15, DOI 10.1007/BF00405848	24	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24594	24598		10.1074/jbc.272.39.24594	http://dx.doi.org/10.1074/jbc.272.39.24594			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305926	hybrid, Green Published			2022-12-25	WOS:A1997XY51500077
J	Bounacer, A; Wicker, R; Caillou, B; Cailleux, AF; Sarasin, A; Schlumberger, M; Suarez, HG				Bounacer, A; Wicker, R; Caillou, B; Cailleux, AF; Sarasin, A; Schlumberger, M; Suarez, HG			High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation	ONCOGENE			English	Article						radiation-associated tumors; ret protooncogene; activating rearrangements; RET/PTC oncogene	CHERNOBYL NUCLEAR ACCIDENT; TYROSINE KINASE; PAPILLARY CARCINOMAS; MOLECULAR CHARACTERIZATION; PROTOONCOGENE ACTIVATION; TRANSFORMING GENE; RET/PTC ONCOGENE; MUTATIONS; CANCER; RAS	A high frequency (about 60%) of ret rearrangements in papillary thyroid carcinomas of children exposed to radioactive fallout in Belarus the Chernobyl after accident, has been reported by three recent studies (Fugazzola et al., 1995; Ito et al., 1994; Klugbauer et al., 1995). These studies suggested that the radiation exposure may be a direct inducer of activating rearrangements in the vet gene. In order to confirm the postulated link between irradiation and the role of the ret protooncogene in thyroid tumorigenesis, we analysed for the presence of ret activating rearrangements using RT-PCR, XL-PCR, Southern blot and direct sequencing techniques, 39 human thyroid tumors (19 papillary carcinomas and 20 follicular adenomas), from patients who had received external radiation for benign or malignant conditions. As controls, eve studied 39 'spontaneous' tumors (20 papillary carcinomas and 19 follicular adenomas). Our data concerning the radiation-associated tumors, showed that: (1) the overall frequency of ret rearrangements was 84% in papillary carcinomas (16/19) and 45% (9/20) in follicular adenomas; (2) in contrast with the results obtained in the Chernobyl tumors, the most frequently observed chimeric gene was RET/PTC1 instead of the RET/PTC3 and (3) all the tumors were negative for RET/PTC2. In the 'spontaneous' tumors, only the papillary carcinomas presented a I et rearrangement (15%:3/20): 1 RET/PTC1, 1 RET/ PTC3 and 1 uncharacterized. In conclusion, our results confirm the crucial role played by the ret proto-oncogene activating rearrangements in the development of radiation-associated thyroid tumors appearing after therapeutic or accidental ionizing irradiation, and show, for the first time, the presence of RET/PTC genes in follicular adenomas appeared after external irradiation.	INST RECH SCI CANC, GENET MOL LAB, UPR 42, CNRS IFC 1, F-94801 VILLEJUIF, FRANCE; INST GUSTAVE ROUSSY, F-94805 VILLEJUIF, FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								BONGARZONE I, 1989, ONCOGENE, V4, P1457; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; CHALLETON C, 1995, ONCOGENE, V11, P601; CONARD RA, 1970, J AMER MED ASSOC, V214, P316, DOI 10.1001/jama.214.2.316; Delvincourt C, 1996, CLIN BIOCHEM, V29, P267, DOI 10.1016/0009-9120(96)00006-9; Diallo I, 1996, RADIOTHER ONCOL, V38, P269, DOI 10.1016/0167-8140(96)01713-6; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DUFFY BJ, 1950, J CLIN ENDOCRINOL, V10, P1296, DOI 10.1210/jcem-10-10-1296; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; Fogelfeld L, 1996, J CLIN ENDOCR METAB, V81, P3039, DOI 10.1210/jc.81.8.3039; FRAKER DL, 1995, SURG CLIN N AM, V75, P365, DOI 10.1016/S0039-6109(16)46627-2; Fugazzola L, 1996, ONCOGENE, V13, P1093; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P259; JACKSON DP, 1989, LANCET, V1, P1391; JHIANG SM, 1992, ONCOGENE, V7, P1331; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; LEMOINE NR, 1988, CANCER RES, V48, P4459; MICHELIN S, 1993, ONCOGENE, V8, P1983; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Nikiforov YE, 1996, ONCOGENE, V13, P687; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; SANGER F, 1977, P NATL ACAD SCI USA, V82, P488; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1994, ONCOGENE, V9, P509; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHORE RE, 1993, AM J EPIDEMIOL, V137, P1068, DOI 10.1093/oxfordjournals.aje.a116610; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; SHORE RE, 1985, J NATL CANCER I, V74, P1177; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; STARY A, 1992, NUCLEIC ACIDS RES, V20, P4269, DOI 10.1093/nar/20.16.4269; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1990, ONCOGENE, V5, P565; Sugg SL, 1996, J CLIN ENDOCR METAB, V81, P3360, DOI 10.1210/jc.81.9.3360; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WAJJWALKU W, 1992, JPN J CANCER RES, V83, P671, DOI 10.1111/j.1349-7006.1992.tb01963.x; WOOD JW, 1969, AM J EPIDEMIOL, V89, P4, DOI 10.1093/oxfordjournals.aje.a120914; WRIGHT PA, 1991, ONCOGENE, V6, P471; WYNFORDTHOMAS D, 1993, CRIT REV ONCOGENESIS, V4, P1; ZOU MJ, 1994, CANCER, V73, P176, DOI 10.1002/1097-0142(19940101)73:1<176::AID-CNCR2820730130>3.0.CO;2-T	56	239	252	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1263	1273		10.1038/sj.onc.1200206	http://dx.doi.org/10.1038/sj.onc.1200206			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315093				2022-12-25	WOS:A1997XV84500003
J	Hocker, M; Henihan, RJ; Rosewicz, S; Riecken, EO; Zhang, ZS; Koh, TJ; Wang, TC				Hocker, M; Henihan, RJ; Rosewicz, S; Riecken, EO; Zhang, ZS; Koh, TJ; Wang, TC			Gastrin and phorbol 12-myristate 13-acetate regulate the human histidine decarboxylase promoter through raf-dependent activation of extracellular signal-regulated kinase-related signaling pathways in gastric cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MAP KINASE; C-JUN; IN-VIVO; HA-RAS; CHOLECYSTOKININ; RECEPTOR; PHOSPHORYLATION; EXPRESSION; TRANSFORMATION	Gastrin stimulates transcription of the human histidine decarboxylase (HDC) gene through binding to the G-protein-coupled cholecystokinin-B/gastrin receptor. We have explored the possibility that mitogen-activated protein kinase cascades play a role in mediating the effects of gastrin on transcription in a gastric cancer (AGS-B) cell line. Gastrin and phorbol 12-myristate 13-acetate (PMA) treatment of AGS-B cells was found to increase the phosphorylation of tyrosine residues of extracellular signal-regulated kinases (ERKs) 1 and 2 and increase ERK activity as determined by the in vitro phosphorylation of myelin basic protein. Reporter gene assays also demonstrated that gastrin and PMA stimulated Elk-1- and c-Myc-dependent transactivation, consistent with gastrin and PMA-induced activation of ERKs. Overexpression of wild type ERK-1 and ERK-2 or activation of endogenous ERKs using activated MEK-1 (mitogen-activated protein kinase kinase or ERK kinase) overexpression stimulated HDC promoter activity in a dose-dependent fashion. Interruption of the ERK-related pathway using expression vectors for kinase-deficient ERKs or an ERK-specific phosphatase (PAC-1) blocked gastrin and PMA-stimulated HDC promoter activity. In contrast, inhibition of the Jun kinase pathway using an interfering dominant negative SEK-1 (stress-activated protein kinase/ERK-1) mutant did not inhibit HDC promoter activity. Furthermore, whereas gastrin stimulated phosphorylation of She proteins and association with Grb2, activation of the HDC promoter was not influenced by expression of dominant negative Ras (N15 or N17) proteins. However, gastrin stimulated Raf-1 kinase activity, and activation of the HDC promoter was blocked by coexpression of a dominant negative Raf-1 construct. Overall, these data demonstrate that gastrin regulates HDC transcription in a Raf-dependent, Ras-independent fashion predominantly through activation of the ERK-related pathway.	MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital					NATIONAL CANCER INSTITUTE [R01CA067463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048077] Funding Source: NIH RePORTER; NCI NIH HHS [CA67463] Funding Source: Medline; NIDDK NIH HHS [DK48077] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BERTRAND V, 1994, INT J CANCER, V56, P427, DOI 10.1002/ijc.2910560324; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CHEN D, 1994, GASTROENTEROLOGY, V107, P18, DOI 10.1016/0016-5085(94)90056-6; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIMALINE R, 1991, FEBS LETT, V281, P20, DOI 10.1016/0014-5793(91)80348-7; DUAN RD, 1994, AM J PHYSIOL, V267, pG401, DOI 10.1152/ajpgi.1994.267.3.G401; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hocker M, 1996, AM J PHYSIOL-GASTR L, V270, pG619, DOI 10.1152/ajpgi.1996.270.4.G619; HOCKER M, 1997, AM J PHYSIOL, V35, P6822; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; Langhans N, 1997, GASTROENTEROLOGY, V112, P280, DOI 10.1016/S0016-5085(97)90000-7; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; NAKATA H, 1992, BIOCHEM BIOPH RES CO, V187, P1151, DOI 10.1016/0006-291X(92)91317-J; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3755; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANDVIK AK, 1994, AM J PHYSIOL, V267, pG254, DOI 10.1152/ajpgi.1994.267.2.G254; Seva C, 1996, FEBS LETT, V378, P74, DOI 10.1016/0014-5793(95)01414-4; SEVA C, 1994, REGUL PEPTIDES, V52, P31, DOI 10.1016/0167-0115(94)90018-3; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TANIGUCHI T, 1994, ONCOGENE, V9, P861; TODISCO A, 1995, J BIOL CHEM, V270, P28337; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WINITZ S, 1993, J BIOL CHEM, V268, P19196; Zhang ZS, 1996, J BIOL CHEM, V271, P14188, DOI 10.1074/jbc.271.24.14188	43	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27015	27024		10.1074/jbc.272.43.27015	http://dx.doi.org/10.1074/jbc.272.43.27015			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341140	hybrid			2022-12-25	WOS:A1997YC65900036
J	Ito, K; Groudine, M				Ito, K; Groudine, M			A new member of the cationic amino acid transporter family is preferentially expressed in adult mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC RETROVIRAL RECEPTOR; CULTURED ANIMAL-CELLS; L-ARGININE TRANSPORT; SMOOTH-MUSCLE CELLS; GENE-EXPRESSION; NOREPINEPHRINE TRANSPORTER; PLASMA-MEMBRANE; MAMMALIAN-CELLS; MESSENGER-RNA; SYSTEM Y(+)	We have isolated and characterized a novel member (CAT3) of the cationic amino acid transporter (CAT) family, In oocyte injection assays, CAT3 cRNA exhibited a saturable, sodium ion-independent transport activity with high affinity for L-arginine and L-lysine (K-m = 40-60 and 115-165 mu M, respectively), Transport of L-arginine was effectively competed only by cationic amino acids in L-form: arginine, lysine, ornithine, and 2,4-diamino-n-butyric acid but not by 2,3-diaminopropionic acid. The presence of L-arginine in the incubation medium stimulated the efflux rate of L-arginine, indicating that CAT3 is subject to trails-stimulation. All these re suits are consistent with the idea that CAT3, along with CAT1 and CAT2, constitutes the transport activity originally assigned to system y(+). Like CAT2, but unlike CAT1, the expression of CAT3 is regulated in a highly tissue-specific manner; when various adult tissues were examined, significant levels of CAT3 transcript were detectable only in brain, In situ hybridization oil brain sections revealed that CAT3 transcripts were localized predominantly along the midbrain-thalamus-hypothalamus axis, whereas neither CAT1 nor CAT2 transcripts demonstrated a similar localization, In contrast to its highly localized expression during the primitive streak stage and in the adult stage, CAT3 expression was detected more widely in 13.5 day post-coitum mouse embryos.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,SCH MED,DEPT RADIAT ONCOL,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle								AHMED A, 1995, J BIOL CHEM, V270, P8482, DOI 10.1074/jbc.270.15.8482; ALBRITTON LM, 1992, GENOMICS, V12, P430, DOI 10.1016/0888-7543(92)90431-Q; Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; CHRISTENSEN HN, 1973, MEMBRANE STRUCTURE M, P233; CHRISTENSEN HN, 1975, CURRENT TOPICS MEMBR, V6, P227; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; Durante W, 1996, J BIOL CHEM, V271, P11838, DOI 10.1074/jbc.271.20.11838; ELENO N, 1994, J PHYSIOL-LONDON, V479, P291, DOI 10.1113/jphysiol.1994.sp020296; Gill DJ, 1996, J BIOL CHEM, V271, P11280, DOI 10.1074/jbc.271.19.11280; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hosokawa H, 1997, J BIOL CHEM, V272, P8717, DOI 10.1074/jbc.272.13.8717; Ing BL, 1996, BIOCHEM BIOPH RES CO, V218, P76, DOI 10.1006/bbrc.1996.0015; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KIM JW, 1993, J BIOL CHEM, V268, P16316; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LOW BC, 1995, J BIOL CHEM, V270, P27577, DOI 10.1074/jbc.270.46.27577; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Melikian HE, 1996, MOL PHARMACOL, V50, P266; Nguyen TT, 1996, J NEUROCHEM, V67, P645; OPRESKO LK, 1991, METHOD CELL BIOL, V36, P117; PUPPI M, 1995, P SOC EXP BIOL MED, V209, P38, DOI 10.3181/00379727-209-43875; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Simmons WW, 1996, J BIOL CHEM, V271, P11694, DOI 10.1074/jbc.271.20.11694; Stevens BR, 1996, J BIOL CHEM, V271, P24017, DOI 10.1074/jbc.271.39.24017; STOLL J, 1993, J NEUROCHEM, V60, P1956, DOI 10.1111/j.1471-4159.1993.tb13428.x; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WHITE MF, 1982, J BIOL CHEM, V257, P4443; WHITE MF, 1982, J BIOL CHEM, V257, P69; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; YOSHIMOTO T, 1991, VIROLOGY, V185, P10, DOI 10.1016/0042-6822(91)90748-Z; YOSHIMOTO T, 1992, J VIROL, V66, P4377, DOI 10.1128/JVI.66.7.4377-4381.1992	45	90	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26780	26786		10.1074/jbc.272.42.26780	http://dx.doi.org/10.1074/jbc.272.42.26780			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334265	hybrid			2022-12-25	WOS:A1997YB13900099
J	Shimoaraiso, M; Nakanishi, T; Kubo, T; Natori, S				Shimoaraiso, M; Nakanishi, T; Kubo, T; Natori, S			Identification of the region in yeast S-II that defines species specificity in its interaction with RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-SII; ASCITES TUMOR-CELLS; PROMOTE READ-THROUGH; TRANSCRIPTION ELONGATION; SACCHAROMYCES-CEREVISIAE; DEPENDENT TRANSCRIPTION; NASCENT TRANSCRIPT; STIMULATORY FACTOR; FACTOR TFIIS; ZINC-FINGER	Yeast S-II was found to stimulate yeast RNA polymerase II only and not mouse RNA polymerase II, To identify the molecular region of S-II that defines species specificity, we constructed six hybrid S-II molecules consisting of three regions from yeast: and/or Ehrlich cell S-II and examined their activity in terms of RNA polymerase II specificity and suppression of 6-azauracil. sensitivity in the yeast S-II null mutant. We found that the region 132-270 (amino acid positions) of yeast S-II is indispensable for specific interaction with yeast RNA polymerase II in vitro and for suppression of 6-azauracil sensitivity in vivo. The corresponding region of Ehrlich cell S-II, the region 132-262, was also shown to be essential for its interaction with mouse RNA polymerase II. This region is known to be less conserved than the Nand C-terminal regions in the S-II family suggesting that it is important in the interaction with transcription machinery proteins in a tissue and/or species-specific manner.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo				Kubo, Takeo/0000-0002-5914-5269				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BITTER GA, 1983, ANAL BIOCHEM, V128, P294, DOI 10.1016/0003-2697(83)90378-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HOMMA K, 1994, J BIOL CHEM, V269, P15258; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KANE CM, 1993, TRANSCRIPTION MECH R, P279; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, FASEB J, V5, P777; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; Morin PE, 1996, P NATL ACAD SCI USA, V93, P10604, DOI 10.1073/pnas.93.20.10604; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NATORI S, 1982, MOL CELL BIOCHEM, V46, P173; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P265; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SEKIMIZU K, 1983, J BIOCHEM-TOKYO, V93, P1523, DOI 10.1093/oxfordjournals.jbchem.a134290; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SEKIMIZU K, 1982, J BIOL CHEM, V257, P2719; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SEKIMIZU K, 1979, EXP CELL RES, V124, P68; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SPENCER CA, 1990, ONCOGENE, V5, P777; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UENO K, 1979, NATURE, V277, P145, DOI 10.1038/277145a0	50	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26550	26554		10.1074/jbc.272.42.26550	http://dx.doi.org/10.1074/jbc.272.42.26550			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334234	hybrid			2022-12-25	WOS:A1997YB13900068
J	Kelley, JA; Knight, KL				Kelley, JA; Knight, KL			Allosteric regulation of RecA protein function is mediated by Gln(194)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; PHAGE-LAMBDA-REPRESSOR; P-LOOP MOTIF; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; DIRECTED CLEAVAGE; MOTOR DOMAIN; BINDING; RECOMBINATION; RESIDUES	Binding of ATP to the RecA protein induces a high affinity DNA binding required for activation of enzyme function. Screens for in vivo recombination and repressor cleavage activities show Gln(194) to be intolerant of all substitutions. Analyses of three mutant proteins (Q194N, Q194E, and Q194A) show that although basal enzyme function is maintained, each protein no longer displays an ATP-induced increase in DNA binding affinity. High salt activation of RecA function is also disrupted by these mutations. In contrast, ATP-induced changes in the oligomeric structure of Reck are maintained in the mutant proteins. These results demonstrate that Gln(194) is a critical ''allosteric switch'' for ATP-induced activation of Reck function but is not the exclusive mediator of ATP-induced changes in RecA.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOL BIOL, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044772] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44772] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNER SL, 1988, J MOL BIOL, V204, P959, DOI 10.1016/0022-2836(88)90055-1; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; DICAPUA E, 1990, J STRUCT BIOL, V104, P91, DOI 10.1016/1047-8477(90)90062-H; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; HEUSER J, 1989, J MOL BIOL, V210, P473, DOI 10.1016/0022-2836(89)90124-1; KONOLA JT, 1995, J BIOL CHEM, V270, P8411, DOI 10.1074/jbc.270.15.8411; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; Logan KM, 1997, J MOL BIOL, V266, P306, DOI 10.1006/jmbi.1996.0751; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NASTRI HG, 1994, J BIOL CHEM, V269, P26311; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PUGH BF, 1988, J BIOL CHEM, V263, P76; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; RUIGROK RWH, 1991, BIOCHIMIE, V73, P191, DOI 10.1016/0300-9084(91)90202-C; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; SILVER MS, 1982, BIOCHEMISTRY-US, V21, P6066, DOI 10.1021/bi00267a007; SKIBA MC, 1994, J BIOL CHEM, V269, P3823; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Voloshin ON, 1996, SCIENCE, V272, P868, DOI 10.1126/science.272.5263.868; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WILSON DH, 1990, J BIOL CHEM, V265, P7351; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2	39	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25778	25782		10.1074/jbc.272.41.25778	http://dx.doi.org/10.1074/jbc.272.41.25778			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325305	hybrid			2022-12-25	WOS:A1997YA35800060
J	MacFarlane, M; Ahmad, M; Srinivasula, SM; FernandesAlnemri, T; Cohen, GM; Alnemri, ES				MacFarlane, M; Ahmad, M; Srinivasula, SM; FernandesAlnemri, T; Cohen, GM; Alnemri, ES			Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH DOMAIN; SIGNALING COMPLEX; CELL-DEATH; APOPTOSIS; PROTEASE; FADD; ACTIVATION; INTERACTS; CD95	A human receptor for the cytotoxic ligand TRAIL (TRAIL receptor-1, designated DR4) was identified recently as a member of the tumor necrosis factor receptor family. In this report we describe the identification of two additional human TRAIL receptors, TRAIL receptor-2 and TRAIL receptor-3, that belong to the tumor necrosis factor receptor family. Interestingly, TRAIL receptor-g but not TRAIL receptor-3 contains a cytoplasmic ''death domain'' necessary for induction of apoptosis and is hence designated death receptor-5 (DR5). Like DR4, DR5 engages the apoptotic pathway independent of the adaptor molecule FADD/MORT1. Because of its lack of a death domain, TRAIL receptor-3 is not capable of inducing apoptosis. However, by competing for TRAIL, it is capable of inhibiting TRAIL-induced apoptosis. Thus, TRAIL receptor-3 may function as an antagonistic decoy receptor to attenuate the cytotoxic effect of TRAIL in most tissues that are TRAIL(+), DR4(+), and DR5(+).	THOMAS JEFFERSON UNIV,KIMMEL CANC INST,CTR APOPTOSIS RES,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT IMMUNOL & MICROBIOL,PHILADELPHIA,PA 19107; UNIV LEICESTER,MRC,TOXICOL UNIT,LEICESTER LE1 9HN,LEICS,ENGLAND	Jefferson University; Jefferson University; University of Leicester			Alnemri, Emad S/B-4526-2010; Cohen, Gerald M/A-1687-2008		NIA NIH HHS [AG 13487] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tsang TC, 1997, BIOTECHNIQUES, V22, P68, DOI 10.2144/97221bm13; Wallach D, 1997, NATURE, V388, P123, DOI 10.1038/40516; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	22	484	546	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25417	25420		10.1074/jbc.272.41.25417	http://dx.doi.org/10.1074/jbc.272.41.25417			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325248	hybrid			2022-12-25	WOS:A1997YA35800003
J	Blostein, R; Wilczynska, A; Karlish, SJD; Arguello, JM; Lingrel, JB				Blostein, R; Wilczynska, A; Karlish, SJD; Arguello, JM; Lingrel, JB			Evidence that Ser(775) in the alpha subunit of Na,K-ATPase is a residue in the cation binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY NA+,K+-ATPASE; 4TH TRANSMEMBRANE SEGMENT; SITE-DIRECTED MUTAGENESIS; FUNCTIONAL CONSEQUENCES; POTASSIUM-IONS; CATALYTIC SUBUNIT; ACTIVE-TRANSPORT; SODIUM-PUMP; SUBSTITUTIONS; AFFINITY	Substitution of alanine for Ser(775) in a ouabain-resistant alpha 1 sheep isoform causes a 30-fold decrease in apparent affinity for K+ as an activator of the Na,K-ATPase, as well as an increase in apparent affinity for ATP (Arguello, J. M., and Lingrel, J. B (1995) J. Biol. Chem. 270, 22764-22771). This study was carried out to determine whether Ser(775) is a direct cation-ligating residue or whether the change in apparent affinity for K+ is secondary to a conformational alteration as evidenced in the change in ATP affinity, with the following results, Kinetics of K+ (Rb+) influx into intact cells show that the change is due to a change in K+ interaction at the extracellular surface, The K+ dependence of formation of K+-occluded enzyme (E-2(K)) and of the rate of formation of deoccluded enzyme from E-2(K) indicate that the Ser(775) --> Ala mutation results in a marked increase (greater than or equal to 30-fold) in rate of release of K+ from E-2(K), The high affinity Na+-like competitive antagonist 1,3-dibromo-2,4,6-tris-(methylisothiouronium)benzene (Br2TITU), which interacts with the E-1 conformation and blocks cytoplasmic cation binding (Hoving, S., Bar-Shimon, M., Tijmes, J. J., Tal, D. M., and Karlish, S. J. D. (1995) J. Biol. Chem, 270, 29788-29793), inhibits Na+-ATPase of the mutant less than the control enzyme, With intact cells, Br2TITU acts as a competitive inhibitor of extracellular K+ activation of both the mutant and control enzymes, In this case, the mutant was more sensitive to inhibition, With vanadate as a probe of conformation, a difference in conformational equilibrium between the mutant and control enzymes could not be detected under turnover conditions (Na+-ATPase) in the absence of K+, These results indicate that the increase in apparent affinity for ATP effected by the Ser(775) --> Ala mutation is secondary to a change in intrinsic cation affinity/selectivity. The large change in affinity for extracellular K+ compared with cytoplasmic Na+ and to Br2TITU binding supports the conclusion that the serine hydroxyl is either part of the K+-gate structure or a direct cation-ligating residue that is shared by at least one Na+ ion, albeit with less consequence on rate constants for Na+ binding or release compared with K+.	MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1A4,CANADA; WEIZMANN INST SCI,IL-76100 REHOVOT,ISRAEL; UNIV CINCINNATI,COLL MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	McGill University; Weizmann Institute of Science; University System of Ohio; University of Cincinnati			Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297	NHLBI NIH HHS [HL 28573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; BEAUGE LA, 1979, J PHYSIOL-LONDON, V289, P17, DOI 10.1113/jphysiol.1979.sp012722; DALY SE, 1994, J BIOL CHEM, V269, P23944; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; DALY SE, 1997, IN PRESS ANN NY ACAD; EISNER DA, 1981, J PHYSIOL-LONDON, V319, P403, DOI 10.1113/jphysiol.1981.sp013917; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GLYNN IM, 1976, J PHYSIOL-LONDON, V256, P465, DOI 10.1113/jphysiol.1976.sp011333; GLYNN IM, 1987, J PHYSIOL-LONDON, V383, P477; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; HOVING S, 1995, J BIOL CHEM, V270, P29788; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KAPLAN JH, 1982, J GEN PHYSIOL, V80, P915, DOI 10.1085/jgp.80.6.915; KARLISH SJD, 1997, IN PRESS ANN NY ACAD; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P16206, DOI 10.1074/jbc.270.27.16206; LEE KH, 1980, NATURE, V285, P338, DOI 10.1038/285338a0; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; POST RL, 1972, J BIOL CHEM, V247, P6530; Post RL, 1967, METHOD ENZYMOL, V10, P773; SACHS JR, 1980, J PHYSIOL-LONDON, V302, P219; TAL DM, 1995, TETRAHEDRON, V51, P3823, DOI 10.1016/0040-4020(95)00105-H; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70	35	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24987	24993		10.1074/jbc.272.40.24987	http://dx.doi.org/10.1074/jbc.272.40.24987			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312104	hybrid			2022-12-25	WOS:A1997XY97000043
J	Haniu, M; Montestruque, S; Bures, EJ; Talvenheimo, J; Toso, R; LewisSandy, S; Welcher, AK; Rohde, MF				Haniu, M; Montestruque, S; Bures, EJ; Talvenheimo, J; Toso, R; LewisSandy, S; Welcher, AK; Rohde, MF			Interactions between brain-derived neurotrophic factor and the TRKB receptor - Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; IMMUNOGLOBULIN-LIKE DOMAIN; LEUCINE-RICH MOTIF; EXTRACELLULAR DOMAIN; GLYCOSYLATION SITES; MONOCLONAL-ANTIBODY; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; FACTOR FAMILY	The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF). Two distinct ligand binding domains of TRKB were isolated from proteolytic digests of the receptor by affinity separation on immobilized BDNF, One of these domains consists of amino acid residues 103-181 and contains both the third leucine-rich motif and the second cysteine cluster domain, The second domain is close to the second immunoglobulin-like domain (amino acid residues 342-394). Each of these two domains can bind BDNF independently, Disulfide linkages present in the first domain are necessary for BDNF binding, probably because of preservation of the native conformation, To study the second domain in greater detail, a truncated form of TRKB containing the second immunoglobulinlike domain (residues 248-398) was expressed in Escherichia coli, This domain was cross-linked to BDNF through a 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide coupling reaction. Several synthetic peptides corresponding to amino acid residues 343-379 were able to bind immobilized BDNF, Amino acid substitution and cross-linking analysis indicated that amino acids Phe(347), Asp(354), and Tyr(361) are intimately involved in BDNF binding, These results, obtained from a variety of experimental techniques, highlight the importance of two distinct regions of the extracellular domain of the TRKB receptor in binding BDNF.	AMGEN INC, DEPT PROT CHEM, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT IMMUNOL, THOUSAND OAKS, CA 91320 USA	Amgen; Amgen	Haniu, M (corresponding author), AMGEN INC, DEPT PROT STRUCT, 1840 DEHAVILLAND DR, THOUSAND OAKS, CA 91320 USA.							Barbacid Mariano, 1993, P123; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BRADY RL, 1993, SCIENCE, V260, P979, DOI 10.1126/science.8493535; CANAS B, 1993, ANAL BIOCHEM, V211, P179, DOI 10.1006/abio.1993.1253; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; Fairlie WD, 1996, EUR J BIOCHEM, V240, P622, DOI 10.1111/j.1432-1033.1996.0622h.x; GOTZ R, 1994, NATURE, V372, P266, DOI 10.1038/372266a0; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HANIU M, 1995, ARCH BIOCHEM BIOPHYS, V322, P256, DOI 10.1006/abbi.1995.1460; Heding A, 1996, J BIOL CHEM, V271, P13948, DOI 10.1074/jbc.271.24.13948; IBANEZ CF, 1995, TRENDS BIOTECHNOL, V13, P217, DOI 10.1016/S0167-7799(00)88949-0; Johnson DL, 1996, PROTEIN EXPRES PURIF, V7, P104, DOI 10.1006/prep.1996.0014; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LESAUTEUR L, 1995, J BIOL CHEM, V270, P6564, DOI 10.1074/jbc.270.12.6564; MALMBORG A, 1992, J IMMUNOL, V36, P643; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; Parker CE, 1996, J IMMUNOL, V157, P198; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; PHILO J, 1994, J BIOL CHEM, V269, P27840; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; Weiergraber O, 1996, FEBS LETT, V379, P122, DOI 10.1016/0014-5793(95)01482-9; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348; ZHAO YM, 1994, ANAL CHEM, V66, P3723, DOI 10.1021/ac00093a029	40	27	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25296	25303		10.1074/jbc.272.40.25296	http://dx.doi.org/10.1074/jbc.272.40.25296			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312147	hybrid			2022-12-25	WOS:A1997XY97000086
J	Heinemeyer, W; Fischer, M; Krimmer, T; Stachon, U; Wolf, DH				Heinemeyer, W; Fischer, M; Krimmer, T; Stachon, U; Wolf, DH			The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; PEPTIDE-HYDROLYZING ACTIVITY; YEAST PROTEASOME; THERMOPLASMA-ACIDOPHILUM; SACCHAROMYCES-CEREVISIAE; INTERFERON-GAMMA; MULTIFUNCTIONAL PROTEINASE; PROTEOLYTIC ACTIVITIES; ANTIGENIC PEPTIDES; ENCODED SUBUNITS	The 26 S proteasome is the central protease involved in ubiquitin-mediated protein degradation and fulfills vital regulatory functions in eukaryotes, The proteolytic core of the complex is the 20 S proteasome, a cylindrical particle with two outer rings each made of 7 different alpha-type subunits and two inner rings made of 7 different beta-type subunits, In the archaebacterial 20 S proteasome ancestor proteolytically active sites reside in the 14 uniform beta-subunits. Their N-terminal threonine residues, released by precursor processing, perform the nucleophilic attack for peptide bond hydrolysis. By directed mutational analysis of 20 S proteasomal beta-type proteins of Saccharomyces cerevisiae, we identified three active site-carrying subunits responsible for different peptidolytic activities as follows: Pre3 for post-glutamyl hydrolyzing, Pup1 for trypsin-like, and Pre2 for chymotrypsin-like activity, Double mutants harboring only trypsin-like or chymotrypsin-like activity were viable, Mutation of two potentially active site threonine residues in the Pre4 subunit excluded its catalytic involvement in any of the three peptidase activities, The generation of different, incompletely processed forms of the Pre4 precursor in active site mutants suggested that maturation of non-active proteasomal beta-type subunits is exerted by active subunits and occurs in the fully assembled particle, This trans-acting proteolytic activity might also account for processing intermediates of the active site mutated Pre2 subunit, which was unable to undergo autocatalytic maturation.	UNIV STUTTGART,INST BIOCHEM,D-70569 STUTTGART,GERMANY	University of Stuttgart								ACHSTETTER T, 1984, J BIOL CHEM, V259, P3344; AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DICK LR, 1994, J IMMUNOL, V152, P3884; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FISCHER M, 1994, FEBS LETT, V355, P69, DOI 10.1016/0014-5793(94)01177-X; FRIEDMAN H, 1994, P NATL ACAD SCI USA, V91, P2031, DOI 10.1073/pnas.91.6.2031; FRIEDMAN H, 1992, GENE, V122, P203, DOI 10.1016/0378-1119(92)90051-P; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HAFFTER P, 1991, NUCLEIC ACIDS RES, V19, P5075, DOI 10.1093/nar/19.18.5075; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HILT W, 1993, J BIOL CHEM, V268, P3479; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; KLEINSCHMIDT JA, 1988, FEBS LETT, V239, P35, DOI 10.1016/0014-5793(88)80540-4; Kopp F, 1997, P NATL ACAD SCI USA, V94, P2939, DOI 10.1073/pnas.94.7.2939; KOPP F, 1995, J MOL BIOL, V248, P264; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHAUER TM, 1993, J STRUCT BIOL, V111, P135, DOI 10.1006/jsbi.1993.1044; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SIKORSKI RS, 1989, GENETICS, V122, P19; USTRELL V, 1995, P NATL ACAD SCI USA, V92, P584, DOI 10.1073/pnas.92.2.584; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	59	389	395	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25200	25209		10.1074/jbc.272.40.25200	http://dx.doi.org/10.1074/jbc.272.40.25200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312134	hybrid			2022-12-25	WOS:A1997XY97000073
J	Ogihara, T; Isobe, T; Ichimura, T; Taoka, M; Funaki, M; Sakoda, H; Onishi, Y; Inukai, K; Anai, M; Fukushima, Y; Kikuchi, M; Yazaki, Y; Oka, Y; Asano, T				Ogihara, T; Isobe, T; Ichimura, T; Taoka, M; Funaki, M; Sakoda, H; Onishi, Y; Inukai, K; Anai, M; Fukushima, Y; Kikuchi, M; Yazaki, Y; Oka, Y; Asano, T			14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-DEPENDENT ACTIVATOR; PHOSPHATIDYLINOSITOL 3-KINASE; TRYPTOPHAN HYDROXYLASES; REGULATORY SUBUNIT; IRS-1; TYROSINE; PHOSPHORYLATION; 14-3-3-PROTEIN; DISTINCT; ASSOCIATION	Insulin binding to its receptor induces the phosphorylation of cytosolic substrates, insulin receptor substrate (IRS)-1 and IRS-2, which associate with several Src homology-a domain-containing proteins. To identify unique IRS-1-binding proteins, we screened a human heart cDNA library with P-32-labeled recombinant IRS-I and obtained two isoforms (epsilon and zeta) of the 14-3-3 protein family. 14-3-3 protein has been shown to associate with IRS-I in L6 myotubes, HepG2 hepatoma cells, Chinese hamster ovary cells, and bovine brain tissue. IRS-2, a protein structurally similar to IRS-1, was also shown to form a complex with 14-3-3 protein using a baculovirus expression system. The amount of 14-3-3 protein associated with IRS-I was not affected by insulin stimulation but was increased significantly by treatment with okadaic acid, a potent serine/threonine phosphatase inhibitor. Peptide inhibition experiments using phosphoserine-containing peptides of IFS-I revealed that IRS-1 contains three putative binding sites for 14-3-3 protein (Ser-270, Ser-374, and Ser-641). Among these three, the motif around Ser-270 is located in the phosphotyrosine binding domain of IRS-I, which is responsible for the interaction with the insulin receptor. Indeed, a truncated mutant of IRS-1 consisting of only the phosphotyrosine binding domain retained the capacity to bind to 14-3-3 protein in vivo. Finally, the effect of 14-3-3 protein binding on the insulin-induced phosphorylation of IRS-1 was investigated. Phosphoamino acid analysis revealed that IRS-1 coimmunoprecipitated with anti-14-3-3 antibody to be weakly phosphorylated after insulin stimulation, on tyrosine as well as serine residues, compared with IRS-l immunoprecipitated with anti-IRS-l antibody. Thus, the association with 14-3-3 protein may play a role in the regulation of insulin sensitivity by interrupting the association between the insulin receptor and IRS-1.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; ASAHI LIFE FDN, INST ADULT DIS, SHINJUKU KU, TOKYO 160, JAPAN; YAMAGUCHI UNIV, SCH MED, DEPT INTERNAL MED 3, UBE, YAMAGUCHI 755, JAPAN; TOKYO METROPOLITAN UNIV, FAC SCI, DEPT CHEM, HACHIOJI, TOKYO 19203, JAPAN; NIIGATA UNIV, SCH MED, DEPT CHEM, NIIGATA 951, JAPAN	University of Tokyo; Asahi Life Foundation; Yamaguchi University; Tokyo Metropolitan University; Niigata University			Isobe, Toshiaki/Q-9279-2017	Taoka, Masato/0000-0001-5554-4951				AITKEN A, 1990, NATURE, V344, P594; Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; Bachmann M, 1996, FEBS LETT, V398, P26, DOI 10.1016/S0014-5793(96)01188-X; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BOSTON PF, 1982, J NEUROCHEM, V38, P1466, DOI 10.1111/j.1471-4159.1982.tb07927.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; ISOBE T, 1991, J MOL BIOL, V217, P125, DOI 10.1016/0022-2836(91)90616-E; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PONS S, 1995, MOL CELL BIOL, V15, P4453; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TANTI JF, 1994, J BIOL CHEM, V269, P6051; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	37	134	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25267	25274		10.1074/jbc.272.40.25267	http://dx.doi.org/10.1074/jbc.272.40.25267			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312143	hybrid			2022-12-25	WOS:A1997XY97000082
J	Schoenwaelder, SM; Kulkarni, S; Salem, HH; ImajohOhmi, S; YamaoHarigaya, W; Saido, TC; Jackson, SP				Schoenwaelder, SM; Kulkarni, S; Salem, HH; ImajohOhmi, S; YamaoHarigaya, W; Saido, TC; Jackson, SP			Distinct substrate specificities and functional roles for the 78- and 76-kDa forms of mu-calpain in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; CALCIUM-DEPENDENT PROTEASE; HUMAN BLOOD-PLATELETS; PROCOAGULANT ACTIVITY; MICROPARTICLE FORMATION; MEMBRANE SKELETON; PLASMA-MEMBRANE; CLEAVAGE; AUTOLYSIS; PLASMINOGEN	The intracellular thiol protease mu-calpain exists as a heterodimeric proenzyme, consisting of a large 80-kDa catalytic subunit and a smaller 30 kDa regulatory subunit, Activation of mu-calpain requires calcium influx across the plasma membrane and the subsequent autoproteolytic conversion of the 80-kDa large subunit to a 78-kDa ''intermediate'' and a 76-kDa fully autolyzed form, Currently, there is Limited information on the substrate specificities and functional roles of these distinct active forms of mu-calpain within the cell, Using antibodies that can distinguish among the 80-, 78, and 76-kDa forms of mu-calpain, we have demonstrated a close correlation between the autolytic generation of the 78 kDa enzyme and the proteolysis of the non-receptor tyrosine phosphatase, PTP-1B, in ionophore A23187-stimulated platelets, Time course studies revealed that pp60(c-src) proteolysis lagged well behind that of PTP-1B and correlated closely with the generation of the fully proteolyzed form of mu-calpain (76 kDa), In citro proteolysis experiments with purified mu-calpain and immunoprecipitated PTP-1B or pp60(c-src) confirmed selective proteolysis of pp60(c-src) by the 76-kDa enzyme, whereas PTP-1B cleavage was mediated by both the 76- and 78-kDa forms of mu-calpain. Studies using selective pharmacological inhibitors against the different autolytic forms of mu-calpain have demonstrated that the initial conversion of the mu-calpain large subunit to the 78-kDa form is responsible for the reduction in platelet-mediated clot retraction, whereas complete proteolytic activation of mu-calpain (76 kDa) is responsible for the shedding of procoagulant-rich membrane vesicles from the cell surface, These studies demonstrate the existence of multiple active forms of mu-calpain within the cell, that have unique substrate specificities and distinct functional roles.	BOX HILL HOSP, DEPT PATHOL, BOX HILL, VIC 3128, AUSTRALIA; AUSTRALIAN CTR BLOOD DIS, MONASH MED SCH, DEPT MED, BOX HILL, VIC 3128, AUSTRALIA; TOKYO METROPOLITAN INST MED SCI, TOKYO 113, JAPAN; UNIV TOKYO, INST MED SCI, TOKYO 108, JAPAN	Box Hill Hospital; Monash University; Tokyo Metropolitan Institute of Medical Science; University of Tokyo			Jackson, Shaun P/E-9633-2011; Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021; Schoenwaelder, Simone/E-9506-2011	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Jackson, Shaun/0000-0002-4750-1991; Schoenwaelder, Simone/0000-0003-0465-5840				ARIYOSHI H, 1995, PLATELETS, V6, P185, DOI 10.3109/09537109509078452; Baki A, 1996, BIOCHEM J, V318, P897, DOI 10.1042/bj3180897; BASSE F, 1994, BBA-BIOMEMBRANES, V1190, P217, DOI 10.1016/0005-2736(94)90077-9; BECKERLE MC, 1986, J CELL BIOCHEM, V30, P259, DOI 10.1002/jcb.240300307; CARILLO S, 1994, ONCOGENE, V9, P1679; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DacharyPrigent J, 1996, SEMIN THROMB HEMOST, V22, P157, DOI 10.1055/s-2007-999004; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; FOX JEB, 1990, BLOOD, V76, P2510; FOX JEB, 1983, J BIOL CHEM, V258, P9973; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1991, J BIOL CHEM, V266, P13289; FOX JEB, 1990, J CELL BIOL, V111, P483, DOI 10.1083/jcb.111.2.483; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Goll DE, 1990, INTRACELLULAR CALCIU, P3; HATHAWAY DR, 1982, J BIOL CHEM, V257, P9072; HAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1094, P249, DOI 10.1016/0167-4889(91)90083-A; IMAJOH S, 1986, J BIOCHEM-TOKYO, V99, P1281, DOI 10.1093/oxfordjournals.jbchem.a135593; INOMATA M, 1988, J BIOL CHEM, V263, P19783; INOMATA M, 1985, J BIOCHEM-TOKYO, V98, P407, DOI 10.1093/oxfordjournals.jbchem.a135295; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; JAKOBSEN E, 1973, Thrombosis Research, V3, P145, DOI 10.1016/0049-3848(73)90065-0; KUNITADA S, 1992, BLOOD, V79, P1420; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; ODA A, 1993, J BIOL CHEM, V268, P12603; Pasquet JM, 1996, THROMB RES, V82, P509, DOI 10.1016/0049-3848(96)00101-6; Pasquet JM, 1996, EUR J BIOCHEM, V239, P647, DOI 10.1111/j.1432-1033.1996.0647u.x; SABOVIC M, 1989, THROMB HAEMOSTASIS, V62, P1083; SABOVIC M, 1990, THROMB HAEMOSTASIS, V64, P450; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SUZUKI K, 1988, ADV ENZYME REGUL, V27, P153; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; Tompa P, 1996, J BIOL CHEM, V271, P33161, DOI 10.1074/jbc.271.52.33161; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJINAKA T, 1983, BIOCHEM INT, V6, P71; YAMAMOTO K, 1986, THROMB RES, V43, P41, DOI 10.1016/0049-3848(86)90043-5; YANO Y, 1993, THROMB RES, V71, P385, DOI 10.1016/0049-3848(93)90163-I; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZWAAL RFA, 1992, BIOCHIM BIOPHYS ACTA, V1180, P1, DOI 10.1016/0925-4439(92)90019-J	46	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24876	24884		10.1074/jbc.272.40.24876	http://dx.doi.org/10.1074/jbc.272.40.24876			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312088	hybrid			2022-12-25	WOS:A1997XY97000027
J	Sun, LZ; Chen, CG				Sun, LZ; Chen, CG			Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA-CELLS; TGF-BETA; PROTEOGLYCAN BETAGLYCAN; DISEASE PROGRESSION; ENDOTHELIAL-CELLS; PROSTATE-CANCER; TUMOR-GROWTH; C-MYC; FACTOR-BETA-1; GROWTH-FACTOR-BETA-1	Transforming growth factor beta (TGF-beta) promotes tumor progression in some model systems including human breast cancer cells. In this study, we report that human breast cancer cell lines express reduced amounts of TGF-beta type III receptor (RIII) when compared with untransformed human mammary epithelial cells. Consequently, me examined whether expression of RIII in human breast cancer MDA-MB-231 cells could reduce TGF-beta's tumor promoting activity by sequestering active TGF-beta isoforms produced by the cells. A tetracycline-repressible human RIII expression vector was stably transfected into the cell line. RIII expression in a pool of transfected clones and a single clone was found to be reversibly repressed by tetracycline treatment. Expression of RIII reduced the amount of active TGF-beta(1) and TGF-beta(2) in the conditioned medium. The medium conditioned by control cells showed a significantly higher growth inhibitory effect than that conditioned by RIII-transfected cells on the growth of the mink lung epithelial CCL64 cells. A conditioned medium collected from RIII-transfected cells treated with tetracycline significantly increased its growth inhibitory activity to that of control cells. Expression of RIII also reduced tumor incidence and growth rate in two separate experiments when the cells were inoculated in athymic nude mice. Treatment of the mice with tetracycline repressed RIII expression in the tumors generated by RIII-transfected cells and increased tumor incidence and growth rate. These results suggest that TGF-beta RIII can reduce tumorigenicity of MDA-MB-231 cells apparently by sequestering TGF-beta isoforms produced by these cells.	UNIV KENTUCKY,COLL MED,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536	University of Kentucky	Sun, LZ (corresponding author), UNIV KENTUCKY,MED CTR,DEPT PHARMACOL,MS 311,800 ROSE ST,LEXINGTON,KY 40536, USA.		, LuZhe/AAW-4095-2021		NATIONAL CANCER INSTITUTE [R29CA063480, R01CA075253] Funding Source: NIH RePORTER; NCI NIH HHS [CA75253, CA63480] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES JL, 1991, J BIOL CHEM, V266, P23282; ANDRES JL, 1992, J BIOL CHEM, V267, P5927; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ARRICK BA, 1990, CANCER RES, V50, P299; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; ARTEAGA CL, 1988, CANCER RES, V48, P3898; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; BARRETTLEE P, 1990, BRIT J CANCER, V61, P612, DOI 10.1038/bjc.1990.136; Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHANG HL, 1993, CANCER RES, V53, P4391; CHEIFETZ S, 1988, J BIOL CHEM, V263, P10783; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOMBES RC, 1990, J STEROID BIOCHEM, V37, P833, DOI 10.1016/0960-0760(90)90428-N; DALY RJ, 1990, J CELL BIOCHEM, V43, P199, DOI 10.1002/jcb.240430302; Fakhrai H, 1996, P NATL ACAD SCI USA, V93, P2909, DOI 10.1073/pnas.93.7.2909; FLAUMENHAFT R, 1992, J CELL BIOL, V118, P901, DOI 10.1083/jcb.118.4.901; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GORSCH SM, 1992, CANCER RES, V52, P6949; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kim IY, 1996, CLIN CANCER RES, V2, P1255; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MILLER DM, 1992, MOL ENDOCRINOL, V6, P694, DOI 10.1210/me.6.5.694; MIYAMOTO H, 1995, CANCER, V75, P2565, DOI 10.1002/1097-0142(19950515)75:10<2565::AID-CNCR2820751025>3.0.CO;2-M; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; MURPHY CS, 1991, COLD SPRING HARB SYM, V56, P129; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SOSROSENO W, 1995, BRIT J BIOMED SCI, V52, P142; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; STEINER MS, 1994, ENDOCRINOLOGY, V135, P2240, DOI 10.1210/en.135.5.2240; SUN LZ, 1994, J BIOL CHEM, V269, P26449; SUN LZ, 1994, EXP CELL RES, V214, P215, DOI 10.1006/excr.1994.1251; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tsushima H, 1996, GASTROENTEROLOGY, V110, P375, DOI 10.1053/gast.1996.v110.pm8566583; UEKI N, 1992, BIOCHIM BIOPHYS ACTA, V1137, P189; VanBelle P, 1996, AM J PATHOL, V148, P1887; WALKER RA, 1992, EUR J CANCER, V28A, P641, DOI 10.1016/S0959-8049(05)80116-9; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; XIE WQ, 1991, BIOTECHNIQUES, V11, P324; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	77	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25367	25372		10.1074/jbc.272.40.25367	http://dx.doi.org/10.1074/jbc.272.40.25367			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312157	hybrid			2022-12-25	WOS:A1997XY97000096
J	Xie, W; Jiang, HP; Wu, DQ				Xie, W; Jiang, HP; Wu, DQ			Two basic amino acids in the second inner loop of the interleukin-8 receptor are essential for G alpha 16 coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; FORMYL PEPTIDE RECEPTOR; G-PROTEIN ACTIVATION; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; SIGNAL-TRANSDUCTION; BINDING-SITES; SPECIFICITY; SEQUENCES; DOMAINS	The involvement of basic residues of interleukin (IL)-8 receptors in coupling to the Gi and G16 proteins was investigated by using a series of IL-8 receptor mutants, Substitution of the basic amino acids in the third inner loop of the receptor does not alter the abilities of the receptor mutants to activate recombinant G alpha 16 or phosphoinositide-specific phospholipase C (PLC) beta 2 expressed in COS-7 cells. However, an IL-8 receptor mutant with double mutations at residues Lys(158) and Arg(159) of the second inner loop loses its abilities to activate G alpha 16 but retains its ability to activate PLC beta 2. The activation of PLC beta 2 by an IL-8 receptor that is sensitive to pertussis toxin has been previously demonstrated to be mediated through G beta gamma. Surprisingly, the IL-8 receptor mutants with substitution of Ala for either residue Lys(158) or Arg(159) can still activate G alpha 16, which suggests that either of the two basic residues in the second inner loop of the IL-8 receptor is sufficient for G alpha 16 coupling.	UNIV ROCHESTER,DEPT PHARMACOL PHYSIOL & ONCOL,ROCHESTER,NY 14642	University of Rochester					NIGMS NIH HHS [GM 53162, GM 54597] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054597, R29GM053162] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOMMAKANTI RK, 1995, BIOCHEMISTRY-US, V34, P6720, DOI 10.1021/bi00020a017; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; Damaj BB, 1996, FASEB J, V10, P1426, DOI 10.1096/fasebj.10.12.8903513; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; WONG SKF, 1994, J BIOL CHEM, V269, P18968; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1995, J BIOL CHEM, V270, P16008, DOI 10.1074/jbc.270.27.16008; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1995, J BIOL CHEM, V270, P9828, DOI 10.1074/jbc.270.17.9828; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	24	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24948	24951		10.1074/jbc.272.40.24948	http://dx.doi.org/10.1074/jbc.272.40.24948			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312098	hybrid			2022-12-25	WOS:A1997XY97000037
J	Huang, MT; Lee, CF; Dobson, GP				Huang, MT; Lee, CF; Dobson, GP			Epinephrine enhances glycogen turnover and depresses glucose uptake in vivo in rat heart	FASEB JOURNAL			English	Article						skeletal muscle; liver; 2-deoxyglucose; [3-H-3]glucose	CONSCIOUS RATS; INSULIN; METABOLISM; INVIVO; LIVER; MYOCARDIUM; SYNTHASE; MUSCLE	In vivo effects of epinephrine on glucose uptake and glycogen turnover in rat heart were studied and compared to liver and skeletal muscle, Fasted ketamine-anesthetized rats were intravenously infused with saline or epinephrine. Both the low and high doses of epinephrine resulted in hyperglycemia (40-50%) and hyperlactemia (threefold) at the end of infusion, Glucose uptake, determined by the phosphorylation of the intravenously injected [C-14]2-deoxyglucose, was found to decrease in the heart and skeletal muscle of epinephrine-infused rats, Glycogen in livers, skeletal muscles, and hearts of the epinephrine-infused rats decreased to varying degrees relative to the saline-infused rats, indicating enhanced glycogenolysis in all three organs, Glycogen synthesis, determined by the incorporation of the co-infused [3-H-3]glucose into glycogen, was found to decrease in liver and skeletal muscle, However, glycogen synthesis in the heart was found to increase 50% in Epi-1 and 280% in Epi-2 compared to the saline-infused rats, We conclude that glucose utilization in the in vivo heart may be preferentially channeled through glycogen turnover in the presence of epinephrine, That both synthesis and degradation of glycogen can be simultaneously activated appears to be unique to the heart and is protective against a loss of glycogen art a time of enhanced glucose utilization.	JAMES COOK UNIV N QUEENSLAND,DEPT PHYSIOL & PHARMACOL,TOWNSVILLE,QLD 4811,AUSTRALIA	James Cook University	Huang, MT (corresponding author), CHANG GUNG COLL MED & TECHNOL,DEPT BIOCHEM,259 WEN HUA 1ST RD,TAYUAN,TAIWAN.							ARNALL DA, 1986, AM J PHYSIOL, V250, pE641, DOI 10.1152/ajpendo.1986.250.6.E641; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, VVol. 3., P1196; CLARKE K, 1996, CIRCULATION, V91, P2299; COLINSNAKAI RL, 1994, AM J PHYSIOL, V267, pH1862; CRAIG JW, 1964, NATURE, V202, P971, DOI 10.1038/202971a0; Cross HR, 1996, CIRC RES, V78, P482, DOI 10.1161/01.RES.78.3.482; DOBSON GP, 1990, J BIOL CHEM, V265, P16350; FURNSINN C, 1994, AM J PHYSIOL, V267, pE300, DOI 10.1152/ajpendo.1994.267.2.E300; Goodwin GW, 1996, J CLIN INVEST, V97, P1409, DOI 10.1172/JCI118561; GOODWIN GW, 1995, J BIOL CHEM, V270, P9234, DOI 10.1074/jbc.270.16.9234; GREKINIS D, 1995, INT J BIOCHEM CELL B, V27, P565, DOI 10.1016/1357-2725(95)00029-O; GUTMANN I, 1974, METHOD ENZYMAT AN, P1465; HARIHARAN R, 1995, CIRCULATION, V91, P2435, DOI 10.1161/01.CIR.91.9.2435; Henning SL, 1996, CIRCULATION, V93, P1549, DOI 10.1161/01.CIR.93.8.1549; HUANG MT, 1988, J CLIN INVEST, V81, P872, DOI 10.1172/JCI113397; HUANG MT, 1991, J APPL PHYSIOL, V71, P359, DOI 10.1152/jappl.1991.71.1.359; JAMES DE, 1986, J BIOL CHEM, V261, P6366; JAMES DE, 1985, J MOL CELL CARDIOL, V17, P981, DOI 10.1016/S0022-2828(85)80078-X; Jensen J, 1997, AM J PHYSIOL-ENDOC M, V272, pE649, DOI 10.1152/ajpendo.1997.272.4.E649; Lang G., 1974, METHODS ENZYMATIC AN, P1238; LAUGHLIN MR, 1991, DIABETES, V40, P385, DOI 10.2337/diabetes.40.3.385; LAUGHLIN MR, 1992, AM J PHYSIOL, V262, pE875, DOI 10.1152/ajpendo.1992.262.6.E875; LAUGHLIN MR, 1994, AM J PHYSIOL, V267, pH217, DOI 10.1152/ajpheart.1994.267.1.H217; MACDONALD TF, 1971, PFLUGERS ARCH, V322, P95; NEELY JR, 1970, AM J PHYSIOL, V219, P1083; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; RALL TW, 1956, BIOCHIM BIOPHYS ACTA, V20, P69, DOI 10.1016/0006-3002(56)90264-5; RAMACHANDRAN C, 1982, J BIOL CHEM, V257, P1448; RATTIGAN S, 1991, BIOCHIM BIOPHYS ACTA, V1094, P217, DOI 10.1016/0167-4889(91)90012-M; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; WEISS J, 1985, J CLIN INVEST, V75, P436, DOI 10.1172/JCI111718; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; WILLIAMS BJ, 1966, MOL PHARMACOL, V2, P454; WILLIAMSON JR, 1966, MOL PHARMACOL, V2, P206; WISNESKI JA, 1985, J CLIN INVEST, V76, P1819, DOI 10.1172/JCI112174	35	15	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1997	11	12					973	980		10.1096/fasebj.11.12.9337150	http://dx.doi.org/10.1096/fasebj.11.12.9337150			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337150				2022-12-25	WOS:A1997YA72400007
J	Wellmann, A; Doseeva, V; Butscher, W; Raffeld, M; Fukushima, P; StetlerStevenson, M; Gardner, K				Wellmann, A; Doseeva, V; Butscher, W; Raffeld, M; Fukushima, P; StetlerStevenson, M; Gardner, K			The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts	FASEB JOURNAL			English	Article						plasmid vector; gene expression; cytosolic membrane; antibody; PTK	NON-HODGKINS-LYMPHOMA; DNA-BINDING ACTIVITY; TRANSFORMING ACTIVITY; KI-1 LYMPHOMA; KAPPA-B; T-CELLS; PROTEIN; PHOSPHORYLATION; TRANSLOCATION; ONCOPROTEIN	More than 60% of anaplastic large-cell lymphomas (Ki-1 lymphoma) are associated with a t(2;5)(p23;q35) translocation that produces an 80 kDa hyperphosphorylated chimeric protein (p80) derived from the fusion of the anaplastic lymphoma kinase (ALK) with nucleophosmin (NPM). The NPM-ALK chimeric gene is an activated tyrosine kinase that has been shown to be a potent oncogene, We have developed a cellular model for the study of p80 action in rat 1a fibroblasts, Expression of cDNA's encoding NPM-ALK (p80) in rat 1a fibroblasts induces anchorage-independent growth in soft agar and promotes foci formation in culture, Cells expressing exogenous p80 showed significantly increased proliferation characterized by accelerated cell cycle entry into S-phase. Consistent with increased G(0)/G(1) to S-phase transition, there is also marked up-regulation of cyclin A and cyclin D1 expression, In addition, p80 transformed cells showed elevated expression of several immediate early genes involved in cellular proliferation, including fos, jun, and c-myc, DNA binding analysis of nuclear extracts prepared from p80 transformed cells reveal marked up-regulation of AP-1 DNA binding activity, Functional AP-1-specific transfection assays also show up-regulation of AP-1-dependent transcriptional activation, These finding demonstrate that p80 transformed rat 1a fibroblast can be a highly useful model system for the molecular and biochemical characterization of the mechanisms of action of this interesting new oncogene.	NIH, PATHOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA			Stetler-Stevenson, Maryalice/AAV-7393-2020					BARTKOVA J, 1995, ONCOGENE, V10, P775; BENNETT V, 1981, P NATL ACAD SCI-BIOL, V78, P7550, DOI 10.1073/pnas.78.12.7550; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DEKAN R, 1993, NETH J MED, V43, P277; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARINA AR, 1993, J BIOL CHEM, V268, P26466; FISCHER P, 1988, BLOOD, V72, P234; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GARDNER K, 1994, J BIOL CHEM, V269, P32963; HERBER, 1994, ONCOGENE, V9, P2105; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Hunter T, 1996, BIOCHEM SOC T, V24, P307, DOI 10.1042/bst0240307; HUNTER T, 1992, COLD SPRING HARB SYM, V57, P25, DOI 10.1101/SQB.1992.057.01.005; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Mathew P, 1997, BLOOD, V89, P1678, DOI 10.1182/blood.V89.5.1678.1678_1678_1685; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; QUINN JP, 1991, FEBS LETT, V286, P225, DOI 10.1016/0014-5793(91)80979-D; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SEYNAEVE CM, 1993, CANCER RES, V53, P2081; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIOTA M, 1994, BLOOD, V84, P3648, DOI 10.1182/blood.V84.11.3648.bloodjournal84113648; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	28	55	57	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1997	11	12					965	972		10.1096/fasebj.11.12.9337149	http://dx.doi.org/10.1096/fasebj.11.12.9337149			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337149				2022-12-25	WOS:A1997YA72400006
J	Hecht, K; CarlstedtDuke, J; Stierna, P; Gustafsson, JA; Bronnegard, M; Wikstrom, AC				Hecht, K; CarlstedtDuke, J; Stierna, P; Gustafsson, JA; Bronnegard, M; Wikstrom, AC			Evidence that the beta-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING DOMAIN; TRANSCRIPTION; EXPRESSION; ANTIBODIES; PROTEINS; RNA	Alternative splicing of the human glucocorticoid receptor (hGR) primary transcript generates two receptor isoforms, hGR alpha and hGR beta, with different carboxyl termini diverging at amino acid 727, By reverse transcriptase-polymerase chain reactions it was previously demonstrated that the hGR beta message had a widespread tissue distribution, To demonstrate the presence of hGR beta as protein we produced specific rabbit antisera to hGR beta, as well as a hGR beta-specific mouse monoclonal IgM antibody, by peptide immunizations, By SDS-polyacrylamide gel electrophoresis and Western immunoblotting we showed that hGR beta is endogenously expressed at the protein level in HeLa cells and human lymphatic leukemia cells. Using an antibody directed against an epitope shared by both isoforms we showed a relatively lower expression of the hGR beta form, We also showed that hGR beta bound to hsp90 by immunoprecipitation of in vitro translated hGR beta in reticulocyte lysate with hsp90-specific antibodies, a coprecipitation occurring also in the presence of dexamethasone. We could not demonstrate that hGR beta inhibited the effects of dexamethasone-activated hGR alpha on a glucocorticoid-responsive reporter gene. In conclusion, low hGR beta expression levels and hGR beta-hsp90 interaction maintained in the presence of ligand and lack of inhibition of hormone-activated hGR alpha effects challenge the concept of the hGR beta isoform as a proposed dominant negative inhibitor of hGR alpha activity.	HUDDINGE UNIV HOSP,KAROLINSKA INST,NOVUM,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN; HUDDINGE UNIV HOSP,KAROLINSKA INST,NOVUM,DEPT OTORHINOLARYNGOL,S-14186 HUDDINGE,SWEDEN; HUDDINGE UNIV HOSP,KAROLINSKA INST,NOVUM,DEPT PEDIAT,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet								ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; BRONNEGARD M, 1987, BIOCHEMISTRY-US, V26, P1697; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; deCastro M, 1996, MOL MED, V2, P597, DOI 10.1007/BF03401643; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; MCEWAN IJ, 1994, J BIOL CHEM, V269, P25629; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; URDA LA, 1989, MOL ENDOCRINOL, V3, P251, DOI 10.1210/mend-3-2-251; VEGATO E, 1993, MOL ENDOCRINOL, V7, P1244; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	21	122	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26659	26664		10.1074/jbc.272.42.26659	http://dx.doi.org/10.1074/jbc.272.42.26659			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334248	hybrid			2022-12-25	WOS:A1997YB13900082
J	Hinson, DD; Chambliss, KL; Hoffmann, GF; Krisans, S; Keller, RK; Gibson, KM				Hinson, DD; Chambliss, KL; Hoffmann, GF; Krisans, S; Keller, RK; Gibson, KM			Identification of an active site alanine in mevalonate kinase through characterization of a novel mutation in mevalonate kinase deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CHOLESTEROL-BIOSYNTHESIS; SYNTHASE GENE; RAT-LIVER; ACIDURIA; FIBROBLASTS; PROMOTER; PATHWAY	Sequencing of polymerase chain reaction-amplified cDNAs from cultured cells of three patients with mevalonate kinase deficiency revealed a G --> A transversion at nucleotide 1000 of the coding region, converting alanine to threonine at position 331 (A334T). To characterize this defect, we expressed wild-type and mutant cDNAs in Escherichia coli as the glutathione S-transferase fusion proteins, with purification by affinity chromatography. SDS-polyacrylamide gel electrophoresis analysis for wild-type and mutant fusion proteins indicated an expected molecular mass of 12-43 kDa. Kinetic characterization of the wild-type fusion protein yielded K-m values of 150 +/- 23 and 440 +/- 190 mu m (mean +/- S.E.) for substrates (RS)-mevalonate and ATP, respectively. Expressed wild-type mevalonate kinase (MKase) had a maximum velocity of 13.6 +/- 1.4 units/mg of protein (n = 22, +/- S.E.), whereas the A334T mutation yielded an enzyme with average V-max of 0.26 +/- 0.02 unit/mg of protein (n = 6, +/-S.E.), representing a decrease to 1.4% of control V-max. Restriction digestion with HhaI, in conjunction with direct sequencing of cDNAs, revealed that two patients were homozygous and one heterozygous for the A334T allele, establishing autosomal recessive inheritance within families. Although the A334T enzyme had a normal K-m for ATP of 680 +/- 226 mu m (n = 3, +/-S.E.), the Michaelis constant for (RS)-mevalonate was increased >30-fold to 4623 +/- 1167 mu M (n = 4, +/-S.E.) under standard assay conditions. Comparable kinetic results were obtained using extracts of lymphoblasts, which were homozygous for the A334T allele. Alanine 334 is invariant in MKase from bacteria to mall and located in a glycine-rich region postulated to have homology with ATP-binding sequences. Our results indicate that the bacterial expression system for human MKase will provide a useful model system in which to analyze inherited mutations and identify the first active site residue in MKase associated with stabilization of mevalonate binding.	UNIV MARBURG, DEPT METAB DIS & NEUROPEDIAT, D-35033 MARBURG, GERMANY; SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, INST MOL BIOL, SAN DIEGO, CA 92182 USA; UNIV S FLORIDA, COLL MED, DEPT BIOCHEM & MOL BIOL, TAMPA, FL 33612 USA; UNIV TEXAS, SW MED CTR, DEPT NEUROL, DALLAS, TX 75235 USA	Philipps University Marburg; California State University System; San Diego State University; California State University System; San Diego State University; State University System of Florida; University of South Florida; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hinson, DD (corresponding author), BAYLOR UNIV, MED CTR, INST METAB DIS, 3812 ELM ST, DALLAS, TX 75226 USA.		Keller, Ronald/A-1386-2012					BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Clayton P, 1996, LANCET, V348, P404, DOI 10.1016/S0140-6736(05)65020-9; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GIBSON KM, 1988, EUR J PEDIATR, V148, P250, DOI 10.1007/BF00441413; GIBSON KM, 1989, ENZYME, V41, P47, DOI 10.1159/000469050; GIBSON KM, 1990, J LIPID RES, V31, P515; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRAEF E, 1995, VIROLOGY, V208, P696, DOI 10.1006/viro.1995.1201; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HINSON DD, 1997, IN PRESS J LIPID RES; HOFFMANN GF, 1993, PEDIATRICS, V91, P915; HUBNER C, 1993, PEDIATR RES, V34, P129; JABALQUINTO AM, 1981, ARCH BIOCHEM BIOPHYS, V210, P132, DOI 10.1016/0003-9861(81)90173-9; Potter D, 1997, J BIOL CHEM, V272, P5741, DOI 10.1074/jbc.272.9.5741; Salen G, 1996, J LIPID RES, V37, P1169; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; SOLER M, 1979, INT J BIOCHEM, V10, P931, DOI 10.1016/0020-711X(79)90126-5; TANAKA RD, 1990, J BIOL CHEM, V265, P2391; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; Weinberger C, 1996, TRENDS ENDOCRIN MET, V7, P1, DOI 10.1016/1043-2760(95)00180-8	20	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26756	26760		10.1074/jbc.272.42.26756	http://dx.doi.org/10.1074/jbc.272.42.26756			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334262	hybrid			2022-12-25	WOS:A1997YB13900096
J	Ramirez, MI; Rishi, AK; Cao, YX; Williams, MC				Ramirez, MI; Rishi, AK; Cao, YX; Williams, MC			TGT3, thyroid transcription factor I, and Sp1 elements regulate transcriptional activity of the 1.3-kilobase pair promoter of T1 alpha, a lung alveolar type I cell gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-B; DNA-BINDING SPECIFICITY; SECRETORY PROTEIN; EPITHELIAL-CELLS; EXPRESSION PATTERNS; TRANSGENIC MICE; A PROMOTER; CC10 GENE; C GENE; TTF-1	Alveolar type I epithelial cells form the major surface for gas exchange in the lung. To explore how type I cells differ in gene expression from their progenitor alveolar type II cells, we analyzed transcriptional regulation of T1 alpha, a gene expressed by adult type I but not type II cells. In vivo developmental patterns of T1 alpha expression in lung and brain suggest active gene regulation. We cloned and sequenced 1.25 kilobase pairs of the T1 alpha promoter that can drive reporter expression in lung epithelial cell lines. Deletion analyses identified regions important for lung cell expression. The base pair (bp) -100 to -170 fragment conferred differential regulation in lung epithelial cells compared with fibroblasts. Sequence alignment of this fragment with type II-specific surfactant protein B and C promoters shows similar consensus elements arranged in a different order, Gel retardation studies with alveolar epithelial cell line nuclear extracts, thyroid transcription factor I (TTF-1) homeodomain, hepatic nuclear factor (HNF)-3 beta, or Sp1 proteins, and supershift assays were used to characterize TTF-1, HNF-3 (TGT3), and Sp1/Sp3 binding sites. The TGT3 site binds factors with binding properties similar to HNF-3/Fkh (hepatic nuclear factor-3/forkhead) proteins but different from HNF-3 alpha or HNF-3 beta. Co-transfection with a TTF-1 expression vector moderately transactivated the -170 bp-reporter construct. Mutational analysis of these three binding sites showed reduced transcriptional activity of the -170 bp promoter. Therefore, several regulatory sequences involved in type II cell gene regulation are also present in the T1 alpha promoter, suggesting that genes of the peripheral lung epithelium may be regulated by similar factors.	BOSTON UNIV,SCH MED,PULM CTR R3,DEPT ANAT,BOSTON,MA 02118	Boston University	Ramirez, MI (corresponding author), BOSTON UNIV,SCH MED,PULM CTR R3,DEPT MED,80 E CONCORD ST,BOSTON,MA 02118, USA.			Ramirez, Maria Isabel/0000-0001-6294-4419	NHLBI NIH HHS [P01 HL047049, HL47049] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047049] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benvenuto G, 1996, MOL CELL BIOL, V16, P2736; BINGLE CD, 1993, BIOCHEM J, V295, P227, DOI 10.1042/bj2950227; BOAM DSW, 1995, J BIOL CHEM, V270, P19487, DOI 10.1074/jbc.270.33.19487; BOGGARAM V, 1989, J BIOL CHEM, V264, P11421; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BOROK Z, 1995, AM J RESP CELL MOL, V12, P50, DOI 10.1165/ajrcmb.12.1.7811470; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CLEMENT A, 1991, EXP CELL RES, V196, P198, DOI 10.1016/0014-4827(91)90251-O; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COSTA RH, 1994, LIVER GENE EXPRESSIO, V10, P183; CRAPO JD, 1982, AM REV RESPIR DIS, V125, P332; DOBBS LG, 1988, BIOCHIM BIOPHYS ACTA, V970, P146, DOI 10.1016/0167-4889(88)90173-5; ENERBACK S, 1992, MOL CELL BIOL, V12, P4622, DOI 10.1128/MCB.12.10.4622; EVANS MJ, 1975, EXP MOL PATHOL, V22, P142, DOI 10.1016/0014-4800(75)90059-3; Fabbro D, 1996, NUCLEIC ACIDS RES, V24, P3283, DOI 10.1093/nar/24.17.3283; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HACKETT BP, 1994, AM J RESP CELL MOL, V11, P123, DOI 10.1165/ajrcmb.11.2.8049073; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; Kamakaka RT, 1997, TRENDS BIOCHEM SCI, V22, P124, DOI 10.1016/S0968-0004(96)10074-8; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; KANG BH, 1993, AM J RESP CELL MOL, V9, P350, DOI 10.1165/ajrcmb/9.4.350; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; KELLY SE, 1995, AM J RESP CRIT CARE, V151, P163; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kovarik A, 1996, J BIOL CHEM, V271, P18140, DOI 10.1074/jbc.271.30.18140; LACAZEMASMONTEIL T, 1992, EUR J BIOCHEM, V206, P613, DOI 10.1111/j.1432-1033.1992.tb16966.x; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LI F, 1995, AM J PHYSIOL-LUNG C, V269, pL241, DOI 10.1152/ajplung.1995.269.2.L241; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; LUZI P, 1995, BIOCHEM BIOPH RES CO, V208, P153, DOI 10.1006/bbrc.1995.1317; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; Michael LF, 1996, MOL ENDOCRINOL, V10, P159, DOI 10.1210/me.10.2.159; Minoo P, 1995, DEV BIOL, V172, P694, DOI 10.1006/dbio.1995.8080; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; NAGAE A, 1993, AM J RESP CELL MOL, V9, P221, DOI 10.1165/ajrcmb/9.2.221; NOSE K, 1990, CELL GROWTH DIFFER, V1, P511; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RISHI AK, 1995, DEV BIOL, V167, P294, DOI 10.1006/dbio.1995.1024; Rust K, 1996, AM J RESP CELL MOL, V14, P121, DOI 10.1165/ajrcmb.14.2.8630261; SAIARDI A, 1995, BIOCHEM J, V310, P491, DOI 10.1042/bj3100491; Sambrook J., 2002, MOL CLONING LAB MANU; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; SAWAYA PL, 1994, J BIOL CHEM, V269, P22211; Stahlman MT, 1996, J HISTOCHEM CYTOCHEM, V44, P673, DOI 10.1177/44.7.8675988; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; VENKATESH VC, 1995, AM J PHYSIOL-LUNG C, V268, pL674, DOI 10.1152/ajplung.1995.268.4.L674; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Wetterwald A, 1996, BONE, V18, P125, DOI 10.1016/8756-3282(95)00457-2; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Williams MC, 1996, AM J RESP CELL MOL, V14, P577, DOI 10.1165/ajrcmb.14.6.8652186; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Young PP, 1996, AM J PHYSIOL-LUNG C, V271, pL287, DOI 10.1152/ajplung.1996.271.2.L287; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	70	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26285	26294		10.1074/jbc.272.42.26285	http://dx.doi.org/10.1074/jbc.272.42.26285			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334198	hybrid			2022-12-25	WOS:A1997YB13900032
J	Regan, LM; Mollica, JS; Rezaie, AR; Esmon, CT				Regan, LM; Mollica, JS; Rezaie, AR; Esmon, CT			The interaction between the endothelial cell protein C receptor and protein C is dictated by the gamma-carboxyglutamic acid domain of protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-THROMBOMODULIN COMPLEX; GROWTH-FACTOR DOMAIN; FACTOR-X ACTIVATION; HUMAN FACTOR-IX; BINDING PROPERTIES; PROTEOLYTIC FORMATION; ESCHERICHIA-COLI; HOMOLOGY DOMAIN; FACTOR-VIIIA; FACTOR-VA	The endothelial cell protein C receptor (EPCR) binds to both protein C and activated protein C (APC) with similar affinity. Removal of the Gla domain of protein C results in the loss of most of the binding affinity. This observation is compatible with at least two models: 1) the Gla domain of protein C interacts with phospholipid on cell surfaces to stabilize interaction with EPCR or 2) the Gla domain of protein C makes specific protein protein interactions with EPCR. The latter model predicts that chimeric proteins containing the protein C Gla domain should interact with EPCR, To test this, we constructed a prothrombin chimera in which the Gla domain and aromatic stack of prothrombin were replaced with the corresponding region of protein C. The I-125-labeled chimera (K-d = 176 nM) and I-125-APC (K-d = 65 nM) both bound specifically to 293 cells stably transfected with EPCR, but both bound poorly to sham-transfected cells. The chimera also blocked APC binding to EPCR-transfected cells in a dose-dependent fashion (K-i approximate to 139 nM) similarly to protein C (K-i approximate to 75 nM). Chimera binding to EPCR-transfected cells was blocked by soluble EPCR, demonstrating direct protein-protein interaction between the chimera and EPCR, Consistent with this conclusion, the isolated Gla domain of protein C blocked APC binding to EPCR-transfected cells (IC50 = 2 mu M). No inhibition was observed with the isolated prothrombin Gla domain, A protein C chimera with the prothrombin Gla domain and aromatic stack failed to bind to EPCR detectably. These data suggest that the Gla domain of protein C is responsible for much of the binding energy and specificity of the protein C-EPCR interaction.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOL MOL,OKLAHOMA CITY,OK 73104; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	Regan, LM (corresponding author), OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1992, J BIOL CHEM, V267, P8571; APPELLA E, 1987, J BIOL CHEM, V262, P4437; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; BANGALORE N, 1994, THROMB HAEMOSTASIS, V72, P465; BEVERS EM, 1991, BLOOD REV, V5, P146, DOI 10.1016/0268-960X(91)90031-7; Bevington P. R., 1969, DATA REDUCTION ERROR; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; CASTELLINO FJ, 1995, TRENDS CARDIOVAS MED, V5, P55, DOI 10.1016/1050-1738(94)00031-X; Cheung WF, 1996, P NATL ACAD SCI USA, V93, P11068, DOI 10.1073/pnas.93.20.11068; CHEUNG WF, 1992, J BIOL CHEM, V267, P20529; CHRISTIANSEN WT, 1994, BIOCHEMISTRY-US, V33, P5901, DOI 10.1021/bi00185a030; COLPITTS TL, 1994, BIOCHEMISTRY-US, V33, P3501, DOI 10.1021/bi00178a006; COMP PC, 1982, J CLIN INVEST, V70, P127, DOI 10.1172/JCI110584; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; ESMON CT, 1995, TRENDS CARDIOVAS MED, V5, P141, DOI 10.1016/1050-1738(95)00054-D; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P5548; Fukudome K, 1996, J BIOL CHEM, V271, P17491, DOI 10.1074/jbc.271.29.17491; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; FURMANIAKKAZMIERCZAK E, 1993, BLOOD, V81, P405; GENG JP, 1995, BIOCHEMISTRY-US, V34, P8449, DOI 10.1021/bi00026a028; GILES AR, 1982, BLOOD, V9, P401; GREY ST, 1994, J IMMUNOL, V153, P3664; HANSON SR, 1993, J CLIN INVEST, V92, P2003, DOI 10.1172/JCI116795; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P651; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MILETICH JP, 1977, P NATL ACAD SCI USA, V74, P4035; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; OWEN WG, 1974, J BIOL CHEM, V249, P594; REGAN LM, 1994, J BIOL CHEM, V269, P9445; Regan LM, 1996, J BIOL CHEM, V271, P17499, DOI 10.1074/jbc.271.29.17499; REZAIE AR, 1993, J BIOL CHEM, V268, P19943; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; RIVARD GE, 1995, J PEDIATR-US, V126, P646, DOI 10.1016/S0022-3476(95)70369-1; SHEN L, 1994, J BIOL CHEM, V269, P18735; SMALLEY DM, 1988, ANAL BIOCHEM, V172, P241, DOI 10.1016/0003-2697(88)90438-1; SMIRNOV M, 1996, CIRCULATION, V94, P694; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; SUGO T, 1984, J BIOL CHEM, V259, P5705; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	51	68	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26279	26284		10.1074/jbc.272.42.26279	http://dx.doi.org/10.1074/jbc.272.42.26279			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334197	hybrid			2022-12-25	WOS:A1997YB13900031
J	Jackson, DD; Stevens, TH				Jackson, DD; Stevens, TH			VMA12 encodes a yeast endoplasmic reticulum protein required for vacuolar H+-ATPase assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; CYCLOPHILIN HOMOLOG NINAA; AMINO-ACID PERMEASES; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEIN; GENE ENCODES; SECRETORY PATHWAY; TRANSPORT VESICLES; SHUTTLE VECTORS; SUBUNIT VPH1P	The Saccharomyces cerevisiae vacuolar membrane proton-translocating ATPase (V-ATPase) can be divided into a peripheral membrane complex (V-1) containing at least eight polypeptides of 69, 60, 54, 42, 32, 27, 14, and 13 kDa, and an integral membrane complex (V-0) containing at least five polypeptides of 100, 36, 23, 17, and 16 kDa. Other yeast genes have been identified that are required for V-ATPase assembly but whose protein products do not co-purify with the enzyme complex. One such gene, VMA12, encodes a 25-kDa protein (Vma12p) that is predicted to contain two membrane-spanning domains. Biochemical analysis has revealed that Vma12p behaves as an integral membrane protein with both the N and C termini oriented toward the cytosol, and this protein immunolocalizes to the endoplasmic reticulum (ER). In cells lacking Vma12p (vma12 Delta), the 100-kDa subunit of the V-0 complex (which contains six to eight putative membrane-spanning domains) was rapidly degraded (t(1/2) similar to 30 min). Protease protection assays revealed that the 100-kDa subunit was inserted/translocated correctly into the ER membrane of vma12 Delta cells. These data indicate that Vma12p functions in the ER after the insertion of V-0 subunits into the ER membrane. We propose that Vma12p functions directly in the assembly of the V-0 subunits into a complex in the ER, and that assembly is required for the stability of the V-0 subunits and their transport as a complex out of this compartment.	UNIV OREGON, INST MOL BIOL, EUGENE, OR 97403 USA	University of Oregon				Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HILL KJ, 1995, J BIOL CHEM, V270, P22329, DOI 10.1074/jbc.270.38.22329; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1991, J BIOL CHEM, V266, P13971; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PIPER RC, 1994, EUR J CELL BIOL, V65, P305; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOLF DH, 1975, J BACTERIOL, V123, P1150, DOI 10.1128/JB.123.3.1150-1156.1975; Xie XS, 1996, J BIOL CHEM, V271, P30980; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	55	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25928	25934		10.1074/jbc.272.41.25928	http://dx.doi.org/10.1074/jbc.272.41.25928			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325326	hybrid			2022-12-25	WOS:A1997YA35800081
J	Nguyen, T; Sudhof, TC				Nguyen, T; Sudhof, TC			Binding properties of neuroligin 1 and neurexin 1 beta reveal function as heterophilic cell adhesion molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-NERVE BARRIER; DROSOPHILA-MELANOGASTER; PROTEIN; DOMAIN; MEMBRANE; LAMININ; HOMOLOGY; CADHERIN; ALPHA	beta-Neurexins and neuroligins are plasma membrane proteins that are displayed on the neuronal cell surface. We have now investigated the interaction of neurexin 1 beta with neuroligin 1 to evaluate their potential to function as heterophilic cell adhesion molecules. Using detergent-solubilized neuroligins and secreted neurexin 1 beta-IgG fusion protein, we observed binding of these proteins to each other only in the presence of Ca2+ and in no other divalent cation tested. Only neurexin 1 beta lacking an insert in splice site 4 bound neuroligins, whereas neurexin 1 beta containing an insert was inactive. Half-maximal binding required 1-3 mu M free Ca2+, which probably acts by binding to neuroligin 1 but not to neurexin 1 beta. To determine if neurexin 1 beta and neuroligin 1 can also interact with each other when present in a native membrane environment on the cell surface, we generated transfected cell lines expressing neuroligin 1 and neurexin 1 beta. Upon mixing different cell populations, we found that cells aggregate only if cells expressing neurexin 1 beta are mixed with cells expressing neuroligin 1. Aggregation was dependent on Ca2+ and was inhibited by the addition of soluble neurexin 1 beta lacking an insert in splice site 4 but not by the addition of neurexin 1 beta containing an insert in splice site 4. We conclude that neurexin 1 beta and neuroligin 1 (and, by extension, other beta-neurexins and neuroligins) function as heterophilic cell adhesion molecules in a Ca2+-dependent reaction that is regulated by alternative splicing of beta-neurexins.	UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH52804] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AULD VJ, 1995, CELL, V81, P757, DOI 10.1016/0092-8674(95)90537-5; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; DARBOUX I, 1996, EMBO J, V15, P4853; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GEPPERT M, 1992, COLD SPRING HARB SYM, V57, P483, DOI 10.1101/SQB.1992.057.01.053; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hata Y, 1996, J NEUROSCI, V16, P2488; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MURPHYERDOSH C, 1995, J CELL BIOL, V129, P1379, DOI 10.1083/jcb.129.5.1379; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Petrenko AG, 1996, J NEUROSCI, V16, P4360; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; USHKARYOV YA, 1994, J BIOL CHEM, V269, P1197; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314	28	173	179	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26032	26039		10.1074/jbc.272.41.26032	http://dx.doi.org/10.1074/jbc.272.41.26032			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325340	hybrid			2022-12-25	WOS:A1997YA35800095
J	Srikrishna, G; Varki, NM; Newell, PC; Varki, A; Freeze, HH				Srikrishna, G; Varki, NM; Newell, PC; Varki, A; Freeze, HH			An IgG monoclonal antibody against Dictyostelium discoideum glycoproteins specifically recognizes Fuc alpha 1,6GlcNAc beta in the core of N-linked glycans - Localized expression of core-fucosylated glycoconjugates in human tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOPROTEINS; HIGH-MANNOSE-TYPE; ALPHA-FETOPROTEIN; HEPATOCELLULAR-CARCINOMA; DEVELOPMENTAL REGULATION; HUMAN LACTOTRANSFERRIN; CARBOHYDRATE EPITOPE; H-1-NMR SPECTROSCOPY; HUMAN-SKIN; LECTINS	Core fucosylation of N-linked oligosaccharides (GlcNAc beta 1,4(Fuc alpha 1,6)GlcNAc beta 1-Asn) is a common modification in animal glycans, but little is known about the distribution of core-fucosylated glycoproteins in mammalian tissues, Two monoclonal antibodies, CAB2 and CAB4, previously raised against carbohydrate epitopes of Dictyostelium discoideum glycoproteins (Crandall, I, E, and Newell, P, C, (1989) Development 107, 87-94), specifically recognize fucose residues in alpha 1,6-linkage to the asparagine-bound GlcNAc of N-linked oligosaccharides. These IgG3 antibodies do not cross-react with glycoproteins containing alpha-fucoses in other linkages commonly seen in N- or O-linked sugar chains, CAB4 recognizes core alpha 1,6 fucose regardless of terminal sugars, branching pattern, sialic acid linkage, or polylactosamine substitution, This contrasts to lentil and pea lectins that recognize a similar epitope in only a subset of these structures, Additional GlcNAc residues found in the core of N-glycans from dominant Chinese hamster ovary cell mutants LEC14 and LEC18 progressively decrease binding, These antibodies show that many proteins in human tissues are core-fucosylated, but their expression is localized to skin keratinocytes, vascular and visceral smooth muscle cells, epithelia, and some extracellular matrix-like material surrounding subpopulations of lymphocytes. The availability of these antibodies now allows for an extended investigation of; core fucose epitope expression in development and malignancy and in genetically manipulated mice.	BURNHAM INST,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,CTR CANC,DEPT MED,GLYCOBIOL PROGRAM,LA JOLLA,CA 92093; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of Oxford				Freeze, Hudson/0000-0001-6316-0501	NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032485] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA 38701] Funding Source: Medline; NIGMS NIH HHS [R01-GM 32485] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAGI Y, 1993, CANCER-AM CANCER SOC, V72, P615, DOI 10.1002/1097-0142(19930715)72:2<615::AID-CNCR2820720246>3.0.CO;2-T; AOYAGI Y, 1985, BIOCHIM BIOPHYS ACTA, V830, P217, DOI 10.1016/0167-4838(85)90277-8; AOYAGI Y, 1988, CANCER-AM CANCER SOC, V61, P769, DOI 10.1002/1097-0142(19880215)61:4<769::AID-CNCR2820610422>3.0.CO;2-M; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BELL CM, 1984, BRIT J DERMATOL, V111, P517, DOI 10.1111/j.1365-2133.1984.tb06620.x; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BHAT NR, 1988, J NEUROCHEM, V50, P375, DOI 10.1111/j.1471-4159.1988.tb02922.x; BOURNE Y, 1992, J BIOL CHEM, V267, P197; BOURNE Y, 1994, STRUCTURE, V2, P209, DOI 10.1016/S0969-2126(00)00022-8; CAMPBELL C, 1984, J BIOL CHEM, V259, P3370; CAPALDI MJ, 1985, HISTOCHEM J, V17, P81, DOI 10.1007/BF01003405; CRANDALL IE, 1989, DEVELOPMENT, V107, P87; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; DAMJANOV I, 1987, LAB INVEST, V57, P5; DANGUY A, 1994, HISTOL HISTOPATHOL, V9, P155; DASILVA MLC, 1994, ARCH BIOCHEM BIOPHYS, V312, P151, DOI 10.1006/abbi.1994.1293; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; DINTER A, 1995, ADV EXP MED BIOL, V376, P53; Endo T, 1996, EUR J BIOCHEM, V236, P579, DOI 10.1111/j.1432-1033.1996.t01-1-00579.x; FAYE L, 1993, ANAL BIOCHEM, V209, P104, DOI 10.1006/abio.1993.1088; FREEZE HH, 1992, CELL SURFACE CARBOHY, P285; GEORGE ST, 1986, J BIOL CHEM, V261, P6559; GOODARZI MT, 1995, CLIN CHIM ACTA, V236, P161, DOI 10.1016/0009-8981(95)06049-J; GREEN ED, 1988, J BIOL CHEM, V263, P18253; HASLAM SM, 1994, GLYCOBIOLOGY, V4, P105, DOI 10.1093/glycob/4.2.105; ISHIHARA H, 1979, J BIOL CHEM, V254, P715; ISHII S, 1992, DEV NEUROSCI-BASEL, V14, P221, DOI 10.1159/000111666; IVATT RL, 1984, CELL, V38, P561, DOI 10.1016/0092-8674(84)90510-5; Kamath VP, 1996, GLYCOCONJUGATE J, V13, P315, DOI 10.1007/BF00731506; KATZ F, 1988, EMBO J, V7, P3471, DOI 10.1002/j.1460-2075.1988.tb03222.x; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; LEMIEUX RU, 1981, BIOCHEMISTRY-US, V20, P199, DOI 10.1021/bi00504a033; LIN AI, 1994, GLYCOBIOLOGY, V4, P895, DOI 10.1093/glycob/4.6.895; LONGMORE GD, 1982, CARBOHYD RES, V100, P365, DOI 10.1016/S0008-6215(00)81049-6; NAKAGAWA F, 1986, CELL TISSUE RES, V245, P579; NEMANIC MK, 1983, J HISTOCHEM CYTOCHEM, V31, P887, DOI 10.1177/31.7.6854004; PEREIRA MEA, 1978, ARCH BIOCHEM BIOPHYS, V185, P108, DOI 10.1016/0003-9861(78)90149-2; Raju TS, 1996, J BIOL CHEM, V271, P7484, DOI 10.1074/jbc.271.13.7484; Raju TS, 1995, J BIOL CHEM, V270, P30294, DOI 10.1074/jbc.270.51.30294; REGAN CM, 1991, INT J BIOCHEM, V23, P513; RICE KG, 1992, ANAL BIOCHEM, V206, P278, DOI 10.1016/0003-2697(92)90367-G; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; SAWUTZ DG, 1987, MOL PHARMACOL, V32, P565; SHARKEY DJ, 1991, J BIOL CHEM, V266, P18485; SHIRAKAWA O, 1983, BIOCHEM BIOPH RES CO, V115, P814, DOI 10.1016/S0006-291X(83)80007-2; SPICER SS, 1992, J HISTOCHEM CYTOCHEM, V40, P1, DOI 10.1177/40.1.1370305; SPIK G, 1982, EUR J BIOCHEM, V121, P413, DOI 10.1111/j.1432-1033.1982.tb05803.x; Stubbs HJ, 1996, BIOCHEMISTRY-US, V35, P937, DOI 10.1021/bi9513719; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; TAI T, 1975, J BIOL CHEM, V250, P8569; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; TRUONG LD, 1988, HISTOCHEMISTRY, V90, P51, DOI 10.1007/BF00495707; Uozumi N, 1996, J BIOL CHEM, V271, P27810, DOI 10.1074/jbc.271.44.27810; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Varki Ajit, 1995, Seminars in Developmental Biology, V6, P127, DOI 10.1016/S1044-5781(06)80022-8; VOYNOW JA, 1991, J BIOL CHEM, V266, P21572; WALKER RA, 1985, J PATHOL, V146, P123, DOI 10.1002/path.1711460207; WALKER RA, 1989, PATHOL RES PRACT, V185, P826, DOI 10.1016/S0344-0338(89)80282-1; WEST CM, 1986, MOL CELL BIOCHEM, V72, P121; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476; ZACHARIAH B, 1991, INDIAN J BIOCHEM BIO, V28, P412	65	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25743	25752		10.1074/jbc.272.41.25743	http://dx.doi.org/10.1074/jbc.272.41.25743			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325301	hybrid			2022-12-25	WOS:A1997YA35800056
J	Szabo, I; Bathori, G; Tombola, F; Brini, M; Coppola, A; Zoratti, M				Szabo, I; Bathori, G; Tombola, F; Brini, M; Coppola, A; Zoratti, M			DNA translocation across planar bilayers containing Bacillus subtilis ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-SENSITIVE CHANNEL; ESCHERICHIA-COLI-CELLS; NUCLEAR-PORE COMPLEX; OUTER-MEMBRANE; PATCH-CLAMP; MECHANOSENSITIVE CHANNELS; CONDUCTING CHANNELS; ACTIVATED CHANNELS; TRANSPORT PROTEIN; CATIONIC CHANNEL	The mechanisms by which genetic material crosses prokaryotic membranes are incompletely understood. We have developed a new methodology to study the translocation of genetic material via pores in a reconstituted system, using techniques from electrophysiology and molecular biology. We report here that planar bilayer membranes become permeable to double-stranded DNA (kilobase range) if Bacillus subtilis membrane vesicles containing high conductance channels have been fused into them. The translocation is an electrophoretic process, since it does not occur if a transmembrane electrical field opposing the movement of DNA, a polyanion, is applied. It is not an aspecific permeation through the phospholipid bilayer, since it does not take place if no proteins have been incorporated into the membrane. The transport is also not due simply to the presence of polypeptides in the membrane, since it does not occur if the latter contains gramicidin A or a eukaryotic, multiprotein vesicle fraction exhibiting 30-picosiemens anion-selective channel activity, The presence of DNA alters the behavior of the bacterial channels, indicating that it interacts with the pores and may travel through their lumen, These results support the idea that DNA translocation may lake place through proteic pores and suggest that some of the high conductance bacterial channels observed in electrophysiological experiments may be constituents of the DNA translocating machinery in these organisms.	UNIV PADUA,DEPT BIOMED SCI,UNIT STUDY BIOMEMBRANES,CNR,I-35121 PADUA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Padua			Tombola, Francesco/C-7311-2011; Brini, Marisa/K-5189-2016; Szabo, Ildiko/AAW-5972-2021; Tombola, Francesco/ABA-6002-2020; Padova, Ildiko/K-5344-2016	Szabo, Ildiko/0000-0002-3637-3947; Tombola, Francesco/0000-0002-9315-0352; Brini, Marisa/0000-0001-5141-0243	Telethon [A.059] Funding Source: Medline	Telethon(Fondazione Telethon)		ALCAYAGA C, 1992, FEBS LETT, V311, P246, DOI 10.1016/0014-5793(92)81112-Y; Alvarez O., 1986, ION CHANNEL RECONSTI, P115; BENZ R, 1993, ZBL BAKT-INT J MED M, V278, P187, DOI 10.1016/S0934-8840(11)80836-4; BERRIER C, 1993, J MEMBRANE BIOL, V133, P119; Berrier C, 1996, J MEMBRANE BIOL, V151, P175, DOI 10.1007/s002329900068; BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; BEZRUKOV SM, 1994, NATURE, V370, P279, DOI 10.1038/370279a0; Bonhivers M, 1996, EMBO J, V15, P1850, DOI 10.1002/j.1460-2075.1996.tb00535.x; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOULANGER P, 1992, J BIOL CHEM, V267, P3168; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BUECHNER M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P111, DOI 10.1016/0005-2736(90)90214-9; BUSATH DD, 1993, ANNU REV PHYSIOL, V55, P473; BUSTAMANTE JO, 1995, J MEMBRANE BIOL, V146, P253; BUSTAMANTE JO, 1995, J MEMBRANE BIOL, V146, P239; CITOVSKY V, 1993, ANNU REV MICROBIOL, V47, P167, DOI 10.1146/annurev.mi.47.100193.001123; CUI C, 1995, J MEMBRANE BIOL, V144, P31; DREISEIKELMANN B, 1994, MICROBIOL REV, V58, P293, DOI 10.1128/MMBR.58.3.293-316.1994; DUBNAU D, 1991, MICROBIOL REV, V55, P395, DOI 10.1128/MMBR.55.3.395-424.1991; Evans CH, 1990, BIOCH LANTHANIDES, P85; FEUCHT A, 1990, J BIOL CHEM, V265, P18561; GLASERWUTTKE G, 1989, BIOCHIM BIOPHYS ACTA, V985, P239, DOI 10.1016/0005-2736(89)90408-2; GUIHARD G, 1992, J BIOL CHEM, V267, P3173; HIGGINS NP, 1992, TRENDS BIOCHEM SCI, V17, P207, DOI 10.1016/0968-0004(92)90376-K; JUIN P, 1995, BIOCHEM BIOPH RES CO, V211, P92, DOI 10.1006/bbrc.1995.1782; Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770; KILLIAN JA, 1992, BIOCHIM BIOPHYS ACTA, V1113, P391; KILLMANN H, 1993, EMBO J, V12, P3007, DOI 10.1002/j.1460-2075.1993.tb05969.x; KORCHEV YE, 1995, J MEMBRANE BIOL, V147, P233; KUBALSKI A, 1993, J MEMBRANE BIOL, V131, P151, DOI 10.1007/BF02260105; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; LORENZ MG, 1994, MICROBIOL REV, V58, P563, DOI 10.1128/MMBR.58.3.563-602.1994; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MAYNARDSMITH J, 1991, NATURE, V349, P29; PAWLAK M, 1994, BIOCHEMISTRY-US, V33, P283, DOI 10.1021/bi00167a037; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; ROESSNER CA, 1986, J BIOL CHEM, V261, P386; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Sukharev Sergei I., 1996, Biophysical Journal, V70, pA366; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; SZABO I, 1992, BIOCHIM BIOPHYS ACTA, V1112, P29, DOI 10.1016/0005-2736(92)90250-P; SZABO I, 1993, J MEMBRANE BIOL, V131, P203, DOI 10.1007/BF02260109; SZABO I, 1990, BIOCHEM BIOPH RES CO, V171, P280, DOI 10.1016/0006-291X(90)91389-A; THIEFFRY M, 1992, BIOPHYS J, V63, P333, DOI 10.1016/S0006-3495(92)81626-0; VALLETTE FM, 1994, J BIOL CHEM, V269, P13367; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YARMOLINSKY MB, 1995, SCIENCE, V267, P836, DOI 10.1126/science.7846528; ZORATTI M, 1988, FEBS LETT, V240, P105, DOI 10.1016/0014-5793(88)80348-X; ZORATTI M, 1990, BIOCHEM BIOPH RES CO, V168, P443, DOI 10.1016/0006-291X(90)92341-V	59	60	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25275	25282		10.1074/jbc.272.40.25275	http://dx.doi.org/10.1074/jbc.272.40.25275			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312144	hybrid			2022-12-25	WOS:A1997XY97000083
J	Yanagawa, SI; Lee, JS; Haruna, T; Oda, H; Uemura, T; Takeichi, M; Ishimoto, A				Yanagawa, SI; Lee, JS; Haruna, T; Oda, H; Uemura, T; Takeichi, M; Ishimoto, A			Accumulation of armadillo induced by Wingless, Dishevelled, and dominant-negative Zeste-white 3 leads to elevated DE-cadherin in Drosophila clone 8 wing disc cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENT-POLARITY GENE; GLYCOGEN-SYNTHASE KINASE-3; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN; XENOPUS EMBRYOS; SIGNALING PATHWAY; INT-1 PROTOONCOGENE; CYTOPLASMIC DOMAIN; ADHERENS JUNCTION; LIMB DEVELOPMENT	Drosophila genetic studies suggest that in the Wingless (Wg) signaling pathway, the segment polarity gene products, Dishevelled (Dsh), Zeste-white 3 (ZW-3), and Armadillo (Arm), work sequentially; wg and dsh negatively regulate zw-3, which in turn down-regulates arm. To biochemically analyze interactions between the Wg pathway and Drosophila E-cadherin (DE-cadherin) which bind to Arm, we overexpressed Dsh, ZW-3, and Arm, in the Drosophila wing disc cell Line, clone 8, which responds to Wg signal. Dsh overexpression led to accumulation of Arm primarily in the cytosol and elevation of DE-cadherin at cell junctions. Overexpression of wildtype and dominant-negative forms of ZW-3 decreased and increased Arm levels, respectively, indicating that modulation in zw-3 activity negatively regulates Arm levels. Overexpression of an Arm mutant with an aminoterminal deletion elevated DE-cadherin levels, suggesting that Dsh-induced DE-cadherin elevation is caused by the Arm accumulation induced by Dsh. Moreover, the Dsh-, dominant-negative ZW-3-, and truncated Arm-induced accumulation of DE-cadherin protein was accompanied by a marked increase in the steady-state levels of DE-cadherin mRNA, suggesting that transcription of DE-cadherin is activated by Wg signaling. In addition, overexpression of DE-cadherin elevated Arm levels by stabilizing Arm at cell-cell junctions.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	Yanagawa, SI (corresponding author), KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 606,JAPAN.		Takeichi, Masatoshi/G-5903-2012; Oda, Hiroki/AAC-2559-2019	Takeichi, Masatoshi/0000-0002-9931-3378; UEMURA, Tadashi/0000-0001-7204-3606				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COUSO JP, 1994, DEVELOPMENT, V120, P621; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; CUMBERLEDGE S, 1993, NATURE, V363, P549, DOI 10.1038/363549a0; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KLYMKOWSKY MW, 1995, CELL, V83, P5, DOI 10.1016/0092-8674(95)90226-0; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PEEL DJ, 1992, ROUX ARCH DEV BIOL, V201, P120, DOI 10.1007/BF00420423; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; PIERCE SB, 1995, DEVELOPMENT, V121, P755; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; ROTHBACHER U, 1995, DEV BIOL, V170, P717, DOI 10.1006/dbio.1995.1249; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; RUEL L, 1993, EMBO J, V12, P1657, DOI 10.1002/j.1460-2075.1993.tb05811.x; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; THIESEN H, 1994, DEVELOPMENT, V120, P347; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; YANAGAWA SI, 1993, J VIROL, V67, P112, DOI 10.1128/JVI.67.1.112-118.1993; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	81	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25243	25251		10.1074/jbc.272.40.25243	http://dx.doi.org/10.1074/jbc.272.40.25243			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312140	hybrid			2022-12-25	WOS:A1997XY97000079
J	Kim, KS; Donelson, JE				Kim, KS; Donelson, JE			Co-duplication of a variant surface glycoprotein gene and its promoter to an expression site in African trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-I; VSG GENE; ANTIGENIC VARIATION; BRUCEI-RHODESIENSE; POINT MUTATIONS; METACYCLIC VSG; TRANSCRIPTION; PROVIDES; PARP	Activation of the metacyclic variant antigen type 7 (MVAT7) variant surface glycoprotein (VSG) gene in bloodstream Trypanosoma brucei rhodesiense involves a duplicative transposition of the gene. The DNA transposition unit extends from a site similar to 3.0 kilobases upstream of the VSG gene through the coding region and includes a 73-base pair sequence that possesses promoter activity in transient transfections. This MVAT7 promoter has 80% identity to a previously characterized promoter for the MVAT4 VSG gene. Nuclear run-on assays demonstrate that the MVAT7 promoter is active in MVAT7 bloodstream organisms and that its transcript is synthesized by an RNA polymerase resistant to alpha-amanitin, consistent with previously published reports regarding VSG gene transcription. The transcription start site was identified by primer extension studies and a modified rapid amplification of cDNA ends protocol. Selective mutational analysis of the MVAT7 promoter showed that two conserved trinucleotide regions are important for full promoter function. This study demonstrates that the MVAT7 VSG gene is co duplicated with its promoter and transcribed into a monocistronic precursor RNA.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; HOWARD HUGHES MED INST,IOWA CITY,IA 52242	University of Iowa; Howard Hughes Medical Institute			Donelson, John E/F-5795-2010					ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; Borst P, 1996, ARCH MED RES, V27, P379; BROWN SD, 1992, MOL CELL BIOL, V12, P2644, DOI 10.1128/MCB.12.6.2644; CAMPBELL GH, 1979, AM J TROP MED HYG, V28, P974, DOI 10.4269/ajtmh.1979.28.974; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; CROWE JS, 1983, NATURE, V306, P389, DOI 10.1038/306389a0; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; ESSER KM, 1982, J IMMUNOL, V129, P1715; GOTTESDIENER K, 1991, MOL CELL BIOL, V11, P2467, DOI 10.1128/MCB.11.5.2467; GRAHAM SV, 1995, MOL CELL BIOL, V15, P5945; Graham VS, 1996, MOL BIOCHEM PARASIT, V79, P35, DOI 10.1016/0166-6851(96)02642-4; Horn D, 1997, MOL BIOCHEM PARASIT, V84, P189, DOI 10.1016/S0166-6851(96)02794-6; HORN D, 1995, CELL, V83, P555, DOI 10.1016/0092-8674(95)90095-0; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; JANZ L, 1994, MOL CELL BIOL, V14, P5804, DOI 10.1128/MCB.14.9.5804; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LENARDO MJ, 1986, MOL CELL BIOL, V6, P1991, DOI 10.1128/MCB.6.6.1991; LENARDO MJ, 1984, P NATL ACAD SCI-BIOL, V81, P6642, DOI 10.1073/pnas.81.21.6642; LU Y, 1994, MOL CELL BIOL, V14, P3971, DOI 10.1128/MCB.14.6.3971; LU Y, 1993, CELL, V72, P397, DOI 10.1016/0092-8674(93)90116-8; LUMSDEN WHR, 1982, SYST PARASITOL, V4, P373, DOI 10.1007/BF00009977; Maniatis T., 1982, MOL CLONING; McCulloch R, 1997, MOL CELL BIOL, V17, P833, DOI 10.1128/MCB.17.2.833; NAGOSHI YL, 1995, MOL BIOCHEM PARASIT, V72, P33, DOI 10.1016/0166-6851(95)00062-6; PAYS E, 1990, EMBO J, V9, P3145, DOI 10.1002/j.1460-2075.1990.tb07512.x; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; RUDENKO G, 1995, CELL, V83, P547, DOI 10.1016/0092-8674(95)90094-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEA C, 1987, CELL, V50, P603, DOI 10.1016/0092-8674(87)90033-X; TURNER CMR, 1988, PARASITOLOGY, V97, P269, DOI 10.1017/S0031182000058479; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	36	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24637	24645		10.1074/jbc.272.39.24637	http://dx.doi.org/10.1074/jbc.272.39.24637			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305933	hybrid			2022-12-25	WOS:A1997XY51500084
J	King, AJ; Teertstra, WR; vanderVliet, PC				King, AJ; Teertstra, WR; vanderVliet, PC			Dissociation of the protein primer and DNA polymerase after initiation of adenovirus DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; SLIDING-BACK MECHANISM; TERMINAL PROTEIN; BINDING PROTEIN; LINEAR TEMPLATE; PRECURSOR; DOMAIN; VITRO; NUCLEOTIDE; DISTINCT	Initiation of adenovirus DNA replication occurs by a jumping back mechanism in which the precursor terminal priming protein (pTP) forms a pTP trinucleotide complex (pTP CAT) catalyzed by the viral DNA polymerase (pol), This covalent complex subsequently jumps back 3 bases to permit the start of chain elongation, Before initiation, pTP and pol form a tight heterodimer, We investigated the fate of this pTP pol complex during the various steps in replication, Employing in vitro initiation and elongation on both natural viral templates and synthetic oligonucleotides followed by glycerol gradient separation of the reaction products, we established that pTP and pol are separated during elongation, Whereas pTP.C and pTP.CA were still bound to the polymerase, after the formation of pTP.CAT 60% of the pTP pol complex had dissociated, Dissociation coincides with a change in sensitivity to inhibitors and in K-m for dNTPs, suggesting a conformational change in the polymerase, both in the active site and in the pTP interaction domain, In agreement with this, the polymerase becomes a more efficient enzyme after release of the pTP primer, We also investigated whether the synthesis of a pTP initiation intermediate is confined to three nucleotides. Employing synthetic oligonucleotide templates with a sequence repeat of two nucleotides (GAGAGAGA ... instead of the natural GTAGTA ...) we show that G5 rather than G3 is used to start, leading to a pTP tetranucleotide (CTCT) intermediate that subsequently jumps back, This indicates flexibility in the use of the start site with a preference for the synthesis of three or four nucleotides during initiation rather than two.	UNIV UTRECHT, PHYSIOL CHEM LAB, NL-3508 TA UTRECHT, NETHERLANDS	Utrecht University								ARMENTERO MT, 1994, P NATL ACAD SCI USA, V91, P11537, DOI 10.1073/pnas.91.24.11537; CALDENTEY J, 1993, NUCLEIC ACIDS RES, V21, P3725, DOI 10.1093/nar/21.16.3725; COENJAERTS FEJ, 1994, EMBO J, V13, P5401, DOI 10.1002/j.1460-2075.1994.tb06875.x; COENJAERTS FEJ, 1994, NUCLEIC ACIDS RES, V22, P5235, DOI 10.1093/nar/22.24.5235; Coenjaerts FEJ, 1995, METHOD ENZYMOL, V262, P548; Dekker J, 1996, MOL CELL BIOL, V16, P4073; ENOMOTO T, 1981, P NATL ACAD SCI-BIOL, V78, P6779, DOI 10.1073/pnas.78.11.6779; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; FREDMAN JN, 1993, J VIROL, V67, P3384, DOI 10.1128/JVI.67.6.3384-3395.1993; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GRIEP MA, 1990, J BIOL CHEM, V265, P20356; HAY RT, 1996, DNA REPLICATION EUKA, P699; King AJ, 1997, NUCLEIC ACIDS RES, V25, P1745, DOI 10.1093/nar/25.9.1745; KING AJ, 1994, EMBO J, V13, P5786, DOI 10.1002/j.1460-2075.1994.tb06917.x; KWANT MM, 1980, NUCLEIC ACIDS RES, V8, P3993, DOI 10.1093/nar/8.17.3993; LICHY JH, 1982, P NATL ACAD SCI-BIOL, V79, P5225, DOI 10.1073/pnas.79.17.5225; LICHY JH, 1981, P NATL ACAD SCI-BIOL, V78, P2678, DOI 10.1073/pnas.78.5.2678; LINDENBAUM JO, 1986, J BIOL CHEM, V261, P218; Martin AC, 1996, J MOL BIOL, V260, P369, DOI 10.1006/jmbi.1996.0407; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MUL YM, 1989, NUCLEIC ACIDS RES, V17, P8917, DOI 10.1093/nar/17.22.8917; MUL YM, 1993, NUCLEIC ACIDS RES, V21, P641, DOI 10.1093/nar/21.3.641; RIJNDERS AWM, 1983, VIROLOGY, V131, P287, DOI 10.1016/0042-6822(83)90497-X; SALAS M, 1996, DNA REPLICATION EUKA, P131; SHINAGAWA M, 1987, GENE, V55, P85; SUSSENBACH JS, 1983, CURR TOP MICROBIOL, V109, P53; Van der Vliet P C, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P1; vanLeeuwen HC, 1997, J BIOL CHEM, V272, P3398, DOI 10.1074/jbc.272.6.3398; WATSON CJ, 1990, NUCLEIC ACIDS RES, V18, P1167, DOI 10.1093/nar/18.5.1167; WEBSTER A, 1994, J VIROL, V68, P7292, DOI 10.1128/JVI.68.11.7292-7300.1994; Webster A, 1997, J VIROL, V71, P539, DOI 10.1128/JVI.71.1.539-547.1997	32	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24617	24623		10.1074/jbc.272.39.24617	http://dx.doi.org/10.1074/jbc.272.39.24617			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305930	hybrid			2022-12-25	WOS:A1997XY51500081
J	Chagovetz, AM; Sweasy, JB; Preston, BD				Chagovetz, AM; Sweasy, JB; Preston, BD			Increased activity and fidelity of DNA polymerase beta on single-nucleotide gapped DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; KINETIC-ANALYSIS; NUCLEAR EXTRACT; PROCESSIVITY; REQUIREMENT; MECHANISM; ALPHA	DNA polymerase beta (pol beta) is an error-prone polymerase that plays a central role in mammalian base excision repair. To better characterize the mechanisms governing rat pol beta activity, we examined polymerization on synthetic primer-templates of different structure. Steady-state kinetic analyses revealed that the catalytic efficiency of pol beta (k(cat)/K-m,dNTP(app)) is strongly influenced by gap size and the presence of a phosphate group at the 5'-margin of the gap. pol beta exhibited the highest catalytic efficiency on 5'-phosphorylated 1-nucleotide gapped DNA. This efficiency was greater than or equal to 500 times higher than on non-phosphorylated 1-nucleotide and 6-nucleotide (with or without PO4) gapped DNAs and 2,500 times higher than on primer-template with no gaps, The nucleotide insertion fidelity of pol beta, as judged by its ability to form G-N mispairs, was also higher (10-100 times) on 5'-phosphorylated single nucleotide gapped DNA compared with the other DNA substrates studied. These data suggest that a primary function of mammalian pol beta is to fill 5'-phosphorylated 1-nucleotide gaps.	UNIV UTAH,ECCLES INST HUMAN GENET,PROGRAM HUMAN MOL BIOL & GENET,DEPT BIOCHEM,SALT LAKE CITY,UT 84112; UNIV UTAH,ECCLES INST HUMAN GENET,PROGRAM HUMAN MOL BIOL & GENET,DEPT RADIAT ONCOL,SALT LAKE CITY,UT 84112; YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06520	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Yale University; Yale University								BAMBARA RA, 1978, J BIOL CHEM, V253, P413; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; CHANG LMS, 1975, J MOL BIOL, V93, P219, DOI 10.1016/0022-2836(75)90129-1; FRIEDBERG EC, 1996, DNA REPLICATION EUKA, P249; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; MATSUKAGE A, 1979, J BIOCHEM-TOKYO, V85, P1551, DOI 10.1093/oxfordjournals.jbchem.a132487; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; Nealon K, 1996, NUCLEIC ACIDS RES, V24, P3763, DOI 10.1093/nar/24.19.3763; Oda N, 1996, J BIOL CHEM, V271, P13816, DOI 10.1074/jbc.271.23.13816; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; PRASAD R, 1994, J BIOL CHEM, V269, P18096; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Roberts J.D., 1996, DNA REPLICATION EUKA, P217; SIEDLECKI JA, 1980, NUCLEIC ACIDS RES, V8, P361, DOI 10.1093/nar/8.2.361; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; WANG TSF, 1980, BIOCHEMISTRY-US, V19, P1782, DOI 10.1021/bi00550a009; Washington SL, 1997, P NATL ACAD SCI USA, V94, P1321, DOI 10.1073/pnas.94.4.1321; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202	26	93	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27501	27504		10.1074/jbc.272.44.27501	http://dx.doi.org/10.1074/jbc.272.44.27501			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346877	hybrid			2022-12-25	WOS:A1997YD47300003
J	Swanson, DJ; Zellmer, E; Lewis, EJ				Swanson, DJ; Zellmer, E; Lewis, EJ			The homeodomain protein Arix interacts synergistically with cyclic AMP to regulate expression of neurotransmitter biosynthetic genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE GENE; DOPAMINE-BETA-HYDROXYLASE; CAMP-RESPONSE-ELEMENT; REPEATED IMMOBILIZATION STRESS; PHEOCHROMOCYTOMA CELL-LINE; DNA-BINDING SPECIFICITY; NERVE GROWTH-FACTOR; MESSENGER-RNA; PC12 CELLS; COOPERATIVE INTERACTIONS	Transcription of the neurotransmitter biosynthetic genes tyrosine hydroxylase and dopamine beta-hydroxylase (DBH) is regulated by cell type-specific transcription factors, including the homeoprotein Arix, and second messengers, including cyclic AMP. The cis-acting regulatory sites of the DBH gene which respond to Arix and cAMP lie adjacent to each other, between bases -180 and -150, in a regulatory element named DBI. Neither Arix nor cyclic AMP analogs alone effectively stimulate transcription from the DBH promoter in nonneuronal cell cultures. However, when Arix is present together with cAMP, transcription is substantially activated, Synergistic transcription from the DBH promoter can also be elicited by cotransfection of Arix with an expression vector encoding the catalytic subunit of protein kinase A. Nuclear extracts from PC12 cells display a cAMP-induced complex binding to the DB1 element, and antisera to transcription factors CREB, CREM, Fos, and Jun indicate that these proteins, or closely related family members, interact with DB1. A dominant negative construct of CREB inhibits the response of the DBH promoter to protein kinase A. These results demonstrate a synergistic interaction between a homeodomain protein and the cAMP signal transduction system and suggest that similar interactions may regulate the tissue-specific expression of neuroendocrine genes.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOL BIOL, PORTLAND, OR 97201 USA	Oregon Health & Science University					NIGMS NIH HHS [GM38696] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038696, R29GM038696] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; Afar R, 1996, MOL BRAIN RES, V36, P79, DOI 10.1016/0169-328X(95)00247-P; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; Ausbel F.M., 1995, CURRENT PROTOCOLS MO; BEST JA, 1995, J NEUROCHEM, V65, P1934; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHU HM, 1994, MOL ENDOCRINOL, V8, P59, DOI 10.1210/me.8.1.59; COLLINSHICOK J, 1994, MOL CELL BIOL, V14, P2837, DOI 10.1128/MCB.14.5.2837; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU XY, 1995, J NEUROSCI, V15, P5420; ERNSBERGER U, 1995, MECH DEVELOP, V52, P125, DOI 10.1016/0925-4773(95)00396-I; FADER D, 1990, MOL BRAIN RES, V8, P25, DOI 10.1016/0169-328X(90)90005-X; FOSSOM LH, 1992, MOL PHARMACOL, V42, P898; FOSSOM LH, 1991, MOL PHARMACOL, V40, P193; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GROVES AK, 1995, DEVELOPMENT, V121, P887; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HIREMAGALUR B, 1993, J BIOL CHEM, V268, P23704; HWANG O, 1995, J NEUROCHEM, V65, P1988; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KIM KS, 1994, J NEUROSCI, V14, P7200; KIM KS, 1993, J BIOL CHEM, V268, P15689; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KONRADI C, 1993, P NATL ACAD SCI USA, V90, P7005, DOI 10.1073/pnas.90.15.7005; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LAMOUROUX A, 1993, J NEUROCHEM, V60, P364, DOI 10.1111/j.1471-4159.1993.tb05861.x; LAZAROFF M, 1995, J BIOL CHEM, V270, P21579, DOI 10.1074/jbc.270.37.21579; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIU JS, 1991, J BIOL CHEM, V266, P19095; MacArthur L, 1996, J NEUROCHEM, V67, P2256; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MCMAHON A, 1992, J NEUROCHEM, V58, P2124, DOI 10.1111/j.1471-4159.1992.tb10954.x; MCMAHON A, 1992, J NEUROCHEM, V59, P2040; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; NANKOVA B, 1993, J NEUROCHEM, V61, P776; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; RICHARD F, 1988, J NEUROSCI RES, V20, P32, DOI 10.1002/jnr.490200106; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; Seo HM, 1996, J NEUROSCI, V16, P4102; SHASKUS J, 1995, J NEUROCHEM, V64, P52; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; STACHOWIAK MK, 1987, BRAIN RES, V359, P256; TANK AW, 1986, MOL PHARMACOL, V30, P497; TANK AW, 1985, J NEUROCHEM, V45, P1030, DOI 10.1111/j.1471-4159.1985.tb05519.x; Tinti C, 1996, J BIOL CHEM, V271, P25375, DOI 10.1074/jbc.271.41.25375; Tiveron MC, 1996, J NEUROSCI, V16, P7649; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WESSELSREIKER M, 1993, J NEUROCHEM, V60, P1018, DOI 10.1111/j.1471-4159.1993.tb03250.x; Zellmer E, 1995, J NEUROSCI, V15, P8109; ZURN AD, 1993, MOL BRAIN RES, V20, P125, DOI 10.1016/0169-328X(93)90117-8	64	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27382	27392		10.1074/jbc.272.43.27382	http://dx.doi.org/10.1074/jbc.272.43.27382			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341190	hybrid			2022-12-25	WOS:A1997YC65900086
J	Zhang, LT; Strickland, DK; Cines, DB; Higazi, AAR				Zhang, LT; Strickland, DK; Cines, DB; Higazi, AAR			Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; SARCOMA-CELLS; TYPE-1; COMPLEX; PROUROKINASE; VITRONECTIN; PROENZYME; RESISTANT; ADHESION	The internalization and degradation of cell associated urokinase type plasminogen activator (uPA) through the alpha(2)-macroglobulin receptor/low density lipoprotein-related receptor (alpha(2)MR/LRP) represent important steps in the control of plasmin formation. Complexes between two chain urokinase (tcuPA) and plasminogen activator type 1 are degraded rapidly whereas single chain urokinase (scuPA) is not, suggesting that alpha(2)MR/LRP requires specific epitopes in the serpin for effective function. We report an alternative mechanism that may contribute to this process. The binding of scuPA to LM-TK- cells that lack the uPA receptor was stimulated by the hexapeptide EEIIMD, corresponding to amino acids 350-355 of plasminogen activator type 1, which contacts the sequence RHRGGS, corresponding to amino acids 179-184 in uPA. EEIIMD increased the B-max of scuPA binding 4-fold with the half-maximal effect achieved at a peptide concentration of 50 mu M. Stimulation was dependent on the charge on the COOH-terminal amino acid but not on the NH2 terminus of the peptide. EEIIMD also stimulated the internalization and degradation of scuPA. Both the binding and internalization of scuPA in the presence of EEIIMD were blocked by recombinant, 39-kDa alpha(2)MR/LRP-associated protein as well as by an anti-alpha(2)MR/LRP antibody. EEIIMD also stimulated the binding of scuPA to purified alpha(2)MR/LRP. EEIIMD had no effect on the binding of tcuPA or of complexes between scuPA and its receptor. These results suggest that EEIIMD regulates the binding of scuPA with alpha(2)MR/LRP. These findings also suggest a potential mechanism by which scuPA can be cleared which is independent of activation by plasmin or binding to uPA receptor.	UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT LAB MED,PHILADELPHIA,PA 19104; AMER RED CROSS,DEPT BIOCHEM,ROCKVILLE,MD 20855; HADASSAH HEBREW UNIV HOSP,DEPT CLIN BIOCHEM,IL-91120 JERUSALEM,ISRAEL	University of Pennsylvania; University of Pennsylvania; American Red Cross; Hebrew University of Jerusalem; Hadassah University Medical Center					NHLBI NIH HHS [HL50790, HL49517, HL40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050790, R01HL049517, P01HL040387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS DS, 1991, J BIOL CHEM, V266, P8476; ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; COLLEN D, 1986, J BIOL CHEM, V261, P1259; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; ELLIS V, 1987, J BIOL CHEM, V262, P14998; ELLIS V, 1990, J BIOL CHEM, V265, P9904; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; Higazi AAR, 1997, J BIOL CHEM, V272, P5348, DOI 10.1074/jbc.272.8.5348; Higazi AAR, 1996, THROMB RES, V84, P243, DOI 10.1016/S0049-3848(96)00184-3; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; Higazi AAR, 1996, BLOOD, V87, P3545, DOI 10.1182/blood.V87.9.3545.bloodjournal8793545; HUSAIN SS, 1991, BIOCHEM, V30, P5707; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KRUITHOF EKO, 1984, BLOOD, V64, P907; KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153; LI H, 1994, J BIOL CHEM, V269, P8153; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P567, DOI 10.1111/j.1432-1033.1994.00567.x; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MANCHANDA N, 1995, J BIOL CHEM, V270, P20032, DOI 10.1074/jbc.270.34.20032; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; Shapiro RL, 1997, AM J PATHOL, V150, P359; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035	35	18	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27053	27057		10.1074/jbc.272.43.27053	http://dx.doi.org/10.1074/jbc.272.43.27053			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341144				2022-12-25	WOS:A1997YC65900040
J	Geiszt, M; Kapus, A; Nemet, K; Farkas, L; Ligeti, E				Geiszt, M; Kapus, A; Nemet, K; Farkas, L; Ligeti, E			Regulation of capacitative Ca2+ influx in human neutrophil granulocytes - Alterations in chronic granulomatous disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CA-2+; PROTEIN-KINASE-C; MEMBRANE-POTENTIAL CHANGES; NADPH OXIDASE; CHEMOTACTIC PEPTIDE; PLASMA-MEMBRANE; CALCIUM-ENTRY; INTRACELLULAR CALCIUM; TRANSIENT INHIBITION; RESPIRATORY BURST	Ca2+ entry through the capacitative (store regulated) pathway was shown to be inhibited in neutrophil granulocytes by the protein kinase C activator phorbol 12-myristate 13-acetate and the chemoattractant N-formylmethionyl-leucyl-phenylalanine (fMLP) by a hitherto unknown mechanism, Measuring both Ca2+ and Mn2+ entry into store-depleted cells we show in the present study that inhibition of the capacitative pathway is absent in various forms of chronic granulomatous disease, To establish the possible relationship between inhibition of the capacitative pathway and ability of O-2(.-) production and consequent membrane depolarization, gradual changes of the membrane potential were evoked in neutrophils of healthy individuals. This was accomplished by pharmacological manipulation of the membrane potential and by variations of the concentration and type of the stimulant, Close relationship was observed between membrane depolarization and inhibition of Mn2+ entry through the capacitative transport route, Our results provide an explanation for the inhibitory action of fMLP and phorbol la-myristate 13-acetate on capacitative cation influx and reveal that upon physiological stimulation, Ca2+ entry into neutrophils is restricted by the depolarization accompanying O-2(.-) production.	SEMMELWEIS UNIV MED,DEPT PHYSIOL,H-1444 BUDAPEST 8,HUNGARY; SEMMELWEIS UNIV MED,LAB CELLULAR & MOL PHYSIOL,H-1444 BUDAPEST 8,HUNGARY; NATL INST HAEMATOL & BLOOD TRANSFUS,H-1113 BUDAPEST,HUNGARY	Semmelweis University; Semmelweis University								AHLIN A, 1995, J LAB CLIN MED, V125, P392; ALLEN RC, 1986, METHOD ENZYMOL, V133, P449; Alonso MT, 1996, J LEUKOCYTE BIOL, V60, P323, DOI 10.1002/jlb.60.3.323; DEMAUREX N, 1992, J CLIN INVEST, V90, P830, DOI 10.1172/JCI115958; DEMAUREX N, 1994, BIOCHEM J, V297, P595, DOI 10.1042/bj2970595; DEWALD B, 1986, BIOCHIM BIOPHYS ACTA, V888, P42, DOI 10.1016/0167-4889(86)90069-8; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P4574; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; Etter EF, 1996, P NATL ACAD SCI USA, V93, P5368, DOI 10.1073/pnas.93.11.5368; FODER B, 1989, CELL CALCIUM, V10, P477, DOI 10.1016/0143-4160(89)90025-0; FURUYA W, 1986, AM J PHYSIOL, V251, pC55; GARCIA RC, 1992, BIOCHEM J, V286, P687, DOI 10.1042/bj2860687; GEISZT M, 1995, BIOCHEM J, V305, P525, DOI 10.1042/bj3050525; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; HJORTH R, 1981, J IMMUNOL METHODS, V43, P95, DOI 10.1016/0022-1759(81)90040-5; JOHANSEN KS, 1983, ACTA PATH MICRO IM C, V91, P349; KAPUS A, 1994, J BIOL CHEM, V269, P4736; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; KOVACS T, 1990, FEBS LETT, V266, P171, DOI 10.1016/0014-5793(90)81532-S; LEVY R, 1990, J IMMUNOL, V145, P2595; LEW PD, 1984, BLOOD, V63, P231; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; LU DJ, 1992, AM J PHYSIOL, V262, pC39, DOI 10.1152/ajpcell.1992.262.1.C39; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; MCCARTHY SA, 1989, BIOCHEM J, V264, P357, DOI 10.1042/bj2640357; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MONTERO M, 1993, J BIOL CHEM, V268, P26911; MONTERO M, 1993, J BIOL CHEM, V268, P13055; MONTERO M, 1994, J BIOL CHEM, V269, P3963; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; NANDA A, 1991, Cellular Physiology and Biochemistry, V1, P65, DOI 10.1159/000154595; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Roos D, 1996, BLOOD, V87, P1663; SARKADI B, 1990, BIOCHIM BIOPHYS ACTA, V1027, P130, DOI 10.1016/0005-2736(90)90076-Z; SCHARFF O, 1993, PHYSIOL REV, V73, P547, DOI 10.1152/physrev.1993.73.3.547; Segal AW, 1996, MOL MED TODAY, V2, P129, DOI 10.1016/1357-4310(96)88723-5; SELIGMANN BE, 1980, J MEMBRANE BIOL, V52, P257, DOI 10.1007/BF01869194; SELIGMANN BE, 1980, J CLIN INVEST, V66, P493, DOI 10.1172/JCI109880; SENGELOV H, 1993, J IMMUNOL, V150, P1535; SMITH RM, 1991, BLOOD, V77, P673; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; WATSON F, 1991, J BIOL CHEM, V266, P7432; WHITIN JC, 1980, J BIOL CHEM, V255, P1874	49	97	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26471	26478		10.1074/jbc.272.42.26471	http://dx.doi.org/10.1074/jbc.272.42.26471			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334224	hybrid			2022-12-25	WOS:A1997YB13900058
J	Giannini, G; Dawson, MI; Zhang, XK; Thiele, CJ				Giannini, G; Dawson, MI; Zhang, XK; Thiele, CJ			Activation of three distinct RXR/RAR heterodimers induces growth arrest and differentiation of neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; HUMAN NEURO-BLASTOMA; X-RECEPTOR; N-MYC; BINDING-PROTEINS; THYROID-HORMONE; NUCLEAR RECEPTORS; RESPONSE ELEMENT; RXR-ALPHA; RAR-ALPHA	Naturally occurring retinoids, like all-trans retinoic acid and 9-cis retinoic acid, are known to affect proliferation and differentiation of sensitive neuroblastoma cell lines. Cellular responsiveness to retinoic acid depends on its interaction with two distinct classes of receptors, the retinoic acid receptors (RARs) and the retinoic X receptors (RXRs). Both receptor classes have three different subtypes (RAR alpha, RAR beta, and RAR gamma and RXR alpha, RAR beta, and RAR gamma) that act as ligand-dependent transcription factors. To examine the involvement of the different receptor classes and subtypes in the biological responses of neuroblastoma cells to retinoids, we analyzed the effects of a panel of receptor selective retinoids on cell growth, differentiation, and gene expression on in vitro cultured KCNR cells. Any association of per se inactive RXR-selective with RAR-selective ligands efficiently regulates growth inhibition, differentiation (neurite extension), and expression of RAR beta, TrkB, and N-myc. SR11383 alone, a very potent retinoid, entirely reproduces the pattern of biological responses induced by naturally occurring retinoids, In contrast to other tumor cell lines, the growth of neuroblastoma cell lines is not altered using AP1-antagonistic retinoids. These studies raise the possibility that three distinct RXR/RAR heterodimers mediate the effects of retinoids on neuroblastoma cells through an AP-1 antagonism-independent mechanism.	NCI,CELL & MOL BIOL SECT,PEDIAT ONCOL BRANCH,NIH,BETHESDA,MD 20892; SRI INT,RETINOID PROGRAM,MENLO PK,CA 94025; BURNHAM INST,LA JOLLA,CA 92037	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); SRI International; Sanford Burnham Prebys Medical Discovery Institute			Giannini, Giuseppe/B-5672-2013	Giannini, Giuseppe/0000-0003-0299-4056				ALBEMAYOR E, 1989, ENV HLTH PERSPECT, V80, P3; ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Apfel CM, 1995, J BIOL CHEM, V270, P30765, DOI 10.1074/jbc.270.51.30765; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOLANDE RP, 1985, SURV SYN PATHOL RES, V4, P296; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; Brooks SC, 1996, BLOOD, V87, P227; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; Cheung B, 1996, BIOCHEM BIOPH RES CO, V229, P349, DOI 10.1006/bbrc.1996.1804; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; HAN GY, 1995, DIFFERENTIATION, V59, P61, DOI 10.1046/j.1432-0436.1995.5910061.x; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kizaki M, 1996, BLOOD, V87, P1977; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LAVSITAPICARD N, 1996, MOL CELL BIOL, V16, P4137; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LUCARELLI E, 1995, J BIOL CHEM, V270, P24725, DOI 10.1074/jbc.270.42.24725; Lutz W, 1996, ONCOGENE, V13, P803; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARSHALL GM, 1995, ONCOGENE, V11, P485; MATSUMOTO K, 1995, CANCER RES, V55, P1798; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; Peverali FA, 1996, ONCOGENE, V12, P457; REDFERN CPF, 1994, BIOCHEM J, V304, P147, DOI 10.1042/bj3040147; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; REYNOLDS CP, 1991, PROG CLIN BIOL RES, V366, P203; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUBERTE E, 1993, DEVELOPMENT, V118, P267; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1991, CANCER METAST REV, V10, P311, DOI 10.1007/BF00554793; WADA RK, 1992, ONCOGENE, V7, P711; Willhite CC, 1996, DRUG METAB REV, V28, P105, DOI 10.3109/03602539608993994; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	55	49	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26693	26701		10.1074/jbc.272.42.26693	http://dx.doi.org/10.1074/jbc.272.42.26693			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334253	hybrid			2022-12-25	WOS:A1997YB13900087
J	Jones, BE; Dossonnet, V; Kuster, E; Hillen, W; Deutscher, J; Klevit, RE				Jones, BE; Dossonnet, V; Kuster, E; Hillen, W; Deutscher, J; Klevit, RE			Binding of the catabolite repressor protein CcpA to its DNA target is regulated by phosphorylation of its corepressor HPr	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; PHOSPHOCARRIER PROTEIN; PHOSPHOTRANSFERASE SYSTEM; PURINE REPRESSOR; SEQUENCE; PHOSPHOENOLPYRUVATE; EXPRESSION; KINASE	Catabolite repression of a number of catabolic operons in bacilli is mediated by the catabolite control protein CcpA, the phosphocarrier protein HPr from the phosphoenolpyruvate-dependent sugar transport system (PTS), and a cis-acting DNA sequence termed the catabolite-responsive element (cre), We present evidence that CcpA interacts with HPr that is phosphorylated at Ser(46) (Ser(P) HPr) and that these proteins form a specific ternary complex with cre DNA, Titration experiments following the circular dichroism signal of the cre DNA indicate that this complex consists of two molecules of Ser(P) HPr, a CcpA dimer, and the cre sequence, Limited proteolysis experiments indicate that the domain structure of CcpA is similar to other members of the LacI/GalR family of helix-turn-helix proteins, comprised of a helix-turn-helix DNA domain and a C-terminal effector domain, NMR titration of Ser(P) HPr demonstrates that the isolated C-terminal domain of CcpA. forms a specific complex with Ser(P) HPr but not with unphosphorylated HPr. Based upon perturbations to the NMR spectrum, we propose that the binding site of the C-terminal domain of CcpA on Ser(P) HPr forms a contiguous surface that encompasses both Sep(P)(46) and His(15), the site of phosphorylation by enzyme I of the PTS. This allows CcpA to recognize the phosphorylation state of HPr, effectively linking the process of sugar import via the PTS to catabolite repression in bacilli.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,BIOMOL STRUCT CTR,SEATTLE,WA 98195; UNIV ERLANGEN NURNBERG,INST MIKROBIOL BIOCHEM & GENET,D-91058 ERLANGEN,GERMANY; CNRS,INST BIOL CHIM PROT,F-69367 LYON 07,FRANCE	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Erlangen Nuremberg; Centre National de la Recherche Scientifique (CNRS)				Kuster-Schock, Elke/0000-0002-9487-6948; Jones, Bryan/0000-0003-4764-6290	NIDDK NIH HHS [R01 DK35187] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035187] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chambliss Glenn H., 1993, P213; Chauvaux S, 1996, RES MICROBIOL, V147, P518, DOI 10.1016/0923-2508(96)84006-X; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; CHOI KY, 1994, J BACTERIOL, V176, P1767, DOI 10.1128/jb.176.6.1767-1772.1994; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DEUTSCHER J, 1994, J BACTERIOL, V176, P3336, DOI 10.1128/jb.176.11.3336-3344.1994; DEUTSCHER J, 1995, MOL MICROBIOL, V15, P1049, DOI 10.1111/j.1365-2958.1995.tb02280.x; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUJITA Y, 1995, MOL MICROBIOL, V17, P953, DOI 10.1111/j.1365-2958.1995.mmi_17050953.x; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gosseringer R, 1997, J MOL BIOL, V266, P665, DOI 10.1006/jmbi.1996.0820; GRAY DM, 1992, METHOD ENZYMOL, V211, P389; HUECK CJ, 1994, RES MICROBIOL, V145, P503, DOI 10.1016/0923-2508(94)90028-0; HUECK CJ, 1995, MOL MICROBIOL, V16, P855, DOI 10.1111/j.1365-2958.1995.tb02313.x; JONES BE, 1997, IN PRESS PROTEIN SCI, V6; KIM JH, 1995, J BACTERIOL, V177, P5129, DOI 10.1128/jb.177.17.5129-5134.1995; Kowalak JA, 1996, PROTEIN SCI, V5, P1625, DOI 10.1002/pro.5560050816; Kruger S, 1996, J BACTERIOL, V178, P2637; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; MARTINVERSTRAETE I, 1995, J BACTERIOL, V177, P6919, DOI 10.1128/jb.177.23.6919-6927.1995; MIWA Y, 1994, MICROBIOL-UK, V140, P2567, DOI 10.1099/00221287-140-10-2567; PLATT T, 1973, J BIOL CHEM, V248, P110; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PULLEN K, 1995, PROTEIN SCI, V4, P2478, DOI 10.1002/pro.5560041204; RAJAGOPAL P, 1994, TECHNIQUES PROTEIN C, V5, P439; REIZER J, 1992, J BIOL CHEM, V267, P9158; Reizer J, 1996, J BACTERIOL, V178, P5480, DOI 10.1128/jb.178.18.5480-5486.1996; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; VANNULAND NAJ, 1995, J MOL BIOL, V246, P180, DOI 10.1006/jmbi.1994.0075; VANNULAND NAJ, 1993, FEBS LETT, V315, P11, DOI 10.1016/0014-5793(93)81122-G; Voskuil MI, 1996, J BACTERIOL, V178, P7014, DOI 10.1128/jb.178.23.7014-7015.1996; WEICKERT MJ, 1990, P NATL ACAD SCI USA, V87, P6238, DOI 10.1073/pnas.87.16.6238; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005	38	123	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26530	26535		10.1074/jbc.272.42.26530	http://dx.doi.org/10.1074/jbc.272.42.26530			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334231	hybrid			2022-12-25	WOS:A1997YB13900065
J	Pazdernik, NJ; Cain, SM; Brooker, RJ				Pazdernik, NJ; Cain, SM; Brooker, RJ			An analysis of suppressor mutations suggests that the two halves of the lactose permease function in a symmetrical manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; LAC CARRIER PROTEIN; SUGAR-TRANSPORT PROTEINS; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; SEQUENCE MOTIF; GENE; EXPRESSION; SEGMENT-2; MUTANT	A conserved motif, GXXX(D/E)(R/K)XG[X](R/K)(R/K), is located in loop 2/3 and loop 8/9 in the lactose permease, and also in hundreds of evolutionarily related transporters, The importance of conserved residues in loop 8/9 was previously investigated (Pazdernik, N. J., Jessen-Marshall, A, E., and Brooker, R. J, (1997) J, Bacteriol. 179, 735-741), Although this loop was tolerant of many substitutions, a few mutations in the first position of the motif were shown to dramatically decrease lactose transport, In the current study, a mutant at the first position in the motif having very low lactose transport, Leu(230), was used as it parental strain to isolate second-site revertants that restore function, A total of 23 independent mutants were sequenced and found to have a second amino acid substitution at several locations (G46C, G46S, F49L, A50T, L212Q, L216Q, S233P, C333G, F354C, G370C, G370S, and G370V). A kinetic analysis revealed that the first-site mutation, Leu(230), had a slightly better affinity for lactose compared with the wild-type strain, but its V-max for lactose transport was over 30-fold lower. The primary effect of the second-site mutations was to increase the V-max for lactose transport, in some cases, to levels that were near the wild-type value. When comparing this study to second-site mutations obtained from loop 2/3 defective strains, a striking observation was made, Mutations in three regions of the protein, codons 45-50, 234-241, and 366-370, were able to restore functionality to both loop 2/3 and loop 8/9 defects, These results are discussed within the context of a C1/C2 alternating conformation model in which lactose translocation occurs by a conformational change at the interface between the two halves of the protein.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities				Pazdernik, Nanette/0000-0002-1037-6437	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1982, P NATL ACAD SCI-BIOL, V79, P6894, DOI 10.1073/pnas.79.22.6894; COPE DL, 1994, BIOCHEM J, V300, P291, DOI 10.1042/bj3000291; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GOSWITZ VC, 1995, PROTEIN SCI, V4, P543; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HENDERSON PJF, 1990, PHILOS T ROY SOC B, V326, P391, DOI 10.1098/rstb.1990.0020; HERZLINGER D, 1984, BIOCHEMISTRY-US, V23, P3688, DOI 10.1021/bi00311a018; JESSENMARSHALL AE, 1995, J BIOL CHEM, V270, P16251, DOI 10.1074/jbc.270.27.16251; JessenMarshall AE, 1996, J BIOL CHEM, V271, P1400, DOI 10.1074/jbc.271.3.1400; JessenMarshall AE, 1997, J BACTERIOL, V179, P2616, DOI 10.1128/jb.179.8.2616-2622.1997; JUNG K, 1993, BIOCHEMISTRY-US, V32, P12272; KIMURA T, 1995, FEBS LETT, V362, P47, DOI 10.1016/0014-5793(95)00205-N; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; LEE JI, 1993, J BIOL CHEM, V268, P20007; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Mandel M, 1970, J MOL BIOL, V53, P154; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Miller J. H., 1972, EXPT MOL GENETICS, P433; Pazdernik NJ, 1997, J BACTERIOL, V179, P735, DOI 10.1128/jb.179.3.735-741.1997; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; Sambrook J., 2002, MOL CLONING LAB MANU; SEGAL IH, 1975, ENZYME KINETICS; Sun JZ, 1996, BIOCHEMISTRY-US, V35, P990, DOI 10.1021/bi952166w; TEATHER RM, 1978, MOL GEN GENET, V159, P239, DOI 10.1007/BF00268260; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; YAMAGUCHI A, 1993, J BIOL CHEM, V268, P6496; YAMAGUCHI A, 1993, FEBS LETT, V324, P131, DOI 10.1016/0014-5793(93)81378-D; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; YAMAGUCHI A, 1995, BIOCHEMISTRY-US, V34, P11800, DOI 10.1021/bi00037a018	38	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26110	26116		10.1074/jbc.272.42.26110	http://dx.doi.org/10.1074/jbc.272.42.26110			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334175	hybrid			2022-12-25	WOS:A1997YB13900009
J	West, AP; Bjorkman, PJ; Dougherty, DA; Lester, HA				West, AP; Bjorkman, PJ; Dougherty, DA; Lester, HA			Expression and circular dichroism studies of the extracellular domain of the alpha subunit of the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; T-CELL RECEPTOR; MOLECULAR-BASIS; ION-CHANNEL; CRYSTAL-STRUCTURE; BINDING SITE; FC RECEPTOR; COMPLEX; FORM; AGGREGATION	To provide material suitable for structural studies of the nicotinic acetylcholine receptor, we have expressed and purified the NH2-terminal extracellular domain of the mouse muscle alpha subunit. Several constructs were initially investigated using Xenopus oocytes as a convenient small scale expression system. A fusion protein (alpha 210GPI) consisting of the 210 NH2-terminal amino acids of the alpha subunit and a glycosylphosphatidylinositol anchorage sequence conferred surface alpha-bungarotoxin binding in oocytes. Coexpression of alpha 210GPI with an analogous construct made from the delta subunit showed no evidence of heterodimer formation. The alpha 210GPI protein was chosen for large scale expression in transfected Chinese hamster ovary cells. The alpha 210GPI protein was cleaved from these cells and purified on an immunoaffinity column. Gel and column chromatography show that the purified protein is processed as expected and exists as a monomer. The purified protein also retains the two distinct, conformation-specific binding sites expected for the correctly folded alpha subunit. Circular dichroism studies of alpha 210GPI suggest that this region of the receptor includes considerable beta-sheet secondary structure, with a small proportion of alpha-helix.	CALTECH,DIV BIOL,PASADENA,CA 91125; CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125; CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125	California Institute of Technology; California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034407, R01NS034407, R01NS011756] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-34407, NS-11756] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANAND R, 1993, FEBS LETT, V327, P241, DOI 10.1016/0014-5793(93)80177-V; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BLOUNT P, 1991, CURR TOP MEMBR, V39, P277; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; CONTITRONCONI BM, 1994, CRIT REV BIOCHEM MOL, V29, P69, DOI 10.3109/10409239409086798; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GRIFFIN WG, 1993, J CHEM SOC FARADAY T, V89, P3395, DOI 10.1039/ft9938903395; KAM W, 1985, P NATL ACAD SCI USA, V82, P8715, DOI 10.1073/pnas.82.24.8715; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Koke J A, 1991, Protein Expr Purif, V2, P51, DOI 10.1016/1046-5928(91)90009-8; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; METHOT N, 1994, BIOCHEMISTRY-US, V33, P7709, DOI 10.1021/bi00190a026; MIELKE DL, 1988, J BIOL CHEM, V263, P3177; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; PERCZEL A, 1992, PROTEINS, V13, P57, DOI 10.1002/prot.340130106; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; QUICK MW, 1994, ION CHANNELS EXCITAB, P261; Sambrook J., 2002, MOL CLONING LAB MANU; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SUMIKAWA K, 1994, MOL BRAIN RES, V25, P257, DOI 10.1016/0169-328X(94)90161-9; Unwin N, 1996, J MOL BIOL, V257, P586, DOI 10.1006/jmbi.1996.0187; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WANG WC, 1993, J BIOL CHEM, V268, P1448; Wang ZZ, 1996, J CELL BIOL, V135, P809, DOI 10.1083/jcb.135.3.809; WHITE SH, 1994, MEMBRANE PROTEIN STR; WHITING PJ, 1986, BIOCHEMISTRY-US, V25, P2082, DOI 10.1021/bi00356a037; WU CSC, 1990, J PROTEIN CHEM, V9, P119, DOI 10.1007/BF01024993	39	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25468	25473		10.1074/jbc.272.41.25468	http://dx.doi.org/10.1074/jbc.272.41.25468			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325259	hybrid, Green Accepted			2022-12-25	WOS:A1997YA35800014
J	Daigle, DM; McKay, GA; Wright, GD				Daigle, DM; McKay, GA; Wright, GD			Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE ANALYSIS; ENTEROCOCCUS; SELECTIVITY; MECHANISM	Bacterial resistance to the aminoglycoside antibiotics is manifested primarily through the expression of enzymes which covalently modify these drugs, One important mechanism of aminoglycoside modification is through ATP-dependent O-phosphorylation, catalyzed by a family of aminoglycoside kinases, The structure of one of these kinases, APH(3')-IIIa has recently been determined by x-ray crystallography, and the general fold is strikingly similar to eukaryotic protein kinases (Hon, W. C., McKay, G. A. Thompson, P. R., Sweet, R. M., Yang, D. S. C., Wright, G. D., and Berghuis, A. M. (1997) Cell 89, 887-895), Based on this similarity, we have examined the effect of known inhibitors of eukaryotic protein kinases on two aminoglycoside kinases, APH(3')-IIIa and the enzyme AAC(6')-APH(2 '') which also exhibits acetyl-CoA-dependent aminoglycoside modification activity, We report that several known protein kinase inhibitors are also good inhibitors of aminoglycoside kinases, Compounds belonging to the isoquinolinesulfonamide group are especially effective in this regard, giving competitive inhibition in the micromolar range with respect to ATP and noncompetitive inhibition versus the aminoglycoside substrate, This study provides the basis for future aminoglycoside kinase inhibitor design and for the development of compounds which could reverse antibiotic resistance in the clinic.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA	McMaster University			Wright, G/ABB-7666-2021	Wright, Gerard/0000-0002-9129-7131				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; *AM SOC MICR, 1995, REPO ASM TASK FORC A; Casnellie J E, 1991, Adv Pharmacol, V22, P167, DOI 10.1016/S1054-3589(08)60035-6; COLE PA, 1995, J BIOL CHEM, V270, P22105, DOI 10.1074/jbc.270.38.22105; COLEMAN K, 1994, J ANTIMICROB CHEMOTH, V33, P1091, DOI 10.1093/jac/33.6.1091; Davies J, 1997, TRENDS MICROBIOL, V5, P234, DOI 10.1016/S0966-842X(97)01033-0; DAVIS BD, 1987, MICROBIOL REV, V51, P341, DOI 10.1128/MMBR.51.3.341-350.1987; EDSON RS, 1991, MAYO CLIN PROC, V66, P1158, DOI 10.1016/S0025-6196(12)65798-X; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; FERRETTI JJ, 1986, J BACTERIOL, V167, P631, DOI 10.1128/jb.167.2.631-638.1986; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIDAKA H, 1993, PROTEIN PHOSPHORYLAT, P87; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; LEATHERBARROW RJ, 1992, GRAFIT 3 0 ED; MADHUSUDAN T, 1994, PROTEIN SCI, V3, P176; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P6936, DOI 10.1021/bi00188a024; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; ROUCH DA, 1987, J GEN MICROBIOL, V133, P3039; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; Thompson PR, 1996, CHEM BIOL, V3, P747, DOI 10.1016/S1074-5521(96)90251-3; Xu RM, 1996, P NATL ACAD SCI USA, V93, P6308, DOI 10.1073/pnas.93.13.6308	23	83	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24755	24758		10.1074/jbc.272.40.24755	http://dx.doi.org/10.1074/jbc.272.40.24755			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312069	hybrid			2022-12-25	WOS:A1997XY97000008
J	Gallagher, MJ; Huang, H; Grant, ER; Lynch, DR				Gallagher, MJ; Huang, H; Grant, ER; Lynch, DR			The NR2B-specific interactions of polyamines and protons with the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED CORTICAL-NEURONS; GLYCINE-BINDING-SITE; H-3 MK-801 BINDING; PROTEIN-KINASE-C; NMDA RECEPTOR; AMINO-ACID; RAT-BRAIN; PHARMACOLOGICAL CHARACTERIZATION; MOLECULAR CHARACTERIZATION; HIPPOCAMPAL-NEURONS	Many compounds exhibit NR2B-specific modulation of the N-methyl-D-aspartate receptor, although their mechanism(s) of action are largely unknown. Using chimeric NR2A/NR2B subunits, we have located a region of NR2B (amino acids 138-238) which regulated glycine-independent polyamine stimulation. Mutation of glutamate 201 in this region affected stimulation by polyamines in the order E201D < E201A < E201N < E201R. The relief of proton inhibition of the N-methyl-D-aspartate-induced currents mediated by these mutant receptors correlated with the reduction in glycine-independent polyamine stimulation. Electrophysiological evidence with a triple mutant of NR2A further supports the hypothesis that polyamine stimulation may be linked to the relief of tonic inhibition by protons and demonstrates the crucial role of amino acids 200 and 201 in polyamine stimulation. Polyamines and protons, therefore, share common NR2B determinants.	UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NIDA NIH HHS [DAO7130, 1F32-DAO5675] Funding Source: Medline; NINDS NIH HHS [CIDA NS01789-01] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [F32DA005675] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BENVENISTE M, 1993, J PHYSIOL-LONDON, V464, P131, DOI 10.1113/jphysiol.1993.sp019627; BROSE N, 1993, J BIOL CHEM, V268, P22663; CARTER C, 1988, J PHARMACOL EXP THER, V247, P1222; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; FAGE D, 1992, J NEUROCHEM, V58, P2170, DOI 10.1111/j.1471-4159.1992.tb10960.x; FAGG GE, 1987, NEUROSCI LETT, V76, P221, DOI 10.1016/0304-3940(87)90719-1; FERRERMONTIEL AV, 1995, P NATL ACAD SCI USA, V92, P8021, DOI 10.1073/pnas.92.17.8021; FLETCHER EJ, 1993, EUR J PHARMACOL, V235, P291, DOI 10.1016/0014-2999(93)90148-B; Gallagher MJ, 1996, J BIOL CHEM, V271, P9603, DOI 10.1074/jbc.271.16.9603; HARMAN RJ, 1981, BRIT J PHARMACOL, V73, P165, DOI 10.1111/j.1476-5381.1981.tb16786.x; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; IKEDA K, 1992, FEBS LETT, V313, P34, DOI 10.1016/0014-5793(92)81178-O; ISHII T, 1993, J BIOL CHEM, V268, P2836; Johnson TD, 1996, TRENDS PHARMACOL SCI, V17, P22, DOI 10.1016/0165-6147(96)81566-5; Kashiwagi K, 1996, MOL PHARMACOL, V49, P1131; KLOOG Y, 1988, BIOCHEMISTRY-US, V27, P843, DOI 10.1021/bi00403a001; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LIPTON SA, 1993, TRENDS NEUROSCI, V16, P527, DOI 10.1016/0166-2236(93)90198-U; LYNCH DR, 1994, MOL PHARMACOL, V45, P540; LYNCH DR, 1995, J NEUROCHEM, V64, P1462; Lynch DR, 1996, J PHARMACOL EXP THER, V279, P154; LYNCH DR, 1996, PHARM RECOMBINANT NM, P325; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; PAOLETTI P, 1995, NEURON, V15, P1109, DOI 10.1016/0896-6273(95)90099-3; PARSONS CG, 1995, NEUROPHARMACOLOGY, V34, P1239, DOI 10.1016/0028-3908(95)00092-K; PASCHEN W, 1992, CEREBROVAS BRAIN MET, V4, P59; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; REYNOLDS GP, 1994, J NEUROL SCI, V125, P46, DOI 10.1016/0022-510X(94)90240-2; ROCK DM, 1992, MOL PHARMACOL, V42, P157; ROCK DM, 1992, MOL PHARMACOL, V41, P83; SACAAN AI, 1989, MOL PHARMACOL, V36, P836; SAKURAI SY, 1993, J NEUROCHEM, V60, P1344, DOI 10.1111/j.1471-4159.1993.tb03295.x; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; WAFFORD KA, 1995, MOL PHARMACOL, V47, P374; WILLIAMS K, 1990, NEURON, V5, P199, DOI 10.1016/0896-6273(90)90309-4; Williams K, 1995, MOL PHARMACOL, V48, P1087; WILLIAMS K, 1994, MOL PHARMACOL, V45, P803; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; WILLIAMS K, 1995, POLYAMINES REGULATIO, P129; ZHENG X, 1994, NEURON, V12, P811; ZHONG J, 1994, MOL PHARMACOL, V45, P846	51	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24971	24979		10.1074/jbc.272.40.24971	http://dx.doi.org/10.1074/jbc.272.40.24971			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312102	hybrid			2022-12-25	WOS:A1997XY97000041
J	Lokuta, AJ; Meyers, MB; Sander, PR; Fishman, GI; Valdivia, HH				Lokuta, AJ; Meyers, MB; Sander, PR; Fishman, GI; Valdivia, HH			Modulation of cardiac ryanodine receptors by sorcin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; FEET STRUCTURES; PROTEIN; PHOSPHORYLATION; RECONSTITUTION; PURIFICATION; ACTIVATION; CALMODULIN	Sorcin is a widely expressed, 22-kDa Ca2+-binding protein initially identified in multidrug-resistant cells, In the heart, sorcin localizes to the dyadic junctions of transverse tubules and sarcoplasmic reticulum and coimmunoprecipitates with the Ca2+ release channel/ryanodine receptor (RyR) (Meyers, M.B., Pickel, V. M., Sheu, S.-S., Sharma, V. K., Scotto, K. W., and Fishman, G. I. (1995) J. Biol. Chem. 270, 26411-26418), We have investigated a possible functional interaction between sorcin and cardiac RyR using purified recombinant sorcin in [H-3]ryanodine binding experiments and single channel recordings of RyR, The open probability of single RyR was decreased significantly by the addition of sorcin to the cytoplasmic side of the channel (IC(50)similar to 480 nM), In addition, sorcin completely inhibited [H-3]ryanodine binding with an IC(50)similar to 700 nM. Inhibition occurred over a wide range of [Ca2+], and sorcin-modulated RyR remained Ca2+-dependent. Furthermore, caffeine-activated RyRs were also inhibited by sorcin at low [Ca2+] (pCa 7), suggesting that Ca2+ is not an obligatory factor for sorcin inhibition of RyR, Comparisons of these inhibitory effects with those of calmodulin and calpain, proteins structurally related to sorcin, suggested that the interaction of sorcin with cardiac RyR was distinct from and independent of either of these modulatory proteins, Phosphorylation of sorcin with the catalytic subunit of protein kinase A significantly decreased the ability of sorcin to modulate RyR, These results suggest that sorcin may modulate RyR function in a normal cell environment and that the level of modulation is in turn influenced by signaling pathways that increase protein kinase A activity.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,SECT MOL CARDIOL,BRONX,NY 10461; UNIV WISCONSIN,SCH MED,DEPT PHYSIOL,MADISON,WI 53706	Yeshiva University; Albert Einstein College of Medicine; University of Wisconsin System; University of Wisconsin Madison				Fishman, Glenn/0000-0002-2366-8527	NHLBI NIH HHS [HL55438] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055438] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERS DM, 1991, EXCITATION CONTRACTI; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; ELHAYEK R, 1995, J BIOL CHEM, V270, P28696, DOI 10.1074/jbc.270.48.28696; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FUENTES O, 1994, CELL CALCIUM, V15, P305, DOI 10.1016/0143-4160(94)90070-1; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20857; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LOKUTA AJ, 1995, J PHYSIOL-LONDON, V487, P609, DOI 10.1113/jphysiol.1995.sp020904; LOKUTA AJ, 1997, BIOPHYS J, V72, P333; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, ANN REV PHYSL, V56, P484; Meyers M. B., 1991, NOVEL CALCIUM BINDIN, P385, DOI 10.1007/978-3-642-76150-8_22; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; MEYERS MB, 1990, STIMULUS RESPONSE CO, P159; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; SHOSHANBARMATZ V, 1994, J MEMBRANE BIOL, V142, P281; STERN MD, 1992, FASEB J, V6, P3092, DOI 10.1096/fasebj.6.12.1325933; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TADA M, 1982, MOL CELL BIOCHEM, V46, P73; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; WIER WG, 1994, J PHYSIOL-LONDON, V474, P463, DOI 10.1113/jphysiol.1994.sp020037	29	126	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25333	25338		10.1074/jbc.272.40.25333	http://dx.doi.org/10.1074/jbc.272.40.25333			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312152	hybrid			2022-12-25	WOS:A1997XY97000091
J	Modriansky, M; MurdzaInglis, DL; Patel, HV; Freemann, KB; Garlid, KD				Modriansky, M; MurdzaInglis, DL; Patel, HV; Freemann, KB; Garlid, KD			Identification by site-directed mutagenesis of three arginines in uncoupling protein that are essential for nucleotide binding and inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; FAT MITOCHONDRIA; PROTON TRANSPORT; ANION UNIPORT; H+-TRANSPORT; MECHANISM; RECONSTITUTION; MEMBRANE; PROBES; YEAST	Primary regulation of uncoupling protein is mediated by purine nucleotides, which bind to the protein and allosterically inhibit fatty acid-induced proton transport. To gain increased understanding of nucleotide regulation, we evaluated the role of basic amino acid residues using site-directed mutagenesis. Mutant and wildtype proteins were expressed in yeast, purified, and reconstituted into liposomes. We studied nucleotide binding as well as inhibition of fatty acid-induced proton transport in wild-type and six mutant uncoupling proteins. None of the mutations interfered with proton transport. Two lysine mutants and a histidine mutant had no effect on nucleotide binding or inhibition, Arg(83) and Arg(182) mutants completely lost both the ability to bind nucleotides and nucleotide inhibition. Surprisingly, the Arg(276) mutant exhibited normal nucleotide binding, but completely lost nucleotide inhibition. To account for this dissociation between binding and inhibition, Foe propose a three-stage binding-conformational change model of nucleotide regulation of uncoupling protein. We have now identified three nucleotides by site-directed mutagenesis that are essential for nucleotide interaction with uncoupling protein.	OREGON GRAD INST,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97291; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA	McMaster University			Modriansky, Martin/A-6338-2008	Modriansky, Martin/0000-0001-7692-0338; Garlid, Keith/0000-0002-6777-1235	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031086] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31086] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; GARLID KD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P151, DOI 10.1016/0005-2728(90)90237-X; Garlid KD, 1995, METHOD ENZYMOL, V260, P331, DOI 10.1016/0076-6879(95)60149-X; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; GASSER SM, 1983, METHOD ENZYMOL, V97, P329; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; HUANG SG, 1995, BIOCHEMISTRY-US, V34, P349, DOI 10.1021/bi00001a043; Huang SG, 1996, BIOCHEMISTRY-US, V35, P7846, DOI 10.1021/bi960244p; JEZEK P, 1994, J BIOL CHEM, V269, P26184; JEZEK P, 1990, J BIOL CHEM, V265, P19296; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KATIYAR SS, 1989, P NATL ACAD SCI USA, V86, P2559, DOI 10.1073/pnas.86.8.2559; KLINGENBERG M, 1988, BIOCHEMISTRY-US, V27, P781, DOI 10.1021/bi00402a044; KLINGENBERG M, 1986, METHOD ENZYMOL, V126, P498; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN CS, 1982, BIOCHEMISTRY-US, V21, P2950, DOI 10.1021/bi00541a023; MAYINGER P, 1992, BIOCHEMISTRY-US, V31, P10536, DOI 10.1021/bi00158a017; MIROUX B, 1993, EMBO J, V12, P3739, DOI 10.1002/j.1460-2075.1993.tb06051.x; MURDZAINGLIS DL, 1994, J BIOL CHEM, V269, P7435; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; MURDZAINGLIS DL, 1995, THESIS MCMASTER U HA; NICHOLLS DG, 1979, BIOCHIM BIOPHYS ACTA, V549, P1, DOI 10.1016/0304-4173(79)90016-8; OROSZ DE, 1993, ANAL BIOCHEM, V210, P7, DOI 10.1006/abio.1993.1143; RAFAEL J, 1994, EUR J BIOCHEM, V223, P971, DOI 10.1111/j.1432-1033.1994.tb19075.x; WINKLER E, 1992, EUR J BIOCHEM, V203, P295, DOI 10.1111/j.1432-1033.1992.tb19859.x; Winkler E, 1997, BIOCHEMISTRY-US, V36, P148, DOI 10.1021/bi962178x; [No title captured]	29	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24759	24762		10.1074/jbc.272.40.24759	http://dx.doi.org/10.1074/jbc.272.40.24759			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312070	hybrid			2022-12-25	WOS:A1997XY97000009
J	Schwalbe, RA; Bianchi, L; Brown, AM				Schwalbe, RA; Bianchi, L; Brown, AM			Mapping the kidney potassium channel ROMK1 - Glycosylation of the pore signature sequence and the COOH terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; RECTIFIER K+ CHANNEL; RECTIFICATION; MUTATIONS; PHOSPHORYLATION; GLYCOPROTEINS; SPERMINE; MEMBRANE; REGION; BLOCK	ROMK1, also known as Kir 1.1, is an inwardly rectifying K+ channel and is the prototypical member of the large Kir gene family. The accepted model of Kir topology predicts intracellular NH2 and COOH termini, and two membrane-spanning segments, M1 and M2, connected by an intramembranous pore-forming segment, H5. The sequence of H5 is similar in voltage-dependent K+ channels and features a strictly conserved GY/FG in its mid-region, which has been proposed as the selectivity filter of the pore. We have been using N-glycosylation substitution mutants to map the extracellular topology of ROMK1 biochemically and have described several loci in H5 that were glycosylated. We now report glycosylation at loci Tyr(144) and Phe(146), which indicates that the signature GYG sequence (143-145) rather than being intramembranous is extracellular, The COOH terminus was predicted to begin at position 178, but contrary to the model, we observed that position 257 was glycosylated and surrounding positions at 199, 222, and 298 were unglycosylated. N-Glycosylation sequon substitution at the latter three positions abolished K+/Na+ selectivity. Our results suggest a major revision of the topology of ROMK1 with H5 and the pore signature sequence now completely extracellular. The COOH terminus appears to form two additional membrane-spanning segments and to contribute to the ion conduction pathway.			Schwalbe, RA (corresponding author), CASE WESTERN RESERVE UNIV, RAMMELKAMP CTR EDUC & RES, METROHLTH CAMPUS, 2500 METROHLTS DR, CLEVELAND, OH 44109 USA.				NHLBI NIH HHS [HL36930, HL55404] Funding Source: Medline; NIDDK NIH HHS [DK52990] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055404, R01HL036930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052990] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; Doi T, 1996, J BIOL CHEM, V271, P17261, DOI 10.1074/jbc.271.29.17261; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; FENG W, 1995, J BIOL CHEM, V270, P11851, DOI 10.1074/jbc.270.20.11851; FENG WJ, 1995, ENDOCRINOLOGY, V136, P52, DOI 10.1210/en.136.1.52; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GIEBISCH G, 1995, KIDNEY INT, V48, P1004, DOI 10.1038/ki.1995.382; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEBERT SC, 1995, KIDNEY INT, V48, P1010, DOI 10.1038/ki.1995.383; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Karolyi L, 1997, HUM MOL GENET, V6, P17; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; LEE WS, 1995, AM J PHYSIOL-RENAL, V268, pF1124, DOI 10.1152/ajprenal.1995.268.6.F1124; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Possee RD., 1992, BACULOVIRUS EXPRESSI; Schwalbe RA, 1996, J BIOL CHEM, V271, P24201, DOI 10.1074/jbc.271.39.24201; SCHWALBE RA, 1995, J BIOL CHEM, V270, P15336, DOI 10.1074/jbc.270.25.15336; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; TAGLIALATELA M, 1994, NEWS PHYSIOL SCI, V9, P169; VIDAL S, 1989, J VIROL, V63, P892, DOI 10.1128/JVI.63.2.892-900.1989; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809; Zhou H, 1996, AM J PHYSIOL-CELL PH, V271, pC1949, DOI 10.1152/ajpcell.1996.271.6.C1949	38	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25217	25223		10.1074/jbc.272.40.25217	http://dx.doi.org/10.1074/jbc.272.40.25217			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312136	hybrid			2022-12-25	WOS:A1997XY97000075
J	Stapulionis, R; Kolli, S; Deutscher, MP				Stapulionis, R; Kolli, S; Deutscher, MP			Efficient mammalian protein synthesis requires an intact F-Actin system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; ELONGATION-FACTOR 1-ALPHA; MESSENGER-RNA; CYTOSKELETAL FRAMEWORK; CYTOCHALASIN-D; SYNTHETASE; ASSOCIATION; BINDING; CELLS; ORGANIZATION	The mammalian protein synthesizing system is highly organized in vivo, and its substrate, tRNA, is channeled throughout the translation process, However, the cellular components responsible for this organization are not known. To examine this question a series of studies was carried out using intact and permeabilized Chinese hamster ovary cells, We show that cold shock dramatically reduces the protein synthetic capacity of these cells by as much as 95%, The loss of activity can be reversed by a short recovery period under conditions that allow energy metabolism to occur; transcription and translation during the recovery period are not needed, While individual components of the translation apparatus are not inactivated by the cold shock, the supramolecular organization of the system appears to be altered and F-actin levels are found to decrease, Resumption of protein synthesis during the recovery period coincides closely with the restoration of F-actin to normal levels. Moreover, disruption of actin filaments, but not microtubules, also leads to a major reduction in translation. These data support the conclusion that the cellular microfilament network plays an important role in the structure and function of the translation system and that perturbations of this network can have profound effects on protein synthesis.	UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOL BIOL, MIAMI, FL 33101 USA; UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06030 USA	University of Miami; University of Connecticut					NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBARESE E, 1995, J CELL SCI, V108, P2781; Bassell G J, 1994, Adv Exp Med Biol, V358, P183; BASSELL GJ, 1994, J CELL BIOL, V126, P863, DOI 10.1083/jcb.126.4.863; BASSELL GJ, 1994, NEURON, V12, P571, DOI 10.1016/0896-6273(94)90213-5; BEKTAS M, 1994, FEBS LETT, V356, P89, DOI 10.1016/0014-5793(94)01239-3; BIEGEL D, 1992, J CELL BIOCHEM, V48, P98, DOI 10.1002/jcb.240480114; CANO ML, 1992, CELL MOTIL CYTOSKEL, V21, P147, DOI 10.1002/cm.970210208; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DANG CV, 1983, J CELL BIOL, V96, P1138, DOI 10.1083/jcb.96.4.1138; DEUTSCHER MP, 1984, J CELL BIOL, V99, P373, DOI 10.1083/jcb.99.2.373; Ganoza MC, 1996, BIOCHIMIE, V78, P51, DOI 10.1016/0300-9084(96)81329-0; Glotzer JB, 1996, SEMIN CELL DEV BIOL, V7, P357, DOI 10.1006/scdb.1996.0045; GOUY M, 1980, FEBS LETT, V115, P151, DOI 10.1016/0014-5793(80)81155-0; GRAF H, 1976, BIOCHIM BIOPHYS ACTA, V425, P175, DOI 10.1016/0005-2787(76)90023-X; Hesketh JE, 1996, EXP CELL RES, V225, P219, DOI 10.1006/excr.1996.0172; HESKETH JE, 1988, FEBS LETT, V231, P62, DOI 10.1016/0014-5793(88)80703-8; HITCHCOCK SE, 1980, J BIOL CHEM, V255, P5668; HOWE JG, 1984, CELL, V37, P85; IRVIN JD, 1972, BIOCHEMISTRY-US, V11, P1915, DOI 10.1021/bi00760a028; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu G, 1996, TRENDS CELL BIOL, V6, P168, DOI 10.1016/0962-8924(96)20013-3; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1985, EXP CELL RES, V156, P91, DOI 10.1016/0014-4827(85)90264-2; MORRIS A, 1980, NATURE, V287, P637, DOI 10.1038/287637a0; MOTORIN YA, 1988, FEBS LETT, V238, P262, DOI 10.1016/0014-5793(88)80492-7; NEGRUTSKII BS, 1992, P NATL ACAD SCI USA, V89, P3601, DOI 10.1073/pnas.89.8.3601; Negrutskii BS, 1996, FEBS LETT, V382, P18, DOI 10.1016/0014-5793(96)00128-7; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; ORNELLES DA, 1986, MOL CELL BIOL, V6, P1650, DOI 10.1128/MCB.6.5.1650; REED VS, 1994, J BIOL CHEM, V269, P32932; RYAZANOV AG, 1987, BIOSYSTEMS, V20, P275, DOI 10.1016/0303-2647(87)90035-9; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHESTAKOVA EA, 1993, CELL BIOL INT, V17, P417, DOI 10.1006/cbir.1993.1080; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; SUPRENANT KA, 1993, CELL MOTIL CYTOSKEL, V25, P1, DOI 10.1002/cm.970250102; UYEDA TQP, 1986, EXP CELL RES, V165, P461, DOI 10.1016/0014-4827(86)90599-9; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; ZAMBETTI G, 1990, EXP CELL RES, V191, P246, DOI 10.1016/0014-4827(90)90011-X	42	91	93	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24980	24986		10.1074/jbc.272.40.24980	http://dx.doi.org/10.1074/jbc.272.40.24980			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312103	hybrid			2022-12-25	WOS:A1997XY97000042
J	Wong, BR; Rho, JR; Arron, J; Robinson, E; Orlinick, J; Chao, M; Kalachikov, S; Cayani, E; Bartlett, FS; Frankel, WN; Lee, SY; Choi, YW				Wong, BR; Rho, JR; Arron, J; Robinson, E; Orlinick, J; Chao, M; Kalachikov, S; Cayani, E; Bartlett, FS; Frankel, WN; Lee, SY; Choi, YW			TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; DENDRITIC CELLS; VIRAL-PROTEINS; FACTOR-ALPHA; KAPPA-B; APOPTOSIS; DEATH; CD40; IDENTIFICATION; EXPRESSION	A novel member of the tumor necrosis factor (TNF) cytokine family, designated TRANCE, was cloned during a search for apoptosis-regulatory genes using a somatic cell genetic approach in T cell hybridomas. The TRANCE gene encodes a type II membrane protein of 316 amino acids with a predicted molecular mass of 35 kDa. Its extracellular domain is most closely related to TRAIL, FasL, and TNF. TRANCE is an immediate early gene up-regulated by TCR stimulation and is controlled by calcineurin-regulated transcription factors. TRANCE is most highly expressed in thymus and lymph nodes but not in nonlymphoid tissues and is abundantly expressed in T cells but not in B cells. Cross hybridization of the mouse cDNA to a human thymus library yielded the human homolog, which encodes a protein 83% identical to the mouse ectodomain. Human TRANCE was mapped to chromosome 13q14 while mouse TRANCE was located to the portion of mouse chromosome 14 syntenic with human chromosome 13q14. A recombinant soluble form of TRANCE composed of the entire ectodomain induced c-Jun N-terminal kinase (JNK) activation in T cells but not in splenic B cells or in bone marrow-derived dendritic cells. These results suggest a role for this TNF-related ligand in the regulation of the T cell-dependent immune response.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV,DEPT CELL BIOL & ANAT,COLL MED,DIV HEMATOL ONCOL,NEW YORK,NY 10021; COLUMBIA PRESBYTERIAN MED CTR,COLL PHYS & SURG,COLUMBIA GENOME CTR,NEW YORK,NY 10032; JACKSON LAB,BAR HARBOR,ME 04609	Howard Hughes Medical Institute; Rockefeller University; Cornell University; Columbia University; NewYork-Presbyterian Hospital; Jackson Laboratory				Rho, Jaerang/0000-0002-0019-4939; Arron, Joseph/0000-0001-7677-9979	NATIONAL CANCER INSTITUTE [R01CA056490] Funding Source: NIH RePORTER; NCI NIH HHS [CA56490] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline; NINDS NIH HHS [NS3336] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barinaga M, 1996, SCIENCE, V274, P724, DOI 10.1126/science.274.5288.724; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; deLecea L, 1997, GENOMICS, V42, P499, DOI 10.1006/geno.1997.4763; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; JOHNSON KR, 1994, MAMM GENOME, V5, P670, DOI 10.1007/BF00426073; KEHRL JH, 1987, SCIENCE, V238, P1144, DOI 10.1126/science.3500512; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Rozzo SJ, 1996, P NATL ACAD SCI USA, V93, P15164, DOI 10.1073/pnas.93.26.15164; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Sutherland CL, 1996, J IMMUNOL, V157, P3381; VANLINT J, 1992, J BIOL CHEM, V267, P25916; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong B, 1997, Semin Immunol, V9, P7, DOI 10.1006/smim.1996.0051; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	34	847	935	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25190	25194		10.1074/jbc.272.40.25190	http://dx.doi.org/10.1074/jbc.272.40.25190			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312132	hybrid			2022-12-25	WOS:A1997XY97000071
J	Corbley, MJ				Corbley, MJ			Transformation by ras suppresses expression of the neurotrophic growth factor pleiotrophin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULE HB-GAM; VIRUS PHOSPHORYLATES TYROSINE; FACTOR SIGNAL-TRANSDUCTION; SARCOMA-VIRUS; CELL-PROLIFERATION; EPITHELIAL-CELLS; DEVELOPING BRAIN; BINDING-PROTEIN; MESSENGER-RNA; HUMAN CANCER	An 18-kDa protein (p18) was detected in lysates and conditioned medium from contact-arrested NIH 3T3 fibroblasts, but was not detected when the cells mere transformed by the oncogene ras. Analysis of transformation-defective cell clones generated after mutagenesis of the ras-retroviral vector used to transduce the ras gene showed an inverse correlation between p18 expression and the degree of transformation. p18 expression was high in non-transformed clones, intermediate in a partially transformed clone, undetectable in fully transformed clones, and detectable only at the non-permissive temperature in a clone which was cold-sensitive for ras transformation. In non-transformed cells, p18 expression varied with the degree of confluence, It was almost undetectable in medium from sparse, proliferating cells, but increased as the cells approached confluence and peaked 2-4 days after confluence, Microsequencing of partially purified pig identified it as the developmentally regulated neurotrophic factor pleiotrophin, In further experiments, pleiotrophin was undetectable or almost undetectable in medium from fully transformed cells expressing the oncogenes v-src, truncated c-raf, activated c-fms, or polyomavirus middle tumor antigen; it was low but easily detectable in medium from SV40 large tumor antigen-expressing cells, which form soft agar colonies but not foci. Thus, pleiotrophin expression in NIH 3T3 cells is associated with quiescence, and suppression of pleiotrophin is related to oncogenic transformation.			Corbley, MJ (corresponding author), DANA FARBER CANC INST,DEPT CANC BIOL,DIV CELLULAR & MOL BIOL,44 BINNEY ST,BOSTON,MA 02115, USA.							BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; CORBLEY MJ, 1994, BIOTECHNIQUES, V17, P1102; CORBLEY MJ, 1988, THESIS HARVARD U ANN; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FINKEL T, 1984, CELL, V37, P151, DOI 10.1016/0092-8674(84)90310-6; FRITZE LMS, 1985, J CELL BIOL, V100, P1041, DOI 10.1083/jcb.100.4.1041; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARVER RI, 1993, AM J RESP CELL MOL, V9, P463, DOI 10.1165/ajrcmb/9.5.463; GRAND RJ, 1991, BIOCHEM J, V279, P165; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; HAUBRUCK H, 1991, BIOCHIM BIOPHYS ACTA, V1072, P215, DOI 10.1016/0304-419X(91)90015-D; HERTZOG PJ, 1994, MOL REPROD DEV, V39, P226; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JOHNSON TC, 1994, PHARMACOL THERAPEUT, V62, P247, DOI 10.1016/0163-7258(94)90013-2; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KOVESDI I, 1990, BIOCHEM BIOPH RES CO, V172, P850, DOI 10.1016/0006-291X(90)90753-A; Kretschmer P J, 1991, Growth Factors, V5, P99, DOI 10.3109/08977199109000275; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINSON AD, 1980, J BIOL CHEM, V255, P1973; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LI YS, 1992, BIOCHEM BIOPH RES CO, V184, P427, DOI 10.1016/0006-291X(92)91211-8; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MAILLEUX P, 1992, NEUROSCI LETT, V142, P31, DOI 10.1016/0304-3940(92)90613-C; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MERENMIES J, 1992, FEBS LETT, V307, P297, DOI 10.1016/0014-5793(92)80699-H; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; OLESZAK E, 1988, EXP CELL RES, V179, P575, DOI 10.1016/0014-4827(88)90295-9; PARKER BW, 1993, J NATL CANCER I, V85, P1068, DOI 10.1093/jnci/85.13.1068; PIWNICAWORMS H, 1986, MOL CELL BIOL, V6, P2033, DOI 10.1128/MCB.6.6.2033; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; RAPP UR, 1991, ONCOGENE, V6, P495; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAULO E, 1992, J BIOL CHEM, V267, P11408; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RAUVALA H, 1989, BIOSCIENCE REP, V9, P1, DOI 10.1007/BF01117507; SALMIVIRTA M, 1995, EXPERIENTIA, V51, P863, DOI 10.1007/BF01921737; SANANTONIO JD, 1992, J CELL PHYSIOL, V150, P8; SCHAFFHAUSEN B, 1982, CRC CR REV BIOCH MOL, V13, P215, DOI 10.3109/10409238209114230; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; STORM S M, 1990, Critical Reviews in Oncogenesis, V2, P1; Szabat E, 1996, DEV BIOL, V178, P77, DOI 10.1006/dbio.1996.0199; TAKE M, 1994, J BIOCHEM-TOKYO, V116, P1063, DOI 10.1093/oxfordjournals.jbchem.a124628; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; VANDERWINDEN JM, 1992, ANAT EMBRYOL, V186, P387; WANAKA A, 1993, DEV BRAIN RES, V72, P133, DOI 10.1016/0165-3806(93)90166-8; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WRIGHT TC, 1987, J CELL PHYSIOL, V132, P255, DOI 10.1002/jcp.1041320209; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	65	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24696	24702		10.1074/jbc.272.39.24696	http://dx.doi.org/10.1074/jbc.272.39.24696			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305941	hybrid			2022-12-25	WOS:A1997XY51500092
J	Melford, SK; Turner, M; Briddon, SJ; Tybulewicz, VLJ; Watson, SP				Melford, SK; Turner, M; Briddon, SJ; Tybulewicz, VLJ; Watson, SP			Syk and Fyn are required by mouse megakaryocytes for the rise in intracellular calcium induced by a collagen-related peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; PROTEIN-TYROSINE KINASES; CELL ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA; HUMAN PLATELETS; SH2 DOMAINS; INDEPENDENT PATHWAYS; CYTOSOLIC CALCIUM; CA2+ MOBILIZATION; IMMUNOGLOBULIN-E	Stimulation of platelets by collagen leads to activation of a tyrosine kinase cascade resulting in secretion and aggregation. We have recently shown that this pathway involves rapid tyrosine phosphorylation of an Fc receptor gamma chain, which contains an immunoreceptor tyrosine-based activation motif(ITAM), enabling interaction with the tandem SH2 domains of the tyrosine kinase Syk. Activation of Syk lies upstream of tyrosine phosphorylation of phospholipase C gamma 2. In the present study we sought to test directly the role of the ITAM/Syk interaction and the role of the Src-related kinases in collagen receptor signaling using mouse megakaryocytes. We demonstrate that the calcium-mobilizing action of a collagen-related peptide (CRP) is kinase-dependent, in hibited by the microinjection of the tandem SH2 domains of Syk and abolished in Syk-deficient mice. Furthermore, the CRP response is abolished by the Src family kinase inhibitor PPI and inhibited in Fyn-deficient mice. In contrast, the calcium response to the G-protein-linked receptor agonist thrombin is not significantly altered under these conditions. These results provide direct evidence of the functional importance of Fyn and Syk in collagen receptor signaling and support the megakaryocyte as a model for the study of proteins involved in this pathway.	UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	University of Oxford; MRC National Institute for Medical Research			Turner, Martin/N-9976-2014; Watson, Stephen P/Q-6292-2016	Turner, Martin/0000-0002-3801-9896; Watson, Stephen P/0000-0002-7846-7423; Briddon, Stephen/0000-0001-8514-0827	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aroca P, 1996, ONCOGENE, V13, P1839; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; BLAKE RA, 1993, BIOCHEM J, V290, P471, DOI 10.1042/bj2900471; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; BRASS LF, 1993, THROMB HAEMOSTASIS, V70, P217; BRETONGORIUS J, 1986, SEMIN HEMATOL, V23, P43; Chen T, 1996, J BIOL CHEM, V271, P25308, DOI 10.1074/jbc.271.41.25308; Costello PS, 1996, ONCOGENE, V13, P2595; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DECKMYN H, 1992, BLOOD, V79, P1466, DOI 10.1182/blood.V79.6.1466.bloodjournal7961466; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; GIBBINS J, 1997, FEBS LETT, V1413, P255; Graessmann A, 1980, Methods Enzymol, V65, P816; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; Ichinohe T, 1997, J BIOL CHEM, V272, P63; ICHINOHE T, 1995, J BIOL CHEM, V270, P28029; Jackson SP, 1996, THROMB HAEMOSTASIS, V76, P640; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nishizumi H, 1997, J IMMUNOL, V158, P2350; Northrop JP, 1996, MOL CELL BIOL, V16, P2255; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; POOLE AW, 1995, BRIT J PHARMACOL, V115, P101, DOI 10.1111/j.1476-5381.1995.tb16326.x; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; Tertyshnikova S, 1997, CELL CALCIUM, V21, P331, DOI 10.1016/S0143-4160(97)90026-9; Uneyama C, 1995, EUR J PHARM-MOLEC PH, V291, P381, DOI 10.1016/0922-4106(95)90080-2; WATSON SP, 1989, BIOCHEM J, V258, P479, DOI 10.1042/bj2580479; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471	44	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27539	27542		10.1074/jbc.272.44.27539	http://dx.doi.org/10.1074/jbc.272.44.27539			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346887	hybrid			2022-12-25	WOS:A1997YD47300013
J	Raats, CJI; Bakker, MAH; vandenBorn, J; Berden, JHM				Raats, CJI; Bakker, MAH; vandenBorn, J; Berden, JHM			Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE-REDUCTIVE DEPOLYMERIZATION; DOXORUBICIN HYDROCHLORIDE NEPHROSIS; BASEMENT-MEMBRANE; SUPEROXIDE-DISMUTASE; MONOCLONAL-ANTIBODY; HYALURONIC-ACID; ANIONIC SITES; AMINONUCLEOSIDE NEPHROSIS; INCREASED PERMEABILITY; DIABETIC NEPHROPATHY	Heparan sulfate, the polysaccharide side chain of heparan sulfate proteoglycan, is important for the permselective properties of the glomerular basement-membrane, In this report, we show a role for hydroxyl radicals in heparan sulfate degradation and an enhanced glomerular basement membrane permeability, First, in enzyme-linked immunosorbent assay, exposure of coated heparan sulfate (proteoglycan) to reactive oxygen species resulted in a +/-50% decrease of binding of a monoclonal antibody against heparan sulfate, whereas binding of an antibody against the cope protein remained unaltered, Second, on polyacrylamide gel electrophoresis, the molecular weight of heparan sulfate exposed to radicals was reduced which indicates depolymepization. Both in enzyme-linked immunosorbent assay and gel electrophoresis, hydroxyl radicals are instrumental for heparan sulfate degradation as shown by the addition of various radical scavengers, Third, in an experimental model for human nephpotic syndrome (Adriamycin nephropathy in rats), glomerular basement membrane staining of two recently described anti-heparan sulfate antibodies (JM403 and KJ865) was reduced by 24 and 43%, Treatment of Adriamycin-exposed rats with the hydroxyl radical scavenger dimethylthiourea both reduced albuminuria by 37% (p < 0.01) and partly prevented loss of heparan sulfate staining by 53% (JM403) and 39% (KJ865) (p < 0.03) In contrast to the heparan sulfate side chains, the core protein expression and the extent of glycanation did not change in Adriamycin nephropathy, We conclude that glomerular basement membrane heparan sulfate is susceptible to depolymerization hydroxyl radicals leading to loss of glomerular basement membrane integrity and albuminuria.			Raats, CJI (corresponding author), UNIV NIJMEGEN ST RADBOUD HOSP, DIV NEPHROL, POB 9101, NL-6500 HB NIJMEGEN, NETHERLANDS.		Berden, J.H.M./H-8009-2014					BARBEY MM, 1989, FREE RADICAL RES COM, V7, P195, DOI 10.3109/10715768909087942; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BERTANI T, 1982, LAB INVEST, V46, P16; BERTOLATUS JA, 1991, J LAB CLIN MED, V118, P435; COTRAN RS, 1983, NEW ENGL J MED, V309, P1050, DOI 10.1056/NEJM198310273091709; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Desassis JF, 1997, NEPHRON, V75, P336, DOI 10.1159/000189558; DIAMOND JR, 1986, KIDNEY INT, V29, P478, DOI 10.1038/ki.1986.24; FARQUHAR MG, 1985, NEPHROLOGY, P580; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; HIEBERT LM, 1990, ATHEROSCLEROSIS, V83, P47, DOI 10.1016/0021-9150(90)90129-7; KANWAR YS, 1980, J CELL BIOL, V86, P688, DOI 10.1083/jcb.86.2.688; KANWAR YS, 1991, SEMIN NEPHROL, V11, P390; KANWAR YS, 1982, J CELL BIOL, V93, P489, DOI 10.1083/jcb.93.2.489; KASHIHARA N, 1992, P NATL ACAD SCI USA, V89, P6309, DOI 10.1073/pnas.89.14.6309; KLEBANOFF SJ, 1993, AM J PATHOL, V143, P907; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LELONGT B, 1987, KIDNEY INT, V31, P1299, DOI 10.1038/ki.1987.143; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LIU ZC, 1994, CARBOHYD RES, V255, P183, DOI 10.1016/S0008-6215(00)90978-9; LYON M, 1990, ANAL BIOCHEM, V185, P63, DOI 10.1016/0003-2697(90)90255-8; METCALFE DD, 1990, BIOCHEM J, V272, P51, DOI 10.1042/bj2720051; MICHELSON AM, 1980, ACTA PHYSIOL SCAND, P67; MILNER LS, 1991, J LAB CLIN MED, V118, P427; MOSELEY R, 1995, BBA-GEN SUBJECTS, V1244, P245, DOI 10.1016/0304-4165(95)00010-9; NAGASAWA K, 1992, CARBOHYD RES, V236, P165, DOI 10.1016/0008-6215(92)85014-Q; NEALE TJ, 1993, P NATL ACAD SCI USA, V90, P3645, DOI 10.1073/pnas.90.8.3645; OKASORA T, 1992, NEPHRON, V60, P199, DOI 10.1159/000186739; PANASYUK A, 1994, FREE RADICAL BIO MED, V16, P157, DOI 10.1016/0891-5849(94)90139-2; PYATAK PS, 1980, RES COMMUN CHEM PATH, V29, P113; RAATS CJI, 1995, J AM SOC NEPHROL, V6, P850; REHAN A, 1984, LAB INVEST, V51, P396; RICARDO SD, 1994, J AM SOC NEPHROL, V4, P1974; ROSENZWEIG LJ, 1982, LAB INVEST, V47, P177; SAARI H, 1993, INFLAMMATION, V17, P403, DOI 10.1007/BF00916581; SATO H, 1988, ARTHRITIS RHEUM, V31, P63, DOI 10.1002/art.1780310110; SCHNEEBERGER EE, 1983, LAB INVEST, V49, P445; SHAH SV, 1989, KIDNEY INT, V35, P1093, DOI 10.1038/ki.1989.96; TAMSMA JT, 1994, DIABETOLOGIA, V37, P313, DOI 10.1007/BF00398060; TAY M, 1990, BIOCHEM INT, V20, P767; THAKUR V, 1988, KIDNEY INT, V34, P494, DOI 10.1038/ki.1988.208; UCHIYAMA H, 1990, J BIOL CHEM, V265, P7753; VANBRUGGEN MCJ, 1995, AM J PATHOL, V146, P753; vanBruggen MCJ, 1997, NEPHROL DIAL TRANSPL, V12, P57, DOI 10.1093/ndt/12.1.57; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; VANDENBORN J, 1993, KIDNEY INT, V43, P454, DOI 10.1038/ki.1993.67; vandenBorn J, 1996, J BIOL CHEM, V271, P22802, DOI 10.1074/jbc.271.37.22802; VANDENBORN J, 1995, DIABETOLOGIA, V38, P1169, DOI 10.1007/BF00422365; VANDENBORN J, 1994, J HISTOCHEM CYTOCHEM, V42, P89, DOI 10.1177/42.1.8263327; VANDENHEUVEL LPWJ, 1989, BIOCHEM J, V264, P457, DOI 10.1042/bj2640457; VOLPI N, 1992, ANAL BIOCHEM, V200, P100, DOI 10.1016/0003-2697(92)90283-D; YOSHIOKA T, 1991, J AM SOC NEPHROL, V2, P902; YURCHENCO PD, 1990, ANN NY ACAD SCI, V580, P195, DOI 10.1111/j.1749-6632.1990.tb17929.x; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	57	100	100	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26734	26741		10.1074/jbc.272.42.26734	http://dx.doi.org/10.1074/jbc.272.42.26734			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334259	hybrid, Green Published			2022-12-25	WOS:A1997YB13900093
J	Chen, H; Srinivasan, G; Thompson, EB				Chen, H; Srinivasan, G; Thompson, EB			Protein-protein interactions are implied in glucocorticoid receptor mutant 465*-mediated cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; FUNCTIONAL ANTAGONISM; HORMONE RECEPTOR; C-JUN; GENE; APOPTOSIS; DOMAINS; LINE	Previously we have shown that ICR-27, a clone of glucocorticoid-resistant human leukemic T cells, showed rapid cell loss upon transient transfection with plas mids expressing certain fragments of the human glucocorticoid receptor lacking the ligand binding domain, An extreme example was the frameshift GR mutant 465*, mutated after amino acid 465. This generated a novel al-amino acid ''tail,'' beginning within the second zinc finger of the human glucocorticoid receptor DNA binding domain, a region required for ICR-27 cell death caused by hologlucocorticoid receptor plus hormone, The cell loss mediated by 465* was faster but quantitatively equivalent to that caused by hologlucocorticoid receptor plus hormone, We are therefore investigating the mechanism of action of 465*. We overexpressed 465* with or without a glutathione S-transferase tag fused to its N terminus and tested its ability to affect glucocorticoid response element (GRE)-driven reactions in vitro, Partially purified 465* showed little binding to a consensus GRE, caused virtually no stimulation of transcription from a GRE, and failed to inhibit GR-driven transcription, However, GST-465* ''trapped'' several proteins from ICR-27 cell extracts, including c-Jun; recombinant c-Jun also was bound in vitro, In co-transfection assays of CV-1 cells, 465* expression reduced phorbol ester (12-O-tetradecanoylphorbol-13-acetate) transcriptional activation from a promoter containing multiple AP-1 sites. Further studies proved the repressive activity of 465* was c-Jun-specific and not due to squelching artifacts, The data suggest that interaction of 465* with other proteins, such as c-Jun, might be responsible for its cell killing function.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston					NCI NIH HHS [CA 41407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041407] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; ASHRAF J, 1993, MOL ENDOCRINOL, V7, P631, DOI 10.1210/me.7.5.631; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HARBOUR DV, 1990, J STEROID BIOCHEM, V35, P1, DOI 10.1016/0022-4731(90)90137-H; HARMON JM, 1981, MOL CELL BIOL, V1, P512, DOI 10.1128/MCB.1.6.512; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; IMAI E, 1988, NATURE, V332, P87; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LANZ RB, 1994, ENDOCRINOLOGY, V135, P2183, DOI 10.1210/en.135.5.2183; LATCHMAN DS, 1998, TRANSCRIPTION FACTOR, P77; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nazareth LV, 1996, LEUKEMIA, V10, P1789; NAZARETH LV, 1991, J BIOL CHEM, V266, P12976; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NORMAN MR, 1977, CANCER RES, V37, P3785; PALMER LA, 1992, CANCER RES, V52, P6612; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; RADLERPOHL A, 1993, ANN NY ACAD SCI, V684, P127, DOI 10.1111/j.1749-6632.1993.tb32277.x; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; RYFFEL GU, 1989, NUCLEIC ACIDS RES, V17, P939, DOI 10.1093/nar/17.3.939; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIMONS SS, 1994, VITAM HORM, V48, P49; Srinivasan G, 1997, J STEROID BIOCHEM, V60, P1, DOI 10.1016/S0960-0760(96)00182-3; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; THOMPSON EB, 1994, MOL ENDOCRINOL, V8, P665, DOI 10.1210/me.8.6.665; THULASI R, 1993, J BIOL CHEM, V268, P18306; TSAI SY, 1990, J BIOL CHEM, V265, P17055; WARRIAR N, 1994, J BIOL CHEM, V269, P29010; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YUH YS, 1989, J BIOL CHEM, V264, P10904; Zhou F, 1996, MOL ENDOCRINOL, V10, P306, DOI 10.1210/me.10.3.306; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	53	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25873	25880		10.1074/jbc.272.41.25873	http://dx.doi.org/10.1074/jbc.272.41.25873			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325319	hybrid			2022-12-25	WOS:A1997YA35800074
J	Hemati, N; Ross, SE; Erickson, RL; Groblewski, GE; MacDougald, OA				Hemati, N; Ross, SE; Erickson, RL; Groblewski, GE; MacDougald, OA			Signaling pathways through which insulin regulates CCAAT/enhancer binding protein alpha (C/EBP alpha) phosphorylation and gene expression in 3T3-L1 adipocytes - Correlation with GLUT4 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE TRANSPORTER; TRANSCRIPTIONAL ACTIVATOR PROTEIN; WHITE ADIPOSE-TISSUE; MESSENGER-RNA; CELL LINE; MAMMALIAN PROTEIN; HEPATOMA-CELLS; DIFFERENTIATION; PREADIPOCYTES; PROMOTER	Treatment of 3T3-L1 adipocytes with insulin (IC50 similar to 200 pM insulin) or insulin-like growth factor-1 (IC50 similar to 200 pM IGF-1) stimulates dephosphorylation of CCAAT/enhancer binding protein alpha (C/EBP alpha), a transcription factor involved in preadipocyte differentiation. As assessed by immunoblot analysis of one-and two-dimensional PAGE, insulin appears to dephosphorylate one site within p30C/EBP alpha and an additional site within p42C/EBP alpha. Consistent with insulin causing dephosphorylation of C/EBP alpha through activation of phosphatidylinositol 3-kinase, addition of phosphatidylinositol 3-kinase inhibitors (e.g. wortmannin) blocks insulin-stimulated dephosphorylation of C/EBP alpha. In the absence of insulin, wortmannin or LY294002 enhance C/EBP alpha phosphorylation. Similarly, blocking the activity of FKBP-rapamycin-associated protein with rapamycin increases phosphorylation of C/EBP alpha in the absence of insulin, Dephosphorylation of C/EBP alpha by insulin is partially blocked by rapamycin, consistent with a model in which activation of FKBP-rapamycin-associated protein by phosphatidylinositol 3-kinase results in dephosphorylation of C/EBP alpha. The dephosphorylation of C/EBP alpha by insulin, in conjunction with the insulin-dependent decline in C/EBP alpha mRNA and protein, has been hypothesized to play a role in repression of GLUT4 transcription by insulin, Consistent with this hypothesis, the decline of GLUT4 mRNA following exposure of adipocytes to insulin correlates with dephosphorylation of C/EBP alpha. However, the repression of C/EBP alpha mRNA and protein levels by insulin is blocked with an inhibitor of the mitogen-activated protein kinase pathway without blocking the repression of GLUT4 mRNA, thus dissociating the regulation of C/EBP alpha and GLUT4 mRNAs by insulin, A decline in C/EBP alpha mRNA and protein may not be required to suppress GLUT4 transcription because insulin also induces expression of the dominant-negative form of C/EBP beta (liver inhibitory protein), which blocks transactivation by C/EBP transcription factors.	UNIV MICHIGAN, MED CTR, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan			Ross, Sarah/HII-3018-2022; Erickson, Robin/AAV-3405-2020	Erickson, Robin/0000-0002-3945-6158; MacDougald, Ormond/0000-0001-6907-7960	NIDDK NIH HHS [R01-DK51562] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051562] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; COOPER JA, 1991, METHOD ENZYMOL, V201, P251; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MACDOUGALD OA, 1995, CURR BIOL, V5, P618, DOI 10.1016/S0960-9822(95)00125-4; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; MACKALL JC, 1977, BIOCHEM BIOPH RES CO, V79, P720, DOI 10.1016/0006-291X(77)91171-8; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; McKnight SL, 1992, TRANSCRIPTIONAL REGU, P771; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Park EA, 1997, BIOCHEM J, V322, P343, DOI 10.1042/bj3220343; POTTER JJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P360, DOI 10.1016/0003-9861(92)90529-6; Ramos RA, 1996, MOL CELL BIOL, V16, P5288; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; WISHART MJ, 1994, AM J PHYSIOL-GASTR L, V267, pG676, DOI 10.1152/ajpgi.1994.267.4.G676	51	142	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25913	25919		10.1074/jbc.272.41.25913	http://dx.doi.org/10.1074/jbc.272.41.25913			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325324	hybrid			2022-12-25	WOS:A1997YA35800079
J	Raffy, S; Teissie, J				Raffy, S; Teissie, J			Electroinsertion of glycophorin A in interdigitation-fusion giant unilamellar lipid vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-CELL MEMBRANE; ELECTRIC-FIELD; ERYTHROCYTE-MEMBRANE; BILAYER-MEMBRANES; MAMMALIAN-CELLS; LIPOSOMES; ELECTROPERMEABILIZATION; INSERTION; BREAKDOWN; PROTEIN	Previously we demonstrated that transmembrane back insertion of glycophorin A, a solubilizable intrinsic protein, can be obtained in dipalmitoylphosphatidylcholine multilamellar vesicles, MLVs, by electropulsation (Raffy, S., and Teissie, J. (1995) Eur. J. Biochem. 230, 722-732). Here we report that transmembrane back insertion of protein is obtained by electropulsion of unilamellar giant vesicles, termed interdigitation-fusion vesicles (IFVs), which are better membrane models than MLVs due to their unilamellarity. Electropulsation promotes a field-dependent local permeabilization of the lipid layer, as shown by the associated leakage of entrapped calcein, Glycophorin insertion is assayed by immunofluorescence. Electroinsertion is obtained by pulsing the vesicle/protein mixture. Glycophorin insertion is observed under more drastic electrical conditions than needed for permeabilization, Direct observation of glycophorin insertion in the vesicles under a microscope shows a localized process in agreement with the theoretical prediction. A quantitative evaluation of the immunofluorescence pattern shows that insertion was higher on one side of the vesicle than on the other. This suggests that an electrophoretic movement of the solubilized glycophorin could take place during electropulsation, Insertion of glycophorin, a prefolded intrinsic protein, is then obtained in the lipid bilayer brought transiently to the electropermeabilized state.	CNRS, INST PHARMACOL & BIOL STRUCT, F-31062 TOULOUSE, FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			Teissie, Justin/AAA-5697-2019	Teissie, Justin/0000-0002-7588-8062				ABIDOR IG, 1979, BIOELECTROCH BIOENER, V6, P37; AHL PL, 1994, BBA-BIOMEMBRANES, V1195, P237, DOI 10.1016/0005-2736(94)90262-3; ANTANAVAGE J, 1978, BIOPHYS J, V21, pA1224; ARMITAGE IM, 1977, BIOCHEMISTRY-US, V16, P1317, DOI 10.1021/bi00626a012; BANGHAM AD, 1972, ANNU REV BIOCHEM, V41, P753, DOI 10.1146/annurev.bi.41.070172.003541; BENZ R, 1980, BIOCHIM BIOPHYS ACTA, V597, P637, DOI 10.1016/0005-2736(80)90236-9; BENZ R, 1981, BIOCHIM BIOPHYS ACTA, V640, P169, DOI 10.1016/0005-2736(81)90542-3; Bochkareva E, 1996, J BIOL CHEM, V271, P22256, DOI 10.1074/jbc.271.36.22256; BUSCHL R, 1982, FEBS LETT, V150, P38, DOI 10.1016/0014-5793(82)81300-8; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V902, P360, DOI 10.1016/0005-2736(87)90204-5; CHERNOMORDIK LV, 1990, BIOCHIM BIOPHYS ACTA, V1024, P179, DOI 10.1016/0005-2736(90)90222-A; DEKRUIJFF B, 1991, MEMBRANE FUSION, P209; ELMASHAK EM, 1985, BIOCHEMISTRY-US, V24, P2884, DOI 10.1021/bi00333a010; ELOUAGARI K, 1993, BIOCHIM BIOPHYS ACTA, V1151, P105, DOI 10.1016/0005-2736(93)90077-D; ELOUAGARI K, 1995, J BIOL CHEM, V270, P26970; ELOUAGARI K, 1994, EUR J BIOCHEM, V219, P1031; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GABRIEL B, 1991, METHOD ENZYMOL, V198, P480; HARBICH W, 1979, Z NATURFORSCH A, V34, P1063; HARGREAVES WR, 1978, BIOCHEMISTRY-US, V17, P3759, DOI 10.1021/bi00611a014; Helfrich W., 1974, Physics Letters A, V50A, P115, DOI 10.1016/0375-9601(74)90899-8; HUB HH, 1982, FEBS LETT, V140, P254, DOI 10.1016/0014-5793(82)80907-1; JAIN MK, 1987, BIOCHIM BIOPHYS ACTA, V906, P33, DOI 10.1016/0304-4157(87)90004-9; LOPEZ A, 1988, BIOCHEMISTRY-US, V27, P1222, DOI 10.1021/bi00404a023; MEHRLE W, 1985, FEBS LETT, V185, P89, DOI 10.1016/0014-5793(85)80746-8; MELIKYAN GB, 1989, ELECTROPORATION ELEC, P181; MOUNEIMNE Y, 1989, BIOCHEM BIOPH RES CO, V159, P34, DOI 10.1016/0006-291X(89)92400-5; MOUNEIMNE Y, 1991, BIOCHIM BIOPHYS ACTA, V1066, P83, DOI 10.1016/0005-2736(91)90254-6; MOUNEIMNE Y, 1990, BIOCHIM BIOPHYS ACTA, V1027, P53, DOI 10.1016/0005-2736(90)90047-R; NEEDHAM D, 1989, BIOPHYS J, V55, P1001, DOI 10.1016/S0006-3495(89)82898-X; NEUMANN E, 1989, ELECTROPORATION ELEC, P61; OKU N, 1983, BIOCHIM BIOPHYS ACTA, V734, P54, DOI 10.1016/0005-2736(83)90074-3; PERKINS WR, 1993, CHEM PHYS LIPIDS, V64, P197, DOI 10.1016/0009-3084(93)90066-C; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; RAFFY S, 1995, EUR J BIOCHEM, V230, P722; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; ROBELLO M, 1989, BIOCHIM BIOPHYS ACTA, V982, P173, DOI 10.1016/0005-2736(89)90189-2; ROLS MP, 1990, BIOPHYS J, V58, P1089, DOI 10.1016/S0006-3495(90)82451-6; ROLS MP, 1992, BIOCHIM BIOPHYS ACTA, V1111, P45, DOI 10.1016/0005-2736(92)90272-N; SCHULTE TH, 1979, BIOCHEMISTRY-US, V18, P275, DOI 10.1021/bi00569a006; SELTZER SE, 1995, RADIOLOGY, V194, P775, DOI 10.1148/radiology.194.3.7862978; SEN K, 1990, P NATL ACAD SCI USA, V87, P743, DOI 10.1073/pnas.87.2.743; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SIXOU S, 1990, BIOCHIM BIOPHYS ACTA, V1028, P154, DOI 10.1016/0005-2736(90)90149-I; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; Sowers A. E., 1992, GUIDE ELECTROPORATIO, P29, DOI DOI 10.1016/B978-0-08-091727-6.50006-X; SPRINGER GF, 1966, BIOCHEMISTRY-US, V5, P3254, DOI 10.1021/bi00874a028; STOICHEVA NG, 1994, BBA-BIOMEMBRANES, V1195, P31, DOI 10.1016/0005-2736(94)90005-1; STULEN G, 1981, BIOCHIM BIOPHYS ACTA, V640, P621, DOI 10.1016/0005-2736(81)90092-4; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TEISSIE J, 1981, BIOCHEMISTRY-US, V20, P1548, DOI 10.1021/bi00509a022; TEISSIE J, 1993, BIOPHYS J, V65, P409, DOI 10.1016/S0006-3495(93)81052-X; TEISSIE J, 1987, BIOCHEMISTRY-US, V26, P840, DOI 10.1021/bi00377a027; TEISSIE J, 1989, ELECTROPORATION ELEC, P203; TEISSIE J, 1990, NATO ASI SER H, V47, P149; WEAVER JC, 1984, BIOELECTROCH BIOENER, V12, P393, DOI 10.1016/0302-4598(84)87018-X; WOLF H, 1994, BIOPHYS J, V66, P524, DOI 10.1016/S0006-3495(94)80805-7; ZEIRA M, 1991, P NATL ACAD SCI USA, V88, P4409, DOI 10.1073/pnas.88.10.4409	59	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25524	25530		10.1074/jbc.272.41.25524	http://dx.doi.org/10.1074/jbc.272.41.25524			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325267	hybrid			2022-12-25	WOS:A1997YA35800022
J	Wang, HY; Iynedjian, PB				Wang, HY; Iynedjian, PB			Acute glucose intolerance iu insulinoma cells with unbalanced overexpression of glucokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLETS; GENE-EXPRESSION; RAT-LIVER; SPECTROSCOPY	The INS-r3-GK27 insulinoma cells are endowed with artificially inducible glucokinase under control of the reverse tetracycline-dependent transcriptional activator. Moderate induction of glucokinase has been shown to result in proportionate increases in glycolytic flux and in potentiation of glucose effects on insulin secretion and pyruvate kinase gene expression, In cells with 20-fold overexpression of glucokinase, however, glucose activation of secretion and gene expression was severely impaired, Measurements of the glycolytic flux in cells with 7- and 21-fold increases in glucokinase activity and determination of the flux control coefficient of this enzyme showed that control of glycolysis at the glucokinase step was lost in the cells at the higher level of overexpression. Challenging the cells with glucose above 6 nM resulted in massive accumulation of glucose 6-phosphate and caused a rapid and sustained depletion of cellular ATP, in contrast with the glucose-induced rise in ATP in cells with wild-type glucokinase levels, Loss of cell viability ensued upon prolonged culture in high glucose. In summary, in insulinoma beta cells strongly overexpressing glucokinase, an imbalance between glucose phosphorylation and turnover of glucose 6-phosphate resulted in acute glucose intolerance due to trapping of cellular orthophosphate in dead-end product and severe paralysis of energy metabolism.	UNIV GENEVA,SCH MED,DIV CLIN BIOCHEM & DIABET RES,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva								ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Cardenas ML, 1997, BIOCHEM SOC T, V25, P131, DOI 10.1042/bst0250131; COORE HG, 1964, BIOCHEM J, V93, P66, DOI 10.1042/bj0930066; DOYLE TC, 1993, YEAST, V9, P867, DOI 10.1002/yea.320090807; Fell D., 1997, UNDERSTANDING CONTRO; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GITZELMANN R, 1995, METABOLIC MOL BASES, P905; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRODSKY GM, 1963, AM J PHYSIOL, V205, P638, DOI 10.1152/ajplegacy.1963.205.4.638; ILES RA, 1985, BIOCHEM J, V229, P141, DOI 10.1042/bj2290141; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; KACSER H, 1995, BIOCHEM SOC T, V23, P341, DOI 10.1042/bst0230341; MARIE S, 1993, J BIOL CHEM, V268, P23881; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; SMALL JR, 1993, EUR J BIOCHEM, V213, P613, DOI 10.1111/j.1432-1033.1993.tb17801.x; STORER AC, 1976, BIOCHEM J, V159, P7, DOI 10.1042/bj1590007; Sweet IR, 1996, AM J PHYSIOL-ENDOC M, V271, pE606, DOI 10.1152/ajpendo.1996.271.3.E606; TAL M, 1992, J BIOL CHEM, V267, P17241; VISCHER U, 1987, BIOCHEM J, V241, P249, DOI 10.1042/bj2410249; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372	24	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25731	25736		10.1074/jbc.272.41.25731	http://dx.doi.org/10.1074/jbc.272.41.25731			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325299	hybrid			2022-12-25	WOS:A1997YA35800054
J	Wang, Q; Mullah, B; Hansen, C; Asundi, J; Robishaw, JD				Wang, Q; Mullah, B; Hansen, C; Asundi, J; Robishaw, JD			Ribozyme-mediated suppression of the G protein gamma(7) subunit suggests a role in hormone regulation of adenylylcyclase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; BETA-SUBUNIT; ALPHA-SUBUNIT; SPECIFICITY; EXPRESSION; CLONING; DOMAIN; BRAIN; ASSOCIATION; RECEPTORS	Human HEK 293 cells present a simple and tractable system to directly test the hypothesis that the G protein gamma subunits contribute to the specificity of receptor signaling pathways in vivo. To begin to elucidate the functions of the individual gamma subunits in these cells, a ribozyme strategy was used to specifically inactivate the mRNA encoding the gamma(7) subunit. A phosphorothioated DNA-RNA chimeric hammerhead ribozyme was constructed and analyzed for specificity toward the targeted gamma(7) subunit. In vitro cleavage analysis of this ribozyme revealed a highly efficient cleavage activity directed exclusively toward the gamma(7) RNA transcript. In particular, this ribozyme did not result in cleavage of the gamma(12) RNA transcript, which is 75% identical to the gamma(7) RNA transcript. Using a transient transfection assay, in vivo analysis of this ribozyme showed a specific reduction in both the mRNA and protein expression of the gamma(7) subunit in HEK 293 cells. Coincident with this loss in gamma(7) subunit, there was a specific reduction in the protein expression of the beta(1) subunit, suggesting that the beta(1) and gamma(7) subunits may functionally interact to form a beta gamma dimer in vivo. Functional analysis of the consequences of ribozyme-mediated suppression of the gamma(7) subunit expression indicated that it was associated with significant attenuation of isoproterenol-, but not prostaglandin E-1-, stimulated adenylylcyclase activity. Suppression of the gamma(7) subunit expression had no effect on carbachol- and ATP-mediated stimulation of phosphatidylinositol turnover. Taken together, these results not only indicate the feasibility of using the ribozyme technology to determine the roles of individual gamma subunits in receptor-G protein-effector pathways in vivo, but they point to a specific role of the gamma(7) subunit in the regulation of adenylylcyclase activity in response to isoproterenol.	PENN STATE UNIV, COLL MED, HENRY HOOD MD RES PROGRAM, DANVILLE, PA 17822 USA; APPL BIOSYST INC, FOSTER CITY, CA 94404 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Thermo Fisher Scientific; Applied Biosystems								Barr AJ, 1997, J BIOL CHEM, V272, P2223; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CHANG PS, 1990, CLIN BIOTECHNOL, V2, P23; ERICKSON R, 1992, GENE REGULATION BIOL, P163; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Figler RA, 1996, MOL PHARMACOL, V50, P1587; FOSTER KA, 1991, MOL CELL BIOCHEM, V104, P63; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; GU JL, 1995, CIRC RES, V77, P14, DOI 10.1161/01.RES.77.1.14; HEIDENREICH O, 1992, J BIOL CHEM, V267, P1904; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KVAPIL P, 1994, EUR J BIOCHEM, V226, P193, DOI 10.1111/j.1432-1033.1994.tb20041.x; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; Mullah B, 1996, NUCLEOS NUCLEOT, V15, P419, DOI 10.1080/07328319608002395; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAY K, 1994, GENE, V149, P337, DOI 10.1016/0378-1119(94)90172-4; Ray K, 1996, TRENDS CARDIOVAS MED, V6, P115, DOI 10.1016/1050-1738(96)00021-7; ROBISHAW JD, 1994, METHOD ENZYMOL, V237, P498; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SARGUEIL B, 1995, BIOCHEMISTRY-US, V34, P7739, DOI 10.1021/bi00023a021; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SHIMAYAMA T, 1993, NUCLEIC ACIDS RES, V21, P2605, DOI 10.1093/nar/21.11.2605; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; TAYLOR NR, 1992, NUCLEIC ACIDS RES, V20, P4559, DOI 10.1093/nar/20.17.4559; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WATSON JB, 1994, J NEUROSCI RES, V39, P108, DOI 10.1002/jnr.490390113; WILCOX MD, 1995, J BIOL CHEM, V270, P4189, DOI 10.1074/jbc.270.9.4189; ZHU BT, 1993, J PHARMACOL TOXICOL, V29, P85, DOI 10.1016/1056-8719(93)90055-J	39	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26040	26048		10.1074/jbc.272.41.26040	http://dx.doi.org/10.1074/jbc.272.41.26040			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325341	hybrid			2022-12-25	WOS:A1997YA35800096
J	Wen, LP; Fahrni, JA; Troie, S; Guan, JL; Orth, K; Rosen, GD				Wen, LP; Fahrni, JA; Troie, S; Guan, JL; Orth, K; Rosen, GD			Cleavage of focal adhesion kinase by caspases during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FAS-MEDIATED APOPTOSIS; ENZYME-LIKE PROTEASE; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; LAMIN-A; V-SRC; PP125(FAK); ICE; ASSOCIATION	Apoptotic cells undergo characteristic morphological changes that include detachment of cell attachment from the substratum and loss of cell-cell interactions. Attachment of cells to the extracellular matrix and to other cells is mediated by integrins. The interactions of integrins with the extracellular matrix activates focal adhesion kinase (FAK) and suppresses apoptosis in diverse cell types. Members of the tumor necrosis family such as Fas and Apo-2L, also known as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), induce apoptosis in both suspension and adherent cells through the activation of caspases. These caspases, when activated, cleave substrates that are important for the maintenance of nuclear and membrane integrity. In this study, we show that FAK is sequentially cleaved into two different fragments early in Apo-2L-induced apoptosis. We also demonstrate that FAK cleavage is mediated by caspases and that FAK shows unique sensitivity to different caspases. Our results suggest that disruption of FAK may contribute to the morphological changes observed in apoptotic suspension and adherent cells.	STANFORD UNIV, MED CTR, DEPT PULM & CRIT CARE MED, STANFORD, CA 94305 USA; CORNELL UNIV, COLL VET MED, DEPT PATHOL, CANC BIOL LABS, ITHACA, NY 14853 USA; UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	Stanford University; Cornell University; University of Michigan System; University of Michigan			Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620; Wen, Longping/0000-0003-0384-4578; Rosen, Glenn/0000-0001-8281-5446	NIGMS NIH HHS [GM52890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Cary LA, 1996, J CELL SCI, V109, P1787; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Crouch DH, 1996, ONCOGENE, V12, P2689; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; Darmon AJ, 1996, J BIOL CHEM, V271, P21699, DOI 10.1074/jbc.271.36.21699; Dixit VM, 1996, ADV EXP MED BIOL, V406, P113; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Otey CA, 1996, INT REV CYTOL, V167, P161, DOI 10.1016/S0074-7696(08)61347-9; OWENS LV, 1995, CANCER RES, V55, P2752; PFEFFER KD, 1994, J IMMUNOL, V153, P1789; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413	51	300	305	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26056	26061		10.1074/jbc.272.41.26056	http://dx.doi.org/10.1074/jbc.272.41.26056			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325343	hybrid			2022-12-25	WOS:A1997YA35800098
J	Coletta, M; Costa, H; DeSanctis, G; Neri, F; Smulevich, G; Turner, DL; Santos, H				Coletta, M; Costa, H; DeSanctis, G; Neri, F; Smulevich, G; Turner, DL; Santos, H			pH dependence of structural and functional properties of oxidized cytochrome c'' from Methylophilus methylotrophus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXIAL HISTIDINE; A-STATE; MECHANISM; RESONANCE; ELECTRON; PROTEINS; DITHIONITE	Cytochrome c '' from Methylophilus methylotrophus is an unusual monoheme protein that undergoes a major redox-linked change in the heme arrangement: one of the two axial histidines bound to the iron in the oxidized form is detached upon reduction and a proton is taken up. The kinetics of reduction by sodium dithionite and the spectroscopic properties of the oxidized cytochrome c '' have been investigated over the pH range between 1.4 and 10.0, The rate of reduction displays proton-linked transitions of pK(a) congruent to 5.5 and 2.4, and a spectroscopic transition with a pK(a) congruent to 2.4 is also observed. The protein displays a complete reversibility after exposure to low pH, and both electronic absorption and resonance Raman spectroscopic properties suggest that the transition at lower pH brings about a drastic change in the heme coordination geometry, Circular dichroism spectra indicate that over the same proton-linked transition, the pro tein undergoes a marked decrease (similar to 60%) of the alpha-helical content toward a random coil arrangement, which is recovered upon increasing the ionic strength, The structural change at low pH is Linked to a concerted two-proton transition, suggesting the detachment and protonation of axial histidine(s), Such kinetic and spectroscopic features along with the remarkable capacity of this protein to recover its native structure after exposure to extremely low pH values makes it a promising model for studying folding processes and stability in heme proteins.	UNIV ROMA LA SAPIENZA,DEPT BIOCHEM SCI ALESSANDRO ROSSI FANELLI,I-00185 ROME,ITALY; UNIV NOVA LISBOA,INST TECNOL QUIM & BIOL,P-2780 OEIRAS,PORTUGAL; UNIV CAMERINO,DEPT MOL CELLULAR & ANIM BIOL,I-62032 CAMERINO,MC,ITALY; UNIV FLORENCE,DEPT CHEM,I-52100 FLORENCE,ITALY; UNIV SOUTHAMPTON,DEPT CHEM,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND	Sapienza University Rome; Universidade Nova de Lisboa; University of Camerino; University of Florence; University of Southampton	Coletta, M (corresponding author), UNIV ROMA TOR VERGATA,DEPT EXPT MED & BIOCHEM SCI,VIA TOR VERGATA 135,I-00133 ROME,ITALY.		Costa, Helena Soares/D-7058-2013; Santos, Helena/B-9141-2011; Coletta, Massimo/N-9049-2015; Turner, David L/B-9061-2011; Coletta, Massimiliano/GSN-5927-2022; smulevich, giulietta/A-6510-2008; Turner, David/B-8267-2009	Costa, Helena Soares/0000-0001-8168-3963; Santos, Helena/0000-0002-8050-9485; Turner, David L/0000-0002-3754-6459; Smulevich, Giulietta/0000-0003-3021-8919; COLETTA, Massimiliano/0000-0002-5489-9467				BARAKAT R, 1982, BIOCHIM BIOPHYS ACTA, V679, P393, DOI 10.1016/0005-2728(82)90159-1; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; COSTA HS, 1992, EUR J BIOCHEM, V208, P427, DOI 10.1111/j.1432-1033.1992.tb17204.x; COSTA HS, 1993, EUR J BIOCHEM, V215, P817, DOI 10.1111/j.1432-1033.1993.tb18097.x; GOTO Y, 1993, BIOCHEMISTRY-US, V32, P11878, DOI 10.1021/bi00095a017; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; HAGIHARA Y, 1994, J MOL BIOL, V237, P336, DOI 10.1006/jmbi.1994.1234; JACKSON JT, 1983, J BIOL CHEM, V258, P1799; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; JORDAN T, 1995, PROTEIN SCI, V4, P716; LAMBETH DO, 1973, J BIOL CHEM, V248, P6095; LEITCH FA, 1984, BIOCHEMISTRY-US, V23, P1831, DOI 10.1021/bi00303a039; LOMMEN A, 1990, EUR J BIOCHEM, V192, P653, DOI 10.1111/j.1432-1033.1990.tb19272.x; MARMORINO JL, 1995, BIOCHEMISTRY-US, V34, P3140, DOI 10.1021/bi00010a002; MAYHEW SG, 1978, EUR J BIOCHEM, V85, P535, DOI 10.1111/j.1432-1033.1978.tb12269.x; MOORE GR, 1980, BIOCHIM BIOPHYS ACTA, V590, P261, DOI 10.1016/0005-2728(80)90030-4; SAFO MK, 1991, J AM CHEM SOC, V113, P5497, DOI 10.1021/ja00015a001; SANTOS H, 1988, BIOCHIM BIOPHYS ACTA, V954, P276	18	18	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24800	24804		10.1074/jbc.272.40.24800	http://dx.doi.org/10.1074/jbc.272.40.24800			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312076	hybrid			2022-12-25	WOS:A1997XY97000015
J	Hong, M; Chen, DCR; Klein, PS; Lee, VMY				Hong, M; Chen, DCR; Klein, PS; Lee, VMY			Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; RABBIT SKELETAL-MUSCLE; CHICK SENSORY NEURONS; ALZHEIMERS-DISEASE; INOSITOL MONOPHOSPHATASE; NEUROFIBRILLARY TANGLES; XENOPUS EMBRYOS; NERVOUS-SYSTEM; SENILE PLAQUES; ALPHA-TUBULIN	Lithium is one of the most widely used drugs for treating bipolar (manic-depressive) disorder. Despite its efficacy, the molecular mechanism underlying its action has not been elucidated, One recent study has proposed that lithium inhibits glycogen synthase kinase-3 and thereby affects multiple cellular functions, Because glycogen synthase kinase-3 regulates the phosphorylation of tau (microtubule binding protein that forms paired helical filaments in neurons of the Alzheimer's disease brain), we hypothesized that lithium could affect tau phosphorylation by inhibiting glycogen synthase kinase-3. Using cultured human NT2N neurons, we demonstrate that lithium reduces the phosphorylation of tau, enhances the binding of tau to microtubules, and promotes microtubule assembly through direct and reversible inhibition of glycogen synthase kinase-3. These results provide new insights into how Lithium mediates its effects in the central nervous system, and these findings could be exploited to develop a novel intervention for Alzheimer's disease.	UNIV PENN,SCH MED,CTR NEURODEGENERAT DIS RES,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED HEMATOL ONCOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,INST AGING,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania				Chen, Daniel/0000-0001-6672-6814				ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; ATACK JR, 1993, J NEUROCHEM, V60, P652, DOI 10.1111/j.1471-4159.1993.tb03197.x; ATACK JR, 1994, J PHARMACOL EXP THER, V270, P70; AUER IA, 1995, ACTA NEUROPATHOL, V90, P547; BARRA HS, 1974, BIOCHEM BIOPH RES CO, V60, P1384, DOI 10.1016/0006-291X(74)90351-9; BENNETT GS, 1991, J NEUROCHEM, V57, P120, DOI 10.1111/j.1471-4159.1991.tb02106.x; BENNETT GS, 1991, J NEUROCHEM, V57, P130, DOI 10.1111/j.1471-4159.1991.tb02107.x; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; BOSCH F, 1986, J BIOL CHEM, V261, P6927; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BURSTEIN DE, 1985, J CELL BIOL, V101, P862, DOI 10.1083/jcb.101.3.862; COHEN P, 1982, EUR J BIOCHEM, V124, P21, DOI 10.1111/j.1432-1033.1982.tb05902.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GUNDERSEN GG, 1987, J CELL BIOL, V105, P251, DOI 10.1083/jcb.105.1.251; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; HOLLANDER BA, 1991, J NEUROSCI RES, V28, P332, DOI 10.1002/jnr.490280304; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; LANG E, 1992, BIOCHEM BIOPH RES CO, V187, P783, DOI 10.1016/0006-291X(92)91264-Q; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEE VMY, 1986, J NEUROSCI, V6, P514; MANJI HK, 1995, ARCH GEN PSYCHIAT, V52, P531; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MawalDewan M, 1996, J NEUROPATH EXP NEUR, V55, P1051, DOI 10.1097/00005072-199655100-00005; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Pierce SB, 1996, DEV BIOL, V175, P256, DOI 10.1006/dbio.1996.0113; PIERCE SB, 1995, DEVELOPMENT, V121, P755; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; SATO SM, 1990, DEV BIOL, V137, P135, DOI 10.1016/0012-1606(90)90014-A; Schmidt ML, 1996, J NEUROPATH EXP NEUR, V55, P534, DOI 10.1097/00005072-199605000-00006; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; YASUMOTO T, 1984, SEAFOOD TOXINS, P207; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	63	391	414	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25326	25332		10.1074/jbc.272.40.25326	http://dx.doi.org/10.1074/jbc.272.40.25326			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312151	hybrid			2022-12-25	WOS:A1997XY97000090
J	Statuto, M; Audebet, C; Tonoli, H; SelmiRuby, S; Rousset, B; MunariSilem, Y				Statuto, M; Audebet, C; Tonoli, H; SelmiRuby, S; Rousset, B; MunariSilem, Y			Restoration of cell-to-cell communication in thyroid cell lines by transfection with and stable expression of the connexin-32 gene - Impact on cell proliferation and tissue-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP JUNCTION PROTEIN; C6 GLIOMA-CELLS; EPITHELIAL-CELLS; TRANSFORMED-CELLS; GROWTH-CONTROL; FACTOR-I; CDNA; DNA; TRANSCRIPTION; SEQUENCE	Normal thyroid epithelial cells coexpress connexin-32 and connexin-43, which form distinct gap functions. In primary culture, connexin-43 is expressed by thyrocytes in monolayers or reorganized into follicles, whereas the, expression of eonnexin-32 is dependent upon the reconstitution of follicles, To study the functional impact of connexin-32 gap junctions in thyroid cells, we transfected connexin-32 cDNA in two thyroid-derived communication-deficient cell lines, FRT and FRTL-5. The selected clones, which stably expressed connexin-32 at high levels and exhibited high gap junction-mediated dye-coupling, presented a reduced proliferation rate as compared with that of the corresponding wild-type FRT and FRTL-5 cells; the mean population doubling time was increased by similar to 35%, The proliferation of connexin-32-transfected FRTL-5 cells remained thyrotropin-dependent; the range of thyrotropin concentrations that stimulated growth was the same in transfected and control cells, The expression of connexin-32 led to an increase of thyroglobulin gene expression in FRTL-5 cells, The expression of two other tissue-specific proteins, thyroid transcription factor-1 and Pax-8, was unchanged, These findings provide evidence that connexin-32 gap junction-mediated cell-to-cell communication participates in the control of growth and differentiation of thyroid cells.	FAC MED LYON,RTH LAENNEC,INSERM,U369,F-69372 LYON 08,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			RUBY, Samia/T-1131-2019; selmi-ruby, Samia/L-3509-2016	RUBY, Samia/0000-0001-9491-9285; 				AMBESIIMPIOMBAT.FS, 1982, COLD SPRING HARBOR C, V9, P483; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BOND SL, 1994, CELL GROWTH DIFFER, V5, P179; BRADSHAW SL, 1993, GROWTH REGULAT, V3, P26; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CHEN SC, 1995, CELL GROWTH DIFFER, V6, P681; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVITAREALE D, 1994, BIOCHEM J, V304, P981, DOI 10.1042/bj3040981; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; DERMIETZEL R, 1990, ANAT EMBRYOL, V182, P517; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; FROMAGET C, 1990, J MOL CELL CARDIOL, V22, P1245, DOI 10.1016/0022-2828(90)90061-6; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; GUERRIER A, 1995, J CELL SCI, V108, P2609; GUTHRIE SC, 1989, TRENDS NEUROSCI, V12, P12, DOI 10.1016/0166-2236(89)90150-1; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUMAR NM, 1995, J CELL SCI, V108, P3725; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MESNIL M, 1995, CANCER RES, V55, P629; MUNARISILEM Y, 1991, ENDOCRINOLOGY, V128, P3299, DOI 10.1210/endo-128-6-3299; MunariSilem Y, 1996, EUR J ENDOCRINOL, V135, P251, DOI 10.1530/eje.0.1350251; MUNARISILEM Y, 1994, ENDOCRINOLOGY, V135, P724, DOI 10.1210/en.135.2.724; NAUS CCG, 1992, CANCER RES, V52, P4208; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; STAGG RB, 1990, ENDOCR REV, V11, P302, DOI 10.1210/edrv-11-2-302; STEWART WW, 1978, CELL, V14, P741, DOI 10.1016/0092-8674(78)90256-8; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; VOZZI C, 1995, J CELL BIOL, V131, P1561, DOI 10.1083/jcb.131.6.1561; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218	41	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24710	24716		10.1074/jbc.272.39.24710	http://dx.doi.org/10.1074/jbc.272.39.24710			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305943	hybrid			2022-12-25	WOS:A1997XY51500094
J	Fukasawa, K; Wiener, F; VandeWoude, GF; Mai, SB				Fukasawa, K; Wiener, F; VandeWoude, GF; Mai, SB			Genomic instability and apoptosis are frequent in p53 deficient young mice	ONCOGENE			English	Article						p53; genomic instability; gene amplification; centrosome; Myc; apoptosis	CELL-CYCLE CONTROL; WILD-TYPE P53; DIHYDROFOLATE-REDUCTASE GENE; C-MYC; CANCER-CELLS; AMPLIFICATION; OVEREXPRESSION; CHECKPOINT; ONCOGENES; MOUSE	The loss of p53 tumor suppressor functions results in genetic instability, characteristically associated with changes in chromosome ploidy and gene amplification. In vivo, we find that cells from various organs of 4 to 6-week old p53-nullizygous (p53 (-/-)) mice display aneuploidy and frequent gene amplification as well as evidence for apoptosis. Regardless of tissue types, many p53 (-/-) cells contain multiple centrosomes and abnormally formed mitotic spindles. Thus, chromosome vivo may be associated with abnormal Moreover, we observed a significant increase in the number of cells overexpressing c-Myc in p53 (-/-) mice. Consistent with previous studies showing that c-Myc overexpression is associated with gene amplification in vitro, many of the p53 (-/-) cells exhibited, in the same cell, c-Myc overexpression and amplified c-myc, dihydrofolate reductase (DHFR), and carbamoyl-phosphate synthetase-aspartate transcarbamoyl-dihydroorotase (CAD) genes. Furthermore, apoptosis was frequently observed in cells isolated from p53 (-/-) mice. The apoptotic cells contained abnormally amplified centrosomes, displayed aneuploidy, high levels of c-Myc expression, as web as gene amplification. These results indicate that a high number of aberrant cells is eliminated by p53-independent pathways in vivo.	MANITOBA CANC TREATMENT & RES FDN, MANITOBA INST CELL BIOL, WINNIPEG, MB R3E 0V9, CANADA; UNIV MANITOBA, DEPT PHYSIOL, WINNIPEG, MB R3E 0V9, CANADA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; UNIV CINCINNATI, COLL MED, DEPT CELL BIOL NEUROBIOL & ANAT, CINCINNATI, OH USA; KAROLINSKA INST, CTR MICROBIOL & TUMOR BIOL, S-17177 STOCKHOLM, SWEDEN	University of Manitoba; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University System of Ohio; University of Cincinnati; Karolinska Institutet			Mai, Sabine/E-5667-2017	Mai, Sabine/0000-0002-5797-2201				ALITALO K, 1985, TRENDS BIOCHEM SCI, V10, P194, DOI 10.1016/0968-0004(85)90190-2; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; BISHOP JM, 1995, GENE DEV, V9, P1309, DOI 10.1101/gad.9.11.1309; BLYTH K, 1995, ONCOGENE, V10, P1717; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENIS N, 1991, ONCOGENE, V6, P1453; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEO S, 1994, ONCOGENE, V9, P955; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hessel H, 1996, HISTOCHEM CELL BIOL, V106, P481, DOI 10.1007/BF02473310; HSU B, 1995, ONCOGENE, V11, P175; HUANG AP, 1994, ONCOGENE, V9, P491; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; KARN J, 1989, ONCOGENE, V4, P773; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KUSCHAK TI, 1997, UNPUB; LI X, 1995, CYTOMETRY, V20, P172, DOI 10.1002/cyto.990200210; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAI S, 1995, GENOME, V38, P780, DOI 10.1139/g95-099; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; Mai S, 1996, ONCOGENE, V12, P277; MAI S, 1997, UNPUB; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Oakley B R, 1992, Trends Cell Biol, V2, P1, DOI 10.1016/0962-8924(92)90125-7; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; OTTO E, 1989, J BIOL CHEM, V264, P3390; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PIENTA KJ, 1989, CANCER RES, V49, P2525; RAGIMOV N, 1993, ONCOGENE, V8, P1183; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STARK G, 1993, ADV CANCER RES, V48, P87; STEWART N, 1995, ONCOGENE, V10, P109; TEMIN HM, 1988, CANCER RES, V48, P1697; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WAHL GM, 1989, CANCER RES, V49, P1333; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	49	133	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1295	1302		10.1038/sj.onc.1201482	http://dx.doi.org/10.1038/sj.onc.1201482			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315097				2022-12-25	WOS:A1997XV84500007
J	Howard, KM; Miller, JE; Miwa, M; Olson, MS				Howard, KM; Miller, JE; Miwa, M; Olson, MS			Cell-specific regulation of expression of plasma-type platelet-activating factor acetylhydrolase in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT KUPFFER CELLS; TUMOR-NECROSIS-FACTOR; ACETYLGLYCERYL ETHER PHOSPHORYLCHOLINE; AGGREGATED IMMUNOGLOBULIN-G; FACTOR PAF ACETYLHYDROLASE; SIGNAL-TRANSDUCTION; INTESTINAL ISCHEMIA; CALCIUM IONOPHORE; PURIFICATION; LIPOPOLYSACCHARIDE	Platelet-activating factor (PAF) is a potent proinflammatory phospholipid mediator that causes hypotension, increases vascular permeability, and has been implicated in anaphylaxis, septic shock and several other inflammatory responses. PAF is hydrolyzed and inactivated by the enzyme PAF-acetylhydrolase. In the intact rat, a mesenteric vein infusion of lipopolysaccharide (LPS) served as an acute, liver-focused model of endotoxemia, Plasma PAF-acetylhydrolase activity increased 2-fold by 24 h following LPS administration. Ribonuclease protection experiments demonstrated very low levels of plasma-type PAF-acetylhydrolase mRNA transcripts in the livers of saline-infused rats; however, 24 h following LPS exposure, a 20-fold induction of PAF-acetylhydrolase mRNA was detected. In cells isolated from endotoxin-exposed rat Livers, Northern blot analyses demonstrated that Kupffer cells but not hepatocytes or endothelial cells were responsible for the increased PAF-acetylhydrolase mRNA levels, In Kupffer cells, plasma-type PAF-acetylhydrolase mRNA was induced by 12 h, peaked at 24 h, and remained substantially elevated at 48 h, Induction of neutropenia prior to LPS administration had no effect on the increase in PAF-acetylhydrolase mRNA seen at 24 h. Although freshly isolated Kupffer cells contain barely detectable levels of plasma-type PAF-acetylhydrolase mRNA when Kupffer cells were established in culture, PAF-acetylhydrolase expression became constitutively activated concomitant with cell adherence to the culture plates, Alterations in plasma-type PAF-acetylhydrolase expression may constitute an important mechanism for elevating plasma PAF-acetylhydrolase levels and an important component in minimizing PAF-mediated pathophysiology in livers exposed to endotoxemia.	UNIV TEXAS, HLTH SCI CTR, DEPT SURG, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Howard, KM (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033538] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33538] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUTTERY LDK, 1994, LAB INVEST, V71, P755; BUXTON DB, 1984, J BIOL CHEM, V259, P3758; BUXTON DB, 1984, J BIOL CHEM, V259, P1468; BUXTON DB, 1986, J BIOL CHEM, V261, P644; BUXTON DB, 1987, BIOCHEM J, V243, P493, DOI 10.1042/bj2430493; CAPLAN MS, 1990, J PEDIATR-US, V116, P960, DOI 10.1016/S0022-3476(05)80661-4; CAPLAN MS, 1990, AM REV RESPIR DIS, V142, P1258, DOI 10.1164/ajrccm/142.6_Pt_1.1258; CHAO W, 1989, BIOCHEM J, V261, P77, DOI 10.1042/bj2610077; CHAO W, 1989, J BIOL CHEM, V264, P13591; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHAO W, 1989, BIOCHEM J, V257, P823, DOI 10.1042/bj2570823; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENDO S, 1994, RES COMMUN CHEM PATH, V83, P289; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURUKAWA M, 1993, PEDIATR RES, V34, P237, DOI 10.1203/00006450-199308000-00027; GANDHI CR, 1992, BIOCHEM J, V281, P485, DOI 10.1042/bj2810485; GATHIRAM P, 1989, CIRC SHOCK, V27, P103; GRAHAM RM, 1994, CRIT CARE MED, V22, P204, DOI 10.1097/00003246-199402000-00009; GRUN M, 1977, ACTA HEPATO-GASTRO, V24, P64; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; KARASAWA K, 1994, J BIOCHEM-TOKYO, V116, P374, DOI 10.1093/oxfordjournals.jbchem.a124534; KNOOK DL, 1976, EXP CELL RES, V99, P444, DOI 10.1016/0014-4827(76)90605-4; KORTH R, 1993, LIPIDS, V28, P193, DOI 10.1007/BF02536639; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; LEMANSKE RF, 1983, J IMMUNOL, V130, P2837; MEADE CJ, 1994, J LIPID MEDIAT CELL, V9, P205; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; MOCHIDA S, 1992, J HEPATOL, V16, P266, DOI 10.1016/S0168-8278(05)80656-7; Mustafa SB, 1996, HEPATOLOGY, V23, P1622, DOI 10.1053/jhep.1996.v23.pm0008675186; NARAHARA H, 1993, ARCH BIOCHEM BIOPHYS, V301, P275, DOI 10.1006/abbi.1993.1144; NIJSSEN JG, 1986, BIOCHIM BIOPHYS ACTA, V876, P611, DOI 10.1016/0005-2760(86)90050-0; OLOFSSON P, 1985, ACTA CHIR SCAND, V151, P635; OLSON MS, 1996, LIVER INNERVATION, P75; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; SATOH K, 1991, J CLIN INVEST, V87, P476, DOI 10.1172/JCI115020; SATOH K, 1989, PROSTAGLANDINS, V37, P673; SATOH K, 1993, METABOLISM, V42, P672, DOI 10.1016/0026-0495(93)90231-C; SHENG ZY, 1992, J TRAUMA, V32, P148, DOI 10.1097/00005373-199202000-00006; SHUKLA SD, 1983, J BIOL CHEM, V258, P212; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1993, J BIOL CHEM, V268, P3857; STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; Svetlov SI, 1996, ARCH BIOCHEM BIOPHYS, V327, P113, DOI 10.1006/abbi.1996.0099; TAFFET SM, 1989, CELL IMMUNOL, V120, P291, DOI 10.1016/0008-8749(89)90198-6; TARBET EB, 1991, J BIOL CHEM, V266, P16667; TETTA C, 1990, INT ARCH ALLER A IMM, V91, P244, DOI 10.1159/000235124; Tew DG, 1996, ARTERIOSCL THROM VAS, V16, P591, DOI 10.1161/01.ATV.16.4.591; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; Tsukioka Kazuharu, 1993, Japanese Journal of Allergology, V42, P167; YU SF, 1990, J LEUKOCYTE BIOL, V48, P412, DOI 10.1002/jlb.48.5.412; ZHOU WG, 1992, HEPATOLOGY, V16, P1236; ZHOU WG, 1992, AM J PHYSIOL, V263, pG587, DOI 10.1152/ajpgi.1992.263.5.G587	58	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27543	27548		10.1074/jbc.272.44.27543	http://dx.doi.org/10.1074/jbc.272.44.27543			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346888	hybrid			2022-12-25	WOS:A1997YD47300014
J	Salazar, D; Zhang, LN; deGala, GD; Frerman, FE				Salazar, D; Zhang, LN; deGala, GD; Frerman, FE			Expression and characterization of two pathogenic mutations in human electron transfer flavoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA DEHYDROGENASE; ACIDEMIA TYPE-II; PIG-LIVER; UBIQUINONE OXIDOREDUCTASE; PEPTOSTREPTOCOCCUS-ELSDENII; CIRCULAR-DICHROISM; REDUCTION; PURIFICATION; FIBROBLASTS; MUTAGENESIS	Defects in electron transfer flavoprotein (ETF) or its electron acceptor, electron transfer flavoprotein-ubiquinone oxidoreductase (ETF-QO), cause the human inherited metabolic disease glutaric acidemia type II, In this disease, electron transfer from nine primary flavoprotein dehydrogenases to the main respiratory chain is impaired, Among these dehydrogenases are the four chain length-specific flavoprotein dehydrogenases of fatty acid beta-oxidation. In this investigation, two mutations in the alpha subunit that have been identified in patients were expressed in Escherichia coli, Of the two mutant alleles, alpha T266M and alpha G116R, the former is the most frequent mutation found in patients with ETF deficiency, The crystal structure of human ETF shows that alpha G116 lies in a hydrophobic pocket, under a contact residue of the alpha/beta subunit interface, and that the hydroxyl hydrogen of alpha T266 is hydrogen bonded to N(5) of the FAD; the amide backbone hydrogen of alpha T266 is hydrogen-bonded to C(4)-O of the flavin prosthetic group (Roberts, D, L,, Frerman, F, E, and Kim, J-J. P, (1996) Proc, Natl, Acad, Sci, U.S.A. 93, 14355-14360). Stable expression of the alpha G116R ETF required coexpression of the chaperonins, GroEL and GroES, alpha G116R ETF folds into a conformation different from the wild type, and is catalytically inactive in crude extracts, It is unstable and could not be extensively purified, The alpha T266M ETF was purified and characterized after stabilization to proteolysis in crude extracts, Although the global structure of this mutant protein is unchanged, its flavin environment is altered as indicated by absorption and circular dichroism spectroscopy and the kinetics of flavin release from the oxidized and reduced protein, The loss of the hydrogen bond at N(5) of the flavin and the altered flavin binding increase the thermodynamic stability of the flavin semiquinone by 10-fold relative to the semiquinone of wild type ETF. The mutation has relatively little effect on the reductive half-reaction of ETF catalyzed by sarcosine and medium chain acyl CoA dehydrogenases which reduce the flavin to the semiquinone, However, k(cat)/K-m of ETF-QO in a coupled acyl-CoA:ubiquinone reductase assay with oxidized alpha T266M ETF as substrate is reduced 33-fold; this decrease is due in largest part to a decrease in the rate of disproportionation of the alpha T266M ETF semiquinone catalyzed by ETF-QO.	UNIV COLORADO,SCH MED,DEPT PEDIAT,DENVER,CO 80262; UNIV COLORADO,SCH MED,PROGRAM CELLULAR & DEV BIOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NICHD NIH HHS [P30 HD04024] Funding Source: Medline; NIDDK NIH HHS [R01 DK49726] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD004024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049726] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKMANN JD, 1985, BIOCHEMISTRY-US, V24, P3913, DOI 10.1021/bi00336a016; BEDZYK LA, 1993, J BIOL CHEM, V268, P20211; BLAUER G, 1993, BIOCHEMISTRY-US, V32, P6674, DOI 10.1021/bi00077a021; Clark W.M., 1960, OXIDATION REDUCTION, P184; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; EDMONDSO.DE, 1971, BIOCHEMISTRY-US, V10, P113; EWEG JK, 1980, J AM CHEM SOC, V102, P51, DOI 10.1021/ja00521a010; FRENEAUX E, 1992, J CLIN INVEST, V90, P1670; FRERMAN FE, 1985, BIOCHEM MED METAB B, V33, P38, DOI 10.1016/0006-2944(85)90124-3; FRERMAN FE, 1985, P NATL ACAD SCI USA, V82, P4517, DOI 10.1073/pnas.82.13.4517; GATENBY AA, 1992, PLANT MOL BIOL, V19, P677, DOI 10.1007/BF00026793; GHISLA S, 1989, EUR J BIOCHEM, V18, P1; GORELICK RJ, 1985, BIOCHEMISTRY-US, V24, P6830, DOI 10.1021/bi00345a015; Griffin KJ, 1997, BIOCHEMISTRY-US, V36, P4194, DOI 10.1021/bi962572v; GUSTAFSON WG, 1986, J BIOL CHEM, V26, P7733; HERRICK KR, 1994, J BIOL CHEM, V269, P32239; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HSU MC, 1971, J AM CHEM SOC, V93, P3515; HUSAIN M, 1983, BIOCHEM J, V209, P541, DOI 10.1042/bj2090541; HUSAIN M, 1984, BIOCHEM J, V219, P1043, DOI 10.1042/bj2191043; KOZIOL J, 1965, BIOCHIM BIOPHYS ACTA, V102, P289, DOI 10.1016/0926-6585(65)90221-9; LOEHR JP, 1990, PEDIATR RES, V27, P311, DOI 10.1203/00006450-199003000-00024; MADDEN M, 1984, BIOCHEM J, V224, P577, DOI 10.1042/bj2240577; MASSEY V, 1963, BIOCHEM Z, V338, P474; Massey V, 1990, FLAVINS FLAVOPROTEIN, P59; MAYHEW SG, 1974, EUR J BIOCHEM, V44, P579, DOI 10.1111/j.1432-1033.1974.tb03515.x; MCILWAIN H, 1937, J CHEM SOC, V2, P1704; MCKEAN MC, 1983, J BIOL CHEM, V258, P1866; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; RAMSAY RR, 1987, BIOCHEM J, V241, P883, DOI 10.1042/bj2410883; ROBERTS DL, 1996, P NATL ACAD SCI USA, V90, P14355; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1993, J BIOCHEM, V114, P215, DOI 10.1093/oxfordjournals.jbchem.a124157; SWENSON RP, 1994, BIOCHEMISTRY-US, V33, P8505, DOI 10.1021/bi00194a015; TATWAWADI SV, 1968, J ELECTROANAL CHEM, V17, P411, DOI 10.1016/S0022-0728(68)80221-9; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; WHITFIELD CD, 1974, J BIOL CHEM, V249, P2801	37	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26425	26433		10.1074/jbc.272.42.26425	http://dx.doi.org/10.1074/jbc.272.42.26425			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334218	hybrid			2022-12-25	WOS:A1997YB13900052
J	Potter, D; Miziorko, HM				Potter, D; Miziorko, HM			Identification of catalytic residues in human mevalonate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI PHOSPHOFRUCTOKINASE; SACCHAROMYCES-CEREVISIAE; ACTIVE-SITE; RAT-LIVER; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; BINDING-SITE; ERG12 GENE; PEROXISOMES	cDNA encoding human mevalonate kinase has been overexpressed and the recombinant enzyme isolated, This stable enzyme is a dimer of 42-kDa subunits and exhibits a V-m = 37 units/mg, K-m(ATP) = 74 mu M, and Km(DL-MVA) = 24 mu M. The sensitivity of enzyme to water-soluble carbodiimide modification of carboxyl groups prompted evaluation of four invariant acidic amino acids (Glu-19, Glu-193, Asp-204, and Glu-296) by site-directed mutagenesis, Elimination of Glu-19's carboxyl group (E19A, E19Q) destabilizes the enzyme, whereas E19D is stable but exhibits only similar to 2-fold changes in V-m and K-m values, E296Q is a stable enzyme, which exhibits kinetic parameters comparable to those measured for wild-type enzyme, E193A is a labile protein, whereas E193Q is stable, exhibiting >50-fold diminution in V-m and elevated K-m values for ATP (similar to 20-fold) and mevalonate (similar to 40-fold). Such effects would be compatible with a role for Glu-193 in interacting with the cation of the MgATP substrate. D204A and D204N are stable enzymes lacking substantial mevalonate kinase activity, The active sites of these Asp-204 mutants are intact, based on their ability to bind a spin-labeled ATP analog with stoichiometries and equilibrium binding constants that are comparable to those determined for wild-type enzyme, Competitive displacement experiments demonstrate that the Asp-204 mutants can bind ATP with K-d values that are comparable to estimates for wild-type enzyme, The >40,000 fold diminution in k(cat) for the Asp-204 mutants and the demonstration that they contain an otherwise intact active site support assignment of a crucial catalytic role to Asp-204. The assignment of Asp-204 as the catalytic base that facilitates deprotonation of the C-5 hydroxyl of mevalonic acid would be compatible with the experimental observations.	MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	Medical College of Wisconsin					NCRR NIH HHS [RR-01008] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; ARORA KK, 1991, J BIOL CHEM, V266, P5359; BERGER SA, 1992, BIOCHEMISTRY-US, V31, P9237, DOI 10.1021/bi00153a017; BEYTIA E, 1970, J BIOL CHEM, V245, P5450; BIARDI L, 1994, J BIOL CHEM, V269, P1197; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUENGER E, 1988, ANAL BIOCHEM, V173, P321, DOI 10.1016/0003-2697(88)90196-0; CHARLIER HA, 1994, BIOCHEMISTRY-US, V33, P9343, DOI 10.1021/bi00197a039; DORSEY JK, 1968, J BIOL CHEM, V243, P4667; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; GIBSON KM, 1988, EUR J PEDIATR, V148, P250, DOI 10.1007/BF00441413; GIBSON KM, 1989, ENZYME, V41, P47, DOI 10.1159/000469050; GRAY JC, 1972, BIOCHIM BIOPHYS ACTA, V279, P290, DOI 10.1016/0304-4165(72)90145-6; GREEN PC, 1993, J BIOL CHEM, V268, P5085; HARWOOD HJ, 1982, J LIPID RES, V23, P754; Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8; HELLINGA HW, 1987, NATURE, V327, P437, DOI 10.1038/327437a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; KOTEICHE HA, 1995, BIOCHEMISTRY-US, V34, P15068, DOI 10.1021/bi00046a012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LEE CS, 1983, BIOCHIM BIOPHYS ACTA, V747, P215, DOI 10.1016/0167-4838(83)90100-0; MILDVAN AS, 1965, J BIOL CHEM, V240, P238; OULMOUDEN A, 1991, CURR GENET, V19, P9, DOI 10.1007/BF00362081; OULMOUDEN A, 1990, GENE, V88, P253, DOI 10.1016/0378-1119(90)90039-T; Potter D, 1997, J BIOL CHEM, V272, P5741, DOI 10.1074/jbc.272.9.5741; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; RIDER MH, 1994, BIOCHEM J, V300, P111, DOI 10.1042/bj3000111; RIOU C, 1994, GENE, V148, P293, DOI 10.1016/0378-1119(94)90701-3; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; Schneider D. J., 1989, BIOL MAGN RESON, V8, P1; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SOLER M, 1979, INT J BIOCHEM, V10, P931, DOI 10.1016/0020-711X(79)90126-5; STAMELLOS KD, 1992, J BIOL CHEM, V267, P5560; TANAKA RD, 1990, J BIOL CHEM, V265, P2391; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; TCHEN TT, 1958, J BIOL CHEM, V233, P1100; TSAY YH, 1991, MOL CELL BIOL, V11, P620, DOI 10.1128/MCB.11.2.620; Wanders RJA, 1996, J INHERIT METAB DIS, V19, P193, DOI 10.1007/BF01799427	40	65	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25449	25454		10.1074/jbc.272.41.25449	http://dx.doi.org/10.1074/jbc.272.41.25449			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325256	hybrid			2022-12-25	WOS:A1997YA35800011
J	Arai, H; Monteclaro, FS; Tsou, CL; Franci, C; Charo, IF				Arai, H; Monteclaro, FS; Tsou, CL; Franci, C; Charo, IF			Dissociation of chemotaxis from agonist-induced receptor internalization in a lymphocyte cell line transfected with CCR2B - Evidence that directed migration does not require rapid modulation of signaling at the receptor level	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOATTRACTANT PROTEIN-1 RECEPTOR; CHEMOKINE; BETA; TAIL; TRANSDUCTION; SPECIFICITY; MECHANISM; BIOLOGY	To investigate the role of the carboxyl-terminal region (52 amino acids) of the monocyte chemoattractant protein 1 receptor (CCR2B) in chemotaxis, we created a series of mutants and expressed them in a murine pre-B lymphocyte cell Line. Truncation of the cytoplasmic carboxyl tail to 20 amino acids had little or no effect on chemotaxis or signal transduction, but further truncation resulted in marked functional defects. Upon incubation with monocyte chemoattractant protein 1, CCR2B underwent rapid and extensive internalization, and this was impaired progressively as the carboxyl tail was truncated from 52 to 8 amino acids. Mutation of all of the serine and threonine residues in the carboxyl tail to alanine also resulted in markedly impaired receptor internalization but did not affect signaling or chemotaxis. We conclude that the membrane-proximal portion of the cytoplasmic carboxyl tail of CCR2B is critically involved in chemotaxis and signal transduction, but neither phosphorylation of carboxyl serines or threonines nor internalization of the receptor is required for robust chemotaxis.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Arai, Hidenori/P-9816-2017	Arai, Hidenori/0000-0002-9000-6849	NHLBI NIH HHS [HL52773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Arai H, 1996, MOL PHARMACOL, V50, P522; BENBARUCH A, 1995, J BIOL CHEM, V270, P9121, DOI 10.1074/jbc.270.16.9121; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; Franci C, 1996, J IMMUNOL, V157, P5606; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; SCHALL TJ, 1994, CYTOKINE HDB, P419; Wong LM, 1997, J BIOL CHEM, V272, P1038, DOI 10.1074/jbc.272.2.1038; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	24	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25037	25042		10.1074/jbc.272.40.25037	http://dx.doi.org/10.1074/jbc.272.40.25037			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312111	hybrid			2022-12-25	WOS:A1997XY97000050
J	Giglione, C; Parrini, MC; Baouz, S; Bernardi, A; Parmeggiani, A				Giglione, C; Parrini, MC; Baouz, S; Bernardi, A; Parmeggiani, A			A new function of p120-GTPase-activating protein - Prevention of the guanine nucleotide exchange factor-stimulated nucleotide exchange on the active form of Ha-Ras p21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; SWITCH-II REGION; SDC25 C-DOMAIN; SACCHAROMYCES-CEREVISIAE; EFFECTOR INTERACTIONS; CATALYTIC DOMAIN; TERMINAL DOMAIN; BINDING DOMAIN; IN-VITRO; GDP	This work studies the coordination of the action of GTPase-activating protein (GAP) and guanine nucleotide exchange factor (GEF) on activated human c-Ha-Ras p21, Purified human p120-GAP was obtained with a new efficient procedure. To distinguish the GTPase-activating effect of p120-GAP from other effects dependent on the interaction with activated Ha-Has, the nonhydrolyzable GTP analogue guanosine 5'-O-(thiotriphosphate) (GTP gamma S) was used, The results showed that the GTP gamma S/GTP gamma S exchange enhanced by the C-terminal catalytic domain of the yeast GEF Sdc25p (C-Sdc25p) is prevented by p120-GAP, This effect is strictly specific for the activated form of Ha-Ras, the target of GAP; no effect on Ha Ras GDP was detectable. The GAP catalytic domain also inhibited C-Sdc25p but to a lower extent, The interfering effect by p120-GAP was also evident in a homologous mammalian system, using full length mouse RasGEF, its C terminal half-molecule, or C-terminal cat alytic domain, As a consequence of this inhibition, presence of p120-GAP enhanced the regeneration of Ha-Ras.GTP gamma S by GEF at a GDP:GTP gamma S ratio mimicking the in vice GDP:GTP ratio, Our work describes a novel function of p120-GAP and suggests a mechanism by which GAP protects Ha-Ras.GTP in vivo against unproductive exchanges, This constrain is likely involved in the regulation of the physiological GDP/GTP cycle of Ras and in the action of p120-GAP as downstream effector of Ras. Helix alpha 3 is proposed as a Ras element playing a key-role in the interference between GAP and GEF on Ras.	ECOLE POLYTECH,EQUIPE 2,GRP BIOPHYS,F-91128 PALAISEAU,FRANCE; UNIV PARIS 07,INST JACQUES MONOD,F-75251 PARIS,FRANCE	Institut Polytechnique de Paris; UDICE-French Research Universities; Universite Paris Cite			Parrini, Maria Carla/J-5390-2016	Parrini, Maria Carla/0000-0002-7082-9792; Giglione, Carmela/0000-0002-7475-1558				ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; CRECHET JB, 1993, J BIOL CHEM, V268, P14836; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HAUBRUCK H, 1991, BIOCHIM BIOPHYS ACTA, V1072, P215, DOI 10.1016/0304-419X(91)90015-D; HOWE LR, 1993, ONCOGENE, V8, P2583; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; MIRISOLA MG, 1994, J BIOL CHEM, V269, P15740; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; NUREKAMAL MSA, 1992, MOL BIOL CELL, V3, P1437, DOI 10.1091/mbc.3.12.1437; PAI EF, 1990, EMBO J, V9, P23512; PARRINI MC, 1995, BIOCHEMISTRY-US, V34, P13776, DOI 10.1021/bi00042a008; Parrini MC, 1996, EMBO J, V15, P1107, DOI 10.1002/j.1460-2075.1996.tb00448.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POULLET P, 1995, EUR J BIOCHEM, V227, P537, DOI 10.1111/j.1432-1033.1995.tb20421.x; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; Sermon BA, 1996, J BIOL CHEM, V271, P1566, DOI 10.1074/jbc.271.3.1566; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; TORTI M, 1992, J BIOL CHEM, V267, P8293; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEIJLAND A, 1992, MOL MICROBIOL, V6, P683, DOI 10.1111/j.1365-2958.1992.tb01516.x; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; WOOD DR, 1994, J BIOL CHEM, V269, P5322; YODERHILL J, 1995, J BIOL CHEM, V270, P27615, DOI 10.1074/jbc.270.46.27615; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	49	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25128	25134		10.1074/jbc.272.40.25128	http://dx.doi.org/10.1074/jbc.272.40.25128			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312123	hybrid			2022-12-25	WOS:A1997XY97000062
J	Pezet, A; Ferrag, F; Kelly, PA; Edery, M				Pezet, A; Ferrag, F; Kelly, PA; Edery, M			Tyrosine docking sites of the rat prolactin receptor required for association and activation of Stat5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; GAMMA SIGNAL-TRANSDUCTION; COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTOR; INTRACELLULAR DOMAIN; DIFFERENTIAL ACTIVATION; FUNCTIONAL-ANALYSIS; CYTOKINE RECEPTORS; CYTOPLASMIC DOMAIN; JAK3 EXPRESSION	Prolactin (PRL) interacts with a single chain prolactin-specific receptor of the cytokine receptor superfamily. PRL triggers activation of Jak2 kinase which phosphorylates the PRL receptor itself and the mammary gland factor, Stat5, a member of the family of signal transducers and activators of transcription (Stat). Selection of the particular substrate (Stat 5), that is characterized by transcriptional responses to PRL, has been shown to be determined by specific tyrosine-based motifs common to many cytokine receptors. PRL-induced activation of Stat5 was abolished in 293 fibroblasts expressing PRL receptor mutants lacking all intracellular tyrosines. We have identified tyrosine phosphorylation sites of the PRL receptor (residues 580, 479, and 473) necessary for maximal Stat5 activation and subsequent Stat5-dependent gene transcription. Moreover, we have shown that none of the tyrosine residues of the PRL receptor are implicated in activation of Jak2. This study demonstrates that only specific tyrosines in the PRL receptor are phosphorylated and are in fact utilized differentially for Stat5-mediated transcriptional signaling.	UNIV PARIS 05, INSERM, U344, F-75730 PARIS 15, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Kelly, Paul/A-7951-2008					BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Berlanga JJ, 1997, J BIOL CHEM, V272, P2050; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Gao J, 1996, MOL ENDOCRINOL, V10, P847, DOI 10.1210/me.10.7.847; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; Hackett RH, 1997, J BIOL CHEM, V272, P11128; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Jabbour HN, 1996, MOL CELL ENDOCRINOL, V123, P17, DOI 10.1016/0303-7207(96)03892-0; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; May P, 1996, FEBS LETT, V394, P221, DOI 10.1016/0014-5793(96)00955-6; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUSSO T, 1995, J EXP MED, V181, P1425, DOI 10.1084/jem.181.4.1425; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pezet A, 1997, MOL CELL ENDOCRINOL, V129, P199, DOI 10.1016/S0303-7207(97)00063-4; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; RUI H, 1994, J BIOL CHEM, V269, P5364; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TORTOLANI PJ, 1995, J IMMUNOL, V155, P5220; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang XZ, 1996, MOL ENDOCRINOL, V10, P1249, DOI 10.1210/me.10.10.1249; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Xu BXC, 1996, J BIOL CHEM, V271, P19768, DOI 10.1074/jbc.271.33.19768; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	72	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25043	25050		10.1074/jbc.272.40.25043	http://dx.doi.org/10.1074/jbc.272.40.25043			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312112	hybrid			2022-12-25	WOS:A1997XY97000051
J	Ehrhart, EJ; Segarini, P; Tsang, MLS; Carroll, AG; BarcellosHoff, MH				Ehrhart, EJ; Segarini, P; Tsang, MLS; Carroll, AG; BarcellosHoff, MH			Latent transforming growth factor beta 1 activation in situ: quantitative and functional evidence after low-dose gamma-irradiation	FASEB JOURNAL			English	Article						ionizing radiation; reactive oxygen species; mammary gland; extracellular matrix; collagen; gene expression	MOLECULAR-WEIGHT COMPLEX; MATRIX GENE-EXPRESSION; MOUSE MAMMARY-GLAND; TGF-BETA; EXTRACELLULAR-MATRIX; IONIZING-RADIATION; PLASMINOGEN-ACTIVATOR; PULMONARY FIBROSIS; COLLAGEN-SYNTHESIS; BINDING-PROTEIN	The biological activity of transforming growth factor beta 1 (TCF-beta) is controlled by its secretion as a latent complex in which it is noncovalently associated with latency-associated peptide (LAP). Activation is the extracellular process in which TGF-beta is released from LAP, and is considered to be a primary regulatory control, We recently reported rapid and persistent changes in TGF-beta immunoreactivity in conjunction with extracellular matrix remodeling in gamma-irradiated mouse mammary gland, Our hypothesis is that these specific changes in immunoreactivity are indicative of latent TGF-beta activation, In the present study, we determined the radiation dose response and tested whether a functional relationship exists between radiation-induced TGF-beta and collagen type III remodeling, After radiation exposures as low as 0.1 Gy, we detected increased TGF-beta immunoreactivity in the mammary epithelium concomitant with decreased LAP immunostaining, which are events consistent with activation, Quantitative image analysis demonstrated a significant (P=0.0005) response at 0.1 Gy without an apparent threshold and a linear dose response to 5 Gy, However, in the adipose stroma, loss of LAP demonstrated a qualitative threshold at 0.5 Gy, Loss of LAP paralleled induction of collagen III immunoreactivity in this tissue compartment, We tested whether TGF-beta mediates collagen III expression by treating animals with TGF-beta panspecific monoclonal antibody, 1D11.16, administered i.p. shortly before irradiation, Radiation-induced collagen III staining in the adipose stroma was blocked in an antibody dose-dependent manner, which persisted through 7 days postirradiation, RNase protection assay revealed that radiation-induced elevation of total gland collagen III mRNA was also blocked by neutralizing antibody treatment, These data provide functional confirmation of the hypothesis that radiation exposure leads to latent TGF-beta activation, support our interpretation of the reciprocal shift in immunoreactivity as evidence of activation, and implicate TGF-beta as a mediator of tissue response to ionizing radiation, The sensitivity of activation to low radiation doses points to a potential role for TGF-beta in orchestrating tissue response to oxidative stress, As such, radiation may be useful as a probe to delineate the consequences of latent TGF-beta 1 activation in situ.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA; COLORADO STATE UNIV, FT COLLINS, CO 80523 USA; CELTRIX PHARMACEUT INC, SANTA CLARA, CA 95050 USA; R&D SYST INC, MINNEAPOLIS, MN 55413 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Colorado State University								ANSCHER MS, 1990, RADIAT RES, V122, P77, DOI 10.2307/3577586; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BAHADORI L, 1995, AM J PATHOL, V146, P1140; Barcellos-Hoff MH, 1996, J MAMMARY GLAND BIOL, V1, P353, DOI 10.1007/BF02017391; BARCELLOSHOFF MH, 1994, J CLIN INVEST, V93, P892, DOI 10.1172/JCI117045; BARCELLOSHOFF MH, 1993, CANCER RES, V53, P3880; BarcellosHoff MH, 1996, MOL ENDOCRINOL, V10, P1077, DOI 10.1210/me.10.9.1077; BARCELLOSHOFF MH, 1995, AM J PATHOL, V147, P1228; BOOTHMAN DA, 1991, CANCER RES, V51, P5587; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; CANNEY PA, 1990, BRIT J RADIOL, V63, P620, DOI 10.1259/0007-1285-63-752-620; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREELY JJ, 1992, AM J PATHOL, V140, P45; DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; DASCH JR, 1989, J IMMUNOL, V142, P1536; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DIMARI SJ, 1991, AM J RESP CELL MOL, V4, P455, DOI 10.1165/ajrcmb/4.5.455; Ehrhart EJ, 1996, RADIAT RES, V145, P157, DOI 10.2307/3579170; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; FLAUMENHAFT R, 1992, MOL BIOL CELL, V3, P1057, DOI 10.1091/mbc.3.10.1057; FLAUMENHAFT R, 1992, J CELL BIOL, V118, P901, DOI 10.1083/jcb.118.4.901; Franko AJ, 1997, RADIAT RES, V147, P245, DOI 10.2307/3579426; FREEMAN BA, 1982, LAB INVEST, V47, P412; FUKUNAGA N, 1992, INT J RADIAT ONCOL, V24, P949, DOI 10.1016/0360-3016(92)90479-2; GROTENDORST GR, 1989, J CELL PHYSIOL, V140, P396, DOI 10.1002/jcp.1041400226; HAINAUT P, 1993, CANCER RES, V53, P4469; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HOYT DG, 1988, J PHARMACOL EXP THER, V246, P765; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; KHALIL N, 1991, AM J RESP CELL MOL, V5, P155, DOI 10.1165/ajrcmb/5.2.155; LAIHO M, 1992, Critical Reviews in Oncogenesis, V3, P1; MAASILTA P, 1991, INT J RADIAT ONCOL, V20, P973, DOI 10.1016/0360-3016(91)90193-8; MARTIN M, 1993, RADIAT RES, V134, P63, DOI 10.2307/3578502; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; METSARANTA M, 1989, BIOCHIM BIOPHYS ACTA, P241; MIYAZONO K, 1993, GROWTH FACTORS, V8, P11, DOI 10.3109/08977199309029130; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NUNES I, 1995, J IMMUNOL, V155, P1450; PANIZZON RG, 1988, RADIAT RES, V116, P145, DOI 10.2307/3577485; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; PIRCHER R, 1986, BIOCHEM BIOPH RES CO, V136, P30, DOI 10.1016/0006-291X(86)90872-7; RAGHU G, 1989, AM REV RESPIR DIS, V140, P95, DOI 10.1164/ajrccm/140.1.95; REISS M, 1997, IN PRESS BR CANC RES; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SHENKAR R, 1994, AM J RESP CELL MOL, V11, P351, DOI 10.1165/ajrcmb.11.3.8086171; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TSAO CH, 1985, RADIAT RES, V103, P393, DOI 10.2307/3576761; VOLLBERG TM, 1991, EXP CELL RES, V193, P93, DOI 10.1016/0014-4827(91)90542-3; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WESTERGRENTHORSSON G, 1990, EXP CELL RES, V186, P192, DOI 10.1016/0014-4827(90)90227-2; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	64	191	196	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1997	11	12					991	1002		10.1096/fasebj.11.12.9337152	http://dx.doi.org/10.1096/fasebj.11.12.9337152			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337152				2022-12-25	WOS:A1997YA72400009
J	Arbuzova, A; Wang, JY; Murray, D; Jacob, J; Cafiso, DS; McLaughlin, S				Arbuzova, A; Wang, JY; Murray, D; Jacob, J; Cafiso, DS; McLaughlin, S			Kinetics of interaction of the myristoylated alanine-rich C kinase substrate, membranes, and calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE UNILAMELLAR VESICLES; MARCKS-RELATED PROTEIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHOLIPID-VESICLES; ELECTROSTATIC SWITCH; CALCIUM-CALMODULIN; DEPENDENT BINDING; ASSOCIATION; PHOSPHORYLATION; PEPTIDES	Membrane binding of the myristoylated alanine-rich C kinase substrate (MARCKS) requires both its myristate chain and basic ''effector'' region. Previous studies with a peptide corresponding to the effector region, MARCKS-(151-175), showed that the 13 basic residues interact electrostatically with acidic lipids and that the 5 hydrophobic phenylalanine residues penetrate the polar head group region of the bilayer, Here we describe the kinetics of the membrane binding of fluorescent (acrylodan-labeled) peptides measured with a stopped-flow technique, Even though the peptide penetrates the polar head group region, the association of MARCKS-(151-175) with membranes is extremely rapid; association occurs with a diffusion-limited association rate constant, For example, k(on) = 10(11) M-1 s(-1) for the peptide binding to 100-nm diameter phospholipid vesicles, As expected theoretically, k(on) is independent of factors that affect the molar partition coefficient, such as the mole fraction of acidic lipid in the vesicle and the salt concentration The dissociation rate constant (k(off)) is similar to 10 s(-1) (lifetime = 0.1 s) for vesicles with 10% acidic lipid in 100 mM KCl. Ca2+-calmodulin (Ca2+. CaM) decreases markedly the lifetime of the peptide on vesicles, e.g. from 0.1 to 0.01 s in the presence of 5 mu M Ca2+. CaM. Our results suggest that Ca2+. CaM collides with the membrane-bound MARCKS (151-175) peptide and pulls the peptide off rapidly, We discuss the biological implications of this switch mechanism, speculating that an increase in the level of Ca2+-calmodulin could rapidly release phosphatidylinositol 4,5-bisphosphate that previous work has suggested is sequestered in lateral domains formed by MARCKS and MARCKS-(151-175).	SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,HLTH SCI CTR,STONY BROOK,NY 11794; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901; UNIV VIRGINIA,BIOPHYS PROGRAM,CHARLOTTESVILLE,VA 22901	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Virginia; University of Virginia				Arbuzova, Anna/0000-0003-2462-147X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024971, R37GM024971, R01GM035215] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24971, GM35215] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; BERG HC, 1983, RANDOM WALKS BIOL, P17; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; COBURN C, 1993, BIOPHYS J, V64, P60; DIEBLER H, 1969, Pure and Applied Chemistry, V20, P93, DOI 10.1351/pac196920010093; EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011; ERTEL A, 1993, BIOPHYS J, V64, P426, DOI 10.1016/S0006-3495(93)81383-3; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; KOELCHENS S, 1993, CHEM PHYS LIPIDSA, V65, P1; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; KUZELOVA K, 1994, BIOCHEMISTRY-US, V33, P9447, DOI 10.1021/bi00198a010; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LU Y, 1995, BIOCHEMISTRY-US, V34, P10777, DOI 10.1021/bi00034a010; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MCINTOSH TJ, 1986, BIOCHEMISTRY-US, V25, P4058, DOI 10.1021/bi00362a011; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MUI BLS, 1993, BIOPHYS J, V64, P443, DOI 10.1016/S0006-3495(93)81385-7; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOYES RM, 1961, PROG REACT KINET MEC, V1, P129; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROUX M, 1988, EUR BIOPHYS J BIOPHY, V16, P267, DOI 10.1007/BF00254062; Schleiff E, 1996, J BIOL CHEM, V271, P26794, DOI 10.1074/jbc.271.43.26794; SCHWARZ G, 1989, BIOCHIM BIOPHYS ACTA, V979, P82, DOI 10.1016/0005-2736(89)90526-9; SCHWARZ G, 1987, BIOPHYS CHEM, V26, P163, DOI 10.1016/0301-4622(87)80019-4; SCHWARZ G, 1987, BIOPHYS J, V52, P685, DOI 10.1016/S0006-3495(87)83263-0; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361	53	69	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27167	27177		10.1074/jbc.272.43.27167	http://dx.doi.org/10.1074/jbc.272.43.27167			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341159	hybrid			2022-12-25	WOS:A1997YC65900055
J	Karlsson, M; Contreras, JA; Hellman, U; Tornqvist, H; Holm, C				Karlsson, M; Contreras, JA; Hellman, U; Tornqvist, H; Holm, C			cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase - Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; ALPHA/BETA-HYDROLASE FOLD; RAT ADIPOSE-TISSUE; NUCLEOTIDE-SEQUENCE; LIPOPROTEIN LIPASE; PURIFICATION; MUTAGENESIS; PROTEINS; SERINE; GENE	Monoglyceride lipase catalyzes the last step in the hydrolysis of stored triglycerides in the adipocyte and presumably also complements the action of lipoprotein lipase in degrading triglycerides from chylomicrons and very low density lipoproteins. Monoglyceride Lipase was cloned from a mouse adipocyte cDNA library. The predicted amino acid sequence consisted of 302 amino acids, corresponding to a molecular weight. of 33,218, The sequence showed no extensive homology to other known mammalian proteins, but a number of microbial proteins, including two bacterial lysophospholipases and a family of haloperoxidases, were found to be distantly related to this enzyme, By means of multiple sequence alignment and secondary structure prediction, the structural elements in monoglyceride lipase, as well as the putative catalytic triad, were identified, The residues of the proposed triad, Ser-122, in a GXSXG motif, Asp-239, and His-269, were confirmed by site-directed mutagenesis experiments. Northern blot analysis revealed that monoglyceride lipase is ubiquitously expressed among tissues, with a transcript size of about 4 kilobases.	LUND UNIV,DEPT CELL & MOL BIOL,SECT MOL SIGNALLING,S-22100 LUND,SWEDEN; LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN; UNIV LUND HOSP,DEPT PEDIAT,S-22185 LUND,SWEDEN; NOVO NORDISK AS,DK-2820 GENTOFTE,DENMARK	Lund University; Ludwig Institute for Cancer Research; Lund University; Skane University Hospital; Novo Nordisk								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CYGLER M, 1993, PROTEIN SCI, V2, P366; DEREWENDA ZS, 1993, ADV PROTEIN CHEM, V45, P1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FELLER G, 1991, DNA CELL BIOL, V10, P381, DOI 10.1089/dna.1991.10.381; FREDRIKSON G, 1986, BIOCHIM BIOPHYS ACTA, V876, P288, DOI 10.1016/0005-2760(86)90286-9; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; HECHT HJ, 1994, NAT STRUCT BIOL, V1, P532, DOI 10.1038/nsb0894-532; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HOLM C, 1986, J BIOL CHEM, V261, P5659; HOLM C, 1994, FEBS LETT, V344, P234, DOI 10.1016/0014-5793(94)00403-X; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; NILSSONEHLE P, 1971, BIOCHIM BIOPHYS ACTA, V248, P114, DOI 10.1016/0005-2760(71)90081-6; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; OZAKI E, 1995, BIOSCI BIOTECH BIOCH, V59, P1204, DOI 10.1271/bbb.59.1204; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SHIRAI K, 1982, J BIOL CHEM, V257, P1253; TORNQVIST H, 1978, J LIPID RES, V19, P654; TORNQVIST H, 1972, J LIPID RES, V13, P424; TORNQVIST H, 1974, J LIPID RES, V15, P291; TORNQVIST H, 1976, J BIOL CHEM, V251, P813; TORNQVIST H, 1978, BIOCHIM BIOPHYS ACTA, V530, P474, DOI 10.1016/0005-2760(78)90167-4	27	319	333	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27218	27223		10.1074/jbc.272.43.27218	http://dx.doi.org/10.1074/jbc.272.43.27218			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341166	hybrid			2022-12-25	WOS:A1997YC65900062
J	Lin, Q; Taylor, SJ; Shalloway, D				Lin, Q; Taylor, SJ; Shalloway, D			Specificity and determinants of Sam68 RNA binding - Implications for the biological function of K homology domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGILE-X SYNDROME; ACTIN MESSENGER-RNA; PROTEIN SAM68; C-SRC; MITOSIS; GENE; SIGNAL; ACTIVATION; POLYMERASE; FMR1	Sam68, a specific target of the Src tyrosine kinase in mitosis, possesses features common to RNA-binding proteins, including a K homology (KH) domain, To elucidate its biological function, we first set out to identify RNA species that bound to Sam68 with high affinity using in vitro selection, From a degenerate 40-mer pool, 15 RNA sequences were selected that bound to Sam68 with K-d values of 12-140 nM. The highest affinity RNA sequences (K-d similar to 12-40 nM) contained a UAAA motif; mutation to UACA abolished binding to Sam68, Binding of the highest affinity ligand, G8-5, was assessed to explore the role of different regions of Sam68 in RNA binding, The KH domain alone did not bind G8-5, but a fragment containing the KH domain and a region of homology within the Sam68 subgroup of KH-containing proteins was sufficient for G8-5 binding, Deletion of the KH domain or mutation of RR domain residues analogous to loss-of-function mutations in the human Fragile X syndrome gene product and the Caenorhabditis elegans tumor suppressor protein Gld-l abolished G8-5 binding, Our results establish that a RB domain-containing protein can bind RNA with specificity and high affinity and suggest that specific RNA binding is integral to the functions of some regulatory proteins in growth and development.	CORNELL UNIV,BIOCHEM MOL & CELL BIOL SECT,ITHACA,NY 14853	Cornell University					NCI NIH HHS [CA32317] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032317] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arning S, 1996, RNA, V2, P794; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346, DOI 10.1016/0968-0004(91)90141-H; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; Ebersole TA, 1996, NAT GENET, V12, P260, DOI 10.1038/ng0396-260; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; Fischer U, 1996, TRENDS CELL BIOL, V6, P290, DOI 10.1016/0962-8924(96)20030-3; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GIBSON TJ, 1993, TRENDS BIOCHEM SCI, V18, P331, DOI 10.1016/0968-0004(93)90068-X; HILL MA, 1994, J CELL BIOL, V126, P1221, DOI 10.1083/jcb.126.5.1221; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; Kislauskis Edward H., 1992, Current Opinion in Cell Biology, V4, P975, DOI 10.1016/0955-0674(92)90128-Y; LATHAM VM, 1994, J CELL BIOL, V126, P1211, DOI 10.1083/jcb.126.5.1211; LIU KB, 1995, P NATL ACAD SCI USA, V92, P5012, DOI 10.1073/pnas.92.11.5012; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; NEEL H, 1995, CURR BIOL, V5, P413, DOI 10.1016/S0960-9822(95)00082-0; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; Sambrook J., 1989, MOL CLONING LAB MANU, V3, P18; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Shi H, 1997, MOL CELL BIOL, V17, P2649, DOI 10.1128/MCB.17.5.2649; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TODA T, 1994, HUM MOL GENET, V3, P465, DOI 10.1093/hmg/3.3.465; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H	42	139	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27274	27280		10.1074/jbc.272.43.27274	http://dx.doi.org/10.1074/jbc.272.43.27274			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341174	hybrid			2022-12-25	WOS:A1997YC65900070
J	Linnekin, D; DeBerry, CS; Mou, S				Linnekin, D; DeBerry, CS; Mou, S			Lyn associates with the Juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CYTOKINE SIGNAL-TRANSDUCTION; FACTOR-INDUCED PROLIFERATION; SRC-FAMILY KINASES; GROWTH-FACTOR; PROTOONCOGENE PRODUCT; AUTOIMMUNE-DISEASE; ESCHERICHIA-COLI; DEFICIENT MICE; RECEPTOR	Stem cell factor (SCF) is a cytokine critical for normal hematopoiesis. The receptor for SCF is c-Kit, a receptor tyrosine kinase. Our laboratory is interested in delineating critical components of the SCF signal transduction pathway in hematopoietic tissue. The present study examines activation of Src family members in response to SCF. Stimulation of cell lines as well as normal progenitor cells with SCF rapidly increased tyrosine phosphorylation of the Src family member Lyn. Peak responses were noted 10-20 min after SCF treatment, and phosphorylation of Lyn returned to basal levels 60-90 min after stimulation, SCF also induced increases in Lyn kinase activity in, vitro. Lyn coimmunoprecipitated with c-Kit, and studies with GST fusion proteins demonstrated that Lyn readily associated with the juxtamembrane region of c-Kit. Treatment of cells with either Lyn antisense oligonucleotides or PPI, a Src family inhibitor, resulted in dramatic inhibition of SCF-induced proliferation. These data demonstrate that SCF rapidly activates Lyn and suggest that Lyn is critical in SCF-induced proliferation in hematopoietic cells.	NCI,FREDERICK CANC RES & DEV CTR,INTRAMURAL RES & SUPPORT PROGRAM,SAIC FREDERICK,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Linnekin, D (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,LAB LEUKOCYTE BIOL,DIV BASIC SCI,BLDG 567,RM 226,FREDERICK,MD 21702, USA.							ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ANDERSON SM, 1995, J IMMUNOL, V155, P1660; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; FRORATH B, 1992, BIOTECHNIQUES, V12, P558; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KAPLAN M, 1996, IMMUNITY, V3, P313; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI Y, 1995, J IMMUNOL, V154, P2165; LI ZH, 1992, BIOCHEM BIOPH RES CO, V187, P1536, DOI 10.1016/0006-291X(92)90477-3; LINNEKIN D, 1994, BLOOD, V84, P94, DOI 10.1182/blood.V84.1.94.bloodjournal84194; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Paulson R F, 1995, Semin Immunol, V7, P267, DOI 10.1006/smim.1995.0031; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SCHEUERMANN RH, 1994, P NATL ACAD SCI USA, V91, P4048, DOI 10.1073/pnas.91.9.4048; SHIMODA L, 1996, NATURE, V380, P627; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; TORIGOE T, 1992, BLOOD, V80, P617; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688	40	140	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27450	27455		10.1074/jbc.272.43.27450	http://dx.doi.org/10.1074/jbc.272.43.27450			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341198	hybrid			2022-12-25	WOS:A1997YC65900094
J	Scheper, GC; Mulder, J; Kleijn, M; Voorma, HO; Thomas, AAM; vanWijk, R				Scheper, GC; Mulder, J; Kleijn, M; Voorma, HO; Thomas, AAM; vanWijk, R			Inactivation of eIF2B and phosphorylation of PHAS-I in heat-shocked rat hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INITIATION-FACTOR 4E; NUCLEOTIDE EXCHANGE FACTOR; CAP-DEPENDENT TRANSLATION; HELA-CELLS; RABBIT RETICULOCYTES; RIBOSOMAL-PROTEINS; GLYCOGEN-SYNTHASE; FACTOR EIF-4E; INSULIN	Various factors are involved in the heat shock-induced inhibition of protein synthesis, Changes upon heat shock in phosphorylation, leading to inactivation, of eukaryotic initiation factors (eIFs) eIF2 and eIF4E have been shown for several cell types, However, in mammalian cells these changes occur at temperatures of 43 degrees C or higher while protein synthesis is already affected at milder heat shock temperatures, In searching far the cranes for the inhibition of protein synthesis, the regulation of eIF2 and eIF4E by additional factors was analyzed. In this respect, the activity of eIF2B was measured during and after heat shook. A very clear correlation was found between the activity of this guanine exchange factor and the levels of protein synthesis, also at mild heat shock conditions. Changes in the phosphorylation of eIF4E and of the eIF4E-binding protein PHAS-I were also analyzed. Surprisingly, in H35 cells as well as in some other cell lines, PHAS-I phosphorylation was increased by heat shock, whereas in others it was decreased, Therefore, decreasing the eIF4E availability under stressful conditions does not seem to be a general mechanism to inhibit protein synthesis by heat shack, Regulation of eIF2B activity appears to be the main mechanism to control translation initiation after heat shock at mild temperatures.			Scheper, GC (corresponding author), UNIV UTRECHT,DEPT MOL CELL BIOL,PADUALAAN 8,NL-3584 CH UTRECHT,NETHERLANDS.		Scheper, Gert C/D-7001-2014					Azpiazu I, 1996, J BIOL CHEM, V271, P5033; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; DUNCAN RF, 1995, BIOCHEMISTRY-US, V34, P2985, DOI 10.1021/bi00009a030; DUNCAN RF, 1996, TRANSLATIONAL CONTRO, P271; ERNST V, 1982, HEAT SHOCK BACTERIA, P215; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HICKEY ED, 1982, BIOCHEMISTRY-US, V21, P1513, DOI 10.1021/bi00536a008; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JOHNSTON AM, 1984, EUR J BIOCHEM, V150, P507; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KENNEDY IM, 1984, FEBS LETT, V169, P267, DOI 10.1016/0014-5793(84)80331-2; Kleijn M, 1995, J CELL BIOCHEM, V59, P443, DOI 10.1002/jcb.240590405; Kleijn M, 1996, FEBS LETT, V396, P165, DOI 10.1016/0014-5793(96)01097-6; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MARIANO TM, 1986, BIOCHEM BIOPH RES CO, V138, P519, DOI 10.1016/S0006-291X(86)80527-7; MCCORMICK W, 1969, J MOL BIOL, V39, P315, DOI 10.1016/0022-2836(69)90320-9; MEHTA HB, 1983, J BIOL CHEM, V258, P3438; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MIZZEN LA, 1988, J CELL BIOL, V109, P1467; NOVER L, 1991, HEAT SHOCK RESPONSE, P299; OLSEN AS, 1983, MOL CELL BIOL, V3, P2017, DOI 10.1128/MCB.3.11.2017; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PANNIERS R, 1988, J BIOL CHEM, V263, P5519; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; Rhoads RE, 1995, CURR TOP MICROBIOL, V203, P131; SCHAMHART DHJ, 1984, RADIAT RES, V98, P82, DOI 10.2307/3576053; SCHARF KD, 1982, CELL, V30, P427, DOI 10.1016/0092-8674(82)90240-9; TAS PWL, 1987, EUR J BIOCHEM, V163, P553, DOI 10.1111/j.1432-1033.1987.tb10903.x; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; VANWIJK R, 1993, INT J HYPERTHER, V9, P137, DOI 10.3109/02656739309061486; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625	54	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26850	26856		10.1074/jbc.272.43.26850	http://dx.doi.org/10.1074/jbc.272.43.26850			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341116	hybrid			2022-12-25	WOS:A1997YC65900012
J	Jin, G; Howe, PH				Jin, G; Howe, PH			Regulation of clusterin gene expression by transforming growth factor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TGF-BETA; APOLIPOPROTEIN J/CLUSTERIN; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; BINDING SEQUENCE; CELLS; RECEPTORS; ELEMENTS	Transforming growth factor beta (TGF beta) induces the expression of a wide variety of genes in many cell types. Our previous studies have shown that TGF beta stimulates both clusterin mRNA and protein levels, and induces its accumulation in the nucleus of CCL64 cells. To further investigate the molecular mechanism of clusterin mRNA induction by TGF beta, we created a 1.3-kilobase rat clusterin promoter/luciferase reporter construct. We demonstrate that TGF beta enhances luciferase activity 2.5-6fold in transient transfection assays of epithelial, endothelial, and fibroblast cell lines. Deletional analysis reveals that an AP-1-binding site (5'-TGAGTCA) in the minimal promoter region is necessary for initiating transactivation by TGF beta. A single T to G base mutation in the AP-1 site (5'-TGAGGCA) abolishes TGF beta-induced clusterin promoter transactivation. In transcription factor decoy experiments, 23-mer oligonucleotides of wild type AP-1 reduce TGF beta induction of clusterin mRNA levels and promoter transactivation, while all oligonucleotide containing the mutated AP-1 site has no effect. Two specific protein kinase C inhibitors, GF109203X and calphostin C, block TGF beta-induced clusterin mRNA levels and promoter transactivation. Together these results indicate that TGF beta regulates clusterin gene expression through an AP-1 site and its cognate transcription factor AP-1, and requires the involvement of protein kinase C.	CLEVELAND CLIN FDN,DEPT CELL BIOL NC1,LERNER RES INST,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Case Western Reserve University					NATIONAL CANCER INSTITUTE [R01CA055536, R29CA055536] Funding Source: NIH RePORTER; NCI NIH HHS [CA55536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Atfi A, 1995, P NATL ACAD SCI USA, V92, P12110, DOI 10.1073/pnas.92.26.12110; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BETTUZZI S, 1991, BIOCHEM BIOPH RES CO, V175, P810, DOI 10.1016/0006-291X(91)91637-R; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRANDES ME, 1991, J IMMUNOL, V147, P1600; Brown TL, 1996, BIOL REPROD, V55, P740, DOI 10.1095/biolreprod55.4.740; BROWN TL, 1995, BIOL REPROD, V52, P1038, DOI 10.1095/biolreprod52.5.1038; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BURKEY BF, 1991, J LIPID RES, V32, P1039; CAMPBELL MJ, 1995, BIOTECHNIQUES, V18, P1027; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; HALSTEAD J, 1995, J BIOL CHEM, V270, P13600, DOI 10.1074/jbc.270.23.13600; HARDARDOTTIR I, 1994, J CLIN INVEST, V94, P1304, DOI 10.1172/JCI117449; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HERAULT Y, 1992, NUCLEIC ACIDS RES, V20, P6377, DOI 10.1093/nar/20.23.6377; Hocevar BA, 1996, P NATL ACAD SCI USA, V93, P7655, DOI 10.1073/pnas.93.15.7655; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI L, 1990, J BIOL CHEM, V265, P1556; LI Q, 1994, J BIOL CHEM, V269, P17508; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; MICHEL D, 1995, EUR J BIOCHEM, V229, P215, DOI 10.1111/j.1432-1033.1995.0215l.x; MILLER DA, 1989, MOL ENDOCRINOL, V3, P1108, DOI 10.1210/mend-3-7-1108; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MORGAN TE, 1995, J NEUROIMMUNOL, V58, P101, DOI 10.1016/0165-5728(94)00194-S; MOSES HL, 1989, ADV GROWTH HORMONE G, P191; MUID RE, 1991, FEBS LETT, V293, P169, DOI 10.1016/0014-5793(91)81178-B; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P6157, DOI 10.1021/bi952981b; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P309, DOI 10.1021/bi951880a; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; ROSEMBLIT N, 1994, J MOL ENDOCRINOL, V13, P69, DOI 10.1677/jme.0.0130069; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TAKESHITA A, 1995, J IMMUNOL, V155, P419; THOMASSALGAR S, 1994, J BIOL CHEM, V269, P17879; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WONG P, 1994, EUR J BIOCHEM, V221, P917, DOI 10.1111/j.1432-1033.1994.tb18807.x; WONG P, 1993, J BIOL CHEM, V268, P5021; WONG P, 1994, BIOCH CELL BIOL, V72, P449; ZWAIN IH, 1994, MOL CELL NEUROSCI, V5, P229, DOI 10.1006/mcne.1994.1027	63	85	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26620	26626		10.1074/jbc.272.42.26620	http://dx.doi.org/10.1074/jbc.272.42.26620			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334243	hybrid			2022-12-25	WOS:A1997YB13900077
J	Li, YT; Wang, LX; Pavlova, NV; Li, SC; Lee, YC				Li, YT; Wang, LX; Pavlova, NV; Li, SC; Lee, YC			alpha-KDOase activity in oyster and synthesis of alpha- and beta-4-methylumbelliferyl ketosides of 3-deoxy-D-manno-octulosonic acid (KDO)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; N-ACETYLNEURAMINIC ACID; FLUOROMETRIC ASSAY; ESCHERICHIA-COLI; NEURAMINIDASE; C-13; LIPOPOLYSACCHARIDES; POLYSACCHARIDE; SUBSTRATE	Although alpha- and beta-linked 3-deoxy-D-manno-octulosonic acid (KDO) is found in lipopolysaccharides (LPSs) of Gram-negative bacteria, capsular polysaccharides of microorganisms, and plants, very little is known about its degradation, Using both thin-layer chromatography and the periodate-thiobarbituric acid reaction, we found that the hepatopancreas of oyster (Crassostrea virginica) contained an enzyme (alpha-KDOase) capable of releasing alpha-linked KDO from LPSs, To facilitate the studies of alpha-KDOase, we have carried out the synthesis of 4-methylumbelliferyl-alpha-KDO (alpha-KDO-MU) by conjugating the glycosyl chloride of the per-O-acetylated methylester of KDO with methylumbelliferone by the S(N)2 type reaction and the catalyzed phase-transfer, In both cases, the beta-anomer was obtained as the major product with a yield of about 80%, whereas the yield of alpha-anomer was only about 7%, Attempts to increase the yield of alpha-anomer were not successful, alpha-BDO-MU was used as substrate to follow the purification of alpha-KDOase from oyster hepatopancreas. The pH optimum for oyster alpha-KDOase was determined to be 4.5 using Re-LPS as substrate and 3.0 using alpha-KDO-MU as substrate. The enzyme was found to be stable in the pH range of 3-8, This enzyme released KDO from different LPSs, including Re-LPS from Escherichia coli and Salmonella minnesota, Rd-LPS from S. minnesota, and de-O-acyl-Re-LPS (Kiang, J., Szu, S, C., Wang, L.X., Tang, M., and Lee, Y. C. (1997) Anal, Biochem, 245, 97-101).	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University	Li, YT (corresponding author), TULANE UNIV,SCH MED,DEPT BIOCHEM SL43,1430 TULANE AVE,NEW ORLEANS,LA 70112, USA.		wang, xl/Y-8251-2019; Wang, Lai-Xi/E-8790-2019; Wang, Lai-Xi/E-8755-2019	Wang, Lai-Xi/0000-0003-4293-5819; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009970, R01DK009970] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 09970] Funding Source: Medline; NINDS NIH HHS [NS 09626] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BHATTACHARJEE AK, 1978, BIOCHEMISTRY-US, V17, P645, DOI 10.1021/bi00597a013; CLAESSON A, 1982, ACTA CHEM SCAND B, V36, P719, DOI 10.3891/acta.chem.scand.36b-0719; DROGE W, 1970, EUR J BIOCHEM, V14, P175, DOI 10.1111/j.1432-1033.1970.tb00276.x; FURUHATA K, 1986, CHEM PHARM BULL, V34, P2725; GHALAMBOR MA, 1966, J BIOL CHEM, V241, P3207; HARRIS G, 1954, CHEM IND-LONDON, P249; HORI H, 1988, TETRAHEDRON LETT, V29, P6317, DOI 10.1016/S0040-4039(00)82335-7; ITOH M, 1986, CHEM PHARM BULL, V34, P1479; Kiang J, 1997, ANAL BIOCHEM, V245, P97, DOI 10.1006/abio.1996.9951; LEDUR A, 1978, EUR J BIOCHEM, V84, P579, DOI 10.1111/j.1432-1033.1978.tb12201.x; MYERS RW, 1980, ANAL BIOCHEM, V101, P166, DOI 10.1016/0003-2697(80)90056-1; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; ROTHERMEL J, 1990, CARBOHYD RES, V196, P29, DOI 10.1016/0008-6215(90)84104-3; SCHWARCZ JA, 1972, CAN J CHEMISTRY, V50, P3667, DOI 10.1139/v72-581; STRAIN SM, 1983, J BIOL CHEM, V258, P2906; STRAIN SM, 1983, J BIOL CHEM, V258, P3466; TAYLOR PW, 1974, BIOCHEM BIOPH RES CO, V61, P148, DOI 10.1016/0006-291X(74)90546-4; Unger F. M., 1981, ADV CARBOHYD CHEM BI, V38, P323; UNGER FM, 1980, CARBOHYD RES, V80, P191, DOI 10.1016/S0008-6215(00)85325-2; YORK WS, 1985, CARBOHYD RES, V138, P109, DOI 10.1016/0008-6215(85)85228-9	20	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26419	26424		10.1074/jbc.272.42.26419	http://dx.doi.org/10.1074/jbc.272.42.26419			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334217	hybrid			2022-12-25	WOS:A1997YB13900051
J	Obata, H; Hayashi, K; Nishida, W; Momiyama, T; Uchida, A; Ochi, T; Sobue, K				Obata, H; Hayashi, K; Nishida, W; Momiyama, T; Uchida, A; Ochi, T; Sobue, K			Smooth muscle cell phenotype-dependent transcriptional regulation of the alpha 1 integrin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; CHICKEN CALDESMON GENE; LONG TERMINAL REPEAT; PROMOTER ELEMENTS; TRANSGENIC MICE; C-FOS; EXPRESSION; ACTIN; IDENTIFICATION; COLLAGEN	The expressional regulation of chicken alpha 1 integrin in smooth muscle cells was studied. The alpha 1 integrin mRNA was expressed developmentally and was distributed dominantly in vascular and visceral smooth muscles in chick embryos. In a primary culture of smooth muscle cells, alpha 1 integrin expression was dramatically down-regulated during serum-induced dedifferentiation. Promoter analyses revealed that the 5'-upstream region (-516 to +281) was sufficient for transcriptional activation in differentiated smooth muscle cells but not in dedifferentiated smooth muscle cells or chick embryo fibroblasts. Like other alpha integrin promoters, the promoter region of the alpha 1 integrin gene lacks TATA and CCAAT boxes and contains binding sites for AP1 and AP2. The essential difference from other alpha integrin promoters is the presence of a CArG box-like motif. Deletion and site-directed mutation analyses revealed that the CArG box-like motif was an essential cis-element for transcriptional activation in differentiated smooth muscle cells, whereas the binding sites for AP1 and AP2 were not. Using specific antibodies, a nuclear protein factor specifically bound to the CArG; box-like motif was identified as serum response factor. These results indicate that (yl integrin expression in smooth muscle cells is regulated transcriptionally in a phenotype-dependent manner and that serum response factor binding plays a crucial role in this regulation.	OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT NEUROCHEM & NEUROPHARMACOL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT ORTHOPAED SURG, SUITA, OSAKA 565, JAPAN; MIE UNIV, SCH MED, DEPT ORTHOPAED SURG, TSU, MIE 514, JAPAN	Osaka University; Osaka University; Mie University								AUDET JF, 1994, DNA CELL BIOL, V13, P1071, DOI 10.1089/dna.1994.13.1071; BELKIN AM, 1988, J BIOL CHEM, V263, P6631; BELKIN VM, 1990, J CELL BIOL, V111, P2159, DOI 10.1083/jcb.111.5.2159; BIRUKOV KG, 1991, CELL TISSUE RES, V266, P579, DOI 10.1007/BF00318599; BLANK RS, 1992, J BIOL CHEM, V267, P984; BORRIONE AC, 1989, EUR J BIOCHEM, V183, P413, DOI 10.1111/j.1432-1033.1989.tb14943.x; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; DUBAND JL, 1992, DEVELOPMENT, V116, P585; GILGENKRANTZ H, 1992, J BIOL CHEM, V267, P10823; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HARUNA M, 1993, BIOCHEM BIOPH RES CO, V197, P145, DOI 10.1006/bbrc.1993.2453; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HEDIN U, 1990, DIFFERENTIATION, V44, P222, DOI 10.1111/j.1432-0436.1990.tb00621.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; IGNATIUS MJ, 1988, NEURON, V1, P713, DOI 10.1016/0896-6273(88)90170-5; Kashiwada K, 1997, J BIOL CHEM, V272, P15396, DOI 10.1074/jbc.272.24.15396; KATOH Y, 1994, J BIOL CHEM, V269, P30538; KEMP PR, 1995, BIOCHEM J, V310, P1037, DOI 10.1042/bj3101037; KORHONEN M, 1990, J CELL BIOL, V111, P1245, DOI 10.1083/jcb.111.3.1245; KOTELIANSKY VE, 1985, FEBS LETT, V182, P67, DOI 10.1016/0014-5793(85)81155-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; LIU SH, 1995, DEV GENET, V16, P229, DOI 10.1002/dvg.1020160303; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; MECHTERSHEIMER G, 1994, AM J PATHOL, V144, P1172; Moessler H, 1996, DEVELOPMENT, V122, P2415; NAKANO Y, 1991, GENE, V99, P285; NUEDA A, 1993, J BIOL CHEM, V268, P19305; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Samaha FF, 1996, J BIOL CHEM, V271, P395, DOI 10.1074/jbc.271.1.395; SEALEY L, 1987, MOL CELL BIOL, V7, P787, DOI 10.1128/MCB.7.2.787; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SKINNER MP, 1994, AM J PATHOL, V145, P1070; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Soulez M, 1996, BIOCHEM BIOPH RES CO, V219, P418, DOI 10.1006/bbrc.1996.0248; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; UEKI N, 1987, P NATL ACAD SCI USA, V84, P9049, DOI 10.1073/pnas.84.24.9049; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; YANO H, 1995, J BIOL CHEM, V270, P23661, DOI 10.1074/jbc.270.40.23661; YANO H, 1994, BIOCHEM BIOPH RES CO, V201, P618, DOI 10.1006/bbrc.1994.1746; ZUTTER MM, 1994, J BIOL CHEM, V269, P463	52	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26643	26651		10.1074/jbc.272.42.26643	http://dx.doi.org/10.1074/jbc.272.42.26643			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334246	hybrid			2022-12-25	WOS:A1997YB13900080
J	Pourquier, P; Pilon, AA; Kohlhagen, G; Mazumder, A; Sharma, A; Pommier, Y				Pourquier, P; Pilon, AA; Kohlhagen, G; Mazumder, A; Sharma, A; Pommier, Y			Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps - Importance of DNA end phosphorylation and camptothecin effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ILLEGITIMATE RECOMBINATION; EUKARYOTIC TOPOISOMERASE; BINDING SEQUENCE; CLEAVAGE SITES; DUPLEX DNA; STRAND; INHIBITORS; CELL; BASE; REPLICATION	We used purified mammalian topoisomerases I (top1) and oligonucleotides containing a unique top1 cleavage site to study top1-mediated cleavage and recombination in the presence of nicks and short gaps mimicking DNA damage, In general, top1 cleavage was not induced opposite to the nicks, and nicks upstream from the top1 cleavage site suppressed top1 activity, Irreversible top1 cleavage complexes (''suicide products'' or ''aborted complexes'') were produced in DNA containing nicks or short gaps just opposite to the normal top1 cleavage site, Camptothecin enhanced the formation of the aborted top1 complexes only for nicks downstream from the cleavage site, These aborted (suicide) complexes can mediate DNA recombination and promote illegitimate recombination by catalyzing the ligation of nonhomologous DNA fragments (accepters), We report for the first time that top1-mediated recombination is greatly en enhanced by the presence of a phosphate at the 5' terminus of the top1 aborted complex (donor DNA), By contrast, phosphorylation of the 3' terminus of the gap did not affect recombination, At concentrations that strongly enhanced inhibition of intramolecular religation, resulting in an increase of top1 cleavable complexes, camptothecin did not reduce recombination (intermolecular religation). Nicks or gaps with 5'-phosphate termini would be expected to be produced directly by ionizing radiations or by processing of abasic sites and DNA lesions induced by carcinogens or drugs used in cancer chemotherapy, Thus, these results further demonstrate that DNA damage can efficiently trap top1-cleavable complexes and enhance top1 mediated DNA recombination.	NCI,MOL PHARMACOL LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Pourquier, Philippe/O-8030-2018	Pourquier, Philippe/0000-0001-5326-3005				ANDERSON RD, 1994, MUTAT RES-FUND MOL M, V309, P109, DOI 10.1016/0027-5107(94)90048-5; [Anonymous], 1985, DNA REPAIR; BACKER LC, 1990, MUTAGENESIS, V5, P541, DOI 10.1093/mutage/5.6.541; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; CHAMPOUX JJ, 1988, GENETIC RECOMBINATIO, P655; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; Chen AY, 1997, CANCER RES, V57, P1529; CHEN AY, 1994, ANN REV PHARM TOXICO, V94, P194; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; DEGRASSI F, 1989, MUTAT RES, V211, P125, DOI 10.1016/0027-5107(89)90112-7; DENNY CT, 1986, SCIENCE, V234, P197, DOI 10.1126/science.3092355; FUJIMORI A, 1995, CANCER RES, V55, P1339; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HENNINGFELD KA, 1995, BIOCHEMISTRY-US, V34, P6120, DOI 10.1021/bi00018a015; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1989, CANCER RES, V49, P5077; JAXEL C, 1991, J BIOL CHEM, V266, P20418; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LETEURTRE F, 1994, J BIOL CHEM, V269, P7893; MCCOUBREY WK, 1986, J BIOL CHEM, V261, P5130; POMMIER Y, 1995, MUTAT RES-DNA REPAIR, V337, P135, DOI 10.1016/0921-8777(95)00019-G; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; POMMIER Y, 1993, CAUSES CONSEQUENCES, P277; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; RABBITTS TH, 1984, CHROMOSOMAL TRANSLOC, P164; Roth D., 1988, GENETIC RECOMBINATIO, P621; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5157, DOI 10.1093/nar/21.22.5157; WANG HP, 1991, J VIROL, V65, P2381, DOI 10.1128/JVI.65.5.2381-2392.1991; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; YEH YC, 1994, J BIOL CHEM, V269, P15498; ZHELKOVSKY AM, 1994, PROTEIN EXPRES PURIF, V5, P364, DOI 10.1006/prep.1994.1053; ZHOU W, 1995, CELL, V82, P577, DOI 10.1016/0092-8674(95)90030-6; Zhu J, 1996, MOL CELL BIOL, V16, P1805	47	151	154	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26441	26447		10.1074/jbc.272.42.26441	http://dx.doi.org/10.1074/jbc.272.42.26441			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334220	Green Published, hybrid			2022-12-25	WOS:A1997YB13900054
J	Wang, RH; Tao, L; Trumbore, MW; Berger, SL				Wang, RH; Tao, L; Trumbore, MW; Berger, SL			Turnover of the acyl phosphates of human and murine prothymosin alpha in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEAR-PROTEIN; MESSENGER-RNA; GENE; PHOSPHORYLATION; EXPRESSION; PRODUCTS; TISSUES; PROLIFERATION; PARATHYMOSIN	Prothymosin alpha is a small, highly acidic, abundant, nuclear, mammalian protein which is essential for cell growth, Our laboratory has recently shown that primate prothymosin alpha contains stoichiometric amounts of phosphate on the glutamyl groups of the protein and that in vitro the phosphate undergoes rapid hydrolysis or transfer to a nearby serine residue, Here an assay for the presence of acyl phosphates in vivo has been developed by measuring stable phosphoserine and phosphothreonine in. vitro, The assay was used to determine the half-life of the acyl phosphates on prothymosin alpha in vivo by pulse-labeling HeLa cells with [P-32]orthophosphate and chasing using three different techniques: permeabilization with digitonin to allow extracellular ATP to equilibrate with the intracellular pool; electroporation in the presence of ATP to reduce the specific activity of [P-32]ATP by expansion of the pool; and incubation with inorganic phosphate, Regardless of the method, the phosphate turned over with a half-life of 75-90 min. The ability of cells to phosphorylate old prothymosin alpha molecules was established by demonstrating equivalent labeling of the protein with [P-32]orthophosphate in the presence and absence of cycloheximide. The half-life of the acyl phosphates was also studied in resting and growing NIH3T3 cells, with measured values of 30-35 and 70 min, respectively. Our data suggest that the ''activity'' of prothymosin alpha involves the turnover of its acyl phosphates and that it participates in a function common to all nucleated mammalian cells regardless of whether they are quiescent or undergoing rapid proliferation, This is the first measurement of the stability of protein-bound acyl phosphates in vivo.	NCI,SECT GENES & GENE PROD,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BARCIA MG, 1992, FEBS LETT, V312, P152, DOI 10.1016/0014-5793(92)80924-6; BERGER SL, 1987, METHOD ENZYMOL, V152, P49; BUSTELO XR, 1991, J BIOL CHEM, V266, P1443; CLINTON M, 1989, ARCH BIOCHEM BIOPHYS, V269, P256, DOI 10.1016/0003-9861(89)90107-0; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; COHENSOLAL L, 1979, P NATL ACAD SCI USA, V76, P4327, DOI 10.1073/pnas.76.9.4327; COHENSOLAL L, 1985, ANAL BIOCHEM, V151, P82, DOI 10.1016/0003-2697(85)90055-7; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEGANI C, 1973, J BIOL CHEM, V248, P8222; ECONOMOU M, 1988, FEBS LETT, V233, P342, DOI 10.1016/0014-5793(88)80456-3; ERIKSSON AM, 1991, EUR J BIOCHEM, V198, P471; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; FRILLINGOS S, 1991, MOL CELL BIOCHEM, V109, P85; GAST K, 1995, BIOCHEMISTRY-US, V34, P13211, DOI 10.1021/bi00040a037; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1391, DOI 10.1073/pnas.81.5.1391; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P343, DOI 10.1073/pnas.82.2.343; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KOSHLAND DE, 1993, SCIENCE, V262, P532, DOI 10.1126/science.8211179; KOSHLAND DE, 1952, J AM CHEM SOC, V74, P2286, DOI 10.1021/ja01129a035; KUBOTA S, 1995, EUR J BIOCHEM, V233, P48, DOI 10.1111/j.1432-1033.1995.048_1.x; LEE JJ, 1992, DEV BIOL, V149, P415, DOI 10.1016/0012-1606(92)90296-S; MANROW RE, 1991, J BIOL CHEM, V266, P3916; MOL PC, 1995, MOL CELL BIOL, V15, P6999; PALVIMO J, 1990, FEBS LETT, V277, P257, DOI 10.1016/0014-5793(90)80860-L; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; SASVARISZEKELY M, 1975, BIOCHIM BIOPHYS ACTA, V395, P221, DOI 10.1016/0005-2787(75)90192-6; Sburlati A R, 1990, Protein Expr Purif, V1, P184, DOI 10.1016/1046-5928(90)90014-P; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SBURLATI AR, 1993, BIOCHEMISTRY-US, V32, P4587, DOI 10.1021/bi00068a015; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT G, 1991, BIOCHIM BIOPHYS ACTA, V1088, P442, DOI 10.1016/0167-4781(91)90141-8; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; Trumbore MW, 1997, J BIOL CHEM, V272, P26394, DOI 10.1074/jbc.272.42.26394; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; WATTS JD, 1989, FEBS LETT, V245, P17, DOI 10.1016/0014-5793(89)80182-6; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; ZUURENDONK PF, 1974, BIOCHIM BIOPHYS ACTA, V333, P393, DOI 10.1016/0005-2728(74)90022-X	40	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26405	26412		10.1074/jbc.272.42.26405	http://dx.doi.org/10.1074/jbc.272.42.26405			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334215	hybrid			2022-12-25	WOS:A1997YB13900049
J	Wo, YYP; Stewart, J; Greenlee, WF				Wo, YYP; Stewart, J; Greenlee, WF			Functional analysis of the promoter for the human CYP1B1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	34th Annual Meeting of the Society-of-Toxicology	MAR 05-09, 1995	BALTIMORE, MD	Soc Toxicol			TRANSCRIPTION FACTOR; REGULATORY ELEMENTS; ADRENAL CYTOCHROME-P450; HYDROCARBON METABOLISM; INDUCIBLE EXPRESSION; NUCLEAR FACTOR; MESSENGER-RNA; DNA-SEQUENCES; RAT CYP1B1; TATA	Our laboratory has cloned the cDNA (Sutter, T. R., Tang Y, M., Hayes, C. L., Wo, Y.-Y. P., Jabs, E. W., Li, X., Yin, H., Cody, C. W., and Greenlee, W. P. (1994) J. Biol. Chem. 269, 13092-13099) and gene (Tang, Y. M., Wo, Y.-Y.P., Jabs, E. pi,, Stewart, J. C., Sutter, T. R. and Greenlee, W. F. (1996) J. Biol. Chem. 271, 28324-28350) for human CYP1B1, a new member of the cytochrome P450 superfamily, Here, we report on the mapping and function of the CYP1B1 promoter, The CYP1B1 promoter is fully functional, when if: is uncoupled from upstream enhancer elements. Deletion analysis and site-directed mutagenesis identified four regulatory elements required for maximum promoter activity: two antisense Spl sites (-84 to -89 and -68 to -73), a TATA-like box (-84 to -29), and an initiator motif (-5 to +3). The initiator and the TATA-like elements are both required for basal promoter activity, with enhanced activity mediated by the two antisense Sp1 elements. The GYP1B1 initiator was demonstrated by in vitro transcription analysis to be a positioning element that maintained fidelity of transcription from a single site. Specific binding to a CYP1B1 initiator probe by human nuclear extract proteins was competed either by the highly homologous murine terminal deoxynucleotidyl transferase initiator or, to a lesser extent, by the adenovirus major late initiator. Taken together, these results indicate that the structure and function of the CYP1B1 promoter confers constitutive expression of the gene and assures fidelity of transcription initiation from a single site, The CYP1B1 promoter is distinct from the promoters of the closely related cytochrome P450s CYP1A1 and CYP1A2 and is structurally and functionally similar to the promoters of constitutively expressed genes and at least two viruses.	UNIV MASSACHUSETTS, MED CTR, DEPT MOL PHARMACOL & TOXICOL, WORCESTER, MA 01655 USA; PURDUE UNIV, DEPT MOL PHARMACOL & MED CHEM, W LAFAYETTE, IN 47907 USA	University of Massachusetts System; University of Massachusetts Worcester; Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIEHS NIH HHS [ES07009] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007009] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ATCHISON ML, 1989, MOL CELL BIOL, V9, P2067, DOI 10.1128/MCB.9.5.2067; AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BHATTACHARYYA KK, 1995, J BIOL CHEM, V270, P11595, DOI 10.1074/jbc.270.19.11595; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUSING MR, 1994, NUCLEIC ACIDS RES, V22, P669, DOI 10.1093/nar/22.4.669; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FABER PW, 1993, J BIOL CHEM, V268, P9296; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; GAATA BA, 1994, BIOCHIM BIOPHYS ACTA, V1219, P307; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; GROSVELD GC, 1981, CELL, V25, P215, DOI 10.1016/0092-8674(81)90246-4; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HILDEBRAND CE, 1985, NUCLEIC ACIDS RES, V13, P2009, DOI 10.1093/nar/13.6.2009; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JAISWAL A K, 1987, Journal of Experimental Pathology (New York), V3, P1; JONES KW, 1990, MOL CELL BIOL, V10, P5098, DOI 10.1128/MCB.10.10.5098; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; KUDO S, 1994, EUR J BIOCHEM, V223, P319, DOI 10.1111/j.1432-1033.1994.tb18997.x; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; LANS MS, 1994, J BIOL CHEM, V269, P14170; MANOHAR A, 1994, BBA-GENE STRUCT EXPR, V1219, P233, DOI 10.1016/0167-4781(94)90279-8; MCKINNON RA, 1991, HEPATOLOGY, V14, P848, DOI 10.1002/hep.1840140517; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; OTTO S, 1991, ENDOCRINOLOGY, V129, P970, DOI 10.1210/endo-129-2-970; QUATTROCHI LC, 1989, MOL PHARMACOL, V36, P66; RITTNER K, 1995, J MOL BIOL, V248, P562, DOI 10.1006/jmbi.1995.0243; SAGAMI I, 1994, J BIOCHEM-TOKYO, V116, P801, DOI 10.1093/oxfordjournals.jbchem.a124599; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAS U, 1994, J BIOL CHEM, V269, P14905; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SHEN ZY, 1993, P NATL ACAD SCI USA, V90, P11483, DOI 10.1073/pnas.90.24.11483; Shimada T, 1996, CANCER RES, V56, P2979; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; Tang WM, 1996, J BIOL CHEM, V271, P28324, DOI 10.1074/jbc.271.45.28324; WALKER NJ, 1995, CARCINOGENESIS, V16, P1319, DOI 10.1093/carcin/16.6.1319; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1470, DOI 10.1128/MCB.10.4.1470	51	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26702	26707		10.1074/jbc.272.42.26702	http://dx.doi.org/10.1074/jbc.272.42.26702			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	YB139	9334254	hybrid			2022-12-25	WOS:A1997YB13900088
J	Canovas, D; Vargas, C; IglesiasGuerra, F; Csonka, LN; Rhodes, D; Ventosa, A; Nieto, JJ				Canovas, D; Vargas, C; IglesiasGuerra, F; Csonka, LN; Rhodes, D; Ventosa, A; Nieto, JJ			Isolation and characterization of salt-sensitive mutants of the moderate halophile Halomonas elongata and cloning of the ectoine synthesis genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPOSON MUTAGENESIS; AMINO-ACID; EUBACTERIA; PLASMID; BACTERIA; SYSTEM; GENUS; OSMOLYTE	The moderate halophile Halomonas elongata Deustche Sammlung fur Mikroorganismen 3043 accumulated ectoine, hydroxyectoine, glutamate, and glutamine in response to osmotic stress (3 M NaCl), Two Tn1732-induced mutants, CHR62 and CHR63, that were severely affected in their salt tolerance were isolated, Mutant CHR62 could not grow above 0.75 at NaCl, and CHR63 did not grow above 1.5 M NaCl. These mutants did not synthesize ectoine but accumulated ectoine precursors, as shown by C-13 NMR and mass spectroscopy, Mutant CHR62 accumulated low levels of diaminobutyric acid, and mutant CHR63 accumulated high concentrations of N-gamma-acetyl-diaminobutyric acid, These results suggest that strain CHR62 could be defective in the gene for diaminobutyric acid acetyltransferase (ectB), and strain CHR63 could be defective in the gene for the ectoine synthase (ectC), Salt sensitivity of the mutants at 1.5-2.5 M NaCl could be partially corrected by cytoplasmic extracts of the wild-type strain, containing ectoine, and salt sensitivity of strain CHR62 could be partially repaired by the addition of extracts of strain CHR63, which contained N-gamma-acetyldiaminobutyric acid, This is the first evidence for the role of N-gamma-acetyldiaminobutyric acid as osmoprotectant, Finally, a cosmid from the H, elongata genomic library was isolated which complemented the Ect(-) phenotype of both mutants, indicating that it carried at least the genes ectB and ectC of the biosynthetic pathway of ectoine.	UNIV SEVILLE,FAC PHARM,DEPT MICROBIOL & PARASITOL,E-41012 SEVILLE,SPAIN; UNIV SEVILLE,FAC PHARM,DEPT ORGAN CHEM & PHARMACEUT CHEM,E-41012 SEVILLE,SPAIN; PURDUE UNIV,DEPT HORT,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	University of Sevilla; University of Sevilla; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Ventosa, Antonio/K-8239-2017; /AAA-4450-2019; Gutiérrez, Joaquín José Nieto/K-9974-2014; Vargas, Carmen/A-6283-2018; Cánovas, David/L-7628-2014	Ventosa, Antonio/0000-0002-7573-0556; /0000-0002-7203-5777; Gutiérrez, Joaquín José Nieto/0000-0001-8879-819X; Vargas, Carmen/0000-0002-4094-4319; Cánovas, David/0000-0002-7293-7332				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BENTOSA A, 1994, BACTERIAL DIVERSITY, P231; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; Canovas D, 1996, J BACTERIOL, V178, P7221, DOI 10.1128/jb.178.24.7221-7226.1996; Clarke L, 1979, Methods Enzymol, V68, P396; COHEN G N, 1956, Ann Inst Pasteur (Paris), V91, P693; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; Davis R., 1980, ADV BACTERIAL GENETI; FERNANDEZCASTILLO R, 1992, J GEN MICROBIOL, V138, P1133, DOI 10.1099/00221287-138-6-1133; FernandezLinares L, 1996, LETT APPL MICROBIOL, V22, P169, DOI 10.1111/j.1472-765X.1996.tb01135.x; FOWDEN L, 1972, PHYTOCHEMISTRY, V11, P2271, DOI 10.1016/S0031-9422(00)88389-2; Galinski E A, 1995, Adv Microb Physiol, V37, P272, DOI 10.1016/S0065-2911(08)60148-4; GALINSKI EA, 1985, EUR J BIOCHEM, V149, P135, DOI 10.1111/j.1432-1033.1985.tb08903.x; KESSLER B, 1992, MOL GEN GENET, V233, P293, DOI 10.1007/BF00587591; KNAUF VC, 1982, PLASMID, V8, P45, DOI 10.1016/0147-619X(82)90040-3; KUNTE HJ, 1995, FEMS MICROBIOL LETT, V128, P293; Kushner D.J., 1988, HALOPHILIC BACTERIA, V1, P109; LISS I, 1962, PHYTOCHEMISTRY, V1, P87, DOI 10.1016/S0031-9422(00)88005-X; MELLADO E, 1995, J BACTERIOL, V177, P3443, DOI 10.1128/jb.177.12.3443-3450.1995; NIETO JJ, 1989, APPL ENVIRON MICROB, V55, P2385, DOI 10.1128/AEM.55.9.2385-2390.1989; PETERS P, 1990, FEMS MICROBIOL LETT, V71, P157; RHODES D, 1987, PLANT PHYSIOL, V84, P775, DOI 10.1104/pp.84.3.775; Sambrook J., 2002, MOL CLONING LAB MANU; SEVERIN J, 1992, J GEN MICROBIOL, V138, P1629, DOI 10.1099/00221287-138-8-1629; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; UBBEN D, 1986, GENE, V41, P145, DOI 10.1016/0378-1119(86)90093-4; VARGAS C, 1995, MOL GEN GENET, V246, P411, DOI 10.1007/BF00290444; Vargas C, 1997, SYST APPL MICROBIOL, V20, P173, DOI 10.1016/S0723-2020(97)80063-X; VENTOSA A, 1995, WORLD J MICROB BIOT, V11, P85, DOI 10.1007/BF00339138; VREELAND RH, 1980, INT J SYST BACTERIOL, V30, P485, DOI 10.1099/00207713-30-2-485; WOHLFARTH A, 1990, J GEN MICROBIOL, V136, P705, DOI 10.1099/00221287-136-4-705; WOHLFARTH A, 1993, APPL MICROBIOL BIOT, V39, P568, DOI 10.1007/BF00205053	32	67	76	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25794	25801		10.1074/jbc.272.41.25794	http://dx.doi.org/10.1074/jbc.272.41.25794			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325308	Green Published, hybrid			2022-12-25	WOS:A1997YA35800063
J	Higashi, S; Matsumoto, N; Iwanaga, S				Higashi, S; Matsumoto, N; Iwanaga, S			Conformation of factor VIIa stabilized by a labile disulfide bond (Cys-310-Cys-329) in the protease domain is essential for interaction with tissue factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-VII; CARBOXYGLUTAMIC ACID DOMAIN; FACTOR-BINDING; EXTRINSIC PATHWAY; CATALYTIC DOMAIN; CRYSTAL-STRUCTURE; COMPLEX; IDENTIFICATION; ACTIVATION; PURIFICATION	Unlike other trypsin-type serine proteases, zymogen-to-enzyme transition of conformation of factor VII apparently requires not only conversion of the zymogen to active form factor VIIa (VIIa) but also interaction of VIIa with tissue factor (TF), To determine the region of interaction that correlates with maturation of the Wa active site, we modified intramolecular disulfide bonds in VIIa and examined the interaction of the modified VIIa with soluble TF (sTF). We found that partial reduction and S-carboxamidomethylation of disulfide bonds in VIIa led to losses of amidolytic activity and the binding ability to sTF. To determine the sites of modification that associate with the loss of functions, partially S-carboxamidomethylated Ma was separated on a column of immobilized sTF, Each of the sTF-bound and sTF-unbound fractions and native VIIa was then digested by trypsin, and the digest was analyzed by reversed-phase high performance liquid chromatography, We found that reduction and S-carboxamidomethylation of a disulfide bond between Cys-310 and Cys-329 in the protease domain of VIIa led to loss of the binding ability with sTF, and the modification of a disulfide bond between Cys-340 and Cys-368 of VIIa led to loss of the amidolytic activity. In the three-dimensional structures of trypsinogen and trypsin, the disulfide bonds corresponding to Cys-340-Cys-368 and Cys-310-Cys-329 of Ma are, respectively, in and adjacent to the activation domain, which has flexible conformation in trypsinogen but not in trypsin. Furthermore, the crystal structure of human VIIa TF complex indicates that the region next to Cys-310-Cys-329 is in contact with sTF, We speculate that a regional flexibility, reflected by the labile nature of disulfide bonds of Cys-310-Cys-329 and Cys-340-Cys-368 in the protease domain, contributes to the inability of VIIa to attain the active conformation. Interaction of TF with this flexible region may stabilize the structure in a conformation similar to that of the active state of VIIa.	KYUSHU UNIV 33, FAC SCI, DEPT BIOL, FUKUOKA 81281, JAPAN; KYUSHU UNIV 33, GRAD SCH MED SCI, DEPT MOL BIOL, FUKUOKA 81281, JAPAN	Kyushu University; Kyushu University								Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BERNARDI F, 1994, BRIT J HAEMATOL, V86, P610, DOI 10.1111/j.1365-2141.1994.tb04793.x; Bhardwaj D, 1996, J BIOL CHEM, V271, P30685, DOI 10.1074/jbc.271.48.30685; BODE W, 1976, J MOL BIOL, V106, P325, DOI 10.1016/0022-2836(76)90089-9; CHANG JY, 1995, BIOCHEMISTRY-US, V34, P12227, DOI 10.1021/bi00038a017; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HIGASHI S, 1994, J BIOL CHEM, V269, P18891; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; HIGASHI S, 1990, J BIOCHEM-TOKYO, V108, P654, DOI 10.1093/oxfordjournals.jbchem.a123258; KAZAMA Y, 1993, J BIOL CHEM, V268, P16231; KUMAR A, 1991, J BIOL CHEM, V266, P915; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; MATSUSHITA T, 1994, J BIOL CHEM, V269, P7355; MORRISSEY JH, 1993, BLOOD, V81, P734; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; OBRIEN DP, 1991, BLOOD, V78, P132; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SHIGEMATSU Y, 1992, J BIOL CHEM, V267, P21329; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; TAKAYENOKI Y, 1991, BIOCHEM BIOPH RES CO, V181, P1145, DOI 10.1016/0006-291X(91)92058-R; TAKEYA H, 1988, J BIOL CHEM, V263, P14868; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; Varallyay V, 1997, BIOCHEM BIOPH RES CO, V230, P592, DOI 10.1006/bbrc.1996.6009; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290	35	27	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25724	25730		10.1074/jbc.272.41.25724	http://dx.doi.org/10.1074/jbc.272.41.25724			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325298	hybrid			2022-12-25	WOS:A1997YA35800053
J	Sienaert, I; Missiaen, L; DeSmedt, H; Parys, JB; Sipma, H; Casteels, R				Sienaert, I; Missiaen, L; DeSmedt, H; Parys, JB; Sipma, H; Casteels, R			Molecular and functional evidence for multiple Ca2+-binding domains in the type 1 inositol 1,4,5,-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE-INDUCED CA2+ RELEASE; INDUCED CALCIUM-RELEASE; LIGAND-BINDING SITE; LUMINAL CA2+; TRISPHOSPHATE RECEPTOR; CYTOSOLIC CA2+; CEREBELLAR MICROSOMES; POSSIBLE MECHANISM; SMOOTH-MUSCLE; CELLS	Structural and functional analyses were used to investigate the regulation of the inositol 1,4,5-trisphosphate (InsP(3)) receptor (InsP(3)R) by Ca2+. To define the structural determinants for Ca2+ binding, cDNAs encoding GST fusion proteins that covered the complete linear cytosolic sequence of the InsP(3)R-1 were expressed in bacteria, The fusion proteins were screened for Ca2+ and ruthenium red binding through the use of Ca-45(2+) and ruthenium red overlay procedures, Six new cytosolic Ca2+-binding regions were detected on the InsP(3)R in addition to the one described earlier (Sienaert, I., De Smedt, H., Parys, J. B., Missiaen, L., Vanlingen, S., Sipma, H., and Casteels, R. (1996) J, Biol, Chem. 271, 27005-27012), Strong Ca-45(2+) and ruthenium red binding domains were localized in the N-terminal region of the InsP(3)R as follows: two Ca2+-binding domains were located within the InsP(3)-binding domain, and three Ca2+ binding stretches were localized in a 500-amino acid region just downstream of the InsP(3)-binding domain, A sixth Ca2+-binding stretch was detected in the proximity of the calmodulin-binding domain, Evidence for the involvement of multiple Ca2+-binding sites in the regulation of the InsP(3)R was obtained from functional studies on permeabilized A7r5 cells, in which we characterized the effects of Ca2+ and Sr2+ on the EC50 and cooperativity of the InsP(3)-induced Ca2+ release, The activation by cytosolic Ca2+ was due to a shift in EC50 toward lower InsP(3) concentrations, and this effect was mimicked by Sr2+. The inhibition by cytosolic Ca2+ was caused by a decrease in cooperativity and by a shift in EC50 toward higher InsP(3) concentrations, The effect on the cooperativity occurred at lower Ca2+ concentrations than the inhibitory effect on the EC50. In addition, Sr2+ mimicked the effect of Ca2+ on the cooperativity but not the inhibitory effect on the EC50. The different [Ca2+] and [Sr2+] dependencies suggest that three different cytosolic interaction sites were involved, Luminal Ca2+ stimulated the release without affecting the Hill coefficient or the EC50, excluding the involvement of one of the cytosolic Ca2+-binding sites. We conclude that multiple Ca2+-binding sites are localized on the InsP(3)R-1 and that at least four different Ca2+-interaction sites may be involved in the complex feedback regulation of the release by Ca2+.			Sienaert, I (corresponding author), KATHOLIEKE UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG O-N, HERESTR 49, B-3000 LOUVAIN, BELGIUM.			Parys, Jan/0000-0002-3591-4967				BENEVOLENSKY D, 1994, BIOCHEM J, V299, P631, DOI 10.1042/bj2990631; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CARDY TJA, 1997, J PHYSIOL-LONDON, V449, pP2; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; COMBETTES L, 1994, J BIOL CHEM, V269, P17561; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; DeSmedt H, 1997, BIOCHEM J, V322, P575; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Dufour JF, 1997, J BIOL CHEM, V272, P2675, DOI 10.1074/jbc.272.5.2675; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GAMBERUCCI A, 1995, CELL CALCIUM, V17, P431, DOI 10.1016/0143-4160(95)90089-6; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HANNAERTMERAH Z, 1995, CELL CALCIUM, V18, P390, DOI 10.1016/0143-4160(95)90054-3; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; HORNE JH, 1995, BIOCHEMISTRY-US, V34, P12738, DOI 10.1021/bi00039a033; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MARSHALL ICB, 1994, BIOCHEM J, V301, P591, DOI 10.1042/bj3010591; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; Missiaen L, 1997, BIOCHEM J, V325, P661, DOI 10.1042/bj3250661; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; Missiaen L, 1996, J BIOL CHEM, V271, P12287, DOI 10.1074/jbc.271.21.12287; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; Niki I, 1996, J BIOCHEM, V120, P685; NUNN DL, 1992, MOL PHARMACOL, V41, P115; Oancea E, 1996, J BIOL CHEM, V271, P17253, DOI 10.1074/jbc.271.29.17253; OLDERSHAW KA, 1993, BIOCHEM J, V292, P631, DOI 10.1042/bj2920631; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PARYS JB, 1993, J BIOL CHEM, V268, P25206; PIETRI F, 1990, J BIOL CHEM, V265, P17478; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; SUGIYAMA T, 1995, AM J PHYSIOL-CELL PH, V269, pC813, DOI 10.1152/ajpcell.1995.269.3.C813; Tanimura A, 1996, J CELL BIOL, V132, P607, DOI 10.1083/jcb.132.4.607; TAYLOR CW, 1995, J MEMBRANE BIOL, V145, P109; VANDELDEN C, 1993, J BIOL CHEM, V268, P12443; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; Xu X, 1996, J BIOL CHEM, V271, P11737, DOI 10.1074/jbc.271.20.11737; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	63	115	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25899	25906		10.1074/jbc.272.41.25899	http://dx.doi.org/10.1074/jbc.272.41.25899			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325322	hybrid			2022-12-25	WOS:A1997YA35800077
J	Bodi, I; Yamaguchi, H; Hara, M; He, M; Schwartz, A; Varadi, G				Bodi, I; Yamaguchi, H; Hara, M; He, M; Schwartz, A; Varadi, G			Molecular studies on the voltage dependence of dihydropyridine action on L-type Ca2+ channels - Critical involvement of tyrosine residues in motif IIIS6 and IVS6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; ALPHA-1 SUBUNIT; FUNCTIONAL EXPRESSION; 1,4-DIHYDROPYRIDINE SENSITIVITY; BINDING DOMAINS; CHARGE MOVEMENT; BETA-SUBUNIT; IDENTIFICATION; DETERMINANTS; RECEPTOR	The interaction site(s) of dihydropyridine (DHP) antagonists and agonists have been identified by site-directed mutagenesis and localized on motifs IIIS5, IIIS6, and IVS6 of L-type voltage gated calcium channels, In this study, we investigated the voltage-dependent action of DHPs with mutants of the IIIS6 and IVS6 segments of a cardiac calcium channel, Tyrosine residues in both motifs (Tyr(1178) and Tyr(1489)) strongly contributed to the action of DHP agonists and antagonists. When these two sites mere mutated, the communication between the voltage sensor and the DHP interaction site(s) was substantially impaired. In contrast, mutants of a nearby Ile (Ile(1182)) had much less influence on DHP agonist and antagonist interaction, and the voltage dependence of DHP antagonists was very similar to that of the wild type. The effect of a mutating of Ile(1182), on agonist or antagonist action, however, depended strongly on the type of amino acid change, When Ile(1182) was substituted with alanine, small changes were noted for DHP agonist and antagonist action, Changing this site into phenylalanine, however, significantly decreased the action of the DHP antagonist. These data show that Ile(1182) can preferentially interact with DHP antagonists, but has a lesser contribution in agonist interaction. Thus, even though the agonist and antagonist interaction sites for DHPs with L-type calcium channels may overlap, some amino acids in this site may exhibit a preference for either DHP enantiomers.	UNIV CINCINNATI,COLL MED,INST MOL PHARMACOL & BIOPHYS,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL043231, P01HL022619] Funding Source: NIH RePORTER; NHLBI NIH HHS [5R37-HL43231-08, P01 HL22619-19] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAN BP, 1984, P NATL ACAD SCI-BIOL, V81, P6388, DOI 10.1073/pnas.81.20.6388; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BROWN AM, 1986, J PHYSIOL-LONDON, V379, P495, DOI 10.1113/jphysiol.1986.sp016266; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; COLLIN T, 1994, EUR J BIOCHEM, V220, P257, DOI 10.1111/j.1432-1033.1994.tb18621.x; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; He M, 1997, J BIOL CHEM, V272, P2629, DOI 10.1074/jbc.272.5.2629; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Hille B., 1992, IONIC CHANNELS EXCIT; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; Josephson IR, 1996, BIOPHYS J, V70, P1285, DOI 10.1016/S0006-3495(96)79685-6; KALASZ H, 1993, FEBS LETT, V331, P177, DOI 10.1016/0014-5793(93)80321-K; KAMP TJ, 1989, CIRC RES, V64, P338, DOI 10.1161/01.RES.64.2.338; Kraus R, 1996, J BIOL CHEM, V271, P20113, DOI 10.1074/jbc.271.33.20113; LANGS DA, 1990, J COMPUT AID MOL DES, V4, P215, DOI 10.1007/BF00125011; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; NEELY A, 1994, BIOPHYS J, V66, P1895, DOI 10.1016/S0006-3495(94)80983-X; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; SANGUINETTI MC, 1986, J GEN PHYSIOL, V88, P369, DOI 10.1085/jgp.88.3.369; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; SLISH DF, 1989, FEBS LETT, V250, P509, DOI 10.1016/0014-5793(89)80786-0; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; Strube C, 1996, BIOPHYS J, V71, P2531, DOI 10.1016/S0006-3495(96)79446-8; TANG SQ, 1993, J BIOL CHEM, V268, P13026; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; WATANABE T, 1993, FEBS LETT, V334, P261, DOI 10.1016/0014-5793(93)80690-V; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0	42	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24952	24960		10.1074/jbc.272.40.24952	http://dx.doi.org/10.1074/jbc.272.40.24952			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312099	hybrid			2022-12-25	WOS:A1997XY97000038
J	Chuang, PI; Young, BA; Thiagarajan, RR; Cornejo, C; Winn, RK; Harlan, JM				Chuang, PI; Young, BA; Thiagarajan, RR; Cornejo, C; Winn, RK; Harlan, JM			Cytoplasmic domain of E-selectin contains a non-tyrosine endocytosis signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; HUMAN ENDOTHELIAL-CELLS; DI-LEUCINE MOTIF; LYSOSOMAL ACID-PHOSPHATASE; PLASMA-MEMBRANE; INTERNALIZATION SIGNAL; P-SELECTIN; TRANSFERRIN RECEPTOR; SORTING SIGNALS; EXPRESSION	E-selectin is an activation-dependent, endothelial cell-restricted adhesion molecule that is internalized and degraded rapidly once expressed on the cell surface. Tyrosine-containing structural motifs play an important role in the internalization of a number of integral proteins, and the membrane-proximal E-selectin cytoplasmic tyrosine residue (Tyr(582)) conforms to the endocytosis motif proposed previously, To determine the endocytosis motif in E-selectin, we selectively introduced truncation, substitution and deletion mutations to the cytoplasmic tail of E-selectin. We analyzed the internalization kinetics of surface-expressed wild-type and mutant E-selectin constructs in transiently transfected Chinese hamster ovary cells using I-125-labeled E-selectin monoclonal antibody (I-126-P6E2) in an acid elution assay. Interestingly, truncation immediately membrane proximal to Tyr(582) (Delta DGS construct) did not alter internalization kinetics significantly (Delta DGS versus wild-type, mean surface half-life = 42 versus 45 min, respectively). Thus, it appears that the tyrosine residues are not required for internalization of E-selectin. Additional analyses indicated that Ser(581) was necessary but alone was insufficient for surface E-selectin endocytosis. Thus, we conclude that there exists a novel non-tyrosine-containing endocytosis signal in the cytoplasmic tail which in volves Ser(581) and residues membrane-proximal to it.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT SURG,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chuang, PI (corresponding author), UNIV WASHINGTON,DIV PULM & CRIT CARE MED,DEPT MED,BOX 356522,SEATTLE,WA 98195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL030542, P01HL018645] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645, HL30542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBASSI O, 1993, J CLIN INVEST, V92, P2719, DOI 10.1172/JCI116889; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CARTWRIGHT JE, 1995, EXP CELL RES, V217, P329, DOI 10.1006/excr.1995.1094; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ISSEKUTZ AC, 1993, IMMUNOLOGY, V79, P600; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; KANE WH, 1990, BIOCHEMISTRY-US, V29, P6762, DOI 10.1021/bi00481a003; Kansas GS, 1996, J IMMUNOL, V157, P321; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUIJPERS TW, 1994, J IMMUNOL, V152, P5060; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LAWRENCE MB, 1993, J IMMUNOL, V151, P6338; LECA G, 1995, J IMMUNOL, V154, P1069; LEEUWENBERG JFM, 1990, J IMMUNOL, V145, P2110; LEEUWENBERG JFM, 1992, IMMUNOLOGY, V77, P543; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NORRIS P, 1991, J INVEST DERMATOL, V96, P763, DOI 10.1111/1523-1747.ep12471720; OGATA S, 1994, J BIOL CHEM, V269, P5210; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; OLOFSSON AM, 1994, BLOOD, V84, P2749, DOI 10.1182/blood.V84.8.2749.bloodjournal8482749; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; ROST B, 1995, PROTEINS, V23, P295, DOI 10.1002/prot.340230304; SETIADI H, 1995, J BIOL CHEM, V270, P26818, DOI 10.1074/jbc.270.45.26818; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SMEETS EF, 1993, EUR J IMMUNOL, V23, P147, DOI 10.1002/eji.1830230124; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; SPERTINI O, 1991, LEUKEMIA, V5, P300; SUBRAMANIAM M, 1993, MOL BIOL CELL, V4, P791, DOI 10.1091/mbc.4.8.791; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TROWBRIDGE IS, 1992, J INORG BIOCHEM, V47, P209, DOI 10.1016/0162-0134(92)84066-V; VERREY F, 1990, CELL REGUL, V1, P471, DOI 10.1091/mbc.1.6.471; VONANDRIAN UH, 1993, J CLIN INVEST, V91, P2893, DOI 10.1172/JCI116535; VONASMUTH EJU, 1992, EUR J IMMUNOL, V22, P2519, DOI 10.1002/eji.1830221009; WILDE A, 1994, J BIOL CHEM, V269, P7131; Yoshida M, 1996, J CELL BIOL, V133, P445, DOI 10.1083/jcb.133.2.445	57	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24813	24818		10.1074/jbc.272.40.24813	http://dx.doi.org/10.1074/jbc.272.40.24813			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312078	hybrid			2022-12-25	WOS:A1997XY97000017
J	Corbett, SA; Lee, L; Wilson, CL; Schwarzbauer, JE				Corbett, SA; Lee, L; Wilson, CL; Schwarzbauer, JE			Covalent cross-linking of fibronectin to fibrin is required for maximal cell adhesion to a fibronectin-fibrin matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA FACTOR-XIIIA; COLD-INSOLUBLE GLOBULIN; COAGULATION FACTOR-XIII; PIG LIVER-ENZYME; STRUCTURAL FEATURES; BLOOD-COAGULATION; STABILIZING FACTOR; DOMAIN-STRUCTURE; TRANSGLUTAMINASES; BINDING	In a blood clot, fibrin and plasma fibronectin (pFN) are covalently cross linked by activated factor XIII (factor XIIIa) to form pFN-fibrin multimers, To determine the functional significance of covalent pFN-fibrin interactions, we have developed an in vitro model which allows the incorporation of recombinant FN (recFN) molecules into a covalently cross-linked recFN-fibrin matrix, Using the baculovirus expression system, we have expressed recFN monomers composed of the amino-terminal 70-kDa region and the first 11 type III repeats (WT) with mutations in the glutamines at positions 3 and 4 (Q2) or at 3, 4, and 16 (Q3), Examination of the covalent incorporation of these recFNs into fibrin clots confirms that glutamines 3 and 4 are major participants in FN-fibrin cross-linking as the mutation of these sites reduces cross-linking efficiency by 65%. Additional mutation of the glutamine at position 16, however, eliminates >99% of cross-linking suggesting that it also may be factor XIIIa reactive, When the Q3 recFN-fibrin clots were used as substrates for cell adhesion, there was a decrease in both cell attachment and spreading when compared with the WT recFN-fibrin clots, These data demonstrate that for maximal cell attachment to a FN-fibrin clot, FN must be cross-linked to fibrin by factor XIIIa.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT SURG,NEW BRUNSWICK,NJ 08703; WASHINGTON UNIV,SCH MED,DIV DERMATOL,ST LOUIS,MO 63110	Princeton University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Washington University (WUSTL)				Schwarzbauer, Jean/0000-0003-1012-7593	NCI NIH HHS [CA-44627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; Chen R, 1971, Biochemistry, V10, P4487; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; Clark RAF, 1989, CURR OPIN CELL BIOL, V1, P1000, DOI 10.1016/0955-0674(89)90072-0; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; Corbett SA, 1996, BLOOD, V88, P158; Dalton BA, 1996, BIOTECHNIQUES, V21, P298; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; ERICKSON HP, 1983, J BIOL CHEM, V258, P4539; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GORMAN JJ, 1984, J BIOL CHEM, V259, P9007; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; GORMAN JJ, 1981, J BIOL CHEM, V256, P2712; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRINNELL F, 1980, CELL, V19, P517, DOI 10.1016/0092-8674(80)90526-7; HAYASHI M, 1983, J BIOL CHEM, V258, P3332; Hynes RO, 1990, FIBRONECTINS; KESKIOJA J, 1976, CELL, V9, P29, DOI 10.1016/0092-8674(76)90049-0; KNOX P, 1986, J CELL BIOL, V102, P2318, DOI 10.1083/jcb.102.6.2318; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUKA YV, 1994, J BIOL CHEM, V269, P9539; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; MORTENSEN SB, 1981, FEBS LETT, V129, P314, DOI 10.1016/0014-5793(81)80191-3; MOSESSON M W, 1992, Seminars in Hematology, V29, P177; MOSHER DF, 1976, J BIOL CHEM, V251, P1639; Mosher DF, 1989, FIBRONECTIN; ODERMATT E, 1989, FIBRONECTIN, P25; POTTS JR, 1994, CURR OPIN CELL BIOL, V6, P648, DOI 10.1016/0955-0674(94)90090-6; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; SEKIGUCHI K, 1983, J BIOL CHEM, V258, P3967; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; TRAN H, 1995, J BIOL CHEM, V270, P19458, DOI 10.1074/jbc.270.33.19458; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973; WILSON CL, 1992, J CELL BIOL, V119, P923, DOI 10.1083/jcb.119.4.923	42	103	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24999	25005		10.1074/jbc.272.40.24999	http://dx.doi.org/10.1074/jbc.272.40.24999			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312106	hybrid			2022-12-25	WOS:A1997XY97000045
J	Gardner, PR; Costantino, G; Szabo, C; Salzman, AL				Gardner, PR; Costantino, G; Szabo, C; Salzman, AL			Nitric oxide sensitivity of the aconitases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-RESONANCE CHARACTERIZATION; ACTIVE-SITE RESIDUES; ESCHERICHIA-COLI; MAMMALIAN-CELLS; 4FE-4S CLUSTER; IRON; SUPEROXIDE; BINDING; PEROXYNITRITE; GLUTATHIONE	Aconitases are important cellular targets of nitric oxide (NO.) toxicity, and NO.-derived species, rather than NO. per se, have been proposed to mediate their inactivation, NO.-mediated inactivation of the Escherichia coli aconitase and the porcine mitochondrial aconitase was investigated. In E. coli, aconitase activity decreased by similar to 70% during a 2-h exposure to an atmosphere containing 120 ppm NO. in N-2. The NO.-inactivated aconitase reactivated poorly in E. coli under anaerobic or aerobic conditions, Elevated superoxide dismutase activity did not affect the aerobic inactivation of aconitase by NO., thus indicating a limited role of the NO.- and superoxide-derived species peroxynitrite. Glutathione-deficient and glutathione-containing E. coli were comparably sensitive to NO.-mediated aconitase inactivation, thus excluding the participation of S-nitrosoglutathione or more oxidizing NO.-derived species, NO. progressively decreased aconitase activity in extracts in the presence of substrates, and inactivation was greatest at an acidic pH with cis-aconitate. The porcine mitochondrial aconitase was sensitive to NO. when exposed at pH 6.5, but not at pH 7.5, and irreversible inactivation occurred during catalysis, The requirement of an acidic pH or substrates for sensitivity may explain the reported resistance of aconitases to NO. in vitro (Castro, L., Rodriguez, M., and Radi, R. (1994) J. Biol. Chem. 269, 29409-29415; Hausladen, A., and Fridovich, I, (1994) J. Biol, Chem. 269, 29405-29408), An S-nitrosation of the aconitase [4Fe-4S] center catalyzed by the solvent-exposed electron withdrawing iron atom (Fe-a) is proposed.	CHILDRENS HOSP, MED CTR, DIV CRIT CARE, CINCINNATI, OH 45229 USA	Cincinnati Children's Hospital Medical Center			Szabo, Csaba/ABG-2644-2021; Szabo, Csaba/D-1882-2013	Gardner, Paul/0000-0001-8189-0903				APONTOWEIL P, 1975, BIOCHIM BIOPHYS ACTA, V399, P1, DOI 10.1016/0304-4165(75)90205-6; BENNETT B, 1995, EUR J BIOCHEM, V233, P317, DOI 10.1111/j.1432-1033.1995.317_1.x; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CZAPSKI G, 1995, FREE RADICAL BIO MED, V19, P785, DOI 10.1016/0891-5849(95)00081-8; DEGROOTE MA, 1995, CLIN INFECT DIS, V21, P162; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; Drapier JC, 1996, METHOD ENZYMOL, V269, P26; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; DRAPIER JC, 1994, J IMMUNOL, V14, P2829; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; Gardner PR, 1997, BIOSCIENCE REP, V17, P33, DOI 10.1023/A:1027383100936; GARDNER PR, 1993, ARCH BIOCHEM BIOPHYS, V301, P98, DOI 10.1006/abbi.1993.1120; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1993, J BIOL CHEM, V268, P12958; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GORETSKI J, 1990, J BIOL CHEM, V265, P11535; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; Hobbs AJ, 1996, METHOD ENZYMOL, V269, P134; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; JI XB, 1988, BIOCHEM BIOPH RES CO, V157, P106, DOI 10.1016/S0006-291X(88)80018-4; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Maniatis T., 1982, MOL CLONING; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROSE IA, 1967, J BIOL CHEM, V242, P1870; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; SALZMAN AL, 1994, AM J PHYSIOL, V266, pG633, DOI 10.1152/ajpgi.1994.266.4.G633; STADLER J, 1991, AM J PHYSIOL, V260, pC910, DOI 10.1152/ajpcell.1991.260.5.C910; STADLER J, 1991, ARCH SURG-CHICAGO, V126, P186; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TELSER J, 1986, J BIOL CHEM, V261, P4840; VANDENBROEK PJ, 1989, REV INFECT DIS, V11, P213; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10526, DOI 10.1021/bi00498a015; ZHENG L, 1992, J BIOL CHEM, V267, P7895	50	200	204	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25071	25076		10.1074/jbc.272.40.25071	http://dx.doi.org/10.1074/jbc.272.40.25071			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312115	hybrid			2022-12-25	WOS:A1997XY97000054
J	Osuga, Y; Hayashi, M; Kudo, M; Conti, M; Kobilka, B; Hsueh, AJW				Osuga, Y; Hayashi, M; Kudo, M; Conti, M; Kobilka, B; Hsueh, AJW			Co-expression of defective luteinizing hormone receptor fragments partially reconstitutes ligand-induced signal generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN CHORIOGONADOTROPIN RECEPTOR; FOLLICLE-STIMULATING-HORMONE; PROTEIN-COUPLED RECEPTORS; MOLECULAR-CLONING; CHORIONIC-GONADOTROPIN; THYROTROPIN RECEPTOR; ADRENERGIC-RECEPTORS; GRANULOSA-CELLS; HIGH-AFFINITY; ACTIVATION	Gonadotropin receptors are unique members of the seven-transmembrane (TM), G protein-coupled receptor family with a large extracellular (EC) sequence forming the high-affinity ligand binding domain. In a patient with Leydig cell hypoplasia, we identified a mutant LH receptor that is truncated at TM5. This protein retains limited ligand binding ability but cannot mediate cAMP responses, To study interactions between receptor fragments defective in either ligand binding or signal transduction, we co-expressed this truncated receptor together with a chimeric receptor containing the EC region of the FSH receptor and the TM region of the LH receptor. Although the chimeric receptor could not respond to human chorionic gonadotropin in producing cAMP, co-expression with the truncated LH receptor allowed partial restoration of ligand signaling through intermolecular interactions, In addition, co-expression of the same truncated LH receptor with an N-terminally truncated LH receptor that lacked the EC ligand binding domain also partially restored ligand signaling, Further shortening of the TM region in the mutant receptor found in the patient indicated that the EC domain and TM1 were sufficient for interactions with the N terminally truncated receptor. In contrast, co-expression of the N terminally truncated receptor together with cell-associated or soluble EC region of the LH receptor did not allow ligand signaling, Unlike thrombin receptors, co-expression of the anchored EC region of the LH receptor together with the N-terminally truncated receptor did not allow ligand signaling despite moderate levels of human chorionic gonadotropin binding in transfected cells, These studies demonstrate that the co-expression of binding (+)/signaling (-) and binding (-)/signaling (+) receptor fragments partially restores ligand-induced signal generation and indicate the importance of TM1 of the LH receptor in the proper orientation of the EC ligand binding domain.	STANFORD UNIV, SCH MED, DEPT OBSTET & GYNECOL, DIV REPROD BIOL, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University				Kobilka, Brian/0000-0001-5958-3990	NICHD NIH HHS [HD-23273] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD023273, R01HD023273] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Bousfield George R., 1994, P1749; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN J, 1994, J BIOL CHEM, V269, P16041; DAVOREN JB, 1985, BIOL REPROD, V33, P37, DOI 10.1095/biolreprod33.1.37; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HSUEH AJW, 1992, TRENDS ENDOCRIN MET, V3, P164, DOI 10.1016/1043-2760(92)90166-X; HSUEH AJW, 1989, RECENT PROG HORM RES, V45, P209; HUANG KS, 1981, J BIOL CHEM, V256, P3802; JI I, 1991, J BIOL CHEM, V266, P13076; JI IH, 1993, J BIOL CHEM, V268, P22971; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; LAUE L, 1995, HUM MOL GENET, V4, P1429, DOI 10.1093/hmg/4.8.1429; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MIYACHI Y, 1972, J CLIN ENDOCR METAB, V34, P23, DOI 10.1210/jcem-34-1-23; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; POPOT JL, 1987, J MOL BIOL, V198, P655, DOI 10.1016/0022-2836(87)90208-7; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Ryu KS, 1996, MOL CELL ENDOCRINOL, V125, P93, DOI 10.1016/S0303-7207(96)03951-2; SALESSE R, 1991, BIOCHIMIE, V73, P109, DOI 10.1016/0300-9084(91)90083-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TILLY JL, 1992, ENDOCRINOLOGY, V131, P799, DOI 10.1210/en.131.2.799; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WONG SKF, 1990, J BIOL CHEM, V265, P6219; XIE YB, 1990, J BIOL CHEM, V265, P21411	46	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25006	25012		10.1074/jbc.272.40.25006	http://dx.doi.org/10.1074/jbc.272.40.25006			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312107	hybrid			2022-12-25	WOS:A1997XY97000046
J	Gualix, J; Fideu, MD; Pintor, J; Rotllan, P; GarciaCarmona, F; MirasPortugal, MT				Gualix, J; Fideu, MD; Pintor, J; Rotllan, P; GarciaCarmona, F; MirasPortugal, MT			Characterization of diadenosine polyphosphate transport into chromaffin granules from adrenal medulla	FASEB JOURNAL			English	Article						diadenosine polyphosphates; vesicular transport; mnemonic transporter; purinergic transmission	CELLS; PURINOCEPTORS; AP4A; ATP; SYNAPTOSOMES; NUCLEOTIDE; CHANNELS; RECEPTOR; BINDING; RELEASE	The transport of diadenosine polyphosphates into chromaffin granules from bovine adrenal medulla has been studied by using the radiolabeled substrate [H-3]Ap(5)A and the fluorescent substrate analog di(1,N-6-ethenoadenosine)polyphosphate, epsilon-(Ap(n)A) (n=3-5). The vesicular concentration increase was time dependent and the substrates were not metabolized to any extent during the transport experiments. The saturation curve indicates the existence of kinetic and allosteric cooperativity during Ap(n)A (diadenosine polyphosphates) transport and could be the result of the presence of various affinity states of the transporter with K values of 16 +/- 1 mu M and 75 +/- 6 mu M, and corresponding Hill numbers of 2 and 4, when epsilon-(Ap(4)A) was the substrate, The saturation studies for [H-3]Ap(5)A were performed in a broader concentration range; in this case a three-step curve was obtained with K values of 16 +/- 2 mu M, 125 +/- 9 mu M, and 545 +/- 11 mu M; the corresponding Hill numbers were 2, 4, and 6. This kinetic behavior can be explained on the basis of a mnemonic model, as already demonstrated for the vesicular transport of ATP. The nonhydrolyzable adenine nucleotide analogs, ATP gamma S and ADP beta S, inhibited the diadenosine polyphosphate transport at concentrations in the millimolar range. Ap(n)A transport was also inhibited by the P2 receptor antagonist suramin, the mitochondrial ATP/ADP exchange inhibitor atractyloside, the proton translocator FCCP, and N-ethylmaleimide.	UNIV COMPLUTENSE MADRID,FAC VET,DEPT BIOQUIM,E-28040 MADRID,SPAIN; UNIV LA LAGUNA,FAC BIOL,DEPT BIOQUIM,E-38206 TENERIFE,CANARY ISLANDS,SPAIN; UNIV MURCIA,FAC BIOL,DEPT BIOQUIM,MURCIA 30080,SPAIN	Complutense University of Madrid; Universidad de la Laguna; University of Murcia			Garcia-Carmona, Francisco/K-6520-2017; Miras-Portugal, Maria Teresa/L-7137-2014; Gualix, Javier/C-5783-2017	Gualix, Javier/0000-0001-7215-6483; Pintor, Jesus/0000-0002-9191-7679				ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; ABERER W, 1978, BIOCHEM J, V172, P353, DOI 10.1042/bj1720353b; [Anonymous], ALLOSTERIC ENZYMES K; BAILEY SJ, 1994, BRIT J PHARMACOL, V112, P219, DOI 10.1111/j.1476-5381.1994.tb13055.x; BAKER JC, 1986, P NATL ACAD SCI USA, V83, P2350, DOI 10.1073/pnas.83.8.2350; Bankston LA, 1996, J BIOL CHEM, V271, P17132, DOI 10.1074/jbc.271.29.17132; BAXI MD, 1995, BIOCHEMISTRY-US, V34, P9700, DOI 10.1021/bi00030a007; CASILLAS T, 1993, BIOCHEMISTRY-US, V32, P14203, DOI 10.1021/bi00214a020; DELCASTILLO AR, 1988, J NEUROCHEM, V51, P1696, DOI 10.1111/j.1471-4159.1988.tb01147.x; GRUMMT F, 1979, P NATL ACAD SCI USA, V76, P6081, DOI 10.1073/pnas.76.12.6081; GRUNINGER HA, 1983, NEUROSCIENCE, V9, P917, DOI 10.1016/0306-4522(83)90280-4; Gualix J, 1996, J BIOL CHEM, V271, P1957, DOI 10.1074/jbc.271.4.1957; Holden CP, 1996, J NEUROCHEM, V67, P574; IRVING MG, 1973, BIOCHEM J, V131, P287, DOI 10.1042/bj1310287; IRVING MG, 1973, BIOCHEM J, V131, P303, DOI 10.1042/bj1310303; Jovanovic A, 1996, BRIT J PHARMACOL, V117, P233, DOI 10.1111/j.1476-5381.1996.tb15180.x; KAGAN ZS, 1973, BIOCHIM BIOPHYS ACTA, V302, P110, DOI 10.1016/0005-2744(73)90014-4; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; LEINHARD GE, 1973, J BIOL CHEM, V248, P1121; LUTHJE J, 1983, BIOCHEM BIOPH RES CO, V115, P253, DOI 10.1016/0006-291X(83)90997-X; Mateo J, 1996, BRIT J PHARMACOL, V119, P1; MCLENNAN AG, 1992, APA4A OTHER DINUCLEO; Neet K E, 1980, Methods Enzymol, V64, P139; NELSON N, 1992, J EXP BIOL, V172, P149; NG KME, 1987, NUCLEIC ACIDS RES, V15, P3573, DOI 10.1093/nar/15.8.3573; PINTOR J, 1992, NEUROSCI RES COMMUN, V10, P9; PINTOR J, 1992, ANAL BIOCHEM, V200, P296, DOI 10.1016/0003-2697(92)90469-N; Pintor J, 1997, MOL PHARMACOL, V51, P277, DOI 10.1124/mol.51.2.277; PINTOR J, 1993, BRIT J PHARMACOL, V108, P1094, DOI 10.1111/j.1476-5381.1993.tb13510.x; PINTOR J, 1995, BRIT J PHARMACOL, V115, P895, DOI 10.1111/j.1476-5381.1995.tb15894.x; Pintor J, 1996, BRIT J PHARMACOL, V119, P1006, DOI 10.1111/j.1476-5381.1996.tb15771.x; Pivorun EB, 1996, J NEUROSCI RES, V44, P478, DOI 10.1002/(SICI)1097-4547(19960601)44:5<478::AID-JNR8>3.0.CO;2-C; RAMOS A, 1995, ANAL BIOCHEM, V228, P74, DOI 10.1006/abio.1995.1317; RAMOS A, 1995, BBA-PROTEIN STRUCT M, V1253, P103, DOI 10.1016/0167-4838(95)00154-M; RAPAPORT E, 1976, P NATL ACAD SCI USA, V73, P3984, DOI 10.1073/pnas.73.11.3984; Ripoll C, 1996, DIABETES, V45, P1431, DOI 10.2337/diabetes.45.10.1431; ROTLLAN P, 1985, EUR J BIOCHEM, V151, P365, DOI 10.1111/j.1432-1033.1985.tb09110.x; ROTLLAN P, 1991, FEBS LETT, V280, P371; SCHLUTER H, 1994, NATURE, V367, P186, DOI 10.1038/367186a0; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SILLERO MAG, 1991, EUR J BIOCHEM, V202, P507; SOMERO GN, 1969, NATURE, V223, P194, DOI 10.1038/223194a0; TORRES M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P291, DOI 10.1016/0005-2736(92)90207-3; VARON R, 1991, BIOCHEM J, V178, P91; VARONCASTELLANO.R, 1995, COMPUTERIZED DERIVAT; WINKLER H, 1982, SECRETORY PROCESS, V1, P3; ZAMECNIK PC, 1966, BIOCHEM BIOPH RES CO, V24, P91, DOI 10.1016/0006-291X(66)90415-3	47	24	25	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1997	11	12					981	990		10.1096/fasebj.11.12.9337151	http://dx.doi.org/10.1096/fasebj.11.12.9337151			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337151				2022-12-25	WOS:A1997YA72400008
J	Li, TJ; Rawlings, DJ; Park, H; Kato, RM; Witte, ON; Satterthwaite, AB				Li, TJ; Rawlings, DJ; Park, H; Kato, RM; Witte, ON; Satterthwaite, AB			Constitutive membrane association potentiates activation of Bruton tyrosine kinase	ONCOGENE			English	Article						Btk; pleckstrin homology domain; membrane targeting; transformation	X-LINKED AGAMMAGLOBULINEMIA; PLECKSTRIN HOMOLOGY DOMAIN; BETA-GAMMA-SUBUNITS; SIGMA-II SPECTRIN; SRC FAMILY; SIGNAL-TRANSDUCTION; PH DOMAIN; B-CELLS; PLASMA-MEMBRANE; POINT MUTATION	Mutations in the nonreceptor tyrosine kinase Btk result in the B cell, immunodeficiencies X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (xid) in mice. Genetic and biochemical evidence implicates Btk as a key component of several B cell signaling pathways. Activation of Btk by a point mutation (E41K) within the PH domain (Btk*) results in fibroblast transformation and is correlated with increased membrane localization of Btk. When wild type Btk is activated by coexpression with Lyn, the tyrosine phosphorylated pool of Btk is highly enriched in the membrane fraction. To determine whether membrane association is sufficient to activate Btk, we targeted Btk to the plasma membrane using a series of fusion proteins including GagBtk, CD16Btk and CD4Btk. Constitutive membrane association greatly enhanced the ability of Btk to transform Rat2 fibroblasts in the presence of high levels of Src activity. All membrane targeted forms of Btk were highly tyrosine phosphorylated. Transformation required membrane localization, Btk kinase activity, transphosphorylation by Src family kinases, and an intact SH2 domain but not the PH or SH3 domains. These data suggest that membrane localization is a critical early step in Btk activation.	UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV IMMUNOL RHEUMATOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOL GENET,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NCI NIH HHS [CA-12800, CA-09056] Funding Source: Medline; NIAMS NIH HHS [AR01912] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA012800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K11AR001912] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Afar DEH, 1996, MOL CELL BIOL, V16, P3465; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P475; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHU KT, 1994, J BIOL CHEM, V269, P24095; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HINSHELWOOD S, 1995, EUR J IMMUNOL, V25, P1113, DOI 10.1002/eji.1830250439; HITOSHI Y, 1993, INT IMMUNOL, V5, P1183, DOI 10.1093/intimm/5.9.1183; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JASIN M, 1991, J VIROL, V65, P440, DOI 10.1128/JVI.65.1.440-444.1991; JONES TA, 1990, J VIROL, V64, P2265, DOI 10.1128/JVI.64.5.2265-2279.1990; KASLAUSKAS A, 1989, CELL, V58, P1121; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOIKE M, 1995, INT IMMUNOL, V7, P21, DOI 10.1093/intimm/7.1.21; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Ochs HD, 1996, MEDICINE, V75, P287, DOI 10.1097/00005792-199611000-00001; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8521; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SAFFRAN DC, 1994, NEW ENGL J MED, V330, P1488, DOI 10.1056/NEJM199405263302104; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SANTOSARGUMEDO L, 1995, IMMUNOLOGY, V85, P248; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, P NATL ACAD SCI USA, V91, P11256; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1995, BIOCHEMISTRY-US, V34, P1475, DOI 10.1021/bi00005a002; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang DS, 1996, BIOCHEM BIOPH RES CO, V225, P420, DOI 10.1006/bbrc.1996.1189; Wang DS, 1995, BIOCHEM BIOPH RES CO, V217, P608, DOI 10.1006/bbrc.1995.2818; WICKER LS, 1986, CURR TOP MICROBIOL, V124, P87; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	71	67	68	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1375	1383		10.1038/sj.onc.1201308	http://dx.doi.org/10.1038/sj.onc.1201308			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333013	Bronze			2022-12-25	WOS:A1997XW41100001
J	FtouhiPaquin, N; Hauer, CR; Stack, RF; Tarentino, AL; Plummer, TH				FtouhiPaquin, N; Hauer, CR; Stack, RF; Tarentino, AL; Plummer, TH			Molecular cloning, primary structure, and properties of a new glycoamidase from the fungus Aspergillus tubigensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-N-4-(N-ACETYL-BETA-D-GLUCOSAMINYL)ASPARAGINE AMIDASE-F; ASPARAGINE-LINKED GLYCANS; POLYMERASE CHAIN-REACTION; AMINO-ACID-SEQUENCE; N-GLYCOSIDASE-F; FLAVOBACTERIUM-MENINGOSEPTICUM; PEPTIDE; DEGLYCOSYLATION; GLYCOSYLASPARAGINASE; CARBOXYPEPTIDASE	A new glycoamidase, peptide-N-4-(N-acetyl-beta-D-glucosaminyl)asparagine amidase (PNGase) At, was discovered in the eukaryote Aspergillus tubigensis. The enzyme was purified to homogeneity, and the DNA sequence was determined by cloning in Escherichia coli. Over 80% of the deduced amino acid sequence was verified independently by Edman analysis and/or electrospray ionization-mass spectrometry of protease fragments of native PNGase At. This glycoamidase contains 12 potential asparagine-linked glycosylation sites, of which at least 9 sites are occupied with typical high mannose oligosaccharides. PNGase At consists of two non-identical glycosylated subunits that are derived from a single polypeptide gene precursor, Evidence is presented suggesting that autocatalysis is involved in subunit formation, PNGase At is an important new tool for analysis of asparagine-linked glycans; it can hydrolyze a broad range of glycopeptides, including those with core-linked alpha 1-->6 or alpha 1-->3 fucose, under conditions not favorable with existing glycoamidases.	SUNY ALBANY,SCH PUBL HLTH,ALBANY,NY 12201	State University of New York (SUNY) System; State University of New York (SUNY) Albany	FtouhiPaquin, N (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,DIV MOL MED,ALBANY,NY 12201, USA.			Hauer, Christoph/0000-0001-8704-2198	PHS HHS [30471] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P84, DOI 10.1007/BF00731873; Aronson NN, 1996, GLYCOBIOLOGY, V6, P669, DOI 10.1093/glycob/6.7.669; BLOOMQUIST BT, 1992, DNA CELL BIOL, V11, P791, DOI 10.1089/dna.1992.11.791; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUR SJ, 1987, STRUCTURE ORG FILAME, P93; KUHN P, 1994, BIOCHEMISTRY-US, V33, P11699, DOI 10.1021/bi00205a005; KUHN P, 1995, J BIOL CHEM, V270, P29493, DOI 10.1074/jbc.270.49.29493; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; PLUMMER TH, 1978, J BIOL CHEM, V253, P3907; Plummer TH, 1996, ANAL BIOCHEM, V235, P98; PLUMMER TH, 1987, EUR J BIOCHEM, V163, P167, DOI 10.1111/j.1432-1033.1987.tb10751.x; PLUMMER TH, 1981, J BIOL CHEM, V256, P243; SCHAEFER BC, 1995, ANAL BIOCHEM, V227, P255, DOI 10.1006/abio.1995.1279; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; SUZUKI T, 1994, GLYCOBIOLOGY, V4, P779; TAKAHASHI N, 1978, J BIOCHEM-TOKYO, V84, P1467, DOI 10.1093/oxfordjournals.jbchem.a132270; TAKAHASHI N, 1992, HDB ENDOGLYCOSIDASES, P183; TAPUHI Y, 1981, ANAL BIOCHEM, V115, P123, DOI 10.1016/0003-2697(81)90534-0; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V316, P399, DOI 10.1006/abbi.1995.1053; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TARENTINO AL, 1990, J BIOL CHEM, V265, P6961; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; VANDENHOMBERGH JPTW, 1994, GENE, V151, P73, DOI 10.1016/0378-1119(94)90634-3; Weitzhandler M, 1996, ANAL BIOCHEM, V241, P128, DOI 10.1006/abio.1996.0386	26	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22960	22965		10.1074/jbc.272.36.22960	http://dx.doi.org/10.1074/jbc.272.36.22960			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9312552	hybrid			2022-12-25	WOS:A1997XV49200083
J	Dickinson, JR; Lanterman, MM; Danner, DJ; Pearson, BM; Sanz, P; Harrison, SJ; Hewlins, MJE				Dickinson, JR; Lanterman, MM; Danner, DJ; Pearson, BM; Sanz, P; Harrison, SJ; Hewlins, MJE			A C-13 nuclear magnetic resonance investigation of the metabolism of leucine to isoamyl alcohol in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXOSE-MONOPHOSPHATE PATHWAY; ACETYL-COA HYDROLASE; SOLE NITROGEN-SOURCE; CHAIN AMINO-ACIDS; PYRUVATE DECARBOXYLASE; DEHYDROGENASE; GENE; ENZYMES; PURIFICATION; SPORULATION	The metabolism of leucine to isoamyl alcohol in yeast was examined by C-13 nuclear magnetic resonance spectroscopy. The product of leucine transamination, alpha-ketoisocaproate had four potential routes to isoamyl alcohol. The first, via branched-chain alpha-keto acid dehydrogenase to isovaleryl-CoA with subsequent conversion to isovalerate by acyl-CoA hydrolase operates in wild-type cells where isovalerate appears to be an end product. This pathway is not required for the synthesis of isoamyl alcohol because abolition of branched-chain alpha-keto acid dehydrogenase activity in an lpd1 disruption mutant did not prevent the formation of isoamyl alcohol. A second possible route was via pyruvate decarboxylase; however, elimination of pyruvate decarboxylase activity in a pdc1 pdc5 pdc6 triple mutant did not decrease the levels of isoamyl alcohol produced. A third route utilizes alpha-ketoisocaproate reductase (a novel activity in Saccharomyces cerevisiae) but with no role in the formation of isoamyl alcohol from alpha-hydroxyisocaproate because cell homogenates could not convert alpha-hydroxyisocaproate to isoamyl alcohol. The final possibility was that a pyruvate decarboxylase-like enzyme encoded by YDL080c appears to be the major route of decarboxylation of alpha-ketoisocaproate to isoamyl alcohol although disruption of this gene reveals that at least one other unidentified decarboxylase can substitute to a minor extent.	EMORY UNIV, SCH MED, DEPT GENET, ATLANTA, GA 30322 USA; INST FOOD RES, NORWICH NR4 7UA, NORFOLK, ENGLAND; CSIC, INST AGROQUIM & TECNOL ALIMENTOS, E-46010 VALENCIA, SPAIN; UNIV WALES COLL CARDIFF, DEPT CHEM, CARDIFF CF1 3TB, S GLAM, WALES	Emory University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA); Cardiff University	Dickinson, JR (corresponding author), UNIV WALES COLL CARDIFF, SCH PURE & APPL BIOL, POB 915, CARDIFF CF1 3TL, S GLAM, WALES.		Sanz, Pascual/K-2751-2014	Sanz, Pascual/0000-0002-2399-4103; Pearson, Bruce/0000-0002-9223-7712				Bender D.A., 1975, AMINO ACID METABOLIS; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; DERRICK S, 1993, J GEN MICROBIOL, V139, P2783, DOI 10.1099/00221287-139-11-2783; DICKINSON JR, 1991, J GEN MICROBIOL, V137, P1033, DOI 10.1099/00221287-137-5-1033; DICKINSON JR, 1983, P NATL ACAD SCI-BIOL, V80, P5847, DOI 10.1073/pnas.80.19.5847; DICKINSON JR, 1993, FEBS LETT, V326, P29, DOI 10.1016/0014-5793(93)81754-N; DICKINSON JR, 1986, MOL GEN GENET, V204, P103; DICKINSON JR, 1992, J GEN MICROBIOL, V138, P2029, DOI 10.1099/00221287-138-10-2029; DICKINSON JR, 1988, J GEN MICROBIOL, V134, P333; Dickinson JR, 1996, MICROBIOL-UK, V142, P1391, DOI 10.1099/13500872-142-6-1391; DICKINSON JR, 1995, MICROBIOL-UK, V141, P385, DOI 10.1099/13500872-141-2-385; DICKINSON JR, 1988, J GEN MICROBIOL, V133, P135; Ehrlich F, 1907, BER DTSCH CHEM GES, V40, P1027, DOI 10.1002/cber.190704001156; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HOHMANN S, 1990, EUR J BIOCHEM, V188, P615, DOI 10.1111/j.1432-1033.1990.tb15442.x; HOHMANN S, 1991, J BACTERIOL, V173, P7963, DOI 10.1128/jb.173.24.7963-7969.1991; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P193; Lanterman MM, 1996, HUM MOL GENET, V5, P1643, DOI 10.1093/hmg/5.10.1643; Large P. J., 1986, YEAST, V2, P1; LEE FJS, 1990, J BIOL CHEM, V265, P7413; LEE FJS, 1989, EUR J BIOCHEM, V184, P21, DOI 10.1111/j.1432-1033.1989.tb14985.x; LERCH HP, 1989, GENE, V78, P47, DOI 10.1016/0378-1119(89)90313-2; Mortimer R K, 1975, Methods Cell Biol, V11, P221, DOI 10.1016/S0091-679X(08)60325-8; Neubauer O, 1911, H-S Z PHYSIOL CHEM, V70, P326; NISHIMURA H, 1992, J BACTERIOL, V174, P4701, DOI 10.1128/JB.174.14.4701-4706.1992; REPTTO B, 1991, MOL CELL BIOL, V11, P3931; SCHMITT HD, 1982, J BACTERIOL, V151, P1146, DOI 10.1128/JB.151.3.1146-1152.1982; Sherman F, 1975, Methods Cell Biol, V11, P189, DOI 10.1016/S0091-679X(08)60323-4; SINCLAIR DA, 1995, GENETICS, V140, P1213; SINCLAIR DA, 1993, BIOCHEM MOL BIOL INT, V31, P911; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; WEBB A. DINSMOOR, 1963, ADVAN APPL MICROBIOL, V5, P317, DOI 10.1016/S0065-2164(08)70014-5	32	157	172	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26871	26878		10.1074/jbc.272.43.26871	http://dx.doi.org/10.1074/jbc.272.43.26871			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341119	hybrid			2022-12-25	WOS:A1997YC65900015
J	Arata, Y; Hirabayashi, J; Kasai, K				Arata, Y; Hirabayashi, J; Kasai, K			Structure of the 32-kDa galectin gene of the nematode Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; CARBOHYDRATE-RECOGNITION DOMAINS; MACROPHAGE MANNOSE RECEPTOR; AMINO-ACID-SEQUENCE; SITE-DIRECTED MUTAGENESIS; NEGATIVE GROWTH-FACTOR; FULL-LENGTH CDNA; C-ELEGANS; ANIMAL LECTINS; MESSENGER-RNA	Galectins are a family of soluble beta-galacto side-binding lectins distributed in both vertebrates and invertebrates and, more recently, found also in fungus, The 32-kDa galectin isolated from the nematode Caenorhabditis elegans (Hirabayashi, J., Satoh, M., and Kasai, K. (1992) J. Biol. Chem. 267, 15485-15490) was the first ''tandem repeat-type'' galectin, containing two homologous carbohydrate-binding sites. Here, we report the structure of the nematode 32-kDa galectin gene, Physical mapping by yeast artificial chromosome polytene filter hybridization revealed that the 32-kDa galectin gene is located on chromosome II. Analysis of the transcript (1.4 kilobases) showed the presence at its 5'-end of a 22-nucleotide trans-spliced leader sequence (SL1), The entire genomic structure spanning >5 kilobase pairs (kbp), including the 5'-noncoding region, two intervening sequences (introns 1 and 2), and the 3'-noncoding region, was completely determined by the combination of genomic polymerase chain reaction and conventional colony hybridization, Intron 1 was relatively long (2.4 kbp) and was found to be inserted after the ninth codon (TAG) from the initiation codon, This position proved to be almost homologous to the conserved first intron insertion position in the vertebrate galectin genes (i.e. genes of mammalian galectin-1, -2, and -3 and chick 14-kDa galectin), On the other hand, intron 2 was much shorter (0.6 kbp), and it was inserted into the central region of the second carbohydrate-binding site. Although such an insertion pattern has never been observed in the vertebrate galectin genes, it seems to be common in C. elegans tandem repeat-type galectin genes, as predicted by the C. elegans genome project (Coulson, A., and the C. elegans Genome Consortium (1996) Biochem, Sec. Trans, 24, 289-291), Based on extensive sequence comparison, the origin and molecular evolution of the tandem repeat-type galectins are discussed.			Arata, Y (corresponding author), TEIKYO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,SAGAMIKO,KANAGAWA 19901,JAPAN.							ABBOTT WM, 1989, BIOCHEM J, V259, P283, DOI 10.1042/bj2590283; ACKERMAN SJ, 1993, J IMMUNOL, V150, P456; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arata Y, 1997, J BIOCHEM-TOKYO, V121, P1002, DOI 10.1093/oxfordjournals.jbchem.a021686; Arata Y, 1996, HISTOCHEM J, V28, P201, DOI 10.1007/BF02331444; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRENNER S, 1974, GENETICS, V77, P71; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHIARIOTTI L, 1991, BIOCHIM BIOPHYS ACTA, V1089, P54, DOI 10.1016/0167-4781(91)90084-Y; CHIU ML, 1994, J BIOL CHEM, V269, P31770; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; CONRAD R, 1993, EMBO J, V12, P1249, DOI 10.1002/j.1460-2075.1993.tb05766.x; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; Cooper DNW, 1997, J BIOL CHEM, V272, P1514, DOI 10.1074/jbc.272.3.1514; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; Coulson A, 1996, BIOCHEM SOC T, V24, P289, DOI 10.1042/bst0240289; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; Epstein HF, 1995, METHODS CELL BIOL, V48; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; GITT MA, 1995, GLYCOCONJUGATE J, V12, P548; GRITZMACHER CA, 1992, BIOCHEMISTRY-US, V31, P9533, DOI 10.1021/bi00155a004; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HARRIS N, 1994, BIOCHEM BIOPH RES CO, V198, P682, DOI 10.1006/bbrc.1994.1099; HARRIS N, 1992, BLOOD, V80, P2363; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; Hirabayashi J, 1996, J BIOL CHEM, V271, P2497, DOI 10.1074/jbc.271.5.2497; HIRABAYASHI J, 1988, J BIOCHEM-TOKYO, V104, P1; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; HIRABAYASHI J, 1989, BIOCHIM BIOPHYS ACTA, V1008, P85, DOI 10.1016/0167-4781(89)90173-5; HIRABAYASHI J, 1994, GLYCOCONJUGATE J, V11, P437, DOI 10.1007/BF00731280; HIRABAYASHI J, 1992, J BIOCHEM-TOKYO, V111, P553, DOI 10.1093/oxfordjournals.jbchem.a123794; Hirabayashi J, 1997, TRENDS GLYCOSCI GLYC, V9, P1; HIRABAYASHI J, 1993, TRENDS GLYCOSCI GLYC, V5, P251; JIA SH, 1988, J BIOL CHEM, V263, P6009; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KIM SJ, 1992, GENOMICS, V14, P721, DOI 10.1016/S0888-7543(05)80174-0; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; MAGNALDO T, 1995, DEV BIOL, V168, P259, DOI 10.1006/dbio.1995.1078; ODA Y, 1993, J BIOL CHEM, V268, P5929; ODA Y, 1991, GENE, V99, P279; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Sambrook J., 2002, MOL CLONING LAB MANU; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; Wood WB, 1988, NEMATODE CAENORHABDI	63	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26669	26677		10.1074/jbc.272.42.26669	http://dx.doi.org/10.1074/jbc.272.42.26669			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334250	hybrid			2022-12-25	WOS:A1997YB13900084
J	Katahira, J; Sugiyama, H; Inoue, N; Horiguchi, Y; Matsuda, M; Sugimoto, N				Katahira, J; Sugiyama, H; Inoue, N; Horiguchi, Y; Matsuda, M; Sugimoto, N			Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERO CELLS; RABBIT ILEUM; TOXIN; BINDING; GENE; RAT; PERMEABILITY; TRANSCRIPTS; CALCIUM; HELA	Human and mouse cDNAs showing homology to the Clostridium perfringens enterotoxin (CPE) receptor gene (CPE-R) from Vero cells (DDBJ/EMBL/GenBank(TM) accession no. D88492) (Katahira, J,, Inoue, N., Horiguchi, Y., Matsuda, M., and Sugimoto, N. (1997) J. Cell Biol. 136, 1239-1247) were cloned, They were classified into two groups, the Vero cell CPE receptor homologues and rat androgen withdrawal apoptosis protein (RVP1; accession no. M74067) homologues, based on the similarities of primary amino acid sequences. L929 cells that were originally insensitive to CPE became sensitive to CPE on their transfection with cDNAs encoding either the CPE receptor or RVP1 homologues, indicating that these gene products are not only structurally similar but also functionally active as receptors for CPE. Ey binding assay, the human RVP1 homologue showed differences in affinity and capacity of binding from those of the human CPE receptor, Northern blot analysis showed that mouse homologues of the CPE receptor and RVP1 are expressed abundantly in mouse small intestine. The expression of CPE-R mRNA in the small intestine was restricted to cryptic enterocytes, indicating that the CPE receptor is expressed in intestinal epithelial cells. These results are consistent with reports that CPE binds to the small intestinal cells via two different kinds of receptors, High levels of expression of CPE-R and/or RVP1 mRNA were also detected in other organs, including the lungs, liver, and kidneys, but only low levels were expressed in heart; and skeletal muscles. These results indicate that CPE uses structurally related cellular proteins as functional receptors in vivo and that organs that have not so far been recognized as CPE-sensitive have the potential to be targets of CPE.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT BACTERIAL TOXICOL,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT IMMUNOREGULAT,SUITA,OSAKA 565,JAPAN; NATL INST HLTH,DEPT PARASITOL,SHINJUKU KU,TOKYO 162,JAPAN	Osaka University; Osaka University				Katahira, Jun/0000-0001-5188-0368				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRIEHL MM, 1991, MOL ENDOCRINOL, V5, P1381, DOI 10.1210/mend-5-10-1381; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HORIGUCHI Y, 1985, FEMS MICROBIOL LETT, V28, P131; Innis MA, 1990, PCR PROTOCOLS GUIDE; Katahira J, 1997, J CELL BIOL, V136, P1239, DOI 10.1083/jcb.136.6.1239; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MATSUDA M, 1979, BIOCHEM BIOPH RES CO, V91, P629, DOI 10.1016/0006-291X(79)91568-7; MATSUDA M, 1986, BIOCHEM BIOPH RES CO, V141, P704, DOI 10.1016/S0006-291X(86)80229-7; MCCLANE BA, 1981, BIOCHIM BIOPHYS ACTA, V641, P401, DOI 10.1016/0005-2736(81)90496-X; MCCLANE BA, 1979, J CELL PHYSIOL, V99, P191, DOI 10.1002/jcp.1040990205; MCCLANE BA, 1987, MICROB PATHOGENESIS, V3, P195, DOI 10.1016/0882-4010(87)90096-9; McDonel J. L., 1986, Pharmacology of bacterial toxins, P477; MCDONEL JL, 1979, BIOCHEM BIOPH RES CO, V87, P497, DOI 10.1016/0006-291X(79)91823-0; MCDONEL JL, 1975, INFECT IMMUN, V12, P1214, DOI 10.1128/IAI.12.5.1214-1218.1975; MCDONEL JL, 1980, BIOCHEMISTRY-US, V19, P4801, DOI 10.1021/bi00562a014; MCDONEL JL, 1978, LAB INVEST, V39, P210; Ohishi K, 1996, GENOMICS, V34, P340, DOI 10.1006/geno.1996.0296; SAKAGUCHI G, 1973, APPL MICROBIOL, V27, P762; SKJELKVALE R, 1980, ACTA PATH MICRO IM B, V88, P95; STARK RL, 1971, INFECT IMMUN, V4, P89, DOI 10.1128/IAI.4.2.89-96.1971; SUGIMOTO N, 1988, BIOCHEM BIOPH RES CO, V156, P551, DOI 10.1016/S0006-291X(88)80877-5; SUGIMOTO N, 1985, European Journal of Epidemiology, V1, P264; TOLLESHAUG H, 1982, INFECT IMMUN, V37, P486, DOI 10.1128/IAI.37.2.486-491.1982; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; Watanabe R, 1996, J BIOL CHEM, V271, P26868, DOI 10.1074/jbc.271.43.26868; WNEK AP, 1986, MICROB PATHOGENESIS, V1, P89, DOI 10.1016/0882-4010(86)90035-5	29	210	222	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26652	26658		10.1074/jbc.272.42.26652	http://dx.doi.org/10.1074/jbc.272.42.26652			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334247	hybrid			2022-12-25	WOS:A1997YB13900081
J	Muresan, Z; Arvan, P				Muresan, Z; Arvan, P			Thyroglobulin transport along the secretory pathway - Investigation of the role of molecular chaperone, GRP94, in protein export from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; IMMUNOGLOBULIN HEAVY-CHAIN; INFLUENZA HEMAGGLUTININ; CONGENITAL GOITER; SEQUENTIAL INTERACTION; SELECTIVE PROTEINS; GOLGI-COMPLEX; BIP; CELLS; GLYCOPROTEIN	GRP94 serves as a molecular chaperone in the endoplasmic reticulum (ER), In normal thyrocytes, GRP94 interacts transiently with thyroglobulin (Tg), and in thyrocytes of animals suffering from congenital hypothyroid goiter with defective thyroglobulin, GRP94 and thyroglobulin associate in a protracted fashion. In order explore possible consequences of GRP94 binding, we have studied recombinant nonmutant thyroglobulin expressed in control Chinese hamster ovary (CHO) cells in comparison to that produced in CHO cells genetically manipulated for selectively increased GRP94 expression. Levels of ER chaperones other than GRP94 did not detectably differ, and thyroglobulin achieved transport competence in both kinds of CHO cells. However, increased availability of GRP94 caused the residence time of Tg in the ER to be remarkably prolonged, This was accompanied by a major increase in Tg directly associated with GRP94 and an increase in the ER pool size of Tg. Importantly, co-immunoprecipitation analysis revealed disulfide-linked Tg complexes (previously reported as an early Tg-folding intermediate) especially associated with GRP94. Indeed, non-native Tg, GRP94, and a 78-kDa protein likely to be BiP, appeared in ternary complexes. Under these conditions, GRP94 association appears directly involved in prolongation of Tg folding and export, consistent with a role in quality control in the ER.	HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02215	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040344, F32DK009411, R29DK040344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09411, DK40344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arvan P, 1997, THYROID, V7, P89, DOI 10.1089/thy.1997.7.89; ARVAN P, 1991, J CELL BIOL, V112, P365, DOI 10.1083/jcb.112.3.365; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BEAMER WG, 1987, ENDOCRINOLOGY, V120, P838, DOI 10.1210/endo-120-2-838; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; DORNER AJ, 1994, BIOLOGICALS, V22, P103, DOI 10.1006/biol.1994.1016; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GRAVES PN, 1990, MOL ENDOCRINOL, V4, P155, DOI 10.1210/mend-4-1-155; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HURTLEY SM, 1989, J CELL BIOL, V108, P2116; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KIM PS, 1991, J BIOL CHEM, V266, P12412; KIM PS, 1993, AM J PHYSIOL, V265, pC704, DOI 10.1152/ajpcell.1993.265.3.C704; KIM PS, 1993, J BIOL CHEM, V268, P4873; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MAKI RG, 1990, P NATL ACAD SCI USA, V87, P5658, DOI 10.1073/pnas.87.15.5658; MALTHIERY Y, 1989, BIOCHIMIE, V71, P195, DOI 10.1016/0300-9084(89)90057-6; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; MAYDRHOFER A, 1988, J HERED, V79, P200; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MedeirosNeto G, 1996, J CLIN INVEST, V98, P2838, DOI 10.1172/JCI119112; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MERCKEN L, 1985, NATURE, V316, P647, DOI 10.1038/316647a0; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; NAVARRO D, 1991, VIROLOGY, V184, P253, DOI 10.1016/0042-6822(91)90842-Y; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RAJASEKARAN AK, 1993, J CELL SCI, V105, P333; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHMITZ A, 1995, EMBO J, V14, P1091, DOI 10.1002/j.1460-2075.1995.tb07092.x; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; TAYLOR BA, 1987, P NATL ACAD SCI USA, V84, P1986, DOI 10.1073/pnas.84.7.1986; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WATOWICH SS, 1991, J VIROL, V65, P3590, DOI 10.1128/JVI.65.7.3590-3597.1991; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WIEST DL, 1990, J CELL BIOL, V110, P1501, DOI 10.1083/jcb.110.5.1501	67	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26095	26102		10.1074/jbc.272.42.26095	http://dx.doi.org/10.1074/jbc.272.42.26095			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334173	hybrid			2022-12-25	WOS:A1997YB13900007
J	Pang, P; Meathrel, K; Ko, KT				Pang, P; Meathrel, K; Ko, KT			A component of the chloroplast protein import apparatus functions in bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SECA-PROTEIN; PRECURSOR PROTEIN; THYLAKOID MEMBRANE; PEA-CHLOROPLASTS; CDNA CLONE; TRANSPORT; IDENTIFICATION; HOMOLOG; TRANSLOCATION	Toc36 is a family of 44-kDa envelope polypeptides previously identified as components of the chloroplast protein import apparatus by virtue of their close physical proximity to translocating proteins. An indication of their function thus remains at large. A heterologous in vivo approach for studying the function of Toc36 was developed in this study by introducing a member of Toc36 into E. coli to assess its effect on bacterial protein translocation. The presence of Toc36 enhances the translocation of two bacterial periplasmic proteins in a manner resembling the chloroplast system. Translocation of the two bacterial periplasmic proteins was less sensitive to sodium azide, resembling more the azide-insensitive nature of the chloroplast protein import process. Mutated Toc36 proteins were not capable of causing the same effect as that observed for unaltered Toc36. Toc36 was also capable of complementing bacterial strains with temperature-sensitive secA mutations that affected protein translocation. The combined results provide evidence that Toc36 plays a central role in the chloroplast protein translocation process.	QUEENS UNIV, DEPT BIOL, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada								CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; GUTTERIDGE S, 1995, PLANT CELL, V7, P809, DOI 10.1105/tpc.7.7.809; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; KARKHANIS YD, 1978, ANAL BIOCHEM, V85, P595, DOI 10.1016/0003-2697(78)90260-9; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KIM YJ, 1994, CELL, V78, P845; KIM YJ, 1994, FEBS LETT, V339, P175, DOI 10.1016/0014-5793(94)80410-9; KNOTT TG, 1994, J BIOL CHEM, V269, P7843; KO K, 1995, J BIOL CHEM, V270, P28601, DOI 10.1074/jbc.270.48.28601; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; LEVY SB, 1984, ANTIMICROBIAL DRUG R, P191; NAKAI M, 1994, J BIOL CHEM, V269, P31338; NOHARA T, 1995, FEBS LETT, V364, P305, DOI 10.1016/0014-5793(95)00415-6; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; REITH M, 1993, PLANT CELL, V5, P465, DOI 10.1105/tpc.5.4.465; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNELL DJ, 1995, CELL, V83, P521, DOI 10.1016/0092-8674(95)90090-X; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; WU CB, 1993, J BIOL CHEM, V268, P19384; WU CB, 1994, J BIOL CHEM, V269, P32264; YAMATO I, 1975, J BIOCHEM, V77, P705, DOI 10.1093/oxfordjournals.jbchem.a130774; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	28	23	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25623	25627		10.1074/jbc.272.41.25623	http://dx.doi.org/10.1074/jbc.272.41.25623			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325283	hybrid			2022-12-25	WOS:A1997YA35800038
J	He, SM; Withers, SG				He, SM; Withers, SG			Assignment of sweet almond beta-glucosidase as a family 1 glycosidase and identification of its active site nucleophile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GLYCOSYL HYDROLASES; CLASSIFICATION; INHIBITORS; MECHANISM; SIMILARITIES; INTERMEDIATE; PROBES	Sweet almond P-glucosidase is a well studied glycosidase, having been subjected to numerous kinetic analyses and inhibition studies. However, it is not known to which glycosidase family it belongs, nor is the identity of the active site nucleophile known with certainty, It can be inactivated using the specific, mechanism-based enzyme inactivator 2-deoxy-2-fluoro-beta-D-glucopyranosyl fluoride, which functions by forming a stable 2-deoxy-2-fluoro-alpha-D-glucopyranosyl-enzyme intermediate. The glycosylated peptide present in a peptic digest of this trapped glycosyl-enzyme intermediate was identified by use of neutral loss scans on an electrospray ionization triple quadrupole mass spectrometer, Comparative liquid chromatographic/mass spectrometric analysis of peptic digests of labeled and unlabeled enzyme samples confirmed the unique presence of this peptide of m/z = 1011 in the labeled sample, The sequence of this peptide was determined to be Ile-Thr-Glu-Gln-Gly-Val-Asp-Glu by further tandem mass spectrometric analysis in the daughter ion scan mode in conjunction with Edman degradation of the purified peptide. The identity of the labeled side chain was determined by further tandem mass spectrometric analysis in the daughter ion scan mode of a partially purified sample of the labeled peptide subjected to methyl esterification, the fragmentation pattern being consistent only with the first Glu in the sequence being labeled. The sequence around this residue is identical to that surrounding the catalytic nucleophile in many members of glycosidase Family 1, confirming the assignment of this enzyme to that family, The residue labeled is, however, different from that (Asp) identified previously in the enzyme from bitter almonds by use of conduritol epoxide affinity labels, although apparently close in the primary sequence.	PROT ENGN NETWORK CTR EXCELLENCE CANADA,VANCOUVER,BC V6T 1Z1,CANADA; UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER,BC V6T 1Z1,CANADA	University of British Columbia								ADAMSON J, 1970, CARBOHYD RES, V15, P351, DOI 10.1016/S0008-6215(00)80451-6; BARRETT T, 1995, STRUCTURE, V3, P951, DOI 10.1016/S0969-2126(01)00229-5; DALE MP, 1986, BIOCHEMISTRY-US, V25, P2522, DOI 10.1021/bi00357a036; DALE MP, 1985, BIOCHEMISTRY-US, V24, P3530, DOI 10.1021/bi00335a022; EVELEIGH DE, 1969, CARBOHYD RES, P87; Febbraio F, 1997, BIOCHEMISTRY-US, V36, P3068, DOI 10.1021/bi962496w; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GROVER AK, 1977, BIOCHIM BIOPHYS ACTA, V482, P98, DOI 10.1016/0005-2744(77)90358-8; HALL LD, 1971, CAN J CHEMISTRY, V49, P118, DOI 10.1139/v71-017; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; LEGLER G, 1970, H-S Z PHYSIOL CHEM, V351, P25, DOI 10.1515/bchm2.1970.351.1.25; LEGLER G, 1978, BIOCHIM BIOPHYS ACTA, V524, P102, DOI 10.1016/0005-2744(78)90108-0; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; Mackenzie LF, 1997, BIOCHEMISTRY-US, V36, P5893, DOI 10.1021/bi962962h; Mackenzie LF, 1997, J BIOL CHEM, V272, P3161, DOI 10.1074/jbc.272.6.3161; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MIAO SC, 1994, J BIOL CHEM, V269, P10975; SHULMAN ML, 1976, BIOCHIM BIOPHYS ACTA, V445, P169, DOI 10.1016/0005-2744(76)90170-4; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STREET IP, 1986, BIOCHEMISTRY-US, V25, P6021, DOI 10.1021/bi00368a028; TULL D, 1995, ANAL BIOCHEM, V224, P509, DOI 10.1006/abio.1995.1080; WEBER JP, 1980, J BIOL CHEM, V255, P9030; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; WITHERS SG, 1987, J AM CHEM SOC, V109, P7530, DOI 10.1021/ja00258a047; WITHERS SG, 1995, PROTEIN SCI, V4, P361	29	56	57	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24864	24867		10.1074/jbc.272.40.24864	http://dx.doi.org/10.1074/jbc.272.40.24864			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312086	hybrid			2022-12-25	WOS:A1997XY97000025
J	Hettasch, JM; Peoples, KA; Greenberg, CS				Hettasch, JM; Peoples, KA; Greenberg, CS			Analysis of factor XIII substrate specificity using recombinant human factor XIII and tissue transglutaminase chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XIII; FIBRIN-STABILIZING FACTOR; PLASMA FACTOR-XIIIA; PIG LIVER-ENZYME; AMINE-DONOR LYSINE; CROSS-LINKING; ALPHA-2-PLASMIN INHIBITOR; STRUCTURAL FEATURES; CATALYTIC ACTIVITY; BLOOD-PLASMA	Human factor XIII (FXIII) and tissue transglutaminase (tTG) are homologous proteins, FXIII requires thrombin for activation and cross-links the gamma chains of fibrin(ogen) more efficiently than the A alpha chains, On the other hand, tTG is thrombin-independent and forms predominantly A alpha and A alpha-gamma chain complexes, Previous work from this laboratory demonstrated that amino acid residues within exon 7 of FXIII were important for catalysis (Hettasch, J. M., and Greenberg, C. S. (1994) J. Biol. Chem. 269, 28309-28313), To determine to what extent the primary amino acid sequence within exon 7 defines substrate specificity, exon 7 of FXIII was replaced with the corresponding exon of tTG using gene splicing by overlap extension, Other work from this laboratory (Achyuthan, K.E., Slaughter, T.F., Santiago, M. A. Enghild, J. J., and Greenberg, C. S. (1993) J. Biol. Chem, 268, 21284-21292) using synthetic peptides identified two other domains that might play a role in substrate recognition (located in exons 3 and 5), Therefore, recombinant chimeras of FXIII/tTG were also created in which these two exons were exchanged, FXIII, tTG, and chimeras 3, 5, and 7 were expressed in Escherichia coli, purified, and the nature of the fibrin cross-linking pattern of these five proteins was determined by immunoblot analysis, FXIII preferentially formed the gamma-gamma dimer, whereas tTG formed A alpha-gamma complexes, Chimera 7 formed A alpha-gamma complexes that resembled the cross-linking pattern of tTG, This finding demonstrates that the primary amino acid sequence of exon 7 of tTG confers some of the specificity for the A alpha and A alpha-gamma cross-link pattern characteristic of tTG. Chimera 5 exhibited reduced crosslinking activity (50% of FXIII activity) but still retained preference for formation of the gamma-gamma dimer, whereas chimera 3 was not active, In conclusion, exchanging the primary amino acid sequence of the active site exon of human FXIII with that of human tTG modifies the enzyme such that the fibrin cross-linking pattern more closely resembles that of tTG (A alpha and A alpha-gamma complexes) instead of FXIII (gamma-gamma dimers).	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University; Duke University					NHLBI NIH HHS [HL28391, HL38245, HL26309] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038245, P60HL028391, P50HL026309] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHYUTHAN KE, 1993, J BIOL CHEM, V268, P21284; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BLOMBACK B, 1958, ARK KEMI, V12, P173; Chen R, 1971, Biochemistry, V10, P4487; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; DOOLITTLE RF, 1983, ANN NY ACAD SCI, V408, P13, DOI 10.1111/j.1749-6632.1983.tb23231.x; DOOLITTLE RF, 1971, BIOCHEM BIOPH RES CO, V44, P94, DOI 10.1016/S0006-291X(71)80163-8; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; FRANCIS CW, 1988, BLOOD, V71, P1361; GAFFNEY PJ, 1979, THROMB RES, V14, P85, DOI 10.1016/0049-3848(79)90027-6; GORMAN JJ, 1984, J BIOL CHEM, V259, P9007; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; GORMAN JJ, 1981, J BIOL CHEM, V256, P2712; GREENBERG CS, 1988, BIOCHEM J, V256, P1013, DOI 10.1042/bj2561013; GROENEN PJTA, 1994, EUR J BIOCHEM, V220, P795, DOI 10.1111/j.1432-1033.1994.tb18681.x; GROOTJANS JJ, 1995, J BIOL CHEM, V270, P22855, DOI 10.1074/jbc.270.39.22855; GROSS M, 1977, J BIOL CHEM, V252, P3752; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HERMANS J, 1982, SEMIN THROMB HEMOST, V8, P11, DOI 10.1055/s-2007-1005039; Hettasch JM, 1996, LAB INVEST, V75, P637; HETTASCH JM, 1994, J BIOL CHEM, V269, P28309; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KIM SY, 1994, J BIOL CHEM, V269, P27979; KUROCHKIN IV, 1995, J MOL BIOL, V248, P414, DOI 10.1016/S0022-2836(95)80060-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI TS, 1994, J BIOL CHEM, V269, P24596; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; LORAND L, 1972, ANN NY ACAD SCI, V202, P6, DOI 10.1111/j.1749-6632.1972.tb16319.x; LORAND L, 1964, ARCH BIOCHEM BIOPHYS, V105, P58, DOI 10.1016/0003-9861(64)90235-8; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; MICANOVIC R, 1994, J BIOL CHEM, V269, P9190; MOSESSON MW, 1989, P NATL ACAD SCI USA, V86, P1113, DOI 10.1073/pnas.86.4.1113; Mosher D F, 1978, Ann N Y Acad Sci, V312, P38, DOI 10.1111/j.1749-6632.1978.tb16791.x; MURTHY SNP, 1990, P NATL ACAD SCI USA, V87, P9679, DOI 10.1073/pnas.87.24.9679; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SAKATA Y, 1984, BLOOD, V63, P1393; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRODE J, 1979, J BIOL CHEM, V254, P653; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; Shainoff J R, 1990, Blood Coagul Fibrinolysis, V1, P499, DOI 10.1097/00001721-199010000-00025; SHAINOFF JR, 1991, J BIOL CHEM, V266, P6429; SHEN L, 1983, J CLIN INVEST, V71, P1336, DOI 10.1172/JCI110885; SIEBENLIST KR, 1992, BIOCHEMISTRY-US, V31, P936, DOI 10.1021/bi00118a040; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; TAMAKI T, 1981, BIOCHIM BIOPHYS ACTA, V661, P280, DOI 10.1016/0005-2744(81)90016-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENZUELA R, 1992, AM J PATHOL, V141, P861; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296	54	15	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25149	25156		10.1074/jbc.272.40.25149	http://dx.doi.org/10.1074/jbc.272.40.25149			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312126	hybrid			2022-12-25	WOS:A1997XY97000065
J	Inoue, D; Santiago, P; Horne, WC; Baron, R				Inoue, D; Santiago, P; Horne, WC; Baron, R			Identification of an osteoclast transcription factor that binds to the human T cell leukemia virus type I-long terminal repeat enhancer element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-RESPONSIVE ELEMENT; HTLV-I; C-FOS; CYCLIC-AMP; INTERLEUKIN-2 RECEPTOR; BONE-RESORPTION; TRANSGENIC MICE; DNA-BINDING; TAX; PROTEIN	Transgenic mice expressing human T cell leukemia virus type I (HTLV-I)-tax under the control of HTLV-I-long terminal repeat (LTR) promoter develop skeletal abnormalities with high bone turnover and myelofibrosis, In these animals, Tax is highly expressed in bone with a pattern of expression restricted to osteoclasts and spindle-shaped cells within the endosteal myelofibrosis, To test the hypothesis that lineage-specific transcription factors promote transgene expression from the HTLV-I-LTR in osteoclasts, we first examined tax expression in transgenic bone marrow cultures, Expression was dependent on 1 alpha,25-dihydroxycholecalciferol and coincided with tartrate-resistant acid phosphatase (TRAP) expression, a marker of osteoclast differentiation, Furthermore, Tax was expressed in vitronectin receptor positive mononuclear precursors as well as in mature osteoclast-libe cells (OCLs), Consistent with our hypothesis, electrophoretic mobility shift assays revealed the presence of an OCL nuclear factor (NFOC-1) that binds to the LTR 21-base pair direct repeat, a region critical for the promoter activity, This binding is further enhanced by Tax. Since NFOC-1 is absent in macro phages and conserved in osteoclasts among species including human, such a factor may play a role in lineage determination and/or in expression of the differentiated osteoclast phenotype.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT ORTHOPAED,NEW HAVEN,CT 06510	Yale University; Yale University								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; BURGER EH, 1982, J EXP MED, V156, P1604, DOI 10.1084/jem.156.6.1604; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNTHARAPAI A, 1993, EXP CELL RES, V205, P345, DOI 10.1006/excr.1993.1096; DAVID JP, 1996, J BONE MINER RES  S1, V11, pS111; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GALIEN GM, 1994, RES VIROLOGY, V145, P361; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; GREENE WC, 1986, ANN INTERN MED, V105, P560, DOI 10.7326/0003-4819-105-4-560; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HOGAN B, 1994, MANIPULATING MOUSE E, P291; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; LASKY SR, 1995, J BIOL CHEM, V270, P19676, DOI 10.1074/jbc.270.34.19676; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MARUYAMA M, 1987, CELL, V48, P493; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OHSAKI Y, 1992, ENDOCRINOLOGY, V131, P2229, DOI 10.1210/en.131.5.2229; OSAME M, 1986, LANCET, V1, P1031; RUDDLE NH, 1993, VIROLOGY, V197, P196, DOI 10.1006/viro.1993.1580; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; TUGORES A, 1992, J IMMUNOL, V148, P2300; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	47	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25386	25393		10.1074/jbc.272.40.25386	http://dx.doi.org/10.1074/jbc.272.40.25386			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312160	hybrid			2022-12-25	WOS:A1997XY97000099
J	Kozawa, O; Suzuki, A; Kaida, T; Tokuda, H; Uematsu, T				Kozawa, O; Suzuki, A; Kaida, T; Tokuda, H; Uematsu, T			Tumor necrosis factor-alpha autoregulates interleukin-6 synthesis via activation of protein kinase C - Function of sphingosine 1-phosphate and phosphatidylcholine-specific phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-LIKE CELLS; SWISS 3T3 CELLS; BONE-RESORPTION; INOSITOL TRISPHOSPHATE; GROWTH-FACTOR; DIFFERENTIATION; HYDROLYSIS; BREAKDOWN; CERAMIDE; TNF	We investigated the mechanism of interleukin-6 (IL-6) synthesis induced by tumor necrosis factor-alpha (TNF) in osteoblast-like MC3T3-E1 cells. TNF stimulated the synthesis of IL-6 dose dependently in the range between 1 and 30 ng/ml. Staurosporine and calphostin C, inhibitors of protein kinase C (PKC), significantly enhanced the TNF-induced synthesis of IL-6. 1-Oleoyl-2-acetylglycerol, a specific activator of PKC, inhibited the TNF-induced IL-6 synthesis. The stimulative effect of TNF was markedly increased in the PKC down-regulated cells, TNF produced diacylglycerol. TNF had little effect on the formation of inositol phosphates and choline, On the contrary, TNF significantly stimulated the formation of phosphocholine dose dependently. D-609, an inhibitor of phosphatidylcholine-specific phospholipase C, suppressed the TNF-induced diacylglycerol production, The TNF-induced IL-6 synthesis was significantly enhanced by D-609, TNF induced sphingomyelin hydrolysis. Neither C-2-ceramide nor sphingosine but sphingosine 1-phosphate significantly stimulated the synthesis of IL-6. PKC down-regulation amplified the IL-6 synthesis by sphingosine 1-phosphate. These results strongly suggest that sphingosine 1-phosphate may act as a second messenger for TNF-induced IL-6 synthesis and that TNF autoregulates IL-6 synthesis due to PKC activation via phosphatidylcholine-specific phospholipase C in osteoblast-like cells.	NAGOYA UNIV, SCH MED, DEPT INTERNAL MED 1, NAGOYA, AICHI 466, JAPAN; CHUBA NATL HOSP, NATL INST LONGEV SCI, DEPT INTERNAL MED, AICHI 474, JAPAN	Nagoya University	Kozawa, O (corresponding author), GIFU UNIV, SCH MED, DEPT PHARMACOL, GIFU 500, JAPAN.							AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; AMEMIYA Y, 1988, NATURE, V336, P89, DOI 10.1038/336089a0; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; EXTON JH, 1990, J BIOL CHEM, V265, P1; FEYEN JHM, 1989, J BONE MINER RES, V4, P633, DOI 10.1002/jbmr.5650040422; FRANCHIMONT N, 1995, ENDOCRINOLOGY, V136, P5469, DOI 10.1210/en.136.12.5469; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLE M, 1988, EUR J IMMUNOL, V18, P957, DOI 10.1002/eji.1830180619; ISHIMI Y, 1990, J IMMUNOL, V145, P3297; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kodama HA., 1981, JPN J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899; NIJWEIDE PJ, 1986, PHYSIOL REV, V66, P855, DOI 10.1152/physrev.1986.66.4.855; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; PAPPU AS, 1983, NEUROCHEM RES, V8, P1565, DOI 10.1007/BF00964158; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROODMAN GD, 1992, J BONE MINER RES, V7, P475, DOI 10.1002/jbmr.5650070502; SAKAI T, 1992, CELL CALCIUM, V13, P329, DOI 10.1016/0143-4160(92)90068-4; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SHINODA J, 1995, AM J PHYSIOL-ENDOC M, V269, pE524, DOI 10.1152/ajpendo.1995.269.3.E524; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Suzuki A, 1996, J CELL PHYSIOL, V168, P209, DOI 10.1002/(SICI)1097-4652(199607)168:1<209::AID-JCP25>3.0.CO;2-0; Suzuki A, 1996, J CELL BIOCHEM, V63, P491, DOI 10.1002/(SICI)1097-4644(19961215)63:4<491::AID-JCB10>3.0.CO;2-H; SUZUKI A, 1994, J CELL BIOCHEM, V54, P487, DOI 10.1002/jcb.240540416; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THOMSON BM, 1987, J IMMUNOL, V138, P775; THOMSON BM, 1986, J EXP MED, V164, P104, DOI 10.1084/jem.164.1.104; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689	39	52	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25099	25104		10.1074/jbc.272.40.25099	http://dx.doi.org/10.1074/jbc.272.40.25099			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312119	hybrid			2022-12-25	WOS:A1997XY97000058
J	Maundrell, K; Antonsson, B; Magnenat, E; Camps, M; Muda, M; Chabert, C; Gillieron, C; Boschert, U; VialKnecht, E; Martinou, JC; Arkinstall, S				Maundrell, K; Antonsson, B; Magnenat, E; Camps, M; Muda, M; Chabert, C; Gillieron, C; Boschert, U; VialKnecht, E; Martinou, JC; Arkinstall, S			Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INDUCED APOPTOSIS; PROTOONCOGENE; SPECIFICITY; PATHWAY; JNK; INACTIVATION; PHOSPHATASE; SURVIVAL; FAMILY	We have studied the phosphorylation of the Bcl-2 family of proteins by different mitogen-activated protein (MAP) kinases. Purified Bcl-2 was found to be phosphorylated by the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) p54-SAPK beta, and this is specific insofar as the extracellular signal-regulated kinase 1 (ERK1) and p38/RK/CSBP (p38) catalyzed only weak modification. Bcl-2 undergoes similar phosphorylation in COS-7 when coexpressed together with p54-SAPK beta and the constitutive Rac1 mutant G12V, This is seen by both (PO4)-P-32 labeling and the appearance of five discrete Bcl-2 bands with reduced gel mobility. As anticipated, both intracellular p54-SAPK beta activation and Bcl-2 phosphorylation are blocked by co-transfection with the MAP kinase specific phosphatase MKP3/PYST1. MAP kinase specificity is also seen in COS-7 cells as Bcl-2 undergoes only weak phosphorylation when co-expressed with enzymatically activated ERK1 or p38, Four critical residues undergoing phosphorylation in COS-7 cells were identified by expression of the quadruple Bcl-2 point mutant T56A, S70A, T74A, S87A. Sequencing phosphopeptides derived from tryptic digests of Bcl-2 indicates that purified GST-p54-SAPK beta phosphorylates identical sites in vitro. This is the first report of Bcl-2 phosphorylation by the JNK/SAPK class of MAP kinases and could indicate a key modification allowing control of Bcl-2 function by cell surface receptors, Rho family GTPases, and/or cellular stresses.	GLAXO WELLCOME RES & DEV SA,GENEVA BIOMED RES INST,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND	GlaxoSmithKline				martinou, Jean-claude/0000-0002-9847-2051; Camps, Montserrat/0000-0002-9849-8657				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COHEN P, 1997, IN PRESS TRENDS CELL; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shu CH, 1996, APOPTOSIS, V1, P141, DOI 10.1007/BF01321020; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	38	349	363	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25238	25242		10.1074/jbc.272.40.25238	http://dx.doi.org/10.1074/jbc.272.40.25238			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312139	hybrid			2022-12-25	WOS:A1997XY97000078
J	Sun, C; Woolford, JL				Sun, C; Woolford, JL			The yeast nucleolar protein Nop4p contains four RNA recognition motifs necessary for ribosome biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; HETERONUCLEAR MAGNETIC-RESONANCE; BINDING DOMAIN; SACCHAROMYCES-CEREVISIAE; A-PROTEIN; HNRNP A1; CONSENSUS SEQUENCE; STRUCTURAL DOMAINS; CRYSTAL-STRUCTURE; SPLICING FACTORS	The Saccharomyces cerevisiae nucleolar protein Nop4p is necessary for processing of rRNA and assembly of 60 S ribosomal subunits, Nop4p is unusual in that it contains four RNA recognition motifs (RRMs) including one noncanonical RRM, as well as several auxiliary motifs, two acidic regions between the RRMs, and a carboxyl-terminal domain rich in lysines and arginines. To examine the functional importance of these motifs, we isolated random and site-directed mutations in NOP4 and assayed Nop4p function in vivo. Our results indicate that each RRM is essential for Nop4p function; mutations in conserved aromatic residues of Nop4p cause a temperature-sensitive lethal phenotype and diminished 60 S ribosomal subunit production, The carboxyl-terminal 68 amino acids are important but apparently not essential; carboxyl-terminal truncation of Nop4p causes slow growth, decreased ribosome production, and mislocalization of Nop4p. Deletion of both acidic motifs is lethal but replacement of most of the acidic residues with alanine has no apparent phenotype. These acidic residues may serve as spacers or tethers to separate the RRMs.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	Carnegie Mellon University				Woolford, John/0000-0002-7553-7043	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28301] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; Allmang C, 1996, RNA, V2, P63; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BERGES T, 1994, EMBO J, V13, P3136, DOI 10.1002/j.1460-2075.1994.tb06612.x; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P4611, DOI 10.1093/nar/19.17.4611; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; COETZEE T, 1994, GENE DEV, V8, P1575, DOI 10.1101/gad.8.13.1575; COPELAND CS, 1993, YEAST, V9, P235, DOI 10.1002/yea.320090304; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P82; GARRETT DS, 1994, BIOCHEMISTRY-US, V33, P2852, DOI 10.1021/bi00176a015; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GRUSS C, 1992, BIOESSAYS, V14, P1, DOI 10.1002/bies.950140102; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE AL, 1994, BIOCHEMISTRY-US, V33, P13775, DOI 10.1021/bi00250a031; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Leung DW, 1989, TECHNIQUE, V1, P11; LIAO XLC, 1993, GENE DEV, V7, P419, DOI 10.1101/gad.7.3.419; LUTZ CS, 1994, GENE DEV, V8, P576, DOI 10.1101/gad.8.5.576; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; MCCUSKER JH, 1991, YEAST, V7, P607, DOI 10.1002/yea.320070608; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; Methot N, 1996, RNA, V2, P38; MORITZ M, 1990, J CELL BIOL, V111, P2261, DOI 10.1083/jcb.111.6.2261; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NAGAI K, 1994, RNA PROTEIN INTERACT, P150; NARANDA T, 1994, J BIOL CHEM, V269, P14465; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; RAUE HA, 1995, GENE EXPRESSION, V5, P71; ROTENBERG MO, 1988, GENE DEV, V2, P160, DOI 10.1101/gad.2.2.160; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SHAMOO Y, 1995, NUCLEIC ACIDS RES, V23, P725, DOI 10.1093/nar/23.5.725; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Sherman F., 1986, METHODS YEAST GENETI; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; SUN C, 1994, EMBO J, V13, P3127, DOI 10.1002/j.1460-2075.1994.tb06611.x; SUROWY CS, 1989, MOL CELL BIOL, V9, P4179, DOI 10.1128/MCB.9.10.4179; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; vanNues RW, 1995, BIOCHEM CELL BIOL, V73, P789, DOI 10.1139/o95-087; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; Weeks KM, 1996, SCIENCE, V271, P345, DOI 10.1126/science.271.5247.345; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7; YAN C, 1993, J CELL BIOL, V123, P1081, DOI 10.1083/jcb.123.5.1081; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	65	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25345	25352		10.1074/jbc.272.40.25345	http://dx.doi.org/10.1074/jbc.272.40.25345			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312154	hybrid			2022-12-25	WOS:A1997XY97000093
J	Wu, YL; Aghdasi, B; Dou, SJ; Zhang, JZ; Liu, SQ; Hamilton, SL				Wu, YL; Aghdasi, B; Dou, SJ; Zhang, JZ; Liu, SQ; Hamilton, SL			Functional interactions between cytoplasmic domains of the skeletal muscle Ca2+ release channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM VESICLES; RYANODINE RECEPTOR GENE; RAPID CALCIUM RELEASE; MALIGNANT HYPERTHERMIA; CA-2+ RELEASE; REACTIVE OXYGEN; BINDING-SITES; NITRIC-OXIDE; PROTEIN; IDENTIFICATION	The skeletal muscle Ca2+ release channel (RYR1), which plays a critical role in excitation-contraction coupling, is a homotetramer with a subunit molecular mass of 565 kDa, Oxidation of the channel increases its activity and produces intersubunit cross-links within the RYR1 tetramer (Aghdasi, B., Zhang, J., Wu, Y., Reid, M. B., and Hamilton, S. L. (1997) J. Biol. Chem. 272, 3739-3748), Alkylation of hyperreactive sulfhydryls on RYR1 with N-ethylmaleimide (NEM) inhibits channel function and blocks the intersubunit cross-linking, We used calpain and tryptic cleavage, two dimensional SDS polyacrylamide gel electrophoresis, N-terminal sequencing, sequence-specific antibody Western blotting, and [C-14]NEM labeling to identify the domains involved in these effects, Our data are consistent with a model in which 1) diamide, an oxidizing agent, simultaneously produces an intermolecular cross-link between adjacent subunits within the RYR1 tetramer and an intramolecular cross-link within a single subunit; 2) all of the cysteines involved in both cross-links are in either the region between amino acids similar to 2100 and 2843 or the region between amino acids 2844 and 4685; 3) oxidation exposes a new calpain cleavage site in the central domain of the RYR1 (in the region around amino acid 2100); 4) sulfhydryls that react most rapidly with NEM are located in the N-terminal domain (between amino acids 426 and 1396); 5) alkylation of the N-terminal cysteines completely inhibits the formation of both inter- and intra-subunit cross-links, In summary, we present evidence for interactions between the N-terminal region and the putatively cytoplasmic central domains of RYR1 that appear to influence subunit subunit interactions and channel activity.	BAYLOR COLL MED,DEPT MOL PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine				Hamilton, Susan/0000-0003-0241-9369	NIAMS NIH HHS [AR41802] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041802] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMSON JJ, 1983, P NATL ACAD SCI-BIOL, V80, P1526, DOI 10.1073/pnas.80.6.1526; ABRAMSON JJ, 1988, J BIOL CHEM, V263, P18750; ABRAMSON JJ, 1995, J BIOL CHEM, V270, P29644; ABRAMSON JJ, 1988, ARCH BIOCHEM BIOPHYS, V263, P245, DOI 10.1016/0003-9861(88)90633-9; Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; BALON TW, 1994, J APPL PHYSIOL, V77, P2519, DOI 10.1152/jappl.1994.77.6.2519; BINDOLI A, 1983, ARCH BIOCHEM BIOPHYS, V221, P458, DOI 10.1016/0003-9861(83)90164-9; BRANDT NR, 1992, J MEMBRANE BIOL, V127, P35; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; CHEN SRW, 1994, P NATL ACAD SCI USA, V91, P11953, DOI 10.1073/pnas.91.25.11953; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; DIAZ PT, 1993, J APPL PHYSIOL, V75, P540, DOI 10.1152/jappl.1993.75.2.540; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20857; GILLARD EF, 1991, GENOMICS, V11, P751, DOI 10.1016/0888-7543(91)90084-R; GILLARD EF, 1992, GENOMICS, V13, P1247, DOI 10.1016/0888-7543(92)90042-Q; GRUNWALD R, 1995, J BIOL CHEM, V270, P11338, DOI 10.1074/jbc.270.19.11338; HAMILTON SL, 1991, CELLULAR CALCIUM, P313; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; PHILLIPS MS, 1994, HUM MOL GENET, V3, P2181, DOI 10.1093/hmg/3.12.2181; QUANE KA, 1993, NAT GENET, V5, P51, DOI 10.1038/ng0993-51; QUANE KA, 1994, HUM MOL GENET, V3, P471, DOI 10.1093/hmg/3.3.471; RARDON DP, 1990, CIRC RES, V67, P84, DOI 10.1161/01.RES.67.1.84; REID MB, 1993, J APPL PHYSIOL, V75, P1081, DOI 10.1152/jappl.1993.75.3.1081; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; SEILER S, 1984, J BIOL CHEM, V259, P8550; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; WAGENKNECHT T, 1995, BIOPHYS J, V66, pA416; Wang JP, 1996, J BIOL CHEM, V271, P8387, DOI 10.1074/jbc.271.14.8387; WANG K, 1974, J BIOL CHEM, V249, P8005; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725; ZHANG YL, 1993, NAT GENET, V5, P46, DOI 10.1038/ng0993-46; ZORZATO F, 1986, J BIOL CHEM, V261, P3252; Zorzato F, 1996, J BIOL CHEM, V271, P22759, DOI 10.1074/jbc.271.37.22759; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	46	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25051	25061		10.1074/jbc.272.40.25051	http://dx.doi.org/10.1074/jbc.272.40.25051			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312113	hybrid			2022-12-25	WOS:A1997XY97000052
J	Hickey, MJ; Sharkey, KA; Sihota, EG; Reinhardt, PH; Macmicking, JD; Nathan, C; Kubes, P				Hickey, MJ; Sharkey, KA; Sihota, EG; Reinhardt, PH; Macmicking, JD; Nathan, C; Kubes, P			Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia	FASEB JOURNAL			English	Article						adhesion; selectin; rolling; neutrophil	NF-KAPPA-B; P-SELECTIN; ADHESION MOLECULE-1; MESSENGER-RNA; SEPTIC SHOCK; IN-VIVO; INHIBITION; EXPRESSION; INFLAMMATION; SUPEROXIDE	Nitric oxide (NO) from constitutive NO synthase (NOS) has been postulated to be a homeostatic regulator of leukocyte-endothelial cell interactions. By contrast, the inducible NO synthase (iNOS) isoform has been invoked as a potential pathogenic enzyme in numerous inflammatory diseases. The objective of this study was to determine whether the iNOS isoform is also capable of functioning as a regulator of leukocyte recruitment. Mice received endotoxin (LPS, 30 mu g/kg, i.v.); 2-4 h later, intravital microscopy was used to examine leukocyte rolling and adhesion in postcapillary venules of the cremaster muscle and the sinusoids and postsinusoidal venules of the hepatic microcirculation. Leukocyte recruitment into the lung was also examined. RT-PCR confirmed that this treatment induced iNOS mRNA expression in wild-type mice as early as 2 h after LPS treatment. Between 2 and 4 h after LPS administration, the number of rolling and adherent leukocytes in cremasteric postcapillary venules and of adherent cells in liver postsinusoidal venules of iNOS-deficient mice were significantly higher than in wild-type mice. Leukocyte accumulation in the lung (measured by myeloperoxidase assay) was also significantly elevated in iNOS-deficient animals. These effects could not be attributed to differences in systemic blood pressure, shear rates, circulating leukocyte numbers, or baseline levels of rolling and adhesion because these parameters were not different between the two groups. To establish whether the differences in leukocyte recruitment were related to the leukocytes per se, perfusion of iNOS(+/+) or iNOS(-/-) septic blood over purified E-selectin (using parallel plate flow chambers) revealed much larger recruitment of iNOS(-/-) leukocytes. These results suggest that iNOS induced in response to LPS releases NO that is capable of reducing leukocyte accumulation by affecting leukocytes directly and raises the possibility that induction of iNOS is a homeostatic regulator for leukocyte recruitment.	UNIV CALGARY,HLTH SCI CTR,IMMUNOL RES GRP,CALGARY,AB T2N 4N1,CANADA; UNIV CALGARY,HLTH SCI CTR,GASTROINTESTINAL RES GRP,CALGARY,AB T2N 4N1,CANADA; CORNELL UNIV COLL,DEPT MED,BEATRICE & SAMUEL A SEAVER LAB,NEW YORK,NY 10021	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; Cornell University			Hickey, Michael J./A-5429-2012	Hickey, Michael J./0000-0003-2354-357X; Sharkey, Keith/0000-0001-9560-1711				ASAKO H, 1994, J CLIN INVEST, V93, P1508, DOI 10.1172/JCI117129; AVONTUUR JAM, 1995, CIRC RES, V76, P418, DOI 10.1161/01.RES.76.3.418; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVENPECK KL, 1994, GASTROENTEROLOGY, V107, P1050, DOI 10.1016/0016-5085(94)90229-1; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; Gaboury JP, 1996, CIRCULATION, V93, P318, DOI 10.1161/01.CIR.93.2.318; GAUTHIER TW, 1994, AM J PHYSIOL-GASTR L, V267, pG562, DOI 10.1152/ajpgi.1994.267.4.G562; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; HARBRECHT BG, 1992, J LEUKOCYTE BIOL, V52, P390, DOI 10.1002/jlb.52.4.390; HENDERSON JL, 1994, ARCH SURG-CHICAGO, V129, P1271; Hickey MJ, 1997, J IMMUNOL, V158, P3391; HOUSE SD, 1987, MICROVASC RES, V34, P363, DOI 10.1016/0026-2862(87)90068-9; Kanwar S, 1997, J EXP MED, V185, P1077, DOI 10.1084/jem.185.6.1077; Khan BV, 1996, P NATL ACAD SCI USA, V93, P9114, DOI 10.1073/pnas.93.17.9114; King JM, 1997, J IMMUNOL, V158, P880; KISHIMOTO TK, 1992, INFLAMMATION BASIC P, P353; KOLLS J, 1994, P SOC EXP BIOL MED, V205, P220; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUBES P, 1992, AM J PHYSIOL, V262, pH611, DOI 10.1152/ajpheart.1992.262.2.H611; Kunkel EJ, 1996, J EXP MED, V183, P57, DOI 10.1084/jem.183.1.57; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; LAWRENCE MB, 1990, BLOOD, V75, P227; Lefer DJ, 1997, J CLIN INVEST, V99, P684, DOI 10.1172/JCI119212; LUSCINSKAS FW, 1995, J EXP MED, V181, P1179, DOI 10.1084/jem.181.3.1179; LUSCINSKAS FW, 1996, J IMMUNOL, V156, P326; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; NISHIDA J, 1994, AM J PHYSIOL-GASTR L, V267, pG1135, DOI 10.1152/ajpgi.1994.267.6.G1135; NOLTE D, 1994, AM J PHYSIOL-HEART C, V267, pH1637, DOI 10.1152/ajpheart.1994.267.4.H1637; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; VOLLMAR B, 1994, AM J PHYSIOL-GASTR L, V267, pG786, DOI 10.1152/ajpgi.1994.267.5.G786; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; Wheeler MA, 1997, J CLIN INVEST, V99, P110, DOI 10.1172/JCI119121; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95	43	249	252	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1997	11	12					955	964		10.1096/fasebj.11.12.9337148	http://dx.doi.org/10.1096/fasebj.11.12.9337148			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337148				2022-12-25	WOS:A1997YA72400005
J	SanchezGongora, E; Ruiz, F; Mingorance, J; An, W; Corrales, FJ; Mato, JM				SanchezGongora, E; Ruiz, F; Mingorance, J; An, W; Corrales, FJ; Mato, JM			Interaction of liver methionine adenosyltransferase with hydroxyl radical	FASEB JOURNAL			English	Article						CHO cell; liver MAT; desferrioxamine; hydrogen peroxide	S-ADENOSYLMETHIONINE SYNTHETASE; B TRANSCRIPTION FACTOR; RAT-LIVER; MOLECULAR-CLONING; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; MESSENGER-RNA; KAPPA-B; CDNA; GLUTATHIONE	Liver methionine adenosyltransferase (MAT) plays a critical role in the metabolism of methionine converting this amino acid, in the presence of ATP, into S-adenosylmethionine. Here we report that hydrogen peroxide (H2O2), via generation of hydroxyl radical, inactivates liver MAT by reversibly and covalently oxidizing an enzyme site, In vitro studies using pure liver recombinant enzyme and mutants of MAT, where each of the 10 cysteine residues of the enzyme subunit were individually changed to serine by site-directed mutagenesis, identified cysteine 121 as the site of molecular interaction between H2O2 and liver MAT, Cysteine 121 is specific to the hepatic enzyme and is localized at a ''flexible loop'' over the active site cleft of MAT, In vivo studies, using wildtype Chinese hamster ovary (CHO) cells and CHO cells stably expressing liver MAT, demonstrate that the inactivation of MAT by H2O2 is specific to the hepatic enzyme, resulting from the modification of the cysteine residue 121, and that this effect is mediated by the generation of the hydroxyl radical, Our results suggest that H2O2-induced MAT inactivation might be the cause of reduced MAT activity and abnormal methionine metabolism observed in patients with alcoholic liver disease.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			MATO, JOSE/A-5187-2011; Ruiz, Felix A./B-1032-2008; Mingorance, Jesus/B-7562-2009	MATO, JOSE/0000-0003-1264-3153; Ruiz, Felix A./0000-0003-0748-5015; Mingorance, Jesus/0000-0001-6173-5711; Corrales, Fernando/0000-0002-0231-5159				ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Avila MA, 1997, HEPATOLOGY, V25, P391; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BERGER R, 1983, CLIN CHIM ACTA, V134, P129, DOI 10.1016/0009-8981(83)90191-2; CABRERO C, 1988, HEPATOLOGY, V8, P1530, DOI 10.1002/hep.1840080610; CABRERO C, 1987, EUR J BIOCHEM, V170, P299, DOI 10.1111/j.1432-1033.1987.tb13699.x; CORRALES F, 1991, HEPATOLOGY, V14, P528, DOI 10.1002/hep.1840140320; CORRALES F, 1992, HEPATOLOGY, V16, P1022, DOI 10.1002/hep.1840160427; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Gil B, 1996, HEPATOLOGY, V24, P876; GILBERT HF, 1989, GLUTATHIONE CENTENNI, P73; GRIFFITH OW, 1979, J BIOL CHEM, V239, P538; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARDWICK DF, 1970, METABOLIS, V19, P381, DOI 10.1016/0026-0495(70)90135-6; HORIKAWA S, 1989, EUR J BIOCHEM, V184, P497, DOI 10.1111/j.1432-1033.1989.tb15042.x; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; HORIKAWA S, 1991, BIOCHEM INT, V25, P81; HORIKAWA S, 1992, FEBS LETT, V312, P37, DOI 10.1016/0014-5793(92)81405-B; HOROWITZ JH, 1981, GASTROENTEROLOGY, V81, P668; Inoue Masayasu, 1994, P443; KINSELL LW, 1947, SCIENCE, V106, P589, DOI 10.1126/science.106.2763.589; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Lieber C. S., 1992, MED NUTR COMPLICATIO; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; MARTINDUCE C, 1988, HEPATOLOGY, V8, P65; MATO JM, 1997, PHARMACOL THERAPEUT, V73, P1; Mingorance J, 1996, BIOCHEM J, V315, P761, DOI 10.1042/bj3150761; Mingorance J, 1997, INT J BIOCHEM CELL B, V29, P485, DOI 10.1016/S1357-2725(96)00151-3; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; OKADA G, 1981, BIOCHEMISTRY-US, V20, P934, DOI 10.1021/bi00507a045; PAJARES MA, 1992, J BIOL CHEM, V267, P17598; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; PINKUS R, 1995, BIOCHEMISTRY-US, V34, P81, DOI 10.1021/bi00001a010; SanchezGongora E, 1996, BIOCHEM J, V319, P767, DOI 10.1042/bj3190767; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; Takusagawa F, 1996, BIOCHEMISTRY-US, V35, P2586, DOI 10.1021/bi952604z; Weiner Francis R., 1994, P1383; YAN SD, 1994, J BIOL CHEM, V269, P9889	45	69	70	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1997	11	12					1013	1019		10.1096/fasebj.11.12.9337154	http://dx.doi.org/10.1096/fasebj.11.12.9337154			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337154				2022-12-25	WOS:A1997YA72400011
J	Crusius, K; Auvinen, E; Alonso, A				Crusius, K; Auvinen, E; Alonso, A			Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein	ONCOGENE			English	Article						EGFR; TGF-alpha; PMA; TPA; fos; raf	EPIDERMAL GROWTH-FACTOR; SIGNAL-REGULATED KINASE; TYROSINE KINASE; BOVINE PAPILLOMAVIRUS; FACTOR RECEPTOR; C-FOS; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL ACTIVATION; TRANSFORMING ACTIVITY; GENE-PRODUCT	In this report we demonstrate that cells expressing the human papillomavirus type 16 E5 open reading frame (HPV16-E5) show a greatly enhanced transcription of the immediate early genes after EGF or PMA treatment compared to control cells. This enhancement is due to amplification of the signal transduction pathways in response to growth factors or phorbol esters. Upon short-time EGF treatment of the E5-expressing cells we observed an increase in the activation of EGF receptors, resulting in a stronger activation of MAP kinases ERK1/2 compared to control-transfected cells. We also observed that in E5-expressing cells, treatment with PMA results in an increase in membrane-associated PKC activity, and a superactivation of the ERK1/2 MAP kinases. This superactivation is PKC-dependent, since pretreatment of the cells with the PKC inhibitor Ro 31-8220 inhibits MAP kinase activation and early gene transcription almost completely. Furthermore, treatment with genistein strongly reduces the PMA-mediated superactivation of ERK1/2 kinases, demonstrating a PKC-mediated, tyrosine kinase-dependent pathway in the superinduction of MAP kinase activation. Thus, HPV16-E5 effects superactivation of MAP kinases over at least two different pathways, a PKC-mediated, and another, receptor tyrosine-kinase mediated, PKC-independent one.	DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CONRAD M, 1994, VIROLOGY, V200, P796, DOI 10.1006/viro.1994.1244; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DANESCH U, 1994, J BIOL CHEM, V269, P27258; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIMAIO D, 1991, ADV CANCER RES, V56, P133; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; HARVAT BL, 1995, CELL GROWTH DIFFER, V6, P955; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PIM D, 1992, ONCOGENE, V7, P27; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Sambrook J, 1989, MOL CLONING; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHILLER JT, 1986, J VIROL, V57, P1; SEGER R, 1995, J BIOL CHEM, V270, P28325; STONE RL, 1994, J BIOL CHEM, V269, P31323; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; VALLE GF, 1995, J GEN VIROL, V76, P1239, DOI 10.1099/0022-1317-76-5-1239; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	48	81	88	3	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	1997	15	12					1437	1444		10.1038/sj.onc.1201312	http://dx.doi.org/10.1038/sj.onc.1201312			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333019	Bronze			2022-12-25	WOS:A1997XW41100007
J	Cao, WS; BritosBray, M; Claxton, DF; Kelley, CA; Speck, NA; Liu, PP; Friedman, AD				Cao, WS; BritosBray, M; Claxton, DF; Kelley, CA; Speck, NA; Liu, PP; Friedman, AD			CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells	ONCOGENE			English	Article						CBF beta-SMMHC; inv(16); CBF; leukemia; myeloid; cell cycle	MYOSIN HEAVY-CHAIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; ACUTE MYELOMONOCYTIC LEUKEMIA; FACTOR-RECEPTOR PROMOTER; TRANSCRIPTION FACTOR; FUSION TRANSCRIPT; CHIMERIC PROTEIN; NUCLEAR FACTOR	CBF beta-SMMHC is expressed from the inv(16) chromosome in M4Eo AML. Mice lacking CBF subunits or expressing the CBF beta-SMMHC or AML1-ETO onco-proteins failed to develop definitive hematopoiesis. To investigate these effects on hematopoiesis, we expressed CBF beta-SMMHC from the metallothionein promoter, in both 32D c13 myeloid cells and Ba/F3 B-lymphoid cells. Addition of zinc increased CBF beta-SMMHC levels more than tenfold, with higher levels evident in Ba/F3 lines. Levels obtained in 32D c13 cells were similar to those of endogenous CBF beta. Indirect immunofluorescence revealed zinc-inducible speckled, nuclear staining in Ba/F3 cells and diffuse nuclear staining in 32D c13 cells. CBF beta-SMMHC reduced endogenous CBF DNA-binding fivefold in both cell types, increased cell generation time 1.9-fold, on average, in 32D c13 cells and 1.5-fold in Ba/ F3 cells and decreased tritiated thymidine incorporation into DNA correspondingly. CBFP beta-SMMHC increased the proportion of cells in G1 1.7-fold, on average, in 32D c13 and Ba/F3 cells, and decreased the proportion of cells in S phase by a similar degree. CBF beta-SMMHC induced a marked increase in hypophosphorylated Rb, but did not alter IL-3 Receptor alpha or beta subunit levels. Neither apoptosis nor 32D differentiation was induced by zinc in IL-3 in these lines. Induction of CBF beta-SMMHC WC in 32D c13 cells did not inhibit their differentiation to neutrophils or their expression of myeloperoxidase mRNA in GCSF, and did not produce an eosinophilic phenotype. Additional, proliferative genetic changes in M4eo AMLs might potentiate inhibition of differentiation by CBF beta-SMMHC by allowing its increased expression.	JOHNS HOPKINS UNIV, CTR ONCOL, DIV PEDIAT ONCOL, BALTIMORE, MD 21287 USA; UNIV TEXAS, DEPT HEMATOL, HOUSTON, TX 77030 USA; NHLBI, NIH, BETHESDA, MD 20892 USA; DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; NIH, NATL CTR HUMAN GENOME RES, BETHESDA, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Dartmouth College; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			Liu, Paul/A-7976-2012	Liu, Paul/0000-0002-6779-025X	NHLBI NIH HHS [R01 HL51388] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051388] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARTHUR DC, 1983, BLOOD, V61, P994; BAE SC, 1993, ONCOGENE, V8, P809; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BritosBray M, 1996, LEUKEMIA, V10, P984; BRITOSBRAY M, 1997, IN PRESS MOL CELL BI; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Claxton D, 1996, LEUKEMIA, V10, P1479; CLAXTON DF, 1994, BLOOD, V83, P1750; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICKSON P, 1992, BLOOD, V80, P1825; Frank R, 1995, ONCOGENE, V11, P2667; Friedman AD, 1996, CANCER RES, V56, P3250; FRIEDMAN AD, 1991, BLOOD, V78, P2426; FRIEDMAN AD, 1994, BLOOD, V84, pA374; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Haferlach T, 1996, BLOOD, V87, P2459, DOI 10.1182/blood.V87.6.2459.bloodjournal8762459; Hiddemann W., 1995, Blood, V86, p267A; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; McLean TW, 1996, BLOOD, V88, P4252; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1996, BLOOD, V88, P1148; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SACCHI N, 1994, GENE CHROMOSOME CANC, V11, P226, DOI 10.1002/gcc.2870110405; Sacchi N, 1996, ONCOGENE, V12, P437; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SCOTT LM, 1992, BLOOD, V80, P1725; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TIGHE JE, 1994, BLOOD, V84, P2115, DOI 10.1182/blood.V84.7.2115.bloodjournal8472115; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	67	71	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1315	1327		10.1038/sj.onc.1201305	http://dx.doi.org/10.1038/sj.onc.1201305			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315100				2022-12-25	WOS:A1997XV84500010
J	Panagopoulos, I; Lassen, C; Isaksson, M; Mitelman, F; Mandahl, N; Aman, P				Panagopoulos, I; Lassen, C; Isaksson, M; Mitelman, F; Mandahl, N; Aman, P			Characteristic sequence motifs at the breakpoints of the hybrid genes FUS/CHOP, EWS/CHOP and FUS/ERG in myxoid liposarcoma and acute myeloid leukemia	ONCOGENE			English	Article						chromosome translocations; DNA sequence; breakpoints; tumors	ACUTE PROMYELOCYTIC LEUKEMIA; RNA-BINDING PROTEIN; CHROMOSOMAL TRANSLOCATION; MOLECULAR ANALYSIS; FUSION; ONCOGENE; CHOP; ERG; RECOMBINATION; CELL	We have sequenced the breakpoint regions in one acute myeloid leukemia (AML) with t(16;21)(pll;q22) resulting in the formation of a FUS/ERG hybrid gene and in four myxoid liposarcomas (MLS), three of which had the t(12;16) (q13:p11) and translocation a FUS/CHOP fusion gene and one with t(12;22;20)(q13;q12;q11) and an EWS/CHOP hybrid gene. The breakpoints were localized to intron 7 of FUS, intron 1 of CHOP, an intronic sequence of ERG and intron 7 of EWS. In two MLS cases with t(12;16) and in the AML, the breaks in intron 7 of FUS had occurred close to each other, a few nucleotides downstream from a TG dinucleotide repeat region. The break in the two MLS had occurred in the same ATGGTG hexamer and in the AML 40 nucleotides upstream from the hexamer. The third case of t(12;16) MLS had a break upstream and near a TC-dinucleotide repeat region and a sequence similar to the chi bacterial recombination element was found to flank the breakpoint. In the MLS with the EWS/ CHOP hybrid gene, the break in intron 7 of EWS had occurred close to an Alu sequence. Similarly, in all 4 MLS, the breaks in intron 1 of CHOP mere near an Alu sequence. No Alu or other repetitive sequences were found 250 bp upstream or downstream from the break in the ERG intron involved in the AML case. In the AML, the MLS with ESW/CHOP and in one MLS with FUS/CHOP there were one, two and six, respectively, nucleotide identity between the contributing germline sequences in the breakpoint. In the other two MLS cases, two and three extra nucleotides of unknown origin were inserted between the FUS and CHOP sequences. At the junction and/or in its close vicinity, identical oligomers, frequently containing a trinucleotide TGG, were found in both partner genes. Our data thus show that all four genes-PUS, EWS, CHOP and ERG-contain characteristic motifs in the breakpoint regions which may serve as specific recognition sites for DNA-binding proteins and have functional importance in the recombination events taking place between the chromosomes. Different sequence motifs may, however, play a role in each individual case.			Panagopoulos, I (corresponding author), UNIV LUND HOSP,DEPT CLIN GENET,S-22185 LUND,SWEDEN.			Mitelman, Felix/0000-0002-3757-7212; Aman, Pierre/0000-0002-1482-8875; Panagopoulos, Ioannis/0000-0003-2159-5341				ADACHI M, 1990, ONCOGENE, V5, P1653; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BHAGIRATH T, 1995, GENE CHROMOSOME CANC, V13, P126, DOI 10.1002/gcc.2870130209; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DOMER PH, 1995, LEUKEMIA, V9, P1305; DONG S, 1993, GENE CHROMOSOME CANC, V6, P133, DOI 10.1002/gcc.2870060302; FELIX CA, 1995, CANCER RES, V55, P4287; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JAEGER U, 1993, BLOOD, V81, P1833; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KAGAN J, 1993, HEMATOL PATHOL, V7, P159; KASAI M, 1992, MOL CELL BIOL, V12, P4751, DOI 10.1128/MCB.12.10.4751; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; PAPADOPOULOS PC, 1990, GENE CHROMOSOME CANC, V1, P233, DOI 10.1002/gcc.2870010308; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHOWE LC, 1987, ANNU REV IMMUNOL, V5, P253, DOI 10.1146/annurev.iy.05.040187.001345; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; SPITZNER JR, 1989, NUCLEIC ACIDS RES, V18, P1; YOSHIDA H, 1995, GENE CHROMOSOME CANC, V12, P37, DOI 10.1002/gcc.2870120107	33	51	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1357	1362		10.1038/sj.onc.1201281	http://dx.doi.org/10.1038/sj.onc.1201281			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315104				2022-12-25	WOS:A1997XV84500014
J	Enyedi, A; Elwess, NL; Filoteo, AG; Verma, AK; Paszty, K; Penniston, JT				Enyedi, A; Elwess, NL; Filoteo, AG; Verma, AK; Paszty, K; Penniston, JT			Protein kinase C phosphorylates the ''a'' forms of plasma membrane Ca2+ pump isoforms 2 and 3 and prevents binding of calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ PUMP; DEPENDENT PHOSPHORYLATION; SARCOLEMMAL CA-2+-ATPASE; HUMAN-ERYTHROCYTES; SMOOTH-MUSCLE; CALCIUM-PUMP; DOMAIN; CA2+-ATPASE; EXPRESSION; PRODUCTS	Phosphorylation by protein kinase C of the ''a'' and ''b'' variants of plasma membrane Ca2+ pump isoforms 2 and 3 was studied. Full-length versions of these isoforms were assembled and expressed in COS cells, Whereas the ''a'' forms were phosphorylated easily with PKC, isoform 2b was phosphorylated only a little, and isoform 3b was not phosphorylated at all. Phosphorylation of isoforms 2a and 3a did not affect their basal activity, but pre vented the stimulation of their activity by calmodulin and their binding to calmodulin-Sepharose. This indicated that phosphorylation prevented activation of these isoforms by preventing calmodulin binding. Based on these results, phosphorylation of the pump with PHC would be expected to increase free intracellular Ca2+ levels in those cells where isoforms 2a and 3a are expressed.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; NATL INST HAEMATOL & IMMUNOL,H-1113 BUDAPEST,HUNGARY	Mayo Clinic			Pászty, Katalin/X-3785-2019; Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376; Paszty, Katalin/0000-0003-2457-8555	NIGMS NIH HHS [GM 28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURK SE, 1992, J BIOL CHEM, V267, P19683; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FARRAR YJK, 1994, FASEB J, V8, pA1390; FUKUDA T, 1990, J BIOCHEM-TOKYO, V108, P629, DOI 10.1093/oxfordjournals.jbchem.a123254; FURUKAWA KI, 1989, J BIOL CHEM, V264, P4844; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; JAMES P, 1988, J BIOL CHEM, V263, P2905; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KUO TH, 1991, J BIOL CHEM, V266, P2520; OGURUSU T, 1990, J BIOCHEM-TOKYO, V108, P222, DOI 10.1093/oxfordjournals.jbchem.a123184; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; Verma AK, 1996, J BIOL CHEM, V271, P3714; VERMA AK, 1994, J BIOL CHEM, V269, P1687; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WANG KKW, 1991, J BIOL CHEM, V266, P9078	22	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27525	27528		10.1074/jbc.272.44.27525	http://dx.doi.org/10.1074/jbc.272.44.27525			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346883	hybrid			2022-12-25	WOS:A1997YD47300009
J	Neznanov, N; Umezawa, A; Oshima, RG				Neznanov, N; Umezawa, A; Oshima, RG			A regulatory element within a coding exon modulates keratin 18 gene expression in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; SEQUENCES DOWNSTREAM; GLOBIN GENE; C-FOS; REGION; TRANSCRIPTION; ACTIVATION; CELLS; MOUSE; PROMOTER	Multiple tissue specific, DNase-hypersensitive sites are correlated with known or potential regulatory regions of the human keratin 18 (R18) gene. One of these sites is found within exon 6, close to a potential AP-1 binding site. Footprint analysis confirmed that this site is capable of binding c-Jun and c-Fos in vitro. However, exon 6 can stimulate expression of a reporter gene driven by the R18 proximal promoter independent of AP-1 in F9 cells and additionally modulates AP-1 responsiveness when in combination with an intron enhancer. Analysis in transgenic mice and by transient transfections of mutant forms of the K18 gene showed that exon 6 contributes to the expression of the K18 gene, However, substitution of part of exon 6 with the corresponding part of the keratin 19 gene which lacks an AP-1 site decreased but did not destroy the regulatory activity of the exon, Furthermore, this mutation did not alter either the tissue specificity or the position-independent and copy number-dependent behavior of the K18 gene. In contrast, a frameshift mutation within exon 6 dramatically decreased the expression of the gene. K18 RNA expression from the frameshift mutation was less than 10% of the wild type K18 transgene, This decline in expression was the result of a combination of decreased stability of mutant K18 RNA and the creation of a negative regulatory element that can interact with the first intron regulatory elements and actively suppress K18 expression. These results demonstrate that a protein-coding portion of the K18 gene also has a regulatory function.	BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [P30 CA30199, R01 CA42302] Funding Source: Medline; NICHD NIH HHS [N01-HD-0-2911] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002911] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042302, P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1990, J CELL BIOL, V111, P1197, DOI 10.1083/jcb.111.3.1197; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOEBEN RC, 1995, BLOOD, V85, P2447, DOI 10.1182/blood.V85.9.2447.bloodjournal8592447; HURT MM, 1989, P NATL ACAD SCI USA, V86, P4450, DOI 10.1073/pnas.86.12.4450; HURT MM, 1991, MOL CELL BIOL, V11, P2929, DOI 10.1128/MCB.11.6.2929; JAMESPEDERSON M, 1995, J BIOL CHEM, V270, P3965, DOI 10.1074/jbc.270.8.3965; JONES BK, 1995, MOL CELL BIOL, V15, P7010; KU NO, 1995, J CELL BIOL, V131, P1303, DOI 10.1083/jcb.131.5.1303; KULESH DA, 1989, MOL CELL BIOL, V9, P1553, DOI 10.1128/MCB.9.4.1553; KULESH DA, 1989, GENOMICS, V4, P339, DOI 10.1016/0888-7543(89)90340-6; KULESH DA, 1988, MOL CELL BIOL, V8, P267; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MANIATIS T, 1989, MOL CLONING LAB MANU, P14; MOUS J, 1985, MOL CELL BIOL, V5, P2764, DOI 10.1128/MCB.5.10.2764; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; NAKATANI Y, 1990, P NATL ACAD SCI USA, V87, P4289, DOI 10.1073/pnas.87.11.4289; NEZNANOV N, 1993, MOL CELL BIOL, V13, P2214, DOI 10.1128/MCB.13.4.2214; Neznanov N, 1996, MOL BIOL CELL, V7, P541, DOI 10.1091/mbc.7.4.541; NEZNANOV NS, 1993, MOL CELL BIOL, V13, P1815, DOI 10.1128/MCB.13.3.1815; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; STOVER DM, 1992, MOL CELL BIOL, V12, P2230, DOI 10.1128/MCB.12.5.2230; THOREY IS, 1993, DEV BIOL, V160, P519, DOI 10.1006/dbio.1993.1326; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; YANG-YEN H-F, 1990, New Biologist, V2, P351	37	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27549	27557		10.1074/jbc.272.44.27549	http://dx.doi.org/10.1074/jbc.272.44.27549			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346889	hybrid			2022-12-25	WOS:A1997YD47300015
J	Venning, JD; Grimley, RL; Bizouarn, T; Cotton, NPJ; Jackson, JB				Venning, JD; Grimley, RL; Bizouarn, T; Cotton, NPJ; Jackson, JB			Evidence that the transfer of hydride ion equivalents between nucleotides by proton-translocating transhydrogenase is direct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOSPIRILLUM-RUBRUM; ESCHERICHIA-COLI; DINUCLEOTIDE TRANSHYDROGENASE; RHODOBACTER-CAPSULATUS; ADENINE-DINUCLEOTIDE; ENERGY; RESOLUTION; ENZYME; MITOCHONDRIA; REDUCTION	The molecular masses of the purified, recombinant nucleotide-binding domains (domains I and III) of transhydrogenase from Rhodospirillum rubrum were determined by electrospray mass spectrometry, The values obtained, 40,273 and 21,469 Da, for domains I and III, respectively, are similar to those estimated from the amino acid sequences of the proteins, Evidently, there are no prosthetic groups or metal centers that can serve as reducible intermediates in hydride transfer between nucleotides bound to these proteins. The transient-state kinetics of hydride transfer catalyzed by mixtures of recombinant domains I and III were studied by stopped-flow spectrophotometry, The data indicate that oxidation of NADPH, bound to domain III, and reduction of acetylpyridine adenine dinucleotide (an NAD(+) analogue), bound to domain I, are simultaneous and very fast. The transient-state reaction proceeds as a biphasic burst of hydride transfer before establishment of a steady state, which is limited by slow release of NADP(+). Hydride transfer between the nucleotides is evidently direct, This conclusion indicates that the nicotinamide rings of the nucleotides are in close apposition during the hydride transfer reaction, and it imposes firm constraints on the mechanism by which transhydrogenation is linked to proton translocation.	UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham			bizouarn, tania/W-6782-2019		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bizouarn T, 1996, EUR J BIOCHEM, V239, P737, DOI 10.1111/j.1432-1033.1996.0737u.x; Bizouarn T, 1997, BBA-BIOENERGETICS, V1320, P265, DOI 10.1016/S0005-2728(97)00030-3; BIZOUARN T, 1997, IN PRESS BIOCH BIOPH; CUNNINGHAM IJ, 1992, BIOCHIM BIOPHYS ACTA, V1100, P332, DOI 10.1016/0167-4838(92)90490-5; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; Diggle C, 1996, EUR J BIOCHEM, V241, P162, DOI 10.1111/j.1432-1033.1996.0162t.x; ENANDER K, 1982, J BIOL CHEM, V257, P4760; FISHER R. R., 1982, PYRIDINE NUCLEOTIDE, P279; FISHER RR, 1971, J BIOL CHEM, V246, P4687; HANSON RL, 1979, J BIOL CHEM, V254, P888; Hatefi Y, 1996, FASEB J, V10, P444, DOI 10.1096/fasebj.10.4.8647343; Hojeberg B, 1979, Methods Enzymol, V55, P275; HOMYK M, 1979, BIOCHIM BIOPHYS ACTA, V571, P201, DOI 10.1016/0005-2744(79)90091-3; HU X, 1995, BBA-BIOENERGETICS, V1229, P64, DOI 10.1016/0005-2728(94)00187-A; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; JACKSON JB, 1991, J BIOENERG BIOMEMBR, V23, P715, DOI 10.1007/BF00785998; JACOBS E, 1979, BIOCHEMISTRY-US, V18, P4315, DOI 10.1021/bi00587a009; LEVER TM, 1991, EUR J BIOCHEM, V197, P247, DOI 10.1111/j.1432-1033.1991.tb15905.x; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; MEULLER J, 1997, BIOCHEM J, V234, P681; OLAUSSON T, 1995, BBA-BIOENERGETICS, V1231, P1, DOI 10.1016/0005-2728(95)00058-Q; PALMER T, 1992, BIOCHIM BIOPHYS ACTA, V1099, P157, DOI 10.1016/0304-4173(92)90022-7; PERSSON B, 1987, BIOCHEM BIOPH RES CO, V142, P573, DOI 10.1016/0006-291X(87)90312-3; RIZZO V, 1987, PYRIDINE NUCLEOTID A, P99; SIEGEL JM, 1959, ARCH BIOCHEM BIOPHYS, V82, P288, DOI 10.1016/0003-9861(59)90124-9; Stilwell SN, 1997, BBA-BIOENERGETICS, V1320, P83, DOI 10.1016/S0005-2728(97)00016-9; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; WILLIAMS R, 1994, MICROBIOL-UK, V140, P1595, DOI 10.1099/13500872-140-7-1595; Woenckhaus C., 1987, PYRIDINE NUCLEOTID A, P449; Yamaguchi M, 1997, BBA-BIOENERGETICS, V1318, P225, DOI 10.1016/S0005-2728(96)00139-9	30	40	40	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27535	27538		10.1074/jbc.272.44.27535	http://dx.doi.org/10.1074/jbc.272.44.27535			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346886	hybrid			2022-12-25	WOS:A1997YD47300012
J	Byzova, TV; Plow, EF				Byzova, TV; Plow, EF			Networking in the hemostatic system - Integrin alpha(IIIb)beta(3) binds prothrombin and influences its activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE MONOCLONAL-ANTIBODY; GLYCOPROTEIN-IIB-IIIA; HUMAN-PLATELETS; FACTOR-X; VONWILLEBRAND-FACTOR; CLINICAL RESTENOSIS; FIBRINOGEN BINDING; THROMBIN; RECEPTOR; SITE	Prothrombin activation is a pivotal event in thrombosis and hemostasis because thrombin can mediate fibrin formation and can activate and aggregate platelets. Platelet aggregation depends upon the binding of adhesive proteins to integrin alpha(IIb)beta(3) on the platelet surface. In the present study, a novel interface between the blood coagulation system and platelets is demonstrated by showing that 1) prothrombin binds to alpha(IIb)beta(3) and 2) this interaction accelerates prothrombin activation. Prothrombin bound to purified alpha(IIb)beta(3) in a specific, saturable, and divalent cation-dependent manner, This interaction was inhibited by certain monoclonal antibodies to alpha(IIb)beta(3), by the alpha(IIb)beta(3) ligands fibrinogen and RGD peptides, but not by thrombin or unrelated proteins, Prothrombin also interacted with alpha(IIb)beta(3) on resting and stimulated platelets as demonstrated by soluble ligand binding and platelet adhesion assays, Activation of prothrombin by Factor Xa alone or Factor Xa-Va was accelerated by alpha(IIb)beta(3), and this enhancement was blocked by a monoclonal antibody that inhibited prothrombin binding to the receptor, Taken together, these data identify a previously unrecognized linkage between platelets and the blood coagulation system that may have a significant regulatory consequence.	CLEVELAND CLIN FDN, JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL, DEPT MOL CARDIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation				Byzova, Tatiana/0000-0002-2615-875X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054924] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54924] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BARSHAVIT R, 1995, ISRAEL J MED SCI, V31, P86; BARSHAVIT R, 1991, J CELL BIOL, V112, P335, DOI 10.1083/jcb.112.2.335; BODE W, 1992, PROTEIN SCI, V1, P426; BOVILL EG, 1995, ARTERIOSCL THROM VAS, V15, P754, DOI 10.1161/01.ATV.15.6.754; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHARO IF, 1991, J BIOL CHEM, V266, P1415; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; DACHARYPRIGENT J, 1993, BLOOD, V81, P2554; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; HAVERSTICK DM, 1985, BLOOD, V66, P946; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; Mazurov AV, 1996, FEBS LETT, V391, P84, DOI 10.1016/0014-5793(96)00709-0; PIOTROWICZ RS, 1988, J CELL BIOL, V106, P1359, DOI 10.1083/jcb.106.4.1359; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLOW EF, 1985, BLOOD, V66, P724; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; Reverter JC, 1996, J CLIN INVEST, V98, P863, DOI 10.1172/JCI118859; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8890, DOI 10.1021/bi9525029; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SMITH JW, 1994, J BIOL CHEM, V269, P960; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; Weiss HJ, 1997, BLOOD, V89, P1599, DOI 10.1182/blood.V89.5.1599.1599_1599_1611	37	105	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27183	27188		10.1074/jbc.272.43.27183	http://dx.doi.org/10.1074/jbc.272.43.27183			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341161	hybrid			2022-12-25	WOS:A1997YC65900057
J	Eskandari, S; Loo, DDF; Dai, G; Levy, O; Wright, EM; Carrasco, N				Eskandari, S; Loo, DDF; Dai, G; Levy, O; Wright, EM; Carrasco, N			Thyroid Na+/I- symporter - Mechanism, stoichiometry, and specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTES; GLUCOSE COTRANSPORTER; ELECTROGENIC PROPERTIES; MEMBRANE-VESICLES; TRANSPORT; CHANNELS; IODIDE; KINETICS; CELLS	The rat thyroid Na+/l(-) symporter (NIS) was expressed in Xenopus laevis oocytes and characterized using electrophysiological, tracer uptake, and electron microscopic methods, MS activity was found to be electrogenic and Na+-dependent (Na+ much greater than Li+ much greater than H+). The apparent affinity constants for Na+ and I- were 28 +/- 3 mM and 33 +/- 9 mu M, respectively, Stoichiometry of Na+/anion cotransport was 2:1. MS was capable of transporting a wide variety of anions (I-, ClO3-, SCN-, SeCN-, NO3-, Br-, BF4-, IO4-, BrO3-, but perchlorate (ClO4-) was not transported, In the absence of anion substrate, NIS exhibited a Na+-dependent leak current (similar to 35% of maximum substrate-induced current) with an apparent Na+ affinity of 74 +/- 14 mM and a Hill coefficient (n) of 1. In response to step voltage changes, MS exhibited current transients that relaxed with a time constant of 8-14 ms, Presteady-state charge movements (integral of the current transients) versus voltage relations obey a Boltzmann relation, The voltage for half-maximal charge translocation (V-0.5) was -15 +/- 3 mV, and the apparent valence of the movable charge was 1. Total charge was insensitive to [Na+](o), but V-0.5 shifted to more negative potentials as [Na+](o) was reduced. MS charge movements are attributed to the conformational changes of the empty transporter within the membrane electric field, The turnover rate of NIS was greater than or equal to 22 s(-1) in the Na+ uniport mode and greater than or equal to 36 s(-1) in the Na+/I- cotransport mode, Transporter density in the plasma membrane was determined using freeze-fracture electron microscopy, Expression of NIS in oocytes led to a similar to 2,5-fold increase in the density of plasma membrane protoplasmic face intramembrane particles. On the basis of the kinetic results, we propose an ordered simultaneous transport mechanism in which the binding of Na+ to NIS occurs first.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	Eskandari, S (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90095, USA.		Carrasco, Nancy/AAH-1053-2019	Carrasco, Nancy/0000-0003-4137-6162	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041544, R01DK019567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS025554] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19567, DK41544] Funding Source: Medline; NINDS NIH HHS [NS25554] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANBAR M, 1959, J APPL RADIAT ISOT, V7, P87; BEZANILLA F, 1994, ANNU REV BIOPH BIOM, V23, P819, DOI 10.1146/annurev.bb.23.060194.004131; BOORER KJ, 1994, J BIOL CHEM, V269, P20417; Cao Yongwei, 1997, Biophysical Journal, V72, pA407; CARRASCO N, 1993, BIOCHIM BIOPHYS ACTA, V1154, P65, DOI 10.1016/0304-4157(93)90017-I; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; HALMI NS, 1961, VITAM HORM, V19, P138; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; Hirayama BA, 1997, J BIOL CHEM, V272, P2110; HIRAYAMA BA, 1994, J BIOL CHEM, V269, P21407; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; KAMINSKY SM, 1991, EUR J BIOCHEM, V200, P203, DOI 10.1111/j.1432-1033.1991.tb21068.x; Lauger P., 1991, ELECTROGENIC ION PUM; Loo DDF, 1996, FEBS LETT, V392, P250, DOI 10.1016/0014-5793(96)00823-X; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; NAKAMURA Y, 1988, J BIOCHEM-TOKYO, V104, P544, DOI 10.1093/oxfordjournals.jbchem.a122507; ONEILL B, 1987, BIOCHIM BIOPHYS ACTA, V896, P263, DOI 10.1016/0005-2736(87)90187-8; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Segel I.H., 1975, ENZYME KINETICS; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1108, DOI 10.1210/endo-114-4-1108; WOLFF J, 1964, PHYSIOL REV, V44, P45, DOI 10.1152/physrev.1964.44.1.45; WRIGHT EM, 1977, PHYSIOL REV, V57, P109, DOI 10.1152/physrev.1977.57.1.109; WRIGHT EM, 1974, J PHYSIOL-LONDON, V240, P535, DOI 10.1113/jphysiol.1974.sp010622; Yoshida A, 1997, BIOCHEM BIOPH RES CO, V231, P731, DOI 10.1006/bbrc.1997.6178; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	34	359	376	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27230	27238		10.1074/jbc.272.43.27230	http://dx.doi.org/10.1074/jbc.272.43.27230			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341168	hybrid			2022-12-25	WOS:A1997YC65900064
J	Giasson, E; Servant, MJ; Meloche, S				Giasson, E; Servant, MJ; Meloche, S			Cyclic AMP-mediated inhibition of angiotensin II-induced protein synthesis is associated with suppression of tyrosine phosphorylation signaling in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C ACTIVATION; SWISS 3T3 CELLS; CELLULAR HYPERTROPHY; HAMSTER FIBROBLASTS; JAK/STAT PATHWAY; MESANGIAL CELLS; GENE-EXPRESSION; FACTOR RECEPTOR; FOS EXPRESSION; MESSENGER-RNA	In the present study, we have examined the effect of increased cyclic AMP (cAMP) levels on the stimulatory action of angiotensin II (Ang II) on protein synthesis. Treatment with cAMP-elevating agents potently inhibited Ang II-induced protein synthesis in rat aortic smooth muscle cells and in rat fibroblasts expressing the human AT(1) receptor, The inhibition was dose-dependent and was observed at all concentrations of the peptide, To explore the mechanism of cAMP action, we have analyzed the effects of forskolin and 3-isobutyl-1-methylxanthine on various receptor-mediated re sponses. Elevation of cAMP did not alter the binding properties of the AT(1) receptor and did not interfere with the activation of phospholipase C or the induction of early growth response genes by Ang II. Likewise, Ang II-dependent activation of the mitogen-activated protein kinases ERK1/ERK2 and p70 S6 kinase was unaffected by cAMP, In contrast, we found that increased concentration of cAMP strongly inhibited the stimulatory effect of Ang II on protein tyrosine phosphorylation. Specifically, cAMP abolished Ang II-induced tyrosine phosphorylation of the focal adhesion-associated protein paxillin and of the tyrosine kinase Tyk2. These results identify a novel mechanism by which the cAMP signaling system may exert growth-inhibitory effects in specific cell types.	HOP HOTEL DIEU,CTR RECH,MONTREAL,PQ H2W 1T8,CANADA; UNIV MONTREAL,DEPT PHARMACOL,MONTREAL,PQ H2W 1T8,CANADA	Universite de Montreal; Universite de Montreal								BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BLOMHOFF HK, 1987, J CELL PHYSIOL, V131, P426, DOI 10.1002/jcp.1041310315; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Catt KJ, 1993, CELLULAR MOL BIOL RE, P307; Chiu A T, 1991, Receptor, V1, P133; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; David M, 1996, J BIOL CHEM, V271, P4585; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; EARP HS, 1995, J BIOL CHEM, V270, P28440; FORCE T, 1991, J BIOL CHEM, V266, P6650; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HELDIN NE, 1989, J CELL PHYSIOL, V138, P17, DOI 10.1002/jcp.1041380104; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAHARA Y, 1988, BIOCHEM BIOPH RES CO, V150, P52, DOI 10.1016/0006-291X(88)90485-8; LALLI E, 1994, J BIOL CHEM, V269, P17359; LAMBERT C, 1995, CIRC RES, V77, P1001, DOI 10.1161/01.RES.77.5.1001; LEDUC I, 1995, J BIOL CHEM, V270, P4401, DOI 10.1074/jbc.270.9.4401; LEDUC I, 1995, MOL PHARMACOL, V48, P582; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MELOCHE S, 1986, MOL PHARMACOL, V30, P537; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAFTILAN AJ, 1989, HYPERTENSION, V13, P706, DOI 10.1161/01.HYP.13.6.706; PASTAN I, 1978, NATURE, V274, P645, DOI 10.1038/274645a0; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PRATT RE, 1993, CELLULAR MOL BIOL RE, P471; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROTHMAN A, 1994, J BIOL CHEM, V269, P6399; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SACHINIDIS A, 1992, FEBS LETT, V313, P109, DOI 10.1016/0014-5793(92)81423-J; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SCHELLING P, 1991, J HYPERTENS, V9, P3; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SECKL M, 1993, J BIOL CHEM, V268, P9548; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TOVEY KC, 1974, CLIN CHIM ACTA, V56, P221, DOI 10.1016/0009-8981(74)90133-8; TREPEL JB, 1987, MOL CELL BIOL, V7, P2644, DOI 10.1128/MCB.7.7.2644; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; TURNER CE, 1995, J CELL SCI, V108, P333; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WOLF G, 1991, CELL REGUL, V2, P219, DOI 10.1091/mbc.2.3.219; WOLF G, 1993, NEPHROL DIAL TRANSPL, V8, P128; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	71	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26879	26886		10.1074/jbc.272.43.26879	http://dx.doi.org/10.1074/jbc.272.43.26879			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341120	hybrid			2022-12-25	WOS:A1997YC65900016
J	JandrotPerrus, M; Lagrue, AH; Okuma, M; Bon, C				JandrotPerrus, M; Lagrue, AH; Okuma, M; Bon, C			Adhesion and activation of human platelets induced by convulxin involve glycoprotein VI and integrin alpha(2)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROTALUS-DURISSUS-CASCAVELLA; COLLAGEN-INDUCED AGGREGATION; PHOSPHOLIPASE C-GAMMA-2; TYROSINE PHOSPHORYLATION; MEMBRANE; VENOM; PROTEINS; DEFICIENCY; THROMBIN; RECEPTOR	We analyzed the interaction of convulxin (Cvx), a 72-kDa protein isolated from the venom of Crotalus durissus terrificus, with human platelets. Cvx is a potent platelet agonist that induces an increase in the intracellular Ca2+ concentration ([Ca2+](i)), granule exocytosis and aggregation. I-125-Labeled Cvx binds specifically and rapidly to platelets at binding sites of high and moderate affinity. Platelets adhere to immobilized Cvx in a time-dependent but cation-independent manner. Platelet exocytosis and aggregation induced by Cvx were inhibited by an anti-integrin alpha(2) beta(1) monoclonal antibody (6F1) and by the Fab fragments of a polyclonal antiglycoprotein VI (GPVI) antibody. Both the adhesion of platelets to Cvx and the Cvx-induced increase in [Ca2+](i) were inhibited by anti-GPVI Fab fragments but not by 6F1. Ligand blotting assay showed that I-125-CvX binds to a 57-kDa platelet protein with an electrophoretic mobility identical to that of GPVI. In addition, we observed the following: (i) I-125-CvX binds to GPVI immunoprecipitated by the anti-GPVI antibody from a platelet lysate, and (ii) Cvx inhibits the binding of anti-GPVI IgG to GPVI. Taken together, these results demonstrate that GPVI behaves as a Cvx receptor and that the alpha(2) beta(1) integrin appears to be involved in the later stages of Cvx-induced platelet activation, i.e. exocytosis and aggregation.	INST PASTEUR,UNITE VENINS,F-75724 PARIS 15,FRANCE; KYOTO UNIV,FAC MED,DEPT INTERNAL MED,SAKYO KU,KYOTO 60601,JAPAN	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Kyoto University	JandrotPerrus, M (corresponding author), UNIV PARIS 07,LAB RECH HEMOSTASE & THROMBOSE,BP 416,F-75870 PARIS 18,FRANCE.		Jandrot-Perrus, Martine/GZM-1526-2022	JANDROT-PERRUS, Martine/0000-0002-8450-9247				BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; Brinkhous K.M., 1988, Hematology (New York), V7, P363; CLEMETSON KJ, 1995, THROMB HAEMOSTASIS, V74, P111; COLLER BS, 1989, BLOOD, V74, P182; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; FAILI A, 1994, BIOCHEM J, V298, P87, DOI 10.1042/bj2980087; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Fujimura Y, 1996, THROMB HAEMOSTASIS, V76, P633; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; ICHINOHE T, 1995, J BIOL CHEM, V270, P28029; JANDROTPERRUS M, 1987, THROMB HAEMOSTASIS, V58, P915; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; KEHREL B, 1988, BLOOD, V71, P1074; KROLL MH, 1989, BLOOD, V74, P1181; KUNICKI TJ, 1993, BLOOD, V82, P2693; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARLAS G, 1983, BIOCHIMIE, V65, P619; MARLAS G, 1983, BIOCHIMIE, V65, P405, DOI 10.1016/S0300-9084(83)80060-1; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; NIEUWENHUIS HK, 1986, BLOOD, V68, P692; NURDEN P, 1994, SEMIN HEMATOL, V31, P240; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; PRADOFRANCESCHI J, 1981, TOXICON, V19, P875, DOI 10.1016/0041-0101(81)90085-4; RYO R, 1992, AM J HEMATOL, V39, P25, DOI 10.1002/ajh.2830390107; SANOMARTINS IS, 1992, TOXICON, V30, P141, DOI 10.1016/0041-0101(92)90467-J; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SUGIYAMA T, 1987, BLOOD, V69, P1712; VARGAFTIG BB, 1980, EUR J PHARMACOL, V68, P451, DOI 10.1016/0014-2999(80)90420-3; VARGAFTIG BB, 1983, EUR J PHARMACOL, V92, P57, DOI 10.1016/0014-2999(83)90108-5; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; ZINGALI RB, 1991, ANN I PASTEUR, V4, P267	32	148	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27035	27041		10.1074/jbc.272.43.27035	http://dx.doi.org/10.1074/jbc.272.43.27035			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341142	hybrid			2022-12-25	WOS:A1997YC65900038
J	Peters, JM; Hennuyer, N; Staels, B; Fruchart, JC; Fievet, C; Gonzalez, FJ; Auwerx, J				Peters, JM; Hennuyer, N; Staels, B; Fruchart, JC; Fievet, C; Gonzalez, FJ; Auwerx, J			Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN C-III; COENZYME-A OXIDASE; FATTY-ACIDS; GENE-EXPRESSION; PPAR; HYPERCHOLESTEROLEMIA; DIFFERENTIATION; FENOFIBRATE; INDUCTION; LIGAND	The peroxisome proliferator-activated receptor-alpha (PPAR alpha) controls gene expression in response to a diverse class of compounds collectively referred to as peroxisome proliferators. Whereas most known peroxisome proliferators are of exogenous origin and include hypolipidemic drugs and other industrial chemicals, several endogenous PPAR alpha activators have been identified such as fatty acids and steroids, The latter finding and the fact that PPAR alpha modulates target genes encoding enzymes involved in lipid metabolism suggest a role for PPAR alpha in lipid metabolism, This was investigated in the PPAR alpha-deficient mouse model, Basal levels of total serum cholesterol, high density lipoprotein cholesterol, hepatic apolipoprotein A-I mRNA, and serum apolipoprotein A-I in PPAR alpha-deficient mice are significantly higher compared with wild type controls, Treatment with the fibrate Wy 14,643 decreased apoA-I serum levels and hepatic mRNA levels in wild-type mice, whereas no effect was detected in the PPAR alpha-deficient mice, Administration of the fibrate Wy 14,643 to wild-type mice results in marked depression of hepatic apolipoprotein C-III mRNA and serum triglycerides compared with un treated controls, In contrast, PPAR alpha-deficient mice were unaffected by Wy 14,643 treatment, These studies demonstrate that PPAR alpha modulates basal levels of serum cholesterol, in particular high density lipoprotein cholesterol, and establish that fibrate induced modulation in hepatic apolipoprotein A-I, C-III mRNA, and serum triglycerides observed in wild-type mice is mediated by PPAR alpha.	INST PASTEUR,U325 INSERM,DEPT ATHEROSCLEROSE,F-59019 LILLE,FRANCE; NCI,LAB METAB,NIH,BETHESDA,MD 20892	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Peters, Jeffrey/D-8847-2011; Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503; Auwerx, Johan/0000-0002-5065-5393; Peters, Jeffrey/0000-0003-2782-2998; HENNUYER, Nathalie/0000-0003-0303-7258				AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; BERTHOU L, 1995, EUR J BIOCHEM, V232, P179, DOI 10.1111/j.1432-1033.1995.tb20797.x; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; BROUSSEAU T, 1993, CLIN CHEM, V39, P960; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESVERGNE B, 1994, INDUCIBLE GENE EXPRE, P253; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DUVERGER N, 1993, BIOCHEMISTRY-US, V32, P12372, DOI 10.1021/bi00097a014; FIELDING CJ, 1995, J LIPID RES, V36, P211; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Green S, 1995, MUTAT RES-FUND MOL M, V333, P101, DOI 10.1016/0027-5107(95)00136-0; Haubenwallner S, 1995, J LIPID RES, V36, P2541; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALMENDIER CL, 1985, ATHEROSCLEROSIS, V55, P161, DOI 10.1016/0021-9150(85)90095-4; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MELLIES MJ, 1987, ATHEROSCLEROSIS, V63, P57, DOI 10.1016/0021-9150(87)90082-7; MILLER NE, 1987, AM HEART J, V112, P825; SAAD MJA, 1994, MOL ENDOCRINOL, V8, P545, DOI 10.1210/me.8.5.545; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SCHOONJANS K, 1993, EUR J BIOCHEM, V216, P615, DOI 10.1111/j.1432-1033.1993.tb18181.x; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Schoonjans K, 1996, J LIPID RES, V37, P907; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118	33	369	386	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27307	27312		10.1074/jbc.272.43.27307	http://dx.doi.org/10.1074/jbc.272.43.27307			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341179	hybrid			2022-12-25	WOS:A1997YC65900075
J	Comte, B; Vincent, G; Bouchard, B; DesRosiers, C				Comte, B; Vincent, G; Bouchard, B; DesRosiers, C			Probing the origin of acetyl-CoA and oxaloacetate entering the citric acid cycle from the C-13 labeling of citrate released by perfused rat hearts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY MASS-SPECTROMETRY; FATTY-ACID; PYRUVATE CARBOXYLATION; SUBSTRATE SELECTION; ISOTOPOMER ANALYSIS; GLUCOSE-METABOLISM; NMR-SPECTROSCOPY; CORONARY FLOW; OXIDATION; GLUCONEOGENESIS	We present a strategy for simultaneous assessment of the relative contributions of anaplerotic pyruvate carboxylation, pyruvate decarboxylation, and fatty acid oxidation to citrate formation in the perfused rat heart, This requires perfusing with a mix of C-13-substrates and determining the C-13 labeling pattern of a single metabolite, citrate, by gas chromatography-mass spectrometry, The mass isotopomer distributions of the oxaloacetate and acetyl moieties of citrate allow calculation of the flux ratios: (pyruvate carboxylation)/(pyruvate decarboxylation), (pyruvate carboxylation)/(citrate synthesis), (pyruvate decarboxylation)/(citrate synthesis) (pyruvate carboxylation)/(fatty acid oxidation), and (pyruvate decarboxylation)/(fatty acid oxidation), Calculations, based on precursor-product relationship, are independent of pool size, The utility of our method was demonstrated for hearts perfused under normoxia with [U-C-13(3)](lactate + pyruvate) and [1-C-13]octanoate under steady-state conditions, Under these conditions, effluent and tissue citrate were similarly enriched in all C-13 mass isotopomers, The use of effluent citrate instead of tissue citrate allows probing substrate fluxes through the various reactions non-invasively in the intact heart, The methodology should also be applicable to hearts perfused with other C-13-substrates, such as 1-C-13-labeled long chain fatty acid, and under various conditions, provided that assumptions on which equations are developed are valid.	UNIV MONTREAL, DEPT NUTR, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, DEPT BIOCHEM, MONTREAL, PQ H3C 3J7, CANADA	Universite de Montreal; Universite de Montreal			Rosiers, Christine Des/O-6285-2014					Abdelaleem S, 1996, J MOL CELL CARDIOL, V28, P825, DOI 10.1006/jmcc.1996.0077; BARANYAI JM, 1989, BIOCHEM J, V258, P121, DOI 10.1042/bj2580121; BARRON JT, 1994, AM J PHYSIOL, V267, pH764, DOI 10.1152/ajpheart.1994.267.2.H764; BEYLOT M, 1995, J BIOL CHEM, V270, P1509, DOI 10.1074/jbc.270.4.1509; BROSNAN JT, 1985, METABOLISM, V34, P588, DOI 10.1016/0026-0495(85)90199-4; BRUNET J, 1995, FREE RADICAL BIO MED, V19, P627, DOI 10.1016/0891-5849(95)00077-B; BUNGER R, 1989, EUR J BIOCHEM, V180, P221, DOI 10.1111/j.1432-1033.1989.tb14637.x; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; CHATHAM JC, 1995, J BIOL CHEM, V270, P7999, DOI 10.1074/jbc.270.14.7999; CLINE GW, 1995, J BIOL CHEM, V270, P28062; COHEN DM, 1994, AM J PHYSIOL, V266, pE341, DOI 10.1152/ajpendo.1994.266.3.E341; COMTE B, 1995, CIRCULATION, V92, P3703; COMTE B, 1997, FASEB J, V11, P268; COMTE B, 1997, J BIOL CHEM, V272, P46145; DAVID F, 1994, ANAL BIOCHEM, V218, P143, DOI 10.1006/abio.1994.1153; DESROSIERS C, 1994, J BIOL CHEM, V269, P27179; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; FERNANDEZ CA, 1995, J BIOL CHEM, V270, P10037, DOI 10.1074/jbc.270.17.10037; GAMBLE J, 1994, BBA-MOL BASIS DIS, V1225, P191, DOI 10.1016/0925-4439(94)90078-7; HEATH DF, 1985, BIOCHEM J, V227, P851, DOI 10.1042/bj2270851; JEFFREY FMH, 1995, BASIC RES CARDIOL, V90, P388, DOI 10.1007/BF00788500; JESSEN ME, 1993, J CLIN INVEST, V92, P831, DOI 10.1172/JCI116657; KATZ J, 1989, J BIOL CHEM, V264, P12994; KELLEHER JK, 1985, AM J PHYSIOL, V248, pE252, DOI 10.1152/ajpendo.1985.248.2.E252; KELLEHER JK, 1986, AM J PHYSIOL, V250, pE296, DOI 10.1152/ajpendo.1986.250.3.E296; KELLEHER JK, 1994, AM J PHYSIOL, V266, pE384, DOI 10.1152/ajpendo.1994.266.3.E384; KERBEY AL, 1976, BIOCHEM J, V154, P327, DOI 10.1042/bj1540327; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; LANOUE K, 1970, J BIOL CHEM, V245, P102; Laplante A, 1997, AM J PHYSIOL-ENDOC M, V272, pE74, DOI 10.1152/ajpendo.1997.272.1.E74; LAPLANTE A, 1995, ANAL BIOCHEM, V224, P580, DOI 10.1006/abio.1995.1090; Lee W. N. P., 1989, J BIOL CHEM, V264, P13002; LEE WNP, 1993, J BIOL CHEM, V268, P25522; LEWANDOWSKI ED, 1990, AM J PHYSIOL, V258, pH1357, DOI 10.1152/ajpheart.1990.258.5.H1357; LEWANDOWSKI ED, 1992, BIOCHEMISTRY-US, V31, P8916, DOI 10.1021/bi00152a031; LOPASCHUK GD, 1992, MOL CELL BIOCHEM, V116, P111, DOI 10.1007/BF01270577; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MARTIN G, 1994, J BIOL CHEM, V269, P26034; MCVEIGH JJ, 1990, AM J PHYSIOL, V259, pH1079, DOI 10.1152/ajpheart.1990.259.4.H1079; MULLHOFER G, 1977, EUR J BIOCHEM, V75, P331, DOI 10.1111/j.1432-1033.1977.tb11533.x; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; PEUHKURINEN KJ, 1982, BIOCHEM J, V202, P67, DOI 10.1042/bj2020067; PEUHKURINEN KJ, 1982, BIOCHEM J, V208, P577, DOI 10.1042/bj2080577; PEUHKURINEN KJ, 1983, BIOCHEM J, V210, P193, DOI 10.1042/bj2100193; PLUMMER DT, 1971, INTRO PRACTICAL BIOC, P313; RENSTROM B, 1990, CIRC RES, V66, P282, DOI 10.1161/01.RES.66.2.282; ROGNSTAD R, 1993, BIOCHEM ARCH, V9, P15; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; ROSIERS CD, 1988, ANAL BIOCHEM, V173, P96, DOI 10.1016/0003-2697(88)90165-0; ROSIERS CD, 1991, J BIOL CHEM, V266, P1574; RUSSELL RR, 1991, AM J PHYSIOL, V261, pH1756, DOI 10.1152/ajpheart.1991.261.6.H1756; SADDIK M, 1993, J BIOL CHEM, V268, P25836; SCHULZ H, 1994, J NUTR, V124, P165, DOI 10.1093/jn/124.2.165; SLUSE FE, 1971, FEBS LETT, V18, P149, DOI 10.1016/0014-5793(71)80432-5; SUNDQVIST KE, 1989, BIOCHEM J, V257, P913, DOI 10.1042/bj2570913; VINCENT G, 1997, FASEB J, V11, P269; WEISS RG, 1989, P NATL ACAD SCI USA, V86, P6426, DOI 10.1073/pnas.86.16.6426; WEISS RG, 1992, CIRC RES, V70, P392, DOI 10.1161/01.RES.70.2.392; WEISS RG, 1989, J MOL CELL CARDIOL, V21, P469, DOI 10.1016/0022-2828(89)90787-6	60	43	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26117	26124		10.1074/jbc.272.42.26117	http://dx.doi.org/10.1074/jbc.272.42.26117			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334176	hybrid			2022-12-25	WOS:A1997YB13900010
J	Mishima, Y; Kaizu, H; Kominami, R				Mishima, Y; Kaizu, H; Kominami, R			Pairing of DNA fragments containing (GGA:TCC)(n) repeats and promotion by high mobility group protein 1 and histone H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKER HISTONES; NUCLEOPROTEIN STRUCTURES; 4-STRANDED COMPLEXES; BINDING PROTEIN; TELOMERIC DNA; STRANDED DNA; HMG-D; CHROMATIN; CONFORMATION; DISTAMYCIN	Tandemly repealed DNA sequences of(GGA:TCC)(n) are found in tracts up to 50 base pairs long, dispersed at thousands of sites throughout the genomes of eukaryotes, Here we demonstrate the formation of complexes paired between two DNAs containing such repeats in vitro and show enhancement of the pairing by glutathione S-transferase fusion proteins of high mobility group protein 1 and histone H1, This assembly depends on incubation time at 37 degrees C and concentrations of the proteins and DNA, and the enhancement is inhibited by distamycin and actinomycin D interacting DNA through the minor groove, Structure of the DNA-DNA complex is deduced by comparison of its mobility in gel electrophoresis with those of synthetic markers of heterotetramers. Three synthetic and genomic DNA fragments containing repeats that have different arrangements exhibit different efficiencies of DNA pairing, implying that the pairing is affected by the number of repeat units and the arrangement of repeats in a sequence, Intriguingly, pairing occurs between homologous fragments but not between heterologous DNAs among the three, These results suggest that the repeat-mediated DNA pairing plays a role in organization of higher order architecture of chromatin and possibly chromosome segregation requiring sequence-specific association events of DNA molecules.			Mishima, Y (corresponding author), NIIGATA UNIV,SCH MED,DEPT BIOCHEM,ASAHIMACHI DORI 1-757,NIIGATA 951,JAPAN.							BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BELLORINI M, 1995, NUCLEIC ACIDS RES, V23, P1657, DOI 10.1093/nar/23.10.1657; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BONNEANDREA C, 1984, EMBO J, V3, P1193, DOI 10.1002/j.1460-2075.1984.tb01950.x; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; DRESCHER U, 1987, DNA-J MOLEC CELL BIO, V6, P307, DOI 10.1089/dna.1987.6.307; FALCIOLA L, 1994, NUCLEIC ACIDS RES, V22, P285, DOI 10.1093/nar/22.3.285; FESEN M, 1989, J BIOL CHEM, V264, P11354; GAILLARD C, 1994, SCIENCE, V264, P433, DOI 10.1126/science.8153633; GE H, 1994, J BIOL CHEM, V269, P17136; GOODWIN GH, 1977, FEBS LETT, V73, P85, DOI 10.1016/0014-5793(77)80021-5; GRAZIANO V, 1994, NATURE, V368, P351, DOI 10.1038/368351a0; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HOFFMANLIEBERMANN B, 1986, MOL CELL BIOL, V6, P3632, DOI 10.1128/MCB.6.11.3632; ISACKSON PJ, 1980, FEBS LETT, V119, P337, DOI 10.1016/0014-5793(80)80284-5; KOHWISHIGEMATSU T, 1985, CELL, V43, P199, DOI 10.1016/0092-8674(85)90024-8; KUEHL L, 1984, J CELL BIOL, V99, P648, DOI 10.1083/jcb.99.2.648; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; Mishima Y, 1996, J BIOCHEM, V119, P805; MORTENSEN UH, 1990, NUCLEIC ACIDS RES, V18, P1983, DOI 10.1093/nar/18.8.1983; MURAISO T, 1992, NUCLEIC ACIDS RES, V20, P6631, DOI 10.1093/nar/20.24.6631; NER SS, 1994, EMBO J, V13, P1817, DOI 10.1002/j.1460-2075.1994.tb06450.x; Nightingale K, 1996, EMBO J, V15, P548, DOI 10.1002/j.1460-2075.1996.tb00387.x; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; READ CM, 1994, EMBO J, V13, P5369; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SOBELL HM, 1974, SCI AM, V231, P82, DOI 10.1038/scientificamerican0874-82; Suda T, 1996, NUCLEIC ACIDS RES, V24, P4733, DOI 10.1093/nar/24.23.4733; SUDA T, 1995, NUCLEIC ACIDS RES, V23, P3771, DOI 10.1093/nar/23.18.3771; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; Takayanagi K, 1997, DNA Res, V4, P241, DOI 10.1093/dnares/4.3.241; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0; WAGA S, 1989, BIOCHIM BIOPHYS ACTA, V1007, P209, DOI 10.1016/0167-4781(89)90041-9; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WOLFFE A, 1995, CHROMATIN STRUCTURE, P6; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X	50	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26578	26584		10.1074/jbc.272.42.26578	http://dx.doi.org/10.1074/jbc.272.42.26578			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334238	hybrid			2022-12-25	WOS:A1997YB13900072
J	Surinya, KH; Cox, TC; May, BK				Surinya, KH; Cox, TC; May, BK			Transcriptional regulation of the human erythroid 5-aminolevulinate synthase gene - Identification of promoter elements and role of regulatory proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; KRUPPEL-LIKE FACTOR; DELTA-AMINOLEVULINATE SYNTHASE; LINKED SIDEROBLASTIC ANEMIA; IRON-RESPONSIVE ELEMENT; LEUCINE ZIPPER PROTEIN; BETA-GLOBIN PROMOTER; FACTOR GATA-1; BINDING PROTEINS; HYPERSENSITIVE SITES	We have characterized the 5'-flanking region of the human erythroid-specific 5-amino levulinate synthase (ALAS) gene (the ALAS2 gene) and shown that the first 300 base pairs of promoter sequence gives maximal expression in erythroid cells, Transcription factor binding sites clustered within this promoter sequence include GATA motifs and CACCC boxes, critical regulatory sequences of many erythroid cell-expressed genes, GATA sites at -126/-121 (on the noncoding strand) and -102/-97 were each recognized by GATA-1 protein in vitro using erythroid cell nuclear extracts, Promoter mutagenesis and transient expression assays in erythroid cells established that both GATA-1 binding sites were functional and exogenously expressed GATA-1 increased promoter activity through these sites in transactivation experiments, A noncanonical TATA sequence at the expected TATA box location (-30/-23) bound GATA-1- or TATA-binding protein (TBP) in vitro, Conversion of this sequence to a canonical TATA box reduced expression in erythroid cells, suggesting a specific role for GATA-1 at this site. However, expression was also markedly reduced when the -30/-23 sequence was converted to a consensus GATA-1 sequence (that did not bind TBP in vitro), suggesting that a functional interaction of both factors with this sequence is important. A sequence comprising two overlapping CACCC boxes at -59/-48 (on the noncoding strand) was demon strated by mutagenesis to be functionally important. This CACCC sequence bound Spl, erythroid Kruppel-like factor, and basic Kruppel-like factor in vitro, while in transactivation experiments erythroid Kruppel-like factor activated ALAS2 promoter expression through this sequence, A sequence at -49/-39 with a 9/11 match to the consensus for the erythroid specific factor NF-E2 was not functional, Promoter constructs with 5'-flanking sequence from 293 base pairs to 10.3 kilobase pairs expressed efficiently in COS-1 cells as well as in erythroid cells, indicating that an enhancer sequence located elsewhere or native chromatin structure may be required for the tissue-restricted expression of the gene in vivo.	UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA 5005,AUSTRALIA; UNIV ADELAIDE,DEPT GENET,ADELAIDE,SA 5005,AUSTRALIA	University of Adelaide; University of Adelaide				Surinya, Kathy/0000-0003-0507-2962				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARTON MC, 1993, GENE DEV, V7, P1796, DOI 10.1101/gad.7.9.1796; BEAUMONT C, 1984, EXP CELL RES, V154, P474, DOI 10.1016/0014-4827(84)90171-X; BHASKER CR, 1993, J BIOL CHEM, V268, P12699; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; BOTTOMLEY SS, 1995, J BIOENERG BIOMEMBR, V27, P161, DOI 10.1007/BF02110031; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; CONBOY JG, 1992, J BIOL CHEM, V267, P18753; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; COX TC, 1994, NEW ENGL J MED, V330, P675, DOI 10.1056/NEJM199403103301004; COX TC, 1990, AM J HUM GENET, V46, P107; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; Dierks P, 1990, BIOSYNTHESIS HEME CH, P201; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FENG WC, 1994, J BIOL CHEM, V269, P1493; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; JAMESPEDERSON M, 1995, J BIOL CHEM, V270, P3965, DOI 10.1074/jbc.270.8.3965; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kappas A, 1995, METABOLIC MOL BASES, P2103; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KAYA AH, 1994, GENOMICS, V19, P242, DOI 10.1006/geno.1994.1054; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KULOZIK AE, 1991, BLOOD, V77, P2054; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; LIM KC, 1994, NUCLEIC ACIDS RES, V22, P1226, DOI 10.1093/nar/22.7.1226; MAGUIRE DJ, 1986, NUCLEIC ACIDS RES, V14, P1379, DOI 10.1093/nar/14.3.1379; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MAY BK, 1995, PROG NUCLEIC ACID RE, V51, P1, DOI 10.1016/S0079-6603(08)60875-2; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; ORKIN SH, 1984, J BIOL CHEM, V259, P8679; Partington GA, 1997, DEV BIOL, V181, P144, DOI 10.1006/dbio.1996.8432; PERKINS AC, 1995, NATURE, V375, P318; PORCHER C, 1991, J BIOL CHEM, V266, P10562; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOENHAUT DS, 1989, NUCLEIC ACIDS RES, V17, P7013, DOI 10.1093/nar/17.17.7013; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUTHERLAND GR, 1988, AM J HUM GENET, V43, P331; Sutherland HGE, 1997, MOL CELL BIOL, V17, P1607, DOI 10.1128/MCB.17.3.1607; TAKETANI S, 1995, GENOMICS, V29, P698, DOI 10.1006/geno.1995.9949; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; TUGORES A, 1994, J BIOL CHEM, V269, P30789; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; YOMOGIDA K, 1993, J BIOCHEM-TOKYO, V113, P364, DOI 10.1093/oxfordjournals.jbchem.a124052; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	72	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26585	26594		10.1074/jbc.272.42.26585	http://dx.doi.org/10.1074/jbc.272.42.26585			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334239	hybrid			2022-12-25	WOS:A1997YB13900073
J	Zahringer, U; Wagner, F; Rietschel, ET; BenMenachem, G; Deutsch, J; Rottem, S				Zahringer, U; Wagner, F; Rietschel, ET; BenMenachem, G; Deutsch, J; Rottem, S			Primary structure of a new phosphocholine-containing glycoglycerolipid of Mycoplasma fermentans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINE PHOSPHATE; LIPOTEICHOIC ACID; C-POLYSACCHARIDE; MEMBRANE-LIPIDS	The chemical structure of a novel phosphocholine-containing glycoglycerolipid, the major polar lipid in the cell membrane of Mycoplasma fermentans PG18, was investigated by chemical analyses, gas-liquid chromatography-mass spectrometry, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, as well as one-and two-dimensional homo-and heteronuclear NMR spectroscopy and identified as 6'-O-(3 ''-phosphocholine-2 ''-amino-1 ''-phospho- 1 '',3 ''-propanediol)-alpha-D-glucopyranosyl-(1'-->3)-1,2-diacyl-glycerol (MfGL-II), Palmitate (16:0) and stearate (18:0), in a 3.6:1 molar ratio, constitute the major fatty acids present, MALDI-TOF mass spectrometry revealed two major pseudomolecular ions at m/z 1049.5 [M-I + H](+) and 1077.3 [M-II + H](+) representing a dipalmitoyl as the major component and a palmitoyl-stearoyl structure as a minor component. This is the first report of 2-amino-1,3-propanediol-1,3-bisphosphate present in a natural product, This glycoglycerolipid is the second phosphocholine-containing glycoglycerolipid found in M. fermentans.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MEMBRANE & ULTRASTRUCT RES,IL-91010 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,DEPT PHARMACEUT CHEM,SCH PHARM,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Zahringer, U (corresponding author), RES CTR BORSTEL,CTR MED & BIOSCI,PK ALLEE 22,D-23845 BORSTEL,GERMANY.							BEHR T, 1992, EUR J BIOCHEM, V207, P1063, DOI 10.1111/j.1432-1033.1992.tb17143.x; BLANCHARD A, 1994, ANNU REV MICROBIOL, V48, P687, DOI 10.1146/annurev.mi.48.100194.003351; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DEUTSCH J, 1995, EUR J BIOCHEM, V227, P897, DOI 10.1111/j.1432-1033.1995.tb20216.x; DITTMER JC, 1964, J LIPID RES, V5, P126; FISCHER W, 1994, EUR J BIOCHEM, V223, P879, DOI 10.1111/j.1432-1033.1994.tb19065.x; FISCHER W, 1993, EUR J BIOCHEM, V215, P851, DOI 10.1111/j.1432-1033.1993.tb18102.x; FRANZOSO G, 1992, FEBS LETT, V303, P251, DOI 10.1016/0014-5793(92)80531-K; JOHNSTON NC, 1994, MICROBIOL-UK, V140, P105, DOI 10.1099/13500872-140-1-105; MATSUDA K, 1994, J BIOL CHEM, V269, P33123; MATSUDA K, 1995, MICROBIOL IMMUNOL, V39, P307, DOI 10.1111/j.1348-0421.1995.tb02206.x; Risberg A, 1997, EUR J BIOCHEM, V243, P701, DOI 10.1111/j.1432-1033.1997.00701.x; SALMAN M, 1994, FEMS MICROBIOL LETT, V123, P255, DOI 10.1111/j.1574-6968.1994.tb07233.x; SHIELDS R, 1960, ANAL CHEM, V32, P885, DOI 10.1021/ac60163a053; SLOMIANY BL, 1977, EUR J BIOCHEM, V78, P33, DOI 10.1111/j.1432-1033.1977.tb11711.x; SUGITA M, 1992, J BIOL CHEM, V267, P22595; VINOGRADOV EV, 1992, EUR J BIOCHEM, V210, P491, DOI 10.1111/j.1432-1033.1992.tb17447.x; VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612; Weiser JN, 1997, INFECT IMMUN, V65, P943, DOI 10.1128/IAI.65.3.943-950.1997; WISE KS, 1993, INFECT IMMUN, V61, P3327, DOI 10.1128/IAI.61.8.3327-3333.1993	22	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26262	26270		10.1074/jbc.272.42.26262	http://dx.doi.org/10.1074/jbc.272.42.26262			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334195	hybrid			2022-12-25	WOS:A1997YB13900029
J	Fang, KC; Raymond, WW; Blount, JL; Caughey, GH				Fang, KC; Raymond, WW; Blount, JL; Caughey, GH			Dog mast cell alpha-chymase activates progelatinase B by cleaving the Phe(88)-Gln(89) and Phe(91)-Glu(92) bonds of the catalytic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE-3 STROMELYSIN; IV COLLAGENASE; GELATINASE-B; FIBROBLAST COLLAGENASE; 92-KDA GELATINASE; MOLECULAR-CLONING; TUMOR-CELLS; EXPRESSION; PROCOLLAGENASE; TRYPTASE	In prior work we showed that a metallogelatinase is secreted from dog mastocytoma cells and directly activated by exocytosed mast cell alpha-chymase. The current work identifies the protease as a canine homologue of progelatinase B (92-kDa gelatinase, MMP-9), determines the sites cleaved by alpha-chymase, and explores the regulation of gelatinase expression in mastocytoma cells. To obtain a cDNA encoding the complete sequence of mastocytoma gelatinase B, a 2.3-kilobase clone encoding progelatinase was isolated from a BR mastocytoma library. The sequenced cDNA predicts a 704-amino acid protein 80% identical to human progelatinase B. Regions thought to be critical for active site latency, such as the Cys-containing propeptide sequence, PRCGVPD, and the catalytic domain sequence, HEFGHALGLDHSS, are entirely conserved. Cleavage of progelatinase B by purified dog alpha-chymase yielded an similar to 84-kDa product that contained two NH2-terminal amino acid sequences, QTFEGDLKXH and EGDLKXHHND, which correspond to residues 89-98 and 92-101 of the cDNA predicted sequence, respectively. Thus, alpha-chymase cleaves the catalytic domain of gelatinase B at the Phe(88)-Gln(89) and Phe(91)-Glu(92) bonds. Like BR cells, the C2 line of dog mastocytoma cells constitutively secrete progelatinase B which is activated by alpha-chymase. By contrast, non-chymase-producing C1 cells secrete a gelatinase B (which remains in its preform) only in response to 12-O-tetradecanoylphorbol-13-acetate. Whereas 12-O-tetradecanoylphorbol-13-acetate stimulation of BR cells produced a similar to 15-fold increase in gelatinase B mRNA expression, dexamethasone down-regulated its expression by similar to 5-fold. Thus, extracellular stimuli may regulate the amount of mast cell progelatinase B expressed by mast cells. These data further support a role for mast cell alpha-chymase in tissue remodeling involving gelatinase B-mediated degradation of matrix proteins.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Fang, KC (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,BOX 0911,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [HL-24136, HL-07185, HL-09133] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009133, P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benbow U, 1996, J BIOL CHEM, V271, P10715, DOI 10.1074/jbc.271.18.10715; BERGMANN U, 1995, BIOCHEMISTRY-US, V34, P2819, DOI 10.1021/bi00009a011; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; CANETESOLER R, 1994, AM J PATHOL, V144, P518; CAUGHEY GH, 1988, BIOCHIM BIOPHYS ACTA, V952, P142, DOI 10.1016/0167-4838(88)90109-4; DENHOLM EM, 1993, AM J PHYSIOL, V265, pL581, DOI 10.1152/ajplung.1993.265.6.L581; DEVINNEY R, 1990, AM J RESP CELL MOL, V3, P413, DOI 10.1165/ajrcmb/3.5.413; Fang KC, 1996, J CLIN INVEST, V97, P1589, DOI 10.1172/JCI118583; FINI ME, 1995, INVEST OPHTH VIS SCI, V36, P622; FINI ME, 1994, J BIOL CHEM, V269, P28620; GOLDSTEIN SM, 1992, J IMMUNOL, V148, P2475; GRANT GA, 1987, J BIOL CHEM, V262, P5886; GRUBER BL, 1989, J CLIN INVEST, V84, P1657, DOI 10.1172/JCI114344; HE C, 1989, P NATL ACAD SCI USA, V66, P2632; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; KJELDSEN L, 1993, BLOOD, V82, P3183; KNAUPER V, 1993, BIOCHEM J, V295, P581; LEES M, 1994, EUR J BIOCHEM, V223, P171, DOI 10.1111/j.1432-1033.1994.tb18980.x; LOHI J, 1992, J CELL BIOCHEM, V50, P337, DOI 10.1002/jcb.240500402; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; Maniatis T., 1982, MOL CLONING; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATSUBARA M, 1991, INVEST OPHTH VIS SCI, V32, P3221; MATSUBARA M, 1991, DEV BIOL, V147, P425, DOI 10.1016/0012-1606(91)90300-R; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA A, 1995, GENE, V164, P317, DOI 10.1016/0378-1119(95)00447-E; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; POWERS JC, 1985, BIOCHEMISTRY-US, V24, P2048, DOI 10.1021/bi00329a037; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; SALO T, 1994, LAB INVEST, V70, P176; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; SARRET Y, 1992, J INVEST DERMATOL, V99, P836, DOI 10.1111/1523-1747.ep12614800; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SATO H, 1993, ONCOGENE, V8, P395; SCHULMAN ES, 1993, CRIT REV IMMUNOL, V13, P35; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; SUZUKI K, 1995, BIOCHEM J, V305, P301, DOI 10.1042/bj3050301; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; TANAKA H, 1993, BIOCHEM BIOPH RES CO, V190, P732, DOI 10.1006/bbrc.1993.1110; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; WEEKS BS, 1993, J CELL PHYSIOL, V157, P644, DOI 10.1002/jcp.1041570326; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	47	145	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25628	25635		10.1074/jbc.272.41.25628	http://dx.doi.org/10.1074/jbc.272.41.25628			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325284	hybrid			2022-12-25	WOS:A1997YA35800039
J	Honda, Z; Suzuki, T; Hirose, N; Aihara, M; Shimizu, T; Nada, S; Okada, M; Ra, CS; Morita, Y; Ito, K				Honda, Z; Suzuki, T; Hirose, N; Aihara, M; Shimizu, T; Nada, S; Okada, M; Ra, CS; Morita, Y; Ito, K			Roles of C-terminal Src kinase in the initiation and the termination of the high affinity IgE receptor-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FC-EPSILON-RI; ACTIVATING-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; MAP KINASE; T-CELL; CYTOPLASMIC DOMAINS; IMMUNOGLOBULIN-E; GAMMA-SUBUNITS; FAMILY KINASES	As an attempt to analyze the roles of C-terminal Src kinase (Csk) in the high affinity IgE receptor (Fc epsilon RI)-mediated signaling, we overexpressed Csk, a membrane-targeted form of Csk (mCsk), and a kinase-defective, membrane-targeted form of Csk (mCsk(-)) in rat basophil leukemia (RBL) 2H3 cells. Specific activity of Lyn at the basal state was decreased in Csk-expressing cells, and further decreased in mCsk-expressing cells. In mCsk(-)-expressing cells, basal specific activity of Lyn was increased, thereby indicating that mCsk(-) functioned as a dominant negative molecule. The onset of Fc epsilon RI-mediated Lyn activation was delayed in Csk-expressing cells, and further delayed in mCsk-expressing cells. In mCsk(-)-expressing cells, Lyn activation was rapid and quite long lasting. These findings indicate (i) Csk negatively regulates rapid Fc epsilon RI/Lyn coupling, and (ii) Csk activity is potentially required for its termination. The onsets of the series of events including tyrosyl phosphorylation of Syk, mitogen-activated protein (MAP) kinase activation, elevation of intracellular calcium concentration ([Ca2+](i)), and histamine release were all stepwisely delayed in Csk-expressing cells and in mCsk-expressing cells. The durations of Syk phosphorylation and MAP kinase activation also closely correlated with those of Lyn activation, but [Ca2+](i) elevation and histamine release followed different temporal patterns: the delayed responses in Csk-expressing cells and in mCsk-expressing cells led to sustained [Ca2+](i) oscillation and histamine release, while the prompt responses in parent cells and mCsk(-)-expressing cells rapidly subsided. These findings provide further evidence that the initiations of the Fc epsilon RI-mediated signals are upstreamly regulated by Src family protein tyrosine kinases and revealed that their terminations are regulated by Lyn-dependent (Syk and MAP kinase) and -independent ([Ca2+](i) elevation and histamine release) mechanisms.	UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; OSAKA UNIV,INST PROT RES,DIV PROT METAB,SUITA,OSAKA 565,JAPAN; JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; Osaka University; Juntendo University	Honda, Z (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED & PHYS THERAPY,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.							ALBER G, 1991, J BIOL CHEM, V266, P22613; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; EISEMAN E, 1992, J BIOL CHEM, V267, P21027; EISEMAN E, 1992, NATURE, V355, P78; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GROSS JA, 1995, J EXP MED, V181, P463, DOI 10.1084/jem.181.2.463; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Jouvin M H, 1995, Semin Immunol, V7, P29, DOI 10.1016/1044-5323(95)90005-5; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; MIYAZAKI J, 1989, GENE, V79, P269; Mori M, 1996, J NEUROSCI, V16, P3590; MORITA Y, 1989, INT ARCH ALLER A IMM, V88, P332, DOI 10.1159/000234820; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEET K, 1995, MOL CELL BIOL, V15, P4908; OKADA M, 1991, J BIOL CHEM, V266, P24249; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; TOBE K, 1991, J BIOL CHEM, V266, P24793; Tobe K, 1996, MOL CELL BIOL, V16, P4765; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILSON BS, 1995, J BIOL CHEM, V270, P4013, DOI 10.1074/jbc.270.8.4013; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	59	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25753	25760		10.1074/jbc.272.41.25753	http://dx.doi.org/10.1074/jbc.272.41.25753			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325302	hybrid			2022-12-25	WOS:A1997YA35800057
J	Wu, SH; McDowell, MT; Lagarias, JC				Wu, SH; McDowell, MT; Lagarias, JC			Phycocyanobilin is the natural precursor of the phytochrome chromophore in the green alga Mesotaenium caldariorum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIVERDIN-IX-ALPHA; CYANIDIUM-CALDARIUM; PARTIAL-PURIFICATION; BIOSYNTHESIS; PHYCOBILINS; EXPRESSION; HOLOPHYTOCHROME; ARABIDOPSIS; SEQUENCES; EVOLUTION	Compared with phytochromes isolated from etiolated higher plant tissues and a number of lower plant species, the absorption spectrum of phytochrome isolated from the unicellular green alga Mesotaenium caldariorum is blue-shifted (Kidd, D. G., and Lagarias, J. C. (1990) J. Biol. Chem. 265, 7029-7035). The present studies were undertaken to determine whether this blue shift is due to a chromophore other than phytochromobilin or reflects a different protein environment for the phytochromobilin prosthetic group. Using reversed phase high performance liquid chromatography, we show that soluble protein extracts prepared from algal chloroplasts contain the enzyme activities for ferredoxin-dependent conversions of biliverdin IX alpha to (3Z)-phytochromobilin and (3Z)-phytochromobilin to (3Z)-phycocyanobilin. In vitro assembly of recombinant algal apophytochrome was undertaken with (3E)-phytochromobilin and (3E)-phycocyanobilin. The difference spectrum of the (3E)-phycocyanobilin adduct was indistinguishable from that of phytochrome isolated from dark-adapted algal cells, while the (3E)-phytochromobilin adduct displayed red-shifted absorption maxima relative to purified algal phytochrome. These studies indicate that phycocyanobilin is the immediate precursor of the green algal phytochrome chromophore and that phytochromobilin is an intermediate in its biosynthesis in Mesotaenium.	UNIV CALIF DAVIS,SECT MOL & CELL BIOL,DAVIS,CA 95616	University of California System; University of California Davis			Lagarias, John Clark/L-3139-2013; Wu, Shu-Hsing/B-4317-2009	Lagarias, John Clark/0000-0002-2093-0403; Wu, Shu-Hsing/0000-0002-7179-3138				BEALE SI, 1983, PLANT PHYSIOL, V71, P263, DOI 10.1104/pp.71.2.263; BEALE SI, 1991, J BIOL CHEM, V266, P22328; BEALE SI, 1991, J BIOL CHEM, V266, P22333; BEALE SI, 1991, J BIOL CHEM, V266, P22341; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLACK T, 1994, PLANT MOL BIOL, V25, P413, DOI 10.1007/BF00043870; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; CORDONNIER MM, 1986, BIOCHEMISTRY-US, V25, P7657, DOI 10.1021/bi00371a057; CORNEJO J, 1992, J BIOL CHEM, V267, P14790; ELICH TD, 1989, J BIOL CHEM, V264, P12902; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KIDD DG, 1990, J BIOL CHEM, V265, P7029; Koornneef Maarten, 1994, P601; Lamparter T, 1995, J PLANT PHYSIOL, V147, P426, DOI 10.1016/S0176-1617(11)82178-4; LI LM, 1992, J BIOL CHEM, V267, P19204; LINDEMANN P, 1989, PLANTA, V178, P436, DOI 10.1007/BF00963812; MACHEMER C, 1964, THESIS HASRVARD U CA; MCDONAGH AF, 1980, BIOCHEM J, V189, P193, DOI 10.1042/bj1890193; OYAMA H, 1990, PLANT CELL PHYSIOL, V31, P1229; PRATT LH, 1995, PHOTOCHEM PHOTOBIOL, V61, P10, DOI 10.1111/j.1751-1097.1995.tb09238.x; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; RHIE GE, 1992, J BIOL CHEM, V267, P16088; SAGER R, 1953, ANN NY ACAD SCI, V56, P831, DOI 10.1111/j.1749-6632.1953.tb30261.x; SHARROCK RA, 1989, GENE DEV, V3, P1745, DOI 10.1101/gad.3.11.1745; TAYLOR AO, 1967, PLANT PHYSIOL, V42, P762, DOI 10.1104/pp.42.6.762; TERRY MJ, 1995, J BIOL CHEM, V270, P11111, DOI 10.1074/jbc.270.19.11111; TERRY MJ, 1993, J BIOL CHEM, V268, P26099; Terry MJ, 1997, PLANT CELL ENVIRON, V20, P740, DOI 10.1046/j.1365-3040.1997.d01-102.x; TERRY MJ, 1991, J BIOL CHEM, V266, P22215; TOHUHISA JG, 1987, PLANTA, V172, P371; VIERSTRA RD, 1982, PLANTA, V156, P158, DOI 10.1007/BF00395430; WADA M, 1989, ANNU REV PLANT PHYS, V40, P169; WAHLEITHNER JA, 1991, P NATL ACAD SCI USA, V88, P10387, DOI 10.1073/pnas.88.23.10387; WELLER JP, 1980, CHEM BER-RECL, V113, P1603, DOI 10.1002/cber.19801130439; Wu SH, 1996, P NATL ACAD SCI USA, V93, P8989, DOI 10.1073/pnas.93.17.8989	36	55	61	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25700	25705		10.1074/jbc.272.41.25700	http://dx.doi.org/10.1074/jbc.272.41.25700			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325294	hybrid			2022-12-25	WOS:A1997YA35800049
J	Orford, K; Crockett, C; Jensen, JP; Weissman, AM; Byers, SW				Orford, K; Crockett, C; Jensen, JP; Weissman, AM; Byers, SW			Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; TUMOR-SUPPRESSOR PROTEIN; SIGNAL-TRANSDUCTION; XENOPUS EMBRYOS; CELL-ADHESION; ARMADILLO; PATHWAY; STABILITY; COMPLEX; INSULIN	Several lines of evidence suggest that accumulation of cytoplasmic beta-catenin transduces an oncogenic signal We show that beta-catenin is ubiquitinated and degraded by the proteosome and that beta-catenin stability is regulated by a diacylglycerol-independent protein kinase C-like kinase activity, which is required for beta-catenin ubiquitination. We also define a sis-amino acid sequence found in both beta-catenin and the NF-kappa B regulatory protein I kappa B alpha, which, upon phosphorylation, targets both proteins for ubiquitination. Mutation of a single serine within the ubiquitination targeting sequence prevents ubiquitination of beta-catenin. Mutations within the ubiquitination targeting sequence of beta-catenin may be oncogenic.	GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; NCI,DCBD,NIH,BETHESDA,MD 20892	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL CANCER INSTITUTE [T32CA009686] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Byers S, 1996, ENDOCRINOLOGY, V137, P3265, DOI 10.1210/en.137.8.3265; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GOODE N, 1992, J BIOL CHEM, V267, P16878; Gumbiner B, 1997, CURR OPIN CELL BIOL, V7, P634; HOU D, 1994, J BIOL CHEM, V269, P14244; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; MANJI HK, 1995, ARCH GEN PSYCHIAT, V52, P531; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SOMMERS CL, 1994, CANCER RES, V54, P3544; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; WOODGETT JR, 1993, BIOCHEM SOC T, V21, P905, DOI 10.1042/bst0210905; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	29	615	639	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24735	24738		10.1074/jbc.272.40.24735	http://dx.doi.org/10.1074/jbc.272.40.24735			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312064	hybrid			2022-12-25	WOS:A1997XY97000003
J	Engfelt, WH; Shackelford, JE; Aboushadi, N; Jessani, N; Masuda, K; Paton, VG; Keller, GA; Krisans, SK				Engfelt, WH; Shackelford, JE; Aboushadi, N; Jessani, N; Masuda, K; Paton, VG; Keller, GA; Krisans, SK			Characterization of UT2 cells - The induction of peroxisomal 3-hydroxy-3-methylglutaryl-coenzyme A reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HMG-COA REDUCTASE; RAT-LIVER PEROXISOMES; MEVALONATE-DERIVED PRODUCT; MESSENGER-RNA; ENDOPLASMIC-RETICULUM; IMMUNOELECTRON MICROSCOPY; SACCHAROMYCES-CEREVISIAE; REGULATED DEGRADATION; MEMBRANE DOMAIN	In the liver 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is present not only in the endoplasmic reticulum but also in the peroxisomes, However, to date no information is available regarding the function of the peroxisomal HMG-CoA reductase in cholesterol/isoprenoid metabolism, and the structure of the peroxisomal HMG-CoA reductase has yet to be determined. We have identified a mammalian cell line that expresses only one HMG-CoA reductase protein and that is localized exclusively to peroxisomes, This cell line was obtained by growing UT2 cells (which lack the en doplasmic reticulum HMG-CoA reductase) in the absence of mevalonate. The cells exhibited a marked increase in a 90-kDa HMG-CoA reductase that was localized exclusively to peroxisomes, The wild type Chinese hamster ovary cells contain two HMG-CoA reductase proteins, the well characterized 97-kDa protein, localized in the endoplasmic reticulum, and a 90-kDa protein localized in peroxisomes. The UT2 cells grown in the absence of mevalonate containing the up-regulated peroxisomal HMG-CoA reductase are designated UT2*. A detailed characterization and analysis of this cell line is presented in this study.	SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182; GENENTECH INC,DEPT PRECLIN PHARMACOL,S SAN FRANCISCO,CA 94080	California State University System; San Diego State University; Roche Holding; Genentech					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032852] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 32852] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPELKVIST EL, 1989, EUR J BIOCHEM, V185, P503, DOI 10.1111/j.1432-1033.1989.tb15142.x; BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; BASSON ME, 1986, P NATL ACAD SCI USA, V83, P5563, DOI 10.1073/pnas.83.15.5563; BIARDI L, 1994, J BIOL CHEM, V269, P1197; BURMESTER A, 1994, EUR J BIOCHEM, V220, P403, DOI 10.1111/j.1432-1033.1994.tb18637.x; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P7704, DOI 10.1073/pnas.79.24.7704; CHOI D, 1992, PLANT CELL, V4, P1333, DOI 10.1105/tpc.4.10.1333; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHYE ML, 1992, PLANT MOL BIOL, V19, P473, DOI 10.1007/BF00023395; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P230, DOI 10.1016/S0962-8924(00)89016-9; DIMSTERDENK D, 1994, MOL BIOL CELL, V5, P655, DOI 10.1091/mbc.5.6.655; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; EDWARDS PA, 1979, J LIPID RES, V20, P40; ENJUTO M, 1994, P NATL ACAD SCI USA, V91, P927, DOI 10.1073/pnas.91.3.927; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; Hampton R, 1996, TRENDS BIOCHEM SCI, V21, P140, DOI 10.1016/S0968-0004(96)80168-X; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1984, P NATL ACAD SCI-BIOL, V81, P5744, DOI 10.1073/pnas.81.18.5744; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; LISCUM L, 1983, J BIOL CHEM, V258, P8450; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MOSLEY ST, 1983, J BIOL CHEM, V258, P3875; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NARITA JO, 1989, PLANT CELL, V1, P181, DOI 10.1105/tpc.1.2.181; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; PARKER RA, 1993, J BIOL CHEM, V268, P11230; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; PEFFLEY DM, 1992, SOMAT CELL MOLEC GEN, V18, P19, DOI 10.1007/BF01233446; RAMHARACK R, 1990, DNA CELL BIOL, V9, P677, DOI 10.1089/dna.1990.9.677; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; RUSNAK N, 1987, BIOCHEM BIOPH RES CO, V148, P890, DOI 10.1016/0006-291X(87)90959-4; SHAPIRO DJ, 1974, BIOCHIM BIOPHYS ACTA, V370, P369, DOI 10.1016/0005-2744(74)90098-9; STERMER BA, 1994, J LIPID RES, V35, P1133; STRAKA MS, 1995, ARCH BIOCHEM BIOPHYS, V317, P235, DOI 10.1006/abbi.1995.1158; TANAKA RD, 1983, J BIOL CHEM, V258, P3331; VOLKL A, 1986, JPN SOC CELL BIOL, V289, P13	42	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24579	24587		10.1074/jbc.272.39.24579	http://dx.doi.org/10.1074/jbc.272.39.24579			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305924	hybrid			2022-12-25	WOS:A1997XY51500075
J	Harrington, C; Lan, Y; Akman, SA				Harrington, C; Lan, Y; Akman, SA			The identification and characterization of a G4-DNA resolvase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TELOMERE-BINDING-PROTEIN; QUADRUPLEX NUCLEIC-ACIDS; G-QUARTET FORMATION; YEAST GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; TOPOISOMERASE-II; MAMMALIAN-CELLS; BETA-SUBUNIT; GENOMIC RNA; DNA	There is increasing evidence that four-stranded Hoogsteen-bonded DNA structures, G4-DNA, play an important role in cellular processes such as meiosis and recombination. The Hoogsteen-bonded G4-DNA is thermodynamically more stable than duplex DNA, and many guanine-rich genomic DNA sequences with the ability to form G4-DNA have been identified. A protein-dependent activity that resolves G4-DNA into single-stranded DNA has been identified in human placental tissue. The resolvase activity was purified from any apparent nuclease activity and is dependent on NTP hydrolysis and MgCl2. Resolvase activity is optimal with 5 mM MgCl2. The V-max/K-m of ATP is 0.055%/min/mu M, higher than the V-max/K-m of the other dNTPs. The products of the resolvase reaction are unmodified single-stranded DNA. The resolvase is not a duplex DNA helicase or a topoisomerase II activity and does not unwind Hoogsteen-bonded tripler DNA. Resolvase is a novel activity that unwinds stable G4-DNA structures using a dNTP-dependent mechanism producing unmodified single-stranded DNA. Potential in vivo roles for this G4-DNA resolvase activity are discussed.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT CANC BIOL, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, CTR COMPREHENS CANC, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKMAN SA, 1991, BIOCHEMISTRY-US, V30, P8648, DOI 10.1021/bi00099a022; AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CHUNG IK, 1992, NUCLEIC ACIDS RES, V20, P1973, DOI 10.1093/nar/20.8.1973; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; FRANTZ JD, 1995, J BIOL CHEM, V270, P20692, DOI 10.1074/jbc.270.35.20692; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; HAMMONDKOSACK MCU, 1992, NUCLEIC ACIDS RES, V20, P231, DOI 10.1093/nar/20.2.231; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KIM JM, 1990, GENETICS, V126, P799; KORNBERG A, 1992, DNA REPLICATION, P379; LU M, 1993, BIOCHEMISTRY-US, V32, P598, DOI 10.1021/bi00053a027; Lui Z., 1993, P NATL ACAD SCI USA, V90, P3157; LUI Z, 1994, CELL, V77, P1083; MAINE IP, 1994, BIOCHEM BIOPH RES CO, V204, P1119, DOI 10.1006/bbrc.1994.2578; MORAES EC, 1990, CARCINOGENESIS, V11, P283, DOI 10.1093/carcin/11.2.283; PELEG M, 1995, NUCLEIC ACIDS RES, V23, P1292, DOI 10.1093/nar/23.8.1292; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIERER T, 1994, BIOCHEMISTRY-US, V33, P2240, DOI 10.1021/bi00174a034; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SMITH SS, 1989, BIOCHEM BIOPH RES CO, V160, P1397, DOI 10.1016/S0006-291X(89)80159-7; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WALSH K, 1992, J BIOL CHEM, V267, P13714; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; WANG Y, 1993, J MOL BIOL, V234, P1171, DOI 10.1006/jmbi.1993.1668; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; WEISMANSHOMER P, 1994, BIOCHEM BIOPH RES CO, V205, P305, DOI 10.1006/bbrc.1994.2665; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7	36	51	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24631	24636		10.1074/jbc.272.39.24631	http://dx.doi.org/10.1074/jbc.272.39.24631			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305932	hybrid			2022-12-25	WOS:A1997XY51500083
J	Fesquet, D; Morin, N; Doree, M; Devault, A				Fesquet, D; Morin, N; Doree, M; Devault, A			Is Cdk7 cyclin H MAT1 the genuine cdk activating kinase in cycling xenopus egg extracts?	ONCOGENE			English	Article						cdk; cdk7; CAK; phosphorylation; cell cycle; Xenopus	MATURATION-PROMOTING FACTOR; RING FINGER PROTEIN; CELL-CYCLE; DEPENDENT KINASES; DNA-REPLICATION; BUDDING YEAST; CAK; PHOSPHORYLATION; P34CDC2; CDC2	Formation of active cdk (cyclin dependent kinase)/ cyclin kinases involves phosphorylation of a conserved threonine residue in the T loop of the cdk catalytic subunit by CAK (Cdk Activating Kinase). CAK was first purified biochemically from higher eukaryotes and identified as a trimeric complex containing a cdk7 catalytic subunit, cyclin H and MAT1 (Menage a trois), a member of the RING finger family. The same trimeric complex is also part of basal transcription factor TFIIH. In budding yeast, the closest homologs of cdk7 and cyclin H, KIN28 and CCL1, respectively, also associate with TFIIH. However, the KIN28/CCL1 complex does not display CAK activity and a distinct protein kinase able to phosphorylate monomeric CDC28 and GST-cdk2 was recently identified, challenging the identification of cdk7 as the physiological CAK in higher eukaryotes. Here we demonstrate that immunodepletion of cdk7 suppresses CAK activity from cycling Xenopus egg extracts, and arrest them before M-phase. We also show that specific translation of mRNAs encoding Xenopus cdk7 and its associated subunits restores CAK activity in cdk7-immunodepleted Xenopus egg extracts. Hence, the cdk7 complex is necessary and sufficient for activation of cdk-cyclin complexes in cycling Xenopus egg extracts.	CTR RECH BIOCHIM MACROMOL,CNRS ERS 155,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Fesquet, didier/M-9750-2019; Fesquet, Didier/A-1490-2009	Fesquet, didier/0000-0001-5657-9689; Morin, Nathalie/0000-0001-8677-1401				Buck V, 1995, EMBO J, V14, P6173, DOI 10.1002/j.1460-2075.1995.tb00308.x; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; Damagnez V, 1995, EMBO J, V14, P6164, DOI 10.1002/j.1460-2075.1995.tb00307.x; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KREK W, 1992, NEW BIOL, V4, P323; LOHKA MJ, 1984, DEV BIOL, V103, P434, DOI 10.1016/0012-1606(84)90331-2; MATTHEWS G, 1994, CELL BIOL LAB HDB, P131; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORIN N, 1994, EMBO J, V13, P4343, DOI 10.1002/j.1460-2075.1994.tb06754.x; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; POON RYC, 1995, CURR BIOL, V5, P1243; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; Wagner M, 1997, EMBO J, V16, P1305, DOI 10.1093/emboj/16.6.1305	29	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1303	1307		10.1038/sj.onc.1201300	http://dx.doi.org/10.1038/sj.onc.1201300			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315098				2022-12-25	WOS:A1997XV84500008
J	Asano, K; Vornlocher, HP; RichterCook, NJ; Merrick, WC; Hinnebusch, AG; Hershey, JWB				Asano, K; Vornlocher, HP; RichterCook, NJ; Merrick, WC; Hinnebusch, AG; Hershey, JWB			Structure of cDNAs encoding human eukaryotic initiation factor 3 subunits - Possible roles in RNA binding and macromolecular assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN PROTEIN-SYNTHESIS; SACCHAROMYCES-CEREVISIAE; RABBIT RETICULOCYTES; TRANSLATIONAL INITIATION; FACTOR EIF-3; MOV-34 GENE; HELA-CELLS; COMPLEX; CLONING; YEAST	The mammalian translation initiation factor 3 (eIF3), is a multiprotein complex of similar to 600 kDa that binds to the 40 S ribosome and promotes the binding of methionyl-tRNA(i) and mRNA. cDNA encoding 5 of the 10 subunits, namely eIF3-p170,-p116,-110,-p48, and -p36, have been isolated previously. Here we report the cloning and characterization of human cDNAs encoding the major RNA binding subunit, eIF3-p66, and two additional sub-units, eIF3-p47 and eIF3-p40. Each of these proteins is present in immunoprecipitates formed with affinity-purified anti-eIF3-p170 antibodies. Human eIF3-p66 shares 64% sequence identity with a hypothetical Caenorhabditis elegans protein, presumably the p66 homolog. Deletion analyses of recombinant derivatives of eIF3-p66 show that the RNA-binding domain lies within an N-terminal 71-amino acid region rich in lysine and arginine. The N-terminal regions of human eIF3-p40 and eIF3-p47 are related to each other and to 17 other erkaryotic proteins, including murine Mov-34, a subunit of the 26 S proteasome. Phylogenetic analyses of the 19 related protein sequences, called the Mov-34 family, distinguish five major subgroups, where eIF3-p40, eIF3-p47, and Mov-34 are each found in a different subgroup. The subunit composition of eIF3 appears to be highly conserved in Drosophila melanogaster, C. elegans, and Arabidopsis thaliana, whereas only 5 homologs of the 10 subunits of mammalian eIF3 are encoded in S. cerevisiae.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; NICHHD,LAB EUKARYOT GENE REGULAT,NIH,BETHESDA,MD 20892	University of California System; University of California Davis; Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135, R01GM036467, R01GM026796] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36467, GM26796, GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; BENNE R, 1976, J BIOL CHEM, V251, P7675; BENNE R, 1978, J BIOL CHEM, V253, P3078; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; DUBIEL W, 1995, FEBS LETT, V363, P97, DOI 10.1016/0014-5793(95)00288-K; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; GRIDLEY T, 1991, GENOMICS, V11, P501, DOI 10.1016/0888-7543(91)90056-K; GU ZY, 1992, P NATL ACAD SCI USA, V89, P10355, DOI 10.1073/pnas.89.21.10355; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; Johnson KR, 1997, J BIOL CHEM, V272, P7106, DOI 10.1074/jbc.272.11.7106; KENRICK S, 1992, HUM MOL GENET, V1, P179; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Maniatis T., 1982, MOL CLONING; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; METHOT N, 1994, MOL CELL BIOL, V14, P3207; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; MILBURN SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P6, DOI 10.1016/0003-9861(90)90002-G; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; *NAT CTR BIOT INF, SUMM DBEST HUM LIB; NYGARD O, 1982, NUCLEIC ACIDS RES, V10, P1327, DOI 10.1093/nar/10.4.1327; RINALDI T, 1995, GENE, V160, P135, DOI 10.1016/0378-1119(95)00212-O; SHIMANUKI M, 1995, J CELL SCI, V108, P569; TABER S, 1985, P NATL ACAD SCI USA, V82, P1074; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; TSURUMI C, 1995, BIOCHEM BIOPH RES CO, V210, P600, DOI 10.1006/bbrc.1995.1701; WEI CL, 1995, J BIOL CHEM, V270, P5764, DOI 10.1074/jbc.270.11.5764; WEI CL, 1995, J BIOL CHEM, V270, P22788, DOI 10.1074/jbc.270.39.22788; WESTERMANN P, 1984, NUCLEIC ACIDS RES, V12, P887; Wool I. G., 1996, TRANSLATIONAL CONTRO, P685; Yang WM, 1996, MOL CELL BIOL, V16, P6603	43	145	164	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27042	27052		10.1074/jbc.272.43.27042	http://dx.doi.org/10.1074/jbc.272.43.27042			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341143	hybrid			2022-12-25	WOS:A1997YC65900039
J	Lange, A; Gebremedhin, D; Narayanan, J; Harder, D				Lange, A; Gebremedhin, D; Narayanan, J; Harder, D			20-hydroxyeicosatetraenoic acid-induced vasoconstriction and inhibition of potassium current in cerebral vascular smooth muscle is dependent on activation of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR SPECIFIC SUBSTRATE; RENAL ARCUATE ARTERIES; ARACHIDONIC-ACID; PHORBOL 12,13-DIBUTYRATE; BASILAR ARTERY; FATTY-ACIDS; CELLS; TRANSDUCTION; METABOLITES; K+	20-Hydroxyeicosatetraenoic acid (20-HETE), a cytochrome P450 metabolite of arachidonic acid, is a potent vasoconstrictor, and has been implicated in the myogenic activation of renal and cerebral arteries. We examined the role of protein kinase C (PKC) in the signal transduction pathway by which 20-HETE induces vasoconstriction and inhibition of whole-cell K+ current in cat cerebral vascular smooth muscle, 20-HETE induced a concentration-dependent constriction in isolated pressurized cat middle cerebral arteries (-29 +/- 8% at 1 mu M). However, in the presence of an N-myristoylated PKC pseudosubstrate inhibitor peptide (Myr Psi PKC-I(19-27)) 20-HETE induced a concentration-dependent vasodilation (26 +/- 4% at 1 mu M). In whole-cell voltage clamp studies, application of 20-HETE inhibited whole-cell K+ current recorded in cat cerebral vascular smooth muscle cells, an effect that was attenuated by Myr Psi PKC-I(19-27). Further evidence for the role of PKC activation in response to 20-HETE is the finding that 20-HETE increased the phosphorylation of myristoylated, alanine rich PKC substrate in cultured cat cerebral vascular smooth muscle cells in a concentration-and PKC-dependent manner. These data provide evidence that PKC is an integral part of the signal transduction pathway by which 20-HETE elicits vasoconstriction of cerebral arteries and inhibition of whole-cell K+ current in cat cerebral vascular smooth muscle.	MED COLL WISCONSIN, CARDIOVASC RES CTR, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT PHYSIOL, MILWAUKEE, WI 53226 USA; CLEMENT J ZABLOCKI VET AFFAIRS MED CTR, MILWAUKEE, WI 53295 USA	Medical College of Wisconsin; Medical College of Wisconsin					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032321] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33883-13] Funding Source: Medline; NINDS NIH HHS [R01 NS 32321-03] Funding Source: Medline; VA [VA 3440-06P] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); VA(US Department of Veterans Affairs)		ABRAHAM NG, 1991, BLOOD, V78, P1461; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; Amlal H, 1996, AM J PHYSIOL-CELL PH, V271, pC455, DOI 10.1152/ajpcell.1996.271.2.C455; Birks EK, 1997, AM J PHYSIOL-LUNG C, V272, pL823, DOI 10.1152/ajplung.1997.272.5.L823; BLOBE GC, 1995, PROSTAG LEUKOTR ESS, V52, P129, DOI 10.1016/0952-3278(95)90011-X; CAROLL MA, 1996, AM J PHYSIOL, V271, pR863; CAROLL MA, 1993, CIRC RES, V72, P126; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CLARK AH, 1991, BRIT J PHARMACOL, V102, P415, DOI 10.1111/j.1476-5381.1991.tb12188.x; CROOK RB, 1992, J CELL PHYSIOL, V153, P214, DOI 10.1002/jcp.1041530126; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; ENCABO A, 1993, J PHARM PHARMACOL, V45, P274, DOI 10.1111/j.2042-7158.1993.tb05552.x; ESCALANTE B, 1994, AM J PHYSIOL, V266, pC1775, DOI 10.1152/ajpcell.1994.266.6.C1775; FERRER M, 1992, BRAIN RES, V599, P186, DOI 10.1016/0006-8993(92)90390-U; GEBREMEDHIN D, 1997, IN PRESS J PHYSL LON; Goodman AI, 1997, P SOC EXP BIOL MED, V214, P54; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSSON A, 1986, BIOCHEM BIOPH RES CO, V134, P1215, DOI 10.1016/0006-291X(86)90380-3; Harder DR, 1997, J VASC RES, V34, P237, DOI 10.1159/000159228; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; HARDER DR, 1994, AM J PHYSIOL, V266, pH2098, DOI 10.1152/ajpheart.1994.266.5.H2098; HARDER DR, 1995, TRENDS CARDIOVAS MED, V5, P7, DOI 10.1016/1050-1738(94)00026-R; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; HORSBURGH K, 1990, EUR J PHARMACOL, V191, P205, DOI 10.1016/0014-2999(90)94148-Q; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Imig JD, 1996, AM J PHYSIOL-REG I, V270, pR217, DOI 10.1152/ajpregu.1996.270.1.R217; KAUSER K, 1991, CIRC RES, V68, P1154, DOI 10.1161/01.RES.68.4.1154; KAZUSHI M, 1993, BIOCHEM BIOPH RES CO, V190, P263; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; Lin FM, 1995, AM J PHYSIOL-RENAL, V269, pF806, DOI 10.1152/ajprenal.1995.269.6.F806; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; MA YH, 1993, CIRC RES, V72, P126, DOI 10.1161/01.RES.72.1.126; MACICA C, 1993, AM J PHYSIOL, V265, pG735, DOI 10.1152/ajpgi.1993.265.4.G735; MURAKAMI K, 1986, J BIOL CHEM, V261, P5424; MURRAY MA, 1992, HYPERTENSION, V19, P739, DOI 10.1161/01.HYP.19.6.739; Nowicki S, 1997, J CLIN INVEST, V99, P1224, DOI 10.1172/JCI119279; Ominato M, 1996, J MEMBRANE BIOL, V152, P235, DOI 10.1007/s002329900101; RIBALET B, 1995, J MEMBRANE BIOL, V148, P111; RIBEIRO CMP, 1994, AM J PHYSIOL, V266, pF497, DOI 10.1152/ajprenal.1994.266.3.F497; ROBINSON PJ, 1993, ANAL BIOCHEM, V210, P172, DOI 10.1006/abio.1993.1169; ROMAN RJ, 1993, J AM SOC NEPHROL, V4, P986; SALAICES M, 1990, J PHARMACOL EXP THER, V255, P66; SEKIGUCHI K, 1987, BIOCHEM BIOPH RES CO, V145, P797, DOI 10.1016/0006-291X(87)91035-7; Shipston MJ, 1996, J PHYSIOL-LONDON, V493, P665, DOI 10.1113/jphysiol.1996.sp021413; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; WALSH MP, 1994, CAN J PHYSIOL PHARM, V72, P1392, DOI 10.1139/y94-201; WANG WH, 1995, J GEN PHYSIOL, V106, P727, DOI 10.1085/jgp.106.4.727; ZHANG H, 1995, PHARMACOLOGY, V50, P247, DOI 10.1159/000139289; ZOU AP, 1994, AM J PHYSIOL, V266, pF275, DOI 10.1152/ajprenal.1994.266.2.F275; Zou AP, 1996, AM J PHYSIOL-REG I, V270, pR228, DOI 10.1152/ajpregu.1996.270.1.R228	51	146	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27345	27352		10.1074/jbc.272.43.27345	http://dx.doi.org/10.1074/jbc.272.43.27345			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341185	hybrid			2022-12-25	WOS:A1997YC65900081
J	Mueller, GA; Smith, AM; Williams, DC; Hakkaart, GAJ; Aalberse, RC; Chapman, MD; Rule, GS; Benjamin, DC				Mueller, GA; Smith, AM; Williams, DC; Hakkaart, GAJ; Aalberse, RC; Chapman, MD; Rule, GS; Benjamin, DC			Expression and secondary structure determination by NMR methods of the major house dust mite allergen Der p 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGKISTRODON-PISCIVORUS-PISCIVORUS; 3-DIMENSIONAL SOLUTION STRUCTURE; MAGNETIC-RESONANCE SPECTROSCOPY; SITE-DIRECTED MUTAGENESIS; GROUP-II DERMATOPHAGOIDES; SIDE-CHAIN RESONANCES; C-13/N-15-ENRICHED PROTEINS; C-13-LABELED PROTEINS; ANTIGENIC STRUCTURE; C-13 MAGNETIZATION	There exists a strong correlation between asthma and sensitization to indoor allergens, This study reports on the secondary structure of the major house dust mite allergen Der p 2, determined using heteronuclear NMR methods, The DNA was subcloned from the yeast expression vector pSAY1 into the high yield bacterial expression vector pET21a, resulting in yields of 50 mg/liter, The recombinant protein was shown to have immunoreactivity comparable with that of the natural mite protein using competitive inhibition enzyme-linked immunosorbent assay (ELISA) and a modified monoclonal radioallergosorbent test (RAST), The secondary structure was determined by examining chemical shifts, short and long range NOESYs, J(HN-HA) coupling constants, and amide exchange rates, From these data, it is clear that Der p 2 is composed of beta-sheets and random coil, Based on long range distance constraints, a number of beta strands were aligned into two three-stranded, antiparallel beta-sheets.	UNIV VIRGINIA,HLTH SCI CTR,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,ASTHMA & ALLERG DIS CTR,CHARLOTTESVILLE,VA 22908; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,NL-1006 AD AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,CLIN & EXPT IMMUNOL LAB,NL-1006 AD AMSTERDAM,NETHERLANDS; CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	University of Virginia; University of Virginia; University of Amsterdam; Carnegie Mellon University			Mueller, Geoffrey A/I-2909-2017; Rule, Gordon S/Q-2422-2015	Mueller, Geoffrey A/0000-0001-8361-5323; Rule, Gordon S/0000-0002-4396-3363; Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034607, U01AI034607] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-34607] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRIERCHECK DM, 1997, J BIOMOL NMR, V8, P429; CHUA KY, 1991, CLIN EXP ALLERGY, V21, P161, DOI 10.1111/j.1365-2222.1991.tb00825.x; CLUBB RT, 1992, J BIOMOL NMR, V2, P203, DOI 10.1007/BF01875531; DRISCOLL PC, 1990, J MAGN RESON, V88, P425; FRENKIEL T, 1990, J MAGN RESON, V90, P420, DOI 10.1016/0022-2364(90)90152-Y; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; Jerala R, 1996, J MAGN RESON SER B, V110, P87, DOI 10.1006/jmrb.1996.0013; Jerala R, 1996, J BIOMOL NMR, V7, P107; KAY LE, 1993, J AM CHEM SOC, V115, P2055, DOI 10.1021/ja00058a072; LATHROP BK, 1992, PROTEIN EXPRES PURIF, V3, P512, DOI 10.1016/1046-5928(92)90069-9; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; MAJUMDAR A, 1993, J MAGN RESON SER B, V102, P242, DOI 10.1006/jmrb.1993.1093; METZLER WJ, 1992, BIOCHEMISTRY-US, V31, P5117, DOI 10.1021/bi00137a005; METZLER WJ, 1992, BIOCHEMISTRY-US, V31, P8697, DOI 10.1021/bi00152a003; NISHIYAMA C, 1994, INT ARCH ALLERGY IMM, V105, P62, DOI 10.1159/000236804; Nishiyama C, 1995, MOL IMMUNOL, V32, P1021, DOI 10.1016/0161-5890(95)00091-7; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; PENNINGTON CJ, 1992, BIOCHEMISTRY-US, V11, P2912; PLATTSMILLS TAE, 1997, IN PRESS J ALLERGY C; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1111/j.1365-2222.1997.tb00667.x; Sambrook J., 2002, MOL CLONING LAB MANU; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; SMITH AM, 1991, J IMMUNOL, V146, P1254; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEWART GA, 1992, J ALLERGY CLIN IMMUN, V90, P141, DOI 10.1016/S0091-6749(06)80029-1; THOMAS W, 1996, MOL ANAL IMMEDIATE H, P77; THOMAS WR, 1995, CLIN EXP ALLERGY, V25, P667, DOI 10.1111/j.1365-2222.1995.tb01117.x; TOPHAM CM, 1994, PROTEIN ENG, V7, P869, DOI 10.1093/protein/7.7.869; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033	44	51	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26893	26898		10.1074/jbc.272.43.26893	http://dx.doi.org/10.1074/jbc.272.43.26893			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341122	hybrid, Green Published			2022-12-25	WOS:A1997YC65900018
J	Ren, B; Thelen, AP; Peters, JM; Gonzalez, FJ; Jump, DB				Ren, B; Thelen, AP; Peters, JM; Gonzalez, FJ; Jump, DB			Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X RECEPTOR; COA DESATURASE-1 GENE; HYDROGENATED FISH OIL; RAT-LIVER; BETA-OXIDATION; MESSENGER-RNA; CROSS-TALK; DIFFERENTIAL EXPRESSION; EICOSAPENTAENOIC ACID; SIGNALING PATHWAYS	Dietary polyunsaturated fatty acids (PUFA) induce hepatic peroxisomal and microsomal fatty acid oxidation and suppress lipogenic gene expression. The peroxisome proliferator-activated receptor alpha (PPAR alpha) has been implicated as a mediator of fatty acid effects on gene transcription. This report uses the PPAR alpha-deficient mouse to examine the role of PPAR alpha in the PUFA regulation of mRNAs encoding hepatic lipogenic (fatty acid synthase (FAS) and the 514 protein (514)), microsomal (cytochrome P450 4A2 (CYP4A2)), and peroxisomal (acyl-CoA oxidase (AOX)) enzymes, PUFA ingestion induced mRNA(AOX) (2.3-fold) and mRNA(CYP4A2) (8-fold) and suppressed mRNA(FAS) and mRNA(S14) by greater than or equal to 80% in wild type mice, In PPAR alpha-deficient mice, PUFA did not induce mRNA(AOX) or mRNA(CYP4A2), indicating a requirement for PPAR alpha in the PUFA-mediated induction of these enzymes, However, PUFA still suppressed mRNA(FAS) and mRNA(S14) in the PPAR alpha-deficient mice, Studies in rats provided additional support for the differential regulation of lipogenic and peroxisomal enzymes by PUFA. These studies provide evidence for two distinct pathways for PUFA control of hepatic lipid metabolism. One requires PPAR alpha and is involved in regulating peroxisomal and microsomal enzymes, The other pathway does not require PPAR alpha and is involved in the PUFA mediated suppression of lipogenic gene expression.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT PHYSIOL, E LANSING, MI 48824 USA; NCI, LAB METAB, NIH, BETHESDA, MD 20892 USA	Michigan State University; Michigan State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Peters, Jeffrey/D-8847-2011	Peters, Jeffrey/0000-0003-2782-2998	NIDDK NIH HHS [R01 DK043220] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARSLAND A, 1990, LIPIDS, V25, P546, DOI 10.1007/BF02537162; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CHU RY, 1995, P NATL ACAD SCI USA, V92, P11593, DOI 10.1073/pnas.92.25.11593; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; CLARKE SD, 1990, J NUTR, V120, P218, DOI 10.1093/jn/120.2.218; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; FLATMARK T, 1988, BIOCHIM BIOPHYS ACTA, V962, P122, DOI 10.1016/0005-2760(88)90103-8; GEARING KL, 1994, CELL, V79, P1147; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; Hertz R, 1996, J BIOL CHEM, V271, P218, DOI 10.1074/jbc.271.1.218; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; HUANG Q, 1994, J BIOL CHEM, V269, P8493; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; JUMP DB, 1994, J LIPID RES, V35, P1076; JUMP DB, 1995, PROSTAG LEUKOTR ESS, V52, P107, DOI 10.1016/0952-3278(95)90007-1; KAIKAUS RM, 1993, J BIOL CHEM, V268, P9593; KAIKAUS RM, 1993, J BIOL CHEM, V268, P26866; KELLER H, 1995, MOL ENDOCRINOL, V9, P794, DOI 10.1210/me.9.7.794; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LALWANI ND, 1983, HUM TOXICOL, V2, P27, DOI 10.1177/096032718300200103; LANDSCHULZ KT, 1994, BIOCHEM BIOPH RES CO, V200, P763, DOI 10.1006/bbrc.1994.1516; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Miller CW, 1996, P NATL ACAD SCI USA, V93, P9443, DOI 10.1073/pnas.93.18.9443; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEAT CE, 1980, BIOCHEM J, V186, P369, DOI 10.1042/bj1860369; NILSSON A, 1987, BIOCHIM BIOPHYS ACTA, V920, P114, DOI 10.1016/0005-2760(87)90250-5; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; RAMB, 1996, LIPIDS, V31, pS45; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; RUSTAN AC, 1992, BIOCHEM J, V283, P333, DOI 10.1042/bj2830333; RUSTAN AC, 1988, J LIPID RES, V29, P1417; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schoonjans K, 1996, J LIPID RES, V37, P907; THOMASSEN MS, 1982, BIOCHEM J, V206, P195, DOI 10.1042/bj2060195; TOUSSANT MJ, 1981, J NUTR, V111, P146, DOI 10.1093/jn/111.1.146; VALDES E, 1995, LIPIDS, V30, P955, DOI 10.1007/BF02537488; WILLUMSEN N, 1993, J LIPID RES, V34, P13; YOKOMIZO T, 1995, J LIPID MEDIAT CELL, V12, P321, DOI 10.1016/0929-7855(95)00041-N	52	208	215	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26827	26832		10.1074/jbc.272.43.26827	http://dx.doi.org/10.1074/jbc.272.43.26827			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341113	hybrid			2022-12-25	WOS:A1997YC65900009
J	Vernallis, AB; Hudson, KR; Heath, JK				Vernallis, AB; Hudson, KR; Heath, JK			An antagonist for the leukemia inhibitory factor receptor inhibits leukemia inhibitory factor, cardiotrophin-1, ciliary neurotrophic factor, and oncostatin M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; SIGNAL TRANSDUCER GP130; HUMAN MYELOMA CELLS; CNTF RECEPTOR; HUMAN INTERLEUKIN-6; LIF RECEPTOR; SYMPATHETIC NEURONS; ALPHA COMPONENT; RATIONAL DESIGN; GROWTH-FACTORS	The leukemia inhibitory factor receptor (LIF-R) is activated not only by LlF, but also by cardiotrophin-1, ciliary neurotrophic factor with its receptor, and oncostatin M (OSM). Each of these cytokines induces the hetero oligomerization of LIF-R with gp130, a signal-transducing subunit shared with interleukin-6 and interleukin-11. The introduction of mutations into human LIF that reduced the affinity for gp130 while retaining affinity for LIF-R has generated antagonists for LIF. In the current study, a LIF antagonist that was free of detectable agonistic activity was tested for antagonism against the family of LIF-R ligands. On cells that express LIF-R and gp130, all LIF-R ligands were antagonized. On cells that also express OSM receptor, OSM was not antagonized, demonstrating that the antagonist is specific for LIF-R. Ligand-triggered tyrosine phosphorylation of both LIF-R and gp130 was blocked by the antagonist. The antagonist is therefore likely to work by preventing receptor oligomerization.	UNIV BIRMINGHAM,SCH BIOCHEM,CRC,GROWTH FACTOR GRP,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham								AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; BANNER LR, 1994, P NATL ACAD SCI USA, V91, P7109, DOI 10.1073/pnas.91.15.7109; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; Bellido T, 1996, J CLIN INVEST, V97, P431, DOI 10.1172/JCI118432; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BROWN MA, 1994, CYTOKINE, V6, P300, DOI 10.1016/1043-4666(94)90027-2; CORDINGLEY MG, 1990, J BIOL CHEM, V265, P9062; Crichton MB, 1996, MOL CELL ENDOCRINOL, V118, P215, DOI 10.1016/0303-7207(96)03761-6; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DEHON FD, 1994, J EXP MED, V180, P2395, DOI 10.1084/jem.180.6.2395; DiMarco A, 1996, P NATL ACAD SCI USA, V93, P9247, DOI 10.1073/pnas.93.17.9247; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; EHLERS M, 1995, J BIOL CHEM, V270, P8158, DOI 10.1074/jbc.270.14.8158; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1992, CIBA F SYMP, V167, P245; Grunewald SM, 1997, J BIOL CHEM, V272, P1480, DOI 10.1074/jbc.272.3.1480; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kurek JB, 1996, MUSCLE NERVE, V19, P1291, DOI 10.1002/(SICI)1097-4598(199610)19:10<1291::AID-MUS6>3.0.CO;2-9; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; LECRON JC, 1993, CLIN EXP IMMUNOL, V92, P23; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LONG AC, 1989, FEBS LETT, V258, P75, DOI 10.1016/0014-5793(89)81619-9; LOTZ M, 1992, J CLIN INVEST, V90, P888, DOI 10.1172/JCI115964; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Neophytou C, 1997, DEVELOPMENT, V124, P2345; ODORISIO MS, 1992, REGUL PEPTIDES, V37, P213; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; Omori N, 1996, LAB INVEST, V75, P15; Owczarek CM, 1996, J BIOL CHEM, V271, P5495, DOI 10.1074/jbc.271.10.5495; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PIQUETPELLORCE C, 1994, EXP CELL RES, V213, P340, DOI 10.1006/excr.1994.1208; Rajan P, 1996, J NEUROSCI RES, V43, P403, DOI 10.1002/(SICI)1097-4547(19960215)43:4<403::AID-JNR2>3.0.CO;2-J; RAO MS, 1992, NEUROREPORT, V3, P865, DOI 10.1097/00001756-199210000-00011; ROBINSON RC, 1994, CELL, V77, P1; RUDGE JS, 1994, EUR J NEUROSCI, V6, P693, DOI 10.1111/j.1460-9568.1994.tb00981.x; SAGGIO I, 1994, ANAL BIOCHEM, V221, P387, DOI 10.1006/abio.1994.1430; Sambrook J., 2002, MOL CLONING LAB MANU; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sporeno E, 1996, BLOOD, V87, P4510, DOI 10.1182/blood.V87.11.4510.bloodjournal87114510; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Sun Y, 1996, EUR J NEUROSCI, V8, P2213, DOI 10.1111/j.1460-9568.1996.tb00744.x; SUN Y, 1994, J NEUROBIOL, V25, P415, DOI 10.1002/neu.480250407; Sun Y, 1996, J NEUROCHEM, V67, P1751; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Taga T, 1996, J NEUROCHEM, V67, P1; THOMA B, 1994, J BIOL CHEM, V269, P6215; Thompson SWN, 1997, EUR J NEUROSCI, V9, P1244, DOI 10.1111/j.1460-9568.1997.tb01479.x; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; ULICH TR, 1994, AM J PHYSIOL-LUNG C, V267, pL442, DOI 10.1152/ajplung.1994.267.4.L442; WARE CB, 1995, DEVELOPMENT, V121, P1283; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; YANG YC, 1986, CELL, V47, P8; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	76	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26947	26952		10.1074/jbc.272.43.26947	http://dx.doi.org/10.1074/jbc.272.43.26947			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341130	hybrid, Green Accepted			2022-12-25	WOS:A1997YC65900026
J	Birn, H; Verroust, PJ; Nexo, E; Hager, H; Jacobsen, C; Christensen, EI; Moestrup, SK				Birn, H; Verroust, PJ; Nexo, E; Hager, H; Jacobsen, C; Christensen, EI; Moestrup, SK			Characterization of an epithelial similar to 460-kDa protein that facilitates endocytosis of intrinsic factor-vitamin B-12 and binds receptor-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHRITIS ANTIGENIC COMPLEX; BRUSH-BORDER MEMBRANE; FACTOR-COBALAMIN; TRANSCOBALAMIN-II; ALPHA-2-MACROGLOBULIN RECEPTOR; MONOCLONAL-ANTIBODIES; RAT-KIDNEY; GP330; LIPOPROTEIN; IDENTIFICATION	By using receptor-associated protein (RAP) as an affinity target, an intrinsic factor-vitamin B-12 (IF-B-12)-binding renal epithelial protein of similar to 460 kDa was copurified together with the transcobalamin-B-12-binding 600-kDa receptor, megalin, IF-B-12 affinity chromatography of renal cortex membrane from rabbit and man yielded the same similar to 460-kDa protein. Binding studies including surface plasmon resonance analyses of the protein demonstrated a calcium-dependent and high affinity binding of IF-B-12 to a site distinct from the RAP binding site. The high affinity binding of IF-B-12 was dependent on complex formation with vitamin B-12. Light and electron microscope autoradiography of rat renal cortex cryosections incubated directly with IF-Co-57-B-12 and rat proximal tubules microinjected in vivo with the radioligand demonstrated binding of the ligand to endocytic invaginations of proximal tubule membranes followed by endocytosis and targeting of vitamin B-12 to lysosomes. Polyclonal antibodies recognizing the similar to 460-kDa receptor inhibited the uptake, Immunohistochemistry of kidney and intestine showed colocalization of the IF-B-12 receptor and megalin in both tissues. In conclusion, we have identified the epithelial IF-B-12-binding receptor as a similar to 460-kDa RAP-binding protein facilitating endocytosis.	AARHUS UNIV,DEPT BIOCHEM MED,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,DEPT CELL BIOL,DK-8000 AARHUS C,DENMARK; AARHUS KOMMUNE HOSP,DEPT CLIN BIOCHEM,DK-8000 AARHUS C,DENMARK; HOP TENON,INSERM,U64,F-75020 PARIS,FRANCE	Aarhus University; Aarhus University; Aarhus University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite			Moestrup, Søren Kragh/AAD-1735-2019; Birn, Henrik/C-3931-2009; Moestrup, Søren Kragh/A-1403-2014	Birn, Henrik/0000-0003-3715-7266; Moestrup, Søren Kragh/0000-0003-3862-2107; Nexo, Ebba/0000-0001-9406-9081				BOSE S, 1995, J BIOL CHEM, V270, P8152, DOI 10.1074/jbc.270.14.8152; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; COOPER BA, 1968, BRIT J HAEMATOL, V14, P73, DOI 10.1111/j.1365-2141.1968.tb01474.x; DAN N, 1994, J BIOL CHEM, V269, P18849; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; FYFE JC, 1991, J BIOL CHEM, V266, P4489; GRASBECK R, 1960, ACTA MED SCAND, V167, P289; HAKAMI N, 1971, NEW ENGL J MED, V285, P1163, DOI 10.1056/NEJM197111182852103; Hjalm G, 1996, EUR J BIOCHEM, V239, P132, DOI 10.1111/j.1432-1033.1996.0132u.x; HOOPER DC, 1973, J CLIN INVEST, V52, P3074, DOI 10.1172/JCI107506; IMERSLUND O, 1960, Acta Paediatr Suppl, V49(Suppl 119), P1; JACOBSEN DW, 1994, ADV T ADDISONS DIS, V1, P229; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LePanse S, 1997, EUR J CELL BIOL, V72, P257; LEPANSE S, 1994, AM J PATHOL, V145, P1526; MACKENZIE IL, 1968, J EXP MED, V123, P375; MAUNSBACH AB, 1966, J ULTRA MOL STRUCT R, V15, P197, DOI 10.1016/S0022-5320(66)80108-9; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MOESTRUP SK, 1990, EXP CELL RES, V190, P195, DOI 10.1016/0014-4827(90)90185-D; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; NEXO E, 1975, BIOCHIM BIOPHYS ACTA, V379, P189, DOI 10.1016/0005-2795(75)90021-5; NEXO E, 1977, BIOCHIM BIOPHYS ACTA, V494, P395, DOI 10.1016/0005-2795(77)90168-4; NEXO E, 1982, B12 BIOCH MED, P57; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; RACHOWDURY R, 1989, SCIENCE, V244, P1163; RAMANUJAM KS, 1992, BIOCHEM BIOPH RES CO, V182, P439, DOI 10.1016/0006-291X(92)91751-B; RAMANUJAM KS, 1990, BIOCHIM BIOPHYS ACTA, V1030, P157, DOI 10.1016/0005-2736(90)90251-I; ROTHENBERG SP, 1968, J CLIN INVEST, V47, P913, DOI 10.1172/JCI105783; SAHALI D, 1988, J EXP MED, V167, P213, DOI 10.1084/jem.167.1.213; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SEETHARAM B, 1981, J BIOL CHEM, V256, P3785; SEETHARAM B, 1983, BIOCHEM BIOPH RES CO, V115, P238, DOI 10.1016/0006-291X(83)90995-6; Seetharam B, 1997, J CLIN INVEST, V99, P2317, DOI 10.1172/JCI119411; SEETHARAM B, 1988, J BIOL CHEM, V263, P4443; SEETHARAM B, 1994, ADV T ADDISONS DISEA, V2, P293; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; VANKAPEL J, 1988, CLIN CHIM ACTA, V172, P297, DOI 10.1016/0009-8981(88)90336-1; WAHLSTEDT V, 1985, J LAB CLIN MED, V106, P439; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; YANG YM, 1985, J CLIN INVEST, V76, P2037	47	118	123	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26497	26504		10.1074/jbc.272.42.26497	http://dx.doi.org/10.1074/jbc.272.42.26497			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334227	hybrid			2022-12-25	WOS:A1997YB13900061
J	Phalipou, S; Cotte, N; Carnazzi, E; Seyer, R; Mahe, E; Jard, S; Barberis, C; Mouillac, B				Phalipou, S; Cotte, N; Carnazzi, E; Seyer, R; Mahe, E; Jard, S; Barberis, C; Mouillac, B			Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; P NK-1 RECEPTOR; MOLECULAR-CLONING; SUBSTANCE-P; FUNCTIONAL EXPRESSION; OXYTOCIN; SITE; AGONISTS; LIGAND; CELLS	The study of antagonist binding domains of the hu man Via vasopressin receptor was performed using a radioiodinated photoreactive peptide antagonist, This ligand displayed a high affinity for the receptor expressed in Chinese hamster ovary cell membranes, and specifically labeled two protein bands with apparent molecular mass at 85-90 and 46 kDa. Our results clearly show that the V1a receptor is degraded during incubation with the ligand and that the 46-kDa. species is probably the result of the 65-90-kDa species proteolytic cleavage, Truncation of the receptor was then confirmed by deglycosylation with N-glycosidase F, A monoclonal antibody directed against a c-Myc epitope added at the receptor NH,terminus allowed. immunoprecipitation of the 85-90-kDa photolabeled species, The 46 kDa photolabeled protein never immunoprecipitated, indicating that the truncated form of the receptor lacks the NN, terminus region. To localize photolabeled domains of the receptor, the 46 kDa protein was cleaved with V8 and/or Lys-C endoproteinases, The identity of the smallest photolabeled fragment, observed at approximately 6 kDa, was then confirmed by mutation of the potential V8 cleavage sites, Our results indicate that covalent labeling of the vasopressin Via receptor with the photoreactive antagonist: occurs in a region including transmembrane domain VII (residues Asn(327)-Lys(370)).	CNRS, INSERM, U469, CCIPE, F-34094 MONTPELLIER 05, FRANCE; CNRS, CCIPE, UPR 9023, F-34094 MONTPELLIER 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS)			MOUILLAC, Bernard/M-3896-2014	MOUILLAC, Bernard/0000-0002-3906-8673				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARBEAU D, 1992, J MED CHEM, V35, P151, DOI 10.1021/jm00079a020; BARBERIS C, 1995, NEUROENDOCRINOLOGY, V62, P135, DOI 10.1159/000126998; Barberis C, 1996, CRIT REV NEUROBIOL, V10, P119; BERDE B, 1968, HDB EXPERIMENTAL PHA, V23, P802; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BOER R, 1985, J BIOL CHEM, V260, P5051; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; CARNAZZI E, 1994, J MED CHEM, V37, P1841, DOI 10.1021/jm00038a013; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAHRENHOLZ F, 1986, EUR J BIOCHEM, V161, P321, DOI 10.1111/j.1432-1033.1986.tb10450.x; FONG TM, 1994, J BIOL CHEM, V269, P2728; Girault S, 1996, EUR J BIOCHEM, V240, P215, DOI 10.1111/j.1432-1033.1996.0215h.x; HRUBY VJ, 1987, PEPTIDES, V8, P77; JARD S, 1988, INT CONGR SER, V799, P1183; KASSIS S, 1984, J BIOL CHEM, V259, P4910; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; KOJRO E, 1995, J BIOL CHEM, V270, P6476, DOI 10.1074/jbc.270.12.6476; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; MAHE L, 1992, J AM CHEM SOC, V114, P7904, DOI 10.1021/ja00046a042; MAHLMANN S, 1994, P NATL ACAD SCI USA, V91, P1342, DOI 10.1073/pnas.91.4.1342; MANNING M, 1988, INT J PEPT PROT RES, V32, P455; MANNING M, 1993, J RECEPTOR RES, V13, P195, DOI 10.3109/10799899309073655; MANNING M, 1992, INT J PEPT PROT RES, V40, P261; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MOUILLAC B, 1995, J BIOL CHEM, V270, P25774; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Park C, 1996, BIOCHEMISTRY-US, V35, P9807, DOI 10.1021/bi9602223; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHAMBYE HT, 1995, MOL PHARMACOL, V47, P425; SCHMIDT A, 1991, FEBS LETT, V282, P77, DOI 10.1016/0014-5793(91)80448-C; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; TURCATTI G, 1995, BIOCHEMISTRY-US, V34, P3972, DOI 10.1021/bi00012a015; UFER E, 1995, FEBS LETT, V362, P19, DOI 10.1016/0014-5793(95)00150-8; VANKESTEREN RE, 1995, NEURON, V15, P897, DOI 10.1016/0896-6273(95)90180-9	48	46	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26536	26544		10.1074/jbc.272.42.26536	http://dx.doi.org/10.1074/jbc.272.42.26536			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334232	hybrid			2022-12-25	WOS:A1997YB13900066
J	Aghdasi, B; Reid, MB; Hamilton, SL				Aghdasi, B; Reid, MB; Hamilton, SL			Nitric oxide protects the skeletal muscle Ca2+ release channel from oxidation induced activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; REACTIVE OXYGEN; CALCIUM-RELEASE; MEMBRANES	Reactive oxygen intermediates and nitric oxide modulate the contractile function of skeletal muscle fibers, possibly via direct interaction with the Ca2+ release channel, Oxidants produce disulfide bonds between subunits of the Ca2+ release channel tetramer, and this is accompanied by an increase in channel activity, The sulfhydryl alkylating agent N-ethylmaleimide has three distinct effects on Ca2+ release channel activity: first, channel activity is decreased (phase 1); then with continued exposure the activity is dramatically increased (phase 2); and finally, the channel is again inhibited (phase 3) (Aghdasi, B., Zhang, J. Z., Wu, Y., Reid, M. B., and Hamilton, S. L., (1997) J. Biol. Chem. 272, 3739-3749). Both H2O2 and nitric oxide (NO) block the phase 1 inhibitory effect of N-ethylmaleimide. NO donors, at concentrations that have no detectable effect on channel activity, block intersubunit cross-linking and prevent activation of the channel by the disulfide inducing agent, diamide, These findings support a model in which NO modulates the activity of the Ca2+ release channel by preventing oxidation of regulatory sulfhydryls. However, higher concentrations of NO donors activate the channel and produce intersubunit cross-links, supporting a bifunctional effect of NO on channel activity, Low NO concentrations prevent oxidation of the Ca2+ release channel whereas higher concentrations oxidize it.	BAYLOR COLL MED,DEPT MOL PHYSIOL & BIOPHYS,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine				Hamilton, Susan/0000-0003-0241-9369	NHLBI NIH HHS [HL45721] Funding Source: Medline; NIAMS NIH HHS [AR41802] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041802] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; AGHDASI B, 1996, BIOPHYS J, V70, pA147; BORASO A, 1994, AM J PHYSIOL, V267, pH1010, DOI 10.1152/ajpheart.1994.267.3.H1010; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20857; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; HAMILTON SL, 1991, CELLULAR CALCIUM, P313; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; LIU GH, 1994, MOL PHARMACOL, V45, P189; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meszaros LG, 1996, FEBS LETT, V380, P49, DOI 10.1016/0014-5793(96)00003-8; MESZAROS LG, 1996, BIOPHYS J, V70, pA1453; RARDON DP, 1990, CIRC RES, V67, P84, DOI 10.1161/01.RES.67.1.84; Reid MB, 1996, NEWS PHYSIOL SCI, V11, P114, DOI 10.1152/physiologyonline.1996.11.3.114; REID MB, 1993, J APPL PHYSIOL, V75, P1081, DOI 10.1152/jappl.1993.75.3.1081; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; ROSEMBLATT M, 1981, J BIOL CHEM, V256, P8140; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; STOYANOVSKY TD, 1996, BIOPHYS J, V70, pA257	21	106	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25462	25467		10.1074/jbc.272.41.25462	http://dx.doi.org/10.1074/jbc.272.41.25462			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325258	hybrid			2022-12-25	WOS:A1997YA35800013
J	DelNery, E; Juliano, MA; Lima, APCA; Scharfstein, J; Juliano, L				DelNery, E; Juliano, MA; Lima, APCA; Scharfstein, J; Juliano, L			Kininogenase activity by the major cysteinyl proteinase (Cruzipain) from Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-CELL INVASION; PORPHYROMONAS-GINGIVALIS; MAMMALIAN-CELLS; INHIBITORS; GP57/51; PROTEASE; IDENTIFICATION; EPIMASTIGOTES; PURIFICATION; SPECIFICITY	The major isoform of Trypanosona cruzi cysteinyl proteinase (cruzipain) has generated Lys-bradykinin (Lys-BK or kallidin), a proinflammatory peptide, by proteolysis of kininogen. The releasing of this peptide was demonstrated by mass spectrometry, radioimmunoassay, and ileum contractile responses, The kinin-releasing activity was immunoabsorbed selectively by monoclonal antibodies to the characteristic COOH-terminal domain of cruzipain. To determine the hydrolysis steps that account for the kininogenase activity of cruzipain, we synthesized a fluorogenic peptide (o-aminobenzoyl-Leu-Gly-Met-Ile-Ser-Leu-Met-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg(389)-Ser(390)-Ser-Arg-Ile-NH2) based on the sequence Leu(373) to Ile(393) of the human high molecular weight kininogen, The hydrolysis products from this peptide were isolated by high performance liquid chromatography, and Lys-BK was characterized as the major released kinin by mass spectrometry. Intramolecularly quenched fluorogenic peptides spanning the Met(379)-Lys(380) and Arg(389)-Ser(390) bradykinin-flanking sequences were then used to assess the substrate specificity re requirements of the parasite-derived protease compared with two COOH-terminal truncated recombinant isoforms (cruzain and cruzipain 2). In contrast to the high catalytic efficiency of parasite-derived cruzipain, the recombinant proteinases cleaved the bradykinin-flanking sites at markedly different rates. In addition, we also demonstrated that cruzipain activates plasmatic prekallikrein, which would be a second and indirect way of the parasite protease to release bradykinin.	UNIV FED SAO PAULO, ESCOLA PAULISTA MED, DEPT BIOPHYS, BR-04044020 SAO PAULO, BRAZIL; UNIV FED RIO DE JANEIRO, INST BIOFIS CARLOS CHAGAS FILHO, LAB MOL IMMUNOL, BR-21949 RIO DE JANEIRO, BRAZIL	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal do Rio de Janeiro			Lima, Ana Paula CA/G-4122-2012; Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822; LIMA, ANA PAULA C. A./0000-0003-4631-2694				ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; ASLUND L, 1991, MOL BIOCHEM PARASIT, V33, P33; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BONALDO MC, 1991, PARASITOL RES, V77, P567, DOI 10.1007/BF00931014; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P349; CAMPETELLA O, 1990, FEMS MICROBIOL LETT, V67, P145, DOI 10.1111/j.1574-6968.1990.tb13852.x; CAMPETELLA O, 1992, MOL BIOCHEM PARASIT, V50, P225, DOI 10.1016/0166-6851(92)90219-A; CAZZULO JJ, 1989, MOL BIOCHEM PARASIT, V33, P33, DOI 10.1016/0166-6851(89)90039-X; CHAGAS JR, 1995, BIOCHEM J, V306, P63, DOI 10.1042/bj3060063; CIBOROWSKI P, 1994, J BACTERIOL, V176, P4549, DOI 10.1128/JB.176.15.4549-4557.1994; DELNERY E, 1995, BIOCHEM J, V312, P233, DOI 10.1042/bj3120233; DelNery E, 1997, BIOCHEM J, V323, P427, DOI 10.1042/bj3230427; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; HARTH G, 1993, MOL BIOCHEM PARASIT, V58, P17, DOI 10.1016/0166-6851(93)90086-D; HERRERA EM, 1994, MOL BIOCHEM PARASIT, V65, P73, DOI 10.1016/0166-6851(94)90116-3; Herwald H, 1996, J EXP MED, V184, P665, DOI 10.1084/jem.184.2.665; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; IMAMURA T, 1994, J CLIN INVEST, V94, P361, DOI 10.1172/JCI117330; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LIMA APCA, 1992, MOL BIOCHEM PARASIT, V56, P335, DOI 10.1016/0166-6851(92)90183-K; LIMA APCD, 1994, MOL BIOCHEM PARASIT, V67, P333, DOI 10.1016/0166-6851(94)00144-8; MCGRATH ME, 1995, J MOL BIOL, V247, P251, DOI 10.1006/jmbi.1994.0137; MCKERROW JH, 1995, PARASITOL TODAY, V11, P279, DOI 10.1016/0169-4758(95)80039-5; MEIRELLES MNL, 1992, MOL BIOCHEM PARASIT, V52, P175, DOI 10.1016/0166-6851(92)90050-T; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; Morrot A, 1997, INT IMMUNOL, V9, P825, DOI 10.1093/intimm/9.6.825; MURTA ACM, 1990, MOL BIOCHEM PARASIT, V43, P27, DOI 10.1016/0166-6851(90)90127-8; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; SCHARFSTEIN J, 1986, J IMMUNOL, V137, P1336; SCHARFSTEIN J, 1995, J IMMUNOL METHODS, V182, P63, DOI 10.1016/0022-1759(95)00023-4; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCOTT CF, 1993, J BIOL CHEM, V268, P7935; Serveau C, 1996, BIOCHEM J, V313, P951, DOI 10.1042/bj3130951; SHIMAMOTO K, 1978, J LAB CLIN MED, V91, P721; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; STOKA V, 1995, FEBS LETT, V370, P101, DOI 10.1016/0014-5793(95)00798-E; TARDIEUX I, 1994, J EXP MED, V179, P1017, DOI 10.1084/jem.179.3.1017; VERNET T, 1993, PROTEIN ENG, V6, P213, DOI 10.1093/protein/6.2.213; WEBSTER ME, 1970, METHOD ENZYMOL, V19, P681; [No title captured]	43	97	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25713	25718		10.1074/jbc.272.41.25713	http://dx.doi.org/10.1074/jbc.272.41.25713			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325296	hybrid			2022-12-25	WOS:A1997YA35800051
J	Manes, S; Mira, E; Barbacid, MD; Cipres, A; FernandezResa, P; Buesa, JM; Merida, I; Aracil, M; Marquez, G; Martinez, C				Manes, S; Mira, E; Barbacid, MD; Cipres, A; FernandezResa, P; Buesa, JM; Merida, I; Aracil, M; Marquez, G; Martinez, C			Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; IGF-I; MATRIX METALLOPROTEINASES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; MOUSE STROMELYSIN-3; BIOLOGICAL ACTIONS; CELLS; TUMOR	To elucidate the physiological role of human stromelysin-3 (hST-3) in tumor progression and/or wound healing, insulin-like growth factor-binding protein-1 (IGFBP-1) was analyzed as a potential physiological substrate. hST-3 proteolysis generates two fragments of 16 and 9 kDa that react with IGFBP-1 monoclonal antibody, although they do not bind insulin-like growth factor-I (IGF-I) in ligand blot. N-terminal sequencing shows that hST-3 cleaves IGFBP-1 at the His(140)-Val(141) bond located in the IGFBP-1 midregion. We show that IGFBP-1 inhibits IGF-I-induced survival and proliferation of BAF/3 cells, as well as IGF-I-mediated activation of phosphatidylinositol 3-kinase (PI 3-K). Co-incubation of the IGF-I . IGFBP-1 complex with hST-3 restores IGF-I-induced proliferation and PI 3-K kinase activity in these cells. BAF/3 proliferation is significantly increased with the hST-3-treated IGF-I . IGFBP-1 complex compared with that obtained using IGF-I alone. To produce this enhanced proliferation, IGF-I must bind to IGFBP-1 before hST-3 proteolysis, demonstrated using an IGF-I variant that does not bind IGFBP. IGFBP-1 also inhibits IGF-I-induced proliferation of the MCF-7 breast adenocarcinoma, and this inhibition was not seen in hST-3-transfected MCF-7 cells. Such proteolysis may thus play a role in in vivo tumor progression. These results indicate that hST-3 may regulate IGF-I bioavailability by proteolyzing IGFBP, thus favoring cell survival and proliferation.			Manes, S (corresponding author), UNIV AUTONOMA MADRID,CSIC,CTR NACL BIOTECNOL,DEPT IMMUNOL & ONCOL,CAMPUS CANTOBLANCO,E-28049 MADRID,SPAIN.		Merida, Isabel/A-9713-2014; Ciprés, Ángel/ABH-6863-2020; Manes, Santos/E-4725-2011; MIRA, EMILIA/K-2456-2014	Merida, Isabel/0000-0003-2762-6241; MIRA, EMILIA/0000-0002-4226-1829; Manes, Santos/0000-0001-8023-957X; Cipres, Angel/0000-0001-7086-2704				ADASHI EY, 1992, J CLIN INVEST, V90, P15933; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BLAT C, 1994, J CLIN INVEST, V93, P2286, DOI 10.1172/JCI117229; CAMACHOHUBNER C, 1991, J CELL PHYSIOL, V148, P281, DOI 10.1002/jcp.1041480214; CAMPBELL PG, 1992, ENDOCRINOLOGY, V130, P1401, DOI 10.1210/en.130.3.1401; CLEMMONS DR, 1993, ANN NY ACAD SCI, V692, P10; CLEMMONS DR, 1992, INSULIN LIKE GROWTH; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; COHEN P, 1994, J ENDOCRINOL, V142, P407, DOI 10.1677/joe.0.1420407; CONOVER CA, 1995, J CLIN ENDOCR METAB, V80, P987, DOI 10.1210/jc.80.3.987; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CONOVER CA, 1995, J BIOL CHEM, V270, P4395, DOI 10.1074/jbc.270.9.4395; deTuriso JAL, 1996, J BIOTECHNOL, V46, P235, DOI 10.1016/0168-1656(96)00002-8; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; ENGEL G, 1994, INT J CANCER, V58, P830, DOI 10.1002/ijc.2910580614; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; FIELDER PJ, 1994, GROWTH REGULAT, V1, P164; Flaumenhaft R, 1991, CURR OPIN CELL BIOL, V3, P817, DOI 10.1016/0955-0674(91)90055-4; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; FOWLKES JL, 1994, ENDOCRINOLOGY, V135, P2810, DOI 10.1210/en.135.6.2810; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Galiano RD, 1996, J CLIN INVEST, V98, P2462, DOI 10.1172/JCI119064; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Lalou C, 1996, ENDOCRINOLOGY, V137, P3206, DOI 10.1210/en.137.8.3206; LAMSON G, 1993, GROWTH REGULAT, V3, P91; Manes S, 1997, ENDOCRINOLOGY, V138, P905, DOI 10.1210/en.138.3.905; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MERIDA I, 1991, J IMMUNOL, V147, P2202; MURPHY G, 1993, J BIOL CHEM, V268, P15435; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; OH Y, 1993, J BIOL CHEM, V268, P26045; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Quesada AR, 1997, CLIN EXP METASTAS, V15, P26; Rajah R, 1996, ENDOCRINOLOGY, V137, P2676, DOI 10.1210/en.137.7.2676; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHIMASAKI S, 1991, PROG GROWTH FACTOR R, V51, P5107; SINGH P, 1994, CANCER RES, V54, P6563; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WOFSY L, 1983, METHOD ENZYMOL, V92, P472; WOLF C, 1992, J INVEST DERMATOL, V99, P870, DOI 10.1111/1523-1747.ep12614846; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337	56	158	166	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25706	25712		10.1074/jbc.272.41.25706	http://dx.doi.org/10.1074/jbc.272.41.25706			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325295	hybrid			2022-12-25	WOS:A1997YA35800050
J	Solanes, G; VidalPuig, A; Grujic, D; Flier, JS; Lowell, BB				Solanes, G; VidalPuig, A; Grujic, D; Flier, JS; Lowell, BB			The human uncoupling protein-3 gene - Genomic structure, chromosomal localization, and genetic basis for short and long form transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; MULTIFACTORIAL MOUSE MODEL; SKELETAL-MUSCLE; OBESITY; THERMOGENESIS; FAT; EPINEPHRINE; EXPRESSION; MECHANISM; EVOLUTION	Uncoupling protein-3 (UCP3) is a recently identified candidate mediator of adaptive thermogenesis in humans. Unlike UCP1 and UCP2, UCP3 is expressed preferentially and at high levels in human skeletal muscle and exists as short and long form transcripts, UCP3(S) and UCP3(L). UCP3(S) is predicted to encode a protein which lacks the last 37 C-terminal residues of UCP3(L). In the present study, we have defined the intron-exon structure for the human UCP3 gene and determined that UCP3(S) is generated when a cleavage and polyadenylation signal (AATAAA) located in the last intron prematurely terminates message elongation. In addition we have mapped UCP3 to the distal segment of human chromosome 11q13 (between framework markers D11S916 and D11S911), adjacent to UCP2. Of note, UCP2 and UCP3 in both mice and humans colocalize in P1 and BAC genomic clones indicating that these two UCPs are located within 75-150 kilobases of each other and most likely resulted from a gene duplication event. Previous studies have noted that mouse UCP2 maps to a region of chromosome 7 which is coincident with three independently mapped quantitative trait loci for obesity. Our study shows that UCP3 is also coincident with these quantitative trait loci raising the possibility that abnormalities in UCP3 are responsible for obesity in these models.	BETH ISRAEL DEACONESS MED CTR,DIV ENDOCRINOL,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Flier, jeffrey/AAG-6223-2019	Vidal-Puig, Antonio/0000-0003-4220-9577	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049569, K08DK002119, R37DK053477] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49569, DK02119, R37 DK053477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASTRUP A, 1985, AM J PHYSIOL, V248, pE507, DOI 10.1152/ajpendo.1985.248.5.E507; ASTRUP A, 1989, AM J PHYSIOL, V257, pE340, DOI 10.1152/ajpendo.1989.257.3.E340; Beales PL, 1997, J MED GENET, V34, P92, DOI 10.1136/jmg.34.2.92; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOUILLAUD F, 1994, EMBO J, V13, P1990, DOI 10.1002/j.1460-2075.1994.tb06468.x; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; Bruford EA, 1997, GENOMICS, V41, P93, DOI 10.1006/geno.1997.4613; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; LEPPERT M, 1994, NAT GENET, V7, P108, DOI 10.1038/ng0594-108; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; MICHELSON AM, 1983, J BIOL CHEM, V258, P5245; MURDZAINGLIS DL, 1994, J BIOL CHEM, V269, P7435; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; RAVUSSIN E, 1996, DIABETES REV, V4, P403; SELDIN MF, 1994, J CLIN INVEST, V94, P269, DOI 10.1172/JCI117317; SIMONSEN L, 1992, AM J PHYSIOL, V263, pE850, DOI 10.1152/ajpendo.1992.263.5.E850; SPRAUL M, 1993, J CLIN INVEST, V92, P1730, DOI 10.1172/JCI116760; Taylor BA, 1996, GENOMICS, V34, P389, DOI 10.1006/geno.1996.0302; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WARDEN CH, 1993, J CLIN INVEST, V92, P773, DOI 10.1172/JCI116649; WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827; WHITE PC, 1992, J CLIN ENDOCR METAB, V74, P6, DOI 10.1210/jc.74.1.6; ZURLO F, 1990, J CLIN INVEST, V86, P1423, DOI 10.1172/JCI114857	34	176	187	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25433	25436		10.1074/jbc.272.41.25433	http://dx.doi.org/10.1074/jbc.272.41.25433			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325252	hybrid			2022-12-25	WOS:A1997YA35800007
J	Langlois, MF; Zanger, K; Monden, T; Safer, JD; Hollenberg, AN; Wondisford, FE				Langlois, MF; Zanger, K; Monden, T; Safer, JD; Hollenberg, AN; Wondisford, FE			A unique role of the beta-2 thyroid hormone receptor isoform in negative regulation by thyroid hormone - Mapping of a novel amino-terminal domain important for ligand-independent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE PROMOTER ACTIVITY; RESPONSE ELEMENTS; SUBUNIT GENE; CO-REPRESSOR; TRANSCRIPTIONAL ACTIVATION; STRUCTURAL-ANALYSIS; VARIANT ALPHA-2; BINDING-SITES; RETINOIC ACID; HALF-SITE	Negative regulation by thyroid hormone is mediated by nuclear thyroid hormone receptors (TRs) acting on thyroid hormone response elements (TREs). We examine here the role of human TR-beta 2, a TR isoform with central nervous system-restricted expression, in the regulation of target genes whose expression are decreased by tri-iodothyronine (T-3), Using transient transfection studies, we found that TR-beta 2 achieved significantly greater ligand-independent activation on the thyrotropin-releasing hormone (TRH) and common glycoprotein alpha-subunit genes than either TR-beta 1 or TR-alpha 1. A chimeric TR-beta isoform containing the TR-beta 2 amino terminus linked to the TR-beta 2 DNA-and ligand-binding domains functioned like the TR-beta 2 isoform on these promoters, confirming that the amino terminus of TR-beta 2 was both necessary and sufficient to mediate this effect. By constructing deletion mutants of the TR-beta 2 amino terminus, we demonstrate that amino acids 89-116 mediate this function. This domain, important in ligand-independent activation on negative TREs, is discrete from a previously described activation domain in the amino-terminal portion of TR-beta 2. We conclude that the central nervous system-restricted TR-beta 2 isoform has a unique effect on negative regulation by T-3 that can be mapped to amino acids 89-116 of the amino terminus of the human TR-beta 2.	BETH ISRAEL DEACONESS MED CTR, THYROID UNIT, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002354, R29DK043653] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43653, DK-02354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BREATHNACH R, 1983, NUCLEIC ACIDS RES, V11, P7119, DOI 10.1093/nar/11.20.7119; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARR FE, 1989, MOL ENDOCRINOL, V3, P709, DOI 10.1210/mend-3-4-709; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COHEN O, 1995, J BIOL CHEM, V270, P13899, DOI 10.1074/jbc.270.23.13899; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; FENG P, 1994, BIOCHEM BIOPH RES CO, V200, P171, DOI 10.1006/bbrc.1994.1430; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATZ D, 1993, J BIOL CHEM, V268, P20904; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KRISHNA V, 1991, J CLIN INVEST, V87, P1977, DOI 10.1172/JCI115225; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LECHAN RM, 1994, ENDOCRINOLOGY, V135, P92, DOI 10.1210/en.135.1.92; LECHAN RM, 1993, ENDOCRINOLOGY, V132, P2461, DOI 10.1210/en.132.6.2461; Li M, 1996, ENDOCRINOLOGY, V137, P1272, DOI 10.1210/en.137.4.1272; LIU RT, 1995, MOL ENDOCRINOL, V9, P86, DOI 10.1210/me.9.1.86; Maia AL, 1996, THYROID, V6, P325, DOI 10.1089/thy.1996.6.325; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; NG L, 1995, MOL ENDOCRINOL, V9, P1202, DOI 10.1210/me.9.9.1202; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; ONATE SA, 1995, SCIENCE, V270, P1354; RINDT H, 1995, P NATL ACAD SCI USA, V92, P1540, DOI 10.1073/pnas.92.5.1540; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Safer JD, 1997, MOL ENDOCRINOL, V11, P16, DOI 10.1210/me.11.1.16; SAKURAI A, 1990, MOL CELL ENDOCRINOL, V71, P83; SAKURAI A, 1989, MOL ENDOCRINOL, V3, P392, DOI 10.1210/mend-3-2-392; Satoh T, 1996, J BIOL CHEM, V271, P27919, DOI 10.1074/jbc.271.44.27919; SCHWARTZ HL, 1994, J BIOL CHEM, V269, P24777; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; SURKS MI, 1973, J BIOL CHEM, V248, P7066; THOMPSON KL, 1992, MOL ENDOCRINOL, V6, P627, DOI 10.1210/me.6.4.627; TomicCanic M, 1996, J BIOL CHEM, V271, P1416, DOI 10.1074/jbc.271.3.1416; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YEN PM, 1991, ENDOCRINOLOGY, V129, P3331, DOI 10.1210/endo-129-6-3331; Zavacki AM, 1996, ENDOCRINOLOGY, V137, P1438, DOI 10.1210/en.137.4.1438	52	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24927	24933		10.1074/jbc.272.40.24927	http://dx.doi.org/10.1074/jbc.272.40.24927			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312095	hybrid			2022-12-25	WOS:A1997XY97000034
J	Murata, T; Takase, K; Yamato, I; Igarashi, K; Kakinuma, Y				Murata, T; Takase, K; Yamato, I; Igarashi, K; Kakinuma, Y			Purification and reconstitution of Na+-translocating vacuolar ATPase from Enterococcus hirae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-FAECALIS; H+-ATPASE; EVOLUTION; SUBUNIT; GENE; COMPONENT; TRANSPORT; SEQUENCE; ARCHAEON; CELLS	Vacuolar ATPases make up a family of proton pumps distributed widely from bacteria to higher organisms. An unusual member of this family, a sodium-translocating ATPase, has been found in the eubacterium Enterococcus hirae. We report here the purification of enterococcal Na+-ATPase from the plasma membrane of cells, whose ATPase content was highly amplified by expression of the cloned ntp operon that encodes this Na+-ATPase (ntpFIKECGABDHJ). The purified enzyme appears to consist of nine Ntp polypeptides, all the above except for the ntpH and ntpJ gene products. ATPase activity was strictly dependent on the presence of Na+ or Li+ ions and was inhibited by nitrate, N-ethylmaleimide, and the peptide antibiotic destruxin B. When the purified ATPase was reconstituted into liposomes prepared from Enterococcus faecalis phospholipids, ATP-driven Na+ uptake was observed; uptake was blocked by nitrate, destruxin B, and monensin, but it accelerated by carbonyl cyanide m-chlorophenylhydrazone and valinomycin. These data demonstrate that E. hirae Na+-ATPase is an electrogenic sodium pump of the vacuolar type. This is a promising system for research on the fundamental molecular structure and mechanism of vacuolar ATPase.	CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN; SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,INAGE KU,NODA,CHIBA 278,JAPAN	Chiba University; Tokyo University of Science			Murata, Takeshi/F-6114-2011; Murata, Takeshi/J-6181-2017	Murata, Takeshi/0000-0002-5748-4670; Igarashi, Kazuei/0000-0003-3751-3187				ABRAMS A, 1985, ENZYMES BIOL MEMBR, V4, P177; ANRAKU Y, 1996, HDB BIOL PHYSICS, P93; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HANADA K, 1988, J BIOL CHEM, V263, P7181; HARVEY WR, 1992, J EXP BIOL, V172, P1; HEEFNER DL, 1982, P NATL ACAD SCI-BIOL, V79, P2798, DOI 10.1073/pnas.79.9.2798; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; KAKINUMA Y, 1990, J BACTERIOL, V172, P1732, DOI 10.1128/jb.172.4.1732-1735.1990; KAKINUMA Y, 1989, J BIOENERG BIOMEMBR, V21, P679, DOI 10.1007/BF00762686; KAKINUMA Y, 1985, J BIOL CHEM, V260, P2086; KAKINUMA Y, 1994, J BIOCHEM-TOKYO, V116, P1302, DOI 10.1093/oxfordjournals.jbchem.a124679; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; KAKINUMA Y, 1990, FEBS LETT, V271, P102, DOI 10.1016/0014-5793(90)80382-S; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KANE PM, 1989, J BIOL CHEM, V264, P19236; KOBAYASHI H, 1978, J BIOL CHEM, V253, P2085; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Murata T, 1996, J BIOL CHEM, V271, P10042, DOI 10.1074/jbc.271.17.10042; Murata T, 1996, J BIOL CHEM, V271, P23661, DOI 10.1074/jbc.271.39.23661; MUROI M, 1994, BIOCHEM BIOPH RES CO, V205, P1358, DOI 10.1006/bbrc.1994.2815; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; PENG SB, 1994, J BIOL CHEM, V269, P11356; SCHAFER G, 1992, ANN NY ACAD SCI, V671, P293, DOI 10.1111/j.1749-6632.1992.tb43804.x; SOLIOZ M, 1990, BIOCHIMIE, V72, P279, DOI 10.1016/0300-9084(90)90084-T; STEVENS TH, 1992, J EXP BIOL, V172, P47; TAKASE K, 1993, J BIOL CHEM, V268, P11610; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Wilms R, 1996, J BIOL CHEM, V271, P18843, DOI 10.1074/jbc.271.31.18843	35	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24885	24890		10.1074/jbc.272.40.24885	http://dx.doi.org/10.1074/jbc.272.40.24885			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312089	hybrid			2022-12-25	WOS:A1997XY97000028
J	Vitale, N; Moss, J; Vaughan, M				Vitale, N; Moss, J; Vaughan, M			Characterization of a GDP dissociation inhibitory region of ADP-ribosylation factor domain protein ARD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; NUCLEOTIDE-EXCHANGE PROTEIN; GUANINE-NUCLEOTIDE; BREFELDIN-A; CHOLERA-TOXIN; BINDING-PROTEIN; AMINO-TERMINUS; FACTOR ARF; FACTOR-I; GOLGI	ADP-ribosylation factors (ARFs) are similar to 20-kDa guanine nucleotide-binding proteins initially identified by their ability to stimulate cholera toxin ADP ribosyltransferase activity and later recognized as critical components in intracellular vesicular transport and phospholipase D activation, ARF domain protein 1 (ARD1) is a member of the ARF family that differs from other ARFs by the presence of a 46-kDa amino-terminal extension, We previously reported that this extension acts as a GTPase-activating protein for the ARF domain of ARD1 (Vitale, N., Moss, J., and Vaughan, M. (1996) Proc, Natl, Acad, Sci. U. S. A. 93, 1941-1944), Both GTP binding and GTP hydrolysis are necessary for physiological function of guanine nucleotide binding proteins, and the rates of GDP/GTP exchange and GTPase activity are critical in the activation/deactivation cycle. Dissociation of GDP from the ARF domain of ARD1 was faster than from ARD1 itself (both proteins synthesized in Escherichia coli). Using deletion mutations, it was demonstrated that the 15 amino acids directly preceding the ARF domain were responsible for decreasing the rate of GDP dissociation but not guanosine 5-[gamma-thio]triphosphate dissociation, By site specific mutagenesis it was shown that hydrophobic amino acids in this region were particularly important in stabilizing the GDP-bound form of ARD1. It is suggested that, Like the amino-terminal segment of ARF, the equivalent region in ARD1, located between the GTPase activating protein and ARF domains, may act as a GDP dissociation inhibitor.			Vitale, N (corresponding author), NHLBI,PULM CRIT CARE MED BRANCH,NIH,RM 5N-307,BLDG 10,10 CTR DR,MSC 1434,BETHESDA,MD 20892, USA.		Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907				Acharya S, 1996, J BIOL CHEM, V271, P25406, DOI 10.1074/jbc.271.41.25406; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HONG JX, 1995, P NATL ACAD SCI USA, V92, P3056, DOI 10.1073/pnas.92.7.3056; HONG JX, 1994, J BIOL CHEM, V269, P9743; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; TSAI SC, 1993, J BIOL CHEM, V268, P10820; Vitale N, 1997, J BIOL CHEM, V272, P3897, DOI 10.1074/jbc.272.7.3897; Vitale N, 1996, P NATL ACAD SCI USA, V93, P1941, DOI 10.1073/pnas.93.5.1941; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	35	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25077	25082		10.1074/jbc.272.40.25077	http://dx.doi.org/10.1074/jbc.272.40.25077			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312116	hybrid			2022-12-25	WOS:A1997XY97000055
J	DeFlora, S; Izzotti, A; Walsh, D; Degan, P; Petrilli, GL; Lewtas, J				DeFlora, S; Izzotti, A; Walsh, D; Degan, P; Petrilli, GL; Lewtas, J			Molecular epidemiology of atherosclerosis	FASEB JOURNAL			English	Article						aging; dyslipidosis; cigarette smoke; hypertension; smooth muscle cells; DNA adducts; oxidative DNA damage	SMOOTH-MUSCLE CELLS; OXIDATIVE DNA-DAMAGE; CANCER BIOMARKERS; ADDUCT FORMATION; ARTERIAL-WALL; IN-VIVO; BENZO<A>PYRENE; PROLIFERATION; RAT; PLAQUES	It has been hypothesized that mutational events may be involved in the atherogenetic process and that at least a portion of atherosclerotic plaques may develop according to an initiation-promotion process of arterial smooth muscle cells, akin to benign tumors. We conducted a study to evaluate the occurrence of oxidative DNA damage and formation of DNA adducts in human atherosclerotic lesions and to assess the relationships of these promutagenic alterations with exposure to atherogenic risk factors. Pure DNA was extracted from the tunica media (composed mainly of smooth muscle cells) of abdominal aorta fragments taken at surgery from 85 patients suffering from severe atherosclerotic lesions. DNA adducts were detected by synchronous fluorescence spectrophotometry and P-32 postlabeling after enrichment of adducts with either butanol or nuclease P1. 8-Hydroxy-2'-deoxguanosine (8-OH-dG), a typical indicator of oxidative DNA damage, was measured by HPLC/electrochemical detection. A complete questionnaire reporting general, clinical, and laboratory characteristics was available for each patient. All 84 samples tested by P-32 postlabeling were positive by displaying the presence of diagonal radioactive zones and up to 9 individual DNA adducts. Of 52 samples tested, 32 (61.5%) yielded typical positive signals at synchronous fluorescence spectrophotometry. All but one of 39 samples tested had very high levels of 8-OH-dG, thus showing a remarkable oxidative DNA damage. Statistically significant correlations were found between the levels of molecular biomarkers and atherogenic risk factors including age, number of currently smoked cigarettes, ratio of total-to-high density lipoprotein blood cholesterol, blood triglycerides, and blood pressure. The DNA alterations detected in our study may be only one component of the genetic basis of atherogenesis. Moreover, no causal role in the atherogenetic process can be inferred from our results. However, DNA alterations, including oxidative damage and adduction of reactive molecules of either endogenous or exogenous source, were systematically present in the smooth muscle cells of human atherosclerotic lesions and their intensity was significantly correlated with the occurrence of atherogenic risk factors in the patients.	UNIV GENOA, INST HYG & PREVENT MED, I-16132 GENOA, ITALY; US EPA, EPIDEMIOL & BIOMARKER BRANCH, RES TRIANGLE PK, NC 27711 USA; GALLIERA HOSP, DIV VASC SURG, GENOA, ITALY; NATL INST CANC RES, GENOA, ITALY	University of Genoa; United States Environmental Protection Agency; Ente Ospedaliero Ospedali Galliera; University of Genoa; IRCCS AOU San Martino IST			degan, paolo/AAB-6713-2019; degan, paolo/AAB-4093-2019	degan, paolo/0000-0003-0855-8896; izzotti, alberto/0000-0002-8588-0347				AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; [Anonymous], 1984, ARCH INTERN MED, V144, P1045; Baik SC, 1996, CANCER RES, V56, P1279; BASHIR S, 1993, ANN RHEUM DIS, V52, P659, DOI 10.1136/ard.52.9.659; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; Bogliolo M, 1996, CHEM-BIOL INTERACT, V102, P55, DOI 10.1016/0009-2797(96)03731-3; BOND JA, 1979, LIFE SCI, V25, P425, DOI 10.1016/0024-3205(79)90574-5; BRIDGES B A, 1990, Mutation Research, V239, P143, DOI 10.1016/0165-1110(90)90002-S; BURCHFIEL CM, 1995, CIRCULATION, V92, P1430, DOI 10.1161/01.CIR.92.6.1430; BUSBEE DL, 1982, CARCINOGENESIS, V3, P1107, DOI 10.1093/carcin/3.10.1107; CHOBANIAN AV, 1990, HYPERTENSION, V15, P666, DOI 10.1161/01.HYP.15.6.666; CLAUSEN J, 1993, CANCER LETT, V72, P163, DOI 10.1016/0304-3835(93)90123-Q; CRAWFORD DW, 1991, ATHEROSCLEROSIS, V89, P97, DOI 10.1016/0021-9150(91)90049-9; DAGOSTINI F, 1995, CANCER EPIDEM BIOMAR, V4, P111; DEGAN P, 1995, CARCINOGENESIS, V16, P735, DOI 10.1093/carcin/16.4.735; DEGAN P, 1991, CARCINOGENESIS, V12, P865, DOI 10.1093/carcin/12.5.865; Duthie G G, 1989, Nutr Res Rev, V2, P51, DOI 10.1079/NRR19890007; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943; GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081; HANSEN ES, 1990, MUTAT RES, V239, P163, DOI 10.1016/0165-1110(90)90004-U; HOGG SI, 1982, COMP BIOCHEM PHYS B, V73, P669, DOI 10.1016/0305-0491(82)90094-3; IMAI H, 1980, SCIENCE, V207, P651, DOI 10.1126/science.7352277; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; International Agency for Research on Cancer, 1986, IARC MON EV CARC RIS, V38; IZZOTTI A, 1994, CANCER RES, V54, pS1994; IZZOTTI A, 1991, CARCINOGENESIS, V12, P1281, DOI 10.1093/carcin/12.7.1281; IZZOTTI A, 1995, CANCER EPIDEM BIOMAR, V4, P105; IZZOTTI A, 1992, CARCINOGENESIS, V13, P2187, DOI 10.1093/carcin/13.11.2187; KANNEL WB, 1981, AM HEART J, V101, P319, DOI 10.1016/0002-8703(81)90197-6; KENDALL CW, 1992, CANCER LETT, V66, P241, DOI 10.1016/0304-3835(92)90253-R; LEWTAS J, 1995, P 86 ANN M AM ASS CA, V36, P652; LEWTAS J, 1993, ENV HLTH PERSPECT, V99, P88; MAJESKY MW, 1985, P NATL ACAD SCI USA, V82, P3450, DOI 10.1073/pnas.82.10.3450; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; OU X, 1995, ARCH BIOCHEM BIOPHYS, V760, P354; PAIGEN B, 1986, CANCER RES, V46, P3321; PARK JW, 1992, FREE RADICAL BIO MED, V12, P245, DOI 10.1016/0891-5849(92)90111-S; PARKES JL, 1991, AM J PATHOL, V138, P765; PENG SK, 1978, ARCH PATHOL LAB MED, V102, P57; PENN A, 1986, P NATL ACAD SCI USA, V83, P7951, DOI 10.1073/pnas.83.20.7951; PENN A, 1991, ARTERIOSCLER THROMB, V11, P1053, DOI 10.1161/01.ATV.11.4.1053; PENN A, 1988, CARCINOGENESIS, V9, P2185, DOI 10.1093/carcin/9.12.2185; RAMOS KS, 1996, CASARETT DOULLS TOXI, P487; RANDERATH E, 1989, J NATL CANCER I, V81, P341, DOI 10.1093/jnci/81.5.341; RANDERATH E, 1994, DIETARY RESTRICTION, P299; RANDERATH K, 1995, MCBU, P77; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, AM J PATHOL, V143, P987; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SEVANIAN A, 1986, FOOD CHEM TOXICOL, V24, P1103, DOI 10.1016/0278-6915(86)90295-4; SHIMODA R, 1994, CANCER RES, V54, P3171; Smith LL, 1981, CHOLESTEROL AUTOXIDA, P49; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P5397, DOI 10.1073/pnas.91.12.5397; TROSKO JE, 1980, MED HYPOTHESES, V6, P455, DOI 10.1016/0306-9877(80)90098-5; VAHAKANGAS K, 1988, IARC SCI PUBL, V89, P208; *WHO, 1985, WHO TECH REP SERV, V143, P1; YOSHIDA Y, 1990, ANN NY ACAD SCI, V598, P256, DOI 10.1111/j.1749-6632.1990.tb42298.x; Zhang Y, 1997, MUTAT RES-FUND MOL M, V373, P285, DOI 10.1016/S0027-5107(96)00213-8; ZWIJSEN RML, 1992, CARCINOGENESIS, V13, P1913, DOI 10.1093/carcin/13.10.1913; ZWIJSEN RML, 1990, MUTAT RES, V230, P111, DOI 10.1016/0027-5107(90)90048-9	63	132	135	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1997	11	12					1021	1031		10.1096/fasebj.11.12.9337155	http://dx.doi.org/10.1096/fasebj.11.12.9337155			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337155				2022-12-25	WOS:A1997YA72400012
J	Marrero, MB; Schieffer, B; Li, B; Sun, JM; Harp, JB; Ling, BN				Marrero, MB; Schieffer, B; Li, B; Sun, JM; Harp, JB; Ling, BN			Role of Janus kinase signal transducer and activator of transcription and mitogen-activated protein kinase cascades in angiotensin II- and platelet-derived growth factor-induced vascular smooth muscle cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; RECEPTOR; JAK2; PP60(C-SRC); PATHWAY	In vascular smooth muscle cells, the induction of early growth response genes involves the janus kinase (JAK)/signal transducer and activators of transcription (STAT) and the Ras/Raf-1/mitogen-activated protein kinase cascades. In the present study, we found that electroporation of antibodies against MEH1 or ERK1 abolished vascular smooth muscle cell proliferation in response to either platelet-derived growth factor or angiotensin II, However, anti-STAT1 or -STAT3 antibody electroporation abolished proliferative responses only to angiotensin II and not to platelet-derived growth factor, AG-490, a specific inhibitor of the JAK2 tyrosine kinase, prevented proliferation of vascular smooth muscle cells, complex formation between JAK2 and Raf-1, the tyrosine phosphorylation of Raf-1, and the activation of ERK1 in response to either angiotensin II or platelet-derived growth factor. However AG-490 had no effect on angiotensin II- or platelet-derived growth factor-induced Ras/Raf-1 complex formation, Our results indicate that: 1) STAT proteins play an essential role in angiotensin II-induced vascular smooth muscle cell proliferation, 2) JAK2 plays an essential role in the tyrosine phosphorylation of Raf-1, and 3) convergent mitogenic signaling cascades involving the cytosolic kinases JAK2, MEK1, and ERK1 mediate vascular smooth muscle cell proliferation in response to both growth factor and G protein-coupled receptors.	EMORY UNIV,SCH MED,DEPT PATHOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT MED,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DIV RENAL,ATLANTA,GA 30322; VET AFFAIRS MED CTR,ATLANTA,GA 30322; UNIV FREIBURG,MED KLIN 3,D-7800 FREIBURG,GERMANY	Emory University; Emory University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; University of Freiburg	Marrero, MB (corresponding author), EMORY UNIV,SCH MED,CTR CELL & MOL SIGNALLING,079 PHYSIOL BLDG,1648 PIERCE DR NE,ATLANTA,GA 30322, USA.				NIDDK NIH HHS [DK-02111, P01-DK50268] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050268, K08DK002111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bernstein KE, 1996, TRENDS CARDIOVAS MED, V6, P179, DOI 10.1016/S1050-1738(96)00053-9; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DHAR A, 1994, J BIOL CHEM, V269, P9123; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Marrero MB, 1996, AM J PHYSIOL-CELL PH, V270, pC1834, DOI 10.1152/ajpcell.1996.270.6.C1834; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MARRERO MB, 1996, J MOL MED, V74, P85; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; WANG XY, 1995, J BIOL CHEM, V270, P27999; Wilmer WA, 1997, J BIOL CHEM, V272, P10877; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681	25	203	216	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24684	24690		10.1074/jbc.272.39.24684	http://dx.doi.org/10.1074/jbc.272.39.24684			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305939	hybrid			2022-12-25	WOS:A1997XY51500090
J	Gritti, C; Choukroun, V; Soulier, J; Madani, A; Dastot, H; Leblond, V; RadfordWeiss, I; Valensi, F; Varet, B; Sigaux, F; Stern, MH				Gritti, C; Choukroun, V; Soulier, J; Madani, A; Dastot, H; Leblond, V; RadfordWeiss, I; Valensi, F; Varet, B; Sigaux, F; Stern, MH			Alternative origin of p13(MTCP1)-encoding transcripts in mature T-cell proliferations with t(X;14) translocations	ONCOGENE			English	Article						MTCP1; TCL1; alternative promoter T-cell prolymphocytic leukemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; ATAXIA-TELANGIECTASIA; PROLYMPHOCYTIC LEUKEMIA; GENE; CHROMOSOME; EXPRESSION; ONCOGENE; MTCP-1; ABNORMALITIES; MALIGNANCIES	The MTCP1 gene is involved in the t(X;14)(q28;q11) translocation associated with T-cell prolymphocytic leukemia and related conditions. This gene is unusual in that it codes for two distinct proteins: a small mitochondrial protein, p8(MTCP1), putative oncogenic protein, p13(MTCP1). Scarcity of material from t(X;14)-associated proliferations and very low levels of mRNA expression have so far prevented a thorough description of p13(MTCP1)-encoding transcripts. Here, we characterize two additional t(X;14) bearing leukemias allowing this analysis. In one case, with a breakpoint located 5' to the MTCP1 gene, the level of transcription of previously described p13(MTCP1)-encoding transcripts is enhanced. In the second case, with a breakpoint within the MTCP1 intron I, an alternative transcription initiation site is demonstrated in the tumor cells at 229 bp upstream to exon II. The identification of this internal promoter, together with the similarity between TCL1 and MTCP1 genomic structures, allow us to propose a model in which the duplication of an ancestral gene was followed by the insertion of one copy within the intron of a p8-encoding gene, accounting for the unusual feature of the MTCP1 gene.	HOP ST LOUIS, INSERM U462, CTR HAYEM, F-75475 PARIS 10, FRANCE; HOP LA PITIE SALPETRIERE, DEPT HEMATOL, F-75631 PARIS 13, FRANCE; HOP NECKER ENFANTS MALAD, DEPT HEMATOL, F-75743 PARIS 15, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite			Stern, Marc-Henri/A-2728-2011	Stern, Marc-Henri/0000-0002-8100-2272				AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; BEATTY DW, 1986, S AFR MED J, V69, P115; CANKI N, 1983, ZDRAV VESTN, V52, P567; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALLAPICCOLA B, 1984, INT J CANCER, V34, P171, DOI 10.1002/ijc.2910340206; DURO D, 1995, ONCOGENE, V11, P21; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FISCH P, 1993, ONCOGENE, V8, P3271; FU TB, 1994, CANCER RES, V54, P6297; GOYNS MH, 1993, LEUKEMIA, V7, P848; LABARRIERE N, 1995, J BIOL CHEM, V270, P19205, DOI 10.1074/jbc.270.33.19205; MADANI A, 1995, ONCOGENE, V10, P2259; Madani A, 1996, BLOOD, V87, P1923; QUELLE DE, 1995, CELL, V83, P993; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOULIER J, 1994, ONCOGENE, V9, P3565; STERN MH, 1993, ONCOGENE, V8, P2475; TAYLOR AMR, 1981, INT J CANCER, V27, P311, DOI 10.1002/ijc.2910270309; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; THICK J, 1994, LEUKEMIA, V8, P564; Thick J, 1996, ONCOGENE, V12, P379; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; WITZIG TE, 1986, AM J HEMATOL, V21, P139, DOI 10.1002/ajh.2830210204	26	6	6	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1329	1335		10.1038/sj.onc.1201303	http://dx.doi.org/10.1038/sj.onc.1201303			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315101				2022-12-25	WOS:A1997XV84500011
J	Rarick, HM; Tu, XH; Solaro, RJ; Martin, AF				Rarick, HM; Tu, XH; Solaro, RJ; Martin, AF			The C terminus of cardiac troponin I is essential for full inhibitory activity and Ca2+ sensitivity of rat myofibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE FIBERS; CALCIUM-BINDING SITES; BIOLOGICAL-ACTIVITY; THIOL MUTANTS; COMPLEX; RABBIT; ACTIN; PEPTIDE; MUTATION; SEQUENCE	Although the C terminus of troponin I is known to be important in myofilament Ca2+ regulation in skeletal muscle, the regulatory function of this region of cardiac troponin I (cTnI) has not been defined. To address this question, the following recombinant proteins were expressed in Escherichia coli and purified: mouse wildtype cTnI (WT cTnI; 211 residues), cTnI-(1-199) (missing 12 residues), cTnI-(1-188) (missing 23 residues), and cTnI-(1-151) (missing 60 residues), The inhibitory activity of cTnI and the mutants was tested in myofibrils, from which cTnI.cTnC was extracted by exchanging endogenous cardiac troponin with exogenous cTnT causing the Ca2+ sensitivity of the myofibrils to be lost, Addition of increasing amounts of exogenous WT cTnI or cTnI-(1-199) to cTnT-treated myofibrils at pCa 8 caused a concentration-dependent inhibition of the maximum ATPase activity, However, cTnI-(1-188) and cTnI-(l-151) inhibited this activity to about 75% and 50% of that of the WT cTnI, respectively, We also formed a complex of either WT cTnI or each of the mutants with cTnC, reconstituted the complex into the cTnT-treated myofibrils, and measured the Mg2+-ATPase activity as a function of pCa, We found that the cTnI-(1-188).cTnC complex only partially restored Ca2+ sensitivity, whereas the cTnI-(1-151).cTnC complex did not restore any Ca2+ sensitivity, Each cTnI C terminal deletion mutant was able to bind to cTnC, as shown by urea-polyacrylamide gel-shift analysis and size exclusion chromatography, Each mutant also co-sedimented with actin, Our results indicate that residues 152-199 (C-terminal to the inhibitory re gion) of cTnI are essential for full inhibitory activity and Ca2+ sensitivity of myofibrillar ATPase activity in the heart.			Rarick, HM (corresponding author), UNIV ILLINOIS,COLL MED MC901,DEPT PHYSIOL & BIOPHYS,835 S WOLCOTT AVE,CHICAGO,IL 60612, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049934, F32HL009009] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-49934, F32-HL-09009] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHANDRA M, 1997, IN PRESS BIOCHEMISTR; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6754, DOI 10.1021/bi9622276; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FARAH CS, 1994, J BIOL CHEM, V269, P5230; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GUO XD, 1994, J BIOL CHEM, V269, P15210; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; Jha PK, 1996, BIOCHEMISTRY-US, V35, P11026, DOI 10.1021/bi960406h; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; KLEERKOPER Q, 1995, BIOCHEMISTRY-US, V34, P13343, DOI 10.1021/bi00041a010; KOBAYASHI T, 1994, J BIOL CHEM, V269, P5725; KRUDY GA, 1994, J BIOL CHEM, V269, P23731; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NOZAKI S, 1980, CHEM LETT, V3, P345; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PAGANI ED, 1984, METHOD PHARMACOL, P49; Pan BS, 1996, J BIOL CHEM, V271, P817, DOI 10.1074/jbc.271.2.817; PAN BS, 1987, J BIOL CHEM, V262, P7839; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pearlstone JR, 1997, BIOCHEMISTRY-US, V36, P7601, DOI 10.1021/bi970200w; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; PUTKEY JA, 1991, J BIOL CHEM, V266, P14881; Rarick HM, 1996, J BIOL CHEM, V271, P27039, DOI 10.1074/jbc.271.43.27039; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Solaro R.J., 1995, PHYSL PATHOPHYSIOLOG, P355; SPYRACOPOULOS L, 1997, IN PRESS BIOCHEMISTR; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1989, BIOCHEMISTRY-US, V28, P5902, DOI 10.1021/bi00440a029; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VANEYK JE, 1993, FEBS LETT, V323, P223, DOI 10.1016/0014-5793(93)81344-Y; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; VANEYK JE, 1993, BIOCHEMISTRY-US, V30, P9974; WANG C, 1994, J MOL BIOL, V190, P509; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; Zhang R., 1995, Biophysical Journal, V68, pA165	48	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26887	26892		10.1074/jbc.272.43.26887	http://dx.doi.org/10.1074/jbc.272.43.26887			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341121	hybrid			2022-12-25	WOS:A1997YC65900017
J	Recio, JA; Aranda, A				Recio, JA; Aranda, A			Activation of the HIV-1 long terminal repeat by nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSCRIPTION FACTOR; TYPE-1 PROMOTER; GENE-EXPRESSION; FACTOR RECEPTOR; PC12 CELLS; IN-VITRO; PROTEIN; ENHANCER	The brain is an important target for the human immunodeficiency virus type 1 (HIV-1), We show here that nerve growth factor (NGF), which induces neuronal differentiation and survival, causes a strong activation of the HIV-1 long terminal repeat by a Ras/Raf-dependent mechanism in PC12 cells, Mutation of the kappa B sequences contained whithin the long terminal repeat reduces NGF-mediated stimulation, NGF does not activate NF-kappa B in PC12 cells, but rather increases binding of other nuclear factors to the kappa B sequences. Furthermore, a nuclear receptor response element contributes to the stimulatory effect of NGF, The retinoids receptors have been identified as components of the nuclear binding to the nuclear receptor response element in NGF-treated PC12 cells. These results reveal the importance of neurotrophins and nuclear receptor signaling pathways as specific activators of HIV-1 gene expression in neural cells.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Aranda, Ana/ABG-8820-2020	Aranda, Ana/0000-0002-8338-9589; Recio, Juan Angel/0000-0002-7320-3832				Bagetta G, 1996, P NATL ACAD SCI USA, V93, P928, DOI 10.1073/pnas.93.2.928; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CORBOY JR, 1992, SCIENCE, V258, P1804, DOI 10.1126/science.1465618; Cosgaya JM, 1996, ONCOGENE, V12, P2651; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DUBOISDALCQ M, 1995, CURR OPIN NEUROBIOL, V5, P647, DOI 10.1016/0959-4388(95)80071-9; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; LADIAS JAA, 1994, J BIOL CHEM, V269, P5944; LEE MO, 1994, P NATL ACAD SCI USA, V91, P5632, DOI 10.1073/pnas.91.12.5632; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; Sawaya BE, 1996, J BIOL CHEM, V271, P23572, DOI 10.1074/jbc.271.38.23572; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	27	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26807	26810		10.1074/jbc.272.43.26807	http://dx.doi.org/10.1074/jbc.272.43.26807			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341108	hybrid			2022-12-25	WOS:A1997YC65900004
J	Trejo, SR; Fahl, WE; Ratner, L				Trejo, SR; Fahl, WE; Ratner, L			The Tax protein of human T-cell leukemia virus type 1 mediates the transactivation of the c-sis/platelet-derived growth factor-B promoter through interactions with the zinc finger transcription factors Sp1 and NGFI-A/Egr-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; ELEMENT-BINDING PROTEIN; HORMONE-RELATED PROTEIN; SIMIAN SARCOMA-VIRUS; HTLV-I; GENE-EXPRESSION; ALPHA-AMANITIN; DNA-BINDING; 21-BASE-PAIR REPEATS; REGULATORY ELEMENTS	Transcriptional up-regulation of the c-sis/platelet-derived growth factor-B (PDGF-B) proto-oncogene by the Tax protein of human T cell leukemia virus type 1 has been implicated as one possible mechanism of cellular transformation by human T-cell leukemia virus type 1. In previous work, we identified an essential site in the c-sis/PDGF-B promoter, Tax-responsive element 1 (TRE1), necessary for transactivation by Tax. We also identified Sp1, Sp3, and NGFI-AIEgr-1 as the primary nuclear transcription factors binding to TRE1 which mediate Tax responsiveness. In the present work, we have investigated the mechanism(s) whereby Tax transactivates the c-sis/PDGF-B proto-oncogene. In vitro transcription assays showed that Tax was able to significantly increase the transcriptional activity of a template containing the -257 to +74 region of the c-sis/ PDGF-B promoter. Electrophoretic mobility shift assay analysis showed that Tax increased the DNA binding activity of both Spl and NGFI-A/Egr-1 using a TRE1 probe. Analysis of Tax mutants showed that two mutants, IEXC29S and IEXL320G, were unable to significantly transactivate the c-sis/PDGF-B promoter. Finally, co-immunoprecipitation analysis revealed that Tax is able to stably bind to both Spl and NGFI-A/Egr-1. Interestingly, co-immunoprecipitation analysis also revealed that Tax mutant IEXC29S is unable to interact with NGFI-A/Egr1, whereas Tax mutant IEXL320G is able to interact with NGFI-A/Egr-1.	WASHINGTON UNIV, SCH MED, DIV MOL ONCOL, ST LOUIS, MO 63110 USA; UNIV WISCONSIN, SCH MED, MCARDLE LAB CANC RES, MADISON, WI 53706 USA	Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison				Ratner, Lee/0000-0003-2744-7294	NCI NIH HHS [CA63417] Funding Source: Medline; NHLBI NIH HHS [5 T32 HL07088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063417] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ALTMAN R, 1988, J VIROL, V62, P1339, DOI 10.1128/JVI.62.4.1339-1346.1988; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BANGHAM CRM, 1988, EMBO J, V7, P4179, DOI 10.1002/j.1460-2075.1988.tb03314.x; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BHAGAVATI S, 1988, NEW ENGL J MED, V318, P1141, DOI 10.1056/NEJM198805053181801; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; CONNOR LM, 1993, VIROLOGY, V195, P569, DOI 10.1006/viro.1993.1408; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P1119, DOI 10.1093/nar/23.7.1119; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DUVALL JF, 1995, J VIROL, V69, P5077, DOI 10.1128/JVI.69.8.5077-5086.1995; EBERT SN, 1994, J BIOL CHEM, V269, P20885; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; Goustin AS, 1990, GROWTH FACTORS, V2, P189, DOI 10.3109/08977199009071505; HART CE, 1990, J INVEST DERMATOL, V94, pS53, DOI 10.1111/1523-1747.ep12875065; JACOB ST, 1970, NATURE, V225, P60, DOI 10.1038/225060b0; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JIN HM, 1994, J BIOL CHEM, V269, P28648; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; JOSEPHS SF, 1984, SCIENCE, V225, P636, DOI 10.1126/science.6740330; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KRAMER B, 1995, J INFLAMM, V45, P183; KUDO S, 1994, EUR J BIOCHEM, V223, P319, DOI 10.1111/j.1432-1033.1994.tb18997.x; Langton B., 1988, MED VIROL, V8, P295; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490; LIANG Y, 1996, ONCOGENE, V12, P1; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; MARRIOTT SJ, 1989, MOL CELL BIOL, V9, P4152, DOI 10.1128/MCB.9.10.4152; MATTHEWS MAH, 1992, MOL CELL BIOL, V12, P1986, DOI 10.1128/MCB.12.5.1986; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PANTAZIS P, 1987, ONCOGENE, V1, P285; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PIRAS G, 1994, J VIROL, V68, P6170, DOI 10.1128/JVI.68.10.6170-6179.1994; RATNER L, 1989, NUCLEIC ACIDS RES, V17, P4101, DOI 10.1093/nar/17.11.4101; RATNER L, 1988, MEDICINE, V67, P401, DOI 10.1097/00005792-198811000-00004; ROSS R, 1978, CELL, V14, P203, DOI 10.1016/0092-8674(78)90107-1; SEELER JS, 1993, VIROLOGY, V196, P442, DOI 10.1006/viro.1993.1500; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1990, GENE DEV, V4, P1875; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Trejo SR, 1996, J BIOL CHEM, V271, P14584, DOI 10.1074/jbc.271.24.14584; UITTENBOGAARD MN, 1994, J BIOL CHEM, V269, P22466; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YIN MJ, 1995, J VIROL, V69, P6209, DOI 10.1128/JVI.69.10.6209-6218.1995; YU CY, 1991, J BIOL CHEM, V266, P8907; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	68	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27411	27421		10.1074/jbc.272.43.27411	http://dx.doi.org/10.1074/jbc.272.43.27411			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341193	hybrid			2022-12-25	WOS:A1997YC65900089
J	Barik, S; Taylor, RE; Chakrabarti, D				Barik, S; Taylor, RE; Chakrabarti, D			Identification, cloning, and mutational analysis of the casein kinase 1 cDNA of the malaria parasite, Plasmodium falciparum - Stage-specific expression of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED PROTEIN-KINASE; ERYTHROCYTE-MEMBRANE; MOLECULAR-CLONING; SURFACE-ANTIGEN; PHOSPHORYLATION; YEAST; PURIFICATION; SEQUENCE; CELL; PHOSPHOPROTEINS	The cDNA for casein kinase 1 (CK1) of Plasmodium falciparum was cloned, sequenced, and expressed in bacteria, The single major open reading frame of the 1,2-kilobase pair cDNA coded for a 324-amino acid polypeptide of similar to 37 kDa, the predicted sequence of which showed strong identity with known CK1 isoforms, The purified recombinant enzyme exhibited properties characteristic of CK1, such as inhibition by CK1-7, the ability to phosphorylate a highly specific peptide substrate, and a strong preference for ATP over GTP, A casein kinase activity, partially purified from soluble extracts of P. falciparum by affinity chromatography through CK1-7 columns displayed identical properties, The activity showed a stage-specific expression in the parasite, in the order trophozoite > ring much greater than schizont. Northern analysis indicated the existence of two major CK1 mRNAs, 2.4 and 3.2 kilobase pairs long, the levels of which mere in the order ring > schizont > trophozoite. Mutagenesis of recombinant CK1 defined important amino acid residues and their potential role in the conformation of the enzyme, The malarial CK1 appeared to be the one of the smallest and perhaps the most primitive CK1 enzymes known, containing little sequence information beyond the minimal catalytic domain.	UNIV CENT FLORIDA, DEPT MOL BIOL & MICROBIOL, ORLANDO, FL 32816 USA	State University System of Florida; University of Central Florida	Barik, S (corresponding author), UNIV S ALABAMA, DEPT BIOCHEM & MOL BIOL, MOBILE, AL 36688 USA.							[Anonymous], 1991, MALARIA OBSTACLES OP; Ansai T, 1996, J BIOL CHEM, V271, P24401, DOI 10.1074/jbc.271.40.24401; Barik S, 1996, Subcell Biochem, V26, P115; BARIK S, 1995, METH NEUROSCI, V26, P309; CARMEL G, 1994, J BIOL CHEM, V269, P7304; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; CHAKRABARTI D, 1993, P NATL ACAD SCI USA, V90, P12020, DOI 10.1073/pnas.90.24.12020; CHAKRABARTI D, 1994, MOL BIOCHEM PARASIT, V66, P97, DOI 10.1016/0166-6851(94)90039-6; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CHISHTI AH, 1994, BLOOD, V83, P3339; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; Eadie GS, 1942, J BIOL CHEM, V146, P85; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; HALDAR K, 1985, J BIOL CHEM, V260, P4969; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KEARNEY PH, 1994, BIOCHEM BIOPH RES CO, V203, P231, DOI 10.1006/bbrc.1994.2172; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LUSTIGMAN S, 1990, MOL BIOCHEM PARASIT, V38, P261, DOI 10.1016/0166-6851(90)90029-L; MAZUMDER B, 1994, VIROLOGY, V205, P93, DOI 10.1006/viro.1994.1623; MEGGIO F, 1991, FEBS LETT, V283, P303, DOI 10.1016/0014-5793(91)80614-9; MILNE DM, 1992, ONCOGENE, V7, P1361; MURRAY MC, 1989, MOL BIOCHEM PARASIT, V34, P229, DOI 10.1016/0166-6851(89)90051-0; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SUETTERLIN BW, 1991, MOL BIOCHEM PARASIT, V46, P113, DOI 10.1016/0166-6851(91)90205-K; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Tuazon P. T., 1991, ADV 2 MESSENGER PHOS, V23, P123; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; WANG PC, 1994, J BIOL CHEM, V269, P12014; WISER MF, 1987, EXP PARASITOL, V64, P328, DOI 10.1016/0014-4894(87)90043-9; WISER MF, 1985, MOL BIOCHEM PARASIT, V17, P179, DOI 10.1016/0166-6851(85)90017-9; WISER MF, 1983, J CELL BIOCHEM, V2, P305; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x	41	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26132	26138		10.1074/jbc.272.42.26132	http://dx.doi.org/10.1074/jbc.272.42.26132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334178	hybrid			2022-12-25	WOS:A1997YB13900012
J	Otto, C; Reichardt, HM; Schutz, G				Otto, C; Reichardt, HM; Schutz, G			Absence of glucocorticoid receptor-beta in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; GENE; LOCALIZATION; PROTEINS; ISOFORM; SITE; CDNA	Two human glucocorticoid receptor (GR) isoforms, GR alpha and GR beta, are derived from the same gene by alternative splicing involving exon 9 of the GR locus, The non-ligand binding isoform GR beta was proposed to act as a transdominant negative inhibitor of GR alpha, thus modulating glucocorticoid responsiveness of target tissues, To study GR beta in mice we characterized the genomic region around exon 9 of the murine GR gene. Sequence analysis revealed that the presumed exon 9 beta contained an open reading frame of 59 amino acids, In contrast, human exon 9 beta encoded only 15 amino acids, Using reverse transcriptase polymerase chain reaction the ab absence of GR beta mRNA was demonstrated in all adult mouse tissues examined, To exclude the possibility that the polymerase chain reaction conditions employed were not suitable for the amplification of GR beta mRNA, we synthesized an artificial template corresponding to the presumed GRP mRNA spanning exons 7, 8, and 9 beta, Various amounts of this template were added to brain cDNA preparations and as little as 25 molecules were detectable under the polymerase chain reaction conditions chosen, Since GR beta is not conserved across species its physiological significance in humans appears questionable.	GERMAN CANC RES CTR,DIV MOL BIOL CELL 1,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Reichardt, Holger/AAF-3048-2020	Reichardt, Holger/0000-0003-4647-057X				BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; deCastro M, 1996, MOL MED, V2, P597, DOI 10.1007/BF03401643; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; Hecht K, 1997, J BIOL CHEM, V272, P26659, DOI 10.1074/jbc.272.42.26659; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRATT WB, 1993, J BIOL CHEM, V268, P21455; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; STRAHLE U, 1992, P NATL ACAD SCI USA, V89, P6731, DOI 10.1073/pnas.89.15.6731; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	21	83	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26665	26668		10.1074/jbc.272.42.26665	http://dx.doi.org/10.1074/jbc.272.42.26665			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334249	hybrid			2022-12-25	WOS:A1997YB13900083
J	Sheikh, MS; Carrier, F; Papathanasiou, MA; Hollander, MC; Zhan, QM; Yu, K; Fornace, AJ				Sheikh, MS; Carrier, F; Papathanasiou, MA; Hollander, MC; Zhan, QM; Yu, K; Fornace, AJ			Identification of several human homologs of hamster DNA damage-inducible transcripts - Cloning and characterization of a novel UV-inducible cDNA that codes for a putative RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION FACTOR-5; CELL NUCLEAR ANTIGEN; MESSENGER-RNA; RECOGNITION MOTIF; MAMMALIAN-CELLS; EXCISION-REPAIR; LEUKEMIA-CELLS; GENE; INDUCTION; GROWTH	Low Patio hybridization subtraction technique was previously used in this laboratory to enrich and isolate a number of low abundance UV-inducible hamster transcripts (Fornace, A. J., Jr., Alamo, I. J., and Hollander, M. C. (1988) Proc. Natl. Acad, Sci. U. S. A. 85, 8800-8804) that led to the identification and cloning of five important hamster and human GADD genes (Fornace, A. J., Jr., Nebert, D. W., Hollander, M. C,, Luethy, J. D., Papathanasiou, M., Fargnoli, J., and Holbrook, N. J. (1989) Mol, Cell. Biol. 9, 4196-4205), In this study we have characterized the remaining DNA damage-inducible (DDI) transcripts. Of the 24 DDI clones, 3 clones (A13, A20, and A113) representing different regions of the same hamster cDNA exhibited near perfect homology to human p21(WAF1/CIP1) cDNA. The DDI clones A26, A88, and A99 displayed very high sequence homologies with the human proliferating nuclear antigen, rat translation initiation factor-5 (eIF-5), and human thrombomodulin, respectively, whereas clones A29 and A121 matched with express sequence tagged sequences of unknown identity, The DDI clones A18, 106, and A107 were different isolates of the same hamster cDNA (hereafter referred to as A18) and displayed high sequence homology with the members in the heterogeneous ribonucleoprotein (hnRNP) family, Using the hamster A18 partial-length cDNA as a probe, we screened human fibroblast cDNA library and isolated the corresponding full-length human cDNA. The deduced amino acid sequence revealed that the putative protein contains all the canonical features of a novel glycine-rich hnRNP. The A18 mRNA levels mere specifically increased in response to DNA damage induced by UV irradiation or UV mimetic agents, Thus the putative A18 hnRNP is the first hnRNP whose mRNA is specifically regulated in response to UV-induced DNA damage; accordingly, it may play some role in repair of W-type DNA damage.			Sheikh, MS (corresponding author), NCI, MOL PHARMACOL LAB, NIH, BLDG 37, RM 5D02, BETHESDA, MD 20892 USA.		Carrier, France/C-3063-2008; Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Carrier, France/0000-0002-5517-5284				BAE IS, 1995, CANCER RES, V55, P2387; BIAMONTI G, 1994, NUCLEIC ACIDS RES, V22, P1996, DOI 10.1093/nar/22.11.1996; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; CONWAY EM, 1994, J BIOL CHEM, V269, P22804; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARGNOLI J, 1990, ANAL BIOCHEM, V187, P364, DOI 10.1016/0003-2697(90)90471-K; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GOMEZ J, 1988, NATURE, V334, P262, DOI 10.1038/334262a0; HARPER JW, 1993, CELL, V75, P805; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1996, NUCLEIC ACIDS RES, V12, P387; HOLLANDER MC, 1994, DNA REPAIR MECH IMPA, P221; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KUMAR A, 1986, J BIOL CHEM, V261, P1266; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Nishiyama H, 1997, J CELL BIOL, V137, P899, DOI 10.1083/jcb.137.4.899; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REBAGLIATI M, 1989, CELL, V58, P231, DOI 10.1016/0092-8674(89)90834-9; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SHIRAI T, 1988, J BIOCHEM-TOKYO, V103, P281, DOI 10.1093/oxfordjournals.jbchem.a122261; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1995, INT J ONCOL, V6, P937; ZHANG W, 1995, CANCER RES, V55, P668	47	80	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26720	26726		10.1074/jbc.272.42.26720	http://dx.doi.org/10.1074/jbc.272.42.26720			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334257	hybrid			2022-12-25	WOS:A1997YB13900091
J	Aronson, D; Dufresne, SD; Goodyear, LJ				Aronson, D; Dufresne, SD; Goodyear, LJ			Contractile activity stimulates the c-Jun NH2-terminal kinase pathway in rat skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; CARDIAC MYOCYTES; GENE-EXPRESSION; MECHANICAL-STRESS; GAMMA-RADIATION; JNK ACTIVATION; PHOSPHORYLATION; FOS	Contractile activity plays a critical role in the regulation of gene transcription in skeletal muscle, which in turn determines muscle functional capabilities. However, little is known about the molecular signaling mechanisms that convert contractile activity into gene regulatory responses in skeletal muscle. In the current study we determined the effects of contractile activity in vivo on the c-Jun NH2-terminal kinase (JNK) pathway, a signaling cascade that has been implicated in the regulation of transcription. Electrical stimulation of the sciatic nerve to produce contractions in anaesthetized rats increased JNK activity by up to 7-fold above basal. Maximal enzyme activity occurred at 15 min of contraction and remained elevated at 60 min of contraction. The upstream activators of JNK, the mitogen-activated protein kinase kinase 4 and the mitogen-activated protein kinase kinase kinase 1 followed a similar time course of activation in response to contractile activity. In contrast, contraction induced a rapid and transient activation of the extracellular-regulated kinase pathway, indicating that the regulation of JNK signaling is distinct from that of extracellular-regulated kinase. The activation of the JNK signaling cascade was temporally associated with an increased expression of c-jun mRNA. These results demonstrate that contractile activity regulates JNK activity in skeletal muscle and suggest that activation of JNK may regulate contraction-induced gene expression in skeletal muscle.	BRIGHAM & WOMENS HOSP,DEPT MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Aronson, Doron/F-3390-2010		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042238, R29AR042238] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-42238] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAM LP, 1995, CIRC RES, V76, P183, DOI 10.1161/01.RES.76.2.183; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; Aronson D, 1997, J CLIN INVEST, V99, P1251, DOI 10.1172/JCI119282; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BOOTH FW, 1991, PHYSIOL REV, V71, P541, DOI 10.1152/physrev.1991.71.2.541; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN WE, 1983, J BIOL CHEM, V258, P4686; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; IWAKI K, 1990, J BIOL CHEM, V265, P13809; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; Williams RS, 1996, HDB PHYSL EXERCISE R, P1124; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; XU O, 1996, J CLIN INVEST, V97, P508; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	40	73	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25636	25640		10.1074/jbc.272.41.25636	http://dx.doi.org/10.1074/jbc.272.41.25636			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325285	hybrid			2022-12-25	WOS:A1997YA35800040
J	Misaki, A; Kakuta, M; Meah, Y; Goldstein, IJ				Misaki, A; Kakuta, M; Meah, Y; Goldstein, IJ			Purification and characterization of the alpha-1,3-mannosylmannose-recognizing lectin of Crocus vernus bulbs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-SPECIFIC LECTINS; OLIGOSACCHARIDES; MANNANS; MOIETY; YEAST	A unique mannose-binding lectin, highly specific for terminal Man(alpha 1,3)Man groups, was isolated from bulbs of crocus (Crocus vernus All.), The lectin failed to bind to a mannose affinity column and was purified by simple gel permeation chromatography (Sephacryl S200). The purified lectin, obtained in crystalline form, had a molecular mass of 44 kDa on gel filtration and showed a single peptide band with a molecular mass of 11 kDa on SDS-polyacrylamide gel electrophoresis, indicating it to be a tetrameric protein composed of four identical subunits, The N-terminal amino acid sequence analysis of the crocus lectin showed essentially no homology with that of other mannose-binding bulb lectins. The crocus lectin selectively interacted with the wild type Saccharomyces cerevisiae and other mannans carrying terminal Man(alpha 1,3)Man but not with those lacking this disaccharide unit, In hapten inhibition studies, methyl alpha-mannopyranoside did not inhibit the mannan-lectin interaction, Of various alpha-mannooligosaccharides, those having the Man(alpha 1,3)Man sequence showed the highest inhibitory potency, confirming the strict requirement of lectin for terminal alpha 1,3-linked mannosylmannose units, An affinity column of immobilized lectin enabled the complete resolution of yeast mannan and glycogen, The immobilized lectin may provide a useful tool for purification and analysis of biologically important polysaccharides and glycoproteins.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Misaki, A (corresponding author), KONAN WOMENS UNIV,6-2-23 MORIKITA MACHI,KOBE,HYOGO 658,JAPAN.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU CE, 1973, J BIOL CHEM, V248, P4667; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; HESTER G, 1995, NAT STRUCT BIOL, V2, P473; KAKU H, 1990, ARCH BIOCHEM BIOPHYS, V279, P298, DOI 10.1016/0003-9861(90)90495-K; KAKU H, 1992, CARBOHYD RES, V229, P347, DOI 10.1016/S0008-6215(00)90580-9; KAKU H, 1992, CARBOHYD RES, V229, P337, DOI 10.1016/S0008-6215(00)90579-2; KAKU H, 1991, CARBOHYD RES, V213, P109, DOI 10.1016/S0008-6215(00)90602-5; KONISI Y, 1976, ANN M JAP AGR CHEM S, P22; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MISAKI A, 1982, CARBOHYD RES, V109, P207, DOI 10.1016/0008-6215(82)84039-1; MISAKI A, 1980, CARBOHYD RES, V84, P273, DOI 10.1016/S0008-6215(00)85557-3; MISAKI A, 1977, J BIOL CHEM, V252, P6995; ODA Y, 1985, EUR J BIOCHEM, V159, P239; OHTANI K, 1980, CARBOHYD RES, V87, P275, DOI 10.1016/S0008-6215(00)85214-3; PEUMANS WJ, 1995, PLANT PHYSIOL, V109, P347, DOI 10.1104/pp.109.2.347; SAITO K, 1993, EUR J BIOCHEM, V217, P677, DOI 10.1111/j.1432-1033.1993.tb18293.x; SAITO K, 1997, IN PRESS LGYCOCONJ J, V14; SARKAR AK, 1989, CARBOHYD RES, V190, P181, DOI 10.1016/0008-6215(89)84124-2; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SO LUCY L., 1967, J BIOL CHEM, V242, P1617; TORGOV VI, 1984, BIOORG KHIM+, V10, P946; VANDAMME EJM, 1988, PHYSIOL PLANTARUM, V73, P52, DOI 10.1111/j.1399-3054.1988.tb09192.x	23	10	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25455	25461		10.1074/jbc.272.41.25455	http://dx.doi.org/10.1074/jbc.272.41.25455			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325257	hybrid			2022-12-25	WOS:A1997YA35800012
J	Sarkar, AK; Rostand, KS; Jain, RK; Matta, KL; Esko, JD				Sarkar, AK; Rostand, KS; Jain, RK; Matta, KL; Esko, JD			Fucosylation of disaccharide precursors of sialyl Lewis(X) inhibit selectin-mediated cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; ATTENUATES REPERFUSION INJURY; N-LINKED OLIGOSACCHARIDES; HAMSTER OVARY CELLS; RAT ADIPOSE-TISSUE; ALPHA-L-FUCOSIDASE; P-SELECTIN; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; RABBIT EAR	We showed previously that HL-60 and F9 mouse embryonal carcinoma cells will take up and deblock peracetylated Gal beta 1-4GlcNAc beta-O-naphthalenemethanol (Gal beta 1-4GlcNAc-NM) and use the disaccharide as a primer of oligosaccharide chains (Sarkar, A. K., Fritz, T. A., Taylor, W. H., and Esko, J. D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3323-3327). We now report that another disaccharide, acetylated GlcNAc beta 1-3Gal-naphthalenemethanol (GlcNAc beta 1-3Gal-NM), has even greater potency and that both compounds will inhibit sialyl Lewis(X) (sLe(x))-dependent cell adhesion. When fed to U937 cells, acetylated forms of Galpl-1GrlcNAc-NM and GlcNAc beta 1-3Gal-NM primed oligosaccharides in a dose-dependent manner. Analysis of compounds assembled on Gal beta 1-4GlcNAc-NM showed only one product, namely Gal beta 1-4(Fuc alpha 1-3)GlcNAc-NM. In contrast, Glc-NAc beta 1-3Gal-NM generated Gal beta 1-4GlcNAc beta 1-3Gal-NM, Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal-NM, NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal-NM, and NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal-NM. Both compounds decreased the incorporation of [H-3]fucose into cellular glycoconjugates, without affecting the incorporation of [H-3]mannosamine, a precursor of sialic acid residues. Moreover, the overall extent of sialylation was not affected based on the reactivity of cells to fluorescein isothiocyanate-conjugated Maackia amurensis lectin. Priming inhibited expression of sLe(x) on cell surface glycoconjugates, which reduced E-selectin-dependent cell adhesion to tumor necrosis factor-cu-activated human umbilical vein endothelial cells. GlcNAc beta 1-3Gal-NM and Gal beta 1-4Glc-NAc-NM represent starting points for making enzyme-specific, site-directed inhibitors of glycosyltransferases that could act in living cells.	UNIV CALIF SAN DIEGO,CTR CANC,GLYCOBIOL PROGRAM,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093; UNIV ALABAMA,SCH MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294; ROSWELL PK CANC INST,DEPT GYNECOL ONCOL,BUFFALO,NY 14263	University of California System; University of California San Diego; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Roswell Park Cancer Institute					NCI NIH HHS [CA35329, CA46462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035329, R01CA046462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; BERTOZZI CR, 1995, BIOCHEMISTRY-US, V34, P14271, DOI 10.1021/bi00044a001; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BRIGGS JB, 1995, GLYCOBIOLOGY, V5, P583, DOI 10.1093/glycob/5.6.583; BUERKE M, 1994, J CLIN INVEST, V93, P1140, DOI 10.1172/JCI117066; CECCONI O, 1994, J BIOL CHEM, V269, P15060; Chammas R, 1996, MOL BIOL CELL, V7, P1691, DOI 10.1091/mbc.7.11.1691; Clarke JL, 1996, J BIOL CHEM, V271, P10317, DOI 10.1074/jbc.271.17.10317; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Etchison JR, 1996, GLYCOBIOLOGY, V6, P177, DOI 10.1093/glycob/6.2.177; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FRITZ TA, 1994, J BIOL CHEM, V269, P300; Fuhlbrigge RC, 1996, J CELL BIOL, V135, P837, DOI 10.1083/jcb.135.3.837; GABRIEL O, 1992, GLYCOBIOLOGY, V2, P427; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; HAN KT, 1995, J IMMUNOL, V155, P4011; HARANO T, 1988, J BIOCHEM-TOKYO, V103, P149, DOI 10.1093/oxfordjournals.jbchem.a122221; Hicke BJ, 1996, J CLIN INVEST, V98, P2688, DOI 10.1172/JCI119092; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HUGHES RC, 1964, BIOCHEMISTRY-US, V3, P1535, DOI 10.1021/bi00898a025; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KAWASHIMA H, 1993, J BIOL CHEM, V268, P27118; KHAN SH, 1993, J BIOL CHEM, V268, P2468; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; KUAN SF, 1989, J BIOL CHEM, V264, P19271; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LOWARY TL, 1994, CARBOHYD RES, V251, P33, DOI 10.1016/0008-6215(94)84275-2; LOWARY TL, 1994, CARBOHYD RES, V256, P257, DOI 10.1016/0008-6215(94)84212-4; LOWE JB, 1991, J BIOL CHEM, V266, P17467; Lowe JB, 1997, J CLIN INVEST, V99, P822, DOI 10.1172/JCI119244; MA XL, 1993, CIRCULATION, V88, P649, DOI 10.1161/01.CIR.88.2.649; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MARTENS CL, 1995, J BIOL CHEM, V270, P21129, DOI 10.1074/jbc.270.36.21129; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MENTLEIN R, 1988, BIOCHIM BIOPHYS ACTA, V964, P319, DOI 10.1016/0304-4165(88)90032-3; MIHELCIC D, 1994, BLOOD, V84, P2322; MULLIGAN MS, 1993, J IMMUNOL, V151, P6410; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; MULLIGAN MS, 1993, J EXP MED, V178, P62; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NELSON RM, 1993, BLOOD, V82, P3253; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; OConnell D, 1996, P NATL ACAD SCI USA, V93, P5883, DOI 10.1073/pnas.93.12.5883; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1994, PROGR BRAIN RES, P179; Portner A, 1996, GLYCOBIOLOGY, V6, P7, DOI 10.1093/glycob/6.1.7; RAO BNN, 1994, J BIOL CHEM, V269, P19663; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; ROUX L, 1988, J BIOL CHEM, V263, P8879; SANO M, 1992, J BIOL CHEM, V267, P1522; SARKAR AK, 1995, P NATL ACAD SCI USA, V92, P3323, DOI 10.1073/pnas.92.8.3323; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; TSUJITA T, 1982, BIOCHIM BIOPHYS ACTA, V715, P181, DOI 10.1016/0304-4165(82)90357-9; TSUJITA T, 1988, J BIOCHEM, V103, P327, DOI 10.1093/oxfordjournals.jbchem.a122269; TSUJITA T, 1992, J BIOL CHEM, V267, P23489; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WANG WC, 1988, J BIOL CHEM, V263, P4576; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WINN RK, 1993, J CLIN INVEST, V92, P2042, DOI 10.1172/JCI116799; WOYNAROWSKA B, 1989, CANCER RES, V49, P5598; Woynarowska B, 1996, GLYCOCONJUGATE J, V13, P663, DOI 10.1007/BF00731455; YANO T, 1985, AGR BIOL CHEM TOKYO, V49, P3179, DOI 10.1080/00021369.1985.10867252; ZHUANG D, 1991, Glycobiology, V1, P425, DOI 10.1093/glycob/1.4.425	74	89	93	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25608	25616		10.1074/jbc.272.41.25608	http://dx.doi.org/10.1074/jbc.272.41.25608			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325281	hybrid			2022-12-25	WOS:A1997YA35800036
J	Tjalsma, H; Noback, MA; Bron, S; Venema, G; Yamane, K; vanDijl, JM				Tjalsma, H; Noback, MA; Bron, S; Venema, G; Yamane, K; vanDijl, JM			Bacillus subtilis contains four closely related type I signal peptidases with overlapping substrate specificities - Constitutive and temporally controlled expression of different sip genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; ESCHERICHIA-COLI; MOLECULAR-CLONING; CATALYTIC MECHANISM; SEQUENCE SIMILARITY; ALPHA-AMYLASE; MEMBRANE; PROTEINS; GENOME; AMYLOLIQUEFACIENS	Most biological membranes contain one or two type I signal peptidases for the removal of signal peptides from secretory precursor proteins. In this respect, the Grampositive bacterium Bacillus subtilis seems to be exceptional, because it contains at least four chromosomally-encoded type I signal peptidases, denoted SipS, SipT, SipU, and SipV. Here, we report the identification of the sipT and sipV genes, and the functional characterization of SipT, SipU, and SipV. The four signal peptidases have similar substrate specificities, as they can all process the same beta-lactamase precursor. Nevertheless, they seem to prefer different pre-proteins, as indicated by studies on the processing of the pre-alpha-amylase of Bacillus amyloliquefaciens in strains lacking SipS, SipT, SipU, or SipV. The sipU and sipV genes are constitutively transcribed at a low level, suggesting that they are required for processing of (pre-)proteins secreted during all growth phases. In contrast, the transcription of sipS and sipT is temporally controlled, in concert with the expression of the genes for most secretory proteins, which suggests that SipS and SipT serve to increase the secretory capacity of B. subtilis. Taken together, our findings suggest that SipS, SipT, SipU, and SipV serve different functions during the exponential and post-exponential growth phase of B. subtilis.	GRONINGEN BIOMOL SCI & BIOTECHNOL INST,DEPT GENET,NL-9751 NN HAREN,NETHERLANDS; UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN	University of Groningen; University of Tsukuba			van Dijl, Jan Maarten/G-1205-2013; Tjalsma, Harold/I-7146-2012					Akagawa E, 1995, MICROBIOL-UK, V141, P3241, DOI 10.1099/13500872-141-12-3241; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BLACK MT, 1992, BIOCHEM J, V282, P539, DOI 10.1042/bj2820539; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; Bolhuis A, 1996, MOL MICROBIOL, V22, P605, DOI 10.1046/j.1365-2958.1996.d01-4676.x; BRON S, 1972, MUTAT RES, V15, P1, DOI 10.1016/0027-5107(72)90086-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cregg KM, 1996, J BACTERIOL, V178, P5712, DOI 10.1128/jb.178.19.5712-5718.1996; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DALBEY RE, 1994, SIGNAL PEPTIDASES, P5; DATE T, 1983, J BACTERIOL, V154, P76, DOI 10.1128/JB.154.1.76-83.1983; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Ferrari Eugenio, 1993, P917; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GAY P, 1983, J BACTERIOL, V153, P1133, DOI 10.1128/JB.153.3.1133-1137.1983; HOANG V, 1995, BBA-MOL CELL RES, V1269, P64, DOI 10.1016/0167-4889(95)00101-W; Klug G, 1997, MOL GEN GENET, V253, P666, DOI 10.1007/s004380050370; KONTINEN VP, 1988, J GEN MICROBIOL, V134, P2333; KUO DW, 1993, ARCH BIOCHEM BIOPHYS, V303, P274, DOI 10.1006/abbi.1993.1283; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; LIVELY MO, 1994, SIGNAL PEPTIDASES, P59; MEIJER WJJ, 1995, MOL MICROBIOL, V17, P621, DOI 10.1111/j.1365-2958.1995.mmi_17040621.x; Miller J. H., 1982, EXPT MOL GENETICS; Msadek Tarek, 1993, P729; Muller P, 1995, MOL MICROBIOL, V18, P831, DOI 10.1111/j.1365-2958.1995.18050831.x; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; Oliver SG, 1996, NATURE, V379, P597, DOI 10.1038/379597a0; PACKER JCL, 1995, PLANT MOL BIOL, V27, P199, DOI 10.1007/BF00019191; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; PALVA I, 1982, GENE, V19, P81, DOI 10.1016/0378-1119(82)90191-3; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; Pratje E., 1994, SIGNAL PEPTIDASES, P105; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; SMITH H, 1987, J BACTERIOL, V169, P3321, DOI 10.1128/jb.169.7.3321-3328.1987; SOROKIN A, 1993, MOL MICROBIOL, V10, P385, DOI 10.1111/j.1365-2958.1993.tb02670.x; SPIZIZEN J, 1958, P NATL ACAD SCI USA, V44, P1072, DOI 10.1073/pnas.44.10.1072; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANDIJL JM, 1991, J GEN MICROBIOL, V137, P2073, DOI 10.1099/00221287-137-9-2073; VANDIJL JM, 1990, MOL GEN GENET, V223, P233, DOI 10.1007/BF00265059; VANDIJL JM, 1988, MOL GEN GENET, V214, P55; VANSINDEREN D, 1990, MOL GEN GENET, V224, P396, DOI 10.1007/BF00262434; Von Heijne Gunnar, 1994, V22, P1; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; WOLFE PB, 1983, J BIOL CHEM, V258, P2073	58	103	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25983	25992		10.1074/jbc.272.41.25983	http://dx.doi.org/10.1074/jbc.272.41.25983			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325333	hybrid			2022-12-25	WOS:A1997YA35800088
J	Yaworsky, PJ; Gardner, DP; Kappen, C				Yaworsky, PJ; Gardner, DP; Kappen, C			Transgenic analyses reveal developmentally regulated neuron- and muscle-specific elements in the murine neurofilament light chain gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-L; TRANSCRIPTION FACTORS; BINDING-FACTOR; POLYOMAVIRUS ENHANCER; NERVOUS-SYSTEM; EXPRESSION; MICE; PROTEINS; SUBUNIT; CELLS	We report here the developmental activity of regula tory elements that reside within 1.7 kilobases of the murine neurofilament light chain (NF-L) gene promoter. NF-L promoter activity is first detected at embryonic day 8.5 in neuroepithelial cells. Neuron specific gene expression is maintained in the spinal cord until embryonic day 12.5 and at later developmental stages in the brain and sensory neuroepithelia. After day 14.5, the promoter becomes active in myogenic cells. Transgene expression in both neurons and muscle is consistent with the detection of endogenous NF-L transcript in both neuronal and myogenic tissues of neonates by reverse transcriptase-polymerase chain reaction. Neuron- and muscle-specific activities of the NF-L promoter decrease and are nearly undetectable after birth. Thus, the 1.7-kilobase NF-L promoter contains regulatory elements for initiation but not maintenance of transcription from the NF-L locus. Deletion analyses reveal that independent regulatory elements control the observed tissue-specific activities and implicate a potential MyoD binding site as the muscle-specific enhancer. Our results demonstrate that the NF-L promoter contains distinct regulatory elements for both neuron-and muscle-specific gene expression and that these activities are temporally separated during embryogenesis.	MAYO CLIN ARIZONA,SAMUEL C JOHNSON MED RES CTR,SCOTTSDALE,AZ 85259	Mayo Clinic; Mayo Clinic Phoenix								ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BEAUDET L, 1993, MOL BRAIN RES, V18, P23, DOI 10.1016/0169-328X(93)90170-T; BEAUDET L, 1992, GENE, V116, P205, DOI 10.1016/0378-1119(92)90517-S; BEGEMANN M, 1990, P NATL ACAD SCI USA, V87, P9042, DOI 10.1073/pnas.87.22.9042; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BYRNE GW, 1989, P NATL ACAD SCI USA, V86, P5473, DOI 10.1073/pnas.86.14.5473; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Charron G, 1995, J BIOL CHEM, V270, P30604, DOI 10.1074/jbc.270.51.30604; COCHARD P, 1984, J NEUROSCI, V4, P2080; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Gardner DP, 1996, TRANSGENIC RES, V5, P37, DOI 10.1007/BF01979920; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HOGAN B, 1986, MANIPULATING MOUSE E, P153; HSU C, 1995, MOL BRAIN RES, V32, P241, DOI 10.1016/0169-328X(95)00082-4; IKENAKA K, 1990, J BIOL CHEM, V265, P19782; IVANOV TR, 1992, J NEUROSCI RES, V32, P149, DOI 10.1002/jnr.490320204; JULIEN JP, 1987, BIOCHIM BIOPHYS ACTA, V909, P10, DOI 10.1016/0167-4781(87)90041-8; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; KRISTIE TM, 1984, P NATL ACAD SCI-BIOL, V81, P4065, DOI 10.1073/pnas.81.13.4065; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LECONTE L, 1995, J MOL NEUROSCI, V5, P273; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; LEE VMY, 1992, MOL BRAIN RES, V15, P76, DOI 10.1016/0169-328X(92)90154-4; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; MONTEIRO MJ, 1989, J CELL BIOL, V108, P579, DOI 10.1083/jcb.108.2.579; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; PETERSOHN D, 1995, J BIOL CHEM, V270, P24361, DOI 10.1074/jbc.270.41.24361; PLEASURE SJ, 1989, J NEUROSCI, V9, P698; POSPELOV VA, 1994, CELL GROWTH DIFFER, V5, P187; REEBEN M, 1995, J NEUROSCI RES, V40, P177, DOI 10.1002/jnr.490400206; REEBEN M, 1993, BIOCHEM BIOPH RES CO, V192, P177; ROTH HJ, 1991, MOL CELL BIOL, V11, P1488, DOI 10.1128/MCB.11.3.1488; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLAEPFER WW, 1990, J NEUROSCI RES, V25, P39, DOI 10.1002/jnr.490250106; SCHWARTZ ML, 1995, J BIOL CHEM, V270, P26364, DOI 10.1074/jbc.270.44.26364; SCHWARTZ ML, 1994, J BIOL CHEM, V269, P13444; SHIRAKATA M, 1988, MOL CELL BIOL, V8, P2581, DOI 10.1128/MCB.8.6.2581; SHNEIDMAN PS, 1992, MOL BRAIN RES, V13, P127, DOI 10.1016/0169-328X(92)90052-D; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; YAZDANBAKHSH K, 1993, NUCLEIC ACIDS RES, V21, P455, DOI 10.1093/nar/21.3.455; ZOPF D, 1990, NUCLEIC ACIDS RES, V18, P521, DOI 10.1093/nar/18.3.521	55	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25112	25120		10.1074/jbc.272.40.25112	http://dx.doi.org/10.1074/jbc.272.40.25112			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312121	hybrid			2022-12-25	WOS:A1997XY97000060
J	Smith, KE; Forray, C; Walker, MW; Jones, KA; Tamm, JA; Bard, J; Branchek, TA; Linemeyer, DL; Gerald, C				Smith, KE; Forray, C; Walker, MW; Jones, KA; Tamm, JA; Bard, J; Branchek, TA; Linemeyer, DL; Gerald, C			Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; XENOPUS OOCYTES; GUINEA-PIG; SEROTONIN RECEPTORS; ANTERIOR-PITUITARY; MOLECULAR-CLONING; CHIMERIC PEPTIDE; NERVE INJURY; SPINAL-CORD; BRAIN	The neuropeptide galanin is widely distributed throughout the central and peripheral nervous systems and participates in the regulation of processes such as nociception, cognition, feeding behavior, and insulin secretion. Multiple galanin receptors are predicted to underlie its physiological effects, We now report the isolation by expression cloning of a rat galanin receptor cDNA distinct from GALR1. The receptor, termed GALR2, was isolated from a Pat hypothalamus cDNA library using a I-125-porcine galanin (I-125-pGAL) binding assay. The GALR2 cDNA encoded a protein of 372 amino acids exhibiting 38% amino acid identity with rat GALR1. Binding of I-125-pGAL to transiently expressed GALR2 receptors was saturable (K-D = 0.15 naa) and displaceable by galanin peptides and analogues in rank order: porcine galanin similar or equal to M32 similar or equal to M35 similar or equal to M40 greater than or equal to galanin-(1-16) similar or equal to M15 similar or equal to [D-Trp(2)]galanin-(1-29) > C7 much greater than galanin-(3-29). This profile resembles that of the rat, GALR1 receptor with the notable exception that [D-Trp(2)]galanin exhibited significant selectivity for GALR2 over GALR1, Activation of GALR2 receptors with porcine galanin and other galanin analogues increased inositol phospholipid turnover and intracellular calcium levels in stably transfected Chinese hamster ovary cells and generated calcium-activated chloride currents in Xenopus oocytes, suggesting that the rat. GALR2 receptor is primarily coupled to the activation of phospholipase C.	SYNAPT PHARMACEUT CORP,DEPT PHARMACOL,PARAMUS,NJ 07652		Smith, KE (corresponding author), SYNAPT PHARMACEUT CORP,DEPT MOL BIOL,215 COLL RD,PARAMUS,NJ 07652, USA.							AHMAD S, 1996, 8 WORLD C PAIN VANC, P134; Ahren B, 1996, BIOCHEM BIOPH RES CO, V221, P89, DOI 10.1006/bbrc.1996.0550; AHREN B, 1992, INT J PANCREATOL, V11, P147; BARD JA, 1993, J BIOL CHEM, V268, P23422; BARTFAI T, 1993, P NATL ACAD SCI USA, V90, P11287, DOI 10.1073/pnas.90.23.11287; BARTFAI T, 1991, P NATL ACAD SCI USA, V88, P10961, DOI 10.1073/pnas.88.23.10961; BARTFAI T, 1993, CRIT REV NEUROBIOL, V7, P229; BAUER FE, 1986, GASTROENTEROLOGY, V91, P877, DOI 10.1016/0016-5085(86)90689-X; BENNET WM, 1991, J ENDOCRINOL, V130, P463, DOI 10.1677/joe.0.1300463; BOYLE MR, 1994, REGUL PEPTIDES, V50, P1, DOI 10.1016/0167-0115(94)90185-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan-Palay V, 1990, Adv Neurol, V51, P253; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; ELFVIN LG, 1994, MICROSC RES TECHNIQ, V29, P131, DOI 10.1002/jemt.1070290210; Forray C., 1996, Society for Neuroscience Abstracts, V22, P1304; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; GREGERSEN S, 1993, EUR J PHARMACOL, V232, P35, DOI 10.1016/0014-2999(93)90725-W; GU ZF, 1995, J PHARMACOL EXP THER, V272, P371; GUNDERSEN CB, 1983, PROC R SOC SER B-BIO, V219, P103, DOI 10.1098/rspb.1983.0062; Gustafson EL, 1996, NEUROREPORT, V7, P953, DOI 10.1097/00001756-199603220-00025; HABERTORTOLI E, 1994, P NATL ACAD SCI USA, V91, P9780, DOI 10.1073/pnas.91.21.9780; HARDWICK JC, 1992, J AUTONOM NERV SYST, V40, P87, DOI 10.1016/0165-1838(92)90019-D; HEDLUND PB, 1992, EUR J PHARMACOL, V224, P203, DOI 10.1016/0014-2999(92)90806-F; Howard AD, 1997, FEBS LETT, V405, P285, DOI 10.1016/S0014-5793(97)00196-8; KALKBRENNER F, 1995, EMBO J, V14, P4728, DOI 10.1002/j.1460-2075.1995.tb00154.x; KAPLAN LM, 1988, P NATL ACAD SCI USA, V85, P7408, DOI 10.1073/pnas.85.19.7408; Kask K, 1995, CELL MOL NEUROBIOL, V15, P653, DOI 10.1007/BF02071130; LANGEL U, 1992, INT J PEPT PROT RES, V39, P516; MERCHENTHALER I, 1993, PROG NEUROBIOL, V40, P711, DOI 10.1016/0301-0082(93)90012-H; Parker EM, 1995, MOL BRAIN RES, V34, P179, DOI 10.1016/0169-328X(95)00159-P; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; QUICK MW, 1994, METH NEUROSCI, V19, P261; SETHI T, 1991, CANCER RES, V51, P1674; SHEN Y, 1993, J BIOL CHEM, V268, P18200; SKOFITSCH G, 1985, PEPTIDES, V6, P509, DOI 10.1016/0196-9781(85)90118-4; TAKAHASHI T, 1987, P NATL ACAD SCI USA, V84, P5063, DOI 10.1073/pnas.84.14.5063; VILLAR MJ, 1989, NEUROSCIENCE, V33, P587, DOI 10.1016/0306-4522(89)90411-9; VRONTAKIS ME, 1987, J BIOL CHEM, V262, P16755; WARDEN D, 1968, J GEN VIROL, V3, P371, DOI 10.1099/0022-1317-3-3-371; Wetzel JM, 1996, RECEPTOR CHANNEL, V4, P165; WIESENFELDHALLIN Z, 1992, P NATL ACAD SCI USA, V89, P3334, DOI 10.1073/pnas.89.8.3334; WYNICK D, 1993, P NATL ACAD SCI USA, V90, P4231, DOI 10.1073/pnas.90.9.4231	43	174	186	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24612	24616		10.1074/jbc.272.39.24612	http://dx.doi.org/10.1074/jbc.272.39.24612			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305929	hybrid			2022-12-25	WOS:A1997XY51500080
J	Lerner, EC; Zhang, TT; Knowles, DB; Qian, YM; Hamilton, AD; Sebti, SM				Lerner, EC; Zhang, TT; Knowles, DB; Qian, YM; Hamilton, AD; Sebti, SM			Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines	ONCOGENE			English	Article						Ras; prenylation; human tumors; FTase inhibitors	PROTEIN GERANYLGERANYLATION; FARNESYL; GROWTH; BLOCKS	The farnesyltransferase (FTase) inhibitor FTI-277 is highly effective at blocking oncogenic H-Ras but not K-Ras4B processing and signaling. While inhibition of processing and signaling of oncogenic K-Ras4B is more sensitive to the geranylgeranyltransferase I (GGTase I) inhibitor GGTI-286 than it is to FTI-277 in K-Ras4B-transformed NIH3T3 cells, the sensitivity of K-Ras as well as H-and N-Ras to the CAAX peptidomimetics in human tumor cell lines is not known. Here, we report that a panel of five human carcinoma cell lines from pancreatic, pulmonary, and bladder origins all express H-, N-, and K-Ras, and their respective prenylation sensitivities to the FTase and GGTase I inhibitors is variable. In all of the cell lines investigated, the prenylation of N-Ras was highly sensitive to FTI-277, and in two of the cell lines, N-Ras showed slight sensitivity to GGTI-298, an analog of GGTI-286. Although the prenylation of H-Ras was also sensitive to FTI-277, complete inhibition of H-Ras processing even at high concentrations of FTI-277 and/or GGTI-298 was never achieved. The prenylation of K-Ras, on the other hand, was highly resistant to FTI-277 and GGTI-298. Most significantly, treatment of human tumor cell lines with both inhibitors inhibition of K-Ras prenylation. In human lung adenocarcinoma A-549, prenylation of K-Ras was highly resistant even when co-treated with both inhibitors. Furthermore, soft agar experiments demonstrated that in all the human tumor cell lines tested inhibition of K-Ras prenylation was not necessary for inhibition of anchorage-independent growth. In addition, although GGTI-298 had very little effect on soft agar growth, the combination of FTI-277 and GGTI-298 resulted in significant growth inhibition. Therefore, the results demonstrate that while FTI-277 inhibits N-Ras and H-Ras processing in the human tumor cell lines evaluated, inhibition of K-Ras processing requires both an FTase inhibitor as well as a GGTase I inhibitor, and that inhibition of human tumor growth in soft agar does not require inhibition of oncogenic K-Ras processing.	UNIV PITTSBURGH,DEPT PHARMACOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,DEPT CHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [U19-CA67771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Buss JE, 1995, CHEM BIOL, V2, P787, DOI 10.1016/1074-5521(95)90083-7; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; NAGASU T, 1995, CANCER RES, V55, P5310; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SATTLER I, 1996, REGULATION RAS SIGNA, P95; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	17	202	214	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1283	1288		10.1038/sj.onc.1201296	http://dx.doi.org/10.1038/sj.onc.1201296			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315095				2022-12-25	WOS:A1997XV84500005
J	Oda, T; Kujovich, J; Reis, M; Newman, B; Druker, BJ				Oda, T; Kujovich, J; Reis, M; Newman, B; Druker, BJ			Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase	ONCOGENE			English	Article						c-Abl; tyrosine kinase; SH2 domains; yeast two hybrid screen	CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; RNA-POLYMERASE-II; MIDDLE-T-ANTIGEN; C-ABL; SIGNAL-TRANSDUCTION; SRC HOMOLOGY-2; BCR-ABL; PHILADELPHIA-CHROMOSOME; BINDING DOMAINS	To further our understanding of the molecular mechanism of Bcr-Abl mediated transformation, a yeast two hybrid screen was used to identify proteins binding to the Abl tyrosine kinase. Two partial cDNAs encoding novel SH2 domain-containing proteins were cloned and designated Shd and She. Both have homology to Shb, a previously reported SH2 domain-containing protein. Northern blot analysis showed that She is expressed in heart, lung, brain, and skeletal muscle, while expression of Shd is restricted to the brain. The deduced amino acid sequence of the full length mouse Shd cDNA contains an amino-terminal proline-rich region, and a carboxy-terminal SH2 domain. A bacterially expressed Shd domain bound multiple tyrosine-phosphorylated proteins with relative molecular weights of 200, 170, 130, 100, 90, 78, 72 and 32 kDa from K562 cell lysates. Shd contains five YXXP motifs, a substrate sequence preferred by Abl tyrosine kinases. Shd was tyrosine phosphorylated in COS-7 cells co-transfected with Shd and c-Abl or Bcr-Abl. These results suggest that Shd may be a physiological substrate of c-Abl and may function as an adapter protein in the central nervous system.	OREGON HLTH SCI UNIV,DIV HEMATOL & MED ONCOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL & DEV BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University			Oda, Tsukasa/ABI-1855-2020	Oda, Tsukasa/0000-0002-8941-161X; Druker, Brian/0000-0001-8331-8206	NCI NIH HHS [CA65823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1996, MOL CELL BIOL, V16, P3361; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BURNS LA, 1993, J BIOL CHEM, V268, P17659; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DAVIS RL, 1985, MOL CELL BIOL, V5, P204, DOI 10.1128/MCB.5.1.204; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DRUKER BJ, 1991, NUCLEIC ACIDS RES, V19, P6855, DOI 10.1093/nar/19.24.6855; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GOGA A, 1995, ONCOGENE, V11, P791; GREENBERGER JS, 1983, P NATL ACAD SCI USA, V80, P2391; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harlow E., 1988, ANTIBODIES LAB MANUA; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KANAKURA Y, 1990, BLOOD, V76, P706; KARLSSON T, 1995, ONCOGENE, V10, P1475; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Nakamura T, 1996, ONCOGENE, V13, P1111; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; ODA T, 1994, J BIOL CHEM, V269, P22925; ODA T, 1995, LEUKEMIA, V9, P295; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P174; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WELSH M, 1994, ONCOGENE, V9, P19; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	61	20	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1255	1262		10.1038/sj.onc.1201299	http://dx.doi.org/10.1038/sj.onc.1201299			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315092				2022-12-25	WOS:A1997XV84500002
J	Irminger, JC; Verchere, CB; Meyer, K; Halban, PA				Irminger, JC; Verchere, CB; Meyer, K; Halban, PA			Proinsulin targeting to the regulated pathway is not impaired in carboxypeptidase E-deficient Cpe(fat)/Cpe(fat) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PROTEINS; SORTING SIGNAL; CELLS; PROOPIOMELANOCORTIN; IDENTIFICATION; CONVERSION; INSULIN; CLEAVAGE; GRANULES; MUTATION	Sorting of proinsulin from the trans-Golgi network to secretory granules is critical for its conversion to insulin as well as for regulated insulin secretion. The proinsulin sorting mechanism is unknown. Recently, carboxypeptidase E (CPE) was proposed as a sorting receptor for prohormones. To know whether CPE is implicated in proinsulin sorting, pancreatic islets were isolated from CPE-deficient Cpe(fat)/Cpe(fat) mice and Cpe(fat)/+ controls, pulse-labeled ([H-3]leucine), and then chased in basal medium (90 min) to examine constitutive secretion followed by medium with secretagogues (60 min) to stimulate regulated secretion. Secretion of labeled proinsulin via the constitutive pathway was <2% even in Cpe(fat)/Cpe(fat) islets. After a 150-min chase, only 13% of radioactivity remained as proinsulin in Cpe(fat)/+ islets compared with 46% in Cpe(fat)/Cpe(fat) islets, reflecting slower conversion. Regulated secretion was stimulated to an equal extent from Cpe(fat)/+ and Cpe(fat)/Cpe(fat) mice with 20% of the total content of labeled (pro)insulin released during the 60-min stimulatory period. It is concluded that in CPE-deficient Cpe(fat)/ Cpe(fat) mice, proinsulin is efficiently routed to the regulated pathway and its release can be effectively stimulated by secretagogues. CPE is thus not essential for sorting proinsulin to granules.			Irminger, JC (corresponding author), UNIV GENEVA,LABS RECH LOUIS JEANTET,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.							CASTLE AM, 1992, J BIOL CHEM, V267, P13093; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; GORR SU, 1995, FEBS LETT, V361, P8, DOI 10.1016/0014-5793(95)00142-V; GUEST PC, 1995, MOL CELL ENDOCRINOL, V113, P99, DOI 10.1016/0303-7207(95)03619-I; HALBAN PA, 1994, BIOCHEM J, V299, P1; IRMINGER JC, 1994, J BIOL CHEM, V269, P1756; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; ROY P, 1991, MOL CELL ENDOCRINOL, V82, P237, DOI 10.1016/0303-7207(91)90037-S; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; Shen FS, 1997, P NATL ACAD SCI USA, V94, P5314, DOI 10.1073/pnas.94.10.5314; SIZONENKO SV, 1991, BIOCHEM J, V278, P621, DOI 10.1042/bj2780621; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; Thiele C, 1997, CURR BIOL, V7, pR496, DOI 10.1016/S0960-9822(06)00247-8	25	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27532	27534		10.1074/jbc.272.44.27532	http://dx.doi.org/10.1074/jbc.272.44.27532			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346885	hybrid			2022-12-25	WOS:A1997YD47300011
J	Adelman, K; Orsini, G; Kolb, A; Graziani, L; Brody, EN				Adelman, K; Orsini, G; Kolb, A; Graziani, L; Brody, EN			The interaction between the AsiA protein of bacteriophage T4 and the sigma(70) subunit of Escherichia coli RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC UV5 PROMOTER; OPEN-COMPLEX-FORMATION; TRANSCRIPTION INITIATION; MIDDLE PROMOTERS; SIGMA-70 SUBUNIT; MOTA PROTEIN; DNA; SPECIFICITY; RECOGNITION; BINDING	The AsiA protein of bacteriophage T4 binds to the sigma 70 subunit of Escherichia coli RNA polymerase and plays a dual regulatory role during T4 development: (i) inhibition of host and phage early transcription, and (ii) coactivation of phage middle-mode transcription, which also requires the T4 DNA binding transcriptional activator, MotA. We report that the interaction between AsiA and sigma(70) occurs with a 1:1 stoichiometry, When preincubated with RNA polymerase, AsiA is a potent inhibitor of open complex formation at the lac UV5 promoter, whereas it does not perturb preformed open or intermediate promoter complexes. DNase I footprinting and electrophoretic mobility shift analyses of RNA polymerase-DNA complexes formed at the T4 early promoter P15.0 show that AsiA blocks the initial RNA polymerase binding step that leads to the formation of specific closed promoter complexes, A contrasting result is obtained on the T4 middle promoter PrIIB2, where AsiA stimulates the formation of both closed complexes and open complexes, Therefore, we propose that AsiA modulates initial DNA binding by the RNA polymerase, switching promoter usage at the level of closed complex formation.	UNIV PARIS 06, CNRS, UPR 9061, CTR GENET MOL, LAB ASSOCIE, F-91198 GIF SUR YVETTE, FRANCE; INST PASTEUR, CNRS, URA 1149, UNITE PHYSICOCHIM MACROMOL BIOL, F-75724 PARIS 15, FRANCE; SUNY BUFFALO, DEPT CHEM, BUFFALO, NY 14260 USA; UNIV COLORADO, DEPT MOL CELLULAR & DEV BIOL, BOULDER, CO 80309 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Colorado System; University of Colorado Boulder				Adelman, Karen/0000-0001-5364-334X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050700] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50700] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRODY EN, 1995, FEMS MICROBIOL LETT, V128, P1; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BUCKLE M, 1992, EMBO J, V11, P2619, DOI 10.1002/j.1460-2075.1992.tb05327.x; BUCKLE M, 1994, TRANSCRIPTION MECH R, P207; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Burns HD, 1996, BIOCHEM J, V317, P305, DOI 10.1042/bj3170305; Busby S, 1994, Methods Mol Biol, V30, P397; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GUILD N, 1988, J MOL BIOL, V199, P241, DOI 10.1016/0022-2836(88)90311-7; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HINTON DM, 1991, J BIOL CHEM, V266, P18034; Hinton DM, 1996, J MOL BIOL, V256, P235, DOI 10.1006/jmbi.1996.0082; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; KUMAR A, 1993, J MOL BIOL, V232, P406, DOI 10.1006/jmbi.1993.1400; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MACDONALD PM, 1984, GENETICS, V106, P17; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MCCOY M I M, 1979, Biochimica et Biophysica Acta, V562, P149; Mosig Gisela, 1994, P127; ORSINI G, 1993, J BACTERIOL, V175, P85, DOI 10.1128/JB.175.1.85-93.1993; OUHAMMOUCH M, 1995, P NATL ACAD SCI USA, V92, P1451, DOI 10.1073/pnas.92.5.1451; OUHAMMOUCH M, 1994, J BACTERIOL, V176, P5194, DOI 10.1128/jb.176.16.5194.1994; OZOLINE ON, 1995, NUCLEIC ACIDS RES, V23, P4533, DOI 10.1093/nar/23.22.4533; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; RICHET E, 1991, J MOL BIOL, V218, P529; SCHAEFFER F, 1982, EMBO J, V1, P99, DOI 10.1002/j.1460-2075.1982.tb01131.x; Severinova E, 1996, J MOL BIOL, V263, P637, DOI 10.1006/jmbi.1996.0604; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STEVENS A, 1977, BIOCHIM BIOPHYS ACTA, V475, P193, DOI 10.1016/0005-2787(77)90355-0; Stevens A., 1976, RNA POLYMERASE, P617; Stitt Barbara, 1994, P142; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; TRAVERS AA, 1987, CRIT REV BIOCHEM MOL, V22, P181, DOI 10.3109/10409238709101483; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; WILKENS K, 1994, MOL BIOL BACTERIOP T, V4, P132; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	43	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27435	27443		10.1074/jbc.272.43.27435	http://dx.doi.org/10.1074/jbc.272.43.27435			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341196	hybrid			2022-12-25	WOS:A1997YC65900092
J	Okada, N; Watarai, M; Ozeri, V; Hanski, E; Caparon, M; Sasakawa, C				Okada, N; Watarai, M; Ozeri, V; Hanski, E; Caparon, M; Sasakawa, C			A matrix form of fibronectin mediates enhanced binding of Streptococcus pyogenes to host tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; PROTEIN-F; SURFACE PROTEIN; EXTRACELLULAR-MATRIX; MULTIPLE BINDING; ESCHERICHIA-COLI; ADHERENCE; RECEPTOR; ADHESINS; DOMAIN	The pathogenic Gram-positive bacterium Streptococcus pyogenes (group A streptococcus) binds to fibronectin via protein P. In this study, we have investigated the binding properties of protein F to various multimeric tissue forms of fibronectin that appear on cell surfaces and in the extracellular matrix, We show that binding of S. pyogenes through protein F is more efficient to an in vitro-derived polymerized form of fibronectin (superfibronectin) than to soluble fibronectin immobilized ins a solid phase, In addition, Chinese hamster ovary cells overexpressing the alpha(5) beta(1) integrin produced an increased amount of a fibronectin matrix and consequently bound a higher number of S. pyogenes cells. Inhibition and direct binding assays using purified Proteins demonstrated that binding to a fibronectin matrix involved both domains of protein F (UR and RD2) that have previously been implicated in interactions with fibronectin, Using intact S. pyogenes bacteria in which various domains of protein F were expressed as hybrids with the surface-exposed region of an unrelated protein, we revealed that, in contrast to the predominantly UR-mediated binding to soluble fibronectin, the maximal binding to the fibronectin matrix required RD2 inn addition to UR. Since in some infections a pyogenes may initially encounter a matrix form of fibronectin, these results suggest that UR and RD2 may be important for the initiation of streptococcal infectious processes.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT CLIN MICROBIOL,IL-91010 JERUSALEM,ISRAEL; WASHINGTON UNIV,SCH MED,DEPT MOL MICROBIOL,ST LOUIS,MO 63110	Hebrew University of Jerusalem; Washington University (WUSTL)	Okada, N (corresponding author), UNIV TOKYO,INST MED SCI,DEPT BACTERIOL,MINATO KU,4-6-1 SHIROKANEDAI,TOKYO 108,JAPAN.		hanski, emanuel/M-2696-2018	hanski, emanuel/0000-0001-5054-0628				BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; CAPARON MG, 1992, J BACTERIOL, V174, P5693, DOI 10.1128/JB.174.17.5693-5701.1992; COURTNEY HS, 1994, INFECT IMMUN, V62, P3937, DOI 10.1128/IAI.62.9.3937-3946.1994; COURTNEY HS, 1992, CURR MICROBIOL, V25, P245, DOI 10.1007/BF01575856; FOGG GC, 1994, MOL MICROBIOL, V11, P671, DOI 10.1111/j.1365-2958.1994.tb00345.x; FRICK IM, 1995, EMBO J, V14, P1674, DOI 10.1002/j.1460-2075.1995.tb07156.x; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HANSKI E, 1995, METHOD ENZYMOL, V253, P269; HANSKI E, 1992, P NATL ACAD SCI USA, V89, P6172, DOI 10.1073/pnas.89.13.6172; HASTY DL, 1992, INFECT IMMUN, V60, P2147, DOI 10.1128/IAI.60.6.2147-2152.1992; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KREIKEMEYER B, 1995, MOL MICROBIOL, V17, P137, DOI 10.1111/j.1365-2958.1995.mmi_17010137.x; Lee JY, 1996, INFECT IMMUN, V64, P413, DOI 10.1128/IAI.64.2.413-421.1996; LOWRANCE JH, 1988, INFECT IMMUN, V56, P2279, DOI 10.1128/IAI.56.9.2279-2285.1988; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; NATANSON S, 1995, J INFECT DIS, V171, P871, DOI 10.1093/infdis/171.4.871; OKADA N, 1994, J CLIN INVEST, V94, P965, DOI 10.1172/JCI117463; Ozeri V, 1996, EMBO J, V15, P989, DOI 10.1002/j.1460-2075.1996.tb00435.x; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; PATTI JM, 1994, CURR OPIN CELL BIOL, V6, P752, DOI 10.1016/0955-0674(94)90104-X; PEAKE P, 1993, INFECT IMMUN, V61, P4828, DOI 10.1128/IAI.61.11.4828-4834.1993; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; RAKONJAC JV, 1995, INFECT IMMUN, V63, P622, DOI 10.1128/IAI.63.2.622-631.1995; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SCHMIDT KH, 1993, FEMS IMMUNOL MED MIC, V7, P135; SCHULZEKOOPS H, 1993, INFECT IMMUN, V61, P2513, DOI 10.1128/IAI.61.6.2513-2519.1993; SCOTT JR, 1974, VIROLOGY, V62, P344, DOI 10.1016/0042-6822(74)90397-3; SCOTT JR, 1986, J EXP MED, V164, P1641, DOI 10.1084/jem.164.5.1641; SELA S, 1993, MOL MICROBIOL, V10, P1049, DOI 10.1111/j.1365-2958.1993.tb00975.x; SIMPSON WA, 1987, REV INFECT DIS, V9, pS351; TALAY SR, 1994, MOL MICROBIOL, V13, P531, DOI 10.1111/j.1365-2958.1994.tb00448.x; TALAY SR, 1992, INFECT IMMUN, V60, P3837, DOI 10.1128/IAI.60.9.3837-3844.1992; TALAY SR, 1991, MOL MICROBIOL, V5, P1727, DOI 10.1111/j.1365-2958.1991.tb01921.x; TAMURA GS, 1995, MOL MICROBIOL, V15, P581, DOI 10.1111/j.1365-2958.1995.tb02271.x; VONDERFLIER M, 1995, INFECT IMMUN, V63, P4317; WANNAMAKER LW, 1970, NEW ENGL J MED, V282, P23, DOI 10.1056/NEJM197001082820206; Watarai M, 1996, J EXP MED, V183, P991, DOI 10.1084/jem.183.3.991; WESTERLUND B, 1989, FEBS LETT, V243, P199, DOI 10.1016/0014-5793(89)80129-2	42	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26978	26984		10.1074/jbc.272.43.26978	http://dx.doi.org/10.1074/jbc.272.43.26978			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341135	hybrid			2022-12-25	WOS:A1997YC65900031
J	Miyamoto, Y; Imamoto, N; Sekimoto, T; Tachibana, T; Seki, T; Tada, S; Enomoto, T; Yoneda, Y				Miyamoto, Y; Imamoto, N; Sekimoto, T; Tachibana, T; Seki, T; Tada, S; Enomoto, T; Yoneda, Y			Differential modes of nuclear localization signal (NLS) recognition by three distinct classes of NLS receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-TARGETING COMPLEX; AMINO-ACID MOTIF; PROTEIN IMPORT; HUMAN HOMOLOG; HELA-CELLS; IDENTIFICATION; BINDING; INTERACTS; TRANSPORT; RAN/TC4	The targeting of karyophilic proteins to nuclear pores is mediated via the formation of a nuclear pore-targeting complex, through the interaction of nuclear localization signal (NLS) with its NLS receptor. Recently, a novel human protein, Qip1, was identified from a yeast two-hybrid system with DNA helicase Q1. This study demonstrates that Qip1 is a novel third class of NLS receptor that efficiently recognizes the NLS of the helicase Q1. Moreover, the data obtained in this study show that the specific interaction between Qip1 and the NLS of the helicase Q1 requires its upstream sequence of the minimal essential NLS. By using purified recombinant proteins alone in the digitonin-permeabilized cell-free transport system, it was demonstrated that the two known human NLS receptors, Rch1 and NPI-1, are able to transport all the tested NLS substrates into the nucleus, while Qip1 most efficiently transports the helicase Q1-NLS substrates, which contain its upstream sequence in so far as we have examined the system. Furthermore, in HeLa cell crude cytosol, it was found that endogenous Rch1 binds to all the tested NLS substrates, while the binding of endogenous NPI-1 is restricted to only some NLSs, despite the fact that NPI-1 itself shows binding activity to a variety of NLSs. These results indicate that at least three structurally and functionally distinct NLS receptors exist in the human single cell population, and suggest that the nuclear import of karyophilic proteins may be controlled in a complex manner at the NLS recognition step by the existence of a variety of NLS receptors with various specificities to each NLS.	OSAKA UNIV, SCH MED, DEPT ANAT & CELL BIOL, SUITA, OSAKA 565, JAPAN; UNIV TOKYO, FAC PHARMACEUT SCI, DEPT PHYSIOL CHEM, BUNKYO KU, TOKYO 113, JAPAN; TOHOKU UNIV, FAC PHARMACEUT SCI, DEPT MOL CELL BIOL, AOBA KU, SENDAI, MIYAGI 98077, JAPAN	Osaka University; University of Tokyo; Tohoku University			Imamoto, Naoko/A-7458-2015	Imamoto, Naoko/0000-0002-2886-3022; Miyamoto, Yoichi/0000-0003-4016-1119				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Hicks GR, 1996, PLANT CELL, V8, P1337, DOI 10.1105/tpc.8.8.1337; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; SEKI M, 1994, J BIOCHEM-TOKYO, V115, P523, DOI 10.1093/oxfordjournals.jbchem.a124369; Seki T, 1997, BIOCHEM BIOPH RES CO, V234, P48, DOI 10.1006/bbrc.1997.6535; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; Tada S, 1996, CELL STRUCT FUNCT, V21, P123, DOI 10.1247/csf.21.123; TOROK I, 1995, J CELL BIOL, V129, P1473, DOI 10.1083/jcb.129.6.1473; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3; Yoneda Y, 1996, ARCH HISTOL CYTOL, V59, P97, DOI 10.1679/aohc.59.97	50	149	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26375	26381		10.1074/jbc.272.42.26375	http://dx.doi.org/10.1074/jbc.272.42.26375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334211	hybrid			2022-12-25	WOS:A1997YB13900045
J	Palaparti, A; Baratz, A; Stifani, S				Palaparti, A; Baratz, A; Stifani, S			The groucho/transducin-like enhancer of split transcriptional repressors interact with the genetically defined a amino-terminal silencing domain of histone H3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX REPRESSOR; DROSOPHILA-ENHANCER; SACCHAROMYCES-CEREVISIAE; COREPRESSOR COMPLEX; CHROMATIN STRUCTURE; GROUCHO TRANSCRIPT; GLUCOSE REPRESSION; BHLH PROTEINS; GENE-PRODUCT; WRPW MOTIF	Groucho is a transcriptional repressor implicated in Notch signaling and involved in neural development and segmentation in Drosophila. We are investigating the molecular mechanisms underlying the functions of Groucho and its mammalian homologs, the transducin-like Enhancer of split (TLE) proteins, We report that Groucho/TLEs are associated with chromatin in live cells and that they co-purify with isolated histones. Affinity chromatography and far Western blotting studies show further that native Groucho/TLE proteins interact specifically with histone H3 and not with other core histones. This interaction is mediated by the H8 aminoterminal domain previously shown by genetic analysis in yeast to be essential for the role of H3 in transcriptional silencing, We also demonstrate that Groucho/TLEs form oligomeric structures in vivo, These combined findings suggest that transcription complexes containing Groucho/TLEs may associate with chromatin through interactions with the amino terminus of histone H3 and that these interactions may be propagated along the chromosome due to the ability of Groucho/TLEs to participate in higher order structures.	MCGILL UNIV,MONTREAL NEUROL INST,CTR NEURONAL SURVIVAL,MONTREAL,PQ H3A 2B4,CANADA	McGill University				Stifani, Stefano/0000-0002-2376-7701				ANDERSSON LO, 1972, FEBS LETT, V20, P199, DOI 10.1016/0014-5793(72)80793-2; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; AXEL R, 1973, P NATL ACAD SCI USA, V70, P2029, DOI 10.1073/pnas.70.7.2029; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; DECELIS JF, 1995, DEVELOPMENT, V121, P3467; DEHNI G, 1995, MECH DEVELOP, V53, P369, DOI 10.1016/0925-4773(95)00452-1; DELIDAKIS C, 1991, GENETICS, V129, P803; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; FISCHERVIZE JA, 1992, DEVELOPMENT, V115, P89; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Heitzler P, 1996, DEVELOPMENT, V122, P161; Hubbard EJA, 1996, SCIENCE, V273, P112, DOI 10.1126/science.273.5271.112; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; KAGEYAMA R, 1995, CRIT REV NEUROBIOL, V9, P177; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KNUST E, 1992, GENETICS, V132, P505; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Koop KE, 1996, MECH DEVELOP, V59, P73, DOI 10.1016/0925-4773(96)00582-5; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; MALLO M, 1995, DEV DYNAM, V204, P338, DOI 10.1002/aja.1002040311; MALLO M, 1993, MECH DEVELOP, V42, P67, DOI 10.1016/0925-4773(93)90099-J; MIYASAKA H, 1993, EUR J BIOCHEM, V216, P343, DOI 10.1111/j.1432-1033.1993.tb18151.x; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pinto M, 1996, J BIOL CHEM, V271, P33026, DOI 10.1074/jbc.271.51.33026; ROTH SY, 1995, CURR OPIN GENET DEV, V5, P168, DOI 10.1016/0959-437X(95)80004-2; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHMIDT CJ, 1993, J BIOL CHEM, V268, P25681; SCHRONS H, 1992, GENETICS, V132, P481; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; VANDERWE.DR, 1971, FEBS LETT, V14, P333, DOI 10.1016/0014-5793(71)80294-6; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; Varanasi US, 1996, MOL CELL BIOL, V16, P6707; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307	47	130	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26604	26610		10.1074/jbc.272.42.26604	http://dx.doi.org/10.1074/jbc.272.42.26604			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334241	hybrid			2022-12-25	WOS:A1997YB13900075
J	Sun, B; Murray, NR; Fields, AP				Sun, B; Murray, NR; Fields, AP			A role for nuclear phosphatidylinositol-specific phospholipase C in the G(2)/M phase transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN LEUKEMIC-CELLS; RAT-LIVER NUCLEI; LAMIN-B; DIFFERENTIATION; ACTIVATION; PHOSPHORYLATION; PROLIFERATION; INHIBITION; INDUCTION	Protein kinase C (PKC) is activated at the nucleus during the G(2) phase of cell cycle, where it is required for mitosis, However, the mechanisms controlling cell cycle-dependent activation of nuclear PKC are not known, We now report that nuclear levels of the major physiologic PKC activator diacylglycerol (DAG) fluctuate during cell cycle. Specifically, nuclear DAG levels in G(2)/M phase cells are 2.5-3-fold higher than in G(1) phase cells, In synchronized cells, nuclear DAG levels rise to a peak coincident with the G(2)/M phase transition and return to basal levels in G(1) phase cells, This increase in DAG level is sufficient to stimulate beta(II) PKC-mediated phosphorylation of its mitotic nuclear envelope substrate lamin B in vitro, Isolated nuclei from G(2) phase cells contain an active phospholipase activity capable of generating DAG in vitro, Nuclear phospholipase activity is inhibited by the selective phosphatidylinositol-specific phospholipase C (PI-PLC) inhibitor 1-O-octadeyl-2-O-methyl-sn-glycero-3-phosphocholine and neomycin sulfate, but not by the phosphatidylcholine-PLC selective inhibitor D609 or inhibitors of phospholipase D-mediated DAG generation, Treatment of synchronized cells with 1-O-octadeyl-2-O-methyl-sn-glycero-3-phosphocholine leads to decreased nuclear PI-PLC activity and cell cycle blockade in the G(2) phase, suggesting a role for nuclear PI-PLC in the G(2)/M phase transition, Our data are consistent with the hypothesis that nuclear PI-PLC generates DAG to activate nuclear beta(II) PKC, whose activity is required for mitosis.	UNIV TEXAS,MED BRANCH,SEALY CTR ONCOL & HEMATOL,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston								ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; CLEMENS MJ, 1992, J CELL SCI, V103, P881; DIOMEDE L, 1994, INT J CANCER, V57, P645, DOI 10.1002/ijc.2910570506; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1995, BIOCHEM J, V312, P63, DOI 10.1042/bj3120063; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; GOSS VL, 1994, J BIOL CHEM, V269, P19074; HEESBEEN EC, 1993, LEUKEMIA RES, V17, P143, DOI 10.1016/0145-2126(93)90059-T; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; KURIKI H, 1992, J BIOCHEM-TOKYO, V111, P283, DOI 10.1093/oxfordjournals.jbchem.a123750; LISCOVITCH M, 1991, BIOCHEM J, V279, P319, DOI 10.1042/bj2790319; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; MOLLINEDO F, 1993, BIOCHEM BIOPH RES CO, V192, P603, DOI 10.1006/bbrc.1993.1458; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; MURRAY NR, 1997, PROTEIN KINASE C, P97; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; OKAMOTO S, 1987, CANCER RES, V47, P2599; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PAPPU AS, 1983, NEUROCHEM RES, V8, P1565, DOI 10.1007/BF00964158; POWIS G, 1992, CANCER RES, V52, P2835; PRIESS JE, 1987, METHOD ENZYMOL, V141, P294; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; TOKER A, 1994, J BIOL CHEM, V269, P32358; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156	36	106	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26313	26317		10.1074/jbc.272.42.26313	http://dx.doi.org/10.1074/jbc.272.42.26313			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334202	hybrid			2022-12-25	WOS:A1997YB13900036
J	Zhang, Y; Scandura, JM; VanNostrand, WE; Walsh, PN				Zhang, Y; Scandura, JM; VanNostrand, WE; Walsh, PN			The mechanism by which heparin promotes the inhibition of coagulation factor XIa by protease nexin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; ANTITHROMBIN-III; HUMAN PLATELETS; ALPHA-1-PROTEASE INHIBITOR; SLOW-BINDING; FACTOR-XA; THROMBIN; PURIFICATION	Previous kinetic studies have shown that protease nexin-2 is a potent, reversible, and competitive inhibitor of factor XIa. Here we show that high molecular weight heparin potentiates the ability of protease nexin-2 to inhibit factor XIa with a parabolic concentration dependence, predominantly because of an increase of the association rate constant with little perturbation of the dissociation rate constant. No effect on factor XIa inhibition by protease nexin-a was observed with heparin preparations of 6-22 saccharide units (0.1 nM-10 mu M), whereas heparin preparations with 32-64 saccharide units potentiated factor XIa inhibition by protease nexin-2 in a size-and concentration-dependent manner. We propose a model wherein heparin exerts this effect by providing a template for the assembly of factor XIa-protease nexin-a complexes, and only heparin polymers consisting of greater than 32 saccharide units (M-r similar to 10,000) are sufficiently long to provide a template to which factor XIa and protease nexin-a molecules can bind simultaneously. Heparin-mediated enhancement of factor XIa inhibition by protease nexin-2 was partially abrogated by high molecular weight kininogen, suggesting that high molecular weight kininogen may play a role in regulating factor XIa activity.	TEMPLE UNIV,SCH MED,SOL SHERRY THROMBOSIS RES CTR,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT MED,PHILADELPHIA,PA 19140; SUNY STONY BROOK,DEPT MED,STONY BROOK,NY 11794	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Scandura, Joseph/0000-0002-9525-143X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056153, R01HL046213, P50HL045486] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45486, HL56153, HL46213] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEELER DL, 1986, BLOOD, V67, P1488; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BROEKMAN MJ, 1975, BRIT J HAEMATOL, V31, P51, DOI 10.1111/j.1365-2141.1975.tb00831.x; BUSH AI, 1990, J BIOL CHEM, V265, P15977; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; HOLMER E, 1981, BIOCHEM J, V193, P395, DOI 10.1042/bj1930395; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOMIYAMA Y, 1992, THROMB RES, V66, P397, DOI 10.1016/0049-3848(92)90289-M; LANE DA, 1986, J BIOL CHEM, V261, P3980; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; MELHADO LL, 1982, J AM CHEM SOC, V104, P7299, DOI 10.1021/ja00389a065; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NESHEIM M, 1986, J BIOL CHEM, V261, P3214; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; SALVESEN G, 1994, HEMOSTASIS THROMBOSI; Scandura JM, 1997, BIOCHEMISTRY-US, V36, P412, DOI 10.1021/bi9612576; SCOTT CF, 1982, J CLIN INVEST, V69, P844, DOI 10.1172/JCI110524; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VANNOSTRAND WE, 1995, THROMB RES, V78, P43, DOI 10.1016/0049-3848(95)00033-X; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; WALSH PN, 1987, J CLIN INVEST, V80, P1578, DOI 10.1172/JCI113244	33	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26139	26144		10.1074/jbc.272.42.26139	http://dx.doi.org/10.1074/jbc.272.42.26139			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334179	hybrid			2022-12-25	WOS:A1997YB13900013
J	Fredenburgh, JC; Stafford, AR; Weitz, JI				Fredenburgh, JC; Stafford, AR; Weitz, JI			Evidence for allosteric linkage between exosites 1 and 2 of thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; PROTEIN-C ACTIVATION; BLOOD-COAGULATION PROTEINASES; PROTHROMBIN FRAGMENT-2; ACTIVE-SITE; FACTOR-VA; STRUCTURAL-CHANGES; PPACK-THROMBIN; CATALYTIC SITE; BINDING	Investigations to date have demonstrated that ligand binding to exosites 1 or 2 on thrombin produces conformational changes at the active site. In this study, we directly compared the effect of ligand binding to exosites 1 and 2 on the structure and function of the active site of thrombin and investigated functional linkage between the two exosites. Binding studies were performed in solution with fluorescein-Phe-Pro-Arg-CH2Cl (FPR)-thrombin. Hirudin-(54-65) and sF2, a synthetic peptide corresponding to residues 63-116 of prothrombin fragment 2, were used as ligands for exosites 1 and 2 of thrombin, respectively. The two ligands produce diametric changes in the fluorescence of fluorescein-FPR-thrombin and also have opposing effects on the rate of thrombin hydrolysis of a number of chromogenic substrates. These results indicate that sF2 and hirudin-(54-65) differentially affect the conformation of the active site. Experiments then were performed to investigate whether both ligands can bind to thrombin simultaneously. When thrombin-bound fluorescein-sF2 is titrated with hirudin-(54-65), complete displacement of fluorescein-sF2 is observed. Likewise, when thrombin-bound fluorescein-hirudin-(54-65) is titrated with sF2, complete displacement occurs. Additional support for reciprocal binding was obtained in fluorescence experiments where both probes were labeled and in experiments monitoring ligand binding to agarose-immobilized thrombin. This mutually exclusive binding of either ligand can be explained by reciprocal, allosteric modulation of ligand affinity between the two exosites. Thus, not only do the two exosites differentially influence the active site, they also affect the binding properties of the opposing exosite.	HAMILTON CIV HOSP, RES CTR, HAMILTON, ON L8V 1C3, CANADA; MCMASTER UNIV, HAMILTON, ON L8V 1C3, CANADA	McMaster University; McMaster University			Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1992, PROTEIN SCI, V1, P426; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; Bray A M, 1995, J Pept Sci, V1, P80, DOI 10.1002/psc.310010110; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CHURCH WR, 1991, J BIOL CHEM, V266, P8384; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; DECRISTOFARO R, 1995, J MOL BIOL, V245, P447; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; Hogg PJ, 1996, J BIOL CHEM, V271, P26088, DOI 10.1074/jbc.271.42.26088; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; JACKMAN MP, 1992, J BIOL CHEM, V267, P15375; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; KARSHIKOV A, 1992, PROTEIN SCI, V1, P727, DOI 10.1002/pro.5560010605; KOTKOW KJ, 1995, J BIOL CHEM, V270, P4551, DOI 10.1074/jbc.270.9.4551; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU LW, 1991, J BIOL CHEM, V266, P16977; LIU LW, 1994, J BIOL CHEM, V269, P11807; LIU LW, 1991, J BIOL CHEM, V266, P23632; Mann KG., 1994, HEMOSTASIS THROMBOSI, P184; MAO SJT, 1988, BIOCHEMISTRY-US, V27, P8170, DOI 10.1021/bi00421a027; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; NASKI MC, 1990, J BIOL CHEM, V265, P13484; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OLSON TA, 1986, ANN NY ACAD SCI, V485, P96, DOI 10.1111/j.1749-6632.1986.tb34571.x; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; STEVENS WK, 1993, BIOCHEMISTRY-US, V32, P2787, DOI 10.1021/bi00062a008; STONE SR, 1987, EUR J BIOCHEM, V169, P373, DOI 10.1111/j.1432-1033.1987.tb13622.x; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WALKER FJ, 1979, J BIOL CHEM, V254, P5618; WEITZ JI, 1991, J CLIN INVEST, V87, P1082, DOI 10.1172/JCI115069; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1993, J BIOL CHEM, V268, P2373; YE J, 1994, J BIOL CHEM, V269, P17965	44	92	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25493	25499		10.1074/jbc.272.41.25493	http://dx.doi.org/10.1074/jbc.272.41.25493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325262	hybrid			2022-12-25	WOS:A1997YA35800017
J	Curmi, PA; Andersen, SSL; Lachkar, S; Gavet, O; Karsenti, E; Knossow, M; Sobel, A				Curmi, PA; Andersen, SSL; Lachkar, S; Gavet, O; Karsenti, E; Knossow, M; Sobel, A			The stathmin/tubulin interaction in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STAGE-SPECIFIC EXPRESSION; MICROTUBULE DYNAMICS; PHYLOGENETIC CONSERVATION; DEVELOPMENTAL REGULATION; MAJOR PHOSPHOPROTEIN; LIVER-REGENERATION; MESSENGER-RNA; GENE FAMILY; RAT-BRAIN	Stathmin is a highly conserved ubiquitous cytoplasmic protein, phosphorylated in response to extracellular signals and during the cell cycle, Stathmin has recently been shown to destabilize microtubules, but the molecular mechanisms of this function remained unclear. We show here that stathmin directly interacts with tubulin, We assessed the conditions of this interaction and determined some its quantitative parameters using plasmon resonance, gel filtration chromatography, and analytical ultracentrifugation. The stathmin/tubulin interaction leads to the formation of a 7.7 S complex with a 60-Angstrom Stokes radius, associating one stathmin with two tubulin heterodimer molecules as determined by direct quantification by Western blotting, This interaction is sensitive to pH and ionic environment. Its equilibrium dissociation constant, determined by plasmon resonance measurement of kinetic constants, has an optimum value of 0.5 mu M at pH 6.5. The affinity was lowered with a fully ''pseudophosphorylated'' 4-Glu mutant form of stathmin, suggesting that it is modulated in vivo by stathmin phosphorylation. Finally, analysis of microtubule dynamics by video microscopy shows that, in our conditions, stathmin reduces the growth rate of microtubules with no effect on the catastrophe frequency. Overall, our results suggest that the stathmin destabilizing activity on microtubules is related to tubulin sequestration by stathmin.	EUROPEAN MOL BIOL LAB,CELL BIOL PROGRAM,D-69012 HEIDELBERG,GERMANY; CNRS,LAB ENZYMOL & BIOL STRUCT,UPR 9063,F-91198 GIF SUR YVETTE,FRANCE	European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Curmi, PA (corresponding author), INSERM,U440,17 RUE FER MOULIN,F-75005 PARIS,FRANCE.		CURMI, Patrick/G-4036-2013; Andersen, Søren S. L./O-1915-2017	Andersen, Søren S. L./0000-0002-3625-1640; CURMI, Patrick A./0000-0001-5045-8501				ALLEN RD, 1981, CELL MOTIL CYTOSKEL, V1, P291, DOI 10.1002/cm.970010303; AMAT JA, 1991, DEV BRAIN RES, V60, P205, DOI 10.1016/0165-3806(91)90049-O; ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; Balogh A, 1996, EXP CELL RES, V224, P8, DOI 10.1006/excr.1996.0106; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1993, J BIOL CHEM, V268, P20076; BERETTA L, 1988, ENDOCRINOLOGY, V122, P40, DOI 10.1210/endo-122-1-40; CHNEIWEISS H, 1992, J NEUROCHEM, V58, P282, DOI 10.1111/j.1471-4159.1992.tb09308.x; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; COOPER HL, 1991, J IMMUNOL, V146, P3689; CURMI PA, 1994, BIOCHEM J, V300, P331, DOI 10.1042/bj3000331; DOYE V, 1992, DIFFERENTIATION, V50, P89, DOI 10.1111/j.1432-0436.1992.tb00489.x; DOYE V, 1990, J BIOL CHEM, V265, P11650; FRIEDRICH B, 1995, PROSTATE, V27, P102, DOI 10.1002/pros.2990270207; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; HAILAT N, 1990, ONCOGENE, V5, P1615; HANASH SM, 1988, J BIOL CHEM, V263, P12813; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KOPPEL J, 1993, FEBS LETT, V331, P65, DOI 10.1016/0014-5793(93)80298-9; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; LEGOUVELLO S, 1991, FEBS LETT, V287, P80, DOI 10.1016/0014-5793(91)80020-4; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; MAUCUER A, 1993, J BIOL CHEM, V268, P16420; MAUCUER A, 1997, J BIOL CHEM, V272; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; OKAZAKI T, 1993, FEBS LETT, V336, P8, DOI 10.1016/0014-5793(93)81598-T; OZON S, 1997, IN PRESS EUR J BIOCH, V248; PAMPFER S, 1992, REPROD FERT DEVELOP, V4, P205, DOI 10.1071/RD9920205; PASMANTIER R, 1986, ENDOCRINOLOGY, V19, P1229; PESCHANSKI M, 1993, J COMP NEUROL, V337, P655, DOI 10.1002/cne.903370410; PRAKASH V, 1997, J MOL BIOL, V160, P499; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; SCHUBART UK, 1988, J BIOL CHEM, V263, P12156; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; Schubart UK, 1996, J BIOL CHEM, V271, P14062, DOI 10.1074/jbc.271.24.14062; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SOBEL A, 1983, J BIOL CHEM, V258, P312; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; [No title captured]	48	186	193	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25029	25036		10.1074/jbc.272.40.25029	http://dx.doi.org/10.1074/jbc.272.40.25029			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312110	hybrid			2022-12-25	WOS:A1997XY97000049
J	Inagaki, N; Goto, H; Ogawara, M; Nishi, Y; Ando, S; Inagaki, M				Inagaki, N; Goto, H; Ogawara, M; Nishi, Y; Ando, S; Inagaki, M			Spatial patterns of Ca2+ signals define intracellular distribution of a signaling by Ca2+/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENTS; INOSITOL TRISPHOSPHATE; ASTROCYTES; VIMENTIN; CELLS; PHOSPHORYLATION; VISUALIZATION; OSCILLATIONS; LOCALIZATION; ACTIVATION	Ca2+ plays a central role in cell signaling, and Ca2+/ calmodulin-dependent protein kinase II (CaMKII) is a major mediator of Ca2+ actions. The spatial distribution of intracellular Ca2+ signaling is not homogenous, rather it is dynamically organized, and it has been speculated that spatial patterns of Ca2+ signals may function as a form of cellular information transmitted to downstream molecules, To address this issue, we studied the intracellular distributions of the signalings by CaMKII and Ca2+ in the same astrocytes. The former was visualized by monitoring site-specific phosphorylation of a cytoskeletal protein vimentin, using site-and phosphorylation-specific antibodies, while the latter was examined by fura-2-based Ca2+ microscopy, Local Ca2+ sig- nals induced vimentin phosphorylation by CaMKII localized in the same area, On the other hand, Ca2+ waves in astrocytes induced global phosphorylation of vimentin by CaMKII, A small population of vimentin filaments highly phosphorylated by CaMKII underwent structural alteration into short filaments at electron microscopic level, These results indicate that CaMKII transmits spatial patterns of Ca2+ signals to vimentin as cellular information, The possibility is discussed that spatial patterns of vimentin phosphorylation may be important for intracellular organization of vimentin filament networks.	TOKYO METROPOLITAN INST GERONTOL, DEPT NEUROPHYSIOL, ITABASHI KU, TOKYO 173, JAPAN; TOKYO METROPOLITAN INST GERONTOL, DEPT MEMBRANE BIOCHEM, ITABASHI KU, TOKYO 173, JAPAN; MIE UNIV, SCH MED, DEPT PEDIAT, TSU, MIE 514, JAPAN	Tokyo Metropolitan Institute of Gerontology; Tokyo Metropolitan Institute of Gerontology; Mie University	Inagaki, N (corresponding author), AICHI CANC CTR, RES INST, BIOCHEM LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN.		Inagaki, Masaki/B-9920-2016	Goto, Hidemasa/0000-0002-6796-4467; Inagaki, Naoyuki/0000-0002-2664-9196				Augustine G J, 1992, Curr Opin Neurobiol, V2, P302, DOI 10.1016/0959-4388(92)90119-6; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; FEDOROFF S, 1983, DEV BRAIN RES, V7, P303, DOI 10.1016/0165-3806(83)90187-6; FRANKE WW, 1981, COLD SPRING HARB SYM, V46, P431, DOI 10.1101/SQB.1982.046.01.041; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GILBERT SH, 1994, J CELL BIOL, V127, P489, DOI 10.1083/jcb.127.2.489; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Inagaki M, 1997, J BIOCHEM, V121, P407; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; INAGAKI N, 1994, GLIA, V11, P102, DOI 10.1002/glia.440110205; INAGAKI N, 1991, P NATL ACAD SCI USA, V88, P4215, DOI 10.1073/pnas.88.10.4215; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; POENIE M, 1987, EMBO J, V6, P2223, DOI 10.1002/j.1460-2075.1987.tb02494.x; SCHOLZ WK, 1988, J NEUROSCI, V8, P1039; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Takai Y, 1996, SEMIN CELL DEV BIOL, V7, P741, DOI 10.1006/scdb.1996.0091; Takai Y, 1996, J CELL BIOL, V133, P141, DOI 10.1083/jcb.133.1.141; TAKEMURA K, 1994, PATHOBIOLOGY, V62, P149, DOI 10.1159/000163895; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; YANO S, 1994, J BIOL CHEM, V269, P5428; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	32	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25195	25199		10.1074/jbc.272.40.25195	http://dx.doi.org/10.1074/jbc.272.40.25195			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312133	hybrid			2022-12-25	WOS:A1997XY97000072
J	Muller, S; Goletz, S; Packer, N; Gooley, A; Lawson, AM; Hanisch, FG				Muller, S; Goletz, S; Packer, N; Gooley, A; Lawson, AM; Hanisch, FG			Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1 - All putative sites within the tandem repeat are glycosylation targets in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; SKIM MILK MUCINS; UDP-GALNAC; LINKED POLYLACTOSAMINOGLYCANS; MASS-SPECTROMETRY; IN-VIVO; SPECIFICITY; PROTEINS; PEPTIDES; CORE	Since there is no consensus sequence directing the initial GalNAc incorporation into mucin peptides, O-glycosylation sites are not reliably predictable. We have developed a mass spectrometric sequencing strategy that allows the identification of in vivo O-glycosylation sites on mucin-derived glycopeptides. Lactation-associated MUC1 was isolated from human milli and partially deglycosylated by trifluoromethanesulfonic acid to the level of core GalNAc residues, The product was fragmented by the Arg-C-specific endopeptidase clostripain to yield tandem repeat icosapeptides starting with the PAP motif, PAP20 glycopeptides were subjected to sequencing by post-source decay matrix-assisted laser desorption ionization mass spectrometry or by solid phase Edman degradation to localize the glycosylation sites, The masses of C- or N-terminal fragments registered for the mono-to pentasubstituted PAP20 indicated that GalNAc was linked to the peptide at Ser(5), Thr(6) (GSTA) and Thr(14) (VTSA) but contrary to previous in vitro glycosylation studies also at Thr(19) and Ser(15) located within the PDTR or VTSA motifs, respectively, Quantitative data from solid phase Edman sequencing revealed no preferential glycosylation of the threonines, These discrepancies between in vivo and in vitro glycosylation patterns may be explained by assuming that O-glycosylation of adjacent peptide positions is a dynamically regulated process that depends on changes of the substrate qualities induced by glycosylation at vicinal sites.	UNIV COLOGNE, FAC MED, INST BIOCHEM, D-50931 COLOGNE, GERMANY; MAX DELBRUCK CTR MOL MED, D-13125 BERLIN, GERMANY; MACQUARIE UNIV, CTR ANALYT BIOTECHNOL, SYDNEY, NSW 2109, AUSTRALIA; NORTHWICK PK HOSP & CLIN RES CTR, IMPERIAL COLL SCH MED, MRC, GLYCOSCI LAB, HARROW HA1 3UJ, MIDDX, ENGLAND	University of Cologne; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Macquarie University; Imperial College London			Goletz, Steffen/AAR-2654-2021; Packer, Nicolle/Q-8929-2019	Goletz, Steffen/0000-0003-1463-5448; Packer, Nicolle/0000-0002-7532-4021				AITKEN A, 1989, PROTEIN SEQUENCING P, P43; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BHAVANANDAN VP, 1993, ANAL BIOCHEM, V213, P438, DOI 10.1006/abio.1993.1445; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Brockhausen I, 1996, GLYCOCONJUGATE J, V13, P849, DOI 10.1007/BF00702349; BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155; Chaplin MF, 1986, CARBOHYDRATE ANAL PR; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; GERKEN TA, 1992, BIOCHEMISTRY-US, V31, P639, DOI 10.1021/bi00118a002; Gerken TA, 1997, J BIOL CHEM, V272, P9709; GOLETZ S, 1997, IN PRESS GLYCOBIOLOG; GOOLEY AA, 1994, GLYCOBIOLOGY, V4, P413, DOI 10.1093/glycob/4.4.413; HANISCH FG, 1995, CANCER RES, V55, P4036; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HANISCH FG, 1985, EUR J BIOCHEM, V149, P323, DOI 10.1111/j.1432-1033.1985.tb08929.x; HANISCH FG, 1990, GLYCOCONJUGATE J, V7, P525, DOI 10.1007/BF01189075; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; JEROME KR, 1991, CANCER RES, V51, P2908; KAUFMANN R, 1994, INT J MASS SPECTROM, V131, P355, DOI 10.1016/0168-1176(93)03876-N; MERKLE RK, 1994, METHOD ENZYMOL, V230, P1; MONSIGNY M, 1988, ANAL BIOCHEM, V175, P525, DOI 10.1016/0003-2697(88)90578-7; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; NISHIMORI I, 1994, J BIOL CHEM, V269, P16123; NISHIMORI I, 1994, CANCER RES, V54, P3738; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OSHANNESSY DJ, 1987, ANAL BIOCHEM, V163, P204, DOI 10.1016/0003-2697(87)90114-X; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; PISANO A, 1994, GLYCOBIOLOGY, V4, P837, DOI 10.1093/glycob/4.6.837; PISANO A, 1997, TECHNIQUES GLYCOBIOL, P299; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SHIMIZU M, 1982, J BIOCHEM, V91, P515, DOI 10.1093/oxfordjournals.jbchem.a133724; SOJAR HT, 1987, ARCH BIOCHEM BIOPHYS, V259, P52, DOI 10.1016/0003-9861(87)90469-3; Spencer DIR, 1996, CANCER LETT, V100, P11, DOI 10.1016/0304-3835(95)04055-2; STADIE TRE, 1995, EUR J BIOCHEM, V229, P140, DOI 10.1111/j.1432-1033.1995.tb20448.x; TAYLORPAPADIMITRIOU J, 1994, TRENDS BIOTECHNOL, V12, P227, DOI 10.1016/0167-7799(94)90121-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728	38	131	140	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24780	24793		10.1074/jbc.272.40.24780	http://dx.doi.org/10.1074/jbc.272.40.24780			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312074	hybrid			2022-12-25	WOS:A1997XY97000013
J	Haberland, J; Becker, J; Gerke, V				Haberland, J; Becker, J; Gerke, V			The acidic C-terminal domain of rna1p is required for the binding of Ran center dot GTP and for RanGAP activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN IMPORT; LEUCINE-RICH REPEATS; SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; ACTIVATING PROTEIN; PORE COMPLEX; SCHIZOSACCHAROMYCES-POMBE; CYTOSOLIC FACTORS; TRANSPORT FACTORS; CRYSTAL-STRUCTURE	The small GTP binding protein Ran is an essential component of the nuclear protein import machinery whose GTPase cycle is regulated by the nuclear guanosine nucleotide exchange factor RCC1 and by the cytosolic GTPase activating protein RanGAP. In the yeasts Schizosaccharomyces pombe and Saccharomyces cerevisiae the RanGAP activity is encoded by the RNA1 genes which are essential for cell viability and nucleocytoplasmic transport in vivo. Although of limited sequence identity the two yeast proteins show a conserved structural organization characterized by an N-terminal domain of eight leucine-rich repeats, motifs implicated in protein-protein interactions, and a C-terminal domain rich in acidic amino acid residues. By analyzing the RanGAP activity of a series of recombinantly expressed rna1p mutant derivatives, we show that the highly acidic sequence in the C-terminal domain of both yeast proteins is indispensable for activating Ran-mediated GTP hydrolysis. Chemical cross-linking reveals that the same sequence in rna1p is required for rnalp.Ran complex formation indicating that the loss of GAP activity in the C-terminally truncated rna1p mutants results from an impaired interaction with Ran. The predominant species stabilized through the covalent cross-link is a rna1p.Ran heterodimer whose formation requires the GTP-bound conformation of Ran. As the acidic C-terminal domain of rna1p is required for establishing the interaction with Ran, the leucine-rich repeats domain in rna1p is potentially available for additional protein interactions perhaps required for directing a fraction of rna1p to the nuclear pore.	UNIV MUNSTER, INST MED BIOCHEM, D-48149 D-48149..MUNSTER, GERMANY; MAX PLANCK INST MOL PHYSIOL, DEPT BIOL STRUCT, D-44139 DORTMUND, GERMANY	University of Munster; Max Planck Society								ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK KL, 1989, MOL CELL BIOL, V9, P2682, DOI 10.1128/MCB.9.6.2682; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FLEISCHMANN M, 1991, MOL GEN GENET, V227, P417, DOI 10.1007/BF00273932; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GOLDBERG MW, 1995, CURR OPIN CELL BIOL, V7, P301, DOI 10.1016/0955-0674(95)80083-2; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HABERLAND J, 1995, FEBS LETT, V357, P173, DOI 10.1016/0014-5793(94)01353-3; HARTMANN E, 1995, TRENDS CELL BIOL, V5, P192, DOI 10.1016/S0962-8924(00)88992-8; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; JOHN J, 1988, J BIOL CHEM, V263, P11792; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; SAITOH H, 1995, J BIOL CHEM, V270, P10658, DOI 10.1074/jbc.270.18.10658; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; SWEET DJ, 1995, TRENDS CELL BIOL, V5, P444, DOI 10.1016/S0962-8924(00)89108-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAGLIA HM, 1989, MOL CELL BIOL, V9, P2989, DOI 10.1128/MCB.9.7.2989; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	58	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24717	24726		10.1074/jbc.272.39.24717	http://dx.doi.org/10.1074/jbc.272.39.24717			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305944	hybrid			2022-12-25	WOS:A1997XY51500095
J	Lambeth, DO; Mehus, JG; Ivey, MA; Milavetz, BI				Lambeth, DO; Mehus, JG; Ivey, MA; Milavetz, BI			Characterization and cloning of a nucleoside-diphosphate kinase targeted to matrix of mitochondria in pigeon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; X-RAY STRUCTURE; SUCCINIC THIOKINASE; CRYSTAL-STRUCTURE; DICTYOSTELIUM-DISCOIDEUM; TUMOR-METASTASIS; NM23 GENE; DROSOPHILA; RESOLUTION; CELLS	Nucleoside-diphosphate kinase (NDP kinase) from the matrix space of mitochondria in pigeon liver was purified to homogeneity, Degenerate oligonucleotide primers to the N-terminal sequence of the purified protein and the region containing the active site histidine were used in reverse transcriptase-polymerase chain reaction to obtain a major portion of the coding sequence for the mature protein, The sequences of the C and N termini of the mature protein, and eight residues in the signal peptide, were obtained by rapid amplification of cDNA end procedures, The entire coding sequence of a cytosolic form of NDP kinase was also determined, Both isoforms, which share 53% sequence identity, possess the characteristically conserved regions of known NDP kinases, The mature mitochondrial NDP kinase protein migrates in molecular sieving columns with an apparent molecular mass of about 66 kDa. It shows very high thermal stability even though it lacks the proline residue in the killer of prune loop, and the Tyr/Glu C termini that are important in stabilizing other NDP kinases, The affinity of the mitochondrial isoform for adenine and guanine nucleotides is much higher than for pyrimidine nucleotides, but the enzyme is especially susceptible to substrate inhibition by GDP. Semi-quantitative reverse transcriptase-polymerase chain reaction showed that the relative levels of expression of the mitochondrial isoform are Liver > kidney much greater than heart = brain > breast muscle, The cytosolic isoform is strongly and approximately equally expressed in these same five tissues, This work is the first characterization of a NDP kinase isoform that is found in the matrix space of mitochondria.			Lambeth, DO (corresponding author), UNIV N DAKOTA,SCH MED & HLTH SCI,DEPT BIOCHEM & MOL BIOL,BOX 9037,GRAND FORKS,ND 58202, USA.				NIGMS NIH HHS [GM54260] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM054260] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMAULA N, 1995, J BACTERIOL, V177, P2524, DOI 10.1128/jb.177.9.2524-2529.1995; BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BIONDI RM, 1995, ARCH BIOCHEM BIOPHYS, V323, P187, DOI 10.1006/abbi.1995.0025; Brodbeck M, 1996, EUR J BIOCHEM, V239, P208, DOI 10.1111/j.1432-1033.1996.0208u.x; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; COLOMB MG, 1969, BIOCHEMISTRY-US, V8, P1926, DOI 10.1021/bi00833a024; COLOMB MG, 1972, BIOCHEMISTRY-US, V11, P3370, DOI 10.1021/bi00768a009; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; ERECINSKA M, 1984, J BIOL CHEM, V259, P904; GARCES E, 1969, BIOCHEMISTRY-US, V8, P633, DOI 10.1021/bi00830a026; Giartosio A, 1996, J BIOL CHEM, V271, P17845, DOI 10.1074/jbc.271.30.17845; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GLEZE RP, 1967, J BIOL CHEM, V242, P2139; GOFFEAU A, 1968, J BIOL CHEM, V243, P1685; GOFFEAU A, 1967, J BIOL CHEM, V242, P1845; HAMILTON ML, 1981, FEBS LETT, V123, P252, DOI 10.1016/0014-5793(81)80300-6; HANSFORD RG, 1973, FEBS LETT, V31, P317, DOI 10.1016/0014-5793(73)80130-9; HELDT HW, 1967, EUR J BIOCHEM, V1, P199, DOI 10.1111/j.1432-1033.1967.tb00064.x; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; ISAYA G, 1995, METHOD ENZYMOL, V248, P556; JACOBUS WE, 1977, J BIOL CHEM, V252, P4232; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; Karlsson A, 1996, J BIOL CHEM, V271, P19928, DOI 10.1074/jbc.271.33.19928; KREBS HA, 1953, BIOCHIM BIOPHYS ACTA, V12, P172, DOI 10.1016/0006-3002(53)90136-X; LAMBETH DO, 1993, ANAL BIOCHEM, V209, P192, DOI 10.1006/abio.1993.1102; LASCU I, 1992, J BIOL CHEM, V267, P12775; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; MORERA S, 1994, J MOL BIOL, V243, P873, DOI 10.1006/jmbi.1994.1689; MUHONEN WW, 1995, COMP BIOCHEM PHYS B, V110, P211, DOI 10.1016/0305-0491(94)00123-C; NAKAMURA H, 1966, J BIOL CHEM, V241, P4917; OTTAWAY JH, 1981, INT J BIOCHEM, V13, P401, DOI 10.1016/0020-711X(81)90111-7; PEDERSEN PL, 1973, J BIOL CHEM, V248, P3956; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SANADI DR, 1954, BIOCHIM BIOPHYS ACTA, V14, P434, DOI 10.1016/0006-3002(54)90205-X; SANADI DR, 1955, J BIOL CHEM, V218, P505; Schaertl S, 1996, FEBS LETT, V394, P316, DOI 10.1016/0014-5793(96)00978-7; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TOKUMITSU Y, 1973, BIOCHIM BIOPHYS ACTA, V292, P310, DOI 10.1016/0005-2728(73)90038-8; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; TROLL H, 1993, J BIOL CHEM, V268, P25469; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WADKINS CL, 1963, J BIOL CHEM, V238, P2555; WEAVER RH, 1962, ENZYMES, V6, P151; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673	53	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24604	24611		10.1074/jbc.272.39.24604	http://dx.doi.org/10.1074/jbc.272.39.24604			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305928	hybrid			2022-12-25	WOS:A1997XY51500079
J	Janson, W; Brandner, G; Siegel, J				Janson, W; Brandner, G; Siegel, J			Butyrate modulates DNA-damage-induced p53 response by induction of p53-independent differentiation and apoptosis	ONCOGENE			English	Article						p53; butyrate; DNA damage; differentiation; apoptosis	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; TUMOR-SUPPRESSOR GENE; BREAST-CANCER CELLS; LARGE-T-ANTIGEN; SODIUM-BUTYRATE; IN-VIVO; MONOCLONAL-ANTIBODIES; P53-DEPENDENT APOPTOSIS; P53-DEFICIENT MICE	Butyrate, a physiologically occurring agent, has been reported to decrease constitutively high expressed p53 levels in transformed cells. To elucidate,whether butyrate also inhibits DNA-damage-induced p53 response we investigated the effects of butyrate and the anticancer drug mitomycin C in normal C3H10T1/2 cells harbouring wild-type p53. In comparison with p53-deficient fibroblasts we examined p53 protein level, cell cycle arrest, differentiation, and apoptosis. Butyrate induced G1 phase arrest, differentiation, and p53-independent increase in p21(waf1/cip1) protein. Moreover, butyrate induced p53-independent apoptosis, which was, as well as p53-mediated apoptosis, associated with a dose-dependent increase in Bax and c-Myc protein. Pretreatment with butyrate repressed dose-dependently mitomycin-C-induced p53 accumulation and interfered with p53-dependent cell cycle arrest. Butyrate further partially inhibited p53-mediated apoptosis, but low doses of butyrate were more effective than higher concentrations. This was reflected in an enhanced decrease in c-Myc and Bax protein in response to mitomycin C with low concentrations of butyrate. Our data indicate that the differentiation stimulus of butyrate, in association with p21(waf1/cip1) induction, and apoptosis, may explain antineoplastic effects of butyrate. Co-carcinogenic features of butyrate may result from inhibition of p53-mediated DNA damage response.	UNIV FREIBURG,INST MED MICROBIOL & HYG,DEPT VIROL,D-79104 FREIBURG,GERMANY	University of Freiburg								ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BERRY RD, 1988, CARCINOGENESIS, V9, P447, DOI 10.1093/carcin/9.3.447; BOUFFLER SD, 1995, CANCER RES, V55, P3883; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CALABRESSE C, 1993, BIOCHEM BIOPH RES CO, V195, P31, DOI 10.1006/bbrc.1993.2005; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CHEN YQ, 1995, CANCER RES, V55, P4536; COLEMAN WB, 1994, CARCINOGENESIS, V15, P145, DOI 10.1093/carcin/15.2.145; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FORBES IJ, 1992, EXP CELL RES, V198, P367, DOI 10.1016/0014-4827(92)90393-M; FRITSCHE M, 1993, ONCOGENE, V8, P307; FRITSCHE M, 1991, THESIS FREIBURG GERM; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GAZITT Y, 1994, CANCER RES, V54, P950; GOETZ C, 1995, INT J ONCOL, V6, P1129; GOLDBERG YP, 1992, J CELL BIOCHEM, V49, P74, DOI 10.1002/jcb.240490113; GOPE R, 1993, CELL MOL BIOL, V39, P589; GORCZYCA W, 1993, CANCER RES, V53, P3186; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HALDAR S, 1994, CANCER RES, V54, P2095; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HERUTH DP, 1993, J BIOL CHEM, V268, P20466; HOJO ETS, 1994, MUTAT RES-FUND MOL M, V309, P165, DOI 10.1016/0027-5107(94)90089-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOWE GR, 1992, J NATL CANCER I, V84, P1887, DOI 10.1093/jnci/84.24.1887; JANSON W, 1996, THESIS FREIBURG GERM; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KITAMURA N, 1993, P ELECTROCHEM SOC, V12, P187; KRUH J, 1982, MOL CELL BIOCHEM, V42, P5; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERRITT AJ, 1994, CANCER RES, V54, P614; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOLINARI M, 1995, ONCOGENE, V10, P1849; MOLLINEDO F, 1993, BIOCHEM J, V294, P137, DOI 10.1042/bj2940137; MONDAL S, 1976, NATURE, V260, P710, DOI 10.1038/260710a0; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OLTAVI ZN, 1993, CELL, V74, P609; RAGIMOV N, 1993, ONCOGENE, V8, P1183; ROBB JA, 1973, EXP CELL RES, V81, P120, DOI 10.1016/0014-4827(73)90118-3; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SAITO Y, 1995, ONCOGENE, V11, P1013; SANKARANARAYANA.K, 1984, GENET RES, V56, P267; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAO ZM, 1995, ONCOGENE, V11, P493; SIEGEL J, 1995, ONCOGENE, V11, P1363; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOBALLE PW, 1994, MELANOMA RES, V4, P213, DOI 10.1097/00008390-199408000-00003; SOLARY E, 1993, BLOOD, V81, P1359; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STEINMEYER JE, 1988, ONCOGENE, V5, P1691; STEMMERMANN GN, 1973, CANCER-AM CANCER SOC, V31, P1260, DOI 10.1002/1097-0142(197305)31:5<1260::AID-CNCR2820310535>3.0.CO;2-N; STEWART N, 1995, ONCOGENE, V7, P1513; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TOSCANI A, 1988, ONCOGENE RES, V3, P223; UTESCH D, 1993, CARCINOGENESIS, V14, P457, DOI 10.1093/carcin/14.3.457; WAGA S, 1994, NATURE, V369, P578; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WARELL RP, 1993, NEW ENGL J MED, V329, P177; WINTERSBERGER E, 1984, FEBS LETT, V166, P326, DOI 10.1016/0014-5793(84)80105-2; WINTERSBERGER E, 1983, J CELL BIOCHEM, V21, P239, DOI 10.1002/jcb.240210306; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052	89	59	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1395	1406		10.1038/sj.onc.1201304	http://dx.doi.org/10.1038/sj.onc.1201304			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333015				2022-12-25	WOS:A1997XW41100003
J	Kornmann, M; Ishiwata, T; Beger, HG; Korc, M				Kornmann, M; Ishiwata, T; Beger, HG; Korc, M			Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions	ONCOGENE			English	Article						fibroblast growth factor-5; fibroblast growth factor receptor splice variant; in situ hybridization; mitogenic signaling; pancreatic cancer; protein kinases	FGF RECEPTORS; CELL-LINES; EXPRESSION; TRANSDUCTION; FAMILY; SPECIFICITY; ACTIVATION; MECHANISMS; INDUCTION; ONCOGENES	Fibroblast growth factor (FGF)-1 and -2 are overexpressed in human pancreatic cancer. In this study the role of FGF-5 in human pancreatic cancer was investigated, as FGF-5 has a classical signal sequence for secretion not found in FGF-1 or -2. Northern blot analysis with a 306 bp FGF-5 cDNA revealed the presence of 4.0 kb and 1.6 kb FGF-5 mRNA transcripts in both normal and cancerous pancreatic tissues. Densitometric analysis indicated that 4.0 kb and 1.6 kb FGF-5 mRNA transcripts levels were increased 2.4- and 2.7-fold in the cancers by comparison with normal tissues, respectively (P<0.002, P<0.0001). Immunohistochemistry and in situ hybridization demonstrated that FGF-5 localized in the cancer cells, stromal fibroblast and inflitrating macrophages. FGF-5 mRNA was also detected in COLO-357 human pancreatic cancer cells. Furthermore, secreted FGF-5 protein was present in conditioned medium of COLO-357 cells. Exogeneous FGF-5 (0.37 nM) increased the growth of COLO-357 cells by 48% (P<0.0001) and increased mitogen-activated protein kinase activity. COLO-357 cells expressed the IIIc isoform of the type I FGF receptor, the preferred FGF receptor for FGF-5. These observations suggest that FGF-5 may participate in autocrine and paracrine pathways promoting pancreatic cancer cell growth in vivo.	UNIV CALIF IRVINE,MED SCI INST C240,DEPT MED BIOL CHEM & PHARMACOL,IRVINE,CA 92697; UNIV ULM,DEPT GEN SURG,D-89075 ULM,GERMANY	University of California System; University of California Irvine; Ulm University			Ishiwata, Toshiyuki/H-1151-2014	Ishiwata, Toshiyuki/0000-0002-4180-0069	NIDDK NIH HHS [DK-44948] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044948] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; ALTORKI N, 1993, CANCER-AM CANCER SOC, V72, P649, DOI 10.1002/1097-0142(19930801)72:3<649::AID-CNCR2820720305>3.0.CO;2-L; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; Burgess W. H., 1996, P154; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EBERT M, 1995, INT J CANCER, V62, P529, DOI 10.1002/ijc.2910620507; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GAMBARINI AG, 1993, MOL CELL BIOCHEM, V124, P121, DOI 10.1007/BF00929204; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GILBERT E, 1993, MOL CELL BIOL, V13, P5441; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOLDFARB M, 1991, ANN NY ACAD SCI, V638, P38, DOI 10.1111/j.1749-6632.1991.tb49016.x; Hannon K, 1996, J CELL BIOL, V132, P1151, DOI 10.1083/jcb.132.6.1151; HAUB O, 1990, P NATL ACAD SCI USA, V87, P8022, DOI 10.1073/pnas.87.20.8022; HERBERT JM, 1991, DEVELOPMENT, V112, P407; HUGHES RA, 1993, NEURON, V10, P369, DOI 10.1016/0896-6273(93)90327-N; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KITAOKA T, 1994, INVEST OPHTH VIS SCI, V35, P3189; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; NGUYEN C, 1988, ONCOGENE, V3, P703; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; SIDDIQI I, 1995, BIOCHEM BIOPH RES CO, V215, P309, DOI 10.1006/bbrc.1995.2467; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WERNER S, 1991, ONCOGENE, V6, P2137; YAMANAKA Y, 1993, CANCER RES, V53, P5289; YAMASAKI M, 1996, J BIOL CHEM, V271, P15919; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yoshimura K, 1996, CANCER LETT, V103, P91, DOI 10.1016/0304-3835(96)04198-5; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	41	91	93	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1417	1424		10.1038/sj.onc.1201307	http://dx.doi.org/10.1038/sj.onc.1201307			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333017				2022-12-25	WOS:A1997XW41100005
J	Dai, Y; Wang, CC				Dai, Y; Wang, CC			A mutant truncated protein disulfide isomerase with no chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROLYL 4-HYDROXYLASE; SITE-DIRECTED MUTAGENESIS; ENDOPLASMIC-RETICULUM; BETA-SUBUNIT; PEPTIDE BINDING; THIOREDOXIN; POLYPEPTIDE; AGGREGATION; RESIDENT; LYSOZYME	A mutant human protein disulfide isomerase with the COOH-terminal 51 amino acid residues deleted (abb'a') has been expressed in Escherichia coli. Its secondary structures are very similar to those of the native bovine enzyme. The mutant enzyme shows neither peptide binding ability nor chaperone activity in assisting the refolding of denatured D-glyceraldehyde-3-phosphate dehydrogenase but keeps most of the catalytic activities for reduction of insulin and isomerization of scrambled ribonuclease. It assists the reactivation of denatured and reduced proteins containing disulfide bonds, acid phospholipase A(2), and lysozyme to different levels, which are significantly lower than those by the native bovine enzyme.	ACAD SINICA,INST BIOPHYS,NATL LAB BIOMACROMOL,BEIJING 100101,PEOPLES R CHINA	Chinese Academy of Sciences; Institute of Biophysics, CAS								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CAI H, 1994, J BIOL CHEM, V269, P24550; Darby NJ, 1996, BIOCHEMISTRY-US, V35, P10517, DOI 10.1021/bi960763s; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gao Y, 1997, J BIOTECHNOL, V54, P105, DOI 10.1016/S0168-1656(97)01695-7; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; Hayano T, 1995, FEBS LETT, V377, P505, DOI 10.1016/0014-5793(95)01410-1; HUA QX, 1984, BIOCHIM BIOPHYS ACTA, V189, P234; KEMMINK J, 1995, PROTEIN SCI, V4, P2587, DOI 10.1002/pro.5560041216; KOIVU J, 1987, J BIOL CHEM, V262, P6447; Koivunen P, 1996, BIOCHEM J, V316, P599, DOI 10.1042/bj3160599; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; Lamberg A, 1996, BIOCHEM J, V315, P533, DOI 10.1042/bj3150533; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LIANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P240, DOI 10.1016/0167-4838(90)90211-W; LILIE H, 1994, J BIOL CHEM, V269, P14290; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; NOIVA R, 1994, PROTEIN EXPRES PURIF, V5, P1, DOI 10.1006/prep.1994.1001; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PUIG A, 1994, J BIOL CHEM, V269, P7764; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; VUORI K, 1992, J BIOL CHEM, V267, P7211; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; WANG CC, 1997, PROLYL HYDROXYLASE P; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801; Wu X.-f., 1984, Acta Biochimica et Biophysica Sinica, V16, P664; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651; Zheng WD, 1997, ARCH BIOCHEM BIOPHYS, V337, P326, DOI 10.1006/abbi.1996.9783	39	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27572	27576		10.1074/jbc.272.44.27572	http://dx.doi.org/10.1074/jbc.272.44.27572			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346892	hybrid			2022-12-25	WOS:A1997YD47300018
J	Chuang, LF; Killam, KF; Chuang, RY				Chuang, LF; Killam, KF; Chuang, RY			Induction and activation of mitogen-activated protein kinases of human lymphocytes as one of the signaling pathways of the immunomodulatory effects of morphine sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PERIPHERAL-BLOOD; RECEPTOR GENE-EXPRESSION; T-CELL; PHOSPHORYLATION; IDENTIFICATION; INSULIN; HIV-1; MEK; PURIFICATION; COMPLEX	Morphine sulfate causes immunomodulatory and immunosuppressive effects in human, In this study, the signaling pathway involved in these morphine effects was studied, Addition of morphine sulfate to human CEMx174 lymphocytic cells resulted in increased ex pression of mitogen-activated protein kinase cascade proteins, Morphine enhanced the cellular levels of ERK1 (44 kDa), ERK2 (42 kDa), a 54-kDa ERK, MEK1 (45 kDa), and MEKK (78 kDa), A time-dependent increase in the activated (Thr and Tyr dually phosphorylated) state of ERK1 and ERK2 was also observed, Naloxone, a morphine antagonist, reversed the observed morphine effects, implicating a mu opioid receptor-mediated process. These findings suggest that mitogen activated protein kinases are important intermediates in signal transduction pathways initiated by morphine receptors in immune cells.	UNIV CALIF DAVIS,SCH MED,DEPT MED PHARMACOL & TOXICOL,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010433, R01DA005901] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 10433, DA 05901] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROWN SM, 1974, ARCH INTERN MED, V134, P1001, DOI 10.1001/archinte.134.6.1001; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Chuang L F, 1993, In Vivo, V7, P159; CHUANG LF, 1993, BIOCHEM BIOPH RES CO, V195, P1165, DOI 10.1006/bbrc.1993.2167; Chuang LF, 1997, ADDICT BIOL, V2, P421, DOI 10.1080/13556219772471; CHUANG LF, 1995, BIOCHEM BIOPH RES CO, V209, P1003, DOI 10.1006/bbrc.1995.1597; CHUANG LF, 1994, BIOCHEM BIOPH RES CO, V202, P1291, DOI 10.1006/bbrc.1994.2071; CHUANG TK, 1995, BIOCHEM BIOPH RES CO, V216, P922, DOI 10.1006/bbrc.1995.2709; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DONAHOE RM, 1988, ADV BIOCHEM PSYCHOPH, V44, P145; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; GOWDA SD, 1989, J IMMUNOL, V142, P773; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PETERSON PK, 1990, AIDS, V4, P869, DOI 10.1097/00002030-199009000-00006; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; VOELKERDING KV, 1995, ONCOGENE, V10, P515	24	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26815	26817		10.1074/jbc.272.43.26815	http://dx.doi.org/10.1074/jbc.272.43.26815			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341110	hybrid			2022-12-25	WOS:A1997YC65900006
J	Deloulme, JC; Prichard, L; Delattre, O; Storm, DR				Deloulme, JC; Prichard, L; Delattre, O; Storm, DR			The prooncoprotein EWS binds calmodulin and is phosphorylated by protein kinase C through an IQ domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING FACTOR PSF; NUCLEAR MATRIX; CELL-NUCLEUS; PREMESSENGER RNA; SENSITIVE METHOD; HNRNP PROTEINS; CDNA CLONING; EWING FAMILY; NEUROMODULIN; IDENTIFICATION	A growing family of proteins is regulated by protein kinase C and calmodulin through IQ domains, a regulatory motif originally identified in neuromodulin (Alexander, K. A., Wakim, B. T., Doyle, G. S., Walsh, K. A., and Storm, D. R. (1988) J. Biol. Chem, 263, 7544-7549). Here we report that EWS, a nuclear RNA-binding proonco-protein, contains an IQ domain, is phosphorylated by protein kinase C, and interacts with calmodulin, Interestingly, PKC phosphorylation of EWS inhibits its binding to RNA homopolymers, and conversely, RNA binding to EWS interferes with PKC phosphorylation, Several other RNA-binding proteins, including TLS/FUS and PSF, co-purify with EWS, PKC phosphorylation of these proteins also inhibits their binding to RNA in vitro. These data suggest that PKC may regulate interactions of EWS and other RNA-binding proteins with their RNA targets and that IQ domains may provide a regulatory link between Ca2+ signal transduction pathways and RNA processing.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; INST CURIE, INSERM, U434, F-75231 PARIS 05, FRANCE	University of Washington; University of Washington Seattle; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Deloulme, Jean Christophe/P-6858-2017	Deloulme, Jean Christophe/0000-0002-2234-5865; delattre, olivier/0000-0002-8730-2276	NINDS NIH HHS [NS 20498] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020498] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BACHS O, 1994, CELL CALCIUM, V16, P289, DOI 10.1016/0143-4160(94)90092-2; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BACHS O, 1987, J BIOL CHEM, V262, P10786; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; BOSSER R, 1995, MOL CELL BIOL, V15, P661; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brill S, 1996, MOL CELL BIOL, V16, P4869; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; BUELT MK, 1994, J BIOL CHEM, V269, P29367; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CALVIO C, 1995, RNA, V1, P724; Chao S, 1996, MOL BRAIN RES, V40, P195, DOI 10.1016/0169-328X(96)00049-6; CHAPMAN ER, 1991, PROG BRAIN RES, V89, P37; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIVECHA N, 1994, CELL CALCIUM, V16, P297, DOI 10.1016/0143-4160(94)90093-0; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Gamby C, 1996, J BIOL CHEM, V271, P26698, DOI 10.1074/jbc.271.43.26698; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; GERENDASY DD, 1994, J MOL NEUROSCI, V5, P133, DOI 10.1007/BF02736729; GETZENBERG RH, 1994, J CELL BIOCHEM, V55, P22, DOI 10.1002/jcb.240550105; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IDRISS H, 1994, BIOCHEMISTRY-US, V33, P11382, DOI 10.1021/bi00203a037; Irvine R F, 1992, Semin Cell Biol, V3, P225, DOI 10.1016/1043-4682(92)90024-P; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIN C, 1994, CELL CALCIUM, V16, P247, DOI 10.1016/0143-4160(94)90088-4; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; Mattern KA, 1996, J CELL BIOCHEM, V62, P275, DOI 10.1002/(SICI)1097-4644(199608)62:2<275::AID-JCB15>3.0.CO;2-K; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MAY WA, 1993, MOL CELL BIOL, V13, P7397; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; Munshi HG, 1996, BIOCHEMISTRY-US, V35, P15883, DOI 10.1021/bi962107y; NEEL VA, 1994, DEVELOPMENT, V120, P2235; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; Petrova TV, 1996, J BIOL CHEM, V271, P26646, DOI 10.1074/jbc.271.43.26646; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Schalinske KL, 1996, J BIOL CHEM, V271, P7168, DOI 10.1074/jbc.271.12.7168; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SERRATOSA J, 1988, BIOCHEM BIOPH RES CO, V150, P1162, DOI 10.1016/0006-291X(88)90751-6; SHEU FS, 1994, MOL BRAIN RES, V21, P62, DOI 10.1016/0169-328X(94)90378-6; SHEU FS, 1995, ARCH BIOCHEM BIOPHYS, V316, P335, DOI 10.1006/abbi.1995.1045; Slemmon JR, 1996, J BIOL CHEM, V271, P15911, DOI 10.1074/jbc.271.27.15911; TAKAGI T, 1990, J BIOL CHEM, V265, P19721; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRICHE TJ, 1997, ENCY CANC, V1, P652; vanDriel R, 1995, INT REV CYTOL, V162A, P151; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; ZINI N, 1995, HISTOCHEM CELL BIOL, V103, P447, DOI 10.1007/BF01457544; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	74	63	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27369	27377		10.1074/jbc.272.43.27369	http://dx.doi.org/10.1074/jbc.272.43.27369			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341188	hybrid			2022-12-25	WOS:A1997YC65900084
J	Dharmavaram, RM; Liu, G; Mowers, SD; Jimenez, SA				Dharmavaram, RM; Liu, G; Mowers, SD; Jimenez, SA			Detection and characterization of Sp1 binding activity in human chondrocytes and its alterations during chondrocyte dedifferentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; COLLAGEN GENE; ARTICULAR CHONDROCYTES; PROCOLLAGEN GENE; ALGINATE BEADS; NUCLEAR FACTOR; CELL-SHAPE; 1ST INTRON; PROMOTER; CARTILAGE	We have detected DNA binding activity for a synthetic oligonucleotide containing an Sp1 consensus sequence in nuclear extracts from human chondrocytes. Changes in the levels of Sp1 oligonucleotide binding activity were examined in nuclear extracts from freshly isolated human chondrocytes, from chondrocytes that had beets cultured under conditions that allowed the maintenance of a chondrocyte-specific phenotype on plastic dishes coated with the hydrogel poly(2-hydroxyethyl methacrylate), and from chondrocytes induced to dedifferentiate into fibroblast-like cells by passage in monolayer culture on plastic substrate, It was observed that Spl binding was 2-3-fold greater in nuclear extracts from dedifferentiated chondrocytes than in nuclear extracts from either freshly isolated chondrocytes or from cells cultured in suspension. The Sp1 binding activity was specific, since it was competed by unlabeled Sp1 but not by AP1 or AP2, The addition of a polyclonal antibody against Sp1 to nuclear extracts from freshly isolated chondrocytes or to extracts isolate from chondrocytes cultured in monolayer decreased the binding of Sp1 by similar to 85%, However, when the same experiment was carried out with nuclear extracts prepared from cells cultured on poly(2-hydroxyethyl methacrylate)-coated plates, only a very slight inhibition of Sp1 binding was observed, When fragments of the COL2A1 promoter containing putative Spl binding sites amplified by polymerase chain reaction were examined, it was found that the amounts of DNA-protein complex formed with nuclear extracts from dedifferentiated chondrocytes were 2-3-fold greater than the amounts formed with nuclear extracts from freshly isolated chondrocytes or from cells cultured in suspension, Quantitation of DNA binding activity by titration experiments demonstrated that nuclear extracts from fibroblast-like cells contained approximately 2-fold greater Sp-1 specific binding activity than nuclear extracts from chondrocytes. The direct role of Sp1 in type II collagen gene transcription was demonstrated by co-transfection experiments of COL2A1 promoter-CAT constructs in Drosophila Schneider line L2 cells that lack Sp1 homologs. This is the first demonstration of Sp1 binding activity in human chondrocytes and of differences in Sp1 DNA binding activity between differentiated and dedifferentiated chondrocytes.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT MED, DIV RHEUMATOL, PHILADELPHIA, PA 19107 USA	Jefferson University				Jimenez, Sergio/0000-0001-5213-1203	NIAMS NIH HHS [AR39740, AR07583] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740, T32AR007583] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARCHER CW, 1990, J CELL SCI, V97, P361; BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BENYA PD, 1979, ARCH BIOCHEM BIOPHYS, V192, P327, DOI 10.1016/0003-9861(79)90100-0; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EYRE DR, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P119; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HAUSELMANN HJ, 1994, J CELL SCI, V107, P17; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JIANPING Y, 1996, MOL CELL BIOL, V16, P157; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; Jimenez SA, 1997, MATRIX BIOL, V16, P29, DOI 10.1016/S0945-053X(97)90114-1; KUETTNER KE, 1982, J CELL BIOL, V93, P751, DOI 10.1083/jcb.93.3.751; LIYE L, 1995, GENE, V164, P229; MAATTA A, 1993, BIOCHEM J, V294, P365, DOI 10.1042/bj2940365; MALLEINGERIN F, 1990, DIFFERENTIATION, V43, P204, DOI 10.1111/j.1432-0436.1990.tb00447.x; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; REFOJO MF, 1965, J APPL POLYM SCI, V9, P2425, DOI 10.1002/app.1965.070090707; REGINATO AM, 1994, ARTHRITIS RHEUM, V37, P1338, DOI 10.1002/art.1780370912; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SIERON AL, 1993, J BIOL CHEM, V268, P21232; VIKKULA M, 1992, BIOCHEM J, V285, P287, DOI 10.1042/bj2850287; VONDERMARK K, 1977, NATURE, V267, P531, DOI 10.1038/267531a0; VONDERMARK K, 1986, CONNECTIVE TISSUE BI, P272; WANG LQ, 1991, J BIOL CHEM, V266, P19878; WICHTERLE O, 1960, NATURE, V185, P117, DOI 10.1038/185117a0	36	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26918	26925		10.1074/jbc.272.43.26918	http://dx.doi.org/10.1074/jbc.272.43.26918			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341126	hybrid, Green Published			2022-12-25	WOS:A1997YC65900022
J	Micheva, KD; Kay, BK; McPherson, PS				Micheva, KD; Kay, BK; McPherson, PS			Synaptojanin forms two separate complexes in the nerve terminal - Interactions with endophilin and amphiphysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; SRC HOMOLOGY-3 DOMAINS; I PROTEIN-I; SYNAPTIC VESICLES; SYNAPSIN-I; BINDING-SITE; SH3 DOMAINS; DYNAMIN; ENDOCYTOSIS; MEMBRANE	Endophilin is a recently discovered src homology 3 domain-containing protein that is a major in vitro binding partner for synaptojanin. To further characterize endophilin, we generated an antipeptide antibody. Endophilin is enriched in the brain, and immunofluorescence analysis reveals a high concentration of the protein in synaptic terminals, where it colocalizes with synaptojanin. In vitro binding assays demonstrate that endophilin binds through its src homology 3 domain to synaptojanin, and immunoprecipitation analysis with the antiendophilin antibody reveals that endophilin is stably associated with synaptojanin in the nerve terminal. Immunoprecipitation with an antibody against amphiphysin I and II, which interact through their src homology 3 domains with dynamin and synaptojanin at sites distinct from those for endophilin, reveals a second stable complex, which includes dynamin and synaptojanin but excludes endophilin. These data demonstrate that synaptojanin is present in two separate complexes in the nerve terminal and support an important role for endophilin in the regulation of synaptojanin function.	MCGILL UNIV,MONTREAL NEUROL INST,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	McGill University; University of North Carolina; University of North Carolina Chapel Hill			Micheva, Kristina/ABH-6913-2020	Micheva, Kristina/0000-0003-1138-3732				Blackstad TW, 1961, J COMP NEUROL, V117, P113; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JUNG MW, 1993, HIPPOCAMPUS, V3, P165, DOI 10.1002/hipo.450030209; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MCPHERSON PS, 1990, J BIOL CHEM, V265, P1854; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; SHARP AH, 1993, J NEUROSCI, V13, P3051; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Woscholski R, 1997, J BIOL CHEM, V272, P9625	45	112	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27239	27245		10.1074/jbc.272.43.27239	http://dx.doi.org/10.1074/jbc.272.43.27239			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341169	hybrid			2022-12-25	WOS:A1997YC65900065
J	Sun, WM; Williams, CH; Massey, V				Sun, WM; Williams, CH; Massey, V			The role of glycine 99 in L-lactate monooxygenase from Mycobacterium smegmatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SPINACH GLYCOLATE OXIDASE; AMINO-ACID-SEQUENCE; ACTIVE-SITE; ESCHERICHIA-COLI; TRANSITION-STATE; BAKERS-YEAST; FLAVOCYTOCHROME-B2; MECHANISM; DEHYDROGENASE	Glycine 99 in L-lactate monooxygenase (LMO) from Mycobacterium smegmatis was mutated to serine and threonine, and the resultant mutants were studied extensively to explore the role of this residue in maintaining monooxygenase activity and in controlling the reactivity with molecular oxygen. Both mutants were observed to lose monooxygenase activity completely and generate H2O2 and pyruvate as reaction products. However, the mutants have much lower activities than a true L-lactate oxidase. The oxygen reactivities of the reduced and semiquinone forms of the mutant enzymes were significantly different from those of wild type enzyme. These results confirm our previous suggestion that the electronic interactions in the active site are a crucial factor that governs the oxygen reactivity of the enzyme (Sun, W., Williams, C. H., Jr., and Massey, V. (1996) J. Biol. Chem. 271, 17226-17233). In addition, the mutants cause a dramatic decrease of the rate of flavin reduction by L-lactate compared with the wild type enzyme, mainly due to the much lower stabilization of the transition state.	DEPT VET AFFAIRS MED CTR,ANN ARBOR,MI 48105		Sun, WM (corresponding author), UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NIGMS NIH HHS [GM 11106, GM 21444] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CEDERLUND E, 1988, EUR J BIOCHEM, V173, P523, DOI 10.1111/j.1432-1033.1988.tb14029.x; CHOONG YS, 1980, J BIOL CHEM, V255, P8672; CLARK WM, 1960, OXIDATION REDUCTION, P504; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; GHISLA S, 1975, J BIOL CHEM, V250, P577; GHISLA S, 1979, J BIOL CHEM, V254, P662; GHISLA S, 1977, J BIOL CHEM, V252, P6729; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; GIEGEL DA, 1990, J BIOL CHEM, V265, P6626; HAYAISHI O, 1957, J AM CHEM SOC, V79, P4809, DOI 10.1021/ja01574a060; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE KHD, 1991, J BIOL CHEM, V266, P20877; LEDERER F, 1985, EUR J BIOCHEM, V152, P419, DOI 10.1111/j.1432-1033.1985.tb09213.x; LEDERER F, 1991, CHEM BIOCH FLAVOENZY, V2, P153; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; MAEDAYORITA K, 1995, BIOCHIMIE, V77, P631, DOI 10.1016/0300-9084(96)88178-8; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1977, J BIOL CHEM, V252, P5612; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MUH U, 1994, J BIOL CHEM, V269, P7982; MUH U, 1994, J BIOL CHEM, V269, P7994; MUH U, 1994, J BIOL CHEM, V269, P7989; MULLER F, 1969, J BIOL CHEM, V244, P4007; MULLER F, 1972, Z NATURFORSCH PT B, VB 27, P1023; SMEKAL O, 1993, BIOCHEM J, V290, P103, DOI 10.1042/bj2900103; STANKOVICH M, 1983, BIOCHEMISTRY-US, V22, P4466, DOI 10.1021/bi00288a018; SULLIVAN PA, 1977, BIOCHEM J, V165, P375, DOI 10.1042/bj1650375; SULLIVAN PA, 1968, BIOCHEM J, V110, P363, DOI 10.1042/bj1100363; Sun WM, 1996, J BIOL CHEM, V271, P17226, DOI 10.1074/jbc.271.29.17226; TSOU AY, 1990, BIOCHEMISTRY-US, V29, P9856, DOI 10.1021/bi00494a015; VOLOKITA M, 1987, J BIOL CHEM, V262, P15825; WALSH C, 1973, J BIOL CHEM, V248, P7049; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; XIA ZX, 1987, P NATL ACAD SCI USA, V84, P2629, DOI 10.1073/pnas.84.9.2629; Yorita K, 1996, J BIOL CHEM, V271, P28300, DOI 10.1074/jbc.271.45.28300	36	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27065	27076		10.1074/jbc.272.43.27065	http://dx.doi.org/10.1074/jbc.272.43.27065			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341146	hybrid			2022-12-25	WOS:A1997YC65900042
J	Gum, JR; Ho, JJL; Pratt, WS; Hicks, JW; Hill, AS; Vinall, LE; Roberton, AM; Swallow, DM; Kim, YS				Gum, JR; Ho, JJL; Pratt, WS; Hicks, JW; Hill, AS; Vinall, LE; Roberton, AM; Swallow, DM; Kim, YS			MUC3 human intestinal mucin - Analysis of gene structure, the carboxyl terminus, and a novel upstream repetitive region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; MOLECULAR-CLONING; COLON-CANCER; EPITHELIAL MUCIN; EXPRESSION; CDNA; SEQUENCE; GROWTH; CELLS; RICH	MUC3 is a large mucin glycoprotein expressed by the human intestine and gall bladder. in this manuscript, we present details of the deduced protein structure of MUC3. The MUC3 carboxyl-terminal domain is 617 residues in length, including 511 residues of a non-repetitive mucin-like domain (27% Thr, 22% Ser and 11% Pro) and a 106-residue Cys-rich domain with homology to the epidermal growth factor (EGF) - like structural motifs found in many proteins. The region of MUGS located upstream of the previously described. 51-base pair (bp) tandem repeats, which encode a major Ser and Thr-rich domain, consists of a second type of repetitive structure with an imperfect periodicity of approximately 1125 bp. This domain is also mucin-like and appears to be considerably larger than 2000 residues (6000 bp), The MUC3 gene itself is large and complex, using pulse field gel electrophoresis and blot analysis, the smallest fragment found that contained all human genomic DNA hybridizing 60 the 51-bp tandem repeat probe was 200 kilobases with restriction enzyme SwaI. Both PvuII and PstI produced two sets of hybridizing fragments that were hypervariable within the human population with a pattern suggestive of both a variation in the number of tandem repeats (VNTR) and sequence polymorphism These fragments varied independently of each other, bat no genetic recombination was detected in a study of 40 human families. Thus, the MUC3 gene encodes a very large glycoprotein with a structure very different from that of any mucin currently described.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT VET AFFAIRS MED CTR,GASTROINTESTINAL RES LAB 151M2,SAN FRANCISCO,CA 94121; UNIV LONDON UNIV COLL,GALTON LAB,MRC,HUMAN BIOCHEM GENET UNIT,LONDON NW1 2HE,ENGLAND	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of London; University College London	Gum, JR (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94121, USA.				NATIONAL CANCER INSTITUTE [R01CA024321] Funding Source: NIH RePORTER; NCI NIH HHS [CA 24321] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN A, 1981, PHYSL GASTROINTESTIN, P627; ASKER N, 1995, BIOCHEM J, V308, P873, DOI 10.1042/bj3080873; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BAECKSTROM D, 1994, J BIOL CHEM, V269, P14430; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; Carlstedt I, 1995, BIOCHEM SOC T, V23, P845, DOI 10.1042/bst0230845; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; DUPERAT VG, 1995, BIOCHEM J, V305, P211, DOI 10.1042/bj3050211; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FOX MF, 1992, ANN HUM GENET, V56, P281, DOI 10.1111/j.1469-1809.1992.tb01154.x; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GREEN F, 1987, GENE, V57, P101, DOI 10.1016/0378-1119(87)90181-8; Gress TM, 1996, ONCOGENE, V13, P1819; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1991, J BIOL CHEM, V266, P22733; Gum JR, 1995, BIOCHEM SOC T, V23, P795, DOI 10.1042/bst0230795; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILL AS, 1995, CYTOGENET CELL GENET, V71, P25; HO SB, 1993, CANCER RES, V53, P641; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; JEFFREY GP, 1994, GASTROENTEROLOGY, V106, P336, DOI 10.1016/0016-5085(94)90590-8; KLOMP LWJ, 1995, BIOCHEM J, V308, P831, DOI 10.1042/bj3080831; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LAN MS, 1990, J BIOL CHEM, V265, P15294; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; LESUFFLEUR T, 1993, J CELL SCI, V106, P771; MCCOOL DJ, 1994, BIOCHEM J, V302, P111, DOI 10.1042/bj3020111; McGuckin MA, 1996, BIOCHEM CELL BIOL, V74, P87, DOI 10.1139/o96-009; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; NARDELLI J, 1988, PANCREAS, V3, P631, DOI 10.1097/00006676-198812000-00002; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; SANDS BE, 1995, J BIOL CHEM, V270, P9353, DOI 10.1074/jbc.270.16.9353; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; Shankar V, 1997, AM J RESP CELL MOL, V16, P232, DOI 10.1165/ajrcmb.16.3.9070607; Sheehan JK, 1996, BIOCHEM J, V315, P1055, DOI 10.1042/bj3151055; Spurr N. K., 1994, European Journal of Human Genetics, V2, P193; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; Toribara NW, 1997, J BIOL CHEM, V272, P16398, DOI 10.1074/jbc.272.26.16398	49	84	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26678	26686		10.1074/jbc.272.42.26678	http://dx.doi.org/10.1074/jbc.272.42.26678			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334251	hybrid			2022-12-25	WOS:A1997YB13900085
J	Summers, H; Fleming, A; Frappier, L				Summers, H; Fleming, A; Frappier, L			Requirements for Epstein-Barr nuclear antigen 1 (EBNA1)-induced permanganate sensitivity of the Epstein-Barr virus latent origin of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; EBNA1; ORIP; SITES; DOMAINS; CELLS; IDENTIFICATION; PURIFICATION; DISTORTION; MECHANISM	Epstein-Barr nuclear antigen 1 (EBNA1) activates DNA replication from the Epstein-Barr virus latent origin of DNA replication, oriP. EBNA1 binds cooperatively to four recognition sites in the dyad symmetry (DS) element of oriP, causing alterations in the origin DNA structure, which can be detected by the increased sensitivity of one Thy residue in two of the binding sites to permanganate oxidation. To better understand the significance of this EBNA1-induced origin distortion we have investigated the DNA sequence and EBNA1 amino acid requirements far permanganate sensitivity. We have shown that the EBNA1. DNA binding and dimerization domains are sufficient to induce permanganate sensitivity and that amino acids 463-467, which form an extended chain that, travels along the minor groove of the EBNA1 recognition site, play an important role in generating the DNA distortion. The EBNA1-induced permanganate sensitivity is independent of cooperative interactions between EBNA1 molecules on the origin and requires a specific sequence within the EBNA1 binding site. Using synthetic EBNA1 binding sites, we found that the inversion of a single AT base pair in the EBNA1 recognition sequence is sufficient to confer EBNA1-induced permanganate sensitivity. These studies indicate that permanganate oxidation can detect very minor alterations in DNA structure.	MCMASTER UNIV,INST MOL BIOL & BIOTECHNOL,CANC RES GRP,HAMILTON,ON L8N 3Z5,CANADA	McMaster University								ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BARWELL JA, 1995, J BIOL CHEM, V270, P20556, DOI 10.1074/jbc.270.35.20556; Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; BOROWIEC JA, 1991, J VIROL, V65, P1228, DOI 10.1128/JVI.65.3.1228-1235.1991; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BRUSH GS, 1996, DNA REPLICATION EUKA, P1; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P45; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; FRAPPIER L, 1992, J VIROL, V66, P1786, DOI 10.1128/JVI.66.3.1786-1790.1992; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FRAPPIER L, 1994, J BIOL CHEM, V269, P1057; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GOLDSMITH K, 1993, J VIROL, V67, P3418, DOI 10.1128/JVI.67.6.3418-3426.1993; HARRISON S, 1994, J VIROL, V68, P1913, DOI 10.1128/JVI.68.3.1913-1925.1994; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; IIDA S, 1970, BIOCHIM BIOPHYS ACTA, V213, P1, DOI 10.1016/0005-2787(70)90002-X; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; Laine A, 1995, J BIOL CHEM, V270, P30914, DOI 10.1074/jbc.270.52.30914; MACKEY D, 1995, J VIROL, V69, P6199, DOI 10.1128/JVI.69.10.6199-6208.1995; NILLER HH, 1995, J BIOL CHEM, V270, P12864, DOI 10.1074/jbc.270.21.12864; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Summers H, 1996, J VIROL, V70, P1228, DOI 10.1128/JVI.70.2.1228-1231.1996; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WYSOKENSKI DA, 1989, J VIROL, V63, P2657, DOI 10.1128/JVI.63.6.2657-2666.1989; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991	33	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26434	26440		10.1074/jbc.272.42.26434	http://dx.doi.org/10.1074/jbc.272.42.26434			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334219	hybrid			2022-12-25	WOS:A1997YB13900053
J	Conchon, S; Barrault, MB; Miserey, S; Corvol, P; Clauser, E				Conchon, S; Barrault, MB; Miserey, S; Corvol, P; Clauser, E			The C-terminal third intracellular loop of the rat AT(1A) angiotensin receptor plays a key role in G protein coupling specificity and transduction of the mitogenic signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II TYPE-1 RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; CONSTITUTIVE ACTIVATION; TRANSMEMBRANE DOMAIN; AGONIST ACTIVATION; INSULIN-RECEPTOR; PHOSPHOLIPASE-C; MUTATION; IDENTIFICATION; MUTAGENESIS	To identify the role(s) of the third intracellular loop of the angiotensin II (AngII) type 1A (AT(1A)) receptor in G protein coupling specificity and receptor activation, several chimerae were constructed and characterized, The cDNA sequence encoding the C-terminal segment of the third intracellular loop of the AT(1A) receptor (residues 234-240) was replaced with the homologous regions of the alpha(1B) adrenergic (alpha(1B)-AR), the beta(2) adrenergic (beta(2)-AR), and the AngII type 2 (AT(2)) receptors. These chimeric receptors were stably expressed in Chinese hamster ovary cells, and their pharmacological and functional properties were characterized, including AngII-induced inositol phosphate and cyclic AMP (cAMP) productions, [H-3]thymidine incorporation into DNA, and internalization. The affinities of these chimeric receptors for [Sar(1)]AngII, [Sar(1),Ile(8)]AngII, and losartan were essentially normal; however, the affinity of these mutants was increased by a factor of 10-40 for the AT(2)-specific ligand CGP42112A. The functional properties of the alpha(1B)-AR chimera were essentially identical to those of the wild type AT(1A) receptor. On the other hand, replacement with the beta(2)-AR segment produced a partial reduction of the inositol phosphate production, a measurable AngII-induced cAMP accumulation, a reduced internalization, and a total impairment to transduce the mitogenic effect of AngII. The AT(2) chimera presented a normal internalization, but was inactive in all the other functional tests. In conclusion, the distal segment of the third intracellular loop of the rat AT(1A) receptor plays a pivotal role in coupling selectivity and receptor signaling via G protein(s) as well as in the activation of the specific signaling pathways involved in the mitogenic actions of AngII.	COLL FRANCE,INSERM,U36,F-75005 PARIS,FRANCE; CTR ETUD SACLAY,SERV BIOL CELLULAIRE,F-91191 GIF SUR YVETTE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France				Conchon, Sophie/0000-0003-2602-3385				BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BLUML K, 1994, J BIOL CHEM, V269, P18870; BUISSON B, 1995, J BIOL CHEM, V270, P1670, DOI 10.1074/jbc.270.4.1670; Clauser E, 1996, EUR J ENDOCRINOL, V134, P403, DOI 10.1530/eje.0.1340403; CONCHON S, 1994, BIOCHEM BIOPH RES CO, V199, P1347, DOI 10.1006/bbrc.1994.1379; CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; Eason MG, 1996, J BIOL CHEM, V271, P12826, DOI 10.1074/jbc.271.22.12826; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Gilchrist RL, 1996, J BIOL CHEM, V271, P19283, DOI 10.1074/jbc.271.32.19283; Griendling K K, 1994, Adv Pharmacol, V28, P269, DOI 10.1016/S1054-3589(08)60498-6; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; GUIRAMAND J, 1995, J BIOL CHEM, V270, P7354, DOI 10.1074/jbc.270.13.7354; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; Hayashida W, 1996, J BIOL CHEM, V271, P21985, DOI 10.1074/jbc.271.36.21985; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Hunyady L, 1996, P NATL ACAD SCI USA, V93, P10040, DOI 10.1073/pnas.93.19.10040; IWAI N, 1992, BIOCHEM BIOPH RES CO, V182, P1094, DOI 10.1016/0006-291X(92)91844-G; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LECONTE I, 1994, J BIOL CHEM, V269, P18062; Liu J, 1996, J BIOL CHEM, V271, P6172, DOI 10.1074/jbc.271.11.6172; MARIE J, 1994, J BIOL CHEM, V269, P20815; MARIN P, 1990, EUR J NEUROSCI, V2, P1110, DOI 10.1111/j.1460-9568.1990.tb00022.x; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PARMA J, 1994, MOL CELL ENDOCRINOL, V100, P159, DOI 10.1016/0303-7207(94)90296-8; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Perez DM, 1996, MOL PHARMACOL, V49, P112; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Shibata T, 1996, BIOCHEM BIOPH RES CO, V218, P383, DOI 10.1006/bbrc.1996.0067; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TORRENS Y, 1989, J NEUROCHEM, V52, P1913, DOI 10.1111/j.1471-4159.1989.tb07276.x; TSENG MJ, 1995, J BIOL CHEM, V270, P17884, DOI 10.1074/jbc.270.30.17884; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677; Wen YS, 1996, AM J PHYSIOL-CELL PH, V271, pC1212, DOI 10.1152/ajpcell.1996.271.4.C1212; WONG SKF, 1994, J BIOL CHEM, V269, P18968; Zhang JS, 1996, J BIOL CHEM, V271, P15026, DOI 10.1074/jbc.271.25.15026	46	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25566	25572		10.1074/jbc.272.41.25566	http://dx.doi.org/10.1074/jbc.272.41.25566			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325274	hybrid			2022-12-25	WOS:A1997YA35800029
J	Huang, JR; Nueda, A; Yoo, S; Dynan, WS				Huang, JR; Nueda, A; Yoo, S; Dynan, WS			Heat shock transcription factor 1 binds selectively in vitro to Ku protein and the catalytic subunit of the DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; COILED-COIL; HSP70 EXPRESSION; ACTIVATION; AUTOANTIGEN; PHOSPHORYLATION; DOMAIN; OLIGOMERIZATION; TRIMERIZATION; TRANSITION	Heat shock transcription factor 1 (HSF1) functions as the master regulator of the heat shock response in eukaryotes, We have previously shown that, in addition to its role as a transcription factor, HSF1 stimulates the activity of the DNA-dependent protein kinase (DNA-PK). DNA-PK is composed of two components: a 460-kDa catalytic subunit and a 70- and 86-kDa heterodimeric regulatory component, also known as the Ku protein. We report here that HSF1 binds specifically to each of the two components of DNA-PK. Binding occurs in the absence of DNA. The complex with the Ku protein is stable and forms at a stoichiometry close to unity between the Ku protein heterodimer and the active HSF1 trimer, The binding is blocked by antibodies against HSF1. Our results show that HSF1 also binds directly, but more weakly, to the catalytic subunit of DNA-PK. Both interactions are dependent on a specific region within the HSF1 regulatory domain, This sequence is necessary but not sufficient for HSF1 stimulation of DNA-PK activity. The ability of HSF1 to interact with both components of DNA-PK provides a potential mechanism for the activation of DNA-PK in response to heat and other forms of stress.	MED COLL GEORGIA,INST MOL MED & GENET,GENE REGULAT PROGRAM,AUGUSTA,GA 30912	University System of Georgia; Augusta University				Dynan, William/0000-0002-4045-5662; Nueda, Arsenio/0000-0001-8373-500X	NIGMS NIH HHS [GM35866] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035866] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; DYNAN WS, 1987, GENETIC ENG PRINCIPL, V9, P75; ENGELBERG D, 1994, MOL CELL BIOL, V14, P4929, DOI 10.1128/MCB.14.7.4929; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; GOODSON ML, 1995, J BIOL CHEM, V270, P2447, DOI 10.1074/jbc.270.6.2447; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; KIM D, 1995, J BIOL CHEM, V270, P15277, DOI 10.1074/jbc.270.25.15277; KIM J, 1997, IN PRESS J CELL BIOC; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LI GC, 1995, P NATL ACAD SCI USA, V92, P4512, DOI 10.1073/pnas.92.10.4512; McConnell K, 1996, CURR OPIN CELL BIOL, V8, P325, DOI 10.1016/S0955-0674(96)80005-6; MIVECHI NF, 1995, CANCER RES, V55, P5512; Newton EM, 1996, MOL CELL BIOL, V16, P839; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; Yang SH, 1996, MOL CELL BIOL, V16, P3799, DOI 10.1128/mcb.16.7.3799; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	39	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26009	26016		10.1074/jbc.272.41.26009	http://dx.doi.org/10.1074/jbc.272.41.26009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325337	hybrid			2022-12-25	WOS:A1997YA35800092
J	Jin, DY; Teramoto, H; Giam, CZ; Chun, RF; Gutkind, JS; Jeang, KT				Jin, DY; Teramoto, H; Giam, CZ; Chun, RF; Gutkind, JS; Jeang, KT			A human suppressor of c-Jun N-terminal kinase 1 activation by tumor necrosis factor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; BETA-GAMMA-SUBUNITS; MAP KINASE; SIGNAL-TRANSDUCTION; HA-RAS; TAX; PATHWAY	Tumor necrosis factor alpha (TNF alpha) has pleiotropic effects on cellular metabolism. One of the signaling paths from the TNF alpha receptor induces a stress-activated protein kinase cascade. Components within this TNF alpha kinase cascade include mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1) and stress-activated protein kinase/extracellular signal-regulated kinase kinase (SEK), which regulate the activity of c-Jun N-terminal kinase 1 (JNK1). Currently, molecules upstream of MEKK1 that link TNF alpha receptor to downstream kinases are not well understood. Besides TNF alpha, many other stimuli including several oncoproteins can activate JNK1. In most cases, the signaling cascade(s) leading from oncoproteins to JNK1 is poorly elucidated. We report here that the human T-cell lymphotrophic virus, type I (HTLV-I) oncoprotein, Tax, can activate JNK1. We isolated a novel human cell factor, G-protein pathway suppressor 2 (GPS2), by its ability to bind the HTLV-I oncoprotein, and we show that this factor can potently suppress Tax activation of JNK1. In trying to understand the mechanism of GPS2 activity, we found that it also suppressed TNF alpha activation of JNK1 but not TNF alpha activation of p38 kinase nor phorbol activation of extracellular signal-regulated kinase 2. Because GPS2 has minimal effect on MEKK1- or SEK-regulated JNK1 activity, it could act at a point between the TNF alpha receptor and MEKK1 in the initial step(s) of this kinase cascade. Alternatively, it is not excluded that GPS2 could work in a parallel pathway that leads from TNF alpha to JNK1. GPS2 represents a new molecule that could contribute important insights toward how cytokine-and oncoprotein-mediated signal transduction might converge.	NIAID, MOL MICROBIOL LAB, MOL VIROL SECT, NIH, BETHESDA, MD 20892 USA; NIDR, CELLULAR DEV & ONCOL LAB, NIH, BETHESDA, MD 20892 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT MICROBIOL & IMMUNOL, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Uniformed Services University of the Health Sciences - USA			Chun, Rene/A-9415-2010; Gutkind, J. Silvio/J-1201-2016	Chun, Rene/0000-0002-0190-0807; Gutkind, J. Silvio/0000-0002-5150-4482				BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; ELION EA, 1995, J CELL BIOL, V130, P1283, DOI 10.1083/jcb.130.6.1283; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; Gao MH, 1996, CANCER RES, V56, P4229; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Liu Delong, 1994, Journal of Biomedical Science, V1, P65, DOI 10.1007/BF02257980; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; MIDEN A, 1994, SCIENCE, V266, P1719; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; RADLERPOHL A, 1993, ANN NY ACAD SCI, V684, P127, DOI 10.1111/j.1749-6632.1993.tb32277.x; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Spain BH, 1996, MOL CELL BIOL, V16, P6698; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; YAN MH, 1994, NATURE, V372, P798; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	42	90	92	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25816	25823		10.1074/jbc.272.41.25816	http://dx.doi.org/10.1074/jbc.272.41.25816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325311	hybrid			2022-12-25	WOS:A1997YA35800066
J	Ojaniemi, M; Vuori, K				Ojaniemi, M; Vuori, K			Epidermal growth factor modulates tyrosine phosphorylation of p130(Cas) - Involvement of phosphatidylinositol 3'-kinase and actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MEDIATED CELL-ADHESION; CRK-ASSOCIATED SUBSTRATE; STRESS FIBERS; PHOSPHOINOSITIDE 3-KINASE; EXTRACELLULAR-MATRIX; RECEPTOR MUTANTS; DIRECT BINDING; PROTEIN; SRC	Epidermal growth factor (EGF) treatment of Rat-1 cells expressing human EGF receptor results in the modification of the tyrosine phosphorylation of the p130 Crk-associated substrate (Cas), a novel signaling molecule residing in focal adhesions. At low, mitogenic concentrations (<10 ng/ml), EGF treatment induced a rapid and transient tyrosine phosphorylation of Cas and promoted the formation of a Cas-adapter protein Crk complex in intact cells. The increase in tyrosine phosphorylation of Cas paralleled an increase in the cellular content of actin stress fibers and occurred via a pathway that depended on the integrity of the cytoskeleton. Further, phosphatidylinositol 3'-kinase activity was found to be required for the EGF-stimulated Cas phosphorylation and actin polymerization. At high concentrations (>30 ng/ml), EGF treatment resulted in the tyrosine dephosphorylation of Cas in a time-dependent manner with a concomitant decrease in the length and number of actin stress fibers. Thus, Cas exhibits an unusual bell-shaped dose-response curve in response to EGF stimulation, These results demonstrate a novel signaling role for EGF in inducing changes in tyrosine phosphorylation of Cas and Cas-Crk complex formation and suggest that Cas could be a signaling component in EGF-mediated signal transduction.	LA JOLLA CANC RES CTR, BURNHAM INST, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [K08CA072560] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72560] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Astier A, 1997, J BIOL CHEM, V272, P228; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Ishino M, 1995, ONCOGENE, V11, P2331; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Law SF, 1996, MOL CELL BIOL, V16, P3327; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; PATCH LA, 1995, J CELL SCI, V108, P1371; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHRAW W, 1995, BIOCHEMISTRY-US, V34, P13760, DOI 10.1021/bi00042a006; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tobe K, 1996, MOL CELL BIOL, V16, P4765; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YANO H, 1993, J BIOL CHEM, V268, P25846	59	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25993	25998		10.1074/jbc.272.41.25993	http://dx.doi.org/10.1074/jbc.272.41.25993			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325334	hybrid			2022-12-25	WOS:A1997YA35800089
J	Fiedler, K; Rothman, JE				Fiedler, K; Rothman, JE			Sorting determinants in the transmembrane domain of p24 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING DOMAIN; COPII-COATED VESICLES; AMINO-ACID PERMEASES; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; GOLGI TRANSPORT; STRUCTURAL REQUIREMENTS; HELICAL INTERACTIONS; RETENTION; LOCALIZATION	Members of the p24 family of putative cargo receptors are proposed to contain retrograde and anterograde trafficking signals in their cytoplasmic domain to facilitate coat protein binding and cycling in the secretory pathway. We have analyzed the role of the transmembrane domain (TMD) of a p24 protein isolated from COPI-coated intra-Golgi transport vesicles. CD8-p24 chimeras were transiently expressed in COS7 cells and analyzed by immunofluorescence and pulse-chase experiments. The localization and transit of the wild-type chimera from the endoplasmic reticulum (ER) through the Golgi complex involved a glutamic acid residue and a conserved glutamine in the TMD. The TMD glutamic acid mediated the localization of the chimeras to the ER in the absence of the conserved glutamine. Efficient ER exit required the TMD glutamine and was further facilitated by a pair of phenylalanine residues in the cytoplasmic bail. TMD residues of p24 proteins may mediate the interaction with integral membrane proteins of the vesicle budding machinery to ensure p24 packaging into transport vesicles.			Fiedler, K (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.			Fiedler, Klaus/0000-0001-9398-1116				ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Blum R, 1996, J BIOL CHEM, V271, P17183, DOI 10.1074/jbc.271.29.17183; BOEHM J, 1994, EMBO J, V13, P3696, DOI 10.1002/j.1460-2075.1994.tb06679.x; Boehm J, 1997, J CELL SCI, V110, P991; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; Chen LI, 1997, J CELL BIOL, V137, P619, DOI 10.1083/jcb.137.3.619; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gayle MA, 1996, J BIOL CHEM, V271, P5784, DOI 10.1074/jbc.271.10.5784; GRAHAM TR, 1995, MOL BIOL CELL, V6, P809, DOI 10.1091/mbc.6.7.809; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KIM T, 1995, J NEUROSCI RES, V42, P413, DOI 10.1002/jnr.490420316; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; LANKFORD SP, 1993, J BIOL CHEM, V268, P4814; Lazarovits J, 1996, J CELL BIOL, V134, P339, DOI 10.1083/jcb.134.2.339; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MACHAMER CE, 1993, MOL BIOL CELL, V4, P695, DOI 10.1091/mbc.4.7.695; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; Poster JB, 1996, J BIOL CHEM, V271, P3837; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; SATO K, 1995, MOL BIOL CELL, V6, P1459, DOI 10.1091/mbc.6.11.1459; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; Tsukada M, 1996, J CELL SCI, V109, P2471; WADA I, 1991, J BIOL CHEM, V266, P19599; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; Zacchetti D, 1995, FEBS LETT, V377, P465, DOI 10.1016/0014-5793(95)01396-2	61	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24739	24742		10.1074/jbc.272.40.24739	http://dx.doi.org/10.1074/jbc.272.40.24739			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312065	hybrid			2022-12-25	WOS:A1997XY97000004
J	Pentikainen, MO; Lehtonen, EMP; Oorni, K; Lusa, S; Somerharju, P; Jauhiainen, M; Kovanen, PT				Pentikainen, MO; Lehtonen, EMP; Oorni, K; Lusa, S; Somerharju, P; Jauhiainen, M; Kovanen, PT			Human arterial proteoglycans increase the rate of proteolytic fusion of low density lipoprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATHEROSCLEROTIC LESIONS; LIPID DEPOSITS; RABBIT; AORTA; CHOLESTEROL; BINDING; INTIMA; CELLS; ATHEROGENESIS; ACCUMULATION	Low density lipoprotein (LDL) particles can undergo fusion in the arterial intima, where they are bound to proteoglycans. Here we studied the effect of human arterial proteoglycans on proteolytic fusion of LDL in vitro. For this purpose, an assay was devised based on fluorescence resonance energy transfer that allowed continuous monitoring of fusion of proteoglycan-bound LDL particles, We found that addition of human arterial proteoglycans markedly increased the rate of proteolytic fusion of LDL, The glycosaminoglycans isolated from the proteoglycans also increased the rate of fusion, demonstrating that this effect was produced by the negatively charged sulfated polysaccharides In the proteoglycans, Furthermore, heparin, chondroitin 6-sulfate, and dextran sulfate, three commercially available sulfated polysaccharides, also increased the rate of LDL fusion, with heparin and chondroitin g-sulfate being as effective as and dextran sulfate more effective than hu man proteoglycans. The ability of the sulfated polysaccharides to increase the rate of proteolytic fusion of LDL depended critically on their ability to form insoluble complexes with LDL, which, in turn, resulted in an increased rate of LDL proteolysis and, in consequence, in an increased rate of LDL fusion, The results reveal a novel mechanism regulating LDL fusion and point to the potentially important role of arterial proteoglycans in the generation of LDL-derived lipid droplets in the arterial intima during atherogenesis.	WIHURI RES INST, SF-00140 HELSINKI, FINLAND; UNIV HELSINKI, DEPT MED CHEM, INST BIOMED, HELSINKI 00014, FINLAND; NATL PUBL HLTH INST, DEPT BIOCHEM, SF-00300 HELSINKI, FINLAND	Wihuri Research Institute; University of Helsinki; Finland National Institute for Health & Welfare			Oorni, Katariina/G-2484-2011	Oorni, Katariina/0000-0002-9525-0250				BARTOLD PM, 1985, ANAL BIOCHEM, V150, P320, DOI 10.1016/0003-2697(85)90517-2; BERGMEYER HU, 1985, METHOD ENZYMAT AN, V8, P1; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CAMEJO G, 1993, J BIOL CHEM, V268, P14131; CAMEJO G, 1991, BIOCHIM BIOPHYS ACTA, V1096, P253, DOI 10.1016/0925-4439(91)90013-Y; CAMEJO G, 1982, ADV LIPID RES, V19, P1; FRANK JS, 1989, J LIPID RES, V30, P967; GUYTON JR, 1992, AM J PATHOL, V141, P925; GUYTON JR, 1990, EUR HEART J, V11, P20, DOI 10.1093/eurheartj/11.suppl_E.20; GUYTON JR, 1991, J LIPID RES, V32, P953; GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; KAARTINEN M, 1994, CIRCULATION, V90, P1669, DOI 10.1161/01.CIR.90.4.1669; KAARTINEN M, 1995, ARTERIOSCL THROM VAS, V15, P2047, DOI 10.1161/01.ATV.15.11.2047; KOKKONEN JO, 1989, J BIOL CHEM, V264, P10749; KOKKONEN JO, 1995, MAST CELL PROTEASES, P257; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACEK J, 1987, J CHROMATOGR-BIOMED, V414, P156, DOI 10.1016/0378-4347(87)80034-8; MORA R, 1987, ATHEROSCLEROSIS, V67, P143, DOI 10.1016/0021-9150(87)90274-7; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; OHNISHI T, 1990, J LIPID RES, V31, P397; PAANANEN K, 1995, J BIOL CHEM, V270, P12257, DOI 10.1074/jbc.270.20.12257; PASQUINELLI G, 1989, SCANNING MICROSCOPY, V3, P1151; Pentikainen MO, 1996, J LIPID RES, V37, P2638; PIHA M, 1995, BIOCHEMISTRY-US, V34, P10120, DOI 10.1021/bi00032a004; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schwenke DC, 1996, CIRCULATION, V94, P2295; Smith E B, 1974, Adv Lipid Res, V12, P1; SRINIVASAN SR, 1989, BIOCHIM BIOPHYS ACTA, V1006, P159, DOI 10.1016/0005-2760(89)90190-2; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; TIRZIU D, 1995, ATHEROSCLEROSIS, V112, P101, DOI 10.1016/0021-9150(94)05405-8; VIA DP, 1982, J LIPID RES, V23, P570; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	37	21	21	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25283	25288		10.1074/jbc.272.40.25283	http://dx.doi.org/10.1074/jbc.272.40.25283			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312145	hybrid			2022-12-25	WOS:A1997XY97000084
J	Berns, K; Hijmans, EM; Bernards, R				Berns, K; Hijmans, EM; Bernards, R			Repression of c-Myc responsive genes in cycling cells causes G(1) arrest through reduction of cyclin E CDK2 kinase activity	ONCOGENE			English	Article						c-Myc; cell cycle; cyclin; CDK	ORNITHINE DECARBOXYLASE GENE; RETINOBLASTOMA-PROTEIN; DEPENDENT KINASES; EPIDERMAL DIFFERENTIATION; TRANSCRIPTIONAL REPRESSOR; ONCOGENIC ACTIVITY; MESSENGER-RNA; IN-VIVO; S-PHASE; MAX	The c-myc gene encodes a sequence-specific DNA binding protein involved in proliferation and oncogenesis. Activation of c-myc expression in quiescent cells is sufficient to mediate cell cycle entry, whereas inhibition of c-myc expression causes cycling cells to withdraw from the cell cycle. To search for components of the cell cycle machinery that are targets of c-Myc, we have made a mutant c-Myc protein, named MadMyc, that actively represses c-myc target genes. Expression of MadMyc in cycling NIH3T3 cells causes a significant accumulation of cells in G(1). The MadMyc-induced G(1) arrest is rescued by ectopic expression of cyclin E/CDK2 and cyclin D1/ CDK4, but not by Cdc25A, a known cell cycle target of c-Myc. The MadMyc G(1) arrest does not require the presence of a functional retinoblastoma protein and is associated with a strong reduction in cyclin E/CDK2 kinase activity in arrested cells. MadMyc does not cause alterations in the expression levels of cyclin E, CDK2, p27(kip1), cyclin DI or CDK4 in G(1)-arrested cells. These data indicate that inhibition of c-Myc activity in exponentially growing cells leads to G(1) arrest through loss of cyclin E-associated kinase activity.	NETHERLANDS CANC INST,DIV MOL CARCINOGENESIS,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Bernards, Rene/0000-0001-8677-3423				ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CERNI C, 1995, ONCOGENE, V11, P587; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GORUPPI S, 1994, ONCOGENE, V9, P1537; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1995, ONCOGENE, V11, P1409; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KELLY K, 1983, CELL, V35, P600; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Marhin WW, 1996, ONCOGENE, V12, P43; Mayol X, 1996, ONCOGENE, V13, P237; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; THOMPSON CR, 1986, NATURE, V314, P363; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wu SJ, 1996, ONCOGENE, V12, P621; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	67	95	97	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1347	1356		10.1038/sj.onc.1201280	http://dx.doi.org/10.1038/sj.onc.1201280			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315103	Green Published			2022-12-25	WOS:A1997XV84500013
J	Kondo, T; Minamino, N; NagamuraInoue, T; Matsumoto, M; Taniguchi, T; Tanaka, N				Kondo, T; Minamino, N; NagamuraInoue, T; Matsumoto, M; Taniguchi, T; Tanaka, N			Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity	ONCOGENE			English	Article						IRF-1; NPM; tumor suppressor; human cancers	REGULATORY FACTOR-I; IFN-BETA-GENE; NUCLEAR FACTOR; DNA-DAMAGE; EXPRESSION; PROTEINS; LEUKEMIA; GROWTH; P53; TRANSFORMATION	Interferon regulatory factor-1 (IRF-1) acts as a transcriptional activator in the interferon system and as a tumor suppressor. The loss of functional IRF-1 has been observed in a significant number of patients with myelodysplastic syndrome (MDS) and leukemia, suggesting a potentially critical role of IRF-1 in human oncostasis. Here we report an alternative mechanism by which IRF-1 may be inactivated. We purified an IRF-1 association molecule which was revealed to be identical to a nuclear factor nucleophosmin (NPM)/B23/numatrin. Functional analysis showed that NPM inhibited the DNA-binding and transcriptional activity of IRF-1. Moreover, NPM was overexpressed in several clinical leukemia samples and human-derived leukemia cell lines. Finally, overexpression of NPM in NIH3T3 cells resulted in malignant transformation. These results suggest the possible involvement of NPM in inactivating IRF-1-dependent anti-oncogenic surveillance in human cancer development.	UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; NATL CARDIOVASC CTR,RES INST,SUITA,OSAKA 565,JAPAN	University of Tokyo; National Cerebral & Cardiovascular Center - Japan			Kondo, Takeshi/G-2103-2012	Kondo, Takeshi/0000-0001-7455-5824; Tanaka, Nobuyuki/0000-0002-6373-2220				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BENETT JM, 1985, ANN INTERN MED, V103, P626; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; LEBEAU MM, 1989, CANCER CEL, V7, P53; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NAKANO H, 1994, NUCLEIC ACIDS RES, V22, P543, DOI 10.1093/nar/22.3.543; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PETRICOIN E, 1994, MOL CELL BIOL, V14, P1477, DOI 10.1128/MCB.14.2.1477; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tan RSP, 1996, CANCER RES, V56, P2417; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIEBEL F, 1969, J CELL PHYSIOL, V74, P191, DOI 10.1002/jcp.1040740211; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	39	152	159	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1275	1281		10.1038/sj.onc.1201286	http://dx.doi.org/10.1038/sj.onc.1201286			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315094				2022-12-25	WOS:A1997XV84500004
J	Foger, B; SantamarinaFojo, S; Shamburek, RD; Parrot, CL; Talley, GD; Brewer, HB				Foger, B; SantamarinaFojo, S; Shamburek, RD; Parrot, CL; Talley, GD; Brewer, HB			Plasma phospholipid transfer protein - Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID TRANSFER PROTEINS; APOLIPOPROTEIN-A-I; GENE; EXCHANGE; SUBPOPULATIONS; REPLACEMENT; CONVERSION; EXPRESSION; MECHANISM; VECTORS	In vitro studies have shown that plasma phospholipid transfer protein (PLTP) converts isolated human high density lipoprotein-3 (HDL,) into larger HDL particles and generates lipid poor apoA-I containing nascent HDL, To evaluate the role of PLTP in vivo we generated recombinant adenovirus vectors containing either human PLTP cDNA (rPLTP.AdV) or the reporter luciferase cDNA as a control. After intravenous infusion of 4 x 10(7) plaque-forming units (low dose) and 4 x 10(8) plaque forming units (high dose) of rPLTP.AdV into mice, PLTP activity in plasma increased from base-line levels of 8.4 +/- 0.2 to 108 +/- 17 and from 8.9 +/- 0.6 to 352 +/- 31 mu mol/ml/h, respectively, on day 4 (both p < 0.001). Thus, both low and high doses of rPLTP.AdV led to pronounced overexpression of human PLTP in mice. On day 4 after treatment, mice treated with low and high doses of rPLTP.AdV showed decreased HDL cholesterol (-54% and -91%) and apoA-I (-64% and -98%) (all p < 0.05). Kinetic studies revealed that the fractional catabolic rates of HDL labeled with [H-3] phosphatidylcholine, [C-14]phosphatidylcholine ether, [H-3]cholesteryl ether, and I-125-labeled mouse apoA-I were increased by 8.5-, 8.7-, 3.8-, and 2.8-fold, respectively, in mice treated with low dose rPLTP.AdV (all p < 0.001). After injection of labeled HDL, mice treated with rPLTP.AdV showed an increased accumulation of labeled PC ether (+304%) and cholesteryl ether (+92%) in the liver (both p < 0.05), Two-dimensional gel electrophoresis of plasma 5 min after injection of HDL labeled with I-125 apoA-I demonstrated increased levels of newly generated pre-beta-HDL in mice overexpressing PLTP, In conclusion, HDL remodeling mediated by PLTP generates nascent, lipid-poor apoA-I in vivo and accelerates the hepatic uptake of HDL surface and core lipids in mice treated with rPLTP.AdV. Accelerated catabolism of HDL in mice overexpressing PLTP leads to low HDL levels. Our data indicate an important role for PLTP in modulating reverse cholesterol transport in vivo.			Foger, B (corresponding author), NHLBI,MOL DIS BRANCH,NIH,BLDG 10,ROOM 7N102,10 CTR DR,MSC 1666,BETHESDA,MD 20892, USA.							ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; ALBERS JJ, 1984, ARTERIOSCLEROSIS, V4, P49, DOI 10.1161/01.ATV.4.1.49; Albers JJ, 1996, CURR OPIN LIPIDOL, V7, P88, DOI 10.1097/00041433-199604000-00007; ApplebaumBowden D, 1996, J CLIN INVEST, V97, P799, DOI 10.1172/JCI118479; Barter PJ, 1996, ATHEROSCLEROSIS, V121, P1, DOI 10.1016/0021-9150(95)05675-0; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BERMAN M, 1978, DHEW PUBLICATION, V78, P180; Cheung MC, 1996, BBA-LIPID LIPID MET, V1303, P103, DOI 10.1016/0005-2760(96)00082-3; DAMEN J, 1982, BIOCHIM BIOPHYS ACTA, V712, P444, DOI 10.1016/0005-2760(82)90271-5; DAY JR, 1994, J BIOL CHEM, V269, P9388; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FIELDING CJ, 1995, J LIPID RES, V36, P211; FOLCH J, 1957, J BIOL CHEM, V226, P497; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREGG RE, 1984, J LIPID RES, V25, P1167; Halperin G, 1986, Methods Enzymol, V129, P816; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; JIANG XC, 1995, J BIOL CHEM, V270, P17133, DOI 10.1074/jbc.270.29.17133; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KOPFLER WP, 1994, CIRCULATION, V90, P1319, DOI 10.1161/01.CIR.90.3.1319; KOSTNER GM, 1995, BIOCHEM J, V305, P659, DOI 10.1042/bj3050659; KOZAR RA, 1993, J SURG RES, V55, P548, DOI 10.1006/jsre.1993.1182; Lusa S, 1996, BIOCHEM J, V313, P275, DOI 10.1042/bj3130275; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MORTON RE, 1981, J BIOL CHEM, V256, P1992; Murdoch SJ, 1996, BBA-LIPID LIPID MET, V1303, P222, DOI 10.1016/0005-2760(96)00105-1; NICHOLS AV, 1987, J LIPID RES, V28, P719; Nishida HI, 1997, J BIOL CHEM, V272, P6959, DOI 10.1074/jbc.272.11.6959; POWNALL HJ, 1991, J LIPID RES, V32, P793; PUSSINEN P, 1995, J LIPID RES, V36, P975; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; Shamburek RD, 1996, AM J PHYSIOL-ENDOC M, V271, pE1073, DOI 10.1152/ajpendo.1996.271.6.E1073; SPEIJER H, 1991, ATHEROSCLEROSIS, V90, P159, DOI 10.1016/0021-9150(91)90110-O; TALL AR, 1983, J BIOL CHEM, V258, P2174; TALL AR, 1985, J LIPID RES, V26, P842; TALL AR, 1993, J LIPID RES, V34, P1255; TALL AR, 1983, J LIPID RES, V24, P277; Tollefson J H, 1986, Methods Enzymol, V129, P797; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; TU AY, 1993, J BIOL CHEM, V268, P23098; TU AY, 1995, BIOCHEM BIOPH RES CO, V207, P552, DOI 10.1006/bbrc.1995.1223; vonEckardstein A, 1996, BBA-LIPID LIPID MET, V1301, P255, DOI 10.1016/0005-2760(96)00050-1; WHITMORE TE, 1995, GENOMICS, V28, P599, DOI 10.1006/geno.1995.1198	48	130	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27393	27400		10.1074/jbc.272.43.27393	http://dx.doi.org/10.1074/jbc.272.43.27393			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341191	hybrid			2022-12-25	WOS:A1997YC65900087
J	Hanada, T; Lin, LH; Chandy, KG; Oh, SS; Chishti, AH				Hanada, T; Lin, LH; Chandy, KG; Oh, SS; Chishti, AH			Human homologue of the Drosophila discs large tumor suppressor binds to p56(lck) tyrosine kinase and shaker type Kv1.3 potassium channel in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MICE LACKING; K+ CHANNELS; IN-VITRO; RECEPTOR; ACTIVATION; PROTEINS; FAMILY; DOMAINS; ASSOCIATION	Human homologue of the Drosophila discs large tumor suppressor protein (hDlg) belongs to a newly discovered family of proteins termed MAGUKs that appear to have structural as well as signaling functions, Consistent with the multi-domain organization of MAGUKs, hDlg consists of three copies of the PDZ (PSD-95/Discs large/zO-1) domain, an SH3 motif, and a guanylate ki nase-like domain, In addition, the hDlg contains an amino-terminal proline-rich domain that is absent in other MAGUKs. To explore the role of hDlg in cell signaling pathways, we used human T lymphocytes as a model system to investigate interaction of hDlg with known tyrosine kinases, In human T lymphocyte cell lines, binding properties of hDlg were studied by immunoprecipitation, immunoblotting, and immune complex kinase assays. Our results show that protein tyrosine kinase activity is associated with the immunoprecipitates of hDlg, Immunoblotting experiments revealed that the immunoprecipitates of hDlg contain p56(lck), a member of the Src family of tyrosine kinases, The specificity of the interaction is demonstrated by the lack of p59(fyn) tyrosine kinase and phosphotidylinositol 3-kinase in the hDlg immunoprecipitates, Direct interaction between hDlg and p56(lck) is demonstrated using glutathione S-transferase fusion proteins of hDlg and recombinant p56(lck) expressed in the baculovirus infected Sf9 cells, The p56(lck) binding site was localized within the aminoterminal segment of hDlg containing proline-rich domain, In addition, we show in vivo association of hDlg with Kv1.3 channel, which was expressed in T lymphocytes as an epitope-tagged protein using a vaccinia virus expression system, Taken together, these results provide the first evidence of a direct interaction between hDlg and p56(lck) tyrosine kinase and suggest a novel function of hDlg in coupling tyrosine kinase and voltage-gated potassium channel in T lymphocytes.	TUFTS UNIV,SCH MED,ST ELIZABETHS MED CTR,TUMOR CELL BIOL LAB,BOSTON,MA 02135; UNIV CALIF IRVINE,DEPT MICROBIOL,IRVINE,CA 92697; UNIV CALIF IRVINE,DEPT MOL GENET,IRVINE,CA 92697	St. Elizabeth's Medical Center; Tufts University; University of California System; University of California Irvine; University of California System; University of California Irvine					NCI NIH HHS [CA66263] Funding Source: Medline; NIAID NIH HHS [AI24783] Funding Source: Medline; NIGMS NIH HHS [GM-OD54872-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM054872] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; CAI YC, 1993, J BIOL CHEM, V268, P23720; CHANDY KG, 1984, J EXP MED, V160, P369, DOI 10.1084/jem.160.2.369; CHANDY KG, 1993, SEMIN NEUROSCI, V5, P125; CHANDY KG, 1995, HDB RECEPTORS CHANNE, V1; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Gibson S, 1996, J BIOL CHEM, V271, P7079, DOI 10.1074/jbc.271.12.7079; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Kim AC, 1996, GENOMICS, V31, P223, DOI 10.1006/geno.1996.0035; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Koo GC, 1997, J IMMUNOL, V158, P5120; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NGUYEN QA, 1996, MOL PHARMACOL, V50, P1672; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; Rader RK, 1996, J IMMUNOL, V156, P1425; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Spencer RH, 1997, J BIOL CHEM, V272, P2389; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Taher TEI, 1996, J BIOL CHEM, V271, P2863, DOI 10.1074/jbc.271.5.2863; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Weissenhorn W, 1996, EUR J BIOCHEM, V238, P440, DOI 10.1111/j.1432-1033.1996.0440z.x; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	42	101	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26899	26904		10.1074/jbc.272.43.26899	http://dx.doi.org/10.1074/jbc.272.43.26899			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341123	hybrid			2022-12-25	WOS:A1997YC65900019
J	Koslov, ER; Maupin, P; Pradhan, D; Morrow, JS; Rimm, DL				Koslov, ER; Maupin, P; Pradhan, D; Morrow, JS; Rimm, DL			alpha-catenin can form asymmetric homodimeric complexes and/or heterodimeric complexes with beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; RECOMBINANT PROTEINS; ACTIN-BINDING; CELL-ADHESION; F-ACTIN; CADHERIN; VINCULIN; ASSOCIATION; EXPRESSION	The cadherin-based transmembrane cell-cell adhesive complex is thought to be composed of a cadherin molecule, a beta-catenin, and an alpha-catenin, which connects the complex to the cytoskeleton. The precise stoichiometry of this complex remains uncertain. We have used a series of recombinant molecules and biophysical techniques to assess the multimeric state of human alpha- and beta-catenin in vitro and then visualized them by electron microscopy after rotary shadowing. Calculated solution molecular masses are 213 kDa for alpha-catenin, 73 kDa for beta-catenin, and 186 kDa for both, This suggests that alpha-catenin exists as a homodimer in solution, beta-catenin is a monomer, and when both are present, they form alpha/beta-catenin heterodimers. Go-precipitation and surface plasmon resonance assays localize the site of alpha-catenin dimerization to the NH2-terminal 228 amino acids. This region encompasses a high-affinity (K-d = 100 nM) binding site for beta-catenin that lies between residues 54 and 157. We anticipate that the oligomeric state of alpha-catenin and the relative stoichiometry of the components in the membrane adhesion complex will be dynamic and regulated by beta-catenin, cell adhesion, and probably other factors as well.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; JOHNS HOPKINS UNIV,SCH MED,DEPT ANAT & CELL BIOL,BALTIMORE,MD 21205	Yale University; Johns Hopkins University			Pradhan, Debabrata/W-5476-2019; Aljarah, Ali/Q-7105-2016	Pradhan, Debabrata/0000-0003-4995-6882; Rimm, David/0000-0001-5820-4397; Aljarah, Ali/0000-0003-0535-090X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26338] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERLE H, 1994, J CELL SCI, V107, P3655; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Nieset JE, 1997, J CELL SCI, V110, P1013; Obama H, 1997, J BIOL CHEM, V272, P11017; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; RIMM DL, 1994, BIOCHEM BIOPH RES CO, V203, P1691, DOI 10.1006/bbrc.1994.2381; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0	25	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27301	27306		10.1074/jbc.272.43.27301	http://dx.doi.org/10.1074/jbc.272.43.27301			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341178	hybrid			2022-12-25	WOS:A1997YC65900074
J	Meech, R; Mackenzie, PI				Meech, R; Mackenzie, PI			UDP-glucuronosyltransferase, the role of the amino terminus in dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INACTIVATION ANALYSIS; PEPTIDASE CLEAVAGE SITE; LIVER; BILIRUBIN; FORM; TESTOSTERONE; GLUCURONIDE; EXPRESSION; VARIANT; PHENOL	UDP-glucuronosyltransferases (UGTs) comprise an important enzyme system in mammals that is involved in detoxification of a variety of small hydrophobic compounds of both endogenous and exogenous origin, Some evidence suggests that these enzymes may function as oligomers; however, little is known about the domain of interaction or the mechanism of oligomerization, In this work, evidence for a functional dimerization between UGTs is provided by studies on mutated forms of UGTSB1. When two inactive forms of UGT2B1 were coexpressed in cell culture, catalytic activity was restored, indicating that UGT2B1 forms functional dimers. To delineate the dimerization domain, inactive fusion proteins containing the amino-or carboxyl-terminal domains of UGT2B1 were generated and expressed with active UGT2B1, Expression of a fusion protein containing only the amino-terminal half of UGT2B1 with active UGT2B1 caused a reduction in UGT2B1 catalytic activity, This reduction in activity was not observed when UGT2B1 was co-expressed with a fusion protein containing only the carboxyl terminal half of UGT2B1, strongly suggesting that the amino-terminal domain is involved in dimerization. Truncation of the immediate amino terminus of UGT2B1 abolished UGT2B1 activity and dimer formation. Activity was also abolished by an L4R substitution in this region of the mature protein, which is highly conserved in the UGT family. These results indicate that UGTs can interact through their amino-terminal domains to form catalytically active dimers. Possible mechanisms resulting in the formation and stabilization of the UGT2B1 dimer are discussed.	FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT CLIN PHARMACOL,SCH MED,BEDFORD PK,SA 5042,AUSTRALIA	Flinders University South Australia				Meech, Robyn/0000-0002-6831-0801; Mackenzie, Peter/0000-0002-0697-6878				BRENNAN SO, 1990, P NATL ACAD SCI USA, V87, P26, DOI 10.1073/pnas.87.1.26; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; DALY M, 1990, FEBS LETT, V273, P87, DOI 10.1016/0014-5793(90)81057-U; GSCHAIDMEIER H, 1994, BIOCHEM PHARMACOL, V48, P1545, DOI 10.1016/0006-2952(94)90198-8; Ikushiro S, 1997, BIOCHEMISTRY-US, V36, P7154, DOI 10.1021/bi9702344; Koiwai O, 1996, HUM MOL GENET, V5, P645, DOI 10.1093/hmg/5.5.645; MACKENZIE PI, 1984, ARCH BIOCHEM BIOPHYS, V231, P487, DOI 10.1016/0003-9861(84)90412-0; MACKENZIE PI, 1986, J BIOL CHEM, V261, P6119; MACKENZIE PI, 1987, J BIOL CHEM, V262, P9744; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MACKENZIE PI, 1995, REV BIOCHEM TOXICOL, V11, P29; MACKENZIE PI, 1990, FRONTIERS BIOTRANSFO, V2, P211; MATERN H, 1982, J BIOL CHEM, V257, P7422; Meech R, 1996, DNA CELL BIOL, V15, P489, DOI 10.1089/dna.1996.15.489; MORTLOCK D, 1993, J TISSUE CULTURE MET, V15, P176; OWENS IS, 1992, PHARMACOGENETICS, V2, P93, DOI 10.1097/00008571-199206000-00001; PETERS WHM, 1984, J BIOL CHEM, V259, P1701; PRITCHARD M, 1994, MOL PHARMACOL, V45, P42; RITTER JK, 1992, J BIOL CHEM, V267, P3257; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH PC, 1990, DRUG METAB DISPOS, V18, P639; WILLIAMS AM, 1992, BIOCHEM PHARMACOL, V43, P745, DOI 10.1016/0006-2952(92)90239-F	24	97	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26913	26917		10.1074/jbc.272.43.26913	http://dx.doi.org/10.1074/jbc.272.43.26913			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341125	hybrid			2022-12-25	WOS:A1997YC65900021
J	Barrett, MG; Belinsky, GS; Tashjian, AH				Barrett, MG; Belinsky, GS; Tashjian, AH			A new action of parathyroid hormone - Receptor-mediated stimulation of extracellular acidification in human osteoblast-like SaOS-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BONE-RESORPTION; ALKALINE-PHOSPHATASE; SARCOMA CELLS; INTRACELLULAR CALCIUM; SIGNAL-TRANSDUCTION; COUPLED RECEPTOR; DOWN-REGULATION; UMR-106 CELLS; LINE UMR-106	The major physiological function of parathyroid hormone (PTH) is the maintenance of Ca2+/P-i homeostasis via the parathyroid hormone/parathyroid hormone-related protein receptor (PTHR) in kidney and bone, An important consequence of PTHR activation in bone is enhanced local acidification of the extracellular space. Agonist activation of some seven transmembrane-domain receptors increases the extracellular acidification rate (ECAR). We utilized microphysiometry to investigate PTH-stimulated, receptor-mediated increases in ECAR in human osteoblast-like SaOS-2 cells, PTH-(1-34) elicited a large, acute, dose-dependent increase in ECAR with an EC50 of about 2 nM. The PTH-induced increase in ECAR was specific to cells expressing the PTHR, and was inhibited by PTHR antagonists. Rapid, partial, homologous desensitization of the PTH-induced increase in ECAR was observed. Incubation of SaOS-2 cells with 8-bromo-cyclic AMP neither mimicked nor abrogated the PTH effect, and PTH stimulated an acute increase in ECAR in cAMP-resistant SaOS-2 Ca#4A cells. Stimulation of ECAR by PTH was independent of transient increases in cytosolic free calcium, Both inhibition and down-regulation of PKC reduced the PTH-induced increase in ECAR. inhibition of Na+/H+ exchange did not affect the PTH-induced ECAR response. me conclude that PTH caused a receptor-mediated, concentration-dependent, increase in ECAR, which was not dependent on the cAMP/PKA signaling pathway or the Na+/H+ exchanger but involved the action of PKC, Thus, acid production in bone, a physiologically important action of PTH, is not confined to osteoclasts as previously considered but is also mediated by osteoblasts.	HARVARD UNIV, SCH PUBL HLTH, DEPT MOL & CELLULAR TOXICOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 10206, DK 46655] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046655, R01DK010206] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1994, ENDOCRINOLOGY, V135, P2588, DOI 10.1210/en.135.6.2588; Arnett TR, 1996, BONE, V18, P277, DOI 10.1016/8756-3282(95)00486-6; ATKINS D, 1975, J ENDOCRINOL, V64, P573, DOI 10.1677/joe.0.0640573; AURBACH GD, 1985, WILLIAMS TXB ENDOCRI, P1153; Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931; AZARANI A, 1995, J BIOL CHEM, V270, P23166, DOI 10.1074/jbc.270.39.23166; Baron R, 1995, ACTA ORTHOP SCAND, V66, P66, DOI 10.3109/17453679509157650; BERGWITZ C, 1994, BBA-MOL CELL RES, V1222, P447, DOI 10.1016/0167-4889(94)90053-1; BIDWELL JP, 1991, ENDOCRINOLOGY, V128, P1021, DOI 10.1210/endo-128-2-1021; BLIND E, 1995, ENDOCRINOLOGY, V136, P4271, DOI 10.1210/en.136.10.4271; Bliziotes M, 1996, J BONE MINER RES, V11, P820; BOLAND CJ, 1986, ENDOCRINOLOGY, V118, P980, DOI 10.1210/endo-118-3-980; BUSHINSKY DA, 1994, MINER ELECTROL METAB, V20, P40; Bushinsky DA, 1996, AM J PHYSIOL-RENAL, V271, pF216, DOI 10.1152/ajprenal.1996.271.1.F216; CHIO CL, 1994, J BIOL CHEM, V269, P11813; CHIO CL, 1994, MOL PHARMACOL, V45, P51; DresnerPollak R, 1996, J BONE MINER RES, V11, P1061; DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223; FELIX R, 1978, AM J PHYSIOL, V234, pC51, DOI 10.1152/ajpcell.1978.234.1.C51; FERRIER J, 1992, BONE MINER, V19, P103, DOI 10.1016/0169-6009(92)90919-5; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; FUKAYAMA S, 1991, CELL REGUL, V2, P889, DOI 10.1091/mbc.2.11.889; FUKAYAMA S, 1988, ENDOCRINOLOGY, V123, P2841, DOI 10.1210/endo-123-6-2841; FUKAYAMA S, 1992, ENDOCRINOLOGY, V131, P1757, DOI 10.1210/en.131.4.1757; GRAHAM CS, 1992, BIOCHEM J, V288, P137, DOI 10.1042/bj2880137; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUPTA A, 1994, AM J PHYSIOL, V266, pC1083, DOI 10.1152/ajpcell.1994.266.4.C1083; HALDIMANN B, 1977, AM J PHYSIOL, V232, pE535, DOI 10.1152/ajpendo.1977.232.6.E535; HERRMANNERLEE MPM, 1977, EUR J PHARMACOL, V46, P51, DOI 10.1016/0014-2999(77)90143-1; HOHMANN EL, 1984, ENDOCRINOLOGY, V114, P1321, DOI 10.1210/endo-114-4-1321; IVEY JL, 1976, J CLIN INVEST, V58, P1327, DOI 10.1172/JCI108588; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KAJI H, 1992, BIOCHEM BIOPH RES CO, V182, P1356, DOI 10.1016/0006-291X(92)91882-Q; KAJI H, 1993, HORM METAB RES, V25, P421, DOI 10.1055/s-2007-1002136; KRAMER IM, 1989, J BIOL CHEM, V264, P5876; KRUG E, 1987, J BIOL CHEM, V262, P11852; LEE SK, 1994, J BONE MINER RES, V9, P781; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MITCHELL J, 1990, ENDOCRINOLOGY, V126, P2650, DOI 10.1210/endo-126-5-2650; Monroe JJ, 1996, AM J PHYSIOL-CELL PH, V270, pC1277, DOI 10.1152/ajpcell.1996.270.5.C1277; OWICKI JC, 1992, BIOSENS BIOELECTRON, V7, P255, DOI 10.1016/0956-5663(92)87004-9; OWICKI JC, 1990, P NATL ACAD SCI USA, V87, P4007, DOI 10.1073/pnas.87.10.4007; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; PITCHFORD S, 1995, AM J PHYSIOL-CELL PH, V268, pC936, DOI 10.1152/ajpcell.1995.268.4.C936; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; RICHARDSON UI, 1976, J CELL PHYSIOL, V88, P287, DOI 10.1002/jcp.1040880304; SCHLESINGER PH, 1994, MINER ELECTROL METAB, V20, P31; SUGIMOTO T, 1986, CALCIFIED TISSUE INT, V39, P171, DOI 10.1007/BF02555114; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; VAES G, 1968, J CELL BIOL, V39, P676, DOI 10.1083/jcb.39.3.676; VIGNERY A, 1978, CALC TISS RES, V26, P23, DOI 10.1007/BF02013229; WHITFIELD JF, 1995, TRENDS PHARMACOL SCI, V16, P382, DOI 10.1016/S0165-6147(00)89079-3; WILTINK A, 1993, CELL CALCIUM, V14, P591, DOI 10.1016/0143-4160(93)90059-F	54	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26346	26353		10.1074/jbc.272.42.26346	http://dx.doi.org/10.1074/jbc.272.42.26346			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334207	hybrid			2022-12-25	WOS:A1997YB13900041
J	Bi, WM; Wu, L; Coustry, F; deCrombrugghe, B; Maity, SN				Bi, WM; Wu, L; Coustry, F; deCrombrugghe, B; Maity, SN			DNA binding specificity of the CCAAT-binding factor CBF/NF-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR NF-Y; TRANSCRIPTION FACTOR; B-SUBUNIT; FUNCTIONAL DOMAINS; SEQUENCE IDENTITY; COLLAGEN PROMOTER; UBIQUITOUS FACTOR; HISTONE FOLD; YEAST HAP2; C-SUBUNIT	CBF is a heterotrimeric protein that binds to DNA containing CCAAT motifs, Here we have analyzed interactions of recombinant CBF with DNA using hydroxyl radical footprinting and methylation interference assays, In the CBF-DNA complex, three separate DNA regions are protected from hydroxyl radical cleavage, one located over and immediately adjacent to the CCAAT motif itself and the other two located on both sides of the CCAAT motif, The methylation interference assay showed, however, that only in the CCAAT motif region methylation of bases was able to interfere with the for mation of a CBF-DNA complex, suggesting that CBF makes sequence-specific contacts only in the CCAAT motif region, To further determine the specific DNA sequences necessary for CBF binding, we employed a polymerase chain reaction-mediated random binding site selection method, This analysis showed that CBF binding to DNA requires the CCAAT sequence and other specific sequences immediately flanking both ends of the CCAAT motif, We also showed that the nature of the flanking nucleotide sequences affects the affinity of CBF for DNA, Interestingly, most of the CCAAT motifs present in various higher eukaryotic promoters correspond to the CBF binding sites that were selected, consistent with the hypothesis that these motifs are binding sites for CBF and, hence, that CBF could regulate transcription of numerous eukaryotic genes.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center				Maity, Sankar/0000-0002-2387-6545	NCI NIH HHS [CA49515] Funding Source: Medline; NIAMS NIH HHS [AR43660] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043660] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; BALDWIN AS, 1994, CURRENT PROTOCOL S25; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Hasegawa T, 1996, NUCLEIC ACIDS RES, V24, P3253, DOI 10.1093/nar/24.16.3253; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; Hung HL, 1996, J BIOL CHEM, V271, P2323, DOI 10.1074/jbc.271.4.2323; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; Kim IS, 1996, MOL CELL BIOL, V16, P4003; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P8286; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MAXAM AM, 1980, METHOD ENZYMOL, V65, P497; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; ROY B, 1995, MOL CELL BIOL, V15, P2263; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Tezuka KI, 1996, J BIOL CHEM, V271, P22713, DOI 10.1074/jbc.271.37.22713; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VANHUISJDUIJNEN RH, 1990, EMBO J, V10, P3119; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x	38	92	98	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26562	26572		10.1074/jbc.272.42.26562	http://dx.doi.org/10.1074/jbc.272.42.26562			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334236	hybrid			2022-12-25	WOS:A1997YB13900070
J	Hara, K; Yonezawa, K; Kozlowski, MT; Sugimoto, T; Andrabi, K; Weng, QP; Kasuga, M; Nishimoto, I; Avruch, J				Hara, K; Yonezawa, K; Kozlowski, MT; Sugimoto, T; Andrabi, K; Weng, QP; Kasuga, M; Nishimoto, I; Avruch, J			Regulation of eIF-4E BP1 phosphorylation by mTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MAMMALIAN PROTEIN; SERINE RESIDUE; RAPAMYCIN; YEAST; COMPLEX; TARGET; FKBP12-RAPAMYCIN; FKBP12	The proteins eIF-4E BP1 and p70 S6 kinase each undergo an insulin/mitogen-stimulated phosphorylation in situ that is partially inhibited by rapamycin. Previous work has established that the protein known as mTOR/RAFT-1/FRAP is the target through which the rapamycin.FKBP12 complex acts to dephosphorylate/deactivate the p70 S6 kinase; thus, some mTOR mutants that have lost the ability to bind to the rapamycin.FKBP12 complex in vitro can protect the p70 S6 kinase against rapamycin-induced dephosphorylation/deactivation in situ, We show herein that such mTOR mutants also protect eIF-4E BP1 against rapamycin-induced dephosphorylation, and for both p70 S6 kinase and eIF-4E BP1, such protection requires that the rapamycin-resistant mTOR variant retains an active catalytic domain, In contrast, mutants of p70 S6 kinase rendered intrinsically resistant to inhibition by rapamycin in situ are not able to protect coexpressed eIF-4E BP1 from rapamycin-induced dephosphorylation. We conclude that mTOR is an upstream regulator of eIF-4E BP1 as well as the p70 S6 kinase; moreover, these two mTOR targets are regulated in a parallel rather than sequential manner.	MASSACHUSETTS GEN HOSP,DIABET UNIT,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; KOBE UNIV,BIOSIGNAL RES CTR,KOBE,HYOGO 657,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,KOBE,HYOGO 657,JAPAN; KEIO UNIV,SCH MED,DEPT PHARMACOL & NEUROSCI,TOKYO 160,JAPAN	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Kobe University; Kobe University; Keio University				andrabi, Khurshid/0000-0003-0314-5662	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017776, R37DK017776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK17776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarcon CM, 1996, GENE DEV, V10, P279, DOI 10.1101/gad.10.3.279; AZIPIAZU I, 1996, J BIOL CHEM, V271, P5033; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; DIGGLE TA, 1996, BIOCHEM J, V315, P146; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REINHARD G, 1994, EMBO J, V1, P1557; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STAN R, 1994, J BIOL CHEM, V269, P32027; WENG QP, 1995, MOL CELL BIOL, V15, P2333; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	33	393	402	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26457	26463		10.1074/jbc.272.42.26457	http://dx.doi.org/10.1074/jbc.272.42.26457			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334222	hybrid, Green Published			2022-12-25	WOS:A1997YB13900056
J	Krieg, J; Glasner, W; Vicentini, A; Doucey, MA; Loffler, A; Hess, D; Hofsteenge, J				Krieg, J; Glasner, W; Vicentini, A; Doucey, MA; Loffler, A; Hess, D; Hofsteenge, J			C-mannosylation of human RNase 2 is an intracellular process performed by a variety of cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-PROTOPLASTS; U-S; GLYCOSYLATION; EXPRESSION; TRYPTOPHAN; PROTEINS; PURIFICATION; RIBONUCLEASE; RECEPTOR; RESIDUE	C-2-alpha-Mannosyltryptophan was discovered in RNase 2 from human urine, representing a novel way of attaching carbohydrate to a protein, Here, we have addressed two questions related to the biosynthesis of this modification: (i) is C-mannosylation part of the normal intracellular biosynthetic route, and (ii) how general is it, i.e. which organisms perform this kind of glycosylation? To answer the first question, RNase 2, which is identical to the eosinophil-derived neurotoxin, was isolated from intracellular stores of cultured human HL-60 cells. The enzyme was C-mannosylated at Trp-7, showing that the modification occurs intracellularly, before secretion of the protein, The second question was investigated by immunological and chemical analysis of RNase 2 purified from the supernatant of transiently transformed cells from different organisms, This revealed that C-mannosylation occurs in cells from man, green monkey, pig, mouse, and hamster, The observation that pig kidney cells contain the machinery for C-mannosylation of Trp-7 of human RNase 2 but that the homologous RNase from porcine kidney is not a substrate, since it does not contain a tryptophan at position 7, strongly suggests that C-mannosylated proteins other than RNase 2 exist, Recombinant RNase 2 isolated from insect cells, plant protoplasts, and Escherichia coli was not C-mannosylated, These results not only form the basis for further studies on the biochemical aspects of C-mannosylation but also have implications for the choice of cells for production of recombinant glycoproteins.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ASSELBERGS FAM, 1993, ANAL BIOCHEM, V209, P327, DOI 10.1006/abio.1993.1128; BEINTEMA JJ, 1988, BIOCHEMISTRY-US, V27, P4530, DOI 10.1021/bi00412a046; BELOCOPITOW E, 1977, MOL CELL BIOCHEM, V16, P127, DOI 10.1007/BF01732053; CHAZENBALK GD, 1995, J BIOL CHEM, V270, P1543, DOI 10.1074/jbc.270.4.1543; DEBEER T, 1995, BIOCHEMISTRY-US, V34, P11785, DOI 10.1021/bi00037a016; DELMER DP, 1978, PLANT PHYSIOL, V61, P25, DOI 10.1104/pp.61.1.25; DURACK DT, 1979, P NATL ACAD SCI USA, V76, P1443, DOI 10.1073/pnas.76.3.1443; ETCHEVERRY T, 1995, PROTEIN ENG, P163; FISCHKOFF SA, 1984, J EXP MED, V160, P179, DOI 10.1084/jem.160.1.179; FISCHKOFF SA, 1986, BLOOD, V68, P185; FOMINAYA JM, 1988, BIOCHIM BIOPHYS ACTA, V954, P216, DOI 10.1016/0167-4838(88)90074-X; GADE G, 1992, BIOCHEM BIOPH RES CO, V189, P1303, DOI 10.1016/0006-291X(92)90215-7; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; Gordon MH, 1933, BRIT MED J, V1933, P641, DOI 10.1136/bmj.1.3771.641; HOFSTEENGE J, 1994, BIOCHEMISTRY-US, V33, P13524, DOI 10.1021/bi00250a003; Hofsteenge J, 1996, TECHNIQUES PROTEIN C, V7, P163; Hohn T, 1996, P NATL ACAD SCI USA, V93, P8334, DOI 10.1073/pnas.93.16.8334; IRIE M, 1988, J BIOCHEM-TOKYO, V104, P289, DOI 10.1093/oxfordjournals.jbchem.a122460; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; Loffler A, 1996, BIOCHEMISTRY-US, V35, P12005, DOI 10.1021/bi9610515; NEWTON DL, 1994, J BIOL CHEM, V269, P26739; RIBO M, 1994, BIOL CHEM H-S, V375, P357; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT TGM, 1993, PROTEIN ENG, V6, P109, DOI 10.1093/protein/6.1.109; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHNEIDER I, 1964, J EXP ZOOL, V156, P91, DOI 10.1002/jez.1401560107; SNYDER MR, 1997, RIBONUCLEASES STRUCT, P425; STANLEY P, 1995, FASEB J, V9, P1436, DOI 10.1096/fasebj.9.14.7589985; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; TIFFANY HL, 1995, J LEUKOCYTE BIOL, V58, P49	31	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26687	26692		10.1074/jbc.272.42.26687	http://dx.doi.org/10.1074/jbc.272.42.26687			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334252	hybrid			2022-12-25	WOS:A1997YB13900086
J	Natoli, G; Costanzo, A; Moretti, F; Fulco, M; Balsano, C; Levrero, M				Natoli, G; Costanzo, A; Moretti, F; Fulco, M; Balsano, C; Levrero, M			Tumor necrosis factor (TNF) receptor 1 signaling downstream of TNF receptor-associated factor 2 - Nuclear factor kappa B (NF kappa B)-inducing kinase requirement for activation of activating protein 1 and NF kappa B but not of c-Jun N-terminal kinase/stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; MAP KINASE; TRANSDUCTION PATHWAY; PROLONGED ACTIVATION; INDUCED APOPTOSIS; FACTOR-ALPHA; DOMAIN; PHOSPHORYLATION; TRANSCRIPTION; INTERACTS	Like other members of the tumor necrosis factor (TNF) receptor family, p55 TNF receptor 1 (TNF-R1) lacks intrinsic signaling capacity and transduces signals by recruiting associating molecules, The TNF-R1 associated death domain protein interacts with the p55 TNF-R1 cytoplasmic domain and recruits the Fas-associated death domain protein (which directly activates the apoptotic proteases), the protein kinase receptor interacting protein, and TNF receptor-associated factor 2 (TRAF2), TRAF2 has previously been demonstrated to activate both transcription factor nuclear factor kappa B (NF kappa B) and the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) pathway, which in turn stimulates transcription factor activating protein 1 (AP1) mainly via phosphorylation of the c-Jun component. We have investigated the signaling properties of NF kappa B-inducing kinase (NIK), a TRAF2-associated protein kinase that mediates NF kappa B induction, NM was found to be unable to activate JNK/SAPK, mitogen-activated protein kinase, or p38 kinase, Moreover, NIK was not required for JNK/SAPK activation by TNF-R1, thus representing the first TNF-R1 complex component to dissect the NF kappa B and the JNK/SAPK pathways. Despite being unable to activate JNK/SAPK and mitogen-activated protein kinase, NIK strongly activated AP1 and was required for TNF-R1-induced AP1 activation, Therefore, NIK links TNF-R1 to a novel, JNK/SAPK-independent, AP1 activation pathway.	UNIV ROMA LA SAPIENZA,FDN ANDREA CESALPINO,I-00161 ROME,ITALY; UNIV PALERMO,IST MED INTERNA,I-90100 PALERMO,ITALY; UNIV AQUILA,DIPARTIMENTO MED INTERNA,I-86100 LAQUILA,ITALY	Sapienza University Rome; University of Palermo; University of L'Aquila	Natoli, G (corresponding author), UNIV ROMA LA SAPIENZA,IST CLIN MED 1,POLICLIN UMBERTO I,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Natoli, gioacchino/ABB-8679-2020; Natoli, gioacchino/J-2100-2018; Costanzo, Antonio/D-3896-2012; Balsano, Clara/AAK-9870-2020; Costanzo, Antonio/GZG-2433-2022; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Costanzo, Antonio/0000-0001-9697-2557; Levrero, Massimo/0000-0002-4978-0875; Natoli, Gioacchino/0000-0003-0711-2411				AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Baker SJ, 1996, ONCOGENE, V12, P1; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; TEWARY M, 1996, CURR OPIN GENE DEV, V6, P89; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VIETOR I, 1993, J BIOL CHEM, V268, P18994; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAN MH, 1994, NATURE, V372, P798	41	106	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26079	26082		10.1074/jbc.272.42.26079	http://dx.doi.org/10.1074/jbc.272.42.26079			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334169	hybrid			2022-12-25	WOS:A1997YB13900003
J	Yoshimura, Y; Yamauchi, T				Yoshimura, Y; Yamauchi, T			Phosphorylation-dependent reversible association of Ca2+/calmodulin-dependent protein kinase II with the postsynaptic densities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; MOLECULAR-CLONING; ALPHA-SUBUNIT; BETA-SUBUNIT; MUTANT MICE; PURIFICATION; AUTOPHOSPHORYLATION; TRANSLOCATION; THREONINE-286; EXPRESSION	The association of soluble Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) with postsynaptic densities (PSDs) was determined by activity assay, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and immunoblotting of the enzyme. Soluble CaM kinase II was autophosphorylated with ATP in the presence of Ca2+ and calmodulin, and then it was incubated with PSDs, Autophosphorylated CaM kinase II rt as precipitated with PSDs by centrifugation. The kinase that was not autophosphorylated did not precipitate with PSDs, These results indicate that the soluble previously autophosphorylated CaM kinase II associates with PSDs and forms PSD-CaM kinase II complex. A maximum of about GO mu g of soluble CaM kinase II bound to 1 mg of PSD protein under the experimental conditions. Ca2+-independent activity generated by autophosphorylation of the kinase was retained in the PSD-CaM kinase II complex, The CaM kinase II thus associated with PSDs phosphorylated a number of PSD proteins in both the absence and presence of Ca2+. When the CaM kinase II-PSD complex was incubated at 30 degrees C, its Ca2+-independent activity was gradually decreased. This decrease was correlated with dephosphorylation of the kinase and its release from PSD-CaM kinase II complex, These results indicate that CaM kinase IT reversibly translocates to PSDs in a phosphorylation-dependent manner.	UNIV TOKUSHIMA, FAC PHARMACEUT SCI, DEPT BIOCHEM, TOKUSHIMA 770, JAPAN	Tokushima University								BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; FONG YL, 1989, J BIOL CHEM, V264, P16759; GOIDENRING JR, 1984, J NEUROCHEM, V42, P1077; GOLDENRING JR, 1983, J BIOL CHEM, V258, P2632; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; ICHIKAWA T, 1992, J CHEM NEUROANAT, V5, P383, DOI 10.1016/0891-0618(92)90054-T; ICHINOSE M, 1990, BRAIN RES, V533, P137, DOI 10.1016/0006-8993(90)91806-R; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; Kennedy M B, 1993, Curr Opin Neurobiol, V3, P732, DOI 10.1016/0959-4388(93)90145-O; KENNEDY MB, 1981, P NATL ACAD SCI-BIOL, V78, P1293, DOI 10.1073/pnas.78.2.1293; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; OCHIISHI T, 1993, BRAIN RES, V610, P97, DOI 10.1016/0006-8993(93)91222-E; OHSAKO S, 1991, J BIOCHEM-TOKYO, V109, P137, DOI 10.1093/oxfordjournals.jbchem.a123334; RICH D P, 1990, Molecular and Cellular Neuroscience, V1, P107; RICH DP, 1989, J NEUROCHEM, V53, P807, DOI 10.1111/j.1471-4159.1989.tb11777.x; SAHYOUN N, 1985, J BIOL CHEM, V260, P1230; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SUGIURA H, 1992, BRAIN RES, V593, P97, DOI 10.1016/0006-8993(92)91269-K; SUZUKI T, 1994, J NEUROCHEM, V63, P1529, DOI 10.1046/j.1471-4159.1994.63041529.x; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; WAXHAM MN, 1990, P NATL ACAD SCI USA, V87, P1273, DOI 10.1073/pnas.87.4.1273; WU K, 1986, J NEUROCHEM, V46, P831, DOI 10.1111/j.1471-4159.1986.tb13047.x; WU K, 1992, P NATL ACAD SCI USA, V89, P3015, DOI 10.1073/pnas.89.7.3015; YAMAUCHI T, 1980, FEBS LETT, V116, P141, DOI 10.1016/0014-5793(80)80628-4; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x; Yoshimura Y, 1996, J BIOCHEM, V119, P268	42	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26354	26359		10.1074/jbc.272.42.26354	http://dx.doi.org/10.1074/jbc.272.42.26354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334208	hybrid			2022-12-25	WOS:A1997YB13900042
J	Fu, Y; Shearing, LN; Haynes, S; Crewther, P; Tilley, L; Anders, RF; Foley, M				Fu, Y; Shearing, LN; Haynes, S; Crewther, P; Tilley, L; Anders, RF; Foley, M			Isolation from phage display libraries of single chain variable fragment antibodies that recognize conformational epitopes in the malaria vaccine candidate, apical membrane antigen-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-KNOWLESI; SEQUENCE-ANALYSIS; SURFACE-ANTIGEN; I AMA-1; PROTEIN; EXPRESSION; INHIBIT; FAB; IGG	Phage display of single chain variable fragment (scFv) antibodies is a powerful tool for the selection of important and useful antibody specificities. We have constructed such a library from mice protected from malaria challenge by immunization with recombinant Plasmodium chabaudi DS apical membrane antigen (AMA-1). Panning on refolded AMA-1 enriched a population of scFvs which specifically bound the antigen. The single chain antibodies recognize conformational epitopes on AMA-1 from the P. chabaudi DS strain but not on AMA-1 of the 556KA strain of P. chabaudi. A subset of the antibody fragments recognized AMA-1 from the human malaria parasite Plasmodium falciparum. Nucleotide sequencing revealed that at least four unique scFv genes were selected by the panning procedure. These scFv antibodies are valuable reagents for probing the structure and function of AMA-1 and will be used to test the feasibility of using recombinant antibodies in a passive immunization therapy against malaria.	LA TROBE UNIV,SCH BIOCHEM,BUNDOORA,VIC 3083,AUSTRALIA; WALTER & ELIZA HALL INST MED RES,COOPERAT RES CTR DIAGNOST TECHNOL,MELBOURNE,VIC 3050,AUSTRALIA	La Trobe University; Walter & Eliza Hall Institute			Tilley, Leann/AAU-5281-2020	Foley, Michael/0000-0003-1349-4698; Tilley, Leann/0000-0001-9910-0199; fu, ying/0000-0002-1261-3336; Anders, Robin/0000-0002-0693-4547				ANDERS RF, 1997, MOL IMMUNOLOGICAL CO, P167; ANDERS RF, 1997, IN PRESS VACCINE, V15; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; CHENG Q, 1994, MOL BIOCHEM PARASIT, V65, P183, DOI 10.1016/0166-6851(94)90127-9; COLLINS WE, 1994, AM J TROP MED HYG, V51, P711, DOI 10.4269/ajtmh.1994.51.711; Crewther PE, 1996, INFECT IMMUN, V64, P3310, DOI 10.1128/IAI.64.8.3310-3317.1996; DEANS JA, 1982, CLIN EXP IMMUNOL, V49, P297; DEANS JA, 1988, PARASITE IMMUNOL, V10, P535, DOI 10.1111/j.1365-3024.1988.tb00241.x; DUTTA S, 1995, MOL BIOCHEM PARASIT, V73, P267, DOI 10.1016/0166-6851(95)00112-E; ELGAVISH RA, 1993, BIOTECHNIQUES, V15, P1066; Giudicelli V, 1997, NUCLEIC ACIDS RES, V25, P206, DOI 10.1093/nar/25.1.206; Hodder AN, 1996, J BIOL CHEM, V271, P29446, DOI 10.1074/jbc.271.46.29446; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; MARSHALL VM, 1989, MOL BIOCHEM PARASIT, V37, P281, DOI 10.1016/0166-6851(89)90160-6; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; PETERSON MG, 1989, MOL CELL BIOL, V9, P3151, DOI 10.1128/MCB.9.7.3151; PETERSON MG, 1990, MOL BIOCHEM PARASIT, V39, P279, DOI 10.1016/0166-6851(90)90067-V; Samuelsson A, 1996, EUR J IMMUNOL, V26, P3029, DOI 10.1002/eji.1830261231; SAUL A, 1987, PARASITE IMMUNOL, V9, P1, DOI 10.1111/j.1365-3024.1987.tb00483.x; SIEGEL DL, 1994, BLOOD, V83, P2334, DOI 10.1182/blood.V83.8.2334.bloodjournal8382334; THOMAS AW, 1984, MOL BIOCHEM PARASIT, V13, P187, DOI 10.1016/0166-6851(84)90112-9; WATERS AP, 1990, J BIOL CHEM, V265, P17974; WATERS AP, 1991, MOL BIOCHEM PARASIT, V44, P141, DOI 10.1016/0166-6851(91)90230-4; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	25	18	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25678	25684		10.1074/jbc.272.41.25678	http://dx.doi.org/10.1074/jbc.272.41.25678			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325291	hybrid			2022-12-25	WOS:A1997YA35800046
J	Stennicke, HR; Salvesan, GS				Stennicke, HR; Salvesan, GS			Biochemical characteristics of caspases-3, -6, -7, and -8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROGRAMMED CELL-DEATH; PROTEASE ACTIVATION; CYSTEINE PROTEASE; C-ELEGANS; APOPTOSIS; ACIDIFICATION; EQUILIBRIA; EVENTS; PAPAIN	The observation that the nematode cell, death effector gene product Ced-3 is homologous to human interleukin-1 beta-converting enzyme (caspase-1) has led to the discovery of at least nine other human caspases, many of which are implicated as mediators of apoptosis. Significant interest has been given to aspects of the cell biology and substrate specificity of this family of proteases; however, quantitative descriptions of their biochemical characteristics have lagged behind. We describe the influence of a number of environmental parameters, including pH, ionic strength, detergent, and specific ion concentrations, on the activity and stability of four caspases involved in death receptor-mediated apoptosis. Based on these observations, we recommend the following buffer as optimal for investigation of their characteristics in vitro: 20 mM piperazine-N,N'-bis-(2-ethanesulfonic acid) (PIPES), 100 mM NaCl, 10 mM dithiothreitol, 1 mM EDTA, 0.1% 3-[(3-cholamidopropyl) -dimethylammonio]-2-hydroxy-1-propanesulfonic acid (CHAPS), 10% sucrose, pH 7.2. Caspase activity is not affected by concentrations of Ca2+ below 100 mM, but is abolished by Zn2+ in the submicromolar range, a common characteristic of cysteine proteases. Optimal pH values vary from 6.8 for caspase-8 to 7.4 for caspase-3, and activity of all is relatively stable between 0 and 150 mM NaCl. Consequently, changes in the physiologic pH and ionic strength would not significantly alter the activity of the enzymes, inasmuch as all four caspases are optimally active within the range of these parameters found in the cytosol of living and dying human cells.	BURNHAM INST,PROGRAM APOPTOSIS & CELL DEATH,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; BLACK RA, 1989, J BIOL CHEM, V264, P5323; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOND JS, 1989, PROTEOLYTIC ENZYMES, P232; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CERETTI DP, 1992, SCIENCE, V256, P97; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; GODT RE, 1988, AM J PHYSIOL, V254, pC891; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; KERR JFR, 1991, APOPTOSIS MOL BASIS, P321; LEATHERBARROW RJ, 1993, GRAFIT VERSION 3 01; LEWIS SD, 1981, BIOCHEMISTRY-US, V20, P48, DOI 10.1021/bi00504a009; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; MILLER DK, 1996, THERAPEUTIC MODULATI, P143; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; SLUYTERMAN LAA, 1976, EUR J BIOCHEM, V71, P383, DOI 10.1111/j.1432-1033.1976.tb11125.x; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Talanian RV, 1996, J BIOL CHEM, V271, P21853, DOI 10.1074/jbc.271.36.21853; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	40	460	488	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25719	25723		10.1074/jbc.272.41.25719	http://dx.doi.org/10.1074/jbc.272.41.25719			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325297	hybrid			2022-12-25	WOS:A1997YA35800052
J	Roux, P; Delepierre, M; Goldberg, ME; Chaffotte, AF				Roux, P; Delepierre, M; Goldberg, ME; Chaffotte, AF			Kinetics of secondary structure recovery during the refolding of reduced hen egg white lysozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; CYTOCHROME-C; FOLDING PATHWAY; DISULFIDE BONDS; PROTEIN; RENATURATION; H-1-NMR; NMR; SPECTROSCOPY; INTERMEDIATE	We have shown previously that, in less than 4 ms, the unfolded/oxidized hen lysozyme recovered its native secondary structure, while the reduced protein remained fully unfolded, To investigate the role played by disulfide bridges in the acquisition of the secondary structure at later stages of the renaturation/oxidation, the complete refolding of reduced lysozyme was studied, This was done in a renaturation buffer containing 0.5 M guanidinium chloride, 60 mu M oxidized glutathione, and 20 mu M reduced dithiothreitol, in which the aggregation of lysozyme was minimized and where a renaturation yield of 80% was obtained, The refolded protein could not be distinguished from the native lysozyme by activity, compactness, stability, and several spectroscopic measurements, The kinetics of renaturation were then studied by following the reactivation and the changes in fluorescence and circular dichroism signals, When bi- or triphasic sequential models were fitted to the experimental data, the first two phases had the same calculated rate constants for all the signals showing that, within the time resolution of these experiments, the folding/oxidation of hen lysozyme is highly cooperative, with the secondary structure, the tertiary structure, and the integrity of the active site appearing simultaneously.	INST PASTEUR,UNITE BIOCHIM CELLULAIRE,CNRS,URA 1129,F-75724 PARIS 15,FRANCE; INST PASTEUR,LAB RMN,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ACHARYA AS, 1976, J BIOL CHEM, V251, P6934; ANDERSON WL, 1976, J BIOL CHEM, V251, P3147; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BALDWIN RL, 1995, J BIOMOL NMR, V5, P103; CHAFFOTTE AF, 1992, BIOCHEMISTRY-US, V31, P9694, DOI 10.1021/bi00155a024; CHAFFOTTE AF, 1992, BIOCHEMISTRY-US, V31, P4303, DOI 10.1021/bi00132a022; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; ELOVE GA, 1992, BIOCHEMISTRY-US, V31, P6876, DOI 10.1021/bi00145a003; FISHER WR, 1973, J BIOL CHEM, V248, P3188; FITCH WL, 1994, J ORG CHEM, V59, P7955, DOI 10.1021/jo00105a006; Goldberg, 1995, Fold Des, V1, P21; GOLDBERG ME, 1994, PROTEIN SCI, V3, P883; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GUIJARRO JI, 1995, BIOCHEMISTRY-US, V34, P2998, DOI 10.1021/bi00009a031; HARRISON SC, 1985, P NATL ACAD SCI USA, V82, P4028, DOI 10.1073/pnas.82.12.4028; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KUWAJIMA K, 1991, BIOCHEMISTRY-US, V30, P7693, DOI 10.1021/bi00245a005; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; ORSINI G, 1978, J BIOL CHEM, V253, P3453; PRIVALOV G, 1995, ANAL BIOCHEM, V232, P79, DOI 10.1006/abio.1995.9957; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; Raman B, 1996, J BIOL CHEM, V271, P17067, DOI 10.1074/jbc.271.29.17067; REDFIELD C, 1988, BIOCHEMISTRY-US, V27, P122, DOI 10.1021/bi00401a020; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SAWANO H, 1992, FEBS LETT, V303, P11, DOI 10.1016/0014-5793(92)80466-T; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SOPHIANOPOULOS AJ, 1964, BIOCHEMISTRY-US, V3, P1920, DOI 10.1021/bi00900a023; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; VARLEY P, 1993, SCIENCE, V260, P1110, DOI 10.1126/science.8493553	32	45	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24843	24849		10.1074/jbc.272.40.24843	http://dx.doi.org/10.1074/jbc.272.40.24843			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312083	hybrid			2022-12-25	WOS:A1997XY97000022
J	Silver, DL; Vorotnikov, AV; Watterson, DM; Shirinsky, VP; Sellers, JR				Silver, DL; Vorotnikov, AV; Watterson, DM; Shirinsky, VP; Sellers, JR			Sites of interaction between kinase-related protein and smooth muscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; C-PROTEIN; HEAVY-MEROMYOSIN; SKELETAL-MUSCLE; CARBOXYL-TERMINUS; 10S CONFORMATION; CHICKEN GIZZARD; MYBP-C; BINDING; PHOSPHORYLATION	Kinase-related protein, also known as KRP or telokin, is an independently expressed protein product derived from a gene within the gene for myosin light chain kinase (MLCK). KRP binds to unphosphorylated smooth muscle myosin filaments and stabilizes them against ATP-induced depolymerization in vitro. KRP competes with MLCK for binding to myosin, suggesting that both proteins bind to myosin by the KRP domain (Shirinsky, V. P., Vorotnikov, A. V., Birukov, K. G., Nanaev, A. K., Collinge, M., Lukas, T. J., Sellers, J. R., and Watterson, D. M. (1993) J. Biol. Chem. 268, 16578-16583). In this study, we investigated which regions of myosin and KRP interact in vitro. Using cosedimentation assays, we determined that HRP binds to unphosphorylated myosin with a stoichiometry of 1 mol of KRP/1 mol of myosin and an affinity of 5.5 mu m. KRP slows the rate of proteolytic cleavage of the head-tail junction of heavy meromyosin by papain and chymotrypsin, suggesting it is binding to this region of myosin. In addition, competition experiments, using soluble headless fragments of nonmuscle myosin, confirmed that KRP interacts with the regulatory light chain binding region of myosin. The regions important for KRP's binding to myosin were investigated using bacterially expressed KRP truncation mutants. We determined that the acid-rich sequence between Gly(138) and Asp(151) of KRP is required for high affinity myosin binding, and that the amino terminus and beta-barrel regions weakly interact with myosin. All KRP truncations, at concentrations comparable to their K-D values, exhibited some stabilization of myosin filaments against ATP depolymerization in vitro, suggesting that KRP's ability to stabilize myosin filaments is commensurate with its myosin binding affinity. HRP weakened the K-m but not the V-max of phosphorylation of myosin by MLCK, demonstrating that bound HRP does not prevent MLCK from activating myosin.	NHLBI,MOL CARDIOL LAB,BETHESDA,MD 20892; RUSSIAN ACAD MED SCI,CARDIOL RES CTR,INST EXPT CARDIOL,MOL ENDOCRINOL LAB,MOSCOW 121552,RUSSIA; NORTHWESTERN UNIV,DRUG DISCOVERY PROGRAM,CHICAGO,IL 60611; NORTHWESTERN UNIV,DEPT BIOL CHEM & MOL PHARMACOL,CHICAGO,IL 60611	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Medical Research Center of Cardiology; Russian Academy of Medical Sciences; Northwestern University; Northwestern University			Shirinsky, Vladimir/AAN-3938-2020; Vorotnikov, Alexander/A-8392-2014; Vorotnikov, Alexander/AAN-3080-2020	Vorotnikov, Alexander/0000-0002-1460-971X; Vorotnikov, Alexander/0000-0002-1460-971X; Watterson, Daniel/0000-0001-7605-5866; Silver, Debra/0000-0001-9189-844X	NIGMS NIH HHS [GM30861] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030861] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; Benian GM, 1996, J CELL BIOL, V132, P835, DOI 10.1083/jcb.132.5.835; COLLINGE M, 1992, MOL CELL BIOL, V12, P2359, DOI 10.1128/MCB.12.5.2359; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; Gilbert R, 1996, J CELL SCI, V109, P101; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Godfraind-De Becker A, 1988, Adv Exp Med Biol, V226, P149; GUERRIERO V, 1981, CELL, V27, P449, DOI 10.1016/0092-8674(81)90386-X; HERRING BP, 1992, J BIOL CHEM, V267, P25945; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HOROWITS R, 1986, NATURE, V323, P160, DOI 10.1038/323160a0; HOROWITZ A, 1994, J CELL BIOL, V126, P1195, DOI 10.1083/jcb.126.5.1195; HOUMEIDA A, 1995, J CELL BIOL, V131, P1471, DOI 10.1083/jcb.131.6.1471; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; ITO M, 1989, J BIOL CHEM, V264, P13971; KATOH T, 1995, J BIOCHEM-TOKYO, V118, P428, DOI 10.1093/oxfordjournals.jbchem.a124925; Kobe B, 1996, EMBO J, V15, P6810, DOI 10.1002/j.1460-2075.1996.tb01072.x; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin PJ, 1997, J BIOL CHEM, V272, P7412, DOI 10.1074/jbc.272.11.7412; Masato T, 1997, J BIOCHEM, V121, P225; MOOS C, 1975, J MOL BIOL, V97, P1, DOI 10.1016/S0022-2836(75)80017-9; MURPHY RA, 1994, FASEB J, V8, P311, DOI 10.1096/fasebj.8.3.8143937; OKAGAKI T, 1993, J CELL BIOL, V123, P619, DOI 10.1083/jcb.123.3.619; Olney JJ, 1996, J BIOL CHEM, V271, P20375, DOI 10.1074/jbc.271.34.20375; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; ONISHI H, 1984, J BIOCHEM, V95, P899, DOI 10.1093/oxfordjournals.jbchem.a134685; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SELLERS JR, 1988, BIOCHEMISTRY-US, V27, P6977, DOI 10.1021/bi00418a046; SELLERS JR, 1987, ENZYMES, P381; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; Silver D. L., 1996, Biophysical Journal, V70, pA52; SOMLYO AV, 1981, NATURE, V294, P567, DOI 10.1038/294567a0; STARR R, 1978, BIOCHEM J, V171, P813, DOI 10.1042/bj1710813; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; VOROTNIKOV AV, 1995, BIOPHYS J, V17, pA153	44	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25353	25359		10.1074/jbc.272.40.25353	http://dx.doi.org/10.1074/jbc.272.40.25353			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312155	hybrid			2022-12-25	WOS:A1997XY97000094
J	Nguyen, H; Lin, RT; Hiscott, J				Nguyen, H; Lin, RT; Hiscott, J			Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins	ONCOGENE			English	Article						interferon regulatory factor (IRF)-1; STAT1 (p91); apoptosis; transcription	TRANSCRIPTION FACTOR IRF-1; IFN-BETA; TYROSINE PHOSPHORYLATION; MAMMALIAN-CELLS; INTERFERON GENE; VIRUS INDUCTION; NUCLEAR FACTOR; FACTOR-I; KINASE; TRANSFORMATION	Interferon Regulatory Factor (IRF)-1 has been characterized as an important growth regulatory and immunomodulatory transcription factor. To further characterize the potential targets of IRF-1 antiproliferative activity, IRF-1 was expressed under the control of the tetracycline-inducible system in murine NIH3T3 cells. Due to their ability to mimic IRF-1 transactivator function, the regulatory potential of IRF-1/RelA and IRF-2/RelA fusion proteins consisting of the DNA binding domains of IRF-1 or IRF-2 fused to the transactivation domain of NF-kappa B RelA(p65) was also examined. Cells inducibly expressing IRF-1 or IRF/RelA in response to doxycycline treatment displayed significantly reduced growth rates compared to control cells, and inhibition of cell growth correlated directly with the level of transgene expression. Interestingly, IRF-1 and IRF/RelA expression also induced a low level of apoptosis, as detected by microscopic analyses. Furthermore, expression of the interferon inducible, double stranded RNA dependent kinase PKR was increased following IRF-1 or IRF/RelA induction. Most strikingly, induction of IRF-1 and IRF/RelA expression resulted in a significant increase in STAT1 (p91) protein and increased ISGF3 DNA binding activity, suggesting that IRF-1 tumor suppressor activity may involve a novel mechanism which activates the JAK-STAT pathway through STAT1. WAF1 levels were also constitutively elevated in IRF-1 and IRF-1/RelA cells. These studies demonstrate that inducible expression of the transactivation function of IRF-1 or IRF/RelA mediates tumor suppressor activity by inducing cell growth arrest, apoptosis and the differential activation of growth regulatory genes such as PKR, STAT1 and WAF1.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,TERRY FOX MOL ONCOL GRP,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3T 1E2,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University			Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				BARBER GN, 1993, GENOMICS, V16, P765, DOI 10.1006/geno.1993.1262; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HANASH SM, 1995, GENES CHROM CANC, V8, P34; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HISCOTT J, 1995, SEMIN VIROL, V6, P161, DOI 10.1006/smvy.1995.0021; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEHTONEN A, IN PRESS J IMMUNOL; LIN RT, 1994, J BIOL CHEM, V269, P17542; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NGUYEN H, 1995, ONCOGENE, V11, P537; OZAWA H, 1996, NATURE, V382, P816; PENNINGER JM, 1994, IMMUNOL REV, V142, P231, DOI 10.1111/j.1600-065X.1994.tb00892.x; PEPIN N, 1994, VIROLOGY, V204, P706, DOI 10.1006/viro.1994.1586; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SQUIRE J, 1993, GENOMICS, V16, P768, DOI 10.1006/geno.1993.1263; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; UEGAKI K, 1993, PROTEIN ENG, V6, P195, DOI 10.1093/protein/6.2.195; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; XANTHOUDAKIS S, 1989, J BIOL CHEM, V264, P1139; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; [No title captured]	44	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1425	1435		10.1038/sj.onc.1201318	http://dx.doi.org/10.1038/sj.onc.1201318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333018				2022-12-25	WOS:A1997XW41100006
J	Schaefer, G; Fitzpatrick, VD; Sliwkowski, MX				Schaefer, G; Fitzpatrick, VD; Sliwkowski, MX			gamma-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175	ONCOGENE			English	Article						neuregulin; receptor tyrosine kinase; autocrine growth stimulation	NEU-DIFFERENTIATION FACTOR; FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; CARCINOMA CELLS; GENE-PRODUCT; FACTOR-ALPHA; TUMOR-CELLS; ERBB2; FAMILY; EGF	A novel neuregulin isoform, termed gamma-HRG, was cloned and characterized from the human breast cancer cell line, MDA-MB-175. As observed with other neuregulins, gamma-HRG, is a product of alternative mRNA splicing of the neuregulin gene, gamma-HRG contains the EGF-like and immunoglobulin-like domains that are commonly found in other family members, but lacks a transmembrane and cytoplasmic region. The new isoform possesses a unique N-terminal region that includes a hydrophobic domain that may function as a secretion signal. A purified recombinant version of gamma-HRG competes for binding to soluble ErbB3- and ErbB4-IgG fusion proteins with affinities similar to those observed for rHRG beta 1(177-244). gamma-HRG has a wide distribution in mesenchymal or neuronal tissues but in contrast to other neuregulins, it is not present in breast, lung, liver and small intestine. Expression of gamma-HRG with its cognate receptors, ErbB3 and ErbB2 suggested that the growth of the MDA-MB-175 cell line might be a result of the stimulation of a growth factor signaling pathway. Treatment of MDA-MB-175 cells with an anti-ErbB2 monoclonal antibody that interferes with the ligand-dependent formation of ErbB2-ErbB3 heterodimer complexes shows a strong growth inhibitory effect on this cell line. Moreover, incubation with a receptor-IgG fusion protein that neutralizes secreted gamma-HRG, also inhibits cell growth. These data suggest that the secretion of gamma-HRG by MDA-MB-175 cells leads to the formation of a constitutively active receptor complex and stimulates the growth of these cells in an autocrine manner.	GENENTECH INC,S SAN FRANCISCO,CA 94080; UNIV FREIBURG,DEPT BIOL,D-7800 FREIBURG,GERMANY	Roche Holding; Genentech; University of Freiburg				Schaefer, Gabriele/0000-0001-9727-3555				ALIMANDI M, 1995, ONCOGENE, V10, P1813; AVILA MA, 1995, ONCOGENE, V10, P963; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BURDEN S, 1997, IN PRESS NEURON; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE R, 1993, BREAST CANCER RES TR, V24, P227, DOI 10.1007/BF01833263; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Ethier SP, 1996, MOL CARCINOGEN, V15, P134; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; FENDLY BM, 1990, CANCER RES, V50, P1550; GOUSTIN AS, 1986, CANCER RES, V46, P1015; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEVI ADO, 1995, J NEUROSCI, V15, P1329; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Lewis GD, 1996, CANCER RES, V56, P1457; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MODJTAHEDI H, 1994, INT J ONCOL, V4, P277; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; PARK JW, 1993, P AM ASSOC CANC RES, V84, P3107; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Sadick MD, 1996, ANAL BIOCHEM, V235, P207, DOI 10.1006/abio.1996.0114; Sambrook J., 2002, MOL CLONING LAB MANU; Scher HI, 1995, CLIN CANCER RES, V1, P545; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; Tang CK, 1996, CANCER RES, V56, P3350; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; ZHANG D, 1997, IN PRESS P NATL AC S; Zhang K, 1996, J BIOL CHEM, V271, P3884	50	88	111	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1385	1394		10.1038/sj.onc.1201317	http://dx.doi.org/10.1038/sj.onc.1201317			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333014				2022-12-25	WOS:A1997XW41100002
J	Chen, CM; Xie, Y; Stevenson, MA; Auron, PE; Calderwood, SK				Chen, CM; Xie, Y; Stevenson, MA; Auron, PE; Calderwood, SK			Heat shock factor 1 represses Ras-induced transcriptional activation of the c-fos gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; PROMOTER ELEMENTS; HSP70 GENE; EXPRESSION; PROTEIN; BINDING; PHOSPHORYLATION; ONCOGENES; CELLS; EUKARYOTES	Heat shock factor 1, the critical molecular regulator of the stress response is conserved throughout eukaryotic organisms and activates the transcription of heat shock genes. We now show that heat shock factor 1 inhibits the expression of c-fos, an immediate early gene that controls responses to extracellular stimuli for growth and differentiation. Heat shock factor 1 inhibits the transcription of the c-fos gene and antagonizes the activating effects of the signal transducing protein Has on the c-fos promoter and on the promoter of another Has responsive gene uPA. This property was specific for heat shock factor 1; c-fos repression was not seen with the structurally related protein heat shock factor 2, Repression involved different molecular mechanisms compared with those involved in transcriptional activation by heat shock factor 1 and specifically did not require binding to the c-fos promoter. Thus, in addition to its known role as a transcriptional activator of the cellular heat shock response, heat shock factor 1 also antagonizes the expression of Fos, a key component of the ubiquitous AP-1 transcription factor complex and as such could influence multiple aspects of cell regulation.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,CTR BLOOD RES,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School					NCI NIH HHS [CA4707, CA50642, CA31303] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050642, P01CA031303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; BOS JL, 1989, CANCER RES, V49, P4682; Cahill CM, 1996, J BIOL CHEM, V271, P24874; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4505, DOI 10.1210/en.136.10.4505; COLETTA F, 1990, BIOCHEM BIOPH RES CO, V168, P1013; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; GEORGOPOLIS C, 1993, ANN REV CELL BIOL, V22, P631; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gray S, 1996, GENE DEV, V10, P700, DOI 10.1101/gad.10.6.700; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HRUGER MJ, 1996, INFECT DIS N AM, V10, P1; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; METZ R, 1991, ONCOGENE, V6, P2165; Oesterreich S, 1996, BIOCHEM BIOPH RES CO, V222, P155, DOI 10.1006/bbrc.1996.0714; OPPERMANN J, 1989, NATURE, V341, P125; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SAL GD, 1988, NUCLEIC ACIDS RES, V16, P9878; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Yang BS, 1996, MOL CELL BIOL, V16, P538	38	69	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					26803	26806		10.1074/jbc.272.43.26803	http://dx.doi.org/10.1074/jbc.272.43.26803			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341107	hybrid			2022-12-25	WOS:A1997YC65900003
J	Chu, P; Murray, S; Lissin, D; vonZastrow, M				Chu, P; Murray, S; Lissin, D; vonZastrow, M			delta and kappa opioid receptors are differentially regulated by dynamin-dependent endocytosis when activated by the same alkaloid agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; PROTEIN-KINASE-C; OPIATE RECEPTOR; MOLECULAR MECHANISMS; DOWN-REGULATION; INTERNALIZATION; DESENSITIZATION; SEQUESTRATION; RESENSITIZATION; MUTANT	Many alkaloid drugs used as analgesics activate multiple opioid receptors. Mechanisms that distinguish the actions of these drugs on the regulation of individual mu, delta, and kappa receptors are not understood. We have observed that individual cloned opioid receptors differ Significantly in their regulation by rapid endocytosis in the presence of alkaloid drug etorphine, a potent agonist of mu, delta, and kappa opioid receptors. Internalization of epitope-tagged delta opioid receptors from the plasma membrane is detectable within 10 min in the presence of etorphine. In contrast, kappa receptors expressed in the same cells remain in the plasma membrane and are not internalized for greater than or equal to 60 min, even when cells are exposed to saturating concentrations of etorphine. The rapid internalization of delta receptors is specifically inhibited in cells expressing K44E mutant dynamin I, suggesting that type-specific internalization of opioid receptors is mediated by clathrin-coated pits. Examination of a series of chimeric mutant kappa/delta receptors indicates that at least two receptor domains, including the highly divergent carboxyl-termindi cytoplasmic tail, determine the type specificity of this endocytic mechanism. We conclude that structurally homologous opioid receptors are differentially sorted by clathrin-mediated endocytosis following-activation by the same agonist ligand. These studies identify a fundamental mechanism of receptor regulation mediating type-specific effects of analgesic drugs that activate more than one type of opioid receptor.	UNIV CALIF SAN FRANCISCO,NINA IRELAND LAB,LANGLEY PORTER INST,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR NEUROBIOL & PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019552] Funding Source: NIH RePORTER; NIDA NIH HHS [DA00218] Funding Source: Medline; NIMH NIH HHS [MH19552] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Akil H, 1996, NIDA Res Monogr, V161, P127; Baba T, 1995, COLD SPRING HARB SYM, V60, P235, DOI 10.1101/SQB.1995.060.01.027; Blake AD, 1996, CHEM BIOL, V3, P967, DOI 10.1016/S1074-5521(96)90163-5; Blake AD, 1997, J BIOL CHEM, V272, P782, DOI 10.1074/jbc.272.2.782; Bohm SK, 1996, J BIOL CHEM, V271, P22003; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Evans CJ, 1993, BIOL BASIS SUBSTANCE, P31; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HUGHES J, 1977, BRIT MED BULL, V33, P157, DOI 10.1093/oxfordjournals.bmb.a071416; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Krueger KM, 1997, J BIOL CHEM, V272, P5; LAW PY, 1984, J BIOL CHEM, V259, P4096; Law PY, 1997, MOL PHARMACOL, V51, P152, DOI 10.1124/mol.51.1.152; LAW PY, 1982, MOL PHARMACOL, V72, P1; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; Mostafapour S, 1996, RECEPT SIGNAL TRANS, V6, P151; PEI G, 1995, MOL PHARMACOL, V48, P173; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Raynor K, 1996, NIDA Res Monogr, V161, P83; Reisine T, 1996, ANN NY ACAD SCI, V780, P168, DOI 10.1111/j.1749-6632.1996.tb15121.x; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	35	133	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27124	27130		10.1074/jbc.272.43.27124	http://dx.doi.org/10.1074/jbc.272.43.27124			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341153	hybrid			2022-12-25	WOS:A1997YC65900049
J	VazquezPrado, J; Medina, LD; GarciaSainz, JA				VazquezPrado, J; Medina, LD; GarciaSainz, JA			Activation of endothelin ETA receptors induces phosphorylation of alpha(1b)-adrenoreceptors in rat-1 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; INOSITOL PHOSPHOLIPID-METABOLISM; PHORBOL-MYRISTATE ACETATE; KINASE-C ISOFORMS; ADRENERGIC-RECEPTOR; ALPHA-1-ADRENERGIC RECEPTORS; TYROSINE PHOSPHORYLATION; LYSOPHOSPHATIDIC ACID; REGULATORY PROTEINS; CROSS-TALK	The effect of endothelin-l on the phosphorylation of alpha(1b)-adrenoreceptors, transfected into rat-1 fibroblasts, was studied, Basal alpha(1b)-adrenoreceptor phosphorylation was markedly increased by endothelin-l, norepinephrine, and phorbol esters, The effect of endothelin-l was dose dependent (EC50 approximate to 1 nM), reached its maximum 5 min after stimulation, and was inhibited by BQ-123, an antagonist selective for ETA receptors. Endothelin-1-induced alpha(1b)-adrenoreceptor phosphorylation was attenuated by staurosporine or genistein and essentially abolished when both inhibitors were used together. The effect of norepinephrine. was not modified by either staurosporine or genistein alone, and it was only partially inhibited when both were used together. These data suggest the participation of protein kinase C and tyrosine kinase(s) in endothelin-l-induced receptor phosphorylation. However, phosphoaminoacid analysis revealed the presence of phosphoserine and traces of phosphothreonine, but not of phosphotyrosine, suggesting that the putative tyrosine kinase(s), activated by endothelin, could act in a step previous to receptor phosphorylation. The effect of endothelin-1 on alpha(1b)-adrenoreceptor phosphorylation was not mediated through pertussis toxin-sensitive G proteins. Calcium mobilization induced by norepinephrine was diminished by endothelin-l, Norepinephrine and endothelin-1 increased [S-35]GTP gamma S binding to control membranes. The effect of norepinephrine was abolished in membranes obtained from cells pretreated with endothelin-l. Interestingly, genistein plus staurosporine inhibited this effect of the endothelial peptide, Endothelin-l did not induce alpha(1b)-adrenoreceptor internalization, Our data indicate that activation of ETA receptors by endothelin-1 induces alpha(1b)-adrenoreceptor phosphorylation and alters G protein coupling.	NATL AUTONOMOUS UNIV MEXICO,INST FISIOL CELULAR,DEPT CELL BIOL,MEXICO CITY 04510,DF,MEXICO; UNIV AUTONOMA METROPOLITANA IZTAPALAPA,DEPT REPROD BIOL,DIV CBS,MEXICO CITY 09340,DF,MEXICO	Universidad Nacional Autonoma de Mexico; Universidad Autonoma Metropolitana - Mexico			GARCIA-SAINZ, JESUS ADOLFO/A-5389-2008; VAZQUEZ-PRADO, JOSE/C-1630-2017	GARCIA-SAINZ, JESUS ADOLFO/0000-0002-5235-0657; VAZQUEZ-PRADO, JOSE/0000-0001-5797-6643				AMBAR I, 1993, EUR J PHARM-MOLEC PH, V245, P31, DOI 10.1016/0922-4106(93)90166-7; BEELER JF, 1995, BIOCHEM J, V305, P73, DOI 10.1042/bj3050073; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BERTI L, 1994, J BIOL CHEM, V269, P3381; BOUVIER M, 1987, J BIOL CHEM, V262, P3106; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHAU LY, 1993, J NEUROCHEM, V60, P454, DOI 10.1111/j.1471-4159.1993.tb03172.x; Chen X, 1995, BIOCHEM BIOPH RES CO, V217, P445, DOI 10.1006/bbrc.1995.2796; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; CLERK A, 1994, J BIOL CHEM, V269, P32848; COOPER RH, 1985, J BIOL CHEM, V260, P3281; CORVERA S, 1986, J BIOL CHEM, V261, P520; CORVERA S, 1984, BIOCHEM BIOPH RES CO, V119, P1128, DOI 10.1016/0006-291X(84)90892-1; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DAMRON DS, 1993, J BIOL CHEM, V268, P27335; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Diviani D, 1996, J BIOL CHEM, V271, P5049; DONOSO MV, 1994, BRIT J PHARMACOL, V111, P473, DOI 10.1111/j.1476-5381.1994.tb14761.x; FONSECA MI, 1995, J BIOL CHEM, V270, P8902, DOI 10.1074/jbc.270.15.8902; GARCIASAINZ JA, 1989, AM J PHYSIOL, V256, pC384, DOI 10.1152/ajpcell.1989.256.2.C384; Graham RM, 1996, CIRC RES, V78, P737, DOI 10.1161/01.RES.78.5.737; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HABER E, 1994, NATURE, V370, P252, DOI 10.1038/370252a0; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HIEBLE JP, 1995, PHARMACOL REV, V47, P267; JAMES AF, 1994, NATURE, V370, P297, DOI 10.1038/370297a0; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; LYNCH CJ, 1985, J BIOL CHEM, V260, P2844; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MATTINGLY RR, 1992, J BIOL CHEM, V267, P7470; MINNEMAN KP, 1994, ANNU REV PHARMACOL, V34, P117; Nambi P, 1996, J PHARMACOL EXP THER, V277, P1567; ONO K, 1994, NATURE, V370, P301, DOI 10.1038/370301a0; PACHTER JA, 1993, BIOCHEM J, V294, P153, DOI 10.1042/bj2940153; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; SAVILLE MK, 1994, BIOCHEM J, V301, P407, DOI 10.1042/bj3010407; SEKURA RD, 1983, J BIOL CHEM, V258, P4647; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VazquezPrado J, 1996, MOL PHARMACOL, V50, P17; WIELAND T, 1994, METHOD ENZYMOL, V237, P3; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZUZAGA JL, 1996, EMBO J, V15, P6220	50	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27330	27337		10.1074/jbc.272.43.27330	http://dx.doi.org/10.1074/jbc.272.43.27330			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341183	hybrid			2022-12-25	WOS:A1997YC65900079
J	Zhang, SH; Kobayashi, R; Graves, PR; PiwnicaWorms, H; Tonks, NK				Zhang, SH; Kobayashi, R; Graves, PR; PiwnicaWorms, H; Tonks, NK			Serine phosphorylation-dependent association of the band 4.1-related protein-tyrosine phosphatase PTPH1 with 14-3-3 beta protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL-ASSOCIATED PROTEINS; MULTIPLE SIGNALING PATHWAYS; SEQUENCE HOMOLOGY; IN-VIVO; T-CELLS; 14-3-3-PROTEINS; KINASE; CLONING; IDENTIFICATION; EXPRESSION	PTPH1 is a human protein-tyrosine phosphatase with homology to the band 4.1 superfamily of cytoskeletal-associated proteins. PTPH1 was found to associate with 14-3-3 beta using a yeast two-hybrid screen, and its interaction could be reconstituted in vitro using recombinant proteins. Examination of the interaction between 14-3-3 beta and various deletion mutants of PTPH1 by two-hybrid tests suggested that the integrity of the PTP is important for this binding. Although both PTPH1 and Raf-1 form complexes with 14-3-3 beta, they appear to do so independently, Binding of 14-3-3 beta to PTPH1 in vitro was abolished by pretreating PTPH1 with potato acid phosphatase and was greatly enhanced by pretreating with Cdc25C-associated protein kinase. Thus the association between PTPH1 and 14-3-3 beta is phosphorylation-dependent. Two novel motifs (RSLSVE)-V-359 and (RVDSEP)-E-853 in PTPH1 were identified as major 14-3-3 beta-binding sites, both of which are distinct from the consensus binding motif RSXSXP recently found in Raf-l. Mutation of Ser(359) and Ser(853) to alanine significantly reduced the association between 14-3-3 beta and PTPH1. Furthermore, association of PTPH1 and 14-3-3 beta was detected in several cell lines and was regulated in response to extracellular signals. These results raise the possibility that 14-3-3 beta may function as an adaptor molecule in the regulation of PTPH1 and may provide a link between serine/threonine and tyrosine phosphorylation-dependent signaling pathways.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Washington University (WUSTL)			Piwnica-Worms, Helen/C-5214-2012		NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018428] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840] Funding Source: Medline; NIGMS NIH HHS [GM18428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; LABBE D, 1994, FEBS LETT, V356, P351, DOI 10.1016/0014-5793(94)01305-5; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; OGG S, 1994, J BIOL CHEM, V269, P30461; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SAHIN M, 1995, P NATL ACAD SCI USA, V92, P7859, DOI 10.1073/pnas.92.17.7859; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SAWADA M, 1994, BIOCHEM BIOPH RES CO, V203, P479, DOI 10.1006/bbrc.1994.2207; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; SMITH AL, 1995, BIOCHEM BIOPH RES CO, V209, P959, DOI 10.1006/bbrc.1995.1591; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG SH, 1995, J BIOL CHEM, V270, P20067, DOI 10.1074/jbc.270.34.20067; ZHANG SH, 1994, J BIOL CHEM, V269, P17593	49	87	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	1997	272	43					27281	27287		10.1074/jbc.272.43.27281	http://dx.doi.org/10.1074/jbc.272.43.27281			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YC659	9341175	hybrid			2022-12-25	WOS:A1997YC65900071
J	Banik, U; Wang, GA; Wagner, PD; Kaufman, S				Banik, U; Wang, GA; Wagner, PD; Kaufman, S			Interaction of phosphorylated tryptophan hydroxylase with 14-3-3 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; BIOSPECIFIC INTERACTION ANALYSIS; HIGH-LEVEL EXPRESSION; RAT BRAIN-STEM; TYROSINE-HYDROXYLASE; ACTIVATOR PROTEIN; ESCHERICHIA-COLI; PHENYLALANINE-HYDROXYLASE; CEREBROSPINAL-FLUID; MOLECULAR-CLONING	Rabbit brain tryptophan hydroxylase (TPH) has been expressed in insect cells (Spodoptera frugiperda) as a histidine-tagged enzyme. The specific activity of the purified fusion enzyme is 80 nmol of 5-hydroxytryptophan/min/mg. Multifunctional regulatory 14-3-3 proteins were purified from fresh bovine brain. Phosphorylation and 14-3-3 proteins play important roles in the regulation of TPH activity. We have found that phosphorylation of TPH by cAMP-dependent protein kinase increased the activity of the hydroxylase by 25-30% and that 14-3-3 proteins increased the hydroxylase activity of phosphorylated TPH by similar to 45%. Under these conditions, the 14-3-3 proteins were not phosphorylated, and unphosphorylated TPH was not activated by 14-3-3 proteins. Surface plasmon resonance analysis demonstrated that 14-3-3 proteins bind to phosphorylated TPH with an affinity constant (K-a) of 4.5 x 10(7) M-1. Binding studies using affinity chromatography also showed that 14-3-3 proteins interact with phosphorylated TPH. The dephosphorylation of TPH by protein phosphatase-l was inhibited by 14-3-3 proteins. Our results demonstrate that 14-3-3 proteins form a complex with phosphorylated brain TPH, thereby increasing its enzymatic activity and inhibiting its dephosphorylation.	NCI, BIOCHEM LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Banik, U (corresponding author), NIMH, NEUROCHEM LAB, NIH, BLDG 36, RM 3D30, BETHESDA, MD 20892 USA.							AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; ATKINSON J, 1987, J NEUROCHEM, V49, P1241, DOI 10.1111/j.1471-4159.1987.tb10016.x; BOSTON PF, 1982, J NEUROCHEM, V38, P1466, DOI 10.1111/j.1471-4159.1982.tb07927.x; BOSTON PF, 1982, J NEUROCHEM, V38, P1475, DOI 10.1111/j.1471-4159.1982.tb07928.x; Brown S-L, 1991, ROLE SEROTONIN PSYCH; CHEN FS, 1994, FEBS LETT, V347, P128, DOI 10.1016/0014-5793(94)00520-6; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FISHER DB, 1973, J BIOL CHEM, V248, P4345; FITZPATRICK PF, 1990, J BIOL CHEM, V265, P2042; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FRIEDMAN PA, 1972, J BIOL CHEM, V247, P4165; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FUNAKOSHI H, 1991, J BIOL CHEM, V266, P15614; GOLDEN RN, 1990, PSYCHIAT ANN, V20, P558, DOI 10.3928/0048-5713-19901001-05; Goldman ER, 1997, BIOCHEMISTRY-US, V36, P49, DOI 10.1021/bi961769k; HASEGAWA H, 1987, METHOD ENZYMOL, V142, P88; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ICHIMURA T, 1987, FEBS LETT, V219, P79, DOI 10.1016/0014-5793(87)81194-8; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; JEQUIER E, 1967, MOL PHARMACOL, V3, P274; JOHANSEN PA, 1995, J NEUROCHEM, V65, P882; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KAUFMAN S, 1970, METHODS ENZYMOL    A, V17, P603; Kaufman S., 1974, MOL MECH OXYGEN ACTI, P285; KIM KS, 1991, MOL BRAIN RES, V9, P277; Kuhn DM, 1997, J NEUROCHEM, V68, P2220; KUHN DM, 1980, J BIOL CHEM, V255, P4137; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LOVENBERG W, 1967, SCIENCE, V155, P217, DOI 10.1126/science.155.3759.217; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; MAKITA Y, 1990, FEBS LETT, V268, P185, DOI 10.1016/0014-5793(90)81004-8; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NAKATA H, 1982, EUR J BIOCHEM, V122, P41, DOI 10.1111/j.1432-1033.1982.tb05845.x; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PHILLIPS RS, 1984, J BIOL CHEM, V259, P2474; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; SHIMAN R, 1970, METHODS ENZYMOLOGY A, V17, P609; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STOLL J, 1990, GENOMICS, V7, P88, DOI 10.1016/0888-7543(90)90522-V; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; TANJI M, 1994, J NEUROCHEM, V63, P1908; TIPPER JP, 1994, ARCH BIOCHEM BIOPHYS, V315, P445, DOI 10.1006/abbi.1994.1523; TONG JH, 1975, J BIOL CHEM, V250, P4152; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; VRANA KE, 1994, LIFE SCI, V55, P1045, DOI 10.1016/0024-3205(94)00639-3; WANG YH, 1991, P NATL ACAD SCI USA, V88, P8779, DOI 10.1073/pnas.88.19.8779; WHITAKERAZMITIA PM, 1990, ANN NY ACAD SCI, V600, P315, DOI 10.1111/j.1749-6632.1990.tb16892.x; WU YN, 1992, BIOCHEM J, V285, P697, DOI 10.1042/bj2850697; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YAMAUCHI T, 1981, BIOCHEM BIOPH RES CO, V100, P807, DOI 10.1016/S0006-291X(81)80246-X; YAMAUCHI T, 1979, ARCH BIOCHEM BIOPHYS, V198, P219, DOI 10.1016/0003-9861(79)90413-2; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404; YANG XJ, 1994, P NATL ACAD SCI USA, V91, P6659, DOI 10.1073/pnas.91.14.6659; Zoche M, 1996, BIOCHEMISTRY-US, V35, P8742, DOI 10.1021/bi960445t	64	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26219	26225		10.1074/jbc.272.42.26219	http://dx.doi.org/10.1074/jbc.272.42.26219			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334190	hybrid			2022-12-25	WOS:A1997YB13900024
J	Basuyaux, JP; Ferreira, E; Stehelin, D; Buttice, G				Basuyaux, JP; Ferreira, E; Stehelin, D; Buttice, G			The Ets transcription factors interact with each other and with the c-Fos/c-Jun complex via distinct protein domains in a DNA-dependent and -independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN STROMELYSIN GENE; BINDING MOTIF; AP-1 SITE; FAMILY; EXPRESSION; INHIBITION; PROMOTER; ERG; TPA; TRANSACTIVATION	The transcription factors Fos,Jun, and Ets regulate the expression of human stromelysin-1 and collagenase-1 genes, Recently, we found that ERG, an Ets family member, activates collagenase-1 gene but not stromely-sin-1 by physically interacting with c-Fos/c-Jun, Interestingly, ERG binds to stromelysin-1 promoter and represses its activation by ETS2. Here, to investigate the molecular mechanism of this regulation, we have used an in vitro protein-protein interaction assay and studied the transcription factor interactions of ETS2. We found that ETS2 could weakly associate with in vitro synthesized ETS1, c-Fos, and c-Jun and strongly with c-Fos/c-Jun complex and ERG via several distinct ETS2: domains including the C-terminal region that contains the DNA-binding domain, Strikingly, these interactions were stabilized in vitro by DNA as they were inhibited by ethidium bromide, Both the N-terminal region, comprising the transactivation domain, and the C-terminal region of ETS2 associated with ERG and, interestingly, the interaction of ERG through the transactivation domain of ETS2 was DNA-independent, The DNA-dependent interaction of ETS2 with c-Fos/c-Jun was enhanced by specific DNA fragments requiring two Ets-binding-sites of the stromelysin-1 promoter, Using the two hybrid system, we also demonstrated that ETS2 interacts with c-Jun or ERG in vivo.	INST BIOL,CNRS IFR3,F-59021 LILLE,FRANCE					Buttice', Giovanna/0000-0001-6550-5585				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KURAS L, 1995, MOL CELL BIOL, V15, P208, DOI 10.1128/MCB.15.1.208; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; Min W, 1996, MOL CELL BIOL, V16, P359; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; QUINONES S, 1989, J BIOL CHEM, V264, P8339; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129	37	96	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26188	26195		10.1074/jbc.272.42.26188	http://dx.doi.org/10.1074/jbc.272.42.26188			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334186	hybrid			2022-12-25	WOS:A1997YB13900020
J	Kelm, RJ; Elder, PK; Strauch, AR; Getz, MJ				Kelm, RJ; Elder, PK; Strauch, AR; Getz, MJ			Sequence of cDNAs encoding components of vascular actin single-stranded DNA-binding factor 2 establish identity to Pur alpha and Pur beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CELLULAR PROTEINS YB-1; FAR UPSTREAM ELEMENT; GENE PROMOTER; C-MYC; STIMULATES TRANSCRIPTION; ATHEROMATOUS PLAQUE; IDENTIFICATION; FIBROBLASTS; ENHANCER	Transcriptional repression of the mouse vascular smooth muscle cu-actin gene in fibroblasts and myoblasts is mediated, in part, by the interaction of two single-stranded DNA binding activities with opposite strands of an essential transcription enhancer factor-1 recognition element (Sun, S., Stoflet, E. S., Cogan, J. G., Strauch, A. R., and Getz, M. J. (1995) Mol. Cell. Biol. 15, 2429-2436). One of these activities, previously designated vascular actin single-stranded DNA-binding factor 2 includes two distinct polypeptides (p44 and p46) which specifically interact with the purine rich strand of both the enhancer and a related element in a protein coding exon of the gene (Kelm, R. J., Jr., Sun, S., Strauch, A. R., and Getz, M. J. (1996) J. Biol. Chem. 271, 24278-24285). Expression screening of a mouse lung cDNA library with a vascular actin single-stranded DNA-binding factor 2 recognition element has now resulted in the isolation of two distinct cDNA clones that encode p46 and p44, One of these proteins is identical to Pur alpha, a retinoblastoma-binding; protein previously implicated in both transcriptional activation and DNA replication, The other is a related family member, presumably Pur beta, Comparative band shift and Southwestern blot analyses conducted with cellular p46, p44, and cloned Pur proteins synthesized in vitro and in vivo, establish identity of p46 with Pur alpha and p44 with Pur beta. This study implicates Pur alpha and/or Pur beta in the control of vascular smooth muscle alpha-actin gene transcription.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; OHIO STATE UNIV,COLL MED,DEPT ANAT CELL BIOL & NEUROBIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,BIOCHEM PROGRAM,COLUMBUS,OH 43210	Mayo Clinic; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NHLBI NIH HHS [R01 HL54281] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054281] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELBASSET EM, 1991, NEUROSCI LETT, V125, P117, DOI 10.1016/0304-3940(91)90005-E; ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; BABAEV VR, 1990, AM J PATHOL, V136, P1031; BAZAR L, 1995, J BIOL CHEM, V270, P8241, DOI 10.1074/jbc.270.14.8241; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; BETZ E, 1991, J CELL PHYSIOL, V147, P385, DOI 10.1002/jcp.1041470302; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; COGAN JG, 1994, MOL BIOL CELL, V5, P950; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; Duncan R, 1996, MOL CELL BIOL, V16, P2274; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; GROSSMANN ME, 1995, J BIOL CHEM, V270, P10968, DOI 10.1074/jbc.270.18.10968; HAAS S, 1995, J BIOL CHEM, V270, P12503, DOI 10.1074/jbc.270.21.12503; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; HERAULT Y, 1993, CELL MOL BIOL RES, V39, P717; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Jurk M, 1996, NUCLEIC ACIDS RES, V24, P2799, DOI 10.1093/nar/24.14.2799; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; KOCHER O, 1991, LAB INVEST, V65, P459; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LECAIN E, 1991, J NEUROSCI RES, V28, P601, DOI 10.1002/jnr.490280417; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; MA ZW, 1994, GENE, V149, P311, DOI 10.1016/0378-1119(94)90167-8; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MIN BH, 1990, J BIOL CHEM, V265, P16667; PAN WT, 1990, J BIOL CHEM, V265, P7022; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; SCHURCH W, 1992, HISTOLOGY PATHOLOGIS, P109; SEALEY L, 1987, MOL CELL BIOL, V7, P787, DOI 10.1128/MCB.7.2.787; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; Skalli O., 1988, MOL CELLULAR BIOL WO; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; TANUMA Y, 1995, MOL CELL BIOL, V15, P517, DOI 10.1128/MCB.15.1.517; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; WILKISON WO, 1990, J BIOL CHEM, V265, P477	45	73	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26727	26733		10.1074/jbc.272.42.26727	http://dx.doi.org/10.1074/jbc.272.42.26727			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334258	hybrid			2022-12-25	WOS:A1997YB13900092
J	Trumbore, MW; Wang, RH; Enkemann, SA; Berger, SL				Trumbore, MW; Wang, RH; Enkemann, SA; Berger, SL			Prothymosin alpha in vivo contains phosphorylated glutamic acid residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; BINDS HISTONES; RAT THYMUS; IN-VITRO; C-MYC; GENE; EXPRESSION; PROTEIN; NUCLEOPLASMIN; LOCALIZATION	Human and monkey prothymosin alpha contain activated carbonyl groups on glutamic acid residues. Three lines of evidence indicate the existence of unusual phosphates. 1) Prothymosin alpha continued to be metabolically labeled with [P-32]orthophosphoric acid despite a mutation at Ser(1), the sole site of phosphate in purified bovine prothymosin alpha (Sburlati, A. R., De La Rosa, A., Batey D. W., Kurys, G. L., Manrow, R. E., Pannell, L. K., Martin, B. M., Sheeley, D. M., and Berger, S. L. (1993) Biochemistry 32, 4587-4596), 2) Immediately upon cell lysis, the pH stability curves of metabolically label ed native [P-32]prothymosin alpha or a [P-32]histidine-tagged variant resembled the pH stability curve of acetyl phosphate. 3) After a brief incubation at pH ?, these curves changed from a pattern diagnostic for an acyl phosphate to that characteristic of a serine or threonine phosphate, an observation consistent with transfer of phosphate in vitro. Our data indicate that most of prothymosin alpha's phosphates are subject instantaneously to hydrolysis, based on the observation that greater than 90% of the phosphate initially found at pH 7 disappeared at the extremes of pH. Rapid loss of phosphate was not affected by the presence of phosphatase inhibitors including 50 mM sodium fluoride, 1 mM okadaic acid, and 0.5 mM calyculin A. The amount of phosphate missing could not be ascertained, but the trifling amount recovered on Ser or Thr depended heavily on conditions favoring the transient survival of labile phosphate. Further analysis using COS cells lysed in the presence of sodium borohydride showed that: 1) phosphate recovered on prothymosin alpha decreased 8-fold when lysates were treated with borohydride; 2) the reagent caused 4-8 glutamic acid residues/molecule to vanish; 3) using [H-3]NaBH4, label was introduced into proline, a product derived from reductive cleavage of phosphoglutamate; and 4) [H-3]proline was localized almost exclusively to a peptide with pronounced homology to the histone binding site of nucleoplasmin, a chromatin remodeling protein found in Xenopus laevis. Our data demonstrate that prothymosin a is energy-rich by virtue of stoichiometric amounts of glutamyl phosphate.	NCI, SECT GENES & GENE PROD, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANTHONY RS, 1972, J BIOL CHEM, V247, P2120; Appleby JL, 1996, CELL, V86, P845, DOI 10.1016/S0092-8674(00)80158-0; BARCIA MG, 1992, FEBS LETT, V312, P152, DOI 10.1016/0014-5793(92)80924-6; BERGER SL, 1994, ANAL BIOCHEM, V222, P1, DOI 10.1006/abio.1994.1445; BLACK S, 1955, J BIOL CHEM, V213, P27; BURGLIN TR, 1987, GENE DEV, V1, P97, DOI 10.1101/gad.1.1.97; BUSTELO XR, 1991, J BIOL CHEM, V266, P1443; COHENSOLAL L, 1979, BIOCHEM J, V177, P81, DOI 10.1042/bj1770081; COHENSOLAL L, 1979, P NATL ACAD SCI USA, V76, P4327, DOI 10.1073/pnas.76.9.4327; COHENSOLAL L, 1985, ANAL BIOCHEM, V151, P82, DOI 10.1016/0003-2697(85)90055-7; COTTAM GL, 1969, BIOCHEM BIOPH RES CO, V35, P895, DOI 10.1016/0006-291X(69)90708-6; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DELAMO FF, 1995, FEBS LETT, V359, P15, DOI 10.1016/0014-5793(94)01427-3; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; Dingwall C, 1990, Semin Cell Biol, V1, P11; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; DOSIL M, 1990, FEBS LETT, V269, P373, DOI 10.1016/0014-5793(90)81196-U; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; FRILLINGOS S, 1991, MOL CELL BIOCHEM, V108, P85; GAST K, 1995, BIOCHEMISTRY-US, V34, P13211, DOI 10.1021/bi00040a037; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1391, DOI 10.1073/pnas.81.5.1391; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1008, DOI 10.1073/pnas.81.4.1008; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P343, DOI 10.1073/pnas.82.2.343; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Jencks W. P., 1976, HDB BIOCH MOL BIOL, V1, P296; KAHLENBERG A, 1968, ARCH BIOCHEM BIOPHYS, V126, P331, DOI 10.1016/0003-9861(68)90589-4; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KOSHLAND DE, 1993, SCIENCE, V262, P532, DOI 10.1126/science.8211179; KOSHLAND DE, 1952, J AM CHEM SOC, V74, P2286, DOI 10.1021/ja01129a035; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; KUBOTA S, 1995, EUR J BIOCHEM, V233, P48, DOI 10.1111/j.1432-1033.1995.048_1.x; LANDAIS JC, 1989, CONNECT TISSUE RES, V19, P1, DOI 10.3109/03008208909016810; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; MALIN EL, 1989, ANAL BIOCHEM, V181, P315, DOI 10.1016/0003-2697(89)90249-2; MANROW RE, 1993, J MOL BIOL, V234, P281, DOI 10.1006/jmbi.1993.1583; MANROW RE, 1991, J BIOL CHEM, V266, P3916; MARDH S, 1971, BIOCHIM BIOPHYS ACTA, V251, P419, DOI 10.1016/0005-2795(71)90131-0; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; MORI M, 1993, ONCOGENE, V8, P2821; PAPAMARCAKI T, 1994, FEBS LETT, V345, P71, DOI 10.1016/0014-5793(94)00439-0; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; POST RL, 1973, ORG ENERGY TRANSDUCI, P25; ROBSON E, 1993, HISTOCHEM J, V25, P497; Sburlati A R, 1990, Protein Expr Purif, V1, P184, DOI 10.1016/1046-5928(90)90014-P; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SBURLATI AR, 1993, BIOCHEMISTRY-US, V32, P4587, DOI 10.1021/bi00068a015; SEALY L, 1986, BIOCHEMISTRY-US, V25, P3064, DOI 10.1021/bi00358a049; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; SUZUKI F, 1969, J BIOCHEM, V66, P767, DOI 10.1093/oxfordjournals.jbchem.a129206; Vareli K, 1996, EUR J BIOCHEM, V238, P799, DOI 10.1111/j.1432-1033.1996.0799w.x; Wang RH, 1997, J BIOL CHEM, V272, P26405, DOI 10.1074/jbc.272.42.26405; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	59	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26394	26404		10.1074/jbc.272.42.26394	http://dx.doi.org/10.1074/jbc.272.42.26394			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334214	hybrid			2022-12-25	WOS:A1997YB13900048
J	Wu, WJ; Leonard, DA; ACerione, R; Manor, D				Wu, WJ; Leonard, DA; ACerione, R; Manor, D			Interaction between Cdc42Hs and RhoGDI is mediated through the Rho insert region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEINS; GUANINE-NUCLEOTIDE EXCHANGE; WISKOTT-ALDRICH SYNDROME; RASGAP-RELATED PROTEIN; DBL ONCOGENE PRODUCT; ACTIN POLYMERIZATION; KINASE; IDENTIFICATION; RAC	Members of the Rho subfamily of GTP binding proteins contain a region of amino acid sequence (residues 122-134) that is absent from other Ras-like proteins and is termed the Rho insert region, To address the functional role of this domain, we have constructed a Cdc42Hs/Ras chimera in which loop 8 from Ha-Ras was substituted for the region in Cdc42Hs that contains the 13-amino acid insert region, Our data indicate that the insert region of Cdc42Hs is not essential for its interactions with various target/effector molecules or for interactions with the guanine nucleotide exchange factor, Dbl, or the Cdc42 GTPase-activating protein (GAP), However, the regulation of GDP dissociation and GTP hydrolysis on Cdc42Hs by the Rho GDP-dissociation inhibitor (GDI) is extremely sensitive to changes in the insert region, such that a Cdc42Hs/Ha-Ras chimera that lacks this insert is no longer susceptible to a GDI-induced inhibition of GDP dissociation and GTP hydrolysis, The insensitivity to GDI activity is not due to the inability of the GDI molecule to bind to the Cdc42Hs/Ha-Ras chimera, and in fact, the GDI is fully capable of stimulating the release of this chimera from membranes.	CORNELL UNIV,CTR VET MED,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University					NEI NIH HHS [EY06429] Funding Source: Medline; NIGMS NIH HHS [GM47458] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Best A, 1996, J BIOL CHEM, V271, P3756; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CERIONE RA, 1996, CURR OPIN CELL BIOL, V8, P205; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEONARD D, 1992, J BIOL CHEM, V267, P22860; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Nomanbhoy TK, 1996, BIOCHEMISTRY-US, V35, P4602, DOI 10.1021/bi951743d; OLSON ME, 1995, SCIENCE, V269, P53; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; SUTCLIFF M, 1995, PROTEIN PEPTIDE LETT, V1, P84; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; UEDA T, 1990, J BIOL CHEM, V265, P9373; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517	36	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26153	26158		10.1074/jbc.272.42.26153	http://dx.doi.org/10.1074/jbc.272.42.26153			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334181	hybrid			2022-12-25	WOS:A1997YB13900015
J	ChapmanSmith, A; Forbes, BE; Wallace, JC; Cronan, JE				ChapmanSmith, A; Forbes, BE; Wallace, JC; Cronan, JE			Covalent modification of an exposed surface turn alters the global conformation of the biotin carrier domain of Escherichia coli acetyl-CoA carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE MULTIENZYME COMPLEX; YEAST PYRUVATE-CARBOXYLASE; LIPOYL DOMAIN; 3-DIMENSIONAL STRUCTURE; H-PROTEIN; SEQUENCE; SUBUNIT; PURIFICATION; REPRESSOR; COENZYME	We have studied the apo (unbiotinylated) and hole (biotinylated) forms of BCCP87, an 87-residue COOH-terminal peptide comprising the biotin carrier domain of the biotin carboxyl carrier protein subunit of Escherichia coli acetyl-CoA carboxylase. The apo; protein spontaneously formed disulfide-linked dimers and was modified readily by sulfhydryl reagents, whereas the hole protein remained monomeric and was unreactive toward sulfhydryl reagents unless a protein denaturant was present, These data indicated that the single cysteine residue of the domain (Cys-116) was much more reactive in the apo form of the protein. Incubation of apoBCCP87 with biotin ligase for different times, followed by reaction with fluorescein-5-maleimide, clearly showed that the loss of Cys-116 reactivity was the result of modification with biotin, In addition, reaction of Cys-116 with 5,5'-dithiobis(2-nitrobenzoic acid) showed that apoBCCP87 denatured at lower urea concentrations than holoBCCP87. We also found that apoBCCP87 was at least 10-fold more sensitive than the hole form to proteolysis by a range of proteases, Identification of the cleavage sites indicated that the differences in protease sensitivity could not be attributed to shielding of susceptible bonds by the biotin moiety of the hole protein, These data indicate that a conformational change accompanies biotinylation of the biotin domain. Thus, modification of a beta-turn protruding from the protein surface results in alteration of the overall structure of this protein domain.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	ChapmanSmith, A (corresponding author), UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA 5005,AUSTRALIA.		, John/AAP-5150-2020; Cronan, John/V-6626-2019; Forbes, Briony/R-1838-2019	Forbes, Briony/0000-0003-4360-9927	NIAID NIH HHS [AI15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; BROCKLEHURST SM, 1993, PROTEIN SCI, V2, P626; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P831; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DARDEL F, 1991, EUR J BIOCHEM, V201, P203, DOI 10.1111/j.1432-1033.1991.tb16275.x; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; EISENBERG MA, 1982, J BIOL CHEM, V257, P5167; FALL RR, 1973, J BIOL CHEM, V248, P2078; FALL RR, 1972, J BIOL CHEM, V247, P8005; FONTANA A, 1997, J MOL BIOL, V266, P228; GREEN JDF, 1995, J MOL BIOL, V248, P328, DOI 10.1006/jmbi.1995.0225; Hobba GD, 1996, J BIOL CHEM, V271, P30529, DOI 10.1074/jbc.271.48.30529; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEONDELRIO A, 1994, J BIOL CHEM, V269, P22964; LI SJ, 1992, J BIOL CHEM, V267, P855; LIM F, 1988, J BIOL CHEM, V263, P11493; Nenortas E, 1996, J BIOL CHEM, V271, P7559, DOI 10.1074/jbc.271.13.7559; NERVI AM, 1971, ARCH BIOCHEM BIOPHYS, V143, P401, DOI 10.1016/0003-9861(71)90227-X; PARES S, 1994, P NATL ACAD SCI USA, V91, P4850, DOI 10.1073/pnas.91.11.4850; REED KE, 1991, J BIOL CHEM, V266, P11425; ROBERTS EL, 1996, THESIS U CAMBRIDGE C; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHMID FX, 1989, PROTEIN STRUCTURE PR, P265; SUTTON MR, 1977, J BIOL CHEM, V252, P3934; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; Xu Y, 1995, BIOCHEMISTRY-US, V34, P16624, DOI 10.1021/bi00051a010	29	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26017	26022		10.1074/jbc.272.41.26017	http://dx.doi.org/10.1074/jbc.272.41.26017			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325338	hybrid			2022-12-25	WOS:A1997YA35800093
J	Williams, JA; Shacter, E				Williams, JA; Shacter, E			Regulation of macrophage cytokine production by prostaglandin E-2 - Distinct roles of cyclooxygenase-1 and -2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ENDOPEROXIDE SYNTHASE CYCLOOXYGENASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MATRIX METALLOPROTEINASE PRODUCTION; ARACHIDONIC-ACID METABOLITES; SWISS 3T3 CELLS; INDUCIBLE CYCLOOXYGENASE; MESSENGER-RNA; PERITONEAL-MACROPHAGES; RHEUMATOID-ARTHRITIS	Prostaglandin E-2 (PGE(2)) modulates a variety of physiological processes including the production of inflammatory cytokines. There are two cyclooxygenase (Cox) enzymes, Cox-1 and Cox-2, that are responsible for initiating PGE(2) synthesis. These isozymes catalyze identical biosynthetic reactions but are regulated by different mechanisms in the cell. This report examines differ differences in the roles of Cox-1 and Cox-2 in regulating cytokine synthesis in macrophages. We employed agents that selectively modulate the activity of each isozyme and measured their effects on synthesis of interleukin (IL)-6, IL-1, and tumor necrosis factor-alpha by peritoneal macrophages. Among these three cytokines, only IL-6 synthesis was stimulated by production of endogenous PGE(2). This effect was specifically linked to activation of Cox-2 and not Cox-1. The specificity derives, partly, from the timing of the production of PGE(2) following stimulation of each isozyme and from induction of ancillary signals that control the response to PGE(2). The experimental findings demonstrate that the effects of Cox-1 and Cox-2 activity on macrophage IL-6 synthesis are segregated. This provides a mechanism for IL-6 to be induced selectively during inflammation.	US FDA,CBER,HFM 538,IMMUNOL LAB,BETHESDA,MD 20892	US Food & Drug Administration (FDA)								Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; Arakawa T, 1996, J BIOL CHEM, V271, P29569, DOI 10.1074/jbc.271.47.29569; BHARDWAJ N, 1989, J IMMUNOL, V143, P2153; BRANDWEIN SR, 1986, J BIOL CHEM, V261, P8624; CALLERY MP, 1990, J SURG RES, V48, P523, DOI 10.1016/0022-4804(90)90224-P; CORCORAN ML, 1994, ARCH BIOCHEM BIOPHYS, V310, P481, DOI 10.1006/abbi.1994.1196; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; ERTEL W, 1991, ANN SURG, V214, P141, DOI 10.1097/00000658-199108000-00008; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FIEREN MWJ, 1991, IMMUNOL LETT, V31, P85; FLETCHER JR, 1993, ARCH SURG-CHICAGO, V128, P1192; FU JY, 1990, J BIOL CHEM, V265, P16737; FUTAKI N, 1993, J PHARM PHARMACOL, V45, P753, DOI 10.1111/j.2042-7158.1993.tb07103.x; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; GOSS JA, 1993, AM J PHYSIOL, V264, pG601, DOI 10.1152/ajpgi.1993.264.4.G601; GUERNE PA, 1989, J CLIN INVEST, V83, P585, DOI 10.1172/JCI113921; HABIB A, 1993, J BIOL CHEM, V268, P23448; HELLE M, 1988, EUR J IMMUNOL, V18, P1535, DOI 10.1002/eji.1830181010; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Hinson RM, 1996, P NATL ACAD SCI USA, V93, P4885, DOI 10.1073/pnas.93.10.4885; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; HUMES JL, 1977, NATURE, V269, P149, DOI 10.1038/269149a0; KARGMAN SL, 1995, CANCER RES, V55, P2556; KASSIS S, 1989, AGENTS ACTIONS, V27, P274, DOI 10.1007/BF01972795; KOMATSU H, 1981, INT J IMMUNOPHARMACO, V13, P1137; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KUNKEL SL, 1986, J IMMUNOL, V136, P186; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LEE SH, 1992, J BIOL CHEM, V267, P25934; LEISTEN JC, 1990, CLIN IMMUNOL IMMUNOP, V56, P108, DOI 10.1016/0090-1229(90)90174-O; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MEHINDATE K, 1995, J IMMUNOL, V155, P3570; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OGLE CK, 1994, INFLAMMATION, V18, P175, DOI 10.1007/BF01534558; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; PHILLIPS TA, 1993, J LEUKOCYTE BIOL, V53, P411, DOI 10.1002/jlb.53.4.411; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; PRUIMBOOM WM, 1994, IMMUNOL LETT, V41, P255, DOI 10.1016/0165-2478(94)90142-2; REDDY ST, 1994, J BIOL CHEM, V269, P15473; RENZ H, 1988, J IMMUNOL, V141, P2388; Richardson C, 1996, DRUG SAFETY, V15, P249, DOI 10.2165/00002018-199615040-00003; RIMARACHIN JA, 1994, ARTERIOSCLER THROMB, V14, P1021, DOI 10.1161/01.ATV.14.7.1021; Rola-Pleszczynski M, 1992, Mediators Inflamm, V1, P5, DOI 10.1155/S0962935192000024; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; ROTH GJ, 1994, BLOOD, V83, P885; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; SEIBERT K, 1994, RECEPTOR, V4, P17; SHACTER E, 1987, J IMMUNOL METHODS, V99, P259, DOI 10.1016/0022-1759(87)90136-0; SHACTER E, 1993, BLOOD, V82, P2853; SHACTER E, 1988, CARCINOGENESIS, V9, P2297, DOI 10.1093/carcin/9.12.2297; SHACTER E, 1992, BLOOD, V80, P194; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; SPENGLER RN, 1989, J IMMUNOL, V142, P4346; THEISENPOPP P, 1992, INT J IMMUNOPHARMACO, V14, P565, DOI 10.1016/0192-0561(92)90117-4; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	67	157	161	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25693	25699		10.1074/jbc.272.41.25693	http://dx.doi.org/10.1074/jbc.272.41.25693			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325293	hybrid			2022-12-25	WOS:A1997YA35800048
J	Heyeck, SD; Wilcox, HM; Bunnell, SC; Berg, LJ				Heyeck, SD; Wilcox, HM; Bunnell, SC; Berg, LJ			Lck phosphorylates the activation loop tyrosine of the Itk kinase domain and activates Itk kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; CELL ANTIGEN RECEPTOR; ATP-BINDING SITE; TEC FAMILY KINASE; SRC FAMILY; PROTEIN-KINASE; T-CELLS; GENE; IDENTIFICATION; BTK	The Tec family tyrosine kinase Itk has been implicated in T cell receptor (TCR) signaling, yet its precise role and mechanism of activation remain undefined. To investigate these issues, we examined the biochemical response of Itk to TCR stimulation. We found that Itk is tyrosine-phosphorylated after TCR cross-linking and that this phosphorylation depends on the presence of functional Lck. To determine if this Lck dependence results from direct phosphorylation of Itk by Lck, we generated recombinant Itk and Lck using a baculovirus expression system and used these proteins in subsequent biochemical analyses, We found that Lck phosphorylates Itk upon co-expression in insect cells and, further, that this phosphorylation of Itk results in increased Itk in vitro kinase activity. The major site of Lck phosphorylation on Itk was mapped to the conserved tyrosine (Tyr(511)) in the activation loop of the Itk kinase domain. Substitution of this tyrosine with phenylalanine abolishes Itk kinase activity in insect cells, indicating that phosphorylation at this site plays a critical role in regulating Itk function.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University				Bunnell, Stephen/0000-0001-6887-0828	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037584] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37584] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Afar DEH, 1996, MOL CELL BIOL, V16, P3465; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, V2; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; Gibson S, 1996, J IMMUNOL, V156, P2716; Gibson S, 1996, J BIOL CHEM, V271, P7079, DOI 10.1074/jbc.271.12.7079; GIBSON S, 1993, BLOOD, V82, P1561; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; King PD, 1997, J IMMUNOL, V158, P580; King PD, 1996, INT IMMUNOL, V8, P1707, DOI 10.1093/intimm/8.11.1707; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TANAKA N, 1993, FEBS LETT, V324, P1, DOI 10.1016/0014-5793(93)81520-A; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Watts JD, 1996, FEBS LETT, V398, P217, DOI 10.1016/S0014-5793(96)01241-0; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x	44	134	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25401	25408		10.1074/jbc.272.40.25401	http://dx.doi.org/10.1074/jbc.272.40.25401			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312162	hybrid			2022-12-25	WOS:A1997XY97000101
J	Vishnevetsky, M; Ovadis, M; Itzhaki, H; Vainstein, A				Vishnevetsky, M; Ovadis, M; Itzhaki, H; Vainstein, A			CHRC, encoding a chromoplast-specific carotenoid-associated protein, is an early gibberellic acid-responsive gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUCUMIS-SATIVUS COROLLAS; PHYTOENE SYNTHASE; BARLEY ALEURONE; EXPRESSION; PETUNIA; TRANSDUCTION; BIOGENESIS; PROMOTER	CHRC, a corolla-specific carotenoid-associated protein, is a major component of carotenoid-lipoprotein complexes in Cucumis sativus chromoplasts. Using an in vitro flower bud culture system that mimics in vivo flower development, CHRC mRNA levels in corollas were shown to be specifically up regulated by gibberellic acid, The response to gibberellic acid was very rapid (within 20 min) and insensitive to protein synthesis inhibition by cycloheximide. Abscisic acid, known to antagonize gibberellin in many developmental systems, strongly down-regulated CHRC mRNA levels. The gibberellin synthesis inhibitor paclobutrazol exhibited a similar negative effect on CHRC expression. Inclusion of exogenous gibberellic acid into the in. vitro bud culture system with the paclobutrazol not only prevented the CHRC mRNA down-regulation, it up-regulated transcript accumulation to the level of gibberellic acid-treated corollas, CHRC mRNA accumulation in response to gibberellic acid displayed a dose-dependent increase up to 10(-4) M gibberellic acid, The up-regulation could be detected with as little as 10(-7) M gibberellic acid. Based on these data, we suggest that CHRC is the first structural gene identified to date whose expression is regulated by gibberellic acid in a primary fashion, The critical role of the rapid response of CHRC to gibberellic acid in aiding carotenoid sequestration while preserving chromoplast structural organization is discussed.	HEBREW UNIV JERUSALEM,FAC AGR,KENNEDY LEIGH CTR HORT RES,IL-76100 REHOVOT,ISRAEL; HEBREW UNIV JERUSALEM,FAC AGR,OTTO WARBURG CTR BIOTECHNOL AGR,IL-76100 REHOVOT,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem								Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; BARTLEY GE, 1995, PLANT CELL, V7, P1027, DOI 10.1105/tpc.7.7.1027; CHORY J, 1987, PLANT PHYSIOL, V83, P15, DOI 10.1104/pp.83.1.15; FRASER PD, 1995, PLANTA, V196, P321, DOI 10.1007/BF00201391; FRAY RG, 1995, PLANT J, V8, P693, DOI 10.1046/j.1365-313X.1995.08050693.x; GRAY JC, 1987, ADV BOT RES, V14, P25; GUBLER F, 1995, PLANT CELL, V7, P1879, DOI 10.1105/tpc.7.11.1879; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOOLEY R, 1994, PLANT MOL BIOL, V26, P1529, DOI 10.1007/BF00016489; HUTTLY AK, 1995, PHYSIOL PLANTARUM, V95, P310, DOI 10.1111/j.1399-3054.1995.tb00843.x; HUTTLY AK, 1989, EMBO J, V8, P1907, DOI 10.1002/j.1460-2075.1989.tb03593.x; KARVOUNI Z, 1995, PLANT MOL BIOL, V27, P1153, DOI 10.1007/BF00020888; Kuo AL, 1996, PLANT CELL, V8, P259, DOI 10.1105/tpc.8.2.259; LibalWeksler Y, 1997, PLANT PHYSIOL, V113, P59, DOI 10.1104/pp.113.1.59; MUR L, 1995, THESIS VRIJE U AMSTE; Penson SP, 1996, PLANT CELL, V8, P2325, DOI 10.1105/tpc.8.12.2325; RAVEN HP, 1992, BIOL PLANTS, P545; Sambrook J., 2002, MOL CLONING LAB MANU; Schuurink RC, 1996, PLANT PHYSIOL, V111, P371, DOI 10.1104/pp.111.2.371; SMIRRA I, 1993, PLANT PHYSIOL, V102, P491, DOI 10.1104/pp.102.2.491; Swain SM, 1996, PLANT PHYSIOL, V112, P11, DOI 10.1104/pp.112.1.11; VAINSTEIN A, 1993, PHYSIOL PLANTARUM, V89, P192, DOI 10.1111/j.1399-3054.1993.tb01805.x; VAINSTEIN A, 1994, PLANT PHYSIOL, V104, P321, DOI 10.1104/pp.104.2.321; Vishnevetsky M, 1996, PLANT J, V10, P1111, DOI 10.1046/j.1365-313X.1996.10061111.x; WEISS D, 1995, PLANT PHYSIOL, V107, P695, DOI 10.1104/pp.107.3.695; WEISS D, 1992, PLANT PHYSIOL, V98, P191, DOI 10.1104/pp.98.1.191	27	16	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24747	24750		10.1074/jbc.272.40.24747	http://dx.doi.org/10.1074/jbc.272.40.24747			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312067	hybrid			2022-12-25	WOS:A1997XY97000006
J	Leroux, MR; Melki, R; Gordon, B; Batelier, G; Candido, EPM				Leroux, MR; Melki, R; Gordon, B; Batelier, G; Candido, EPM			Structure-function studies on small heat shock protein oligomeric assembly and interaction with unfolded polypeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							BOVINE ALPHA-CRYSTALLIN; CHAPERONE-LIKE ACTIVITY; CAENORHABDITIS-ELEGANS; MOLECULAR CHAPERONES; CITRATE SYNTHASE; IN-VITRO; H-1-NMR SPECTROSCOPY; A-CRYSTALLIN; B-CRYSTALLIN; BETA-TUBULIN	The small heat shock protein (smHSP) and alpha-crystallin genes encode a family of 12-43-kDa proteins which assemble into large multimeric structures, function as chaperones by preventing protein aggregation, and contain a conserved region termed the alpha-crystallin domain, Here we report on the structural and functional characterization of Caenorhabditis elegans HSP16-2, a 16-kDa smRSP produced only under stress conditions. A combination of sedimentation velocity, size exclusion chromatography, and cross-linking analyses on wild-type HSP16-2 and five derivatives demonstrate that the N-terminal domain but not most of the the C-terminal extension which follows the alpha-crystallin domain is essential for the oligomerization of the smHSP into high molecular weight complexes. The N terminus of HSP16-2 is found to be buried within complexes which can accommodate at least an additional 4-kDa of heterologous sequence per subunit. Studies on the interaction of HSP16-2 with fluorescently-labeled and radiolabeled actin and tubulin reveal that this smHSP possesses a high affinity for unfolded intermediates which form early on the aggregation pathway, but has no apparent substrate specificity, Furthermore, both wild-type and C-terminally-truncated HSP16-2 can function as molecular chaperones by suppressing the thermally-induced aggregation of citrate synthase., Taken together our data on HSP16-2 and a unique 12.6-kDa smHSP we have recently characterized demonstrate that multimerization is a prerequisite for the interaction of smHSPs with unfolded protein as well as for chaperone activity.	UNIV BRITISH COLUMBIA, DEPT BIOCHEM & MOL BIOL, VANCOUVER, BC V6T 1Z3, CANADA; CNRS, LAB ENZYMOL & BIOCHIM STRUCT, F-91198 GIF SUR YVETTE, FRANCE	University of British Columbia; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; BENTLEY NJ, 1992, YEAST, V8, P95, DOI 10.1002/yea.320080204; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CANDIDO EPM, 1989, GENOME, V31, P690, DOI 10.1139/g89-126; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; CARVER JA, 1994, BBA-PROTEIN STRUCT M, V1204, P195, DOI 10.1016/0167-4838(94)90009-4; CARVER JA, 1995, FEBS LETT, V369, P305, DOI 10.1016/0014-5793(95)00770-A; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; CARVER JA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P22, DOI 10.1016/0167-4838(93)90107-3; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Chang ZY, 1996, J BIOL CHEM, V271, P7218, DOI 10.1074/jbc.271.12.7218; CHIESI M, 1990, MOL CELL BIOCHEM, V97, P129; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DETMERS P, 1981, J BIOL CHEM, V256, P99; DIXON DK, 1990, DNA CELL BIOL, V9, P177, DOI 10.1089/dna.1990.9.177; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; Feder ME, 1996, J EXP BIOL, V199, P1837; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; Gesierich U, 1996, FEBS LETT, V393, P151, DOI 10.1016/0014-5793(96)00867-8; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOPALAKRISHNAN S, 1992, CURR EYE RES, V11, P929, DOI 10.3109/02713689209033490; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOCKERTZ MK, 1991, FEBS LETT, V280, P375, DOI 10.1016/0014-5793(91)80335-Z; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Huot J, 1996, CANCER RES, V56, P273; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Jones D, 1996, TOXICOLOGY, V109, P119, DOI 10.1016/0300-483X(96)03316-1; JONES D, 1986, J BIOL CHEM, V261, P2006; KATO K, 1994, J BIOL CHEM, V269, P11274; KING CR, 1983, CELL, V32, P707, DOI 10.1016/0092-8674(83)90056-9; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; KUNTZ ID, 1971, J AM CHEM SOC, V93, P514, DOI 10.1021/ja00731a036; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; LIN TH, 1991, J BIOL CHEM, V266, P1635; Linder B, 1996, J BIOL CHEM, V271, P30158, DOI 10.1074/jbc.271.47.30158; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P121, DOI 10.1007/BF00221053; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MEJILLANO MR, 1989, BIOCHEMISTRY-US, V28, P6518, DOI 10.1021/bi00441a053; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Melki R, 1996, BIOCHEMISTRY-US, V35, P10422, DOI 10.1021/bi960788r; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, MOL BIOL REP, V18, P209, DOI 10.1007/BF01674432; MERCK KB, 1993, J BIOL CHEM, V268, P1046; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; RUSSNAK RH, 1985, MOL CELL BIOL, V5, P1268, DOI 10.1128/MCB.5.6.1268; RUSSNAK RH, 1983, NUCLEIC ACIDS RES, V11, P3187, DOI 10.1093/nar/11.10.3187; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SIEZEN RJ, 1980, EUR J BIOCHEM, V107, P243, DOI 10.1111/j.1432-1033.1980.tb04644.x; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V748, P56, DOI 10.1016/0167-4838(83)90027-4; SINGH K, 1995, FEBS LETT, V372, P283, DOI 10.1016/0014-5793(95)00980-N; SINGH M, 1970, J BIOL CHEM, V245, P4636; SMULDERS RHPH, 1995, J BIOL CHEM, V270, P13916, DOI 10.1074/jbc.270.23.13916; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANDENOETELAAR PJM, 1989, BIOCHIM BIOPHYS ACTA, V995, P91, DOI 10.1016/0167-4838(89)90238-0; WANG KY, 1994, J BIOL CHEM, V269, P13601; Wang KY, 1996, EUR J BIOCHEM, V242, P56, DOI 10.1111/j.1432-1033.1996.0056r.x; WANG Z, 1992, PROTEIN SCI, V1, P522; Waters ER, 1996, J EXP BOT, V47, P325, DOI 10.1093/jxb/47.3.325; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WELCH WJ, 1985, J CELL BIOL, V101, P1198, DOI 10.1083/jcb.101.4.1198; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; YEH KW, 1994, BIOTECHNOL APPL BIOC, V19, P41; [No title captured]	105	191	199	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24646	24656		10.1074/jbc.272.39.24646	http://dx.doi.org/10.1074/jbc.272.39.24646			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305934	hybrid			2022-12-25	WOS:A1997XY51500085
